ID,title,study_design,clinical_specialty,report_section,taxonomy_term,keyword,implementation,full_bibliographic_reference,authors,journal_title,year,volume,issue,page_numbers,date_of_publication,language,doi,pmid_id,pmid_url,relevant_urls,explanation_and_elaboration_papers,guideline_history,relevant_more,website_url,acronym,provided_for,additional_languages,additional_information,relevant_editorials,primary_guideline,other,other_relevant_research,equator_comments,sticky,date_of_entry,date_last_updated,slug,scraped_data
22449,Reporting guideline for Chatbot Health Advice studies: the CHART statement,Artificial intelligence/Machine learning studies, ,Whole report, , , ,"Huo B, Collins G, Chartash D, Thirunavukarasu A, Flanagin A, Iorio A, Cacciamani G, Chen X, Liu N, Mathur P, Chan AW, Laine C, Pacella D, Berkwits M, Antoniou SA, Camaradou JC, Canfield C, Mittelman M, Feeney T, Loder E, Agha R, Saha A, Mayol J, Sunjaya A, Harvey H, Ng JY, McKechnie T, Lee Y, Verma N, Stiglic G, McCradden M, Ramji K, Boudreau V, Ortenzi M, Meerpohl J, Vandvik PO, Agoritsas T, Samuel D, Frankish H, Anderson M, Yao X, Loeb S, Lokker C, Liu X, Guallar E, Guyatt G. Reporting guideline for Chatbot Health Advice studies: the CHART statement.

This guideline was published simultaneously in 6 journals. You can read the guideline in any of these journals using the links below.

Annals of Family Medicine: PMID 40750305
Artificial Intelligence in Medicine: PMID 40753040
BMC Medicine: PMID 40745595
BMJ Medicine: PMID 40761518
British Journal of Surgery: PMID 40747825
JAMA Network Open: PMID 40747871

","Huo B, Collins G, Chartash D, Thirunavukarasu A, Flanagin A, Iorio A, Cacciamani G, Chen X, Liu N, Mathur P, Chan AW, Laine C, Pacella D, Berkwits M, Antoniou SA, Camaradou JC, Canfield C, Mittelman M, Feeney T, Loder E, Agha R, Saha A, Mayol J, Sunjaya A, Harvey H, Ng JY, McKechnie T, Lee Y, Verma N, Stiglic G, McCradden M, Ramji K, Boudreau V, Ortenzi M, Meerpohl J, Vandvik PO, Agoritsas T, Samuel D, Frankish H, Anderson M, Yao X, Loeb S, Lokker C, Liu X, Guallar E, Guyatt G", , , , , , ,English, , , , ,"CHART Collaborative. Reporting guidelines for chatbot health advice studies: explanation and elaboration for the Chatbot Assessment Reporting Tool (CHART). BMJ. 2025; 390: e083305. PMID: 40750271

", , , ,CHART,Reporting recommendations for studies evaluating the performance of generative artificial intelligence (AI)-driven chatbots when summarizing clinical evidence and providing health advice., , , , , , , ,no,2025-08-02 20:57:02,2025-08-06 17:49:29,reporting-guideline-for-chatbot-health-advice-studies-the-chart-statement,"[('title', 'Reporting guideline for Chatbot Health Advice studies: the CHART statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting recommendations for studies evaluating the performance of generative artificial intelligence (AI)-driven chatbots when summarizing clinical evidence and providing health advice.'), ('Full bibliographic reference', 'Huo B, Collins G, Chartash D, Thirunavukarasu A, Flanagin A, Iorio A, Cacciamani G, Chen X, Liu N, Mathur P, Chan AW, Laine C, Pacella D, Berkwits M, Antoniou SA, Camaradou JC, Canfield C, Mittelman M, Feeney T, Loder E, Agha R, Saha A, Mayol J, Sunjaya A, Harvey H, Ng JY, McKechnie T, Lee Y, Verma N, Stiglic G, McCradden M, Ramji K, Boudreau V, Ortenzi M, Meerpohl J, Vandvik PO, Agoritsas T, Samuel D, Frankish H, Anderson M, Yao X, Loeb S, Lokker C, Liu X, Guallar E, Guyatt G. Reporting guideline for Chatbot Health Advice studies: the CHART statement.\n\n \n\n This guideline was published simultaneously in 6 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n[Annals of Family Medicine](https://www.annfammed.org/content/early/2025/07/29/afm.250386): [PMID 40750305](https://pubmed.ncbi.nlm.nih.gov/40750305/)\n\n[Artificial Intelligence in Medicine](https://www.sciencedirect.com/science/article/pii/S0933365725001575): [PMID 40753040](https://pubmed.ncbi.nlm.nih.gov/40753040/)\n\n[BMC Medicine](https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-025-04274-w): [PMID 40745595](https://pubmed.ncbi.nlm.nih.gov/40745595/)\n\n[BMJ Medicine](https://bmjmedicine.bmj.com/content/4/1/e001632): [PMID 40761518](https://pubmed.ncbi.nlm.nih.gov/40761518/)\n\n[British Journal of Surgery](https://academic.oup.com/bjs/article/112/8/znaf142/8220472): [PMID 40747825](https://pubmed.ncbi.nlm.nih.gov/40747825/)\n\n[JAMA Network Open](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2837224): [PMID 40747871](https://pubmed.ncbi.nlm.nih.gov/40747871/)\n\n \n\n'), ('Language', 'English'), ('Explanation and elaboration papers', 'CHART Collaborative. Reporting guidelines for chatbot health advice studies: explanation and elaboration for the Chatbot Assessment Reporting Tool (CHART). BMJ. 2025; 390: e083305. PMID: [40750271](https://pubmed.ncbi.nlm.nih.gov/40750271/)\n\n \n\n'), ('Reporting guideline acronym', 'CHART'), ('Study design', 'Artificial intelligence/Machine learning studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'August 6, 2025')]"
22445,ELEVATE-GenAI,"Artificial intelligence/Machine learning studies, Economic evaluations", ,Whole report, , , ,"Fleurence RL, Dawoud D, Bian J, Higashi MK, Wang X, Xu H, Chhatwal J, Ayer T; ISPOR Working Group on Generative AI. ELEVATE-GenAI: Reporting Guidelines for the Use of Large Language Models in Health Economics and Outcomes Research: an ISPOR Working Group on Generative AI Report. Value Health. 2025","Fleurence RL, Dawoud D, Bian J, Higashi MK, Wang X, Xu H, Chhatwal J, Ayer T",Value Health,2025, , , , ,English,10.1016/j.jval.2025.06.018,40653157,https://pubmed.ncbi.nlm.nih.gov/40653157/, , , , , ,ELEVATE-GenAI,Structured guidance for reporting research using large language models (LLMs) in Health Economics and Outcomes Research, , , ,Read the full text of ELEVATE-GenAI., , , ,no,2025-07-31 19:52:49,2025-07-31 19:52:49,elevate-genai,"[('title', 'ELEVATE-GenAI'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Structured guidance for reporting research using large language models (LLMs) in Health Economics and Outcomes Research'), ('Full bibliographic reference', 'Fleurence RL, Dawoud D, Bian J, Higashi MK, Wang X, Xu H, Chhatwal J, Ayer T; ISPOR Working Group on Generative AI. ELEVATE-GenAI: Reporting Guidelines for the Use of Large Language Models in Health Economics and Outcomes Research: an ISPOR Working Group on Generative AI Report. Value Health. 2025'), ('Language', 'English'), ('DOI', '10.1016/j.jval.2025.06.018'), ('PubMed ID', '[40653157](https://pubmed.ncbi.nlm.nih.gov/40653157/)'), ('Primary guideline publication', 'Read the full text of [ELEVATE-GenAI](https://www.sciencedirect.com/science/article/abs/pii/S1098301525024556).'), ('Reporting guideline acronym', 'ELEVATE-GenAI'), ('Study design', 'Artificial intelligence/Machine learning studies, Economic evaluations'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'July 31, 2025')]"
22443,The LEADING guideline,Observational studies,Psychiatry,Whole report, , , ,"Eijsbroek VC, Kjell K, Schwartz HA, Boehnke JR, Fried EI, Klein DN, Gustafsson P, Augenstein I, Bossuyt PMM, Kjell ONE. The LEADING guideline: Reporting standards for expert panel, best-estimate diagnosis, and longitudinal expert all data (LEAD) methods. Compr Psychiatry. 2025; 141: 152603","Eijsbroek VC, Kjell K, Schwartz HA, Boehnke JR, Fried EI, Klein DN, Gustafsson P, Augenstein I, Bossuyt PMM, Kjell ONE.",Compr Psychiatry,2025,141, ,152603, ,English,10.1016/j.comppsych.2025.152603,40479924,https://pubmed.ncbi.nlm.nih.gov/40479924/,A reporting template can be found on the LEADING project website., , , ,https://www.leading-guideline.org,LEADING,"Reporting standards for expert panel, best-estimate diagnosis, and longitudinal expert all data methods.", , , ,Read the full text of the paper., , , ,no,2025-07-31 09:23:46,2025-07-31 09:23:46,the-leading-guideline,"[('title', 'The LEADING guideline'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting standards for expert panel, best-estimate diagnosis, and longitudinal expert all data methods.'), ('Full bibliographic reference', 'Eijsbroek VC, Kjell K, Schwartz HA, Boehnke JR, Fried EI, Klein DN, Gustafsson P, Augenstein I, Bossuyt PMM, Kjell ONE. The LEADING guideline: Reporting standards for expert panel, best-estimate diagnosis, and longitudinal expert all data (LEAD) methods. Compr Psychiatry. 2025; 141: 152603'), ('Language', 'English'), ('DOI', '10.1016/j.comppsych.2025.152603'), ('PubMed ID', '[40479924](https://pubmed.ncbi.nlm.nih.gov/40479924/)'), ('Relevant URLs\n\n(full-text if available)', 'A reporting template can be found on the LEADING project [website](https://www.leading-guideline.org/).'), ('Primary guideline publication', 'Read the full text of the [paper](https://www.sciencedirect.com/science/article/pii/S0010440X25000318).'), ('Reporting guideline website URL', '<https://www.leading-guideline.org>'), ('Reporting guideline acronym', 'LEADING'), ('Study design', 'Observational studies'), ('Clinical area', 'Psychiatry'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'July 31, 2025')]"
22433,Reporting guideline for the use of Generative Artificial intelligence tools in MEdical Research: the GAMER Statement,Artificial intelligence/Machine learning studies, ,Whole report, , , ,"Luo X, Tham YC, Giuffr\xe8 M, Ranisch R, Daher M, Lam K, Eriksen AV, Hsu CW, Ozaki A, Moraes FY, Khanna S, Su KP, Begagi? E, Bian Z, Chen Y, Estill J; GAMER Working Group. Reporting guideline for the use of Generative Artificial intelligence tools in MEdical Research: the GAMER Statement. BMJ Evid Based Med. 2025 May 13:bmjebm-2025-113825.","Luo X, Tham YC, Giuffr\xe8 M, Ranisch R, Daher M, Lam K, Eriksen AV, Hsu CW, Ozaki A, Moraes FY, Khanna S, Su KP, Begagi? E, Bian Z, Chen Y, Estill J;",BMJ Evid Based Med,2025, , , , , ,10.1136/bmjebm-2025-113825,40360239,https://pubmed.ncbi.nlm.nih.gov/40360239/, , , , , ,GAMER,Standardised guideline for generative artificial intelligence use in medical research,The GAMER Checklist is available in Chinese., , ,Read the full text of GAMER., , , ,no,2025-07-28 19:04:19,2025-07-28 19:08:03,reporting-guideline-for-the-use-of-generative-artificial-intelligence-tools-in-medical-research-the-gamer-statement,"[('title', 'Reporting guideline for the use of Generative Artificial intelligence tools in MEdical Research: the GAMER Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Standardised guideline for generative artificial intelligence use in medical research'), ('Full bibliographic reference', 'Luo X, Tham YC, Giuffrè M, Ranisch R, Daher M, Lam K, Eriksen AV, Hsu CW, Ozaki A, Moraes FY, Khanna S, Su KP, Begagić E, Bian Z, Chen Y, Estill J; GAMER Working Group. Reporting guideline for the use of Generative Artificial intelligence tools in MEdical Research: the GAMER Statement. BMJ Evid Based Med. 2025 May 13:bmjebm-2025-113825.'), ('DOI', '10.1136/bmjebm-2025-113825'), ('PubMed ID', '[40360239](https://pubmed.ncbi.nlm.nih.gov/40360239/)'), ('Primary guideline publication', 'Read the full text of [GAMER](https://ebm.bmj.com/content/early/2025/05/13/bmjebm-2025-113825.long).'), ('Availability in additional languages', 'The GAMER Checklist is available in [Chinese](https://www.equator-network.org/wp-content/uploads/2025/07/GAMER-checklist-Chinese-version.docx).'), ('Reporting guideline acronym', 'GAMER'), ('Study design', 'Artificial intelligence/Machine learning studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'July 28, 2025')]"
22414,Reporting guidelines for tear fluid research,"Experimental studies, Observational studies",Ophthalmology,Whole report, , , ,"Schmeetz J, van de Sande N, Rojas-Carabali W, Mergen B, Bonnet C, Boychev N, Cifuentes-Gonz\xe1lez C, Kessal K, Brignole-Baudouin F, Asbell P, Kilicaslan NA, Lengyel I, Ibanez IC, Agrawal R, Gijs M. International reporting guidelines for tear fluid research: A Delphi consensus. Cont Lens Anterior Eye 2025 [doi: 10.1016/j.clae.2025.102448]","Schmeetz J, van de Sande N, Rojas-Carabali W, Mergen B, Bonnet C, Boychev N, Cifuentes-Gonz\xe1lez C, Kessal K, Brignole-Baudouin F, Asbell P, Kilicaslan NA, Lengyel I, Ibanez IC, Agrawal R, Gijs M",Cont Lens Anterior Eye,2025, , , , , ,10.1016/j.clae.2025.102448,40484775, ,"Read the full text of the guideline.

The checklists can be downloaded TEAR-Reporting Guidelines.", , , , , ,Reporting guidelines for tear fluid research, , , , , , , ,no,2025-07-11 09:44:35,2025-07-11 09:44:35,reporting-guidelines-for-tear-fluid-research,"[('title', 'Reporting guidelines for tear fluid research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting guidelines for tear fluid research'), ('Full bibliographic reference', 'Schmeetz J, van de Sande N, Rojas-Carabali W, Mergen B, Bonnet C, Boychev N, Cifuentes-González C, Kessal K, Brignole-Baudouin F, Asbell P, Kilicaslan NA, Lengyel I, Ibanez IC, Agrawal R, Gijs M. International reporting guidelines for tear fluid research: A Delphi consensus. Cont Lens Anterior Eye 2025 [doi: 10.1016/j.clae.2025.102448]'), ('DOI', '10.1016/j.clae.2025.102448'), ('PubMed ID', '40484775'), ('Relevant URLs\n\n(full-text if available)', 'Read the full text of the [guideline](https://linkinghub.elsevier.com/retrieve/pii/S1367-0484(25)00082-7).\n\n \n\n The checklists can be downloaded [TEAR-Reporting Guidelines](https://www.equator-network.org/wp-content/uploads/2025/07/TEAR-Reporting-Guidelines.pdf).'), ('Study design', 'Experimental studies, Observational studies'), ('Clinical area', 'Ophthalmology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'July 11, 2025')]"
22367,DID-METAB Checklist,Observational studies,Nutrition and dietetics,Whole report, , , ,"Ferguson JJA, Clarke ED, Stanford J, G\xf3mez-Mart\xedn M, Jakstas T, Collins CE; DID?METAB Delphi Working Group Authors. Strengthening the reporting of diet item details in feeding studies measuring the dietary metabolome: The DID-METAB core outcome set statement. Eur J Clin Invest. 2025l; 55:e70030.","Ferguson JJA, Clarke ED, Stanford J, G\xf3mez-Mart\xedn M, Jakstas T, Collins CE",Eur J Clin Invest,2025,55,7,e70030,2025,English,10.1111/eci.70030,40189732,https://pubmed.ncbi.nlm.nih.gov/40189732/,"Read the full text of DID-METAB. The checklist is in Table 1 of the paper.

Read the full text of the Explanation and Elaboration paper.","Ferguson JJ, Clarke ED, Stanford J, G\xf3mez-Mart\xedn M, Jakstas T, Collins CE; DID-METAB Delphi Working Group. Diet Item Details: Reporting Checklist for Feeding Studies Measuring the Dietary Metabolome (DID-METAB Checklist) - Explanation and Elaboration Report on the Development of the Checklist by the DID-METAB Delphi Working Group. Adv Nutr. 2025; 16:100420. doi: 10.1016/j.advnut.2025.100420.", , , ,DID-METAB,"The DID-\xadMETAB Checklist can be used for reporting metabolomic data obtained from biospecimens (e.g., saliva, urine, blood, stool) collected within human feeding studies in which the dietary intervention involves any of the following: 1. Provision of a single food; 2. Partial diet provision?only some food/beverages are provided; 3. Whole diet provision?all foods/beverages are provided; 4. Dietary prescription *?nutrition counselling and/or educational material provided to support self-\xad implementation of a dietary intervention.", , , , , , , ,no,2025-06-20 09:21:57,2025-06-20 09:21:57,did-metab-checklist,"[('title', 'DID-METAB Checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'The DID-\xadMETAB Checklist can be used for reporting metabolomic data obtained from biospecimens (e.g., saliva, urine, blood, stool) collected within human feeding studies in which the dietary intervention involves any of the following: 1. Provision of a single food; 2. Partial diet provision—only some food/beverages are provided; 3. Whole diet provision—all foods/beverages are provided; 4. Dietary prescription \\*—nutrition counselling and/or educational material provided to support self-\xad implementation of a dietary intervention.'), ('Full bibliographic reference', 'Ferguson JJA, Clarke ED, Stanford J, Gómez-Martín M, Jakstas T, Collins CE; DID‐METAB Delphi Working Group Authors. Strengthening the reporting of diet item details in feeding studies measuring the dietary metabolome: The DID-METAB core outcome set statement. Eur J Clin Invest. 2025l; 55:e70030.'), ('Date of publication / Ahead of print date', '2025'), ('Language', 'English'), ('DOI', '10.1111/eci.70030'), ('PubMed ID', '[40189732](https://pubmed.ncbi.nlm.nih.gov/40189732/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full text](https://onlinelibrary.wiley.com/doi/10.1111/eci.70030) of DID-METAB. The checklist is in Table 1 of the paper.\n\n \n\n Read the full text of the Explanation and Elaboration paper.'), ('Explanation and elaboration papers', 'Ferguson JJ, Clarke ED, Stanford J, Gómez-Martín M, Jakstas T, Collins CE; DID-METAB Delphi Working Group. Diet Item Details: Reporting Checklist for Feeding Studies Measuring the Dietary Metabolome (DID-METAB Checklist) - Explanation and Elaboration Report on the Development of the Checklist by the DID-METAB Delphi Working Group. Adv Nutr. 2025; 16:100420. doi: 10.1016/j.advnut.2025.100420.'), ('Reporting guideline acronym', 'DID-METAB'), ('Study design', 'Observational studies'), ('Clinical area', 'Nutrition and dietetics'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'June 20, 2025')]"
22365,Endo-STAR,"Clinical trials, Experimental studies, Study protocols", ,Protocol-whole report, , , ,"Zywicka EM, Moore AJ, Twine C, Behrendt CA, Bosiers M, Brodmann M, Choke E, deBorst GJ, Diamantopoulos A, Enzmann F, Farber A, Ansel G, Gattuso D, Goh GS, Yann G, Jansen S, Landini M, Lejay A, Lichtenberg M, Menard M, Mezes P, Mills J, Nixon J, Nordanstig J, O'Connell K, Ozdemir B, Patrone L, Puppala S, Saratzis A, Secemsky EA, Sigrid N, Stavroulakis K, Steiner S, Teraa M, Van Herzeele I, Venermo M, Zeller T, Mouton R, Hinchliffe RJ. Endovascular treatment of peripheral arterial disease: Endo-STAR framework for the design, conduct, and reporting of trials. Br J Surg. 2025; 112: 4.","Zywicka EM, Moore AJ, Twine C, Behrendt CA, Bosiers M, Brodmann M, Choke E, deBorst GJ, Diamantopoulos A, Enzmann F, Farber A, Ansel G, Gattuso D, Goh GS, Yann G, Jansen S, Landini M, Lejay A, Lichtenberg M, Menard M, Mezes P, Mills J, Nixon J, Nordanstig J, O'Connell K, Ozdemir B, Patrone L, Puppala S, Saratzis A, Secemsky EA, Sigrid N, Stavroulakis K, Steiner S, Teraa M, Van Herzeele I, Venermo M, Zeller T, Mouton R, Hinchliffe RJ.",Br J Surg,2025,112, ,4,2025,English,10.1093/bjs/znaf020,40241414,https://pubmed.ncbi.nlm.nih.gov/40241414/,"Read the full text of Endo-STAR.

The Endo-STAR checklists can be found on the project website.", , , , , ,Reporting of future clinical trials for infrainguinal endovascular treatments of peripheral arterial disease., , , , , , , ,no,2025-06-20 09:09:33,2025-06-20 09:09:33,endo-star,"[('title', 'Endo -STAR'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of future clinical trials for infrainguinal endovascular treatments of peripheral arterial disease.'), ('Full bibliographic reference', ""Zywicka EM, Moore AJ, Twine C, Behrendt CA, Bosiers M, Brodmann M, Choke E, deBorst GJ, Diamantopoulos A, Enzmann F, Farber A, Ansel G, Gattuso D, Goh GS, Yann G, Jansen S, Landini M, Lejay A, Lichtenberg M, Menard M, Mezes P, Mills J, Nixon J, Nordanstig J, O'Connell K, Ozdemir B, Patrone L, Puppala S, Saratzis A, Secemsky EA, Sigrid N, Stavroulakis K, Steiner S, Teraa M, Van Herzeele I, Venermo M, Zeller T, Mouton R, Hinchliffe RJ. Endovascular treatment of peripheral arterial disease: Endo-STAR framework for the design, conduct, and reporting of trials. Br J Surg. 2025; 112: 4.""), ('Date of publication / Ahead of print date', '2025'), ('Language', 'English'), ('DOI', '10.1093/bjs/znaf020'), ('PubMed ID', '[40241414](https://pubmed.ncbi.nlm.nih.gov/40241414/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full text](https://academic.oup.com/bjs/article/112/4/znaf020/8114921#supplementary-data) of Endo-STAR.\n\n \n\n The Endo-STAR checklists can be found on the [project website](https://endo-star.com/).'), ('Study design', 'Clinical trials, Experimental studies, Study protocols'), ('Applies to the whole report or to individual sections of the report?', 'Protocol-whole report'), ('Record last updated on', 'June 20, 2025')]"
22363,"Development, Evaluation, and Assessment of Large Language Models (DEAL) Checklist","Artificial intelligence/Machine learning studies, Diagnostic and prognostic studies", ,Whole report, , , ,"Tripathi S, Alkhulaifat D, Doo FX, Rajpurkar P, McBeth R, Daye D, Cook TS. Development, Evaluation, and Assessment of Large Language Models (DEAL) Checklist: A Technical Report. NEJM AI. 2025; 2: 6.","Tripathi S, Alkhulaifat D, Doo FX, Rajpurkar P, McBeth R, Daye D, Cook TS.",NEJM AI,2025,2, ,6,2025,English,10.1056/AIp2401106, , ,"Read the full text of DEAL.

The DEAL checklists can be found in the supplementary material.", , , , ,DEAL,"DEAL-A: Intended for studies involving substantial LLM development, advanced techniques, or comprehensive fine-tuning

DEAL-B: Tailored for more straightforward applications utilizing pretrained LLMs with minimal adjustments or a focus on prompt engineering", , , , , , , ,no,2025-06-20 08:59:41,2025-06-20 08:59:41,development-evaluation-and-assessment-of-large-language-models-deal-checklist,"[('title', 'Development, Evaluation, and Assessment of Large Language Models (DEAL) Checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'DEAL-A: Intended for studies involving substantial LLM development, advanced techniques, or comprehensive fine-tuning\n\n \n\n DEAL-B: Tailored for more straightforward applications utilizing pretrained LLMs with minimal adjustments or a focus on prompt engineering'), ('Full bibliographic reference', 'Tripathi S, Alkhulaifat D, Doo FX, Rajpurkar P, McBeth R, Daye D, Cook TS. Development, Evaluation, and Assessment of Large Language Models (DEAL) Checklist: A Technical Report. NEJM AI. 2025; 2: 6.'), ('Date of publication / Ahead of print date', '2025'), ('Language', 'English'), ('DOI', '10.1056/AIp2401106'), ('Relevant URLs\n\n(full-text if available)', '[Read the full text](https://ai.nejm.org/doi/full/10.1056/AIp2401106) of DEAL.\n\n \n\n[The DEAL checklists](https://ai.nejm.org/doi/suppl/10.1056/AIp2401106/suppl_file/aip2401106_appendix.pdf) can be found in the supplementary material.'), ('Reporting guideline acronym', 'DEAL'), ('Study design', 'Artificial intelligence/Machine learning studies, Diagnostic and prognostic studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'June 20, 2025')]"
22361,"Guidelines for reporting artificial intelligence studies in medicines, pharmacotherapy, and pharmaceutical services: MedinAI development, validation and statement",Artificial intelligence/Machine learning studies, , , , , ,"Bottacin WE, Teles de Souza R, Torelli Reis WC, Carolina Melchiors A. Guidelines for reporting artificial intelligence studies in medicines, pharmacotherapy, and pharmaceutical services: MedinAI development, validation and statement. Int J Clin Pharm. 2025.","Bottacin WE, Teles de Souza R, Torelli Reis WC, Carolina Melchiors A.",Int J Clin Pharm,2025, , , ,2025,English,10.1007/s11096-025-01905-3,40202573,https://pubmed.ncbi.nlm.nih.gov/40202573/,"Read the full text of MedinAI.

The MedinAI checklist is available in the supplementary material.

Read the full text of the Explanation and Elaboration.","Bottacin WE, Teles de Souza R, Torelli Reis WC, Carolina Melchiors A.Explanation and elaboration of MedinAI: guidelines for reporting artificial intelligence studies in medicines, pharmacotherapy, and pharmaceutical services. Int J Clin Pharm. 2025.", , , ,MedinAI,"Reporting AI studies in medicines, pharmacotherapy, and pharmaceutical services", , , , , , , ,no,2025-06-19 08:52:07,2025-06-19 08:52:07,guidelines-for-reporting-artificial-intelligence-studies-in-medicines-pharmacotherapy-and-pharmaceutical-services-medinai-development-validation-and-statement,"[('title', 'Guidelines for reporting artificial intelligence studies in medicines, pharmacotherapy, and pharmaceutical services: Medin AI development, validation and statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting AI studies in medicines, pharmacotherapy, and pharmaceutical services'), ('Full bibliographic reference', 'Bottacin WE, Teles de Souza R, Torelli Reis WC, Carolina Melchiors A. Guidelines for reporting artificial intelligence studies in medicines, pharmacotherapy, and pharmaceutical services: MedinAI development, validation and statement. Int J Clin Pharm. 2025.'), ('Date of publication / Ahead of print date', '2025'), ('Language', 'English'), ('DOI', '10.1007/s11096-025-01905-3'), ('PubMed ID', '[40202573](https://pubmed.ncbi.nlm.nih.gov/40202573/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full text](https://link.springer.com/article/10.1007/s11096-025-01905-3) of MedinAI.\n\n \n\n The [MedinAI checklist](https://static-content.springer.com/esm/art%3A10.1007%2Fs11096-025-01905-3/MediaObjects/11096_2025_1905_MOESM2_ESM.docx) is available in the supplementary material.\n\n \n\n[Read the full text](https://link.springer.com/article/10.1007/s11096-025-01906-2) of the Explanation and Elaboration.'), ('Explanation and elaboration papers', 'Bottacin WE, Teles de Souza R, Torelli Reis WC, Carolina Melchiors A.Explanation and elaboration of MedinAI: guidelines for reporting artificial intelligence studies in medicines, pharmacotherapy, and pharmaceutical services. Int J Clin Pharm. 2025.'), ('Reporting guideline acronym', 'MedinAI'), ('Study design', 'Artificial intelligence/Machine learning studies'), ('Record last updated on', 'June 19, 2025')]"
22358,Clinician-informed explainable artificial intelligence evaluation checklist with metrics (CLIX-M) for AI-powered clinical decision support systems,"Artificial intelligence/Machine learning studies, Diagnostic and prognostic studies, Observational studies", ,Whole report, , , ,"Brankovic A, Cook D, Rahman J, Delaforce A, Li J, Magrabi F, Cabitza F, Coiera E, Bradford D. Clinician-informed XAI evaluation checklist with metrics (CLIX-M) for AI-powered clinical decision support systems. NPJ Digital Medicine. 2025; 8: 364.","Brankovic A, Cook D, Rahman J, Delaforce A, Li J, Magrabi F, Cabitza F, Coiera E, Bradford D.",NPJ Digital Medicine,2025,8, ,364, ,English,10.1038/s41746-025-01764-2,40517152,https://pubmed.ncbi.nlm.nih.gov/40517152/,"Read the full text of CLIX-M.

The CLIX-M checklist is available in the supplementary information.", , , , ,CLIX-M,Studies reporting the development and evaluation phases of explainable artificial intelligence (AI) component in AI-powered CDSS development, , , , , , , ,no,2025-06-19 07:36:35,2025-06-19 07:36:35,clinician-informed-explainable-artificial-intelligence-evaluation-checklist-with-metrics-clix-m-for-ai-powered-clinical-decision-support-systems,"[('title', 'Clinician-informed explainable artificial intelligence evaluation checklist with metrics (CLIX-M) for AI-powered clinical decision support systems'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Studies reporting the development and evaluation phases of explainable artificial intelligence (AI) component in AI-powered CDSS development'), ('Full bibliographic reference', 'Brankovic A, Cook D, Rahman J, Delaforce A, Li J, Magrabi F, Cabitza F, Coiera E, Bradford D. Clinician-informed XAI evaluation checklist with metrics (CLIX-M) for AI-powered clinical decision support systems. NPJ Digital Medicine. 2025; 8: 364.'), ('Language', 'English'), ('DOI', '10.1038/s41746-025-01764-2'), ('PubMed ID', '[40517152](https://pubmed.ncbi.nlm.nih.gov/40517152/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full text](https://www.nature.com/articles/s41746-025-01764-2) of CLIX-M.\n\n \n\n The CLIX-M checklist is available in the [supplementary information.](https://static-content.springer.com/esm/art%3A10.1038%2Fs41746-025-01764-2/MediaObjects/41746_2025_1764_MOESM1_ESM.docx)'), ('Reporting guideline acronym', 'CLIX-M'), ('Study design', 'Artificial intelligence/Machine learning studies, Diagnostic and prognostic studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'June 19, 2025')]"
22356,The GREENBEAN checklist for reporting studies evaluating the effectiveness of EEG-based biomarkers,Diagnostic and prognostic studies, ,Whole report, , , ,"Ewen JB, Bablioni C, Collins GS, Ethridge LE, Gotman J, Ikeda A, Karoly PJ, Potter WZ, Rampp S, Seeck M, Beniczky S. The GREENBEAN checklist for reporting studies evaluating the effectiveness of EEG-based biomarkers. Clinical Neurophysiology. 2025; 176: 2110777.","Ewen JB, Bablioni C, Collins GS, Ethridge LE, Gotman J, Ikeda A, Karoly PJ, Potter WZ, Rampp S, Seeck M, Beniczky S.",Clinical Neurophysiology,2025,176, ,2110777,2025,English,10.1016/j.clinph.2025.2110777, , ,Read the full text of GREENBEAN.,"The GREENBEAN checklist can be downloaded from here.

The explanation and elaboration can be found in the supplementary material of the article.", , , ,GREENBEAN,Reporting of studies evaluating the effectiveness of EEG-based biomarkers., , , , , , , ,no,2025-06-19 07:21:58,2025-07-09 06:45:39,the-greenbean-checklist-for-reporting-studies-evaluating-the-effectiveness-of-eeg-based-biomarkers,"[('title', 'The GREENBEAN checklist for reporting studies evaluating the effectiveness of EEG-based biomarkers'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of studies evaluating the effectiveness of EEG-based biomarkers.'), ('Full bibliographic reference', 'Ewen JB, Bablioni C, Collins GS, Ethridge LE, Gotman J, Ikeda A, Karoly PJ, Potter WZ, Rampp S, Seeck M, Beniczky S. The GREENBEAN checklist for reporting studies evaluating the effectiveness of EEG-based biomarkers. Clinical Neurophysiology. 2025; 176: 2110777.'), ('Date of publication / Ahead of print date', '2025'), ('Language', 'English'), ('DOI', '10.1016/j.clinph.2025.2110777'), ('Relevant URLs\n\n(full-text if available)', '[Read the full text](https://www.sciencedirect.com/science/article/pii/S1388245725006297) of GREENBEAN.'), ('Explanation and elaboration papers', 'The GREENBEAN checklist can be downloaded from [here](https://www.equator-network.org/wp-content/uploads/2025/06/GREENBEAN-Checklist.docx).\n\n \n\n The explanation and elaboration can be found in the [supplementary material](https://ars.els-cdn.com/content/image/1-s2.0-S1388245725006297-mmc1.docx) of the article.'), ('Reporting guideline acronym', 'GREENBEAN'), ('Study design', 'Diagnostic and prognostic studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'July 9, 2025')]"
22278,SQUIRE-SIM (Standards for Quality Improvement Reporting Excellence for SIMulation): Publication Guidelines for Simulation-Based Quality Improvement Projects,Quality improvement studies, ,Whole report, ,"healthcare improvement, healthcare improvements, improvement, quality, quality improvement, quality improvements, simulate, simulated, simulation, simulations, SQUIRE extension, SQUIRE-SIM", ,"Stone KP, Rutman L, Calhoun AW, Reid J, Maa T, Bajaj K, Auerbach MA, Cheng A, Davies L, Deutsch E, Harwayne-Gidansky I, Kessler DO, Ogrinc G, Patterson M, Thomas A, Doughty C; And for the International Network in Simulation-Based Innovation, Research and Education (INSPIRE) SQUIRE-SIM Reporting Guidelines Investigators. SQUIRE-SIM (Standards for Quality Improvement Reporting Excellence for SIMulation): Publication Guidelines for Simulation-Based Quality Improvement Projects. Simul Healthc. 2024.

","Stone KP, Rutman L, Calhoun AW, Reid J, Maa T, Bajaj K, Auerbach MA, Cheng A, Davies L, Deutsch E, Harwayne-Gidansky I, Kessler DO, Ogrinc G, Patterson M, Thomas A, Doughty C; And for the International Network in Simulation-Based Innovation, Research and Education (INSPIRE) SQUIRE-SIM Reporting Guidelines Investigators.",Simulation in Healthcare [Simul Healthc.],2024, , , , ,English, ,39162794,https://pubmed.ncbi.nlm.nih.gov/39162794/, , , ,"Generic
SQUIRE 2.0: Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.

BMJ Qual Saf. 2015. PMID: 26369893
J Nurs Care Qual. 2015. PMID: 26429125
Am J Crit Care. 2015. PMID: 26523003
Perm J. 2015. PMID: 26517437
J Surg Res. 2015. PMID: 26515734
J Contin Educ Nurs. 2015. PMID: 26509402
J Am Coll Surg. 2016;222(3):317-323. PMID: 26385723

Specialised
SQUIRE-EDU: Ogrinc G, Armstrong GE, Dolansky MA, Singh MK, Davies L. SQUIRE-EDU (Standards for QUality Improvement Reporting Excellence in Education): Publication Guidelines for Educational Improvement. Acad Med. 2019 Oct;94(10):1461-1470. PMID: 30998575

",http://www.squire-statement.org/,SQUIRE-SIM,Reporting on simulation-specific elements of healthcare improvement research., , , , , , , ,yes,2025-03-26 14:46:07,2025-03-26 14:46:07,squire-sim-standards-for-quality-improvement-reporting-excellence-for-simulation-publication-guidelines-for-simulation-based-quality-improvement-projects,"[('title', 'SQUIRE-SIM  (Standards for Quality Improvement Reporting Excellence for SIMulation) : Publication Guidelines for Simulation -Based Quality Improvement Projects'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting on simulation-specific elements of healthcare improvement research.'), ('Full bibliographic reference', 'Stone KP, Rutman L, Calhoun AW, Reid J, Maa T, Bajaj K, Auerbach MA, Cheng A, Davies L, Deutsch E, Harwayne-Gidansky I, Kessler DO, Ogrinc G, Patterson M, Thomas A, Doughty C; And for the International Network in Simulation-Based Innovation, Research and Education (INSPIRE) SQUIRE-SIM Reporting Guidelines Investigators. SQUIRE-SIM (Standards for Quality Improvement Reporting Excellence for SIMulation): Publication Guidelines for Simulation-Based Quality Improvement Projects. Simul Healthc. 2024.\n\n \n\n'), ('Language', 'English'), ('PubMed ID', '[39162794](https://pubmed.ncbi.nlm.nih.gov/39162794/)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**SQUIRE 2.0**](https://www.equator-network.org/reporting-guidelines/squire/): Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.\n\n \n\n BMJ Qual Saf. 2015. PMID: [26369893](http://www.ncbi.nlm.nih.gov/pubmed/26369893)\n\n J Nurs Care Qual. 2015. PMID: [26429125](http://www.ncbi.nlm.nih.gov/pubmed/26429125)\n\n Am J Crit Care. 2015. PMID: [26523003](http://www.ncbi.nlm.nih.gov/pubmed/26523003)\n\n Perm J. 2015. PMID: [26517437](http://www.ncbi.nlm.nih.gov/pubmed/26517437)\n\n J Surg Res. 2015. PMID: 26515734\n\n J Contin Educ Nurs. 2015. PMID: [26509402](http://www.ncbi.nlm.nih.gov/pubmed/26509402)\n\n J Am Coll Surg. 2016;222(3):317-323. PMID: [26385723](http://www.ncbi.nlm.nih.gov/pubmed/26385723)\n\n \n\n**Specialised**\n\n[**SQUIRE-EDU**](https://www.equator-network.org/reporting-guidelines/squire-edu-standards-for-quality-improvement-reporting-excellence-in-education-publication-guidelines-for-educational-improvement/): Ogrinc G, Armstrong GE, Dolansky MA, Singh MK, Davies L. SQUIRE-EDU (Standards for QUality Improvement Reporting Excellence in Education): Publication Guidelines for Educational Improvement. Acad Med. 2019 Oct;94(10):1461-1470. PMID: [30998575](https://pubmed.ncbi.nlm.nih.gov/30998575/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.squire-statement.org/>'), ('Reporting guideline acronym', 'SQUIRE-SIM'), ('Study design', 'Quality improvement studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'March 26, 2025')]"
22274,Development of GROVE: A Guideline for RepOrting Vignette Experiments conducted in a healthcare context,Experimental studies, ,"Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)", ,"checklist, checklists, experiment, experimental, experimental studies, experimental study, experiments, GROVE, GROVE checklist, scenario, scenarios, scripted scenario, scripted scenarios, vignette, vignette experiment, vignette experiments, vignettes", ,"Hillen MA, Visser LNC, Labrie NHM, van Vliet LM, Saha S, Blanch-Hartigan D, Smets EMA; GROVE Working group. Development of GROVE: A Guideline for RepOrting Vignette Experiments conducted in a healthcare context. Patient Educ Couns. 2025;136:108750.","Hillen MA, Visser LNC, Labrie NHM, van Vliet LM, Saha S, Blanch-Hartigan D, Smets EMA; GROVE Working group.",Patient Education and Counseling [Patient Educ Couns.],2025,136, ,108750, ,English, ,40107182,https://pubmed.ncbi.nlm.nih.gov/40107182/, , , , , ,GROVE,"Reporting experimental vignette studies.



GROVE Checklist (Word)

", , , , , , , ,no,2025-03-26 12:07:13,2025-03-26 12:08:22,development-of-grove-a-guideline-for-reporting-vignette-experiments-conducted-in-a-healthcare-context,"[('title', 'Development of GROVE : A Guideline for RepOrting Vignette Experiments conducted in a healthcare context'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting experimental vignette studies.\n\n \n\n \xa0\n\n \n\n[GROVE Checklist (Word)](https://www.equator-network.org/wp-content/uploads/2025/03/GROVE-Checklist.docx)\n\n \n\n'), ('Full bibliographic reference', 'Hillen MA, Visser LNC, Labrie NHM, van Vliet LM, Saha S, Blanch-Hartigan D, Smets EMA; GROVE Working group. Development of GROVE: A Guideline for RepOrting Vignette Experiments conducted in a healthcare context. Patient Educ Couns. 2025;136:108750.'), ('Language', 'English'), ('PubMed ID', '[40107182](https://pubmed.ncbi.nlm.nih.gov/40107182/)'), ('Reporting guideline acronym', 'GROVE'), ('Study design', 'Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'March 26, 2025')]"
22270,ITRUSST consensus on standardised reporting for transcranial ultrasound stimulation,"Animal pre-clinical research, Observational studies","Neurology, Radiology",Intervention (exposure), ,"checklist, checklists, ITRUSST, ITRUSST consensus, low intensity TUS, neurological, neurology, observation, observational, pre clinical, radiological, radiology, transcranial, transcranial ultrasound, transcranial ultrasound neuromodulation, transcranial ultrasound stimulation, TUS, ultrasound", ,"Martin E, Aubry JF, Schafer M, Verhagen L, Treeby B, Pauly KB. ITRUSST consensus on standardised reporting for transcranial ultrasound stimulation. Brain Stimul. 2024;17(3):607-615.

","Martin E, Aubry JF, Schafer M, Verhagen L, Treeby B, Pauly KB.",Brain Stimulation [ Brain Stimul.],2024,17,3,607-615, ,English, ,38670224,https://pubmed.ncbi.nlm.nih.gov/38670224/, , , , , ,ITRUSST,Reporting of low intensity transcranial ultrasound stimulation (TUS) studies., , , , , , , ,no,2025-03-12 15:37:17,2025-03-12 15:38:17,itrusst-consensus-on-standardised-reporting-for-transcranial-ultrasound-stimulation,"[('title', 'ITRUSST consensus on standardised reporting for transcranial ultrasound stimulation'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of low intensity transcranial ultrasound stimulation (TUS) studies.'), ('Full bibliographic reference', 'Martin E, Aubry JF, Schafer M, Verhagen L, Treeby B, Pauly KB. ITRUSST consensus on standardised reporting for transcranial ultrasound stimulation. Brain Stimul. 2024;17(3):607-615.\n\n \n\n'), ('Language', 'English'), ('PubMed ID', '[38670224](https://pubmed.ncbi.nlm.nih.gov/38670224/)'), ('Reporting guideline acronym', 'ITRUSST'), ('Study design', 'Animal pre-clinical research, Observational studies'), ('Clinical area', 'Neurology, Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'March 12, 2025')]"
22268,Standardised reporting of burden of disease studies: the STROBOD statement,Observational studies,Public health,Whole report, ,"BOD, burden of disease, checklist, checklists, DALY, disability, Disability-Adjusted Life Year, Disability-Adjusted Life Years, epidemiological, epidemiology, life expectancy, life years, observation, observational, population, population health, public, public health, STROBOD, STROBOD checklist, STROBOD Statement, Years Lost due to Disability, Years of Life Lost, YLD, YLL", ,"Devleesschauwer B, Charalampous P, Gorasso V, Assun\xe7\xe3o R, Hilderink H, Idavain J, Lesnik T, Santric-Milicevic M, Pallari E, Pires SM, Plass D, Wyper GMA, Von der Lippe E, Haagsma JA. Standardised reporting of burden of disease studies: the STROBOD statement. Popul Health Metr. 2024;22(1):28.

","Devleesschauwer B, Charalampous P, Gorasso V, Assun\xe7\xe3o R, Hilderink H, Idavain J, Lesnik T, Santric-Milicevic M, Pallari E, Pires SM, Plass D, Wyper GMA, Von der Lippe E, Haagsma JA.",Population Health Metrics [Popul Health Metr.],2024,22,1,28, ,English, ,39375690,https://pubmed.ncbi.nlm.nih.gov/39375690/, , , , , ,STROBOD,Reporting of burden of disease (BOD) studies., , , , , , , ,no,2025-03-12 11:42:23,2025-03-12 11:42:23,standardised-reporting-of-burden-of-disease-studies-the-strobod-statement,"[('title', 'Standardised reporting of burden of disease studies: the STROBOD statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of burden of disease (BOD) studies.'), ('Full bibliographic reference', 'Devleesschauwer B, Charalampous P, Gorasso V, Assunção R, Hilderink H, Idavain J, Lesnik T, Santric-Milicevic M, Pallari E, Pires SM, Plass D, Wyper GMA, Von der Lippe E, Haagsma JA. Standardised reporting of burden of disease studies: the STROBOD statement. Popul Health Metr. 2024;22(1):28.\n\n \n\n'), ('Language', 'English'), ('PubMed ID', '[39375690](https://pubmed.ncbi.nlm.nih.gov/39375690/)'), ('Reporting guideline acronym', 'STROBOD'), ('Study design', 'Observational studies'), ('Clinical area', 'Public health'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'March 12, 2025')]"
22265,Development of a Reporting Guideline for Trochim?s Concept Mapping,Mixed methods studies, ,Whole report, ,"cluster map, clustering, concept map, concept mapping, ConMapT, GCM, group concept mapping, map, mapping, mixed method, mixed methods, Trochim, Trochim?s concept mapping", ,"Pantha S, Jones M, Gray R. Development of a Reporting Guideline for Trochim?s Concept Mapping. Methods Protoc. 2025;8(2):24.","Pantha S, Jones M, Gray R.",Methods and Protocols [Methods Protoc.],2025,8,2,24, ,English, , , ,"Read the full-text of this reporting guideline.

", , , , ,ConMapT,Reporting of concept mapping research., ,"Read the protocol for the development of this reporting guideline.

Read the systematic review that informed the development of this reporting guideline.

", , , , , ,no,2025-03-11 16:38:03,2025-03-11 16:40:30,development-of-a-reporting-guideline-for-trochims-concept-mapping,"[('title', 'Development of a Reporting Guideline for Trochim’s Concept Mapping'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of concept mapping research.'), ('Full bibliographic reference', 'Pantha S, Jones M, Gray R. Development of a Reporting Guideline for Trochim’s Concept Mapping. Methods Protoc. 2025;8(2):24.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.mdpi.com/2409-9279/8/2/24) of this reporting guideline.\n\n \n\n'), ('Reporting guideline acronym', 'ConMapT'), ('Study design', 'Mixed methods studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', '[Read the protocol](https://pubmed.ncbi.nlm.nih.gov/35742523/) for the development of this reporting guideline.\n\n \n\n[Read the systematic review](https://pubmed.ncbi.nlm.nih.gov/37888033/) that informed the development of this reporting guideline.\n\n \n\n'), ('Record last updated on', 'March 11, 2025')]"
22243,Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration,"Clinical trials, Experimental studies", ,Whole report, ,"checklist, checklists, clinical trial, clinical trials, cluster, cluster randomised crossover trial, cluster randomised crossover trials, cluster randomized crossover trial, cluster randomized crossover trials, clusters, CONSORT CRXO, CONSORT CRXO checklist, CONSORT CRXO extension, CONSORT extension, crossing, crossover, CRXO, CRXO trial, CRXO trials, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472.

","McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB.",BMJ.,2025,388, ,e080472, ,English, ,39761979,https://pubmed.ncbi.nlm.nih.gov/39761979/,"Read the full-text of the CONSORT CRXO reporting guideline.

", , ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster: Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal: Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts: Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture: MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738. PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

", ,CONSORT CRXO,Reporting of cluster randomised crossover trials., ,"Arnup SJ, Forbes AB, Kahan BC, Morgan KE, McKenzie JE. The quality of reporting in cluster randomised crossover trials: proposal for reporting items and an assessment of reporting quality. Trials. 2016; 17(1):575. PMID: 27923384

", , , , , ,yes,2025-02-14 11:03:54,2025-05-30 09:27:54,reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration,"[('title', 'Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of cluster randomised crossover trials.'), ('Full bibliographic reference', 'McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472.\n\n \n\n'), ('Language', 'English'), ('PubMed ID', '[39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.bmj.com/content/388/bmj-2024-080472) of the CONSORT CRXO reporting guideline.\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](https://www.equator-network.org/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](https://www.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](https://www.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](https://www.equator-network.org/reporting-guidelines/consort-cluster/): Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](https://www.equator-network.org/reporting-guidelines/consort-herbal/): Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](https://www.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](https://www.equator-network.org/reporting-guidelines/consort-abstracts/): Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](https://www.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](https://www.equator-network.org/reporting-guidelines/consort-stricta/): MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](https://www.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](https://www.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738. PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](https://www.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](https://www.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](https://www.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](https://www.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](https://www.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://www.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](https://www.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](https://www.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](https://www.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](https://www.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](https://www.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://www.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://www.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://www.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://www.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n'), ('Reporting guideline acronym', 'CONSORT CRXO'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Arnup SJ, Forbes AB, Kahan BC, Morgan KE, McKenzie JE. The quality of reporting in cluster randomised crossover trials: proposal for reporting items and an assessment of reporting quality. Trials. 2016; 17(1):575. PMID: [27923384](https://pubmed.ncbi.nlm.nih.gov/27923384/)\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
22207,Guidelines for Reporting Oral Epidemiologic Studies to Inform Burden Estimation (GROESBE),Observational studies,Dentistry,Whole report, ,"checklist, checklists, dental caries, edentulism, epidemiologic, epidemiology, GROESBE, GROESBE checklist, GROESBE guideline, GROESBE guidelines, Guidelines for Reporting Oral Epidemiologic Studies to Inform Burden Estimation, mouth, observation, observational, observational studies, observational study, oral, periodontal, periodontal disease, periodontal diseases, periodontitis, tooth loss", ,"Bernab\xe9 E, Salomon-Ibarra CC, Marcenes W. Guidelines for Reporting Oral Epidemiologic Studies to Inform Burden Estimation (GROESBE). J Dent Res. 2025;104(2):140-146.","Bernab\xe9 E, Salomon-Ibarra CC, Marcenes W.",Journal of Dental Research [J Dent Res.],2025,104,2,140-146, ,English, ,39639484,https://pubmed.ncbi.nlm.nih.gov/39639484/, , , , , ,GROESBE,"Reporting of descriptive oral epidemiologic studies of common oral conditions.

", , , , , , , ,no,2025-02-07 16:28:14,2025-02-07 16:28:14,guidelines-for-reporting-oral-epidemiologic-studies-to-inform-burden-estimation-groesbe,"[('title', 'Guidelines for Reporting Oral Epidemiologic Studies to Inform Burden Estimation (GROESBE)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of descriptive oral epidemiologic studies of common oral conditions.\n\n \n\n'), ('Full bibliographic reference', 'Bernabé E, Salomon-Ibarra CC, Marcenes W. Guidelines for Reporting Oral Epidemiologic Studies to Inform Burden Estimation (GROESBE). J Dent Res. 2025;104(2):140-146.'), ('Language', 'English'), ('PubMed ID', '[39639484](https://pubmed.ncbi.nlm.nih.gov/39639484/)'), ('Reporting guideline acronym', 'GROESBE'), ('Study design', 'Observational studies'), ('Clinical area', 'Dentistry'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'February 7, 2025')]"
22183,Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Whole report, ,"checklist, checklists, living, living review, living reviews, living systematic review, living systematic reviews, LSR, LSRs, PRISMA 2020 statement for living systematic reviews, PRISMA 2020 statement for LSRs, PRISMA extension, PRISMA-LSR, PRISMA-LSR checklist, review, reviews, systematic review, systematic reviews", ,"Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183.","Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group.",BMJ.,2024,387, ,e079183, ,English, ,39562017,https://pubmed.ncbi.nlm.nih.gov/39562017/,"Read the full-text of the PRISMA-LSR reporting guideline.

", , ,"Generic
PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

Specialised
PRISMA-Equity: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: 23222917

Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.
Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

PRISMA-Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.

PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246

PRISMA-IPD: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: 25919529

PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634

PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668

PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement &amp; Checklist. J Clin Epidemiol. 2017. PMID: 28720516

PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: 29362800

PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033

PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367

PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791

PRISMA-CHM: Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: 32907365

PRISMA-M 2020: Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: 33100229

PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.
Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535

",https://www.prisma-statement.org/lsr,PRISMA-LSR,"Reporting living systematic reviews (LSRs).



PRISMA-LSR checklist (Word)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 PRISMA-LSR checklist (PDF)

PRISMA-LSR tailored flow diagram (ShinyApp)

", ,Read the protocol for development of the guideline., , , , , ,yes,2025-02-06 11:21:10,2025-02-06 11:46:41,prisma-lsr,"[('title', 'Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR) : checklist and explanation'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting living systematic reviews (LSRs).\n\n \n\n \xa0\n\n \n\n[PRISMA-LSR checklist (Word)](https://www.prisma-statement.org/s/PRISMA-LSR-checklist.docx) [PRISMA-LSR checklist (PDF)](https://www.prisma-statement.org/s/PRISMA-LSR-checklist.pdf)\n\n \n\n[PRISMA-LSR tailored flow diagram (ShinyApp)](https://estech.shinyapps.io/livingprismaflow)\n\n \n\n'), ('Full bibliographic reference', 'Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183.'), ('Language', 'English'), ('PubMed ID', '[39562017](https://pubmed.ncbi.nlm.nih.gov/39562017/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.bmj.com/content/387/bmj-2024-079183) of the PRISMA-LSR reporting guideline.\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n**[PRISMA 2020 Statement](https://www.equator-network.org/reporting-guidelines/prisma/)**: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.\n\n \n\n PLoS Med. 2021;18(3):e1003583. PMID: [33780438](https://pubmed.ncbi.nlm.nih.gov/33780438/)\n\n BMJ 2021;372:n71. PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)\n\n Int J Surg. 2021:105906. PMID: [33789826](https://pubmed.ncbi.nlm.nih.gov/33789826/)\n\n J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: [33789819](https://pubmed.ncbi.nlm.nih.gov/33789819/)\n\n Syst Rev. 2021;10(1):89. PMID: [33781348](https://pubmed.ncbi.nlm.nih.gov/33781348/)\n\n \n\n**Specialised**\n\n[**PRISMA-Equity**](https://www.equator-network.org/reporting-guidelines/prisma-equity/): Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: [23222917](http://www.ncbi.nlm.nih.gov/pubmed/23222917)\n\n \n\n Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.\n\n Int J Equity Health. 2015;14(1):92. PMID: [26450828](http://www.ncbi.nlm.nih.gov/pubmed/26450828)\n\n J Clin Epidemiol. 2015. PMID: [26348799](http://www.ncbi.nlm.nih.gov/pubmed/26348799)\n\n \n\n[**PRISMA-Abstracts 2020**](https://www.equator-network.org/reporting-guidelines/prisma-abstracts/): The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.\n\n \n\n[**PRISMA-P**](https://www.equator-network.org/reporting-guidelines/prisma-protocols/): Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: [25554246](http://www.ncbi.nlm.nih.gov/pubmed/25554246)\n\n \n\n[**PRISMA-IPD**](https://www.equator-network.org/reporting-guidelines/prisma-ipd/): Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: [25919529](http://www.ncbi.nlm.nih.gov/pubmed/25919529)\n\n \n\n[**PRISMA extension for network meta-analyses**](https://www.equator-network.org/reporting-guidelines/prisma-extension-network-meta-analyses/): Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: [26030634](http://www.ncbi.nlm.nih.gov/pubmed/26030634)\n\n \n\n[**PRISMA-harms**](https://www.equator-network.org/reporting-guidelines/prisma-harms/): Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: [26830668](http://www.ncbi.nlm.nih.gov/pubmed/26830668)\n\n \n\n[**PRISMA-CI**](https://www.equator-network.org/reporting-guidelines/prisma-ci-extension-statement-checklist/): Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: [28720516](https://www.ncbi.nlm.nih.gov/pubmed/28720516)\n\n \n\n[**PRISMA-DTA**](https://www.equator-network.org/reporting-guidelines/prisma-dta/): McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: [29362800](https://www.ncbi.nlm.nih.gov/pubmed/29362800)\n\n \n\n[**PRISMA-ScR**](https://www.equator-network.org/reporting-guidelines/prisma-scr/): Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: [30178033](https://www.ncbi.nlm.nih.gov/pubmed/30178033)\n\n \n\n[**PRISMA-A**](https://www.equator-network.org/reporting-guidelines/prisma-acupuncture/): Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: [31405367](https://www.ncbi.nlm.nih.gov/pubmed/31405367)\n\n \n\n[**PRISMA-DTA for Abstracts**](https://www.equator-network.org/reporting-guidelines/prisma-dta-for-abstracts/): Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: [33722791](https://pubmed.ncbi.nlm.nih.gov/33722791/)\n\n \n\n[**PRISMA-CHM**](https://www.equator-network.org/reporting-guidelines/prisma-chinese-herbal-medicines-2020/): Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: [32907365](https://pubmed.ncbi.nlm.nih.gov/32907365/)\n\n \n\n[**PRISMA-M 2020**](https://www.equator-network.org/reporting-guidelines/prisma-extension-for-moxibustion-2020/): Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: [33100229](https://pubmed.ncbi.nlm.nih.gov/33100229/)\n\n \n\n[**PRISMA-S**](https://www.equator-network.org/reporting-guidelines/prisma-s/): Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.\n\n Syst Rev. 2021;10(1):39. PMID: [33499930](https://pubmed.ncbi.nlm.nih.gov/33499930/)\n\n J Med Libr Assoc. 2021;109(2):174-200. PMID: [34285662](https://pubmed.ncbi.nlm.nih.gov/34285662/)\n\n \n\n[**PRISMA-COSMIN for OMIs**](https://www.equator-network.org/reporting-guidelines/guideline-for-reporting-systematic-reviews-of-outcome-measurement-instruments-omis-prisma-cosmin-for-omis-2024/): Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.\n\n J Clin Epidemiol. 2024:111422. PMID: [38849061](https://pubmed.ncbi.nlm.nih.gov/38849061/)\n\n Qual Life Res. 2024. PMID: [38980635](https://pubmed.ncbi.nlm.nih.gov/38980635/)\n\n Health Qual Life Outcomes. 2024;22(1):48. PMID: [38978063](https://pubmed.ncbi.nlm.nih.gov/38978063/)\n\n J Patient Rep Outcomes. 2024;8(1):64. PMID: [38977535](https://pubmed.ncbi.nlm.nih.gov/38977535/)\n\n \n\n""), ('Reporting guideline website URL', '<https://www.prisma-statement.org/lsr>'), ('Reporting guideline acronym', 'PRISMA-LSR'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', '[Read the protocol](https://f1000research.com/articles/11-109) for development of the guideline.'), ('Record last updated on', 'February 6, 2025')]"
22179,Developing the TIDieR-Rehab checklist: a modified Delphi process to extend the Template for Intervention Description and Replication (TIDieR) for rehabilitation intervention reporting,"Clinical trials, Experimental studies, Observational studies","Occupational therapy, Physiotherapy, Psychology, Rehabilitation medicine","Harms/adverse effects/safety data, Intervention (exposure), Study characteristics (participants etc.)", ,"checklist, checklists, clinical trial, clinical trials, intervention, interventions, non-pharmacological, observation, observational, occupational therapy, physical therapies, physical therapy, physio, physiotherapy, psychology, psychosocial, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, recovery, rehab, rehabilitation, speech-language therapy, Template for Intervention Description and Replication, TIDieR-Rehab, TIDieR-Rehab checklist, trial, trials", ,"Signal N, Olsen S, Gomes E, McGeorge C, Taylor D, Alder G. Developing the TIDieR-Rehab checklist: a modified Delphi process to extend the Template for Intervention Description and Replication (TIDieR) for rehabilitation intervention reporting. BMJ Open. 2024;14(11):e084319.

","Signal N, Olsen S, Gomes E, McGeorge C, Taylor D, Alder G.",BMJ Open,2024,14,11,e084319, ,English, ,39609016,https://pubmed.ncbi.nlm.nih.gov/39609016/,"Read the full-text of TIDieR-Rehab. The checklist is in Table 2.

","Signal N, Gomes E, Olsen S, Alder G. Enhancing the reporting quality of rehabilitation interventions through an extension of the Template for Intervention Description and Replication (TIDieR): the TIDieR-Rehab checklist and supplementary manual. BMJ Open. 2024;14(11):e084320. PMID: 39608992

", , , ,TIDieR-Rehab,Reporting of rehabilitation interventions., , , , , , , ,no,2025-01-13 15:46:15,2025-01-13 16:15:56,developing-the-tidier-rehab-checklist-a-modified-delphi-process-to-extend-the-template-for-intervention-description-and-replication-tidier-for-rehabilitation-intervention-reporting,"[('title', 'Developing the TIDieR-Rehab checklist: a modified Delphi process to extend the Template for Intervention Description and Replication (TIDieR) for rehabilitation intervention reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of rehabilitation interventions.'), ('Full bibliographic reference', 'Signal N, Olsen S, Gomes E, McGeorge C, Taylor D, Alder G. Developing the TIDieR-Rehab checklist: a modified Delphi process to extend the Template for Intervention Description and Replication (TIDieR) for rehabilitation intervention reporting. BMJ Open. 2024;14(11):e084319.\n\n \n\n'), ('Language', 'English'), ('PubMed ID', '[39609016](https://pubmed.ncbi.nlm.nih.gov/39609016/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://bmjopen.bmj.com/content/14/11/e084319.long) of TIDieR-Rehab. The checklist is in Table 2.\n\n \n\n'), ('Explanation and elaboration papers', 'Signal N, Gomes E, Olsen S, Alder G. Enhancing the reporting quality of rehabilitation interventions through an extension of the Template for Intervention Description and Replication (TIDieR): the TIDieR-Rehab checklist and supplementary manual. BMJ Open. 2024;14(11):e084320. PMID: [39608992](https://pubmed.ncbi.nlm.nih.gov/39608992/)\n\n \n\n'), ('Reporting guideline acronym', 'TIDieR-Rehab'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Occupational therapy, Physiotherapy, Psychology, Rehabilitation medicine'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Study characteristics (participants etc.)'), ('Record last updated on', 'January 13, 2025')]"
22171,The TRIPOD-LLM reporting guideline for studies using large language models,Artificial intelligence/Machine learning studies, ,Whole report, ,"AI, artificial intelligence, chatbot, chatbots, generative AI, large language, large language model, large language models, LLM, LLMs, machine learning, natural language processing, NLP, predict, prediction, TRIPOD extension, TRIPOD-LLM, TRIPOD-LLM statement", ,"Gallifant J, Afshar M, Ameen S, Aphinyanaphongs Y, Chen S, Cacciamani G, Demner-Fushman D, Dligach D, Daneshjou R, Fernandes C, Hansen LH, Landman A, Lehmann L, McCoy LG, Miller T, Moreno A, Munch N, Restrepo D, Savova G, Umeton R, Gichoya JW, Collins GS, Moons KGM, Celi LA, Bitterman DS. The TRIPOD-LLM reporting guideline for studies using large language models. Nat Med. 2025.

","Gallifant J, Afshar M, Ameen S, Aphinyanaphongs Y, Chen S, Cacciamani G, Demner-Fushman D, Dligach D, Daneshjou R, Fernandes C, Hansen LH, Landman A, Lehmann L, McCoy LG, Miller T, Moreno A, Munch N, Restrepo D, Savova G, Umeton R, Gichoya JW, Collins GS, Moons KGM, Celi LA, Bitterman DS.",Nature Medicine [Nat. Med.],2025, , , , ,English, ,39779929,https://pubmed.ncbi.nlm.nih.gov/39779929/,Read the full-text of the TRIPOD-LLM guideline., , ,"Generic
TRIPOD+AI Statement: Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, Ghassemi M, Liu X, Reitsma JB, van Smeden M, Boulesteix AL, Camaradou JC, Celi LA, Denaxas S, Denniston AK, Glocker B, Golub RM, Harvey H, Heinze G, Hoffman MM, Kengne AP, Lam E, Lee N, Loder EW, Maier-Hein L, Mateen BA, McCradden MD, Oakden-Rayner L, Ordish J, Parnell R, Rose S, Singh K, Wynants L, Logullo P. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. PMID: 38626948

Specialised
TRIPOD-SRMA: Snell KIE, Levis B, Damen JAA, Dhiman P, Debray TPA, Hooft L, Reitsma JB, Moons KGM, Collins GS, Riley RD. Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA). BMJ. 2023;381:e073538. PMID: 37137496

TRIPOD-Cluster: Debray TPA, Collins GS, Riley RD, Snell KIE, Van Calster B, Reitsma JB, Moons KGM. Transparent reporting of multivariable prediction models developed or validated using clustered data: TRIPOD-Cluster checklist. BMJ. 2023;380:e071018. PMID: 36750242

",https://tripod-llm.vercel.app/,TRIPOD-LLM,"Reporting of studies that are developing, tuning, prompt engineering or evaluating a large language model (LLM).", , , , ,"The guideline includes a separate checklist for journal or conference abstracts of LLM-based studies (TRIPOD-LLM for abstracts).

", , ,no,2025-01-10 15:30:47,2025-01-10 15:31:48,the-tripod-llm-reporting-guideline-for-studies-using-large-language-models,"[('title', 'The TRIPOD-LLM reporting guideline for studies using large language models'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of studies that are developing, tuning, prompt engineering or evaluating a large language model (LLM).'), ('Full bibliographic reference', 'Gallifant J, Afshar M, Ameen S, Aphinyanaphongs Y, Chen S, Cacciamani G, Demner-Fushman D, Dligach D, Daneshjou R, Fernandes C, Hansen LH, Landman A, Lehmann L, McCoy LG, Miller T, Moreno A, Munch N, Restrepo D, Savova G, Umeton R, Gichoya JW, Collins GS, Moons KGM, Celi LA, Bitterman DS. The TRIPOD-LLM reporting guideline for studies using large language models. Nat Med. 2025.\n\n \n\n'), ('Language', 'English'), ('PubMed ID', '[39779929](https://pubmed.ncbi.nlm.nih.gov/39779929/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.nature.com/articles/s41591-024-03425-5) of the TRIPOD-LLM guideline.'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**TRIPOD+AI Statement**](https://www.equator-network.org/reporting-guidelines/tripod-statement/): Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, Ghassemi M, Liu X, Reitsma JB, van Smeden M, Boulesteix AL, Camaradou JC, Celi LA, Denaxas S, Denniston AK, Glocker B, Golub RM, Harvey H, Heinze G, Hoffman MM, Kengne AP, Lam E, Lee N, Loder EW, Maier-Hein L, Mateen BA, McCradden MD, Oakden-Rayner L, Ordish J, Parnell R, Rose S, Singh K, Wynants L, Logullo P. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. PMID: [38626948](https://pubmed.ncbi.nlm.nih.gov/38626948/)\n\n \n\n**Specialised**\n\n**[TRIPOD-SRMA](https://www.equator-network.org/reporting-guidelines/tripod-srma/)**: Snell KIE, Levis B, Damen JAA, Dhiman P, Debray TPA, Hooft L, Reitsma JB, Moons KGM, Collins GS, Riley RD. Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA). BMJ. 2023;381:e073538. PMID: [37137496](https://pubmed.ncbi.nlm.nih.gov/37137496/)\n\n \n\n[**TRIPOD-Cluster**](https://www.equator-network.org/reporting-guidelines/tripod-cluster/): Debray TPA, Collins GS, Riley RD, Snell KIE, Van Calster B, Reitsma JB, Moons KGM. Transparent reporting of multivariable prediction models developed or validated using clustered data: TRIPOD-Cluster checklist. BMJ. 2023;380:e071018. PMID: [36750242](https://pubmed.ncbi.nlm.nih.gov/36750242/)\n\n \n\n'), ('Reporting guideline website URL', '<https://tripod-llm.vercel.app/>'), ('Reporting guideline acronym', 'TRIPOD-LLM'), ('Study design', 'Artificial intelligence/Machine learning studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Other', 'The guideline includes a separate checklist for journal or conference abstracts of LLM-based studies (TRIPOD-LLM for abstracts).\n\n \n\n'), ('Record last updated on', 'January 10, 2025')]"
22165,A child-centred research checklist to improve the design and reporting of paediatric research studies: A descriptive mixed methods study, ,Paediatrics,"Data, Ethical issues (consent etc.), Procedure/Method, Study characteristics (participants etc.)", ,"checklist, checklists, child, child-centred, children, consent, data, paediatric, pediatric", ,"Foster M, Lisa Whitehead L, O'Sullivan TA, Hill J, M\xf6relius E. A child-centred research checklist to improve the design and reporting of paediatric research studies: A descriptive mixed methods study. Int J Nurs Stud. 2024;162:104958.","Foster M, Lisa Whitehead L, O'Sullivan TA, Hill J, M\xf6relius E.",International Journal of Nursing Studies [Int J Nurs Stud.],2024,162, ,104958, ,English, ,39615432,https://pubmed.ncbi.nlm.nih.gov/39615432/, , , , , , ,Reporting of paediatric research studies., , , , , , , ,no,2024-12-09 16:00:17,2024-12-09 16:00:17,a-child-centred-research-checklist-to-improve-the-design-and-reporting-of-paediatric-research-studies-a-descriptive-mixed-methods-study,"[('title', 'A child-centred research checklist to improve the design and reporting of paediatric research studies: A descriptive mixed methods study'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of paediatric research studies.'), ('Full bibliographic reference', ""Foster M, Lisa Whitehead L, O'Sullivan TA, Hill J, Mörelius E. A child-centred research checklist to improve the design and reporting of paediatric research studies: A descriptive mixed methods study. Int J Nurs Stud. 2024;162:104958.""), ('Language', 'English'), ('PubMed ID', '[39615432](https://pubmed.ncbi.nlm.nih.gov/39615432/)'), ('Clinical area', 'Paediatrics'), ('Applies to the whole report or to individual sections of the report?', 'Data, Ethical issues (consent etc.), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'December 9, 2024')]"
22154,Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension,"Clinical trials, Experimental studies",Neurology,Whole report, ,"checklist, checklists, clinical trial, clinical trials, CONSORT extension, CONSORT-iNeurostim, CONSORT-iNeurostim extension, device, devices, experimental studies, experimental study, implantable neurostimulation device, implantable neurostimulation devices, intervention, interventional, interventions, nerve, nerves, nervous system, neurological, neurology, neuromodulation, neurostimulation, neurostimulation device, neurostimulation devices, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, stimulation, trial, trials", ,"Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932.","Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS.",EClinicalMedicine.,2024,78, ,102932, ,English, ,39606687,https://pubmed.ncbi.nlm.nih.gov/39606687/, , , ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster: Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal: Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts: Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture: MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738. PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,CONSORT-iNeurostim,Reporting trials of implantable neurostimulation devices., , , , , , , ,no,2024-12-06 15:57:02,2025-05-30 09:27:40,reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension,"[('title', 'Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting trials of implantable neurostimulation devices.'), ('Full bibliographic reference', 'Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932.'), ('Language', 'English'), ('PubMed ID', '[39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](https://www.equator-network.org/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](https://www.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](https://www.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](https://www.equator-network.org/reporting-guidelines/consort-cluster/): Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](https://www.equator-network.org/reporting-guidelines/consort-herbal/): Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](https://www.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](https://www.equator-network.org/reporting-guidelines/consort-abstracts/): Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](https://www.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](https://www.equator-network.org/reporting-guidelines/consort-stricta/): MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](https://www.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](https://www.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738. PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](https://www.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](https://www.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](https://www.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](https://www.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](https://www.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://www.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](https://www.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](https://www.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](https://www.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](https://www.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](https://www.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://www.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://www.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://www.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://www.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'CONSORT-iNeurostim'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Neurology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 30, 2025')]"
22142,Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension,"Clinical trials, Experimental studies, Study protocols",Neurology,Whole report, ,"checklist, checklists, clinical trial, clinical trials, device, devices, experimental studies, experimental study, implantable neurostimulation device, implantable neurostimulation devices, intervention, interventional, interventions, nerve, nerves, nervous system, neurological, neurology, neuromodulation, neurostimulation, neurostimulation device, neurostimulation devices, protocol, protocols, randomised controlled trial, randomised controlled trial protocol, randomised controlled trial protocols, randomised controlled trials, randomised trial, randomised trial protocol, randomised trial protocols, randomised trials, randomized controlled trial, randomized controlled trial protocol, randomized controlled trial protocols, randomized controlled trials, randomized trial, randomized trial protocol, randomized trial protocols, randomized trials, RCT, RCTs, SPIRIT Extension, SPIRIT-iNeurostim, SPIRIT-iNeurostim extension, stimulation, trial, trial protocol, trial protocols, trials", ,"Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933.","Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV.",EClinicalMedicine.,2024,78, ,102933, ,English, ,39610902,https://pubmed.ncbi.nlm.nih.gov/39610902/, , , ,"Generic

SPIRIT 2025 Statement: Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hr\xf3bjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.

BMJ. 2025; 388:e081660. PMID:\xa040294956
JAMA. 2025.\xa0PMID: 40294593
Lancet 2025.
Nat Med. 2025.\xa0PMID: 40295741
PLoS Med. 2025; 22(4): e1004587.\xa0PMID: 40294521

Specialised
SPIRIT-PRO: Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. Link to abstract

SPIRIT-TCM: Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: 30484022

SPENT 2019: Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. Link to full-text.

SPIRIT-AI: Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.
BMJ. 2020;370:m3210. PMID: 32907797
Nat Med. 2020;26(9):1351?1363. PMID: 32908284
Lancet Digital Health. 2020;2(10):e549-e560. PMID: 33328049

SPIRIT-Path: Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: 34592193

SPIRIT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: 36512367

SPIRIT-DEFINE: Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: 37863491

SPIRIT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: 38051535

SPIRIT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: 38981624

", ,SPIRIT-iNeurostim,Reporting of protocols of trials of implantable neurostimulation devices., , , , , , , ,no,2024-12-06 15:26:14,2025-05-30 09:12:08,reporting-guidelines-for-protocols-of-randomised-controlled-trials-of-implantable-neurostimulation-devices-the-spirit-ineurostim-extension,"[('title', 'Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of protocols of trials of implantable neurostimulation devices.'), ('Full bibliographic reference', 'Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933.'), ('Language', 'English'), ('PubMed ID', '[39610902](https://pubmed.ncbi.nlm.nih.gov/39610902/)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n \n\n**[SPIRIT 2025 Statement](https://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/):** Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hróbjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.\n\n \n\nBMJ. 2025; 388:e081660. [PMID:40294956](https://pubmed.ncbi.nlm.nih.gov/40294956/)\n\n JAMA. 2025.[PMID:](https://pubmed.ncbi.nlm.nih.gov/40294593/) [40294593](https://pubmed.ncbi.nlm.nih.gov/40294593/)\n\n Lancet 2025.\n\n Nat Med. 2025.[PMID: 40295741](https://pubmed.ncbi.nlm.nih.gov/40295741)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID: 40294521](https://pubmed.ncbi.nlm.nih.gov/40294521/)\n\n \n\n**Specialised**\n\n[**SPIRIT-PRO**](https://www.equator-network.org/reporting-guidelines/spirit-pro/): Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. [Link to abstract](https://jamanetwork.com/journals/jama/article-abstract/2671472)\n\n \n\n[**SPIRIT-TCM**](https://www.equator-network.org/reporting-guidelines/standard-protocol-items-for-clinical-trials-with-traditional-chinese-medicine-spirit-tcm-extension-2018/): Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: [30484022](https://www.ncbi.nlm.nih.gov/pubmed/30484022)\n\n \n\n[**SPENT 2019**](https://www.equator-network.org/reporting-guidelines/spirit-extension-n-of-1-trials-spent-2019/): Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. [Link to full-text](https://www.bmj.com/content/368/bmj.m122).\n\n \n\n[**SPIRIT-AI**](https://www.equator-network.org/reporting-guidelines/spirit-artificial-intelligence/): Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.\n\n BMJ. 2020;370:m3210. PMID: [32907797](https://pubmed.ncbi.nlm.nih.gov/32907797/)\n\n Nat Med. 2020;26(9):1351–1363. PMID: [32908284](https://pubmed.ncbi.nlm.nih.gov/32908284/)\n\n Lancet Digital Health. 2020;2(10):e549-e560. PMID: [33328049](https://pubmed.ncbi.nlm.nih.gov/33328049/)\n\n \n\n[**SPIRIT-Path**](https://www.equator-network.org/reporting-guidelines/spirit-path/): Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: [34592193](https://pubmed.ncbi.nlm.nih.gov/34592193/)\n\n \n\n[**SPIRIT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-protocols-the-spirit-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: [36512367](https://pubmed.ncbi.nlm.nih.gov/36512367/)\n\n \n\n[**SPIRIT-DEFINE**](https://www.equator-network.org/reporting-guidelines/spirit-define/): Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: [37863491](https://pubmed.ncbi.nlm.nih.gov/37863491/)\n\n \n\n[**SPIRIT Factorial**](https://www.equator-network.org/reporting-guidelines/consensus-statement-for-protocols-of-factorial-randomized-trials-extension-of-the-spirit-2013-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: [38051535](https://pubmed.ncbi.nlm.nih.gov/38051535/)\n\n \n\n[**SPIRIT-Surrogate**](https://www.equator-network.org/reporting-guidelines/spirit-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: [38981624](https://pubmed.ncbi.nlm.nih.gov/38981624/)\n\n \n\n""), ('Reporting guideline acronym', 'SPIRIT-iNeurostim'), ('Study design', 'Clinical trials, Experimental studies, Study protocols'), ('Clinical area', 'Neurology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 30, 2025')]"
22137,Guidelines for reporting research using systematic coding of observed human behaviour (SCOBe),Observational studies, ,"Data, Procedure/Method", ,"behavior, behavioral coding, behaviour, behavioural coding, code, codes, coding, coding behaviour, data, observation, observational, observed human behaviour, SCOBe", ,"Hillen MA, Hoeben EM, Kok R, McHale C, Sexton MM, van der Asdonk S, van de Bongardt D, Bowman B, Brown R, Branje S, Chorney J, Donker MH, Ejbye-Ernst P, Geeraerts S, Van der Giessen D, Humphris G, Larsen H, Philpot R, Portell M, Yuan S, van der Veen C, Noordman J. Guidelines for reporting research using systematic coding of observed human behaviour (SCOBe). Qual Quant. 2024.","Hillen MA, Hoeben EM, Kok R, McHale C, Sexton MM, van der Asdonk S, van de Bongardt D, Bowman B, Brown R, Branje S, Chorney J, Donker MH, Ejbye-Ernst P, Geeraerts S, Van der Giessen D, Humphris G, Larsen H, Philpot R, Portell M, Yuan S, van der Veen C, Noordman J.",Quality and Quantity [Qual Quant.],2024, , , , ,English, , , ,"Read the full-text of this guideline.

", , , , , ,"Reporting of systematic coding of observed human behaviour (SCOBe) research.



SCOBe checklist (Word) \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 SCOBe checklist (PDF)

", , , , , , , ,no,2024-11-29 15:25:48,2024-12-09 11:06:05,guidelines-for-reporting-research-using-systematic-coding-of-observed-human-behaviour-scobe,"[('title', 'Guidelines for reporting research using systematic coding of observed human behaviour (SCOBe)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of systematic coding of observed human behaviour (SCOBe) research.\n\n \n\n \xa0\n\n \n\n[SCOBe checklist (Word)](https://www.equator-network.org/wp-content/uploads/2024/11/SCOBe-checklist.docx)  [SCOBe checklist (PDF)](https://www.equator-network.org/wp-content/uploads/2024/11/SCOBe-checklist.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Hillen MA, Hoeben EM, Kok R, McHale C, Sexton MM, van der Asdonk S, van de Bongardt D, Bowman B, Brown R, Branje S, Chorney J, Donker MH, Ejbye-Ernst P, Geeraerts S, Van der Giessen D, Humphris G, Larsen H, Philpot R, Portell M, Yuan S, van der Veen C, Noordman J. Guidelines for reporting research using systematic coding of observed human behaviour (SCOBe). Qual Quant. 2024.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://link.springer.com/article/10.1007/s11135-024-01969-9) of this guideline.\n\n \n\n'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method'), ('Record last updated on', 'December 9, 2024')]"
22135,STROBE-GEMA: a STROBE extension for reporting of geographically explicit ecological momentary assessment studies,Observational studies,"Behavioural medicine, Health informatics, Psychology, Public health",Whole report, ,"ambulatory assessment, behavior, behaviour, checklist, checklists, Ecological Momentary Assessment, environment, environmental exposure, experience sampling method, GEMA, GEMA checklist, GEMA studies, GEMA study, geographic information system, geographical, geographically, geographically explicit momentary assessment, geolocation, GIS, global positioning system, GPS, location, momentary, momentary assessment, momentary measurement, public health, sensor, sensors, STROBE, STROBE-GEMA, STROBE-GEMA checklist", ,"Kingsbury C, Buzzi M, Chaix B, Kanning M, Khezri S, Kiani B, Kirchner TR, Maurel A, Thierry B, Kestens Y. STROBE-GEMA: a STROBE extension for reporting of geographically explicit ecological momentary assessment studies. Arch Public Health. 2024;82(1):84.","Kingsbury C, Buzzi M, Chaix B, Kanning M, Khezri S, Kiani B, Kirchner TR, Maurel A, Thierry B, Kestens Y.",Archives of Public Health. [Arch Public Health.],2024,82,1,84, ,English, ,38867286,https://pubmed.ncbi.nlm.nih.gov/38867286/, , , , , ,STROBE-GEMA,Reporting of geographically explicit momentary assessment (GEMA) studies., , , , , , , ,no,2024-11-29 14:47:15,2024-11-29 14:47:15,strobe-gema-a-strobe-extension-for-reporting-of-geographically-explicit-ecological-momentary-assessment-studies,"[('title', 'STROBE-GEMA : a STROBE extension for reporting of geographically explicit ecological momentary assessment studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of geographically explicit momentary assessment (GEMA) studies.'), ('Full bibliographic reference', 'Kingsbury C, Buzzi M, Chaix B, Kanning M, Khezri S, Kiani B, Kirchner TR, Maurel A, Thierry B, Kestens Y. STROBE-GEMA: a STROBE extension for reporting of geographically explicit ecological momentary assessment studies. Arch Public Health. 2024;82(1):84.'), ('Language', 'English'), ('PubMed ID', '[38867286](https://pubmed.ncbi.nlm.nih.gov/38867286/)'), ('Reporting guideline acronym', 'STROBE-GEMA'), ('Study design', 'Observational studies'), ('Clinical area', 'Behavioural medicine, Health informatics, Psychology, Public health'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 29, 2024')]"
22129,Reflexology specific guidance for using the template for the intervention description and replication (TIDieR): A delphi study,"Clinical trials, Experimental studies",Complementary and alternative medicine,Intervention (exposure), ,"application consolidation contexualisation, checklist, checklists, clinical trial, clinical trials, complementary therapies, complementary therapy, intervention, interventions, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, reflex, reflexes, reflexologist, reflexologists, reflexology, reflexology intervention, reflexology interventions, reflexotherapy, template for the intervention description and replication, TIDieR, TIDieR checklist, trial, trials, zone therapies, zone therapy", ,"James J, Costello JT, Edwards-Price S, Smith T, McAuley A, Scott BE, Dimitrakoulas S, Edwards M, Kelly D, Wayte DL, Porritt AF, Drahota AK. Reflexology specific guidance for using the template for the intervention description and replication (TIDieR): A delphi study. Eur J Integr Med. 2024;72.

","James J, Costello JT, Edwards-Price S, Smith T, McAuley A, Scott BE, Dimitrakoulas S, Edwards M, Kelly D, Wayte DL, Porritt AF, Drahota AK.",European Journal of Integrative Medicine [Eur J Integr Med.],2024,72, , , ,English, , , ,Read the full-text of this guideline., , , , , ,Reporting of reflexology intervention studies., ,"Read the systematic review that was conducted to inform the development of this guideline.

", , ,"Read the protocol available on the OSF.

", , ,no,2024-11-29 11:46:31,2024-11-29 14:34:14,reflexology-specific-guidance-for-using-the-template-for-the-intervention-description-and-replication-tidier-a-delphi-study,"[('title', 'Reflexology specific guidance for using the template for the intervention description and replication (TIDieR) : A delphi study'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of reflexology intervention studies.'), ('Full bibliographic reference', 'James J, Costello JT, Edwards-Price S, Smith T, McAuley A, Scott BE, Dimitrakoulas S, Edwards M, Kelly D, Wayte DL, Porritt AF, Drahota AK. Reflexology specific guidance for using the template for the intervention description and replication (TIDieR): A delphi study. Eur J Integr Med. 2024;72.\n\n \n\n'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'Read the [full-text](https://www.sciencedirect.com/science/article/pii/S1876382024000854) of this guideline.'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Other', '[Read the protocol](https://osf.io/reavn/) available on the OSF.\n\n \n\n'), ('Additional information', '[Read the systematic review](https://www.sciencedirect.com/science/article/pii/S187638202400060X) that was conducted to inform the development of this guideline.\n\n \n\n'), ('Record last updated on', 'November 29, 2024')]"
22103,Delphi studies in social and health sciences-Recommendations for an interdisciplinary standardized reporting (DELPHISTAR). Results of a Delphi study,"Clinical practice guidelines, Qualitative research", ,Whole report, ,"checklist, checklists, consensus, Delphi, Delphi studies, Delphi study, DELPHISTAR, DELPHISTAR checklist, DELPHISTAR guideline, guideline, guidelines, Remove term: DELPHISTAR guideline DELPHISTAR guidelines", ,"Niederberger M, Schifano J, Deckert S, Hirt J, Homberg A, K\xf6berich S, Kuhn R, Rommel A, Sonnberger M; DEWISS network. Delphi studies in social and health sciences-Recommendations for an interdisciplinary standardized reporting (DELPHISTAR). Results of a Delphi study. PLoS One. 2024;19(8):e0304651.","Niederberger M, Schifano J, Deckert S, Hirt J, Homberg A, K\xf6berich S, Kuhn R, Rommel A, Sonnberger M; DEWISS network.
",PLoS One,2024,26,19,e0304651, ,English, ,39186713,https://pubmed.ncbi.nlm.nih.gov/39186713/,Read the full-text of the DELPHISTAR guideline., , , ,https://delphi.ph-gmuend.de/,DELPHISTAR,"Reporting Delphi studies in the health and social sciences



DELPHISTAR checklist (Word)\xa0 \xa0 \xa0 \xa0 \xa0DELPHISTAR checklist (PDF)

","The DELPHISTAR Statement has been translated into German in Word | PDF.

","Read the reviews that informed the development of DELPHISTAR:

Spranger J, Homberg A, Sonnberger M, Niederberger M. Reporting guidelines for Delphi techniques in health sciences: A methodological review. Z Evid Fortbild Qual Gesundhwes. 2022;172:1-11. PMID: 35718726

Niederberger M, Spranger J. Delphi Technique in Health Sciences: A Map. Front Public Health. 2020;8:457. PMID: 33072683

", , ,The DELPHISTAR project was registered at the OSF platform and can be assessed on this page: https://osf.io/gc4jk, , ,no,2024-11-28 09:49:42,2024-11-28 10:50:44,delphi-studies-in-social-and-health-sciences-recommendations-for-an-interdisciplinary-standardized-reporting-delphistar-results-of-a-delphi-study,"[('title', 'Delphi studies in social and health sciences -Recommendations for an interdisciplinary standardized reporting (DELPHISTAR) . Results of a Delphi study'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting Delphi studies in the health and social sciences\n\n \n\n \xa0\n\n \n\n DELPHISTAR checklist ([Word](https://www.equator-network.org/wp-content/uploads/2024/11/RG_DELPHISTAR_engl-2.docx))\xa0 \xa0 \xa0 \xa0 \xa0DELPHISTAR checklist [(PDF](https://www.equator-network.org/wp-content/uploads/2024/11/RG_DELPHISTAR_engl-1.pdf))\n\n \n\n'), ('Full bibliographic reference', 'Niederberger M, Schifano J, Deckert S, Hirt J, Homberg A, Köberich S, Kuhn R, Rommel A, Sonnberger M; DEWISS network. Delphi studies in social and health sciences-Recommendations for an interdisciplinary standardized reporting (DELPHISTAR). Results of a Delphi study. PLoS One. 2024;19(8):e0304651.'), ('Language', 'English'), ('PubMed ID', '[39186713](https://pubmed.ncbi.nlm.nih.gov/39186713/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0304651) of the DELPHISTAR guideline.'), ('Availability in additional languages', 'The DELPHISTAR Statement has been translated into German in [Word](https://www.equator-network.org/wp-content/uploads/2024/11/RG_DELPHISTAR_ger.docx) | [PDF](https://www.equator-network.org/wp-content/uploads/2024/11/RG_DELPHISTAR_ger.pdf).\n\n \n\n'), ('Reporting guideline website URL', '<https://delphi.ph-gmuend.de/>'), ('Reporting guideline acronym', 'DELPHISTAR'), ('Study design', 'Clinical practice guidelines, Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Other', 'The DELPHISTAR project was registered at the OSF platform and can be assessed on this page: <https://osf.io/gc4jk>'), ('Additional information', 'Read the reviews that informed the development of DELPHISTAR:\n\n \n\n Spranger J, Homberg A, Sonnberger M, Niederberger M. Reporting guidelines for Delphi techniques in health sciences: A methodological review. Z Evid Fortbild Qual Gesundhwes. 2022;172:1-11. PMID: [35718726](https://pubmed.ncbi.nlm.nih.gov/35718726/)\n\n \n\n Niederberger M, Spranger J. Delphi Technique in Health Sciences: A Map. Front Public Health. 2020;8:457. PMID: [33072683](https://pubmed.ncbi.nlm.nih.gov/33072683/)\n\n \n\n'), ('Record last updated on', 'November 28, 2024')]"
22057,"LETter To the EditoR Standards (LETTERS): Considerations for Authors, Reviewers, and Editors",Letters to the editor/Correspondence, ,Whole report, ,"checklist, checklists, communication, communications, correspondence, letter, letter to the editor, Letter to the Editor Standards, letters, LETTERS checklist, letters to the editor", ,"Coskun Benlidayi I, Gupta L. LETter To the EditoR Standards (LETTERS): Considerations for Authors, Reviewers, and Editors. J Korean Med Sci. 2024;39(37):e296.","Coskun Benlidayi I, Gupta L.",Journal of Korean Medical Science [J Korean Med Sci.],2024,39,37,e296, ,English, ,39355953,https://pubmed.ncbi.nlm.nih.gov/39355953/, , , , , ,LETTERS,Reporting in letters to the editor., , , , , , , ,no,2024-11-22 16:02:14,2024-11-22 16:02:15,letter-to-the-editor-standards-letters-considerations-for-authors-reviewers-and-editors,"[('title', 'LETter To the EditoR Standards (LETTERS) : Considerations for Authors, Reviewers, and Editors'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting in letters to the editor.'), ('Full bibliographic reference', 'Coskun Benlidayi I, Gupta L. LETter To the EditoR Standards (LETTERS): Considerations for Authors, Reviewers, and Editors. J Korean Med Sci. 2024;39(37):e296.'), ('Language', 'English'), ('PubMed ID', '[39355953](https://pubmed.ncbi.nlm.nih.gov/39355953/)'), ('Reporting guideline acronym', 'LETTERS'), ('Study design', 'Letters to the editor/Correspondence'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 22, 2024')]"
22055,"CAse-BAsed REview sTandards (CABARET): Considerations for Authors, Reviewers, and Editors",Observational studies, ,Whole report, ,"CABARET, CABARET checklist, case, case report, case reports, case studies, case study, CAse-BAsed REview sTandards, case-based reviews, cases, checklist, checklists, observational, observational studies, observational study, review of reported cases", ,"Benlidayi IC, Gupta L. CAse-BAsed REview sTandards (CABARET): Considerations for Authors, Reviewers, and Editors. J Korean Med Sci. 2024;39(30):e225.","Benlidayi IC, Gupta L.",Journal of Korean Medical Science [J Korean Med Sci.],2024,39,30,e225, ,English, ,39106889,https://pubmed.ncbi.nlm.nih.gov/39106889/, , , , , ,CABARET,Reporting of case-based reviews., , , , , , , ,no,2024-11-22 15:13:50,2024-11-22 15:13:50,case-based-review-standards-cabaret-considerations-for-authors-reviewers-and-editors,"[('title', 'CAse-BAsed  REview sTandards (CABARET) : Considerations for Authors, Reviewers, and Editors'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of case-based reviews.'), ('Full bibliographic reference', 'Benlidayi IC, Gupta L. CAse-BAsed REview sTandards (CABARET): Considerations for Authors, Reviewers, and Editors. J Korean Med Sci. 2024;39(30):e225.'), ('Language', 'English'), ('PubMed ID', '[39106889](https://pubmed.ncbi.nlm.nih.gov/39106889/)'), ('Reporting guideline acronym', 'CABARET'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 22, 2024')]"
22045,A consensus guideline on preferred items for reporting case series in homeopathy: The PITCH statement,Observational studies,Complementary and alternative medicine,Whole report, ,"CAM, case, case series, checklist, checklists, complementary and alternative medicine, complementary medicine, complementary therapies, complementary therapy, homeopathic, homeopathy, observation, observational, observational studies, observational study, PITCH, PITCH checklist", ,Dutta A. A consensus guideline on preferred items for reporting case series in homeopathy: The PITCH statement. J Ayurveda Integr Med. 2024;15(5):101023.,Dutta A.,Journal of Ayurveda and Integrated Medicine [J Ayurveda Integr Med.],2024,15,5,101023, ,English, ,39396436,https://pubmed.ncbi.nlm.nih.gov/39396436/, , , , , ,PITCH,Reporting of case series in homeopathy., , , , , , , ,no,2024-11-07 16:05:35,2024-11-07 16:05:35,a-consensus-guideline-on-preferred-items-for-reporting-case-series-in-homeopathy-the-pitch-statement,"[('title', 'A consensus guideline on preferred items for reporting case series in homeopathy: The PITCH statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of case series in homeopathy.'), ('Full bibliographic reference', 'Dutta A. A consensus guideline on preferred items for reporting case series in homeopathy: The PITCH statement. J Ayurveda Integr Med. 2024;15(5):101023.'), ('Language', 'English'), ('PubMed ID', '[39396436](https://pubmed.ncbi.nlm.nih.gov/39396436/)'), ('Reporting guideline acronym', 'PITCH'), ('Study design', 'Observational studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 7, 2024')]"
22041,Reporting guidelines for evidence-based practice projects: A Delphi study and publication checklist,Observational studies, ,Whole report, ,"checklist, checklists, EBP, EBP project, EBP projects, evidence-based practice, evidence-based practice project, evidence?based practice, nurse, nurses, nursing, project, projects", ,"Whalen M, Bissett K, Ascenzi J, Budhathoki C. Reporting guidelines for evidence-based practice projects: A Delphi study and publication checklist. Worldviews Evid Based Nurs. 2024.","Whalen M, Bissett K, Ascenzi J, Budhathoki C.",Worldviews on Evidence- Based Nursing [Worldviews Evid Based Nurs.],2024, , , , ,English, ,39367549,https://pubmed.ncbi.nlm.nih.gov/39367549/, , , , , , ,"Reporting of evidence-based practice (EBP) projects.



EBP project checklist (PDF)

", , , , , , , ,no,2024-11-07 15:18:59,2024-11-28 10:23:53,reporting-guidelines-for-evidence-based-practice-projects-a-delphi-study-and-publication-checklist,"[('title', 'Reporting guidelines for evidence-based practice projects: A Delphi study and publication checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of evidence-based practice (EBP) projects.\n\n \n\n \xa0\n\n \n\n[EBP project checklist (PDF)](https://www.equator-network.org/wp-content/uploads/2024/11/Evidence-based-practice-project-checklist.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Whalen M, Bissett K, Ascenzi J, Budhathoki C. Reporting guidelines for evidence-based practice projects: A Delphi study and publication checklist. Worldviews Evid Based Nurs. 2024.'), ('Language', 'English'), ('PubMed ID', '[39367549](https://pubmed.ncbi.nlm.nih.gov/39367549/)'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 28, 2024')]"
22034,REFORMS: Consensus-based Recommendations for Machine-learning-based Science,Artificial intelligence/Machine learning studies, ,"Data, Procedure/Method, Statistical methods and analyses", ,"AI, artificial intelligence, checklist, checklists, code, data, machine learning, ML, ML method, ML methods, ML model, ML models, ML-based science, model, modeling, modelling, models, prediction, prediction modeling, prediction modelling, predictive, predictive modeling, predictive modelling, recommendations for machine-learning-based science, REFORMS, REFORMS checklist, reinforcement learning, statistical, statistics, supervised learning, unsupervised learning", ,"Kapoor S, Cantrell EM, Peng K, Pham TH, Bail CA, Gundersen OE, Hofman JM, Hullman J, Lones MA, Malik MM, Nanayakkara P, Poldrack RA, Raji ID, Roberts M, Salganik MJ, Serra-Garcia M, Stewart BM, Vandewiele G, Narayanan A. REFORMS: Consensus-based Recommendations for Machine-learning-based Science. Sci Adv. 2024;10(18):eadk3452.","Kapoor S, Cantrell EM, Peng K, Pham TH, Bail CA, Gundersen OE, Hofman JM, Hullman J, Lones MA, Malik MM, Nanayakkara P, Poldrack RA, Raji ID, Roberts M, Salganik MJ, Serra-Garcia M, Stewart BM, Vandewiele G, Narayanan A.",Science Advances [Sci Adv.],2024,10,18,eadk3452, ,English, ,38691601,https://pubmed.ncbi.nlm.nih.gov/38691601/, , , , , , ,Reporting machine learning (ML) based science., , , , , , , ,no,2024-10-24 17:22:50,2024-10-24 17:22:50,reforms-consensus-based-recommendations-for-machine-learning-based-science,"[('title', 'REFORMS : Consensus-based Recommendations for Machine-learning-based Science'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting machine learning (ML) based science.'), ('Full bibliographic reference', 'Kapoor S, Cantrell EM, Peng K, Pham TH, Bail CA, Gundersen OE, Hofman JM, Hullman J, Lones MA, Malik MM, Nanayakkara P, Poldrack RA, Raji ID, Roberts M, Salganik MJ, Serra-Garcia M, Stewart BM, Vandewiele G, Narayanan A. REFORMS: Consensus-based Recommendations for Machine-learning-based Science. Sci Adv. 2024;10(18):eadk3452.'), ('Language', 'English'), ('PubMed ID', '[38691601](https://pubmed.ncbi.nlm.nih.gov/38691601/)'), ('Study design', 'Artificial intelligence/Machine learning studies'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method, Statistical methods and analyses'), ('Record last updated on', 'October 24, 2024')]"
22032,Moving Forward on Tumor Pathology Research Reporting: A Guide for Pathologists From the World Health Organization Classification of Tumors Living Evidence Gap Map by Tumour Type Group,"Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies","Oncology, Pathology",Whole report, ,"cancer, case series, case-control, checklist, checklists, clinical trial, clinical trials, cohort, diagnosis, diagnostic, histopathology, neoplasia, observational, oncology, pathological, pathologist, pathologists, pathology, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials, tumor, tumor pathology, tumour, tumour pathology", ,"Colling R, Indave I, Del Aguilla J, Cierco Jimenez R, Campbell F, Chechlinska M, Kowalewska M, Holdenrieder S, Trulson I, Worf K Poll\xe1n M, Plans-Beriso E, P\xe9rez-G\xf3mez B, Craciun O, Garc\xeda-Ovejero E, Irmina Maria Michalek 9, Maslova K, Rymkiewicz G, Didkowska J, Hoon Tan P, Diyana Bte Md Nasir N, Myles N, Giesen C, Goldman-L\xe9vy G, Lokuhetty D, Cree IA. Moving Forward on Tumor Pathology Research Reporting: A Guide for Pathologists From the World Health Organization Classification of Tumors Living Evidence Gap Map by Tumour Type Group. Mod Pathol. 2024;37(7):100515.","Colling R, Indave I, Del Aguilla J, Cierco Jimenez R, Campbell F, Chechlinska M, Kowalewska M, Holdenrieder S, Trulson I, Worf K Poll\xe1n M, Plans-Beriso E, P\xe9rez-G\xf3mez B, Craciun O, Garc\xeda-Ovejero E, Irmina Maria Michalek 9, Maslova K, Rymkiewicz G, Didkowska J, Hoon Tan P, Diyana Bte Md Nasir N, Myles N, Giesen C, Goldman-L\xe9vy G, Lokuhetty D, Cree IA.",Modern Pathology [Mod Pathol.],2024,37,7,100515, ,English, ,38763419,https://pubmed.ncbi.nlm.nih.gov/38763419/, , , , , , ,Reporting histopathology-based studies., , , , , , , ,no,2024-10-24 16:33:50,2025-06-19 08:14:44,moving-forward-on-tumor-pathology-research-reporting-a-guide-for-pathologists-from-the-world-health-organization-classification-of-tumors-living-evidence-gap-map-by-tumour-type-group,"[('title', 'Moving Forward on Tumor Pathology Research Reporting: A Guide for Pathologists From the World Health Organization Classification of Tumors Living Evidence Gap Map by Tumour Type Group'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting histopathology-based studies.'), ('Full bibliographic reference', 'Colling R, Indave I, Del Aguilla J, Cierco Jimenez R, Campbell F, Chechlinska M, Kowalewska M, Holdenrieder S, Trulson I, Worf K Pollán M, Plans-Beriso E, Pérez-Gómez B, Craciun O, García-Ovejero E, Irmina Maria Michalek 9, Maslova K, Rymkiewicz G, Didkowska J, Hoon Tan P, Diyana Bte Md Nasir N, Myles N, Giesen C, Goldman-Lévy G, Lokuhetty D, Cree IA. Moving Forward on Tumor Pathology Research Reporting: A Guide for Pathologists From the World Health Organization Classification of Tumors Living Evidence Gap Map by Tumour Type Group. Mod Pathol. 2024;37(7):100515.'), ('Language', 'English'), ('PubMed ID', '[38763419](https://pubmed.ncbi.nlm.nih.gov/38763419/)'), ('Study design', 'Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies'), ('Clinical area', 'Oncology, Pathology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'June 19, 2025')]"
22030,Guideline for RSA and CT-RSA implant migration measurements: an update of standardizations and recommendations,"Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies","Radiology, Rheumatology, Surgery","Abstract, Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.), Title", ,"checklist, checklists, computed radiography, computed tomography, computed tomography (CT)-based migration measurements, CT-RSA, diagnosis, diagnostic, digital radiography, hip, implant, implants, joint, joint prosthesis, joint replacement, joint replacements, joints, knee, migration, migration analysis, orthopaedic, orthopaedics, orthopedic, orthopedics, prostheses, prosthesis, prosthesis migration, radiograph, radiographs, radiostereometric, radiostereometric analysis, radiostereometry, roentgen stereophotogrammetric analysis, RSA", ,"Kaptein BL, Pijls B, Koster L, K\xe4rrholm J, Hull M, Niesen A, Heesterbeek P, Callary S, Teeter M, Gascoyne T, R\xf6hrl SM, Flivik G, Bragonzoni L, Laende E, Sandberg O, Solomon LB, Nelissen R, Stilling M. Guideline for RSA and CT-RSA implant migration measurements: an update of standardizations and recommendations. Acta Orthop. 2024;95:256-267.","Kaptein BL, Pijls B, Koster L, K\xe4rrholm J, Hull M, Niesen A, Heesterbeek P, Callary S, Teeter M, Gascoyne T, R\xf6hrl SM, Flivik G, Bragonzoni L, Laende E, Sandberg O, Solomon LB, Nelissen R, Stilling M.",Acta Orthopaedica [Acta Orthop.],2024,95, ,256-267, ,English, ,38819193,https://pubmed.ncbi.nlm.nih.gov/38819193/, , , , , , ,Reporting of prosthesis migration studies., , , , , , , ,no,2024-10-24 15:52:57,2024-10-24 15:52:57,guideline-for-rsa-and-ct-rsa-implant-migration-measurements-an-update-of-standardizations-and-recommendations,"[('title', 'Guideline for RSA and CT-RSA implant migration measurements: an update of standardizations and recommendations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of prosthesis migration studies.'), ('Full bibliographic reference', 'Kaptein BL, Pijls B, Koster L, Kärrholm J, Hull M, Niesen A, Heesterbeek P, Callary S, Teeter M, Gascoyne T, Röhrl SM, Flivik G, Bragonzoni L, Laende E, Sandberg O, Solomon LB, Nelissen R, Stilling M. Guideline for RSA and CT-RSA implant migration measurements: an update of standardizations and recommendations. Acta Orthop. 2024;95:256-267.'), ('Language', 'English'), ('PubMed ID', '[38819193](https://pubmed.ncbi.nlm.nih.gov/38819193/)'), ('Study design', 'Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies'), ('Clinical area', 'Radiology, Rheumatology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Abstract, Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.), Title'), ('Record last updated on', 'October 24, 2024')]"
22028,Publication guidelines for human heart rate and heart rate variability studies in psychophysiology-Part 1: Physiological underpinnings and foundations of measurement,"Clinical trials, Experimental studies, Observational studies","Cardiovascular medicine, Neurology, Psychology","Data, Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)", ,"arrhythmia, brain, cardiac, cardiology, clinical trial, clinical trials, electrocardiographic, heart, heart rate, heart rate variability, heart rhythm, heartbeat, HR, HRV, observational, photoplethysmographic, physiology, psychology, psychophysiological, psychophysiology, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, respiratory sinus arrhythmia, trial, trials, vascular", ,"Quigley KS, Gianaros PJ, Norman GJ, Jennings JR, Berntson GG, de Geus EJC. Publication guidelines for human heart rate and heart rate variability studies in psychophysiology-Part 1: Physiological underpinnings and foundations of measurement. Psychophysiology. 2024;61(9):e14604.","Quigley KS, Gianaros PJ, Norman GJ, Jennings JR, Berntson GG, de Geus EJC.",Psychophysiology,2024,61,9,e14604, ,English, ,38873876,https://pubmed.ncbi.nlm.nih.gov/38873876/, , , , , , ,Reporting heart rate (HR) and heart rate variability (HRV) studies., , , , , , , ,no,2024-10-24 14:20:31,2024-10-24 14:20:31,publication-guidelines-for-human-heart-rate-and-heart-rate-variability-studies-in-psychophysiology-part-1-physiological-underpinnings-and-foundations-of-measurement,"[('title', 'Publication guidelines for human heart rate and heart rate variability studies in psychophysiology -Part 1: Physiological underpinnings and foundations of measurement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting heart rate (HR) and heart rate variability (HRV) studies.'), ('Full bibliographic reference', 'Quigley KS, Gianaros PJ, Norman GJ, Jennings JR, Berntson GG, de Geus EJC. Publication guidelines for human heart rate and heart rate variability studies in psychophysiology-Part 1: Physiological underpinnings and foundations of measurement. Psychophysiology. 2024;61(9):e14604.'), ('Language', 'English'), ('PubMed ID', '[38873876](https://pubmed.ncbi.nlm.nih.gov/38873876/)'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Cardiovascular medicine, Neurology, Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'October 24, 2024')]"
22026,Standardized reporting on studies of psychiatric pharmacist interventions,"Clinical trials, Experimental studies, Observational studies, Qualitative research","Pharmaceutical medicine, Psychiatry",Intervention (exposure), ,"BCPP intervention, BCPP interventions, Board-Certified Psychiatric Pharmacist (BCPP) intervention, Board-Certified Psychiatric Pharmacist (BCPP) interventions, checklist, checklists, clinical trial, clinical trials, drug, drugs, EPaCIR, EPaCIR checklist, intervention, interventions, medication, medications, medicine, medicines, observational, PaCIR, pharmacist, pharmacists, pharmacy, psychiatric, psychiatry, qualitative, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Parmentier BL, Lister JF, Moore TD, Reinstatler K, Santos RT, Payne GH. Standardized reporting on studies of psychiatric pharmacist interventions. Ment Health Clin. 2024;14(4):271-276.","Parmentier BL, Lister JF, Moore TD, Reinstatler K, Santos RT, Payne GH.",The Mental Health Clinician [Ment Health Clin.],2024,14,4,271-276, ,English, ,39104438,https://pubmed.ncbi.nlm.nih.gov/39104438/, , , , , ,EPaCIR,Reporting psychiatric pharmacist interventions in research studies., , , , , , , ,no,2024-10-24 11:39:49,2024-10-24 11:39:49,standardized-reporting-on-studies-of-psychiatric-pharmacist-interventions,"[('title', 'Standardized reporting on studies of psychiatric pharmacist interventions'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting psychiatric pharmacist interventions in research studies.'), ('Full bibliographic reference', 'Parmentier BL, Lister JF, Moore TD, Reinstatler K, Santos RT, Payne GH. Standardized reporting on studies of psychiatric pharmacist interventions. Ment Health Clin. 2024;14(4):271-276.'), ('Language', 'English'), ('PubMed ID', '[39104438](https://pubmed.ncbi.nlm.nih.gov/39104438/)'), ('Reporting guideline acronym', 'EPaCIR'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Qualitative research'), ('Clinical area', 'Pharmaceutical medicine, Psychiatry'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'October 24, 2024')]"
21990,PRIDASE 2024 guidelines for reporting diagnostic accuracy studies in endodontics: A consensus-based development,Diagnostic and prognostic studies,Dentistry,Whole report, ,"checklist, checklists, Dentist, Dentistry, diagnosis, diagnostic, diagnostic accuracy studies, diagnostic accuracy study, endodontic, Endodontics, endodontology, Preferred Reporting Items for Diagnostic Accuracy Studies in Endodontics, PRIDASE, PRIDASE 2024, PRIDASE 2024 checklist, PRIDASE checklist, prognosis, prognostic", ,"Nagendrababu V, Pigg M, Duncan HF, Abbott PV, Fouad AF, Kruse C, Patel S, Rechenberg DK, Setzer FC, Rossi-Fedele G, Dummer PMH. PRIDASE 2024 guidelines for reporting diagnostic accuracy studies in endodontics: A consensus-based development. Int Endod J. 2024;57(8):996-1005.","Nagendrababu V, Pigg M, Duncan HF, Abbott PV, Fouad AF, Kruse C, Patel S, Rechenberg DK, Setzer FC, Rossi-Fedele G, Dummer PMH.",International Endodontic Journal [Int Endod J.],2024,57,8,996-1005, ,English, ,38669132,https://pubmed.ncbi.nlm.nih.gov/38669132/, ,"Pigg M, Nagendrababu V, Duncan HF, Abbott PV, Fouad AF, Kruse C, Patel S, Rechenberg DK, Suresh N, Shetty YN, Dummer PMH. PRIDASE 2024 guidelines for reporting diagnostic accuracy studies in endodontics: Explanation and elaboration. Int Endod J. 2024. PMID: 39298282", , ,https://pride-endodonticguidelines.org/pridase/,PRIDASE,Reporting diagnostic accuracy studies in endodontics., , , , , , , ,no,2024-10-03 17:05:03,2024-10-03 17:05:03,pridase-2024-guidelines-for-reporting-diagnostic-accuracy-studies-in-endodontics-a-consensus-based-development,"[('title', 'PRIDASE 2024 guidelines for reporting diagnostic accuracy studies in endodontics: A consensus-based development'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting diagnostic accuracy studies in endodontics.'), ('Full bibliographic reference', 'Nagendrababu V, Pigg M, Duncan HF, Abbott PV, Fouad AF, Kruse C, Patel S, Rechenberg DK, Setzer FC, Rossi-Fedele G, Dummer PMH. PRIDASE 2024 guidelines for reporting diagnostic accuracy studies in endodontics: A consensus-based development. Int Endod J. 2024;57(8):996-1005.'), ('Language', 'English'), ('PubMed ID', '[38669132](https://pubmed.ncbi.nlm.nih.gov/38669132/)'), ('Explanation and elaboration papers', 'Pigg M, Nagendrababu V, Duncan HF, Abbott PV, Fouad AF, Kruse C, Patel S, Rechenberg DK, Suresh N, Shetty YN, Dummer PMH. PRIDASE 2024 guidelines for reporting diagnostic accuracy studies in endodontics: Explanation and elaboration. Int Endod J. 2024. PMID: [39298282](https://pubmed.ncbi.nlm.nih.gov/39298282/)'), ('Reporting guideline website URL', '<https://pride-endodonticguidelines.org/pridase/>'), ('Reporting guideline acronym', 'PRIDASE'), ('Study design', 'Diagnostic and prognostic studies'), ('Clinical area', 'Dentistry'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 3, 2024')]"
21988,"Enhancing the quality of evidence, comparability, and reproducibility in ventriculoatrial shunt research for normal pressure hydrocephalus: A systematic review and VAS-NPH reporting guideline","Experimental studies, Observational studies","Neurology, Surgery",Whole report, ,"checklist, checklists, neurology, neuroscience, neurosurgery, neurosurgical, normal pressure hydrocephalus, NPH, VAS, VAS-NPH, ventriculoatrial shunt", ,"Yuri Ferreira M, Oliveira LB, Porto J\xfanior S, Semione G, Palavani LB, Batista S, Pari Mitre L, Borges PGLB, Abrantes Barros E, Andre\xe3o F, Porto Sousa M, Gomez D, Bertani R, Hakim F. Enhancing the quality of evidence, comparability, and reproducibility in ventriculoatrial shunt research for normal pressure hydrocephalus: A systematic review and VAS-NPH reporting guideline. J Clin Neurosci. 2024;126:328-337.","Yuri Ferreira M, Oliveira LB, Porto J\xfanior S, Semione G, Palavani LB, Batista S, Pari Mitre L, Borges PGLB, Abrantes Barros E, Andre\xe3o F, Porto Sousa M, Gomez D, Bertani R, Hakim F.",Journal of Clinical Neuroscience [J Clin Neurosci.],2024,126, ,328-337, ,English, ,39024937,https://pubmed.ncbi.nlm.nih.gov/39024937/, , , , , ,VAS-NPH,Reporting of studies of ventriculoatrial shunt (VAS) treatment for normal pressure hydrocephalus (NPH)., , , , , , , ,no,2024-10-03 16:04:48,2024-10-03 16:07:18,enhancing-the-quality-of-evidence-comparability-and-reproducibility-in-ventriculoatrial-shunt-research-for-normal-pressure-hydrocephalus-a-systematic-review-and-vas-nph-reporting-guideline,"[('title', 'Enhancing the quality of evidence, comparability, and reproducibility in ventriculoatrial shunt research for normal pressure hydrocephalus: A systematic review and VAS-NPH reporting guideline'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of studies of ventriculoatrial shunt (VAS) treatment for normal pressure hydrocephalus (NPH).'), ('Full bibliographic reference', 'Yuri Ferreira M, Oliveira LB, Porto Júnior S, Semione G, Palavani LB, Batista S, Pari Mitre L, Borges PGLB, Abrantes Barros E, Andreão F, Porto Sousa M, Gomez D, Bertani R, Hakim F. Enhancing the quality of evidence, comparability, and reproducibility in ventriculoatrial shunt research for normal pressure hydrocephalus: A systematic review and VAS-NPH reporting guideline. J Clin Neurosci. 2024;126:328-337.'), ('Language', 'English'), ('PubMed ID', '[39024937](https://pubmed.ncbi.nlm.nih.gov/39024937/)'), ('Reporting guideline acronym', 'VAS-NPH'), ('Study design', 'Experimental studies, Observational studies'), ('Clinical area', 'Neurology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 3, 2024')]"
21986,Development and validation of observational and qualitative study protocol reporting checklists for novice researchers (ObsQual checklist),"Observational studies, Qualitative research, Study protocols", ,Whole report, ,"checklist, checklists, observation, observational, observational study protocol, ObsQual, ObsQual checklist, protocol, protocols, qualitative, qualitative study protocol", ,"Low GK, Subedi S, Omosumwen OF, Jiee SF, Devkota S, Shanmuganathan S, Doyle Z. Development and validation of observational and qualitative study protocol reporting checklists for novice researchers (ObsQual checklist). Eval Program Plann. 2024;106:102468.","Low GK, Subedi S, Omosumwen OF, Jiee SF, Devkota S, Shanmuganathan S, Doyle Z.",Evaluation and Program Planning [Eval Program Plann.],2024,106, ,102468, ,English, ,39029287,https://pubmed.ncbi.nlm.nih.gov/39029287/, , , , , ,ObsQual,Reporting of observational and qualitative study protocols., , , , , , , ,no,2024-10-03 15:39:30,2024-10-03 15:39:30,development-and-validation-of-observational-and-qualitative-study-protocol-reporting-checklists-for-novice-researchers-obsqual-checklist,"[('title', 'Development and validation of observational and qualitative study protocol reporting checklists for novice researchers (ObsQual checklist)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of observational and qualitative study protocols.'), ('Full bibliographic reference', 'Low GK, Subedi S, Omosumwen OF, Jiee SF, Devkota S, Shanmuganathan S, Doyle Z. Development and validation of observational and qualitative study protocol reporting checklists for novice researchers (ObsQual checklist). Eval Program Plann. 2024;106:102468.'), ('Language', 'English'), ('PubMed ID', '[39029287](https://pubmed.ncbi.nlm.nih.gov/39029287/)'), ('Reporting guideline acronym', 'ObsQual'), ('Study design', 'Observational studies, Qualitative research, Study protocols'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 3, 2024')]"
21984,"ChecKAP: A Checklist for Reporting a Knowledge, Attitude, and Practice (KAP) Study",Qualitative research,Public health,Whole report, ,"ChecKAP, checklist, Checklist for Reporting Items for Knowledge Attitude and Practice, checklists, KAP, KAP checklist, KAP studies, KAP study, KAP survey, KAP surveys, knowledge, knowledge attitudes practices, knowledge attitudes practices studies, knowledge attitudes practices study, population, public health, qualitative, survey, surveys", ,"Zarei F, Dehghani A, Ratansiri A, Ghaffari M, Raina SK, Halimi A, Rakhshanderou S, Isamel SA, Amiri P, Aminafshar A, Mosavi Jarrahi A. ChecKAP: A Checklist for Reporting a Knowledge, Attitude, and Practice (KAP) Study. Asian Pac J Cancer Prev. 2024;25(7):2573-2577.","Zarei F, Dehghani A, Ratansiri A, Ghaffari M, Raina SK, Halimi A, Rakhshanderou S, Isamel SA, Amiri P, Aminafshar A, Mosavi Jarrahi A.",Asian Pacific Journal of Cancer Prevention [Asian Pac J Cancer Prev.],2024,25,7,2573-2577, ,English, ,39068593,https://pubmed.ncbi.nlm.nih.gov/39068593/, , , , , ,ChecKAP,"Reporting Knowledge, Attitude, and Practices (KAP) Studies.", ,The checklist can be found in appendix 1 of the supplementary file., , , , , ,no,2024-10-03 15:03:13,2024-10-03 15:03:13,checkap-a-checklist-for-reporting-a-knowledge-attitude-and-practice-kap-study,"[('title', 'Chec KAP : A Checklist for Reporting a Knowledge, Attitude, and Practice (KAP) Study'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting Knowledge, Attitude, and Practices (KAP) Studies.'), ('Full bibliographic reference', 'Zarei F, Dehghani A, Ratansiri A, Ghaffari M, Raina SK, Halimi A, Rakhshanderou S, Isamel SA, Amiri P, Aminafshar A, Mosavi Jarrahi A. ChecKAP: A Checklist for Reporting a Knowledge, Attitude, and Practice (KAP) Study. Asian Pac J Cancer Prev. 2024;25(7):2573-2577.'), ('Language', 'English'), ('PubMed ID', '[39068593](https://pubmed.ncbi.nlm.nih.gov/39068593/)'), ('Reporting guideline acronym', 'ChecKAP'), ('Study design', 'Qualitative research'), ('Clinical area', 'Public health'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'The checklist can be found in appendix 1 of the supplementary file.'), ('Record last updated on', 'October 3, 2024')]"
21977,A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist,"Economic evaluations, Qualitative research", ,Whole report, ,"checklist, checklists, DCE, DCEs, DIRECT, DIRECT checklist, discrete choice experiment, DIscrete choice experiment REporting ChecklisT, discrete choice experiments, economic, economic evaluations, economics, economy, health preference, health preference research, health preferences, preference, preferences, qualitative, survey, surveys", ,"Ride J, Goranitis I, Meng Y, LaBond C, Lancsar E. A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist. Pharmacoeconomics. 2024;42(10):1161-1175.","Ride J, Goranitis I, Meng Y, LaBond C, Lancsar E.",Pharmacoeconomics.,2024,42,10,1161-1175, ,English, ,39227559,https://pubmed.ncbi.nlm.nih.gov/39227559/, , , , , ,DIRECT,Reporting of discrete choice experiments (DCEs) in health research., , , , , , , ,no,2024-10-01 12:03:20,2024-10-01 12:20:58,a-reporting-checklist-for-discrete-choice-experiments-in-health-the-direct-checklist,"[('title', 'A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of discrete choice experiments (DCEs) in health research.'), ('Full bibliographic reference', 'Ride J, Goranitis I, Meng Y, LaBond C, Lancsar E. A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist. Pharmacoeconomics. 2024;42(10):1161-1175.'), ('Language', 'English'), ('PubMed ID', '[39227559](https://pubmed.ncbi.nlm.nih.gov/39227559/)'), ('Reporting guideline acronym', 'DIRECT'), ('Study design', 'Economic evaluations, Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 1, 2024')]"
21876,Improving laboratory animal genetic reporting: LAG-R guidelines,Animal pre-clinical research, ,"Procedure/Method, Study characteristics (participants etc.), Terminology/definitions", ,"animal, animal model, animal models, animal research, animal studies, animal study, animals, experiment, experimental, experiments, gene, genes, genetic, genetics, genome, genomes, genomic, laboratories, laboratory, laboratory animal genetic reporting guidelines, LAG-R, LAG-R guidelines, pre clinical research, pre clinical studies, pre clinical study", ,"Teboul L, Amos-Landgraf J, Benavides FJ, Birling MC, Brown SDM, Bryda E, Bunton-Stasyshyn R, Chin HJ, Crispo M, Delerue F, Dobbie M, Franklin CL, Fuchtbauer EM, Gao X, Golzio C, Haffner R, H\xe9rault Y, Hrabe de Angelis M, Lloyd KCK, Magnuson TR, Montoliu L, Murray SA, Nam KH, Nutter LMJ, Pailhoux E, Pardo Manuel de Villena F, Peterson K, Reinholdt L, Sedlacek R, Seong JK, Shiroishi T, Smith C, Takeo T, Tinsley L, Vilotte JL, Warming S, Wells S, Whitelaw CB, Yoshiki A; Asian Mouse Mutagenesis Resource Association; CELPHEDIA infrastructure; INFRAFRONTIER consortium; International Mammalian Genome Society; International Mouse Phenotyping Consortium; International Society for Transgenic Technologies; Mutant Mouse Resource and Research Centers; Phenomics Australia; RRRC- Rat Resource and Research Center; Pavlovic G. Improving laboratory animal genetic reporting: LAG-R guidelines. Nat Commun. 2024;15(1):5574.","Teboul L, Amos-Landgraf J, Benavides FJ, Birling MC, Brown SDM, Bryda E, Bunton-Stasyshyn R, Chin HJ, Crispo M, Delerue F, Dobbie M, Franklin CL, Fuchtbauer EM, Gao X, Golzio C, Haffner R, H\xe9rault Y, Hrabe de Angelis M, Lloyd KCK, Magnuson TR, Montoliu L, Murray SA, Nam KH, Nutter LMJ, Pailhoux E, Pardo Manuel de Villena F, Peterson K, Reinholdt L, Sedlacek R, Seong JK, Shiroishi T, Smith C, Takeo T, Tinsley L, Vilotte JL, Warming S, Wells S, Whitelaw CB, Yoshiki A; Asian Mouse Mutagenesis Resource Association; CELPHEDIA infrastructure; INFRAFRONTIER consortium; International Mammalian Genome Society; International Mouse Phenotyping Consortium; International Society for Transgenic Technologies; Mutant Mouse Resource and Research Centers; Phenomics Australia; RRRC- Rat Resource and Research Center; Pavlovic G.",Nature Communications [Nat Commun.],2024,15,1,5574, ,English, ,38956430,https://pubmed.ncbi.nlm.nih.gov/38956430/, , , , , ,LAG-R,Reporting laboratory animals? genetic makeup in research studies., , , , , , , ,no,2024-07-29 14:18:36,2024-07-29 14:18:36,improving-laboratory-animal-genetic-reporting-lag-r-guidelines,"[('title', 'Improving laboratory animal genetic reporting: LAG-R guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting laboratory animals’ genetic makeup in research studies.'), ('Full bibliographic reference', 'Teboul L, Amos-Landgraf J, Benavides FJ, Birling MC, Brown SDM, Bryda E, Bunton-Stasyshyn R, Chin HJ, Crispo M, Delerue F, Dobbie M, Franklin CL, Fuchtbauer EM, Gao X, Golzio C, Haffner R, Hérault Y, Hrabe de Angelis M, Lloyd KCK, Magnuson TR, Montoliu L, Murray SA, Nam KH, Nutter LMJ, Pailhoux E, Pardo Manuel de Villena F, Peterson K, Reinholdt L, Sedlacek R, Seong JK, Shiroishi T, Smith C, Takeo T, Tinsley L, Vilotte JL, Warming S, Wells S, Whitelaw CB, Yoshiki A; Asian Mouse Mutagenesis Resource Association; CELPHEDIA infrastructure; INFRAFRONTIER consortium; International Mammalian Genome Society; International Mouse Phenotyping Consortium; International Society for Transgenic Technologies; Mutant Mouse Resource and Research Centers; Phenomics Australia; RRRC- Rat Resource and Research Center; Pavlovic G. Improving laboratory animal genetic reporting: LAG-R guidelines. Nat Commun. 2024;15(1):5574.'), ('Language', 'English'), ('PubMed ID', '[38956430](https://pubmed.ncbi.nlm.nih.gov/38956430/)'), ('Reporting guideline acronym', 'LAG-R'), ('Study design', 'Animal pre-clinical research'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'July 29, 2024')]"
21866,The OHStat Guidelines for Reporting Observational Studies and Clinical Trials in Oral Health Research: Manuscript Checklist,"Clinical trials, Experimental studies, Observational studies",Dentistry,Whole report, ,"checklist, checklists, clinical trial, clinical trials, dental, Dentist, Dentistry, nonrandomised trial, nonrandomised trials, nonrandomized trial, nonrandomized trials, observation, observational, OHStat, OHStat checklist, OHStat guidelines, oral, oral health, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Best AM, Lang TA, Greenberg BL, Gunsolley JC, Ioannidou E; Task Force on Design and Analysis in Oral Health Research. The OHStat Guidelines for Reporting Observational Studies and Clinical Trials in Oral Health Research: Manuscript Checklist.

This guideline was published simultaneously in 5 journals. You can read the guideline in any of these journals using the links below.

J Am Dent Assoc. 2024:S0002-8177(24)00315-5. PMID: 39001724
J Endod. 2024:S0099-2399(24)00302-9. PMID: 39007795
J Dent Res. 2024:220345241247028. PMID: 38993043
J Oral Maxillofac Surg. 2024:S0278-2391(24)00585-8. PMID: 39033786
Angle Orthod (2024). Link to full-text.

","Best AM, Lang TA, Greenberg BL, Gunsolley JC, Ioannidou E; Task Force on Design and Analysis in Oral Health Research.", , , , , , ,English, , , , ,"Best AM, Lang TA, Greenberg BL, Gunsolley JC, Ioannidou E; Task Force on Design and Analysis in Oral Health Research. The OHStat Guidelines for Reporting Observational Studies and Clinical Trials in Oral Health Research: explanation and elaboration.

J Am Dent Assoc. 2024:S0002-8177(24)00316-7. PMID: 39001723
JDR Clin Trans Res. 2024:23800844241247029. PMID: 38993046
J Oral Maxillofac Surg. 2024. Link to full-text.

", , , ,OHStat,Reporting observational studies and clinical trials in oral health research., , , , , , , ,no,2024-07-29 11:48:03,2024-07-29 11:48:03,the-ohstat-guidelines-for-reporting-observational-studies-and-clinical-trials-in-oral-health-research-manuscript-checklist,"[('title', 'The OHStat Guidelines for Reporting Observational Studies and Clinical Trials in Oral Health Research: Manuscript Checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting observational studies and clinical trials in oral health research.'), ('Full bibliographic reference', 'Best AM, Lang TA, Greenberg BL, Gunsolley JC, Ioannidou E; Task Force on Design and Analysis in Oral Health Research. The OHStat Guidelines for Reporting Observational Studies and Clinical Trials in Oral Health Research: Manuscript Checklist.\n\n \n\n This guideline was published simultaneously in 5 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n J Am Dent Assoc. 2024:S0002-8177(24)00315-5. PMID: [39001724](https://pubmed.ncbi.nlm.nih.gov/39001724/)\n\n J Endod. 2024:S0099-2399(24)00302-9. PMID: [39007795](https://pubmed.ncbi.nlm.nih.gov/39007795/)\n\n J Dent Res. 2024:220345241247028. PMID: [38993043](https://pubmed.ncbi.nlm.nih.gov/38993043/)\n\n J Oral Maxillofac Surg. 2024:S0278-2391(24)00585-8. PMID: [39033786](https://pubmed.ncbi.nlm.nih.gov/39033786/)\n\n Angle Orthod (2024). [Link to full-text](https://meridian.allenpress.com/angle-orthodontist/article/doi/10.2319/OHStat_Guidelines.1/501485/The-OHStat-guidelines-for-reporting-observational).\n\n \n\n'), ('Language', 'English'), ('Explanation and elaboration papers', 'Best AM, Lang TA, Greenberg BL, Gunsolley JC, Ioannidou E; Task Force on Design and Analysis in Oral Health Research. The OHStat Guidelines for Reporting Observational Studies and Clinical Trials in Oral Health Research: explanation and elaboration.\n\n \n\n J Am Dent Assoc. 2024:S0002-8177(24)00316-7. PMID: [39001723](https://pubmed.ncbi.nlm.nih.gov/39001723/)\n\n JDR Clin Trans Res. 2024:23800844241247029. PMID: [38993046](https://pubmed.ncbi.nlm.nih.gov/38993046/)\n\n J Oral Maxillofac Surg. 2024. [Link to full-text](https://www.joms.org/article/S0278-2391(24)00584-6/fulltext).\n\n \n\n'), ('Reporting guideline acronym', 'OHStat'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Dentistry'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'July 29, 2024')]"
21851,Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI&F Checklist,Clinical practice guidelines, ,"Conflict of interest, Funding", ,"checklist, checklists, COI, COIs, conflict, conflict of interest, conflicts, conflicts of interest, funding, guidance, guideline, guidelines, health care guideline, health care guidelines, healthcare guideline, healthcare guidelines, policies, policy, RIGHT extension, RIGHT-COI&amp;F, RIGHT-COI&amp;F checklist", ,"Xun Y, Estill J, Khabsa J, Florez ID, Guyatt GH, Norris SL, Lee MS, Ozaki A, Qaseem A, Sch\xfcnemann HJ, Shao R, Chen Y, Akl EA; RIGHT-COI&amp;F Working Groups. Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI&amp;F Checklist. Ann Intern Med. 2024;177(6):782-790.","Xun Y, Estill J, Khabsa J, Florez ID, Guyatt GH, Norris SL, Lee MS, Ozaki A, Qaseem A, Sch\xfcnemann HJ, Shao R, Chen Y, Akl EA; RIGHT-COI&amp;F Working Groups.",Ann Intern Med.,2024,177,6,782-790, ,English, ,38739919,https://pubmed.ncbi.nlm.nih.gov/38739919/, , , ,"Generic
RIGHT: Chen Y, Yang K, Maru?i? A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Sch\xfcnemann HJ, Chan ESY, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; for the RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group. A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166(2):128-132. PMID: 27893062

Specialised
RIGHT-TCM: Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, Xia L, Guo Y. The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Pharmacol Res. 2020;160:105178. PMID: 32889127

RIGHT-PVG: Wang X, Chen Y, Akl EA, Tokali? R, Maru?i? A, Qaseem A, Falck-Ytter Y, Lee MS, Siedler M, Barber SL, Zhang M, Chan ESY, Estill J, Kwong JSW, Okumura A, Zhou Q, Yang K, Norris SL; RIGHT working group. The reporting checklist for public versions of guidelines: RIGHT-PVG. Implement Sci. 2021;16(1):10. PMID: 33430911

RIGHT for Acupuncture: Tang C, Duan Y, Zhang Y, Zhang Y, Chen Z, Tang X, Zeng J, Riley D, Lee MS, Kim YS, Zhao H, Marrone G, Zhu X, Ge S, Wen H, Zhao W, Zheng X, Solos I, Chen Y, Guyatt G, Lu L, Xu N; RIGHT (Reporting Items for Practice Guidelines in Healthcare) for Acupuncture Working Group. RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture. J Clin Epidemiol. 2021:S0895-4356(21)00173-6. PMID: 34091023

RIGHT for INT: Zhou Q, Xing D, Li Q, Zhang J, Luo X, Yang N, Wang X, Yang K, Tian J, Li H, Li B, Cai Y, Jin Y, Lv L, Sun F, Shang S, Yuan B, Li J, Ma B, Li X, Yuan Y, Wu L, Wang B, Jiang L, Wang Z, Chen Y, Liang D. An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT. J Evid Based Med. 2022;15(1):55-63. PMID: 35416438

RIGHT-Ad@pt: Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RWM, Arayssi T, Bhaumik S, Chen Y, Ghersi D, Langlois EV, Fuentes Padilla P, Sch\xfcnemann HJ, Akl EA, Mart\xednez Garc\xeda L; RIGHT-Ad@pt Working Group*, Amer Y, Arevalo-Rodriguez I, Barnes S, Barreto J, Collis D, Dyer S, Fahim C, Florez I, Gallegos-Rivero V, Klugar M, Kuijpers T, Mathew JL, Munn Z, Norris S, Pati\xf1o-Lugo DF, Pramesh CS, Rodriguez J, Roy S, Shin ES, Sosa O, Vandvik PO, Velez M, Woodcraft R; RIGHT-Ad@pt Working Group. A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Ann Intern Med. 2022;175(5):710-719. PMID: 35286143

RIGHT for CPM: Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C. The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. Pharmacol Res. 2024;199:107015. PMID: 38036197

",http://www.right-statement.org/extensions/23,RIGHT-COI&F,Reporting of conflicts of interest and funding in healthcare guideline development., ,Read the study protocol., , , , , ,yes,2024-07-26 14:49:22,2024-07-26 15:29:54,reporting-conflicts-of-interest-and-funding-in-health-care-guidelines-the-right-coif-checklist,"[('title', 'Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI &F Checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of conflicts of interest and funding in healthcare guideline development.'), ('Full bibliographic reference', 'Xun Y, Estill J, Khabsa J, Florez ID, Guyatt GH, Norris SL, Lee MS, Ozaki A, Qaseem A, Schünemann HJ, Shao R, Chen Y, Akl EA; RIGHT-COI&F Working Groups. Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI&F Checklist. Ann Intern Med. 2024;177(6):782-790.'), ('Language', 'English'), ('PubMed ID', '[38739919](https://pubmed.ncbi.nlm.nih.gov/38739919/)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**RIGHT**](https://www.equator-network.org/reporting-guidelines/right-statement/): Chen Y, Yang K, Marušić A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Schünemann HJ, Chan ESY, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; for the RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group. A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166(2):128-132. PMID: [27893062](https://www.ncbi.nlm.nih.gov/pubmed/27893062)\n\n \n\n**Specialised**\n\n[**RIGHT-TCM**](https://www.equator-network.org/reporting-guidelines/the-right-extension-statement-for-traditional-chinese-medicine-development-recommendations-and-explanation/): Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, Xia L, Guo Y. The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Pharmacol Res. 2020;160:105178. PMID: [32889127](https://pubmed.ncbi.nlm.nih.gov/32889127)\n\n \n\n[**RIGHT-PVG**](https://www.equator-network.org/reporting-guidelines/the-reporting-checklist-for-public-versions-of-guidelines-right-pvg/): Wang X, Chen Y, Akl EA, Tokalić R, Marušić A, Qaseem A, Falck-Ytter Y, Lee MS, Siedler M, Barber SL, Zhang M, Chan ESY, Estill J, Kwong JSW, Okumura A, Zhou Q, Yang K, Norris SL; RIGHT working group. The reporting checklist for public versions of guidelines: RIGHT-PVG. Implement Sci. 2021;16(1):10. PMID: [33430911](https://pubmed.ncbi.nlm.nih.gov/33430911/)\n\n \n\n[**RIGHT for Acupuncture**](https://www.equator-network.org/reporting-guidelines/right-for-acupuncture/): Tang C, Duan Y, Zhang Y, Zhang Y, Chen Z, Tang X, Zeng J, Riley D, Lee MS, Kim YS, Zhao H, Marrone G, Zhu X, Ge S, Wen H, Zhao W, Zheng X, Solos I, Chen Y, Guyatt G, Lu L, Xu N; RIGHT (Reporting Items for Practice Guidelines in Healthcare) for Acupuncture Working Group. RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture. J Clin Epidemiol. 2021:S0895-4356(21)00173-6. PMID: [34091023](https://pubmed.ncbi.nlm.nih.gov/34091023/)\n\n \n\n[**RIGHT for INT**](https://www.equator-network.org/reporting-guidelines/an-extension-of-the-right-statement-for-introductions-and-interpretations-of-clinical-practice-guidelines-right-for-int/): Zhou Q, Xing D, Li Q, Zhang J, Luo X, Yang N, Wang X, Yang K, Tian J, Li H, Li B, Cai Y, Jin Y, Lv L, Sun F, Shang S, Yuan B, Li J, Ma B, Li X, Yuan Y, Wu L, Wang B, Jiang L, Wang Z, Chen Y, Liang D. An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT. J Evid Based Med. 2022;15(1):55-63. PMID: [35416438](https://pubmed.ncbi.nlm.nih.gov/35416438/)\n\n \n\n[**RIGHT-Ad@pt**](https://www.equator-network.org/reporting-guidelines/a-reporting-tool-for-adapted-guidelines-in-health-care-the-right-adapt-checklist/): Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RWM, Arayssi T, Bhaumik S, Chen Y, Ghersi D, Langlois EV, Fuentes Padilla P, Schünemann HJ, Akl EA, Martínez García L; RIGHT-Ad@pt Working Group\\*, Amer Y, Arevalo-Rodriguez I, Barnes S, Barreto J, Collis D, Dyer S, Fahim C, Florez I, Gallegos-Rivero V, Klugar M, Kuijpers T, Mathew JL, Munn Z, Norris S, Patiño-Lugo DF, Pramesh CS, Rodriguez J, Roy S, Shin ES, Sosa O, Vandvik PO, Velez M, Woodcraft R; RIGHT-Ad@pt Working Group. A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Ann Intern Med. 2022;175(5):710-719. PMID: [35286143](https://pubmed.ncbi.nlm.nih.gov/35286143/)\n\n \n\n[**RIGHT for CPM**](https://www.equator-network.org/reporting-guidelines/the-reporting-checklist-for-chinese-patent-medicine-guidelines-right-for-cpm/): Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C. The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. Pharmacol Res. 2024;199:107015. PMID: [38036197](https://pubmed.ncbi.nlm.nih.gov/38036197/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.right-statement.org/extensions/23>'), ('Reporting guideline acronym', 'RIGHT-COI&F'), ('Study design', 'Clinical practice guidelines'), ('Applies to the whole report or to individual sections of the report?', 'Conflict of interest, Funding'), ('Additional information', 'Read the [study protocol](https://pubmed.ncbi.nlm.nih.gov/35845491/).'), ('Record last updated on', 'July 26, 2024')]"
21799,Reporting guidelines for precision medicine research of clinical relevance: the BePRECISE checklist, , ,Whole report, ,"BePRECISE, BePRECISE checklist, individualised medicine, individualized medicine, personalised medicine, personalized medicine, precision medicine", ,"Lim SS, Semnani-Azad Z, Morieri ML, Ng AH, Ahmad A, Fitipaldi H, Boyle J, Collin C, Dennis JM, Langenberg C, Loos RJF, Morrison M, Ramsay M, Sanyal AJ, Sattar N, Hivert MF, Gomez MF, Merino J, Tobias DK, Trenell MI, Rich SS, Sargent JL, Franks PW. Reporting guidelines for precision medicine research of clinical relevance: the BePRECISE checklist. Nat Med. 2024.30:1874?1881.","Lim SS, Semnani-Azad Z, Morieri ML, Ng AH, Ahmad A, Fitipaldi H, Boyle J, Collin C, Dennis JM, Langenberg C, Loos RJF, Morrison M, Ramsay M, Sanyal AJ, Sattar N, Hivert MF, Gomez MF, Merino J, Tobias DK, Trenell MI, Rich SS, Sargent JL, Franks PW.",Nature Medicine [Nat Med.],2024,30, ,1874?1881, ,English, , , ,Read the full-text of the BePRECISE reporting guideline., , , , ,BePRECISE,"Reporting of clinically relevant precision medicine research.



BePRECISE Checklist (Word) \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 BePRECISE Checklist (PDF)

", , , , , , , ,no,2024-07-19 09:05:27,2024-07-19 09:05:27,reporting-guidelines-for-precision-medicine-research-of-clinical-relevance-the-beprecise-checklist,"[('title', 'Reporting guidelines for precision medicine research of clinical relevance: the Be PRECISE checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of clinically relevant precision medicine research.\n\n \n\n \xa0\n\n \n\n[BePRECISE Checklist (Word)](https://www.equator-network.org/wp-content/uploads/2024/07/BePRECISE-Checklist.docx)  [BePRECISE Checklist (PDF)](https://www.equator-network.org/wp-content/uploads/2024/07/BePRECISE-Checklist.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Lim SS, Semnani-Azad Z, Morieri ML, Ng AH, Ahmad A, Fitipaldi H, Boyle J, Collin C, Dennis JM, Langenberg C, Loos RJF, Morrison M, Ramsay M, Sanyal AJ, Sattar N, Hivert MF, Gomez MF, Merino J, Tobias DK, Trenell MI, Rich SS, Sargent JL, Franks PW. Reporting guidelines for precision medicine research of clinical relevance: the BePRECISE checklist. Nat Med. 2024.30:1874–1881.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.nature.com/articles/s41591-024-03033-3) of the BePRECISE reporting guideline.'), ('Reporting guideline acronym', 'BePRECISE'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'July 19, 2024')]"
21797,Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration,"Clinical trials, Experimental studies", ,Whole report, ,"checklist, checklists, clinical trial, clinical trials, CONSORT extension, CONSORT-Surrogate, endpoint, endpoints, experimental studies, experimental study, outcome, outcomes, randomised, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, surrogate, surrogate endpoint, surrogate endpoints, surrogate outcome, surrogate outcomes, trial, trials", ,"Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524.","Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O.",BMJ. [BMJ],2024,386, ,e078524, ,English, ,38981645,https://pubmed.ncbi.nlm.nih.gov/38981645/,"Read the full-text of the CONSORT-Surrogate guideline.

Access the CONSORT-Surrogate checklist (PDF).

", , ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster: Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal: Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts: Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture: MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738. PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,CONSORT-Surrogate,Reporting of trials using surrogate endpoints as the primary outcome(s)., ,"Read the protocol for the development of this reporting guideline.

Read a commentary in the journal Trials.

", , , , , ,yes,2024-07-16 14:38:14,2025-05-30 09:27:23,consort-surrogate,"[('title', 'Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate) : extension checklist with explanation and elaboration'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of trials using surrogate endpoints as the primary outcome(s).'), ('Full bibliographic reference', 'Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524.'), ('Language', 'English'), ('PubMed ID', '[38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.bmj.com/content/386/bmj-2023-078524.long) of the CONSORT-Surrogate guideline.\n\n \n\n Access the [CONSORT-Surrogate checklist (PDF)](https://www.bmj.com/content/bmj/suppl/2024/07/09/bmj-2023-078524.DC1/mana078524.ww3.pdf).\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](https://www.equator-network.org/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](https://www.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](https://www.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](https://www.equator-network.org/reporting-guidelines/consort-cluster/): Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](https://www.equator-network.org/reporting-guidelines/consort-herbal/): Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](https://www.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](https://www.equator-network.org/reporting-guidelines/consort-abstracts/): Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](https://www.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](https://www.equator-network.org/reporting-guidelines/consort-stricta/): MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](https://www.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](https://www.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738. PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](https://www.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](https://www.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](https://www.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](https://www.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](https://www.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://www.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](https://www.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](https://www.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](https://www.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](https://www.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](https://www.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://www.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://www.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://www.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://www.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'CONSORT-Surrogate'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', '[Read the protocol](https://bmjopen.bmj.com/content/12/10/e064304) for the development of this reporting guideline.\n\n \n\n[Read a commentary](https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06904-7) in the journal Trials.\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
21795,Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration,"Clinical trials, Experimental studies, Study protocols", ,Whole report, ,"checklist, checklists, clinical studies, clinical study, clinical trial, clinical trial protocol, clinical trial protocols, clinical trials, endpoint, endpoints, experimental studies, experimental study, interventional trial, interventional trials, outcome, outcomes, protocol, protocols, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, SPIRIT Extension, SPIRIT-Surrogate, surrogate endpoint, surrogate endpoints, surrogate outcome, surrogate outcomes, trial, trial protocol, trial protocols, trials", ,"Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525.","Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O.",BMJ. [BMJ],2024,386, ,e078525, ,English, ,38981624,https://pubmed.ncbi.nlm.nih.gov/38981624/,"Read the full-text of the SPIRIT-Surrogate guideline.

Access the SPIRIT-Surrogate checklist (PDF).

", , ,"Generic

SPIRIT 2025 Statement: Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hr\xf3bjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.

BMJ. 2025; 388:e081660. PMID:\xa040294956
JAMA. 2025.\xa0PMID: 40294593
Lancet 2025.
Nat Med. 2025.\xa0PMID: 40295741
PLoS Med. 2025; 22(4): e1004587.\xa0PMID: 40294521

Specialised
SPIRIT-PRO: Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. Link to abstract

SPIRIT-TCM: Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: 30484022

SPENT 2019: Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. Link to full-text.

SPIRIT-AI: Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.
BMJ. 2020;370:m3210. PMID: 32907797
Nat Med. 2020;26(9):1351?1363. PMID: 32908284
Lancet Digital Health. 2020;2(10):e549-e560. PMID: 33328049

SPIRIT-Path: Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: 34592193

SPIRIT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: 36512367

SPIRIT-DEFINE: Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: 37863491

SPIRIT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: 38051535

SPIRIT-iNeurostim: Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: 39610902

", ,SPIRIT-Surrogate,Reporting of trial protocols using surrogate endpoints as the primary outcome(s)., ,"Read the protocol for the development of this reporting guideline.

Read a commentary in the journal Trials.

", , , , , ,yes,2024-07-16 14:27:21,2025-05-30 09:14:41,spirit-surrogate,"[('title', 'Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate) : extension checklist with explanation and elaboration'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of trial protocols using surrogate endpoints as the primary outcome(s).'), ('Full bibliographic reference', 'Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525.'), ('Language', 'English'), ('PubMed ID', '[38981624](https://pubmed.ncbi.nlm.nih.gov/38981624/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.bmj.com/content/386/bmj-2023-078525) of the SPIRIT-Surrogate guideline.\n\n \n\n Access the [SPIRIT-Surrogate checklist (PDF)](https://www.bmj.com/content/bmj/suppl/2024/07/09/bmj-2023-078525.DC1/mana078525.ww2.pdf).\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n \n\n**[SPIRIT 2025 Statement](https://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/):** Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hróbjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.\n\n \n\nBMJ. 2025; 388:e081660. [PMID:40294956](https://pubmed.ncbi.nlm.nih.gov/40294956/)\n\n JAMA. 2025.[PMID:](https://pubmed.ncbi.nlm.nih.gov/40294593/) [40294593](https://pubmed.ncbi.nlm.nih.gov/40294593/)\n\n Lancet 2025.\n\n Nat Med. 2025.[PMID: 40295741](https://pubmed.ncbi.nlm.nih.gov/40295741)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID: 40294521](https://pubmed.ncbi.nlm.nih.gov/40294521/)\n\n \n\n**Specialised**\n\n[**SPIRIT-PRO**](https://www.equator-network.org/reporting-guidelines/spirit-pro/): Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. [Link to abstract](https://jamanetwork.com/journals/jama/article-abstract/2671472)\n\n \n\n[**SPIRIT-TCM**](https://www.equator-network.org/reporting-guidelines/standard-protocol-items-for-clinical-trials-with-traditional-chinese-medicine-spirit-tcm-extension-2018/): Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: [30484022](https://www.ncbi.nlm.nih.gov/pubmed/30484022)\n\n \n\n[**SPENT 2019**](https://www.equator-network.org/reporting-guidelines/spirit-extension-n-of-1-trials-spent-2019/): Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. [Link to full-text](https://www.bmj.com/content/368/bmj.m122).\n\n \n\n[**SPIRIT-AI**](https://www.equator-network.org/reporting-guidelines/spirit-artificial-intelligence/): Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.\n\n BMJ. 2020;370:m3210. PMID: [32907797](https://pubmed.ncbi.nlm.nih.gov/32907797/)\n\n Nat Med. 2020;26(9):1351–1363. PMID: [32908284](https://pubmed.ncbi.nlm.nih.gov/32908284/)\n\n Lancet Digital Health. 2020;2(10):e549-e560. PMID: [33328049](https://pubmed.ncbi.nlm.nih.gov/33328049/)\n\n \n\n[**SPIRIT-Path**](https://www.equator-network.org/reporting-guidelines/spirit-path/): Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: [34592193](https://pubmed.ncbi.nlm.nih.gov/34592193/)\n\n \n\n[**SPIRIT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-protocols-the-spirit-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: [36512367](https://pubmed.ncbi.nlm.nih.gov/36512367/)\n\n \n\n[**SPIRIT-DEFINE**](https://www.equator-network.org/reporting-guidelines/spirit-define/): Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: [37863491](https://pubmed.ncbi.nlm.nih.gov/37863491/)\n\n \n\n[**SPIRIT Factorial**](https://www.equator-network.org/reporting-guidelines/consensus-statement-for-protocols-of-factorial-randomized-trials-extension-of-the-spirit-2013-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: [38051535](https://pubmed.ncbi.nlm.nih.gov/38051535/)\n\n \n\n[**SPIRIT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-protocols-of-randomised-controlled-trials-of-implantable-neurostimulation-devices-the-spirit-ineurostim-extension/): Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: [39610902](https://pubmed.ncbi.nlm.nih.gov/39610902/)\n\n \n\n""), ('Reporting guideline acronym', 'SPIRIT-Surrogate'), ('Study design', 'Clinical trials, Experimental studies, Study protocols'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', '[Read the protocol](https://bmjopen.bmj.com/content/12/10/e064304) for the development of this reporting guideline.\n\n \n\n[Read a commentary](https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06904-7) in the journal Trials.\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
21787,Supporting best practice in reflexive thematic analysis reporting in Palliative Medicine: A review of published research and introduction to the Reflexive Thematic Analysis Reporting Guidelines (RTARG),Qualitative research,Palliative care,Whole report, ,"coding, data, palliative, qualitative, reflexive, reflexive thematic analysis, Reflexive Thematic Analysis Reporting Guidelines, reflexively, RTARG, thematic, thematic analyses, thematic analysis, theme, themes", ,"Braun V, Clarke V. Supporting best practice in reflexive thematic analysis reporting in Palliative Medicine: A review of published research and introduction to the Reflexive Thematic Analysis Reporting Guidelines (RTARG). Palliat Med. 2024;38(6):608-616.","Braun V, Clarke V.",Palliative Medicine [Palliat Med.],2024,38,6,608-616, ,English, ,38469804,https://pubmed.ncbi.nlm.nih.gov/38469804/, , , , , ,RTARG,Reporting of thematic analysis., , , , , , , ,no,2024-06-25 13:07:41,2024-06-25 13:07:41,supporting-best-practice-in-reflexive-thematic-analysis-reporting-in-palliative-medicine-a-review-of-published-research-and-introduction-to-the-reflexive-thematic-analysis-reporting-guidelines-rtarg,"[('title', 'Supporting best practice in reflexive thematic analysis reporting in Palliative Medicine: A review of published research and introduction to the Reflexive Thematic Analysis Reporting Guidelines (RTARG)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of thematic analysis.'), ('Full bibliographic reference', 'Braun V, Clarke V. Supporting best practice in reflexive thematic analysis reporting in Palliative Medicine: A review of published research and introduction to the Reflexive Thematic Analysis Reporting Guidelines (RTARG). Palliat Med. 2024;38(6):608-616.'), ('Language', 'English'), ('PubMed ID', '[38469804](https://pubmed.ncbi.nlm.nih.gov/38469804/)'), ('Reporting guideline acronym', 'RTARG'), ('Study design', 'Qualitative research'), ('Clinical area', 'Palliative care'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'June 25, 2024')]"
21781,TRIPLE C reporting principles for case study evaluations of the role of context in complex interventions,Observational studies,Public health,Whole report, ,"case studies, case study, case study evaluation, case study evaluations, complex, complex health intervention, complex health interventions, complex intervention, complex interventions, context, observation, observational, public health, TRIPLE C", ,"Shaw SE, Paparini S, Murdoch J, Green J, Greenhalgh T, Hanckel B, James HM, Petticrew M, Wood GW, Papoutsi C. TRIPLE C reporting principles for case study evaluations of the role of context in complex interventions. BMC Med Res Methodol. 2023;23(1):115.","Shaw SE, Paparini S, Murdoch J, Green J, Greenhalgh T, Hanckel B, James HM, Petticrew M, Wood GW, Papoutsi C.",BMC Medical Research Methodology [BMC Med Res Methodol.],2023,23,1,115, ,English, ,37179308,https://pubmed.ncbi.nlm.nih.gov/37179308/,Read the full-text of the TRIPLE C reporting guideline., , , , ,TRIPLE C,Reporting of case study evaluations of complex interventions., , , , , , , ,no,2024-06-21 15:23:19,2024-06-21 15:23:19,triple-c-reporting-principles-for-case-study-evaluations-of-the-role-of-context-in-complex-interventions,"[('title', 'TRIPLE C reporting principles for case study evaluations of the role of context in complex interventions'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of case study evaluations of complex interventions.'), ('Full bibliographic reference', 'Shaw SE, Paparini S, Murdoch J, Green J, Greenhalgh T, Hanckel B, James HM, Petticrew M, Wood GW, Papoutsi C. TRIPLE C reporting principles for case study evaluations of the role of context in complex interventions. BMC Med Res Methodol. 2023;23(1):115.'), ('Language', 'English'), ('PubMed ID', '[37179308](https://pubmed.ncbi.nlm.nih.gov/37179308/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-023-01888-7) of the TRIPLE C reporting guideline.'), ('Reporting guideline acronym', 'TRIPLE C'), ('Study design', 'Observational studies'), ('Clinical area', 'Public health'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'June 21, 2024')]"
21763,Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,"Abstract, Whole report", ,"checklist, checklist for abstracts, checklists, COSMIN, measurement properties, OMI, OMIs, outcome, outcome measure, outcome measurement, outcome measurement instrument, outcome measurement instruments, outcome measurements, outcome measures, outcomes, PRISMA extension, PRISMA-COSMIN, PRISMA-COSMIN for abstracts, PRISMA-COSMIN for OMIs, PRISMA-COSMIN for OMIs 2024, review, reviews, systematic review, systematic reviews", ,"Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.

This guideline was published simultaneously in 4 journals. You can read the guideline in any of these journals using the links below.

J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535

","Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M.", ,2024, , , , ,English, , , , , , ,"Generic
PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

Specialised
PRISMA-Equity: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: 23222917

Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.
Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

PRISMA-Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.

PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246

PRISMA-IPD: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: 25919529

PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634

PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668

PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement &amp; Checklist. J Clin Epidemiol. 2017. PMID: 28720516

PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: 29362800

PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033

PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367

PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791

PRISMA-CHM: Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: 32907365

PRISMA-M 2020: Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: 33100229

PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.
Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

PRISMA-LSR: Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: 39562017

",http://www.prisma-cosmin.ca/,PRISMA-COSMIN for OMIs,Reporting of systematic reviews of outcome measurement instruments (OMIs)., ,Read the protocol for the development of PRISMA-COSMIN., , , , , ,yes,2024-06-18 14:00:35,2025-02-06 12:16:44,guideline-for-reporting-systematic-reviews-of-outcome-measurement-instruments-omis-prisma-cosmin-for-omis-2024,"[('title', 'Guideline for reporting systematic reviews of outcome measurement instruments (OMIs) : PRISMA-COSMIN for OMIs 2024'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of systematic reviews of outcome measurement instruments (OMIs).'), ('Full bibliographic reference', 'Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.\n\n \n\n This guideline was published simultaneously in 4 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n J Clin Epidemiol. 2024:111422. PMID: [38849061](https://pubmed.ncbi.nlm.nih.gov/38849061/)\n\n Qual Life Res. 2024. PMID: [38980635](https://pubmed.ncbi.nlm.nih.gov/38980635/)\n\n Health Qual Life Outcomes. 2024;22(1):48. PMID: [38978063](https://pubmed.ncbi.nlm.nih.gov/38978063/)\n\n J Patient Rep Outcomes. 2024;8(1):64. PMID: [38977535](https://pubmed.ncbi.nlm.nih.gov/38977535/)\n\n \n\n'), ('Language', 'English'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n[**PRISMA 2020 Statement**](https://dev.equator-network.org/reporting-guidelines/prisma/): Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.\n\n \n\n PLoS Med. 2021;18(3):e1003583. PMID: [33780438](https://pubmed.ncbi.nlm.nih.gov/33780438/)\n\n BMJ 2021;372:n71. PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)\n\n Int J Surg. 2021:105906. PMID: [33789826](https://pubmed.ncbi.nlm.nih.gov/33789826/)\n\n J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: [33789819](https://pubmed.ncbi.nlm.nih.gov/33789819/)\n\n Syst Rev. 2021;10(1):89. PMID: [33781348](https://pubmed.ncbi.nlm.nih.gov/33781348/)\n\n \n\n**Specialised**\n\n[**PRISMA-Equity**](https://www.equator-network.org/reporting-guidelines/prisma-equity/): Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: [23222917](http://www.ncbi.nlm.nih.gov/pubmed/23222917)\n\n \n\n Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.\n\n Int J Equity Health. 2015;14(1):92. PMID: [26450828](http://www.ncbi.nlm.nih.gov/pubmed/26450828)\n\n J Clin Epidemiol. 2015. PMID: [26348799](http://www.ncbi.nlm.nih.gov/pubmed/26348799)\n\n \n\n[**PRISMA-Abstracts 2020**](https://www.equator-network.org/reporting-guidelines/prisma-abstracts/): The PRISMA 2020 for Abstracts reporting guideline is contained within the main [PRISMA 2020 Statement paper](https://www.equator-network.org/reporting-guidelines/prisma/).\n\n \n\n[**PRISMA-P**](https://www.equator-network.org/reporting-guidelines/prisma-protocols/): Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: [25554246](http://www.ncbi.nlm.nih.gov/pubmed/25554246)\n\n \n\n[**PRISMA-IPD**](https://www.equator-network.org/reporting-guidelines/prisma-ipd/): Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: [25919529](http://www.ncbi.nlm.nih.gov/pubmed/25919529)\n\n \n\n[**PRISMA extension for network meta-analyses**](https://www.equator-network.org/reporting-guidelines/prisma-extension-network-meta-analyses/): Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: [26030634](http://www.ncbi.nlm.nih.gov/pubmed/26030634)\n\n \n\n[**PRISMA-harms**](https://www.equator-network.org/reporting-guidelines/prisma-harms/): Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: [26830668](http://www.ncbi.nlm.nih.gov/pubmed/26830668)\n\n \n\n[**PRISMA-CI**](https://www.equator-network.org/reporting-guidelines/prisma-ci-extension-statement-checklist/): Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: [28720516](https://www.ncbi.nlm.nih.gov/pubmed/28720516)\n\n \n\n[**PRISMA-DTA**](https://www.equator-network.org/reporting-guidelines/prisma-dta/): McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: [29362800](https://www.ncbi.nlm.nih.gov/pubmed/29362800)\n\n \n\n[**PRISMA-ScR**](https://www.equator-network.org/reporting-guidelines/prisma-scr/): Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: [30178033](https://www.ncbi.nlm.nih.gov/pubmed/30178033)\n\n \n\n[**PRISMA-A**](https://www.equator-network.org/reporting-guidelines/prisma-acupuncture/): Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: [31405367](https://www.ncbi.nlm.nih.gov/pubmed/31405367)\n\n \n\n[**PRISMA-DTA for Abstracts**](https://www.equator-network.org/reporting-guidelines/prisma-dta-for-abstracts/): Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: [33722791](https://pubmed.ncbi.nlm.nih.gov/33722791/)\n\n \n\n[**PRISMA-CHM**](https://www.equator-network.org/reporting-guidelines/prisma-chinese-herbal-medicines-2020/): Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: [32907365](https://pubmed.ncbi.nlm.nih.gov/32907365/)\n\n \n\n[**PRISMA-M 2020**](https://www.equator-network.org/reporting-guidelines/prisma-extension-for-moxibustion-2020/): Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: [33100229](https://pubmed.ncbi.nlm.nih.gov/33100229/)\n\n \n\n[**PRISMA-S**](https://www.equator-network.org/reporting-guidelines/prisma-s/): Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.\n\n Syst Rev. 2021;10(1):39. PMID: [33499930](https://pubmed.ncbi.nlm.nih.gov/33499930/)\n\n J Med Libr Assoc. 2021;109(2):174-200. PMID: [34285662](https://pubmed.ncbi.nlm.nih.gov/34285662/)\n\n \n\n[**PRISMA-LSR**](https://www.equator-network.org/reporting-guidelines/prisma-lsr/): Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: [39562017](https://pubmed.ncbi.nlm.nih.gov/39562017/)\n\n \n\n""), ('Reporting guideline website URL', '<http://www.prisma-cosmin.ca/>'), ('Reporting guideline acronym', 'PRISMA-COSMIN for OMIs'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Abstract, Whole report'), ('Additional information', '[Read the protocol](https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-022-01994-5) for the development of PRISMA-COSMIN.'), ('Record last updated on', 'February 6, 2025')]"
21743,Consolidated Health Economic Evaluation Reporting Standards for Interventions that use Artificial Intelligence (CHEERS-AI),"Artificial intelligence/Machine learning studies, Economic evaluations", ,Whole report, ,"AI, artificial intelligence, CHEERS extension, CHEERS-AI, CHEERS-AI checklist, cost effectiveness, economic, economic evaluation, economic evaluations, economics, EE, EEs, health economic evaluation", ,"Elvidge J, Hawksworth C, Av?ar TS, Zemplenyi A, Chalkidou A, Petrou S, Petyk\xf3 Z, Srivastava D, Chandra G, Delaye J, Denniston A, Gomes M, Knies S, Nousios P, Siirtola P, Wang J, Dawoud D. Consolidated Health Economic Evaluation Reporting Standards for Interventions that use Artificial Intelligence (CHEERS-AI). Value Health. 2024:S1098-3015(24)02366-0.","Elvidge J, Hawksworth C, Av?ar TS, Zemplenyi A, Chalkidou A, Petrou S, Petyk\xf3 Z, Srivastava D, Chandra G, Delaye J, Denniston A, Gomes M, Knies S, Nousios P, Siirtola P, Wang J, Dawoud D.",Value in Health [Value Health.],2024, , ,S1098-3015(24)02366-0, ,English, ,38795956,https://pubmed.ncbi.nlm.nih.gov/38795956/, , , ,"Generic
CHEERS: Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S; CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.

Value Health. 2022;25(1):3-9. PMID: 35031096
BMC Med. 2022;20(1):23. PMID: 35022047
J Manag Care Spec Pharm. 2022:1-10. PMID: 35016547
BMJ. 2022;376:e067975. PMID: 35017145
Pharmacoeconomics. 2022. PMID: 35015272
Appl Health Econ Health Policy. 2022. PMID: 35015207
Int J Technol Assess Health Care. 2022;38(1):e13. PMID: 35007499
J Med Econ. 2022;25(sup1):1-7. PMID: 35012427
BJOG. 2022;129(3):336-344. PMID: 35014160
Eur J Health Econ. 2022. PMID: 35084632
BMC Health Serv Res. 2022;22(1):114. PMID: 35081957
BMC Public Health. 2022;22(1):179. PMID: 35081920
Health Policy OPEN. Volume 3, December 2022.
MDM Policy Pract. 2022;7(1):23814683211061097. PMID: 35036563
Clin Ther. 2022;S0149-2918(22)00016-9. PMID: 35168801

Specialised
CHEERS-VOI: Kunst N, Siu A, Drummond M, Grimm S, Grutters J, Husereau D, Koffijberg H, Rothery C, Wilson EC, Heath A. CHEERS Value of Information (CHEERS-VOI) Reporting Standards - Explanation and Elaboration. Value Health. 2023. PMID: 37414276

", ,CHEERS-AI,Reporting an economic evaluation of an intervention that uses artificial intelligence to perform its function., , , , , , , ,no,2024-06-13 14:35:13,2024-06-13 14:35:13,consolidated-health-economic-evaluation-reporting-standards-for-interventions-that-use-artificial-intelligence-cheers-ai,"[('title', 'Consolidated Health Economic Evaluation Reporting Standards for Interventions that use Artificial Intelligence (CHEERS-AI)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting an economic evaluation of an intervention that uses artificial intelligence to perform its function.'), ('Full bibliographic reference', 'Elvidge J, Hawksworth C, Avşar TS, Zemplenyi A, Chalkidou A, Petrou S, Petykó Z, Srivastava D, Chandra G, Delaye J, Denniston A, Gomes M, Knies S, Nousios P, Siirtola P, Wang J, Dawoud D. Consolidated Health Economic Evaluation Reporting Standards for Interventions that use Artificial Intelligence (CHEERS-AI). Value Health. 2024:S1098-3015(24)02366-0.'), ('Language', 'English'), ('PubMed ID', '[38795956](https://pubmed.ncbi.nlm.nih.gov/38795956/)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n**[CHEERS](https://www.equator-network.org/reporting-guidelines/cheers/)**: Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S; CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.\n\n \n\n Value Health. 2022;25(1):3-9. PMID: [35031096](https://pubmed.ncbi.nlm.nih.gov/35031096/)\n\n BMC Med. 2022;20(1):23. PMID: [35022047](https://pubmed.ncbi.nlm.nih.gov/35022047/)\n\n J Manag Care Spec Pharm. 2022:1-10. PMID: [35016547](https://pubmed.ncbi.nlm.nih.gov/35016547/)\n\n BMJ. 2022;376:e067975. PMID: [35017145](https://pubmed.ncbi.nlm.nih.gov/35017145/)\n\n Pharmacoeconomics. 2022. PMID: [35015272](https://pubmed.ncbi.nlm.nih.gov/35015272/)\n\n Appl Health Econ Health Policy. 2022. PMID: [35015207](https://pubmed.ncbi.nlm.nih.gov/35015207/)\n\n Int J Technol Assess Health Care. 2022;38(1):e13. PMID: [35007499](https://pubmed.ncbi.nlm.nih.gov/35007499/)\n\n J Med Econ. 2022;25(sup1):1-7. PMID: [35012427](https://pubmed.ncbi.nlm.nih.gov/35012427/)\n\n BJOG. 2022;129(3):336-344. PMID: [35014160](https://pubmed.ncbi.nlm.nih.gov/35014160/)\n\n Eur J Health Econ. 2022. PMID: [35084632](https://pubmed.ncbi.nlm.nih.gov/35084632/)\n\n BMC Health Serv Res. 2022;22(1):114. PMID: [35081957](https://pubmed.ncbi.nlm.nih.gov/35081957/)\n\n BMC Public Health. 2022;22(1):179. PMID: [35081920](https://pubmed.ncbi.nlm.nih.gov/35081920/)\n\n Health Policy OPEN. [Volume 3, December 2022](https://doi.org/10.1016/j.hpopen.2021.100063).\n\n MDM Policy Pract. 2022;7(1):23814683211061097. PMID: [35036563](https://pubmed.ncbi.nlm.nih.gov/35036563/)\n\n Clin Ther. 2022;S0149-2918(22)00016-9. PMID: [35168801](https://pubmed.ncbi.nlm.nih.gov/35168801/)\n\n \n\n**Specialised**\n\n**[CHEERS-VOI](https://www.equator-network.org/reporting-guidelines/cheers-voi/)**: Kunst N, Siu A, Drummond M, Grimm S, Grutters J, Husereau D, Koffijberg H, Rothery C, Wilson EC, Heath A. CHEERS Value of Information (CHEERS-VOI) Reporting Standards - Explanation and Elaboration. Value Health. 2023. PMID: [37414276](https://pubmed.ncbi.nlm.nih.gov/37414276/)\n\n \n\n'), ('Reporting guideline acronym', 'CHEERS-AI'), ('Study design', 'Artificial intelligence/Machine learning studies, Economic evaluations'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'June 13, 2024')]"
21737,The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement,Observational studies,"Pharmaceutical medicine, Public health","Abstract, Whole report", ,"adverse drug reaction, adverse drug reactions, adverse reaction, adverse reactions, case report, case reports, case safety report, checklist, disproportionality, disproportionality analyses, disproportionality analysis, drug, drug safety, medicine, medicines, observation, observational, pharmacoepidemiological, pharmacoepidemiology, pharmacology, pharmacovigilance, READUS-PV, READUS-PV checklist, READUS-PV guideline, READUS-PV guidelines, READUS-PV statement, regulatory, safety signal, safety signals", ,"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Nor\xe9n GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement. Drug Saf. 2024;47(6):575-584.","Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Nor\xe9n GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C.",Drug Safety [Drug Saf.],2024,47,6,575-584, ,English, ,38713346,https://pubmed.ncbi.nlm.nih.gov/38713346/,Access the READUS-PV checklist and the READUS-PV checklist for abstracts.,"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Nor\xe9n GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration. Drug Saf. 2024;47(6):585-599. PMID: 38713347

", , ,http://www.readus-statement.org/,READUS-PV,Reporting of disproportionality analyses., , , , , , , ,no,2024-06-12 11:28:38,2024-06-12 11:28:38,the-reporting-of-a-disproportionality-analysis-for-drug-safety-signal-detection-using-individual-case-safety-reports-in-pharmacovigilance-readus-pv-development-and-statement,"[('title', 'The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV) : Development and Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of disproportionality analyses.'), ('Full bibliographic reference', 'Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Norén GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement. Drug Saf. 2024;47(6):575-584.'), ('Language', 'English'), ('PubMed ID', '[38713346](https://pubmed.ncbi.nlm.nih.gov/38713346/)'), ('Relevant URLs\n\n(full-text if available)', 'Access the [READUS-PV checklist](https://readus-statement.org/readus-statement/) and the [READUS-PV checklist for abstracts](https://readus-statement.org/readus-statement/).'), ('Explanation and elaboration papers', 'Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Norén GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration. Drug Saf. 2024;47(6):585-599. PMID: [38713347](https://pubmed.ncbi.nlm.nih.gov/38713347/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.readus-statement.org/>'), ('Reporting guideline acronym', 'READUS-PV'), ('Study design', 'Observational studies'), ('Clinical area', 'Pharmaceutical medicine, Public health'), ('Applies to the whole report or to individual sections of the report?', 'Abstract, Whole report'), ('Record last updated on', 'June 12, 2024')]"
21732,The Reporting Recommendations Intended for Pharmaceutical Risk Minimization Evaluation Studies: Standards for Reporting of Implementation Studies Extension (RIMES-SE),"Mixed methods studies, Observational studies","Pharmaceutical medicine, Public health",Whole report, ,"checklist, checklists, complex intervention, complex interventions, drug, drug safety, implementation, medicine, medicines, mixed methods, observation, observational, pharmaceutical, pharmaceutical risk minimisation evaluation studies, pharmaceutical risk minimisation evaluation study, pharmaceutical risk minimization evaluation studies, pharmaceutical risk minimization evaluation study, pharmacoepidemiology, pharmacovigilance, pharmacy, regulatory, RIMES StaRI extension, RIMES-SE, RIMES-SE checklist, RIMES-SE Statement, risk minimisation, risk minimization, StaRi, StaRI extension", ,"Smith MY, Morrato EH, Mora N, Nguyen V, Pinnock H, Winterstein AG. The Reporting Recommendations Intended for Pharmaceutical Risk Minimization Evaluation Studies: Standards for Reporting of Implementation Studies Extension (RIMES-SE). Drug Saf. 2024.","Smith MY, Morrato EH, Mora N, Nguyen V, Pinnock H, Winterstein AG.",Drug Safety [Drug Saf.],2024, , , , ,English, ,38478350,https://pubmed.ncbi.nlm.nih.gov/38478350/,The checklist is available in Supplemental File 3 (PDF).,The E&amp;E document is available in Supplemental File 4 (PDF)., ,"Generic
StaRI: Pinnock H, Barwick M, Carpenter CR, Eldridge S, Grandes G, Griffiths CJ, Rycroft-Malone J, Meissner P, Murray E, Patel A, Sheikh A, Taylor SJC, for the StaRI group. Standards for Reporting Implementation Studies (StaRI) statement. BMJ. 2017;356:i6795. PMID: 28264797

", ,RIMES-SE,Reporting of risk minimisation programme evaluations., , , , , , , ,no,2024-06-12 10:38:52,2024-06-12 10:38:52,the-reporting-recommendations-intended-for-pharmaceutical-risk-minimization-evaluation-studies-standards-for-reporting-of-implementation-studies-extension-rimes-se,"[('title', 'The Reporting Recommendations Intended for Pharmaceutical Risk Minimization Evaluation Studies: Standards for Reporting of Implementation Studies Extension (RIMES-SE)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of risk minimisation programme evaluations.'), ('Full bibliographic reference', 'Smith MY, Morrato EH, Mora N, Nguyen V, Pinnock H, Winterstein AG. The Reporting Recommendations Intended for Pharmaceutical Risk Minimization Evaluation Studies: Standards for Reporting of Implementation Studies Extension (RIMES-SE). Drug Saf. 2024.'), ('Language', 'English'), ('PubMed ID', '[38478350](https://pubmed.ncbi.nlm.nih.gov/38478350/)'), ('Relevant URLs\n\n(full-text if available)', 'The checklist is available in [Supplemental File 3 (PDF)](https://static-content.springer.com/esm/art%3A10.1007%2Fs40264-024-01417-5/MediaObjects/40264_2024_1417_MOESM3_ESM.pdf).'), ('Explanation and elaboration papers', 'The E&E document is available in [Supplemental File 4 (PDF)](https://static-content.springer.com/esm/art%3A10.1007%2Fs40264-024-01417-5/MediaObjects/40264_2024_1417_MOESM4_ESM.pdf).'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**StaRI**](https://www.equator-network.org/reporting-guidelines/stari-statement/): Pinnock H, Barwick M, Carpenter CR, Eldridge S, Grandes G, Griffiths CJ, Rycroft-Malone J, Meissner P, Murray E, Patel A, Sheikh A, Taylor SJC, for the StaRI group. Standards for Reporting Implementation Studies (StaRI) statement. BMJ. 2017;356:i6795. PMID: [28264797](https://www.ncbi.nlm.nih.gov/pubmed/28264797)\n\n \n\n'), ('Reporting guideline acronym', 'RIMES-SE'), ('Study design', 'Mixed methods studies, Observational studies'), ('Clinical area', 'Pharmaceutical medicine, Public health'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'June 12, 2024')]"
21662,Consensus reporting guidelines to address gaps in descriptions of ultra-rare genetic conditions,Observational studies,"Genetics, Paediatrics","Data, Study characteristics (participants etc.)", ,"checklist, checklists, child, children, data, genetic, genetic disease, genetic diseases, genetics, Mendelian disorders, observation, observational, paediatrics, pediatrics, PHELIX, PHELIX checklist, phenotype, PHEnotype LIsting fiX, phenotypic, phenotyping, rare genetic condition, rare genetic conditions, rare genetic disease, rare genetic diseases, rare genetic disorder, rare genetic disorders", ,"AlMail A, Jamjoom A, Pan A, Feng MY, Chau V, D'Gama AM, Howell K, Liang NSY, McTague A, Poduri A, Wiltrout K; IPCHiP Executive Committee; Bassett AS, Christodoulou J, Dupuis L, Gill P, Levy T, Siper P, Stark Z, Vorstman JAS, Diskin C, Jewitt N, Baribeau D, Costain G. Consensus reporting guidelines to address gaps in descriptions of ultra-rare genetic conditions. NPJ Genom Med. 2024;9(1):27.","AlMail A, Jamjoom A, Pan A, Feng MY, Chau V, D'Gama AM, Howell K, Liang NSY, McTague A, Poduri A, Wiltrout K; IPCHiP Executive Committee; Bassett AS, Christodoulou J, Dupuis L, Gill P, Levy T, Siper P, Stark Z, Vorstman JAS, Diskin C, Jewitt N, Baribeau D, Costain G.",NPJ Genomic Medicine [NPJ Genom Med.],2024,9,1,27, ,English, ,38582909,https://pubmed.ncbi.nlm.nih.gov/38582909/,The PHELIX checklists are available in Tables 9 and 10 in the supplementary materials (PDF)., , , , ,PHELIX,Reporting phenotype descriptions for rare genetic diseases., , , , , , , ,no,2024-04-17 16:38:16,2024-04-17 16:56:43,consensus-reporting-guidelines-to-address-gaps-in-descriptions-of-ultra-rare-genetic-conditions,"[('title', 'Consensus reporting guidelines to address gaps in descriptions of ultra-rare genetic conditions'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting phenotype descriptions for rare genetic diseases.'), ('Full bibliographic reference', ""AlMail A, Jamjoom A, Pan A, Feng MY, Chau V, D'Gama AM, Howell K, Liang NSY, McTague A, Poduri A, Wiltrout K; IPCHiP Executive Committee; Bassett AS, Christodoulou J, Dupuis L, Gill P, Levy T, Siper P, Stark Z, Vorstman JAS, Diskin C, Jewitt N, Baribeau D, Costain G. Consensus reporting guidelines to address gaps in descriptions of ultra-rare genetic conditions. NPJ Genom Med. 2024;9(1):27.""), ('Language', 'English'), ('PubMed ID', '[38582909](https://pubmed.ncbi.nlm.nih.gov/38582909/)'), ('Relevant URLs\n\n(full-text if available)', 'The PHELIX checklists are available in Tables 9 and 10 in the [supplementary materials (PDF)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10998895/bin/41525_2024_408_MOESM1_ESM.pdf).'), ('Reporting guideline acronym', 'PHELIX'), ('Study design', 'Observational studies'), ('Clinical area', 'Genetics, Paediatrics'), ('Applies to the whole report or to individual sections of the report?', 'Data, Study characteristics (participants etc.)'), ('Record last updated on', 'April 17, 2024')]"
21660,Biofield therapies: Guidelines for reporting clinical trials,"Clinical trials, Experimental studies",Complementary and alternative medicine,Intervention (exposure), ,"allopathic medicine, BFTs, BiFi REGs, biofield, biofield therapies, biofield therapy, clinical trial, clinical trials, complementary therapies, complementary therapy, External Qigong, Healing Touch, integrative health practice, integrative health practices, integrative medicine, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, Reiki, Therapeutic Touch, trial, trials", ,"Hammerschlag R, Sprengel ML, Baldwin AL. Biofield therapies: Guidelines for reporting clinical trials.

This guideline was published simultaneously in 4 journals. You can read the guideline in any of these journals using the links below.

Complement Ther Med. 2024;82:103011. PMID: 38307809
Explore (NY). 2024;20(2):196-205. PMID: 38307816
Glob Adv Integr Med Health. 2024;13:27536130231202501. PMID: 38304734
J Integr Complement Med. 2024;30(2):133-145. PMID: 38300148

","Hammerschlag R, Sprengel ML, Baldwin AL.", , , , , , , , , , , , , , , ,BiFi REGs,Reporting biofield therapy trials., , , , , , , ,no,2024-04-17 15:27:48,2024-04-17 15:27:48,biofield-therapies-guidelines-for-reporting-clinical-trials,"[('title', 'Biofield therapies: Guidelines for reporting clinical trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting biofield therapy trials.'), ('Full bibliographic reference', 'Hammerschlag R, Sprengel ML, Baldwin AL. Biofield therapies: Guidelines for reporting clinical trials.\n\n \n\n This guideline was published simultaneously in 4 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n Complement Ther Med. 2024;82:103011. PMID: [38307809](https://pubmed.ncbi.nlm.nih.gov/38307809/)\n\n Explore (NY). 2024;20(2):196-205. PMID: [38307816](https://pubmed.ncbi.nlm.nih.gov/38307816/)\n\n Glob Adv Integr Med Health. 2024;13:27536130231202501. PMID: [38304734](https://pubmed.ncbi.nlm.nih.gov/38304734/)\n\n J Integr Complement Med. 2024;30(2):133-145. PMID: [38300148](https://pubmed.ncbi.nlm.nih.gov/38300148/)\n\n \n\n'), ('Reporting guideline acronym', 'BiFi REGs'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'April 17, 2024')]"
21656,The PICOTS-ComTeC Framework for Defining Digital Health Interventions: An ISPOR Special Interest Group Report,"Economic evaluations, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,Intervention (exposure), ,"AI, artificial intelligence, DHIs, digital health, digital health intervention, digital health interventions, digital therapeutics, economic, economic evaluation, economic evaluations, economics, health economics, health outcomes, health technology assessment, HTA, patient-facing digital health intervention, patient-facing digital health interventions, pharmacoeconomics, PICOTS-ComTeC, PICOTS-ComTeC framework, remote monitoring, virtual reality, VR, wearables", ,"Zrubka Z, Champion A, Holtorf AP, Di Bidino R, Earla JR, Boltyenkov AT, Tabata-Kelly M, Asche C, Burrell A. The PICOTS-ComTeC Framework for Defining Digital Health Interventions: An ISPOR Special Interest Group Report. Value Health. 2024;27(4):383-396.","Zrubka Z, Champion A, Holtorf AP, Di Bidino R, Earla JR, Boltyenkov AT, Tabata-Kelly M, Asche C, Burrell A.",Value in Health. [Value Health.],2024,27,4,383-396, ,English, ,38569772,https://pubmed.ncbi.nlm.nih.gov/38569772/, , , , , ,PICOTS-ComTeC,Reporting of patient-facing digital health interventions., , , , , , , ,no,2024-04-15 10:55:07,2024-04-15 10:55:07,the-picots-comtec-framework-for-defining-digital-health-interventions-an-ispor-special-interest-group-report,"[('title', 'The PICOTS-ComTeC Framework for Defining Digital Health Interventions: An ISPOR Special Interest Group Report'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of patient-facing digital health interventions.'), ('Full bibliographic reference', 'Zrubka Z, Champion A, Holtorf AP, Di Bidino R, Earla JR, Boltyenkov AT, Tabata-Kelly M, Asche C, Burrell A. The PICOTS-ComTeC Framework for Defining Digital Health Interventions: An ISPOR Special Interest Group Report. Value Health. 2024;27(4):383-396.'), ('Language', 'English'), ('PubMed ID', '[38569772](https://pubmed.ncbi.nlm.nih.gov/38569772/)'), ('Reporting guideline acronym', 'PICOTS-ComTeC'), ('Study design', 'Economic evaluations, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'April 15, 2024')]"
21648,REPORT-SCS: minimum reporting standards for spinal cord stimulation studies in spinal cord injury,"Animal pre-clinical research, Clinical trials, Experimental studies, Observational studies",Neurology,"Intervention (exposure), Procedure/Method", ,"autonomic function, checklist, checklists, clinical trial, clinical trials, electrical spinal cord stimulation, epidural SCS, motor function, neural, neurological, neurology, neuropathic, observation, observational, pre clinical, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, REPORT-SCS, SCI, SCS, spinal, spinal cord injury, spinal cord stimulation, spine, stimulation, stimulation parameter, stimulation parameters, transcutaneous SCS, trial, trials", ,"Malik RN, Samejima S, Shackleton C, Miller T, Pedrocchi ALG, Rabchevsky AG, Moritz CT, Darrow D, Field-Fote EC, Guanziroli E, Ambrosini E, Molteni F, Gad P, Mushahwar VK, Sachdeva R, Krassioukov AV. REPORT-SCS: minimum reporting standards for spinal cord stimulation studies in spinal cord injury. J Neural Eng. 2024;21(1).","Malik RN, Samejima S, Shackleton C, Miller T, Pedrocchi ALG, Rabchevsky AG, Moritz CT, Darrow D, Field-Fote EC, Guanziroli E, Ambrosini E, Molteni F, Gad P, Mushahwar VK, Sachdeva R, Krassioukov AV.",Journal of Neural Engineering [J Neural Eng.],2024,21,1, , ,English, ,38271712,https://pubmed.ncbi.nlm.nih.gov/38271712/, , , , , ,REPORT-SCS,Reporting electrical spinal cord stimulation (SCS) parameters in pre-clinical and clinical spinal cord injury (SCI) studies involving non-invasive and invasive electrical SCS., , , , , , , ,no,2024-04-02 16:13:07,2024-04-02 16:29:14,report-scs-minimum-reporting-standards-for-spinal-cord-stimulation-studies-in-spinal-cord-injury,"[('title', 'REPORT-SCS : minimum reporting standards for spinal cord stimulation studies in spinal cord injury'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting electrical spinal cord stimulation (SCS) parameters in pre-clinical and clinical spinal cord injury (SCI) studies involving non-invasive and invasive electrical SCS.'), ('Full bibliographic reference', 'Malik RN, Samejima S, Shackleton C, Miller T, Pedrocchi ALG, Rabchevsky AG, Moritz CT, Darrow D, Field-Fote EC, Guanziroli E, Ambrosini E, Molteni F, Gad P, Mushahwar VK, Sachdeva R, Krassioukov AV. REPORT-SCS: minimum reporting standards for spinal cord stimulation studies in spinal cord injury. J Neural Eng. 2024;21(1).'), ('Language', 'English'), ('PubMed ID', '[38271712](https://pubmed.ncbi.nlm.nih.gov/38271712/)'), ('Reporting guideline acronym', 'REPORT-SCS'), ('Study design', 'Animal pre-clinical research, Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Neurology'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Procedure/Method'), ('Record last updated on', 'April 2, 2024')]"
21645,CARE-radiology statement explanation and elaboration: reporting guideline for radiological case reports,Observational studies,Radiology,Whole report, ,"CARE case extension, CARE-radiology, CARE-radiology checklist, case report, case reports, checklist, checklists, diagnosis, observation, observational, radiological, radiological case report, radiological case reports, radiology", ,"Wang M, Luo X, Xiao X, Zhang L, Wang Q, Wang S, Wang X, Xue H, Zhang L, Chen Y, Lei J, ?tupnik T, Scarci M, Fiorelli A, Laisaar T, Fruscio R, Elkhayat H, Novoa NM, Davoli F, Waseda R, Estill J, Norris SL, Riley DS, Tian J. CARE-radiology statement explanation and elaboration: reporting guideline for radiological case reports. BMJ Evid Based Med. 2024:bmjebm-2023-112695.","Wang M, Luo X, Xiao X, Zhang L, Wang Q, Wang S, Wang X, Xue H, Zhang L, Chen Y, Lei J, ?tupnik T, Scarci M, Fiorelli A, Laisaar T, Fruscio R, Elkhayat H, Novoa NM, Davoli F, Waseda R, Estill J, Norris SL, Riley DS, Tian J.",BMJ Evidence Based Medicine [BMJ Evid Based Med.],2024, , ,bmjebm-2023-112695, ,English, ,38458654,https://pubmed.ncbi.nlm.nih.gov/38458654/,"Read the full-text of the CARE-radiology reporting guideline.

", , ,"Generic
CARE: Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; the CARE Group. The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development.

BMJ Case Rep. 2013; doi: 10.1136/bcr-2013-201554 PMID: 24155002
Global Adv Health Med. 2013;10.7453/gahmj.2013.008
Dtsch Arztebl Int. 2013;110(37):603-608. PMID: 24078847 Full-text in English / Full-text in German
J Clin Epidemiol. 2014;67(1):46-51. PMID: 24035173
J Med Case Rep. 2013;7(1):223. PMID: 24228906 Full-text.
J Diet Suppl. 2013;10(4):381-390. PMID: 24237192
Headache. 2013;53(10):1541-1547. PMID: 24266334

Specialised
Therapeutic Massage and Bodywork: Munk N, Boulanger K. Adaptation of the CARE Guidelines for Therapeutic Massage and Bodywork Publications: Efforts To Improve the Impact of Case Reports. Int J Ther Massage Bodywork. 2014;7(3):32-40. PMID: 25184013

", ,CARE-radiology,Reporting radiological case reports., ,Read the study protocol for the development of CARE-radiology., , , , , ,no,2024-04-02 15:23:31,2024-04-02 15:42:37,care-radiology-statement-explanation-and-elaboration-reporting-guideline-for-radiological-case-reports,"[('title', 'CARE-radiology statement explanation and elaboration: reporting guideline for radiological case reports'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting radiological case reports.'), ('Full bibliographic reference', 'Wang M, Luo X, Xiao X, Zhang L, Wang Q, Wang S, Wang X, Xue H, Zhang L, Chen Y, Lei J, Štupnik T, Scarci M, Fiorelli A, Laisaar T, Fruscio R, Elkhayat H, Novoa NM, Davoli F, Waseda R, Estill J, Norris SL, Riley DS, Tian J. CARE-radiology statement explanation and elaboration: reporting guideline for radiological case reports. BMJ Evid Based Med. 2024:bmjebm-2023-112695.'), ('Language', 'English'), ('PubMed ID', '[38458654](https://pubmed.ncbi.nlm.nih.gov/38458654/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://ebm.bmj.com/content/early/2024/03/08/bmjebm-2023-112695.long) of the CARE-radiology reporting guideline.\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CARE**](https://www.equator-network.org/reporting-guidelines/care/): Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; the CARE Group. The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development.\n\n \n\n BMJ Case Rep. 2013; doi: 10.1136/bcr-2013-201554 PMID: [24155002](http://www.ncbi.nlm.nih.gov/pubmed/24155002)\n\n Global Adv Health Med. 2013;[10.7453/gahmj.2013.008](http://www.gahmj.com/doi/abs/10.7453/gahmj.2013.008)\n\n Dtsch Arztebl Int. 2013;110(37):603-608. PMID: [24078847](http://www.ncbi.nlm.nih.gov/pubmed/24078847)  [Full-text in English](http://www.aerzteblatt.de/int/archive/article/145667/The-CARE-Guidelines-Consensus-Based-Clinical-Case-Reporting-Guideline-Development) / [Full-text in German](http://www.aerzteblatt.de/archiv/145657/Die-Case-Reporting-%28CARE%29-Guideline-Entwicklung-einer-konsensbasierten-Leitlinie-fuer-die-Erstellung-klinischer-Fallberichte)\n\n J Clin Epidemiol. 2014;67(1):46-51. PMID: [24035173](http://www.ncbi.nlm.nih.gov/pubmed/24035173)\n\n J Med Case Rep. 2013;7(1):223. PMID: [24228906](http://www.ncbi.nlm.nih.gov/pubmed/24228906)  [Full-text](http://www.jmedicalcasereports.com/content/7/1/223).\n\n J Diet Suppl. 2013;10(4):381-390. PMID: [24237192](http://www.ncbi.nlm.nih.gov/pubmed/24237192)\n\n Headache. 2013;53(10):1541-1547. PMID: [24266334](http://www.ncbi.nlm.nih.gov/pubmed/24266334)\n\n \n\n**Specialised**\n\n**[Therapeutic Massage and Bodywork](https://www.equator-network.org/reporting-guidelines/adaptation-of-the-care-guidelines-for-therapeutic-massage-and-bodywork-publications-efforts-to-improve-the-impact-of-case-reports/)**: Munk N, Boulanger K. Adaptation of the CARE Guidelines for Therapeutic Massage and Bodywork Publications: Efforts To Improve the Impact of Case Reports. Int J Ther Massage Bodywork. 2014;7(3):32-40. PMID: [25184013](https://www.ncbi.nlm.nih.gov/pubmed/25184013)\n\n \n\n'), ('Reporting guideline acronym', 'CARE-radiology'), ('Study design', 'Observational studies'), ('Clinical area', 'Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', '[Read the study protocol](https://atm.amegroups.org/article/view/88322/html) for the development of CARE-radiology.'), ('Record last updated on', 'April 2, 2024')]"
21641,Trial Forge Guidance 4: a guideline for reporting the results of randomised Studies Within A Trial (SWATs),"Clinical trials, Experimental studies", ,Whole report, ,"checklist, checklists, clinical trial, clinical trials, embedded randomised controlled trial, embedded randomized controlled trial, embedded trial, embedded trials, randomised controlled trial, randomised controlled trials, randomised SWAT, randomised SWAT evaluation, randomised SWAT evaluations, randomised SWATs, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized SWAT, randomized SWAT evaluation, randomized SWAT evaluations, randomized SWATs, randomized trial, randomized trials, RCT, RCTs, Studies Within A Trial, Study Within A Trial, SWAT, SWATs, trial, trials", ,"Arundel CE, Clark LK, Parker A, Beard D, Coleman E, Cooper C, Devane D, Eldridge S, Galvin S, Gillies K, Hewitt CE, Sutton C, Torgerson DJ, Treweek S; PROMETHEUS GROUP. Trial Forge Guidance 4: a guideline for reporting the results of randomised Studies Within A Trial (SWATs). Trials. 2024;25(1):183.","Arundel CE, Clark LK, Parker A, Beard D, Coleman E, Cooper C, Devane D, Eldridge S, Galvin S, Gillies K, Hewitt CE, Sutton C, Torgerson DJ, Treweek S; PROMETHEUS GROUP.",Trials.,2024,25,1,183, ,English, ,38475795,https://pubmed.ncbi.nlm.nih.gov/38475795/,Read the full-text of this reporting guideline., , , , , ,"Reporting the results of randomised Studies Within A Trial (SWATs).

An editable version of the checklist is available here.", , , , , , , ,no,2024-04-02 11:01:46,2025-05-30 15:02:33,trial-forge-guidance-4-a-guideline-for-reporting-the-results-of-randomised-studies-within-a-trial-swats,"[('title', 'Trial Forge Guidance 4: a guideline for reporting the results of randomised Studies Within A Trial (SWATs)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the results of randomised Studies Within A Trial (SWATs).\n\n \n\n An editable version of the checklist is available [here](https://www.trialforge.org/resource/trial-forge-guidance-4-a-guideline-for-reporting-the-results-of-randomised-studies-within-a-trial-swats/).'), ('Full bibliographic reference', 'Arundel CE, Clark LK, Parker A, Beard D, Coleman E, Cooper C, Devane D, Eldridge S, Galvin S, Gillies K, Hewitt CE, Sutton C, Torgerson DJ, Treweek S; PROMETHEUS GROUP. Trial Forge Guidance 4: a guideline for reporting the results of randomised Studies Within A Trial (SWATs). Trials. 2024;25(1):183.'), ('Language', 'English'), ('PubMed ID', '[38475795](https://pubmed.ncbi.nlm.nih.gov/38475795/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-024-08004-0) of this reporting guideline.'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 30, 2025')]"
21633,The RETRIEVE Checklist for Studies Reporting the Elicitation of Stated Preferences for Child Health-Related Quality of Life,"Economic evaluations, Qualitative research",Paediatrics,"Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)", ,"checklist, checklists, child, child health valuation, child health-related quality of life, child HRQOL, childhood, children, cost benefit, cost effectiveness, cost-effective, econometric, economic, economic evaluation, health economics, health-related quality of life, HRQOL, HRQoL values, paediatrics, pediatrics, preference weights, preference-based values, psychometric, QALY, QALYS, quality of life, REporting invenToRy chIld hEalth ValuEs, RETRIEVE, RETRIEVE checklist, value, value set, value sets, values, young people, young person", ,"Bailey C, Howell M, Raghunandan R, Dalziel K, Howard K, Mulhern B, Petrou S, Rowen D, Salisbury A, Viney R, Lancsar E, Devlin N. The RETRIEVE Checklist for Studies Reporting the Elicitation of Stated Preferences for Child Health-Related Quality of Life. Pharmacoeconomics. 2024;42(4):435-446.","Bailey C, Howell M, Raghunandan R, Dalziel K, Howard K, Mulhern B, Petrou S, Rowen D, Salisbury A, Viney R, Lancsar E, Devlin N.",Pharmacoeconomics.,2024,42,4,435-446, ,English, ,38217776,https://pubmed.ncbi.nlm.nih.gov/38217776/, , , , , ,RETRIEVE,Reporting of methods and results from studies of values for childhood health-related quality of life (HRQoL)., , , , , , , ,no,2024-03-14 17:03:33,2024-03-14 17:03:33,the-retrieve-checklist-for-studies-reporting-the-elicitation-of-stated-preferences-for-child-health-related-quality-of-life,"[('title', 'The RETRIEVE Checklist for Studies Reporting the Elicitation of Stated Preferences for Child Health -Related Quality of Life'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of methods and results from studies of values for childhood health-related quality of life (HRQoL).'), ('Full bibliographic reference', 'Bailey C, Howell M, Raghunandan R, Dalziel K, Howard K, Mulhern B, Petrou S, Rowen D, Salisbury A, Viney R, Lancsar E, Devlin N. The RETRIEVE Checklist for Studies Reporting the Elicitation of Stated Preferences for Child Health-Related Quality of Life. Pharmacoeconomics. 2024;42(4):435-446.'), ('Language', 'English'), ('PubMed ID', '[38217776](https://pubmed.ncbi.nlm.nih.gov/38217776/)'), ('Reporting guideline acronym', 'RETRIEVE'), ('Study design', 'Economic evaluations, Qualitative research'), ('Clinical area', 'Paediatrics'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'March 14, 2024')]"
21610,We don't know what you did last summer. On the importance of transparent reporting of reaction time data pre-processing,"Experimental studies, Observational studies","Behavioural medicine, Psychology","Data, Procedure/Method, Statistical methods and analyses, Study characteristics (participants etc.)", ,"behavior, behaviour, checklist, checklists, cognition, cognitive, cognitive processes, data, data pre-processing, data pre-processing decisions, data processing, experiment, experimental, observation, observational, pre-processing, pre-processing methods, psychological, psychology, psychophysiological, psychophysiology, reaction time, reaction time measurement, reaction time measurements", ,"Loenneker HD, Buchanan EM, Martinovici A, Primbs MA, Elsherif MM, Baker BJ, Dudda LA, ?ur?evi? DF, Mi?i? K, Peetz HK, R\xf6er JP, Schulze L, Wagner L, Wolska JK, K\xfchrt C, Pronizius E. We don't know what you did last summer. On the importance of transparent reporting of reaction time data pre-processing. Cortex. 2023;172:14-37.","Loenneker HD, Buchanan EM, Martinovici A, Primbs MA, Elsherif MM, Baker BJ, Dudda LA, ?ur?evi? DF, Mi?i? K, Peetz HK, R\xf6er JP, Schulze L, Wagner L, Wolska JK, K\xfchrt C, Pronizius E.",Cortex.,2023,172, ,14-37, ,English, ,38154375,https://pubmed.ncbi.nlm.nih.gov/38154375/, , , , , , ,Reporting of reaction time data pre-processing., , , , , , , ,no,2024-02-16 10:45:44,2024-02-16 10:45:44,we-dont-know-what-you-did-last-summer-on-the-importance-of-transparent-reporting-of-reaction-time-data-pre-processing,"[('title', 'We don’t know what you did last summer. On the importance of transparent reporting of reaction time data pre-processing'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of reaction time data pre-processing.'), ('Full bibliographic reference', ""Loenneker HD, Buchanan EM, Martinovici A, Primbs MA, Elsherif MM, Baker BJ, Dudda LA, Đurđević DF, Mišić K, Peetz HK, Röer JP, Schulze L, Wagner L, Wolska JK, Kührt C, Pronizius E. We don't know what you did last summer. On the importance of transparent reporting of reaction time data pre-processing. Cortex. 2023;172:14-37.""), ('Language', 'English'), ('PubMed ID', '[38154375](https://pubmed.ncbi.nlm.nih.gov/38154375/)'), ('Study design', 'Experimental studies, Observational studies'), ('Clinical area', 'Behavioural medicine, Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'February 16, 2024')]"
21606,Introducing SoNHR-Reporting guidelines for Social Networks In Health Research,"Observational studies, Qualitative research", ,"Data, Ethical issues (consent etc.), Procedure/Method, Results, Statistical methods and analyses", ,"checklist, checklists, network, network analyses, network analysis, network methods, network science, network studies, network study, networks, observation, observational, qualitative, social, social network, social networks, SoNHR, SoNHR checklist, SoNHR guidelines, SoNHR recommendations, SoNHR-Social Networks in Health Research", ,"Luke DA, Tsai E, Carothers BJ, Malone S, Prusaczyk B, Combs TB, Vogel MT, Neal JW, Neal ZP. Introducing SoNHR-Reporting guidelines for Social Networks In Health Research. PLoS One. 2023;18(12):e0285236.","Luke DA, Tsai E, Carothers BJ, Malone S, Prusaczyk B, Combs TB, Vogel MT, Neal JW, Neal ZP.",PLoS One.,2023,18,12,e0285236, ,English, ,38096166,https://pubmed.ncbi.nlm.nih.gov/38096166/, , , , , ,SoNHR,Reporting of social network studies in the health sciences., , , , , , , ,no,2024-02-14 15:53:30,2024-02-14 15:53:30,introducing-sonhr-reporting-guidelines-for-social-networks-in-health-research,"[('title', 'Introducing So NHR-Reporting guidelines for Social Networks In Health Research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of social network studies in the health sciences.'), ('Full bibliographic reference', 'Luke DA, Tsai E, Carothers BJ, Malone S, Prusaczyk B, Combs TB, Vogel MT, Neal JW, Neal ZP. Introducing SoNHR-Reporting guidelines for Social Networks In Health Research. PLoS One. 2023;18(12):e0285236.'), ('Language', 'English'), ('PubMed ID', '[38096166](https://pubmed.ncbi.nlm.nih.gov/38096166/)'), ('Reporting guideline acronym', 'SoNHR'), ('Study design', 'Observational studies, Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Data, Ethical issues (consent etc.), Procedure/Method, Results, Statistical methods and analyses'), ('Record last updated on', 'February 14, 2024')]"
21604,"Reporting standard for describing first responder systems, smartphone alerting systems, and AED networks", ,"Cardiovascular medicine, Emergency medicine","Data, Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Statistical methods and analyses, Study characteristics (participants etc.), Terminology/definitions", ,"alert system, alert systems, alerting system, alerting systems, automated external defibrillator, automated external defibrillators, basic life support, cardiac, cardiac arrest, cardiac resuscitation, cardiology, citizen first responder, citizen first responders, community first responder, defibrillator, defibrillators, emergencies, emergency, first responder, first responder system, first responder systems, first responders, heart, life support, mobile phone, out-of-hospital, prehospital resuscitation, response, response time, resuscitation, smartphone, smartphone alerting system, smartphone alerting systems, smartphones, volunteer community responder, volunteer community responders", ,"M\xfcller MP, Metelmann C, Thies KC, Greif R, Scquizzato T, Deakin CD, Auricchio A, Barry T, Berglund E, B\xf6ttiger BW, Burkart R, Busch HJ, Caputo ML, Cheskes S, Cresta R, Damjanovic D, Degraeuwe E, Ekkel MM, Elschenbroich D, Fredman D, Ganter J, Gregers MCT, Gronewald J, H\xe4nsel M, Henriksen FL, Herzberg L, Jonsson M, Joos J, Kooy TA, Krammel M, Marks T, Monsieurs K, Ng WM, Osche S, Salcido DD, Scapigliati A, Schwietring J, Semeraro F, Snobelen P, Sowa J, Stieglis R, Tan HL, Trummer G, Unterrainer J, Vercammen S, Wetsch WA, Metelmann B. Reporting standard for describing first responder systems, smartphone alerting systems, and AED networks. Resuscitation. 2023:110087.","M\xfcller MP, Metelmann C, Thies KC, Greif R, Scquizzato T, Deakin CD, Auricchio A, Barry T, Berglund E, B\xf6ttiger BW, Burkart R, Busch HJ, Caputo ML, Cheskes S, Cresta R, Damjanovic D, Degraeuwe E, Ekkel MM, Elschenbroich D, Fredman D, Ganter J, Gregers MCT, Gronewald J, H\xe4nsel M, Henriksen FL, Herzberg L, Jonsson M, Joos J, Kooy TA, Krammel M, Marks T, Monsieurs K, Ng WM, Osche S, Salcido DD, Scapigliati A, Schwietring J, Semeraro F, Snobelen P, Sowa J, Stieglis R, Tan HL, Trummer G, Unterrainer J, Vercammen S, Wetsch WA, Metelmann B.",Resuscitation,2023, , ,110087, ,English, ,38097108,https://pubmed.ncbi.nlm.nih.gov/38097108/, , , , , , ,"Reporting of studies involving first responder systems, smartphone alerting systems, and automated external defibrillator (AED) networks.", , , , , , , ,no,2024-02-14 14:13:39,2024-02-14 14:13:39,reporting-standard-for-describing-first-responder-systems-smartphone-alerting-systems-and-aed-networks,"[('title', 'Reporting standard for describing first responder systems, smartphone alerting systems, and AED networks'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of studies involving first responder systems, smartphone alerting systems, and automated external defibrillator (AED) networks.'), ('Full bibliographic reference', 'Müller MP, Metelmann C, Thies KC, Greif R, Scquizzato T, Deakin CD, Auricchio A, Barry T, Berglund E, Böttiger BW, Burkart R, Busch HJ, Caputo ML, Cheskes S, Cresta R, Damjanovic D, Degraeuwe E, Ekkel MM, Elschenbroich D, Fredman D, Ganter J, Gregers MCT, Gronewald J, Hänsel M, Henriksen FL, Herzberg L, Jonsson M, Joos J, Kooy TA, Krammel M, Marks T, Monsieurs K, Ng WM, Osche S, Salcido DD, Scapigliati A, Schwietring J, Semeraro F, Snobelen P, Sowa J, Stieglis R, Tan HL, Trummer G, Unterrainer J, Vercammen S, Wetsch WA, Metelmann B. Reporting standard for describing first responder systems, smartphone alerting systems, and AED networks. Resuscitation. 2023:110087.'), ('Language', 'English'), ('PubMed ID', '[38097108](https://pubmed.ncbi.nlm.nih.gov/38097108/)'), ('Clinical area', 'Cardiovascular medicine, Emergency medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data, Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Statistical methods and analyses, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'February 14, 2024')]"
21600,The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM,Clinical practice guidelines,Complementary and alternative medicine,Whole report, ,"acupuncture, alternative medicine, checklist, checklists, Chinese herbal medicine, Chinese patent medicine, Chinese patent medicines, clinical guideline, clinical guidelines, clinical practice guideline, clinical practice guidelines, complementary medicine, CPM, CPM checklist, patent, patents, RIGHT extension, RIGHT for CPM, RIGHT for CPM checklist, TCM, traditional Chinese medicine, traditional medicine", ,"Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C. The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. Pharmacol Res. 2024;199:107015.","Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C.",Pharmacological Research [Pharmacol Res.],2024,199, ,107015, ,English, ,38036197,https://pubmed.ncbi.nlm.nih.gov/38036197/, , , ,"Generic
RIGHT: Chen Y, Yang K, Maru?i? A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Sch\xfcnemann HJ, Chan ESY, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; for the RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group. A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166(2):128-132. PMID: 27893062

Specialised
RIGHT-TCM: Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, Xia L, Guo Y. The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Pharmacol Res. 2020;160:105178. PMID: 32889127

RIGHT-PVG: Wang X, Chen Y, Akl EA, Tokali? R, Maru?i? A, Qaseem A, Falck-Ytter Y, Lee MS, Siedler M, Barber SL, Zhang M, Chan ESY, Estill J, Kwong JSW, Okumura A, Zhou Q, Yang K, Norris SL; RIGHT working group. The reporting checklist for public versions of guidelines: RIGHT-PVG. Implement Sci. 2021;16(1):10. PMID: 33430911

RIGHT for Acupuncture: Tang C, Duan Y, Zhang Y, Zhang Y, Chen Z, Tang X, Zeng J, Riley D, Lee MS, Kim YS, Zhao H, Marrone G, Zhu X, Ge S, Wen H, Zhao W, Zheng X, Solos I, Chen Y, Guyatt G, Lu L, Xu N; RIGHT (Reporting Items for Practice Guidelines in Healthcare) for Acupuncture Working Group. RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture. J Clin Epidemiol. 2021:S0895-4356(21)00173-6. PMID: 34091023

RIGHT for INT: Zhou Q, Xing D, Li Q, Zhang J, Luo X, Yang N, Wang X, Yang K, Tian J, Li H, Li B, Cai Y, Jin Y, Lv L, Sun F, Shang S, Yuan B, Li J, Ma B, Li X, Yuan Y, Wu L, Wang B, Jiang L, Wang Z, Chen Y, Liang D. An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT. J Evid Based Med. 2022;15(1):55-63. PMID: 35416438

RIGHT-Ad@pt: Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RWM, Arayssi T, Bhaumik S, Chen Y, Ghersi D, Langlois EV, Fuentes Padilla P, Sch\xfcnemann HJ, Akl EA, Mart\xednez Garc\xeda L; RIGHT-Ad@pt Working Group*, Amer Y, Arevalo-Rodriguez I, Barnes S, Barreto J, Collis D, Dyer S, Fahim C, Florez I, Gallegos-Rivero V, Klugar M, Kuijpers T, Mathew JL, Munn Z, Norris S, Pati\xf1o-Lugo DF, Pramesh CS, Rodriguez J, Roy S, Shin ES, Sosa O, Vandvik PO, Velez M, Woodcraft R; RIGHT-Ad@pt Working Group. A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Ann Intern Med. 2022;175(5):710-719. PMID: 35286143

RIGHT-COI&amp;F: Xun Y, Estill J, Khabsa J, Florez ID, Guyatt GH, Norris SL, Lee MS, Ozaki A, Qaseem A, Sch\xfcnemann HJ, Shao R, Chen Y, Akl EA; RIGHT-COI&amp;F Working Groups. Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI&amp;F Checklist. Ann Intern Med. 2024;177(6):782-790. PMID: 38739919

",http://www.right-statement.org/extensions/59,RIGHT for CPM,Reporting of Chinese patent medicine guidelines., , , , , , , ,yes,2024-02-09 16:07:38,2024-07-26 15:13:27,the-reporting-checklist-for-chinese-patent-medicine-guidelines-right-for-cpm,"[('title', 'The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of Chinese patent medicine guidelines.'), ('Full bibliographic reference', 'Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C. The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. Pharmacol Res. 2024;199:107015.'), ('Language', 'English'), ('PubMed ID', '[38036197](https://pubmed.ncbi.nlm.nih.gov/38036197/)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**RIGHT**](https://www.equator-network.org/reporting-guidelines/right-statement/): Chen Y, Yang K, Marušić A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Schünemann HJ, Chan ESY, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; for the RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group. A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166(2):128-132. PMID: [27893062](https://www.ncbi.nlm.nih.gov/pubmed/27893062)\n\n \n\n**Specialised**\n\n[**RIGHT-TCM**](https://www.equator-network.org/reporting-guidelines/the-right-extension-statement-for-traditional-chinese-medicine-development-recommendations-and-explanation/): Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, Xia L, Guo Y. The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Pharmacol Res. 2020;160:105178. PMID: [32889127](https://pubmed.ncbi.nlm.nih.gov/32889127)\n\n \n\n[**RIGHT-PVG**](https://www.equator-network.org/reporting-guidelines/the-reporting-checklist-for-public-versions-of-guidelines-right-pvg/): Wang X, Chen Y, Akl EA, Tokalić R, Marušić A, Qaseem A, Falck-Ytter Y, Lee MS, Siedler M, Barber SL, Zhang M, Chan ESY, Estill J, Kwong JSW, Okumura A, Zhou Q, Yang K, Norris SL; RIGHT working group. The reporting checklist for public versions of guidelines: RIGHT-PVG. Implement Sci. 2021;16(1):10. PMID: [33430911](https://pubmed.ncbi.nlm.nih.gov/33430911/)\n\n \n\n[**RIGHT for Acupuncture**](https://www.equator-network.org/reporting-guidelines/right-for-acupuncture/): Tang C, Duan Y, Zhang Y, Zhang Y, Chen Z, Tang X, Zeng J, Riley D, Lee MS, Kim YS, Zhao H, Marrone G, Zhu X, Ge S, Wen H, Zhao W, Zheng X, Solos I, Chen Y, Guyatt G, Lu L, Xu N; RIGHT (Reporting Items for Practice Guidelines in Healthcare) for Acupuncture Working Group. RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture. J Clin Epidemiol. 2021:S0895-4356(21)00173-6. PMID: [34091023](https://pubmed.ncbi.nlm.nih.gov/34091023/)\n\n \n\n[**RIGHT for INT**](https://www.equator-network.org/reporting-guidelines/an-extension-of-the-right-statement-for-introductions-and-interpretations-of-clinical-practice-guidelines-right-for-int/): Zhou Q, Xing D, Li Q, Zhang J, Luo X, Yang N, Wang X, Yang K, Tian J, Li H, Li B, Cai Y, Jin Y, Lv L, Sun F, Shang S, Yuan B, Li J, Ma B, Li X, Yuan Y, Wu L, Wang B, Jiang L, Wang Z, Chen Y, Liang D. An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT. J Evid Based Med. 2022;15(1):55-63. PMID: [35416438](https://pubmed.ncbi.nlm.nih.gov/35416438/)\n\n \n\n[**RIGHT-Ad@pt**](https://www.equator-network.org/reporting-guidelines/a-reporting-tool-for-adapted-guidelines-in-health-care-the-right-adapt-checklist/): Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RWM, Arayssi T, Bhaumik S, Chen Y, Ghersi D, Langlois EV, Fuentes Padilla P, Schünemann HJ, Akl EA, Martínez García L; RIGHT-Ad@pt Working Group\\*, Amer Y, Arevalo-Rodriguez I, Barnes S, Barreto J, Collis D, Dyer S, Fahim C, Florez I, Gallegos-Rivero V, Klugar M, Kuijpers T, Mathew JL, Munn Z, Norris S, Patiño-Lugo DF, Pramesh CS, Rodriguez J, Roy S, Shin ES, Sosa O, Vandvik PO, Velez M, Woodcraft R; RIGHT-Ad@pt Working Group. A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Ann Intern Med. 2022;175(5):710-719. PMID: [35286143](https://pubmed.ncbi.nlm.nih.gov/35286143/)\n\n \n\n[**RIGHT-COI&F**](https://www.equator-network.org/reporting-guidelines/reporting-conflicts-of-interest-and-funding-in-health-care-guidelines-the-right-coif-checklist/): Xun Y, Estill J, Khabsa J, Florez ID, Guyatt GH, Norris SL, Lee MS, Ozaki A, Qaseem A, Schünemann HJ, Shao R, Chen Y, Akl EA; RIGHT-COI&F Working Groups. Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI&F Checklist. Ann Intern Med. 2024;177(6):782-790. PMID: [38739919](https://pubmed.ncbi.nlm.nih.gov/38739919/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.right-statement.org/extensions/59>'), ('Reporting guideline acronym', 'RIGHT for CPM'), ('Study design', 'Clinical practice guidelines'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'July 26, 2024')]"
21598,The SHARE: SHam Acupuncture REporting guidelines and a checklist in clinical trials,"Clinical trials, Experimental studies",Complementary and alternative medicine,Intervention (exposure), ,"acupuncture, acupuncturist, alternative medicine, checklist, checklists, clinical trial, clinical trials, complementary medicine, intervention, interventions, needle, placebo, placebos, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, sham, sham acupuncture, SHARE, SHARE checklist, STRICTA extension, trial, trials", ,"Ma P, Liu X, Liu Z, Guo Y, Zhou K, Bian Z, Sun C, Liu T, Xiong Z, Xie Y, Lu Y, Lao L, He L, Liu B, Liu C, Yan S; SHARE Workgroup. The SHARE: SHam Acupuncture REporting guidelines and a checklist in clinical trials. J Evid Based Med. 2023;16(4):428-431.","Ma P, Liu X, Liu Z, Guo Y, Zhou K, Bian Z, Sun C, Liu T, Xiong Z, Xie Y, Lu Y, Lao L, He L, Liu B, Liu C, Yan S; SHARE Workgroup.",Journal of Evidence Based Medicine [J Evid Based Med.],2023,16,4,428-431, ,English, ,37906211,https://pubmed.ncbi.nlm.nih.gov/37906211/, , , , , ,SHARE,Reporting of sham acupuncture in acupuncture clinical trials., , , , , , , ,no,2024-02-08 11:14:02,2024-02-08 11:14:02,the-share-sham-acupuncture-reporting-guidelines-and-a-checklist-in-clinical-trials,"[('title', 'The SHARE : SHam Acupuncture REporting guidelines and a checklist in clinical trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of sham acupuncture in acupuncture clinical trials.'), ('Full bibliographic reference', 'Ma P, Liu X, Liu Z, Guo Y, Zhou K, Bian Z, Sun C, Liu T, Xiong Z, Xie Y, Lu Y, Lao L, He L, Liu B, Liu C, Yan S; SHARE Workgroup. The SHARE: SHam Acupuncture REporting guidelines and a checklist in clinical trials. J Evid Based Med. 2023;16(4):428-431.'), ('Language', 'English'), ('PubMed ID', '[37906211](https://pubmed.ncbi.nlm.nih.gov/37906211/)'), ('Reporting guideline acronym', 'SHARE'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'February 8, 2024')]"
21596,REPCAN: Guideline for REporting Population-based CANcer Registry Data,Observational studies,Oncology,Whole report, ,"cancer, checklist, checklists, data, epidemiologic, eplidemiology, guideline for REporting Population-based CANcer registry data, observation, observational, oncology, population, population-based cancer registry, register, registries, registry, registry data, REPCAN", ,"Roshandel G, Badar F, Barchuk A, Roder DM, Sangrajrang S, Mery L, Nobuyuki H, Halimi A, Mathur P, Shrestha G, Mosavi Jarrahi A. REPCAN: Guideline for REporting Population-based CANcer Registry Data. Asian Pac J Cancer Prev. 2023;24(9):3297-3303.","Roshandel G, Badar F, Barchuk A, Roder DM, Sangrajrang S, Mery L, Nobuyuki H, Halimi A, Mathur P, Shrestha G, Mosavi Jarrahi A.",Asian Pacific Journal of Cancer Prevention [Asian Pac J Cancer Prev.],2023,24,9,3297-3303, ,English, ,37777857,https://pubmed.ncbi.nlm.nih.gov/37777857/, , , , , ,REPCAN,Reporting of population-based cancer registry studies., , , , , , , ,no,2024-02-08 10:53:21,2024-02-08 10:53:21,repcan-guideline-for-reporting-population-based-cancer-registry-data,"[('title', 'REPCAN : Guideline for REporting Population-based CANcer Registry Data'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of population-based cancer registry studies.'), ('Full bibliographic reference', 'Roshandel G, Badar F, Barchuk A, Roder DM, Sangrajrang S, Mery L, Nobuyuki H, Halimi A, Mathur P, Shrestha G, Mosavi Jarrahi A. REPCAN: Guideline for REporting Population-based CANcer Registry Data. Asian Pac J Cancer Prev. 2023;24(9):3297-3303.'), ('Language', 'English'), ('PubMed ID', '[37777857](https://pubmed.ncbi.nlm.nih.gov/37777857/)'), ('Reporting guideline acronym', 'REPCAN'), ('Study design', 'Observational studies'), ('Clinical area', 'Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'February 8, 2024')]"
21571,The Test Adaptation Reporting Standards (TARES): reporting test adaptations, ,Psychology,Whole report, ,"adapting tests, education, psychological, psychology, TARES, TARES statement, test, test adaptation, test adaptation procedure, test adaptation procedures, Test Adaptation Reporting Standards, test adaptations, testing, tests", ,"Iliescu D, Bartram D, Zeinoun P, Ziegler M, Elosua P, Sireci S, Geisinger KF, Odendaal A, Oliveri ME, Twing J, Camara W. The Test Adaptation Reporting Standards (TARES): reporting test adaptations. International Journal of Testing. 2024; 24(1):80-102.","Iliescu D, Bartram D, Zeinoun P, Ziegler M, Elosua P, Sireci S, Geisinger KF, Odendaal A, Oliveri ME, Twing J, Camara W.",International Journal of Testing,2024,24,1,80-102, ,English, , , ,"The full-text of the TARES reporting guideline is available from the TARES website.

Access the TARES checklists.

", , , ,https://tares-statement.org/wp/,TARES,Reporting of test adaptations., , , , , , , ,no,2024-01-26 14:12:46,2024-01-26 14:13:51,the-test-adaptation-reporting-standards-tares-reporting-test-adaptations,"[('title', 'The Test Adaptation Reporting Standards (TARES) : reporting test adaptations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of test adaptations.'), ('Full bibliographic reference', 'Iliescu D, Bartram D, Zeinoun P, Ziegler M, Elosua P, Sireci S, Geisinger KF, Odendaal A, Oliveri ME, Twing J, Camara W. The Test Adaptation Reporting Standards (TARES): reporting test adaptations. International Journal of Testing. 2024; 24(1):80-102.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the TARES reporting guideline is available from the [TARES website](https://tares-statement.org/wp/download/).\n\n \n\n Access the TARES [checklists](https://tares-statement.org/wp/checklist/).\n\n \n\n'), ('Reporting guideline website URL', '<https://tares-statement.org/wp/>'), ('Reporting guideline acronym', 'TARES'), ('Clinical area', 'Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 26, 2024')]"
21573,ACCORD (ACcurate COnsensus Reporting Document): A reporting guideline for consensus methods in biomedicine developed via a modified Delphi,"Clinical practice guidelines, Qualitative research", ,Whole report, ,"ACCORD, ACCORD checklist, ACcurate COnsensus Reporting Document, checklist, checklists, consensus, consensus exercise, consensus method, consensus methods, consensus panel, consensus panels, consensus process, consensus studies, consensus study, consensus-based studies, consensus-based study, Delphi, nominal group technique, RAM, RAND appropriateness method, UCLA appropriateness method", ,"Gattrell WT, Logullo P, van Zuuren EJ, Price A, Hughes EL, Blazey P, Winchester CC, Tovey D, Goldman K, Hungin AP, Harrison N. ACCORD (ACcurate COnsensus Reporting Document): A reporting guideline for consensus methods in biomedicine developed via a modified Delphi. PLoS Med. 2024;21(1):e1004326.","Gattrell WT, Logullo P, van Zuuren EJ, Price A, Hughes EL, Blazey P, Winchester CC, Tovey D, Goldman K, Hungin AP, Harrison N.",PLoS Medicine [PLoS Med.],2024,21,1,e1004326, ,English, ,38261576,https://pubmed.ncbi.nlm.nih.gov/38261576/,"Read the full-text of the ACCORD guideline.

","Logullo P, van Zuuren EJ, Winchester CC, Tovey D, Gattrell WT, Price A, Harrison N, Goldman K, Chisholm A, Walters K, Blazey P. ACcurate COnsensus Reporting Document (ACCORD) explanation and elaboration: Guidance and examples to support reporting consensus methods. PLoS Med. 2024;21(5):e1004390. PMID: 38709851

", , ,https://www.ismpp.org/accord,ACCORD,"Reporting consensus methods used in biomedical research.



ACCORD checklist (Word)

", ,"Read the ACCORD study protocol.

Read the systematic review that informed development of the ACCORD reporting guideline.

", , ,"The ACCORD project was registered at the OSF platform and can be assessed on this page: https://osf.io/2rzm9

", , ,no,2024-01-24 16:44:01,2024-06-10 15:03:49,accord-accurate-consensus-reporting-document-a-reporting-guideline-for-consensus-methods-in-biomedicine,"[('title', 'ACCORD  (ACcurate  COnsensus Reporting Document): A reporting guideline for consensus methods in biomedicine developed via a modified Delphi'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting consensus methods used in biomedical research.\n\n \n\n \xa0\n\n \n\n[ACCORD checklist (Word)](https://www.ismpp.org/assets/ACCORD/ACCORD%20checklist%20editable.docx)\n\n \n\n'), ('Full bibliographic reference', 'Gattrell WT, Logullo P, van Zuuren EJ, Price A, Hughes EL, Blazey P, Winchester CC, Tovey D, Goldman K, Hungin AP, Harrison N. ACCORD (ACcurate COnsensus Reporting Document): A reporting guideline for consensus methods in biomedicine developed via a modified Delphi. PLoS Med. 2024;21(1):e1004326.'), ('Language', 'English'), ('PubMed ID', '[38261576](https://pubmed.ncbi.nlm.nih.gov/38261576/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004326) of the ACCORD guideline.\n\n \n\n'), ('Explanation and elaboration papers', 'Logullo P, van Zuuren EJ, Winchester CC, Tovey D, Gattrell WT, Price A, Harrison N, Goldman K, Chisholm A, Walters K, Blazey P. ACcurate COnsensus Reporting Document (ACCORD) explanation and elaboration: Guidance and examples to support reporting consensus methods. PLoS Med. 2024;21(5):e1004390. PMID: [38709851](https://pubmed.ncbi.nlm.nih.gov/38709851/)\n\n \n\n'), ('Reporting guideline website URL', '<https://www.ismpp.org/accord>'), ('Reporting guideline acronym', 'ACCORD'), ('Study design', 'Clinical practice guidelines, Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Other', 'The ACCORD project was registered at the OSF platform and can be assessed on this page: <https://osf.io/2rzm9>\n\n \n\n'), ('Additional information', 'Read the [ACCORD study protocol](https://researchintegrityjournal.biomedcentral.com/articles/10.1186/s41073-022-00122-0).\n\n \n\n Read the [systematic review](https://bmjopen.bmj.com/content/12/9/e065154.long) that informed development of the ACCORD reporting guideline.\n\n \n\n'), ('Record last updated on', 'June 10, 2024')]"
21569,Consolidated Reporting Guidelines for Prognostic and Diagnostic Machine Learning Modeling Studies: Development and Validation,"Artificial intelligence/Machine learning studies, Diagnostic and prognostic studies", ,Whole report, ,"checklist, checklists, diagnostic model, diagnostic modeling, diagnostic modelling, diagnostic models, diagnostic studies, diagnostic study, in-silico, machine learning, machine learning studies, machine learning study, ML, ML model, ML modeling, ML modelling, ML models, model development, model evaluation, model training, model validation, prediction model, prediction modeling, prediction modelling, prediction models, prediction studies, prediction study, prognostic model, prognostic modeling, prognostic modelling, prognostic models, prognostic studies, prognostic study, shadow mode", ,"Klement W, El Emam K. Consolidated Reporting Guidelines for Prognostic and Diagnostic Machine Learning Modeling Studies: Development and Validation. J Med Internet Res. 2023;25:e48763.","Klement W, El Emam K.",Journal of Medical Internet Research [J Med Internet Res.],2023,25, ,e48763, ,English, ,37651179,https://pubmed.ncbi.nlm.nih.gov/37651179/,The reporting checklist can accessed from the journal website in Multimedia Appendix 1 (Word)., , , , , ,Reporting of prognostic and diagnostic machine learning (ML) modeling studies., , , , , , , ,no,2024-01-24 15:22:38,2024-01-25 11:19:13,consolidated-reporting-guidelines-for-prognostic-and-diagnostic-machine-learning-modeling-studies-development-and-validation,"[('title', 'Consolidated Reporting Guidelines for Prognostic and Diagnostic Machine Learning Modeling Studies: Development and Validation'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of prognostic and diagnostic machine learning (ML) modeling studies.'), ('Full bibliographic reference', 'Klement W, El Emam K. Consolidated Reporting Guidelines for Prognostic and Diagnostic Machine Learning Modeling Studies: Development and Validation. J Med Internet Res. 2023;25:e48763.'), ('Language', 'English'), ('PubMed ID', '[37651179](https://pubmed.ncbi.nlm.nih.gov/37651179/)'), ('Relevant URLs\n\n(full-text if available)', 'The reporting checklist can accessed from the journal website in [Multimedia Appendix 1 (Word)](https://jmir.org/api/download?alt_name=jmir_v25i1e48763_app1.docx&filename=c8cfc620c0d2755b817722cd383b9f41.docx).'), ('Study design', 'Artificial intelligence/Machine learning studies, Diagnostic and prognostic studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 25, 2024')]"
21565,Development of the Reporting Infographics and Visual Abstracts of Comparative studies (RIVA-C) checklist and guide,"Clinical trials, Experimental studies, Observational studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,Abstract, ,"abstract, abstracts, checklist, checklists, clinical trial, clinical trials, cohort, cohort studies, cohort study, comparative studies, comparative study, graphical abstract, graphical abstracts, infographic, infographics, information graphics, observational, observational studies, observational study, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, Reporting Infographics and Visual Abstracts of Comparative studies checklist, review, reviews, RIVA-C, RIVA-C checklist, systematic review, systematic reviews, trial, trials, visual abstract, visual abstracts", ,"Zadro JR, Ferreira GE, Stahl-Timmins W, Egger V, Elkins MR, Gamble AR, O'Keeffe M, McCaffery KJ, Harris IA, Ardern CL, West CA, Maher CG, Hoffmann TC. Development of the Reporting Infographics and Visual Abstracts of Comparative studies (RIVA-C) checklist and guide. BMJ Evid Based Med. 2024:bmjebm-2023-112784.","Zadro JR, Ferreira GE, Stahl-Timmins W, Egger V, Elkins MR, Gamble AR, O'Keeffe M, McCaffery KJ, Harris IA, Ardern CL, West CA, Maher CG, Hoffmann TC.",BMJ Evidence-based Medicine [BMJ Evid Based Med.],2024, , ,bmjebm-2023-112784, ,English, ,38242568,https://pubmed.ncbi.nlm.nih.gov/38242568/,"The RIVA-C reporting checklist can be accessed from the journal website in supplementary file 6 (PDF), pages 117-120.

The RIVA-C explanation and examples can be accessed from the journal website in supplementary file 1 (PDF), pages 1-36.

", , , , ,RIVA-C,Reporting of infographics which summarise comparative studies of health and medical interventions., , , , , , , ,no,2024-01-24 11:58:55,2024-01-24 15:54:58,development-of-the-reporting-infographics-and-visual-abstracts-of-comparative-studies-riva-c-checklist-and-guide,"[('title', 'Development of the Reporting Infographics and Visual Abstracts of Comparative studies (RIVA-C) checklist and guide'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of infographics which summarise comparative studies of health and medical interventions.'), ('Full bibliographic reference', ""Zadro JR, Ferreira GE, Stahl-Timmins W, Egger V, Elkins MR, Gamble AR, O'Keeffe M, McCaffery KJ, Harris IA, Ardern CL, West CA, Maher CG, Hoffmann TC. Development of the Reporting Infographics and Visual Abstracts of Comparative studies (RIVA-C) checklist and guide. BMJ Evid Based Med. 2024:bmjebm-2023-112784.""), ('Language', 'English'), ('PubMed ID', '[38242568](https://pubmed.ncbi.nlm.nih.gov/38242568/)'), ('Relevant URLs\n\n(full-text if available)', 'The RIVA-C reporting checklist can be accessed from the journal website in [supplementary file 6 (PDF)](https://ebm.bmj.com/content/ebmed/early/2024/01/19/bmjebm-2023-112784/DC1/embed/inline-supplementary-material-1.pdf?download=true), pages 117-120.\n\n \n\n The RIVA-C explanation and examples can be accessed from the journal website in [supplementary file 1 (PDF)](https://ebm.bmj.com/content/ebmed/early/2024/01/19/bmjebm-2023-112784/DC1/embed/inline-supplementary-material-1.pdf?download=true), pages 1-36.\n\n \n\n'), ('Reporting guideline acronym', 'RIVA-C'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Abstract'), ('Record last updated on', 'January 24, 2024')]"
21534,Preliminary guideline for reporting bibliometric reviews of the biomedical literature (BIBLIO): a minimum requirements,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Whole report, ,"BIBLIO, BIBLIO checklist, bibliography, bibliometric, bibliometric review, bibliometric reviews, bibliometric studies, bibliometric study, bibliometrics, checklist, checklists, literature, review, reviews", ,"Montazeri A, Mohammadi S, M Hesari P, Ghaemi M, Riazi H, Sheikhi-Mobarakeh Z. Preliminary guideline for reporting bibliometric reviews of the biomedical literature (BIBLIO): a minimum requirements. Syst Rev. 2023;12(1):239.","Montazeri A, Mohammadi S, M Hesari P, Ghaemi M, Riazi H, Sheikhi-Mobarakeh Z.",Systematic Reviews [Syst Rev.],2023,12,1,239, ,English, ,38102710,https://pubmed.ncbi.nlm.nih.gov/38102710/, , , , , ,BIBLIO,"Reporting of bibliometric reviews.



BIBLIO Checklist (Word) \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 BIBLIO Checklist (PDF)

", , , , , , , ,no,2024-01-05 14:43:19,2024-01-10 10:15:54,preliminary-guideline-for-reporting-bibliometric-reviews-of-the-biomedical-literature-biblio-a-minimum-requirements,"[('title', 'Preliminary guideline for reporting bibliometric reviews of the biomedical literature (BIBLIO) : a minimum requirements'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of bibliometric reviews.\n\n \n\n \xa0\n\n \n\n[BIBLIO Checklist (Word)](https://www.equator-network.org/wp-content/uploads/2024/01/BIBLIO-Checklist.docx)  [BIBLIO Checklist (PDF)](https://www.equator-network.org/wp-content/uploads/2024/01/BIBLIO-Checklist.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Montazeri A, Mohammadi S, M Hesari P, Ghaemi M, Riazi H, Sheikhi-Mobarakeh Z. Preliminary guideline for reporting bibliometric reviews of the biomedical literature (BIBLIO): a minimum requirements. Syst Rev. 2023;12(1):239.'), ('Language', 'English'), ('PubMed ID', '[38102710](https://pubmed.ncbi.nlm.nih.gov/38102710/)'), ('Reporting guideline acronym', 'BIBLIO'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 10, 2024')]"
21523,"Appropriate design and reporting of superiority, equivalence and non-inferiority clinical trials incorporating a benefit-risk assessment: the BRAINS study including expert workshop","Clinical trials, Experimental studies, Study protocols", ,"Harms/adverse effects/safety data, Procedure/Method, Results", ,"adverse effect, adverse effects, B?R analyses, B?R analysis, B?R assessment, B?R assessments, B?R method, B?R methods, benefit, benefit-risk, benefits, checklist, checklists, clinical trial, clinical trials, equivalence, harm, harms, non-inferiority, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, risk, risks, superiority, trade-off, trial, trials", ,"Totton N, Julious SA, Coates E, Hughes DA, Cook JA, Biggs K, Hewitt C, Day S, Cook A. Appropriate design and reporting of superiority, equivalence and non-inferiority clinical trials incorporating a benefit-risk assessment: the BRAINS study including expert workshop. Health Technol Assess. 2023;27(20):1-58.","Totton N, Julious SA, Coates E, Hughes DA, Cook JA, Biggs K, Hewitt C, Day S, Cook A.",Health Technology Assessment [Health Technol Assess.],2023,27,20,1-58, ,English, ,37982521,https://pubmed.ncbi.nlm.nih.gov/37982521/,"Read the full-text of the reporting recommendations.

Checklists have been developed for reporting the trial design and for reporting the trial results and these are available in appendix 5.

", , , , , ,Reporting of benefit-risk assessments when incorporated within a clinical trial., , , , , , , ,no,2024-01-04 16:26:34,2024-01-04 16:43:44,appropriate-design-and-reporting-of-superiority-equivalence-and-non-inferiority-clinical-trials-incorporating-a-benefit-risk-assessment-the-brains-study-including-expert-workshop,"[('title', 'Appropriate design and reporting of superiority, equivalence and non-inferiority clinical trials incorporating a benefit-risk assessment: the BRAINS study including expert workshop'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of benefit-risk assessments when incorporated within a clinical trial.'), ('Full bibliographic reference', 'Totton N, Julious SA, Coates E, Hughes DA, Cook JA, Biggs K, Hewitt C, Day S, Cook A. Appropriate design and reporting of superiority, equivalence and non-inferiority clinical trials incorporating a benefit-risk assessment: the BRAINS study including expert workshop. Health Technol Assess. 2023;27(20):1-58.'), ('Language', 'English'), ('PubMed ID', '[37982521](https://pubmed.ncbi.nlm.nih.gov/37982521/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.journalslibrary.nihr.ac.uk/hta/BHQZ7691/#/s5) of the reporting recommendations.\n\n \n\n Checklists have been developed for reporting the trial design and for reporting the trial results and these are available in [appendix 5](https://www.journalslibrary.nihr.ac.uk/hta/BHQZ7691/#/app5).\n\n \n\n'), ('Study design', 'Clinical trials, Experimental studies, Study protocols'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Procedure/Method, Results'), ('Record last updated on', 'January 4, 2024')]"
21496,Preferred Reporting Items for Resistance Exercise Studies (PRIRES): A Checklist Developed Using an Umbrella Review of Systematic Reviews,"Clinical trials, Experimental studies, Study protocols",Sport and exercise medicine,Intervention (exposure), ,"athletics, CERT, clinical trial, clinical trials, exercise, exercising, kinesiology, Preferred Reporting Items for Resistance Exercise Studies, PRIRES, PRIRES checklist, protocol, protocols, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, resistance, resistance exercise, sport, sports, strength, training, trial, trials, weight, weights", ,"Lin TY, Chueh TY, Hung TM. Preferred Reporting Items for Resistance Exercise Studies (PRIRES): A Checklist Developed Using an Umbrella Review of Systematic Reviews. Sports Med Open. 2023;9(1):114.","Lin TY, Chueh TY, Hung TM.",Sports Medicine - Open. [Sports Med Open.],2023,9,1,114, ,English, ,38040927,https://pubmed.ncbi.nlm.nih.gov/38040927/, , , , , ,PRIRES,Reporting resistance exercise intervention studies., ,A PRIRES Checklist for Protocols has also been developed., , , , , ,no,2023-12-14 17:29:36,2023-12-14 17:32:35,preferred-reporting-items-for-resistance-exercise-studies-prires-a-checklist-developed-using-an-umbrella-review-of-systematic-reviews,"[('title', 'Preferred Reporting Items for Resistance Exercise Studies (PRIRES) : A Checklist Developed Using an Umbrella Review of Systematic Reviews'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting resistance exercise intervention studies.'), ('Full bibliographic reference', 'Lin TY, Chueh TY, Hung TM. Preferred Reporting Items for Resistance Exercise Studies (PRIRES): A Checklist Developed Using an Umbrella Review of Systematic Reviews. Sports Med Open. 2023;9(1):114.'), ('Language', 'English'), ('PubMed ID', '[38040927](https://pubmed.ncbi.nlm.nih.gov/38040927/)'), ('Reporting guideline acronym', 'PRIRES'), ('Study design', 'Clinical trials, Experimental studies, Study protocols'), ('Clinical area', 'Sport and exercise medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Additional information', 'A PRIRES Checklist for Protocols has also been developed.'), ('Record last updated on', 'December 14, 2023')]"
21493,ENLIGHT: A consensus checklist for reporting laboratory-based studies on the non-visual effects of light in humans, ,"Ophthalmology, Psychology","Intervention (exposure), Study characteristics (participants etc.)", ,"checklist, checklists, chronobiology, circadian, ENLIGHT, ENLIGHT checklist, Expert Network on LIGHT Interventions, eye, light, neurobiological, neurobiology, neuroscience, non-visual, non-visual effects of light, ocular, ophthalmology, physiology, psychology, sleep, vision", ,"Spitschan M, Kervezee L, Lok R, McGlashan E, Najjar RP; ENLIGHT Consortium. ENLIGHT: A consensus checklist for reporting laboratory-based studies on the non-visual effects of light in humans. EBioMedicine. 2023;98:104889.","Spitschan M, Kervezee L, Lok R, McGlashan E, Najjar RP; ENLIGHT Consortium.",EBioMedicine.,2023,98, ,104889, ,English, ,38043137,https://pubmed.ncbi.nlm.nih.gov/38043137/,"The ENLIGHT Checklist is available in Table 2 of the main guideline paper and a fillable version of the ENLIGHT Checklist (PDF) is also available.

","Read the ENLIGHT Explanation &amp; Elaboration document (PDF).

", , ,https://enlight-statement.org/,ENLIGHT,Reporting ocular light-based interventions in human studies., , , , , , , ,no,2023-12-14 16:42:28,2023-12-14 16:49:00,enlight-a-consensus-checklist-for-reporting-laboratory-based-studies-on-the-non-visual-effects-of-light-in-humans,"[('title', 'ENLIGHT : A consensus checklist for reporting laboratory-based studies on the non-visual effects of light in humans'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting ocular light-based interventions in human studies.'), ('Full bibliographic reference', 'Spitschan M, Kervezee L, Lok R, McGlashan E, Najjar RP; ENLIGHT Consortium. ENLIGHT: A consensus checklist for reporting laboratory-based studies on the non-visual effects of light in humans. EBioMedicine. 2023;98:104889.'), ('Language', 'English'), ('PubMed ID', '[38043137](https://pubmed.ncbi.nlm.nih.gov/38043137/)'), ('Relevant URLs\n\n(full-text if available)', 'The ENLIGHT Checklist is available in [Table 2](https://www.sciencedirect.com/science/article/pii/S2352396423004553?via%3Dihub#tbl2) of the main guideline paper and a fillable version of the [ENLIGHT Checklist (PDF)](https://github.com/ENLIGHT-Project/ENLIGHT-Checklist/blob/06ee653046cffe833753028c2b4bc71cdb6a711b/1.0.2/ENLIGHT_Checklist_Release_1.0.2_20231016.pdf) is also available.\n\n \n\n'), ('Explanation and elaboration papers', 'Read the [ENLIGHT Explanation & Elaboration document (PDF)](https://github.com/ENLIGHT-Project/ENLIGHT-Checklist/blob/06ee653046cffe833753028c2b4bc71cdb6a711b/1.0.2/ENLIGHT_E%26E_Release_1.0.2_20231016.pdf).\n\n \n\n'), ('Reporting guideline website URL', '<https://enlight-statement.org/>'), ('Reporting guideline acronym', 'ENLIGHT'), ('Clinical area', 'Ophthalmology, Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Study characteristics (participants etc.)'), ('Record last updated on', 'December 14, 2023')]"
21470,Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement,Study protocols, ,Protocol-whole report, ,"2?\xd7?2, checklist, checklists, clinical trial, clinical trials, factor, factorial, factors, interaction, interactions, protocol, protocols, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, SPIRIT, SPIRIT Extension, trial, trials", ,"Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121.","Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA.",JAMA Network Open [JAMA Netw Open.],2023,6,12,e2346121, ,English, ,38051535,https://pubmed.ncbi.nlm.nih.gov/38051535/, ,"Kahan BC, Juszczak E, Beller E, Birchenall M, Chan AW, Hall S, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Elbourne D, Montgomery A. Guidance for protocol content and reporting of factorial randomised trials: explanation and elaboration of the CONSORT 2010 and SPIRIT 2013 extensions. BMJ. 2025;388:e080785. PMID: 39904527

", ,"Generic

SPIRIT 2025 Statement: Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hr\xf3bjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.

BMJ. 2025; 388:e081660. PMID:\xa040294956
JAMA. 2025.\xa0PMID: 40294593
Lancet 2025.
Nat Med. 2025.\xa0PMID: 40295741
PLoS Med. 2025; 22(4): e1004587.\xa0PMID: 40294521

Specialised
SPIRIT-PRO: Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. Link to abstract

SPIRIT-TCM: Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: 30484022

SPENT 2019: Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. Link to full-text.

SPIRIT-AI: Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.
BMJ. 2020;370:m3210. PMID: 32907797
Nat Med. 2020;26(9):1351?1363. PMID: 32908284
Lancet Digital Health. 2020;2(10):e549-e560. PMID: 33328049

SPIRIT-Path: Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: 34592193

SPIRIT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: 36512367

SPIRIT-DEFINE: Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: 37863491

SPIRIT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: 38981624

SPIRIT-iNeurostim: Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: 39610902

", ,SPIRIT Factorial,Reporting of factorial trial protocols., ,"Read the protocol for the development of this guideline (PDF).

Read about the methods used to develop this guideline:

Hall SS, Juszczak E, Birchenall M, Elbourne D, Beller E, Chan AW, Little P, Montgomery AA, Kahan BC. Mixed-methods study to develop extensions to the SPIRIT and CONSORT statements for factorial randomised trials: the Reporting Factorial Trials (RAFT) study. BMJ Open. 2025;15(2):e082917. PMID: 39961717

", , ,"The checklist for reporting of factorial randomised trials: extension of the SPIRIT 2013 Statement is located in Table 3.

", , ,yes,2023-12-07 16:54:05,2025-05-30 09:14:27,consensus-statement-for-protocols-of-factorial-randomized-trials-extension-of-the-spirit-2013-statement,"[('title', 'Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of factorial trial protocols.'), ('Full bibliographic reference', 'Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121.'), ('Language', 'English'), ('PubMed ID', '[38051535](https://pubmed.ncbi.nlm.nih.gov/38051535/)'), ('Explanation and elaboration papers', 'Kahan BC, Juszczak E, Beller E, Birchenall M, Chan AW, Hall S, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Elbourne D, Montgomery A. Guidance for protocol content and reporting of factorial randomised trials: explanation and elaboration of the CONSORT 2010 and SPIRIT 2013 extensions. BMJ. 2025;388:e080785. PMID: [39904527](https://pubmed.ncbi.nlm.nih.gov/39904527/)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n \n\n**[SPIRIT 2025 Statement](https://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/):** Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hróbjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.\n\n \n\nBMJ. 2025; 388:e081660. [PMID:40294956](https://pubmed.ncbi.nlm.nih.gov/40294956/)\n\n JAMA. 2025.[PMID:](https://pubmed.ncbi.nlm.nih.gov/40294593/) [40294593](https://pubmed.ncbi.nlm.nih.gov/40294593/)\n\n Lancet 2025.\n\n Nat Med. 2025.[PMID: 40295741](https://pubmed.ncbi.nlm.nih.gov/40295741)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID: 40294521](https://pubmed.ncbi.nlm.nih.gov/40294521/)\n\n \n\n**Specialised**\n\n[**SPIRIT-PRO**](https://www.equator-network.org/reporting-guidelines/spirit-pro/): Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. [Link to abstract](https://jamanetwork.com/journals/jama/article-abstract/2671472)\n\n \n\n[**SPIRIT-TCM**](https://www.equator-network.org/reporting-guidelines/standard-protocol-items-for-clinical-trials-with-traditional-chinese-medicine-spirit-tcm-extension-2018/): Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: [30484022](https://www.ncbi.nlm.nih.gov/pubmed/30484022)\n\n \n\n[**SPENT 2019**](https://www.equator-network.org/reporting-guidelines/spirit-extension-n-of-1-trials-spent-2019/): Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. [Link to full-text](https://www.bmj.com/content/368/bmj.m122).\n\n \n\n[**SPIRIT-AI**](https://www.equator-network.org/reporting-guidelines/spirit-artificial-intelligence/): Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.\n\n BMJ. 2020;370:m3210. PMID: [32907797](https://pubmed.ncbi.nlm.nih.gov/32907797/)\n\n Nat Med. 2020;26(9):1351–1363. PMID: [32908284](https://pubmed.ncbi.nlm.nih.gov/32908284/)\n\n Lancet Digital Health. 2020;2(10):e549-e560. PMID: [33328049](https://pubmed.ncbi.nlm.nih.gov/33328049/)\n\n \n\n[**SPIRIT-Path**](https://www.equator-network.org/reporting-guidelines/spirit-path/): Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: [34592193](https://pubmed.ncbi.nlm.nih.gov/34592193/)\n\n \n\n[**SPIRIT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-protocols-the-spirit-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: [36512367](https://pubmed.ncbi.nlm.nih.gov/36512367/)\n\n \n\n[**SPIRIT-DEFINE**](https://www.equator-network.org/reporting-guidelines/spirit-define/): Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: [37863491](https://pubmed.ncbi.nlm.nih.gov/37863491/)\n\n \n\n[**SPIRIT-Surrogate**](https://www.equator-network.org/reporting-guidelines/spirit-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: [38981624](https://pubmed.ncbi.nlm.nih.gov/38981624/)\n\n \n\n[**SPIRIT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-protocols-of-randomised-controlled-trials-of-implantable-neurostimulation-devices-the-spirit-ineurostim-extension/): Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: [39610902](https://pubmed.ncbi.nlm.nih.gov/39610902/)\n\n \n\n""), ('Reporting guideline acronym', 'SPIRIT Factorial'), ('Study design', 'Study protocols'), ('Applies to the whole report or to individual sections of the report?', 'Protocol-whole report'), ('Other', 'The checklist for reporting of factorial randomised trials: extension of the SPIRIT 2013 Statement is located in Table 3.\n\n \n\n'), ('Additional information', '[Read the protocol for the development of this guideline (PDF)](https://www.equator-network.org/wp-content/uploads/2021/12/RAFT-Study_Protocol_Final-version-1.1_27-Sept-2021_OSF.pdf).\n\n \n\n Read about the methods used to develop this guideline:\n\n \n\n Hall SS, Juszczak E, Birchenall M, Elbourne D, Beller E, Chan AW, Little P, Montgomery AA, Kahan BC. Mixed-methods study to develop extensions to the SPIRIT and CONSORT statements for factorial randomised trials: the Reporting Factorial Trials (RAFT) study. BMJ Open. 2025;15(2):e082917. PMID: [39961717](https://pubmed.ncbi.nlm.nih.gov/39961717/)\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
21468,Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement,"Clinical trials, Experimental studies", ,Whole report, ,"2?\xd7?2, checklist, checklists, clinical trial, clinical trials, CONSORT, CONSORT extension, factor, factorial, factors, interaction, interactions, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114.","Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA.",JAMA.,2023,330,21,2106-2114, ,English, ,38051324,https://pubmed.ncbi.nlm.nih.gov/38051324/, ,"Kahan BC, Juszczak E, Beller E, Birchenall M, Chan AW, Hall S, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Elbourne D, Montgomery A. Guidance for protocol content and reporting of factorial randomised trials: explanation and elaboration of the CONSORT 2010 and SPIRIT 2013 extensions. BMJ. 2025;388:e080785. PMID: 39904527

", ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster: Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal: Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts: Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture: MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738. PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,CONSORT Factorial,Reporting of factorial randomised trials., ,"Read the protocol for the development of this guideline (PDF).

Read about the methods used to develop this guideline:

Hall SS, Juszczak E, Birchenall M, Elbourne D, Beller E, Chan AW, Little P, Montgomery AA, Kahan BC. Mixed-methods study to develop extensions to the SPIRIT and CONSORT statements for factorial randomised trials: the Reporting Factorial Trials (RAFT) study. BMJ Open. 2025;15(2):e082917. PMID: 39961717

", , ,"The CONSORT checklist of information to include when reporting factorial randomised trials is located in Table 2.

The checklist of items to include when reporting a randomised factorial trial in a journal or conference abstract is located in Table 3.

", , ,yes,2023-12-07 16:36:42,2025-05-30 09:27:03,reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement,"[('title', 'Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of factorial randomised trials.'), ('Full bibliographic reference', 'Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114.'), ('Language', 'English'), ('PubMed ID', '[38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)'), ('Explanation and elaboration papers', 'Kahan BC, Juszczak E, Beller E, Birchenall M, Chan AW, Hall S, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Elbourne D, Montgomery A. Guidance for protocol content and reporting of factorial randomised trials: explanation and elaboration of the CONSORT 2010 and SPIRIT 2013 extensions. BMJ. 2025;388:e080785. PMID: [39904527](https://pubmed.ncbi.nlm.nih.gov/39904527/)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](https://www.equator-network.org/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](https://www.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](https://www.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](https://www.equator-network.org/reporting-guidelines/consort-cluster/): Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](https://www.equator-network.org/reporting-guidelines/consort-herbal/): Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](https://www.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](https://www.equator-network.org/reporting-guidelines/consort-abstracts/): Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](https://www.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](https://www.equator-network.org/reporting-guidelines/consort-stricta/): MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](https://www.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](https://www.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738. PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](https://www.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](https://www.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](https://www.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](https://www.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](https://www.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://www.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](https://www.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](https://www.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](https://www.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](https://www.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](https://www.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://www.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://www.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://www.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://www.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'CONSORT Factorial'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Other', 'The CONSORT checklist of information to include when reporting factorial randomised trials is located in Table 2.\n\n \n\n The checklist of items to include when reporting a randomised factorial trial in a journal or conference abstract is located in Table 3.\n\n \n\n'), ('Additional information', '[Read the protocol for the development of this guideline (PDF)](https://www.equator-network.org/wp-content/uploads/2021/12/RAFT-Study_Protocol_Final-version-1.1_27-Sept-2021_OSF.pdf).\n\n \n\n Read about the methods used to develop this guideline:\n\n \n\n Hall SS, Juszczak E, Birchenall M, Elbourne D, Beller E, Chan AW, Little P, Montgomery AA, Kahan BC. Mixed-methods study to develop extensions to the SPIRIT and CONSORT statements for factorial randomised trials: the Reporting Factorial Trials (RAFT) study. BMJ Open. 2025;15(2):e082917. PMID: [39961717](https://pubmed.ncbi.nlm.nih.gov/39961717/)\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
21433,Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting,"Clinical trials, Experimental studies",Oncology,Statistical methods and analyses, ,"2-stage adjustment, cancer, checklist, checklists, clinical trial, clinical trials, controlled trial, controlled trials, inverse probability of censoring weights, IPCW, model, modeling, modelling, models, oncology, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, rank preserving structural failure time model, RCT, RCTs, RPSFTM, statistical, statistics, switching, switching-adjusted, switching-adjusted analyses, switching-adjusted analysis, treatment switching, trial, trials", ,"Sullivan TR, Latimer NR, Gray J, Sorich MJ, Salter AB, Karnon J. Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting. Value Health. 2020;23(3):388-396.","Sullivan TR, Latimer NR, Gray J, Sorich MJ, Salter AB, Karnon J.",Value in Health. [Value Health.],2020,23,3,388-396, ,English, ,32197735,https://pubmed.ncbi.nlm.nih.gov/32197735/, , , , , , ,Reporting of switching-adjusted analyses in oncology trials., , , , , , , ,no,2023-11-10 14:05:53,2023-11-10 14:05:53,adjusting-for-treatment-switching-in-oncology-trials-a-systematic-review-and-recommendations-for-reporting,"[('title', 'Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of switching-adjusted analyses in oncology trials.'), ('Full bibliographic reference', 'Sullivan TR, Latimer NR, Gray J, Sorich MJ, Salter AB, Karnon J. Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting. Value Health. 2020;23(3):388-396.'), ('Language', 'English'), ('PubMed ID', '[32197735](https://pubmed.ncbi.nlm.nih.gov/32197735/)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Record last updated on', 'November 10, 2023')]"
21431,Modeling Infectious Diseases in Healthcare Network (MInD-Healthcare) Framework for Describing and Reporting Multidrug-resistant Organism and Healthcare-Associated Infections Agent-based Modeling Methods,Observational studies,"Infectious diseases, Public health",Statistical methods and analyses, ,"ABMs, agent-based, agent-based modeling, agent-based modelling, antimicrobial resistance, epidemiology, healthcare-associated infection, healthcare-associated infections, infection, infections, infectious, infectious disease, infectious diseases, mathematical model, mathematical models, MDROs, MInD-Healthcare, model, modeling, Modeling Infectious Diseases in Healthcare Network, Modeling Infectious Diseases in Healthcare Network framework, modelling, models, multidrug, multidrug resistant, multidrug-resistant organism, multidrug-resistant organisms, observation, observational, pathogen, pathogens, public health, statistical, statistics", ,"Slayton RB, O'Hagan JJ, Barnes S, Rhea S, Hilscher R, Rubin M, Lofgren E, Singh B, Segre A, Paul P. Modeling Infectious Diseases in Healthcare Network (MInD-Healthcare) Framework for Describing and Reporting Multidrug-resistant Organism and Healthcare-Associated Infections Agent-based Modeling Methods. Clin Infect Dis. 2020;71(9):2527-2532.","Slayton RB, O'Hagan JJ, Barnes S, Rhea S, Hilscher R, Rubin M, Lofgren E, Singh B, Segre A, Paul P.",Clinical Infectious Diseases [Clin Infect Dis.],2020,71,9,2527-2532, ,English, ,32155235,https://pubmed.ncbi.nlm.nih.gov/32155235/, , , , , , ,Reporting Multidrug Resistant Organism (MDRO) and Healthcare-Associated Infections (HAIs) transmission modeling studies., , , , , , , ,no,2023-11-10 11:00:06,2023-11-10 11:00:06,modeling-infectious-diseases-in-healthcare-network-mind-healthcare-framework-for-describing-and-reporting-multidrug-resistant-organism-and-healthcare-associated-infections-agent-based-modeling-metho,"[('title', 'Modeling Infectious Diseases in Healthcare Network (MInD-Healthcare) Framework for Describing and Reporting Multidrug-resistant Organism and Healthcare -Associated Infections Agent-based Modeling Methods'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting Multidrug Resistant Organism (MDRO) and Healthcare-Associated Infections (HAIs) transmission modeling studies.'), ('Full bibliographic reference', ""Slayton RB, O'Hagan JJ, Barnes S, Rhea S, Hilscher R, Rubin M, Lofgren E, Singh B, Segre A, Paul P. Modeling Infectious Diseases in Healthcare Network (MInD-Healthcare) Framework for Describing and Reporting Multidrug-resistant Organism and Healthcare-Associated Infections Agent-based Modeling Methods. Clin Infect Dis. 2020;71(9):2527-2532.""), ('Language', 'English'), ('PubMed ID', '[32155235](https://pubmed.ncbi.nlm.nih.gov/32155235/)'), ('Study design', 'Observational studies'), ('Clinical area', 'Infectious diseases, Public health'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Record last updated on', 'November 10, 2023')]"
21418,LEVEL (Logical Explanations & Visualizations of Estimates in Linear mixed models): recommendations for reporting multilevel data and analyses,"Clinical trials, Experimental studies, Observational studies", ,"Data, Statistical methods and analyses", ,"checklist, checklists, clinical trial, clinical trials, correlated data, correlated data analyses, correlated data analysis, data, epidemiological, epidemiology, LEVEL, linear mixed model, linear mixed models, model, modeling, modelling, models, multilevel data, multilevel diagram, multilevel model, multilevel models, observational, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, statistical, statistics, trial, trials, variance partition coefficient, variance partition coefficients", ,"Monsalves MJ, Bangdiwala AS, Thabane A, Bangdiwala SI. LEVEL (Logical Explanations &amp; Visualizations of Estimates in Linear mixed models): recommendations for reporting multilevel data and analyses. BMC Med Res Methodol. 2020;20(1):3.","Monsalves MJ, Bangdiwala AS, Thabane A, Bangdiwala SI.",BMC Medical Research Methodology [BMC Med Res Methodol.],2020,20,1,3, ,English, ,31906857,https://pubmed.ncbi.nlm.nih.gov/31906857/, , , , , ,LEVEL,Reporting multilevel data and modelling analyses., , , , , , , ,no,2023-11-02 11:53:05,2023-11-02 11:53:05,level-logical-explanations-visualizations-of-estimates-in-linear-mixed-models-recommendations-for-reporting-multilevel-data-and-analyses,"[('title', 'LEVEL  (Logical Explanations & Visualizations of Estimates in Linear mixed models): recommendations for reporting multilevel data and analyses'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting multilevel data and modelling analyses.'), ('Full bibliographic reference', 'Monsalves MJ, Bangdiwala AS, Thabane A, Bangdiwala SI. LEVEL (Logical Explanations & Visualizations of Estimates in Linear mixed models): recommendations for reporting multilevel data and analyses. BMC Med Res Methodol. 2020;20(1):3.'), ('Language', 'English'), ('PubMed ID', '[31906857](https://pubmed.ncbi.nlm.nih.gov/31906857/)'), ('Reporting guideline acronym', 'LEVEL'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Data, Statistical methods and analyses'), ('Record last updated on', 'November 2, 2023')]"
21416,Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting,Observational studies,Pharmaceutical medicine,Data, ,"checklist, checklists, data, data linkage, dataset, electronic healthcare data, epidemiological, epidemiology, International Society for Pharmacoepidemiology, ISPE, linkage, observational, pharmacoepidemiologic, pharmacoepidemiology, pharmacological, pharmacology, RECORD-PE", ,"Pratt NL, Mack CD, Meyer AM, Davis KJ, Hammill BG, Hampp C, Setoguchi S, Raman SR, Chun DS, St\xfcrmer T, Lund JL. Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting. Pharmacoepidemiol Drug Saf. 2020;29(1):9-17.","Pratt NL, Mack CD, Meyer AM, Davis KJ, Hammill BG, Hampp C, Setoguchi S, Raman SR, Chun DS, St\xfcrmer T, Lund JL.",Pharmacoepidemiology and Drug Safety [Pharmacoepidemiol Drug Saf.],2020,29,1,9-17, ,English, ,31736248,https://pubmed.ncbi.nlm.nih.gov/31736248/, , , , , , ,Reporting data linkage for pharmacoepidemiologic studies., , , , , , , ,no,2023-11-02 10:58:46,2023-11-02 10:58:46,data-linkage-in-pharmacoepidemiology-a-call-for-rigorous-evaluation-and-reporting,"[('title', 'Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting data linkage for pharmacoepidemiologic studies.'), ('Full bibliographic reference', 'Pratt NL, Mack CD, Meyer AM, Davis KJ, Hammill BG, Hampp C, Setoguchi S, Raman SR, Chun DS, Stürmer T, Lund JL. Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting. Pharmacoepidemiol Drug Saf. 2020;29(1):9-17.'), ('Language', 'English'), ('PubMed ID', '[31736248](https://pubmed.ncbi.nlm.nih.gov/31736248/)'), ('Study design', 'Observational studies'), ('Clinical area', 'Pharmaceutical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'November 2, 2023')]"
21414,Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure,"Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies","Cardiovascular medicine, Radiology",Whole report, ,"cardiology, cardiovascular, checklist, checklists, clinical trial, clinical trials, diagnosis, diagnostic, epidemiological, epidemiology, heart, heart failure, HF, lung, lung ultrasound, LUS, observational, prognosis, prognostic, pulmonary, pulmonary congestion, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials, ultrasound", ,"Platz E, Jhund PS, Girerd N, Pivetta E, McMurray JJV, Peacock WF, Masip J, Martin-Sanchez FJ, Mir\xf3 \xd2, Price S, Cullen L, Maisel AS, Vrints C, Cowie MR, DiSomma S, Bueno H, Mebazaa A, Gualandro DM, Tavares M, Metra M, Coats AJS, Ruschitzka F, Seferovic PM, Mueller C; Study Group on Acute Heart Failure of the Acute Cardiovascular Care Association and the Heart Failure Association of the European Society of Cardiology. Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. Eur J Heart Fail. 2019;21(7):844-851.","Platz E, Jhund PS, Girerd N, Pivetta E, McMurray JJV, Peacock WF, Masip J, Martin-Sanchez FJ, Mir\xf3 \xd2, Price S, Cullen L, Maisel AS, Vrints C, Cowie MR, DiSomma S, Bueno H, Mebazaa A, Gualandro DM, Tavares M, Metra M, Coats AJS, Ruschitzka F, Seferovic PM, Mueller C; Study Group on Acute Heart Failure of the Acute Cardiovascular Care Association and the Heart Failure Association of the European Society of Cardiology.",European Journal of Heart Failure [Eur J Heart Fail.],2019,21,7,844-851, ,English, ,31218825,https://pubmed.ncbi.nlm.nih.gov/31218825/, , , , , , ,Reporting of lung ultrasound (LUS) in heart failure research., , , , , , , ,no,2023-11-02 10:23:17,2023-11-02 11:13:56,expert-consensus-document-reporting-checklist-for-quantification-of-pulmonary-congestion-by-lung-ultrasound-in-heart-failure,"[('title', 'Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of lung ultrasound (LUS) in heart failure research.'), ('Full bibliographic reference', 'Platz E, Jhund PS, Girerd N, Pivetta E, McMurray JJV, Peacock WF, Masip J, Martin-Sanchez FJ, Miró Ò, Price S, Cullen L, Maisel AS, Vrints C, Cowie MR, DiSomma S, Bueno H, Mebazaa A, Gualandro DM, Tavares M, Metra M, Coats AJS, Ruschitzka F, Seferovic PM, Mueller C; Study Group on Acute Heart Failure of the Acute Cardiovascular Care Association and the Heart Failure Association of the European Society of Cardiology. Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. Eur J Heart Fail. 2019;21(7):844-851.'), ('Language', 'English'), ('PubMed ID', '[31218825](https://pubmed.ncbi.nlm.nih.gov/31218825/)'), ('Study design', 'Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies'), ('Clinical area', 'Cardiovascular medicine, Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 2, 2023')]"
21410,Commentary: minimum reporting standards should be expected for preclinical radiobiology irradiators and dosimetry in the published literature,Animal pre-clinical research,Oncology,"Harms/adverse effects/safety data, Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)", ,"animal, animals, dosimetry, exposure, irradiation, irradiators, preclinical, radiation, radiation dosimetry, radiation-exposure studies, radiation-exposure study, radiobiology", ,"Trompier F, DeWerd LA, Poirier Y, Dos Santos M, Sheng K, Kunugi KA, Winters TA, DiCarlo AL, Satyamitra M. Commentary: minimum reporting standards should be expected for preclinical radiobiology irradiators and dosimetry in the published literature. Int J Radiat Biol. 2023:1-6.","Trompier F, DeWerd LA, Poirier Y, Dos Santos M, Sheng K, Kunugi KA, Winters TA, DiCarlo AL, Satyamitra M.",International Journal of Radiation Biology [Int J Radiat Biol.],2023, , ,1-6, ,English, ,37695653,https://pubmed.ncbi.nlm.nih.gov/37695653/, , , , , , ,Reporting radiation dosimetry information in preclinical radiation studies., , , , , , , ,no,2023-11-01 11:00:06,2023-11-01 11:06:32,commentary-minimum-reporting-standards-should-be-expected-for-preclinical-radiobiology-irradiators-and-dosimetry-in-the-published-literature,"[('title', 'Commentary: minimum reporting standards should be expected for preclinical radiobiology irradiators and dosimetry in the published literature'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting radiation dosimetry information in preclinical radiation studies.'), ('Full bibliographic reference', 'Trompier F, DeWerd LA, Poirier Y, Dos Santos M, Sheng K, Kunugi KA, Winters TA, DiCarlo AL, Satyamitra M. Commentary: minimum reporting standards should be expected for preclinical radiobiology irradiators and dosimetry in the published literature. Int J Radiat Biol. 2023:1-6.'), ('Language', 'English'), ('PubMed ID', '[37695653](https://pubmed.ncbi.nlm.nih.gov/37695653/)'), ('Study design', 'Animal pre-clinical research'), ('Clinical area', 'Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'November 1, 2023')]"
21407,Best practice guidelines for citizen science in mental health research: systematic review and evidence synthesis,"Clinical practice guidelines, Clinical trials, Economic evaluations, Experimental studies, Observational studies, Qualitative research, Quality improvement studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews","Psychiatry, Psychology","Acknowledgements, Data, Ethical issues (consent etc.), Funding, Narrative sections (discussion etc.), Procedure/Method, Title", ,"case report, case reports, case series, checklist, checklists, citizen, citizen science, citizen scientist, citizen scientists, clinical trial, clinical trials, cohort studies, cohort study, community, community science, crowd, economic evaluation, economic evaluations, mental health, mental ill health, observational, participant, participants, participatory, patient, patient and public involvement, PPI, psychiatry, psychology, public, public engagement, public involvement, qualitative, quality improvement, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, review, reviews, systematic review, systematic reviews, trial, trials", ,"Todowede O, Lewandowski F, Kotera Y, Ashmore A, Rennick-Egglestone S, Boyd D, Moran S, \xd8rjas\xe6ter KB, Repper J, Robotham D, Rowe M, Katsampa D, Slade M. Best practice guidelines for citizen science in mental health research: systematic review and evidence synthesis. Front Psychiatry. 2023;14:1175311.","Todowede O, Lewandowski F, Kotera Y, Ashmore A, Rennick-Egglestone S, Boyd D, Moran S, \xd8rjas\xe6ter KB, Repper J, Robotham D, Rowe M, Katsampa D, Slade M.",Frontiers in Psychiatry. [Front Psychiatry.],2023,14, ,1175311, ,English, ,37743990,https://pubmed.ncbi.nlm.nih.gov/37743990/, , , , , , ,Reporting mental health citizen science research., , , , , , , ,no,2023-10-25 17:03:52,2023-10-25 17:10:13,best-practice-guidelines-for-citizen-science-in-mental-health-research-systematic-review-and-evidence-synthesis,"[('title', 'Best practice guidelines for citizen science in mental health research: systematic review and evidence synthesis'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting mental health citizen science research.'), ('Full bibliographic reference', 'Todowede O, Lewandowski F, Kotera Y, Ashmore A, Rennick-Egglestone S, Boyd D, Moran S, Ørjasæter KB, Repper J, Robotham D, Rowe M, Katsampa D, Slade M. Best practice guidelines for citizen science in mental health research: systematic review and evidence synthesis. Front Psychiatry. 2023;14:1175311.'), ('Language', 'English'), ('PubMed ID', '[37743990](https://pubmed.ncbi.nlm.nih.gov/37743990/)'), ('Study design', 'Clinical practice guidelines, Clinical trials, Economic evaluations, Experimental studies, Observational studies, Qualitative research, Quality improvement studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Clinical area', 'Psychiatry, Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Acknowledgements, Data, Ethical issues (consent etc.), Funding, Narrative sections (discussion etc.), Procedure/Method, Title'), ('Record last updated on', 'October 25, 2023')]"
21405,Evaluating the quality of studies reporting on clinical applications of stromal vascular fraction: A systematic review and proposed reporting guidelines (CLINIC-STRA-SVF),"Clinical trials, Experimental studies, Observational studies", ,Whole report, ,"adipose, adipose tissue, adipose tissue stem cells, adipose-derived stem cells, ADSVF, case report, case reports, case series, checklist, checklists, CLINIC-STRA-SVF, clinical trial, clinical trials, cohort studies, cohort study, observational, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, regenerative medicine, stem cell, stem cells, Strengthening Reporting in Therapeutic Applications of the Stromal Vascular Fraction Guideline, stromal vascular fraction, SVF, trial, trials", ,"Ferreira MY, Carvalho Junior JDC, Ferreira LM. Evaluating the quality of studies reporting on clinical applications of stromal vascular fraction: A systematic review and proposed reporting guidelines (CLINIC-STRA-SVF). Regen Ther. 2023;24:332-342.","Ferreira MY, Carvalho Junior JDC, Ferreira LM.",Regenerative Therapy [Regen Ther.],2023,24, ,332-342, ,English, ,37662694,https://pubmed.ncbi.nlm.nih.gov/37662694/, , , , , ,CLINIC-STRA-SVF,Reporting studies evaluating therapies related to stromal vascular fraction (SVF)., , , , , , , ,no,2023-10-25 16:18:21,2023-10-25 17:11:51,evaluating-the-quality-of-studies-reporting-on-clinical-applications-of-stromal-vascular-fraction-a-systematic-review-and-proposed-reporting-guidelines-clinic-stra-svf,"[('title', 'Evaluating the quality of studies reporting on clinical applications of stromal vascular fraction: A systematic review and proposed reporting guidelines (CLINIC-STRA-SVF)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting studies evaluating therapies related to stromal vascular fraction (SVF).'), ('Full bibliographic reference', 'Ferreira MY, Carvalho Junior JDC, Ferreira LM. Evaluating the quality of studies reporting on clinical applications of stromal vascular fraction: A systematic review and proposed reporting guidelines (CLINIC-STRA-SVF). Regen Ther. 2023;24:332-342.'), ('Language', 'English'), ('PubMed ID', '[37662694](https://pubmed.ncbi.nlm.nih.gov/37662694/)'), ('Reporting guideline acronym', 'CLINIC-STRA-SVF'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 25, 2023')]"
21402,Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance,"Clinical trials, Experimental studies", ,Whole report, ,"checklist, checklists, clinical trial, clinical trials, CONSORT, CONSORT Dose-finding Extension, CONSORT Dose-finding Extension statement, CONSORT extension, CONSORT-DEFINE, CONSORT-DEFINE for abstracts, DEFINE, dosage, dose, dosing, early phase, early phase dose-finding, EPDF, EPDF trial, EPDF trials, first-in-human, intervention, interventions, non-pharmacological, pharmacological, phase 1, phase 1/2, phase I, phase I/II, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387.","Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ.",BMJ.,2023,383, ,e076387, ,English, ,37863501,https://pubmed.ncbi.nlm.nih.gov/37863501/,"Read the full-text of the CONSORT-DEFINE guideline.

This reporting guideline includes the CONSORT-DEFINE for abstracts extension checklist.

", , ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster: Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal: Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts: Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture: MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738. PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

",https://www.icr.ac.uk/our-research/researchers-and-teams/professor-christina-yap/dose-finding-consort-extension-project,CONSORT-DEFINE,Reporting early phase dose-finding trials., ,"Read a paper published in BMC Medicine about the development of the guideline.

Read the guideline development protocol (PDF).

", , , , , ,yes,2023-10-24 16:49:32,2025-05-30 09:26:43,consort-define,"[('title', 'Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting early phase dose-finding trials.'), ('Full bibliographic reference', 'Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387.'), ('Language', 'English'), ('PubMed ID', '[37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.bmj.com/content/383/bmj-2023-076387) of the CONSORT-DEFINE guideline.\n\n \n\n This reporting guideline includes the CONSORT-DEFINE for abstracts extension checklist.\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](https://www.equator-network.org/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](https://www.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](https://www.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](https://www.equator-network.org/reporting-guidelines/consort-cluster/): Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](https://www.equator-network.org/reporting-guidelines/consort-herbal/): Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](https://www.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973\n\n \n\n[**CONSORT Abstracts**](https://www.equator-network.org/reporting-guidelines/consort-abstracts/): Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](https://www.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](https://www.equator-network.org/reporting-guidelines/consort-stricta/): MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](https://www.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](https://www.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738. PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](https://www.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](https://www.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](https://www.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](https://www.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](https://www.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://www.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](https://www.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](https://www.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](https://www.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](https://www.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](https://www.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://www.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://www.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://www.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://www.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline website URL', '<https://www.icr.ac.uk/our-research/researchers-and-teams/professor-christina-yap/dose-finding-consort-extension-project>'), ('Reporting guideline acronym', 'CONSORT-DEFINE'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', '[Read a paper](https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-023-02937-0) published in BMC Medicine about the development of the guideline.\n\n \n\n Read the guideline development [protocol (PDF)](https://www.equator-network.org/wp-content/uploads/2022/05/DF-CONSORT-protocol-v1.2_FINAL.pdf).\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
21399,Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance,"Clinical trials, Experimental studies, Study protocols", ,Protocol-whole report, ,"checklist, checklists, clinical trial protocol, DEFINE, dosage, dose, dosing, early phase, early phase dose-finding, EPDF, EPDF trial, EPDF trials, first-in-human, intervention, interventions, non-pharmacological, pharmacological, phase 1, phase 1/2, phase I, phase I/II, protocol, protocols, randomised controlled trial protocol, randomised trial protocol, randomized controlled trial protocol, randomized trial protocol, RCT protocol, SPIRIT, SPIRIT Dose-finding, SPIRIT Dose-finding Extension, SPIRIT Dose-finding Extension statement, SPIRIT Extension, SPIRIT-DEFINE, trial protocol", ,"Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386.","Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J.",BMJ.,2023,383, ,e076386, ,English, ,37863491,https://pubmed.ncbi.nlm.nih.gov/37863491/, , , ,"Generic

SPIRIT 2025 Statement: Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hr\xf3bjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.

BMJ. 2025; 388:e081660. PMID:\xa040294956
JAMA. 2025.\xa0PMID: 40294593
Lancet 2025.
Nat Med. 2025.\xa0PMID: 40295741
PLoS Med. 2025; 22(4): e1004587.\xa0PMID: 40294521

Specialised
SPIRIT-PRO: Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. Link to abstract

SPIRIT-TCM: Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: 30484022

SPENT 2019: Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. Link to full-text.

SPIRIT-AI: Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.
BMJ. 2020;370:m3210. PMID: 32907797
Nat Med. 2020;26(9):1351?1363. PMID: 32908284
Lancet Digital Health. 2020;2(10):e549-e560. PMID: 33328049

SPIRIT-Path: Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: 34592193

SPIRIT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: 36512367

SPIRIT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: 38051535

SPIRIT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: 38981624

SPIRIT-iNeurostim: Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: 39610902

",https://www.icr.ac.uk/our-research/researchers-and-teams/professor-christina-yap/dose-finding-consort-extension-project,SPIRIT-DEFINE,Reporting early phase dose-finding clinical trial protocols., ,"Read a paper published in BMC Medicine about the development of the guideline.

Read the guideline development protocol (PDF)

", , , , , ,yes,2023-10-24 14:50:27,2025-05-30 09:14:15,spirit-define,"[('title', 'Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting early phase dose-finding clinical trial protocols.'), ('Full bibliographic reference', 'Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386.'), ('Language', 'English'), ('PubMed ID', '[37863491](https://pubmed.ncbi.nlm.nih.gov/37863491/)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n \n\n**[SPIRIT 2025 Statement](https://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/):** Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hróbjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.\n\n \n\nBMJ. 2025; 388:e081660. [PMID:40294956](https://pubmed.ncbi.nlm.nih.gov/40294956/)\n\n JAMA. 2025.[PMID:](https://pubmed.ncbi.nlm.nih.gov/40294593/) [40294593](https://pubmed.ncbi.nlm.nih.gov/40294593/)\n\n Lancet 2025.\n\n Nat Med. 2025.[PMID: 40295741](https://pubmed.ncbi.nlm.nih.gov/40295741)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID: 40294521](https://pubmed.ncbi.nlm.nih.gov/40294521/)\n\n \n\n**Specialised**\n\n[**SPIRIT-PRO**](https://www.equator-network.org/reporting-guidelines/spirit-pro/): Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. [Link to abstract](https://jamanetwork.com/journals/jama/article-abstract/2671472)\n\n \n\n[**SPIRIT-TCM**](https://www.equator-network.org/reporting-guidelines/standard-protocol-items-for-clinical-trials-with-traditional-chinese-medicine-spirit-tcm-extension-2018/): Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: [30484022](https://www.ncbi.nlm.nih.gov/pubmed/30484022)\n\n \n\n[**SPENT 2019**](https://www.equator-network.org/reporting-guidelines/spirit-extension-n-of-1-trials-spent-2019/): Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. [Link to full-text](https://www.bmj.com/content/368/bmj.m122).\n\n \n\n[**SPIRIT-AI**](https://www.equator-network.org/reporting-guidelines/spirit-artificial-intelligence/): Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.\n\n BMJ. 2020;370:m3210. PMID: [32907797](https://pubmed.ncbi.nlm.nih.gov/32907797/)\n\n Nat Med. 2020;26(9):1351–1363. PMID: [32908284](https://pubmed.ncbi.nlm.nih.gov/32908284/)\n\n Lancet Digital Health. 2020;2(10):e549-e560. PMID: [33328049](https://pubmed.ncbi.nlm.nih.gov/33328049/)\n\n \n\n[**SPIRIT-Path**](https://www.equator-network.org/reporting-guidelines/spirit-path/): Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: [34592193](https://pubmed.ncbi.nlm.nih.gov/34592193/)\n\n \n\n**[SPIRIT-Outcomes](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-protocols-the-spirit-outcomes-2022-extension/)**: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: [36512367](https://pubmed.ncbi.nlm.nih.gov/36512367/)\n\n \n\n[**SPIRIT Factorial**](https://www.equator-network.org/reporting-guidelines/consensus-statement-for-protocols-of-factorial-randomized-trials-extension-of-the-spirit-2013-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: [38051535](https://pubmed.ncbi.nlm.nih.gov/38051535/)\n\n \n\n[**SPIRIT-Surrogate**](https://www.equator-network.org/reporting-guidelines/spirit-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: [38981624](https://pubmed.ncbi.nlm.nih.gov/38981624/)\n\n \n\n[**SPIRIT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-protocols-of-randomised-controlled-trials-of-implantable-neurostimulation-devices-the-spirit-ineurostim-extension/): Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: [39610902](https://pubmed.ncbi.nlm.nih.gov/39610902/)\n\n \n\n""), ('Reporting guideline website URL', '<https://www.icr.ac.uk/our-research/researchers-and-teams/professor-christina-yap/dose-finding-consort-extension-project>'), ('Reporting guideline acronym', 'SPIRIT-DEFINE'), ('Study design', 'Clinical trials, Experimental studies, Study protocols'), ('Applies to the whole report or to individual sections of the report?', 'Protocol-whole report'), ('Additional information', '[Read a paper](https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-023-02937-0) published in BMC Medicine about the development of the guideline.\n\n \n\n Read the guideline development [protocol (PDF)](https://www.equator-network.org/wp-content/uploads/2022/05/SPIRIT-protocol-v1.0-06052022_FINAL1.pdf)\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
21393,ESMO Guidance for Reporting Oncology real-World evidence (GROW),Observational studies,Oncology,Whole report, ,"AI, artificial intelligence, cancer, checklist, checklists, data, dataset, datasets, deep learning, DL, epidemiology, ESMO, ESMO Guidance for Reporting Oncology Real-World Evidence, ESMO-GROW, European Society for Medical Oncology, flow diagram, flowchart, GROW, machine learning, ML, observational, oncology, real world data, real-world evidence, RWD, RWE", ,"Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen JWG, Suijkerbuijk KPM, Dafni U, Dellaporta T, Vogel A, Prelaj A, Groenwold RHH, Martins H, Stahel R, Bliss J, Kather J, Ribelles N, Perrone F, Hall PS, Dienstmann R, Booth CM, Pentheroudakis G, Delaloge S, Koopman M. ESMO Guidance for Reporting Oncology real-World evidence (GROW).

Ann Oncol. 2023:S0923-7534(23)04018-8. PMID: 37848160
ESMO Real World Data and Digital Oncology (2023). Link to full-text

","Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen JWG, Suijkerbuijk KPM, Dafni U, Dellaporta T, Vogel A, Prelaj A, Groenwold RHH, Martins H, Stahel R, Bliss J, Kather J, Ribelles N, Perrone F, Hall PS, Dienstmann R, Booth CM, Pentheroudakis G, Delaloge S, Koopman M.", ,2023, , , , ,English, , , ,Access the GROW interactive checklist tool., , , ,https://www.esmo.org/scales-and-tools/esmo-guidance-for-reporting-oncology-real-world-evidence-esmo-grow,GROW,"Reporting oncology real-world evidence (RWE) studies.



GROW checklist (PDF) \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 GROW flowchart (Word)

", , , , , , , ,no,2023-10-18 15:24:17,2023-10-18 16:54:56,esmo-guidance-for-reporting-oncology-real-world-evidence-grow,"[('title', 'ESMO Guidance for Reporting Oncology real -World evidence (GROW)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting oncology real-world evidence (RWE) studies.\n\n \n\n \xa0\n\n \n\n[GROW checklist (PDF)](https://www.esmo.org/content/download/775073/18293338/1/ESMO-GROW-Checklist.pdf)  [GROW flowchart (Word)](https://www.esmo.org/content/download/775071/18293314/1/ESMO-GROW-Flowchart-Template.docx)\n\n \n\n'), ('Full bibliographic reference', 'Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen JWG, Suijkerbuijk KPM, Dafni U, Dellaporta T, Vogel A, Prelaj A, Groenwold RHH, Martins H, Stahel R, Bliss J, Kather J, Ribelles N, Perrone F, Hall PS, Dienstmann R, Booth CM, Pentheroudakis G, Delaloge S, Koopman M. ESMO Guidance for Reporting Oncology real-World evidence (GROW).\n\n \n\n Ann Oncol. 2023:S0923-7534(23)04018-8. PMID: [37848160](https://pubmed.ncbi.nlm.nih.gov/37848160/)\n\n ESMO Real World Data and Digital Oncology (2023). [Link to full-text](https://www.esmorwd.org/article/S2949-8201(23)00003-6/fulltext)\n\n \n\n'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'Access the [GROW interactive checklist tool](https://grow.esmo.org/).'), ('Reporting guideline website URL', '<https://www.esmo.org/scales-and-tools/esmo-guidance-for-reporting-oncology-real-world-evidence-esmo-grow>'), ('Reporting guideline acronym', 'GROW'), ('Study design', 'Observational studies'), ('Clinical area', 'Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 18, 2023')]"
21388,A systematic review and cluster analysis approach of 103 studies of high-intensity interval training on cardiorespiratory fitness,Study protocols,Sport and exercise medicine,"Narrative sections (discussion etc.), Procedure/Method, Results", ,"AGReHIIT, cardiometabolic, cardiorespiratory, cardiorespiratory fitness, CRF, exercise, exercising, fitness, high-intensity interval training, HIIT, physical, physical activity, protcol, protocols, sport, training", ,"Cadenas-Sanchez C, Fern\xe1ndez-Rodr\xedguez R, Mart\xednez-Vizca\xedno V, de Los Reyes Gonz\xe1lez N, Lavie CJ, Gal\xe1n-Mercant A, Jim\xe9nez-Pav\xf3n D. A systematic review and cluster analysis approach of 103 studies of high-intensity interval training on cardiorespiratory fitness. Eur J Prev Cardiol. 2023:zwad309.","Cadenas-Sanchez C, Fern\xe1ndez-Rodr\xedguez R, Mart\xednez-Vizca\xedno V, de Los Reyes Gonz\xe1lez N, Lavie CJ, Gal\xe1n-Mercant A, Jim\xe9nez-Pav\xf3n D.",European Journal of Preventive Cardiology [Eur J Prev Cardiol.],2023, , ,zwad309, ,English, ,37738464,https://pubmed.ncbi.nlm.nih.gov/37738464/, , , , , ,AGReHIIT,Reporting high-intensity interval training (HIIT) protocols., , , , , , , ,no,2023-10-16 16:15:45,2023-10-16 16:15:45,a-systematic-review-and-cluster-analysis-approach-of-103-studies-of-high-intensity-interval-training-on-cardiorespiratory-fitness,"[('title', 'A systematic review and cluster analysis approach of 103 studies of high-intensity interval training on cardiorespiratory fitness'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting high-intensity interval training (HIIT) protocols.'), ('Full bibliographic reference', 'Cadenas-Sanchez C, Fernández-Rodríguez R, Martínez-Vizcaíno V, de Los Reyes González N, Lavie CJ, Galán-Mercant A, Jiménez-Pavón D. A systematic review and cluster analysis approach of 103 studies of high-intensity interval training on cardiorespiratory fitness. Eur J Prev Cardiol. 2023:zwad309.'), ('Language', 'English'), ('PubMed ID', '[37738464](https://pubmed.ncbi.nlm.nih.gov/37738464/)'), ('Reporting guideline acronym', 'AGReHIIT'), ('Study design', 'Study protocols'), ('Clinical area', 'Sport and exercise medicine'), ('Applies to the whole report or to individual sections of the report?', 'Narrative sections (discussion etc.), Procedure/Method, Results'), ('Record last updated on', 'October 16, 2023')]"
21385,Generate Analysis-Ready Data for Real-world Evidence: Tutorial for Harnessing Electronic Health Records With Advanced Informatic Technologies,"Clinical trials, Experimental studies, Observational studies", ,Data, ,"data, data curation, EHR, EHRs, electronic health record, electronic health records, informatics, postapproval, real world, real world data, real-world evidence, regulation, regulatory, RWD, RWE", ,"Hou J, Zhao R, Gronsbell J, Lin Y, Bonzel CL, Zeng Q, Zhang S, Beaulieu-Jones BK, Weber GM, Jemielita T, Wan SS, Hong C, Cai T, Wen J, Ayakulangara Panickan V, Liaw KL, Liao K, Cai T. Generate Analysis-Ready Data for Real-world Evidence: Tutorial for Harnessing Electronic Health Records With Advanced Informatic Technologies. J Med Internet Res. 2023;25:e45662.","Hou J, Zhao R, Gronsbell J, Lin Y, Bonzel CL, Zeng Q, Zhang S, Beaulieu-Jones BK, Weber GM, Jemielita T, Wan SS, Hong C, Cai T, Wen J, Ayakulangara Panickan V, Liaw KL, Liao K, Cai T.",Journal of Medical Internet Research [J Med Internet Res.],2023,25, ,e45662, ,English, ,37227772,https://pubmed.ncbi.nlm.nih.gov/37227772/, , , , , , ,Reporting of data creation in real-world evidence (RWE) research., , , , , , , ,no,2023-10-13 14:58:26,2023-10-13 14:58:26,generate-analysis-ready-data-for-real-world-evidence-tutorial-for-harnessing-electronic-health-records-with-advanced-informatic-technologies,"[('title', 'Generate Analysis -Ready Data for Real-world Evidence: Tutorial for Harnessing Electronic Health Records With Advanced Informatic Technologies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of data creation in real-world evidence (RWE) research.'), ('Full bibliographic reference', 'Hou J, Zhao R, Gronsbell J, Lin Y, Bonzel CL, Zeng Q, Zhang S, Beaulieu-Jones BK, Weber GM, Jemielita T, Wan SS, Hong C, Cai T, Wen J, Ayakulangara Panickan V, Liaw KL, Liao K, Cai T. Generate Analysis-Ready Data for Real-world Evidence: Tutorial for Harnessing Electronic Health Records With Advanced Informatic Technologies. J Med Internet Res. 2023;25:e45662.'), ('Language', 'English'), ('PubMed ID', '[37227772](https://pubmed.ncbi.nlm.nih.gov/37227772/)'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'October 13, 2023')]"
21383,Developing Consensus-Based Guidelines for Case Reporting in Aesthetic Medicine: Enhancing Transparency and Standardization,Observational studies,"Dermatology, Surgery",Whole report, ,"aesthetic, botulinum toxin injection, case reporting, Case REporting in Aesthetic Medicine, case reports, cell therapy, cellular-derived product, checklist, checklists, cosmetic, CREAM, dermal filler, dermatology, laser, observational, plastic, platics, surgery, surgical", ,"Rahman E, Philip-Dormston WG, Webb WR, Rao P, Carruthers JD, Carruthers A, Swift A, Goodman GJ, Mosahebi A, Nahai F. Developing Consensus-Based Guidelines for Case Reporting in Aesthetic Medicine: Enhancing Transparency and Standardization. Aesthet Surg J Open Forum. 2023;5:ojad076.","Rahman E, Philip-Dormston WG, Webb WR, Rao P, Carruthers JD, Carruthers A, Swift A, Goodman GJ, Mosahebi A, Nahai F.",Aesthetic Surgical Journal Open Forum. [Aesthet Surg J Open Forum.],2023,5, ,ojad076, ,English, ,37694226,https://pubmed.ncbi.nlm.nih.gov/37694226/, , , , , ,CREAM,Case reporting in aesthetic medicine., , , , , , , ,no,2023-10-12 10:48:06,2023-10-12 10:48:06,developing-consensus-based-guidelines-for-case-reporting-in-aesthetic-medicine-enhancing-transparency-and-standardization,"[('title', 'Developing Consensus -Based Guidelines for Case Reporting in Aesthetic Medicine: Enhancing Transparency and Standardization'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Case reporting in aesthetic medicine.'), ('Full bibliographic reference', 'Rahman E, Philip-Dormston WG, Webb WR, Rao P, Carruthers JD, Carruthers A, Swift A, Goodman GJ, Mosahebi A, Nahai F. Developing Consensus-Based Guidelines for Case Reporting in Aesthetic Medicine: Enhancing Transparency and Standardization. Aesthet Surg J Open Forum. 2023;5:ojad076.'), ('Language', 'English'), ('PubMed ID', '[37694226](https://pubmed.ncbi.nlm.nih.gov/37694226/)'), ('Reporting guideline acronym', 'CREAM'), ('Study design', 'Observational studies'), ('Clinical area', 'Dermatology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 12, 2023')]"
21380,MINIMAR (MINimum Information for Medical AI Reporting): Developing reporting standards for artificial intelligence in health care,Artificial intelligence/Machine learning studies, ,"Data, Statistical methods and analyses, Study characteristics (participants etc.)", ,"AI, algorithm, algorithms, artificial intelligence, checklist, checklists, classification, clinical decision support, clinical decision tool, data, decision, deep learning, diagnosis, diagnostic, DL, machine learning, MINIMAR, MINimum Information for Medical AI Reporting, ML, model, modeling, modelling, models, prediction, predictive, prognosis, prognostic, statistical, statistics", ,"Hernandez-Boussard T, Bozkurt S, Ioannidis JPA, Shah NH. MINIMAR (MINimum Information for Medical AI Reporting): Developing reporting standards for artificial intelligence in health care. J Am Med Inform Assoc. 2020;27(12):2011-2015.","Hernandez-Boussard T, Bozkurt S, Ioannidis JPA, Shah NH.",Journal of the American Medical Informatics Association [J Am Med Inform Assoc.],2020,27,12,2011-2015, ,English, ,32594179,https://pubmed.ncbi.nlm.nih.gov/32594179/, , , , , ,MINIMAR,Reporting medical artificial intelligence (AI) research., , , , , , , ,no,2023-10-10 17:11:57,2024-01-25 11:27:53,minimar-minimum-information-for-medical-ai-reporting-developing-reporting-standards-for-artificial-intelligence-in-health-care,"[('title', 'MINIMAR  (MINimum Information for Medical AI Reporting): Developing reporting standards for artificial intelligence in health care'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting medical artificial intelligence (AI) research.'), ('Full bibliographic reference', 'Hernandez-Boussard T, Bozkurt S, Ioannidis JPA, Shah NH. MINIMAR (MINimum Information for Medical AI Reporting): Developing reporting standards for artificial intelligence in health care. J Am Med Inform Assoc. 2020;27(12):2011-2015.'), ('Language', 'English'), ('PubMed ID', '[32594179](https://pubmed.ncbi.nlm.nih.gov/32594179/)'), ('Reporting guideline acronym', 'MINIMAR'), ('Study design', 'Artificial intelligence/Machine learning studies'), ('Applies to the whole report or to individual sections of the report?', 'Data, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'January 25, 2024')]"
21378,"Presenting artificial intelligence, deep learning, and machine learning studies to clinicians and healthcare stakeholders: an introductory reference with a guideline and a Clinical AI Research (CAIR) checklist proposal",Artificial intelligence/Machine learning studies,"Rheumatology, Sport and exercise medicine",Whole report, ,"AI, algorithm, algorithms, artificial intelligence, CAIR, CAIR checklist, checklist, checklists, classification, Clinical Artificial Intelligence Research checklist, clinical decision support, clinical decision tool, data, decision, deep learning, diagnosis, diagnostic, DL, machine learning, ML, model, modeling, modelling, models, orthopaedics, orthopedics, prediction, predictive, prognosis, prognostic, statistical, statistics", ,"Olczak J, Pavlopoulos J, Prijs J, Ijpma FFA, Doornberg JN, Lundstr\xf6m C, Hedlund J, Gordon M. Presenting artificial intelligence, deep learning, and machine learning studies to clinicians and healthcare stakeholders: an introductory reference with a guideline and a Clinical AI Research (CAIR) checklist proposal. Acta Orthop. 2021;92(5):513-525.","Olczak J, Pavlopoulos J, Prijs J, Ijpma FFA, Doornberg JN, Lundstr\xf6m C, Hedlund J, Gordon M.",Acta Orthopaedica [Acta Orthop.],2021,92,5,513-525, ,English, ,33988081,https://pubmed.ncbi.nlm.nih.gov/33988081/, , , , , ,CAIR,Reporting of medical artificial intelligence (AI) research to clinicians., , , , , , , ,no,2023-10-10 16:42:54,2024-01-25 11:30:09,presenting-artificial-intelligence-deep-learning-and-machine-learning-studies-to-clinicians-and-healthcare-stakeholders-an-introductory-reference-with-a-guideline-and-a-clinical-ai-research-cair,"[('title', 'Presenting artificial intelligence, deep learning, and machine learning studies to clinicians and healthcare stakeholders: an introductory reference with a guideline and a Clinical AI Research (CAIR) checklist proposal'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of medical artificial intelligence (AI) research to clinicians.'), ('Full bibliographic reference', 'Olczak J, Pavlopoulos J, Prijs J, Ijpma FFA, Doornberg JN, Lundström C, Hedlund J, Gordon M. Presenting artificial intelligence, deep learning, and machine learning studies to clinicians and healthcare stakeholders: an introductory reference with a guideline and a Clinical AI Research (CAIR) checklist proposal. Acta Orthop. 2021;92(5):513-525.'), ('Language', 'English'), ('PubMed ID', '[33988081](https://pubmed.ncbi.nlm.nih.gov/33988081/)'), ('Reporting guideline acronym', 'CAIR'), ('Study design', 'Artificial intelligence/Machine learning studies'), ('Clinical area', 'Rheumatology, Sport and exercise medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 25, 2024')]"
21374,Data Processing Strategies to Determine Maximum Oxygen Uptake: A Systematic Scoping Review and Experimental Comparison with Guidelines for Reporting,"Clinical trials, Experimental studies, Observational studies",Sport and exercise medicine,Data, ,"breath, cardiopulmonary, cardiorespiratory, clinical trial, clinical trials, data, endurance, exercise, exercise physiology, exercising, fitness, observational, oxygen, physiological, physiology, processing strategies, processing strategy, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, sport, sports, trial, trials", ,"Nolte S, Rein R, Quittmann OJ. Data Processing Strategies to Determine Maximum Oxygen Uptake: A Systematic Scoping Review and Experimental Comparison with Guidelines for Reporting. Sports Med. 2023.","Nolte S, Rein R, Quittmann OJ.",Sports Medicine [Sports Med.],2023, , , , ,English, ,37603201,https://pubmed.ncbi.nlm.nih.gov/37603201/, , , , , , ,Reporting maximum oxygen uptake data processing strategies in sports and exercise science studies., , , , , , , ,no,2023-10-06 15:54:29,2023-10-06 15:54:29,data-processing-strategies-to-determine-maximum-oxygen-uptake-a-systematic-scoping-review-and-experimental-comparison-with-guidelines-for-reporting,"[('title', 'Data Processing Strategies to Determine Maximum Oxygen Uptake: A Systematic Scoping Review and Experimental Comparison with Guidelines for Reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting maximum oxygen uptake data processing strategies in sports and exercise science studies.'), ('Full bibliographic reference', 'Nolte S, Rein R, Quittmann OJ. Data Processing Strategies to Determine Maximum Oxygen Uptake: A Systematic Scoping Review and Experimental Comparison with Guidelines for Reporting. Sports Med. 2023.'), ('Language', 'English'), ('PubMed ID', '[37603201](https://pubmed.ncbi.nlm.nih.gov/37603201/)'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Sport and exercise medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'October 6, 2023')]"
21372,Improving the Rigor of Mechanistic Behavioral Science: The Introduction of the Checklist for Investigating Mechanisms in Behavior-Change Research (CLIMBR),"Clinical trials, Experimental studies, Observational studies",Behavioural medicine,Whole report, ,"behavior, behavior change, behavioral, behaviors, behaviour, behaviour change, behavioural, behaviours, checklist, CheckList for Investigating Mechanisms in Behavior-change Research, checklists, CLIMBR, mechanism, mechanisms, mechanistic, mechanistic behavioral science", ,"Birk JL, Otto MW, Cornelius T, Poldrack RA, Edmondson D. Improving the Rigor of Mechanistic Behavioral Science: The Introduction of the Checklist for Investigating Mechanisms in Behavior-Change Research (CLIMBR). Behav Ther. 2023;54(4):708-713.","Birk JL, Otto MW, Cornelius T, Poldrack RA, Edmondson D.",Behavior Therapy [Behav Ther.],2023,54,4,708-713, ,English, ,37330259,https://pubmed.ncbi.nlm.nih.gov/37330259/,The CLIMBR checklist is available to download from the Science of Behavior Change website., , , , ,CLIMBR,Reporting of mechanism-focused behavioural intervention studies., , , , , , , ,no,2023-10-05 17:30:21,2023-10-05 17:34:41,improving-the-rigor-of-mechanistic-behavioral-science-the-introduction-of-the-checklist-for-investigating-mechanisms-in-behavior-change-research-climbr,"[('title', 'Improving the Rigor of Mechanistic Behavioral Science: The Introduction of the Checklist for Investigating Mechanisms in Behavior -Change Research (CLIMBR)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of mechanism-focused behavioural intervention studies.'), ('Full bibliographic reference', 'Birk JL, Otto MW, Cornelius T, Poldrack RA, Edmondson D. Improving the Rigor of Mechanistic Behavioral Science: The Introduction of the Checklist for Investigating Mechanisms in Behavior-Change Research (CLIMBR). Behav Ther. 2023;54(4):708-713.'), ('Language', 'English'), ('PubMed ID', '[37330259](https://pubmed.ncbi.nlm.nih.gov/37330259/)'), ('Relevant URLs\n\n(full-text if available)', 'The CLIMBR checklist is available to download from the [Science of Behavior Change website](https://scienceofbehaviorchange.org/resources/sobc-checklist-for-investigating-mechanisms-in-behavior-change-research-climbr/).'), ('Reporting guideline acronym', 'CLIMBR'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Behavioural medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 5, 2023')]"
21370,An analysis of reporting practices in the top 100 cited health and medicine-related bibliometric studies from 2019 to 2021 based on a proposed guidelines,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Whole report, ,"bibliometric, bibliometric analysis, bibliometrics, checklist, checklists, Preferred Reporting Items for Bibliometric Analysis, PRIBA, scholarly productivity, scientometrics", ,"Koo M, Lin SC. An analysis of reporting practices in the top 100 cited health and medicine-related bibliometric studies from 2019 to 2021 based on a proposed guidelines. Heliyon. 2023;9(6):e16780.","Koo M, Lin SC.",Heliyon.,2023, , , , ,English, ,37292336,https://pubmed.ncbi.nlm.nih.gov/37292336/,The PRIBA checklist is available in Table 1 of the guideline paper., , , , ,PRIBA,Reporting of bibliometric studies., , , , , , , ,no,2023-10-05 17:07:13,2023-10-05 17:07:13,an-analysis-of-reporting-practices-in-the-top-100-cited-health-and-medicine-related-bibliometric-studies-from-2019-to-2021-based-on-a-proposed-guidelines,"[('title', 'An analysis of reporting practices in the top 100 cited health and medicine-related bibliometric studies from 2019 to 2021 based on a proposed guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of bibliometric studies.'), ('Full bibliographic reference', 'Koo M, Lin SC. An analysis of reporting practices in the top 100 cited health and medicine-related bibliometric studies from 2019 to 2021 based on a proposed guidelines. Heliyon. 2023;9(6):e16780.'), ('Language', 'English'), ('PubMed ID', '[37292336](https://pubmed.ncbi.nlm.nih.gov/37292336/)'), ('Relevant URLs\n\n(full-text if available)', 'The [PRIBA checklist](https://www.sciencedirect.com/science/article/pii/S2405844023039877) is available in Table 1 of the guideline paper.'), ('Reporting guideline acronym', 'PRIBA'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 5, 2023')]"
21366,Improving the Reporting of Primary Care Research: Consensus Reporting Items for Studies in Primary Care-the CRISP Statement,"Clinical trials, Experimental studies, Mixed methods studies, Observational studies, Qualitative research",Primary care,Whole report, ,"checklist, checklists, clinical trial, clinical trials, community, Consensus Reporting Items for Studies in Primary Care Checklist, CRiSP, CRISP Statement, family, family medicine, family practice, general practice, GP, mixed methods, observational, PC research, primary care, qualitative, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Phillips WR, Sturgiss E, Glasziou P, Hartman TCO, Orkin AM, Prathivadi P, Reeve J, Russell GM, Weel CV. Improving the Reporting of Primary Care Research: Consensus Reporting Items for Studies in Primary Care-the CRISP Statement. Ann Fam Med. 2023:3029.

","Phillips WR, Sturgiss E, Glasziou P, Hartman TCO, Orkin AM, Prathivadi P, Reeve J, Russell GM, Weel CV.",Annals of Family Medicine [Ann Fam Med.],2023, , , , ,English, ,37788942,https://pubmed.ncbi.nlm.nih.gov/37788942/, ,Read the CRISP Explanation and Examples Guide which is available online in the Supplementary Appendix to the main CRISP Statement., , ,https://crisp-pc.org/,CRISP,"Reporting primary care research.



CRISP Checklist (Word) \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 CRISP Checklist (PDF)

","Statement
The CRISP Statement with explanations and examples, has also been also published in Chinese at:
Phillips WR, Sturgiss, Glasziou P, et al. Improving the Reporting of Primary Care Research: Consensus Reporting Items for Studies in Primary Care?the CRISP Statement. [?.\xa0???????????????????CRISP????[J].\xa0??????.] Chinese General Practice. https://www.chinagp.net/CN/10.12114/j.issn.1007-9572.2024.A0025

Checklist
CRISP checklist Chinese (PDF)
CRISP Explanation and examples Chinese (PDF)
CRISP checklist Turkish (Word)
CRISP checklist Turkish (PDF)

", ,"Phillips WR, Sturgiss EA, Kendall S, Akman M. Reporting study results in primary health care: the CRISP guidelines. Prim Health Care Res Dev. 2024;25:e52. PMID: 39417283

Phillips WR, Sturgiss E. CRISP: A checklist for primary health care and family medicine research in Africa and worldwide. Afr J Prm Health Care Fam Med. 2024;16(1), a4790. https://doi.org/10.4102/phcfm.v16i1.4790

Rodr\xedguez JE, van Vugt VA, Gorin SS. Commentary on the CRISP Statement. Ann Fam Med. 2023;21(6):482. PMID: 38012034

Sturgiss EA, Phillips WR. The Consensus Reporting Items for Studies in Primary Care (CRISP) checklist - the first research reporting guideline made by and for primary care. Aust J Prim Health. 2024;30:PY24115. PMID: 39213388

", , , , ,no,2023-10-05 11:28:58,2025-03-26 14:12:05,improving-the-reporting-of-primary-care-research-consensus-reporting-items-for-studies-in-primary-care-the-crisp-statement,"[('title', 'Improving the Reporting of Primary Care Research: Consensus Reporting Items for Studies in Primary Care-the CRISP Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting primary care research.\n\n \n\n \xa0\n\n \n\n[CRISP Checklist (Word)](https://www.equator-network.org/wp-content/uploads/2023/10/CRISP-Reporting-Checklist-Version-1.0.docx)  [CRISP Checklist (PDF)](https://www.equator-network.org/wp-content/uploads/2023/10/CRISP-Reporting-Checklist-Version-1.0.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Phillips WR, Sturgiss E, Glasziou P, Hartman TCO, Orkin AM, Prathivadi P, Reeve J, Russell GM, Weel CV. Improving the Reporting of Primary Care Research: Consensus Reporting Items for Studies in Primary Care-the CRISP Statement. Ann Fam Med. 2023:3029.\n\n \n\n'), ('Language', 'English'), ('PubMed ID', '[37788942](https://pubmed.ncbi.nlm.nih.gov/37788942/)'), ('Explanation and elaboration papers', '[Read the CRISP Explanation and Examples Guide](https://www.annfammed.org/content/suppl/2023/10/02/afm.3029.DC1) which is available online in the Supplementary Appendix to the main CRISP Statement.'), ('Availability in additional languages', '**Statement\n\n**The CRISP Statement with explanations and examples, has also been also published in Chinese at:\n\nPhillips WR, Sturgiss, Glasziou P, et al. Improving the Reporting of Primary Care Research: Consensus Reporting Items for Studies in Primary Care—the CRISP Statement. [等.\xa0改进基本医疗（初级保健）研究报告内容的CRISP共识声明[J].\xa0中国全科医学.] Chinese General Practice. <https://www.chinagp.net/CN/10.12114/j.issn.1007-9572.2024.A0025>\n\n \n\n**Checklist\n\n**[CRISP checklist Chinese (PDF)](https://crisp-pc.org/wp-content/uploads/2024/11/CRISP-Checklist-Chinese-Version.pdf)\n\n[CRISP Explanation and examples Chinese (PDF)](https://crisp-pc.org/wp-content/uploads/2024/11/CRISP-Explanation-and-Examples-Chinese-Version.pdf)\n\n[CRISP checklist Turkish (Word)](https://crisp-pc.org/wp-content/uploads/2024/10/CRISP-Checklist-Turkish-final-2024.10.1.docx)\n\n[CRISP checklist Turkish (PDF)](https://crisp-pc.org/wp-content/uploads/2024/10/CRISP-Checklist-Turkish-final-2024.10.1-1.pdf)\n\n \n\n'), ('Reporting guideline website URL', '<https://crisp-pc.org/>'), ('Reporting guideline acronym', 'CRISP'), ('Study design', 'Clinical trials, Experimental studies, Mixed methods studies, Observational studies, Qualitative research'), ('Clinical area', 'Primary care'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Selected relevant editorials', 'Phillips WR, Sturgiss EA, Kendall S, Akman M. Reporting study results in primary health care: the CRISP guidelines. Prim Health Care Res Dev. 2024;25:e52. PMID: [39417283](https://pubmed.ncbi.nlm.nih.gov/39417283/)\n\n \n\n Phillips WR, Sturgiss E. CRISP: A checklist for primary health care and family medicine research in Africa and worldwide. Afr J Prm Health Care Fam Med. 2024;16(1), a4790. <https://doi.org/10.4102/phcfm.v16i1.4790>\n\n \n\n Rodríguez JE, van Vugt VA, Gorin SS. Commentary on the CRISP Statement. Ann Fam Med. 2023;21(6):482. PMID: [38012034](https://pubmed.ncbi.nlm.nih.gov/38012034/)\n\n \n\n Sturgiss EA, Phillips WR. The Consensus Reporting Items for Studies in Primary Care (CRISP) checklist - the first research reporting guideline made by and for primary care. Aust J Prim Health. 2024;30:PY24115. PMID: [39213388](https://pubmed.ncbi.nlm.nih.gov/39213388/)\n\n \n\n'), ('Record last updated on', 'March 26, 2025')]"
21347,Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use,"Clinical trials, Experimental studies, Observational studies","Infectious diseases, Public health",Whole report, ,"antiretroviral, antiretrovirals, ART, CEDRIC-HIV, checklist, checklist for studies of drug resistance in HIV, checklists, clinical trial, clinical trials, drug resistance, HIV, HIV drug resistance, HIVDR, HIVDR surveillance, incidence, observational, observational studies, observational study, post-exposure prophylaxis, pre-exposure prophylaxis, PrEP, prevalence, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, surveillance, trial, trials", ,"Mbuagbaw L, Garcia C, Brenner B, Cecchini D, Chakroun M, Djiadeu P, Holguin A, Mor O, Parkin N, Santoro MM, \xc1vila-R\xedos S, Fokam J, Phillips A, Shafer RW, Jordan MR. Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use. Lancet HIV. 2023:S2352-3018(23)00173-X.","Mbuagbaw L, Garcia C, Brenner B, Cecchini D, Chakroun M, Djiadeu P, Holguin A, Mor O, Parkin N, Santoro MM, \xc1vila-R\xedos S, Fokam J, Phillips A, Shafer RW, Jordan MR.",Lancet HIV.,2023, , , , ,English, ,37716367,https://pubmed.ncbi.nlm.nih.gov/37716367/,The checklists are available from the CEDRIC-HIV website., , , ,http://cedric-hiv.com/,CEDRIC-HIV,Reporting of HIV drug resistance (HIVDR) prevalence or incidence studies.,"Translations of the checklist are avilable in French, Portuguese, Chinese, Spanish and Italian.", , , , , , ,no,2023-09-28 15:46:11,2023-09-28 15:46:11,checklist-for-studies-of-hiv-drug-resistance-prevalence-or-incidence-rationale-and-recommended-use,"[('title', 'Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of HIV drug resistance (HIVDR) prevalence or incidence studies.'), ('Full bibliographic reference', 'Mbuagbaw L, Garcia C, Brenner B, Cecchini D, Chakroun M, Djiadeu P, Holguin A, Mor O, Parkin N, Santoro MM, Ávila-Ríos S, Fokam J, Phillips A, Shafer RW, Jordan MR. Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use. Lancet HIV. 2023:S2352-3018(23)00173-X.'), ('Language', 'English'), ('PubMed ID', '[37716367](https://pubmed.ncbi.nlm.nih.gov/37716367/)'), ('Relevant URLs\n\n(full-text if available)', 'The checklists are available from the [CEDRIC-HIV website](http://cedric-hiv.com/checklist/).'), ('Availability in additional languages', '[Translations of the checklist](http://cedric-hiv.com/translations/) are avilable in French, Portuguese, Chinese, Spanish and Italian.'), ('Reporting guideline website URL', '<http://cedric-hiv.com/>'), ('Reporting guideline acronym', 'CEDRIC-HIV'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Infectious diseases, Public health'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 28, 2023')]"
21344,Community-developed checklists for publishing images and image analyses, , ,Images, ,"bioimage, bioimages, checklist, checklists, data, deep learning, image, image analysis, image-analyses, images, imaging, machine learning, microscope, microscopy", ,"Schmied C, Nelson MS, Avilov S, Bakker GJ, Bertocchi C, Bischof J, Boehm U, Brocher J, Carvalho MT, Chiritescu C, Christopher J, Cimini BA, Conde-Sousa E, Ebner M, Ecker R, Eliceiri K, Fernandez-Rodriguez J, Gaudreault N, Gelman L, Grunwald D, Gu T, Halidi N, Hammer M, Hartley M, Held M, Jug F, Kapoor V, Koksoy AA, Lacoste J, Le D\xe9v\xe9dec S, Le Guyader S, Liu P, Martins GG, Mathur A, Miura K, Montero Llopis P, Nitschke R, North A, Parslow AC, Payne-Dwyer A, Plantard L, Ali R, Schroth-Diez B, Sch\xfctz L, Scott RT, Seitz A, Selchow O, Sharma VP, Spitaler M, Srinivasan S, Strambio-De-Castillia C, Taatjes D, Tischer C, Jambor HK. Community-developed checklists for publishing images and image analyses. Nat Methods. 2023.","Schmied C, Nelson MS, Avilov S, Bakker GJ, Bertocchi C, Bischof J, Boehm U, Brocher J, Carvalho MT, Chiritescu C, Christopher J, Cimini BA, Conde-Sousa E, Ebner M, Ecker R, Eliceiri K, Fernandez-Rodriguez J, Gaudreault N, Gelman L, Grunwald D, Gu T, Halidi N, Hammer M, Hartley M, Held M, Jug F, Kapoor V, Koksoy AA, Lacoste J, Le D\xe9v\xe9dec S, Le Guyader S, Liu P, Martins GG, Mathur A, Miura K, Montero Llopis P, Nitschke R, North A, Parslow AC, Payne-Dwyer A, Plantard L, Ali R, Schroth-Diez B, Sch\xfctz L, Scott RT, Seitz A, Selchow O, Sharma VP, Spitaler M, Srinivasan S, Strambio-De-Castillia C, Taatjes D, Tischer C, Jambor HK.",Nature Methods [Nat Methods.],2023, , , , ,English, ,37710020,https://pubmed.ncbi.nlm.nih.gov/37710020/,Access the reporting guideline checklists., , , , , ,Reporting light microscopy images and describing image analyses., , , , , , , ,no,2023-09-18 15:54:30,2023-09-18 15:54:30,community-developed-checklists-for-publishing-images-and-image-analyses,"[('title', 'Community-developed checklists for publishing images and image analyses'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting light microscopy images and describing image analyses.'), ('Full bibliographic reference', 'Schmied C, Nelson MS, Avilov S, Bakker GJ, Bertocchi C, Bischof J, Boehm U, Brocher J, Carvalho MT, Chiritescu C, Christopher J, Cimini BA, Conde-Sousa E, Ebner M, Ecker R, Eliceiri K, Fernandez-Rodriguez J, Gaudreault N, Gelman L, Grunwald D, Gu T, Halidi N, Hammer M, Hartley M, Held M, Jug F, Kapoor V, Koksoy AA, Lacoste J, Le Dévédec S, Le Guyader S, Liu P, Martins GG, Mathur A, Miura K, Montero Llopis P, Nitschke R, North A, Parslow AC, Payne-Dwyer A, Plantard L, Ali R, Schroth-Diez B, Schütz L, Scott RT, Seitz A, Selchow O, Sharma VP, Spitaler M, Srinivasan S, Strambio-De-Castillia C, Taatjes D, Tischer C, Jambor HK. Community-developed checklists for publishing images and image analyses. Nat Methods. 2023.'), ('Language', 'English'), ('PubMed ID', '[37710020](https://pubmed.ncbi.nlm.nih.gov/37710020/)'), ('Relevant URLs\n\n(full-text if available)', 'Access the reporting guideline [checklists](https://quarep-limi.github.io/WG12_checklists_for_image_publishing/intro.html).'), ('Applies to the whole report or to individual sections of the report?', 'Images'), ('Record last updated on', 'September 18, 2023')]"
21340,Systematic Development of Standards for Mixed Methods Reporting in Rehabilitation Health Sciences Research,Mixed methods studies,"Occupational therapy, Physiotherapy, Rehabilitation medicine",Whole report, ,"mixed methods, mixed methods research, MMR, physical, physical therapies, physical therapy, rehab, rehabilitation", ,"Tovin MM, Wormley ME. Systematic Development of Standards for Mixed Methods Reporting in Rehabilitation Health Sciences Research. Phys Ther. 2023.","Tovin MM, Wormley ME.",Physical Therapy [Phys Ther.],2013, , , , ,English, ,37672215,https://pubmed.ncbi.nlm.nih.gov/37672215/, , , , , ,MMR-RHS,"Reporting mixed methods research in rehabilitation and health science.



MMR-RHS checklist (PDF)

", , , , , , , ,no,2023-09-14 12:14:57,2023-11-09 09:20:29,systematic-development-of-standards-for-mixed-methods-reporting-in-rehabilitation-health-sciences-research,"[('title', 'Systematic Development of Standards for Mixed Methods Reporting in Rehabilitation Health Sciences Research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting mixed methods research in rehabilitation and health science.\n\n \n\n \xa0\n\n \n\n[MMR-RHS checklist (PDF)](https://www.equator-network.org/wp-content/uploads/2023/09/MMR-RHS-checklist.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Tovin MM, Wormley ME. Systematic Development of Standards for Mixed Methods Reporting in Rehabilitation Health Sciences Research. Phys Ther. 2023.'), ('Language', 'English'), ('PubMed ID', '[37672215](https://pubmed.ncbi.nlm.nih.gov/37672215/)'), ('Reporting guideline acronym', 'MMR-RHS'), ('Study design', 'Mixed methods studies'), ('Clinical area', 'Occupational therapy, Physiotherapy, Rehabilitation medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 9, 2023')]"
21322,Minimal reporting guideline for research involving eye tracking (2023 edition),"Clinical trials, Experimental studies, Observational studies","Behavioural medicine, Neurology, Ophthalmology, Psychology","Data, Intervention (exposure), Procedure/Method", ,"clinical trial, clinical trials, eye, eye movement, eye movements, eye tracker, eye-tracking, eyes, eyetracker, eyetracking, gaze, observation, observational, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, tracker, tracking, trial, trials, vision, visual", ,"Dunn MJ, Alexander RG, Amiebenomo OM, Arblaster G, Atan D, Erichsen JT, Ettinger U, Giardini ME, Gilchrist ID, Hamilton R, Hessels RS, Hodgins S, Hooge ITC, Jackson BS, Lee H, Macknik SL, Martinez-Conde S, Mcilreavy L, Muratori LM, Niehorster DC, Nystr\xf6m M, Otero-Millan J, Schl\xfcssel MM, Self JE, Singh T, Smyrnis N, Sprenger A. Minimal reporting guideline for research involving eye tracking (2023 edition). Behav Res Methods. 2023.","Dunn MJ, Alexander RG, Amiebenomo OM, Arblaster G, Atan D, Erichsen JT, Ettinger U, Giardini ME, Gilchrist ID, Hamilton R, Hessels RS, Hodgins S, Hooge ITC, Jackson BS, Lee H, Macknik SL, Martinez-Conde S, Mcilreavy L, Muratori LM, Niehorster DC, Nystr\xf6m M, Otero-Millan J, Schl\xfcssel MM, Self JE, Singh T, Smyrnis N, Sprenger A.",Behavior Research Methods [Behav Res Methods.],2023, , , , ,English, ,37507649,https://pubmed.ncbi.nlm.nih.gov/37507649/, , , , , , ,Reporting of research studies involving an eye tracker and human or non-human primate participant(s)., ,"Visit the GitHub page for more information about continued development and improvement.

", , , , , ,no,2023-08-15 16:34:18,2023-10-05 10:25:42,minimal-reporting-guideline-for-research-involving-eye-tracking-2023-edition,"[('title', 'Minimal reporting guideline for research involving eye tracking (2023 edition)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of research studies involving an eye tracker and human or non-human primate participant(s).'), ('Full bibliographic reference', 'Dunn MJ, Alexander RG, Amiebenomo OM, Arblaster G, Atan D, Erichsen JT, Ettinger U, Giardini ME, Gilchrist ID, Hamilton R, Hessels RS, Hodgins S, Hooge ITC, Jackson BS, Lee H, Macknik SL, Martinez-Conde S, Mcilreavy L, Muratori LM, Niehorster DC, Nyström M, Otero-Millan J, Schlüssel MM, Self JE, Singh T, Smyrnis N, Sprenger A. Minimal reporting guideline for research involving eye tracking (2023 edition). Behav Res Methods. 2023.'), ('Language', 'English'), ('PubMed ID', '[37507649](https://pubmed.ncbi.nlm.nih.gov/37507649/)'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Behavioural medicine, Neurology, Ophthalmology, Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Intervention (exposure), Procedure/Method'), ('Additional information', 'Visit the [GitHub page](https://github.com/dcnieho/ET_reporting_guideline) for more information about continued development and improvement.\n\n \n\n'), ('Record last updated on', 'October 5, 2023')]"
21288,CHEERS Value of Information (CHEERS-VOI) Reporting Standards - Explanation and Elaboration,Economic evaluations, ,Whole report, ,"checklist, checklists, CHEERS extension, CHEERS-VOI, CHEERS-VOI checklist, cost, costs, economic, economic evaluation, economic evaluations, economics, value, value of information, VOI, VOI analyses, VOI analysis", ,"Kunst N, Siu A, Drummond M, Grimm S, Grutters J, Husereau D, Koffijberg H, Rothery C, Wilson EC, Heath A. CHEERS Value of Information (CHEERS-VOI) Reporting Standards - Explanation and Elaboration. Value Health. 2023.","Kunst N, Siu A, Drummond M, Grimm S, Grutters J, Husereau D, Koffijberg H, Rothery C, Wilson EC, Heath A.",Value in Health. [Value Health.],2023, , , , ,English, ,37414276,https://pubmed.ncbi.nlm.nih.gov/37414276/, , , ,"Generic
CHEERS: Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S; CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.

Value Health. 2022;25(1):3-9. PMID: 35031096
BMC Med. 2022;20(1):23. PMID: 35022047
J Manag Care Spec Pharm. 2022:1-10. PMID: 35016547
BMJ. 2022;376:e067975. PMID: 35017145
Pharmacoeconomics. 2022. PMID: 35015272
Appl Health Econ Health Policy. 2022. PMID: 35015207
Int J Technol Assess Health Care. 2022;38(1):e13. PMID: 35007499
J Med Econ. 2022;25(sup1):1-7. PMID: 35012427
BJOG. 2022;129(3):336-344. PMID: 35014160
Eur J Health Econ. 2022. PMID: 35084632
BMC Health Serv Res. 2022;22(1):114. PMID: 35081957
BMC Public Health. 2022;22(1):179. PMID: 35081920
Health Policy OPEN. Volume 3, December 2022.
MDM Policy Pract. 2022;7(1):23814683211061097. PMID: 35036563
Clin Ther. 2022;S0149-2918(22)00016-9. PMID: 35168801

Specialised
CHEERS-AI: Elvidge J, Hawksworth C, Av?ar TS, Zemplenyi A, Chalkidou A, Petrou S, Petyk\xf3 Z, Srivastava D, Chandra G, Delaye J, Denniston A, Gomes M, Knies S, Nousios P, Siirtola P, Wang J, Dawoud D. Consolidated Health Economic Evaluation Reporting Standards for Interventions that use Artificial Intelligence (CHEERS-AI). Value Health. 2024:S1098-3015(24)02366-0. PMID: 38795956

", ,CHEERS-VOI,Reporting economic evaluations that include a value of information (VOI) analysis., , , , , , , ,yes,2023-07-10 16:00:35,2024-06-13 14:40:08,cheers-voi,"[('title', 'CHEERS Value of Information (CHEERS-VOI) Reporting Standards – Explanation and Elaboration'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting economic evaluations that include a value of information (VOI) analysis.'), ('Full bibliographic reference', 'Kunst N, Siu A, Drummond M, Grimm S, Grutters J, Husereau D, Koffijberg H, Rothery C, Wilson EC, Heath A. CHEERS Value of Information (CHEERS-VOI) Reporting Standards - Explanation and Elaboration. Value Health. 2023.'), ('Language', 'English'), ('PubMed ID', '[37414276](https://pubmed.ncbi.nlm.nih.gov/37414276/)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CHEERS**](https://www.equator-network.org/reporting-guidelines/cheers/): Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S; CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.\n\n \n\n Value Health. 2022;25(1):3-9. PMID: [35031096](https://pubmed.ncbi.nlm.nih.gov/35031096/)\n\n BMC Med. 2022;20(1):23. PMID: [35022047](https://pubmed.ncbi.nlm.nih.gov/35022047/)\n\n J Manag Care Spec Pharm. 2022:1-10. PMID: [35016547](https://pubmed.ncbi.nlm.nih.gov/35016547/)\n\n BMJ. 2022;376:e067975. PMID: [35017145](https://pubmed.ncbi.nlm.nih.gov/35017145/)\n\n Pharmacoeconomics. 2022. PMID: [35015272](https://pubmed.ncbi.nlm.nih.gov/35015272/)\n\n Appl Health Econ Health Policy. 2022. PMID: [35015207](https://pubmed.ncbi.nlm.nih.gov/35015207/)\n\n Int J Technol Assess Health Care. 2022;38(1):e13. PMID: [35007499](https://pubmed.ncbi.nlm.nih.gov/35007499/)\n\n J Med Econ. 2022;25(sup1):1-7. PMID: [35012427](https://pubmed.ncbi.nlm.nih.gov/35012427/)\n\n BJOG. 2022;129(3):336-344. PMID: [35014160](https://pubmed.ncbi.nlm.nih.gov/35014160/)\n\n Eur J Health Econ. 2022. PMID: [35084632](https://pubmed.ncbi.nlm.nih.gov/35084632/)\n\n BMC Health Serv Res. 2022;22(1):114. PMID: [35081957](https://pubmed.ncbi.nlm.nih.gov/35081957/)\n\n BMC Public Health. 2022;22(1):179. PMID: [35081920](https://pubmed.ncbi.nlm.nih.gov/35081920/)\n\n Health Policy OPEN. [Volume 3, December 2022](https://doi.org/10.1016/j.hpopen.2021.100063).\n\n MDM Policy Pract. 2022;7(1):23814683211061097. PMID: [35036563](https://pubmed.ncbi.nlm.nih.gov/35036563/)\n\n Clin Ther. 2022;S0149-2918(22)00016-9. PMID: [35168801](https://pubmed.ncbi.nlm.nih.gov/35168801/)\n\n \n\n**Specialised**\n\n[**CHEERS-AI**](https://www.equator-network.org/reporting-guidelines/consolidated-health-economic-evaluation-reporting-standards-for-interventions-that-use-artificial-intelligence-cheers-ai/): Elvidge J, Hawksworth C, Avşar TS, Zemplenyi A, Chalkidou A, Petrou S, Petykó Z, Srivastava D, Chandra G, Delaye J, Denniston A, Gomes M, Knies S, Nousios P, Siirtola P, Wang J, Dawoud D. Consolidated Health Economic Evaluation Reporting Standards for Interventions that use Artificial Intelligence (CHEERS-AI). Value Health. 2024:S1098-3015(24)02366-0. PMID: [38795956](https://pubmed.ncbi.nlm.nih.gov/38795956/)\n\n \n\n'), ('Reporting guideline acronym', 'CHEERS-VOI'), ('Study design', 'Economic evaluations'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'June 13, 2024')]"
21266,Initial Standardized Framework for Reporting Social Media Analytics in Emergency Care Research,"Mixed methods studies, Qualitative research",Emergency medicine,Whole report, ,"checklist, checklist for publication of social media?based research, checklists, critical care, data, data analytics platform, digital platform, emergency, emergency care, engine, media, mixed methods, network, NOECO, NOECO statement, qualitative, social, social media, social media platform, social networking", ,"Roland D, Spurr J, Cabrera D. Initial Standardized Framework for Reporting Social Media Analytics in Emergency Care Research. West J Emerg Med. 2018;19(4):701-706.","Roland D, Spurr J, Cabrera D.",Western Journal of Emergency Medicine [West J Emerg Med.],2018,19,4,701-706, ,English, ,30013707,https://pubmed.ncbi.nlm.nih.gov/30013707/, , , , , ,NOECO,Reporting of social media analytics in emergency care research., , , , , , , ,no,2023-06-20 17:13:35,2023-06-20 17:13:35,initial-standardized-framework-for-reporting-social-media-analytics-in-emergency-care-research,"[('title', 'Initial Standardized Framework for Reporting Social Media Analytics in Emergency Care Research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of social media analytics in emergency care research.'), ('Full bibliographic reference', 'Roland D, Spurr J, Cabrera D. Initial Standardized Framework for Reporting Social Media Analytics in Emergency Care Research. West J Emerg Med. 2018;19(4):701-706.'), ('Language', 'English'), ('PubMed ID', '[30013707](https://pubmed.ncbi.nlm.nih.gov/30013707/)'), ('Reporting guideline acronym', 'NOECO'), ('Study design', 'Mixed methods studies, Qualitative research'), ('Clinical area', 'Emergency medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'June 20, 2023')]"
21264,The adapted Autobiographical interview: A systematic review and proposal for conduct and reporting,Qualitative research,Psychology,"Intervention (exposure), Procedure/Method, Statistical methods and analyses", ,"adapted AI, adapted autobiographical interview, AI, autobiographical, autobiographical interview, autobiographical memory, checklist, checklists, Conduct and Reporting of Autobiographical Interview guidelines, CRAI, CRAI checklist, CRAI guidelines, episodic foresight, episodic memory, episodic simulation, instrument, interview, interviews, memory, mental recall, mental time travel, neuropsychological, prospection, psychological, psychology, qualitative, scene construction", ,"Miloyan B, McFarlane K, V\xe1squez-Echeverr\xeda A. The adapted Autobiographical interview: A systematic review and proposal for conduct and reporting. Behav Brain Res. 2019;370:111881.","Miloyan B, McFarlane K, V\xe1squez-Echeverr\xeda A.",Behav Brain Res.,2019,370, ,111881, ,English, ,30935946,https://pubmed.ncbi.nlm.nih.gov/30935946/, , , , , ,CRAI,Reporting of Autobiographical Interview (AI) studies., , , , , , , ,no,2023-06-20 16:28:17,2023-06-20 16:28:17,the-adapted-autobiographical-interview-a-systematic-review-and-proposal-for-conduct-and-reporting,"[('title', 'The adapted Autobiographical interview: A systematic review and proposal for conduct and reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of Autobiographical Interview (AI) studies.'), ('Full bibliographic reference', 'Miloyan B, McFarlane K, Vásquez-Echeverría A. The adapted Autobiographical interview: A systematic review and proposal for conduct and reporting. Behav Brain Res. 2019;370:111881.'), ('Language', 'English'), ('PubMed ID', '[30935946](https://pubmed.ncbi.nlm.nih.gov/30935946/)'), ('Reporting guideline acronym', 'CRAI'), ('Study design', 'Qualitative research'), ('Clinical area', 'Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Procedure/Method, Statistical methods and analyses'), ('Record last updated on', 'June 20, 2023')]"
21253,Paediatric Ureteroscopy (P-URS) reporting checklist: a new tool to aid studies report the essential items on paediatric ureteroscopy for stone disease,"Clinical trials, Experimental studies, Observational studies","Paediatrics, Surgery, Urology","Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)", ,"checklist, checklists, child, children, clinical trial, clinical trials, endourology, observation, observational, P-URS, P-URS checklist, paediatric, paediatric ureteroscopy checklist, pediatric, pediatric ureteroscopy checklist, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized trial, randomized trials, ranomized controlled trials, RCT, RCTs, stone disease, surgery, surgical, trial, trials, ureteroscopy, urethra, urinary, urolithiasis", ,"Julieb\xf8-Jones P, Ulvik \xd8, Beisland C, Somani BK. Paediatric Ureteroscopy (P-URS) reporting checklist: a new tool to aid studies report the essential items on paediatric ureteroscopy for stone disease. Urolithiasis. 2023;51(1):35.","Julieb\xf8-Jones P, Ulvik \xd8, Beisland C, Somani BK.",Urolithiasis.,2023,51,1,35, ,English, ,36695936,https://pubmed.ncbi.nlm.nih.gov/36695936/, , , , , ,P-URS,Reporting of paediatric ureteroscopy studies., , , , , , , ,no,2023-06-16 11:38:03,2023-06-16 11:40:12,paediatric-ureteroscopy-p-urs-reporting-checklist-a-new-tool-to-aid-studies-report-the-essential-items-on-paediatric-ureteroscopy-for-stone-disease,"[('title', 'Paediatric Ureteroscopy (P-URS) reporting checklist: a new tool to aid studies report the essential items on paediatric ureteroscopy for stone disease'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of paediatric ureteroscopy studies.'), ('Full bibliographic reference', 'Juliebø-Jones P, Ulvik Ø, Beisland C, Somani BK. Paediatric Ureteroscopy (P-URS) reporting checklist: a new tool to aid studies report the essential items on paediatric ureteroscopy for stone disease. Urolithiasis. 2023;51(1):35.'), ('Language', 'English'), ('PubMed ID', '[36695936](https://pubmed.ncbi.nlm.nih.gov/36695936/)'), ('Reporting guideline acronym', 'P-URS'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Paediatrics, Surgery, Urology'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'June 16, 2023')]"
21251,Adult Ureteroscopy (A-URS) Checklist: A New Tool To Standardise Reporting in Endourology,"Clinical trials, Experimental studies, Observational studies","Surgery, Urology","Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)", ,"A-URS, A-URS checklist, adult-ureteroscopy checklist, checklist, checklists, clinical trial, clinical trials, endourology, observation, observational, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, stone disease, surgery, surgical, trial, trials, ureteroscopy, urethra, urinary, urolithiasis, urology", ,"Julieb\xf8-Jones P, Ulvik \xd8, Beisland C, Somani BK. Adult Ureteroscopy (A-URS) Checklist: A New Tool To Standardise Reporting in Endourology. Eur Urol Open Sci. 2023;53:1-5.","Julieb\xf8-Jones P, Ulvik \xd8, Beisland C, Somani BK.",European Urology Open Science [Eur Urol Open Sci.],2923,53, ,1-5, ,English, ,37214155,https://pubmed.ncbi.nlm.nih.gov/37214155/, , , , , ,A-URS,Reporting of ureteroscopy studies., , , , , , , ,no,2023-06-16 11:16:10,2023-06-16 11:39:22,adult-ureteroscopy-a-urs-checklist-a-new-tool-to-standardise-reporting-in-endourology,"[('title', 'Adult Ureteroscopy (A-URS) Checklist: A New Tool To Standardise Reporting in Endourology'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of ureteroscopy studies.'), ('Full bibliographic reference', 'Juliebø-Jones P, Ulvik Ø, Beisland C, Somani BK. Adult Ureteroscopy (A-URS) Checklist: A New Tool To Standardise Reporting in Endourology. Eur Urol Open Sci. 2023;53:1-5.'), ('Language', 'English'), ('PubMed ID', '[37214155](https://pubmed.ncbi.nlm.nih.gov/37214155/)'), ('Reporting guideline acronym', 'A-URS'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Surgery, Urology'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'June 16, 2023')]"
21242,"Recommendations for the development, implementation, and reporting of control interventions in efficacy and mechanistic trials of physical, psychological, and self-management therapies: the CoPPS Statement","Clinical trials, Experimental studies","Behavioural medicine, Occupational therapy, Physiotherapy, Psychology, Rehabilitation medicine, Sport and exercise medicine",Intervention (exposure), ,"checklist, checklists, clinical trial, clinical trials, control, controlled trial, controlled trials, controls, conversation, CoPPS, CoPPS Checklist, CoPPS Statement, education, educational, exercise, healing, intervention, interventions, mechanistic, mind-body, non-pharmacological, physical, physio, physiotherapy, placebo, placebos, psychological, psychology, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, rehabilitation, religious, self-management, sham, spiritual, therapies, therapy, TIDieR-Placebo, trial, trials", ,"Hohenschurz-Schmidt D, Vase L, Scott W, Annoni M, Ajayi OK, Barth J, Bennell K, Berna C, Bialosky J, Braithwaite F, Finnerup NB, Williams ACC, Carlino E, Cerritelli F, Chaibi A, Cherkin D, Colloca L, C\xf4t\xe9 P, Darnall BD, Evans R, Fabre L, Faria V, French S, Gerger H, H\xe4user W, Hinman RS, Ho D, Janssens T, Jensen K, Johnston C, Juhl Lunde S, Keefe F, Kerns RD, Koechlin H, Kongsted A, Michener LA, Moerman DE, Musial F, Newell D, Nicholas M, Palermo TM, Palermo S, Peerdeman KJ, Pogatzki-Zahn EM, Puhl AA, Roberts L, Rossettini G, Tomczak Matthiesen S, Underwood M, Vaucher P, Vollert J, Wartolowska K, Weimer K, Werner CP, Rice ASC, Draper-Rodi J. Recommendations for the development, implementation, and reporting of control interventions in efficacy and mechanistic trials of physical, psychological, and self-management therapies: the CoPPS Statement. BMJ. 2023;381:e072108.","Hohenschurz-Schmidt D, Vase L, Scott W, Annoni M, Ajayi OK, Barth J, Bennell K, Berna C, Bialosky J, Braithwaite F, Finnerup NB, Williams ACC, Carlino E, Cerritelli F, Chaibi A, Cherkin D, Colloca L, C\xf4t\xe9 P, Darnall BD, Evans R, Fabre L, Faria V, French S, Gerger H, H\xe4user W, Hinman RS, Ho D, Janssens T, Jensen K, Johnston C, Juhl Lunde S, Keefe F, Kerns RD, Koechlin H, Kongsted A, Michener LA, Moerman DE, Musial F, Newell D, Nicholas M, Palermo TM, Palermo S, Peerdeman KJ, Pogatzki-Zahn EM, Puhl AA, Roberts L, Rossettini G, Tomczak Matthiesen S, Underwood M, Vaucher P, Vollert J, Wartolowska K, Weimer K, Werner CP, Rice ASC, Draper-Rodi J.",BMJ.,2023,381, ,e072108, ,English, ,37230508,https://pubmed.ncbi.nlm.nih.gov/37230508/,"Read the CoPPS Statement E&amp;E paper (PDF).

Access the CoPPS Statement checklist (PDF).

", , , , ,CoPPS,"Reporting of control interventions in efficacy and mechanistic trials of physical, psychological, and self-management therapies.", , , , , , , ,no,2023-06-02 14:59:20,2023-06-02 14:59:20,recommendations-for-the-development-implementation-and-reporting-of-control-interventions-in-efficacy-and-mechanistic-trials-of-physical-psychological-and-self-management-therapies-the-copps-stat,"[('title', 'Recommendations for the development, implementation, and reporting of control interventions in efficacy and mechanistic trials of physical, psychological, and self-management therapies: the Co PPS Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of control interventions in efficacy and mechanistic trials of physical, psychological, and self-management therapies.'), ('Full bibliographic reference', 'Hohenschurz-Schmidt D, Vase L, Scott W, Annoni M, Ajayi OK, Barth J, Bennell K, Berna C, Bialosky J, Braithwaite F, Finnerup NB, Williams ACC, Carlino E, Cerritelli F, Chaibi A, Cherkin D, Colloca L, Côté P, Darnall BD, Evans R, Fabre L, Faria V, French S, Gerger H, Häuser W, Hinman RS, Ho D, Janssens T, Jensen K, Johnston C, Juhl Lunde S, Keefe F, Kerns RD, Koechlin H, Kongsted A, Michener LA, Moerman DE, Musial F, Newell D, Nicholas M, Palermo TM, Palermo S, Peerdeman KJ, Pogatzki-Zahn EM, Puhl AA, Roberts L, Rossettini G, Tomczak Matthiesen S, Underwood M, Vaucher P, Vollert J, Wartolowska K, Weimer K, Werner CP, Rice ASC, Draper-Rodi J. Recommendations for the development, implementation, and reporting of control interventions in efficacy and mechanistic trials of physical, psychological, and self-management therapies: the CoPPS Statement. BMJ. 2023;381:e072108.'), ('Language', 'English'), ('PubMed ID', '[37230508](https://pubmed.ncbi.nlm.nih.gov/37230508/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the CoPPS Statement E&E paper](https://www.bmj.com/content/bmj/suppl/2023/05/25/bmj-2022-072108.DC1/hohd072108.wt1.pdf) (PDF).\n\n \n\n[Access the CoPPS Statement checklist](https://www.bmj.com/content/bmj/suppl/2023/05/25/bmj-2022-072108.DC1/hohd072108.wt3.pdf) (PDF).\n\n \n\n'), ('Reporting guideline acronym', 'CoPPS'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Behavioural medicine, Occupational therapy, Physiotherapy, Psychology, Rehabilitation medicine, Sport and exercise medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'June 2, 2023')]"
21226,Reporting Eye-tracking Studies In DEntistry (RESIDE) checklist,Observational studies,Dentistry,Whole report, ,"checklist, checklists, dental, Dentist, Dentistry, eye, eye-tracking, observation, observational, Reporting Eye-tracking Studies in DEntistry, RESIDE, RESIDE checklist, vision, visual", ,"Cho VY, Loh XH, Abbott L, Mohd-Isa NA, Anthonappa RP. Reporting Eye-tracking Studies In DEntistry (RESIDE) checklist. J Dent. 2023;129:104359.","Cho VY, Loh XH, Abbott L, Mohd-Isa NA, Anthonappa RP.",Journal of Dentistry [J Dent.],2023,129, ,104359, ,English, ,36403692,https://pubmed.ncbi.nlm.nih.gov/36403692/, , , , , ,RESIDE,Reporting of eye-tracking studies in dentistry., , , , , , , ,no,2023-05-18 15:48:51,2023-05-18 15:48:51,reporting-eye-tracking-studies-in-dentistry-reside-checklist,"[('title', 'Reporting Eye-tracking Studies In DEntistry  (RESIDE) checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of eye-tracking studies in dentistry.'), ('Full bibliographic reference', 'Cho VY, Loh XH, Abbott L, Mohd-Isa NA, Anthonappa RP. Reporting Eye-tracking Studies In DEntistry (RESIDE) checklist. J Dent. 2023;129:104359.'), ('Language', 'English'), ('PubMed ID', '[36403692](https://pubmed.ncbi.nlm.nih.gov/36403692/)'), ('Reporting guideline acronym', 'RESIDE'), ('Study design', 'Observational studies'), ('Clinical area', 'Dentistry'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 18, 2023')]"
21224,AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users,Economic evaluations, ,"Appendix, Statistical methods and analyses", ,"AdViSHE, decision model, decision models, economic, economics, evaluation, health economics, model, modeling, modelling, models, validation, validity", ,"Vemer P, Corro Ramos I, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users. Pharmacoeconomics. 2016;34(4):349-61.","Vemer P, Corro Ramos I, van Voorn GA, Al MJ, Feenstra TL.",Pharmacoeconomics.,2023,34,4,349-61, ,English, ,26660529,https://pubmed.ncbi.nlm.nih.gov/26660529/, , , , , ,AdViSHE,Reporting the validation status of health-economic decision models., , , , , , , ,no,2023-05-18 09:24:08,2023-05-18 09:25:52,advishe-a-validation-assessment-tool-of-health-economic-models-for-decision-makers-and-model-users,"[('title', 'AdVi SHE : A Validation -Assessment Tool of Health -Economic Models for Decision Makers and Model Users'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the validation status of health-economic decision models.'), ('Full bibliographic reference', 'Vemer P, Corro Ramos I, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users. Pharmacoeconomics. 2016;34(4):349-61.'), ('Language', 'English'), ('PubMed ID', '[26660529](https://pubmed.ncbi.nlm.nih.gov/26660529/)'), ('Reporting guideline acronym', 'AdViSHE'), ('Study design', 'Economic evaluations'), ('Applies to the whole report or to individual sections of the report?', 'Appendix, Statistical methods and analyses'), ('Record last updated on', 'May 18, 2023')]"
21217,iCHECK-DH: Guidelines and Checklist for the Reporting on Digital Health Implementations,"Clinical trials, Experimental studies, Observational studies", ,Whole report, ,"checklist, checklists, clinical trial, clinical trials, digital, digital health, Guidelines and Checklist for the Reporting on Digital Health Implementations, iCHECK-DH, iCHECK-DH checklist, implementation, implementations, implementing, intervention, interventions, observation, observational, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, technologies, technology, trial, trials", ,"Perrin Franck C, Babington-Ashaye A, Dietrich D, Bediang G, Veltsos P, Gupta PP, Juech C, Kadam R, Collin M, Setian L, Serrano Pons J, Kwankam SY, Garrette B, Barbe S, Bagayoko CO, Mehl G, Lovis C, Geissbuhler A. iCHECK-DH: Guidelines and Checklist for the Reporting on Digital Health Implementations. J Med Internet Res. 2023;25:e46694.","Perrin Franck C, Babington-Ashaye A, Dietrich D, Bediang G, Veltsos P, Gupta PP, Juech C, Kadam R, Collin M, Setian L, Serrano Pons J, Kwankam SY, Garrette B, Barbe S, Bagayoko CO, Mehl G, Lovis C, Geissbuhler A.",Journal of Medical Internet Research [J Med Internet Res.],2023,25, ,e46694, ,English, ,37163336,https://pubmed.ncbi.nlm.nih.gov/37163336/,Read the full-text of the iCHECK-DH reporting guideline., , , , ,iCHECK-DH,Reporting of digital health implementations., , , , , , , ,no,2023-05-17 14:44:30,2023-05-17 15:23:23,icheck-dh-guidelines-and-checklist-for-the-reporting-on-digital-health-implementations,"[('title', 'i CHECK-DH : Guidelines and Checklist for the Reporting on Digital Health Implementations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of digital health implementations.'), ('Full bibliographic reference', 'Perrin Franck C, Babington-Ashaye A, Dietrich D, Bediang G, Veltsos P, Gupta PP, Juech C, Kadam R, Collin M, Setian L, Serrano Pons J, Kwankam SY, Garrette B, Barbe S, Bagayoko CO, Mehl G, Lovis C, Geissbuhler A. iCHECK-DH: Guidelines and Checklist for the Reporting on Digital Health Implementations. J Med Internet Res. 2023;25:e46694.'), ('Language', 'English'), ('PubMed ID', '[37163336](https://pubmed.ncbi.nlm.nih.gov/37163336/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.jmir.org/2023/1/e46694/) of the iCHECK-DH reporting guideline.'), ('Reporting guideline acronym', 'iCHECK-DH'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 17, 2023')]"
21214,New reporting items and recommendations for randomized trials impacted by COVID-19 and force majeure events: a targeted approach,"Clinical trials, Experimental studies", ,"Abstract, Harms/adverse effects/safety data, Intervention (exposure), Narrative sections (discussion etc.), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)", ,"checklist, checklists, circumstances, clinical trial, clinical trials, CONSORT, Coronavirus, Coronavirus disease, Coronavirus disease 19, COVID-19, COVID-19 pandemic, events, extenuating circumstances, force majeure event, force majeure events, modified, pandemic, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Leung TH, Ho JC, El Helali A, Vokes EE, Wang X, Pang H. New reporting items and recommendations for randomized trials impacted by COVID-19 and force majeure events: a targeted approach. Ann Transl Med.2023;11(1):2.","Leung TH, Ho JC, El Helali A, Vokes EE, Wang X, Pang H.",Annals of Translational Medicine [Ann Transl Med.],2023,11,1,2, ,English, ,36760246,https://pubmed.ncbi.nlm.nih.gov/36760246/, , , , , , ,Reporting of randomised clinical trials impacted by COVID-19 and force majeure events., , , , , , , ,no,2023-05-16 12:36:40,2023-05-16 12:36:40,new-reporting-items-and-recommendations-for-randomized-trials-impacted-by-covid-19-and-force-majeure-events-a-targeted-approach,"[('title', 'New reporting items and recommendations for randomized trials impacted by COVID- 19 and force majeure events: a targeted approach'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of randomised clinical trials impacted by COVID-19 and force majeure events.'), ('Full bibliographic reference', 'Leung TH, Ho JC, El Helali A, Vokes EE, Wang X, Pang H. New reporting items and recommendations for randomized trials impacted by COVID-19 and force majeure events: a targeted approach. Ann Transl Med.2023;11(1):2.'), ('Language', 'English'), ('PubMed ID', '[36760246](https://pubmed.ncbi.nlm.nih.gov/36760246/)'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Abstract, Harms/adverse effects/safety data, Intervention (exposure), Narrative sections (discussion etc.), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'May 16, 2023')]"
21212,"Development, explanation, and presentation of the Physical Literacy Interventions Reporting Template (PLIRT)","Clinical trials, Experimental studies, Qualitative research",Sport and exercise medicine, , ,"checklist, chesklists, clinical trial, clinical trials, exercise, exercising, intervention, interventions, physical, physical activity, physical education, physical literacy, Physical Literacy Interventions Reporting Template, PLIRT, qualitative, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Carl J, Barratt J, Arbour-Nicitopoulos KP, Barnett LM, Dudley DA, Holler P, Keegan R, Kwan M, Scurati R, Sum RK, Wainwright N, Cairney J. Development, explanation, and presentation of the Physical Literacy Interventions Reporting Template (PLIRT). Int J Behav Nutr Phys Act. 2023;20(1):21.","Carl J, Barratt J, Arbour-Nicitopoulos KP, Barnett LM, Dudley DA, Holler P, Keegan R, Kwan M, Scurati R, Sum RK, Wainwright N, Cairney J.",Int J Behav Nutr Phys Act.,2023,20,1,21, ,English, ,36805731,https://pubmed.ncbi.nlm.nih.gov/36805731/, , , , , ,PLIRT,Reporting physical literacy (PL) intervention research., , , , , , , ,no,2023-05-16 12:02:28,2023-05-16 12:02:28,development-explanation-and-presentation-of-the-physical-literacy-interventions-reporting-template-plirt,"[('title', 'Development, explanation, and presentation of the Physical Literacy Interventions Reporting Template (PLIRT)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting physical literacy (PL) intervention research.'), ('Full bibliographic reference', 'Carl J, Barratt J, Arbour-Nicitopoulos KP, Barnett LM, Dudley DA, Holler P, Keegan R, Kwan M, Scurati R, Sum RK, Wainwright N, Cairney J. Development, explanation, and presentation of the Physical Literacy Interventions Reporting Template (PLIRT). Int J Behav Nutr Phys Act. 2023;20(1):21.'), ('Language', 'English'), ('PubMed ID', '[36805731](https://pubmed.ncbi.nlm.nih.gov/36805731/)'), ('Reporting guideline acronym', 'PLIRT'), ('Study design', 'Clinical trials, Experimental studies, Qualitative research'), ('Clinical area', 'Sport and exercise medicine'), ('Record last updated on', 'May 16, 2023')]"
21210,Reporting guidelines for allergy and immunology survey research,Qualitative research,"Allergy, Infectious diseases, Rheumatology","Data, Ethical issues (consent etc.), Intervention (exposure), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)", ,"allergic, allergy, CHAIRS, checklist, CHecklist for Allergy and Immunology Reporting of Survey research, checklists, data, immune, immunological, immunology, interview, interviews, qualitative, questionnaire, sampling, survey, surveys", ,"Moore-Clingenpeel M, Greenhawt M, Shaker M. Reporting guidelines for allergy and immunology survey research. Ann Allergy Asthma Immunol. 2023;130(5):674-680.e1.","Moore-Clingenpeel M, Greenhawt M, Shaker M.","Annals of Allergy, Asthma and Immunology [Ann Allergy Asthma Immunol.]",2023,130,5,674-680, ,English, ,36804464,https://pubmed.ncbi.nlm.nih.gov/36804464/, , , , , ,CHAIRS,Reporting of allergy-immunology survey research., , , , , , , ,no,2023-05-16 11:34:20,2023-05-16 11:34:20,reporting-guidelines-for-allergy-and-immunology-survey-research,"[('title', 'Reporting guidelines for allergy and immunology survey research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of allergy-immunology survey research.'), ('Full bibliographic reference', 'Moore-Clingenpeel M, Greenhawt M, Shaker M. Reporting guidelines for allergy and immunology survey research. Ann Allergy Asthma Immunol. 2023;130(5):674-680.e1.'), ('Language', 'English'), ('PubMed ID', '[36804464](https://pubmed.ncbi.nlm.nih.gov/36804464/)'), ('Reporting guideline acronym', 'CHAIRS'), ('Study design', 'Qualitative research'), ('Clinical area', 'Allergy, Infectious diseases, Rheumatology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Ethical issues (consent etc.), Intervention (exposure), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'May 16, 2023')]"
21208,CheckList for EvaluAtion of Radiomics research (CLEAR): a step-by-step reporting guideline for authors and reviewers endorsed by ESR and EuSoMII, ,Radiology,Whole report, ,"AI, artificial intelligence, checklist, CheckList for EvaluAtion of Radiomics research, checklists, CLEAR, CLEAR checklist, computed tomography, deep learning, diagnosis, diagnostic, image, imaging, machine learning, magnetic resonance imaging, medical image, medical images, ML, model, modeling, modelling, models, predict, prediction, predictive, predictive modeling, predictive modelling, prognosis, prognostic, radiology, radiomic, radiomics, statistical, statistics, texture analysis", ,"Kocak B, Baessler B, Bakas S, Cuocolo R, Fedorov A, Maier-Hein L, Mercaldo N, M\xfcller H, Orlhac F, Pinto Dos Santos D, Stanzione A, Ugga L, Zwanenburg A. CheckList for EvaluAtion of Radiomics research (CLEAR): a step-by-step reporting guideline for authors and reviewers endorsed by ESR and EuSoMII. Insights Imaging. 2023;14(1):75.","Kocak B, Baessler B, Bakas S, Cuocolo R, Fedorov A, Maier-Hein L, Mercaldo N, M\xfcller H, Orlhac F, Pinto Dos Santos D, Stanzione A, Ugga L, Zwanenburg A.",Insights Imaging.,2023,14,1,75, ,English, ,37142815,https://pubmed.ncbi.nlm.nih.gov/37142815/,"The authors have developed two checklists a full version (CLEAR) and a shortened version (CLEAR-S). Dynamic checklists are available online at:

CLEAR Checklist v1.0
CLEAR-S Checklist v1.0 (shortened)

","Kocak B, Borgheresi A, Ponsiglione A, Andreychenko AE, Cavallo AU, Stanzione A, Doniselli FM, Vernuccio F, Triantafyllou M, Cannella R, Trotta R, Ghezzo S, Akinci D'Antonoli T, Cuocolo R. Explanation and Elaboration with Examples for CLEAR (CLEAR-E3): an EuSoMII Radiomics Auditing Group Initiative. Eur Radiol Exp. 2024;8(1):72. PMID: 38740707

", , , ,CLEAR,Reporting clinical radiomics research., , , , , , , ,no,2023-05-09 16:35:38,2024-05-17 10:17:26,checklist-for-evaluation-of-radiomics-research-clear-a-step-by-step-reporting-guideline-for-authors-and-reviewers-endorsed-by-esr-and-eusomii,"[('title', 'CheckList for EvaluAtion of Radiomics research (CLEAR) : a step-by-step reporting guideline for authors and reviewers endorsed by ESR and EuSo MII'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting clinical radiomics research.'), ('Full bibliographic reference', 'Kocak B, Baessler B, Bakas S, Cuocolo R, Fedorov A, Maier-Hein L, Mercaldo N, Müller H, Orlhac F, Pinto Dos Santos D, Stanzione A, Ugga L, Zwanenburg A. CheckList for EvaluAtion of Radiomics research (CLEAR): a step-by-step reporting guideline for authors and reviewers endorsed by ESR and EuSoMII. Insights Imaging. 2023;14(1):75.'), ('Language', 'English'), ('PubMed ID', '[37142815](https://pubmed.ncbi.nlm.nih.gov/37142815/)'), ('Relevant URLs\n\n(full-text if available)', 'The authors have developed two checklists a full version (CLEAR) and a shortened version (CLEAR-S). Dynamic checklists are available online at:\n\n \n\n[CLEAR Checklist v1.0](https://clearchecklist.github.io/clear_checklist/CLEAR.html)\n\n[CLEAR-S Checklist v1.0 (shortened)](https://clearchecklist.github.io/clear_checklist/CLEAR-S.html)\n\n \n\n'), ('Explanation and elaboration papers', ""Kocak B, Borgheresi A, Ponsiglione A, Andreychenko AE, Cavallo AU, Stanzione A, Doniselli FM, Vernuccio F, Triantafyllou M, Cannella R, Trotta R, Ghezzo S, Akinci D'Antonoli T, Cuocolo R. Explanation and Elaboration with Examples for CLEAR (CLEAR-E3): an EuSoMII Radiomics Auditing Group Initiative. Eur Radiol Exp. 2024;8(1):72. PMID: [38740707](https://pubmed.ncbi.nlm.nih.gov/38740707/)\n\n \n\n""), ('Reporting guideline acronym', 'CLEAR'), ('Clinical area', 'Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 17, 2024')]"
21199,Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA),"Artificial intelligence/Machine learning studies, Diagnostic and prognostic studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,Whole report, ,"checklist, checklists, clinical prediction model, clinical prediction models, decision making, diagnosis, diagnostic, meta analyses, meta analysis, model, models, multivariable, multivariable prediction model, multivariable prediction models, predicting, prediction, predictive, prognosis, prognostic, review, reviews, risk, statistical, statistics, systematic review, systematic reviews, TRIPOD, TRIPOD extension, TRIPOD-SRMA", ,"Snell KIE, Levis B, Damen JAA, Dhiman P, Debray TPA, Hooft L, Reitsma JB, Moons KGM, Collins GS, Riley RD. Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA). BMJ. 2023;381:e073538.","Snell KIE, Levis B, Damen JAA, Dhiman P, Debray TPA, Hooft L, Reitsma JB, Moons KGM, Collins GS, Riley RD.",BMJ.,2023,381, ,e073538, ,English, ,37137496,https://pubmed.ncbi.nlm.nih.gov/37137496/,Read the full-text of the TRIPOD-SRMA reporting guideline., , ,"Generic
TRIPOD+AI Statement: Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, Ghassemi M, Liu X, Reitsma JB, van Smeden M, Boulesteix AL, Camaradou JC, Celi LA, Denaxas S, Denniston AK, Glocker B, Golub RM, Harvey H, Heinze G, Hoffman MM, Kengne AP, Lam E, Lee N, Loder EW, Maier-Hein L, Mateen BA, McCradden MD, Oakden-Rayner L, Ordish J, Parnell R, Rose S, Singh K, Wynants L, Logullo P. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. PMID: 38626948

Specialised
TRIPOD-Cluster: Debray TPA, Collins GS, Riley RD, Snell KIE, Van Calster B, Reitsma JB, Moons KGM. Transparent reporting of multivariable prediction models developed or validated using clustered data: TRIPOD-Cluster checklist. BMJ. 2023;380:e071018. PMID: 36750242

TRIPOD-LLM: Gallifant J, Afshar M, Ameen S, Aphinyanaphongs Y, Chen S, Cacciamani G, Demner-Fushman D, Dligach D, Daneshjou R, Fernandes C, Hansen LH, Landman A, Lehmann L, McCoy LG, Miller T, Moreno A, Munch N, Restrepo D, Savova G, Umeton R, Gichoya JW, Collins GS, Moons KGM, Celi LA, Bitterman DS. The TRIPOD-LLM reporting guideline for studies using large language models. Nat Med. 2025. PMID: 39779929

",https://www.tripod-statement.org/,TRIPOD-SRMA,Reporting of systematic reviews and meta-analyses of multivariable prediction models for individual prognosis or diagnosis., , , , , , , ,yes,2023-05-05 12:02:33,2025-01-10 15:44:47,tripod-srma,"[('title', 'Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of systematic reviews and meta-analyses of multivariable prediction models for individual prognosis or diagnosis.'), ('Full bibliographic reference', 'Snell KIE, Levis B, Damen JAA, Dhiman P, Debray TPA, Hooft L, Reitsma JB, Moons KGM, Collins GS, Riley RD. Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA). BMJ. 2023;381:e073538.'), ('Language', 'English'), ('PubMed ID', '[37137496](https://pubmed.ncbi.nlm.nih.gov/37137496/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.bmj.com/content/381/bmj-2022-073538) of the TRIPOD-SRMA reporting guideline.'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**TRIPOD+AI Statement**](https://www.equator-network.org/reporting-guidelines/tripod-statement/): Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, Ghassemi M, Liu X, Reitsma JB, van Smeden M, Boulesteix AL, Camaradou JC, Celi LA, Denaxas S, Denniston AK, Glocker B, Golub RM, Harvey H, Heinze G, Hoffman MM, Kengne AP, Lam E, Lee N, Loder EW, Maier-Hein L, Mateen BA, McCradden MD, Oakden-Rayner L, Ordish J, Parnell R, Rose S, Singh K, Wynants L, Logullo P. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. PMID: [38626948](https://pubmed.ncbi.nlm.nih.gov/38626948/)\n\n \n\n**Specialised**\n\n[**TRIPOD-Cluster**](https://www.equator-network.org/reporting-guidelines/tripod-cluster/): Debray TPA, Collins GS, Riley RD, Snell KIE, Van Calster B, Reitsma JB, Moons KGM. Transparent reporting of multivariable prediction models developed or validated using clustered data: TRIPOD-Cluster checklist. BMJ. 2023;380:e071018. PMID: [36750242](https://pubmed.ncbi.nlm.nih.gov/36750242/)\n\n \n\n[**TRIPOD-LLM**](https://www.equator-network.org/reporting-guidelines/the-tripod-llm-reporting-guideline-for-studies-using-large-language-models/): Gallifant J, Afshar M, Ameen S, Aphinyanaphongs Y, Chen S, Cacciamani G, Demner-Fushman D, Dligach D, Daneshjou R, Fernandes C, Hansen LH, Landman A, Lehmann L, McCoy LG, Miller T, Moreno A, Munch N, Restrepo D, Savova G, Umeton R, Gichoya JW, Collins GS, Moons KGM, Celi LA, Bitterman DS. The TRIPOD-LLM reporting guideline for studies using large language models. Nat Med. 2025. PMID: [39779929](https://pubmed.ncbi.nlm.nih.gov/39779929/)\n\n \n\n'), ('Reporting guideline website URL', '<https://www.tripod-statement.org/>'), ('Reporting guideline acronym', 'TRIPOD-SRMA'), ('Study design', 'Artificial intelligence/Machine learning studies, Diagnostic and prognostic studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 10, 2025')]"
21197,Preferred Reporting Items for Complex Sample Survey Analysis (PRICSSA),"Observational studies, Qualitative research", ,"Data, Statistical methods and analyses", ,"checklist, checklists, code, complex sample survey analysis, complex sample survey data, data, dataset, datasets, methodology, methods, observational, Preferred Reporting Items for Complex Sample Survey Analysis, PRICSSA, qualitative, sample, software, statistical, statistics, survey, surveys", ,"Seidenberg AB, Moser RP, West BT. Preferred Reporting Items for Complex Sample Survey Analysis (PRICSSA). J Surv Stat Methodol. 2023;smac040.","Seidenberg AB, Moser RP, West BT.",Journal of Survey Statistics and Methodology [J Surv Stat Methodol.],2023, , ,smac040, ,English, , , ,Read the full-text of the PRICSSA guideline., , , , ,PRICSSA,Reporting analyses using complex sample survey data., , , , , , , ,no,2023-05-04 09:56:57,2023-05-04 09:56:57,preferred-reporting-items-for-complex-sample-survey-analysis-pricssa,"[('title', 'Preferred Reporting Items for Complex Sample Survey Analysis (PRICSSA)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting analyses using complex sample survey data.'), ('Full bibliographic reference', 'Seidenberg AB, Moser RP, West BT. Preferred Reporting Items for Complex Sample Survey Analysis (PRICSSA). J Surv Stat Methodol. 2023;smac040.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://academic.oup.com/jssam/advance-article/doi/10.1093/jssam/smac040/7136601) of the PRICSSA guideline.'), ('Reporting guideline acronym', 'PRICSSA'), ('Study design', 'Observational studies, Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Data, Statistical methods and analyses'), ('Record last updated on', 'May 4, 2023')]"
21173,Defining measures of kidney function in observational studies using routine health care data: methodological and reporting considerations,Observational studies,Renal medicine,"Data, Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions", ,"acute kidney disease, acute kidney injury, application consolidation contexualisation, chronic kidney disease, CKD, data, EHR, electronic health record, electronic health records, kidney, observational, observational studies, observational study, RECORD-PE, renal, routinely collected health care data", ,"Carrero JJ, Fu EL, Vestergaard SV, Jensen SK, Gasparini A, Mahalingasivam V, Bell S, Birn H, Heide-J\xf8rgensen U, Clase CM, Cleary F, Coresh J, Dekker FW, Gansevoort RT, Hemmelgarn BR, Jager KJ, Jafar TH, Kovesdy CP, Sood MM, Stengel B, Christiansen CF, Iwagami M, Nitsch D. Defining measures of kidney function in observational studies using routine health care data: methodological and reporting considerations. Kidney Int. 2023;103(1):53-69.","Carrero JJ, Fu EL, Vestergaard SV, Jensen SK, Gasparini A, Mahalingasivam V, Bell S, Birn H, Heide-J\xf8rgensen U, Clase CM, Cleary F, Coresh J, Dekker FW, Gansevoort RT, Hemmelgarn BR, Jager KJ, Jafar TH, Kovesdy CP, Sood MM, Stengel B, Christiansen CF, Iwagami M, Nitsch D.",Kidney International [Kidney Int.],2023,103,1,53-69, ,English, ,36280224,https://pubmed.ncbi.nlm.nih.gov/36280224/,The checklist is available in Supplemental Table S2., , , , , ,Reporting definitions of exposures and outcomes in studies of kidney disease using routinely collected health care data., , , , , , , ,no,2023-04-06 17:08:21,2023-04-06 17:08:21,defining-measures-of-kidney-function-in-observational-studies-using-routine-health-care-data-methodological-and-reporting-considerations,"[('title', 'Defining measures of kidney function in observational studies using routine health care data: methodological and reporting considerations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting definitions of exposures and outcomes in studies of kidney disease using routinely collected health care data.'), ('Full bibliographic reference', 'Carrero JJ, Fu EL, Vestergaard SV, Jensen SK, Gasparini A, Mahalingasivam V, Bell S, Birn H, Heide-Jørgensen U, Clase CM, Cleary F, Coresh J, Dekker FW, Gansevoort RT, Hemmelgarn BR, Jager KJ, Jafar TH, Kovesdy CP, Sood MM, Stengel B, Christiansen CF, Iwagami M, Nitsch D. Defining measures of kidney function in observational studies using routine health care data: methodological and reporting considerations. Kidney Int. 2023;103(1):53-69.'), ('Language', 'English'), ('PubMed ID', '[36280224](https://pubmed.ncbi.nlm.nih.gov/36280224/)'), ('Relevant URLs\n\n(full-text if available)', 'The checklist is available in Supplemental Table S2.'), ('Study design', 'Observational studies'), ('Clinical area', 'Renal medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data, Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'April 6, 2023')]"
21171,CORE-CERT Items as a Minimal Requirement for Replicability of Exercise Interventions: Results From Application to Exercise Studies for Breast Cancer Patients,"Clinical trials, Experimental studies","Oncology, Physiotherapy, Sport and exercise medicine",Intervention (exposure), ,"application consolidation contexualisation, breast, cancer, CERT, checklist, checklists, clinical trial, clinical trials, CORE-CERT, CORE-CERT checklist, exercise, exercises, exercising, intervention, interventions, oncology, physical, physical activities, physical activity, physical training, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, sport, sports, trial, trials", ,"B\xfcnzen C, Knuth J, Bucher M, Weisser B, Schmidt T. CORE-CERT Items as a Minimal Requirement for Replicability of Exercise Interventions: Results From Application to Exercise Studies for Breast Cancer Patients. J Strength Cond Res. 2023.","B\xfcnzen C, Knuth J, Bucher M, Weisser B, Schmidt T.",Journal of Strength and Conditioning Research [J Strength Cond Res.],2023, , , , ,English, ,36727977,https://pubmed.ncbi.nlm.nih.gov/36727977/, , , , , ,CORE-CERT,"Reporting key items of exercise studies which are necessary for study replication, with a particular focus on the clinical use of an intervention.", , , , , , , ,no,2023-04-06 11:12:36,2023-04-06 11:12:36,core-cert-items-as-a-minimal-requirement-for-replicability-of-exercise-interventions-results-from-application-to-exercise-studies-for-breast-cancer-patients,"[('title', 'CORE-CERT Items as a Minimal Requirement for Replicability of Exercise Interventions: Results From Application to Exercise Studies for Breast Cancer Patients'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting key items of exercise studies which are necessary for study replication, with a particular focus on the clinical use of an intervention.'), ('Full bibliographic reference', 'Bünzen C, Knuth J, Bucher M, Weisser B, Schmidt T. CORE-CERT Items as a Minimal Requirement for Replicability of Exercise Interventions: Results From Application to Exercise Studies for Breast Cancer Patients. J Strength Cond Res. 2023.'), ('Language', 'English'), ('PubMed ID', '[36727977](https://pubmed.ncbi.nlm.nih.gov/36727977/)'), ('Reporting guideline acronym', 'CORE-CERT'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Oncology, Physiotherapy, Sport and exercise medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'April 6, 2023')]"
21169,Recommendations for Reporting Machine Learning Analyses in Clinical Research,Artificial intelligence/Machine learning studies, ,"Data, Statistical methods and analyses", ,"AI, analysis, artificial intelligence, data, diagnosis, diagnostic accuracy, machine learning, ML, ML analyses, ML analysis, predict, prediction, prognosis, prognostic, statistical, statistics, supervised, unsupervised", ,"Stevens LM, Mortazavi BJ, Deo RC, Curtis L, Kao DP. Recommendations for Reporting Machine Learning Analyses in Clinical Research. Circ Cardiovasc Qual Outcomes. 2020;13(10):e006556.","Stevens LM, Mortazavi BJ, Deo RC, Curtis L, Kao DP.",Circulation. Cardiovascular and Quality Outcomes. [Circ Cardiovasc Qual Outcomes.],2020,13,10,e006556, ,English, ,33079589,https://pubmed.ncbi.nlm.nih.gov/33079589/, , , , , , ,Reporting of machine learning (ML) analyses., , , , , , , ,no,2023-04-05 16:15:40,2024-01-25 11:35:29,recommendations-for-reporting-machine-learning-analyses-in-clinical-research,"[('title', 'Recommendations for Reporting Machine Learning Analyses in Clinical Research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of machine learning (ML) analyses.'), ('Full bibliographic reference', 'Stevens LM, Mortazavi BJ, Deo RC, Curtis L, Kao DP. Recommendations for Reporting Machine Learning Analyses in Clinical Research. Circ Cardiovasc Qual Outcomes. 2020;13(10):e006556.'), ('Language', 'English'), ('PubMed ID', '[33079589](https://pubmed.ncbi.nlm.nih.gov/33079589/)'), ('Study design', 'Artificial intelligence/Machine learning studies'), ('Applies to the whole report or to individual sections of the report?', 'Data, Statistical methods and analyses'), ('Record last updated on', 'January 25, 2024')]"
21166,ACURATE: A guide for reporting sham controls in trials using acupuncture,"Clinical trials, Experimental studies",Complementary and alternative medicine,Intervention (exposure), ,"acupuncture, Acupuncture Controls gUideline for Reporting humAn Trials and Experiments, ACURATE, ACURATE checklist, checklist, checklists, clinical trial, clinical trials, device, intervention, interventions, needle, needles, needling, placebo, placebo acupuncture, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, sham, sham acupuncture, sham control, sham controls, sham placebo, trial, trials", ,"Lee YS, Kim SY, Lee H, Chae Y, Lee MS. ACURATE: A guide for reporting sham controls in trials using acupuncture.

This guideline was published simultaneously in 3 journals. You can read the guideline in any of these journals using the links below.

J Evid Based Med. 2023;16(1):82-90. PMID: 36959765
Integr Med Res. 2023;12(2):100955. PMID: 37250752
J Acupunct Meridian Stud. 2023;16(3):119-126. PMID: 37381034

", , , , , , , ,English, , , , , , , , ,ACURATE,Reporting sham acupuncture in clinical trials., , , , , , , ,no,2023-04-05 14:57:09,2023-08-17 17:30:02,acurate-a-guide-for-reporting-sham-controls-in-trials-using-acupuncture,"[('title', 'ACURATE : A guide for reporting sham controls in trials using acupuncture'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting sham acupuncture in clinical trials.'), ('Full bibliographic reference', 'Lee YS, Kim SY, Lee H, Chae Y, Lee MS. ACURATE: A guide for reporting sham controls in trials using acupuncture.\n\n \n\n This guideline was published simultaneously in 3 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n J Evid Based Med. 2023;16(1):82-90. PMID: [36959765](https://pubmed.ncbi.nlm.nih.gov/36959765/)\n\n Integr Med Res. 2023;12(2):100955. PMID: [37250752](https://pubmed.ncbi.nlm.nih.gov/37250752/)\n\n J Acupunct Meridian Stud. 2023;16(3):119-126. PMID: [37381034](https://pubmed.ncbi.nlm.nih.gov/37381034/)\n\n \n\n'), ('Language', 'English'), ('Reporting guideline acronym', 'ACURATE'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'August 17, 2023')]"
21146,Checklist for Artificial Intelligence in Medical Imaging (CLAIM): 2024 Update,Artificial intelligence/Machine learning studies,Radiology,Whole report, ,"AI, artificial intelligence, checklist, Checklist for AI in Medical Imaging, checklists, CLAIM, CLAIM 2024, CLAIM checklist, image, imaging, medical image, medical images, medical imaging, radiology", ,"Tejani AS, Klontzas ME, Gatti AA, Mongan JT, Moy L, Park SH, Kahn CE Jr; CLAIM 2024 Update Panel. Checklist for Artificial Intelligence in Medical Imaging (CLAIM): 2024 Update. Radiol Artif Intell. 2024;6(4):e240300.","Tejani AS, Klontzas ME, Gatti AA, Mongan JT, Moy L, Park SH, Kahn CE Jr; CLAIM 2024 Update Panel.",Radiology Artificial Intelligence [Radiol Artif Intell.],2024,6,4,e240300, ,English, ,38809149,https://pubmed.ncbi.nlm.nih.gov/38809149/,Read the full-text of the CLAIM reporting guideline., ,"Mongan J, Moy L, Kahn CE Jr. Checklist for Artificial Intelligence in Medical Imaging (CLAIM): A Guide for Authors and Reviewers. Radiol Artif Intell. 2020;2(2):e200029. PMID: 33937821

", ,https://pubs.rsna.org/page/ai/claim,CLAIM,Reporting of artificial intelligence (AI) in Medical Imaging studies., , , , , , , ,no,2023-03-23 12:12:43,2024-06-24 13:43:56,checklist-for-artificial-intelligence-in-medical-imaging-claim-a-guide-for-authors-and-reviewers,"[('title', 'Checklist for Artificial Intelligence in Medical Imaging (CLAIM) : 2024 Update'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of artificial intelligence (AI) in Medical Imaging studies.'), ('Full bibliographic reference', 'Tejani AS, Klontzas ME, Gatti AA, Mongan JT, Moy L, Park SH, Kahn CE Jr; CLAIM 2024 Update Panel. Checklist for Artificial Intelligence in Medical Imaging (CLAIM): 2024 Update. Radiol Artif Intell. 2024;6(4):e240300.'), ('Language', 'English'), ('PubMed ID', '[38809149](https://pubmed.ncbi.nlm.nih.gov/38809149/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://pubs.rsna.org/doi/10.1148/ryai.240300) of the CLAIM reporting guideline.'), ('Reporting guideline website URL', '<https://pubs.rsna.org/page/ai/claim>'), ('Reporting guideline acronym', 'CLAIM'), ('Study design', 'Artificial intelligence/Machine learning studies'), ('Clinical area', 'Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Previous versions of this guideline / Guideline history', 'Mongan J, Moy L, Kahn CE Jr. Checklist for Artificial Intelligence in Medical Imaging (CLAIM): A Guide for Authors and Reviewers. Radiol Artif Intell. 2020;2(2):e200029. PMID: [33937821](https://pubmed.ncbi.nlm.nih.gov/33937821/)\n\n \n\n'), ('Record last updated on', 'June 24, 2024')]"
21137,STandards for Reporting Interventions in Clinical Trials Of Tuina/Massage (STRICTOTM): Extending the CONSORT statement,"Clinical trials, Experimental studies, Observational studies",Complementary and alternative medicine,Intervention (exposure), ,"CAM, checklist, checklists, clinical trial, clinical trials, complementary and alternative medicine, CONSORT extension, intervention, interventions, massage, nonpharmacologic, nonrandomised, nonrandomized, observational studies, observational study, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, STandards for Reporting Interventions in Clinical Trials Of Tuina/Massage, STRICTOTM, STRICTOTM checklist, TCM, traditional Chinese medicine, trial, trials, Tuina", ,"Zhang X, Liang F, Lau CT, Chan JC, Wang N, Deng J, Wang J, Ma Y, Zhong LLD, Zhao C, Yao L, Wu T, Lyu A, Tian G, Shang H, Miao J, Bian Z; STRICTOTM Working Group. STandards for Reporting Interventions in Clinical Trials Of Tuina/Massage (STRICTOTM): Extending the CONSORT statement. J Evid Based Med. 2023.","Zhang X, Liang F, Lau CT, Chan JC, Wang N, Deng J, Wang J, Ma Y, Zhong LLD, Zhao C, Yao L, Wu T, Lyu A, Tian G, Shang H, Miao J, Bian Z; STRICTOTM Working Group.",Journal of Evidence Based Medicine [J Evid Based Med.],2023, , , , ,English, ,36918992,https://pubmed.ncbi.nlm.nih.gov/36918992/,Read the full-text of the STRICTOTM reporting guideline., , , , ,STRICTOTM,Reporting interventions in clinical trials of Tuina/massage., , , , , , , ,no,2023-03-22 16:21:28,2023-03-23 08:39:37,standards-for-reporting-interventions-in-clinical-trials-of-tuina-massage-strictotm-extending-the-consort-statement,"[('title', 'STandards for Reporting Interventions in Clinical Trials Of Tuina/Massage (STRICTOTM) : Extending the CONSORT statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting interventions in clinical trials of Tuina/massage.'), ('Full bibliographic reference', 'Zhang X, Liang F, Lau CT, Chan JC, Wang N, Deng J, Wang J, Ma Y, Zhong LLD, Zhao C, Yao L, Wu T, Lyu A, Tian G, Shang H, Miao J, Bian Z; STRICTOTM Working Group. STandards for Reporting Interventions in Clinical Trials Of Tuina/Massage (STRICTOTM): Extending the CONSORT statement. J Evid Based Med. 2023.'), ('Language', 'English'), ('PubMed ID', '[36918992](https://pubmed.ncbi.nlm.nih.gov/36918992/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://onlinelibrary.wiley.com/doi/10.1111/jebm.12522) of the STRICTOTM reporting guideline.'), ('Reporting guideline acronym', 'STRICTOTM'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'March 23, 2023')]"
21090,Transparent reporting of multivariable prediction models developed or validated using clustered data: TRIPOD-Cluster checklist,"Artificial intelligence/Machine learning studies, Diagnostic and prognostic studies, Observational studies", ,Whole report, ,"cluster, clustered, clustered data, data, dataset, datasets, diagnostic, EHR, electronic healthcare records, external validation, individual participant data, IPD, IPD-MA datasets, model development, modeling, modelling, multivariable, multivariable model, multivariable models, predict, prediction, prediction model, prediction models, predictive, predictors, prognosis, prognostic, TRIPOD, TRIPOD extension, TRIPOD-Cluster", ,"Debray TPA, Collins GS, Riley RD, Snell KIE, Van Calster B, Reitsma JB, Moons KGM. Transparent reporting of multivariable prediction models developed or validated using clustered data: TRIPOD-Cluster checklist. BMJ. 2023;380:e071018.

","Debray TPA, Collins GS, Riley RD, Snell KIE, Van Calster B, Reitsma JB, Moons KGM.",BMJ.,2023,380, ,e071018, ,English, , 36750242,https://pubmed.ncbi.nlm.nih.gov/36750242/,Read the full-text of the TRIPOD-Cluster reporting guideline.,"Debray TPA, Collins GS, Riley RD, Snell KIE, Van Calster B, Reitsma JB, Moons KGM. Transparent reporting of multivariable prediction models developed or validated using clustered data (TRIPOD-Cluster): explanation and elaboration. BMJ. 2023;380:e071058. PMID:  36750236

", ,"Generic
TRIPOD+AI Statement: Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, Ghassemi M, Liu X, Reitsma JB, van Smeden M, Boulesteix AL, Camaradou JC, Celi LA, Denaxas S, Denniston AK, Glocker B, Golub RM, Harvey H, Heinze G, Hoffman MM, Kengne AP, Lam E, Lee N, Loder EW, Maier-Hein L, Mateen BA, McCradden MD, Oakden-Rayner L, Ordish J, Parnell R, Rose S, Singh K, Wynants L, Logullo P. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. PMID: 38626948

Specialised
TRIPOD-SRMA: Snell KIE, Levis B, Damen JAA, Dhiman P, Debray TPA, Hooft L, Reitsma JB, Moons KGM, Collins GS, Riley RD. Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA). BMJ. 2023;381:e073538. PMID: 37137496

TRIPOD-LLM: Gallifant J, Afshar M, Ameen S, Aphinyanaphongs Y, Chen S, Cacciamani G, Demner-Fushman D, Dligach D, Daneshjou R, Fernandes C, Hansen LH, Landman A, Lehmann L, McCoy LG, Miller T, Moreno A, Munch N, Restrepo D, Savova G, Umeton R, Gichoya JW, Collins GS, Moons KGM, Celi LA, Bitterman DS. The TRIPOD-LLM reporting guideline for studies using large language models. Nat Med. 2025. PMID: 39779929

",https://www.tripod-statement.org/clustered/,TRIPOD-Cluster,Reporting of multivariable prediction model studies developed or validated using clustered data., , , , , , , ,yes,2023-02-07 15:51:59,2025-01-10 15:46:23,tripod-cluster,"[('title', 'Transparent reporting of multivariable prediction models developed or validated using clustered data: TRIPOD-Cluster checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of multivariable prediction model studies developed or validated using clustered data.'), ('Full bibliographic reference', 'Debray TPA, Collins GS, Riley RD, Snell KIE, Van Calster B, Reitsma JB, Moons KGM. Transparent reporting of multivariable prediction models developed or validated using clustered data: TRIPOD-Cluster checklist. BMJ. 2023;380:e071018.\n\n \n\n'), ('Language', 'English'), ('PubMed ID', '[36750242](https://pubmed.ncbi.nlm.nih.gov/36750242/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.bmj.com/content/380/bmj-2022-071018) of the TRIPOD-Cluster reporting guideline.'), ('Explanation and elaboration papers', 'Debray TPA, Collins GS, Riley RD, Snell KIE, Van Calster B, Reitsma JB, Moons KGM. Transparent reporting of multivariable prediction models developed or validated using clustered data (TRIPOD-Cluster): explanation and elaboration. BMJ. 2023;380:e071058. PMID:  [36750236](https://pubmed.ncbi.nlm.nih.gov/36750236/)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**TRIPOD+AI Statement**](https://www.equator-network.org/reporting-guidelines/tripod-statement/): Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, Ghassemi M, Liu X, Reitsma JB, van Smeden M, Boulesteix AL, Camaradou JC, Celi LA, Denaxas S, Denniston AK, Glocker B, Golub RM, Harvey H, Heinze G, Hoffman MM, Kengne AP, Lam E, Lee N, Loder EW, Maier-Hein L, Mateen BA, McCradden MD, Oakden-Rayner L, Ordish J, Parnell R, Rose S, Singh K, Wynants L, Logullo P. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. PMID: [38626948](https://pubmed.ncbi.nlm.nih.gov/38626948/)\n\n**\n\n Specialised**\n\n[**TRIPOD-SRMA**](https://www.equator-network.org/reporting-guidelines/tripod-srma/): Snell KIE, Levis B, Damen JAA, Dhiman P, Debray TPA, Hooft L, Reitsma JB, Moons KGM, Collins GS, Riley RD. Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA). BMJ. 2023;381:e073538. PMID: [37137496](https://pubmed.ncbi.nlm.nih.gov/37137496/)\n\n \n\n[**TRIPOD-LLM**](https://www.equator-network.org/reporting-guidelines/the-tripod-llm-reporting-guideline-for-studies-using-large-language-models/): Gallifant J, Afshar M, Ameen S, Aphinyanaphongs Y, Chen S, Cacciamani G, Demner-Fushman D, Dligach D, Daneshjou R, Fernandes C, Hansen LH, Landman A, Lehmann L, McCoy LG, Miller T, Moreno A, Munch N, Restrepo D, Savova G, Umeton R, Gichoya JW, Collins GS, Moons KGM, Celi LA, Bitterman DS. The TRIPOD-LLM reporting guideline for studies using large language models. Nat Med. 2025. PMID: [39779929](https://pubmed.ncbi.nlm.nih.gov/39779929/)\n\n \n\n'), ('Reporting guideline website URL', '<https://www.tripod-statement.org/clustered/>'), ('Reporting guideline acronym', 'TRIPOD-Cluster'), ('Study design', 'Artificial intelligence/Machine learning studies, Diagnostic and prognostic studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 10, 2025')]"
21062,The SUPER reporting guideline suggested for reporting of surgical technique,"Clinical trials, Experimental studies, Observational studies",Surgery,Intervention (exposure), ,"case report, case reports, case series, checklist, checklists, clinical trial, clinical trials, intervention, interventions, intraopterative, observational, observational studies, observational study, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, SUPER, SUPER checklist, SUPER guideline, surgeon, surgery, surgical, surgical innovation, surgical technique, Surgical techniqUe rePorting chEcklist and standaRds, surgical techniques, trial, trials", ,"Zhang K, Ma Y, Wu J, Shi Q, Barchi LC, Scarci M, Petersen RH, Ng CSH, Hochwald S, Waseda R, Davoli F, Fruscio R, Levi Sandri GB, Gonzalez M, Wei B, Piessen G, Shen J, Zhang X, Jiao P, He Y, Novoa NM, Bedetti B, Gilbert S, Sihoe ADL, Toker A, Fiorelli A, Jimenez MF, Lerut T, Oo AY, Li GS, Tang X, Lu Y, Elkhayat H, ?tupnik T, Laisaar T, Abu Akar F, Gonzalez-Rivas D, Su Z, Qiu B, Wang SD, Chen Y, Gao S. The SUPER reporting guideline suggested for reporting of surgical technique. HepatoBiliary Surg Nutr 2023;12(4):534-544.","Zhang K, Ma Y, Wu J, Shi Q, Barchi LC, Scarci M, Petersen RH, Ng CSH, Hochwald S, Waseda R, Davoli F, Fruscio R, Levi Sandri GB, Gonzalez M, Wei B, Piessen G, Shen J, Zhang X, Jiao P, He Y, Novoa NM, Bedetti B, Gilbert S, Sihoe ADL, Toker A, Fiorelli A, Jimenez MF, Lerut T, Oo AY, Li GS, Tang X, Lu Y, Elkhayat H, ?tupnik T, Laisaar T, Abu Akar F, Gonzalez-Rivas D, Su Z, Qiu B, Wang SD, Chen Y, Gao S.",HepatoBiliary Surgery and Nutrition [HepatoBiliary Surg Nutr.],2023,12,4,534-544, ,English, ,37601001,https://pubmed.ncbi.nlm.nih.gov/37601001/,Read the full-text (PDF) of the SUPER reporting guideline.,"Zhang K, Wu J, Su Z, Ma Y, Shi Q, Barchi LC, Laisaar T, Ng CSH, Gilbert S, Zhang X, ?tupnik T, Lerut T, Jiao P, Elkhayat H, Novoa NM, Fruscio R, Waseda R, Petersen RH, Fiorelli A, Sihoe ADL, Gonzalez-Rivas D, Scarci M, Jimenez MF, Li GS, Tang X, Wang SD, Chen Y. The SUPER reporting guideline suggested for reporting of surgical technique: explanation and elaboration. Gland Surg. 2023;12(6):749-766. PMID: 37441012

", , ,https://www.thesuper.org/,SUPER,Reporting of surgical technique., ,"The SUPER guideline development protocol is available at:
Zhang K, Ma Y, Shi Q, Wu J, Shen J, He Y, Zhang X, Jiao P, Li GS, Tang X, Petersen RH, Ng CSH, Fiorelli A, Novoa NM, Bedetti B, Levi Sandri GB, Hochwald S, Lerut T, Sihoe ADL, Barchi LC, Gilbert S, Waseda R, Toker A, Gonzalez-Rivas D, Fruscio R, Scarci M, Davoli F, Piessen G, Qiu B, Wang SD, Chen Y, Gao S. Developing the surgical technique reporting checklist and standards: a study protocol. Gland Surg. 2021;10(8):2591-2599. PMID: 34527570

The scoping review that informed development of the SUPER guideline is available at:
Shi Q, Ma Y, Zhang X, Jiao P, Zhang K, Barchi LC, Bedetti B, Wu J, Wei B, Ng CSH, Toker A, Shen J, Fruscio R, Gilbert S, Petersen RH, Hochwald S, ?tupnik T, Elkhayat H, Scarci M, Levi Sandri GB, Abu Akar F, Waseda R, Sihoe ADL, Fiorelli A, Gonzalez M, Davoli F, Li GS, Tang X, Qiu B, Wang SD, Chen Y, Gao S. Reporting guidelines for surgical technique could be improved: A scoping review and a call for action. J Clin Epidemiol. 2022:S0895-4356(22)00298-0. PMID: 36574532 and the scoping review protocol is at PMID: 34422603

", , , , , ,no,2023-01-19 10:08:03,2023-08-29 11:45:57,the-super-reporting-guideline-suggested-for-reporting-of-surgical-technique,"[('title', 'The SUPER reporting guideline suggested for reporting of surgical technique'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of surgical technique.'), ('Full bibliographic reference', 'Zhang K, Ma Y, Wu J, Shi Q, Barchi LC, Scarci M, Petersen RH, Ng CSH, Hochwald S, Waseda R, Davoli F, Fruscio R, Levi Sandri GB, Gonzalez M, Wei B, Piessen G, Shen J, Zhang X, Jiao P, He Y, Novoa NM, Bedetti B, Gilbert S, Sihoe ADL, Toker A, Fiorelli A, Jimenez MF, Lerut T, Oo AY, Li GS, Tang X, Lu Y, Elkhayat H, Štupnik T, Laisaar T, Abu Akar F, Gonzalez-Rivas D, Su Z, Qiu B, Wang SD, Chen Y, Gao S. The SUPER reporting guideline suggested for reporting of surgical technique. HepatoBiliary Surg Nutr 2023;12(4):534-544.'), ('Language', 'English'), ('PubMed ID', '[37601001](https://pubmed.ncbi.nlm.nih.gov/37601001/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text (PDF)](https://hbsn.amegroups.com/article/view/107955/pdf) of the SUPER reporting guideline.'), ('Explanation and elaboration papers', 'Zhang K, Wu J, Su Z, Ma Y, Shi Q, Barchi LC, Laisaar T, Ng CSH, Gilbert S, Zhang X, Štupnik T, Lerut T, Jiao P, Elkhayat H, Novoa NM, Fruscio R, Waseda R, Petersen RH, Fiorelli A, Sihoe ADL, Gonzalez-Rivas D, Scarci M, Jimenez MF, Li GS, Tang X, Wang SD, Chen Y. The SUPER reporting guideline suggested for reporting of surgical technique: explanation and elaboration. Gland Surg. 2023;12(6):749-766. PMID: [37441012](https://pubmed.ncbi.nlm.nih.gov/37441012/)\n\n \n\n'), ('Reporting guideline website URL', '<https://www.thesuper.org/>'), ('Reporting guideline acronym', 'SUPER'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Additional information', 'The SUPER guideline development protocol is available at:\n\n Zhang K, Ma Y, Shi Q, Wu J, Shen J, He Y, Zhang X, Jiao P, Li GS, Tang X, Petersen RH, Ng CSH, Fiorelli A, Novoa NM, Bedetti B, Levi Sandri GB, Hochwald S, Lerut T, Sihoe ADL, Barchi LC, Gilbert S, Waseda R, Toker A, Gonzalez-Rivas D, Fruscio R, Scarci M, Davoli F, Piessen G, Qiu B, Wang SD, Chen Y, Gao S. Developing the surgical technique reporting checklist and standards: a study protocol. Gland Surg. 2021;10(8):2591-2599. PMID: [34527570](https://pubmed.ncbi.nlm.nih.gov/34527570/)\n\n \n\n The scoping review that informed development of the SUPER guideline is available at:\n\n Shi Q, Ma Y, Zhang X, Jiao P, Zhang K, Barchi LC, Bedetti B, Wu J, Wei B, Ng CSH, Toker A, Shen J, Fruscio R, Gilbert S, Petersen RH, Hochwald S, Štupnik T, Elkhayat H, Scarci M, Levi Sandri GB, Abu Akar F, Waseda R, Sihoe ADL, Fiorelli A, Gonzalez M, Davoli F, Li GS, Tang X, Qiu B, Wang SD, Chen Y, Gao S. Reporting guidelines for surgical technique could be improved: A scoping review and a call for action. J Clin Epidemiol. 2022:S0895-4356(22)00298-0. PMID: [36574532](https://pubmed.ncbi.nlm.nih.gov/36574532/) and the scoping review protocol is at PMID: [34422603](https://pubmed.ncbi.nlm.nih.gov/34422603/)\n\n \n\n'), ('Record last updated on', 'August 29, 2023')]"
21042,Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension,"Clinical trials, Experimental studies", ,"Outcomes (variables), Results, Statistical methods and analyses", ,"clinical trial, clinical trials, CONSORT, CONSORT 2010, CONSORT extension, CONSORT-Outcomes, CONSORT-Outcomes 2022, CONSORT-Outcomes 2022 extension, outcome, outcomes, randomised clinical trial, randomised clinical trials, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized clinical trial, randomized clinical trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264.","Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M.",JAMA.,2022,328,22,2252-2264, ,English, ,36511921,https://pubmed.ncbi.nlm.nih.gov/36511921/,"Read the full-text of the CONSORT-Outcomes reporting guideline.

Five optional additional items for outcome reporting in trial reports and related documents have also been proposed and these can be found in eTable 6 in the supplementary materials available on the JAMA website.

", , ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster: Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal: Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts: Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture: MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738. PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,CONSORT-Outcomes 2022,"Reporting outcomes in clinical trials.



", , , , , , , ,yes,2023-01-04 15:08:51,2025-05-30 09:26:25,guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension,"[('title', 'Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting outcomes in clinical trials.\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264.'), ('Language', 'English'), ('PubMed ID', '[36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://jamanetwork.com/journals/jama/fullarticle/2799401) of the CONSORT-Outcomes reporting guideline.\n\n \n\n Five optional additional items for outcome reporting in trial reports and related documents have also been proposed and these can be found in eTable 6 in the supplementary materials available on the [JAMA website](https://jamanetwork.com/journals/jama/fullarticle/2799401).\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](https://www.equator-network.org/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](https://www.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](https://www.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](https://www.equator-network.org/reporting-guidelines/consort-cluster/): Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](https://www.equator-network.org/reporting-guidelines/consort-herbal/): Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](https://www.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](https://www.equator-network.org/reporting-guidelines/consort-abstracts/): Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](https://www.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](https://www.equator-network.org/reporting-guidelines/consort-stricta/): MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](https://www.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](https://www.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738. PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](https://www.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](https://www.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](https://www.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](https://www.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](https://www.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://www.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](https://www.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](https://www.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](https://www.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](https://www.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](https://www.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://www.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://www.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://www.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://www.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'CONSORT-Outcomes 2022'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Outcomes (variables), Results, Statistical methods and analyses'), ('Record last updated on', 'May 30, 2025')]"
21039,Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension,"Clinical trials, Experimental studies, Study protocols", ,"Outcomes (variables), Statistical methods and analyses", ,"checklist, checklists, clinical trial, clinical trials, outcome, outcomes, protocol, protocols, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, SPIRIT, SPIRIT 2013, SPIRIT 2013 statement, SPIRIT Extension, SPIRIT-Outcomes, SPIRIT-Outcomes 2022, SPIRIT-Outcomes 2022 extension, trial, trials", ,"Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356.","Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M.",JAMA,2022,328,23,2345-2356, ,English, ,36512367,https://pubmed.ncbi.nlm.nih.gov/36512367/,"Read the full-text of the SPIRIT-Outcomes reporting guideline.

Five optional additional items for outcome reporting in trial protocols and/or associated trial documents have also been proposed and these can be found in eTable 6 in the supplementary materials available on the JAMA website.

", , ,"Generic

SPIRIT 2025 Statement: Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hr\xf3bjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.

BMJ. 2025; 388:e081660. PMID:\xa040294956
JAMA. 2025.\xa0PMID: 40294593
Lancet 2025.
Nat Med. 2025.\xa0PMID: 40295741
PLoS Med. 2025; 22(4): e1004587.\xa0PMID: 40294521

Specialised
SPIRIT-PRO: Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. Link to abstract

SPIRIT-TCM: Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: 30484022

SPENT 2019: Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. Link to full-text.

SPIRIT-AI: Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.
BMJ. 2020;370:m3210. PMID: 32907797
Nat Med. 2020;26(9):1351?1363. PMID: 32908284
Lancet Digital Health. 2020;2(10):e549-e560. PMID: 33328049

SPIRIT-Path: Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: 34592193

SPIRIT-DEFINE: Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: 37863491

SPIRIT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: 38051535

SPIRIT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: 38981624

SPIRIT-iNeurostim: Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: 39610902

", ,SPIRIT-Outcomes 2022,"Reporting outcomes in clinical trial protocols.



SPIRIT-Outcomes checklist (for combined completion of SPIRIT 2013 and SPIRIT-Outcomes 2022 items) PDF

SPIRIT-Outcomes extension items only checklist (for separate completion of SPIRIT 2013 and SPIRIT-Outcomes 2022 items) PDF

", , , , , , , ,yes,2023-01-04 11:17:01,2025-05-30 09:14:02,guidelines-for-reporting-outcomes-in-trial-protocols-the-spirit-outcomes-2022-extension,"[('title', 'Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting outcomes in clinical trial protocols.\n\n \n\n \xa0\n\n \n\n SPIRIT-Outcomes checklist (for combined completion of SPIRIT 2013 and SPIRIT-Outcomes 2022 items) [PDF](https://www.spirit-statement.org/wp-content/uploads/Fillable-SPIRIT-Outcomes-2022-Checklist-with-SPIRIT-2013.pdf)\n\n \n\n SPIRIT-Outcomes extension items only checklist (for separate completion of SPIRIT 2013 and SPIRIT-Outcomes 2022 items) [PDF](https://www.spirit-statement.org/wp-content/uploads/Fillable-SPIRIT-Outcomes-2022-Checklist.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356.'), ('Language', 'English'), ('PubMed ID', '[36512367](https://pubmed.ncbi.nlm.nih.gov/36512367/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://jamanetwork.com/journals/jama/fullarticle/2799547) of the SPIRIT-Outcomes reporting guideline.\n\n \n\n Five optional additional items for outcome reporting in trial protocols and/or associated trial documents have also been proposed and these can be found in eTable 6 in the supplementary materials available on the [JAMA website](https://jamanetwork.com/journals/jama/fullarticle/2799547).\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n \n\n**[SPIRIT 2025 Statement](https://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/):** Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hróbjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.\n\n \n\nBMJ. 2025; 388:e081660. [PMID:40294956](https://pubmed.ncbi.nlm.nih.gov/40294956/)\n\n JAMA. 2025.[PMID:](https://pubmed.ncbi.nlm.nih.gov/40294593/) [40294593](https://pubmed.ncbi.nlm.nih.gov/40294593/)\n\n Lancet 2025.\n\n Nat Med. 2025.[PMID: 40295741](https://pubmed.ncbi.nlm.nih.gov/40295741)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID: 40294521](https://pubmed.ncbi.nlm.nih.gov/40294521/)\n\n \n\n**Specialised**\n\n[**SPIRIT-PRO**](https://www.equator-network.org/reporting-guidelines/spirit-pro/): Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. [Link to abstract](https://jamanetwork.com/journals/jama/article-abstract/2671472)\n\n \n\n[**SPIRIT-TCM**](https://www.equator-network.org/reporting-guidelines/standard-protocol-items-for-clinical-trials-with-traditional-chinese-medicine-spirit-tcm-extension-2018/): Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: [30484022](https://www.ncbi.nlm.nih.gov/pubmed/30484022)\n\n \n\n[**SPENT 2019**](https://www.equator-network.org/reporting-guidelines/spirit-extension-n-of-1-trials-spent-2019/): Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. [Link to full-text](https://www.bmj.com/content/368/bmj.m122).\n\n \n\n[**SPIRIT-AI**](https://www.equator-network.org/reporting-guidelines/spirit-artificial-intelligence/): Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.\n\n BMJ. 2020;370:m3210. PMID: [32907797](https://pubmed.ncbi.nlm.nih.gov/32907797/)\n\n Nat Med. 2020;26(9):1351–1363. PMID: [32908284](https://pubmed.ncbi.nlm.nih.gov/32908284/)\n\n Lancet Digital Health. 2020;2(10):e549-e560. PMID: [33328049](https://pubmed.ncbi.nlm.nih.gov/33328049/)\n\n \n\n[**SPIRIT-Path**](https://www.equator-network.org/reporting-guidelines/spirit-path/): Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: [34592193](https://pubmed.ncbi.nlm.nih.gov/34592193/)\n\n \n\n[**SPIRIT-DEFINE**](https://www.equator-network.org/reporting-guidelines/spirit-define/): Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: [37863491](https://pubmed.ncbi.nlm.nih.gov/37863491/)\n\n \n\n[**SPIRIT Factorial**](https://www.equator-network.org/reporting-guidelines/consensus-statement-for-protocols-of-factorial-randomized-trials-extension-of-the-spirit-2013-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: [38051535](https://pubmed.ncbi.nlm.nih.gov/38051535/)\n\n \n\n[**SPIRIT-Surrogate**](https://www.equator-network.org/reporting-guidelines/spirit-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: [38981624](https://pubmed.ncbi.nlm.nih.gov/38981624/)\n\n \n\n[**SPIRIT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-protocols-of-randomised-controlled-trials-of-implantable-neurostimulation-devices-the-spirit-ineurostim-extension/): Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: [39610902](https://pubmed.ncbi.nlm.nih.gov/39610902/)\n\n \n\n""), ('Reporting guideline acronym', 'SPIRIT-Outcomes 2022'), ('Study design', 'Clinical trials, Experimental studies, Study protocols'), ('Applies to the whole report or to individual sections of the report?', 'Outcomes (variables), Statistical methods and analyses'), ('Record last updated on', 'May 30, 2025')]"
21015,PROBE 2023 guidelines for reporting observational studies in Endodontics: A consensus-based development study,Observational studies,Dentistry,Whole report, ,"checklist, checklists, Dentist, Dentistry, endodontic, Endodontics, endodontology, observational, observational studies, observational study, periodontal, PROBE, PROBE 2023, PROBE 2023 checklist, PROBE checklist, root, root canal treatment, teeth, tooth", ,"Nagendrababu V, Duncan HF, Fouad AF, Kirkevang LL, Parashos P, Pigg M, Vaeth M, Jayaraman J, Suresh N, Arias A, Wigsten E, Dummer PMH. PROBE 2023 guidelines for reporting observational studies in Endodontics: A consensus-based development study. Int Endod J. 2023; 56(3):308-317.","Nagendrababu V, Duncan HF, Fouad AF, Kirkevang LL, Parashos P, Pigg M, Vaeth M, Jayaraman J, Suresh N, Arias A, Wigsten E, Dummer PMH.",International Endodontic Journal [Int Endod J.],2023, , , , ,English, ,36416192,https://pubmed.ncbi.nlm.nih.gov/36416192/,Access the PROBE 2023 checklist.,"Nagendrababu V, Duncan HF, Fouad AF, Kirkevang LL, Parashos P, Pigg M, Vaeth M, Jayaraman J, Suresh N, Jakovljevic A, Dummer PMH. PROBE 2023 guidelines for reporting observational studies in endodontics: Explanation and elaboration. Int Endod J. 2023. PMID: 36851874", , ,https://pride-endodonticguidelines.org/probe/,PROBE 2023,Reporting observational studies in endodontics., , , , , , , ,no,2022-12-07 14:45:41,2023-04-06 11:47:56,probe-2023-guidelines-for-reporting-observational-studies-in-endodontics-a-consensus-based-development-study,"[('title', 'PROBE 2023 guidelines for reporting observational studies in Endodontics: A consensus-based development study'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting observational studies in endodontics.'), ('Full bibliographic reference', 'Nagendrababu V, Duncan HF, Fouad AF, Kirkevang LL, Parashos P, Pigg M, Vaeth M, Jayaraman J, Suresh N, Arias A, Wigsten E, Dummer PMH. PROBE 2023 guidelines for reporting observational studies in Endodontics: A consensus-based development study. Int Endod J. 2023; 56(3):308-317.'), ('Language', 'English'), ('PubMed ID', '[36416192](https://pubmed.ncbi.nlm.nih.gov/36416192/)'), ('Relevant URLs\n\n(full-text if available)', 'Access the [PROBE 2023 checklist](https://pride-endodonticguidelines.org/probe/).'), ('Explanation and elaboration papers', 'Nagendrababu V, Duncan HF, Fouad AF, Kirkevang LL, Parashos P, Pigg M, Vaeth M, Jayaraman J, Suresh N, Jakovljevic A, Dummer PMH. PROBE 2023 guidelines for reporting observational studies in endodontics: Explanation and elaboration. Int Endod J. 2023. PMID: [36851874](https://pubmed.ncbi.nlm.nih.gov/36851874/)'), ('Reporting guideline website URL', '<https://pride-endodonticguidelines.org/probe/>'), ('Reporting guideline acronym', 'PROBE 2023'), ('Study design', 'Observational studies'), ('Clinical area', 'Dentistry'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'April 6, 2023')]"
20974,CONFERD-HP: recommendations for reporting COmpeteNcy FramEwoRk Development in health professions,"Mixed methods studies, Qualitative research",Medical education,Whole report, ,"checklist, checklists, competency, competency framework, COmpeteNcy FramEwoRk Development in Health Professions, competency frameworks, CONFERD-HP, education, framework, health professions, health professions education, medical education, mixed methods, practice, professional, professional practice, qualitative", ,"Batt AM, Tavares W, Horsley T, Rich JV, Williams B; CONFERD-HP Collaborators. CONFERD-HP: recommendations for reporting COmpeteNcy FramEwoRk Development in health professions. Br J Surg. 2022:znac394","Batt AM, Tavares W, Horsley T, Rich JV, Williams B; CONFERD-HP Collaborators.",British Journal of Surgery [Br J Surg.],2022, , ,znac394, ,English, ,36413510,https://pubmed.ncbi.nlm.nih.gov/36413510/,The checklist can be downloaded at the CONFERD-HP website., , , ,http://conferd-guideline.org/,CONFERD-HP,Reporting the development of competency frameworks in the health professions., ,"Read the scoping review that informed development of this reporting guideline:

Batt AM, Tavares W, Williams B. The development of competency frameworks in healthcare professions: a scoping review. Adv Health Sci Educ Theory Pract. 2020;25(4):913-987. PMID: 31797195", , , , , ,no,2022-11-23 15:14:14,2022-12-20 11:38:26,conferd-hp-recommendations-for-reporting-competency-framework-development-in-health-professions,"[('title', 'CONFERD-HP : recommendations for reporting COmpeteNcy FramEwoRk Development in health professions'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the development of competency frameworks in the health professions.'), ('Full bibliographic reference', 'Batt AM, Tavares W, Horsley T, Rich JV, Williams B; CONFERD-HP Collaborators. CONFERD-HP: recommendations for reporting COmpeteNcy FramEwoRk Development in health professions. Br J Surg. 2022:znac394'), ('Language', 'English'), ('PubMed ID', '[36413510](https://pubmed.ncbi.nlm.nih.gov/36413510/)'), ('Relevant URLs\n\n(full-text if available)', 'The checklist can be downloaded at the [CONFERD-HP website](http://conferd-guideline.org/conferd-hp-checklist/).'), ('Reporting guideline website URL', '<http://conferd-guideline.org/>'), ('Reporting guideline acronym', 'CONFERD-HP'), ('Study design', 'Mixed methods studies, Qualitative research'), ('Clinical area', 'Medical education'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Read the scoping review that informed development of this reporting guideline:\n\n \n\n Batt AM, Tavares W, Williams B. The development of competency frameworks in healthcare professions: a scoping review. Adv Health Sci Educ Theory Pract. 2020;25(4):913-987. PMID: [31797195](https://pubmed.ncbi.nlm.nih.gov/31797195/)'), ('Record last updated on', 'December 20, 2022')]"
20970,"Development of the ASSESS tool: a comprehenSive tool to Support rEporting and critical appraiSal of qualitative, quantitative, and mixed methods implementation reSearch outcomes","Clinical trials, Economic evaluations, Experimental studies, Mixed methods studies, Observational studies, Qualitative research, Quality improvement studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,Whole report, ,"ASSESS, ASSESS tool, checklist, checklists, implementation, implementation outcome, implementation outcomes, implementation research, implementation science, implementation strategies, implementation strategy, meta analysis, mixed methods, qualitative, quantitative, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, review, reviews, systematic review, systematic reviews, trial, trials", ,"Ryan N, Vieira D, Gyamfi J, Ojo T, Shelley D, Ogedegbe O, Iwelunmor J, Peprah E. Development of the ASSESS tool: a comprehenSive tool to Support rEporting and critical appraiSal of qualitative, quantitative, and mixed methods implementation reSearch outcomes. Implement Sci Commun. 2022;3(1):34.","Ryan N, Vieira D, Gyamfi J, Ojo T, Shelley D, Ogedegbe O, Iwelunmor J, Peprah E.",Implementation Science Communications. [Implement Sci Commun.],2022,3,1,34, ,English, ,35346390,https://pubmed.ncbi.nlm.nih.gov/35346390/,Access the ASSESS tool checklist., , , ,https://publichealth.nyu.edu/w/isee/tools/assess-tool,ASSESS,"Describing studies focused on implementation that use qualitative, quantitative, and/or mixed methodologies.", , , , ,Read a guide (PDF) to reporting guidelines relevant to implementation studies developed by researchers in the Centre for Implementation Science at King?s College London and King?s Improvement Science and led by the National Institute for Health Research Applied Research Collaboration South London (NIHR ARC South London) at King?s College Hospital NHS Foundation Trust and supported by King?s Improvement Science., , ,no,2022-11-21 15:16:21,2023-06-06 08:38:46,development-of-the-assess-tool-a-comprehensive-tool-to-support-reporting-and-critical-appraisal-of-qualitative-quantitative-and-mixed-methods-implementation-research-outcomes,"[('title', 'Development of the ASSESS tool: a comprehenSive tool to Support rEporting and critical appraiSal of qualitative, quantitative, and mixed methods implementation reSearch outcomes'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Describing studies focused on implementation that use qualitative, quantitative, and/or mixed methodologies.'), ('Full bibliographic reference', 'Ryan N, Vieira D, Gyamfi J, Ojo T, Shelley D, Ogedegbe O, Iwelunmor J, Peprah E. Development of the ASSESS tool: a comprehenSive tool to Support rEporting and critical appraiSal of qualitative, quantitative, and mixed methods implementation reSearch outcomes. Implement Sci Commun. 2022;3(1):34.'), ('Language', 'English'), ('PubMed ID', '[35346390](https://pubmed.ncbi.nlm.nih.gov/35346390/)'), ('Relevant URLs\n\n(full-text if available)', 'Access the [ASSESS tool checklist](https://publichealth.nyu.edu/w/isee/tools/assess-tool).'), ('Reporting guideline website URL', '<https://publichealth.nyu.edu/w/isee/tools/assess-tool>'), ('Reporting guideline acronym', 'ASSESS'), ('Study design', 'Clinical trials, Economic evaluations, Experimental studies, Mixed methods studies, Observational studies, Qualitative research, Quality improvement studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Other', '[Read a guide (PDF)](https://arc-sl.nihr.ac.uk/sites/default/files/uploads/files/Imp-Sci-reporting-guidelines-2023.pdf) to reporting guidelines relevant to implementation studies developed by researchers in the Centre for Implementation Science at King’s College London and King’s Improvement Science and led by the National Institute for Health Research Applied Research Collaboration South London (NIHR ARC South London) at King’s College Hospital NHS Foundation Trust and supported by King’s Improvement Science.'), ('Record last updated on', 'June 6, 2023')]"
20957,Guiding document analyses in health professions education research,"Mixed methods studies, Qualitative research, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews",Medical education,Whole report, ,"checklist, checklists, curriculum, curriculum maps, DA, document, document analyses, document analysis, documents, education, educational, exam, examination papers, health professions education, HPE, minutes, notes, policies, procedures, reports", ,"Cleland J, MacLeod A, Ellaway RH. CARDA: Guiding document analyses in health professions education research. Med Educ. 2022.","Cleland J, MacLeod A, Ellaway RH.",Medical Education [Med Educ.],2022, , , , ,English, ,36308050,https://pubmed.ncbi.nlm.nih.gov/36308050/, , , , , ,CARDA,Reporting document analysis (DA) research., , , , , , , ,no,2022-11-15 15:34:01,2022-11-15 15:34:01,guiding-document-analyses-in-health-professions-education-research,"[('title', 'Guiding document analyses in health professions education research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting document analysis (DA) research.'), ('Full bibliographic reference', 'Cleland J, MacLeod A, Ellaway RH. CARDA: Guiding document analyses in health professions education research. Med Educ. 2022.'), ('Language', 'English'), ('PubMed ID', '[36308050](https://pubmed.ncbi.nlm.nih.gov/36308050/)'), ('Reporting guideline acronym', 'CARDA'), ('Study design', 'Mixed methods studies, Qualitative research, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Clinical area', 'Medical education'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 15, 2022')]"
20952,Evidence-based statistical analysis and methods in biomedical research (SAMBR) checklists according to design features,"Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,"Data, Statistical methods and analyses", ,"checklist, checklists, clinical trial, clinical trials, diagnosis, diagnostic, meta?analyses, meta?analysis, observation, observational, prediction, predictive, prognosis, prognostic, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, review, reviews, SAMBR, SAMBR checklist, SAMBR checklists, SAMBR guidance, statistical, statistical analyses, statistical analysis, statistical method, statistical methods, statistics, study design, systematic review, systematic reviews, trial, trials", ,"Dwivedi AK, Shukla R. Evidence-based statistical analysis and methods in biomedical research (SAMBR) checklists according to design features. Cancer Rep (Hoboken). 2020;3(4):e1211.","Dwivedi AK, Shukla R.","Cancer Reports (Hoboken, N.J.) [Cancer Rep (Hoboken)]",2020,3,4,e1211, ,English, ,32794640,https://pubmed.ncbi.nlm.nih.gov/32794640/, , , , , ,SAMBR,Reporting statistical analysis and methods in biomedical research., , , , , , , ,no,2022-11-11 11:06:09,2022-11-11 11:06:09,evidence-based-statistical-analysis-and-methods-in-biomedical-research-sambr-checklists-according-to-design-features,"[('title', 'Evidence-based statistical analysis and methods in biomedical research (SAMBR) checklists according to design features'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting statistical analysis and methods in biomedical research.'), ('Full bibliographic reference', 'Dwivedi AK, Shukla R. Evidence-based statistical analysis and methods in biomedical research (SAMBR) checklists according to design features. Cancer Rep (Hoboken). 2020;3(4):e1211.'), ('Language', 'English'), ('PubMed ID', '[32794640](https://pubmed.ncbi.nlm.nih.gov/32794640/)'), ('Reporting guideline acronym', 'SAMBR'), ('Study design', 'Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Data, Statistical methods and analyses'), ('Record last updated on', 'November 11, 2022')]"
20947,Social Accountability Reporting for Research (SAR4Research): checklist to strengthen reporting on studies on social accountability in the literature,"Mixed methods studies, Observational studies, Qualitative research", ,Whole report, ,"accountability, checklist, checklists, evaluation, evaluations, health programming, mixed methods, observational, participatory, participatory research, SA, SAR4Research, SAR4Research checklist, social, social accountability, social accountability evaluation, Social Accountability Reporting for Research checklist for health programming", ,"Kraft JM, Paina L, Boydell V, Elnakib S, Sihotang A, Bailey A, Tolmie C. Social Accountability Reporting for Research (SAR4Research): checklist to strengthen reporting on studies on social accountability in the literature. Int J Equity Health. 2022;21(Suppl 1):121.","Kraft JM, Paina L, Boydell V, Elnakib S, Sihotang A, Bailey A, Tolmie C.",International Journal for Equity in Health [Int J Equity Health.],2022,21,1,121, ,English, ,36042426,https://pubmed.ncbi.nlm.nih.gov/36042426/, , , , , ,SAR4Research,Reporting of social accountability (SA) intervention evaluations for health programming., , , , , , , ,no,2022-11-03 16:32:17,2022-11-08 14:32:27,social-accountability-reporting-for-research-sar4research-checklist-to-strengthen-reporting-on-studies-on-social-accountability-in-the-literature,"[('title', 'Social Accountability Reporting for Research (SAR 4Research): checklist to strengthen reporting on studies on social accountability in the literature'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of social accountability (SA) intervention evaluations for health programming.'), ('Full bibliographic reference', 'Kraft JM, Paina L, Boydell V, Elnakib S, Sihotang A, Bailey A, Tolmie C. Social Accountability Reporting for Research (SAR4Research): checklist to strengthen reporting on studies on social accountability in the literature. Int J Equity Health. 2022;21(Suppl 1):121.'), ('Language', 'English'), ('PubMed ID', '[36042426](https://pubmed.ncbi.nlm.nih.gov/36042426/)'), ('Reporting guideline acronym', 'SAR4Research'), ('Study design', 'Mixed methods studies, Observational studies, Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 8, 2022')]"
20943,How to Report Data on Bilateral Procedures and Other Issues with Clustered Data: The CLUDA Reporting Guidelines,Observational studies,Surgery,"Data, Narrative sections (discussion etc.), Results, Statistical methods and analyses", ,"bilateral, checklist, checklists, CLUDA, CLUDA checklist, CLUDA guidelines, cluster, clustered, clustering, data, observational, observational studies, observational study, plastic, plastic surgery, statistical, statistics, surgery, surgical", ,"Hemmingsen MN, Nygaard CMT, Kaufmann A, Weltz TK, Larsen A, Forman JL, Wiberg S, Vester-Glowinski P, \xd8rholt M, Herly M. How to Report Data on Bilateral Procedures and Other Issues with Clustered Data: The CLUDA Reporting Guidelines. Plast Reconstr Surg. 2022;150(2):459-464.","Hemmingsen MN, Nygaard CMT, Kaufmann A, Weltz TK, Larsen A, Forman JL, Wiberg S, Vester-Glowinski P, \xd8rholt M, Herly M.",Plastic and Reconstructive Surgery [Plast Reconstr Surg.],2022,150,2,459-464, ,English, ,35687407,https://pubmed.ncbi.nlm.nih.gov/35687407/, , , , , ,CLUDA,Reporting of clustered data from patients undergoing bilateral procedures in plastic surgery., , , , , , , ,no,2022-11-03 15:55:36,2022-11-03 15:55:36,how-to-report-data-on-bilateral-procedures-and-other-issues-with-clustered-data-the-cluda-reporting-guidelines,"[('title', 'How to Report Data on Bilateral Procedures and Other Issues with Clustered Data: The CLUDA Reporting Guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of clustered data from patients undergoing bilateral procedures in plastic surgery.'), ('Full bibliographic reference', 'Hemmingsen MN, Nygaard CMT, Kaufmann A, Weltz TK, Larsen A, Forman JL, Wiberg S, Vester-Glowinski P, Ørholt M, Herly M. How to Report Data on Bilateral Procedures and Other Issues with Clustered Data: The CLUDA Reporting Guidelines. Plast Reconstr Surg. 2022;150(2):459-464.'), ('Language', 'English'), ('PubMed ID', '[35687407](https://pubmed.ncbi.nlm.nih.gov/35687407/)'), ('Reporting guideline acronym', 'CLUDA'), ('Study design', 'Observational studies'), ('Clinical area', 'Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Data, Narrative sections (discussion etc.), Results, Statistical methods and analyses'), ('Record last updated on', 'November 3, 2022')]"
20941,Best practice guidance and reporting items for the development of scoping review protocols,"Study protocols, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,Protocol-whole report, ,"checklist, checklists, evidence syntheses, evidence synthesis, mapping, mapping review, mapping reviews, protocol, protocols, review, reviews, scoping, scoping review, scoping reviews, systematic review, systematic reviews", ,"Peters MDJ, Godfrey C, McInerney P, Khalil H, Larsen P, Marnie C, Pollock D, Tricco AC, Munn Z. Best practice guidance and reporting items for the development of scoping review protocols. JBI Evid Synth. 2022;20(4):953-968.","Peters MDJ, Godfrey C, McInerney P, Khalil H, Larsen P, Marnie C, Pollock D, Tricco AC, Munn Z.",JBI Evidence Synthesis [JBI Evid Synth.],2022,20,4,953-968, ,English, ,35102103,https://pubmed.ncbi.nlm.nih.gov/35102103/, , , , , , ,Reporting scoping review protocols., , , , , , , ,no,2022-11-03 14:43:25,2022-11-03 14:43:25,best-practice-guidance-and-reporting-items-for-the-development-of-scoping-review-protocols,"[('title', 'Best practice guidance and reporting items for the development of scoping review protocols'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting scoping review protocols.'), ('Full bibliographic reference', 'Peters MDJ, Godfrey C, McInerney P, Khalil H, Larsen P, Marnie C, Pollock D, Tricco AC, Munn Z. Best practice guidance and reporting items for the development of scoping review protocols. JBI Evid Synth. 2022;20(4):953-968.'), ('Language', 'English'), ('PubMed ID', '[35102103](https://pubmed.ncbi.nlm.nih.gov/35102103/)'), ('Study design', 'Study protocols, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Protocol-whole report'), ('Record last updated on', 'November 3, 2022')]"
20939,Establishing reporting standards for participant characteristics in post-stroke aphasia research: An international e-Delphi exercise and consensus meeting,"Clinical trials, Experimental studies, Observational studies, Qualitative research","Neurology, Rehabilitation medicine",Study characteristics (participants etc.), ,"aphasia, characteristic, characteristics, checklist, checklists, clinical trial, clinical trials, DESCRIBE, DESCRIBE checklist, language, neurological, neurology, observational, participant, participant characteristic, participant characteristics, participants, patient, patients, post-stroke, qualitative, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, speech, stroke, trial, trials", ,"Wallace SJ, Isaacs M, Ali M, Brady MC. Establishing reporting standards for participant characteristics in post-stroke aphasia research: An international e-Delphi exercise and consensus meeting. Clin Rehabil. 2022:2692155221131241.","Wallace SJ, Isaacs M, Ali M, Brady MC.",Clinical Rehabilitation [Clin Rehabil.],2022, , , , ,English, ,36250530,https://pubmed.ncbi.nlm.nih.gov/36250530/,The checklist can be downloaded from the DESCRIBE web page., , , ,https://www.aphasiatrials.org/describe/,DESCRIBE,Reporting of participant characteristics in post-stroke aphasia research studies., , , , , , , ,no,2022-11-03 13:40:03,2022-11-03 13:51:10,establishing-reporting-standards-for-participant-characteristics-in-post-stroke-aphasia-research-an-international-e-delphi-exercise-and-consensus-meeting,"[('title', 'Establishing reporting standards for participant characteristics in post-stroke aphasia research: An international e -Delphi exercise and consensus meeting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of participant characteristics in post-stroke aphasia research studies.'), ('Full bibliographic reference', 'Wallace SJ, Isaacs M, Ali M, Brady MC. Establishing reporting standards for participant characteristics in post-stroke aphasia research: An international e-Delphi exercise and consensus meeting. Clin Rehabil. 2022:2692155221131241.'), ('Language', 'English'), ('PubMed ID', '[36250530](https://pubmed.ncbi.nlm.nih.gov/36250530/)'), ('Relevant URLs\n\n(full-text if available)', 'The checklist can be downloaded from the [DESCRIBE web page](https://www.aphasiatrials.org/describe/).'), ('Reporting guideline website URL', '<https://www.aphasiatrials.org/describe/>'), ('Reporting guideline acronym', 'DESCRIBE'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Qualitative research'), ('Clinical area', 'Neurology, Rehabilitation medicine'), ('Applies to the whole report or to individual sections of the report?', 'Study characteristics (participants etc.)'), ('Record last updated on', 'November 3, 2022')]"
20926,STARTER Checklist for Antimalarial Therapeutic Efficacy Reporting,"Clinical trials, Experimental studies","Infectious diseases, Tropical medicine","Data, Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)", ,"antimalarial, antimalarials, checklist, checklists, clinical trial, clinical trials, malaria, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trials, ransomized trial, Standardized Antimalarial Therapeutic Efficacy Reporting Checklist, STARTER, STARTER checklist, trial, trials", ,"Plucinski MM, Ashley EA, Bassat Q, Venkatesan M, Rosenthal PJ, Halsey ES. STARTER Checklist for Antimalarial Therapeutic Efficacy Reporting.

This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.

Am J Trop Med Hyg. 2022;107(1):1-3. PMID: 35880678
Malar J. 2022 Jun 13;21(1):187. PMID: 35698123

","Plucinski MM, Ashley EA, Bassat Q, Venkatesan M, Rosenthal PJ, Halsey ES.", , , , , , ,English, , , , , , , , ,STARTER,Reporting the results of antimalarial efficacy studies., , , , , , , ,no,2022-10-28 11:03:27,2022-11-03 13:55:10,starter-checklist-for-antimalarial-therapeutic-efficacy-reporting,"[('title', 'STARTER Checklist for Antimalarial Therapeutic Efficacy Reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the results of antimalarial efficacy studies.'), ('Full bibliographic reference', 'Plucinski MM, Ashley EA, Bassat Q, Venkatesan M, Rosenthal PJ, Halsey ES. STARTER Checklist for Antimalarial Therapeutic Efficacy Reporting.\n\n \n\n This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.\n\n \n\n Am J Trop Med Hyg. 2022;107(1):1-3. PMID: [35880678](https://pubmed.ncbi.nlm.nih.gov/35880678/)\n\n Malar J. 2022 Jun 13;21(1):187. PMID: [35698123](https://pubmed.ncbi.nlm.nih.gov/35698123/)\n\n \n\n'), ('Language', 'English'), ('Reporting guideline acronym', 'STARTER'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Infectious diseases, Tropical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'November 3, 2022')]"
20922,Best Practice in the chemical characterisation of extracts used in pharmacological and toxicological research-The ConPhyMP-Guidelines,"Clinical trials, Experimental studies","Complementary and alternative medicine, Pharmaceutical medicine, Toxicology","Harms/adverse effects/safety data, Intervention (exposure), Terminology/definitions", ,"active ingredient, active ingredients, bioactive herbal preparation, bioactive herbal preparations, botanical, clinical trial, clinical trials, ConPhyMP, Consensus statement on the Phytochemical Characterisation of Medicinal Plant extracts, drug, drugs, ethnopharmacology, herbal extract, herbal extracts, herbal medicine, herbal medicines, medicinal, medicinal plant, medicinal plant extracts, natural health products, natural product, natural products, pharmacokinetics, pharmacological, pharmacology, phytochemical, phytomedicine, phytopharmacological, phytotherapy, plant, plant extract, plant extracts, plants, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, toxicity, toxicology, trial, trials", ,"Heinrich M, Jalil B, Abdel-Tawab M, Echeverria J, Kuli? ?, McGaw LJ, Pezzuto JM, Potterat O, Wang JB. Best Practice in the chemical characterisation of extracts used in pharmacological and toxicological research-The ConPhyMP-Guidelines. Front Pharmacol. 2022;13:953205.","Heinrich M, Jalil B, Abdel-Tawab M, Echeverria J, Kuli? ?, McGaw LJ, Pezzuto JM, Potterat O, Wang JB.",Frontiers in Pharmacology [Front Pharmacol.],2022,13, ,953205, ,English, ,36176427,https://pubmed.ncbi.nlm.nih.gov/36176427/,Read the full-text of the ConPhyMP reporting guideline., , , , ,ConPhyMP,"Reporting the chemical composition of medicinal plant extracts used in pharmacological, toxicological and clinical research studies.", ,"An online fillable open-access ConPhyMP tool is also available via the GA (Society of Medicinal Plants and Natural Products Research) website at https://ga-online.org/best-practice/

", , , , , ,no,2022-10-27 16:28:36,2023-08-16 15:24:12,best-practice-in-the-chemical-characterisation-of-extracts-used-in-pharmacological-and-toxicological-research-the-conphymp-guidelines,"[('title', 'Best Practice in the chemical characterisation of extracts used in pharmacological and toxicological research -The ConPhy MP-Guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the chemical composition of medicinal plant extracts used in pharmacological, toxicological and clinical research studies.'), ('Full bibliographic reference', 'Heinrich M, Jalil B, Abdel-Tawab M, Echeverria J, Kulić Ž, McGaw LJ, Pezzuto JM, Potterat O, Wang JB. Best Practice in the chemical characterisation of extracts used in pharmacological and toxicological research-The ConPhyMP-Guidelines. Front Pharmacol. 2022;13:953205.'), ('Language', 'English'), ('PubMed ID', '[36176427](https://pubmed.ncbi.nlm.nih.gov/36176427/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.frontiersin.org/articles/10.3389/fphar.2022.953205/full) of the ConPhyMP reporting guideline.'), ('Reporting guideline acronym', 'ConPhyMP'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Complementary and alternative medicine, Pharmaceutical medicine, Toxicology'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Terminology/definitions'), ('Additional information', 'An online fillable open-access ConPhyMP tool is also available via the GA (Society of Medicinal Plants and Natural Products Research) website at [https://ga-online.org/best-practice/](https://ga-online.org/best-practice/ ""https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fga-online.org%2Fbest-practice%2F&data=05%7C01%7Cb.jalil%40ucl.ac.uk%7C7eb2e429ba984150554208db9dc7299d%7C1faf88fea9984c5b93c9210a11d9a5c2%7C0%7C0%7C638277250964198929%7CUnknown%7CTWFpbGZsb3"")\n\n \n\n'), ('Record last updated on', 'August 16, 2023')]"
20920,Advising on Preferred Reporting Items for patient-reported outcome instrument development: the PRIPROID,"Clinical trials, Experimental studies, Observational studies, Qualitative research", ,Whole report, ,"checklist, checklists, clinical trial, clinical trials, instrument, instrument development, interview, interviews, measurement, observation, observational, outcome, outcomes, patient, patient-reported outcome, patient-reported outcomes, patients, Preferred Reporting Items for PRO Instrument Development, PRIPROID, PRO, qualitative, quality of life, questionnaire, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, scale, scales, score, scores, trial, trials", ,"Hou ZK, Liu FB, Fang JQ, Li XY, Li LJ, Lin CH. Advising on Preferred Reporting Items for patient-reported outcome instrument development: the PRIPROID. Chin J Integr Med. 2013;19(3):172-81.","Hou ZK, Liu FB, Fang JQ, Li XY, Li LJ, Lin CH.",Chinese Journal of Integrative Medicine [Chin J Integr Med.],2013,19,3,172-81, ,English, ,22903443,https://pubmed.ncbi.nlm.nih.gov/22903443/, , , , , ,PRIPROID,Reporting of patient-reported outcomes (PRO) Instrument Development., , , , , , , ,no,2022-10-27 15:36:34,2022-10-27 15:36:34,advising-on-preferred-reporting-items-for-patient-reported-outcome-instrument-development-the-priproid,"[('title', 'Advising on Preferred Reporting Items for patient-reported outcome instrument development: the PRIPROID'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of patient-reported outcomes (PRO) Instrument Development.'), ('Full bibliographic reference', 'Hou ZK, Liu FB, Fang JQ, Li XY, Li LJ, Lin CH. Advising on Preferred Reporting Items for patient-reported outcome instrument development: the PRIPROID. Chin J Integr Med. 2013;19(3):172-81.'), ('Language', 'English'), ('PubMed ID', '[22903443](https://pubmed.ncbi.nlm.nih.gov/22903443/)'), ('Reporting guideline acronym', 'PRIPROID'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 27, 2022')]"
20917,Recommendations for reporting the results of studies of instrument and scale development and testing,"Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies, Qualitative research, Reliability and agreement studies", ,Whole report, ,"classification, classifications, clinical trial, clinical trials, diagnostic accuracy, diagnostic test, diagnostic tests, instrument, instrument development, instrument validation, instrument validation studies, instrument validation study, instruments, measurement, measurements, observation, observational, psychometric, psychometric test, psychometric testing, psychometric tests, qualitative, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, reliability, reliability and agreement, scale, scales, score, scoring, trial, trials, validity", ,"Streiner DL, Kottner J. Recommendations for reporting the results of studies of instrument and scale development and testing. J Adv Nurs. 2014;70(9):1970-1979.","Streiner DL, Kottner J.",Journal of Advanced Nursing [ J Adv Nurs.],2014,70,9,1970-1979, ,English, ,24684713,https://pubmed.ncbi.nlm.nih.gov/24684713/,Read the full-text of this reporting guideline., , , , , ,Reporting the results of studies of instrument and scale development and testing., , , , , , , ,no,2022-10-27 10:07:00,2022-10-27 10:07:00,recommendations-for-reporting-the-results-of-studies-of-instrument-and-scale-development-and-testing,"[('title', 'Recommendations for reporting the results of studies of instrument and scale development and testing'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the results of studies of instrument and scale development and testing.'), ('Full bibliographic reference', 'Streiner DL, Kottner J. Recommendations for reporting the results of studies of instrument and scale development and testing. J Adv Nurs. 2014;70(9):1970-1979.'), ('Language', 'English'), ('PubMed ID', '[24684713](https://pubmed.ncbi.nlm.nih.gov/24684713/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://onlinelibrary.wiley.com/doi/10.1111/jan.12402) of this reporting guideline.'), ('Study design', 'Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies, Qualitative research, Reliability and agreement studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 27, 2022')]"
20914,Methodical approaches to determine the rate of radial muscle displacement using tensiomyography: A scoping review and new reporting guideline,"Clinical trials, Experimental studies, Observational studies","Neurology, Sport and exercise medicine, Surgery","Data, Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)", ,"athelete, clinical trial, clinical trials, contraction velocity, electric stimulation, exercise, exercises, exercising, measurement protocol, measurement protocols, mechanomyography, muscle, muscles, neurology, neuromuscular, observation, observational, physical activity, radial, radial displacement, radial muscle displacement, randomised controlled trial, randomised controlled trials, randomised trial, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, resistence training, skeletal, skeletal muscle, sport, surgery, surgical, tensiomyography, TMG, trial, trials", ,"Langen G, Sandau I, Uebersch\xe4r O, Nosaka K, Behringer M. Methodical approaches to determine the rate of radial muscle displacement using tensiomyography: A scoping review and new reporting guideline. J Electromyogr Kinesiol. 2022;67:102702.","Langen G, Sandau I, Uebersch\xe4r O, Nosaka K, Behringer M.",Journal of Electromyography and Kinesiology [J Electromyogr Kinesiol.],2022,67, ,102702, ,English, ,36183503,https://pubmed.ncbi.nlm.nih.gov/36183503/, , , , , , ,Reporting of measurement protocols for determining radial muscle displacement using tensiomyography., , , , , , , ,no,2022-10-21 15:24:33,2022-10-21 15:24:33,methodical-approaches-to-determine-the-rate-of-radial-muscle-displacement-using-tensiomyography-a-scoping-review-and-new-reporting-guideline,"[('title', 'Methodical approaches to determine the rate of radial muscle displacement using tensiomyography: A scoping review and new reporting guideline'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of measurement protocols for determining radial muscle displacement using tensiomyography.'), ('Full bibliographic reference', 'Langen G, Sandau I, Ueberschär O, Nosaka K, Behringer M. Methodical approaches to determine the rate of radial muscle displacement using tensiomyography: A scoping review and new reporting guideline. J Electromyogr Kinesiol. 2022;67:102702.'), ('Language', 'English'), ('PubMed ID', '[36183503](https://pubmed.ncbi.nlm.nih.gov/36183503/)'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Neurology, Sport and exercise medicine, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Data, Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'October 21, 2022')]"
20912,Methods for developing and reporting living evidence synthesis,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Whole report, ,"LE, LE synthesis, living, living evidence, living evidence syntheses, living evidence synthesis, living review, living reviews, living systematic review, LSR, LSRs, review, reviews, syntheses, synthesis, systematic review, systematic reviews", ,"Bendersky J, Auladell-Rispau A, Urr\xfatia G, Rojas-Reyes MX. Methods for developing and reporting living evidence synthesis. J Clin Epidemiol. 2022:S0895-4356(22)00241-4.","Bendersky J, Auladell-Rispau A, Urr\xfatia G, Rojas-Reyes MX.",Journal of Clinical Epidemiology [J Clin Epidemiol.],2022, , , , ,English, ,36220626,https://pubmed.ncbi.nlm.nih.gov/36220626/, , , , , , ,Reporting living evidence (LE) synthesis., , , , , , , ,no,2022-10-21 14:50:58,2022-10-21 14:50:58,methods-for-developing-and-reporting-living-evidence-synthesis,"[('title', 'Methods for developing and reporting living evidence synthesis'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting living evidence (LE) synthesis.'), ('Full bibliographic reference', 'Bendersky J, Auladell-Rispau A, Urrútia G, Rojas-Reyes MX. Methods for developing and reporting living evidence synthesis. J Clin Epidemiol. 2022:S0895-4356(22)00241-4.'), ('Language', 'English'), ('PubMed ID', '[36220626](https://pubmed.ncbi.nlm.nih.gov/36220626/)'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 21, 2022')]"
20909,Bayesian Analysis Reporting Guidelines, , ,Statistical methods and analyses, ,"BARG, Bayes, Bayesian, bayesian analyses, Bayesian analysis, Bayesian data analyses, Bayesian data analysis, data, statistic, statistical, statistical analyses, statistical analysis, statistics", ,Kruschke JK. Bayesian Analysis Reporting Guidelines. Nat Hum Behav. 2021;5(10):1282-1291.,Kruschke JK.,Nature Human Behaviour [Nat Hum Behav.],2021,5,10,1282-1291, ,English, ,34400814,https://pubmed.ncbi.nlm.nih.gov/34400814/, , , , , ,BARG,Reporting Bayesian analyses., , , , , , , ,no,2022-10-12 15:33:01,2022-10-12 15:33:01,bayesian-analysis-reporting-guidelines,"[('title', 'Bayesian Analysis Reporting Guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting Bayesian analyses.'), ('Full bibliographic reference', 'Kruschke JK. Bayesian Analysis Reporting Guidelines. Nat Hum Behav. 2021;5(10):1282-1291.'), ('Language', 'English'), ('PubMed ID', '[34400814](https://pubmed.ncbi.nlm.nih.gov/34400814/)'), ('Reporting guideline acronym', 'BARG'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Record last updated on', 'October 12, 2022')]"
20901,Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Whole report, ,"healthcare intervention, healthcare interventions, intervention, interventions, overview, overview of systematic reviews, overviews, overviews of reviews, PRIOR, PRIOR Statement, review of reviews, review of systematic reviews, umbrella review", ,"Gates M, Gates A, Pieper D, Fernandes RM, Tricco AC, Moher D, Brennan SE, Li T, Pollock M, Lunny C, Sep\xfalveda D, McKenzie JE, Scott SD, Robinson KA, Matthias K, Bougioukas KI, Fusar-Poli P, Whiting P, Moss SJ, Hartling L. Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement. BMJ. 2022.","Gates M, Gates A, Pieper D, Fernandes RM, Tricco AC, Moher D, Brennan SE, Li T, Pollock M, Lunny C, Sep\xfalveda D, McKenzie JE, Scott SD, Robinson KA, Matthias K, Bougioukas KI, Fusar-Poli P, Whiting P, Moss SJ, Hartling L.",British Medical Journal [BMJ],2022, , , , ,English, ,35944924,https://pubmed.ncbi.nlm.nih.gov/35944924/,"Read the full-text of the PRIOR Statement.

Read the Prior Statement Explanation and Elaboration document (PDF).

Access the PRIOR Checklist (PDF).

", , , , ,PRIOR,Reporting overviews of reviews of healthcare interventions., ,Read the protocol for the development of the PRIOR Statement., , , , , ,no,2022-09-29 10:32:25,2022-09-29 10:35:57,reporting-guideline-for-overviews-of-reviews-of-healthcare-interventions-development-of-the-prior-statement,"[('title', 'Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting overviews of reviews of healthcare interventions.'), ('Full bibliographic reference', 'Gates M, Gates A, Pieper D, Fernandes RM, Tricco AC, Moher D, Brennan SE, Li T, Pollock M, Lunny C, Sepúlveda D, McKenzie JE, Scott SD, Robinson KA, Matthias K, Bougioukas KI, Fusar-Poli P, Whiting P, Moss SJ, Hartling L. Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement. BMJ. 2022.'), ('Language', 'English'), ('PubMed ID', '[35944924](https://pubmed.ncbi.nlm.nih.gov/35944924/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.bmj.com/content/378/bmj-2022-070849.long) of the PRIOR Statement.\n\n \n\n[Read the Prior Statement Explanation and Elaboration document (PDF)](https://www.bmj.com/highwire/filestream/1072600/field_highwire_adjunct_files/1/gatm070849.ww2.pdf).\n\n \n\n[Access the PRIOR Checklist (PDF)](https://www.bmj.com/content/bmj/suppl/2022/08/09/bmj-2022-070849.DC1/gatm070849.ww3.pdf).\n\n \n\n'), ('Reporting guideline acronym', 'PRIOR'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', '[Read the protocol](https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-019-1252-9) for the development of the PRIOR Statement.'), ('Record last updated on', 'September 29, 2022')]"
20890,The DoCTRINE Guidelines: Defined Criteria To Report INnovations in Education,"Clinical trials, Experimental studies, Observational studies, Qualitative research",Medical education,Whole report, ,"curricula, curriculum, Defined Criteria To Report INnovations in Education, DoCTRINE, DoCTRINE checklist, education, educational, health professional education, health professions education, innovation, innovations, innovations in education, medical education, observational studies, observational study, qualitative, qualitative studies, qualitative study, trial, trials", ,"Blanco M, Prunuske J, DiCorcia M, Learman LA, Mutcheson B, Huang GC. The DoCTRINE Guidelines: Defined Criteria To Report INnovations in Education. Acad Med. 2022;97(5):689-695.","Blanco M, Prunuske J, DiCorcia M, Learman LA, Mutcheson B, Huang GC.",Academic Medicine [Acad Med.],2022,97,5,689-695, ,English, ,35171122,https://pubmed.ncbi.nlm.nih.gov/35171122/, , , , , ,DoCTRINE,"Reporting of educational innovations in curriculum development.



DoCTRINE Checklist (Word)

", , , , , , , ,no,2022-09-15 16:27:24,2023-01-24 11:13:52,the-doctrine-guidelines-defined-criteria-to-report-innovations-in-education,"[('title', 'The Do CTRINE Guidelines: Defined Criteria To Report INnovations in Education'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of educational innovations in curriculum development.\n\n \n\n \xa0\n\n \n\n[DoCTRINE Checklist (Word)](https://www.equator-network.org/wp-content/uploads/2022/09/DoCTRINE-Guideline-Checklist.docx)\n\n \n\n'), ('Full bibliographic reference', 'Blanco M, Prunuske J, DiCorcia M, Learman LA, Mutcheson B, Huang GC. The DoCTRINE Guidelines: Defined Criteria To Report INnovations in Education. Acad Med. 2022;97(5):689-695.'), ('Language', 'English'), ('PubMed ID', '[35171122](https://pubmed.ncbi.nlm.nih.gov/35171122/)'), ('Reporting guideline acronym', 'DoCTRINE'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Qualitative research'), ('Clinical area', 'Medical education'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 24, 2023')]"
20883,"Development of guidelines to reduce, handle and report missing data in palliative care trials: A multi-stakeholder modified nominal group technique","Clinical trials, Experimental studies","Oncology, Palliative care","Data, Narrative sections (discussion etc.), Results, Statistical methods and analyses", ,"cancer, clinical trial, data, lost to follow up, missing data, oncology, palliative, palliative care, palliative medicine, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Hussain JA, White IR, Johnson MJ, Byrne A, Preston NJ, Haines A, Seddon K, Peters TJ. Development of guidelines to reduce, handle and report missing data in palliative care trials: A multi-stakeholder modified nominal group technique. Palliat Med. 2022;36(1):59-70.","Hussain JA, White IR, Johnson MJ, Byrne A, Preston NJ, Haines A, Seddon K, Peters TJ.",Palliative Medicine [Palliat Med.],2022,36,1,59-70, ,English, ,35034529,https://pubmed.ncbi.nlm.nih.gov/35034529/,"Further details about and explanations of the 12 reporting items can be found in the report: Missing data in palliative and end of life care trials Guidance on how to reduce, handle and report incomplete data (PDF) (please see pages 42-49).

", , , , , ,Reporting of missing data in palliative care clinical trials., , , , , , , ,no,2022-09-14 16:31:59,2022-09-14 16:54:24,development-of-guidelines-to-reduce-handle-and-report-missing-data-in-palliative-care-trials-a-multi-stakeholder-modified-nominal-group-technique,"[('title', 'Development of guidelines to reduce, handle and report missing data in palliative care trials: A multi-stakeholder modified nominal group technique'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of missing data in palliative care clinical trials.'), ('Full bibliographic reference', 'Hussain JA, White IR, Johnson MJ, Byrne A, Preston NJ, Haines A, Seddon K, Peters TJ. Development of guidelines to reduce, handle and report missing data in palliative care trials: A multi-stakeholder modified nominal group technique. Palliat Med. 2022;36(1):59-70.'), ('Language', 'English'), ('PubMed ID', '[35034529](https://pubmed.ncbi.nlm.nih.gov/35034529/)'), ('Relevant URLs\n\n(full-text if available)', 'Further details about and explanations of the 12 reporting items can be found in the report: [Missing data in palliative and end of life care trials Guidance on how to reduce, handle and report incomplete data (PDF)](https://www.mariecurie.org.uk/globalassets/media/documents/research/Missing-Guidance-Report-final-June-2022.pdf) (please see pages 42-49).\n\n \n\n'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Oncology, Palliative care'), ('Applies to the whole report or to individual sections of the report?', 'Data, Narrative sections (discussion etc.), Results, Statistical methods and analyses'), ('Record last updated on', 'September 14, 2022')]"
20872,The RIPI-f (Reporting Integrity of Psychological Interventions delivered face-to-face) checklist was developed to guide reporting of treatment integrity in face-to-face psychological interventions,"Clinical trials, Experimental studies, Observational studies",Psychology,Intervention (exposure), ,"behavioral, behavioural, checklist, checklists, clinical trial, clinical trials, cognitive, emotional, face-to-face, face-to-face psychological intervention, intervention, intervention integrity, interventions, observational studies, observational study, psychological, psychology, psychotherapy, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, RIPI-f, RIPI-f checklist, trial, trials", ,"Lopez-Alcalde J, Yakoub N, Wolf M, Munder T, von Elm E, Fl\xfcckiger C, Steinert C, Liebherz S, Rosendahl J, Witt CM, Barth J. The RIPI-f (Reporting Integrity of Psychological Interventions delivered face-to-face) checklist was developed to guide reporting of treatment integrity in face-to-face psychological interventions. J Clin Epidemiol. 2022;151:65-74.","Lopez-Alcalde J, Yakoub N, Wolf M, Munder T, von Elm E, Fl\xfcckiger C, Steinert C, Liebherz S, Rosendahl J, Witt CM, Barth J.",Journal of Clinical Epidemiology [J Clin Epidemiol.],2022,151, ,65-74, ,English, ,35926822,https://pubmed.ncbi.nlm.nih.gov/35926822/, , , , , ,RIPI-f,Reporting intervention integrity in evaluative studies of face-to-face psychological interventions., , , , , , , ,no,2022-09-13 16:33:49,2022-09-13 16:33:49,the-ripi-f-reporting-integrity-of-psychological-interventions-delivered-face-to-face-checklist-was-developed-to-guide-reporting-of-treatment-integrity-in-face-to-face-psychological-interventions,"[('title', 'The RIPI-f  (Reporting Integrity of Psychological Interventions delivered face-to-face) checklist was developed to guide reporting of treatment integrity in face-to-face psychological interventions'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting intervention integrity in evaluative studies of face-to-face psychological interventions.'), ('Full bibliographic reference', 'Lopez-Alcalde J, Yakoub N, Wolf M, Munder T, von Elm E, Flückiger C, Steinert C, Liebherz S, Rosendahl J, Witt CM, Barth J. The RIPI-f (Reporting Integrity of Psychological Interventions delivered face-to-face) checklist was developed to guide reporting of treatment integrity in face-to-face psychological interventions. J Clin Epidemiol. 2022;151:65-74.'), ('Language', 'English'), ('PubMed ID', '[35926822](https://pubmed.ncbi.nlm.nih.gov/35926822/)'), ('Reporting guideline acronym', 'RIPI-f'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'September 13, 2022')]"
20868,The Intraoperative Complications Assessment and Reporting with Universal Standards (ICARUS) Global Surgical Collaboration Project: Development of Criteria for Reporting Adverse Events During Surgical Procedures and Evaluating Their Impact on the Postoperative Course,"Clinical trials, Experimental studies, Observational studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews","Anaesthesia, Surgery",Harms/adverse effects/safety data, ,"adverse event, adverse events, anesthesiologic complications, anesthesiologist, anesthesiologists, clinical trial, clinical trials, iAEs, ICARUS, ICARUS criteria, ICARUS Global Collaboration criteria, intraoperative, intraoperative adverse event, intraoperative complications, Intraoperative Complications Assessment and Reporting with Universal Standards (ICARUS) Global Surgical Collaboration criteria, observational studies, observational study, postoperative, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, review, reviews, surgeon, surgeons, surgery, surgical, surgical complications, systematic review, trial, trials", ,"Cacciamani GE, Sholklapper T, Dell'Oglio P, Rocco B, Annino F, Antonelli A, Amenta M, Borghesi M, Bove P, Bozzini G, Cafarelli A, Celia A, Leonardo C, Ceruti C, Cindolo L, Crivellaro S, Dalpiaz O, Falabella R, Falsaperla M, Galfano A, Gallo F, Greco F, Minervini A, Parma P, Chiara Sighinolfi M, Pastore AL, Pini G, Porreca A, Pucci L, Sciorio C, Schiavina R, Umari P, Varca V, Veneziano D, Verze P, Volpe A, Zaramella S, Lebastchi A, Abreu A, Mitropoulos D, Shekhar Biyani C, Sotelo R, Desai M, Artibani W, Gill I; ICARUS Global Surgical Collaboration Working Group. The Intraoperative Complications Assessment and Reporting with Universal Standards (ICARUS) Global Surgical Collaboration Project: Development of Criteria for Reporting Adverse Events During Surgical Procedures and Evaluating Their Impact on the Postoperative Course. Eur Urol Focus. 2022:S2405-4569(22)00039-6.","Cacciamani GE, Sholklapper T, Dell'Oglio P, Rocco B, Annino F, Antonelli A, Amenta M, Borghesi M, Bove P, Bozzini G, Cafarelli A, Celia A, Leonardo C, Ceruti C, Cindolo L, Crivellaro S, Dalpiaz O, Falabella R, Falsaperla M, Galfano A, Gallo F, Greco F, Minervini A, Parma P, Chiara Sighinolfi M, Pastore AL, Pini G, Porreca A, Pucci L, Sciorio C, Schiavina R, Umari P, Varca V, Veneziano D, Verze P, Volpe A, Zaramella S, Lebastchi A, Abreu A, Mitropoulos D, Shekhar Biyani C, Sotelo R, Desai M, Artibani W, Gill I; ICARUS Global Surgical Collaboration Working Group.",European Urology Focus. [Eur Urol Focus.],2022, , , , ,English, ,35177353,https://pubmed.ncbi.nlm.nih.gov/35177353/, , , , , ,ICARUS,"Reporting of intraoperative adverse events (iAEs).



ICARUS checklist (Word) \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 ICARUS checklist (PDF)

", , , , , , , ,no,2022-09-13 14:12:26,2022-09-16 15:05:45,the-intraoperative-complications-assessment-and-reporting-with-universal-standards-icarus-global-surgical-collaboration-project-development-of-criteria-for-reporting-adverse-events-during-surgical,"[('title', 'The Intraoperative Complications Assessment and Reporting with Universal Standards (ICARUS) Global Surgical Collaboration Project: Development of Criteria for Reporting Adverse Events During Surgical Procedures and Evaluating Their Impact on the Postoperative Course'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of intraoperative adverse events (iAEs).\n\n \n\n \xa0\n\n \n\n[ICARUS checklist (Word)](https://www.equator-network.org/wp-content/uploads/2022/09/ICARUS-checklist.docx)  [ICARUS checklist (PDF)](https://www.equator-network.org/wp-content/uploads/2022/09/ICARUS-checklist.pdf)\n\n \n\n'), ('Full bibliographic reference', ""Cacciamani GE, Sholklapper T, Dell'Oglio P, Rocco B, Annino F, Antonelli A, Amenta M, Borghesi M, Bove P, Bozzini G, Cafarelli A, Celia A, Leonardo C, Ceruti C, Cindolo L, Crivellaro S, Dalpiaz O, Falabella R, Falsaperla M, Galfano A, Gallo F, Greco F, Minervini A, Parma P, Chiara Sighinolfi M, Pastore AL, Pini G, Porreca A, Pucci L, Sciorio C, Schiavina R, Umari P, Varca V, Veneziano D, Verze P, Volpe A, Zaramella S, Lebastchi A, Abreu A, Mitropoulos D, Shekhar Biyani C, Sotelo R, Desai M, Artibani W, Gill I; ICARUS Global Surgical Collaboration Working Group. The Intraoperative Complications Assessment and Reporting with Universal Standards (ICARUS) Global Surgical Collaboration Project: Development of Criteria for Reporting Adverse Events During Surgical Procedures and Evaluating Their Impact on the Postoperative Course. Eur Urol Focus. 2022:S2405-4569(22)00039-6.""), ('Language', 'English'), ('PubMed ID', '[35177353](https://pubmed.ncbi.nlm.nih.gov/35177353/)'), ('Reporting guideline acronym', 'ICARUS'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Clinical area', 'Anaesthesia, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data'), ('Record last updated on', 'September 16, 2022')]"
20855,CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research,"Clinical trials, Experimental studies, Observational studies", ,"Data, Ethical issues (consent etc.), Statistical methods and analyses, Terminology/definitions", ,"checklist, checklists, clinical trial, clinical trials, CODE-EHR, CODE-EHR checklist, CODE-EHR framework, CODE-EHR minimum standards framework, CODE-EHR reporting framework, data, EHR system, EHR systems, electronic health-care record, electronic health-care records, health record, health records, health-care data, observational studies, observational study, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, real world data, routine health-care data, structured electronic health-care records, structured electronic healthcare record, structured electronic healthcare records, trial, trials", ,"Kotecha D, Asselbergs FW, Achenbach S, Anker SD, Atar D, Baigent C, Banerjee A, Beger B, Brobert G, Casadei B, Ceccarelli C, Cowie MR, Crea F, Cronin M, Denaxas S, Derix A, Fitzsimons D, Fredriksson M, Gale CP, Gkoutos GV, Goettsch W, Hemingway H, Ingvar M, Jonas A, Kazmierski R, L\xf8gstrup S, Lumbers RT, L\xfcscher TF, McGreavy P, Pi\xf1a IL, Roessig L, Steinbeisser C, Sundgren M, Tyl B, Thiel GV, Bochove KV, Vardas PE, Villanueva T, Vrana M, Weber W, Weidinger F, Windecker S, Wood A, Grobbee DE; Innovative Medicines Initiative BigData@Heart Consortium, European Society of Cardiology, and CODE-EHR International Consensus Group. CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research.

This guideline was published simultaneously in 3 journals. You can read the guideline in any of these journals using the links below.

Lancet Digit Health. 2022:S2589-7500(22)00151-0. PMID: 36050271
Eur Heart J. 2022;43(37):3578-3588. PMID: 36208161
BMJ. 2022;378:e069048. PMID: 36562446

","Kotecha D, Asselbergs FW, Achenbach S, Anker SD, Atar D, Baigent C, Banerjee A, Beger B, Brobert G, Casadei B, Ceccarelli C, Cowie MR, Crea F, Cronin M, Denaxas S, Derix A, Fitzsimons D, Fredriksson M, Gale CP, Gkoutos GV, Goettsch W, Hemingway H, Ingvar M, Jonas A, Kazmierski R, L\xf8gstrup S, Lumbers RT, L\xfcscher TF, McGreavy P, Pi\xf1a IL, Roessig L, Steinbeisser C, Sundgren M, Tyl B, Thiel GV, Bochove KV, Vardas PE, Villanueva T, Vrana M, Weber W, Weidinger F, Windecker S, Wood A, Grobbee DE; Innovative Medicines Initiative BigData@Heart Consortium, European Society of Cardiology, and CODE-EHR International Consensus Group.", ,2022,S2589-7500(22)00151-0, , , ,English, , , , , , , , ,CODE-EHR,"Reporting structured health-care data in research studies.



CODE-EHR checklist (Word) \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 CODE-EHR checklist (PDF)

", , , , , , , ,no,2022-09-09 15:48:22,2023-01-24 11:16:32,code-ehr-best-practice-framework-for-the-use-of-structured-electronic-health-care-records-in-clinical-research,"[('title', 'CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting structured health-care data in research studies.\n\n \n\n \xa0\n\n \n\n[CODE-EHR checklist (Word)](https://www.equator-network.org/wp-content/uploads/2022/09/CODE-EHR-checklist.docx)  [CODE-EHR checklist (PDF)](https://www.equator-network.org/wp-content/uploads/2022/09/CODE-EHR-checklist.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Kotecha D, Asselbergs FW, Achenbach S, Anker SD, Atar D, Baigent C, Banerjee A, Beger B, Brobert G, Casadei B, Ceccarelli C, Cowie MR, Crea F, Cronin M, Denaxas S, Derix A, Fitzsimons D, Fredriksson M, Gale CP, Gkoutos GV, Goettsch W, Hemingway H, Ingvar M, Jonas A, Kazmierski R, Løgstrup S, Lumbers RT, Lüscher TF, McGreavy P, Piña IL, Roessig L, Steinbeisser C, Sundgren M, Tyl B, Thiel GV, Bochove KV, Vardas PE, Villanueva T, Vrana M, Weber W, Weidinger F, Windecker S, Wood A, Grobbee DE; Innovative Medicines Initiative BigData@Heart Consortium, European Society of Cardiology, and CODE-EHR International Consensus Group. CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research.\n\n \n\n This guideline was published simultaneously in 3 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n Lancet Digit Health. 2022:S2589-7500(22)00151-0. PMID: [36050271](https://pubmed.ncbi.nlm.nih.gov/36050271/)\n\n Eur Heart J. 2022;43(37):3578-3588. PMID: [36208161](https://pubmed.ncbi.nlm.nih.gov/36208161/)\n\n BMJ. 2022;378:e069048. PMID: [36562446](https://pubmed.ncbi.nlm.nih.gov/36562446/)\n\n \n\n'), ('Language', 'English'), ('Reporting guideline acronym', 'CODE-EHR'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Data, Ethical issues (consent etc.), Statistical methods and analyses, Terminology/definitions'), ('Record last updated on', 'January 24, 2023')]"
20818,A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist,Clinical practice guidelines, ,Whole report, ,"adapt, adaptation, adapted guideline, adapted guidelines, adopt, adopting, checklist, checklists, clinical practice, clinical practice guideline, clinical practice guidelines, guideline, guidelines, practice guideline, practice guidelines, RIGHT, RIGHT extension, RIGHT Statement, RIGHT-Ad@pt, RIGHT-Ad@pt checklist", ,"Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RWM, Arayssi T, Bhaumik S, Chen Y, Ghersi D, Langlois EV, Fuentes Padilla P, Sch\xfcnemann HJ, Akl EA, Mart\xednez Garc\xeda L; RIGHT-Ad@pt Working Group*, Amer Y, Arevalo-Rodriguez I, Barnes S, Barreto J, Collis D, Dyer S, Fahim C, Florez I, Gallegos-Rivero V, Klugar M, Kuijpers T, Mathew JL, Munn Z, Norris S, Pati\xf1o-Lugo DF, Pramesh CS, Rodriguez J, Roy S, Shin ES, Sosa O, Vandvik PO, Velez M, Woodcraft R; RIGHT-Ad@pt Working Group. A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Ann Intern Med. 2022;175(5):710-719.","Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RWM, Arayssi T, Bhaumik S, Chen Y, Ghersi D, Langlois EV, Fuentes Padilla P, Sch\xfcnemann HJ, Akl EA, Mart\xednez Garc\xeda L; RIGHT-Ad@pt Working Group*, Amer Y, Arevalo-Rodriguez I, Barnes S, Barreto J, Collis D, Dyer S, Fahim C, Florez I, Gallegos-Rivero V, Klugar M, Kuijpers T, Mathew JL, Munn Z, Norris S, Pati\xf1o-Lugo DF, Pramesh CS, Rodriguez J, Roy S, Shin ES, Sosa O, Vandvik PO, Velez M, Woodcraft R; RIGHT-Ad@pt Working Group.",Annals of Internal Medicine [Ann Intern Med.],2022,175,5,710-719, ,English, ,35286143,https://pubmed.ncbi.nlm.nih.gov/35286143/, , , ,"Generic
RIGHT: Chen Y, Yang K, Maru?i? A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Sch\xfcnemann HJ, Chan ESY, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; for the RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group.\xa0 A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166(2):128-132. PMID: 27893062

Specialised
RIGHT-TCM: Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, Xia L, Guo Y. The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Pharmacol Res. 2020;160:105178. PMID: 32889127

RIGHT-PVG: Wang X, Chen Y, Akl EA, Tokali? R, Maru?i? A, Qaseem A, Falck-Ytter Y, Lee MS, Siedler M, Barber SL, Zhang M, Chan ESY, Estill J, Kwong JSW, Okumura A, Zhou Q, Yang K, Norris SL; RIGHT working group. The reporting checklist for public versions of guidelines: RIGHT-PVG. Implement Sci. 2021;16(1):10. PMID: 33430911

RIGHT for Acupuncture: Tang C, Duan Y, Zhang Y, Zhang Y, Chen Z, Tang X, Zeng J, Riley D, Lee MS, Kim YS, Zhao H, Marrone G, Zhu X, Ge S, Wen H, Zhao W, Zheng X, Solos I, Chen Y, Guyatt G, Lu L, Xu N; RIGHT (Reporting Items for Practice Guidelines in Healthcare) for Acupuncture Working Group. RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture. J Clin Epidemiol. 2021:S0895-4356(21)00173-6. PMID: 34091023

RIGHT for INT: Zhou Q, Xing D, Li Q, Zhang J, Luo X, Yang N, Wang X, Yang K, Tian J, Li H, Li B, Cai Y, Jin Y, Lv L, Sun F, Shang S, Yuan B, Li J, Ma B, Li X, Yuan Y, Wu L, Wang B, Jiang L, Wang Z, Chen Y, Liang D. An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT. J Evid Based Med. 2022;15(1):55-63. PMID: 35416438

RIGHT-COI&amp;F: Xun Y, Estill J, Khabsa J, Florez ID, Guyatt GH, Norris SL, Lee MS, Ozaki A, Qaseem A, Sch\xfcnemann HJ, Shao R, Chen Y, Akl EA; RIGHT-COI&amp;F Working Groups. Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI&amp;F Checklist. Ann Intern Med. 2024;177(6):782-790. PMID: 38739919

RIGHT for CPM: Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C. The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. Pharmacol Res. 2024;199:107015. PMID: 38036197

",http://www.right-statement.org/extensions/13,RIGHT-Ad@pt,"Reporting of adapted guidelines (including recommendations that have been adopted, adapted, or developed de novo).", ,"Read the RIGHT-Ad@pt study protocol:

Song Y, Darzi A, Ballesteros M, Mart\xednez Garc\xeda L, Alonso-Coello P, Arayssi T, Bhaumik S, Chen Y, Cluzeau F, Ghersi D, Padilla PF, Langlois EV, Sch\xfcnemann HJ, Vernooij RWM, Akl EA. Extending the RIGHT statement for reporting adapted practice guidelines in healthcare: the RIGHT-Ad@pt Checklist protocol. BMJ Open. 2019;9(9):e031767. PMID: 31551391

", , , , , ,yes,2022-08-01 15:17:45,2024-07-26 15:34:15,a-reporting-tool-for-adapted-guidelines-in-health-care-the-right-adapt-checklist,"[('title', 'A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of adapted guidelines (including recommendations that have been adopted, adapted, or developed de novo).'), ('Full bibliographic reference', 'Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RWM, Arayssi T, Bhaumik S, Chen Y, Ghersi D, Langlois EV, Fuentes Padilla P, Schünemann HJ, Akl EA, Martínez García L; RIGHT-Ad@pt Working Group\\*, Amer Y, Arevalo-Rodriguez I, Barnes S, Barreto J, Collis D, Dyer S, Fahim C, Florez I, Gallegos-Rivero V, Klugar M, Kuijpers T, Mathew JL, Munn Z, Norris S, Patiño-Lugo DF, Pramesh CS, Rodriguez J, Roy S, Shin ES, Sosa O, Vandvik PO, Velez M, Woodcraft R; RIGHT-Ad@pt Working Group. A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Ann Intern Med. 2022;175(5):710-719.'), ('Language', 'English'), ('PubMed ID', '[35286143](https://pubmed.ncbi.nlm.nih.gov/35286143/)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**RIGHT**](https://www.equator-network.org/reporting-guidelines/right-statement/): Chen Y, Yang K, Marušić A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Schünemann HJ, Chan ESY, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; for the RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group.\xa0 A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166(2):128-132. PMID: [27893062](https://www.ncbi.nlm.nih.gov/pubmed/27893062)\n\n \n\n**Specialised**\n\n[**RIGHT-TCM**](https://www.equator-network.org/reporting-guidelines/the-right-extension-statement-for-traditional-chinese-medicine-development-recommendations-and-explanation/): Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, Xia L, Guo Y. The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Pharmacol Res. 2020;160:105178. PMID: [32889127](https://pubmed.ncbi.nlm.nih.gov/32889127)\n\n \n\n[**RIGHT-PVG**](https://www.equator-network.org/reporting-guidelines/the-reporting-checklist-for-public-versions-of-guidelines-right-pvg/): Wang X, Chen Y, Akl EA, Tokalić R, Marušić A, Qaseem A, Falck-Ytter Y, Lee MS, Siedler M, Barber SL, Zhang M, Chan ESY, Estill J, Kwong JSW, Okumura A, Zhou Q, Yang K, Norris SL; RIGHT working group. The reporting checklist for public versions of guidelines: RIGHT-PVG. Implement Sci. 2021;16(1):10. PMID: [33430911](https://pubmed.ncbi.nlm.nih.gov/33430911/)\n\n \n\n[**RIGHT for Acupuncture**](https://www.equator-network.org/reporting-guidelines/right-for-acupuncture/): Tang C, Duan Y, Zhang Y, Zhang Y, Chen Z, Tang X, Zeng J, Riley D, Lee MS, Kim YS, Zhao H, Marrone G, Zhu X, Ge S, Wen H, Zhao W, Zheng X, Solos I, Chen Y, Guyatt G, Lu L, Xu N; RIGHT (Reporting Items for Practice Guidelines in Healthcare) for Acupuncture Working Group. RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture. J Clin Epidemiol. 2021:S0895-4356(21)00173-6. PMID: [34091023](https://pubmed.ncbi.nlm.nih.gov/34091023/)\n\n \n\n[**RIGHT for INT**](https://www.equator-network.org/reporting-guidelines/an-extension-of-the-right-statement-for-introductions-and-interpretations-of-clinical-practice-guidelines-right-for-int/): Zhou Q, Xing D, Li Q, Zhang J, Luo X, Yang N, Wang X, Yang K, Tian J, Li H, Li B, Cai Y, Jin Y, Lv L, Sun F, Shang S, Yuan B, Li J, Ma B, Li X, Yuan Y, Wu L, Wang B, Jiang L, Wang Z, Chen Y, Liang D. An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT. J Evid Based Med. 2022;15(1):55-63. PMID: [35416438](https://pubmed.ncbi.nlm.nih.gov/35416438/)\n\n \n\n[**RIGHT-COI&F**](https://www.equator-network.org/reporting-guidelines/reporting-conflicts-of-interest-and-funding-in-health-care-guidelines-the-right-coif-checklist/): Xun Y, Estill J, Khabsa J, Florez ID, Guyatt GH, Norris SL, Lee MS, Ozaki A, Qaseem A, Schünemann HJ, Shao R, Chen Y, Akl EA; RIGHT-COI&F Working Groups. Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI&F Checklist. Ann Intern Med. 2024;177(6):782-790. PMID: [38739919](https://pubmed.ncbi.nlm.nih.gov/38739919/)\n\n \n\n[**RIGHT for CPM**](https://www.equator-network.org/reporting-guidelines/the-reporting-checklist-for-chinese-patent-medicine-guidelines-right-for-cpm/): Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C. The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. Pharmacol Res. 2024;199:107015. PMID: [38036197](https://pubmed.ncbi.nlm.nih.gov/38036197/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.right-statement.org/extensions/13>'), ('Reporting guideline acronym', 'RIGHT-Ad@pt'), ('Study design', 'Clinical practice guidelines'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Read the RIGHT-Ad@pt study protocol:\n\n \n\n Song Y, Darzi A, Ballesteros M, Martínez García L, Alonso-Coello P, Arayssi T, Bhaumik S, Chen Y, Cluzeau F, Ghersi D, Padilla PF, Langlois EV, Schünemann HJ, Vernooij RWM, Akl EA. Extending the RIGHT statement for reporting adapted practice guidelines in healthcare: the RIGHT-Ad@pt Checklist protocol. BMJ Open. 2019;9(9):e031767. PMID: [31551391](https://pubmed.ncbi.nlm.nih.gov/31551391/)\n\n \n\n'), ('Record last updated on', 'July 26, 2024')]"
20811,Development of a reporting guideline for systematic reviews of animal experiments in the field of traditional Chinese medicine,"Animal pre-clinical research, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,Whole report, ,"animal, animal experiment, animal experiments, animal pre clinical research, animals, checklist, checklists, Chinese herbs, experiment, experimental, experiments, meta analyses, meta analysis, pre clinical animal research, PRISMA-ATCM, systematic review, systematic reviews, TCM, traditional Chinese medicine", ,"Zhao B, Hu K, Zeng X, Kwong JSW, Li B, Chen H, Tian G, Xiong J, Li Z, Niu J, Jiao M, Yang J, Ding F, Liu C, Du L, Zhang J, Ma B. Development of a reporting guideline for systematic reviews of animal experiments in the field of traditional Chinese medicine. J Evid Based Med. 2022.","Zhao B, Hu K, Zeng X, Kwong JSW, Li B, Chen H, Tian G, Xiong J, Li Z, Niu J, Jiao M, Yang J, Ding F, Liu C, Du L, Zhang J, Ma B.",Journal of Evidence Based Medicine [J Evid Based Med.],2022, , , , ,English, ,35775104,https://pubmed.ncbi.nlm.nih.gov/35775104/, , , , , ,PRISMA-ATCM,Reporting of systematic reviews and meta-analysis of animal experiments in the field of Traditional Chinese medicine (TCM)., , , , , , , ,no,2022-07-11 11:37:48,2022-07-11 11:37:48,development-of-a-reporting-guideline-for-systematic-reviews-of-animal-experiments-in-the-field-of-traditional-chinese-medicine,"[('title', 'Development of a reporting guideline for systematic reviews of animal experiments in the field of traditional Chinese medicine'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of systematic reviews and meta-analysis of animal experiments in the field of Traditional Chinese medicine (TCM).'), ('Full bibliographic reference', 'Zhao B, Hu K, Zeng X, Kwong JSW, Li B, Chen H, Tian G, Xiong J, Li Z, Niu J, Jiao M, Yang J, Ding F, Liu C, Du L, Zhang J, Ma B. Development of a reporting guideline for systematic reviews of animal experiments in the field of traditional Chinese medicine. J Evid Based Med. 2022.'), ('Language', 'English'), ('PubMed ID', '[35775104](https://pubmed.ncbi.nlm.nih.gov/35775104/)'), ('Reporting guideline acronym', 'PRISMA-ATCM'), ('Study design', 'Animal pre-clinical research, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'July 11, 2022')]"
20755,TIDieR-telehealth: precision in reporting of telehealth interventions used in clinical trials - unique considerations for the Template for the Intervention Description and Replication (TIDieR) checklist,"Clinical trials, Experimental studies", ,Intervention (exposure), ,"application consolidation contexualisation, checklist, checklists, clinical trial, clinical trials, controlled clinical trial, controlled clinical trials, intervention, interventions, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, remote, remote delivery, remotely, technology, telehealth, telemedicine, telephone, TIDieR, TIDieR-Telehealth, trial, trials, virtual, virtual care", ,"Rhon DI, Fritz JM, Kerns RD, McGeary DD, Coleman BC, Farrokhi S, Burgess DJ, Goertz CM, Taylor SL, Hoffmann T. TIDieR-telehealth: precision in reporting of telehealth interventions used in clinical trials - unique considerations for the Template for the Intervention Description and Replication (TIDieR) checklist. BMC Med Res Methodol. 2022;22(1):161.","Rhon DI, Fritz JM, Kerns RD, McGeary DD, Coleman BC, Farrokhi S, Burgess DJ, Goertz CM, Taylor SL, Hoffmann T.",BMC Medical Research Methodology [BMC Med Res Methodol.],2022,22,1,161, ,English, ,35655144,https://pubmed.ncbi.nlm.nih.gov/35655144/,Read the full-text of TIDieR-Telehealth., , , , ,TIDieR-Telehealth,Reporting of telehealth interventions., , , , , , , ,no,2022-06-06 15:40:28,2022-06-06 15:40:28,tidier-telehealth-precision-in-reporting-of-telehealth-interventions-used-in-clinical-trials-unique-considerations-for-the-template-for-the-intervention-description-and-replication-tidier-checkli,"[('title', 'TIDieR-telehealth : precision in reporting of telehealth interventions used in clinical trials – unique considerations for the Template for the Intervention Description and Replication (TIDieR) checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of telehealth interventions.'), ('Full bibliographic reference', 'Rhon DI, Fritz JM, Kerns RD, McGeary DD, Coleman BC, Farrokhi S, Burgess DJ, Goertz CM, Taylor SL, Hoffmann T. TIDieR-telehealth: precision in reporting of telehealth interventions used in clinical trials - unique considerations for the Template for the Intervention Description and Replication (TIDieR) checklist. BMC Med Res Methodol. 2022;22(1):161.'), ('Language', 'English'), ('PubMed ID', '[35655144](https://pubmed.ncbi.nlm.nih.gov/35655144/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-022-01640-7) of TIDieR-Telehealth.'), ('Reporting guideline acronym', 'TIDieR-Telehealth'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'June 6, 2022')]"
20753,Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: A scoping review and new tool TEN-SPIDERS,"Clinical trials, Experimental studies, Observational studies",Cardiovascular medicine,"Data, Procedure/Method, Statistical methods and analyses", ,"cardiology, cardiovascular, cardiovascular disease, clinical trial, clinical trials, drug, drug utilisation, drug utilization, drugs, heart, medication, medication adherence, medicine, medicines, observational research, observational studies, observational study, PDC, pharmacoepidemiology, pharmacological, pharmacology, proportion of days covered, proportion of days covered method, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, TEN-SPIDERS, trial, trials", ,"Dalli LL, Kilkenny MF, Arnet I, Sanfilippo FM, Cummings DM, Kapral MK, Kim J, Cameron J, Yap KY, Greenland M, Cadilhac DA. Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: A scoping review and new tool TEN-SPIDERS. Br J Clin Pharmacol. 2022.","Dalli LL, Kilkenny MF, Arnet I, Sanfilippo FM, Cummings DM, Kapral MK, Kim J, Cameron J, Yap KY, Greenland M, Cadilhac DA.",British Journal of Clinical Pharmacology [Br J Clin Pharmacol.],2022, , , , ,English, ,35524398,https://pubmed.ncbi.nlm.nih.gov/35524398/,Read the full-text of this reporting guideline., , , , ,TEN-SPIDERS,Reporting of the proportion of days covered (PDC) for cardiovascular medicine adherence studies., ,Visit the TEN-SPIDERS website, , , , , ,no,2022-06-01 16:47:18,2025-06-24 18:57:31,towards-better-reporting-of-the-proportion-of-days-covered-method-in-cardiovascular-medication-adherence-a-scoping-review-and-new-tool-ten-spiders,"[('title', 'Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: A scoping review and new tool TEN-SPIDERS'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of the proportion of days covered (PDC) for cardiovascular medicine adherence studies.'), ('Full bibliographic reference', 'Dalli LL, Kilkenny MF, Arnet I, Sanfilippo FM, Cummings DM, Kapral MK, Kim J, Cameron J, Yap KY, Greenland M, Cadilhac DA. Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: A scoping review and new tool TEN-SPIDERS. Br J Clin Pharmacol. 2022.'), ('Language', 'English'), ('PubMed ID', '[35524398](https://pubmed.ncbi.nlm.nih.gov/35524398/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15391) of this reporting guideline.'), ('Reporting guideline acronym', 'TEN-SPIDERS'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Cardiovascular medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method, Statistical methods and analyses'), ('Additional information', 'Visit the [TEN-SPIDERS website](https://tenspiders.adherencelab.com/home)'), ('Record last updated on', 'June 24, 2025')]"
20751,Murine models of radiation cardiotoxicity: a systematic review and recommendations for future studies,Animal pre-clinical research,"Oncology, Radiology","Harms/adverse effects/safety data, Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)", ,"animal, animal experiment, animal experiments, animal research, animal studies, animal study, cancer, cardiac, cardiotoxicity, experimental parameter, experimental parameters, heart, irradiation, murine, murine model, murine models, oncology, radiation, radiation cardiac toxicity, radiation toxicity, radiobiologist, radiobiologists, radiotherapy", ,"Walls GM, O'Kane R, Ghita M, Kuburas R, McGarry CK, Cole AJ, Jain S, Butterworth KT. Murine models of radiation cardiotoxicity: a systematic review and recommendations for future studies. Radiother Oncol. 2022:S0167-8140(22)00236-5.","Walls GM, O'Kane R, Ghita M, Kuburas R, McGarry CK, Cole AJ, Jain S, Butterworth KT.",Radiotherapy and Oncology [Radiother Oncol.],2022, , ,S0167-8140(22)00236-5, ,English, ,35533784,https://pubmed.ncbi.nlm.nih.gov/35533784/,Read the full-text of this reporting guideline., , , , , ,Reporting of small animal experiments of radiation induced cardiac toxicity., , , , , , , ,no,2022-06-01 15:43:30,2022-06-01 15:43:30,murine-models-of-radiation-cardiotoxicity-a-systematic-review-and-recommendations-for-future-studies,"[('title', 'Murine models of radiation cardiotoxicity: a systematic review and recommendations for future studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of small animal experiments of radiation induced cardiac toxicity.'), ('Full bibliographic reference', ""Walls GM, O'Kane R, Ghita M, Kuburas R, McGarry CK, Cole AJ, Jain S, Butterworth KT. Murine models of radiation cardiotoxicity: a systematic review and recommendations for future studies. Radiother Oncol. 2022:S0167-8140(22)00236-5.""), ('Language', 'English'), ('PubMed ID', '[35533784](https://pubmed.ncbi.nlm.nih.gov/35533784/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.thegreenjournal.com/article/S0167-8140(22)00236-5/fulltext) of this reporting guideline.'), ('Study design', 'Animal pre-clinical research'), ('Clinical area', 'Oncology, Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'June 1, 2022')]"
20749,Systematic Review and Meta-Analysis of Outcomes After Operative Treatment of Aberrant Subclavian Artery Pathologies and Suggested Reporting Items,Observational studies,"Cardiovascular medicine, Surgery","Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)", ,"aberrant subclavian artery, aorta, aortic, aSA, cardiology, cardiovascular, case report, case series, case study, checklist, checklists, endovascular, lusoria, observational, observational studies, observational study, open aortic repair, SILT, SILT checklist, suggested Reporting Items for Lusoria Treatments, surgery, surgical, TEVAR, thoracic endovascular aortic repair", ,"Konstantinou N, Antonopoulos CN, Tzanis K, K\xf6lbel T, Peter\xdf S, Pichlmaier M, Stana J, Tsilimparis N. Systematic Review and Meta-Analysis of Outcomes After Operative Treatment of Aberrant Subclavian Artery Pathologies and Suggested Reporting Items. Eur J Vasc Endovasc Surg. 2022;63(5):759-767.","Konstantinou N, Antonopoulos CN, Tzanis K, K\xf6lbel T, Peter\xdf S, Pichlmaier M, Stana J, Tsilimparis N.",European Journal of Vascular and Endovascular Surgery [Eur J Vasc Endovasc Surg.],2022,63,5,759-767, ,English, ,35459610,https://pubmed.ncbi.nlm.nih.gov/35459610/, , , , , ,SILT,Reporting surgical treatment of aberrant subclavian artery (aSA) pathologies., , , , , , , ,no,2022-05-31 14:25:32,2022-05-31 14:25:32,systematic-review-and-meta-analysis-of-outcomes-after-operative-treatment-of-aberrant-subclavian-artery-pathologies-and-suggested-reporting-items,"[('title', 'Systematic Review and Meta -Analysis of Outcomes After Operative Treatment of Aberrant Subclavian Artery Pathologies and Suggested Reporting Items'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting surgical treatment of aberrant subclavian artery (aSA) pathologies.'), ('Full bibliographic reference', 'Konstantinou N, Antonopoulos CN, Tzanis K, Kölbel T, Peterß S, Pichlmaier M, Stana J, Tsilimparis N. Systematic Review and Meta-Analysis of Outcomes After Operative Treatment of Aberrant Subclavian Artery Pathologies and Suggested Reporting Items. Eur J Vasc Endovasc Surg. 2022;63(5):759-767.'), ('Language', 'English'), ('PubMed ID', '[35459610](https://pubmed.ncbi.nlm.nih.gov/35459610/)'), ('Reporting guideline acronym', 'SILT'), ('Study design', 'Observational studies'), ('Clinical area', 'Cardiovascular medicine, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'May 31, 2022')]"
20747,Reporting standards for psychological network analyses in cross-sectional data,Observational studies,Psychology,"Data, Results, Statistical methods and analyses", ,"cross sectional, cross-sectional data, data, network, network analyses, network analysis, network model, network models, observational, observational studies, observational study, psychological, psychological network analyses, psychological network analysis, psychology, statistical, statistics", ,"Burger J, Isvoranu AM, Lunansky G, Haslbeck JMB, Epskamp S, Hoekstra RHA, Fried EI, Borsboom D, Blanken TF. Reporting standards for psychological network analyses in cross-sectional data. Psychol Methods. 2022.","Burger J, Isvoranu AM, Lunansky G, Haslbeck JMB, Epskamp S, Hoekstra RHA, Fried EI, Borsboom D, Blanken TF.",Psychological Methods [Psychol Methods.],2022, , , , ,English, ,35404629,https://pubmed.ncbi.nlm.nih.gov/35404629/, , , , , , ,Reporting of psychological network analyses., , , , , , , ,no,2022-05-31 12:11:42,2022-05-31 12:11:42,reporting-standards-for-psychological-network-analyses-in-cross-sectional-data,"[('title', 'Reporting standards for psychological network analyses in cross-sectional data'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of psychological network analyses.'), ('Full bibliographic reference', 'Burger J, Isvoranu AM, Lunansky G, Haslbeck JMB, Epskamp S, Hoekstra RHA, Fried EI, Borsboom D, Blanken TF. Reporting standards for psychological network analyses in cross-sectional data. Psychol Methods. 2022.'), ('Language', 'English'), ('PubMed ID', '[35404629](https://pubmed.ncbi.nlm.nih.gov/35404629/)'), ('Study design', 'Observational studies'), ('Clinical area', 'Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Results, Statistical methods and analyses'), ('Record last updated on', 'May 31, 2022')]"
20745,Reporting ChAracteristics of cadaver training and sUrgical studies: The CACTUS guidelines,Observational studies,"Pathology, Surgery","Ethical issues (consent etc.), Procedure/Method", ,"anatomical, anatomy, CACTUS, CACTUS guidelines, cadaver, cadaver model, cadaveric, cadaveric model, cadaveric models, cadavers, corpse, human corpse, human corpses, pathologist, pathologists, simulation, surgeon, surgeons, surgery, surgical, surgical model, surgical models, training model, training models", ,"Mantica G, Leonardi R, Diaz R, Malinaric R, Parodi S, Tappero S, Paraboschi I, \xc1lvarez-Maestro M, Yuen-Chun Teoh J, Garriboli M, Ortega Polledo LE, Soriero D, Pertile D, De Marchi D, Pini G, Rigatti L, Ghosh SK, Onigbinde OA, Tafuri A, Carrion DM, Nikles S, Antoni A, Fransvea P, Esperto F, Herbella FAM, Oxley da Rocha A, Vanaclocha V, S\xe1nchez-Guill\xe9n L, Wainman B, Quiroga-Garza A, Fregatti P, Murelli F, Van der Merwe A, Gomez Rivas J, Terrone C; CACTUS group. Reporting ChAracteristics of cadaver training and sUrgical studies: The CACTUS guidelines. Int J Surg. 2022;101:106619.","Mantica G, Leonardi R, Diaz R, Malinaric R, Parodi S, Tappero S, Paraboschi I, \xc1lvarez-Maestro M, Yuen-Chun Teoh J, Garriboli M, Ortega Polledo LE, Soriero D, Pertile D, De Marchi D, Pini G, Rigatti L, Ghosh SK, Onigbinde OA, Tafuri A, Carrion DM, Nikles S, Antoni A, Fransvea P, Esperto F, Herbella FAM, Oxley da Rocha A, Vanaclocha V, S\xe1nchez-Guill\xe9n L, Wainman B, Quiroga-Garza A, Fregatti P, Murelli F, Van der Merwe A, Gomez Rivas J, Terrone C; CACTUS group.",International Journal of Surgery [Int J Surg.],2022,101, ,106619, ,English, ,35429658,https://pubmed.ncbi.nlm.nih.gov/35429658/, , , , , ,CACTUS,"Reporting of the characteristics of human cadavers in anatomical, surgical, surgical training, and device training studies.", , , , , , , ,no,2022-05-31 11:07:29,2022-05-31 11:07:29,reporting-characteristics-of-cadaver-training-and-surgical-studies-the-cactus-guidelines,"[('title', 'Reporting ChAracteristics of cadaver training and sUrgical studies: The CACTUS guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of the characteristics of human cadavers in anatomical, surgical, surgical training, and device training studies.'), ('Full bibliographic reference', 'Mantica G, Leonardi R, Diaz R, Malinaric R, Parodi S, Tappero S, Paraboschi I, Álvarez-Maestro M, Yuen-Chun Teoh J, Garriboli M, Ortega Polledo LE, Soriero D, Pertile D, De Marchi D, Pini G, Rigatti L, Ghosh SK, Onigbinde OA, Tafuri A, Carrion DM, Nikles S, Antoni A, Fransvea P, Esperto F, Herbella FAM, Oxley da Rocha A, Vanaclocha V, Sánchez-Guillén L, Wainman B, Quiroga-Garza A, Fregatti P, Murelli F, Van der Merwe A, Gomez Rivas J, Terrone C; CACTUS group. Reporting ChAracteristics of cadaver training and sUrgical studies: The CACTUS guidelines. Int J Surg. 2022;101:106619.'), ('Language', 'English'), ('PubMed ID', '[35429658](https://pubmed.ncbi.nlm.nih.gov/35429658/)'), ('Reporting guideline acronym', 'CACTUS'), ('Study design', 'Observational studies'), ('Clinical area', 'Pathology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Ethical issues (consent etc.), Procedure/Method'), ('Record last updated on', 'May 31, 2022')]"
20741,EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology,Diagnostic and prognostic studies,Rheumatology,"Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)", ,"diagnostic, diagnostic studies, diagnostic study, EULAR, rheumatic, rheumatology, ST, ST research, synovial biopsy, synovial tissue, synovial tissue research", ,"Najm A, Costantino F, Alivernini S, Alunno A, Bianchi E, Bignall J, Boyce B, Ca\xf1ete JD, Carubbi F, Durez P, Fonseca JE, Just SA, Largo R, Manzo A, Maybury M, Naredo E, Orr C, Pitzalis C, Rivellese F, Rom\xe3o VC, van Rompay J, Tas SW, Veale DJ, D'Agostino MA, Filer A. EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology. Ann Rheum Dis. 2022:annrheumdis-2021-221875.","Najm A, Costantino F, Alivernini S, Alunno A, Bianchi E, Bignall J, Boyce B, Ca\xf1ete JD, Carubbi F, Durez P, Fonseca JE, Just SA, Largo R, Manzo A, Maybury M, Naredo E, Orr C, Pitzalis C, Rivellese F, Rom\xe3o VC, van Rompay J, Tas SW, Veale DJ, D'Agostino MA, Filer A.",Annals of the Rheumatic Diseases [Ann Rheum Dis.],2022, , , , ,English, ,35210263,https://pubmed.ncbi.nlm.nih.gov/35210263/,Read the full-text of this reporting guideline., , , , , ,Reporting synovial tissue (ST) research in rheumatology., , , , , , , ,no,2022-05-20 16:32:37,2022-05-20 16:32:37,eular-points-to-consider-for-minimal-reporting-requirements-in-synovial-tissue-research-in-rheumatology,"[('title', 'EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting synovial tissue (ST) research in rheumatology.'), ('Full bibliographic reference', ""Najm A, Costantino F, Alivernini S, Alunno A, Bianchi E, Bignall J, Boyce B, Cañete JD, Carubbi F, Durez P, Fonseca JE, Just SA, Largo R, Manzo A, Maybury M, Naredo E, Orr C, Pitzalis C, Rivellese F, Romão VC, van Rompay J, Tas SW, Veale DJ, D'Agostino MA, Filer A. EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology. Ann Rheum Dis. 2022:annrheumdis-2021-221875.""), ('Language', 'English'), ('PubMed ID', '[35210263](https://pubmed.ncbi.nlm.nih.gov/35210263/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://ard.bmj.com/content/early/2022/03/02/annrheumdis-2021-221875.long) of this reporting guideline.'), ('Study design', 'Diagnostic and prognostic studies'), ('Clinical area', 'Rheumatology'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'May 20, 2022')]"
20739,Methods and Applications of Social Media Monitoring of Mental Health During Disasters: Scoping Review,Observational studies,"Psychiatry, Psychology","Data, Ethical issues (consent etc.), Procedure/Method, Statistical methods and analyses", ,"crisis, digital psychiatry, disaster, disaster mental health, disasters, emergency, mental health, observation, observational, observational studies, observational study, psychiatry, psychology, social media", ,"Teague SJ, Shatte ABR, Weller E, Fuller-Tyszkiewicz M, Hutchinson DM. Methods and Applications of Social Media Monitoring of Mental Health During Disasters: Scoping Review. JMIR Ment Health. 2022;9(2):e33058.","Teague SJ, Shatte ABR, Weller E, Fuller-Tyszkiewicz M, Hutchinson DM.",JMIR Mental Health [JMIR Ment Health.],2022,9,2,e33058, ,English, ,35225815,https://pubmed.ncbi.nlm.nih.gov/35225815/,Read the full-text of this reporting guideline., , , , , ,Reporting of social media monitoring of mental health during disasters research., , , , , , , ,no,2022-05-20 15:44:51,2022-05-20 15:44:51,methods-and-applications-of-social-media-monitoring-of-mental-health-during-disasters-scoping-review,"[('title', 'Methods and Applications of Social Media Monitoring of Mental Health During Disasters: Scoping Review'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of social media monitoring of mental health during disasters research.'), ('Full bibliographic reference', 'Teague SJ, Shatte ABR, Weller E, Fuller-Tyszkiewicz M, Hutchinson DM. Methods and Applications of Social Media Monitoring of Mental Health During Disasters: Scoping Review. JMIR Ment Health. 2022;9(2):e33058.'), ('Language', 'English'), ('PubMed ID', '[35225815](https://pubmed.ncbi.nlm.nih.gov/35225815/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922153/) of this reporting guideline.'), ('Study design', 'Observational studies'), ('Clinical area', 'Psychiatry, Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Ethical issues (consent etc.), Procedure/Method, Statistical methods and analyses'), ('Record last updated on', 'May 20, 2022')]"
20737,Position Statement on Exercise Dosage in Rheumatic and Musculoskeletal Diseases: The Role of the IMPACT-RMD Toolkit,"Clinical trials, Experimental studies",Rheumatology,Intervention (exposure), ,"arthritis, clinical trial, clinical trials, exercise, exercise dosage, exercising, FITT, FITT principles, IMPACT-RMD, IMPACT-RMD toolkit, musculoskeletal, physical activity, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, rheumatic, rheumatology, training, trial, trials", ,"Metsios GS, Brodin N, Vlieland TPMV, Van den Ende CHM, Stavropoulos-Kalinoglou A, Fatouros I, van der Esch M, Fenton SAM, Tzika K, Moe RH, van Zanten JJCSV, Koutedakis Y, Swinnen TW, Veskoukis AS, Bostr\xf6m C, Kennedy N, Nikiphorou E, Fragoulis GE, Niedermann K, Kitas GD; IMPACT-RMD Consortium. Position Statement on Exercise Dosage in Rheumatic and Musculoskeletal Diseases: The Role of the IMPACT-RMD Toolkit. Mediterr J Rheumatol. 2021;32(4):378-385.","Metsios GS, Brodin N, Vlieland TPMV, Van den Ende CHM, Stavropoulos-Kalinoglou A, Fatouros I, van der Esch M, Fenton SAM, Tzika K, Moe RH, van Zanten JJCSV, Koutedakis Y, Swinnen TW, Veskoukis AS, Bostr\xf6m C, Kennedy N, Nikiphorou E, Fragoulis GE, Niedermann K, Kitas GD; IMPACT-RMD Consortium.",Mediterranean Journal of Rheumatology\xa0 [Mediterr J Rheumatol.],2021,32,4,378-385, ,English, ,35128335,https://pubmed.ncbi.nlm.nih.gov/35128335/,Read the full-text of this reporting guideline., , , , ,IMPACT-RMD Toolkit,Reporting of rheumatic and musculoskeletal disease (RMD) exercise trials., , , , , , , ,no,2022-05-20 15:05:31,2022-05-20 15:06:10,position-statement-on-exercise-dosage-in-rheumatic-and-musculoskeletal-diseases-the-role-of-the-impact-rmd-toolkit,"[('title', 'Position Statement on Exercise Dosage in Rheumatic and Musculoskeletal Diseases: The Role of the IMPACT-RMD Toolkit'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of rheumatic and musculoskeletal disease (RMD) exercise trials.'), ('Full bibliographic reference', 'Metsios GS, Brodin N, Vlieland TPMV, Van den Ende CHM, Stavropoulos-Kalinoglou A, Fatouros I, van der Esch M, Fenton SAM, Tzika K, Moe RH, van Zanten JJCSV, Koutedakis Y, Swinnen TW, Veskoukis AS, Boström C, Kennedy N, Nikiphorou E, Fragoulis GE, Niedermann K, Kitas GD; IMPACT-RMD Consortium. Position Statement on Exercise Dosage in Rheumatic and Musculoskeletal Diseases: The Role of the IMPACT-RMD Toolkit. Mediterr J Rheumatol. 2021;32(4):378-385.'), ('Language', 'English'), ('PubMed ID', '[35128335](https://pubmed.ncbi.nlm.nih.gov/35128335/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802196/) of this reporting guideline.'), ('Reporting guideline acronym', 'IMPACT-RMD Toolkit'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Rheumatology'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'May 20, 2022')]"
20735,A checklist for assessing the methodological quality of concurrent tES-fMRI studies (ContES checklist): a consensus study and statement,Experimental studies,"Neurology, Radiology","Intervention (exposure), Procedure/Method", ,"brain, checklist, checklists, concurrent tES fMRI, ContES, ContES checklist, electrical stimulation, experiment, experimental, fMRI, functional magnetic resonance imaging, functional MRI, magnetic resonance imaging, MRI, neural, neuroimaging, neurological, neurology, neuromodulation, neuronal, tES, tES-fMRI, transcranial electrical stimulation", ,"Ekhtiari H, Ghobadi-Azbari P, Thielscher A, Antal A, Li LM, Shereen AD, Cabral-Calderin Y, Keeser D, Bergmann TO, Jamil A, Violante IR, Almeida J, Meinzer M, Siebner HR, Woods AJ, Stagg CJ, Abend R, Antonenko D, Auer T, B\xe4chinger M, Baeken C, Barron HC, Chase HW, Crinion J, Datta A, Davis MH, Ebrahimi M, Esmaeilpour Z, Falcone B, Fiori V, Ghodratitoostani I, Gilam G, Grabner RH, Greenspan JD, Groen G, Hartwigsen G, Hauser TU, Herrmann CS, Juan CH, Krekelberg B, Lefebvre S, Liew SL, Madsen KH, Mahdavifar-Khayati R, Malmir N, Marangolo P, Martin AK, Meeker TJ, Ardabili HM, Moisa M, Momi D, Mulyana B, Opitz A, Orlov N, Ragert P, Ruff CC, Ruffini G, Ruttorf M, Sangchooli A, Schellhorn K, Schlaug G, Sehm B, Soleimani G, Tavakoli H, Thompson B, Timmann D, Tsuchiyagaito A, Ulrich M, Vosskuhl J, Weinrich CA, Zare-Bidoky M, Zhang X, Zoefel B, Nitsche MA, Bikson M. A checklist for assessing the methodological quality of concurrent tES-fMRI studies (ContES checklist): a consensus study and statement. Nat Protoc. 2022;17(3):596-617.","Ekhtiari H, Ghobadi-Azbari P, Thielscher A, Antal A, Li LM, Shereen AD, Cabral-Calderin Y, Keeser D, Bergmann TO, Jamil A, Violante IR, Almeida J, Meinzer M, Siebner HR, Woods AJ, Stagg CJ, Abend R, Antonenko D, Auer T, B\xe4chinger M, Baeken C, Barron HC, Chase HW, Crinion J, Datta A, Davis MH, Ebrahimi M, Esmaeilpour Z, Falcone B, Fiori V, Ghodratitoostani I, Gilam G, Grabner RH, Greenspan JD, Groen G, Hartwigsen G, Hauser TU, Herrmann CS, Juan CH, Krekelberg B, Lefebvre S, Liew SL, Madsen KH, Mahdavifar-Khayati R, Malmir N, Marangolo P, Martin AK, Meeker TJ, Ardabili HM, Moisa M, Momi D, Mulyana B, Opitz A, Orlov N, Ragert P, Ruff CC, Ruffini G, Ruttorf M, Sangchooli A, Schellhorn K, Schlaug G, Sehm B, Soleimani G, Tavakoli H, Thompson B, Timmann D, Tsuchiyagaito A, Ulrich M, Vosskuhl J, Weinrich CA, Zare-Bidoky M, Zhang X, Zoefel B, Nitsche MA, Bikson M.",Nature Protocols [Nat Protoc.],2022,17,3,596-617, ,English, ,35121855,https://pubmed.ncbi.nlm.nih.gov/35121855/,Read the full-text of the ContES reporting guideline., , , , ,ContES checklist,Reporting concurrent transcranial electrical stimulation-functional MRI (tES-fMRI) studies., , , , , , , ,no,2022-05-20 14:39:13,2022-05-20 15:09:55,a-checklist-for-assessing-the-methodological-quality-of-concurrent-tes-fmri-studies-contes-checklist-a-consensus-study-and-statement,"[('title', 'A checklist for assessing the methodological quality of concurrent t ES-fMRI studies (ContES checklist): a consensus study and statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting concurrent transcranial electrical stimulation-functional MRI (tES-fMRI) studies.'), ('Full bibliographic reference', 'Ekhtiari H, Ghobadi-Azbari P, Thielscher A, Antal A, Li LM, Shereen AD, Cabral-Calderin Y, Keeser D, Bergmann TO, Jamil A, Violante IR, Almeida J, Meinzer M, Siebner HR, Woods AJ, Stagg CJ, Abend R, Antonenko D, Auer T, Bächinger M, Baeken C, Barron HC, Chase HW, Crinion J, Datta A, Davis MH, Ebrahimi M, Esmaeilpour Z, Falcone B, Fiori V, Ghodratitoostani I, Gilam G, Grabner RH, Greenspan JD, Groen G, Hartwigsen G, Hauser TU, Herrmann CS, Juan CH, Krekelberg B, Lefebvre S, Liew SL, Madsen KH, Mahdavifar-Khayati R, Malmir N, Marangolo P, Martin AK, Meeker TJ, Ardabili HM, Moisa M, Momi D, Mulyana B, Opitz A, Orlov N, Ragert P, Ruff CC, Ruffini G, Ruttorf M, Sangchooli A, Schellhorn K, Schlaug G, Sehm B, Soleimani G, Tavakoli H, Thompson B, Timmann D, Tsuchiyagaito A, Ulrich M, Vosskuhl J, Weinrich CA, Zare-Bidoky M, Zhang X, Zoefel B, Nitsche MA, Bikson M. A checklist for assessing the methodological quality of concurrent tES-fMRI studies (ContES checklist): a consensus study and statement. Nat Protoc. 2022;17(3):596-617.'), ('Language', 'English'), ('PubMed ID', '[35121855](https://pubmed.ncbi.nlm.nih.gov/35121855/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612687/) of the ContES reporting guideline.'), ('Reporting guideline acronym', 'ContES checklist'), ('Study design', 'Experimental studies'), ('Clinical area', 'Neurology, Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Procedure/Method'), ('Record last updated on', 'May 20, 2022')]"
20729,Application of Mixed Methods in Health Services Management Research: A Systematic Review,Mixed methods studies, ,"Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)", ,"checklist, checklists, health service, health services management research, mixed methodologies, mixed methodology, mixed methods, mixed methods research, MMR, quantitative and qualitative", ,"Lee SD, Iott B, Banaszak-Holl J, Shih SF, Raj M, Johnson KE, Kiessling K, Moore-Petinak N. Application of Mixed Methods in Health Services Management Research: A Systematic Review. Med Care Res Rev. 2022;79(3):331-344.","Lee SD, Iott B, Banaszak-Holl J, Shih SF, Raj M, Johnson KE, Kiessling K, Moore-Petinak N.",Medical Care Research and Review [Med Care Res Rev.],2022,79,3,331-344, ,English, ,34253078,https://pubmed.ncbi.nlm.nih.gov/34253078/, , , , , , ,Reporting mixed methods research (MMR) studies., , , , , , , ,no,2022-05-19 16:10:20,2022-05-19 16:10:20,application-of-mixed-methods-in-health-services-management-research-a-systematic-review,"[('title', 'Application of Mixed Methods in Health Services Management Research: A Systematic Review'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting mixed methods research (MMR) studies.'), ('Full bibliographic reference', 'Lee SD, Iott B, Banaszak-Holl J, Shih SF, Raj M, Johnson KE, Kiessling K, Moore-Petinak N. Application of Mixed Methods in Health Services Management Research: A Systematic Review. Med Care Res Rev. 2022;79(3):331-344.'), ('Language', 'English'), ('PubMed ID', '[34253078](https://pubmed.ncbi.nlm.nih.gov/34253078/)'), ('Study design', 'Mixed methods studies'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'May 19, 2022')]"
20727,Methodological standards for conducting and reporting meta-analyses: Ensuring the replicability of meta-analyses of pharmacist-led medication review,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews,Pharmaceutical medicine,"Data, Statistical methods and analyses", ,"data, medication, meta analyses, meta analysis, meta-analytical, pharmacist, pharmacy, replicability, replication, statistical, statistics, systematic review, systematic reviews", ,"Bonetti AF, Tonin FS, Lucchetta RC, Pontarolo R, Fernandez-Llimos F. Methodological standards for conducting and reporting meta-analyses: Ensuring the replicability of meta-analyses of pharmacist-led medication review. Res Social Adm Pharm. 2022;18(2):2259-2268.","Bonetti AF, Tonin FS, Lucchetta RC, Pontarolo R, Fernandez-Llimos F.",Research in Social and Administrative Pharmacy [Res Social Adm Pharm.],2022,18,2,2259-2268, ,English, ,34144899,https://pubmed.ncbi.nlm.nih.gov/34144899/, , , , , , ,Reporting of meta-analytical calculations in systematic reviews., , , , , , , ,no,2022-05-19 15:16:06,2022-05-19 15:16:06,methodological-standards-for-conducting-and-reporting-meta-analyses-ensuring-the-replicability-of-meta-analyses-of-pharmacist-led-medication-review,"[('title', 'Methodological standards for conducting and reporting meta-analyses: Ensuring the replicability of meta-analyses of pharmacist-led medication review'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of meta-analytical calculations in systematic reviews.'), ('Full bibliographic reference', 'Bonetti AF, Tonin FS, Lucchetta RC, Pontarolo R, Fernandez-Llimos F. Methodological standards for conducting and reporting meta-analyses: Ensuring the replicability of meta-analyses of pharmacist-led medication review. Res Social Adm Pharm. 2022;18(2):2259-2268.'), ('Language', 'English'), ('PubMed ID', '[34144899](https://pubmed.ncbi.nlm.nih.gov/34144899/)'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Clinical area', 'Pharmaceutical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data, Statistical methods and analyses'), ('Record last updated on', 'May 19, 2022')]"
20725,A scoping review of the use of ethnographic approaches in implementation research and recommendations for reporting,Qualitative research, ,"Procedure/Method, Results, Statistical methods and analyses", ,"COREQ, ethnographic, ethnography, implementation, implementation science, observational, qualitative, qualitative studies, qualitative study", ,"Gertner AK, Franklin J, Roth I, Cruden GH, Haley AD, Finley EP, Hamilton AB, Palinkas LA, Powell BJ. A scoping review of the use of ethnographic approaches in implementation research and recommendations for reporting. Implement Res Pract. 2021;2:10.1177/2633489521992743.","Gertner AK, Franklin J, Roth I, Cruden GH, Haley AD, Finley EP, Hamilton AB, Palinkas LA, Powell BJ.",Implementation Research and Practice [Implement Res Pract.],2021,2, , , ,English, ,34056611,https://pubmed.ncbi.nlm.nih.gov/34056611/, , , , , , ,Reporting ethnographic approaches in implementation science (IS)., , , , ,Read a guide (PDF) to reporting guidelines relevant to implementation studies developed by researchers in the Centre for Implementation Science at King?s College London and King?s Improvement Science and led by the National Institute for Health Research Applied Research Collaboration South London (NIHR ARC South London) at King?s College Hospital NHS Foundation Trust and supported by King?s Improvement Science., , ,no,2022-05-19 14:42:00,2023-06-06 08:41:09,a-scoping-review-of-the-use-of-ethnographic-approaches-in-implementation-research-and-recommendations-for-reporting,"[('title', 'A scoping review of the use of ethnographic approaches in implementation research and recommendations for reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting ethnographic approaches in implementation science (IS).'), ('Full bibliographic reference', 'Gertner AK, Franklin J, Roth I, Cruden GH, Haley AD, Finley EP, Hamilton AB, Palinkas LA, Powell BJ. A scoping review of the use of ethnographic approaches in implementation research and recommendations for reporting. Implement Res Pract. 2021;2:10.1177/2633489521992743.'), ('Language', 'English'), ('PubMed ID', '[34056611](https://pubmed.ncbi.nlm.nih.gov/34056611/)'), ('Study design', 'Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method, Results, Statistical methods and analyses'), ('Other', '[Read a guide (PDF)](https://arc-sl.nihr.ac.uk/sites/default/files/uploads/files/Imp-Sci-reporting-guidelines-2023.pdf) to reporting guidelines relevant to implementation studies developed by researchers in the Centre for Implementation Science at King’s College London and King’s Improvement Science and led by the National Institute for Health Research Applied Research Collaboration South London (NIHR ARC South London) at King’s College Hospital NHS Foundation Trust and supported by King’s Improvement Science.'), ('Record last updated on', 'June 6, 2023')]"
20723,The Chest Wall Injury Society Recommendations for Reporting Studies of Surgical Stabilization of Rib Fractures,"Clinical trials, Experimental studies",Surgery,"Intervention (exposure), Outcomes (variables), Statistical methods and analyses, Study characteristics (participants etc.)", ,"chest wall injury, clinical trial, clinical trials, flail chest, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, rib, rib fracture, rib fractures, surgery, surgical, surgical stabilization of rib fractures, trial, trials", ,"Pieracci FM, Schubl S, Gasparri M, Delaplain P, Kirsch J, Towe C, White TW, Whitbeck S, Doben AR. The Chest Wall Injury Society Recommendations for Reporting Studies of Surgical Stabilization of Rib Fractures. Injury. 2021;52(6):1241-1250.","Pieracci FM, Schubl S, Gasparri M, Delaplain P, Kirsch J, Towe C, White TW, Whitbeck S, Doben AR.",Injury.,2021,52,6,1241-1250, ,English, ,33795145,https://pubmed.ncbi.nlm.nih.gov/33795145/, , , , , , ,Reporting of studies of surgical stabilization of rib fractures (SSRF)., , , , , , , ,no,2022-05-19 12:28:55,2022-05-19 12:28:55,the-chest-wall-injury-society-recommendations-for-reporting-studies-of-surgical-stabilization-of-rib-fractures,"[('title', 'The Chest Wall Injury Society Recommendations for Reporting Studies of Surgical Stabilization of Rib Fractures'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of studies of surgical stabilization of rib fractures (SSRF).'), ('Full bibliographic reference', 'Pieracci FM, Schubl S, Gasparri M, Delaplain P, Kirsch J, Towe C, White TW, Whitbeck S, Doben AR. The Chest Wall Injury Society Recommendations for Reporting Studies of Surgical Stabilization of Rib Fractures. Injury. 2021;52(6):1241-1250.'), ('Language', 'English'), ('PubMed ID', '[33795145](https://pubmed.ncbi.nlm.nih.gov/33795145/)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Outcomes (variables), Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'May 19, 2022')]"
20721,How to Report Light Exposure in Human Chronobiology and Sleep Research Experiments, ,Psychology,"Data, Intervention (exposure), Procedure/Method", ,"behavior, behavioral, behaviour, behavioural, chronobiology, circadian, environmental psychology, light, light exposure, non-visual function, physiological, physiology, psychological, psychology, retina, sleep, spectral, spectral data, vision", ,"Spitschan M, Stefani O, Blattner P, Gronfier C, Lockley SW, Lucas RJ. How to Report Light Exposure in Human Chronobiology and Sleep Research Experiments. Clocks Sleep. 2019;1(3):280-289.","Spitschan M, Stefani O, Blattner P, Gronfier C, Lockley SW, Lucas RJ.",Clocks and Sleep. [Clocks Sleep.],2019,1,3,280-289, ,English, ,31281903,https://pubmed.ncbi.nlm.nih.gov/31281903/,Read the full-text of this reporting guideline., , , , , ,"Reporting light exposure and stimulus conditions in chronobiology, sleep research and environmental psychology experiments.", , , , , , , ,no,2022-05-19 11:44:29,2022-05-19 11:44:29,how-to-report-light-exposure-in-human-chronobiology-and-sleep-research-experiments,"[('title', 'How to Report Light Exposure in Human Chronobiology and Sleep Research Experiments'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting light exposure and stimulus conditions in chronobiology, sleep research and environmental psychology experiments.'), ('Full bibliographic reference', 'Spitschan M, Stefani O, Blattner P, Gronfier C, Lockley SW, Lucas RJ. How to Report Light Exposure in Human Chronobiology and Sleep Research Experiments. Clocks Sleep. 2019;1(3):280-289.'), ('Language', 'English'), ('PubMed ID', '[31281903](https://pubmed.ncbi.nlm.nih.gov/31281903/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609447/) of this reporting guideline.'), ('Clinical area', 'Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Intervention (exposure), Procedure/Method'), ('Record last updated on', 'May 19, 2022')]"
20719,Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI,Artificial intelligence/Machine learning studies, ,Whole report, ,"AI, AI system, AI systems, artificial intelligence, checklist, checklists, clinical AI studies, clinical AI study, clinical decision support systems, decision support, Developmental and Exploratory Clinical Investigations of DEcision support systems driven by Artificial Intelligence (DECIDE-AI), early, early-stage", ,"Vasey B, Nagendran M, Campbell B, Clifton DA, Collins GS, Denaxas S, Denniston AK, Faes L, Geerts B, Ibrahim M, Liu X, Mateen BA, Mathur P, McCradden MD, Morgan L, Ordish J, Rogers C, Saria S, Ting DSW, Watkinson P, Weber W, Wheatstone P, McCulloch P; DECIDE-AI expert group. Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI.

This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.

Nat Med. 2022;28(5):924-933. PMID: 35585198
BMJ. 2022;377:e070904. PMID: 35584845

","Vasey B, Nagendran M, Campbell B, Clifton DA, Collins GS, Denaxas S, Denniston AK, Faes L, Geerts B, Ibrahim M, Liu X, Mateen BA, Mathur P, McCradden MD, Morgan L, Ordish J, Rogers C, Saria S, Ting DSW, Watkinson P, Weber W, Wheatstone P, McCulloch P; DECIDE-AI expert group.", , , , , , , , , , ,"Read the full-text of the DECIDE-AI reporting guideline in the BMJ or Nature Medicine.

", , , , ,DECIDE-AI,Reporting of studies describing the early-stage live clinical evaluation of AI-based decision support systems.,The DECIDE-AI checklist is available in Spanish., , , , , , ,no,2022-05-19 11:04:02,2025-02-11 14:04:00,reporting-guideline-for-the-early-stage-clinical-evaluation-of-decision-support-systems-driven-by-artificial-intelligence-decide-ai,"[('title', 'Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of studies describing the early-stage live clinical evaluation of AI-based decision support systems.'), ('Full bibliographic reference', 'Vasey B, Nagendran M, Campbell B, Clifton DA, Collins GS, Denaxas S, Denniston AK, Faes L, Geerts B, Ibrahim M, Liu X, Mateen BA, Mathur P, McCradden MD, Morgan L, Ordish J, Rogers C, Saria S, Ting DSW, Watkinson P, Weber W, Wheatstone P, McCulloch P; DECIDE-AI expert group. Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI.\n\n \n\n This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.\n\n \n\n Nat Med. 2022;28(5):924-933. PMID: [35585198](https://pubmed.ncbi.nlm.nih.gov/35585198/)\n\n BMJ. 2022;377:e070904. PMID: [35584845](https://pubmed.ncbi.nlm.nih.gov/35584845/)\n\n \n\n'), ('Relevant URLs\n\n(full-text if available)', 'Read the full-text of the DECIDE-AI reporting guideline in the [BMJ](https://www.bmj.com/content/377/bmj-2022-070904) or [Nature Medicine](https://www.nature.com/articles/s41591-022-01772-9).\n\n \n\n'), ('Availability in additional languages', 'The DECIDE-AI checklist is available in [Spanish](https://www.equator-network.org/wp-content/uploads/2022/05/DECIDE-AI-Spanish.pdf).'), ('Reporting guideline acronym', 'DECIDE-AI'), ('Study design', 'Artificial intelligence/Machine learning studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'February 11, 2025')]"
20716,Use of actigraphy for assessment in pediatric sleep research,Observational studies,Paediatrics,"Data, Procedure/Method", ,"accelerometer, actigraph, actigraphs, actigraphy, actiwatch, adolescents, ambulatory device, ambulatory devices, children, infants, observation, observational, observational data, observational studies, observational study, paediatric, pediatric, sleep, sleep-wake, wake", ,"Meltzer LJ, Montgomery-Downs HE, Insana SP, Walsh CM. Use of actigraphy for assessment in pediatric sleep research. Sleep Med Rev. 2012;16(5):463-75.","Meltzer LJ, Montgomery-Downs HE, Insana SP, Walsh CM.",Sleep Medicine Reviews [Sleep Med Rev.],2012,16,5,463-75, ,English, ,22424706,https://pubmed.ncbi.nlm.nih.gov/22424706/, , , , , , ,Reporting of actigraphy in paediatric research studies., , , , , , , ,no,2022-05-19 10:32:11,2022-05-19 10:32:11,use-of-actigraphy-for-assessment-in-pediatric-sleep-research,"[('title', 'Use of actigraphy for assessment in pediatric sleep research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of actigraphy in paediatric research studies.'), ('Full bibliographic reference', 'Meltzer LJ, Montgomery-Downs HE, Insana SP, Walsh CM. Use of actigraphy for assessment in pediatric sleep research. Sleep Med Rev. 2012;16(5):463-75.'), ('Language', 'English'), ('PubMed ID', '[22424706](https://pubmed.ncbi.nlm.nih.gov/22424706/)'), ('Study design', 'Observational studies'), ('Clinical area', 'Paediatrics'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method'), ('Record last updated on', 'May 19, 2022')]"
20708,EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology,Observational studies,Rheumatology,"Data, Harms/adverse effects/safety data, Procedure/Method, Statistical methods and analyses, Study characteristics (participants etc.)", ,"biologic register, comparative effectiveness, comparative effectiveness study, effectiveness, EULAR, European Alliance of Associations for Rheumatology, exposure, observational, observational data, observational research, observational studies, observational study, real-world comparative effectiveness studies, real-world comparative effectiveness study, rheumatology, safety, treatment effectiveness over time", ,"Courvoisier DS, Lauper K, Kedra J, de Wit M, Fautrel B, Frisell T, Hyrich KL, Iannone F, Machado PM, \xd8rnbjerg LM, Rotar Z, Santos MJ, Stamm TA, Stones SR, Strangfeld A, Bergstra SA, Landew\xe9 RBM, Finckh A. EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. Ann Rheum Dis. 2022;81(6):780-785.","Courvoisier DS, Lauper K, Kedra J, de Wit M, Fautrel B, Frisell T, Hyrich KL, Iannone F, Machado PM, \xd8rnbjerg LM, Rotar Z, Santos MJ, Stamm TA, Stones SR, Strangfeld A, Bergstra SA, Landew\xe9 RBM, Finckh A.",Annals of Rheumatic Diseases [Ann Rheum Dis.],2022,81,6,780-785, ,English, ,35058229,https://pubmed.ncbi.nlm.nih.gov/35058229/,Read the full-text of this reporting guideline., , , , , ,Reporting comparative effectiveness research using observational data in rheumatology, , , , , , , ,no,2022-05-17 16:31:20,2022-05-17 16:31:20,eular-points-to-consider-when-analysing-and-reporting-comparative-effectiveness-research-using-observational-data-in-rheumatology,"[('title', 'EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting comparative effectiveness research using observational data in rheumatology'), ('Full bibliographic reference', 'Courvoisier DS, Lauper K, Kedra J, de Wit M, Fautrel B, Frisell T, Hyrich KL, Iannone F, Machado PM, Ørnbjerg LM, Rotar Z, Santos MJ, Stamm TA, Stones SR, Strangfeld A, Bergstra SA, Landewé RBM, Finckh A. EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. Ann Rheum Dis. 2022;81(6):780-785.'), ('Language', 'English'), ('PubMed ID', '[35058229](https://pubmed.ncbi.nlm.nih.gov/35058229/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://ard.bmj.com/content/81/6/780.long) of this reporting guideline.'), ('Study design', 'Observational studies'), ('Clinical area', 'Rheumatology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Harms/adverse effects/safety data, Procedure/Method, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'May 17, 2022')]"
20706,International Consensus Based Review and Recommendations for Minimum Reporting Standards in Research on Transcutaneous Vagus Nerve Stimulation (Version 2020),"Clinical trials, Experimental studies, Observational studies", ,"Harms/adverse effects/safety data, Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)", ,"auricular, cervical, cervically implanted VNS, checklist, checklists, clinical trial, clinical trials, iVNS, observational studies, observational study, paVNS, percutaneous auricular VNS, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, stimulation, stimulation parameter, taVNS, tcVNS, transcutaneous, transcutaneous auricular VNS, transcutaneous cervical VNS, transcutaneous vagus nerve stimulation, trial, trials, tVNS, vagus nerve stimulation, VNS", ,"Farmer AD, Strzelczyk A, Finisguerra A, Gourine AV, Gharabaghi A, Hasan A, Burger AM, Jaramillo AM, Mertens A, Majid A, Verkuil B, Badran BW, Ventura-Bort C, Gaul C, Beste C, Warren CM, Quintana DS, H\xe4mmerer D, Freri E, Frangos E, Tobaldini E, Kaniusas E, Rosenow F, Capone F, Panetsos F, Ackland GL, Kaithwas G, O'Leary GH, Genheimer H, Jacobs HIL, Van Diest I, Schoenen J, Redgrave J, Fang J, Deuchars J, Sz\xe9les JC, Thayer JF, More K, Vonck K, Steenbergen L, Vianna LC, McTeague LM, Ludwig M, Veldhuizen MG, De Couck M, Casazza M, Keute M, Bikson M, Andreatta M, D'Agostini M, Weymar M, Betts M, Prigge M, Kaess M, Roden M, Thai M, Schuster NM, Montano N, Hansen N, Kroemer NB, Rong P, Fischer R, Howland RH, Sclocco R, Sellaro R, Garcia RG, Bauer S, Gancheva S, Stavrakis S, Kampusch S, Deuchars SA, Wehner S, Laborde S, Usichenko T, Polak T, Zaehle T, Borges U, Teckentrup V, Jandackova VK, Napadow V, Koenig J. International Consensus Based Review and Recommendations for Minimum Reporting Standards in Research on Transcutaneous Vagus Nerve Stimulation (Version 2020). Front Hum Neurosci. 2021;14:568051.","Farmer AD, Strzelczyk A, Finisguerra A, Gourine AV, Gharabaghi A, Hasan A, Burger AM, Jaramillo AM, Mertens A, Majid A, Verkuil B, Badran BW, Ventura-Bort C, Gaul C, Beste C, Warren CM, Quintana DS, H\xe4mmerer D, Freri E, Frangos E, Tobaldini E, Kaniusas E, Rosenow F, Capone F, Panetsos F, Ackland GL, Kaithwas G, O'Leary GH, Genheimer H, Jacobs HIL, Van Diest I, Schoenen J, Redgrave J, Fang J, Deuchars J, Sz\xe9les JC, Thayer JF, More K, Vonck K, Steenbergen L, Vianna LC, McTeague LM, Ludwig M, Veldhuizen MG, De Couck M, Casazza M, Keute M, Bikson M, Andreatta M, D'Agostini M, Weymar M, Betts M, Prigge M, Kaess M, Roden M, Thai M, Schuster NM, Montano N, Hansen N, Kroemer NB, Rong P, Fischer R, Howland RH, Sclocco R, Sellaro R, Garcia RG, Bauer S, Gancheva S, Stavrakis S, Kampusch S, Deuchars SA, Wehner S, Laborde S, Usichenko T, Polak T, Zaehle T, Borges U, Teckentrup V, Jandackova VK, Napadow V, Koenig J.",Frontiers in Human Neuroscience [Front Hum Neurosci.],2021,14, ,568051, ,English, ,33854421,https://pubmed.ncbi.nlm.nih.gov/33854421/,Read the full-text of this reporting guideline., , , , , ,Reporting of transcutaneous vagus nerve stimulation (tVNS) research., , , , , , , ,no,2022-05-17 15:49:21,2022-05-17 15:49:21,international-consensus-based-review-and-recommendations-for-minimum-reporting-standards-in-research-on-transcutaneous-vagus-nerve-stimulation-version-2020,"[('title', 'International Consensus Based Review and Recommendations for Minimum Reporting Standards in Research on Transcutaneous Vagus Nerve Stimulation (Version 2020)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of transcutaneous vagus nerve stimulation (tVNS) research.'), ('Full bibliographic reference', ""Farmer AD, Strzelczyk A, Finisguerra A, Gourine AV, Gharabaghi A, Hasan A, Burger AM, Jaramillo AM, Mertens A, Majid A, Verkuil B, Badran BW, Ventura-Bort C, Gaul C, Beste C, Warren CM, Quintana DS, Hämmerer D, Freri E, Frangos E, Tobaldini E, Kaniusas E, Rosenow F, Capone F, Panetsos F, Ackland GL, Kaithwas G, O'Leary GH, Genheimer H, Jacobs HIL, Van Diest I, Schoenen J, Redgrave J, Fang J, Deuchars J, Széles JC, Thayer JF, More K, Vonck K, Steenbergen L, Vianna LC, McTeague LM, Ludwig M, Veldhuizen MG, De Couck M, Casazza M, Keute M, Bikson M, Andreatta M, D'Agostini M, Weymar M, Betts M, Prigge M, Kaess M, Roden M, Thai M, Schuster NM, Montano N, Hansen N, Kroemer NB, Rong P, Fischer R, Howland RH, Sclocco R, Sellaro R, Garcia RG, Bauer S, Gancheva S, Stavrakis S, Kampusch S, Deuchars SA, Wehner S, Laborde S, Usichenko T, Polak T, Zaehle T, Borges U, Teckentrup V, Jandackova VK, Napadow V, Koenig J. International Consensus Based Review and Recommendations for Minimum Reporting Standards in Research on Transcutaneous Vagus Nerve Stimulation (Version 2020). Front Hum Neurosci. 2021;14:568051.""), ('Language', 'English'), ('PubMed ID', '[33854421](https://pubmed.ncbi.nlm.nih.gov/33854421/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040977/) of this reporting guideline.'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'May 17, 2022')]"
20704,Refining the CRiSPHe (checklist for reporting research using a simulated patient methodology in Health): a Delphi study,"Clinical trials, Experimental studies, Observational studies", ,Whole report, ,"checklist, checklists, clinical trial, clinical trials, CRiSPHe, mystery shopper, observational studies, observational study, pharmaceutical, pharmacist, pharmacy, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, secret shopper, simulated, simulated patient, simulation, trial, trials", ,"Park JS, Page A, Clifford R, Bond C, Seubert L. Refining the CRiSPHe (checklist for reporting research using a simulated patient methodology in Health): a Delphi study. Int J Pharm Pract. 2024:riae019.","Park JS, Page A, Clifford R, Bond C, Seubert L.",International Journal of Pharmacy Practice [Int J Pharm Pract.],2024, , ,riae019, ,English, ,38752525,https://pubmed.ncbi.nlm.nih.gov/38752525/, , ,"Amaratunge S, Harrison M, Clifford R, Seubert L, Page A, Bond C. Developing a checklist for reporting research using simulated patient methodology (CRiSP): a consensus study. Int J Pharm Pract. 2021;29(3):218-227. PMID: 33792718", , ,CRiSPHe,Reporting research using a simulated patient methodology., , , , , , , ,no,2022-05-17 14:55:01,2024-06-12 12:24:55,developing-a-checklist-for-reporting-research-using-simulated-patient-methodology-crisp-a-consensus-study,"[('title', 'Refining the CRiSPHe (checklist for reporting research using a simulated patient methodology in Health): a Delphi study'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting research using a simulated patient methodology.'), ('Full bibliographic reference', 'Park JS, Page A, Clifford R, Bond C, Seubert L. Refining the CRiSPHe (checklist for reporting research using a simulated patient methodology in Health): a Delphi study. Int J Pharm Pract. 2024:riae019.'), ('Language', 'English'), ('PubMed ID', '[38752525](https://pubmed.ncbi.nlm.nih.gov/38752525/)'), ('Reporting guideline acronym', 'CRiSPHe'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Previous versions of this guideline / Guideline history', 'Amaratunge S, Harrison M, Clifford R, Seubert L, Page A, Bond C. Developing a checklist for reporting research using simulated patient methodology (CRiSP): a consensus study. Int J Pharm Pract. 2021;29(3):218-227. PMID: [33792718](https://pubmed.ncbi.nlm.nih.gov/33792718)'), ('Record last updated on', 'June 12, 2024')]"
20695,Conceptual Ambiguity Surrounding Gamification and Serious Games in Health Care: Literature Review and Development of Game-Based Intervention Reporting Guidelines (GAMING),"Clinical trials, Experimental studies, Qualitative research", ,Intervention (exposure), ,"checklist, checklists, clinical trial, clinical trials, exergames, game-based intervention, Game-Based Intervention Reporting Guidelines, game-based interventions, gamification, gamified, gamify, gamifying, GAMING, qualitative, qualitative research, qualitative studies, qualitative study, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, serious games, trial, trials", ,"Warsinsky S, Schmidt-Kraepelin M, Rank S, Thiebes S, Sunyaev A. Conceptual Ambiguity Surrounding Gamification and Serious Games in Health Care: Literature Review and Development of Game-Based Intervention Reporting Guidelines (GAMING). J Med Internet Res. 2021;23(9):e30390.","Warsinsky S, Schmidt-Kraepelin M, Rank S, Thiebes S, Sunyaev A.",Journal of Medical Internet Research [J Med Internet Res.],2021,23,9,e30390, ,English, ,34505840,https://pubmed.ncbi.nlm.nih.gov/34505840/,Read the full-text of the GAMING guideline., , , , ,GAMING,Reporting of studies that deal with game-based interventions., , , , , , , ,no,2022-05-10 17:08:48,2022-05-10 17:08:48,conceptual-ambiguity-surrounding-gamification-and-serious-games-in-health-care-literature-review-and-development-of-game-based-intervention-reporting-guidelines-gaming,"[('title', 'Conceptual Ambiguity Surrounding Gamification and Serious Games in Health Care: Literature Review and Development of Game -Based Intervention Reporting Guidelines (GAMING)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of studies that deal with game-based interventions.'), ('Full bibliographic reference', 'Warsinsky S, Schmidt-Kraepelin M, Rank S, Thiebes S, Sunyaev A. Conceptual Ambiguity Surrounding Gamification and Serious Games in Health Care: Literature Review and Development of Game-Based Intervention Reporting Guidelines (GAMING). J Med Internet Res. 2021;23(9):e30390.'), ('Language', 'English'), ('PubMed ID', '[34505840](https://pubmed.ncbi.nlm.nih.gov/34505840/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463952/) of the GAMING guideline.'), ('Reporting guideline acronym', 'GAMING'), ('Study design', 'Clinical trials, Experimental studies, Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'May 10, 2022')]"
20693,Improving Reporting of Clinical Studies Using the POSEIDON Criteria: POSORT Guidelines,"Clinical trials, Experimental studies, Observational studies",Obstetrics and gynaecology,Whole report, ,"ART, assisted reproduction, assisted reproductive technology, checklist, checklists, clinical trial, clinical trials, infertile, infertility, observational studies, observational study, POSEIDON, POSEIDON criteria, POSORT, POSORT Guideline, POSORT Guidelines, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, reproduction, reproductive, trial, trials", ,"Esteves SC, Conforti A, Sunkara SK, Carbone L, Picarelli S, Vaiarelli A, Cimadomo D, Rienzi L, Ubaldi FM, Zullo F, Andersen CY, Orvieto R, Humaidan P, Alviggi C. Improving Reporting of Clinical Studies Using the POSEIDON Criteria: POSORT Guidelines. Front Endocrinol (Lausanne). 2021;12:587051.","Esteves SC, Conforti A, Sunkara SK, Carbone L, Picarelli S, Vaiarelli A, Cimadomo D, Rienzi L, Ubaldi FM, Zullo F, Andersen CY, Orvieto R, Humaidan P, Alviggi C.",Frontiers in Endocrinology (Lausanne) [Front Endocrinol (Lausanne)],2021,12, ,587051, ,English, ,33815269,https://pubmed.ncbi.nlm.nih.gov/33815269/,Read the full-text of the POSORT Guideline., , , , ,POSORT,Reporting of clinical infertility studies using the POSEIDON criteria., , , , , , , ,no,2022-05-10 16:35:05,2022-05-10 16:35:05,improving-reporting-of-clinical-studies-using-the-poseidon-criteria-posort-guidelines,"[('title', 'Improving Reporting of Clinical Studies Using the POSEIDON Criteria: POSORT Guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of clinical infertility studies using the POSEIDON criteria.'), ('Full bibliographic reference', 'Esteves SC, Conforti A, Sunkara SK, Carbone L, Picarelli S, Vaiarelli A, Cimadomo D, Rienzi L, Ubaldi FM, Zullo F, Andersen CY, Orvieto R, Humaidan P, Alviggi C. Improving Reporting of Clinical Studies Using the POSEIDON Criteria: POSORT Guidelines. Front Endocrinol (Lausanne). 2021;12:587051.'), ('Language', 'English'), ('PubMed ID', '[33815269](https://pubmed.ncbi.nlm.nih.gov/33815269/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017440/) of the POSORT Guideline.'), ('Reporting guideline acronym', 'POSORT'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Obstetrics and gynaecology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 10, 2022')]"
20690,Six practical recommendations for improved implementation outcomes reporting,"Clinical trials, Economic evaluations, Experimental studies, Mixed methods studies, Observational studies, Qualitative research, Quality improvement studies", ,Whole report, ,"checklist, checklists, implementation, implementation research, implementation science, intervention, interventions, outcome, outcomes", ,"Lengnick-Hall R, Gerke DR, Proctor EK, Bunger AC, Phillips RJ, Martin JK, Swanson JC. Six practical recommendations for improved implementation outcomes reporting. Implement Sci. 2022;17(1):16.","Lengnick-Hall R, Gerke DR, Proctor EK, Bunger AC, Phillips RJ, Martin JK, Swanson JC.",Implementation Science [Implement Sci.],2022,17,1,16, ,English, ,35135566,https://pubmed.ncbi.nlm.nih.gov/35135566/,Read the full-text of this reporting guideline., , , , , ,Reporting implementation outcomes research., , , , ,Read a guide (PDF) to reporting guidelines relevant to implementation studies developed by researchers in the Centre for Implementation Science at King?s College London and King?s Improvement Science and led by the National Institute for Health Research Applied Research Collaboration South London (NIHR ARC South London) at King?s College Hospital NHS Foundation Trust and supported by King?s Improvement Science., , ,no,2022-05-04 15:49:41,2023-06-06 08:42:27,six-practical-recommendations-for-improved-implementation-outcomes-reporting,"[('title', 'Six practical recommendations for improved implementation outcomes reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting implementation outcomes research.'), ('Full bibliographic reference', 'Lengnick-Hall R, Gerke DR, Proctor EK, Bunger AC, Phillips RJ, Martin JK, Swanson JC. Six practical recommendations for improved implementation outcomes reporting. Implement Sci. 2022;17(1):16.'), ('Language', 'English'), ('PubMed ID', '[35135566](https://pubmed.ncbi.nlm.nih.gov/35135566/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822722/) of this reporting guideline.'), ('Study design', 'Clinical trials, Economic evaluations, Experimental studies, Mixed methods studies, Observational studies, Qualitative research, Quality improvement studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Other', '[Read a guide (PDF)](https://arc-sl.nihr.ac.uk/sites/default/files/uploads/files/Imp-Sci-reporting-guidelines-2023.pdf) to reporting guidelines relevant to implementation studies developed by researchers in the Centre for Implementation Science at King’s College London and King’s Improvement Science and led by the National Institute for Health Research Applied Research Collaboration South London (NIHR ARC South London) at King’s College Hospital NHS Foundation Trust and supported by King’s Improvement Science.'), ('Record last updated on', 'June 6, 2023')]"
20688,Recommendations and publication guidelines for studies using frequency domain and time-frequency domain analyses of neural time series, ,"Neurology, Psychology","Data, Statistical methods and analyses", ,"brain, checklist, checklists, connectivity analyses, coupling analyses, data figures, EEG, electrical, electroencephalography, electrophysiology, frequency domain analysis, magnetic, magnetoencephalography, MEG, neural, neural time series, neural time series analysis, neurological, neurology, neuroscience, phase-based analyses, physiology, psychology, psychophysiological, spectral analyses, time-frequency analyses, time-frequency analysis", ,"Keil A, Bernat EM, Cohen MX, Ding M, Fabiani M, Gratton G, Kappenman ES, Maris E, Mathewson KE, Ward RT, Weisz N. Recommendations and publication guidelines for studies using frequency domain and time-frequency domain analyses of neural time series. Psychophysiology. 2022;59(5):e14052.","Keil A, Bernat EM, Cohen MX, Ding M, Fabiani M, Gratton G, Kappenman ES, Maris E, Mathewson KE, Ward RT, Weisz N.",Psychophysiology.,2022,59,5,e14052, ,English, ,35398913,https://pubmed.ncbi.nlm.nih.gov/35398913/,"Read the full-text of this reporting guideline. Reporting checklists are provided for spectral analyses, time-frequency analyses, phase-based analyses, connectivity analyses, coupling analyses, and data figures.", , , , , ,Reporting of studies using frequency domain and time-frequency domain analyses of neural time series., , , , , , , ,no,2022-05-04 15:05:32,2022-05-04 15:05:32,recommendations-and-publication-guidelines-for-studies-using-frequency-domain-and-time-frequency-domain-analyses-of-neural-time-series,"[('title', 'Recommendations and publication guidelines for studies using frequency domain and time-frequency domain analyses of neural time series'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of studies using frequency domain and time-frequency domain analyses of neural time series.'), ('Full bibliographic reference', 'Keil A, Bernat EM, Cohen MX, Ding M, Fabiani M, Gratton G, Kappenman ES, Maris E, Mathewson KE, Ward RT, Weisz N. Recommendations and publication guidelines for studies using frequency domain and time-frequency domain analyses of neural time series. Psychophysiology. 2022;59(5):e14052.'), ('Language', 'English'), ('PubMed ID', '[35398913](https://pubmed.ncbi.nlm.nih.gov/35398913/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://onlinelibrary.wiley.com/doi/10.1111/psyp.14052) of this reporting guideline. Reporting checklists are provided for spectral analyses, time-frequency analyses, phase-based analyses, connectivity analyses, coupling analyses, and data figures.'), ('Clinical area', 'Neurology, Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Statistical methods and analyses'), ('Record last updated on', 'May 4, 2022')]"
20686,EVIDENCE Publication Checklist for Studies Evaluating Connected Sensor Technologies: Explanation and Elaboration,"Experimental studies, Observational studies", ,Whole report, ,"behavior, behavioral, behaviour, behavioural, biometric monitoring technologies, BioMeTs, checklist, checklists, connected sensor, connected sensor technology, device, digital, digital measurement product, digital measures, EValuatIng connecteD sENsor teChnologiEs, EVIDENCE, EVIDENCE checklist, measurement, mobile sensor, mobile sensors, physiological, physiology, portable monitor, remote monitoring, sensor, technology, tracker, wearables", ,"Manta C, Mahadevan N, Bakker J, Ozen Irmak S, Izmailova E, Park S, Poon JL, Shevade S, Valentine S, Vandendriessche B, Webster C, Goldsack JC. EVIDENCE Publication Checklist for Studies Evaluating Connected Sensor Technologies: Explanation and Elaboration. Digit Biomark. 2021;5(2):127-147.","Manta C, Mahadevan N, Bakker J, Ozen Irmak S, Izmailova E, Park S, Poon JL, Shevade S, Valentine S, Vandendriessche B, Webster C, Goldsack JC.",Digital Biomarkers [Digit Biomark.],2021,5,2,127-147, ,English, ,34179682,https://pubmed.ncbi.nlm.nih.gov/34179682/,Read the full-text of the EVIDENCE reporting guideline., , , , ,EVIDENCE,Reporting of studies where the primary objective is an evaluation of a digital measurement product or its constituent parts., , , , , , , ,no,2022-05-04 14:09:52,2022-05-04 14:09:52,evidence-publication-checklist-for-studies-evaluating-connected-sensor-technologies-explanation-and-elaboration,"[('title', 'EVIDENCE Publication Checklist for Studies Evaluating Connected Sensor Technologies: Explanation and Elaboration'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of studies where the primary objective is an evaluation of a digital measurement product or its constituent parts.'), ('Full bibliographic reference', 'Manta C, Mahadevan N, Bakker J, Ozen Irmak S, Izmailova E, Park S, Poon JL, Shevade S, Valentine S, Vandendriessche B, Webster C, Goldsack JC. EVIDENCE Publication Checklist for Studies Evaluating Connected Sensor Technologies: Explanation and Elaboration. Digit Biomark. 2021;5(2):127-147.'), ('Language', 'English'), ('PubMed ID', '[34179682](https://pubmed.ncbi.nlm.nih.gov/34179682/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215946/) of the EVIDENCE reporting guideline.'), ('Reporting guideline acronym', 'EVIDENCE'), ('Study design', 'Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 4, 2022')]"
20684,An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT,Clinical practice guidelines, ,Whole report, ,"checklist, checklists, clinical practice guideline, clinical practice guidelines, CPG, CPGs, guideline interpreter, guideline interpreters, interpret, interpretation, interpretations, interpreter, interpreters, introduce, introduction, introductions, practice guideline, practice guidelines, RIGHT, RIGHT extension, RIGHT for INT, RIGHT for INTroductions and INTerpretations, RIGHT Statement for INTroductions and INTerpretations of Clinical Practice Guidelines", ,"Zhou Q, Xing D, Li Q, Zhang J, Luo X, Yang N, Wang X, Yang K, Tian J, Li H, Li B, Cai Y, Jin Y, Lv L, Sun F, Shang S, Yuan B, Li J, Ma B, Li X, Yuan Y, Wu L, Wang B, Jiang L, Wang Z, Chen Y, Liang D. An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT. J Evid Based Med. 2022;15(1):55-63.","Zhou Q, Xing D, Li Q, Zhang J, Luo X, Yang N, Wang X, Yang K, Tian J, Li H, Li B, Cai Y, Jin Y, Lv L, Sun F, Shang S, Yuan B, Li J, Ma B, Li X, Yuan Y, Wu L, Wang B, Jiang L, Wang Z, Chen Y, Liang D.",Journal of Evidence Based Medicine [Evid Based Med.],2022,15,1,55-63, ,English, ,35416438,https://pubmed.ncbi.nlm.nih.gov/35416438/, , , ,"Generic
RIGHT Statement: Chen Y, Yang K, Maru?i? A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Sch\xfcnemann HJ, Chan ESY, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; for the RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group.\xa0 A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166(2):128-132. PMID: 27893062

Specialised
RIGHT-TCM: Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, Xia L, Guo Y. The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Pharmacol Res. 2020;160:105178. PMID: 32889127

RIGHT-PVG: Wang X, Chen Y, Akl EA, Tokali? R, Maru?i? A, Qaseem A, Falck-Ytter Y, Lee MS, Siedler M, Barber SL, Zhang M, Chan ESY, Estill J, Kwong JSW, Okumura A, Zhou Q, Yang K, Norris SL; RIGHT working group. The reporting checklist for public versions of guidelines: RIGHT-PVG. Implement Sci. 2021;16(1):10. PMID: 33430911

RIGHT for Acupuncture: Tang C, Duan Y, Zhang Y, Zhang Y, Chen Z, Tang X, Zeng J, Riley D, Lee MS, Kim YS, Zhao H, Marrone G, Zhu X, Ge S, Wen H, Zhao W, Zheng X, Solos I, Chen Y, Guyatt G, Lu L, Xu N; RIGHT (Reporting Items for Practice Guidelines in Healthcare) for Acupuncture Working Group. RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture. J Clin Epidemiol. 2021:S0895-4356(21)00173-6. PMID: 34091023

RIGHT-Ad@pt: Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RWM, Arayssi T, Bhaumik S, Chen Y, Ghersi D, Langlois EV, Fuentes Padilla P, Sch\xfcnemann HJ, Akl EA, Mart\xednez Garc\xeda L; RIGHT-Ad@pt Working Group*, Amer Y, Arevalo-Rodriguez I, Barnes S, Barreto J, Collis D, Dyer S, Fahim C, Florez I, Gallegos-Rivero V, Klugar M, Kuijpers T, Mathew JL, Munn Z, Norris S, Pati\xf1o-Lugo DF, Pramesh CS, Rodriguez J, Roy S, Shin ES, Sosa O, Vandvik PO, Velez M, Woodcraft R; RIGHT-Ad@pt Working Group. A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Ann Intern Med. 2022;175(5):710-719. PMID: 35286143

RIGHT-COI&amp;F: Xun Y, Estill J, Khabsa J, Florez ID, Guyatt GH, Norris SL, Lee MS, Ozaki A, Qaseem A, Sch\xfcnemann HJ, Shao R, Chen Y, Akl EA; RIGHT-COI&amp;F Working Groups. Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI&amp;F Checklist. Ann Intern Med. 2024;177(6):782-790. PMID: 38739919

RIGHT for CPM: Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C. The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. Pharmacol Res. 2024;199:107015. PMID: 38036197

",http://www.right-statement.org/extensions/20,RIGHT for INT,Reporting of introductions and interpretations of clinical practice guidelines., , , , , , , ,yes,2022-05-04 12:06:32,2024-07-26 15:37:55,an-extension-of-the-right-statement-for-introductions-and-interpretations-of-clinical-practice-guidelines-right-for-int,"[('title', 'An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of introductions and interpretations of clinical practice guidelines.'), ('Full bibliographic reference', 'Zhou Q, Xing D, Li Q, Zhang J, Luo X, Yang N, Wang X, Yang K, Tian J, Li H, Li B, Cai Y, Jin Y, Lv L, Sun F, Shang S, Yuan B, Li J, Ma B, Li X, Yuan Y, Wu L, Wang B, Jiang L, Wang Z, Chen Y, Liang D. An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT. J Evid Based Med. 2022;15(1):55-63.'), ('Language', 'English'), ('PubMed ID', '[35416438](https://pubmed.ncbi.nlm.nih.gov/35416438/)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**RIGHT Statement**](https://www.equator-network.org/reporting-guidelines/right-statement/): Chen Y, Yang K, Marušić A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Schünemann HJ, Chan ESY, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; for the RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group.\xa0 A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166(2):128-132. PMID: [27893062](https://www.ncbi.nlm.nih.gov/pubmed/27893062)\n\n \n\n**Specialised**\n\n[**RIGHT-TCM**](https://www.equator-network.org/reporting-guidelines/the-right-extension-statement-for-traditional-chinese-medicine-development-recommendations-and-explanation/): Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, Xia L, Guo Y. The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Pharmacol Res. 2020;160:105178. PMID: [32889127](https://pubmed.ncbi.nlm.nih.gov/32889127)\n\n \n\n[**RIGHT-PVG**](https://www.equator-network.org/reporting-guidelines/the-reporting-checklist-for-public-versions-of-guidelines-right-pvg/): Wang X, Chen Y, Akl EA, Tokalić R, Marušić A, Qaseem A, Falck-Ytter Y, Lee MS, Siedler M, Barber SL, Zhang M, Chan ESY, Estill J, Kwong JSW, Okumura A, Zhou Q, Yang K, Norris SL; RIGHT working group. The reporting checklist for public versions of guidelines: RIGHT-PVG. Implement Sci. 2021;16(1):10. PMID: [33430911](https://pubmed.ncbi.nlm.nih.gov/33430911/)\n\n \n\n[**RIGHT for Acupuncture**](https://www.equator-network.org/reporting-guidelines/right-for-acupuncture/): Tang C, Duan Y, Zhang Y, Zhang Y, Chen Z, Tang X, Zeng J, Riley D, Lee MS, Kim YS, Zhao H, Marrone G, Zhu X, Ge S, Wen H, Zhao W, Zheng X, Solos I, Chen Y, Guyatt G, Lu L, Xu N; RIGHT (Reporting Items for Practice Guidelines in Healthcare) for Acupuncture Working Group. RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture. J Clin Epidemiol. 2021:S0895-4356(21)00173-6. PMID: [34091023](https://pubmed.ncbi.nlm.nih.gov/34091023/)\n\n \n\n[**RIGHT-Ad@pt**](https://www.equator-network.org/reporting-guidelines/a-reporting-tool-for-adapted-guidelines-in-health-care-the-right-adapt-checklist/): Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RWM, Arayssi T, Bhaumik S, Chen Y, Ghersi D, Langlois EV, Fuentes Padilla P, Schünemann HJ, Akl EA, Martínez García L; RIGHT-Ad@pt Working Group\\*, Amer Y, Arevalo-Rodriguez I, Barnes S, Barreto J, Collis D, Dyer S, Fahim C, Florez I, Gallegos-Rivero V, Klugar M, Kuijpers T, Mathew JL, Munn Z, Norris S, Patiño-Lugo DF, Pramesh CS, Rodriguez J, Roy S, Shin ES, Sosa O, Vandvik PO, Velez M, Woodcraft R; RIGHT-Ad@pt Working Group. A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Ann Intern Med. 2022;175(5):710-719. PMID: [35286143](https://pubmed.ncbi.nlm.nih.gov/35286143/)\n\n \n\n[**RIGHT-COI&F**](https://www.equator-network.org/reporting-guidelines/reporting-conflicts-of-interest-and-funding-in-health-care-guidelines-the-right-coif-checklist/): Xun Y, Estill J, Khabsa J, Florez ID, Guyatt GH, Norris SL, Lee MS, Ozaki A, Qaseem A, Schünemann HJ, Shao R, Chen Y, Akl EA; RIGHT-COI&F Working Groups. Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI&F Checklist. Ann Intern Med. 2024;177(6):782-790. PMID: [38739919](https://pubmed.ncbi.nlm.nih.gov/38739919/)\n\n \n\n[**RIGHT for CPM**](https://www.equator-network.org/reporting-guidelines/the-reporting-checklist-for-chinese-patent-medicine-guidelines-right-for-cpm/): Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C. The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. Pharmacol Res. 2024;199:107015. PMID: [38036197](https://pubmed.ncbi.nlm.nih.gov/38036197/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.right-statement.org/extensions/20>'), ('Reporting guideline acronym', 'RIGHT for INT'), ('Study design', 'Clinical practice guidelines'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'July 26, 2024')]"
20668,Rasch Reporting Guideline for Rehabilitation Research (RULER): The RULER Statement, ,Rehabilitation medicine,Statistical methods and analyses, ,"checklist, checklists, model, modeling, modelling, outcome assessment, outcome assessments, outcome measures, Rasch, Rasch Measurement, Rasch Measurement Theory, Rasch Reporting Guideline for Rehabilitation Research (RULER), rehabilitation, rehabilitation outcome, reliability, RM analysis, RM studies, RM study, RM Theory, RULER, RULER Statement, statistical, statistics, validity", ,"Mallinson T, Kozlowski AJ, Johnston MV, Weaver J, Terhorst L, Grampurohit N, Juengst S, Ehrlich-Jones L, Heinemann AW, Melvin J, Sood P, Van de Winckel A. Rasch Reporting Guideline for Rehabilitation Research (RULER): The RULER Statement. Arch Phys Med Rehabil. 2022:S0003-9993(22)00323-9.","Mallinson T, Kozlowski AJ, Johnston MV, Weaver J, Terhorst L, Grampurohit N, Juengst S, Ehrlich-Jones L, Heinemann AW, Melvin J, Sood P, Van de Winckel A.",Archives of Physical Medicine and Rehabilitation [Arch Phys Med Rehabil.],2022, , , , ,English, ,35421395,https://pubmed.ncbi.nlm.nih.gov/35421395/, ,"Van de Winckel A, Kozlowski AJ, Johnston MV, Weaver J, Grampurohit N, Terhorst L, Juengst S, Ehrlich-Jones L, Heinemann AW, Melvin J, Sood P, Mallinson T. Reporting Guideline for RULER: Rasch Reporting Guideline for Rehabilitation Research - Explanation &amp; Elaboration manuscript. Arch Phys Med Rehabil. 2022:S0003-9993(22)00343-4. PMID: 35436496", , , ,RULER,Reporting studies that apply Rasch Measurement Theory in a rehabilitation context., , , , , , , ,no,2022-04-26 17:19:54,2023-02-24 09:57:33,rasch-reporting-guideline-for-rehabilitation-research-ruler-the-ruler-statement,"[('title', 'Rasch Reporting Guideline for Rehabilitation Research (RULER) : The RULER Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting studies that apply Rasch Measurement Theory in a rehabilitation context.'), ('Full bibliographic reference', 'Mallinson T, Kozlowski AJ, Johnston MV, Weaver J, Terhorst L, Grampurohit N, Juengst S, Ehrlich-Jones L, Heinemann AW, Melvin J, Sood P, Van de Winckel A. Rasch Reporting Guideline for Rehabilitation Research (RULER): The RULER Statement. Arch Phys Med Rehabil. 2022:S0003-9993(22)00323-9.'), ('Language', 'English'), ('PubMed ID', '[35421395](https://pubmed.ncbi.nlm.nih.gov/35421395/)'), ('Explanation and elaboration papers', 'Van de Winckel A, Kozlowski AJ, Johnston MV, Weaver J, Grampurohit N, Terhorst L, Juengst S, Ehrlich-Jones L, Heinemann AW, Melvin J, Sood P, Mallinson T. Reporting Guideline for RULER: Rasch Reporting Guideline for Rehabilitation Research - Explanation & Elaboration manuscript. Arch Phys Med Rehabil. 2022:S0003-9993(22)00343-4. PMID: [35436496](https://pubmed.ncbi.nlm.nih.gov/35436496/)'), ('Reporting guideline acronym', 'RULER'), ('Clinical area', 'Rehabilitation medicine'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Record last updated on', 'February 24, 2023')]"
20655,Using qualitative research to develop an elaboration of the TIDieR checklist for interventions to enhance vaccination communication: short report,"Clinical trials, Experimental studies",Infectious diseases,Intervention (exposure), ,"application consolidation contexualisation, checklist, checklists, clinical trial, clinical trials, communication, elaboration, infectious, intervention, interventions, qualitative, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, TIDieR, TIDieR checklist elaboration, trial, trials, vaccination, vaccine, vaccines", ,"Glenton C, Carlsen B, Winje BA, Eilers R, Wennekes MD, Hoffmann TC, Lewin S; VITAL Consortium. Using qualitative research to develop an elaboration of the TIDieR checklist for interventions to enhance vaccination communication: short report. Health Res Policy Syst. 2022;20(1):31.","Glenton C, Carlsen B, Winje BA, Eilers R, Wennekes MD, Hoffmann TC, Lewin S; VITAL Consortium.",Health Research Policy and Systems [Health Res Policy Syst.],2022,20,1,31, ,English, ,35305651,https://pubmed.ncbi.nlm.nih.gov/35305651/, , , , , , ,Reporting of vaccination communication interventions in trials., , , , , , , ,no,2022-04-08 16:12:07,2022-04-08 16:31:02,using-qualitative-research-to-develop-an-elaboration-of-the-tidier-checklist-for-interventions-to-enhance-vaccination-communication-short-report,"[('title', 'Using qualitative research to develop an elaboration of the TIDieR checklist for interventions to enhance vaccination communication: short report'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of vaccination communication interventions in trials.'), ('Full bibliographic reference', 'Glenton C, Carlsen B, Winje BA, Eilers R, Wennekes MD, Hoffmann TC, Lewin S; VITAL Consortium. Using qualitative research to develop an elaboration of the TIDieR checklist for interventions to enhance vaccination communication: short report. Health Res Policy Syst. 2022;20(1):31.'), ('Language', 'English'), ('PubMed ID', '[35305651](https://pubmed.ncbi.nlm.nih.gov/35305651/)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Infectious diseases'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'April 8, 2022')]"
20626,Preliminary Minimum Reporting Requirements for In-Vivo Neural Interface Research: I. Implantable Neural Interfaces,"Clinical trials, Experimental studies, Observational studies",Neurology,Whole report, ,"bioelectronic medicine, brain, clinical trial, clinical trials, device, devices, IEEE P2794 Standards Working Group, implant, implantable, in-vivo neural interface research, invasive, neural, neural interface, neurology, neuromodulation, neurorehabilitation, neuroscience, neurosensing, neurotechnological, neurotechnology, NI, NI technologies, NI technology, non-invasive, observation, observational, observational studies, observational study, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, RSNIR, trial, trials", ,"Eiber CD, Delbeke J, Cardoso J, de Neeling M, John SE, Won Lee C, Skefos J, Sun A, Prodanov D, McKinney Z. Preliminary Minimum Reporting Requirements for In-Vivo Neural Interface Research: I. Implantable Neural Interfaces. IEEE Open J Eng Med Biol. 2021;2:74-83.","Eiber CD, Delbeke J, Cardoso J, de Neeling M, John SE, Won Lee C, Skefos J, Sun A, Prodanov D, McKinney Z.",IEEE Open Journal of Engineering in Medicine and Biology [IEEE Open J Eng Med Biol.],2021,2, ,74-83, ,English, ,33997788,https://pubmed.ncbi.nlm.nih.gov/33997788/,Read the full-text of this reporting guideline., , , , , ,Reporting of in vivo research involving implantable neural interfaces (NIs)., , , , , , , ,no,2022-03-17 15:51:36,2022-03-17 15:53:24,preliminary-minimum-reporting-requirements-for-in-vivo-neural-interface-research-i-implantable-neural-interfaces,"[('title', 'Preliminary Minimum Reporting Requirements for In -Vivo Neural Interface Research: I. Implantable Neural Interfaces'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of in vivo research involving implantable neural interfaces (NIs).'), ('Full bibliographic reference', 'Eiber CD, Delbeke J, Cardoso J, de Neeling M, John SE, Won Lee C, Skefos J, Sun A, Prodanov D, McKinney Z. Preliminary Minimum Reporting Requirements for In-Vivo Neural Interface Research: I. Implantable Neural Interfaces. IEEE Open J Eng Med Biol. 2021;2:74-83.'), ('Language', 'English'), ('PubMed ID', '[33997788](https://pubmed.ncbi.nlm.nih.gov/33997788/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118094/) of this reporting guideline.'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Neurology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'March 17, 2022')]"
20624,Standardized Reporting of Machine Learning Applications in Urology: The STREAM-URO Framework,"Artificial intelligence/Machine learning studies, Diagnostic and prognostic studies",Urology,Whole report, ,"AI, artificial intelligence, checklist, checklists, deep learning, diagnosis, diagnostic, machine learning, ML, predict, prediction, prognosis, prognostic, Standardized Reporting of Machine Learning Applications in Urology framework, STREAM-URO, urological, urologist, urology", ,"Kwong JCC, McLoughlin LC, Haider M, Goldenberg MG, Erdman L, Rickard M, Lorenzo AJ, Hung AJ, Farcas M, Goldenberg L, Nguan C, Braga LH, Mamdani M, Goldenberg A, Kulkarni GS. Standardized Reporting of Machine Learning Applications in Urology: The STREAM-URO Framework. Eur Urol Focus. 2021 Jul;7(4):672-682.","Kwong JCC, McLoughlin LC, Haider M, Goldenberg MG, Erdman L, Rickard M, Lorenzo AJ, Hung AJ, Farcas M, Goldenberg L, Nguan C, Braga LH, Mamdani M, Goldenberg A, Kulkarni GS.",European Urolology Focus. [Eur Urol Focus.],2021,7,4,672-682, ,English, ,34362709,https://pubmed.ncbi.nlm.nih.gov/34362709/, , , , , ,STREAM-URO,Reporting of machine learning studies in urology., , , , , , , ,no,2022-03-17 14:38:22,2024-01-25 11:46:32,standardized-reporting-of-machine-learning-applications-in-urology-the-stream-uro-framework,"[('title', 'Standardized Reporting of Machine Learning Applications in Urology: The STREAM-URO Framework'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of machine learning studies in urology.'), ('Full bibliographic reference', 'Kwong JCC, McLoughlin LC, Haider M, Goldenberg MG, Erdman L, Rickard M, Lorenzo AJ, Hung AJ, Farcas M, Goldenberg L, Nguan C, Braga LH, Mamdani M, Goldenberg A, Kulkarni GS. Standardized Reporting of Machine Learning Applications in Urology: The STREAM-URO Framework. Eur Urol Focus. 2021 Jul;7(4):672-682.'), ('Language', 'English'), ('PubMed ID', '[34362709](https://pubmed.ncbi.nlm.nih.gov/34362709/)'), ('Reporting guideline acronym', 'STREAM-URO'), ('Study design', 'Artificial intelligence/Machine learning studies, Diagnostic and prognostic studies'), ('Clinical area', 'Urology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 25, 2024')]"
20622,Guidance for publishing qualitative research in informatics,Qualitative research,Health informatics,Whole report, ,"biomedical informatics, computational, computer, computing, data, digital, health informatics, informatics, qualitative, qualitative research, technology", ,"Ancker JS, Benda NC, Reddy M, Unertl KM, Veinot T. Guidance for publishing qualitative research in informatics. J Am Med Inform Assoc. 2021;28(12):2743-2748.","Ancker JS, Benda NC, Reddy M, Unertl KM, Veinot T.",Journal of the American Medical Informatics Association [J Am Med Inform Assoc.],2021,28,12,2743-2748, ,English, ,34537840,https://pubmed.ncbi.nlm.nih.gov/34537840/,Read the full-text of this reporting guideline., , , , , ,Reporting qualitative research in informatics., , , , , , , ,no,2022-03-14 16:49:02,2022-03-14 16:49:02,guidance-for-publishing-qualitative-research-in-informatics,"[('title', 'Guidance for publishing qualitative research in informatics'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting qualitative research in informatics.'), ('Full bibliographic reference', 'Ancker JS, Benda NC, Reddy M, Unertl KM, Veinot T. Guidance for publishing qualitative research in informatics. J Am Med Inform Assoc. 2021;28(12):2743-2748.'), ('Language', 'English'), ('PubMed ID', '[34537840](https://pubmed.ncbi.nlm.nih.gov/34537840/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633663/) of this reporting guideline.'), ('Study design', 'Qualitative research'), ('Clinical area', 'Health informatics'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'March 14, 2022')]"
20620,Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols,Animal pre-clinical research,Gastroenterology,"Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)", ,"animal, animal fecal transplantation, animal preclinical research, animals, checklist, checklists, faecal, fecal, fecal microbiota transplant, gastrointestinal, graft, Guidelines for Reporting on Animal Fecal Transplantation, gut, mice, microbial, microbiome, microbiota, mouse, murine, preclinical, preclinical animal research, preclinical research, rat, RATS, transplantation", ,"Secombe KR, Al-Qadami GH, Subramaniam CB, Bowen JM, Scott J, Van Sebille YZA, Snelson M, Cowan C, Clarke G, Gheorghe CE, Cryan JF, Wardill HR. Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols. Gut Microbes. 2021;13(1):1979878.","Secombe KR, Al-Qadami GH, Subramaniam CB, Bowen JM, Scott J, Van Sebille YZA, Snelson M, Cowan C, Clarke G, Gheorghe CE, Cryan JF, Wardill HR.",Gut Microbes.,2021,13,1,1979878, ,English, ,34586011,https://pubmed.ncbi.nlm.nih.gov/34586011/,Read the full-text of the GRAFT guidelines., , , , ,GRAFT,Reporting of preclinical fecal microbiota transplant (FMT) studies., , , , , , , ,no,2022-03-14 16:24:56,2022-03-14 16:26:17,guidelines-for-reporting-on-animal-fecal-transplantation-graft-studies-recommendations-from-a-systematic-review-of-murine-transplantation-protocols,"[('title', 'Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of preclinical fecal microbiota transplant (FMT) studies.'), ('Full bibliographic reference', 'Secombe KR, Al-Qadami GH, Subramaniam CB, Bowen JM, Scott J, Van Sebille YZA, Snelson M, Cowan C, Clarke G, Gheorghe CE, Cryan JF, Wardill HR. Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols. Gut Microbes. 2021;13(1):1979878.'), ('Language', 'English'), ('PubMed ID', '[34586011](https://pubmed.ncbi.nlm.nih.gov/34586011/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489962/) of the GRAFT guidelines.'), ('Reporting guideline acronym', 'GRAFT'), ('Study design', 'Animal pre-clinical research'), ('Clinical area', 'Gastroenterology'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'March 14, 2022')]"
20618,"A Scoping Review of Four Decades of Outcomes in Nonsurgical Root Canal Treatment, Nonsurgical Retreatment, and Apexification Studies: Part 3-A Proposed Framework for Standardized Data Collection and Reporting of Endodontic Outcome Studies","Clinical trials, Experimental studies, Observational studies",Dentistry,"Procedure/Method, Results, Study characteristics (participants etc.)", ,"case series, case-control, clinical trial, clinical trials, cohort, cross sectional, dental, dental pulp disease, dental pulp diseases, Dentist, Dentistry, endodontic, Endodontics, observational studies, observational study, outcome, outcome studies, outcome study, outcomes, randomised controlled trails, randomised controlled trial, randomized controlled trial, randomized controlled trials, RCT, RCTs, root canal, teeth, tooth, trial, trials", ,"Azarpazhooh A, Khazaei S, Jafarzadeh H, Malkhassian G, Sgro A, Elbarbary M, Cardoso E, Oren A, Kishen A, Shah PS. A Scoping Review of Four Decades of Outcomes in Nonsurgical Root Canal Treatment, Nonsurgical Retreatment, and Apexification Studies: Part 3-A Proposed Framework for Standardized Data Collection and Reporting of Endodontic Outcome Studies. J Endod. 2022;48(1):40-54.","Azarpazhooh A, Khazaei S, Jafarzadeh H, Malkhassian G, Sgro A, Elbarbary M, Cardoso E, Oren A, Kishen A, Shah PS.",Journal of Endodontics [J Endod.],2022,48,1,40-54, ,English, ,34688792,https://pubmed.ncbi.nlm.nih.gov/34688792/, , , , , , ,Reporting of endodontic outcome studies., , , , , , , ,no,2022-03-14 15:44:32,2022-03-14 15:44:32,a-scoping-review-of-four-decades-of-outcomes-in-nonsurgical-root-canal-treatment-nonsurgical-retreatment-and-apexification-studies-part-3-a-proposed-framework-for-standardized-data-collection-and-r,"[('title', 'A Scoping Review of Four Decades of Outcomes in Nonsurgical Root Canal Treatment, Nonsurgical Retreatment, and Apexification Studies: Part 3 -A Proposed Framework for Standardized Data Collection and Reporting of Endodontic Outcome Studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of endodontic outcome studies.'), ('Full bibliographic reference', 'Azarpazhooh A, Khazaei S, Jafarzadeh H, Malkhassian G, Sgro A, Elbarbary M, Cardoso E, Oren A, Kishen A, Shah PS. A Scoping Review of Four Decades of Outcomes in Nonsurgical Root Canal Treatment, Nonsurgical Retreatment, and Apexification Studies: Part 3-A Proposed Framework for Standardized Data Collection and Reporting of Endodontic Outcome Studies. J Endod. 2022;48(1):40-54.'), ('Language', 'English'), ('PubMed ID', '[34688792](https://pubmed.ncbi.nlm.nih.gov/34688792/)'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Dentistry'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'March 14, 2022')]"
20616,Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting,Economic evaluations, ,"Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)", ,"CEA, CEAs, checklist, checklists, cost, cost effectiveness, cost effectiveness analyses, cost effectiveness analysis, diagnosis, diagnostic, diagnostic test, diagnostic tests, diagnostics, economic, economic evaluation, economic evaluations, economics, health-economic analyses, health-economic analysis", ,"van der Pol S, Rojas Garcia P, Anto\xf1anzas Villar F, Postma MJ, van Asselt ADI. Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting. Pharmacoeconomics. 2021;39(12):1355-1363.","van der Pol S, Rojas Garcia P, Anto\xf1anzas Villar F, Postma MJ, van Asselt ADI.",Pharmacoeconomics,2021,39,12,1355-1363, ,English, ,34719752,https://pubmed.ncbi.nlm.nih.gov/34719752/,Read the full-text of this reporting guideline., , , , , ,Reporting and design of cost-effectiveness analyses (CEAs) of diagnostics., , , , , , , ,no,2022-03-14 15:06:20,2022-03-14 15:06:20,health-economic-analyses-of-diagnostics-guidance-on-design-and-reporting,"[('title', 'Health -Economic Analyses of Diagnostics: Guidance on Design and Reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting and design of cost-effectiveness analyses (CEAs) of diagnostics.'), ('Full bibliographic reference', 'van der Pol S, Rojas Garcia P, Antoñanzas Villar F, Postma MJ, van Asselt ADI. Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting. Pharmacoeconomics. 2021;39(12):1355-1363.'), ('Language', 'English'), ('PubMed ID', '[34719752](https://pubmed.ncbi.nlm.nih.gov/34719752/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599388/) of this reporting guideline.'), ('Study design', 'Economic evaluations'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'March 14, 2022')]"
20614,Reporting guidelines for human microbiome research: the STORMS checklist,Observational studies, ,Whole report, ,"checklist, checklists, epidemiology, flowchart, flowcharts, microbe, microbes, microbial, microbiome, microbiota, microorganism, microorganisms, observational research, observational studies, observational study, Organization and Reporting of Microbiome Studies, STORMS, STORMS checklist", ,"Mirzayi C, Renson A; Genomic Standards Consortium; Massive Analysis and Quality Control Society, Zohra F, Elsafoury S, Geistlinger L, Kasselman LJ, Eckenrode K, van de Wijgert J, Loughman A, Marques FZ, MacIntyre DA, Arumugam M, Azhar R, Beghini F, Bergstrom K, Bhatt A, Bisanz JE, Braun J, Bravo HC, Buck GA, Bushman F, Casero D, Clarke G, Collado MC, Cotter PD, Cryan JF, Demmer RT, Devkota S, Elinav E, Escobar JS, Fettweis J, Finn RD, Fodor AA, Forslund S, Franke A, Furlanello C, Gilbert J, Grice E, Haibe-Kains B, Handley S, Herd P, Holmes S, Jacobs JP, Karstens L, Knight R, Knights D, Koren O, Kwon DS, Langille M, Lindsay B, McGovern D, McHardy AC, McWeeney S, Mueller NT, Nezi L, Olm M, Palm N, Pasolli E, Raes J, Redinbo MR, R\xfchlemann M, Balfour Sartor R, Schloss PD, Schriml L, Segal E, Shardell M, Sharpton T, Smirnova E, Sokol H, Sonnenburg JL, Srinivasan S, Thingholm LB, Turnbaugh PJ, Upadhyay V, Walls RL, Wilmes P, Yamada T, Zeller G, Zhang M, Zhao N, Zhao L, Bao W, Culhane A, Devanarayan V, Dopazo J, Fan X, Fischer M, Jones W, Kusko R, Mason CE, Mercer TR, Sansone SA, Scherer A, Shi L, Thakkar S, Tong W, Wolfinger R, Hunter C, Segata N, Huttenhower C, Dowd JB, Jones HE, Waldron L. Reporting guidelines for human microbiome research: the STORMS checklist. Nat Med. 2021;27(11):1885-1892.","Mirzayi C, Renson A; Genomic Standards Consortium; Massive Analysis and Quality Control Society, Zohra F, Elsafoury S, Geistlinger L, Kasselman LJ, Eckenrode K, van de Wijgert J, Loughman A, Marques FZ, MacIntyre DA, Arumugam M, Azhar R, Beghini F, Bergstrom K, Bhatt A, Bisanz JE, Braun J, Bravo HC, Buck GA, Bushman F, Casero D, Clarke G, Collado MC, Cotter PD, Cryan JF, Demmer RT, Devkota S, Elinav E, Escobar JS, Fettweis J, Finn RD, Fodor AA, Forslund S, Franke A, Furlanello C, Gilbert J, Grice E, Haibe-Kains B, Handley S, Herd P, Holmes S, Jacobs JP, Karstens L, Knight R, Knights D, Koren O, Kwon DS, Langille M, Lindsay B, McGovern D, McHardy AC, McWeeney S, Mueller NT, Nezi L, Olm M, Palm N, Pasolli E, Raes J, Redinbo MR, R\xfchlemann M, Balfour Sartor R, Schloss PD, Schriml L, Segal E, Shardell M, Sharpton T, Smirnova E, Sokol H, Sonnenburg JL, Srinivasan S, Thingholm LB, Turnbaugh PJ, Upadhyay V, Walls RL, Wilmes P, Yamada T, Zeller G, Zhang M, Zhao N, Zhao L, Bao W, Culhane A, Devanarayan V, Dopazo J, Fan X, Fischer M, Jones W, Kusko R, Mason CE, Mercer TR, Sansone SA, Scherer A, Shi L, Thakkar S, Tong W, Wolfinger R, Hunter C, Segata N, Huttenhower C, Dowd JB, Jones HE, Waldron L.",Nature Medicine [Nat Med.],2021,27,11,1885-1892, ,English, ,34789871,https://pubmed.ncbi.nlm.nih.gov/34789871/,Read the full-text of the STORMS guideline., , , ,https://stormsmicrobiome.org/,STORMS,Reporting of human microbiome epidemiology studies., , , , , , , ,no,2022-03-14 11:52:30,2022-03-14 11:54:45,reporting-guidelines-for-human-microbiome-research-the-storms-checklist,"[('title', 'Reporting guidelines for human microbiome research: the STORMS checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of human microbiome epidemiology studies.'), ('Full bibliographic reference', 'Mirzayi C, Renson A; Genomic Standards Consortium; Massive Analysis and Quality Control Society, Zohra F, Elsafoury S, Geistlinger L, Kasselman LJ, Eckenrode K, van de Wijgert J, Loughman A, Marques FZ, MacIntyre DA, Arumugam M, Azhar R, Beghini F, Bergstrom K, Bhatt A, Bisanz JE, Braun J, Bravo HC, Buck GA, Bushman F, Casero D, Clarke G, Collado MC, Cotter PD, Cryan JF, Demmer RT, Devkota S, Elinav E, Escobar JS, Fettweis J, Finn RD, Fodor AA, Forslund S, Franke A, Furlanello C, Gilbert J, Grice E, Haibe-Kains B, Handley S, Herd P, Holmes S, Jacobs JP, Karstens L, Knight R, Knights D, Koren O, Kwon DS, Langille M, Lindsay B, McGovern D, McHardy AC, McWeeney S, Mueller NT, Nezi L, Olm M, Palm N, Pasolli E, Raes J, Redinbo MR, Rühlemann M, Balfour Sartor R, Schloss PD, Schriml L, Segal E, Shardell M, Sharpton T, Smirnova E, Sokol H, Sonnenburg JL, Srinivasan S, Thingholm LB, Turnbaugh PJ, Upadhyay V, Walls RL, Wilmes P, Yamada T, Zeller G, Zhang M, Zhao N, Zhao L, Bao W, Culhane A, Devanarayan V, Dopazo J, Fan X, Fischer M, Jones W, Kusko R, Mason CE, Mercer TR, Sansone SA, Scherer A, Shi L, Thakkar S, Tong W, Wolfinger R, Hunter C, Segata N, Huttenhower C, Dowd JB, Jones HE, Waldron L. Reporting guidelines for human microbiome research: the STORMS checklist. Nat Med. 2021;27(11):1885-1892.'), ('Language', 'English'), ('PubMed ID', '[34789871](https://pubmed.ncbi.nlm.nih.gov/34789871/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.nature.com/articles/s41591-021-01552-x) of the STORMS guideline.'), ('Reporting guideline website URL', '<https://stormsmicrobiome.org/>'), ('Reporting guideline acronym', 'STORMS'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'March 14, 2022')]"
20599,Smartphone-Delivered Ecological Momentary Interventions Based on Ecological Momentary Assessments to Promote Health Behaviors: Systematic Review and Adapted Checklist for Reporting Ecological Momentary Assessment and Intervention Studies,"Clinical trials, Experimental studies, Observational studies",Behavioural medicine,"Procedure/Method, Results", ,"app, apps, behavior, behavior change, behaviour, behaviour change, checklist, checklists, CREMAIs, CREMAS, Ecological Momentary Assessment, ecological momentary intervention, EMA, EMI, health behavior, health behaviour, healthy behavior, healthy behaviour, mhealth, mobile health, mobile phone, smart phone, smartphone, tailored messages", ,"Dao KP, De Cocker K, Tong HL, Kocaballi AB, Chow C, Laranjo L. Smartphone-Delivered Ecological Momentary Interventions Based on Ecological Momentary Assessments to Promote Health Behaviors: Systematic Review and Adapted Checklist for Reporting Ecological Momentary Assessment and Intervention Studies. JMIR Mhealth Uhealth. 2021;9(11):e22890.","Dao KP, De Cocker K, Tong HL, Kocaballi AB, Chow C, Laranjo L.",JMIR Mhealth Uhealth,2021,9,11,e22890, ,English, ,34806995,https://pubmed.ncbi.nlm.nih.gov/34806995/,Read the full-text of the CREMAIs reporting guideline., , , , ,CREMAIs,Reporting smartphone-delivered ecological momentary assessment (EMA) and intervention (EMI) specific aspects in behavior change experiments., , , , , , , ,no,2022-03-10 16:44:42,2022-03-10 16:44:42,smartphone-delivered-ecological-momentary-interventions-based-on-ecological-momentary-assessments-to-promote-health-behaviors-systematic-review-and-adapted-checklist-for-reporting-ecological-momentar,"[('title', 'Smartphone -Delivered Ecological Momentary Interventions Based on Ecological Momentary Assessments to Promote Health Behaviors: Systematic Review and Adapted Checklist for Reporting Ecological Momentary Assessment and Intervention Studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting smartphone-delivered ecological momentary assessment (EMA) and intervention (EMI) specific aspects in behavior change experiments.'), ('Full bibliographic reference', 'Dao KP, De Cocker K, Tong HL, Kocaballi AB, Chow C, Laranjo L. Smartphone-Delivered Ecological Momentary Interventions Based on Ecological Momentary Assessments to Promote Health Behaviors: Systematic Review and Adapted Checklist for Reporting Ecological Momentary Assessment and Intervention Studies. JMIR Mhealth Uhealth. 2021;9(11):e22890.'), ('Language', 'English'), ('PubMed ID', '[34806995](https://pubmed.ncbi.nlm.nih.gov/34806995/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663593/) of the CREMAIs reporting guideline.'), ('Reporting guideline acronym', 'CREMAIs'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Behavioural medicine'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method, Results'), ('Record last updated on', 'March 10, 2022')]"
20597,A Systematic Review of Methods and Procedures Used in Ecological Momentary Assessments of Diet and Physical Activity Research in Youth: An Adapted STROBE Checklist for Reporting EMA Studies (CREMAS),Observational studies,"Nutrition and dietetics, Sport and exercise medicine",Whole report, ,"app, apps, checklist, Checklist for Reporting EMA Studies, checklists, computer, CREMAS, Ecological Momentary Assessment, electronic devices, EMA, EMA survey, EMA surveys, exercise, laptop, mobile device, mobile phone, momentary, nutrition, physical activity, STROBE, technology, young people, youth", ,"Liao Y, Skelton K, Dunton G, Bruening M. A Systematic Review of Methods and Procedures Used in Ecological Momentary Assessments of Diet and Physical Activity Research in Youth: An Adapted STROBE Checklist for Reporting EMA Studies (CREMAS). J Med Internet Res. 2016;18(6):e151.","Liao Y, Skelton K, Dunton G, Bruening M.",Journal of Medical Internet Research [J Med Internet Res.],2016,18,6,e151, ,English, ,27328833,https://pubmed.ncbi.nlm.nih.gov/27328833/,Read the full-text of the CREMAS reporting guideline., , , , ,CREMAS,Reporting ecological momentary assessment (EMA) studies., , , , , , , ,no,2022-03-10 16:18:09,2022-03-10 16:18:09,a-systematic-review-of-methods-and-procedures-used-in-ecological-momentary-assessments-of-diet-and-physical-activity-research-in-youth-an-adapted-strobe-checklist-for-reporting-ema-studies-cremas,"[('title', 'A Systematic Review of Methods and Procedures Used in Ecological Momentary Assessments of Diet and Physical Activity Research in Youth: An Adapted STROBE Checklist for Reporting EMA Studies (CREMAS)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting ecological momentary assessment (EMA) studies.'), ('Full bibliographic reference', 'Liao Y, Skelton K, Dunton G, Bruening M. A Systematic Review of Methods and Procedures Used in Ecological Momentary Assessments of Diet and Physical Activity Research in Youth: An Adapted STROBE Checklist for Reporting EMA Studies (CREMAS). J Med Internet Res. 2016;18(6):e151.'), ('Language', 'English'), ('PubMed ID', '[27328833](https://pubmed.ncbi.nlm.nih.gov/27328833/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933800/) of the CREMAS reporting guideline.'), ('Reporting guideline acronym', 'CREMAS'), ('Study design', 'Observational studies'), ('Clinical area', 'Nutrition and dietetics, Sport and exercise medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'March 10, 2022')]"
20595,Reporting Data on Auditory Brainstem Responses (ABR) in Rats: Recommendations Based on Review of Experimental Protocols and Literature,Animal pre-clinical research,"Audiovestibular medicine, Neurology","Data, Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)", ,"ABR, animal, animal husbandry, animal model, animal models, animal pre clinical research, animal preclinical research, animal research, audiological, auditory, auditory brainstem response, auditory brainstem responses, brainstem, checklist, checklists, experimental, experimental conditions, hear, hearing, preclinical, preclinical animal research, preclinical research, rat, RATS, rodent, rodents, tinnitus rat models", ,"Domarecka E, Kalcioglu MT, Mutlu A, \xd6zg\xfcr A, Smit J, Olze H, Szczepek AJ. Reporting Data on Auditory Brainstem Responses (ABR) in Rats: Recommendations Based on Review of Experimental Protocols and Literature. Brain Sci. 2021;11(12):1596.","Domarecka E, Kalcioglu MT, Mutlu A, \xd6zg\xfcr A, Smit J, Olze H, Szczepek AJ.",Brain Sciences [Brain Sci.],2021,11,12,1596, ,English, ,34942898,https://pubmed.ncbi.nlm.nih.gov/34942898/,Read the full-text of this reporting guideline., , , , , ,Reporting of auditory brainstem responses (ABR) in animal model studies., , , , , , , ,no,2022-03-10 15:28:57,2022-03-10 15:29:38,reporting-data-on-auditory-brainstem-responses-abr-in-rats-recommendations-based-on-review-of-experimental-protocols-and-literature,"[('title', 'Reporting Data on Auditory Brainstem Responses (ABR) in Rats: Recommendations Based on Review of Experimental Protocols and Literature'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of auditory brainstem responses (ABR) in animal model studies.'), ('Full bibliographic reference', 'Domarecka E, Kalcioglu MT, Mutlu A, Özgür A, Smit J, Olze H, Szczepek AJ. Reporting Data on Auditory Brainstem Responses (ABR) in Rats: Recommendations Based on Review of Experimental Protocols and Literature. Brain Sci. 2021;11(12):1596.'), ('Language', 'English'), ('PubMed ID', '[34942898](https://pubmed.ncbi.nlm.nih.gov/34942898/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699229/) of this reporting guideline.'), ('Study design', 'Animal pre-clinical research'), ('Clinical area', 'Audiovestibular medicine, Neurology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'March 10, 2022')]"
20593,"Heterogeneity in the Identification of Potential Drug-Drug Interactions in the Intensive Care Unit: A Systematic Review, Critical Appraisal, and Reporting Recommendations",Observational studies, ,"Procedure/Method, Study characteristics (participants etc.)", ,"checklist, checklists, drug, drug-drug interaction, drug-drug interactions, drugs, ICU, intensive care, intensive care unit, interaction, medication, observational, observational studies, observational study, pDDI, pDDIs, pharmacodynamics, pharmacoepidemiology, pharmacokinetics, polypharmacy, potential drug-drug interactions, RECORD-PE", ,"Bakker T, Dongelmans DA, Nabovati E, Eslami S, de Keizer NF, Abu-Hanna A, Klopotowska JE. Heterogeneity in the Identification of Potential Drug-Drug Interactions in the Intensive Care Unit: A Systematic Review, Critical Appraisal, and Reporting Recommendations. J Clin Pharmacol. 2021.","Bakker T, Dongelmans DA, Nabovati E, Eslami S, de Keizer NF, Abu-Hanna A, Klopotowska JE.",Journal of Clinical Pharmacology [J Clin Pharmacol.],2021, , , , ,English, ,34957573,https://pubmed.ncbi.nlm.nih.gov/34957573/,Read the full-text of this reporting guideline., , , , , ,Reporting of potential drug-drug interaction (pDDI) frequency studies in the intensive care unit (ICU)., , , , , , , ,no,2022-03-10 14:48:45,2022-03-10 15:16:05,heterogeneity-in-the-identification-of-potential-drug-drug-interactions-in-the-intensive-care-unit-a-systematic-review-critical-appraisal-and-reporting-recommendations,"[('title', 'Heterogeneity in the Identification of Potential Drug -Drug Interactions in the Intensive Care Unit: A Systematic Review, Critical Appraisal, and Reporting Recommendations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of potential drug-drug interaction (pDDI) frequency studies in the intensive care unit (ICU).'), ('Full bibliographic reference', 'Bakker T, Dongelmans DA, Nabovati E, Eslami S, de Keizer NF, Abu-Hanna A, Klopotowska JE. Heterogeneity in the Identification of Potential Drug-Drug Interactions in the Intensive Care Unit: A Systematic Review, Critical Appraisal, and Reporting Recommendations. J Clin Pharmacol. 2021.'), ('Language', 'English'), ('PubMed ID', '[34957573](https://pubmed.ncbi.nlm.nih.gov/34957573/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://accp1.onlinelibrary.wiley.com/doi/10.1002/jcph.2020) of this reporting guideline.'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'March 10, 2022')]"
20531,Development of the CLARIFY (CheckList stAndardising the Reporting of Interventions For Yoga) guidelines: a Delphi study,"Clinical trials, Experimental studies, Observational studies",Sport and exercise medicine,Intervention (exposure), ,"asana, breathing, case studies, case study, CheckList stAndardising the Reporting of Interventions For Yoga (CLARIFY) guidelines, CLARIFY, CLARIFY 2021, CLARIFY guidelines, clinical trial, clinical trials, concentration, dhyana, exercise, intervention, interventions, meditation, observation, observational, observational studies, observational study, postures, pranayama, randomised clinical trial, randomised clinical trials, randomised trial, randomised trials, randomized clinical trial, randomized clinical trials, randomized trial, randomized trials, RCT, RCTs, relaxation, stretching, trial, trials, yoga, Yoga intervention, Yoga interventions, Yoga research, yogic", ,"Ward L, Nault D, Cramer H, Moonaz S. Development of the CLARIFY (CheckList stAndardising the Reporting of Interventions For Yoga) guidelines: a Delphi study. BMJ Open. 2022;12(1):e054585.","Ward L, Nault D, Cramer H, Moonaz S.",BMJ Open.,2022,12,1,e054585, ,English, ,35105638,https://pubmed.ncbi.nlm.nih.gov/35105638/,Read the full-text of the CLARIFY 2021 reporting guideline.,"Moonaz S, Nault D, Cramer H, Ward L. CLARIFY 2021: explanation and elaboration of the Delphi-based guidelines for the reporting of yoga research. BMJ Open. 2021;11(8):e045812. PMID: 34353794", , , ,CLARIFY 2021,Reporting of yoga interventions., , ,"Moonaz S, Nault D, Cramer H, Ward L. Releasing CLARIFY: A New Guideline for Improving Yoga Research Transparency and Usefulness. J Altern Complement Med. 2021;27(10):807-809. PMID: 34550773", , , , ,no,2022-02-14 17:02:13,2022-02-25 10:46:46,clarify-2021-reporting-of-yoga-research,"[('title', 'Development of the CLARIFY  (CheckList stAndardising the Reporting of Interventions For Yoga) guidelines: a Delphi study'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of yoga interventions.'), ('Full bibliographic reference', 'Ward L, Nault D, Cramer H, Moonaz S. Development of the CLARIFY (CheckList stAndardising the Reporting of Interventions For Yoga) guidelines: a Delphi study. BMJ Open. 2022;12(1):e054585.'), ('Language', 'English'), ('PubMed ID', '[35105638](https://pubmed.ncbi.nlm.nih.gov/35105638/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://bmjopen.bmj.com/content/12/1/e054585.long) of the CLARIFY 2021 reporting guideline.'), ('Explanation and elaboration papers', 'Moonaz S, Nault D, Cramer H, Ward L. CLARIFY 2021: explanation and elaboration of the Delphi-based guidelines for the reporting of yoga research. BMJ Open. 2021;11(8):e045812. PMID: [34353794](https://pubmed.ncbi.nlm.nih.gov/34353794/)'), ('Reporting guideline acronym', 'CLARIFY 2021'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Sport and exercise medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Selected relevant editorials', 'Moonaz S, Nault D, Cramer H, Ward L. Releasing CLARIFY: A New Guideline for Improving Yoga Research Transparency and Usefulness. J Altern Complement Med. 2021;27(10):807-809. PMID: [34550773](https://pubmed.ncbi.nlm.nih.gov/34550773/)'), ('Record last updated on', 'February 25, 2022')]"
20529,Early phase clinical trials extension to guidelines for the content of statistical analysis plans,"Clinical trials, Experimental studies", ,Statistical analysis plan-whole report, ,"analyses, analysis, analysis plan, checklist, checklists, clinical trial, clinical trial SAP, clinical trials, early phase, early phase clinical trial, early phase clinical trials, early phase trial, early phase trials, non-randomised phase II, non-randomized phase II, phase I, SAP, SAP guidance, SAP guideline, SAPs, statistical, statistical analysis, statistical analysis plan, statistical analysis plans, statistics, trial, trials", ,"Homer V, Yap C, Bond S, Holmes J, Stocken D, Walker K, Robinson EJ, Wheeler G, Brown S, Hinsley S, Schipper M, Weir CJ, Rantell K, Prior T, Yu LM, Kirkpatrick J, Bedding A, Gamble C, Gaunt P. Early phase clinical trials extension to guidelines for the content of statistical analysis plans. BMJ. 2022;376:e068177.","Homer V, Yap C, Bond S, Holmes J, Stocken D, Walker K, Robinson EJ, Wheeler G, Brown S, Hinsley S, Schipper M, Weir CJ, Rantell K, Prior T, Yu LM, Kirkpatrick J, Bedding A, Gamble C, Gaunt P.",BMJ.,2022,376, ,e068177, ,English, ,35131744,https://pubmed.ncbi.nlm.nih.gov/35131744/,Read the full-text of this reporting guideline for early phase clinical trial statistical analysis plans., , ,"Generic
Clinical Trial Statistical Analysis Plans: Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Dor\xe9 C, Williamson PR, Altman DG, Montgomery A, Lim P, Berlin J, Senn S, Day S, Barbachano Y, Loder E. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. JAMA. 2017;318(23):2337-2343. PMID: 29260229", , ,Reporting of early phase (phase I and non-randomised phase II) clinical trial statistical analysis plans (SAPs)., , , , , , , ,no,2022-02-14 15:43:29,2022-02-14 15:49:03,early-phase-clinical-trials-extension-to-guidelines-for-the-content-of-statistical-analysis-plans,"[('title', 'Early phase clinical trials extension to guidelines for the content of statistical analysis plans'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of early phase (phase I and non-randomised phase II) clinical trial statistical analysis plans (SAPs).'), ('Full bibliographic reference', 'Homer V, Yap C, Bond S, Holmes J, Stocken D, Walker K, Robinson EJ, Wheeler G, Brown S, Hinsley S, Schipper M, Weir CJ, Rantell K, Prior T, Yu LM, Kirkpatrick J, Bedding A, Gamble C, Gaunt P. Early phase clinical trials extension to guidelines for the content of statistical analysis plans. BMJ. 2022;376:e068177.'), ('Language', 'English'), ('PubMed ID', '[35131744](https://pubmed.ncbi.nlm.nih.gov/35131744/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.bmj.com/content/376/bmj-2021-068177.long) of this reporting guideline for early phase clinical trial statistical analysis plans.'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n**[Clinical Trial Statistical Analysis Plans](https://www.equator-network.org/reporting-guidelines/guidelines-for-the-content-of-statistical-analysis-plans-in-clinical-trials/)**: Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Doré C, Williamson PR, Altman DG, Montgomery A, Lim P, Berlin J, Senn S, Day S, Barbachano Y, Loder E. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. JAMA. 2017;318(23):2337-2343. PMID: [29260229](https://pubmed.ncbi.nlm.nih.gov/29260229/)'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Statistical analysis plan-whole report'), ('Record last updated on', 'February 14, 2022')]"
20406,PRESENT 2020: Text Expanding on the Checklist for Proper Reporting of Evidence in Sport and Exercise Nutrition Trials,"Clinical trials, Experimental studies","Nutrition and dietetics, Sport and exercise medicine",Whole report, ,"checklist, checklists, clinical trial, clinical trials, exercise, exercise metabolism, metabolism, nutrition, physiology, PRESENT 2020, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, sport, sports nutrition, trial, trials", ,"Betts JA, Gonzalez JT, Burke LM, Close GL, Garthe I, James LJ, Jeukendrup AE, Morton JP, Nieman DC, Peeling P, Phillips SM, Stellingwerff T, van Loon LJC, Williams C, Woolf K, Maughan R, Atkinson G. PRESENT 2020: Text Expanding on the Checklist for Proper Reporting of Evidence in Sport and Exercise Nutrition Trials. Int J Sport Nutr Exerc Metab. 2020;30(1):2-13.","Betts JA, Gonzalez JT, Burke LM, Close GL, Garthe I, James LJ, Jeukendrup AE, Morton JP, Nieman DC, Peeling P, Phillips SM, Stellingwerff T, van Loon LJC, Williams C, Woolf K, Maughan R, Atkinson G.",International Journal of Sport Nutrition and Exercise Metabolism [Int J Sport Nutr Exerc Metab.],2020,30,1,2-13, ,English, ,31945740,https://pubmed.ncbi.nlm.nih.gov/31945740/,Read the full-text of the PRESENT 2020 reporting guideline., , , , ,PRESENT 2020,Reporting sport and exercise nutrition trials, , , , , , , ,no,2022-01-06 14:19:57,2022-01-06 14:19:57,present-2020-text-expanding-on-the-checklist-for-proper-reporting-of-evidence-in-sport-and-exercise-nutrition-trials,"[('title', 'PRESENT 2020: Text Expanding on the Checklist for Proper Reporting of Evidence in Sport and Exercise Nutrition Trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting sport and exercise nutrition trials'), ('Full bibliographic reference', 'Betts JA, Gonzalez JT, Burke LM, Close GL, Garthe I, James LJ, Jeukendrup AE, Morton JP, Nieman DC, Peeling P, Phillips SM, Stellingwerff T, van Loon LJC, Williams C, Woolf K, Maughan R, Atkinson G. PRESENT 2020: Text Expanding on the Checklist for Proper Reporting of Evidence in Sport and Exercise Nutrition Trials. Int J Sport Nutr Exerc Metab. 2020;30(1):2-13.'), ('Language', 'English'), ('PubMed ID', '[31945740](https://pubmed.ncbi.nlm.nih.gov/31945740/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://journals.humankinetics.com/view/journals/ijsnem/30/1/article-p2.xml) of the PRESENT 2020 reporting guideline.'), ('Reporting guideline acronym', 'PRESENT 2020'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Nutrition and dietetics, Sport and exercise medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 6, 2022')]"
20363,Intraoperative fluorescence diagnosis in the brain: a systematic review and suggestions for future standards on reporting diagnostic accuracy and clinical utility,Diagnostic and prognostic studies,"Neurology, Surgery","Intervention (exposure), Procedure/Method, Statistical methods and analyses", ,"biopsies, biopsy, brain, brain tumor, brain tumour, diagnosis, diagnostic, diagnostic accuracy, diagnostic test accuracy, fluorescence, glioma, gliomas, intraoperative, optical, STARD, surgery, surgical, tissue", ,"Stummer W, Koch R, Valle RD, Roberts DW, Sanai N, Kalkanis S, Hadjipanayis CG, Suero Molina E. Intraoperative fluorescence diagnosis in the brain: a systematic review and suggestions for future standards on reporting diagnostic accuracy and clinical utility. Acta Neurochir (Wien). 2019;161(10):2083-2098.","Stummer W, Koch R, Valle RD, Roberts DW, Sanai N, Kalkanis S, Hadjipanayis CG, Suero Molina E.",Acta Neurochirurgica (Wien) [Acta Neurochir (Wien).],2019,161,10,2083-2098, ,English, ,31363920,https://pubmed.ncbi.nlm.nih.gov/31363920/, , , , , , ,Reporting intraoperative optical diagnosis studies., , , , , , , ,no,2021-11-24 17:30:42,2021-11-24 17:30:42,intraoperative-fluorescence-diagnosis-in-the-brain-a-systematic-review-and-suggestions-for-future-standards-on-reporting-diagnostic-accuracy-and-clinical-utility,"[('title', 'Intraoperative fluorescence diagnosis in the brain: a systematic review and suggestions for future standards on reporting diagnostic accuracy and clinical utility'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting intraoperative optical diagnosis studies.'), ('Full bibliographic reference', 'Stummer W, Koch R, Valle RD, Roberts DW, Sanai N, Kalkanis S, Hadjipanayis CG, Suero Molina E. Intraoperative fluorescence diagnosis in the brain: a systematic review and suggestions for future standards on reporting diagnostic accuracy and clinical utility. Acta Neurochir (Wien). 2019;161(10):2083-2098.'), ('Language', 'English'), ('PubMed ID', '[31363920](https://pubmed.ncbi.nlm.nih.gov/31363920/)'), ('Study design', 'Diagnostic and prognostic studies'), ('Clinical area', 'Neurology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Procedure/Method, Statistical methods and analyses'), ('Record last updated on', 'November 24, 2021')]"
20358,Checklist for Theoretical Report in Epidemiological Studies (CRT-EE): explanation and elaboration,"Clinical trials, Experimental studies, Observational studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,Whole report, ,"checklist, checklists, CRT-EE, epidemiological, epidemiology, observational studies, observational study, theoretical, theoretical model, theoretical report, theoretical reports, theories, theory, theory model", ,"de Souza Filho BAB, Tritany EF, Struchiner CJ. Checklist for Theoretical Report in Epidemiological Studies (CRT-EE): explanation and elaboration. Physis Rev Sa\xfade Coletiva. 2021;31(01):e310124.

","de Souza Filho BAB, Tritany EF, Struchiner CJ.",Physis Rev Sa\xfade Coletiva.,2021,31,1,e310124, , , , , ,Read the full-text of the CRT-EE reporting guideline., , , ,https://crt-statement.org/,CRT-EE,"Reporting of aspects related to the theory/theoretical model used in epidemiological studies.



CRT-EE checklist

","The CRT-EE reporting guideline is available in Portuguese.

The CRT-EE checklist is available in Portuguese.

", , , , , , ,no,2021-11-24 16:12:21,2021-11-25 15:54:25,checklist-for-theoretical-report-in-epidemiological-studies-crt-ee-explanation-and-elaboration,"[('title', 'Checklist for Theoretical Report in Epidemiological Studies (CRT-EE) : explanation and elaboration'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of aspects related to the theory/theoretical model used in epidemiological studies.\n\n \n\n \xa0\n\n \n\n[CRT-EE checklist](https://crt-statement.org/elementor-1356/)\n\n \n\n'), ('Full bibliographic reference', 'de Souza Filho BAB, Tritany EF, Struchiner CJ. Checklist for Theoretical Report in Epidemiological Studies (CRT-EE): explanation and elaboration. Physis Rev Saúde Coletiva. 2021;31(01):e310124.\n\n \n\n'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.scielo.br/j/physis/a/VbRxN5JykBvV3SRSm8TDj5v/?lang=en#) of the CRT-EE reporting guideline.'), ('Availability in additional languages', 'The CRT-EE reporting guideline is available in [Portuguese](https://www.scielo.br/j/physis/a/VbRxN5JykBvV3SRSm8TDj5v/?lang=pt).\n\n \n\n The CRT-EE checklist is available in [Portuguese](https://crt-statement.org/crt-ee/).\n\n \n\n'), ('Reporting guideline website URL', '<https://crt-statement.org/>'), ('Reporting guideline acronym', 'CRT-EE'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 25, 2021')]"
20265,STAndard Reporting of CAries Detection and Diagnostic Studies (STARCARDDS),Diagnostic and prognostic studies,Dentistry,Whole report, ,"caries, cariologic, cariology, checklist, checklists, dental, Dentist, Dentistry, detect, detection, diagnosis, diagnostic, in vitro, in vivo, STAndard Reporting of CAries Detection and Diagnostic Studies, STARCARDDS, STARCARDDS checklist, STARD, teeth, tooth", ,"Neuhaus KW, Eggmann F, K\xfchnisch J, Kapor S, Janjic Rankovic M, Sch\xfcler I, Krause F, Lussi A, Michou S, Ekstrand K, Huysmans MC. STAndard Reporting of CAries Detection and Diagnostic Studies (STARCARDDS). Clin Oral Investig. 2021.","Neuhaus KW, Eggmann F, K\xfchnisch J, Kapor S, Janjic Rankovic M, Sch\xfcler I, Krause F, Lussi A, Michou S, Ekstrand K, Huysmans MC.",Clinical Oral Investigations [Clin Oral Investig.],2021, , , , ,English, ,34623505,https://pubmed.ncbi.nlm.nih.gov/34623505/,Read the full-text of the STARCARDDS guideline., , , , ,STARCARDDS,Reporting of caries diagnosis and detection studies (both in vivo and in vitro)., , , , , , , ,no,2021-11-10 17:01:52,2021-11-10 17:01:52,standard-reporting-of-caries-detection-and-diagnostic-studies-starcardds,"[('title', 'STAndard Reporting of CAries Detection and Diagnostic Studies (STARCARDDS)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of caries diagnosis and detection studies (both in vivo and in vitro).'), ('Full bibliographic reference', 'Neuhaus KW, Eggmann F, Kühnisch J, Kapor S, Janjic Rankovic M, Schüler I, Krause F, Lussi A, Michou S, Ekstrand K, Huysmans MC. STAndard Reporting of CAries Detection and Diagnostic Studies (STARCARDDS). Clin Oral Investig. 2021.'), ('Language', 'English'), ('PubMed ID', '[34623505](https://pubmed.ncbi.nlm.nih.gov/34623505/)'), ('Relevant URLs\n\n(full-text if available)', 'Read the full-text of the [STARCARDDS guideline](https://link.springer.com/article/10.1007%2Fs00784-021-04173-3).'), ('Reporting guideline acronym', 'STARCARDDS'), ('Study design', 'Diagnostic and prognostic studies'), ('Clinical area', 'Dentistry'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 10, 2021')]"
20263,"Implementing the 27 PRISMA 2020 Statement items for systematic reviews in the sport and exercise medicine, musculoskeletal rehabilitation and sports science fields: the PERSiST (implementing Prisma in Exercise, Rehabilitation, Sport medicine and SporTs science) guidance",Systematic reviews/Meta-analyses/Reviews/HTA/Overviews,"Physiotherapy, Rheumatology, Sport and exercise medicine",Whole report, ,"application consolidation contexualisation, exercise, musculoskeletal, PERSiST, PERSiST guidance, physical activity, physiotherapy, PRISMA, rehabilitation, review, reviews, rheumatology, sport, sport and exercise medicine, sports medicine, sports science, systematic review, systematic reviews", ,"Ardern CL, B\xfcttner F, Andrade R, Weir A, Ashe MC, Holden S, Impellizzeri FM, Delahunt E, Dijkstra HP, Mathieson S, Rathleff MS, Reurink G, Sherrington C, Stamatakis E, Vicenzino B, Whittaker JL, Wright AA, Clarke M, Moher D, Page MJ, Khan KM, Winters M. Implementing the 27 PRISMA 2020 Statement items for systematic reviews in the sport and exercise medicine, musculoskeletal rehabilitation and sports science fields: the PERSiST (implementing Prisma in Exercise, Rehabilitation, Sport medicine and SporTs science) guidance. Br J Sports Med. 2021:bjsports-2021-103987.","Ardern CL, B\xfcttner F, Andrade R, Weir A, Ashe MC, Holden S, Impellizzeri FM, Delahunt E, Dijkstra HP, Mathieson S, Rathleff MS, Reurink G, Sherrington C, Stamatakis E, Vicenzino B, Whittaker JL, Wright AA, Clarke M, Moher D, Page MJ, Khan KM, Winters M.",British Journal of Sports Medicine [Br J Sports Med.],2021, , , , ,English, ,34625401,https://pubmed.ncbi.nlm.nih.gov/34625401/,Read the full-text of the PERSiST guidance., , , , ,PERSiST ,"Reporting in systematic reviews in sport and exercise medicine (including physical activity), musculoskeletal rehabilitation (including physiotherapy), and sports science.",The PERSiST reporting guideline is available in Italian., , , , , , ,no,2021-11-10 15:34:40,2023-08-16 10:41:00,persist,"[('title', 'Implementing the 27 PRISMA 2020 Statement items for systematic reviews in the sport and exercise medicine, musculoskeletal rehabilitation and sports science fields: the PERSiST (implementing Prisma in Exercise, Rehabilitation, Sport medicine and SporTs science) guidance'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting in systematic reviews in sport and exercise medicine (including physical activity), musculoskeletal rehabilitation (including physiotherapy), and sports science.'), ('Full bibliographic reference', 'Ardern CL, Büttner F, Andrade R, Weir A, Ashe MC, Holden S, Impellizzeri FM, Delahunt E, Dijkstra HP, Mathieson S, Rathleff MS, Reurink G, Sherrington C, Stamatakis E, Vicenzino B, Whittaker JL, Wright AA, Clarke M, Moher D, Page MJ, Khan KM, Winters M. Implementing the 27 PRISMA 2020 Statement items for systematic reviews in the sport and exercise medicine, musculoskeletal rehabilitation and sports science fields: the PERSiST (implementing Prisma in Exercise, Rehabilitation, Sport medicine and SporTs science) guidance. Br J Sports Med. 2021:bjsports-2021-103987.'), ('Language', 'English'), ('PubMed ID', '[34625401](https://pubmed.ncbi.nlm.nih.gov/34625401/)'), ('Relevant URLs\n\n(full-text if available)', 'Read the full-text of the [PERSiST guidance](https://bjsm.bmj.com/content/early/2021/10/08/bjsports-2021-103987.long).'), ('Availability in additional languages', 'The PERSiST reporting guideline is available in [Italian](https://osf.io/preprints/metaarxiv/pwrjv/).'), ('Reporting guideline acronym', 'PERSiST'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Clinical area', 'Physiotherapy, Rheumatology, Sport and exercise medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'August 16, 2023')]"
20180,Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement,Observational studies, ,Whole report, ,"epidemiology, gene, genetic, genetic variant, genetic variants, genetic variation, genotype, instrumental variable framework, mendelian randomization, modifiable exposure, modifiable exposures, MR, observational studies, observational study, risk, risk factor, risk factors, STROBE extension, STROBE-MR, STROBE-MR Statement", ,"Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621.","Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB.",JAMA,2021,326,16,1614-1621, ,English, ,34698778,https://pubmed.ncbi.nlm.nih.gov/34698778/,The full-text of the STROBE-MR guideline is available on the JAMA website.,Read the STROBE-MR explanation and elaboration paper., ,"Generic
STROBE: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Ann Intern Med. 2007;147(8):573-577. PMID: 17938396
PLoS Med. 2007;4(10):e296. PMID: 17941714
BMJ. 2007;335(7624):806-808. PMID: 17947786
Prev Med. 2007;45(4):247-251. PMID: 17950122
Epidemiology. 2007;18(6):800-804. PMID: 18049194
Lancet. 2007;370(9596):1453-1457. PMID: 18064739

Specialised
STREGA: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.

PLoS Med. 2009;6(2):e22. PMID: 19192942
Hum Genet. 2009;125(2):131-151. PMID: 19184668
Eur J Epidemiol. 2009;24(1):37-55. PMID: 19189221
Ann Intern Med. 2009;150(3):206-215. PMID: 19189911
J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: 19217256
Genet Epidemiol. 2009;33(7):581-598. PMID: 19278015
Eur J Clin Invest. 2009;39(4):247-266. PMID: 19297801

STROBE-ME: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: 22023344

STROBE checklist for conference abstracts
First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. Link to full text pdf

STROME-ID: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: 24631223

Longitudinal observational drug studies in rheumatology: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: 24058015

Case-cohort studies: Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: 24972092

STROBE-RDS: White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: 26112433

RECORD: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: 26440803

STROBE-AMS: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schr\xf6der W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: 26895985

STROBE-nut: Lachat C, Hawwash D, Ock\xe9 MC, Berg C, Forsum E, H\xf6rnell A, Larsson C, Sonestedt E, Wirf\xe4lt E, \xc5kesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology?Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: 27270749

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

ROSES-I: Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: 27417916

STROBE-NI: Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: 27633910

Propensity score analysis: Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: 28376195

RECORD-PE: Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.

STROBE-SIIS: International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, H\xe4gglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).

Br J Sports Med. 2020;54(7):372-389. PMID: 32071062
Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: 32118084



", ,STROBE-MR,Reporting mendelian randomization (MR) studies., , , , , , , ,yes,2021-10-27 17:03:32,2021-11-25 15:19:21,strobe-mr-statement,"[('title', 'Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting mendelian randomization (MR) studies.'), ('Full bibliographic reference', 'Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621.'), ('Language', 'English'), ('PubMed ID', '[34698778](https://pubmed.ncbi.nlm.nih.gov/34698778/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the STROBE-MR guideline is available on the [JAMA website](https://jamanetwork.com/journals/jama/fullarticle/2785494).'), ('Explanation and elaboration papers', 'Read the [STROBE-MR explanation and elaboration paper](https://www.bmj.com/content/375/bmj.n2233).'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**STROBE**](https://www.equator-network.org/reporting-guidelines/strobe/): von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.\n\n \n\n Ann Intern Med. 2007;147(8):573-577. PMID: [17938396](http://www.ncbi.nlm.nih.gov/pubmed/17938396)\n\n PLoS Med. 2007;4(10):e296. PMID: [17941714](http://www.ncbi.nlm.nih.gov/pubmed/17941714)\n\n BMJ. 2007;335(7624):806-808. PMID: [17947786](http://www.ncbi.nlm.nih.gov/pubmed/17947786)\n\n Prev Med. 2007;45(4):247-251. PMID: [17950122](http://www.ncbi.nlm.nih.gov/pubmed/17950122)\n\n Epidemiology. 2007;18(6):800-804. PMID: [18049194](http://www.ncbi.nlm.nih.gov/pubmed/18049194)\n\n Lancet. 2007;370(9596):1453-1457. PMID: [18064739](http://www.ncbi.nlm.nih.gov/pubmed/18064739)\n\n \n\n**Specialised**\n\n[**STREGA**](https://www.equator-network.org/reporting-guidelines/strobe-strega/): Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.\n\n \n\n PLoS Med. 2009;6(2):e22. PMID: [19192942](http://www.ncbi.nlm.nih.gov/pubmed/19192942)\n\n Hum Genet. 2009;125(2):131-151. PMID: [19184668](http://www.ncbi.nlm.nih.gov/pubmed/19184668)\n\n Eur J Epidemiol. 2009;24(1):37-55. PMID: [19189221](http://www.ncbi.nlm.nih.gov/pubmed/19189221)\n\n Ann Intern Med. 2009;150(3):206-215. PMID: [19189911](http://www.ncbi.nlm.nih.gov/pubmed/19189911)\n\n J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: [19217256](http://www.ncbi.nlm.nih.gov/pubmed/19217256)\n\n Genet Epidemiol. 2009;33(7):581-598. PMID: [19278015](http://www.ncbi.nlm.nih.gov/pubmed/19278015)\n\n Eur J Clin Invest. 2009;39(4):247-266. PMID: [19297801](http://www.ncbi.nlm.nih.gov/pubmed/19297801)\n\n \n\n[**STROBE-ME**](https://www.equator-network.org/reporting-guidelines/strobe-me/): Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: [22023344](http://www.ncbi.nlm.nih.gov/pubmed/22023344)\n\n \n\n[**STROBE checklist for conference abstracts**](https://www.equator-network.org/reporting-guidelines/strobe-abstracts/)\n\n First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. [Link to full text pdf](https://www.strobe-statement.org/download/strobe-checklist-conference-abstracts)\n\n \n\n[**STROME-ID**](https://www.equator-network.org/reporting-guidelines/strome-id/): Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: [24631223](http://www.ncbi.nlm.nih.gov/pubmed/24631223)\n\n \n\n[**Longitudinal observational drug studies in rheumatology**](https://www.equator-network.org/reporting-guidelines/launch-of-a-checklist-for-reporting-longitudinal-observational-drug-studies-in-rheumatology-a-eular-extension-of-strobe-guidelines-based-on-experience-from-biologics-registries/): Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: [24058015](http://www.ncbi.nlm.nih.gov/pubmed/24058015)\n\n \n\n[**Case-cohort studies**](https://www.equator-network.org/reporting-guidelines/a-review-of-published-analyses-of-case-cohort-studies-and-recommendations-for-future-reporting/): Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: [24972092](https://www.ncbi.nlm.nih.gov/pubmed/24972092)\n\n \n\n[**STROBE-RDS**](https://www.equator-network.org/reporting-guidelines/strobe-rds/): White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: [26112433](http://www.ncbi.nlm.nih.gov/pubmed/26112433)\n\n \n\n[**RECORD**](https://www.equator-network.org/reporting-guidelines/record/): Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: [26440803](http://www.ncbi.nlm.nih.gov/pubmed/26440803)\n\n \n\n[**STROBE-AMS**](https://www.equator-network.org/reporting-guidelines/strobe-ams/): Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schröder W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: [26895985](http://www.ncbi.nlm.nih.gov/pubmed/26895985)\n\n \n\n[**STROBE-nut**](https://www.equator-network.org/reporting-guidelines/strobe-nut/): Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology—Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: [27270749](https://www.ncbi.nlm.nih.gov/pubmed/27270749)\n\n \n\n[**Simulation Research**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**ROSES-I**](https://www.equator-network.org/reporting-guidelines/roses-i-statement/): Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: [27417916](https://www.ncbi.nlm.nih.gov/pubmed/27417916)\n\n \n\n[**STROBE-NI**](https://www.equator-network.org/reporting-guidelines/strobe-ni/): Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: [27633910](https://www.ncbi.nlm.nih.gov/pubmed/27633910)\n\n \n\n[**Propensity score analysis**](https://www.equator-network.org/reporting-guidelines/reporting-and-guidelines-in-propensity-score-analysis-a-systematic-review-of-cancer-and-cancer-surgical-studies/): Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: [28376195](https://www.ncbi.nlm.nih.gov/pubmed/28376195)\n\n \n\n[**RECORD-PE**](https://www.equator-network.org/reporting-guidelines/record-pe/): Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). [BMJ 2018;363:k3532](https://www.bmj.com/content/363/bmj.k3532.full).\n\n \n\n[**STROBE-SIIS**](https://www.equator-network.org/reporting-guidelines/strobe-extension-for-sports-injury-illness-surveillance/): International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, Hägglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).\n\n \n\n Br J Sports Med. 2020;54(7):372-389. PMID: [32071062](https://pubmed.ncbi.nlm.nih.gov/32071062/)\n\n Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: [32118084](https://pubmed.ncbi.nlm.nih.gov/32118084/)\n\n \n\n \xa0\n\n \n\n'), ('Reporting guideline acronym', 'STROBE-MR'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 25, 2021')]"
20177,Recommended reporting items for epidemic forecasting and prediction research: The EPIFORGE 2020 guidelines,Observational studies,Infectious diseases,Whole report, ,"checklist, checklists, epidemic, epidemic forecasting research, epidemics, epidemiologic, epidemiology, EPIFORGE, EPIFORGE 2020, forecast, forecasting, infectious disease, infectious diseases, model, modeling, models, outbreak, prediction", ,"Pollett S, Johansson MA, Reich NG, Brett-Major D, Del Valle SY, Venkatramanan S, Lowe R, Porco T, Berry IM, Deshpande A, Kraemer MUG, Blazes DL, Pan-Ngum W, Vespigiani A, Mate SE, Silal SP, Kandula S, Sippy R, Quandelacy TM, Morgan JJ, Ball J, Morton LC, Althouse BM, Pavlin J, van Panhuis W, Riley S, Biggerstaff M, Viboud C, Brady O, Rivers C. Recommended reporting items for epidemic forecasting and prediction research: The EPIFORGE 2020 guidelines. PLoS Med. 2021 Oct 19;18(10):e1003793.","Pollett S, Johansson MA, Reich NG, Brett-Major D, Del Valle SY, Venkatramanan S, Lowe R, Porco T, Berry IM, Deshpande A, Kraemer MUG, Blazes DL, Pan-Ngum W, Vespigiani A, Mate SE, Silal SP, Kandula S, Sippy R, Quandelacy TM, Morgan JJ, Ball J, Morton LC, Althouse BM, Pavlin J, van Panhuis W, Riley S, Biggerstaff M, Viboud C, Brady O, Rivers C.",PLoS Medicine [PLoS Med.],2021,18,10, , ,English, ,34665805,https://pubmed.ncbi.nlm.nih.gov/34665805/,Read the full-text of the EPIFORGE 2020 reporting guideline., , , , ,EPIFORGE 2020,Reporting of epidemic forecasting research., , , , , , , ,no,2021-10-25 16:50:54,2021-10-25 16:50:54,recommended-reporting-items-for-epidemic-forecasting-and-prediction-research-the-epiforge-2020-guidelines,"[('title', 'Recommended reporting items for epidemic forecasting and prediction research: The EPIFORGE 2020 guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of epidemic forecasting research.'), ('Full bibliographic reference', 'Pollett S, Johansson MA, Reich NG, Brett-Major D, Del Valle SY, Venkatramanan S, Lowe R, Porco T, Berry IM, Deshpande A, Kraemer MUG, Blazes DL, Pan-Ngum W, Vespigiani A, Mate SE, Silal SP, Kandula S, Sippy R, Quandelacy TM, Morgan JJ, Ball J, Morton LC, Althouse BM, Pavlin J, van Panhuis W, Riley S, Biggerstaff M, Viboud C, Brady O, Rivers C. Recommended reporting items for epidemic forecasting and prediction research: The EPIFORGE 2020 guidelines. PLoS Med. 2021 Oct 19;18(10):e1003793.'), ('Language', 'English'), ('PubMed ID', '[34665805](https://pubmed.ncbi.nlm.nih.gov/34665805/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text of the EPIFORGE 2020](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003793) reporting guideline.'), ('Reporting guideline acronym', 'EPIFORGE 2020'), ('Study design', 'Observational studies'), ('Clinical area', 'Infectious diseases'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 25, 2021')]"
20130,Extending the CONSORT Statement to moxibustion,"Clinical trials, Experimental studies",Complementary and alternative medicine,Intervention (exposure), ,"Chinese medicine, clinical trial, clinical trials, CONSORT, moxibustion, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, STandards for Reporting Interventions in Clinical Trials Of Moxibustion, STRICTOM, STRICTOM checklist, TCM, traditional Chinese medicine, trial, trials", ,"Cheng CW, Fu SF, Zhou QH, Wu TX, Shang HC, Tang XD, Liu ZS, Liu J, Lin ZX, Lao L, L\xfc AP, Zhang BL, Liu BY, Bian ZX. Extending the CONSORT Statement to moxibustion. J Integr Med. 2013;11(1):54-63.","Cheng CW, Fu SF, Zhou QH, Wu TX, Shang HC, Tang XD, Liu ZS, Liu J, Lin ZX, Lao L, L\xfc AP, Zhang BL, Liu BY, Bian ZX.",Journal of Integrative Medicine [J Integr Med.],2013,11,1,54-63, ,English, ,23464647,https://pubmed.ncbi.nlm.nih.gov/23464647/, , , , , ,STRICTOM,Reporting of clinical trials of moxibustion., , , , , , , ,no,2021-10-07 16:02:20,2021-10-07 16:02:20,extending-the-consort-statement-to-moxibustion,"[('title', 'Extending the CONSORT Statement to moxibustion'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of clinical trials of moxibustion.'), ('Full bibliographic reference', 'Cheng CW, Fu SF, Zhou QH, Wu TX, Shang HC, Tang XD, Liu ZS, Liu J, Lin ZX, Lao L, Lü AP, Zhang BL, Liu BY, Bian ZX. Extending the CONSORT Statement to moxibustion. J Integr Med. 2013;11(1):54-63.'), ('Language', 'English'), ('PubMed ID', '[23464647](https://pubmed.ncbi.nlm.nih.gov/23464647/)'), ('Reporting guideline acronym', 'STRICTOM'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'October 7, 2021')]"
20128,Consensus-based recommendations for case report in Chinese medicine (CARC),Observational studies,Complementary and alternative medicine,Whole report, ,"CARC, CARC checklist, CARC recommendations, case report, case reporting, case reports, checklist, checklists, Chinese medicine, TCM, traditional Chinese medicine", ,"Fu SF, Cheng CW, Zhang L, Zhong LL, Kun W, Lin J, Zhang BL, Wang YY, Shang HC, Bian ZX. Consensus-based recommendations for case report in Chinese medicine (CARC). Chin J Integr Med. 2016;22(1):73-9.","Fu SF, Cheng CW, Zhang L, Zhong LL, Kun W, Lin J, Zhang BL, Wang YY, Shang HC, Bian ZX.",Chinese Journal of Integrated Traditional and Western Medicine [Chin J Integr Med.],2016,22,1,73-79, ,English, ,26729045,https://pubmed.ncbi.nlm.nih.gov/26729045/, , , , , ,CARC,Reporting case reports in Chinese medicine., , , , , , , ,no,2021-10-07 15:43:30,2021-10-07 15:43:30,consensus-based-recommendations-for-case-report-in-chinese-medicine-carc,"[('title', 'Consensus-based recommendations for case report in Chinese medicine (CARC)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting case reports in Chinese medicine.'), ('Full bibliographic reference', 'Fu SF, Cheng CW, Zhang L, Zhong LL, Kun W, Lin J, Zhang BL, Wang YY, Shang HC, Bian ZX. Consensus-based recommendations for case report in Chinese medicine (CARC). Chin J Integr Med. 2016;22(1):73-9.'), ('Language', 'English'), ('PubMed ID', '[26729045](https://pubmed.ncbi.nlm.nih.gov/26729045/)'), ('Reporting guideline acronym', 'CARC'), ('Study design', 'Observational studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 7, 2021')]"
20118,"Reporting Guidelines for Whole-Body Vibration Studies in Humans, Animals and Cell Cultures: A Consensus Statement from an International Group of Experts", ,"Physiotherapy, Sport and exercise medicine","Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)", ,"checklist, checklists, cognitive function, cognitive functions, exercise, human movement science, muscle activity, muscle function, physical function, physical functions, physical therapy, physiotherapy, rehabilitation, sport, sport science, vibration, vibration exercise, vibration stimulation, vibration therapy, vibrations, WBV, whole body vibration", ,"van Heuvelen MJG, Rittweger J, Judex S, Sa\xf1udo B, Seixas A, Fuermaier ABM, Tucha O, Nyakas C, Mar\xedn PJ, Taiar R, Stark C, Schoenau E, S\xe1-Caputo DC, Bernardo-Filho M, van der Zee EA. Reporting Guidelines for Whole-Body Vibration Studies in Humans, Animals and Cell Cultures: A Consensus Statement from an International Group of Experts. Biology. 2021;10(10):965.","van Heuvelen MJG, Rittweger J, Judex S, Sa\xf1udo B, Seixas A, Fuermaier ABM, Tucha O, Nyakas C, Mar\xedn PJ, Taiar R, Stark C, Schoenau E, S\xe1-Caputo DC, Bernardo-Filho M, van der Zee EA.",Biology,2021,10,10,'965.', ,English, , , ,Read the full-text of this reporting guideline., , , , , ,Reporting of whole-body vibration (WBV) studies., , , , , , , ,no,2021-10-06 14:50:49,2021-10-06 14:50:49,reporting-guidelines-for-whole-body-vibration-studies-in-humans-animals-and-cell-cultures-a-consensus-statement-from-an-international-group-of-experts,"[('title', 'Reporting Guidelines for Whole -Body Vibration Studies in Humans, Animals and Cell Cultures: A Consensus Statement from an International Group of Experts'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of whole-body vibration (WBV) studies.'), ('Full bibliographic reference', 'van Heuvelen MJG, Rittweger J, Judex S, Sañudo B, Seixas A, Fuermaier ABM, Tucha O, Nyakas C, Marín PJ, Taiar R, Stark C, Schoenau E, Sá-Caputo DC, Bernardo-Filho M, van der Zee EA. Reporting Guidelines for Whole-Body Vibration Studies in Humans, Animals and Cell Cultures: A Consensus Statement from an International Group of Experts. Biology. 2021;10(10):965.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'Read the [full-text of this reporting guideline](https://www.mdpi.com/2079-7737/10/10/965).'), ('Clinical area', 'Physiotherapy, Sport and exercise medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'October 6, 2021')]"
20103,Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension,"Clinical trials, Experimental studies, Study protocols",Pathology,Whole report, ,"biological tissue, biological tissues, biomarker, biomarkers, biospecimen, biospecimens, cellular, checklist, checklists, clinical trial protocol, clinical trial protocols, eligibility, histological, laboratory, molecular, pathogenesis, pathological, pathologist, pathology, protocol, protocols, RCT protocol, RCT protocols, reporting guidelines for cellular and molecular pathology content in clinical trial protocols, specimen, specimens, SPIRIT, SPIRIT 2013, SPIRIT Extension, SPIRIT-Path, SPIRIT-Path checklist, SPIRIT-Path extension, trial eligibility, trial protocol, trial protocols", ,"Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445.","Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group.",Lancet Oncology\xa0 [Lancet Oncol.],2021,22,10,e435-e445, ,English, ,34592193,https://pubmed.ncbi.nlm.nih.gov/34592193/,The SPIRIT-Path checklist can be accessed from the NCRI website., , ,"Generic

SPIRIT 2025 Statement: Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hr\xf3bjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.

BMJ. 2025; 388:e081660. PMID:\xa040294956
JAMA. 2025.\xa0PMID: 40294593
Lancet 2025.
Nat Med. 2025.\xa0PMID: 40295741
PLoS Med. 2025; 22(4): e1004587.\xa0PMID: 40294521

Specialised
SPIRIT-PRO: Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. Link to abstract

SPIRIT-TCM: Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: 30484022

SPENT 2019: Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. Link to full-text.

SPIRIT-AI: Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.
BMJ. 2020;370:m3210. PMID: 32907797
Nat Med. 2020;26(9):1351?1363. PMID: 32908284
Lancet Digital Health. 2020;2(10):e549-e560. PMID: 33328049

SPIRIT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: 36512367

SPIRIT-DEFINE: Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: 37863491

SPIRIT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: 38051535

SPIRIT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: 38981624

SPIRIT-iNeurostim: Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: 39610902

",https://www.ncri.org.uk/spirit-path-extension/,SPIRIT-Path,Reporting of cellular and molecular pathology content in clinical trial protocols., , , , , , , ,yes,2021-10-01 16:02:26,2025-05-30 09:13:46,spirit-path,"[('title', 'Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of cellular and molecular pathology content in clinical trial protocols.'), ('Full bibliographic reference', ""Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445.""), ('Language', 'English'), ('PubMed ID', '[34592193](https://pubmed.ncbi.nlm.nih.gov/34592193/)'), ('Relevant URLs\n\n(full-text if available)', 'The SPIRIT-Path checklist can be accessed from the [NCRI website](https://www.ncri.org.uk/publications/spirit-2013-and-spirit-path-extension-checklist).'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n \n\n**[SPIRIT 2025 Statement](https://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/):** Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hróbjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.\n\n \n\nBMJ. 2025; 388:e081660. [PMID:40294956](https://pubmed.ncbi.nlm.nih.gov/40294956/)\n\n JAMA. 2025.[PMID:](https://pubmed.ncbi.nlm.nih.gov/40294593/) [40294593](https://pubmed.ncbi.nlm.nih.gov/40294593/)\n\n Lancet 2025.\n\n Nat Med. 2025.[PMID: 40295741](https://pubmed.ncbi.nlm.nih.gov/40295741)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID: 40294521](https://pubmed.ncbi.nlm.nih.gov/40294521/)\n\n \n\n**Specialised**\n\n[**SPIRIT-PRO**](https://www.equator-network.org/reporting-guidelines/spirit-pro/): Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. [Link to abstract](https://jamanetwork.com/journals/jama/article-abstract/2671472)\n\n \n\n**[SPIRIT-TCM](https://www.equator-network.org/reporting-guidelines/standard-protocol-items-for-clinical-trials-with-traditional-chinese-medicine-spirit-tcm-extension-2018/)**: Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: [30484022](https://www.ncbi.nlm.nih.gov/pubmed/30484022)\n\n \n\n[**SPENT 2019**](https://www.equator-network.org/reporting-guidelines/spirit-extension-n-of-1-trials-spent-2019/): Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. [Link to full-text](https://www.bmj.com/content/368/bmj.m122).\n\n \n\n[**SPIRIT-AI**](https://www.equator-network.org/reporting-guidelines/spirit-artificial-intelligence/): Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.\n\n BMJ. 2020;370:m3210. PMID: [32907797](https://pubmed.ncbi.nlm.nih.gov/32907797/)\n\n Nat Med. 2020;26(9):1351–1363. PMID: [32908284](https://pubmed.ncbi.nlm.nih.gov/32908284/)\n\n Lancet Digital Health. 2020;2(10):e549-e560. PMID: [33328049](https://pubmed.ncbi.nlm.nih.gov/33328049/)\n\n \n\n[**SPIRIT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-protocols-the-spirit-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: [36512367](https://pubmed.ncbi.nlm.nih.gov/36512367/)\n\n \n\n[**SPIRIT-DEFINE**](https://www.equator-network.org/reporting-guidelines/spirit-define/): Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: [37863491](https://pubmed.ncbi.nlm.nih.gov/37863491/)\n\n \n\n[**SPIRIT Factorial**](https://www.equator-network.org/reporting-guidelines/consensus-statement-for-protocols-of-factorial-randomized-trials-extension-of-the-spirit-2013-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: [38051535](https://pubmed.ncbi.nlm.nih.gov/38051535/)\n\n \n\n[**SPIRIT-Surrogate**](https://www.equator-network.org/reporting-guidelines/spirit-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: [38981624](https://pubmed.ncbi.nlm.nih.gov/38981624/)\n\n \n\n[**SPIRIT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-protocols-of-randomised-controlled-trials-of-implantable-neurostimulation-devices-the-spirit-ineurostim-extension/): Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: [39610902](https://pubmed.ncbi.nlm.nih.gov/39610902/)\n\n \n\n'), ('Reporting guideline website URL', '<https://www.ncri.org.uk/spirit-path-extension/>'), ('Reporting guideline acronym', 'SPIRIT-Path'), ('Study design', 'Clinical trials, Experimental studies, Study protocols'), ('Clinical area', 'Pathology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 30, 2025')]"
20092,A Guideline for Reporting Mediation Analyses of Randomized Trials and Observational Studies: The AGReMA Statement,"Clinical trials, Experimental studies, Observational studies", ,Statistical methods and analyses, ,"AGReMA, AGReMA checklist, AGReMA statement, AGReMA-SF, AGReMA-SF checklist, causal mechanism, causal mechanisms, clinical trial, clinical trials, Guideline for Reporting Mediation Analyses, mediation, mediation analyses, mediation analysis, mediation studies, mediation study, observational, observational studies, observational study, primary reports of mediation analyses, randomised, randomised controlled trial, randomised controlled trials, randomised trial, randomized, randomized controlled trial, randomized controlled trials, randomized trial, RCT, RCTs, secondary reports of mediation analyses, trial, trials", ,"Lee H, Cashin AG, Lamb SE, Hopewell S, Vansteelandt S, VanderWeele TJ, MacKinnon DP, Mansell G, Collins GS, Golub RM, McAuley JH; AGReMA group, Localio AR, van Amelsvoort L, Guallar E, Rijnhart J, Goldsmith K, Fairchild AJ, Lewis CC, Kamper SJ, Williams CM, Henschke N. A Guideline for Reporting Mediation Analyses of Randomized Trials and Observational Studies: The AGReMA Statement. JAMA. 2021;326(11):1045-1056.","Lee H, Cashin AG, Lamb SE, Hopewell S, Vansteelandt S, VanderWeele TJ, MacKinnon DP, Mansell G, Collins GS, Golub RM, McAuley JH; AGReMA group, Localio AR, van Amelsvoort L, Guallar E, Rijnhart J, Goldsmith K, Fairchild AJ, Lewis CC, Kamper SJ, Williams CM, Henschke N.",JAMA.,2021,326,11,1045-1056, ,English, ,34546296,https://pubmed.ncbi.nlm.nih.gov/34546296/,"Access the AGReMA checklist for reporting mediation analyses of randomised controlled trials and observational studies as a primary objective.

Access the AGReMA-SF checklist for reporting secondary mediation analyses within primary reports of randomised controlled trials and observational studies.

", , , ,https://agrema-statement.org/,AGReMA,Reporting primary and secondary mediation analyses of randomised trials and observational studies., ,Read about the development of the AGReMA reporting guideline., , , , , ,no,2021-09-23 15:14:21,2021-09-23 15:27:17,a-guideline-for-reporting-mediation-analyses-of-randomized-trials-and-observational-studies-the-agrema-statement,"[('title', 'A Guideline for Reporting Mediation Analyses of Randomized Trials and Observational Studies: The AGReMA Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting primary and secondary mediation analyses of randomised trials and observational studies.'), ('Full bibliographic reference', 'Lee H, Cashin AG, Lamb SE, Hopewell S, Vansteelandt S, VanderWeele TJ, MacKinnon DP, Mansell G, Collins GS, Golub RM, McAuley JH; AGReMA group, Localio AR, van Amelsvoort L, Guallar E, Rijnhart J, Goldsmith K, Fairchild AJ, Lewis CC, Kamper SJ, Williams CM, Henschke N. A Guideline for Reporting Mediation Analyses of Randomized Trials and Observational Studies: The AGReMA Statement. JAMA. 2021;326(11):1045-1056.'), ('Language', 'English'), ('PubMed ID', '[34546296](https://pubmed.ncbi.nlm.nih.gov/34546296/)'), ('Relevant URLs\n\n(full-text if available)', 'Access the [AGReMA checklist](https://agrema-statement.org/index.php/home/agrema/) for reporting mediation analyses of randomised controlled trials and observational studies as a primary objective.\n\n \n\n Access the [AGReMA-SF checklist](https://agrema-statement.org/index.php/home/agrema-sf/) for reporting secondary mediation analyses within primary reports of randomised controlled trials and observational studies.\n\n \n\n'), ('Reporting guideline website URL', '<https://agrema-statement.org/>'), ('Reporting guideline acronym', 'AGReMA'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Additional information', 'Read about the [development of the AGReMA reporting guideline](https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-020-0915-5).'), ('Record last updated on', 'September 23, 2021')]"
20055,Social Innovation For Health Research (SIFHR): Development of the SIFHR Checklist,"Clinical trials, Experimental studies, Observational studies", ,Whole report, ,"checklist, checklists, community, global health, healthcare delivery, healthcare delivery gap, LMIC, LMICs, low- and middle-income countries, SIFHR, SIFHR Checklist, social entrepreneurship, social innovation, social innovation for health research, Social Innovation For Health Research (SIFHR) Checklist, social innovations", ,"Kpokiri EE, Chen E, Li J, Payne S, Shrestha P, Afsana K, Amazigo U, Awor P, de Lavison JF, Khan S, Mier-Alpa\xf1o J, Ong A Jr, Subhedar S, Wachmuth I, Cuervo LG, Mehta KM, Halpaap B, Tucker JD. Social Innovation For Health Research (SIFHR): Development of the SIFHR Checklist. PLoS Med. 2021;18(9):e1003788.","Kpokiri EE, Chen E, Li J, Payne S, Shrestha P, Afsana K, Amazigo U, Awor P, de Lavison JF, Khan S, Mier-Alpa\xf1o J, Ong A Jr, Subhedar S, Wachmuth I, Cuervo LG, Mehta KM, Halpaap B, Tucker JD.",PLoS Medicine [PLoS Med.],2021,18,9,e1003788, ,English, ,34516565,https://pubmed.ncbi.nlm.nih.gov/34516565/,The SIFHR checklist is available to download as a PDF., , , , ,SIFHR,Reporting of social innovation in health research studies., , , , , , , ,no,2021-09-20 16:25:20,2021-10-05 16:46:17,social-innovation-for-health-research-sifhr-development-of-the-sifhr-checklist,"[('title', 'Social Innovation For Health Research (SIFHR) : Development of the SIFHR Checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of social innovation in health research studies.'), ('Full bibliographic reference', 'Kpokiri EE, Chen E, Li J, Payne S, Shrestha P, Afsana K, Amazigo U, Awor P, de Lavison JF, Khan S, Mier-Alpaño J, Ong A Jr, Subhedar S, Wachmuth I, Cuervo LG, Mehta KM, Halpaap B, Tucker JD. Social Innovation For Health Research (SIFHR): Development of the SIFHR Checklist. PLoS Med. 2021;18(9):e1003788.'), ('Language', 'English'), ('PubMed ID', '[34516565](https://pubmed.ncbi.nlm.nih.gov/34516565/)'), ('Relevant URLs\n\n(full-text if available)', 'The SIFHR checklist is available to [download as a PDF.](https://doi.org/10.1371/journal.pmed.1003788.s005)'), ('Reporting guideline acronym', 'SIFHR'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 5, 2021')]"
20053,How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines,Clinical practice guidelines, ,Whole report, ,"AGREE II, checklist, checklists, CheckUp, clinical practice, clinical practice guideline, clinical practice guidelines, GRADE, GRADEpro, guideline, guideline manuscript template, guidelines, manuscript template, RIGHT", ,"Nieuwlaat R, Wiercioch W, Bro?ek JL, Santesso NAM, Kunkle R, Alonso-Coello P, Anderson DR, Bates S, Cushman M, Dahm P, Iorio A, Lim W, Lyman GH, Middeldorp S, Monagle P, Mustafa RA, Neumann I, Ortel T, Rochwerg B, Vesely SK, Witt DM, Cuker A, Schunemann HJ. How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. Blood Adv. 2021.","Nieuwlaat R, Wiercioch W, Bro?ek JL, Santesso NAM, Kunkle R, Alonso-Coello P, Anderson DR, Bates S, Cushman M, Dahm P, Iorio A, Lim W, Lyman GH, Middeldorp S, Monagle P, Mustafa RA, Neumann I, Ortel T, Rochwerg B, Vesely SK, Witt DM, Cuker A, Schunemann HJ.",Blood Advances [Blood Adv.],2021, , , , ,English, ,34521104,https://pubmed.ncbi.nlm.nih.gov/34521104/, , , , , , ,Reporting of guidelines., , , , , , , ,no,2021-09-20 15:34:10,2021-09-20 16:26:20,how-to-write-a-guideline-a-proposal-for-a-manuscript-template-that-supports-the-creation-of-trustworthy-guidelines,"[('title', 'How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of guidelines.'), ('Full bibliographic reference', 'Nieuwlaat R, Wiercioch W, Brożek JL, Santesso NAM, Kunkle R, Alonso-Coello P, Anderson DR, Bates S, Cushman M, Dahm P, Iorio A, Lim W, Lyman GH, Middeldorp S, Monagle P, Mustafa RA, Neumann I, Ortel T, Rochwerg B, Vesely SK, Witt DM, Cuker A, Schunemann HJ. How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. Blood Adv. 2021.'), ('Language', 'English'), ('PubMed ID', '[34521104](https://pubmed.ncbi.nlm.nih.gov/34521104/)'), ('Study design', 'Clinical practice guidelines'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 20, 2021')]"
19969,REPORT-PFP: a consensus from the International Patellofemoral Research Network to improve REPORTing of quantitative PatelloFemoral Pain studies,"Clinical trials, Experimental studies, Observational studies","Rheumatology, Sport and exercise medicine",Whole report, ,"checklist, checklists, exercise, exercise medicine, International Patellofemoral Research Network, knee, knee pain, knees, musculoskeletal, musculoskeletal injuries, musculoskeletal injury, patellofemoral, patellofemoral pain, REPORT-PFP, REPORT-PFP checklist, REPORTing of quantitative PatelloFemoral Pain research, sport, sport and exercise medicine, sports injuries, sports injury, sports medicine", ,"Barton CJ, De Oliveira Silva D, Morton S, Collins NJ, Rathleff MS, Vicenzino B, van Middelkoop M, Crossley KM, Callaghan MJ, Selfe J, Holden S, Lack S, Macri EM, Bazett-Jones DM, Earl-Boehm JE, Riel H, Powers CM, Davis IS, Morrissey D. REPORT-PFP: a consensus from the International Patellofemoral Research Network to improve REPORTing of quantitative PatelloFemoral Pain studies. Br J Sports Med. 2021.","Barton CJ, De Oliveira Silva D, Morton S, Collins NJ, Rathleff MS, Vicenzino B, van Middelkoop M, Crossley KM, Callaghan MJ, Selfe J, Holden S, Lack S, Macri EM, Bazett-Jones DM, Earl-Boehm JE, Riel H, Powers CM, Davis IS, Morrissey D.",British Journal of Sports Medicine\xa0 [Br J Sports Med.],2021, , , , ,English, ,34127482,https://pubmed.ncbi.nlm.nih.gov/34127482/,The REPORT-PFP checklist is freely available from the International Patellofemoral Research Network website., , , ,https://ipfrn.org/report-pfp-checklist/,REPORT-PFP,Reporting of quantitative patellofemoral pain studies., , , , , , , ,no,2021-09-03 16:29:17,2021-09-03 16:36:21,report-pfp-a-consensus-from-the-international-patellofemoral-research-network-to-improve-reporting-of-quantitative-patellofemoral-pain-studies,"[('title', 'REPORT-PFP : a consensus from the International Patellofemoral Research Network to improve REPORTing of quantitative PatelloFemoral Pain studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of quantitative patellofemoral pain studies.'), ('Full bibliographic reference', 'Barton CJ, De Oliveira Silva D, Morton S, Collins NJ, Rathleff MS, Vicenzino B, van Middelkoop M, Crossley KM, Callaghan MJ, Selfe J, Holden S, Lack S, Macri EM, Bazett-Jones DM, Earl-Boehm JE, Riel H, Powers CM, Davis IS, Morrissey D. REPORT-PFP: a consensus from the International Patellofemoral Research Network to improve REPORTing of quantitative PatelloFemoral Pain studies. Br J Sports Med. 2021.'), ('Language', 'English'), ('PubMed ID', '[34127482](https://pubmed.ncbi.nlm.nih.gov/34127482/)'), ('Relevant URLs\n\n(full-text if available)', 'The REPORT-PFP checklist is freely available from the [International Patellofemoral Research Network website](https://ipfrn.org/report-pfp-checklist/).'), ('Reporting guideline website URL', '<https://ipfrn.org/report-pfp-checklist/>'), ('Reporting guideline acronym', 'REPORT-PFP'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Rheumatology, Sport and exercise medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 3, 2021')]"
19934,Reporting stAndards for research in PedIatric Dentistry (RAPID): an expert consensus-based statement, ,Dentistry,Whole report, ,"checklist, checklists, child, children, dental, Dentist, Dentistry, oral medicine, orthodontics, orthodontist, paediatric, paediatric dentistry, pediatric, pediatric dentistry, RAPID, RAPID checklist, RAPID guideline, RAPID guidelines, RAPID statement", ,"Jayaraman J, Dhar V, Donly KJ, Priya E, Raggio DP, Childers NK, Wright TJ, Nagendrababu V, Clarke M, King N, Clarkson J, Innes NPT. Reporting stAndards for research in PedIatric Dentistry (RAPID): an expert consensus-based statement. BMC Oral Health. 2021;21(1):369.","Jayaraman J, Dhar V, Donly KJ, Priya E, Raggio DP, Childers NK, Wright TJ, Nagendrababu V, Clarke M, King N, Clarkson J, Innes NPT.",BMC Oral Health,2021,1, ,369, , , ,34301229,https://pubmed.ncbi.nlm.nih.gov/34301229/,"The full-text of the RAPID reporting guideline is freely available.

Ten reporting checklists have been developed covering:
General; Oral Medicine; Pathology and Radiology; Children with Special Healthcare Needs; Sedation and Hospital Dentistry; Behavior Guidance; Dental Caries; Preventive and Restorative Dentistry; Pulp Therapy; Trauma; Interceptive Orthodontics.", , , ,https://rapid-statement.org/,RAPID,Reporting paediatric dentistry research studies., ,Read the protocol for the development of the RAPID guideline., , , , , ,no,2021-08-06 16:20:42,2021-08-06 16:23:45,reporting-standards-for-research-in-pediatric-dentistry-rapid-an-expert-consensus-based-statement,"[('title', 'Reporting stAndards for research in PedIatric Dentistry (RAPID) : an expert consensus-based statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting paediatric dentistry research studies.'), ('Full bibliographic reference', 'Jayaraman J, Dhar V, Donly KJ, Priya E, Raggio DP, Childers NK, Wright TJ, Nagendrababu V, Clarke M, King N, Clarkson J, Innes NPT. Reporting stAndards for research in PedIatric Dentistry (RAPID): an expert consensus-based statement. BMC Oral Health. 2021;21(1):369.'), ('PubMed ID', '[34301229](https://pubmed.ncbi.nlm.nih.gov/34301229/)'), ('Relevant URLs\n\n(full-text if available)', 'The [full-text of the RAPID reporting guideline](https://bmcoralhealth.biomedcentral.com/articles/10.1186/s12903-021-01698-7) is freely available.\n\n \n\n Ten reporting checklists have been developed covering:\n\n General; Oral Medicine; Pathology and Radiology; Children with Special Healthcare Needs; Sedation and Hospital Dentistry; Behavior Guidance; Dental Caries; Preventive and Restorative Dentistry; Pulp Therapy; Trauma; Interceptive Orthodontics.'), ('Reporting guideline website URL', '<https://rapid-statement.org/>'), ('Reporting guideline acronym', 'RAPID'), ('Clinical area', 'Dentistry'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Read the [protocol](https://pubmed.ncbi.nlm.nih.gov/31411790/) for the development of the RAPID guideline.'), ('Record last updated on', 'August 6, 2021')]"
19633,Improving the reporting quality of reliability generalization meta-analyses: The REGEMA checklist,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Whole report, ,"checklist, checklists, coefficient, meta-analytic, REGEMA, REGEMA checklist, reliability, reliability generalisation, reliability generalisation meta-analyses, reliability generalisation meta-analysis, reliability generalization, reliability generalization meta-analyses, reliability generalization meta-analysis, reliable, RG meta-analyses, RG meta-analysis, test score, test scores", ,"S\xe1nchez-Meca J, Mar\xedn-Mart\xednez F, L\xf3pez-L\xf3pez JA, N\xfa\xf1ez-N\xfa\xf1ez RM, Rubio-Aparicio M, L\xf3pez-Garc\xeda JJ, L\xf3pez-Pina JA, Bl\xe1zquez-Rinc\xf3n DM, L\xf3pez-Ib\xe1\xf1ez C, L\xf3pez-Nicol\xe1s R. Improving the reporting quality of reliability generalization meta-analyses: The REGEMA checklist. Res Synth Methods. 2021.","S\xe1nchez-Meca J, Mar\xedn-Mart\xednez F, L\xf3pez-L\xf3pez JA, N\xfa\xf1ez-N\xfa\xf1ez RM, Rubio-Aparicio M, L\xf3pez-Garc\xeda JJ, L\xf3pez-Pina JA, Bl\xe1zquez-Rinc\xf3n DM, L\xf3pez-Ib\xe1\xf1ez C, L\xf3pez-Nicol\xe1s R.",Research Synthesis Methods [Res Synth Methods.],2021, , , , ,English, ,33742752,https://pubmed.ncbi.nlm.nih.gov/33742752/,The REGEMA checklist and flow chart can be freely downloaded from the reporting guideline development group website., , , ,https://www.um.es/metaanalysis/REGEMA.php,REGEMA,Reporting of reliability generalisation meta-analyses, , , , , , , ,no,2021-07-06 11:54:58,2021-07-06 11:58:07,improving-the-reporting-quality-of-reliability-generalization-meta-analyses-the-regema-checklist,"[('title', 'Improving the reporting quality of reliability generalization meta-analyses: The REGEMA checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of reliability generalisation meta-analyses'), ('Full bibliographic reference', 'Sánchez-Meca J, Marín-Martínez F, López-López JA, Núñez-Núñez RM, Rubio-Aparicio M, López-García JJ, López-Pina JA, Blázquez-Rincón DM, López-Ibáñez C, López-Nicolás R. Improving the reporting quality of reliability generalization meta-analyses: The REGEMA checklist. Res Synth Methods. 2021.'), ('Language', 'English'), ('PubMed ID', '[33742752](https://pubmed.ncbi.nlm.nih.gov/33742752/)'), ('Relevant URLs\n\n(full-text if available)', 'The REGEMA checklist and flow chart can be freely downloaded from the [reporting guideline development group website](https://www.um.es/metaanalysis/REGEMA.php).'), ('Reporting guideline website URL', '<https://www.um.es/metaanalysis/REGEMA.php>'), ('Reporting guideline acronym', 'REGEMA'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'July 6, 2021')]"
19623,Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization,Observational studies,"Infectious diseases, Public health",Whole report, ,"Coronavirus, Coronavirus disease, COVID-19, COVID-19 vaccine, COVID-19 VE evaluation, COVID-19 VE evaluations, evaluation, evaluations, infection, observational, observational studies, observational study, post-implementation, post-introduction, post-introduction evaluation, post-introduction evaluations, post-introduction vaccine effectiveness evaluation, post-introduction vaccine effectiveness evaluations, real-world conditions, SARS-CoV-2, surveillance, vaccination, vaccine, vaccine effectiveness evaluation, vaccine effectiveness evaluations, vaccines, VE, VE evaluation, VE evaluations", ,"Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, Hirve S, Kang G, Katz MA, Lanata CF, L'Azou Jackson M, Joshi S, Lipsitch M, Mwenda JM, Nogareda F, Orenstein WA, Ortiz JR, Pebody R, Schrag SJ, Smith PG, Srikantiah P, Subissi L, Valenciano M, Vaughn DW, Verani JR, Wilder-Smith A, Feikin DR. Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization. Vaccine. 2021:S0264-410X(21)00707-6.","Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, Hirve S, Kang G, Katz MA, Lanata CF, L'Azou Jackson M, Joshi S, Lipsitch M, Mwenda JM, Nogareda F, Orenstein WA, Ortiz JR, Pebody R, Schrag SJ, Smith PG, Srikantiah P, Subissi L, Valenciano M, Vaughn DW, Verani JR, Wilder-Smith A, Feikin DR.",Vaccine.,2021, , , , ,English, ,34119350,https://pubmed.ncbi.nlm.nih.gov/34119350/,"The full-text of this guideline is freely available.

Table 4 presents an extension to the Strengthening the reporting of observational studies in epidemiology (STROBE) checklist with recommended additional elements for reporting COVID-19 vaccine effectiveness studies.", , , , , ,Reporting of post-introduction COVID-19 vaccine effectiveness evaluations., , , , ,"Linkins LA, Iorio A, Little J, Lavis J. Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19. Vaccine. 2022:S0264-410X(22)00422-4. PMID: 35443916", , ,no,2021-06-23 16:49:53,2022-04-29 15:43:36,evaluation-of-post-introduction-covid-19-vaccine-effectiveness-summary-of-interim-guidance-of-the-world-health-organization,"[('title', 'Evaluation of post-introduction COVID- 19 vaccine effectiveness: Summary of interim guidance of the World Health Organization'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of post-introduction COVID-19 vaccine effectiveness evaluations.'), ('Full bibliographic reference', ""Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, Hirve S, Kang G, Katz MA, Lanata CF, L'Azou Jackson M, Joshi S, Lipsitch M, Mwenda JM, Nogareda F, Orenstein WA, Ortiz JR, Pebody R, Schrag SJ, Smith PG, Srikantiah P, Subissi L, Valenciano M, Vaughn DW, Verani JR, Wilder-Smith A, Feikin DR. Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization. Vaccine. 2021:S0264-410X(21)00707-6.""), ('Language', 'English'), ('PubMed ID', '[34119350](https://pubmed.ncbi.nlm.nih.gov/34119350/)'), ('Relevant URLs\n\n(full-text if available)', 'The [full-text of this guideline is freely available](https://www.sciencedirect.com/science/article/pii/S0264410X21007076).\n\n \n\n Table 4 presents an extension to the Strengthening the reporting of observational studies in epidemiology (STROBE) checklist with recommended additional elements for reporting COVID-19 vaccine effectiveness studies.'), ('Study design', 'Observational studies'), ('Clinical area', 'Infectious diseases, Public health'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Other', 'Linkins LA, Iorio A, Little J, Lavis J. Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19. Vaccine. 2022:S0264-410X(22)00422-4. PMID: [35443916](https://pubmed.ncbi.nlm.nih.gov/35443916/)'), ('Record last updated on', 'April 29, 2022')]"
19027,Journal article reporting standards for quantitative research in psychology: The APA Publications and Communications Board task force report,"Clinical trials, Experimental studies, Observational studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews",Psychology,Whole report, ,"American Psychological Association, analytic methods, APA, APA Style, Bayesian, checklist, checklists, clinical trial, clinical trials, experimental, JARS, JARS-Quant, Journal Article Reporting Standards for Quantitative Research, longitudinal, longitudinal studies, longitudinal study, meta analyses, meta analysis, N-of-1, N-of-1 studies, N-of-1 study, non-random assignment, nonexperimental, primary quantitative research, psychological, psychology, quantitative, quantitative research, random assignment, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, replication, replication studies, replication study, statistics, structural equation modeling, structural equation modelling, trial, trials", ,"Appelbaum M, Cooper H, Kline RB, Mayo-Wilson E, Nezu AM, Rao SM. Journal article reporting standards for quantitative research in psychology: The APA Publications and Communications Board task force report. Am Psychol. 2018;73(1):3-25.","Appelbaum M, Cooper H, Kline RB, Mayo-Wilson E, Nezu AM, Rao SM.",The American Psychologist [Am Psychol.],2018,73,1,3-25, ,English, ,29345484,https://pubmed.ncbi.nlm.nih.gov/29345484/,The full-text of the JARS-Quant reporting guideline is freely available., , , ,https://apastyle.apa.org/jars/quantitative,JARS-Quant,Reporting of quantitative research., ,"The following JARS?Quant checklists are available:

General Quantitative Design Reporting Standards (JARS-Quant) - JARS-Quant checklist (PDF)

Experimental Designs checklist (PDF)

Random Assignment checklist (PDF)

Non-Random Assignment checklist (PDF)

Clinical Trials checklist (PDF)

Non-Experimental Designs checklist (PDF)

Longitudinal Studies checklist (PDF)

N-of-1 Studies checklist (PDF)

Replication Studies checklist (PDF)

Structural Equation Modeling checklist (PDF)

Bayesian Statistics checklist (PDF)

Quantitative Meta-Analysis Reporting Standards checklist (PDF)

JARS?Quant Decision Flowchart (PDF)

JARS?Quant Participant Flowchart (PDF)

", , ,"See also the APA JARS-REC reporting standards for Race, Ethnicity, and Culture:

 	JARS-REC standards
 	JARS-REC checklist (PDF)
", , ,no,2021-06-23 15:28:59,2024-10-01 16:32:28,journal-article-reporting-standards-for-quantitative-research-in-psychology-the-apa-publications-and-communications-board-task-force-report,"[('title', 'Journal article reporting standards for quantitative research in psychology: The APA Publications and Communications Board task force report'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of quantitative research.'), ('Full bibliographic reference', 'Appelbaum M, Cooper H, Kline RB, Mayo-Wilson E, Nezu AM, Rao SM. Journal article reporting standards for quantitative research in psychology: The APA Publications and Communications Board task force report. Am Psychol. 2018;73(1):3-25.'), ('Language', 'English'), ('PubMed ID', '[29345484](https://pubmed.ncbi.nlm.nih.gov/29345484/)'), ('Relevant URLs\n\n(full-text if available)', 'The [full-text of the JARS-Quant reporting guideline is freely available](https://content.apa.org/fulltext/2018-00750-002.html).'), ('Reporting guideline website URL', '<https://apastyle.apa.org/jars/quantitative>'), ('Reporting guideline acronym', 'JARS-Quant'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Clinical area', 'Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Other', 'See also the APA [JARS-REC](https://apastyle.apa.org/jars/race-ethnicity-culture) reporting standards for Race, Ethnicity, and Culture:\n\n\n\n* [JARS-REC standards](https://apastyle.apa.org/jars/race-ethnicity-culture-executive-summary) \n\n* [JARS-REC checklist (PDF)](https://apastyle.apa.org/jars/rec-table-1.pdf) \n\n'), ('Additional information', 'The following JARS–Quant checklists are available:\n\n \n\n General Quantitative Design Reporting Standards (JARS-Quant) - [JARS-Quant checklist (PDF)](https://apastyle.apa.org/jars/quant-table-1.pdf)\n\n \n\n[Experimental Designs checklist (PDF)](https://apastyle.apa.org/jars/quant-table-2.pdf)\n\n \n\n[Random Assignment checklist (PDF)](https://apastyle.apa.org/jars/quant-table-2a.pdf)\n\n \n\n[Non-Random Assignment checklist (PDF)](https://apastyle.apa.org/jars/quant-table-2b.pdf)\n\n \n\n[Clinical Trials checklist (PDF)](https://apastyle.apa.org/jars/quant-table-2c.pdf)\n\n \n\n[Non-Experimental Designs checklist (PDF)](https://apastyle.apa.org/jars/quant-table-3.pdf)\n\n \n\n[Longitudinal Studies checklist (PDF)](https://apastyle.apa.org/jars/quant-table-4.pdf)\n\n \n\n[N-of-1 Studies checklist (PDF)](https://apastyle.apa.org/jars/quant-table-5.pdf)\n\n \n\n[Replication Studies checklist (PDF)](https://apastyle.apa.org/jars/quant-table-6.pdf)\n\n \n\n[Structural Equation Modeling checklist (PDF)](https://apastyle.apa.org/jars/quant-table-7.pdf)\n\n \n\n[Bayesian Statistics checklist (PDF)](https://apastyle.apa.org/jars/quant-table-8.pdf)\n\n \n\n[Quantitative Meta-Analysis Reporting Standards checklist (PDF)](https://apastyle.apa.org/jars/quant-table-9.pdf)\n\n \n\n[JARS–Quant Decision Flowchart (PDF)](https://apastyle.apa.org/jars/jars-quant-decision-flowchart.pdf)\n\n \n\n[JARS–Quant Participant Flowchart (PDF)](https://apastyle.apa.org/jars/jars-quant-participant-flowchart.pdf)\n\n \n\n'), ('Record last updated on', 'October 1, 2024')]"
19619,Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement,"Clinical trials, Experimental studies, Study protocols", ,Whole report, ,"checklist, checklists, CONSERVE, CONSERVE-CONSORT, CONSERVE-SPIRIT, CONSORT and SPIRIT Extension for RCTs Revised in Extenuating Circumstances, CONSORT extension, COVID-19, COVID-19 pandemic, extenuating circumstances, interim data analyses, interim data analysis, joint extension for CONSORT and SPIRIT, modification, modifications, protocol, protocols, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, responsible parties, responsible party, SPIRIT Extension, trial, trial modification, trial modifications, trial protocol checklist, trial report checklist, trials, unforeseen circumstances, unplanned change, unplanned changes", ,"Orkin AM, Gill PJ, Ghersi D, Campbell L, Sugarman J, Emsley R, Steg PG, Weijer C, Simes J, Rombey T, Williams HC, Wittes J, Moher D, Richards DP, Kasamon Y, Getz K, Hopewell S, Dickersin K, Wu T, Ayala AP, Schulz KF, Calleja S, Boutron I, Ross JS, Golub RM, Khan KM, Mulrow C, Siegfried N, Heber J, Lee N, Kearney PR, Wanyenze RK, Hr\xf3bjartsson A, Williams R, Bhandari N, J\xfcni P, Chan AW; CONSERVE Group. Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement. JAMA. 2021.","Orkin AM, Gill PJ, Ghersi D, Campbell L, Sugarman J, Emsley R, Steg PG, Weijer C, Simes J, Rombey T, Williams HC, Wittes J, Moher D, Richards DP, Kasamon Y, Getz K, Hopewell S, Dickersin K, Wu T, Ayala AP, Schulz KF, Calleja S, Boutron I, Ross JS, Golub RM, Khan KM, Mulrow C, Siegfried N, Heber J, Lee N, Kearney PR, Wanyenze RK, Hr\xf3bjartsson A, Williams R, Bhandari N, J\xfcni P, Chan AW; CONSERVE Group.",JAMA.,2021, , , , ,English, ,34152382,https://pubmed.ncbi.nlm.nih.gov/34152382/,"The full-text of the CONSERVE 2021 Statement is freely available.

The authors have developed an implementation tool and two reporting checklists for CONSERVE which are included as a supplement to the journal article.", , , , ,CONSERVE ,"Reporting of trials and trial protocols that undergo important modifications in response to extenuating circumstances.



CONSERVE-CONSORT &amp; CONSERVE-SPIRIT Checklists (Word)

", ,The CONSERVE 2021 Statement is an extension to both the CONSORT and SPIRIT Statements., , , , , ,yes,2021-06-22 12:30:51,2021-10-01 16:47:18,guidelines-for-reporting-trial-protocols-and-completed-trials-modified-due-to-the-covid-19-pandemic-and-other-extenuating-circumstances-the-conserve-2021-statement,"[('title', 'Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID- 19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of trials and trial protocols that undergo important modifications in response to extenuating circumstances.\n\n \n\n \xa0\n\n \n\n[CONSERVE-CONSORT & CONSERVE-SPIRIT Checklists (Word)](https://www.equator-network.org/wp-content/uploads/2021/06/CONSERVE-Checklists.docx)\n\n \n\n'), ('Full bibliographic reference', 'Orkin AM, Gill PJ, Ghersi D, Campbell L, Sugarman J, Emsley R, Steg PG, Weijer C, Simes J, Rombey T, Williams HC, Wittes J, Moher D, Richards DP, Kasamon Y, Getz K, Hopewell S, Dickersin K, Wu T, Ayala AP, Schulz KF, Calleja S, Boutron I, Ross JS, Golub RM, Khan KM, Mulrow C, Siegfried N, Heber J, Lee N, Kearney PR, Wanyenze RK, Hróbjartsson A, Williams R, Bhandari N, Jüni P, Chan AW; CONSERVE Group. Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement. JAMA. 2021.'), ('Language', 'English'), ('PubMed ID', '[34152382](https://pubmed.ncbi.nlm.nih.gov/34152382/)'), ('Relevant URLs\n\n(full-text if available)', 'The [full-text of the CONSERVE 2021 Statement is freely available](https://jamanetwork.com/journals/jama/fullarticle/2781397).\n\n \n\n The authors have developed an implementation tool and two reporting checklists for CONSERVE which are included as a supplement to the journal article.'), ('Reporting guideline acronym', 'CONSERVE'), ('Study design', 'Clinical trials, Experimental studies, Study protocols'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'The CONSERVE 2021 Statement is an extension to both the CONSORT and SPIRIT Statements.'), ('Record last updated on', 'October 1, 2021')]"
19617,Describing deprescribing trials better: an elaboration of the CONSORT statement,"Clinical trials, Experimental studies", ,"Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.)", ,"application consolidation contexualisation, CONSORT, deprescribe, deprescribing, deprescribing medication, deprescribing studies, deprescribing study, deprescribing trial, deprescribing trials, discontinuation of medication, medication, medication withdrawal, medications, medicine, medicines, placebo, polypharmacy, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, sham, TIDieR, trial, trials", ,"Blom JW, Muth C, Glasziou P, McCormack JP, Perera R, Poortvliet RKE, Numans ME, Th\xfcrmann P, Thiem U, Thio SL, Van Driel M, Beyer M, Van den Akker M, Knottnerus JA. Describing deprescribing trials better: an elaboration of the CONSORT statement. J Clin Epidemiol. 2020;127:87-95.","Blom JW, Muth C, Glasziou P, McCormack JP, Perera R, Poortvliet RKE, Numans ME, Th\xfcrmann P, Thiem U, Thio SL, Van Driel M, Beyer M, Van den Akker M, Knottnerus JA.",Journal of Clinical Epidemiology [J Clin Epidemiol.],2020,127, ,87-95, ,English, ,32707072,https://pubmed.ncbi.nlm.nih.gov/32707072/, , , , , , ,Reporting deprescribing trials., , , , , , , ,no,2021-06-18 16:46:05,2021-06-18 16:46:05,describing-deprescribing-trials-better-an-elaboration-of-the-consort-statement,"[('title', 'Describing deprescribing trials better: an elaboration of the CONSORT statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting deprescribing trials.'), ('Full bibliographic reference', 'Blom JW, Muth C, Glasziou P, McCormack JP, Perera R, Poortvliet RKE, Numans ME, Thürmann P, Thiem U, Thio SL, Van Driel M, Beyer M, Van den Akker M, Knottnerus JA. Describing deprescribing trials better: an elaboration of the CONSORT statement. J Clin Epidemiol. 2020;127:87-95.'), ('Language', 'English'), ('PubMed ID', '[32707072](https://pubmed.ncbi.nlm.nih.gov/32707072/)'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'June 18, 2021')]"
19615,Comprehensive reporting of pelvic floor muscle training for urinary incontinence: CERT-PFMT,"Clinical trials, Experimental studies","Physiotherapy, Sport and exercise medicine, Urology",Intervention (exposure), ,"application consolidation contexualisation, CERT-PFMT, CERT-PFMT checklist, checklist, checklists, clinical trial, clinical trials, continence, continence physiotherapist, continence physiotherapy, exercise intervention, incontinence, pelvic floor, pelvic floor muscle training, PFMT, PFMT intervention, PFMT interventions, physiotherapist, physiotherapists, physiotherapy, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials, UI, urinary, urinary dysfunction, urinary incontinence, urine, urology", ,"Slade SC, Morris ME, Frawley H, Hay-Smith J. Comprehensive reporting of pelvic floor muscle training for urinary incontinence: CERT-PFMT. Physiotherapy. 2021;112:103-112.","Slade SC, Morris ME, Frawley H, Hay-Smith J.",Physiotherapy.,2021,112, ,103-112, ,English, ,34062452,https://pubmed.ncbi.nlm.nih.gov/34062452/, , , , , ,CERT-PFMT,Reporting of pelvic floor muscle training (PFMT) interventions for urinary incontinence., , , , , , , ,no,2021-06-18 16:09:54,2021-06-18 16:15:32,comprehensive-reporting-of-pelvic-floor-muscle-training-for-urinary-incontinence-cert-pfmt,"[('title', 'Comprehensive reporting of pelvic floor muscle training for urinary incontinence: CERT-PFMT'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of pelvic floor muscle training (PFMT) interventions for urinary incontinence.'), ('Full bibliographic reference', 'Slade SC, Morris ME, Frawley H, Hay-Smith J. Comprehensive reporting of pelvic floor muscle training for urinary incontinence: CERT-PFMT. Physiotherapy. 2021;112:103-112.'), ('Language', 'English'), ('PubMed ID', '[34062452](https://pubmed.ncbi.nlm.nih.gov/34062452/)'), ('Reporting guideline acronym', 'CERT-PFMT'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Physiotherapy, Sport and exercise medicine, Urology'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'June 18, 2021')]"
19612,International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)),Observational studies,Sport and exercise medicine,Whole report, ,"athlete, athletes, checklist, checklists, epidemiological, epidemiological data, epidemiological studies, epidemiological study, epidemiology, exercise, exercise medicine, illness, illness surveillance studies, illness surveillance study, injuries, injury, injury surveillance studies, injury surveillance study, International Olympic Committee, International Olympic Committee consensus statement, observational, observational studies, observational study, sport, sports injuries, sports injury, sports medicine, STROBE extension, STROBE Extension for Sport Injury and Illness Surveillance, STROBE Sports Injury and Illness Surveillance, STROBE-SIIS, STROBE-SIIS checklist, surveillance", ,"International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, H\xe4gglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).

This guideline was published simultaneously in 2 journals. You can read the guideline in any of these journals using the links below.

Br J Sports Med. 2020;54(7):372-389. PMID: 32071062
Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: 32118084","International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, H\xe4gglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K.", ,2020, , , , ,English, , , ,"See also the supplement related to female athlete health domains at:
Moore IS, Crossley KM, Bo K, Mountjoy M, Ackerman KE, Antero JDS, Sundgot Borgen J, Brown WJ, Bolling CS, Clarsen B, Derman W, Dijkstra P, Donaldson A, Elliott-Sale KJ, Emery CA, Haakstad L, Junge A, Mkumbuzi NS, Nimphius S, Palmer D, van Poppel M, Thornton JS, Tom\xe1s R, Zondi PC, Verhagen E. Female athlete health domains: a supplement to the International Olympic Committee consensus statement on methods for recording and reporting epidemiological data on injury and illness in sport. Br J Sports Med. 2023. PMID: 37349084

", , ,"Generic
STROBE: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Ann Intern Med. 2007; 147(8):573-577. PMID: 17938396
PLoS Med. 2007;4(10):e296. PMID: 17941714
BMJ. 2007;335(7624):806-808. PMID: 17947786
Prev Med. 2007;45(4):247-251. PMID: 17950122
Epidemiology. 2007;18(6):800-804. PMID: 18049194
Lancet. 2007;370(9596):1453-1457. PMID: 18064739
J Clin Epidemiol. 2008;61(4):344-349. PMID: 18313558
Bull World Health Organ. 2007;85(11):867-872. PMID: 18038077

Specialised
STREGA: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.

PLoS Med. 2009;6(2):e22. PMID: 19192942
Hum Genet. 2009;125(2):131-151. PMID: 19184668
Eur J Epidemiol. 2009;24(1):37-55. PMID: 19189221
Ann Intern Med. 2009;150(3):206-215. PMID: 19189911
J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: 19217256
Genet Epidemiol. 2009;33(7):581-598. PMID: 19278015
Eur J Clin Invest. 2009;39(4):247-266. PMID: 19297801

STROBE-ME: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: 22023344

STROBE checklist for conference abstracts
First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. Link to full text pdf

STROME-ID: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: 24631223

Longitudinal observational drug studies in rheumatology: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: 24058015

Case-cohort studies: Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: 24972092

STROBE-RDS: White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: 26112433

RECORD: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: 26440803

STROBE-AMS: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schr\xf6der W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: 26895985

STROBE-nut: Lachat C, Hawwash D, Ock\xe9 MC, Berg C, Forsum E, H\xf6rnell A, Larsson C, Sonestedt E, Wirf\xe4lt E, \xc5kesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology?Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: 27270749

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

ROSES-I: Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: 27417916

STROBE-NI: Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: 27633910

Propensity score analysis: Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: 28376195

RECORD-PE: Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.

STROBE-MR: Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: 34698778

", ,STROBE-SIIS,Reporting of injuries and illnesses in sport studies., , , , , , , ,yes,2021-06-17 17:07:11,2023-08-17 16:34:17,strobe-extension-for-sports-injury-illness-surveillance,"[('title', 'International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS))'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of injuries and illnesses in sport studies.'), ('Full bibliographic reference', 'International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, Hägglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).\n\n \n\n This guideline was published simultaneously in 2 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n Br J Sports Med. 2020;54(7):372-389. PMID: [32071062](https://pubmed.ncbi.nlm.nih.gov/32071062/)\n\n Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: [32118084](https://pubmed.ncbi.nlm.nih.gov/32118084/)'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'See also the supplement related to female athlete health domains at:\n\n Moore IS, Crossley KM, Bo K, Mountjoy M, Ackerman KE, Antero JDS, Sundgot Borgen J, Brown WJ, Bolling CS, Clarsen B, Derman W, Dijkstra P, Donaldson A, Elliott-Sale KJ, Emery CA, Haakstad L, Junge A, Mkumbuzi NS, Nimphius S, Palmer D, van Poppel M, Thornton JS, Tomás R, Zondi PC, Verhagen E. Female athlete health domains: a supplement to the International Olympic Committee consensus statement on methods for recording and reporting epidemiological data on injury and illness in sport. Br J Sports Med. 2023. PMID: [37349084](https://pubmed.ncbi.nlm.nih.gov/37349084/)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**STROBE**](https://www.equator-network.org/reporting-guidelines/strobe/): von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.\n\n \n\n Ann Intern Med. 2007; 147(8):573-577. PMID: [17938396](http://www.ncbi.nlm.nih.gov/pubmed/17938396)\n\n PLoS Med. 2007;4(10):e296. PMID: [17941714](http://www.ncbi.nlm.nih.gov/pubmed/17941714)\n\n BMJ. 2007;335(7624):806-808. PMID: [17947786](http://www.ncbi.nlm.nih.gov/pubmed/17947786)\n\n Prev Med. 2007;45(4):247-251. PMID: [17950122](http://www.ncbi.nlm.nih.gov/pubmed/17950122)\n\n Epidemiology. 2007;18(6):800-804. PMID: [18049194](http://www.ncbi.nlm.nih.gov/pubmed/18049194)\n\n Lancet. 2007;370(9596):1453-1457. PMID: [18064739](http://www.ncbi.nlm.nih.gov/pubmed/18064739)\n\n J Clin Epidemiol. 2008;61(4):344-349. PMID: [18313558](http://www.ncbi.nlm.nih.gov/pubmed/18313558)\n\n Bull World Health Organ. 2007;85(11):867-872. PMID: [18038077](http://www.ncbi.nlm.nih.gov/pubmed/18038077)\n\n \n\n**Specialised**\n\n[**STREGA**](https://www.equator-network.org/reporting-guidelines/strobe-strega/): Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.\n\n \n\n PLoS Med. 2009;6(2):e22. PMID: [19192942](http://www.ncbi.nlm.nih.gov/pubmed/19192942)\n\n Hum Genet. 2009;125(2):131-151. PMID: [19184668](http://www.ncbi.nlm.nih.gov/pubmed/19184668)\n\n Eur J Epidemiol. 2009;24(1):37-55. PMID: [19189221](http://www.ncbi.nlm.nih.gov/pubmed/19189221)\n\n Ann Intern Med. 2009;150(3):206-215. PMID: [19189911](http://www.ncbi.nlm.nih.gov/pubmed/19189911)\n\n J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: [19217256](http://www.ncbi.nlm.nih.gov/pubmed/19217256)\n\n Genet Epidemiol. 2009;33(7):581-598. PMID: [19278015](http://www.ncbi.nlm.nih.gov/pubmed/19278015)\n\n Eur J Clin Invest. 2009;39(4):247-266. PMID: [19297801](http://www.ncbi.nlm.nih.gov/pubmed/19297801)\n\n \n\n[**STROBE-ME**](https://www.equator-network.org/reporting-guidelines/strobe-me/): Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: [22023344](http://www.ncbi.nlm.nih.gov/pubmed/22023344)\n\n \n\n[**STROBE checklist for conference abstracts**](https://www.equator-network.org/reporting-guidelines/strobe-abstracts/)\n\n First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. [Link to full text pdf](https://www.strobe-statement.org/download/strobe-checklist-conference-abstracts)\n\n \n\n[**STROME-ID**](https://www.equator-network.org/reporting-guidelines/strome-id/): Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: [24631223](http://www.ncbi.nlm.nih.gov/pubmed/24631223)\n\n \n\n[**Longitudinal observational drug studies in rheumatology**](https://www.equator-network.org/reporting-guidelines/launch-of-a-checklist-for-reporting-longitudinal-observational-drug-studies-in-rheumatology-a-eular-extension-of-strobe-guidelines-based-on-experience-from-biologics-registries/): Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: [24058015](http://www.ncbi.nlm.nih.gov/pubmed/24058015)\n\n \n\n[**Case-cohort studies**](https://www.equator-network.org/reporting-guidelines/a-review-of-published-analyses-of-case-cohort-studies-and-recommendations-for-future-reporting/): Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: [24972092](https://www.ncbi.nlm.nih.gov/pubmed/24972092)\n\n \n\n[**STROBE-RDS**](https://www.equator-network.org/reporting-guidelines/strobe-rds/): White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: [26112433](http://www.ncbi.nlm.nih.gov/pubmed/26112433)\n\n \n\n[**RECORD**](https://www.equator-network.org/reporting-guidelines/record/): Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: [26440803](http://www.ncbi.nlm.nih.gov/pubmed/26440803)\n\n \n\n[**STROBE-AMS**](https://www.equator-network.org/reporting-guidelines/strobe-ams/): Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schröder W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: [26895985](http://www.ncbi.nlm.nih.gov/pubmed/26895985)\n\n \n\n[**STROBE-nut**](https://www.equator-network.org/reporting-guidelines/strobe-nut/): Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology—Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: [27270749](https://www.ncbi.nlm.nih.gov/pubmed/27270749)\n\n \n\n[**Simulation Research**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**ROSES-I**](https://www.equator-network.org/reporting-guidelines/roses-i-statement/): Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: [27417916](https://www.ncbi.nlm.nih.gov/pubmed/27417916)\n\n \n\n[**STROBE-NI**](https://www.equator-network.org/reporting-guidelines/strobe-ni/): Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: [27633910](https://www.ncbi.nlm.nih.gov/pubmed/27633910)\n\n \n\n[**Propensity score analysis**](https://www.equator-network.org/reporting-guidelines/reporting-and-guidelines-in-propensity-score-analysis-a-systematic-review-of-cancer-and-cancer-surgical-studies/): Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: [28376195](https://www.ncbi.nlm.nih.gov/pubmed/28376195)\n\n \n\n[**RECORD-PE**](https://www.equator-network.org/reporting-guidelines/record-pe/): Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). [BMJ 2018;363:k3532](https://www.bmj.com/content/363/bmj.k3532.full).\n\n \n\n[**STROBE-MR**](https://www.equator-network.org/reporting-guidelines/strobe-mr-statement/): Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: [34698778](https://pubmed.ncbi.nlm.nih.gov/34698778/)\n\n \n\n'), ('Reporting guideline acronym', 'STROBE-SIIS'), ('Study design', 'Observational studies'), ('Clinical area', 'Sport and exercise medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'August 17, 2023')]"
19595,RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture,Clinical practice guidelines,Complementary and alternative medicine,Whole report, ,"acupuncture, acupuncture CPG, acupuncture CPGs, acupuncture guideline, acupuncture guidelines, acupuncture intervention, acupuncture interventions, acupuncture therapy, acupuncturist, acupuncturists, checklist, checklists, clinical practice guideline, clinical practice guidelines, CPG, CPGs, RIGHT, RIGHT extension, RIGHT for Acupuncture, RIGHT for Acupuncture checklist, RIGHT Statement for Clinical Practice Guidelines on Acupuncture, TCM, traditional Chinese medicine", ,"Tang C, Duan Y, Zhang Y, Zhang Y, Chen Z, Tang X, Zeng J, Riley D, Lee MS, Kim YS, Zhao H, Marrone G, Zhu X, Ge S, Wen H, Zhao W, Zheng X, Solos I, Chen Y, Guyatt G, Lu L, Xu N; RIGHT (Reporting Items for Practice Guidelines in Healthcare) for Acupuncture Working Group. RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture. J Clin Epidemiol. 2021:S0895-4356(21)00173-6.","Tang C, Duan Y, Zhang Y, Zhang Y, Chen Z, Tang X, Zeng J, Riley D, Lee MS, Kim YS, Zhao H, Marrone G, Zhu X, Ge S, Wen H, Zhao W, Zheng X, Solos I, Chen Y, Guyatt G, Lu L, Xu N; RIGHT (Reporting Items for Practice Guidelines in Healthcare) for Acupuncture Working Group.",Journal of Clinical Epidemiology [J Clin Epidemiol.],2021, , , , ,English, ,34091023,https://pubmed.ncbi.nlm.nih.gov/34091023/, ,The authors have developed an explanation and elaboration document for RIGHT for Acupuncture which is included as a supplement to the journal article., ,"Generic
RIGHT Statement: Chen Y, Yang K, Maru?i? A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Sch\xfcnemann HJ, Chan ESY, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; for the RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group.\xa0 A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166(2):128-132. PMID: 27893062

Specialised
RIGHT-TCM: Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, Xia L, Guo Y. The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Pharmacol Res. 2020;160:105178. PMID: 32889127

RIGHT-PVG: Wang X, Chen Y, Akl EA, Tokali? R, Maru?i? A, Qaseem A, Falck-Ytter Y, Lee MS, Siedler M, Barber SL, Zhang M, Chan ESY, Estill J, Kwong JSW, Okumura A, Zhou Q, Yang K, Norris SL; RIGHT working group. The reporting checklist for public versions of guidelines: RIGHT-PVG. Implement Sci. 2021;16(1):10. PMID: 33430911

RIGHT for INT: Zhou Q, Xing D, Li Q, Zhang J, Luo X, Yang N, Wang X, Yang K, Tian J, Li H, Li B, Cai Y, Jin Y, Lv L, Sun F, Shang S, Yuan B, Li J, Ma B, Li X, Yuan Y, Wu L, Wang B, Jiang L, Wang Z, Chen Y, Liang D. An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT. J Evid Based Med. 2022;15(1):55-63. PMID: 35416438

RIGHT-Ad@pt: Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RWM, Arayssi T, Bhaumik S, Chen Y, Ghersi D, Langlois EV, Fuentes Padilla P, Sch\xfcnemann HJ, Akl EA, Mart\xednez Garc\xeda L; RIGHT-Ad@pt Working Group*, Amer Y, Arevalo-Rodriguez I, Barnes S, Barreto J, Collis D, Dyer S, Fahim C, Florez I, Gallegos-Rivero V, Klugar M, Kuijpers T, Mathew JL, Munn Z, Norris S, Pati\xf1o-Lugo DF, Pramesh CS, Rodriguez J, Roy S, Shin ES, Sosa O, Vandvik PO, Velez M, Woodcraft R; RIGHT-Ad@pt Working Group. A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Ann Intern Med. 2022;175(5):710-719. PMID: 35286143

RIGHT-COI&amp;F: Xun Y, Estill J, Khabsa J, Florez ID, Guyatt GH, Norris SL, Lee MS, Ozaki A, Qaseem A, Sch\xfcnemann HJ, Shao R, Chen Y, Akl EA; RIGHT-COI&amp;F Working Groups. Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI&amp;F Checklist. Ann Intern Med. 2024;177(6):782-790. PMID: 38739919

RIGHT for CPM: Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C. The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. Pharmacol Res. 2024;199:107015. PMID: 38036197

",http://www.right-statement.org/extensions/12,RIGHT for Acupuncture,Reporting of clinical practice guidelines where acupuncture is the main intervention., ,"Read the protocol for the development of RIGHT for Acupuncture:

Tang C, Lu L, Duan Y, Zhang Y, Zhou Q, Luo X, Chen Y, Xu N. Developing an extension of the RIGHT statement for clinical practice guidelines on acupuncture: RIGHT for acupuncture ? A protocol. European Journal of Integrative Medicine. 2019;29:100908. doi.org/10.1016/j.eujim.2019.04.002

", , , , , ,yes,2021-06-11 12:17:51,2024-07-26 15:21:30,right-for-acupuncture,"[('title', 'RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of clinical practice guidelines where acupuncture is the main intervention.'), ('Full bibliographic reference', 'Tang C, Duan Y, Zhang Y, Zhang Y, Chen Z, Tang X, Zeng J, Riley D, Lee MS, Kim YS, Zhao H, Marrone G, Zhu X, Ge S, Wen H, Zhao W, Zheng X, Solos I, Chen Y, Guyatt G, Lu L, Xu N; RIGHT (Reporting Items for Practice Guidelines in Healthcare) for Acupuncture Working Group. RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture. J Clin Epidemiol. 2021:S0895-4356(21)00173-6.'), ('Language', 'English'), ('PubMed ID', '[34091023](https://pubmed.ncbi.nlm.nih.gov/34091023/)'), ('Explanation and elaboration papers', 'The authors have developed an explanation and elaboration document for RIGHT for Acupuncture which is included as a supplement to the journal article.'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**RIGHT Statement**](https://www.equator-network.org/reporting-guidelines/right-statement/): Chen Y, Yang K, Marušić A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Schünemann HJ, Chan ESY, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; for the RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group.\xa0 A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166(2):128-132. PMID: [27893062](https://www.ncbi.nlm.nih.gov/pubmed/27893062)\n\n \n\n**Specialised**\n\n[**RIGHT-TCM**](https://www.equator-network.org/reporting-guidelines/the-right-extension-statement-for-traditional-chinese-medicine-development-recommendations-and-explanation/): Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, Xia L, Guo Y. The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Pharmacol Res. 2020;160:105178. PMID: [32889127](https://pubmed.ncbi.nlm.nih.gov/32889127)\n\n \n\n[**RIGHT-PVG**](https://www.equator-network.org/reporting-guidelines/the-reporting-checklist-for-public-versions-of-guidelines-right-pvg/): Wang X, Chen Y, Akl EA, Tokalić R, Marušić A, Qaseem A, Falck-Ytter Y, Lee MS, Siedler M, Barber SL, Zhang M, Chan ESY, Estill J, Kwong JSW, Okumura A, Zhou Q, Yang K, Norris SL; RIGHT working group. The reporting checklist for public versions of guidelines: RIGHT-PVG. Implement Sci. 2021;16(1):10. PMID: [33430911](https://pubmed.ncbi.nlm.nih.gov/33430911/)\n\n \n\n[**RIGHT for INT**](https://www.equator-network.org/reporting-guidelines/an-extension-of-the-right-statement-for-introductions-and-interpretations-of-clinical-practice-guidelines-right-for-int/): Zhou Q, Xing D, Li Q, Zhang J, Luo X, Yang N, Wang X, Yang K, Tian J, Li H, Li B, Cai Y, Jin Y, Lv L, Sun F, Shang S, Yuan B, Li J, Ma B, Li X, Yuan Y, Wu L, Wang B, Jiang L, Wang Z, Chen Y, Liang D. An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT. J Evid Based Med. 2022;15(1):55-63. PMID: [35416438](https://pubmed.ncbi.nlm.nih.gov/35416438/)\n\n \n\n[**RIGHT-Ad@pt**](https://www.equator-network.org/reporting-guidelines/a-reporting-tool-for-adapted-guidelines-in-health-care-the-right-adapt-checklist/): Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RWM, Arayssi T, Bhaumik S, Chen Y, Ghersi D, Langlois EV, Fuentes Padilla P, Schünemann HJ, Akl EA, Martínez García L; RIGHT-Ad@pt Working Group\\*, Amer Y, Arevalo-Rodriguez I, Barnes S, Barreto J, Collis D, Dyer S, Fahim C, Florez I, Gallegos-Rivero V, Klugar M, Kuijpers T, Mathew JL, Munn Z, Norris S, Patiño-Lugo DF, Pramesh CS, Rodriguez J, Roy S, Shin ES, Sosa O, Vandvik PO, Velez M, Woodcraft R; RIGHT-Ad@pt Working Group. A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Ann Intern Med. 2022;175(5):710-719. PMID: [35286143](https://pubmed.ncbi.nlm.nih.gov/35286143/)\n\n \n\n[**RIGHT-COI&F**](https://www.equator-network.org/reporting-guidelines/reporting-conflicts-of-interest-and-funding-in-health-care-guidelines-the-right-coif-checklist/): Xun Y, Estill J, Khabsa J, Florez ID, Guyatt GH, Norris SL, Lee MS, Ozaki A, Qaseem A, Schünemann HJ, Shao R, Chen Y, Akl EA; RIGHT-COI&F Working Groups. Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI&F Checklist. Ann Intern Med. 2024;177(6):782-790. PMID: [38739919](https://pubmed.ncbi.nlm.nih.gov/38739919/)\n\n \n\n[**RIGHT for CPM**](https://www.equator-network.org/reporting-guidelines/the-reporting-checklist-for-chinese-patent-medicine-guidelines-right-for-cpm/): Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C. The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. Pharmacol Res. 2024;199:107015. PMID: [38036197](https://pubmed.ncbi.nlm.nih.gov/38036197/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.right-statement.org/extensions/12>'), ('Reporting guideline acronym', 'RIGHT for Acupuncture'), ('Study design', 'Clinical practice guidelines'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', '[Read the protocol for the development of RIGHT for Acupuncture](https://doi.org/10.1016/j.eujim.2019.04.002):\n\n \n\n Tang C, Lu L, Duan Y, Zhang Y, Zhou Q, Luo X, Chen Y, Xu N. Developing an extension of the RIGHT statement for clinical practice guidelines on acupuncture: RIGHT for acupuncture – A protocol. European Journal of Integrative Medicine. 2019;29:100908. doi.org/10.1016/j.eujim.2019.04.002\n\n \n\n'), ('Record last updated on', 'July 26, 2024')]"
19555,The APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies,"Clinical trials, Diagnostic and prognostic studies, Observational studies, Study protocols","Neurology, Ophthalmology","Data, Procedure/Method, Statistical methods and analyses, Terminology/definitions", ,"APOSTEL 2.0, APOSTEL recommendations, case report, case reports, case studies, case study, clinical trial, clinical trials, neuro-ophthalmology, neurology, observational research, observational studies, observational study, OCT, ocular, ophthalmology, optical, optical coherence, optical coherence tomography, optical coherence tomography studies, optical coherence tomography study, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, retina, retinal, tomography, trial, trials", ,"Aytulun A, Cruz-Herranz A, Aktas O, Balcer LJ, Balk L, Barboni P, Blanco AA, Calabresi PA, Costello F, Sanchez-Dalmau B, DeBuc DC, Feltgen N, Finger RP, Frederiksen JL, Frohman E, Frohman T, Garway-Heath D, Gabilondo I, Graves JS, Green AJ, Hartung HP, Havla J, Holz FG, Imitola J, Kenney R, Klistorner A, Knier B, Korn T, Kolbe S, Kr\xe4mer J, Lagr\xe8ze WA, Leocani L, Maier O, Mart\xednez-Lapiscina EH, Meuth S, Outteryck O, Paul F, Petzold A, Pihl-Jensen G, Preiningerova JL, Rebolleda G, Ringelstein M, Saidha S, Schippling S, Schuman JS, Sergott RC, Toosy A, Villoslada P, Wolf S, Yeh EA, Yu-Wai-Man P, Zimmermann HG, Brandt AU, Albrecht P. The APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. Neurology. 2021:10.1212/WNL.0000000000012125.","Aytulun A, Cruz-Herranz A, Aktas O, Balcer LJ, Balk L, Barboni P, Blanco AA, Calabresi PA, Costello F, Sanchez-Dalmau B, DeBuc DC, Feltgen N, Finger RP, Frederiksen JL, Frohman E, Frohman T, Garway-Heath D, Gabilondo I, Graves JS, Green AJ, Hartung HP, Havla J, Holz FG, Imitola J, Kenney R, Klistorner A, Knier B, Korn T, Kolbe S, Kr\xe4mer J, Lagr\xe8ze WA, Leocani L, Maier O, Mart\xednez-Lapiscina EH, Meuth S, Outteryck O, Paul F, Petzold A, Pihl-Jensen G, Preiningerova JL, Rebolleda G, Ringelstein M, Saidha S, Schippling S, Schuman JS, Sergott RC, Toosy A, Villoslada P, Wolf S, Yeh EA, Yu-Wai-Man P, Zimmermann HG, Brandt AU, Albrecht P.",Neurology,2021, , , , ,English, ,33910937,https://pubmed.ncbi.nlm.nih.gov/33910937/, , , , , ,APOSTEL 2.0,Reporting quantitative optical coherence tomography research., , , , , , , ,no,2021-05-18 16:31:00,2021-05-18 16:38:06,the-apostel-2-0-recommendations-for-reporting-quantitative-optical-coherence-tomography-studies,"[('title', 'The APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting quantitative optical coherence tomography research.'), ('Full bibliographic reference', 'Aytulun A, Cruz-Herranz A, Aktas O, Balcer LJ, Balk L, Barboni P, Blanco AA, Calabresi PA, Costello F, Sanchez-Dalmau B, DeBuc DC, Feltgen N, Finger RP, Frederiksen JL, Frohman E, Frohman T, Garway-Heath D, Gabilondo I, Graves JS, Green AJ, Hartung HP, Havla J, Holz FG, Imitola J, Kenney R, Klistorner A, Knier B, Korn T, Kolbe S, Krämer J, Lagrèze WA, Leocani L, Maier O, Martínez-Lapiscina EH, Meuth S, Outteryck O, Paul F, Petzold A, Pihl-Jensen G, Preiningerova JL, Rebolleda G, Ringelstein M, Saidha S, Schippling S, Schuman JS, Sergott RC, Toosy A, Villoslada P, Wolf S, Yeh EA, Yu-Wai-Man P, Zimmermann HG, Brandt AU, Albrecht P. The APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. Neurology. 2021:10.1212/WNL.0000000000012125.'), ('Language', 'English'), ('PubMed ID', '[33910937](https://pubmed.ncbi.nlm.nih.gov/33910937/)'), ('Reporting guideline acronym', 'APOSTEL 2.0'), ('Study design', 'Clinical trials, Diagnostic and prognostic studies, Observational studies, Study protocols'), ('Clinical area', 'Neurology, Ophthalmology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method, Statistical methods and analyses, Terminology/definitions'), ('Record last updated on', 'May 18, 2021')]"
19553,Room Indirect Calorimetry Operating and Reporting Standards (RICORS 1.0): A Guide to Conducting and Reporting Human Whole-Room Calorimeter Studies,Observational studies,Nutrition and dietetics,"Data, Procedure/Method, Statistical methods and analyses, Study characteristics (participants etc.)", ,"calorimeter, calorimeter studies, calorimeter study, calorimeters, calorimetry, checklist, checklists, energy, energy expenditure, energy metabolism, exercise, human energy metabolism studies, human energy metabolism study, Human Whole-Room Calorimeter Studies, Human Whole-Room Calorimeter Study, metabolism, nutrition, nutritional, observational, observational research, observational studies, observational study, RICORS, RICORS 1.0, sedentry, substrate oxidation, whole-room, whole-room indirect calorimeter, whole-room indirect calorimeters", ,"Chen KY, Smith S, Ravussin E, Krakoff J, Plasqui G, Tanaka S, Murgatroyd P, Brychta R, Bock C, Carnero E, Schoffelen P, Hatamoto Y, Rynders C, Melanson EL. Room Indirect Calorimetry Operating and Reporting Standards (RICORS 1.0): A Guide to Conducting and Reporting Human Whole-Room Calorimeter Studies. Obesity (Silver Spring). 2020 Sep;28(9):1613-1625.","Chen KY, Smith S, Ravussin E, Krakoff J, Plasqui G, Tanaka S, Murgatroyd P, Brychta R, Bock C, Carnero E, Schoffelen P, Hatamoto Y, Rynders C, Melanson EL.",Obesity (Silver Spring),2020,28,9,1613-1625, ,English, ,32841524,https://pubmed.ncbi.nlm.nih.gov/32841524/, , , , , ,RICORS 1.0,Reporting of human whole-room calorimeter studies., , , , , , , ,no,2021-05-18 12:07:28,2021-05-18 13:30:19,room-indirect-calorimetry-operating-and-reporting-standards-ricors-1-0-a-guide-to-conducting-and-reporting-human-whole-room-calorimeter-studies,"[('title', 'Room Indirect Calorimetry Operating and Reporting Standards (RICORS 1.0): A Guide to Conducting and Reporting Human Whole -Room Calorimeter Studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of human whole-room calorimeter studies.'), ('Full bibliographic reference', 'Chen KY, Smith S, Ravussin E, Krakoff J, Plasqui G, Tanaka S, Murgatroyd P, Brychta R, Bock C, Carnero E, Schoffelen P, Hatamoto Y, Rynders C, Melanson EL. Room Indirect Calorimetry Operating and Reporting Standards (RICORS 1.0): A Guide to Conducting and Reporting Human Whole-Room Calorimeter Studies. Obesity (Silver Spring). 2020 Sep;28(9):1613-1625.'), ('Language', 'English'), ('PubMed ID', '[32841524](https://pubmed.ncbi.nlm.nih.gov/32841524/)'), ('Reporting guideline acronym', 'RICORS 1.0'), ('Study design', 'Observational studies'), ('Clinical area', 'Nutrition and dietetics'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'May 18, 2021')]"
19550,COSMIN reporting guideline for studies on measurement properties of patient-reported outcome measures,"Observational studies, Qualitative research, Reliability and agreement studies", ,Whole report, ,"COSMIN, measurement properties, measurement properties of PROMs, measurement property, outcome measure, outcome measures, patient-reported, patient-reported outcome measure, patient-reported outcome measures, PROM, PROMs", ,"Gagnier JJ, Lai J, Mokkink LB, Terwee CB. COSMIN reporting guideline for studies on measurement properties of patient-reported outcome measures. Qual Life Res. 2021.","Gagnier JJ, Lai J, Mokkink LB, Terwee CB.",Quality of Life Research [Qual Life Res.],2021, , , , ,English, ,33818733,https://pubmed.ncbi.nlm.nih.gov/33818733/, , , , , ,COSMIN,Reporting of primary studies of the measurement properties of patient-reported outcome measures (PROMs)., , , , , , , ,no,2021-05-14 17:13:51,2021-05-14 17:25:36,cosmin-reporting-guideline-for-studies-on-measurement-properties-of-patient-reported-outcome-measures,"[('title', 'COSMIN reporting guideline for studies on measurement properties of patient-reported outcome measures'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of primary studies of the measurement properties of patient-reported outcome measures (PROMs).'), ('Full bibliographic reference', 'Gagnier JJ, Lai J, Mokkink LB, Terwee CB. COSMIN reporting guideline for studies on measurement properties of patient-reported outcome measures. Qual Life Res. 2021.'), ('Language', 'English'), ('PubMed ID', '[33818733](https://pubmed.ncbi.nlm.nih.gov/33818733/)'), ('Reporting guideline acronym', 'COSMIN'), ('Study design', 'Observational studies, Qualitative research, Reliability and agreement studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 14, 2021')]"
19502,Ensuring best practice in genomics education and evaluation: reporting item standards for education and its evaluation in genomics (RISE2 Genomics),"Experimental studies, Mixed methods studies, Observational studies, Qualitative research",Medical education,Whole report, ,"continuing education, education, education intervention, education interventions, evaluation, genetics, genetics education research, genomic, genomic medicine, genomics, genomics education, genomics education and evaluation, genomics education research, genomics evaluation, RISE2 Genomics", ,"Nisselle A, Janinski M, Martyn M, McClaren B, Kaunein N; Reporting Item Standards for Education and its Evaluation in Genomics Expert Group, Barlow-Stewart K, Belcher A, Bernat JA, Best S, Bishop M, Carroll JC, Cornel M, Dissanayake VHW, Dodds A, Dunlop K, Garg G, Gear R, Graves D, Knight K, Korf B, Kumar D, Laurino M, Ma A, Maguire J, Mallett A, McCarthy M, McEwen A, Mulder N, Patel C, Quinlan C, Reed K, Riggs ER, Sinnerbrink I, Slavotinek A, Suppiah V, Terrill B, Tobias ES, Tonkin E, Trumble S, Wessels TM, Metcalfe S, Jordan H, Gaff C. Ensuring best practice in genomics education and evaluation: reporting item standards for education and its evaluation in genomics (RISE2 Genomics). Genet Med. 2021.","Nisselle A, Janinski M, Martyn M, McClaren B, Kaunein N; Reporting Item Standards for Education and its Evaluation in Genomics Expert Group, Barlow-Stewart K, Belcher A, Bernat JA, Best S, Bishop M, Carroll JC, Cornel M, Dissanayake VHW, Dodds A, Dunlop K, Garg G, Gear R, Graves D, Knight K, Korf B, Kumar D, Laurino M, Ma A, Maguire J, Mallett A, McCarthy M, McEwen A, Mulder N, Patel C, Quinlan C, Reed K, Riggs ER, Sinnerbrink I, Slavotinek A, Suppiah V, Terrill B, Tobias ES, Tonkin E, Trumble S, Wessels TM, Metcalfe S, Jordan H, Gaff C.",Genetics in Medicine [Genet Med.],2021, , , , ,English, ,33824503,https://pubmed.ncbi.nlm.nih.gov/33824503/, , , , , ,RISE2 Genomics,Reporting of genomics education interventions and their evaluation., , , , , , , ,no,2021-05-06 17:22:33,2021-05-06 17:22:33,ensuring-best-practice-in-genomics-education-and-evaluation-reporting-item-standards-for-education-and-its-evaluation-in-genomics-rise2-genomics,"[('title', 'Ensuring best practice in genomics education and evaluation: reporting item standards for education and its evaluation in genomics (RISE 2 Genomics)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of genomics education interventions and their evaluation.'), ('Full bibliographic reference', 'Nisselle A, Janinski M, Martyn M, McClaren B, Kaunein N; Reporting Item Standards for Education and its Evaluation in Genomics Expert Group, Barlow-Stewart K, Belcher A, Bernat JA, Best S, Bishop M, Carroll JC, Cornel M, Dissanayake VHW, Dodds A, Dunlop K, Garg G, Gear R, Graves D, Knight K, Korf B, Kumar D, Laurino M, Ma A, Maguire J, Mallett A, McCarthy M, McEwen A, Mulder N, Patel C, Quinlan C, Reed K, Riggs ER, Sinnerbrink I, Slavotinek A, Suppiah V, Terrill B, Tobias ES, Tonkin E, Trumble S, Wessels TM, Metcalfe S, Jordan H, Gaff C. Ensuring best practice in genomics education and evaluation: reporting item standards for education and its evaluation in genomics (RISE2 Genomics). Genet Med. 2021.'), ('Language', 'English'), ('PubMed ID', '[33824503](https://pubmed.ncbi.nlm.nih.gov/33824503/)'), ('Reporting guideline acronym', 'RISE2 Genomics'), ('Study design', 'Experimental studies, Mixed methods studies, Observational studies, Qualitative research'), ('Clinical area', 'Medical education'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 6, 2021')]"
19495,A Consensus-Based Checklist for Reporting of Survey Studies (CROSS),"Observational studies, Qualitative research", ,Whole report, ,"checklist, Checklist for Reporting of Survey Studies, checklists, CROSS, questionnaire, questionnaires, survey, survey research, survey studies, survey study, surveys", ,"Sharma A, Minh Duc NT, Luu Lam Thang T, Nam NH, Ng SJ, Abbas KS, Huy NT, Maru?i? A, Paul CL, Kwok J, Karbwang J, de Waure C, Drummond FJ, Kizawa Y, Taal E, Vermeulen J, Lee GHM, Gyedu A, To KG, Verra ML, Jacqz-Aigrain \xc9M, Leclercq WKG, Salminen ST, Sherbourne CD, Mintzes B, Lozano S, Tran US, Matsui M, Karamouzian M. A Consensus-Based Checklist for Reporting of Survey Studies (CROSS). J Gen Intern Med. 2021.","Sharma A, Minh Duc NT, Luu Lam Thang T, Nam NH, Ng SJ, Abbas KS, Huy NT, Maru?i? A, Paul CL, Kwok J, Karbwang J, de Waure C, Drummond FJ, Kizawa Y, Taal E, Vermeulen J, Lee GHM, Gyedu A, To KG, Verra ML, Jacqz-Aigrain \xc9M, Leclercq WKG, Salminen ST, Sherbourne CD, Mintzes B, Lozano S, Tran US, Matsui M, Karamouzian M.",Journal of General Internal Medicine [J Gen Intern Med.],2021, , , , ,English, ,33886027,https://pubmed.ncbi.nlm.nih.gov/33886027/, , , , , ,CROSS,Reporting of both web- and non-web-based surveys., ,"The CROSS checklist is located in supplementary materials 3, pages 5-7.", , , , , ,no,2021-05-05 16:25:39,2022-05-12 14:34:05,a-consensus-based-checklist-for-reporting-of-survey-studies-cross,"[('title', 'A Consensus -Based Checklist for Reporting of Survey Studies (CROSS)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of both web- and non-web-based surveys.'), ('Full bibliographic reference', 'Sharma A, Minh Duc NT, Luu Lam Thang T, Nam NH, Ng SJ, Abbas KS, Huy NT, Marušić A, Paul CL, Kwok J, Karbwang J, de Waure C, Drummond FJ, Kizawa Y, Taal E, Vermeulen J, Lee GHM, Gyedu A, To KG, Verra ML, Jacqz-Aigrain ÉM, Leclercq WKG, Salminen ST, Sherbourne CD, Mintzes B, Lozano S, Tran US, Matsui M, Karamouzian M. A Consensus-Based Checklist for Reporting of Survey Studies (CROSS). J Gen Intern Med. 2021.'), ('Language', 'English'), ('PubMed ID', '[33886027](https://pubmed.ncbi.nlm.nih.gov/33886027/)'), ('Reporting guideline acronym', 'CROSS'), ('Study design', 'Observational studies, Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'The CROSS checklist is located in supplementary materials 3, pages 5-7.'), ('Record last updated on', 'May 12, 2022')]"
19487,CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration,"Clinical trials, Experimental studies", ,Whole report, ,"administrative database, administrative databases, checklist, checklists, clinical trial, clinical trials, cohort, cohorts, CONSORT extension, CONSORT-ROUTINE, data, education database, education databases, electronic health record, electronic health records, insurance database, insurance databases, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, registries, registry, routine data, routinely collected data, routinely collected database, routinely collected databases, routinely collected health data, social care database, social care databases, trial, trials", ,"Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857.","Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD.",British Medical Journal [BMJ],2021,373, ,n857, ,English, ,33926904,https://pubmed.ncbi.nlm.nih.gov/33926904/,"The full-text of CONSORT-ROUTINE is freely available at: https://www.bmj.com/content/373/bmj.n857

", , ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,CONSORT-ROUTINE,"Reporting of randomised controlled trials conducted using cohorts and routinely collected data.

", ,"Read about the development of CONSORT-ROUTINE:
Imran M, Kwakkenbos L, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. Methods and results used in the development of a consensus-driven extension to the Consolidated Standards of Reporting Trials (CONSORT) statement for trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE). BMJ Open. 2021;11(4):e049093. PMID: 33926985

", , , , , ,yes,2021-04-30 14:30:50,2025-05-30 09:26:07,consort-routine,"[('title', 'CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE) : checklist with explanation and elaboration'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of randomised controlled trials conducted using cohorts and routinely collected data.\n\n \n\n'), ('Full bibliographic reference', 'Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857.'), ('Language', 'English'), ('PubMed ID', '[33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of CONSORT-ROUTINE is freely available at: <https://www.bmj.com/content/373/bmj.n857>\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](https://dev.equator-network.org/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](http://dev.equator-network.org/reporting-guidelines/consort-cluster/):\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](http://dev.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](http://dev.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](http://dev.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text.](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration)\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'CONSORT-ROUTINE'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Read about the development of CONSORT-ROUTINE:\n\n Imran M, Kwakkenbos L, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. Methods and results used in the development of a consensus-driven extension to the Consolidated Standards of Reporting Trials (CONSORT) statement for trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE). BMJ Open. 2021;11(4):e049093. PMID: [33926985](https://pubmed.ncbi.nlm.nih.gov/33926985/)\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
19280,"Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration","Diagnostic and prognostic studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,Abstract, ,"abstract, abstracts, checklist, checklists, conference abstract, conference abstracts, diagnosis, diagnostic, diagnostic test, diagnostic test accuracy, diagnostic test accuracy studies, diagnostic test accuracy study, DTA, journal abstract, journal abstracts, meta analyses, meta analysis, PRISMA extension, PRISMA-DTA, PRISMA-DTA checklist, PRISMA-DTA for Abstracts, review, reviews, systematic review, systematic reviews", ,"Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265.","Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF.",BMJ.,2021,372,n265, , ,English, ,33722791,https://pubmed.ncbi.nlm.nih.gov/33722791/,The full-text of the PRISMA-DTA for Abstracts reporting guideline is freely available at: https://www.bmj.com/content/372/bmj.n265, , ,"Generic
PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

Specialised
PRISMA-Equity: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: 23222917

Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.
Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

PRISMA-Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.

PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246

PRISMA-IPD: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: 25919529

PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634

PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668

PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement &amp; Checklist. J Clin Epidemiol. 2017. PMID: 28720516

PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: 29362800

PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367

PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033

PRISMA-CHM: Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: 32907365

PRISMA-M 2020: Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: 33100229

PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.
Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535

PRISMA-LSR: Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: 39562017

",http://www.prisma-statement.org/Extensions/DTA,PRISMA-DTA for Abstracts,Reporting of journal and conference abstracts of systematic reviews of diagnostic test accuracy (DTA) studies., , , , , , , ,yes,2021-03-18 11:21:49,2025-02-06 12:10:04,prisma-dta-for-abstracts,"[('title', 'Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of journal and conference abstracts of systematic reviews of diagnostic test accuracy (DTA) studies.'), ('Full bibliographic reference', 'Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265.'), ('Language', 'English'), ('PubMed ID', '[33722791](https://pubmed.ncbi.nlm.nih.gov/33722791/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the PRISMA-DTA for Abstracts reporting guideline is freely available at: <https://www.bmj.com/content/372/bmj.n265>'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n[**PRISMA 2020 Statement**](http://dev.equator-network.org/reporting-guidelines/prisma/): Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.\n\n \n\n PLoS Med. 2021;18(3):e1003583. PMID: [33780438](https://pubmed.ncbi.nlm.nih.gov/33780438/)\n\n BMJ 2021;372:n71. PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)\n\n Int J Surg. 2021:105906. PMID: [33789826](https://pubmed.ncbi.nlm.nih.gov/33789826/)\n\n J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: [33789819](https://pubmed.ncbi.nlm.nih.gov/33789819/)\n\n Syst Rev. 2021;10(1):89. PMID: [33781348](https://pubmed.ncbi.nlm.nih.gov/33781348/)\n\n \n\n**Specialised**\n\n[**PRISMA-Equity**](http://dev.equator-network.org/reporting-guidelines/prisma-equity/): Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: [23222917](http://www.ncbi.nlm.nih.gov/pubmed/23222917)\n\n \n\n Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.\n\n Int J Equity Health. 2015;14(1):92. PMID: [26450828](http://www.ncbi.nlm.nih.gov/pubmed/26450828)\n\n J Clin Epidemiol. 2015. PMID: [26348799](http://www.ncbi.nlm.nih.gov/pubmed/26348799)\n\n \n\n[**PRISMA-Abstracts 2020:**](http://dev.equator-network.org/reporting-guidelines/prisma-abstracts/) The PRISMA 2020 for Abstracts reporting guideline is contained within the main [PRISMA 2020 Statement paper](https://www.equator-network.org/reporting-guidelines/prisma/).\n\n \n\n[**PRISMA-P**](http://dev.equator-network.org/reporting-guidelines/prisma-protocols/): Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: [25554246](http://www.ncbi.nlm.nih.gov/pubmed/25554246)\n\n \n\n[**PRISMA-IPD**](http://dev.equator-network.org/reporting-guidelines/prisma-ipd/): Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: [25919529](http://www.ncbi.nlm.nih.gov/pubmed/25919529)\n\n \n\n[**PRISMA extension for network meta-analyses**](http://dev.equator-network.org/reporting-guidelines/prisma-extension-network-meta-analyses/): Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: [26030634](http://www.ncbi.nlm.nih.gov/pubmed/26030634)\n\n \n\n[**PRISMA-harms**](http://dev.equator-network.org/reporting-guidelines/prisma-harms/): Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: [26830668](http://www.ncbi.nlm.nih.gov/pubmed/26830668)\n\n \n\n[**PRISMA-CI**](http://dev.equator-network.org/reporting-guidelines/prisma-ci-extension-statement-checklist/): Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: [28720516](https://www.ncbi.nlm.nih.gov/pubmed/28720516)\n\n \n\n[**PRISMA-DTA**](http://dev.equator-network.org/reporting-guidelines/prisma-dta/): McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: [29362800](https://www.ncbi.nlm.nih.gov/pubmed/29362800)\n\n \n\n[**PRISMA-A**](https://dev.equator-network.org/reporting-guidelines/prisma-acupuncture/): Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: [31405367](https://www.ncbi.nlm.nih.gov/pubmed/31405367)\n\n \n\n[**PRISMA-ScR**](http://dev.equator-network.org/reporting-guidelines/prisma-scr/): Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: [30178033](https://www.ncbi.nlm.nih.gov/pubmed/30178033)\n\n \n\n[**PRISMA-CHM**](https://www.equator-network.org/reporting-guidelines/prisma-chinese-herbal-medicines-2020/): Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: [32907365](https://pubmed.ncbi.nlm.nih.gov/32907365/)\n\n \n\n[**PRISMA-M 2020**](https://www.equator-network.org/reporting-guidelines/prisma-extension-for-moxibustion-2020/): Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: [33100229](https://pubmed.ncbi.nlm.nih.gov/33100229/)\n\n \n\n[**PRISMA-S**](https://dev.equator-network.org/reporting-guidelines/prisma-s/): Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.\n\n Syst Rev. 2021;10(1):39. PMID: [33499930](https://pubmed.ncbi.nlm.nih.gov/33499930/)\n\n J Med Libr Assoc. 2021;109(2):174-200. PMID: [34285662](https://pubmed.ncbi.nlm.nih.gov/34285662/)\n\n \n\n[**PRISMA-COSMIN for OMIs**](https://www.equator-network.org/reporting-guidelines/guideline-for-reporting-systematic-reviews-of-outcome-measurement-instruments-omis-prisma-cosmin-for-omis-2024/): Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.\n\n J Clin Epidemiol. 2024:111422. PMID: [38849061](https://pubmed.ncbi.nlm.nih.gov/38849061/)\n\n Qual Life Res. 2024. PMID: [38980635](https://pubmed.ncbi.nlm.nih.gov/38980635/)\n\n Health Qual Life Outcomes. 2024;22(1):48. PMID: [38978063](https://pubmed.ncbi.nlm.nih.gov/38978063/)\n\n J Patient Rep Outcomes. 2024;8(1):64. PMID: [38977535](https://pubmed.ncbi.nlm.nih.gov/38977535/)\n\n \n\n[**PRISMA-LSR**](https://www.equator-network.org/reporting-guidelines/prisma-lsr/): Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: [39562017](https://pubmed.ncbi.nlm.nih.gov/39562017/)\n\n \n\n""), ('Reporting guideline website URL', '<http://www.prisma-statement.org/Extensions/DTA>'), ('Reporting guideline acronym', 'PRISMA-DTA for Abstracts'), ('Study design', 'Diagnostic and prognostic studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Abstract'), ('Record last updated on', 'February 6, 2025')]"
19246,An analysis of preclinical efficacy testing of antivenoms for sub-Saharan Africa: Inadequate independent scrutiny and poor-quality reporting are barriers to improving snakebite treatment and management,Animal pre-clinical research,Tropical medicine,"Procedure/Method, Results, Study characteristics (participants etc.)", ,"animal preclinical research, antivenom, antivenom efficacy, antivenoms, efficacy testing, in vivo antivenom, preclinical, preclinical animal research, preclinical antivenom efficacy, preclinical efficacy testing, preclinical experiment, preclinical experiments, preclinical research, preclinical studies, preclinical study, preclinical testing, snakebite, snakebite envenoming, snakebites, tropical, tropical disease, tropical diseases, tropical medicine", ,"Ainsworth S, Menzies SK, Casewell NR, Harrison RA.\xa0 An analysis of preclinical efficacy testing of antivenoms for sub-Saharan Africa: Inadequate independent scrutiny and poor-quality reporting are barriers to improving snakebite treatment and management. PLoS Negl Trop Dis. 2020;14(8):e0008579.","Stuart Ainsworth, Stefanie K Menzies, Nicholas R Casewell, Robert A Harrison.",PLoS Neglected Tropical Diseases [PLoS Negl Trop Dis.],2020,14,8,e0008579, ,English, ,32817682,https://pubmed.ncbi.nlm.nih.gov/32817682/, , , , , , ,Reporting preclinical antivenom efficacy., , , , , , , ,no,2021-03-15 15:04:06,2021-03-15 15:05:40,an-analysis-of-preclinical-efficacy-testing-of-antivenoms-for-sub-saharan-africa-inadequate-independent-scrutiny-and-poor-quality-reporting-are-barriers-to-improving-snakebite-treatment-and-managemen,"[('title', 'An analysis of preclinical efficacy testing of antivenoms for sub -Saharan Africa: Inadequate independent scrutiny and poor-quality reporting are barriers to improving snakebite treatment and management'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting preclinical antivenom efficacy.'), ('Full bibliographic reference', 'Ainsworth S, Menzies SK, Casewell NR, Harrison RA.\xa0 An analysis of preclinical efficacy testing of antivenoms for sub-Saharan Africa: Inadequate independent scrutiny and poor-quality reporting are barriers to improving snakebite treatment and management. PLoS Negl Trop Dis. 2020;14(8):e0008579.'), ('Language', 'English'), ('PubMed ID', '[32817682](https://pubmed.ncbi.nlm.nih.gov/32817682/)'), ('Study design', 'Animal pre-clinical research'), ('Clinical area', 'Tropical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'March 15, 2021')]"
19238,"Artificial intelligence in dental research: Checklist for authors, reviewers, readers",Artificial intelligence/Machine learning studies,Dentistry,Whole report, ,"AI, AI application, AI model, AI models, AI studies, AI study, artificial intelligence, checklist, checklists, deep learning, dental, dental research, Dentist, Dentistry, machine learning, teeth", ,"Falk Schwendicke, Tarry Singh, Jae-Hong Lee, Robert Gaudin, Akhilanand Chaurasia, Thomas Wiegand, Sergio Uribe, Joachim Krois, IADR e-oral health network and the ITU WHO focus group AI for Health. Artificial intelligence in dental research: Checklist for authors, reviewers, readers. J Dent. 2021.","Falk Schwendicke, Tarry Singh, Jae-Hong Lee, Robert Gaudin, Akhilanand Chaurasia, Thomas Wiegand, Sergio Uribe, Joachim Krois, IADR e-oral health network and the ITU WHO focus group AI for Health.",Journal of Dentistry [J Dent.],2021, , , , ,English, ,33631303,https://pubmed.ncbi.nlm.nih.gov/33631303/, , , , , , ,Reporting studies on artificial intelligence (AI) in dentistry., , , , , , , ,no,2021-03-11 14:28:48,2024-01-25 11:50:13,artificial-intelligence-in-dental-research-checklist-for-authors-reviewers-readers,"[('title', 'Artificial intelligence in dental research: Checklist for authors, reviewers, readers'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting studies on artificial intelligence (AI) in dentistry.'), ('Full bibliographic reference', 'Falk Schwendicke, Tarry Singh, Jae-Hong Lee, Robert Gaudin, Akhilanand Chaurasia, Thomas Wiegand, Sergio Uribe, Joachim Krois, IADR e-oral health network and the ITU WHO focus group AI for Health. Artificial intelligence in dental research: Checklist for authors, reviewers, readers. J Dent. 2021.'), ('Language', 'English'), ('PubMed ID', '[33631303](https://pubmed.ncbi.nlm.nih.gov/33631303/)'), ('Study design', 'Artificial intelligence/Machine learning studies'), ('Clinical area', 'Dentistry'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 25, 2024')]"
19209,EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs),"Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies",Rheumatology,Whole report, ,"checklist, checklists, EULAR, EULAR recommendations, image, imaging, imaging measurement tool, imaging measurement tools, musculoskeletal, musculoskeletal disease, musculoskeletal diseases, radiology, rheumatic, rheumatological, rheumatology, RMD, RMDs, scan, scanning, ultrasonography, ultrasound, ultrasound studies, ultrasound study", ,"Costantino F, Carmona L, Boers M, Backhaus M, Balint PV, Bruyn GA, Christensen R, Conaghan PG, Ferreira RJO, Garrido-Castro JL, Guillemin F, Hammer HB, van der Heijde D, Iagnocco A, Kortekaas MC, Landew\xe9 RB, Mandl P, Naredo E, Schmidt WA, Terslev L, Terwee CB, Thiele R, D'Agostino MA. EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). Ann Rheum Dis. 2021.","Costantino F, Carmona L, Boers M, Backhaus M, Balint PV, Bruyn GA, Christensen R, Conaghan PG, Ferreira RJO, Garrido-Castro JL, Guillemin F, Hammer HB, van der Heijde D, Iagnocco A, Kortekaas MC, Landew\xe9 RB, Mandl P, Naredo E, Schmidt WA, Terslev L, Terwee CB, Thiele R, D'Agostino MA.",Annals of the Rheumatic Diseases [Ann Rheum Dis.],2021, , , , ,English, ,33483318,https://pubmed.ncbi.nlm.nih.gov/33483318/, , , , , , ,Reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs)., , , , , , , ,no,2021-02-19 16:13:04,2021-02-19 16:13:04,eular-recommendations-for-the-reporting-of-ultrasound-studies-in-rheumatic-and-musculoskeletal-diseases-rmds,"[('title', 'EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs).'), ('Full bibliographic reference', ""Costantino F, Carmona L, Boers M, Backhaus M, Balint PV, Bruyn GA, Christensen R, Conaghan PG, Ferreira RJO, Garrido-Castro JL, Guillemin F, Hammer HB, van der Heijde D, Iagnocco A, Kortekaas MC, Landewé RB, Mandl P, Naredo E, Schmidt WA, Terslev L, Terwee CB, Thiele R, D'Agostino MA. EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). Ann Rheum Dis. 2021.""), ('Language', 'English'), ('PubMed ID', '[33483318](https://pubmed.ncbi.nlm.nih.gov/33483318/)'), ('Study design', 'Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies'), ('Clinical area', 'Rheumatology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'February 19, 2021')]"
19207,PRIASE 2021 guidelines for reporting animal studies in Endodontology: a consensus-based development,Animal pre-clinical research,Dentistry,Whole report, ,"animal experiment, animal experimental, animal experimentation, animal pre clinical research, animal preclinical research, animal research, animal studies, animal study, animal testing, checklist, checklists, Dentistry, Endodontics, endodontology, laboratory animal, laboratory animals, pre clinical animal research, preclinical animal research, Preferred Reporting Items for Animal Studies in Endodontology, PRIASE, PRIASE 2021, PRIASE 2021 guidelines", ,"Nagendrababu V, Kishen A, Murray PE, Nekoofar MH, de Figueiredo JAP, Priya E, Jayaraman J, Pulikkotil SJ, Camilleri J, Silva RM, Dummer PMH. PRIASE 2021 guidelines for reporting animal studies in Endodontology: a consensus-based development. Int Endod J. 2021.","Nagendrababu V, Kishen A, Murray PE, Nekoofar MH, de Figueiredo JAP, Priya E, Jayaraman J, Pulikkotil SJ, Camilleri J, Silva RM, Dummer PMH.",International Endodontic Journal [Int Endod J.],2021, , , , ,English, ,33450080, https://pubmed.ncbi.nlm.nih.gov/33450080/,The full-text of the PRIASE 2021 guideline is freely available at: https://onlinelibrary.wiley.com/doi/10.1111/iej.13477,"Nagendrababu V, Kishen A, Murray PE, Nekoofar MH, de Figueiredo J, Priya E, Jayaraman J, Pulikkotil SJ, Jakovljevic A, Dummer P. PRIASE 2021 guidelines for reporting animal studies in Endodontology: Explanation and Elaboration. Int Endod J. 2021. PMID: 33492704", , ,http://pride-endodonticguidelines.org/priase/,PRIASE 2021,"Reporting animal studies in Endodontology.



PRIASE 2021 Checklist (Word)

PRIASE 2021 Flowchart (Word)

", ,"The protocol for guideline development is available at:

Nagendrababu V, Kishen A, Murray PE, Nekoofar MH, de Figueiredo JAP, Priya E, Jayaraman J, Pulikkotil SJ, Dummer PMH. Preferred Reporting Items for Animal Studies in Endodontology: a development protocol. Int Endod J. 2019;52(9):1290-1296. PMID: 30985938

", , , , , ,no,2021-02-19 11:01:25,2021-02-19 11:11:24,priase-2021-guidelines-for-reporting-animal-studies-in-endodontology-a-consensus-based-development,"[('title', 'PRIASE 2021 guidelines for reporting animal studies in Endodontology: a consensus-based development'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting animal studies in Endodontology.\n\n \n\n \xa0\n\n \n\n[PRIASE 2021 Checklist (Word)](http://pride-endodonticguidelines.org/PRIASE2021checklist.docx)\n\n \n\n[PRIASE 2021 Flowchart (Word)](http://pride-endodonticguidelines.org/FinalPRICEflowchart.docx)\n\n \n\n'), ('Full bibliographic reference', 'Nagendrababu V, Kishen A, Murray PE, Nekoofar MH, de Figueiredo JAP, Priya E, Jayaraman J, Pulikkotil SJ, Camilleri J, Silva RM, Dummer PMH. PRIASE 2021 guidelines for reporting animal studies in Endodontology: a consensus-based development. Int Endod J. 2021.'), ('Language', 'English'), ('PubMed ID', '[33450080]( https://pubmed.ncbi.nlm.nih.gov/33450080/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the PRIASE 2021 guideline is freely available at: <https://onlinelibrary.wiley.com/doi/10.1111/iej.13477>'), ('Explanation and elaboration papers', 'Nagendrababu V, Kishen A, Murray PE, Nekoofar MH, de Figueiredo J, Priya E, Jayaraman J, Pulikkotil SJ, Jakovljevic A, Dummer P. PRIASE 2021 guidelines for reporting animal studies in Endodontology: Explanation and Elaboration. Int Endod J. 2021. PMID: [33492704](https://pubmed.ncbi.nlm.nih.gov/33492704/)'), ('Reporting guideline website URL', '<http://pride-endodonticguidelines.org/priase/>'), ('Reporting guideline acronym', 'PRIASE 2021'), ('Study design', 'Animal pre-clinical research'), ('Clinical area', 'Dentistry'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'The protocol for guideline development is available at:\n\n \n\n Nagendrababu V, Kishen A, Murray PE, Nekoofar MH, de Figueiredo JAP, Priya E, Jayaraman J, Pulikkotil SJ, Dummer PMH. Preferred Reporting Items for Animal Studies in Endodontology: a development protocol. Int Endod J. 2019;52(9):1290-1296. PMID: [30985938](https://pubmed.ncbi.nlm.nih.gov/30985938/)\n\n \n\n'), ('Record last updated on', 'February 19, 2021')]"
19179,The reporting checklist for public versions of guidelines: RIGHT-PVG,Clinical practice guidelines, ,Whole report, ,"checklist, checklists, guidance, guideline, guidelines, patient, patient guideline, patients, public, public guideline, PVG, PVGs, RIGHT extension, RIGHT-PVG", ,"Wang X, Chen Y, Akl EA, Tokali? R, Maru?i? A, Qaseem A, Falck-Ytter Y, Lee MS, Siedler M, Barber SL, Zhang M, Chan ESY, Estill J, Kwong JSW, Okumura A, Zhou Q, Yang K, Norris SL; RIGHT working group. The reporting checklist for public versions of guidelines: RIGHT-PVG. Implement Sci. 2021;16(1):10.","Wang X, Chen Y, Akl EA, Tokali? R, Maru?i? A, Qaseem A, Falck-Ytter Y, Lee MS, Siedler M, Barber SL, Zhang M, Chan ESY, Estill J, Kwong JSW, Okumura A, Zhou Q, Yang K, Norris SL; RIGHT working group.",Implementation Science [Implement Sci],2021,16,1,10, ,English, ,33430911,https://pubmed.ncbi.nlm.nih.gov/33430911/,"The full-text of the RIGHT-PVG guideline is freely available at: https://implementationscience.biomedcentral.com/articles/10.1186/s13012-020-01066-z

", , ,"Generic
RIGHT: Chen Y, Yang K, Maru?i? A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Sch\xfcnemann HJ, Chan ESY, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; for the RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group.\xa0 A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166(2):128-132. PMID: 27893062

Specialised
RIGHT-TCM: Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, Xia L, Guo Y. The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Pharmacol Res. 2020;160:105178. PMID: 32889127

RIGHT for Acupuncture: Tang C, Duan Y, Zhang Y, Zhang Y, Chen Z, Tang X, Zeng J, Riley D, Lee MS, Kim YS, Zhao H, Marrone G, Zhu X, Ge S, Wen H, Zhao W, Zheng X, Solos I, Chen Y, Guyatt G, Lu L, Xu N; RIGHT (Reporting Items for Practice Guidelines in Healthcare) for Acupuncture Working Group. RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture. J Clin Epidemiol. 2021:S0895-4356(21)00173-6. PMID: 34091023

RIGHT for INT: Zhou Q, Xing D, Li Q, Zhang J, Luo X, Yang N, Wang X, Yang K, Tian J, Li H, Li B, Cai Y, Jin Y, Lv L, Sun F, Shang S, Yuan B, Li J, Ma B, Li X, Yuan Y, Wu L, Wang B, Jiang L, Wang Z, Chen Y, Liang D. An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT. J Evid Based Med. 2022;15(1):55-63. PMID: 35416438

RIGHT-Ad@pt: Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RWM, Arayssi T, Bhaumik S, Chen Y, Ghersi D, Langlois EV, Fuentes Padilla P, Sch\xfcnemann HJ, Akl EA, Mart\xednez Garc\xeda L; RIGHT-Ad@pt Working Group*, Amer Y, Arevalo-Rodriguez I, Barnes S, Barreto J, Collis D, Dyer S, Fahim C, Florez I, Gallegos-Rivero V, Klugar M, Kuijpers T, Mathew JL, Munn Z, Norris S, Pati\xf1o-Lugo DF, Pramesh CS, Rodriguez J, Roy S, Shin ES, Sosa O, Vandvik PO, Velez M, Woodcraft R; RIGHT-Ad@pt Working Group. A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Ann Intern Med. 2022;175(5):710-719. PMID: 35286143

RIGHT-COI&amp;F: Xun Y, Estill J, Khabsa J, Florez ID, Guyatt GH, Norris SL, Lee MS, Ozaki A, Qaseem A, Sch\xfcnemann HJ, Shao R, Chen Y, Akl EA; RIGHT-COI&amp;F Working Groups. Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI&amp;F Checklist. Ann Intern Med. 2024;177(6):782-790. PMID: 38739919

RIGHT for CPM: Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C. The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. Pharmacol Res. 2024;199:107015. PMID: 38036197

",http://www.right-statement.org/extensions/11,RIGHT-PVG,Reporting public or patient versions of guidelines., ,Read the protocol (Word) for the development of RIGHT-PVG., , , , , ,yes,2021-02-03 15:14:40,2024-07-26 15:33:06,the-reporting-checklist-for-public-versions-of-guidelines-right-pvg,"[('title', 'The reporting checklist for public versions of guidelines: RIGHT-PVG'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting public or patient versions of guidelines.'), ('Full bibliographic reference', 'Wang X, Chen Y, Akl EA, Tokalić R, Marušić A, Qaseem A, Falck-Ytter Y, Lee MS, Siedler M, Barber SL, Zhang M, Chan ESY, Estill J, Kwong JSW, Okumura A, Zhou Q, Yang K, Norris SL; RIGHT working group. The reporting checklist for public versions of guidelines: RIGHT-PVG. Implement Sci. 2021;16(1):10.'), ('Language', 'English'), ('PubMed ID', '[33430911](https://pubmed.ncbi.nlm.nih.gov/33430911/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the RIGHT-PVG guideline is freely available at: <https://implementationscience.biomedcentral.com/articles/10.1186/s13012-020-01066-z>\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**RIGHT**](https://www.equator-network.org/reporting-guidelines/right-statement/): Chen Y, Yang K, Marušić A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Schünemann HJ, Chan ESY, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; for the RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group.\xa0 A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166(2):128-132. PMID: [27893062](https://www.ncbi.nlm.nih.gov/pubmed/27893062)\n\n \n\n**Specialised**\n\n[**RIGHT-TCM**](https://www.equator-network.org/reporting-guidelines/the-right-extension-statement-for-traditional-chinese-medicine-development-recommendations-and-explanation/): Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, Xia L, Guo Y. The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Pharmacol Res. 2020;160:105178. PMID: [32889127](https://pubmed.ncbi.nlm.nih.gov/32889127)\n\n \n\n[**RIGHT for Acupuncture**](https://www.equator-network.org/reporting-guidelines/right-for-acupuncture/): Tang C, Duan Y, Zhang Y, Zhang Y, Chen Z, Tang X, Zeng J, Riley D, Lee MS, Kim YS, Zhao H, Marrone G, Zhu X, Ge S, Wen H, Zhao W, Zheng X, Solos I, Chen Y, Guyatt G, Lu L, Xu N; RIGHT (Reporting Items for Practice Guidelines in Healthcare) for Acupuncture Working Group. RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture. J Clin Epidemiol. 2021:S0895-4356(21)00173-6. PMID: [34091023](https://pubmed.ncbi.nlm.nih.gov/34091023/)\n\n \n\n[**RIGHT for INT**](https://www.equator-network.org/reporting-guidelines/an-extension-of-the-right-statement-for-introductions-and-interpretations-of-clinical-practice-guidelines-right-for-int/): Zhou Q, Xing D, Li Q, Zhang J, Luo X, Yang N, Wang X, Yang K, Tian J, Li H, Li B, Cai Y, Jin Y, Lv L, Sun F, Shang S, Yuan B, Li J, Ma B, Li X, Yuan Y, Wu L, Wang B, Jiang L, Wang Z, Chen Y, Liang D. An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT. J Evid Based Med. 2022;15(1):55-63. PMID: [35416438](https://pubmed.ncbi.nlm.nih.gov/35416438/)\n\n \n\n[**RIGHT-Ad@pt**](https://www.equator-network.org/reporting-guidelines/a-reporting-tool-for-adapted-guidelines-in-health-care-the-right-adapt-checklist/): Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RWM, Arayssi T, Bhaumik S, Chen Y, Ghersi D, Langlois EV, Fuentes Padilla P, Schünemann HJ, Akl EA, Martínez García L; RIGHT-Ad@pt Working Group\\*, Amer Y, Arevalo-Rodriguez I, Barnes S, Barreto J, Collis D, Dyer S, Fahim C, Florez I, Gallegos-Rivero V, Klugar M, Kuijpers T, Mathew JL, Munn Z, Norris S, Patiño-Lugo DF, Pramesh CS, Rodriguez J, Roy S, Shin ES, Sosa O, Vandvik PO, Velez M, Woodcraft R; RIGHT-Ad@pt Working Group. A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Ann Intern Med. 2022;175(5):710-719. PMID: [35286143](https://pubmed.ncbi.nlm.nih.gov/35286143/)\n\n \n\n[**RIGHT-COI&F**](https://www.equator-network.org/reporting-guidelines/reporting-conflicts-of-interest-and-funding-in-health-care-guidelines-the-right-coif-checklist/): Xun Y, Estill J, Khabsa J, Florez ID, Guyatt GH, Norris SL, Lee MS, Ozaki A, Qaseem A, Schünemann HJ, Shao R, Chen Y, Akl EA; RIGHT-COI&F Working Groups. Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI&F Checklist. Ann Intern Med. 2024;177(6):782-790. PMID: [38739919](https://pubmed.ncbi.nlm.nih.gov/38739919/)\n\n \n\n[**RIGHT for CPM**](https://www.equator-network.org/reporting-guidelines/the-reporting-checklist-for-chinese-patent-medicine-guidelines-right-for-cpm/): Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C. The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. Pharmacol Res. 2024;199:107015. PMID: [38036197](https://pubmed.ncbi.nlm.nih.gov/38036197/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.right-statement.org/extensions/11>'), ('Reporting guideline acronym', 'RIGHT-PVG'), ('Study design', 'Clinical practice guidelines'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', '[Read the protocol (Word)](https://www.equator-network.org/wp-content/uploads/2009/02/Protocol-RIGHT-for-PVG-development.docx) for the development of RIGHT-PVG.'), ('Record last updated on', 'July 26, 2024')]"
19177,SQUIRE-EDU (Standards for QUality Improvement Reporting Excellence in Education): Publication Guidelines for Educational Improvement,Quality improvement studies,Medical education,Whole report, ,"checklist, checklists, education, educational, educational improvement, health professions education, improvement, learners, learning, QI, quality, quality improvement, SQUIRE extension, SQUIRE-EDU, value", ,"Ogrinc G, Armstrong GE, Dolansky MA, Singh MK, Davies L. SQUIRE-EDU (Standards for QUality Improvement Reporting Excellence in Education): Publication Guidelines for Educational Improvement. Acad Med. 2019;94(10):1461-1470.","Ogrinc G, Armstrong GE, Dolansky MA, Singh MK, Davies L.",Academic Medicine [Acad Med],2019,94,10,1461-1470, ,English, , 30998575,https://pubmed.ncbi.nlm.nih.gov/30998575/,"The full-text of the SQUIRE-EDU reporting guideline is freely available.

", , ,"Generic
SQUIRE 2.0: Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.

BMJ Qual Saf. 2015. PMID: 26369893
J Nurs Care Qual. 2015. PMID: 26429125
Am J Crit Care. 2015. PMID: 26523003
Perm J. 2015. PMID: 26517437
J Surg Res. 2015. PMID: 26515734
J Contin Educ Nurs. 2015. PMID: 26509402
J Am Coll Surg. 2016;222(3):317-323. PMID: 26385723

Specialised
SQUIRE-SIM: Stone KP, Rutman L, Calhoun AW, Reid J, Maa T, Bajaj K, Auerbach MA, Cheng A, Davies L, Deutsch E, Harwayne-Gidansky I, Kessler DO, Ogrinc G, Patterson M, Thomas A, Doughty C; And for the International Network in Simulation-Based Innovation, Research and Education (INSPIRE) SQUIRE-SIM Reporting Guidelines Investigators. SQUIRE-SIM (Standards for Quality Improvement Reporting Excellence for SIMulation): Publication Guidelines for Simulation-Based Quality Improvement Projects. Simul Healthc. 2024. PMID: 39162794

",http://www.squire-statement.org/index.cfm?fuseaction=Page.ViewPage&pageId=515,SQUIRE-EDU,Reporting of studies that describe systematic efforts to improve the quality and value of health professions education., , , , , , , ,yes,2021-02-03 11:59:34,2025-03-26 14:50:32,squire-edu-standards-for-quality-improvement-reporting-excellence-in-education-publication-guidelines-for-educational-improvement,"[('title', 'SQUIRE-EDU  (Standards for QUality Improvement Reporting Excellence in Education): Publication Guidelines for Educational Improvement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of studies that describe systematic efforts to improve the quality and value of health professions education.'), ('Full bibliographic reference', 'Ogrinc G, Armstrong GE, Dolansky MA, Singh MK, Davies L. SQUIRE-EDU (Standards for QUality Improvement Reporting Excellence in Education): Publication Guidelines for Educational Improvement. Acad Med. 2019;94(10):1461-1470.'), ('Language', 'English'), ('PubMed ID', '[30998575](https://pubmed.ncbi.nlm.nih.gov/30998575/)'), ('Relevant URLs\n\n(full-text if available)', 'The [full-text of the SQUIRE-EDU](https://journals.lww.com/academicmedicine/Fulltext/2019/10000/SQUIRE_EDU__Standards_for_QUality_Improvement.19.aspx) reporting guideline is freely available.\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**SQUIRE 2.0**](https://www.equator-network.org/reporting-guidelines/squire/): Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.\n\n \n\n BMJ Qual Saf. 2015. PMID: [26369893](http://www.ncbi.nlm.nih.gov/pubmed/26369893)\n\n J Nurs Care Qual. 2015. PMID: [26429125](http://www.ncbi.nlm.nih.gov/pubmed/26429125)\n\n Am J Crit Care. 2015. PMID: [26523003](http://www.ncbi.nlm.nih.gov/pubmed/26523003)\n\n Perm J. 2015. PMID: [26517437](http://www.ncbi.nlm.nih.gov/pubmed/26517437)\n\n J Surg Res. 2015. PMID: [26515734](http://www.ncbi.nlm.nih.gov/pubmed/26515734)\n\n J Contin Educ Nurs. 2015. PMID: [26509402](http://www.ncbi.nlm.nih.gov/pubmed/26509402)\n\n J Am Coll Surg. 2016;222(3):317-323. PMID: [26385723](http://www.ncbi.nlm.nih.gov/pubmed/26385723)\n\n \n\n**Specialised**\n\n[**SQUIRE-SIM**](https://www.equator-network.org/reporting-guidelines/squire-sim-standards-for-quality-improvement-reporting-excellence-for-simulation-publication-guidelines-for-simulation-based-quality-improvement-projects/): Stone KP, Rutman L, Calhoun AW, Reid J, Maa T, Bajaj K, Auerbach MA, Cheng A, Davies L, Deutsch E, Harwayne-Gidansky I, Kessler DO, Ogrinc G, Patterson M, Thomas A, Doughty C; And for the International Network in Simulation-Based Innovation, Research and Education (INSPIRE) SQUIRE-SIM Reporting Guidelines Investigators. SQUIRE-SIM (Standards for Quality Improvement Reporting Excellence for SIMulation): Publication Guidelines for Simulation-Based Quality Improvement Projects. Simul Healthc. 2024. PMID: [39162794](https://pubmed.ncbi.nlm.nih.gov/39162794/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.squire-statement.org/index.cfm?fuseaction=Page.ViewPage&pageId=515>'), ('Reporting guideline acronym', 'SQUIRE-EDU'), ('Study design', 'Quality improvement studies'), ('Clinical area', 'Medical education'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'March 26, 2025')]"
19162,PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Procedure/Method, ,"checklist, checklists, evidence syntheses, evidence synthesis, information retrieval, information source, information sources, information specialist, information specialists, librarian, librarians, literature search, literature searches, methods, PRISMA, PRISMA extension, PRISMA-S, PRISMA-S checklist, reproducibility, review, reviews, search, search methods, search strategies, search strategy, searching, systematic review, systematic reviews", ,"Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.

This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.

Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

","Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group.", , , , , , ,English, , , ,"Read the full-text of the PRISMA-S reporting guideline in Systematic Reviews or the Journal of the Medical Library Association.

", , ,"Generic
PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

Specialised
PRISMA-Equity: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: 23222917

Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.
Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

PRISMA-Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.

PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246

PRISMA-IPD: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: 25919529

PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634

PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668

PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement &amp; Checklist. J Clin Epidemiol. 2017. PMID: 28720516

PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: 29362800

PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367

PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033

PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791

PRISMA-CHM: Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: 32907365

PRISMA-M 2020: Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: 33100229

PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535

PRISMA-LSR: Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: 39562017

",http://www.prisma-statement.org/Extensions/Searching,PRISMA-S,"Reporting literature searches in systematic reviews.



PRISMA-S Checklist (Word)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 PRISMA-S Checklist (PDF)

PRISMA-S Checklist (Excel)

", ,"For terminology and reporting of citation searching use the TARCiS Checklist
Word | PDF | TARCiS website

", , ,"Read the protocol (PDF) for the development of the PRISMA-S guideline.

All data (including data relating to item development, survey instruments, data from the Delphi surveys, and consent documents) is available from the PRISMA-S Reporting Extension OSF site at https://doi.org/10.17605/OSF.IO/YGN9W

", , ,yes,2021-01-27 15:41:10,2025-02-06 12:15:18,prisma-s,"[('title', 'PRISMA-S : an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting literature searches in systematic reviews.\n\n \n\n \xa0\n\n \n\n[PRISMA-S Checklist (Word)](https://osf.io/sfgvq/) [PRISMA-S Checklist (PDF)](https://osf.io/y765x/)\n\n \n\n[PRISMA-S Checklist (Excel)](https://osf.io/4gnq2/)\n\n \n\n'), ('Full bibliographic reference', 'Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.\n\n \n\n This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.\n\n \n\n Syst Rev. 2021;10(1):39. PMID: [33499930](https://pubmed.ncbi.nlm.nih.gov/33499930/)\n\n J Med Libr Assoc. 2021;109(2):174-200. PMID: [34285662](https://pubmed.ncbi.nlm.nih.gov/34285662/)\n\n \n\n'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'Read the full-text of the PRISMA-S reporting guideline in [Systematic Reviews](https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-020-01542-z) or the [Journal of the Medical Library Association](https://jmla.mlanet.org/ojs/jmla/article/view/962).\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n[**PRISMA 2020 Statement**](http://dev.equator-network.org/reporting-guidelines/prisma/): Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.\n\n \n\n PLoS Med. 2021;18(3):e1003583. PMID: [33780438](https://pubmed.ncbi.nlm.nih.gov/33780438/)\n\n BMJ 2021;372:n71. PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)\n\n Int J Surg. 2021:105906. PMID: [33789826](https://pubmed.ncbi.nlm.nih.gov/33789826/)\n\n J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: [33789819](https://pubmed.ncbi.nlm.nih.gov/33789819/)\n\n Syst Rev. 2021;10(1):89. PMID: [33781348](https://pubmed.ncbi.nlm.nih.gov/33781348/)\n\n \n\n**Specialised**\n\n[**PRISMA-Equity**](http://dev.equator-network.org/reporting-guidelines/prisma-equity/): Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: [23222917](http://www.ncbi.nlm.nih.gov/pubmed/23222917)\n\n \n\n Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.\n\n Int J Equity Health. 2015;14(1):92. PMID: [26450828](http://www.ncbi.nlm.nih.gov/pubmed/26450828)\n\n J Clin Epidemiol. 2015. PMID: [26348799](http://www.ncbi.nlm.nih.gov/pubmed/26348799)\n\n \n\n[**PRISMA-Abstracts 2020:**](http://dev.equator-network.org/reporting-guidelines/prisma-abstracts/) The PRISMA 2020 for Abstracts reporting guideline is contained within the main [PRISMA 2020 Statement paper](https://www.equator-network.org/reporting-guidelines/prisma/).\n\n \n\n[**PRISMA-P**](http://dev.equator-network.org/reporting-guidelines/prisma-protocols/): Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: [25554246](http://www.ncbi.nlm.nih.gov/pubmed/25554246)\n\n \n\n[**PRISMA-IPD**](http://dev.equator-network.org/reporting-guidelines/prisma-ipd/): Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: [25919529](http://www.ncbi.nlm.nih.gov/pubmed/25919529)\n\n \n\n[**PRISMA extension for network meta-analyses**](http://dev.equator-network.org/reporting-guidelines/prisma-extension-network-meta-analyses/): Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: [26030634](http://www.ncbi.nlm.nih.gov/pubmed/26030634)\n\n \n\n[**PRISMA-harms**](http://dev.equator-network.org/reporting-guidelines/prisma-harms/): Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: [26830668](http://www.ncbi.nlm.nih.gov/pubmed/26830668)\n\n \n\n[**PRISMA-CI**](http://dev.equator-network.org/reporting-guidelines/prisma-ci-extension-statement-checklist/): Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: [28720516](https://www.ncbi.nlm.nih.gov/pubmed/28720516)\n\n \n\n[**PRISMA-DTA**](http://dev.equator-network.org/reporting-guidelines/prisma-dta/): McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: [29362800](https://www.ncbi.nlm.nih.gov/pubmed/29362800)\n\n \n\n[**PRISMA-A**](https://dev.equator-network.org/reporting-guidelines/prisma-acupuncture/): Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: [31405367](https://www.ncbi.nlm.nih.gov/pubmed/31405367)\n\n \n\n[**PRISMA-ScR**](http://dev.equator-network.org/reporting-guidelines/prisma-scr/): Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: [30178033](https://www.ncbi.nlm.nih.gov/pubmed/30178033)\n\n \n\n[**PRISMA-DTA for Abstracts**](https://dev.equator-network.org/reporting-guidelines/prisma-dta-for-abstracts/): Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: [33722791](https://pubmed.ncbi.nlm.nih.gov/33722791/)\n\n \n\n[**PRISMA-CHM**](https://www.equator-network.org/reporting-guidelines/prisma-chinese-herbal-medicines-2020/): Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: [32907365](https://pubmed.ncbi.nlm.nih.gov/32907365/)\n\n \n\n[**PRISMA-M 2020**](https://www.equator-network.org/reporting-guidelines/prisma-extension-for-moxibustion-2020/): Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: [33100229](https://pubmed.ncbi.nlm.nih.gov/33100229/)\n\n \n\n[**PRISMA-COSMIN for OMIs**](https://www.equator-network.org/reporting-guidelines/guideline-for-reporting-systematic-reviews-of-outcome-measurement-instruments-omis-prisma-cosmin-for-omis-2024/): Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.\n\n J Clin Epidemiol. 2024:111422. PMID: [38849061](https://pubmed.ncbi.nlm.nih.gov/38849061/)\n\n Qual Life Res. 2024. PMID: [38980635](https://pubmed.ncbi.nlm.nih.gov/38980635/)\n\n Health Qual Life Outcomes. 2024;22(1):48. PMID: [38978063](https://pubmed.ncbi.nlm.nih.gov/38978063/)\n\n J Patient Rep Outcomes. 2024;8(1):64. PMID: [38977535](https://pubmed.ncbi.nlm.nih.gov/38977535/)\n\n \n\n[**PRISMA-LSR**](https://www.equator-network.org/reporting-guidelines/prisma-lsr/): Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: [39562017](https://pubmed.ncbi.nlm.nih.gov/39562017/)\n\n \n\n""), ('Reporting guideline website URL', '<http://www.prisma-statement.org/Extensions/Searching>'), ('Reporting guideline acronym', 'PRISMA-S'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method'), ('Other', '[Read the protocol (PDF)](https://www.equator-network.org/wp-content/uploads/2009/02/Protocol-PRISMA-S-Delphi.pdf) for the development of the PRISMA-S guideline.\n\n \n\n All data (including data relating to item development, survey instruments, data from the Delphi surveys, and consent documents) is available from the PRISMA-S Reporting Extension OSF site at <https://doi.org/10.17605/OSF.IO/YGN9W>\n\n \n\n'), ('Additional information', 'For terminology and reporting of citation searching use the TARCiS Checklist\n\n[Word](https://ub.unibas.ch/fileadmin/user_upload/universitaetsbibliothek/Universitaetsbibliothek/5_Standorte/UB_Medizin/TARCiS/TARCiS_Checklist_for_Terminology_and_Reporting_of_Citation_Searching.docx) | [PDF](https://ub.unibas.ch/fileadmin/user_upload/universitaetsbibliothek/Universitaetsbibliothek/5_Standorte/UB_Medizin/TARCiS/TARCiS_Checklist_for_Terminology_and_Reporting_of_Citation_Searching.pdf) | [TARCiS website](https://ub.unibas.ch/de/ub-medizin/tarcis/)\n\n \n\n'), ('Record last updated on', 'February 6, 2025')]"
19100,Anaesthesia Case Report (ACRE) checklist: a tool to promote high-quality reporting of cases in peri-operative practice,Observational studies,Surgery,Whole report, ,"ACRE, ACRE checklist, anaesthesia, Anaesthesia Case Report (ACRE) checklist, Anaesthesia Case Report checklist, anaesthetic, anesthesia, anesthetic, case report, case reports, checklist, checklists, operation, perioperative, surgery, surgical", ,"Shelton CL, Klein AA, Bailey CR, El-Boghdadly K. The Anaesthesia Case Report (ACRE) checklist: a tool to promote high-quality reporting of cases in peri-operative practice. Anaesthesia. 2021.","Shelton CL, Klein AA, Bailey CR, El-Boghdadly K.",Anaesthesia.,2021, , , , ,English, ,33440026,https://pubmed.ncbi.nlm.nih.gov/33440026/,The full-text of the ACRE reporting guideline is freely available at: https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/anae.15391, , , , ,ACRE,Reporting of cases in anaesthesia and peri?operative medicine., , , , , , , ,no,2021-01-19 16:24:50,2021-01-19 16:32:53,anaesthesia-case-report-acre-checklist-a-tool-to-promote-high-quality-reporting-of-cases-in-peri-operative-practice,"[('title', 'Anaesthesia Case Report (ACRE) checklist: a tool to promote high-quality reporting of cases in peri-operative practice'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of cases in anaesthesia and peri‐operative medicine.'), ('Full bibliographic reference', 'Shelton CL, Klein AA, Bailey CR, El-Boghdadly K. The Anaesthesia Case Report (ACRE) checklist: a tool to promote high-quality reporting of cases in peri-operative practice. Anaesthesia. 2021.'), ('Language', 'English'), ('PubMed ID', '[33440026](https://pubmed.ncbi.nlm.nih.gov/33440026/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the ACRE reporting guideline is freely available at: <https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/anae.15391>'), ('Reporting guideline acronym', 'ACRE'), ('Study design', 'Observational studies'), ('Clinical area', 'Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 19, 2021')]"
19039,Strengthening tRansparent reporting of reseArch on uNfinished nursing CARE: The RANCARE guideline,"Clinical trials, Experimental studies, Observational studies", ,Whole report, ,"compromised care, incomplete care, missed care, nurse, nurses, nursing, nursing care, observation, observational, observational research, observational studies, observational study, omitted care, quantitative, quantitative research, RANCARE, RANCARE guideline, rationed care, Strengthening tRansparent reporting of reseArch on uNfinished nursing CARE, underused care, unfinished, unfinished care, unfinished nursing care", ,"Blatter C, Hamilton P, Bachnick S, Z\xfa\xf1iga F, Ausserhofer D, Simon M; RANCARE Consortium. Strengthening tRansparent reporting of reseArch on uNfinished nursing CARE: The RANCARE guideline. Res Nurs Health. 2021.","Blatter C, Hamilton P, Bachnick S, Z\xfa\xf1iga F, Ausserhofer D, Simon M; RANCARE Consortium.",Research in Nursing and Health [Res Nurs Health.],2021, , , , ,English, ,33386768,https://pubmed.ncbi.nlm.nih.gov/33386768/,The full-text of the RANCARE guideline is freely available at:\xa0https://doi.org/ 10.1002/nur.22103, , , , ,RANCARE,Reporting of quantitative research on unfinished nursing care., , , , , , , ,no,2021-01-05 12:13:06,2021-01-05 12:13:06,strengthening-transparent-reporting-of-research-on-unfinished-nursing-care-the-rancare-guideline,"[('title', 'Strengthening tRansparent reporting of reseArch on uNfinished nursing CARE : The RANCARE guideline'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of quantitative research on unfinished nursing care.'), ('Full bibliographic reference', 'Blatter C, Hamilton P, Bachnick S, Zúñiga F, Ausserhofer D, Simon M; RANCARE Consortium. Strengthening tRansparent reporting of reseArch on uNfinished nursing CARE: The RANCARE guideline. Res Nurs Health. 2021.'), ('Language', 'English'), ('PubMed ID', '[33386768](https://pubmed.ncbi.nlm.nih.gov/33386768/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the RANCARE guideline is freely available at:[https://doi.org/ 10.1002/nur.22103](https://doi.org/10.1002/nur.22103)'), ('Reporting guideline acronym', 'RANCARE'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 5, 2021')]"
19025,"Journal article reporting standards for qualitative primary, qualitative meta-analytic, and mixed methods research in psychology: The APA Publications and Communications Board task force report","Mixed methods studies, Qualitative research, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews",Psychology,Whole report, ,"American Psychological Association, APA, APA Style, JARS, JARS-Qual, Journal Article Reporting Standards for Qualitative Research, meta analyses, meta analysis, mixed method, mixed methods, mixed methods research, mixed methods studies, mixed methods study, MMARS, psychological, psychology, QMARS, qualitative, qualitative meta-analyses, qualitative meta-analysis, qualitative research, qualitative studies, qualitative study", ,"Levitt HM, Bamberg M, Creswell JW, Frost DM, Josselson R, Su\xe1rez-Orozco C. Journal article reporting standards for qualitative primary, qualitative meta-analytic, and mixed methods research in psychology: The APA Publications and Communications Board task force report. Am Psychol. 2018;73(1):26-46.","Levitt HM, Bamberg M, Creswell JW, Frost DM, Josselson R, Su\xe1rez-Orozco C.",The American Psychologist [Am Psychol.],2018,73,1,26-46, ,English, ,29345485,https://pubmed.ncbi.nlm.nih.gov/29345485/,The JARS reporting guidelines are available in full-text at https://content.apa.org/fulltext/2018-00750-003.html, , , ,https://apastyle.apa.org/jars, ,"Reporting of qualitative research, mixed methods research and qualitative meta-analysis.", ,"These journal article reporting standards incorporate three separate reporting guidelines for the following study types:

Journal Article Reporting Standards for Qualitative Research (JARS-Qual) - JARS-Qual Checklist (PDF)

Mixed Methods Article Reporting Standards (MMARS) - MMARS Checklist (PDF)

Qualitative Meta-Analysis Article Reporting Standards (QMARS) - QMARS Checklist (PDF)

", , ,"See also the APA JARS-REC reporting standards for Race, Ethnicity, and Culture:

 	JARS-REC standards
 	JARS-REC checklist (PDF)
", , ,no,2020-12-17 15:57:33,2024-10-01 16:33:15,journal-article-reporting-standards-for-qualitative-primary-qualitative-meta-analytic-and-mixed-methods-research-in-psychology-the-apa-publications-and-communications-board-task-force-report,"[('title', 'Journal article reporting standards for qualitative primary, qualitative meta-analytic, and mixed methods research in psychology: The APA Publications and Communications Board task force report'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of qualitative research, mixed methods research and qualitative meta-analysis.'), ('Full bibliographic reference', 'Levitt HM, Bamberg M, Creswell JW, Frost DM, Josselson R, Suárez-Orozco C. Journal article reporting standards for qualitative primary, qualitative meta-analytic, and mixed methods research in psychology: The APA Publications and Communications Board task force report. Am Psychol. 2018;73(1):26-46.'), ('Language', 'English'), ('PubMed ID', '[29345485](https://pubmed.ncbi.nlm.nih.gov/29345485/)'), ('Relevant URLs\n\n(full-text if available)', 'The JARS reporting guidelines are available in full-text at <https://content.apa.org/fulltext/2018-00750-003.html>'), ('Reporting guideline website URL', '<https://apastyle.apa.org/jars>'), ('Study design', 'Mixed methods studies, Qualitative research, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Clinical area', 'Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Other', 'See also the APA [JARS-REC](https://apastyle.apa.org/jars/race-ethnicity-culture) reporting standards for Race, Ethnicity, and Culture:\n\n\n\n* [JARS-REC standards](https://apastyle.apa.org/jars/race-ethnicity-culture-executive-summary) \n\n* [JARS-REC checklist (PDF)](https://apastyle.apa.org/jars/rec-table-1.pdf) \n\n'), ('Additional information', 'These journal article reporting standards incorporate three separate reporting guidelines for the following study types:\n\n \n\n Journal Article Reporting Standards for Qualitative Research (JARS-Qual) - [JARS-Qual Checklist (PDF)](https://apastyle.apa.org/jars/qual-table-1.pdf)\n\n \n\n Mixed Methods Article Reporting Standards (MMARS) - [MMARS Checklist (PDF)](https://apastyle.apa.org/jars/mixed-table-1.pdf)\n\n \n\n Qualitative Meta-Analysis Article Reporting Standards (QMARS) - [QMARS Checklist (PDF)](https://apastyle.apa.org/jars/qual-table-2.pdf)\n\n \n\n'), ('Record last updated on', 'October 1, 2024')]"
19001,Defining Group Care Programs: An Index of Reporting Standards,"Clinical trials, Experimental studies", ,"Intervention (exposure), Outcomes (variables), Study characteristics (participants etc.)", ,"child, children, family, group, group care, group care program, group care programme, group care programmes, group care programs, quasi experimental, quasi-experimental studies, quasi-experimental study, residential, residential care, residential program, residential programme, residential programmes, residential programs, residential treatment, young, youth, youths", ,"Lee BR, Barth RP. Defining Group Care Programs: An Index of Reporting Standards. Child &amp; Youth Care Forum. 2011. 40;253?266.","Lee BR, Barth RP.",Child &amp; Youth Care Forum.,2011,40, ,253?266, ,English, , , ,The full-text of this reporting guideline is available at: https://link.springer.com/article/10.1007/s10566-011-9143-9, , , , , ,Reporting standards for group care programmes., , , , , , , ,no,2020-11-23 16:59:19,2020-11-23 16:59:19,defining-group-care-programs-an-index-of-reporting-standards,"[('title', 'Defining Group Care Programs: An Index of Reporting Standards'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting standards for group care programmes.'), ('Full bibliographic reference', 'Lee BR, Barth RP. Defining Group Care Programs: An Index of Reporting Standards. Child & Youth Care Forum. 2011. 40;253–266.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is available at: <https://link.springer.com/article/10.1007/s10566-011-9143-9>'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Outcomes (variables), Study characteristics (participants etc.)'), ('Record last updated on', 'November 23, 2020')]"
18997,Stakeholder analysis in health innovation planning processes: A systematic scoping review,Qualitative research, ,Whole report, ,"health innovation, health innovation plan, health innovation planning, health innovation plans, health innovations, health planning, qualitative, qualitative research, Reporting Items for Stakeholder Analysis, RISA, RISA tool, stakeholder, stakeholder analyses, stakeholder analysis, stakeholder mapping, stakeholders, strategic, strategic planning, strategy", ,"Franco-Trigo L, Fernandez-Llimos F, Mart\xednez-Mart\xednez F, Benrimoj SI, Sabater-Hern\xe1ndez D. Stakeholder analysis in health innovation planning processes: A systematic scoping review. Health Policy. 2020;124(10):1083-1099.","Franco-Trigo L, Fernandez-Llimos F, Mart\xednez-Mart\xednez F, Benrimoj SI, Sabater-Hern\xe1ndez D.",Health Policy.,2020,124,10,1083-1099, ,English, ,32829927,https://pubmed.ncbi.nlm.nih.gov/32829927/, , , , , ,RISA,Reporting of stakeholder analyses., , , , , , , ,no,2020-11-20 15:01:06,2020-11-20 15:01:06,stakeholder-analysis-in-health-innovation-planning-processes-a-systematic-scoping-review,"[('title', 'Stakeholder analysis in health innovation planning processes: A systematic scoping review'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of stakeholder analyses.'), ('Full bibliographic reference', 'Franco-Trigo L, Fernandez-Llimos F, Martínez-Martínez F, Benrimoj SI, Sabater-Hernández D. Stakeholder analysis in health innovation planning processes: A systematic scoping review. Health Policy. 2020;124(10):1083-1099.'), ('Language', 'English'), ('PubMed ID', '[32829927](https://pubmed.ncbi.nlm.nih.gov/32829927/)'), ('Reporting guideline acronym', 'RISA'), ('Study design', 'Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 20, 2020')]"
18992,"PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration",Systematic reviews/Meta-analyses/Reviews/HTA/Overviews,Complementary and alternative medicine,Whole report, ,"acupoints, checklist, checklists, Chinese medicine, Chinese Medicine pattern, CM, meridians, meta analyses, meta analysis, moxa, moxibustion, moxibustion extension, PRISMA, PRISMA extension, PRISMA moxibustion, PRISMA-M, PRISMA-M 2020, review, reviews, systematic review, systematic reviews, TCM, traditional Chinese medicine", ,"Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247.","Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX.",Systematic Reviews [Syst Rev.],2020,9,1,247, ,English, ,33100229,https://pubmed.ncbi.nlm.nih.gov/33100229/,"The full-text of PRISMA-M 2020 is available at: https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-020-01502-7

", , ,"Generic
PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

Specialised
PRISMA-Equity: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: 23222917

Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.
Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

PRISMA-Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.

PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246

PRISMA-IPD: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: 25919529

PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634

PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668

PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement &amp; Checklist. J Clin Epidemiol. 2017. PMID: 28720516

PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: 29362800

PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033

PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367

PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791

PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.
Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535

PRISMA-LSR: Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: 39562017

", ,PRISMA-M 2020,"Reporting of systematic reviews focusing on moxibustion interventions for specific conditions and/or patterns.



PRISMA-M 2020 checklist Word / PDF

", , , , , , , ,yes,2020-11-19 15:24:03,2025-02-06 12:13:45,prisma-extension-for-moxibustion-2020,"[('title', 'PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of systematic reviews focusing on moxibustion interventions for specific conditions and/or patterns.\n\n \n\n \xa0\n\n \n\n PRISMA-M 2020 checklist [Word](https://www.prisma-statement.org/s/PRISMA-Moxibustion_checklist.docx) / [PDF](https://www.prisma-statement.org/s/PRISMA-Moxibustion_checklist.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247.'), ('Language', 'English'), ('PubMed ID', '[33100229](https://pubmed.ncbi.nlm.nih.gov/33100229/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of PRISMA-M 2020 is available at: <https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-020-01502-7>\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n[**PRISMA 2020 Statement**](https://www.equator-network.org/reporting-guidelines/prisma/): Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.\n\n \n\n PLoS Med. 2021;18(3):e1003583. PMID: [33780438](https://pubmed.ncbi.nlm.nih.gov/33780438/)\n\n BMJ 2021;372:n71. PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)\n\n Int J Surg. 2021:105906. PMID: [33789826](https://pubmed.ncbi.nlm.nih.gov/33789826/)\n\n J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: [33789819](https://pubmed.ncbi.nlm.nih.gov/33789819/)\n\n Syst Rev. 2021;10(1):89. PMID: [33781348](https://pubmed.ncbi.nlm.nih.gov/33781348/)\n\n \n\n**Specialised**\n\n[**PRISMA-Equity**](https://www.equator-network.org/reporting-guidelines/prisma-equity/): Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: [23222917](http://www.ncbi.nlm.nih.gov/pubmed/23222917)\n\n \n\n Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.\n\n Int J Equity Health. 2015;14(1):92. PMID: [26450828](http://www.ncbi.nlm.nih.gov/pubmed/26450828)\n\n J Clin Epidemiol. 2015. PMID: [26348799](http://www.ncbi.nlm.nih.gov/pubmed/26348799)\n\n \n\n[**PRISMA-Abstracts 2020**](https://www.equator-network.org/reporting-guidelines/prisma-abstracts/): The PRISMA 2020 for Abstracts reporting guideline is contained within the main [PRISMA 2020 Statement paper](https://www.equator-network.org/reporting-guidelines/prisma/).\n\n \n\n[**PRISMA-P**](https://www.equator-network.org/reporting-guidelines/prisma-protocols/): Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: [25554246](http://www.ncbi.nlm.nih.gov/pubmed/25554246)\n\n \n\n[**PRISMA-IPD**](https://www.equator-network.org/reporting-guidelines/prisma-ipd/): Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: [25919529](http://www.ncbi.nlm.nih.gov/pubmed/25919529)\n\n \n\n[**PRISMA extension for network meta-analyses**](https://www.equator-network.org/reporting-guidelines/prisma-extension-network-meta-analyses/): Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: [26030634](http://www.ncbi.nlm.nih.gov/pubmed/26030634)\n\n \n\n[**PRISMA-harms**](https://www.equator-network.org/reporting-guidelines/prisma-harms/): Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: [26830668](http://www.ncbi.nlm.nih.gov/pubmed/26830668)\n\n \n\n[**PRISMA-CI**](https://www.equator-network.org/reporting-guidelines/prisma-ci-extension-statement-checklist/): Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: [28720516](https://www.ncbi.nlm.nih.gov/pubmed/28720516)\n\n \n\n[**PRISMA-DTA**](https://www.equator-network.org/reporting-guidelines/prisma-dta/): McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: [29362800](https://www.ncbi.nlm.nih.gov/pubmed/29362800)\n\n \n\n[**PRISMA-ScR**](https://www.equator-network.org/reporting-guidelines/prisma-scr/): Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: [30178033](https://www.ncbi.nlm.nih.gov/pubmed/30178033)\n\n \n\n[**PRISMA-A**](https://www.equator-network.org/reporting-guidelines/prisma-acupuncture/): Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: [31405367](https://www.ncbi.nlm.nih.gov/pubmed/31405367)\n\n \n\n[**PRISMA-DTA for Abstracts**](https://www.equator-network.org/reporting-guidelines/prisma-dta-for-abstracts/): Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: [33722791](https://pubmed.ncbi.nlm.nih.gov/33722791/)\n\n \n\n[**PRISMA-S**](https://www.equator-network.org/reporting-guidelines/prisma-s/): Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.\n\n Syst Rev. 2021;10(1):39. PMID: [33499930](https://pubmed.ncbi.nlm.nih.gov/33499930/)\n\n J Med Libr Assoc. 2021;109(2):174-200. PMID: [34285662](https://pubmed.ncbi.nlm.nih.gov/34285662/)\n\n \n\n[**PRISMA-COSMIN for OMIs**](https://www.equator-network.org/reporting-guidelines/guideline-for-reporting-systematic-reviews-of-outcome-measurement-instruments-omis-prisma-cosmin-for-omis-2024/): Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.\n\n J Clin Epidemiol. 2024:111422. PMID: [38849061](https://pubmed.ncbi.nlm.nih.gov/38849061/)\n\n Qual Life Res. 2024. PMID: [38980635](https://pubmed.ncbi.nlm.nih.gov/38980635/)\n\n Health Qual Life Outcomes. 2024;22(1):48. PMID: [38978063](https://pubmed.ncbi.nlm.nih.gov/38978063/)\n\n J Patient Rep Outcomes. 2024;8(1):64. PMID: [38977535](https://pubmed.ncbi.nlm.nih.gov/38977535/)\n\n \n\n[**PRISMA-LSR**](https://www.equator-network.org/reporting-guidelines/prisma-lsr/): Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: [39562017](https://pubmed.ncbi.nlm.nih.gov/39562017/)\n\n \n\n""), ('Reporting guideline acronym', 'PRISMA-M 2020'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'February 6, 2025')]"
18990,PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020),Systematic reviews/Meta-analyses/Reviews/HTA/Overviews,Complementary and alternative medicine,Whole report, ,"checklist, checklists, Chinese herbal medicine, Chinese herbal medicines, CHM, CHM Extension, CHM formula, CHM formulas, formula, formulas, herb, herbal, herbal medicine, herbal medicines, herbs, meta analyses, meta analysis, PRISMA, PRISMA extension, PRISMA-CHM, PRISMA-CHM 2020, review, reviews, systematic review, systematic reviews, TCM, TCM Pattern differentiation, traditional Chinese medicine", ,"Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313.","Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z.",The American Journal of Chinese Medicine [Am J Chin Med.],2020,48,6,1279-1313, ,English, ,32907365,https://pubmed.ncbi.nlm.nih.gov/32907365/, , , ,"Generic
PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

Specialised
PRISMA-Equity: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: 23222917

Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.
Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

PRISMA-Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.

PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246

PRISMA-IPD: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: 25919529

PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634

PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668

PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement &amp; Checklist. J Clin Epidemiol. 2017. PMID: 28720516

PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: 29362800

PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033

PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367

PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791

PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.
Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535

PRISMA-LSR: Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: 39562017

", ,PRISMA-CHM 2020,Reporting of systematic reviews of studies testing Chinese Herbal Medicines (CHM) interventions., , , , , , , ,yes,2020-11-19 12:09:42,2025-02-06 12:11:45,prisma-chinese-herbal-medicines-2020,"[('title', 'PRISMA  (Preferred Reporting Items for Systematic Reviews and Meta -Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of systematic reviews of studies testing Chinese Herbal Medicines (CHM) interventions.'), ('Full bibliographic reference', 'Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313.'), ('Language', 'English'), ('PubMed ID', '[32907365](https://pubmed.ncbi.nlm.nih.gov/32907365/)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n[**PRISMA 2020 Statement**](https://www.equator-network.org/reporting-guidelines/prisma/): Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.\n\n \n\n PLoS Med. 2021;18(3):e1003583. PMID: [33780438](https://pubmed.ncbi.nlm.nih.gov/33780438/)\n\n BMJ 2021;372:n71. PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)\n\n Int J Surg. 2021:105906. PMID: [33789826](https://pubmed.ncbi.nlm.nih.gov/33789826/)\n\n J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: [33789819](https://pubmed.ncbi.nlm.nih.gov/33789819/)\n\n Syst Rev. 2021;10(1):89. PMID: [33781348](https://pubmed.ncbi.nlm.nih.gov/33781348/)\n\n \n\n**Specialised**\n\n[**PRISMA-Equity**](https://www.equator-network.org/reporting-guidelines/prisma-equity/): Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: [23222917](http://www.ncbi.nlm.nih.gov/pubmed/23222917)\n\n \n\n Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.\n\n Int J Equity Health. 2015;14(1):92. PMID: [26450828](http://www.ncbi.nlm.nih.gov/pubmed/26450828)\n\n J Clin Epidemiol. 2015. PMID: [26348799](http://www.ncbi.nlm.nih.gov/pubmed/26348799)\n\n \n\n[**PRISMA-Abstracts 2020**](https://www.equator-network.org/reporting-guidelines/prisma-abstracts/): The PRISMA 2020 for Abstracts reporting guideline is contained within the main [PRISMA 2020 Statement paper](https://www.equator-network.org/reporting-guidelines/prisma/).\n\n \n\n[**PRISMA-P**](https://www.equator-network.org/reporting-guidelines/prisma-protocols/): Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: [25554246](http://www.ncbi.nlm.nih.gov/pubmed/25554246)\n\n \n\n[**PRISMA-IPD**](https://www.equator-network.org/reporting-guidelines/prisma-ipd/): Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: [25919529](http://www.ncbi.nlm.nih.gov/pubmed/25919529)\n\n \n\n[**PRISMA extension for network meta-analyses**](https://www.equator-network.org/reporting-guidelines/prisma-extension-network-meta-analyses/): Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: [26030634](http://www.ncbi.nlm.nih.gov/pubmed/26030634)\n\n \n\n[**PRISMA-harms**](https://www.equator-network.org/reporting-guidelines/prisma-harms/): Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: [26830668](http://www.ncbi.nlm.nih.gov/pubmed/26830668)\n\n \n\n[**PRISMA-CI**](https://www.equator-network.org/reporting-guidelines/prisma-ci-extension-statement-checklist/): Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: [28720516](https://www.ncbi.nlm.nih.gov/pubmed/28720516)\n\n \n\n[**PRISMA-DTA**](https://www.equator-network.org/reporting-guidelines/prisma-dta/): McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: [29362800](https://www.ncbi.nlm.nih.gov/pubmed/29362800)\n\n \n\n[**PRISMA-ScR**](https://www.equator-network.org/reporting-guidelines/prisma-scr/): Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: [30178033](https://www.ncbi.nlm.nih.gov/pubmed/30178033)\n\n \n\n[**PRISMA-A**](https://www.equator-network.org/reporting-guidelines/prisma-acupuncture/): Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: [31405367](https://www.ncbi.nlm.nih.gov/pubmed/31405367)\n\n \n\n[**PRISMA-DTA for Abstracts**](https://www.equator-network.org/reporting-guidelines/prisma-dta-for-abstracts/): Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: [33722791](https://pubmed.ncbi.nlm.nih.gov/33722791/)\n\n \n\n[**PRISMA-S**](https://www.equator-network.org/reporting-guidelines/prisma-s/): Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.\n\n Syst Rev. 2021;10(1):39. PMID: [33499930](https://pubmed.ncbi.nlm.nih.gov/33499930/)\n\n J Med Libr Assoc. 2021;109(2):174-200. PMID: [34285662](https://pubmed.ncbi.nlm.nih.gov/34285662/)\n\n \n\n[**PRISMA-COSMIN for OMIs**](https://www.equator-network.org/reporting-guidelines/guideline-for-reporting-systematic-reviews-of-outcome-measurement-instruments-omis-prisma-cosmin-for-omis-2024/): Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.\n\n J Clin Epidemiol. 2024:111422. PMID: [38849061](https://pubmed.ncbi.nlm.nih.gov/38849061/)\n\n Qual Life Res. 2024. PMID: [38980635](https://pubmed.ncbi.nlm.nih.gov/38980635/)\n\n Health Qual Life Outcomes. 2024;22(1):48. PMID: [38978063](https://pubmed.ncbi.nlm.nih.gov/38978063/)\n\n J Patient Rep Outcomes. 2024;8(1):64. PMID: [38977535](https://pubmed.ncbi.nlm.nih.gov/38977535/)\n\n \n\n[**PRISMA-LSR**](https://www.equator-network.org/reporting-guidelines/prisma-lsr/): Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: [39562017](https://pubmed.ncbi.nlm.nih.gov/39562017/)\n\n \n\n""), ('Reporting guideline acronym', 'PRISMA-CHM 2020'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'February 6, 2025')]"
18925,Reporting gaps in immunization costing studies: Recommendations for improving the practice,Economic evaluations,Infectious diseases,Whole report, ,"cost data, costing, costing studies, costing study, costs, economic, economics, finance, financial, immunisation, immunisation costing study, immunization, immunization costing study, pricing, vaccine, vaccines", ,"Vaughan K, Ozaltin A, Moi F, Kou Griffiths U, Mallow M, Brenzel L. Reporting gaps in immunization costing studies: Recommendations for improving the practice. Vaccine X. 2020;5:100069.","Vaughan K, Ozaltin A, Moi F, Kou Griffiths U, Mallow M, Brenzel L.",Vaccine X.,2020,5, , , ,English, ,32875287,https://pubmed.ncbi.nlm.nih.gov/32875287/,The full-text of this reporting guideline is available at: https://www.sciencedirect.com/science/article/pii/S2590136220300164, , , , , ,Reporting of immunisation costing studies., , , , , , , ,no,2020-10-02 16:25:25,2020-10-02 16:25:25,reporting-gaps-in-immunization-costing-studies-recommendations-for-improving-the-practice,"[('title', 'Reporting gaps in immunization costing studies: Recommendations for improving the practice'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of immunisation costing studies.'), ('Full bibliographic reference', 'Vaughan K, Ozaltin A, Moi F, Kou Griffiths U, Mallow M, Brenzel L. Reporting gaps in immunization costing studies: Recommendations for improving the practice. Vaccine X. 2020;5:100069.'), ('Language', 'English'), ('PubMed ID', '[32875287](https://pubmed.ncbi.nlm.nih.gov/32875287/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is available at: <https://www.sciencedirect.com/science/article/pii/S2590136220300164>'), ('Study design', 'Economic evaluations'), ('Clinical area', 'Infectious diseases'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 2, 2020')]"
18923,"The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation",Clinical practice guidelines,Complementary and alternative medicine,Intervention (exposure), ,"guideline, guidelines, Reporting Items for practice Guidelines in HealThcare, RIGHT, RIGHT extension, RIGHT Extension Statement for TCM, RIGHT Statement, RIGHT-TCM, TCM, traditional Chinese medicine", ,"Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, Xia L, Guo Y. The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Pharmacol Res. 2020;160:105178.","Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, Xia L, Guo Y.",Pharmacological Research [Pharmacol Res.],2020,160, , , ,English, ,32889127,https://pmlegacy.ncbi.nlm.nih.gov/pubmed/32889127,The full-text of the RIGHT-TCM guideline is available at: https://www.sciencedirect.com/science/article/pii/S1043661820314869?via%3Dihub, , ,"Generic
RIGHT: Chen Y, Yang K, Maru?i? A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Sch\xfcnemann HJ, Chan ESY, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; for the RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group.\xa0 A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166(2):128-132. PMID: 27893062

Specialised
RIGHT-PVG: Wang X, Chen Y, Akl EA, Tokali? R, Maru?i? A, Qaseem A, Falck-Ytter Y, Lee MS, Siedler M, Barber SL, Zhang M, Chan ESY, Estill J, Kwong JSW, Okumura A, Zhou Q, Yang K, Norris SL; RIGHT working group. The reporting checklist for public versions of guidelines: RIGHT-PVG. Implement Sci. 2021;16(1):10. PMID: 33430911

RIGHT for Acupuncture: Tang C, Duan Y, Zhang Y, Zhang Y, Chen Z, Tang X, Zeng J, Riley D, Lee MS, Kim YS, Zhao H, Marrone G, Zhu X, Ge S, Wen H, Zhao W, Zheng X, Solos I, Chen Y, Guyatt G, Lu L, Xu N; RIGHT (Reporting Items for Practice Guidelines in Healthcare) for Acupuncture Working Group. RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture. J Clin Epidemiol. 2021:S0895-4356(21)00173-6. PMID: 34091023

RIGHT for INT: Zhou Q, Xing D, Li Q, Zhang J, Luo X, Yang N, Wang X, Yang K, Tian J, Li H, Li B, Cai Y, Jin Y, Lv L, Sun F, Shang S, Yuan B, Li J, Ma B, Li X, Yuan Y, Wu L, Wang B, Jiang L, Wang Z, Chen Y, Liang D. An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT. J Evid Based Med. 2022;15(1):55-63. PMID: 35416438

RIGHT-Ad@pt: Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RWM, Arayssi T, Bhaumik S, Chen Y, Ghersi D, Langlois EV, Fuentes Padilla P, Sch\xfcnemann HJ, Akl EA, Mart\xednez Garc\xeda L; RIGHT-Ad@pt Working Group*, Amer Y, Arevalo-Rodriguez I, Barnes S, Barreto J, Collis D, Dyer S, Fahim C, Florez I, Gallegos-Rivero V, Klugar M, Kuijpers T, Mathew JL, Munn Z, Norris S, Pati\xf1o-Lugo DF, Pramesh CS, Rodriguez J, Roy S, Shin ES, Sosa O, Vandvik PO, Velez M, Woodcraft R; RIGHT-Ad@pt Working Group. A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Ann Intern Med. 2022;175(5):710-719. PMID: 35286143

RIGHT-COI&amp;F: Xun Y, Estill J, Khabsa J, Florez ID, Guyatt GH, Norris SL, Lee MS, Ozaki A, Qaseem A, Sch\xfcnemann HJ, Shao R, Chen Y, Akl EA; RIGHT-COI&amp;F Working Groups. Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI&amp;F Checklist. Ann Intern Med. 2024;177(6):782-790. PMID: 38739919

RIGHT for CPM: Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C. The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. Pharmacol Res. 2024;199:107015. PMID: 38036197

",http://www.right-statement.org/extensions/10,RIGHT-TCM,Reporting of Traditional Chinese Medicine (TCM) guidelines., , , , , , , ,yes,2020-10-02 15:54:11,2024-07-26 15:35:53,the-right-extension-statement-for-traditional-chinese-medicine-development-recommendations-and-explanation,"[('title', 'The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of Traditional Chinese Medicine (TCM) guidelines.'), ('Full bibliographic reference', 'Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, Xia L, Guo Y. The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Pharmacol Res. 2020;160:105178.'), ('Language', 'English'), ('PubMed ID', '[32889127](https://pmlegacy.ncbi.nlm.nih.gov/pubmed/32889127)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the RIGHT-TCM guideline is available at: <https://www.sciencedirect.com/science/article/pii/S1043661820314869?via%3Dihub>'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**RIGHT**](https://www.equator-network.org/reporting-guidelines/right-statement/): Chen Y, Yang K, Marušić A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Schünemann HJ, Chan ESY, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; for the RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group.\xa0 A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166(2):128-132. PMID: [27893062](https://www.ncbi.nlm.nih.gov/pubmed/27893062)\n\n \n\n**Specialised**\n\n[**RIGHT-PVG**](https://www.equator-network.org/reporting-guidelines/the-reporting-checklist-for-public-versions-of-guidelines-right-pvg/): Wang X, Chen Y, Akl EA, Tokalić R, Marušić A, Qaseem A, Falck-Ytter Y, Lee MS, Siedler M, Barber SL, Zhang M, Chan ESY, Estill J, Kwong JSW, Okumura A, Zhou Q, Yang K, Norris SL; RIGHT working group. The reporting checklist for public versions of guidelines: RIGHT-PVG. Implement Sci. 2021;16(1):10. PMID: [33430911](https://pubmed.ncbi.nlm.nih.gov/33430911/)\n\n \n\n[**RIGHT for Acupuncture**](https://www.equator-network.org/reporting-guidelines/right-for-acupuncture/): Tang C, Duan Y, Zhang Y, Zhang Y, Chen Z, Tang X, Zeng J, Riley D, Lee MS, Kim YS, Zhao H, Marrone G, Zhu X, Ge S, Wen H, Zhao W, Zheng X, Solos I, Chen Y, Guyatt G, Lu L, Xu N; RIGHT (Reporting Items for Practice Guidelines in Healthcare) for Acupuncture Working Group. RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture. J Clin Epidemiol. 2021:S0895-4356(21)00173-6. PMID: [34091023](https://pubmed.ncbi.nlm.nih.gov/34091023/)\n\n \n\n[**RIGHT for INT**](https://www.equator-network.org/reporting-guidelines/an-extension-of-the-right-statement-for-introductions-and-interpretations-of-clinical-practice-guidelines-right-for-int/): Zhou Q, Xing D, Li Q, Zhang J, Luo X, Yang N, Wang X, Yang K, Tian J, Li H, Li B, Cai Y, Jin Y, Lv L, Sun F, Shang S, Yuan B, Li J, Ma B, Li X, Yuan Y, Wu L, Wang B, Jiang L, Wang Z, Chen Y, Liang D. An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT. J Evid Based Med. 2022;15(1):55-63. PMID: [35416438](https://pubmed.ncbi.nlm.nih.gov/35416438/)\n\n \n\n[**RIGHT-Ad@pt**](https://www.equator-network.org/reporting-guidelines/a-reporting-tool-for-adapted-guidelines-in-health-care-the-right-adapt-checklist/): Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RWM, Arayssi T, Bhaumik S, Chen Y, Ghersi D, Langlois EV, Fuentes Padilla P, Schünemann HJ, Akl EA, Martínez García L; RIGHT-Ad@pt Working Group\\*, Amer Y, Arevalo-Rodriguez I, Barnes S, Barreto J, Collis D, Dyer S, Fahim C, Florez I, Gallegos-Rivero V, Klugar M, Kuijpers T, Mathew JL, Munn Z, Norris S, Patiño-Lugo DF, Pramesh CS, Rodriguez J, Roy S, Shin ES, Sosa O, Vandvik PO, Velez M, Woodcraft R; RIGHT-Ad@pt Working Group. A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Ann Intern Med. 2022;175(5):710-719. PMID: [35286143](https://pubmed.ncbi.nlm.nih.gov/35286143/)\n\n \n\n[**RIGHT-COI&F**](https://www.equator-network.org/reporting-guidelines/reporting-conflicts-of-interest-and-funding-in-health-care-guidelines-the-right-coif-checklist/): Xun Y, Estill J, Khabsa J, Florez ID, Guyatt GH, Norris SL, Lee MS, Ozaki A, Qaseem A, Schünemann HJ, Shao R, Chen Y, Akl EA; RIGHT-COI&F Working Groups. Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI&F Checklist. Ann Intern Med. 2024;177(6):782-790. PMID: [38739919](https://pubmed.ncbi.nlm.nih.gov/38739919/)\n\n \n\n[**RIGHT for CPM**](https://www.equator-network.org/reporting-guidelines/the-reporting-checklist-for-chinese-patent-medicine-guidelines-right-for-cpm/): Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C. The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. Pharmacol Res. 2024;199:107015. PMID: [38036197](https://pubmed.ncbi.nlm.nih.gov/38036197/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.right-statement.org/extensions/10>'), ('Reporting guideline acronym', 'RIGHT-TCM'), ('Study design', 'Clinical practice guidelines'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'July 26, 2024')]"
18921,Proposed Requirements for Cardiovascular Imaging-Related Machine Learning Evaluation (PRIME): A Checklist: Reviewed by the American College of Cardiology Healthcare Innovation Council,Artificial intelligence/Machine learning studies,Cardiovascular medicine,"Data, Procedure/Method, Statistical methods and analyses", ,"AI, algorithm, algorithms, artificial intelligence, cardiology, cardiovascular, cardiovascular imaging, checklist, checklists, data, dataset, datasets, digital health, imaging, machine learning, ML, ML model, ML models, PRIME, PRIME checklist, Proposed Recommendations for Cardiovascular Imaging-Related Machine Learning Evaluation, radiology", ,"Sengupta PP, Shrestha S, Berthon B, Messas E, Donal E, Tison GH, Min JK, D'hooge J, Voigt JU, Dudley J, Verjans JW, Shameer K, Johnson K, Lovstakken L, Tabassian M, Piccirilli M, Pernot M, Yanamala N, Duchateau N, Kagiyama N, Bernard O, Slomka P, Deo R, Arnaout R. Proposed Requirements for Cardiovascular Imaging-Related Machine Learning Evaluation (PRIME): A Checklist: Reviewed by the American College of Cardiology Healthcare Innovation Council. JACC Cardiovasc Imaging. 2020;13(9):2017-2035.","Sengupta PP, Shrestha S, Berthon B, Messas E, Donal E, Tison GH, Min JK, D'hooge J, Voigt JU, Dudley J, Verjans JW, Shameer K, Johnson K, Lovstakken L, Tabassian M, Piccirilli M, Pernot M, Yanamala N, Duchateau N, Kagiyama N, Bernard O, Slomka P, Deo R, Arnaout R.",JACC Cardiovasc Imaging.,2020,13,9,2017-2035, ,English, ,32912474,https://pubmed.ncbi.nlm.nih.gov/32912474/, , , , , ,PRIME,Reporting of machine learning (ML) models in cardiovascular imaging studies., , , , , , , ,no,2020-10-02 15:25:58,2024-01-25 11:52:24,proposed-requirements-for-cardiovascular-imaging-related-machine-learning-evaluation-prime-a-checklist-reviewed-by-the-american-college-of-cardiology-healthcare-innovation-council,"[('title', 'Proposed Requirements for Cardiovascular Imaging -Related Machine Learning Evaluation (PRIME) : A Checklist: Reviewed by the American College of Cardiology Healthcare Innovation Council'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of machine learning (ML) models in cardiovascular imaging studies.'), ('Full bibliographic reference', ""Sengupta PP, Shrestha S, Berthon B, Messas E, Donal E, Tison GH, Min JK, D'hooge J, Voigt JU, Dudley J, Verjans JW, Shameer K, Johnson K, Lovstakken L, Tabassian M, Piccirilli M, Pernot M, Yanamala N, Duchateau N, Kagiyama N, Bernard O, Slomka P, Deo R, Arnaout R. Proposed Requirements for Cardiovascular Imaging-Related Machine Learning Evaluation (PRIME): A Checklist: Reviewed by the American College of Cardiology Healthcare Innovation Council. JACC Cardiovasc Imaging. 2020;13(9):2017-2035.""), ('Language', 'English'), ('PubMed ID', '[32912474](https://pubmed.ncbi.nlm.nih.gov/32912474/)'), ('Reporting guideline acronym', 'PRIME'), ('Study design', 'Artificial intelligence/Machine learning studies'), ('Clinical area', 'Cardiovascular medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method, Statistical methods and analyses'), ('Record last updated on', 'January 25, 2024')]"
18919,Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC), ,"Infectious diseases, Pharmaceutical medicine, Public health",Whole report, ,"benefit-risk, benefit-risk assessment, benefit-risk model, benefit-risk models, BRA, BRIVAC, BRIVAC checklist, checklist, checklists, consolidated standards of reporting quantitative benefit-risk models applied to vaccines, infectious, pharmaceutical, public health, qBRm, quantitative benefit-risk models, quantitative BRA, vaccination, vaccine, vaccine qBRm, vaccines", ,"Arlegui H, Bollaerts K, Bauchau V, Nachbaur G, B\xe9gaud B, Praet N. Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC). Drug Saf. 2020;1-16.","Arlegui H, Bollaerts K, Bauchau V, Nachbaur G, B\xe9gaud B, Praet N.",Drug Safety [Drug Saf.],2020, , , , ,English, ,32918682,https://pubmed.ncbi.nlm.nih.gov/32918682/,"The full-text of the BRIVAC reporting guideline is available at: https://link.springer.com/article/10.1007%2Fs40264-020-00982-9

The BRIVAC checklist can be accessed at: https://link.springer.com/article/10.1007/s40264-020-00982-9/tables/2

", , , , ,BRIVAC,Reporting of vaccine quantitative benefit-risk model (qBRm) research., , , , , , , ,no,2020-10-02 14:35:09,2020-10-02 14:35:09,benefit-risk-assessment-of-vaccines-part-ii-proposal-towards-consolidated-standards-of-reporting-quantitative-benefit-risk-models-applied-to-vaccines-brivac,"[('title', 'Benefit -Risk Assessment of Vaccines. Part II : Proposal Towards Consolidated Standards of Reporting Quantitative Benefit -Risk Models Applied to Vaccines (BRIVAC)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of vaccine quantitative benefit-risk model (qBRm) research.'), ('Full bibliographic reference', 'Arlegui H, Bollaerts K, Bauchau V, Nachbaur G, Bégaud B, Praet N. Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC). Drug Saf. 2020;1-16.'), ('Language', 'English'), ('PubMed ID', '[32918682](https://pubmed.ncbi.nlm.nih.gov/32918682/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the BRIVAC reporting guideline is available at: <https://link.springer.com/article/10.1007%2Fs40264-020-00982-9>\n\n \n\n The BRIVAC checklist can be accessed at: <https://link.springer.com/article/10.1007/s40264-020-00982-9/tables/2>\n\n \n\n'), ('Reporting guideline acronym', 'BRIVAC'), ('Clinical area', 'Infectious diseases, Pharmaceutical medicine, Public health'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 2, 2020')]"
18917,BIAS: Transparent reporting of biomedical image analysis challenges, , ,Whole report, ,"algorithm, algorithms, bias, BIAS statement, biomedical challenge, biomedical challenges, biomedical image, biomedical image analysis, biomedical image analysis challenge, biomedical image analysis challenges, biomedical images, challenge, checklist, data, data set, data sets, image analysis, machine learning, Medical Image Computing and Computer Assisted Intervention Society, metric, metrics, MICCAI, open competition, reproducibility", ,"Maier-Hein L, Reinke A, Kozubek M, Martel AL, Arbel T, Eisenmann M, Hanbury A, Jannin P, M\xfcller H, Onogur S, Saez-Rodriguez J, van Ginneken B, Kopp-Schneider A, Landman BA. BIAS: Transparent reporting of biomedical image analysis challenges. Med Image Anal. 2020;66:101796.","Maier-Hein L, Reinke A, Kozubek M, Martel AL, Arbel T, Eisenmann M, Hanbury A, Jannin P, M\xfcller H, Onogur S, Saez-Rodriguez J, van Ginneken B, Kopp-Schneider A, Landman BA.",Medical Image Analysis [Med Image Anal.],2020, , , , , , ,32911207 ,https://pubmed.ncbi.nlm.nih.gov/32911207/,"The full-text of the BIAS statement is available at: https://pubmed.ncbi.nlm.nih.gov/32911207/

Access the BIAS checklist (PDF).

", , , , ,BIAS,Reporting of a biomedical image analysis challenge., ,"Read a background paper in Nature Communications presenting a critical analysis of common research practice related to the design, reporting and execution of biomedical image analysis challenges.", , , , , ,no,2020-10-02 12:38:36,2021-09-08 15:57:58,bias-transparent-reporting-of-biomedical-image-analysis-challenges,"[('title', 'BIAS : Transparent reporting of biomedical image analysis challenges'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of a biomedical image analysis challenge.'), ('Full bibliographic reference', 'Maier-Hein L, Reinke A, Kozubek M, Martel AL, Arbel T, Eisenmann M, Hanbury A, Jannin P, Müller H, Onogur S, Saez-Rodriguez J, van Ginneken B, Kopp-Schneider A, Landman BA. BIAS: Transparent reporting of biomedical image analysis challenges. Med Image Anal. 2020;66:101796.'), ('PubMed ID', '[32911207](https://pubmed.ncbi.nlm.nih.gov/32911207/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the BIAS statement is available at: <https://pubmed.ncbi.nlm.nih.gov/32911207/>\n\n \n\n Access the [BIAS checklist (PDF)](https://ars.els-cdn.com/content/image/1-s2.0-S1361841520301602-mmc1.pdf).\n\n \n\n'), ('Reporting guideline acronym', 'BIAS'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', '[Read a background paper](https://rdcu.be/bhOPd) in Nature Communications presenting a critical analysis of common research practice related to the design, reporting and execution of biomedical image analysis challenges.'), ('Record last updated on', 'September 8, 2021')]"
18915,Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist,Artificial intelligence/Machine learning studies, ,"Data, Results, Study characteristics (participants etc.)", ,"AI, AI model, AI models, algorithm, algorithms, artificial intelligence, checklist, clinical artificial intelligence modeling, data, machine learning, MI-CLAIM, MI-CLAIM checklist, model examination, model performance, model selection, model testing, model training, modeling, modelling, reproducibility, reproducible", ,"Norgeot B, Quer G, Beaulieu-Jones BK, Torkamani A, Dias R, Gianfrancesco M, Arnaout R, Kohane IS, Saria S, Topol E, Obermeyer Z, Yu B, Butte AJ. Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist. Nat Med. 2020;26(9):1320-1324.","Norgeot B, Quer G, Beaulieu-Jones BK, Torkamani A, Dias R, Gianfrancesco M, Arnaout R, Kohane IS, Saria S, Topol E, Obermeyer Z, Yu B, Butte AJ.",Nature Medicine [Nat Med.],2020,26,9,1320-1324, , , ,32908275,https://pubmed.ncbi.nlm.nih.gov/32908275/, , , , , ,MI-CLAIM,Reporting of clinical artificial intelligence (AI) modelling research., , , , , , , ,no,2020-10-02 12:14:12,2024-01-25 11:53:52,minimum-information-about-clinical-artificial-intelligence-modeling-the-mi-claim-checklist,"[('title', 'Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of clinical artificial intelligence (AI) modelling research.'), ('Full bibliographic reference', 'Norgeot B, Quer G, Beaulieu-Jones BK, Torkamani A, Dias R, Gianfrancesco M, Arnaout R, Kohane IS, Saria S, Topol E, Obermeyer Z, Yu B, Butte AJ. Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist. Nat Med. 2020;26(9):1320-1324.'), ('PubMed ID', '[32908275](https://pubmed.ncbi.nlm.nih.gov/32908275/)'), ('Reporting guideline acronym', 'MI-CLAIM'), ('Study design', 'Artificial intelligence/Machine learning studies'), ('Applies to the whole report or to individual sections of the report?', 'Data, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'January 25, 2024')]"
18889,STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline,"Clinical trials, Experimental studies, Observational studies","Genetics, Pharmaceutical medicine",Whole report, ,"clinical trial, clinical trials, drug, drugs, genetic, genetics, observational, observational studies, observational study, pharmaceutical, pharmacogenetic, pharmacogenetic studies, pharmacogenetic study, pharmacogenetics, pharmacogenomic, pharmacogenomics, pharmacy, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, STrengthening the Reporting Of Pharmacogenetic Studies, STROPS, STROPS guideline, trial, trials", ,"Chaplin M, Kirkham JJ, Dwan K, Sloan DJ, Davies G, Jorgensen AL. STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline. PLoS Med. 2020;17(9):e1003344.","Chaplin M, Kirkham JJ, Dwan K, Sloan DJ, Davies G, Jorgensen AL.",PLoS Medicine [PLoS Med.],2020,17,9, , ,English, ,32956352 ,https://pubmed.ncbi.nlm.nih.gov/32956352/,The full-text of the STROPS guideline is available at: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003344,"The STROPS guideline explanation and elaboration document is available at:
https://doi.org/10.1371/journal.pmed.1003344.s007 (MS Word)", , , ,STROPS,Reporting of pharmacogenetic studies.,The STROPS reporting guideline has been translated into Chinese., , , , , , ,no,2020-09-23 16:16:00,2022-06-06 16:50:49,strengthening-the-reporting-of-pharmacogenetic-studies-development-of-the-strops-guideline,"[('title', 'STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of pharmacogenetic studies.'), ('Full bibliographic reference', 'Chaplin M, Kirkham JJ, Dwan K, Sloan DJ, Davies G, Jorgensen AL. STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline. PLoS Med. 2020;17(9):e1003344.'), ('Language', 'English'), ('PubMed ID', '[32956352](https://pubmed.ncbi.nlm.nih.gov/32956352/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the STROPS guideline is available at: <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003344>'), ('Explanation and elaboration papers', 'The STROPS guideline explanation and elaboration document is available at:\n\n<https://doi.org/10.1371/journal.pmed.1003344.s007> (MS Word)'), ('Availability in additional languages', 'The STROPS reporting guideline has been translated into [Chinese](http://rs.yiigle.com/CN112338202205/1377745.htm).'), ('Reporting guideline acronym', 'STROPS'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Genetics, Pharmaceutical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'June 6, 2022')]"
18839,TIDieR-Placebo: a guide and checklist for reporting placebo and sham controls,"Clinical trials, Experimental studies, Observational studies, Study protocols, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,Intervention (exposure), ,"clinical trial, clinical trials, comparator, comparators, control, controlled clinical trial, controlled clinical trials, controls, intervention, interventions, observational studies, observational study, placebo, placebo-controlled trial, placebo-controlled trials, placebos, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, sham, shams, Template for Intervention Description and Replication, TIDieR, TIDieR-Placebo, trial, trials", ,"Howick J, Webster RK, Rees J, Turner R, Macdonald H, 1. Price A, Evers WMA, Bishop FL, Collins GS, Bokelmann K, Hopewell S, Knottnerus A, Lamb S, Madigan C, Napadow V, Papanikitas A, Hoffmann T. TIDieR-Placebo: a guide and checklist for reporting placebo and sham controls. PLoS Med. 2020;17(9):e1003294.","Howick J, Webster RK, Rees J, Turner R, Macdonald H, 1. Price A, Evers WMA, Bishop FL, Collins GS, Bokelmann K, Hopewell S, Knottnerus A, Lamb S, Madigan C, Napadow V, Papanikitas A, Hoffmann T.",PLOS Medicine.,2020, , , , ,English, ,32956344,https://pubmed.ncbi.nlm.nih.gov/32956344/,The full-text of the TIDieR-Placebo reporting guideline can be accessed at: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003294, , ,"Generic
TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Specialisd
TIDieR-PHP: Campbell M, Katikireddi SV, Hoffmann T, Armstrong R, Waters E, Craig P. TIDieR-PHP: a reporting guideline for population health and policy interventions. BMJ. 2018;361:k1079. PMID: 29769210

",http://www.tidierguide.org/,TIDieR-Placebo,Reporting placebo or sham interventions., ,"Read the TIDieR Placebo Protocol (PDF).

Read a background paper: Howick J, Hoffmann T. How placebo characteristics can influence estimates of intervention effects in trials. CMAJ. 2018;190(30):E908-E911. PMID: 30061325

", , , , , ,yes,2020-09-21 20:29:07,2021-09-08 16:00:04,tidier-placebo,"[('title', 'TIDieR-Placebo : a guide and checklist for reporting placebo and sham controls'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting placebo or sham interventions.'), ('Full bibliographic reference', 'Howick J, Webster RK, Rees J, Turner R, Macdonald H, 1. Price A, Evers WMA, Bishop FL, Collins GS, Bokelmann K, Hopewell S, Knottnerus A, Lamb S, Madigan C, Napadow V, Papanikitas A, Hoffmann T. TIDieR-Placebo: a guide and checklist for reporting placebo and sham controls. PLoS Med. 2020;17(9):e1003294.'), ('Language', 'English'), ('PubMed ID', '[32956344](https://pubmed.ncbi.nlm.nih.gov/32956344/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the TIDieR-Placebo reporting guideline can be accessed at: <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003294>'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**TIDieR**](https://www.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n**Specialisd**\n\n[**TIDieR-PHP**](https://www.equator-network.org/reporting-guidelines/tidier-php-a-reporting-guideline-for-population-health-and-policy-interventions/): Campbell M, Katikireddi SV, Hoffmann T, Armstrong R, Waters E, Craig P. TIDieR-PHP: a reporting guideline for population health and policy interventions. BMJ. 2018;361:k1079. PMID: [29769210](https://www.ncbi.nlm.nih.gov/pubmed/29769210)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.tidierguide.org/>'), ('Reporting guideline acronym', 'TIDieR-Placebo'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Study protocols, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Additional information', 'Read the [TIDieR Placebo Protocol (PDF)](https://www.equator-network.org/wp-content/uploads/2019/05/TIDieR-Placebo-Protocol-v11.pdf).\n\n \n\n Read a background paper: Howick J, Hoffmann T. How placebo characteristics can influence estimates of intervention effects in trials. CMAJ. 2018;190(30):E908-E911. PMID: [30061325](https://pubmed.ncbi.nlm.nih.gov/30061325/)\n\n \n\n'), ('Record last updated on', 'September 8, 2021')]"
18816,Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension,"Artificial intelligence/Machine learning studies, Clinical trials, Experimental studies, Study protocols", ,Whole report, ,"AI, AI component, AI components, AI intervention, AI interventions, AI studies, AI study, AI systems, artificial intelligence, checklist, checklists, clinical trial protocol, clinical trial protocols, deep learning, machine learning, protocol, protocols, SPIRIT artificial intelligence, SPIRIT Extension, SPIRIT-AI, SPIRIT-AI checklist, SPIRIT-AI extension, Standard Protocol Items Recommendations for Interventional Trials", ,"Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.

This guideline was published simultaneously in 3 journals. You can read the guideline in any of these journals using the links below.

BMJ. 2020;370:m3210. PMID: 32907797
Nat Med. 2020;26(9):1351?1363. PMID: 32908284
Lancet Digital Health. 2020;2(10):e549-e560. PMID: 33328049

","Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group.", , , , , , , , , , , , , ,"Generic

SPIRIT 2025 Statement: Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hr\xf3bjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.

BMJ. 2025; 388:e081660. PMID:\xa040294956
JAMA. 2025.\xa0PMID: 40294593
Lancet 2025.
Nat Med. 2025.\xa0PMID: 40295741
PLoS Med. 2025; 22(4): e1004587.\xa0PMID: 40294521

Specialised
SPIRIT-PRO: Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. Link to abstract

SPIRIT-TCM: Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: 30484022

SPENT 2019: Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. Link to full-text

SPIRIT-Path: Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: 34592193

SPIRIT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: 36512367

SPIRIT-DEFINE: Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: 37863491

SPIRIT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: 38051535

SPIRIT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: 38981624

SPIRIT-iNeurostim: Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: 39610902

",http://www.clinical-trials.ai/,SPIRIT-AI,Reporting for clinical trial protocols evaluating interventions with an artificial intelligence (AI) component.,Translations of the SPIRIT-AI Statement are available in Spanish and Portuguese., , , , , , ,yes,2020-09-09 16:44:16,2025-05-30 09:13:32,spirit-artificial-intelligence,"[('title', 'Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting for clinical trial protocols evaluating interventions with an artificial intelligence (AI) component.'), ('Full bibliographic reference', 'Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.\n\n \n\n This guideline was published simultaneously in 3 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n[BMJ. 2020;370:m3210.](https://www.bmj.com/content/370/bmj.m3210) PMID: [32907797](https://pubmed.ncbi.nlm.nih.gov/32907797/)\n\n[Nat Med. 2020;26(9):1351–1363.](https://www.nature.com/articles/s41591-020-1037-7) PMID: [32908284](https://pubmed.ncbi.nlm.nih.gov/32908284/)\n\n[Lancet Digital Health. 2020;2(10):e549-e560.](https://www.thelancet.com/journals/landig/article/PIIS2589-7500(20)30219-3/fulltext) PMID: [33328049](https://pubmed.ncbi.nlm.nih.gov/33328049/)\n\n \n\n'), ('Availability in additional languages', 'Translations of the SPIRIT-AI Statement are available in [Spanish](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10832304/) and [Portuguese](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10832304/).'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n \n\n**[SPIRIT 2025 Statement](https://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/):** Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hróbjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.\n\n \n\nBMJ. 2025; 388:e081660. [PMID:40294956](https://pubmed.ncbi.nlm.nih.gov/40294956/)\n\n JAMA. 2025.[PMID:](https://pubmed.ncbi.nlm.nih.gov/40294593/) [40294593](https://pubmed.ncbi.nlm.nih.gov/40294593/)\n\n Lancet 2025.\n\n Nat Med. 2025.[PMID: 40295741](https://pubmed.ncbi.nlm.nih.gov/40295741)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID: 40294521](https://pubmed.ncbi.nlm.nih.gov/40294521/)\n\n \n\n**Specialised**\n\n[**SPIRIT-PRO**](https://www.equator-network.org/reporting-guidelines/spirit-pro/): Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. [Link to abstract](https://jamanetwork.com/journals/jama/article-abstract/2671472)\n\n \n\n[**SPIRIT-TCM**](https://www.equator-network.org/reporting-guidelines/standard-protocol-items-for-clinical-trials-with-traditional-chinese-medicine-spirit-tcm-extension-2018/): Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: [30484022](https://www.ncbi.nlm.nih.gov/pubmed/30484022)\n\n \n\n[**SPENT 2019**](https://www.equator-network.org/reporting-guidelines/spirit-extension-n-of-1-trials-spent-2019/): Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. [Link to full-text](https://www.bmj.com/content/368/bmj.m122)\n\n \n\n[**SPIRIT-Path**](https://www.equator-network.org/reporting-guidelines/spirit-path/): Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: [34592193](https://pubmed.ncbi.nlm.nih.gov/34592193/)\n\n \n\n[**SPIRIT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-protocols-the-spirit-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: [36512367](https://pubmed.ncbi.nlm.nih.gov/36512367/)\n\n \n\n[**SPIRIT-DEFINE**](https://www.equator-network.org/reporting-guidelines/spirit-define/): Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: [37863491](https://pubmed.ncbi.nlm.nih.gov/37863491/)\n\n \n\n[**SPIRIT Factorial**](https://www.equator-network.org/reporting-guidelines/consensus-statement-for-protocols-of-factorial-randomized-trials-extension-of-the-spirit-2013-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: [38051535](https://pubmed.ncbi.nlm.nih.gov/38051535/)\n\n \n\n[**SPIRIT-Surrogate**](https://www.equator-network.org/reporting-guidelines/spirit-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: [38981624](https://pubmed.ncbi.nlm.nih.gov/38981624/)\n\n \n\n[**SPIRIT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-protocols-of-randomised-controlled-trials-of-implantable-neurostimulation-devices-the-spirit-ineurostim-extension/): Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: [39610902](https://pubmed.ncbi.nlm.nih.gov/39610902/)\n\n \n\n""), ('Reporting guideline website URL', '<http://www.clinical-trials.ai/>'), ('Reporting guideline acronym', 'SPIRIT-AI'), ('Study design', 'Artificial intelligence/Machine learning studies, Clinical trials, Experimental studies, Study protocols'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 30, 2025')]"
18814,Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension,"Artificial intelligence/Machine learning studies, Clinical trials, Experimental studies", ,Whole report, ,"AI, AI component, AI components, AI intervention, AI interventions, AI studies, AI study, AI systems, artificial intelligence, checklist, checklists, clinical trial, clinical trials, Consolidated Standards of Reporting Trials, CONSORT 2010, CONSORT artificial intelligence, CONSORT extension, CONSORT-AI, CONSORT-AI checklist, CONSORT-AI extension, deep learning, machine learning, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trial report, trial reports, trials", ,"Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.

This guideline was published simultaneously in 3 journals. You can read the guideline in any of these journals using the links below.

BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

","Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group.", , , , , , , , , , , , , ,"Generic
CONSORT 2025 Statement: Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

",http://www.clinical-trials.ai/,CONSORT-AI,Reporting of clinical trials evaluating interventions with an artificial intelligence (AI) component.,Translations of the CONSORT-AI Statement are available in Spanish and Portuguese., , , , , , ,yes,2020-09-09 16:28:12,2025-05-30 09:25:46,consort-artificial-intelligence,"[('title', 'Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of clinical trials evaluating interventions with an artificial intelligence (AI) component.'), ('Full bibliographic reference', 'Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n \n\n This guideline was published simultaneously in 3 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n[BMJ 2020;370:m3164.](https://www.bmj.com/content/370/bmj.m3164) PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n[Nat Med. 2020:26(9):1364–1374.](https://www.nature.com/articles/s41591-020-1034-x) PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n[Lancet Digital Health. 2020;2(10):e537-e548.](https://www.thelancet.com/journals/landig/article/PIIS2589-7500(20)30218-1/fulltext) PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n'), ('Availability in additional languages', 'Translations of the CONSORT-AI Statement are available in [Spanish](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10863743/) and [Portuguese](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10863743/).'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](https://dev.equator-network.org/reporting-guidelines/consort/): Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](http://dev.equator-network.org/reporting-guidelines/consort-cluster/):\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](http://dev.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](http://dev.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](http://dev.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n**CONSORT for multi-arm parallel-group randomised trials**: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.clinical-trials.ai/>'), ('Reporting guideline acronym', 'CONSORT-AI'), ('Study design', 'Artificial intelligence/Machine learning studies, Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 30, 2025')]"
18713,The IDEAL Reporting Guidelines: A Delphi Consensus Statement Stage specific recommendations for reporting the evaluation of surgical innovation,"Clinical trials, Experimental studies, Observational studies",Surgery,Whole report, ,"case report, case reports, case series, checklist, checklists, clinical trial, clinical trials, cohort studies, cohort study, complex interventions, complex therapeutic technologies, device innovation, early-stage innovation, evaluation, IDEAL, IDEAL Collaboration, IDEAL Framework and Recommendations, IDEAL Reporting Guidelines, IDEAL stage 1, IDEAL stage 2a, IDEAL stage 2b, IDEAL stage 4, IDEAL stages, observational studies, observational study, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, surgery, surgical, surgical innovation, surgical innovation evaluation, surgical research, surgical technique, surgical techniques, surgical trial, surgical trials, therapeutic device, therapeutic devices, trial, trials", ,"Bilbro NA, Hirst A, Paez A, Vasey B, Pufulete M, Sedrakyan A, McCulloch P; IDEAL Collaboration Reporting Guidelines Working Group. The IDEAL Reporting Guidelines: A Delphi Consensus Statement Stage specific recommendations for reporting the evaluation of surgical innovation. Ann Surg. 2021;273(1):82-85.","Bilbro NA, Hirst A, Paez A, Vasey B, Pufulete M, Sedrakyan A, McCulloch P; IDEAL Collaboration Reporting Guidelines Working Group.",Annals of Surgery [Ann Surg.],2020, , , , ,English, ,32649459,https://pubmed.ncbi.nlm.nih.gov/32649459/, , , , ,http://www.ideal-collaboration.net/,IDEAL,Reporting the evaluation of surgical innovation., ,Read the IDEAL guideline development protocol., , , , , ,no,2020-07-17 12:10:58,2023-08-18 11:40:41,the-ideal-reporting-guidelines-a-delphi-consensus-statement-stage-specific-recommendations-for-reporting-the-evaluation-of-surgical-innovation,"[('title', 'The IDEAL Reporting Guidelines: A Delphi Consensus Statement Stage specific recommendations for reporting the evaluation of surgical innovation'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the evaluation of surgical innovation.'), ('Full bibliographic reference', 'Bilbro NA, Hirst A, Paez A, Vasey B, Pufulete M, Sedrakyan A, McCulloch P; IDEAL Collaboration Reporting Guidelines Working Group. The IDEAL Reporting Guidelines: A Delphi Consensus Statement Stage specific recommendations for reporting the evaluation of surgical innovation. Ann Surg. 2021;273(1):82-85.'), ('Language', 'English'), ('PubMed ID', '[32649459](https://pubmed.ncbi.nlm.nih.gov/32649459/)'), ('Reporting guideline website URL', '<http://www.ideal-collaboration.net/>'), ('Reporting guideline acronym', 'IDEAL'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Read the [IDEAL guideline development protocol](https://pubmed.ncbi.nlm.nih.gov/31851736/).'), ('Record last updated on', 'August 18, 2023')]"
18685,The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design,"Clinical trials, Experimental studies", ,"Abstract, Whole report", ,"ACE abstract checklist, ACE checklist, ACE checklists, ACE Statement, AD, AD randomised trial, AD randomised trials, AD randomized trial, AD randomized trials, adaptive design, adaptive designs, Adaptive Designs CONSORT, Adaptive Designs CONSORT Extension, Adaptive Designs CONSORT Extension (ACE) Statement, ADs, clinical trial, clinical trials, CONSORT extension, randomised AD clinical trial, randomised AD clinical trials, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized AD clinical trial, randomized AD clinical trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, trial, trials", ,"Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.

BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

","Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group.", , , , , , ,English, , , ,"The ACE reporting guideline and checklist are freely available to download from:

BMJ. 2020 Jun 17;369:m115.
https://www.bmj.com/content/369/bmj.m115

Trials. 2020 Jun 17;21(1):528.
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04334-x

", , ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

",https://www.sheffield.ac.uk/scharr/research/centres/ctru/ace,ACE Statement,Reporting of randomised adaptive design (AD) clinical trials., ,"Read the ACE Project Protocol (PDF).

Read about the development process published in this paper: Dimairo M, Coates E, Pallmann P, Todd S, Julious SA, Jaki T, Wason J, Mander AP, Weir CJ, Koenig F, Walton MK, Biggs K, Nicholl J, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG. The development process of a consensus-driven CONSORT extension for randomised trials using adaptive design. BMC Med. 2018 Nov 16;16(1):210. PMID: 30442137

", , , , , ,yes,2020-06-22 15:29:54,2025-05-30 09:25:28,the-adaptive-designs-consort-extension-ace-statement,"[('title', 'The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of randomised adaptive design (AD) clinical trials.'), ('Full bibliographic reference', 'Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n \n\n This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.\n\n \n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The ACE reporting guideline and checklist are freely available to download from:\n\n \n\n BMJ. 2020 Jun 17;369:m115.\n\n<https://www.bmj.com/content/369/bmj.m115>\n\n \n\n Trials. 2020 Jun 17;21(1):528.\n\n<https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04334-x>\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](https://dev.equator-network.org/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](http://dev.equator-network.org/reporting-guidelines/consort-cluster/):\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](http://dev.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](http://dev.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](http://dev.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline website URL', '<https://www.sheffield.ac.uk/scharr/research/centres/ctru/ace>'), ('Reporting guideline acronym', 'ACE Statement'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Abstract, Whole report'), ('Additional information', 'Read the [ACE Project Protocol (PDF)](https://www.equator-network.org/wp-content/uploads/2017/12/ACE-Project-Protocol-v2.3.pdf).\n\n \n\n Read about the development process published in this paper: Dimairo M, Coates E, Pallmann P, Todd S, Julious SA, Jaki T, Wason J, Mander AP, Weir CJ, Koenig F, Walton MK, Biggs K, Nicholl J, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG. The development process of a consensus-driven CONSORT extension for randomised trials using adaptive design. BMC Med. 2018 Nov 16;16(1):210. PMID: [30442137](https://pubmed.ncbi.nlm.nih.gov/30442137)\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
18683,Reporting Guideline for Priority Setting of Health Research (REPRISE), , ,Whole report, ,"checklist, checklists, priority, priority setting, Priority Setting of Health Research, REPRISE, REPRISE guideline, research priorities", ,"Tong A, Synnot A, Crowe S, Hill S, Matus S, Scholes-Robertson N, Oliver O, Cowan K, Nasser M, Bhaumik S, Gutman T, Baumgart A, Craig JC. Reporting Guideline for Priority Setting of Health Research (REPRISE). BMC Med Res Methodol. 2019;19(1):243.","Tong A, Synnot A, Crowe S, Hill S, Matus S, Scholes-Robertson N, Oliver O, Cowan K, Nasser M, Bhaumik S, Gutman T, Baumgart A, Craig JC.",BMC Medical Research Methodology [BMC Med Res Methodol.],2019,19,1,243, ,English, ,31883517 ,https://pubmed.ncbi.nlm.nih.gov/31883517/,The full-text of this reporting guideline is freely available at: https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-019-0889-3, , , , ,REPRISE,Reporting research priority setting studies., , , , , , , ,no,2020-06-19 16:10:08,2021-11-19 14:27:24,reporting-guideline-for-priority-setting-of-health-research-reprise,"[('title', 'Reporting Guideline for Priority Setting of Health Research (REPRISE)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting research priority setting studies.'), ('Full bibliographic reference', 'Tong A, Synnot A, Crowe S, Hill S, Matus S, Scholes-Robertson N, Oliver O, Cowan K, Nasser M, Bhaumik S, Gutman T, Baumgart A, Craig JC. Reporting Guideline for Priority Setting of Health Research (REPRISE). BMC Med Res Methodol. 2019;19(1):243.'), ('Language', 'English'), ('PubMed ID', '[31883517](https://pubmed.ncbi.nlm.nih.gov/31883517/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available at: <https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-019-0889-3>'), ('Reporting guideline acronym', 'REPRISE'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 19, 2021')]"
18591,Consensus on the reporting and experimental design of clinical and cognitive-behavioural neurofeedback studies (CRED-nf checklist),"Clinical trials, Experimental studies","Neurology, Psychology","Data, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)", ,"behavioral, behavioural, brain, checklist, checklists, clinical trial, clinical trials, cognition, cognitive, cognitive-behavioral, cognitive-behavioural, cognitive-behavioural neurofeedback, CRED-nf, CRED-nf checklist, data, EEG, electroencephalography, experiment, experimental, feedback, fMRI, fNIRS, functional MRI, functional near infrared spectroscopy, magnetic resonance imaging, magnetoencephalography, MEG, neural, neural feedback, neurofeedback, neurology, neuropsychology, psychology, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Ros T, Enriquez-Geppert S, Zotev V, Young KD, Wood G, Whitfield-Gabrieli S, Wan F, Vuilleumier P, Vialatte F, Van De Ville D, Todder D, Surmeli T, Sulzer JS, Strehl U, Sterman MB, Steiner NJ, Sorger B, Soekadar SR, Sitaram R, Sherlin LH, Sch\xf6nenberg M, Scharnowski F, Schabus M, Rubia K, Rosa A, Reiner M, Pineda JA, Paret C, Ossadtchi A, Nicholson AA, Nan W, Minguez J, Micoulaud-Franchi JA, Mehler DMA, L\xfchrs M, Lubar J, Lotte F, Linden DEJ, Lewis-Peacock JA, Lebedev MA, Lanius RA, K\xfcbler A, Kranczioch C, Koush Y, Konicar L, Kohl SH, Kober SE, Klados MA, Jeunet C, Janssen TWP, Huster RJ, Hoedlmoser K, Hirshberg LM, Heunis S, Hendler T, Hampson M, Guggisberg AG, Guggenberger R, Gruzelier JH, G\xf6bel RW, Gninenko N, Gharabaghi A, Frewen P, Fovet T, Fern\xe1ndez T, Escolano C, Ehlis AC, Drechsler R, Christopher deCharms R, Debener S, De Ridder D, Davelaar EJ, Congedo M, Cavazza M, Breteler MHM, Brandeis D, Bodurka J73, Birbaumer N, Bazanova OM, Barth B, Bamidis PD, Auer T, Arns M, Thibault RT. Consensus on the reporting and experimental design of clinical and cognitive-behavioural neurofeedback studies (CRED-nf checklist). Brain. 2020 Mar 16.","Ros T, Enriquez-Geppert S, Zotev V, Young KD, Wood G, Whitfield-Gabrieli S, Wan F, Vuilleumier P, Vialatte F, Van De Ville D, Todder D, Surmeli T, Sulzer JS, Strehl U, Sterman MB, Steiner NJ, Sorger B, Soekadar SR, Sitaram R, Sherlin LH, Sch\xf6nenberg M, Scharnowski F, Schabus M, Rubia K, Rosa A, Reiner M, Pineda JA, Paret C, Ossadtchi A, Nicholson AA, Nan W, Minguez J, Micoulaud-Franchi JA, Mehler DMA, L\xfchrs M, Lubar J, Lotte F, Linden DEJ, Lewis-Peacock JA, Lebedev MA, Lanius RA, K\xfcbler A, Kranczioch C, Koush Y, Konicar L, Kohl SH, Kober SE, Klados MA, Jeunet C, Janssen TWP, Huster RJ, Hoedlmoser K, Hirshberg LM, Heunis S, Hendler T, Hampson M, Guggisberg AG, Guggenberger R, Gruzelier JH, G\xf6bel RW, Gninenko N, Gharabaghi A, Frewen P, Fovet T, Fern\xe1ndez T, Escolano C, Ehlis AC, Drechsler R, Christopher deCharms R, Debener S, De Ridder D, Davelaar EJ, Congedo M, Cavazza M, Breteler MHM, Brandeis D, Bodurka J73, Birbaumer N, Bazanova OM, Barth B, Bamidis PD, Auer T, Arns M, Thibault RT.",Brain,2020, , , , ,English, ,32176800,https://www.ncbi.nlm.nih.gov/pubmed/32176800, , , , ,http://www.rtfin.org/CREDnf,CRED-nf checklist,Reporting of clinical and cognitive-behavioural neurofeedback experiments., ,The checklist is available either from the online checklist tool available at www.rtfin.org/CREDnf or it can be downloaded from the supplementary material section on the journal website., , , , , ,no,2020-05-13 16:40:28,2021-11-19 14:32:10,consensus-on-the-reporting-and-experimental-design-of-clinical-and-cognitive-behavioural-neurofeedback-studies-cred-nf-checklist,"[('title', 'Consensus on the reporting and experimental design of clinical and cognitive-behavioural neurofeedback studies (CRED-nf checklist)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of clinical and cognitive-behavioural neurofeedback experiments.'), ('Full bibliographic reference', 'Ros T, Enriquez-Geppert S, Zotev V, Young KD, Wood G, Whitfield-Gabrieli S, Wan F, Vuilleumier P, Vialatte F, Van De Ville D, Todder D, Surmeli T, Sulzer JS, Strehl U, Sterman MB, Steiner NJ, Sorger B, Soekadar SR, Sitaram R, Sherlin LH, Schönenberg M, Scharnowski F, Schabus M, Rubia K, Rosa A, Reiner M, Pineda JA, Paret C, Ossadtchi A, Nicholson AA, Nan W, Minguez J, Micoulaud-Franchi JA, Mehler DMA, Lührs M, Lubar J, Lotte F, Linden DEJ, Lewis-Peacock JA, Lebedev MA, Lanius RA, Kübler A, Kranczioch C, Koush Y, Konicar L, Kohl SH, Kober SE, Klados MA, Jeunet C, Janssen TWP, Huster RJ, Hoedlmoser K, Hirshberg LM, Heunis S, Hendler T, Hampson M, Guggisberg AG, Guggenberger R, Gruzelier JH, Göbel RW, Gninenko N, Gharabaghi A, Frewen P, Fovet T, Fernández T, Escolano C, Ehlis AC, Drechsler R, Christopher deCharms R, Debener S, De Ridder D, Davelaar EJ, Congedo M, Cavazza M, Breteler MHM, Brandeis D, Bodurka J73, Birbaumer N, Bazanova OM, Barth B, Bamidis PD, Auer T, Arns M, Thibault RT. Consensus on the reporting and experimental design of clinical and cognitive-behavioural neurofeedback studies (CRED-nf checklist). Brain. 2020 Mar 16.'), ('Language', 'English'), ('PubMed ID', '[32176800](https://www.ncbi.nlm.nih.gov/pubmed/32176800)'), ('Reporting guideline website URL', '<http://www.rtfin.org/CREDnf>'), ('Reporting guideline acronym', 'CRED-nf checklist'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Neurology, Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Additional information', 'The checklist is available either from the online checklist tool available at [www.rtfin.org/CREDnf](http://www.rtfin.org/CREDnf) or it can be downloaded from the supplementary material section on the journal website.'), ('Record last updated on', 'November 19, 2021')]"
18589,PRICE 2020 guidelines for reporting case reports in Endodontics: a consensus-based development,Observational studies,Dentistry,Whole report, ,"case report, case reports, checklist, checklists, dental, Dentist, Dentistry, endodontic, Endodontics, endodontology, figure, figures, flow chart, illustration, illustrations, image, images, Preferred Reporting Items for Case reports in Endodontics (PRICE) 2020 guidelines, PRICE 2020, PRICE 2020 guidelines, PRICE checklist, PRICE flow chart, PRICE guidelines", ,"Nagendrababu V, Chong BS, McCabe P, Shah PK, Priya E, Jayaraman J, Pulikkotil SJ, Setzer FC, Sunde PT, Dummer PMH. PRICE 2020 guidelines for reporting case reports in Endodontics: a consensus-based development. Int Endod J. 2020;53(5):619-626.","Nagendrababu V, Chong BS, McCabe P, Shah PK, Priya E, Jayaraman J, Pulikkotil SJ, Setzer FC, Sunde PT, Dummer PMH.",International Endodontic Journal [Int Endod J],2020,53,5,619-626, ,English, ,32090342,https://www.ncbi.nlm.nih.gov/pubmed/32090342, ,"Nagendrababu V, Chong BS, McCabe P, Shah PK, Priya E, Jayaraman J, Pulikkotil SJ, Dummer PMH. PRICE 2020 guidelines for reporting case reports in Endodontics: explanation and elaboration. Int Endod J. 2020. PMID: 32221975

", , ,http://pride-endodonticguidelines.org/price/,PRICE 2020,"Reporting case reports in the specialty of Endodontology.



PRICE 2020 Checklist (Word)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 PRICE 2020 Flowchart (Word)

", ,"The protocol for guideline development is available at:

Nagendrababu V, Chong BS, McCabe P, Shah PK, Priya E, Jayaraman J, Pulikkotil SJ, Dummer PMH. Guidelines for reporting the quality of clinical case reports in Endodontics: a development protocol. Int Endod J. 2019 Jun;52(6):775-778. PMID: 30586165

", , , , , ,no,2020-05-13 14:26:20,2021-11-19 14:33:51,price-2020-guidelines-for-reporting-case-reports-in-endodontics-a-consensus-based-development,"[('title', 'PRICE 2020 guidelines for reporting case reports in Endodontics: a consensus-based development'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting case reports in the specialty of Endodontology.\n\n \n\n \xa0\n\n \n\n[PRICE 2020 Checklist (Word)](http://pride-endodonticguidelines.org/wp-content/uploads/2020/03/PRICE-2020-Checklist.docx) [PRICE 2020 Flowchart (Word)](http://pride-endodonticguidelines.org/wp-content/uploads/2020/03/PRICE-2020-Flowchart.docx)\n\n \n\n'), ('Full bibliographic reference', 'Nagendrababu V, Chong BS, McCabe P, Shah PK, Priya E, Jayaraman J, Pulikkotil SJ, Setzer FC, Sunde PT, Dummer PMH. PRICE 2020 guidelines for reporting case reports in Endodontics: a consensus-based development. Int Endod J. 2020;53(5):619-626.'), ('Language', 'English'), ('PubMed ID', '[32090342](https://www.ncbi.nlm.nih.gov/pubmed/32090342)'), ('Explanation and elaboration papers', 'Nagendrababu V, Chong BS, McCabe P, Shah PK, Priya E, Jayaraman J, Pulikkotil SJ, Dummer PMH. PRICE 2020 guidelines for reporting case reports in Endodontics: explanation and elaboration. Int Endod J. 2020. PMID: [32221975](https://www.ncbi.nlm.nih.gov/pubmed/32221975)\n\n \n\n'), ('Reporting guideline website URL', '<http://pride-endodonticguidelines.org/price/>'), ('Reporting guideline acronym', 'PRICE 2020'), ('Study design', 'Observational studies'), ('Clinical area', 'Dentistry'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'The protocol for guideline development is available at:\n\n \n\n Nagendrababu V, Chong BS, McCabe P, Shah PK, Priya E, Jayaraman J, Pulikkotil SJ, Dummer PMH. Guidelines for reporting the quality of clinical case reports in Endodontics: a development protocol. Int Endod J. 2019 Jun;52(6):775-778. PMID: [30586165](https://www.ncbi.nlm.nih.gov/pubmed/30586165)\n\n \n\n'), ('Record last updated on', 'November 19, 2021')]"
18587,PRIRATE 2020 guidelines for reporting randomized trials in Endodontics: a consensus-based development,"Clinical trials, Experimental studies",Dentistry,Whole report, ,"checklist, checklists, clinical trial, clinical trials, dental, Dentist, Dentistry, endodontic, Endodontics, endodontology, figure, figures, flow chart, illustration, illustrations, image, images, Preferred Reporting Items for RAndomized Trials in Endodontics, PRIRATE 2020, PRIRATE 2020 guidelines, PRIRATE checklist, PRIRATE flow chart, PRIRATE guidelines, randomised clinical trial, randomised clinical trials, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized clinical trial, randomized clinical trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Nagendrababu V, Duncan HF, Bj\xf8rndal L, Kvist T, Priya E, Jayaraman J, Pulikkotil SJ, Pigg M, Rechenberg DK, Vaeth M, Dummer PMH. PRIRATE 2020 guidelines for reporting randomized trials in Endodontics: a consensus-based development. Int Endod J. 2020;53(6):764-773.","Nagendrababu V, Duncan HF, Bj\xf8rndal L, Kvist T, Priya E, Jayaraman J, Pulikkotil SJ, Pigg M, Rechenberg DK, Vaeth M, Dummer PMH.",International Endodontic Journal [Int Endod J],2020,53,6,764-773, ,English, ,32196696,https://www.ncbi.nlm.nih.gov/pubmed/32196696, ,"Nagendrababu V, Duncan HF, Bj\xf8rndal L, Kvist T, Priya E, Jayaraman J, Pulikkotil SJ, Dummer PMH. PRIRATE 2020 guidelines for reporting randomized trials in Endodontics: explanation and elaboration. Int Endod J. 2020;53(6):774-803. PMID: 32266988

", , ,http://pride-endodonticguidelines.org/prirate/,PRIRATE,"Reporting randomised clinical trials in the specialty of Endodontics.



PRIRATE 2020 Checklist (Word) \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 PRIRATE 2020 Flowchart (Word)

", ,"The protocol for guideline development is available at:

Nagendrababu V, Duncan HF, Bj\xf8rndal L, Kvist T, Priya E, Pulikkotil SJ, Jayaraman J, Dummer PMH. Preferred Reporting Items for RAndomized Trials in Endodontics (PRIRATE) guidelines: a development protocol. Int Endod J. 2019;52(7):974-978.
PMID: 30702139

", , , , , ,no,2020-05-13 13:58:43,2021-11-19 14:35:42,prirate-2020-guidelines-for-reporting-randomized-trials-in-endodontics-a-consensus-based-development,"[('title', 'PRIRATE 2020 guidelines for reporting randomized trials in Endodontics: a consensus-based development'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting randomised clinical trials in the specialty of Endodontics.\n\n \n\n \xa0\n\n \n\n[PRIRATE 2020 Checklist (Word)](http://pride-endodonticguidelines.org/wp-content/uploads/2020/03/PRIRATE-2020-checklist.docx)  [PRIRATE 2020 Flowchart (Word)](http://pride-endodonticguidelines.org/wp-content/uploads/2020/03/PRIRATE-2020-flowchart.docx)\n\n \n\n'), ('Full bibliographic reference', 'Nagendrababu V, Duncan HF, Bjørndal L, Kvist T, Priya E, Jayaraman J, Pulikkotil SJ, Pigg M, Rechenberg DK, Vaeth M, Dummer PMH. PRIRATE 2020 guidelines for reporting randomized trials in Endodontics: a consensus-based development. Int Endod J. 2020;53(6):764-773.'), ('Language', 'English'), ('PubMed ID', '[32196696](https://www.ncbi.nlm.nih.gov/pubmed/32196696)'), ('Explanation and elaboration papers', 'Nagendrababu V, Duncan HF, Bjørndal L, Kvist T, Priya E, Jayaraman J, Pulikkotil SJ, Dummer PMH. PRIRATE 2020 guidelines for reporting randomized trials in Endodontics: explanation and elaboration. Int Endod J. 2020;53(6):774-803. PMID: [32266988](https://www.ncbi.nlm.nih.gov/pubmed/32266988)\n\n \n\n'), ('Reporting guideline website URL', '<http://pride-endodonticguidelines.org/prirate/>'), ('Reporting guideline acronym', 'PRIRATE'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Dentistry'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'The protocol for guideline development is available at:\n\n \n\n Nagendrababu V, Duncan HF, Bjørndal L, Kvist T, Priya E, Pulikkotil SJ, Jayaraman J, Dummer PMH. Preferred Reporting Items for RAndomized Trials in Endodontics (PRIRATE) guidelines: a development protocol. Int Endod J. 2019;52(7):974-978.\n\n PMID: [30702139](https://www.ncbi.nlm.nih.gov/pubmed/30702139)\n\n \n\n'), ('Record last updated on', 'November 19, 2021')]"
18558,Guidance for reporting intervention development studies in health research (GUIDED): an evidence-based consensus study,"Clinical trials, Experimental studies, Observational studies, Study protocols, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,Intervention (exposure), ,"complex intervention, complex interventions, GUIDance for the rEporting of intervention Development, GUIDance for the rEporting of intervention Development checklist, GUIDED, GUIDED checklist, GUIDED intervention development reporting items, GUIDED reporting checklist, intervention, intervention description, intervention descriptions, intervention development, intervention development process, intervention development reporting, intervention development studies, intervention development study, interventions", ,"Duncan E, O'Cathain A, Rousseau N, Croot L, Sworn K, Turner KM, Yardley L, Hoddinott P. Guidance for reporting intervention development studies in health research (GUIDED): an evidence-based consensus study. BMJ Open. 2020 Apr 8;10(4):e033516.","Duncan E, O'Cathain A, Rousseau N, Croot L, Sworn K, Turner KM, Yardley L, Hoddinott P.",BMJ Open,2020,10,4,e033516, ,English, ,32273313,https://www.ncbi.nlm.nih.gov/pubmed/32273313,The full-text of this reporting guideline is freely available at: https://bmjopen.bmj.com/content/10/4/e033516, , , , ,GUIDED,"Reporting of intervention development studies.



GUIDED checklist (PDF)

", , , , , , , ,no,2020-04-14 14:48:30,2021-11-19 14:37:15,guidance-for-reporting-intervention-development-studies-in-health-research-guided,"[('title', 'Guidance for reporting intervention development studies in health research (GUIDED) : an evidence-based consensus study'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of intervention development studies.\n\n \n\n \xa0\n\n \n\n[GUIDED checklist (PDF)](https://bmjopen.bmj.com/content/bmjopen/10/4/e033516/DC1/embed/inline-supplementary-material-1.pdf?download=true)\n\n \n\n'), ('Full bibliographic reference', ""Duncan E, O'Cathain A, Rousseau N, Croot L, Sworn K, Turner KM, Yardley L, Hoddinott P. Guidance for reporting intervention development studies in health research (GUIDED): an evidence-based consensus study. BMJ Open. 2020 Apr 8;10(4):e033516.""), ('Language', 'English'), ('PubMed ID', '[32273313](https://www.ncbi.nlm.nih.gov/pubmed/32273313)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available at: <https://bmjopen.bmj.com/content/10/4/e033516>'), ('Reporting guideline acronym', 'GUIDED'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Study protocols, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'November 19, 2021')]"
18508,"Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018)","Clinical trials, Experimental studies, Study protocols",Complementary and alternative medicine,Protocol-whole report, ,"acupuncture, Chinese herbal formulae, Chinese herbal medicine, Chinese medicine, CHM, CHM formulae, clinical trial, clinical trials, moxibustion, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, SPIRIT Extension, SPIRIT-TCM, SPIRIT-TCM Extension, SPIRIT-TCM Extension 2018, TCM, TCM clinical trial, TCM clinical trials, TCM drugs, TCM intervention, TCM interventions, TCM practice, traditional Chinese medicine, trial, trials", ,"Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79.","Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX.",Chinese Journal of Integrative Medicine [Chin J Integr Med.],2019,25,1,71-79, ,English, ,30484022,https://www.ncbi.nlm.nih.gov/pubmed/30484022, , , ,"Generic

SPIRIT 2025 Statement: Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hr\xf3bjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.

BMJ. 2025; 388:e081660. PMID:\xa040294956
JAMA. 2025.\xa0PMID: 40294593
Lancet 2025.
Nat Med. 2025.\xa0PMID: 40295741
PLoS Med. 2025; 22(4): e1004587.\xa0PMID: 40294521

Specialised
SPIRIT-PRO: Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. Link to abstract

SPENT 2019: Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. Link to full-text.

SPIRIT-AI: Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.
BMJ. 2020;370:m3210. PMID: 32907797
Nat Med. 2020;26(9):1351?1363. PMID: 32908284
Lancet Digital Health. 2020;2(10):e549-e560. PMID: 33328049

SPIRIT-Path: Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: 34592193

SPIRIT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: 36512367

SPIRIT-DEFINE: Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: 37863491

SPIRIT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: 38051535

SPIRIT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: 38981624

SPIRIT-iNeurostim: Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: 39610902

", ,SPIRIT-TCM,Reporting of Traditional Chinese Medicine clinical trial protocols., , , , , , , ,yes,2020-02-28 14:10:09,2025-05-30 09:13:03,standard-protocol-items-for-clinical-trials-with-traditional-chinese-medicine-spirit-tcm-extension-2018,"[('title', 'Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of Traditional Chinese Medicine clinical trial protocols.'), ('Full bibliographic reference', 'Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79.'), ('Language', 'English'), ('PubMed ID', '[30484022](https://www.ncbi.nlm.nih.gov/pubmed/30484022)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n \n\n**[SPIRIT 2025 Statement](https://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/):** Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hróbjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.\n\n \n\nBMJ. 2025; 388:e081660. [PMID:40294956](https://pubmed.ncbi.nlm.nih.gov/40294956/)\n\n JAMA. 2025.[PMID:](https://pubmed.ncbi.nlm.nih.gov/40294593/) [40294593](https://pubmed.ncbi.nlm.nih.gov/40294593/)\n\n Lancet 2025.\n\n Nat Med. 2025.[PMID: 40295741](https://pubmed.ncbi.nlm.nih.gov/40295741)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID: 40294521](https://pubmed.ncbi.nlm.nih.gov/40294521/)\n\n \n\n**Specialised**\n\n[**SPIRIT-PRO**](https://www.equator-network.org/reporting-guidelines/spirit-pro/): Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. [Link to abstract](https://jamanetwork.com/journals/jama/article-abstract/2671472)\n\n \n\n[**SPENT 2019**](https://www.equator-network.org/reporting-guidelines/spirit-extension-n-of-1-trials-spent-2019/): Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. [Link to full-text](https://www.bmj.com/content/368/bmj.m122).\n\n \n\n[**SPIRIT-AI**](https://www.equator-network.org/reporting-guidelines/spirit-artificial-intelligence/): Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.\n\n BMJ. 2020;370:m3210. PMID: [32907797](https://pubmed.ncbi.nlm.nih.gov/32907797/)\n\n Nat Med. 2020;26(9):1351–1363. PMID: [32908284](https://pubmed.ncbi.nlm.nih.gov/32908284/)\n\n Lancet Digital Health. 2020;2(10):e549-e560. PMID: [33328049](https://pubmed.ncbi.nlm.nih.gov/33328049/)\n\n \n\n[**SPIRIT-Path**](https://www.equator-network.org/reporting-guidelines/spirit-path/): Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: [34592193](https://pubmed.ncbi.nlm.nih.gov/34592193/)\n\n \n\n[**SPIRIT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-protocols-the-spirit-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: [36512367](https://pubmed.ncbi.nlm.nih.gov/36512367/)\n\n \n\n[**SPIRIT-DEFINE**](https://www.equator-network.org/reporting-guidelines/spirit-define/): Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: [37863491](https://pubmed.ncbi.nlm.nih.gov/37863491/)\n\n \n\n[**SPIRIT Factorial**](https://www.equator-network.org/reporting-guidelines/consensus-statement-for-protocols-of-factorial-randomized-trials-extension-of-the-spirit-2013-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: [38051535](https://pubmed.ncbi.nlm.nih.gov/38051535/)\n\n \n\n[**SPIRIT-Surrogate**](https://www.equator-network.org/reporting-guidelines/spirit-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: [38981624](https://pubmed.ncbi.nlm.nih.gov/38981624/)\n\n \n\n[**SPIRIT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-protocols-of-randomised-controlled-trials-of-implantable-neurostimulation-devices-the-spirit-ineurostim-extension/): Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: [39610902](https://pubmed.ncbi.nlm.nih.gov/39610902/)\n\n \n\n""), ('Reporting guideline acronym', 'SPIRIT-TCM'), ('Study design', 'Clinical trials, Experimental studies, Study protocols'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Protocol-whole report'), ('Record last updated on', 'May 30, 2025')]"
18506,SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist,"Clinical trials, Experimental studies, Study protocols", ,Protocol-whole report, ,"checklist, checklists, clinical trial, clinical trials, individual, individuals, N-of-1, n-of-1 protocol, n-of-1 protocols, N-of-1 trial, n-of-1 trial protocol, n-of-1 trial protocols, N-of-1 trials, protocol, protocols, SPENT, SPENT 2019 checklist, SPENT checklist, SPENT guideline, SPENT statement, SPIRIT Extension, SPIRIT extension for n-of-1 trials, trial, trial protocol, trial protocols, trials", ,"Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368.","Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A,\xa0 Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group.",BMJ,2020,368, , , ,English, ,32107202,https://pubmed.ncbi.nlm.nih.gov/32107202/,The full-text of the SPENT 2019 checklist is available at: https://www.bmj.com/content/368/bmj.m122, , ,"Generic

SPIRIT 2025 Statement: Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hr\xf3bjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.

BMJ. 2025; 388:e081660. PMID:\xa040294956
JAMA. 2025.\xa0PMID: 40294593
Lancet 2025.
Nat Med. 2025.\xa0PMID: 40295741
PLoS Med. 2025; 22(4): e1004587.\xa0PMID: 40294521

Specialised
SPIRIT-PRO: Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. Link to abstract

SPIRIT-TCM: Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: 30484022

SPIRIT-AI: Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.
BMJ. 2020;370:m3210. PMID: 32907797
Nat Med. 2020;26(9):1351?1363. PMID: 32908284
Lancet Digital Health. 2020;2(10):e549-e560. PMID: 33328049

SPIRIT-Path: Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: 34592193

SPIRIT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: 36512367

SPIRIT-DEFINE: Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: 37863491

SPIRIT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: 38051535

SPIRIT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: 38981624

SPIRIT-iNeurostim: Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: 39610902

", ,SPENT,Reporting of n-of-1 trial protocols., ,Read the SPENT development statement (PDF)., , , , , ,yes,2020-02-28 13:15:22,2025-05-30 09:13:16,spirit-extension-n-of-1-trials-spent-2019,"[('title', 'SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of n-of-1 trial protocols.'), ('Full bibliographic reference', 'Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368.'), ('Language', 'English'), ('PubMed ID', '[32107202](https://pubmed.ncbi.nlm.nih.gov/32107202/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the SPENT 2019 checklist is available at: <https://www.bmj.com/content/368/bmj.m122>'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n \n\n**[SPIRIT 2025 Statement](https://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/):** Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hróbjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.\n\n \n\nBMJ. 2025; 388:e081660. [PMID:40294956](https://pubmed.ncbi.nlm.nih.gov/40294956/)\n\n JAMA. 2025.[PMID:](https://pubmed.ncbi.nlm.nih.gov/40294593/) [40294593](https://pubmed.ncbi.nlm.nih.gov/40294593/)\n\n Lancet 2025.\n\n Nat Med. 2025.[PMID: 40295741](https://pubmed.ncbi.nlm.nih.gov/40295741)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID: 40294521](https://pubmed.ncbi.nlm.nih.gov/40294521/)\n\n \n\n**Specialised**\n\n[**SPIRIT-PRO**](https://www.equator-network.org/reporting-guidelines/spirit-pro/): Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. [Link to abstract](https://jamanetwork.com/journals/jama/article-abstract/2671472)\n\n \n\n[**SPIRIT-TCM**](https://www.equator-network.org/reporting-guidelines/standard-protocol-items-for-clinical-trials-with-traditional-chinese-medicine-spirit-tcm-extension-2018/): Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: [30484022](https://www.ncbi.nlm.nih.gov/pubmed/30484022)\n\n \n\n[**SPIRIT-AI**](https://www.equator-network.org/reporting-guidelines/spirit-artificial-intelligence/): Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.\n\n BMJ. 2020;370:m3210. PMID: [32907797](https://pubmed.ncbi.nlm.nih.gov/32907797/)\n\n Nat Med. 2020;26(9):1351–1363. PMID: [32908284](https://pubmed.ncbi.nlm.nih.gov/32908284/)\n\n Lancet Digital Health. 2020;2(10):e549-e560. PMID: [33328049](https://pubmed.ncbi.nlm.nih.gov/33328049/)\n\n \n\n[**SPIRIT-Path**](https://www.equator-network.org/reporting-guidelines/spirit-path/): Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: [34592193](https://pubmed.ncbi.nlm.nih.gov/34592193/)\n\n \n\n[**SPIRIT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-protocols-the-spirit-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: [36512367](https://pubmed.ncbi.nlm.nih.gov/36512367/)\n\n \n\n[**SPIRIT-DEFINE**](https://www.equator-network.org/reporting-guidelines/spirit-define/): Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: [37863491](https://pubmed.ncbi.nlm.nih.gov/37863491/)\n\n \n\n[**SPIRIT Factorial**](https://www.equator-network.org/reporting-guidelines/consensus-statement-for-protocols-of-factorial-randomized-trials-extension-of-the-spirit-2013-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: [38051535](https://pubmed.ncbi.nlm.nih.gov/38051535/)\n\n \n\n[**SPIRIT-Surrogate**](https://www.equator-network.org/reporting-guidelines/spirit-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: [38981624](https://pubmed.ncbi.nlm.nih.gov/38981624/)\n\n \n\n[**SPIRIT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-protocols-of-randomised-controlled-trials-of-implantable-neurostimulation-devices-the-spirit-ineurostim-extension/): Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: [39610902](https://pubmed.ncbi.nlm.nih.gov/39610902/)\n\n \n\n""), ('Reporting guideline acronym', 'SPENT'), ('Study design', 'Clinical trials, Experimental studies, Study protocols'), ('Applies to the whole report or to individual sections of the report?', 'Protocol-whole report'), ('Additional information', 'Read the [SPENT development statement (PDF)](https://www.equator-network.org/wp-content/uploads/2009/02/SPENT-development-statement.pdf).'), ('Record last updated on', 'May 30, 2025')]"
18501,Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement,"Clinical trials, Experimental studies",Complementary and alternative medicine,Intervention (exposure), ,"alternative therapy, checklist, checklists, clinical trial, clinical trials, complementary therapy, CONSORT extension, cupping, cupping trial, cupping trials, intervention, interventional, interventions, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, standards for reporting interventions in clinical trials of cupping, STRICTOC, STRICTOC checklist, STRICTOC guideline, trial, trials", ,"Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10.","Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z.",Chinese Medicine [Chin Med.],2020,15,10, , ,English, ,32021646,https://www.ncbi.nlm.nih.gov/pubmed/32021646,The full-text of the STRICTOC guideline is freely available at: https://cmjournal.biomedcentral.com/articles/10.1186/s13020-020-0293-2, , ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,STRICTOC,Reporting interventions in clinical trials of cupping., , , , , , , ,yes,2020-02-21 14:05:05,2025-05-30 09:25:11,standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement,"[('title', 'Standards for reporting interventions in clinical trials of cupping (STRICTOC) : extending the CONSORT statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting interventions in clinical trials of cupping.'), ('Full bibliographic reference', 'Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10.'), ('Language', 'English'), ('PubMed ID', '[32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the STRICTOC guideline is freely available at: <https://cmjournal.biomedcentral.com/articles/10.1186/s13020-020-0293-2>'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](https://dev.equator-network.org/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](http://dev.equator-network.org/reporting-guidelines/consort-cluster/):\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](http://dev.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](http://dev.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](http://dev.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n**[CONSORT for pilot and feasibility trials](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/)**: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'STRICTOC'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'May 30, 2025')]"
18433,PaCIR: A tool to enhance pharmacist patient care intervention reporting,"Clinical trials, Experimental studies, Observational studies, Qualitative research, Quality improvement studies",Pharmaceutical medicine,Intervention (exposure), ,"checklist, checklists, complex intervention, complex interventions, disease state management, intervention, interventions, medication management, PaCIR, PaCIR checklist, patient, patient care, patient care services, pharmaceutical, pharmacist, pharmacist patient care intervention, pharmacist patient care interventions, pharmacists, pharmacy, prevention and wellness services", ,"Clay PG, Burns AL, Isetts BJ, Hirsch JD, Kliethermes MA, Planas LG. PaCIR: A tool to enhance pharmacist patient care intervention reporting. J Am Pharm Assoc (2003).2019;59(5):615-623.","Clay PG, Burns AL, Isetts BJ, Hirsch JD, Kliethermes MA, Planas LG.",Journal of the American Pharmacists Association [J Am Pharm Assoc],2019,59,5,615-623, ,English, ,31400991,https://www.ncbi.nlm.nih.gov/pubmed/31400991, , , , , ,PaCIR,Reporting of pharmacist patient care intervention studies., , , , , , , ,no,2020-01-22 15:20:31,2020-01-22 15:20:31,pacir-a-tool-to-enhance-pharmacist-patient-care-intervention-reporting,"[('title', 'Pa CIR : A tool to enhance pharmacist patient care intervention reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of pharmacist patient care intervention studies.'), ('Full bibliographic reference', 'Clay PG, Burns AL, Isetts BJ, Hirsch JD, Kliethermes MA, Planas LG. PaCIR: A tool to enhance pharmacist patient care intervention reporting. J Am Pharm Assoc (2003).2019;59(5):615-623.'), ('Language', 'English'), ('PubMed ID', '[31400991](https://www.ncbi.nlm.nih.gov/pubmed/31400991)'), ('Reporting guideline acronym', 'PaCIR'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Qualitative research, Quality improvement studies'), ('Clinical area', 'Pharmaceutical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'January 22, 2020')]"
18424,Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,"Narrative sections (discussion etc.), Procedure/Method, Results", ,"checklist, checklists, evidence syntheses, evidence synthesis, narrative, narrative synthesis, PRISMA, quantitative, quantitative data, quantitative method, quantitative methods, SWiM, SWiM guideline, syntheses, synthesis, synthesis method, synthesis methods, synthesis without meta-analysis, Synthesis Without Meta-analysis (SWiM), systematic review, systematic reviews", ,"Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, Hartmann-Boyce J, Ryan R, Shepperd S, Thomas J, Welch V, Thomson H. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ 2020;368:l6890.","Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, Hartmann-Boyce J, Ryan R, Shepperd S, Thomas J, Welch V, Thomson H.",BMJ,2020,368, , , ,English, ,31948937,https://www.ncbi.nlm.nih.gov/pubmed/31948937,"The full-text of the SWiM guideline is freely available at:
https://www.bmj.com/content/368/bmj.l6890", , , ,https://swim.sphsu.gla.ac.uk/,SWiM,"Reporting synthesis without meta-analysis in systematic reviews of interventions.



SWiM checklist (Word) \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 SWiM checklist (PDF)

", ,"Read the guideline development protocol.

", , , , , ,no,2020-01-17 10:10:00,2021-11-19 14:59:32,synthesis-without-meta-analysis-swim-in-systematic-reviews-reporting-guideline,"[('title', 'Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting synthesis without meta-analysis in systematic reviews of interventions.\n\n \n\n \xa0\n\n \n\n[SWiM checklist (Word)](https://www.equator-network.org/wp-content/uploads/2020/01/Synthesis-without-Meta-analysis-SWiM-Checklist.docx)  [SWiM checklist (PDF)](https://www.equator-network.org/wp-content/uploads/2020/01/Synthesis-without-Meta-analysis-SWiM-Checklist.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, Hartmann-Boyce J, Ryan R, Shepperd S, Thomas J, Welch V, Thomson H. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ 2020;368:l6890.'), ('Language', 'English'), ('PubMed ID', '[31948937](https://www.ncbi.nlm.nih.gov/pubmed/31948937)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the SWiM guideline is freely available at:\n\n<https://www.bmj.com/content/368/bmj.l6890>'), ('Reporting guideline website URL', '<https://swim.sphsu.gla.ac.uk/>'), ('Reporting guideline acronym', 'SWiM'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Narrative sections (discussion etc.), Procedure/Method, Results'), ('Additional information', 'Read the guideline development [protocol](https://bmjopen.bmj.com/content/8/2/e020064).\n\n \n\n'), ('Record last updated on', 'November 19, 2021')]"
18329,Guidelines for reporting case studies and series on drug-induced QT interval prolongation and its complications following acute overdose,Observational studies,"Cardiovascular medicine, Emergency medicine, Pharmaceutical medicine, Toxicology","Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Study characteristics (participants etc.)", ,"adverse event, adverse events, cardiac, cardiology, cardiovascular, case report, case reporting, case reports, case series, case studies, checklist, checklists, clinical toxicology, drug, drug induced QT interval prolongation, drugs, dysrhythmias, harm, harms, heart rate, malignant dysrhythmia, medication, overdose, pharmacodynamics, pharmacokinetics, poison, poisoned, poisoning, QT, QT interval, QT interval prolongation, QT reporting checklist, TdP, torsade de pointes, toxic, toxicologist, toxicology, toxin, toxins", ,"Berling I, Hatten BW, Hoffman RS, Othong R, Roberts DM, Mustafa RA, Yates C, Cormier M, Gosselin S. Guidelines for reporting case studies and series on drug-induced QT interval prolongation and its complications following acute overdose. Clin Toxicol (Phila). 2019:1-9.","Berling I, Hatten BW, Hoffman RS, Othong R, Roberts DM, Mustafa RA, Yates C, Cormier M, Gosselin S.","Clinical Toxicology (Philadelphia, PA)\xa0 [Clin Toxicol (Phila)]",2019, , ,1-9, ,English, ,31018700,https://www.ncbi.nlm.nih.gov/pubmed/31018700, , , , , , ,Reporting of case studies and series on drug-induced QT interval prolongation and its complications following acute overdose., , , , , , , ,no,2019-11-28 14:41:58,2019-11-28 14:52:22,guidelines-for-reporting-case-studies-and-series-on-drug-induced-qt-interval-prolongation-and-its-complications-following-acute-overdose,"[('title', 'Guidelines for reporting case studies and series on drug-induced QT interval prolongation and its complications following acute overdose'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of case studies and series on drug-induced QT interval prolongation and its complications following acute overdose.'), ('Full bibliographic reference', 'Berling I, Hatten BW, Hoffman RS, Othong R, Roberts DM, Mustafa RA, Yates C, Cormier M, Gosselin S. Guidelines for reporting case studies and series on drug-induced QT interval prolongation and its complications following acute overdose. Clin Toxicol (Phila). 2019:1-9.'), ('Language', 'English'), ('PubMed ID', '[31018700](https://www.ncbi.nlm.nih.gov/pubmed/31018700)'), ('Study design', 'Observational studies'), ('Clinical area', 'Cardiovascular medicine, Emergency medicine, Pharmaceutical medicine, Toxicology'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Study characteristics (participants etc.)'), ('Record last updated on', 'November 28, 2019')]"
18327,Criteria for describing and evaluating training interventions in healthcare professions - CRe-DEPTH,"Clinical trials, Observational studies, Qualitative research", ,Intervention (exposure), ,"checklist, complex intervention, complex interventions, complex training intervention, complex training interventions, continuing education, CRe-DEPTH, CRe-DEPTH criteria, Criteria for Reporting on Development and Evaluation of Professional Training interventions in Healthcare, education, educational, healthcare education, healthcare professionals, intervention, interventions, professional education, professional training, teacher, teaching, teaching content, teaching methods, train, trainer, training, training intervention, training interventions, training programme, training programmes", ,"Van Hecke A, Duprez V, Pype P, Beeckman D, Verhaeghe S. Criteria for describing and evaluating training interventions in healthcare professions - CRe-DEPTH. Nurse Educ Today. 2020;84:104254.","Van Hecke A, Duprez V, Pype P, Beeckman D, Verhaeghe S.",Nurse Education Today [Nurse Educ Today.],2020,84, ,104254, ,English, ,31689586,https://www.ncbi.nlm.nih.gov/pubmed/31689586, , , , , , ,Reporting criteria for descriptions of training interventions in healthcare., , , , , , , ,no,2019-11-26 14:19:00,2019-11-26 14:19:00,criteria-for-describing-and-evaluating-training-interventions-in-healthcare-professions-cre-depth,"[('title', 'Criteria for describing and evaluating training interventions in healthcare professions – CRe-DEPTH'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting criteria for descriptions of training interventions in healthcare.'), ('Full bibliographic reference', 'Van Hecke A, Duprez V, Pype P, Beeckman D, Verhaeghe S. Criteria for describing and evaluating training interventions in healthcare professions - CRe-DEPTH. Nurse Educ Today. 2020;84:104254.'), ('Language', 'English'), ('PubMed ID', '[31689586](https://www.ncbi.nlm.nih.gov/pubmed/31689586)'), ('Study design', 'Clinical trials, Observational studies, Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'November 26, 2019')]"
18184,"CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration","Clinical trials, Experimental studies",Complementary and alternative medicine,Whole report, ,"CENT, CENT 2015, CENT for TCM, CENT for TCM checklist, checklist, checklists, Chinese herbal, Chinese herbal medicine, Chinese herbal medicine formulas, Chinese herbal medicines, Chinese medicine, Chinese medicines, clinical trial, clinical trials, CONSORT CENT for TCM, CONSORT extension, crossover trial, crossover trials, multiple crossover trial, multiple crossover trials, N-of-1, N-of-1 trial, N-of-1 trials, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, TCM, TCM intervention, TCM interventions, traditional Chinese medicine, traditional Chinese medicines, trial, trials", ,"Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188.","Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group.",Complementary Therapies in Medicine [Complement Ther Med.],2019,46, ,180-188, ,English, ,31519276,https://www.ncbi.nlm.nih.gov/pubmed/31519276, , , ,"Generic
CONSORT 2025 Statement:
Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,CENT for TCM,Reporting of N-of-1 trials using traditional Chinese medicine., ,"Read preliminary work undertaken to support development of this guideline: Li J, Gao W, Punja S, Ma B, Vohra S, Duan N, Gabler N, Yang K, Kravitz RL. Reporting quality of N-of-1 trials published between 1985 and 2013: a systematic review. J Clin Epidemiol. 2016;76:57-64. PMID: 26769257

", , , , , ,yes,2019-10-10 09:47:26,2025-05-30 09:24:37,consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine,"[('title', 'CONSORT extension for reporting N-of- 1 trials for traditional Chinese medicine (CENT for TCM) : Recommendations, explanation and elaboration'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of N-of-1 trials using traditional Chinese medicine.'), ('Full bibliographic reference', 'Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188.'), ('Language', 'English'), ('PubMed ID', '[31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](https://www.equator-network.org/reporting-guidelines/consort/):\n\n Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](http://dev.equator-network.org/reporting-guidelines/consort-cluster/):\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](http://dev.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](http://dev.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](http://dev.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'CENT for TCM'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Read preliminary work undertaken to support development of this guideline: Li J, Gao W, Punja S, Ma B, Vohra S, Duan N, Gabler N, Yang K, Kravitz RL. Reporting quality of N-of-1 trials published between 1985 and 2013: a systematic review. J Clin Epidemiol. 2016;76:57-64. PMID: [26769257](https://www.ncbi.nlm.nih.gov/pubmed/26769257)\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
18129,Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews,Complementary and alternative medicine,Whole report, ,"acupoints, acupuncture, checklist, checklists, Chinese medicine, complementary medicine, De-qi, electroacupuncture, Japanese traditional medicine, Korean medicine, meta analyses, meta analysis, needling, PRISMA Acupuncture, PRISMA extension, PRISMA for Acupuncture, PRISMA for Acupuncture checklist, PRISMA-A, systematic review, systematic reviews, TCM, traditional Chinese medicine, traditional medicine", ,"Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208.","Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K.",BMC Complementary and Alternative Medicine [BMC Complement Altern Med.],2019,19,1,208, ,English, ,31405367,https://www.ncbi.nlm.nih.gov/pubmed/31405367,"The full-text of this reporting guideline is available at:
https://bmccomplementalternmed.biomedcentral.com/articles/10.1186/s12906-019-2624-3

", , ,"Generic
PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

Specialised
PRISMA-Equity: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: 23222917

Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.
Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

PRISMA-Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.

PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246

PRISMA-IPD: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: 25919529

PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634

PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668

PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement &amp; Checklist. J Clin Epidemiol. 2017. PMID: 28720516

PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: 29362800

PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033

PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791

PRISMA-CHM: Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: 32907365

PRISMA-M 2020: Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: 33100229

PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.
Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535

PRISMA-LSR: Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: 39562017

",http://www.prisma-statement.org/Extensions/Acupuncture,PRISMA-A,"Reporting of systematic reviews of acupuncture interventions.



PRISMA - A checklist (PDF) \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 \xa0 \xa0 \xa0 PRISMA - A checklist (Word)

","The PRISMA for Acupuncture checklist is available in Chinese (PDF | Word).

","Read additional information (PDF) about PRISMA for Acupuncture development group participants.

", , , , , ,yes,2019-08-20 15:24:31,2025-02-06 12:08:33,prisma-acupuncture,"[('title', 'Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of systematic reviews of acupuncture interventions.\n\n \n\n \xa0\n\n \n\n[PRISMA - A checklist (PDF)](https://www.prisma-statement.org/s/PRISMA-A-checklist-fmgd.pdf)  [PRISMA - A checklist (Word)](https://www.prisma-statement.org/s/PRISMA-A-checklist-m2n3.docx)\n\n \n\n'), ('Full bibliographic reference', 'Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208.'), ('Language', 'English'), ('PubMed ID', '[31405367](https://www.ncbi.nlm.nih.gov/pubmed/31405367)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is available at:\n\n<https://bmccomplementalternmed.biomedcentral.com/articles/10.1186/s12906-019-2624-3>\n\n \n\n'), ('Availability in additional languages', 'The PRISMA for Acupuncture checklist is available in Chinese ([PDF](/wp-content/uploads/2019/08/PRISMA-A-checklist-Chinese.pdf) | [Word](/wp-content/uploads/2019/08/PRISMA-A-checklist-Chinese.docx)).\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n[**PRISMA 2020 Statement**](http://dev.equator-network.org/reporting-guidelines/prisma/): Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.\n\n \n\n PLoS Med. 2021;18(3):e1003583. PMID: [33780438](https://pubmed.ncbi.nlm.nih.gov/33780438/)\n\n BMJ 2021;372:n71. PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)\n\n Int J Surg. 2021:105906. PMID: [33789826](https://pubmed.ncbi.nlm.nih.gov/33789826/)\n\n J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: [33789819](https://pubmed.ncbi.nlm.nih.gov/33789819/)\n\n Syst Rev. 2021;10(1):89. PMID: [33781348](https://pubmed.ncbi.nlm.nih.gov/33781348/)\n\n \n\n**Specialised**\n\n[**PRISMA-Equity**](http://dev.equator-network.org/reporting-guidelines/prisma-equity/): Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: [23222917](http://www.ncbi.nlm.nih.gov/pubmed/23222917)\n\n \n\n Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.\n\n Int J Equity Health. 2015;14(1):92. PMID: [26450828](http://www.ncbi.nlm.nih.gov/pubmed/26450828)\n\n J Clin Epidemiol. 2015. PMID: [26348799](http://www.ncbi.nlm.nih.gov/pubmed/26348799)\n\n \n\n[**PRISMA-Abstracts 2020:**](http://dev.equator-network.org/reporting-guidelines/prisma-abstracts/) The PRISMA 2020 for Abstracts reporting guideline is contained within the main [PRISMA 2020 Statement paper](https://www.equator-network.org/reporting-guidelines/prisma/).\n\n \n\n[**PRISMA-P**](http://dev.equator-network.org/reporting-guidelines/prisma-protocols/): Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: [25554246](http://www.ncbi.nlm.nih.gov/pubmed/25554246)\n\n \n\n[**PRISMA-IPD**](http://dev.equator-network.org/reporting-guidelines/prisma-ipd/): Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: [25919529](http://www.ncbi.nlm.nih.gov/pubmed/25919529)\n\n \n\n[**PRISMA extension for network meta-analyses**](http://dev.equator-network.org/reporting-guidelines/prisma-extension-network-meta-analyses/): Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: [26030634](http://www.ncbi.nlm.nih.gov/pubmed/26030634)\n\n \n\n[**PRISMA-harms**](http://dev.equator-network.org/reporting-guidelines/prisma-harms/): Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: [26830668](http://www.ncbi.nlm.nih.gov/pubmed/26830668)\n\n \n\n[**PRISMA-CI**](http://dev.equator-network.org/reporting-guidelines/prisma-ci-extension-statement-checklist/): Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: [28720516](https://www.ncbi.nlm.nih.gov/pubmed/28720516)\n\n \n\n[**PRISMA-DTA**](http://dev.equator-network.org/reporting-guidelines/prisma-dta/): McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: [29362800](https://www.ncbi.nlm.nih.gov/pubmed/29362800)\n\n \n\n[**PRISMA-ScR**](http://dev.equator-network.org/reporting-guidelines/prisma-scr/): Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: [30178033](https://www.ncbi.nlm.nih.gov/pubmed/30178033)\n\n \n\n[**PRISMA-DTA for Abstracts**](https://dev.equator-network.org/reporting-guidelines/prisma-dta-for-abstracts/): Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: [33722791](https://pubmed.ncbi.nlm.nih.gov/33722791/)\n\n \n\n[**PRISMA-CHM**](https://www.equator-network.org/reporting-guidelines/prisma-chinese-herbal-medicines-2020/): Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: [32907365](https://pubmed.ncbi.nlm.nih.gov/32907365/)\n\n \n\n[**PRISMA-M 2020**](https://www.equator-network.org/reporting-guidelines/prisma-extension-for-moxibustion-2020/): Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: [33100229](https://pubmed.ncbi.nlm.nih.gov/33100229/)\n\n \n\n[**PRISMA-S**](https://dev.equator-network.org/reporting-guidelines/prisma-s/): Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.\n\n Syst Rev. 2021;10(1):39. PMID: [33499930](https://pubmed.ncbi.nlm.nih.gov/33499930/)\n\n J Med Libr Assoc. 2021;109(2):174-200. PMID: [34285662](https://pubmed.ncbi.nlm.nih.gov/34285662/)\n\n \n\n[**PRISMA-COSMIN for OMIs**](https://www.equator-network.org/reporting-guidelines/guideline-for-reporting-systematic-reviews-of-outcome-measurement-instruments-omis-prisma-cosmin-for-omis-2024/): Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.\n\n J Clin Epidemiol. 2024:111422. PMID: [38849061](https://pubmed.ncbi.nlm.nih.gov/38849061/)\n\n Qual Life Res. 2024. PMID: [38980635](https://pubmed.ncbi.nlm.nih.gov/38980635/)\n\n Health Qual Life Outcomes. 2024;22(1):48. PMID: [38978063](https://pubmed.ncbi.nlm.nih.gov/38978063/)\n\n J Patient Rep Outcomes. 2024;8(1):64. PMID: [38977535](https://pubmed.ncbi.nlm.nih.gov/38977535/)\n\n \n\n[**PRISMA-LSR**](https://www.equator-network.org/reporting-guidelines/prisma-lsr/): Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: [39562017](https://pubmed.ncbi.nlm.nih.gov/39562017/)\n\n \n\n""), ('Reporting guideline website URL', '<http://www.prisma-statement.org/Extensions/Acupuncture>'), ('Reporting guideline acronym', 'PRISMA-A'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', '[Read additional information (PDF)](/wp-content/uploads/2018/05/Appendix-1-Contributor-information-PRISMA-for-acupuncture.pdf) about PRISMA for Acupuncture development group participants.\n\n \n\n'), ('Record last updated on', 'February 6, 2025')]"
18127,Consolidated criteria for strengthening reporting of health research involving indigenous peoples: the CONSIDER statement,"Diagnostic and prognostic studies, Experimental studies, Mixed methods studies, Observational studies, Qualitative research, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,"Data, Ethical issues (consent etc.), Funding, Harms/adverse effects/safety data, Narrative sections (discussion etc.), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)", ,"Aboriginal, Aboriginal and Torres Strait Islanders, checklist, checklists, CONSIDER, CONSIDER statement, First Nations, First Nations Peoples, indigenous, indigenous health, Indigenous health outcomes, indigenous health research, indigenous people, indigenous peoples, M?ori, M\xe9tis, Native Hawaiian, Sami, Taiwan Indigenous Tribes", ,"Huria T, Palmer SC, Pitama S, Beckert L, Lacey C, Ewen S, Smith LT. Consolidated criteria for strengthening reporting of health research involving indigenous peoples: the CONSIDER statement. BMC Med Res Methodol. 2019;19(1):173.","Huria T, Palmer SC, Pitama S, Beckert L, Lacey C, Ewen S, Smith LT.",BMC Medical Research Methodology [BMC Med Res Methodol.],2019,19,1,173, ,English, ,31399058,https://www.ncbi.nlm.nih.gov/pubmed/31399058,"The full-text of this reporting guideline is available at:
https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-019-0815-8", , , , ,CONSIDER,Reporting of health research involving Indigenous peoples., , , , , , , ,no,2019-08-20 14:11:25,2021-11-19 15:12:50,consolidated-criteria-for-strengthening-reporting-of-health-research-involving-indigenous-peoples-the-consider-statement,"[('title', 'Consolidated criteria for strengthening reporting of health research involving indigenous peoples: the CONSIDER statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of health research involving Indigenous peoples.'), ('Full bibliographic reference', 'Huria T, Palmer SC, Pitama S, Beckert L, Lacey C, Ewen S, Smith LT. Consolidated criteria for strengthening reporting of health research involving indigenous peoples: the CONSIDER statement. BMC Med Res Methodol. 2019;19(1):173.'), ('Language', 'English'), ('PubMed ID', '[31399058](https://www.ncbi.nlm.nih.gov/pubmed/31399058)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is available at:\n\n<https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-019-0815-8>'), ('Reporting guideline acronym', 'CONSIDER'), ('Study design', 'Diagnostic and prognostic studies, Experimental studies, Mixed methods studies, Observational studies, Qualitative research, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Data, Ethical issues (consent etc.), Funding, Harms/adverse effects/safety data, Narrative sections (discussion etc.), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'November 19, 2021')]"
18115,Checklist for the preparation and review of pain clinical trial publications: a pain-specific supplement to CONSORT,"Clinical trials, Experimental studies", ,"Intervention (exposure), Narrative sections (discussion etc.), Outcomes (variables), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)", ,"analgesic, analgesic RCT, analgesic RCTs, analgesics, checklist, checklists, clinical trial, clinical trials, CONSORT extension, pain, pain clinical trial, pain clinical trials, pain treatment, pain treatments, pain trial, pain trials, randomised clinical trial, randomised clinical trials, randomised trial, randomised trials, randomized clinical trial, randomized clinical trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Gewandter JS, Eisenach JC, Gross RA, Jensen MP, Keefe FJ, Lee DA, Turk DC. Checklist for the preparation and review of pain clinical trial publications: a pain-specific supplement to CONSORT. Pain Rep. 2019;4(3):e621.","Gewandter JS, Eisenach JC, Gross RA, Jensen MP, Keefe FJ, Lee DA, Turk\xa0DC.",Pain Reports [Pain Rep],2019,4,3,e621, ,English, ,28989992,https://www.ncbi.nlm.nih.gov/pubmed/28989992, , , , , , ,Reporting details specific to pain clinical trials., , , , , , , ,no,2019-08-02 15:48:39,2019-11-21 15:33:56,checklist-for-the-preparation-and-review-of-pain-clinical-trial-publications-a-pain-specific-supplement-to-consort-2,"[('title', 'Checklist for the preparation and review of pain clinical trial publications: a pain-specific supplement to CONSORT'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting details specific to pain clinical trials.'), ('Full bibliographic reference', 'Gewandter JS, Eisenach JC, Gross RA, Jensen MP, Keefe FJ, Lee DA, Turk DC. Checklist for the preparation and review of pain clinical trial publications: a pain-specific supplement to CONSORT. Pain Rep. 2019;4(3):e621.'), ('Language', 'English'), ('PubMed ID', '[28989992](https://www.ncbi.nlm.nih.gov/pubmed/28989992)'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Narrative sections (discussion etc.), Outcomes (variables), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'November 21, 2019')]"
18113,Reporting guidelines on remotely collected electronic mood data in mood disorder (eMOOD)-recommendations, ,Psychiatry,"Data, Statistical methods and analyses, Study characteristics (participants etc.)", ,"bipolar disorder, checklist, checklists, data, digital electronic monitoring, electronic mood data, electronic mood monitoring research, eMOOD, mood, mood data, mood deviations, mood disorder, mood disorders, mood episode, mood instability, psychiatric, psychiatrist, psychiatry, remote monitoring, remotely collected electronic mood data, self-monitoring, unipolar disorder", ,"Faurholt-Jepsen M, Geddes JR, Goodwin GM, Bauer M, Duffy A, Vedel Kessing L, Saunders K. Reporting guidelines on remotely collected electronic mood data in mood disorder (eMOOD) - recommendations. Transl Psychiatry. 2019;9(1):162.","Faurholt-Jepsen M, Geddes JR, Goodwin GM, Bauer M, Duffy A, Vedel Kessing L, Saunders K.",Translational Psychiatry [Transl Psychiatry],2019,9,1,162, ,English, ,31175283,https://www.ncbi.nlm.nih.gov/pubmed/31175283,The full-text of this reporting guideline is freely available at: https://www.nature.com/articles/s41398-019-0484-8, , , , ,eMOOD,Reporting of remotely collected electronic mood data., , , , , , , ,no,2019-08-02 15:25:28,2021-11-19 15:13:42,reporting-guidelines-on-remotely-collected-electronic-mood-data-in-mood-disorder-emood-recommendations,"[('title', 'Reporting guidelines on remotely collected electronic mood data in mood disorder (e MOOD)-recommendations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of remotely collected electronic mood data.'), ('Full bibliographic reference', 'Faurholt-Jepsen M, Geddes JR, Goodwin GM, Bauer M, Duffy A, Vedel Kessing L, Saunders K. Reporting guidelines on remotely collected electronic mood data in mood disorder (eMOOD) - recommendations. Transl Psychiatry. 2019;9(1):162.'), ('Language', 'English'), ('PubMed ID', '[31175283](https://www.ncbi.nlm.nih.gov/pubmed/31175283)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available at: <https://www.nature.com/articles/s41398-019-0484-8>'), ('Reporting guideline acronym', 'eMOOD'), ('Clinical area', 'Psychiatry'), ('Applies to the whole report or to individual sections of the report?', 'Data, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'November 19, 2021')]"
18111,CONSORT 2010 statement: extension to randomised crossover trials,"Clinical trials, Experimental studies", , , ,"2\xd72, AB/BA, checklist, checklists, Consolidated Standards of Reporting Trials, CONSORT, CONSORT 2010, CONSORT checklist for randomised crossover RCTs, CONSORT checklist for randomized crossover RCTs, CONSORT extension, CONSORT statement, crossover, crossover design, crossover RCT, crossover RCTs, crossover trial, crossover trials, randomised, randomised crossover trial, randomised crossover trials, randomized, randomized crossover trial, randomized crossover trials, trial, trials", ,"Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378.","Dwan K, Li T, Altman DG, Elbourne D.",BMJ.,2019,366, , , ,English, ,31366597,https://www.ncbi.nlm.nih.gov/pubmed/31366597,The full-text of this CONSORT 2010 extension for randomised crossover trials is available at: https://www.bmj.com/content/366/bmj.l4378, , ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", , ,Reporting of crossover randomised trials., , , , , , , ,yes,2019-08-02 13:45:32,2025-05-30 09:23:05,consort-2010-statement-extension-to-randomised-crossover-trials,"[('title', 'CONSORT 2010 statement: extension to randomised crossover trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of crossover randomised trials.'), ('Full bibliographic reference', 'Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378.'), ('Language', 'English'), ('PubMed ID', '[31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this CONSORT 2010 extension for randomised crossover trials is available at: <https://www.bmj.com/content/366/bmj.l4378>'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n**[CONSORT 2025 Statement](http://dev.equator-network.org/reporting-guidelines/consort/)**:\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](http://dev.equator-network.org/reporting-guidelines/consort-cluster/):\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](http://dev.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](http://dev.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](http://dev.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Study design', 'Clinical trials, Experimental studies'), ('Record last updated on', 'May 30, 2025')]"
17926,Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement,"Clinical trials, Experimental studies", ,Whole report, ,"3 or more groups, arms, checklist, checklists, CONSORT extension, multi-arm, multi-arm parallel-group randomised trials, multi-arm parallel-group randomized trials, multi-arm studies, multi-arm study, multi-arm trial, multi-arm trials, multiple active interventions, multiple arm, multiple comparisons, multiple treatment, multiple treatment groups, multiplicity, parallel-group, parallel-group design, parallel-group designs, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620.","Juszczak E, Altman DG, Hopewell S, Schulz K.",Journal American Medical Association [JAMA],2019,321,16,1610-1620, ,English, ,31012939,https://www.ncbi.nlm.nih.gov/pubmed/31012939,The full-text of this reporting guideline is freely available from https://jamanetwork.com/journals/jama/fullarticle/2731183, , ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster: Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", , ,Reporting of multi-arm parallel-group randomised trials., , , , , , , ,yes,2019-04-26 09:08:25,2025-05-30 09:22:50,consort-multi-arm-parallel-group-randomized-trials,"[('title', 'Reporting of Multi -Arm Parallel -Group Randomized Trials: Extension of the CONSORT 2010 Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of multi-arm parallel-group randomised trials.'), ('Full bibliographic reference', 'Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620.'), ('Language', 'English'), ('PubMed ID', '[31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available from <https://jamanetwork.com/journals/jama/fullarticle/2731183>'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](http://dev.equator-network.org/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](http://dev.equator-network.org/reporting-guidelines/consort-cluster/): Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](http://dev.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](http://dev.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](http://dev.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 30, 2025')]"
17898,Microbiology Investigation Criteria for Reporting Objectively (MICRO): a framework for the reporting and interpretation of clinical microbiology data,"Clinical trials, Experimental studies, Observational studies",Infectious diseases,"Data, Narrative sections (discussion etc.), Procedure/Method, Results", ,"AMR, AMR dataset, AMR datasets, antimicrobial, antimicrobial resistance, antimicrobial susceptibility, antimicrobial susceptibility testing, antimicrobials, AST, checklist, checklists, clinical antimicrobial resistance, clinical antimicrobial resistance data, clinical microbiology, clinical microbiology data, clinical microbiology dataset, clinical microbiology datasets, clinical sampling, data, dataset, datasets, drug resistance, human clinical microbiology data, infection, infections, infectious disease, infectious diseases, laboratories, laboratory, laboratory practice, MICRO, MICRO checklist, microbiologist, microbiologists, microbiology, Microbiology Investigation, Microbiology Investigation Criteria, Microbiology Investigation Criteria for Reporting Objectively, microbiology laboratory results, microbiology results, resistance, surveillance, surveillance data", ,"Turner P, Fox-Lewis A, Shrestha P, Dance DAB, Wangrangsimakul T, Cusack TP, Ling CL, Hopkins J, Roberts T, Limmathurotsakul D, Cooper BS, Dunachie S, Moore CE, Dolecek C, van Doorn HR, Guerin PJ, Day NPJ, Ashley EA. Microbiology Investigation Criteria for Reporting Objectively (MICRO): a framework for the reporting and interpretation of clinical microbiology data. BMC Med. 2019;17(1):70.

","Turner P, Fox-Lewis A, Shrestha P, Dance DAB, Wangrangsimakul T, Cusack TP, Ling CL, Hopkins J, Roberts T, Limmathurotsakul D, Cooper BS, Dunachie S, Moore CE, Dolecek C, van Doorn HR, Guerin PJ, Day NPJ, Ashley EA.

",BMC Medicine,2019,17,1,70, ,English, ,30922309,https://www.ncbi.nlm.nih.gov/pubmed/30922309,The MICRO reporting framework is freely available to access at: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1301-1, , , , ,MICRO,"Reports of studies involving human clinical microbiology data.



MICRO Checklist (Word) \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 MICRO Checklist (PDF)

", , , , , , , ,no,2019-04-16 11:26:38,2021-11-19 15:32:58,microbiology-investigation-criteria-for-reporting-objectively-micro-a-framework-for-the-reporting-and-interpretation-of-clinical-microbiology-data,"[('title', 'Microbiology Investigation Criteria for Reporting Objectively (MICRO) : a framework for the reporting and interpretation of clinical microbiology data'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reports of studies involving human clinical microbiology data.\n\n \n\n \xa0\n\n \n\n[MICRO Checklist (Word)](https://www.equator-network.org/wp-content/uploads/2019/04/MICRO_checklist_V1.docx)  [MICRO Checklist (PDF)](https://www.equator-network.org/wp-content/uploads/2019/04/MICRO_checklist_V1.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Turner P, Fox-Lewis A, Shrestha P, Dance DAB, Wangrangsimakul T, Cusack TP, Ling CL, Hopkins J, Roberts T, Limmathurotsakul D, Cooper BS, Dunachie S, Moore CE, Dolecek C, van Doorn HR, Guerin PJ, Day NPJ, Ashley EA. Microbiology Investigation Criteria for Reporting Objectively (MICRO): a framework for the reporting and interpretation of clinical microbiology data. BMC Med. 2019;17(1):70.\n\n \n\n'), ('Language', 'English'), ('PubMed ID', '[30922309](https://www.ncbi.nlm.nih.gov/pubmed/30922309)'), ('Relevant URLs\n\n(full-text if available)', 'The MICRO reporting framework is freely available to access at: <https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1301-1>'), ('Reporting guideline acronym', 'MICRO'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Infectious diseases'), ('Applies to the whole report or to individual sections of the report?', 'Data, Narrative sections (discussion etc.), Procedure/Method, Results'), ('Record last updated on', 'November 19, 2021')]"
17788,Core Outcome Set-STAndardised Protocol Items: the COS-STAP Statement,Study protocols, ,Protocol-whole report, ,"checklist, checklists, core outcome, core outcome set, core outcome set protocol, Core Outcome Set-STAndardised Protocol Items, Core Outcome Set-STAndardised Protocol Items Statement, core outcome sets, core outcome sets protocol, core outcomes, COS, COS protocol, COS-STAP, COS-STAP Statement, protocol, protocols", ,"Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Tunis S, Williamson PR; COS-STAP Group. Core Outcome Set-STAndardised Protocol Items: the COS-STAP Statement. Trials. 2019 Feb 11;20(1):116.","Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Tunis S, Williamson PR; COS-STAP Group.",Trials,2019,20,1,116, ,English, ,30744706,https://www.ncbi.nlm.nih.gov/pubmed/30744706,The full-text of this reporting guideline is freely available at:\xa0https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3230-x, , , , ,COS-STAP Statement,Reporting core outcome set (COS) development studies., , , , , , , ,no,2019-03-01 09:27:58,2021-11-19 15:33:51,core-outcome-set-standardised-protocol-items-the-cos-stap-statement,"[('title', 'Core Outcome Set -STAndardised Protocol Items: the COS-STAP Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting core outcome set (COS) development studies.'), ('Full bibliographic reference', 'Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Tunis S, Williamson PR; COS-STAP Group. Core Outcome Set-STAndardised Protocol Items: the COS-STAP Statement. Trials. 2019 Feb 11;20(1):116.'), ('Language', 'English'), ('PubMed ID', '[30744706](https://www.ncbi.nlm.nih.gov/pubmed/30744706)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available at:<https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3230-x>'), ('Reporting guideline acronym', 'COS-STAP Statement'), ('Study design', 'Study protocols'), ('Applies to the whole report or to individual sections of the report?', 'Protocol-whole report'), ('Record last updated on', 'November 19, 2021')]"
17786,"The Reporting on ERAS Compliance, Outcomes, and Elements Research (RECOvER) Checklist: A Joint Statement by the ERAS\xae and ERAS\xae USA Societies", ,Surgery,Whole report, ,"checklist, checklists, enhanced recovery, enhanced recovery after surgery, enhanced recovery research, ERAS, ERAS compliance, ERAS elements, ERAS outcomes, ERAS pathway, ERAS pathways, ERAS program, ERAS programme, ERAS programmes, ERAS programs, RECOvER Checklist, RECOvER Checklist for reporting of enhanced recovery research, Reporting on ERAS Compliance Outcomes and Elements Research (RECOvER) Checklist, surgery, surgical", ,"Elias KM, Stone AB, McGinigle K, Tankou JI, Scott MJ, Fawcett WJ, Demartines N, Lobo DN, Ljungqvist O, Urman RD; ERAS\xae Society and ERAS\xae USA. The Reporting on ERAS Compliance, Outcomes, and Elements Research (RECOvER) Checklist: A Joint Statement by the ERAS\xae and ERAS\xae USA Societies. World J Surg. 2019 Jan;43(1):1-8.","Elias KM, Stone AB, McGinigle K, Tankou JI, Scott MJ, Fawcett WJ, Demartines N, Lobo DN, Ljungqvist O, Urman RD; ERAS\xae Society and ERAS\xae USA.",World Journal of Surgery. [World J Surg.],2019,43,1,1-8, ,English, ,30116862,https://www.ncbi.nlm.nih.gov/pubmed/30116862,The full-text of this reporting guideline is available at:\xa0https://link.springer.com/article/10.1007/s00268-018-4753-0, , , , ,RECOvER Checklist,Reporting of enhanced recovery after surgery (ERAS) related studies., , , , , , , ,no,2019-02-28 15:34:33,2021-11-19 15:47:04,the-reporting-on-eras-compliance-outcomes-and-elements-research-recover-checklist-a-joint-statement-by-the-eras-and-eras-usa-societies,"[('title', 'The Reporting on ERAS Compliance, Outcomes, and Elements Research (RECOvER) Checklist: A Joint Statement by the ERAS ® and ERAS ® USA Societies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of enhanced recovery after surgery (ERAS) related studies.'), ('Full bibliographic reference', 'Elias KM, Stone AB, McGinigle K, Tankou JI, Scott MJ, Fawcett WJ, Demartines N, Lobo DN, Ljungqvist O, Urman RD; ERAS® Society and ERAS® USA. The Reporting on ERAS Compliance, Outcomes, and Elements Research (RECOvER) Checklist: A Joint Statement by the ERAS® and ERAS® USA Societies. World J Surg. 2019 Jan;43(1):1-8.'), ('Language', 'English'), ('PubMed ID', '[30116862](https://www.ncbi.nlm.nih.gov/pubmed/30116862)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is available at:<https://link.springer.com/article/10.1007/s00268-018-4753-0>'), ('Reporting guideline acronym', 'RECOvER Checklist'), ('Clinical area', 'Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 19, 2021')]"
17648,Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration,"Clinical trials, Experimental studies", ,Whole report, ,"clinical trial, clinical trials, cluster, clusters, CONSORT extension, CONSORT statement for SW-CRTs, CONSORT SW-CRT, randomised trial, randomised trials, randomized trial, randomized trials, RCT, RCTs, stepped wedge, stepped wedge cluster, stepped wedge cluster randomised trial, stepped wedge cluster randomised trials, stepped wedge cluster randomized trial, stepped wedge cluster randomized trials, SW-CRT, trial, trials", ,"Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM.\xa0Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration.\xa0BMJ. 2018;363:k1614.","Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM.",British Medical Journal [BMJ],2018,363, ,k1614, ,English, ,30413417,https://www.ncbi.nlm.nih.gov/pubmed/30413417,"The full-text of this reporting guideline is freely available to access at:\xa0https://www.bmj.com/content/363/bmj.k1614.long

", , ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster: Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal: Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,SW-CRT,Reporting of stepped wedge cluster randomised trials., ,"Read the protocol (PDF) for the development of this reporting guideline.

Read the interim guidelines published in 2015:
Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. BMJ. 2015;350:h391. PMID: 25662947

","Read a commentary introducing this reporting guideline:
Hemming K, Taljaard M, Grimshaw J. Introducing the new CONSORT extension for stepped-wedge cluster randomised trials. Trials. 2019;20:68.
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-3116-3

", , , , ,yes,2019-01-24 14:48:42,2025-05-30 09:22:35,reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration,"[('title', 'Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of stepped wedge cluster randomised trials.'), ('Full bibliographic reference', 'Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM.\xa0Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration.\xa0BMJ. 2018;363:k1614.'), ('Language', 'English'), ('PubMed ID', '[30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available to access at:<https://www.bmj.com/content/363/bmj.k1614.long>\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](http://dev.equator-network.org/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](http://dev.equator-network.org/reporting-guidelines/consort-cluster/): Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/): Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](http://dev.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](http://dev.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](http://dev.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text.](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration)\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'SW-CRT'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', '[Read the protocol (PDF)](/wp-content/uploads/2009/02/Consort-SW-Protocol-V1.pdf) for the development of this reporting guideline.\n\n \n\n Read the interim guidelines published in 2015:\n\n Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. BMJ. 2015;350:h391. PMID: [25662947](http://www.ncbi.nlm.nih.gov/pubmed/25662947)\n\n \n\n'), ('Selected relevant editorials', 'Read a commentary introducing this reporting guideline:\n\n Hemming K, Taljaard M, Grimshaw J. Introducing the new CONSORT extension for stepped-wedge cluster randomised trials. Trials. 2019;20:68.\n\n<https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-3116-3>\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
17574,Improving reporting of Meta-Ethnography: The eMERGe Reporting Guidance,Qualitative research, ,Whole report, ,"EMERGE, ethnographies, ethnography, meta, meta ethnographies, meta-ethnography, qualitative evidence synthesis, systematic analytic synthesis, theories, theory, theory-based", ,"France EF,\xa0 Cunningham M,\xa0 Ring N, Uny I,\xa0 Duncan EAS, Jepson RG, Maxwell M, Roberts RJ, Turley RL, Booth A, Britten N, Flemming K, Gallagher I, Garside R, Hannes K, Lewin S, Noblit GW, Pope C, Thomas J, Vanstone M, Higginbottom GMA, Noyes J. Improving reporting of Meta-Ethnography: The eMERGe Reporting Guidance.

This guideline was published simultaneously in 4 journals. You can read the guideline in any of these journals using the links below.

BMC Med Res Methodol. 2019;19(1):25. PMID: 30709371
J Adv Nurs. 2019.\xa0PMID: 30644123
Psychooncology. 2019. PMID: 30644150
Review of Education, 2019.\xa0doi.org/10.1002/rev3.3147

","France EF,\xa0 Cunningham M,\xa0 Ring N, Uny I,\xa0 Duncan EAS, Jepson RG, Maxwell M, Roberts RJ, Turley RL, Booth A, Britten N, Flemming K, Gallagher I, Garside R, Hannes K, Lewin S, Noblit GW, Pope C, Thomas J, Vanstone M, Higginbottom GMA, Noyes J.", ,2019, , , , ,English, , , , , , , ,http://emergeproject.org/,eMERGe,Reporting of meta-ethnography studies., ,"Read the protocol for the development of this reporting guideline.

Watch three films about this reporting guideline produced by the eMERGe development team:

eMERGe reporting guidance for meta-ethnography ? their format, content and use (YouTube) (N. Ring) (12 minutes 26 seconds)

eMERGe reporting guidance ? the wider context and their possible use (YouTube) (J. Noyes) (8 minutes 45 seconds)

Overview of the eMERGe project and development of the reporting guidance (YouTube) (E. France) (11 minutes 27 seconds)

", , , , , ,no,2019-01-16 09:50:42,2021-11-19 15:58:21,improving-reporting-of-meta-ethnography-the-emerge-reporting-guidance,"[('title', 'Improving reporting of Meta -Ethnography : The e MERGe Reporting Guidance'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of meta-ethnography studies.'), ('Full bibliographic reference', 'France EF,\xa0 Cunningham M,\xa0 Ring N, Uny I,\xa0 Duncan EAS, Jepson RG, Maxwell M, Roberts RJ, Turley RL, Booth A, Britten N, Flemming K, Gallagher I, Garside R, Hannes K, Lewin S, Noblit GW, Pope C, Thomas J, Vanstone M, Higginbottom GMA, Noyes J. Improving reporting of Meta-Ethnography: The eMERGe Reporting Guidance.\n\n \n\n This guideline was published simultaneously in 4 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n BMC Med Res Methodol. 2019;19(1):25. PMID: [30709371](https://www.ncbi.nlm.nih.gov/pubmed/30709371)\n\n J Adv Nurs. 2019.\xa0PMID: [30644123](https://www.ncbi.nlm.nih.gov/pubmed/30644123)\n\n Psychooncology. 2019. PMID: [30644150](https://www.ncbi.nlm.nih.gov/pubmed/30644150)\n\n Review of Education, 2019.[doi.org/10.1002/rev3.3147](https://onlinelibrary.wiley.com/doi/10.1002/rev3.3147)\n\n \n\n'), ('Language', 'English'), ('Reporting guideline website URL', '<http://emergeproject.org/>'), ('Reporting guideline acronym', 'eMERGe'), ('Study design', 'Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Read the [protocol](https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-015-0068-0) for the development of this reporting guideline.\n\n \n\n Watch three films about this reporting guideline produced by the eMERGe development team:\n\n \n\n[eMERGe reporting guidance for meta-ethnography – their format, content and use (YouTube)](https://www.youtube.com/watch?v=SenAIq8ck0s) (N. Ring) (12 minutes 26 seconds)\n\n \n\n[eMERGe reporting guidance – the wider context and their possible use (YouTube)](https://www.youtube.com/watch?v=1CvXm526AbY) (J. Noyes) (8 minutes 45 seconds)\n\n \n\n[Overview of the eMERGe project and development of the reporting guidance (YouTube)](https://www.youtube.com/watch?v=A9HzPnYm0RA) (E. France) (11 minutes 27 seconds)\n\n \n\n'), ('Record last updated on', 'November 19, 2021')]"
17192,The Reporting Items for Patent Landscapes statement,Patent landscapes, ,Whole report, ,"checklist, checklists, innovation, intellectual properties, intellectual property, intellectual property landscape, landscape, landscapes, landscaping, patent, patent landscape, patent landscapes, patent landscaping, patents, Reporting Items for Patent Landscapes, Reporting Items for Patent Landscapes (RIPL) checklist, RIPL, RIPL checklist, technology", ,"Smith JA, Arshad Z, Trippe A, Collins GS, Brindley DA, Carr AJ. The Reporting Items for Patent Landscapes statement. Nat Biotechnol. 2018;36(11):1043-1047.","Smith JA, Arshad Z, Trippe A, Collins GS, Brindley DA, Carr AJ.",Nature Biotechnology [Nat Biotechnol.],2018,36,11,1043-1047, ,English, ,30412195,https://www.ncbi.nlm.nih.gov/pubmed/30412195, , , , , ,RIPL,Reporting of patent landscapes., ,"Read the background paper by the reporting guideline authors assessing the quality of reporting in patent landscapes in the life sciences:

Smith JA, Arshad Z, Thomas H, Carr AJ, Brindley DA. Evidence of insufficient quality of reporting in patent landscapes in the life sciences. Nat Biotechnol. 2017;35(3): 210-214. PMID: 28267720

", , , , , ,no,2018-11-29 14:57:39,2021-11-19 16:00:11,the-reporting-items-for-patent-landscapes-statement,"[('title', 'The Reporting Items for Patent Landscapes statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of patent landscapes.'), ('Full bibliographic reference', 'Smith JA, Arshad Z, Trippe A, Collins GS, Brindley DA, Carr AJ. The Reporting Items for Patent Landscapes statement. Nat Biotechnol. 2018;36(11):1043-1047.'), ('Language', 'English'), ('PubMed ID', '[30412195](https://www.ncbi.nlm.nih.gov/pubmed/30412195)'), ('Reporting guideline acronym', 'RIPL'), ('Study design', 'Patent landscapes'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Read the background paper by the reporting guideline authors assessing the quality of reporting in patent landscapes in the life sciences:\n\n \n\n Smith JA, Arshad Z, Thomas H, Carr AJ, Brindley DA. Evidence of insufficient quality of reporting in patent landscapes in the life sciences. Nat Biotechnol. 2017;35(3): 210-214. PMID: [28267720](https://www.ncbi.nlm.nih.gov/pubmed/28267720)\n\n \n\n'), ('Record last updated on', 'November 19, 2021')]"
17115,Reporting guidelines on how to write a complete and transparent abstract for overviews of systematic reviews of health care interventions,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Abstract, ,"abstract, abstract of overview of systematic reviews, abstracts, abstracts of overview of systematic reviews, checklist, OoSRs, OoSRs abstract, OoSRs abstracts, overview, overview of systematic reviews, overviews, overviews of systematic reviews, Preferred Reporting Items for OoSRs abstracts, PRIO, PRIO for abstracts, PRIO for abstracts checklist, SRs, systematic review, systematic reviews", ,"Bougioukas KI, Bouras E, Apostolidou-Kiouti F, Kokkali S, Arvanitidou M, Haidich AB. Reporting guidelines on how to write a complete and transparent abstract for overviews of systematic reviews of health care interventions. J Clin Epidemiol. 2019;106:70-79.","Bougioukas KI, Bouras E, Apostolidou-Kiouti F, Kokkali S, Arvanitidou M, Haidich AB.",Journal of Clinical Epidemiology [J Clin Epidemiol.],2019,106, ,70-79, ,English, ,30336211,https://www.ncbi.nlm.nih.gov/pubmed/30336211, , , , , ,PRIO for abstracts,Reporting in abstracts of overviews of intervention systematic reviews., , , , , , , ,no,2018-11-15 15:50:26,2019-01-15 09:16:03,reporting-guidelines-on-how-to-write-a-complete-and-transparent-abstract-for-overviews-of-systematic-reviews-of-health-care-interventions,"[('title', 'Reporting guidelines on how to write a complete and transparent abstract for overviews of systematic reviews of health care interventions'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting in abstracts of overviews of intervention systematic reviews.'), ('Full bibliographic reference', 'Bougioukas KI, Bouras E, Apostolidou-Kiouti F, Kokkali S, Arvanitidou M, Haidich AB. Reporting guidelines on how to write a complete and transparent abstract for overviews of systematic reviews of health care interventions. J Clin Epidemiol. 2019;106:70-79.'), ('Language', 'English'), ('PubMed ID', '[30336211](https://www.ncbi.nlm.nih.gov/pubmed/30336211)'), ('Reporting guideline acronym', 'PRIO for abstracts'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Abstract'), ('Record last updated on', 'January 15, 2019')]"
17113,The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE),Observational studies,Pharmaceutical medicine,Whole report, ,"checklist, EHR, electronic health record, electronic health record data repositories, electronic health record data repository, health data, observational, observational data, observational data quality, observational routinely collected data, observational routinely collected health data, pharmacoeconomics, pharmacoepidemiological, pharmacoepidemiological research, pharmacoepidemiological studies, pharmacoepidemiological study, pharmacoepidemiology, pharmacology, RECORD extension, RECORD extensions, RECORD for pharmacoepidemiology, RECORD for pharmacoepidemiology checklist, RECORD-PE, RECORD-PE checklist, RECORD-PE Statement, routine, routinely, routinely collected, routinely collected data, routinely collected health data, STROBE extension", ,"Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.","Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI.",British Medical Journal [BMJ],2018,363, ,k3532, ,English, ,30429167,https://pubmed.ncbi.nlm.nih.gov/30429167/,The full-text of the RECORD-PE statement is freely available at:\xa0https://www.bmj.com/content/363/bmj.k3532.full, , ,"Generic
RECORD: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: 26440803

",http://www.record-statement.org/checklist-pe.php,RECORD-PE,Reporting of pharmacoepidemiological research undertaken using routinely collected data.,"RECORD-PE is available in:

French (PDF)
Japanese (PDF)
Simplified Chinese: Part 1 (PDF)\xa0 |\xa0 Part 2 (PDF)

", , , , , , ,yes,2018-11-15 15:03:41,2023-01-25 16:58:45,record-pe,"[('title', 'The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of pharmacoepidemiological research undertaken using routinely collected data.'), ('Full bibliographic reference', 'Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.'), ('Language', 'English'), ('PubMed ID', '[30429167](https://pubmed.ncbi.nlm.nih.gov/30429167/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the RECORD-PE statement is freely available at:<https://www.bmj.com/content/363/bmj.k3532.full>'), ('Availability in additional languages', 'RECORD-PE is available in:\n\n \n\n[French (PDF)](https://docs.google.com/viewer?url=http://www.record-statement.org/Files/pubs/2019%20-%20CMAJ%20-%20RECORD-PE%20French%20Translation.pdf)\n\n[Japanese (PDF)](https://docs.google.com/viewer?url=http://www.record-statement.org/Files/pubs/2019%20-%20%20Japanese%20Journal%20of%20Quality%20and%20Safety%20in%20Healthcare%20-%20RECORD-PE%20Translation.pdf)\n\n Simplified Chinese: [Part 1 (PDF)](https://docs.google.com/viewer?url=http://www.record-statement.org/Files/pubs/2019%20-%20%20Chinese%20Journal%20of%20Pharmacoepidemiology%20-%20RECORD-PE%20Translation%20-%201.pdf)| [Part 2 (PDF)](https://docs.google.com/viewer?url=http://www.record-statement.org/Files/pubs/2019%20-%20%20Chinese%20Journal%20of%20Pharmacoepidemiology%20-%20RECORD-PE%20Translation%20-%202.pdf)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**RECORD**](/reporting-guidelines/record/): Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: [26440803](http://www.ncbi.nlm.nih.gov/pubmed/26440803)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.record-statement.org/checklist-pe.php>'), ('Reporting guideline acronym', 'RECORD-PE'), ('Study design', 'Observational studies'), ('Clinical area', 'Pharmaceutical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 25, 2023')]"
16675,PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Whole report, ,"checklist, checklists, evidence map, evidence maps, Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews, PRISMA extension, PRISMA extension for Scoping Reviews, PRISMA Scoping, PRISMA Scoping Reviews, PRISMA-ScR, review, reviews, scope, scoping, scoping review, scoping reviews, systematic review, systematic reviews", ,"Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018.","Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE.",Annals of Internal Medicine [Ann Intern Med.],2018, , , , ,English, ,30178033,https://www.ncbi.nlm.nih.gov/pubmed/30178033,"The full-text of PRISMA-ScR is freely available from:
https://www.acpjournals.org/doi/full/10.7326/M18-0850

", , ,"Generic
PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

Specialised
PRISMA-Equity: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: 23222917

Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.
Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

PRISMA-Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.

PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246

PRISMA-IPD: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: 25919529

PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634

PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668

PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement &amp; Checklist. J Clin Epidemiol. 2017. PMID: 28720516

PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: 29362800

PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367

PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791

PRISMA-CHM: Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: 32907365

PRISMA-M 2020: Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: 33100229

PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.
Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535

PRISMA-LSR: Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: 39562017

",https://www.prisma-statement.org/scoping,PRISMA-ScR,"Reporting of scoping reviews (the extension is also intended to apply to evidence maps).



PRISMA-ScR Checklist\xa0 PDF | Word

","The PRISMA-ScR checklist is available in Japanese (Word).

","An introductory video and a series of tip sheets for reporting each PRISMA-ScR item are available at:
https://knowledgetranslation.net/portfolios/the-prisma-scr-prisma-extension-for-scoping-reviews/

Read the executive summary (PDF) for the development of PRISMA-ScR.

", , , , , ,yes,2018-09-06 09:12:05,2025-02-06 12:06:47,prisma-scr,"[('title', 'PRISMA Extension for Scoping Reviews (PRISMA-ScR) : Checklist and Explanation'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of scoping reviews (the extension is also intended to apply to evidence maps).\n\n \n\n \xa0\n\n \n\nPRISMA-ScR Checklist [PDF](https://www.prisma-statement.org/s/PRISMA-ScR-Fillable-Checklist_11Sept2019.pdf) | [Word](https://www.prisma-statement.org/s/PRISMA-ScR-Fillable-Checklist_10Sept2019.docx)\n\n \n\n'), ('Full bibliographic reference', ""Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018.""), ('Language', 'English'), ('PubMed ID', '[30178033](https://www.ncbi.nlm.nih.gov/pubmed/30178033)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of PRISMA-ScR is freely available from:\n\n<https://www.acpjournals.org/doi/full/10.7326/M18-0850>\n\n \n\n'), ('Availability in additional languages', 'The PRISMA-ScR checklist is available in [Japanese (Word)](https://www.equator-network.org/wp-content/uploads/2021/06/PRISMA-ScR-Checklist-Japanese.docx).\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic\n\n[PRISMA 2020 Statement](http://dev.equator-network.org/reporting-guidelines/prisma/)**: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.\n\n \n\n PLoS Med. 2021;18(3):e1003583. PMID: [33780438](https://pubmed.ncbi.nlm.nih.gov/33780438/)\n\n BMJ 2021;372:n71. PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)\n\n Int J Surg. 2021:105906. PMID: [33789826](https://pubmed.ncbi.nlm.nih.gov/33789826/)\n\n J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: [33789819](https://pubmed.ncbi.nlm.nih.gov/33789819/)\n\n Syst Rev. 2021;10(1):89. PMID: [33781348](https://pubmed.ncbi.nlm.nih.gov/33781348/)\n\n \n\n**Specialised**\n\n**[PRISMA-Equity](http://dev.equator-network.org/reporting-guidelines/prisma-equity/)**: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: [23222917](http://www.ncbi.nlm.nih.gov/pubmed/23222917)\n\n \n\n Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.\n\n Int J Equity Health. 2015;14(1):92. PMID: [26450828](http://www.ncbi.nlm.nih.gov/pubmed/26450828)\n\n J Clin Epidemiol. 2015. PMID: [26348799](http://www.ncbi.nlm.nih.gov/pubmed/26348799)\n\n \n\n[**PRISMA-Abstracts 2020:**](http://dev.equator-network.org/reporting-guidelines/prisma-abstracts/) The PRISMA 2020 for Abstracts reporting guideline is contained within the main [PRISMA 2020 Statement paper](https://www.equator-network.org/reporting-guidelines/prisma/).\n\n \n\n[**PRISMA-P**](http://dev.equator-network.org/reporting-guidelines/prisma-protocols/): Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: [25554246](http://www.ncbi.nlm.nih.gov/pubmed/25554246)\n\n \n\n[**PRISMA-IPD**](http://dev.equator-network.org/reporting-guidelines/prisma-ipd/): Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: [25919529](http://www.ncbi.nlm.nih.gov/pubmed/25919529)\n\n \n\n[**PRISMA extension for network meta-analyses**](http://dev.equator-network.org/reporting-guidelines/prisma-extension-network-meta-analyses/): Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: [26030634](http://www.ncbi.nlm.nih.gov/pubmed/26030634)\n\n \n\n[**PRISMA-harms**](http://dev.equator-network.org/reporting-guidelines/prisma-harms/): Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: [26830668](http://www.ncbi.nlm.nih.gov/pubmed/26830668)\n\n \n\n[**PRISMA-CI**](http://dev.equator-network.org/reporting-guidelines/prisma-ci-extension-statement-checklist/): Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: [28720516](https://www.ncbi.nlm.nih.gov/pubmed/28720516)\n\n \n\n[**PRISMA-DTA**](http://dev.equator-network.org/reporting-guidelines/prisma-dta/): McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: [29362800](https://www.ncbi.nlm.nih.gov/pubmed/29362800)\n\n \n\n[**PRISMA-A**](https://dev.equator-network.org/reporting-guidelines/prisma-acupuncture/): Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: [31405367](https://www.ncbi.nlm.nih.gov/pubmed/31405367)\n\n \n\n[**PRISMA-DTA for Abstracts**](https://dev.equator-network.org/reporting-guidelines/prisma-dta-for-abstracts/): Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: [33722791](https://pubmed.ncbi.nlm.nih.gov/33722791/)\n\n \n\n[**PRISMA-CHM**](https://www.equator-network.org/reporting-guidelines/prisma-chinese-herbal-medicines-2020/): Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: [32907365](https://pubmed.ncbi.nlm.nih.gov/32907365/)\n\n \n\n[**PRISMA-M 2020**](https://www.equator-network.org/reporting-guidelines/prisma-extension-for-moxibustion-2020/): Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: [33100229](https://pubmed.ncbi.nlm.nih.gov/33100229/)\n\n \n\n[**PRISMA-S**](https://dev.equator-network.org/reporting-guidelines/prisma-s/): Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.\n\n Syst Rev. 2021;10(1):39. PMID: [33499930](https://pubmed.ncbi.nlm.nih.gov/33499930/)\n\n J Med Libr Assoc. 2021;109(2):174-200. PMID: [34285662](https://pubmed.ncbi.nlm.nih.gov/34285662/)\n\n \n\n[**PRISMA-COSMIN for OMIs**](https://www.equator-network.org/reporting-guidelines/guideline-for-reporting-systematic-reviews-of-outcome-measurement-instruments-omis-prisma-cosmin-for-omis-2024/): Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.\n\n J Clin Epidemiol. 2024:111422. PMID: [38849061](https://pubmed.ncbi.nlm.nih.gov/38849061/)\n\n Qual Life Res. 2024. PMID: [38980635](https://pubmed.ncbi.nlm.nih.gov/38980635/)\n\n Health Qual Life Outcomes. 2024;22(1):48. PMID: [38978063](https://pubmed.ncbi.nlm.nih.gov/38978063/)\n\n J Patient Rep Outcomes. 2024;8(1):64. PMID: [38977535](https://pubmed.ncbi.nlm.nih.gov/38977535/)\n\n \n\n[**PRISMA-LSR**](https://www.equator-network.org/reporting-guidelines/prisma-lsr/): Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: [39562017](https://pubmed.ncbi.nlm.nih.gov/39562017/)\n\n \n\n""), ('Reporting guideline website URL', '<https://www.prisma-statement.org/scoping>'), ('Reporting guideline acronym', 'PRISMA-ScR'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'An introductory video and a series of tip sheets for reporting each PRISMA-ScR item are available at:\n\n<https://knowledgetranslation.net/portfolios/the-prisma-scr-prisma-extension-for-scoping-reviews/>\n\n \n\n Read the [executive summary (PDF)](/wp-content/uploads/2009/02/Executive-summary_ScR_Dec-9.pdf) for the development of PRISMA-ScR.\n\n \n\n'), ('Record last updated on', 'February 6, 2025')]"
16410,Systems Perspective of Amazon Mechanical Turk for Organizational Research: Review and Recommendations,"Experimental studies, Observational studies",Psychology,"Data, Procedure/Method, Study characteristics (participants etc.)", ,"Amazon Mechanical Turk, behavior, behaviour, mechanical turk, MTurk, MTurk samples, MTurk survey, organisational, organisational behaviour, organisational research, organizational, organizational behavior, organizational research, psychological, psychological research, psychology, research design, sampling", ,"Keith MG, Tay L, Harms PD. Systems Perspective of Amazon Mechanical Turk for Organizational Research: Review and Recommendations. Front Psychol. 2017;8:1359.","Keith MG, Tay L, Harms PD.",Frontiers in Psychology Psychol. [Front Psychol.],2017,8, ,1359, ,English, ,28848474,https://www.ncbi.nlm.nih.gov/pubmed/28848474, , , , , , ,Reporting\xa0MTurk data, , , , , , , ,no,2018-08-14 14:32:21,2018-08-14 14:32:21,systems-perspective-of-amazon-mechanical-turk-for-organizational-research-review-and-recommendations,"[('title', 'Systems Perspective of Amazon Mechanical Turk for Organizational Research: Review and Recommendations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting\xa0MTurk data'), ('Full bibliographic reference', 'Keith MG, Tay L, Harms PD. Systems Perspective of Amazon Mechanical Turk for Organizational Research: Review and Recommendations. Front Psychol. 2017;8:1359.'), ('Language', 'English'), ('PubMed ID', '[28848474](https://www.ncbi.nlm.nih.gov/pubmed/28848474)'), ('Study design', 'Experimental studies, Observational studies'), ('Clinical area', 'Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'August 14, 2018')]"
16408,ESPACOMP Medication Adherence Reporting Guideline (EMERGE),"Clinical trials, Experimental studies, Observational studies", ,Whole report, ,"behavioral science, behavioural science, biostatistics, EMERGE, ESPACOMP, European Society for Patient Adherence COMpliance and Persistence, health economics, medication, medication adherence, Medication Adherence Reporting Guideline, medication compliance, medication non-adherence, medication non-compliance, medication nonadherence, medication noncompliance, medication persistence, medicine, nursing, pharmacometrics, pharmacy, sociology, taxonomy", ,"De Geest S, Zullig LL, Dunbar-Jacob J, Helmy R, Hughes DA, Wilson IB, Vrijens B. ESPACOMP Medication Adherence Reporting Guideline (EMERGE). Ann Intern Med. 2018;169(1):30-35.","De Geest S, Zullig LL, Dunbar-Jacob J, Helmy R, Hughes DA, Wilson IB, Vrijens B.",Annals of Internal Medicine [Ann Intern Med.],2018,169,1,30-35, ,English, ,29946690,https://www.ncbi.nlm.nih.gov/pubmed/29946690, , , , ,http://www.espacomp.eu/emerge,EMERGE,"Reporting of medication adherence research



EMERGE Checklist (Word)

", ,Read the EMERGE Delphi protocol., , , , , ,no,2018-08-14 13:40:18,2021-11-19 16:11:16,espacomp-medication-adherence-reporting-guideline-emerge,"[('title', 'ESPACOMP Medication Adherence Reporting Guideline (EMERGE)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of medication adherence research\n\n \n\n \xa0\n\n \n\n[EMERGE Checklist (Word)](/wp-content/uploads/2018/08/2018-EMERGE-guidelines-Checklist-V1.docx)\n\n \n\n'), ('Full bibliographic reference', 'De Geest S, Zullig LL, Dunbar-Jacob J, Helmy R, Hughes DA, Wilson IB, Vrijens B. ESPACOMP Medication Adherence Reporting Guideline (EMERGE). Ann Intern Med. 2018;169(1):30-35.'), ('Language', 'English'), ('PubMed ID', '[29946690](https://www.ncbi.nlm.nih.gov/pubmed/29946690)'), ('Reporting guideline website URL', '<http://www.espacomp.eu/emerge>'), ('Reporting guideline acronym', 'EMERGE'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Read the [EMERGE Delphi protocol](http://bmjopen.bmj.com/content/7/2/e013496).'), ('Record last updated on', 'November 19, 2021')]"
16147,Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension,"Clinical trials, Experimental studies","Behavioural medicine, Psychology","Abstract, Conference paper/abstract, Conflict of interest, Funding, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)", ,"behavior science, behavioral science, behaviour science, behavioural science, clinical trial, clinical trials, concepts, CONSORT Extension for Abstracts for social and psychological intervention trials, CONSORT Extension for Cluster Randomised Trials for social and psychological intervention trials, CONSORT-SPI, CONSORT-SPI 2018, implementation, intervention, interventions, psychological, psychological intervention, psychological interventions, psychology, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, social, social and psychological intervention, social and psychological interventions, social intervention, social interventions, social science, taxonomies, theories, trial, trials", ,"Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407.","Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group.",Trials.,2018,19, ,407, ,English, ,30060754,https://www.ncbi.nlm.nih.gov/pubmed/30060754,"The full-text of the CONSORT-SPI reporting guideline can be accessed at: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-2733-1

The CONSORT-SPI group have also developed checklist extensions for:

Abstracts

CONSORT-SPI 2018 abstract checklist (Word)
CONSORT-SPI 2018 abstract checklist (PDF)

Cluster trials

CONSORT-SPI 2018 checklist for cluster trials (Word)
CONSORT-SPI 2018 checklist for cluster trials (PDF)

Cluster trial abstracts

CONSORT-SPI 2018 checklist for cluster trial abstracts (Word)
CONSORT-SPI 2018 checklist for cluster trial abstracts (PDF)

","Grant S, Mayo-Wilson E, Montgomery P, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. CONSORT-SPI 2018 Explanation and Elaboration: guidance for reporting social and psychological intervention trials. Trials. 2018;19(1):406.\xa0PMID: 30060763

Full-text access at: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-2735-z

", ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

",https://www.spi.ox.ac.uk/research/site/consort-spi/outputs.html,CONSORT-SPI 2018,"Reporting randomised controlled trials (RCTs) of social and psychological interventions.



CONSORT-SPI 2018 checklist (Word) \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 CONSORT-SPI 2018 checklist (PDF)

", ,"This reporting guideline also includes a CONSORT extension for abstracts for social and psychological intervention trials (table 3) and a CONSORT extension for cluster randomised trials for social and psychological intervention trials (tables 4 and 5).

Read the protocol for the development of the reporting guideline:
Montgomery P, Grant S, Hopewell S, Macdonald G, Moher D, Michie S, Mayo-Wilson E. Protocol for CONSORT-SPI: an extension for social and psychological interventions. Implement Sci. 2013;8:99. PMID: 24004579

","Read an editorial about CONSORT-SPI:
Grant S; CONSORT-SPI Group. The CONSORT-SPI 2018 extension: a new guideline for reporting social and psychological intervention trials. Addiction. 2018. PMID: 30091280

", , , , ,yes,2018-07-31 13:52:01,2025-05-30 09:22:15,consort-spi,"[('title', 'Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting randomised controlled trials (RCTs) of social and psychological interventions.\n\n \n\n \xa0\n\n \n\n[CONSORT-SPI 2018 checklist (Word)](https://www.equator-network.org/wp-content/uploads/2018/07/CONSORT-SPI-2018-Checklist.docx)  [CONSORT-SPI 2018 checklist (PDF)](https://www.equator-network.org/wp-content/uploads/2018/07/CONSORT-SPI-2018-Checklist.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407.'), ('Language', 'English'), ('PubMed ID', '[30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the CONSORT-SPI reporting guideline can be accessed at: <https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-2733-1>\n\n \n\n The CONSORT-SPI group have also developed checklist extensions for:\n\n \n\n Abstracts\n\n \n\n[CONSORT-SPI 2018 abstract checklist (Word)](https://www.equator-network.org/wp-content/uploads/2018/07/CONSORT-SPI-2018-Abstract-Checklist.docx)\n\n[CONSORT-SPI 2018 abstract checklist (PDF)](https://www.equator-network.org/wp-content/uploads/2018/07/CONSORT-SPI-2018-Abstract-Checklist.pdf)\n\n \n\n Cluster trials\n\n \n\n[CONSORT-SPI 2018 checklist for cluster trials (Word)](https://www.equator-network.org/wp-content/uploads/2018/07/CONSORT-SPI-2018-Checklist-with-Cluster-Extension.docx)\n\n[CONSORT-SPI 2018 checklist for cluster trials (PDF)](https://www.equator-network.org/wp-content/uploads/2018/07/CONSORT-SPI-2018-Checklist-with-Cluster-Extension.pdf)\n\n \n\n Cluster trial abstracts\n\n \n\n[CONSORT-SPI 2018 checklist for cluster trial abstracts (Word)](https://www.equator-network.org/wp-content/uploads/2018/07/CONSORT-SPI-Abstract-for-Clusters-Checklist.docx)\n\n[CONSORT-SPI 2018 checklist for cluster trial abstracts (PDF)](https://www.equator-network.org/wp-content/uploads/2018/07/CONSORT-SPI-Abstract-for-Clusters-Checklist.pdf)\n\n \n\n'), ('Explanation and elaboration papers', 'Grant S, Mayo-Wilson E, Montgomery P, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. CONSORT-SPI 2018 Explanation and Elaboration: guidance for reporting social and psychological intervention trials. Trials. 2018;19(1):406.\xa0PMID: [30060763](https://www.ncbi.nlm.nih.gov/pubmed/30060763)\n\n \n\n Full-text access at: <https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-2735-z>\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](http://dev.equator-network.org/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n**[CONSORT Cluster](http://dev.equator-network.org/reporting-guidelines/consort-cluster/)**:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](http://dev.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](http://dev.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](http://dev.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline website URL', '<https://www.spi.ox.ac.uk/research/site/consort-spi/outputs.html>'), ('Reporting guideline acronym', 'CONSORT-SPI 2018'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Behavioural medicine, Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Abstract, Conference paper/abstract, Conflict of interest, Funding, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Additional information', 'This reporting guideline also includes a CONSORT extension for abstracts for social and psychological intervention trials (table 3) and a CONSORT extension for cluster randomised trials for social and psychological intervention trials (tables 4 and 5).\n\n \n\n Read the protocol for the development of the reporting guideline:\n\n Montgomery P, Grant S, Hopewell S, Macdonald G, Moher D, Michie S, Mayo-Wilson E. Protocol for CONSORT-SPI: an extension for social and psychological interventions. Implement Sci. 2013;8:99. PMID: [24004579](https://www.ncbi.nlm.nih.gov/pubmed/24004579)\n\n \n\n'), ('Selected relevant editorials', 'Read an editorial about CONSORT-SPI:\n\n Grant S; CONSORT-SPI Group. The CONSORT-SPI 2018 extension: a new guideline for reporting social and psychological intervention trials. Addiction. 2018. PMID: [30091280](https://www.ncbi.nlm.nih.gov/pubmed/30091280)\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
15979,Reporting guidelines for implementation research on nurturing care interventions designed to promote early childhood development,"Clinical trials, Experimental studies, Observational studies, Qualitative research","Obstetrics and gynaecology, Paediatrics",Whole report, ,"C.A.R.E., child, child development, childhood, children, clinical trial, clinical trials, cognitive development, consolidated advice on reporting ECD implementation research, early childhood, early childhood development, early childhood education, early childhood intervention, early childhood interventions, early learning, ECD, fidelity, implementation, implementation research, intervention, interventions, nurture, nurturing, nurturing care, nurturing care intervention, nurturing care interventions, observational, observational research, observational studies, observational study, paediatric, paediatrics, pediatric, pediatrics, pregnancy, pregnant, prenatal, qualitative, qualitative research, qualitative research studies, qualitative research study, trial, trials", ,"Yousafzai AK, Aboud FE, Nores M, Kaur R. Reporting guidelines for implementation research on nurturing care interventions designed to promote early childhood development. Ann N Y Acad Sci. 2018 May;1419(1):26-37.","Yousafzai AK, Aboud FE, Nores M, Kaur R.",Annals of the New York Academy of Scences [Ann N Y Acad Sci.],2018,1419,1,26-37, ,English, ,29791737,https://www.ncbi.nlm.nih.gov/pubmed/29791737,"The full-text of this reporting guideline is freely available at: https://nyaspubs.onlinelibrary.wiley.com/doi/full/10.1111/nyas.13648

", , , , ,C.A.R.E.,Reporting in implementation research of nurturing care interventions designed to promote early childhood development (ECD)., , , , , , , ,no,2018-05-31 08:11:56,2021-11-19 16:19:59,reporting-guidelines-for-implementation-research-on-nurturing-care-interventions-designed-to-promote-early-childhood-development,"[('title', 'Reporting guidelines for implementation research on nurturing care interventions designed to promote early childhood development'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting in implementation research of nurturing care interventions designed to promote early childhood development (ECD).'), ('Full bibliographic reference', 'Yousafzai AK, Aboud FE, Nores M, Kaur R. Reporting guidelines for implementation research on nurturing care interventions designed to promote early childhood development. Ann N Y Acad Sci. 2018 May;1419(1):26-37.'), ('Language', 'English'), ('PubMed ID', '[29791737](https://www.ncbi.nlm.nih.gov/pubmed/29791737)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available at: <https://nyaspubs.onlinelibrary.wiley.com/doi/full/10.1111/nyas.13648>\n\n \n\n'), ('Reporting guideline acronym', 'C.A.R.E.'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Qualitative research'), ('Clinical area', 'Obstetrics and gynaecology, Paediatrics'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 19, 2021')]"
15967,Strengthening the reporting of empirical simulation studies: Introducing the STRESS guidelines, , ,Whole report, ,"ABS, agent-based, agent-based simulation, DES, discrete-event, discrete-event simulation, Empirical Simulation Studies, model, modelling, modelling studies, modelling study, modelling technique, modelling techniques, models, ORMS, SD, simulation, simulation model, simulation models, simulation studies, simulation study, simulations, stress, STRESS-ABS, STRESS-DES, STRESS-SD, system dynamics", ,"Monks T, Currie CSM, Onggo BS, Robinson S, Kunc M, Taylor SJE. Strengthening the reporting of empirical simulation studies: Introducing the STRESS guidelines. J Simulation. 2018.","Monks T, Currie CSM, Onggo BS, Robinson S, Kunc M, Taylor SJE.",Journal of Simulation [J Simulation.],2018, , , , ,English, , , ,The full-text of the STRESS guideline is freely available at: https://doi.org/10.1080/17477778.2018.1442155, , , , ,STRESS,"Reporting of discrete-event simulation, system dynamics and agent-based simulation models within the field of Operational Research and Management Science.", ,"Three 20-item reporting checklists have been developed to stengthen the reporting of empirical simulation studies:

Discrete-event simulation guidelines STRESS-DES (Word)

Agent-based simulation guidelines STRESS-ABS (Word)

System dynamics guidelines STRESS-SD (Word)

", , , , , ,no,2018-05-23 13:48:26,2021-11-19 16:22:34,strengthening-the-reporting-of-empirical-simulation-studies-introducing-the-stress-guidelines,"[('title', 'Strengthening the reporting of empirical simulation studies: Introducing the STRESS guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of discrete-event simulation, system dynamics and agent-based simulation models within the field of Operational Research and Management Science.'), ('Full bibliographic reference', 'Monks T, Currie CSM, Onggo BS, Robinson S, Kunc M, Taylor SJE. Strengthening the reporting of empirical simulation studies: Introducing the STRESS guidelines. J Simulation. 2018.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the STRESS guideline is freely available at: <https://doi.org/10.1080/17477778.2018.1442155>'), ('Reporting guideline acronym', 'STRESS'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Three 20-item reporting checklists have been developed to stengthen the reporting of empirical simulation studies:\n\n \n\n Discrete-event simulation guidelines [STRESS-DES (Word)](https://www.tandfonline.com/doi/suppl/10.1080/17477778.2018.1442155/suppl_file/tjsm_a_1442155_sm3123.docx)\n\n \n\n Agent-based simulation guidelines [STRESS-ABS (Word)](https://www.tandfonline.com/doi/suppl/10.1080/17477778.2018.1442155/suppl_file/tjsm_a_1442155_sm3069.docx)\n\n \n\n System dynamics guidelines [STRESS-SD (Word)](https://www.tandfonline.com/doi/suppl/10.1080/17477778.2018.1442155/suppl_file/tjsm_a_1442155_sm3083.docx)\n\n \n\n'), ('Record last updated on', 'November 19, 2021')]"
15961,TIDieR-PHP: a reporting guideline for population health and policy interventions,"Clinical trials, Experimental studies, Observational studies, Study protocols, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,Intervention (exposure), ,"clinical trial, clinical trials, environmental interventions, environmental policy interventions, evaluation studies, evaluation study, fiscal interventions, health inequalities, health inequality, health systems policy interventions, intervention, interventions, legal interventions, legislation, observational studies, observational study, organisational interventions, PHP, PHP intervention, PHP interventions, policy intervention, policy interventions, population, population health, population health and policy, populations, protocol, protocols, social policy interventions, structural interventions, systematic review, systematic reviews, TIDieR, TIDieR-PHP, trial, trials", ,"Campbell M, Katikireddi SV, Hoffmann T, Armstrong R, Waters E, Craig P. TIDieR-PHP: a reporting guideline for population health and policy interventions. BMJ. 2018;361:k1079.","Campbell M, Katikireddi SV, Hoffmann T, Armstrong R, Waters E, Craig P.",BMJ.,2018,16,361,k1079, ,English, ,29769210,https://www.ncbi.nlm.nih.gov/pubmed/29769210,"The full-text of the TIDieR-PHP guideline is freely available at: http://dx.doi.org/10.1136/bmj.k1079

", , ,"Generic
TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605", ,TIDieR-PHP,"Reporting public health, health systems, and social and environmental policy interventions.



TIDieR-PHP checklist (PDF)

", , , , , , , ,no,2018-05-23 10:27:56,2021-11-19 16:27:28,tidier-php-a-reporting-guideline-for-population-health-and-policy-interventions,"[('title', 'TIDieR-PHP : a reporting guideline for population health and policy interventions'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting public health, health systems, and social and environmental policy interventions.\n\n \n\n \xa0\n\n \n\n[TIDieR-PHP checklist (PDF)](/wp-content/uploads/2018/05/TIDieR-PHP-checklist.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Campbell M, Katikireddi SV, Hoffmann T, Armstrong R, Waters E, Craig P. TIDieR-PHP: a reporting guideline for population health and policy interventions. BMJ. 2018;361:k1079.'), ('Language', 'English'), ('PubMed ID', '[29769210](https://www.ncbi.nlm.nih.gov/pubmed/29769210)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the TIDieR-PHP guideline is freely available at: [http://dx.doi.org/10.1136/bmj.k1079](https://dx.doi.org/10.1136/bmj.k1079)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**TIDieR**](/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)'), ('Reporting guideline acronym', 'TIDieR-PHP'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Study protocols, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'November 19, 2021')]"
15781,Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension,"Clinical trials, Experimental studies, Study protocols", ,Outcomes (variables), ,"checklist, checklists, clinical trial protocol, clinical trial protocols, health-related quality of life, outcome, outcomes, patient, patient-reported outcome, patient-reported outcomes, patients, PRO, PROs, protocol, protocols, quality of life, SPIRIT, SPIRIT 2013, SPIRIT Extension, SPIRIT-PRO, SPIRIT-PRO Extension, study protocol, trial, trial protocol, trial protocols, trials", ,"Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494.","Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group.",Journal of the American Medical Association [JAMA],2018,319,5,483-494., ,English, ,29411037,https://www.ncbi.nlm.nih.gov/pubmed/29411037,The the full-text of this reporting guideline is available at: https://jamanetwork.com/journals/jama/article-abstract/2671472,"Calvert M, King M, Mercieca-Bebber R, et al. SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. BMJ Open. 2021;11:e045105. doi: 10.1136/bmjopen-2020-045105", ,"Generic

SPIRIT 2025 Statement: Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hr\xf3bjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.

BMJ. 2025; 388:e081660. PMID:\xa040294956
JAMA. 2025.\xa0PMID: 40294593
Lancet 2025.
Nat Med. 2025.\xa0PMID: 40295741
PLoS Med. 2025; 22(4): e1004587.\xa0PMID: 40294521

Specialised
SPIRIT-TCM: Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: 30484022

SPENT 2019: Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. Link to full-text.

SPIRIT-AI: Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.
BMJ. 2020;370:m3210. PMID: 32907797
Nat Med. 2020;26(9):1351?1363. PMID: 32908284
Lancet Digital Health. 2020;2(10):e549-e560. PMID: 33328049

SPIRIT-Path: Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: 34592193

SPIRIT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: 36512367

SPIRIT-DEFINE: Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: 37863491

SPIRIT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: 38051535

SPIRIT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: 38981624

SPIRIT-iNeurostim: Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: 39610902

", ,SPIRIT-PRO,Reporting in clinical trial protocols in which patient-reported outcomes (PROs) are a primary or key secondary outcome.,The SPIRIT-PRO Extension is available in Japanese (PDF)., , , , ,"Cruz Rivera S, Stephens R, Mercieca-Bebber R, Retzer A, Rutherford C, Price G, Slade A, Aiyegbusi OL, Edge P, Roberts L, Gosden L, Verdi R, Wilson R, Calvert M. 'Give Us The Tools!': development of knowledge transfer tools to support the involvement of patient partners in the development of clinical trial protocols with patient-reported outcomes (PROs), in accordance with SPIRIT-PRO Extension. BMJ Open. 2021;11(6):e046450. PMID: 34193492", ,yes,2018-02-07 15:07:57,2025-05-30 09:12:48,spirit-pro,"[('title', 'Guidelines for Inclusion of Patient -Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting in clinical trial protocols in which patient-reported outcomes (PROs) are a primary or key secondary outcome.'), ('Full bibliographic reference', 'Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494.'), ('Language', 'English'), ('PubMed ID', '[29411037](https://www.ncbi.nlm.nih.gov/pubmed/29411037)'), ('Relevant URLs\n\n(full-text if available)', 'The the full-text of this reporting guideline is available at: <https://jamanetwork.com/journals/jama/article-abstract/2671472>'), ('Explanation and elaboration papers', 'Calvert M, King M, Mercieca-Bebber R, et al. SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. BMJ Open. 2021;11:e045105. doi: [10.1136/bmjopen-2020-045105](https://bmjopen.bmj.com/content/11/6/e045105)'), ('Availability in additional languages', 'The SPIRIT-PRO Extension is available in [Japanese (PDF)](https://www.lifescience.co.jp/pro/pro_pdf/PDF7.pdf).'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n \n\n**[SPIRIT 2025 Statement](https://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/):** Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hróbjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.\n\n \n\nBMJ. 2025; 388:e081660. [PMID:40294956](https://pubmed.ncbi.nlm.nih.gov/40294956/)\n\n JAMA. 2025.[PMID:](https://pubmed.ncbi.nlm.nih.gov/40294593/) [40294593](https://pubmed.ncbi.nlm.nih.gov/40294593/)\n\n Lancet 2025.\n\n Nat Med. 2025.[PMID: 40295741](https://pubmed.ncbi.nlm.nih.gov/40295741)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID: 40294521](https://pubmed.ncbi.nlm.nih.gov/40294521/)\n\n \n\n**Specialised\n\n[SPIRIT-TCM](https://www.equator-network.org/reporting-guidelines/standard-protocol-items-for-clinical-trials-with-traditional-chinese-medicine-spirit-tcm-extension-2018/)**: Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: [30484022](https://www.ncbi.nlm.nih.gov/pubmed/30484022)\n\n \n\n[**SPENT 2019**](https://www.equator-network.org/reporting-guidelines/spirit-extension-n-of-1-trials-spent-2019/): Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. [Link to full-text](https://www.bmj.com/content/368/bmj.m122).\n\n \n\n[**SPIRIT-AI**](https://www.equator-network.org/reporting-guidelines/spirit-artificial-intelligence/): Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.\n\n BMJ. 2020;370:m3210. PMID: [32907797](https://pubmed.ncbi.nlm.nih.gov/32907797/)\n\n Nat Med. 2020;26(9):1351–1363. PMID: [32908284](https://pubmed.ncbi.nlm.nih.gov/32908284/)\n\n Lancet Digital Health. 2020;2(10):e549-e560. PMID: [33328049](https://pubmed.ncbi.nlm.nih.gov/33328049/)\n\n \n\n[**SPIRIT-Path**](https://www.equator-network.org/reporting-guidelines/spirit-path/): Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: [34592193](https://pubmed.ncbi.nlm.nih.gov/34592193/)\n\n \n\n[**SPIRIT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-protocols-the-spirit-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: [36512367](https://pubmed.ncbi.nlm.nih.gov/36512367/)\n\n \n\n[**SPIRIT-DEFINE**](https://www.equator-network.org/reporting-guidelines/spirit-define/): Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: [37863491](https://pubmed.ncbi.nlm.nih.gov/37863491/)\n\n \n\n[**SPIRIT Factorial**](https://www.equator-network.org/reporting-guidelines/consensus-statement-for-protocols-of-factorial-randomized-trials-extension-of-the-spirit-2013-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: [38051535](https://pubmed.ncbi.nlm.nih.gov/38051535/)\n\n \n\n[**SPIRIT-Surrogate**](https://www.equator-network.org/reporting-guidelines/spirit-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: [38981624](https://pubmed.ncbi.nlm.nih.gov/38981624/)\n\n \n\n[**SPIRIT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-protocols-of-randomised-controlled-trials-of-implantable-neurostimulation-devices-the-spirit-ineurostim-extension/): Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: [39610902](https://pubmed.ncbi.nlm.nih.gov/39610902/)\n\n \n\n""), ('Reporting guideline acronym', 'SPIRIT-PRO'), ('Study design', 'Clinical trials, Experimental studies, Study protocols'), ('Applies to the whole report or to individual sections of the report?', 'Outcomes (variables)'), (""Other relevant research\n\n(i.e. research regarding the guideline's effectiveness usability, impact etc.)"", ""Cruz Rivera S, Stephens R, Mercieca-Bebber R, Retzer A, Rutherford C, Price G, Slade A, Aiyegbusi OL, Edge P, Roberts L, Gosden L, Verdi R, Wilson R, Calvert M. 'Give Us The Tools!': development of knowledge transfer tools to support the involvement of patient partners in the development of clinical trial protocols with patient-reported outcomes (PROs), in accordance with SPIRIT-PRO Extension. BMJ Open. 2021;11(6):e046450. PMID: [34193492](https://pubmed.ncbi.nlm.nih.gov/34193492/)""), ('Record last updated on', 'May 30, 2025')]"
15756,Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,"Abstract, Whole report", ,"abstract, abstracts, checklist, checklists, diagnostic, diagnostic accuracy, diagnostic accuracy studies, diagnostic accuracy study, diagnostic studies, diagnostic study, diagnostic test, diagnostic test accuracy, diagnostic test accuracy checklist, diagnostic testing, diagnostic tests, DTA, meta analyses, meta analysis, Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagnostic test accuracy guideline, PRISMA, PRISMA diagnostic test accuracy checklist, PRISMA diagnostic test accuracy guideline, PRISMA extension, PRISMA-DTA, PRISMA-DTA abstracts, review, reviews, systematic review, systematic reviews, test accuracy", ,"McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group; Clifford T, Cohen JF, Deeks JJ, Gatsonis C, Hooft L, Hunt HA, Hyde CJ, Korevaar DA, Leeflang MMG, Macaskill P, Reitsma JB, Rodin R, Rutjes AWS, Salameh JP, Stevens A, Takwoingi Y, Tonelli M, Weeks L, Whiting P, Willis BH. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.

","McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group; Clifford T, Cohen JF, Deeks JJ, Gatsonis C, Hooft L, Hunt HA, Hyde CJ, Korevaar DA, Leeflang MMG, Macaskill P, Reitsma JB, Rodin R, Rutjes AWS, Salameh JP, Stevens A, Takwoingi Y, Tonelli M, Weeks L, Whiting P, Willis BH.",Journal of the American Medical Association [JAMA],2018,319,4,388-396, ,English, ,29362800,https://www.ncbi.nlm.nih.gov/pubmed/29362800, ,"Salameh JP, Bossuyt PM, McGrath TA, Thombs BD, Hyde CJ, Macaskill P, Deeks JJ, Leeflang M, Korevaar DA, Whiting P, Takwoingi Y, Reitsma JB, Cohen JF, Frank RA, Hunt HA, Hooft L, Rutjes AWS, Willis BH, Gatsonis C, Levis B, Moher D, McInnes MDF. Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist. BMJ. 2020;370:m2632. PMID: 32816740

", ,"Generic
PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

Specialised
PRISMA-Equity: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: 23222917

Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.
Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

PRISMA-Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.

PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246

PRISMA-IPD: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: 25919529

PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634

PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668

PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement &amp; Checklist. J Clin Epidemiol. 2017. PMID: 28720516

PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033

PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367

PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791

PRISMA-CHM: Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: 32907365

PRISMA-M 2020: Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: 33100229

PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.
Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535

PRISMA-LSR: Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: 39562017

",http://www.prisma-statement.org/Extensions/DTA,PRISMA-DTA,"Reporting systematic reviews and meta-analyses of diagnostic test accuracy studies.



PRISMA-DTA checklist\xa0\xa0 Word / PDF

PRISMA-DTA checklist for abstracts\xa0\xa0 Word / PDF

", ,"Read the guideline development executive summary (PDF) (November 2015)

Read the guideline development protocol (PDF) (May 2017)

", , , , , ,yes,2018-01-25 09:09:55,2025-02-06 12:04:35,prisma-dta,"[('title', 'Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting systematic reviews and meta-analyses of diagnostic test accuracy studies.\n\n \n\n \xa0\n\n \n\n PRISMA-DTA checklist [Word](https://www.prisma-statement.org/s/PRISMA-DTA-Checklist-wx4t.docx) / [PDF](https://www.prisma-statement.org/s/PRISMA-DTA-Checklist-xh5j.pdf)\n\n \n\n PRISMA-DTA checklist for abstracts [Word](https://www.prisma-statement.org/s/PRISMA-DTA-for-Abstracts-Checklist-g623.docx) / [PDF](https://www.prisma-statement.org/s/PRISMA-DTA-for-Abstracts-Checklist-jlfm.pdf)\n\n \n\n'), ('Full bibliographic reference', 'McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group; Clifford T, Cohen JF, Deeks JJ, Gatsonis C, Hooft L, Hunt HA, Hyde CJ, Korevaar DA, Leeflang MMG, Macaskill P, Reitsma JB, Rodin R, Rutjes AWS, Salameh JP, Stevens A, Takwoingi Y, Tonelli M, Weeks L, Whiting P, Willis BH. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.\n\n \n\n'), ('Language', 'English'), ('PubMed ID', '[29362800](https://www.ncbi.nlm.nih.gov/pubmed/29362800)'), ('Explanation and elaboration papers', 'Salameh JP, Bossuyt PM, McGrath TA, Thombs BD, Hyde CJ, Macaskill P, Deeks JJ, Leeflang M, Korevaar DA, Whiting P, Takwoingi Y, Reitsma JB, Cohen JF, Frank RA, Hunt HA, Hooft L, Rutjes AWS, Willis BH, Gatsonis C, Levis B, Moher D, McInnes MDF. Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist. BMJ. 2020;370:m2632. PMID: [32816740](https://pubmed.ncbi.nlm.nih.gov/32816740/)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n[**PRISMA 2020 Statement**](http://dev.equator-network.org/reporting-guidelines/prisma/): Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.\n\n \n\n PLoS Med. 2021;18(3):e1003583. PMID: [33780438](https://pubmed.ncbi.nlm.nih.gov/33780438/)\n\n BMJ 2021;372:n71. PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)\n\n Int J Surg. 2021:105906. PMID: [33789826](https://pubmed.ncbi.nlm.nih.gov/33789826/)\n\n J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: [33789819](https://pubmed.ncbi.nlm.nih.gov/33789819/)\n\n Syst Rev. 2021;10(1):89. PMID: [33781348](https://pubmed.ncbi.nlm.nih.gov/33781348/)\n\n \n\n**Specialised**\n\n[**PRISMA-Equity**](http://dev.equator-network.org/reporting-guidelines/prisma-equity/): Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: [23222917](http://www.ncbi.nlm.nih.gov/pubmed/23222917)\n\n \n\n Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.\n\n Int J Equity Health. 2015;14(1):92. PMID: [26450828](http://www.ncbi.nlm.nih.gov/pubmed/26450828)\n\n J Clin Epidemiol. 2015. PMID: [26348799](http://www.ncbi.nlm.nih.gov/pubmed/26348799)\n\n \n\n[**PRISMA-Abstracts 2020:**](http://dev.equator-network.org/reporting-guidelines/prisma-abstracts/) The PRISMA 2020 for Abstracts reporting guideline is contained within the main [PRISMA 2020 Statement paper](https://www.equator-network.org/reporting-guidelines/prisma/).\n\n \n\n[**PRISMA-P**](http://dev.equator-network.org/reporting-guidelines/prisma-protocols/): Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: [25554246](http://www.ncbi.nlm.nih.gov/pubmed/25554246)\n\n \n\n[**PRISMA-IPD**](http://dev.equator-network.org/reporting-guidelines/prisma-ipd/): Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: [25919529](http://www.ncbi.nlm.nih.gov/pubmed/25919529)\n\n \n\n[**PRISMA extension for network meta-analyses**](http://dev.equator-network.org/reporting-guidelines/prisma-extension-network-meta-analyses/): Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: [26030634](http://www.ncbi.nlm.nih.gov/pubmed/26030634)\n\n \n\n[**PRISMA-harms**](http://dev.equator-network.org/reporting-guidelines/prisma-harms/): Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: [26830668](http://www.ncbi.nlm.nih.gov/pubmed/26830668)\n\n \n\n[**PRISMA-CI**](http://dev.equator-network.org/reporting-guidelines/prisma-ci-extension-statement-checklist/): Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: [28720516](https://www.ncbi.nlm.nih.gov/pubmed/28720516)\n\n \n\n[**PRISMA-ScR**](http://dev.equator-network.org/reporting-guidelines/prisma-scr/): Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: [30178033](https://www.ncbi.nlm.nih.gov/pubmed/30178033)\n\n \n\n[**PRISMA-A**](https://dev.equator-network.org/reporting-guidelines/prisma-acupuncture/): Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: [31405367](https://www.ncbi.nlm.nih.gov/pubmed/31405367)\n\n \n\n[**PRISMA-DTA for Abstracts**](https://dev.equator-network.org/reporting-guidelines/prisma-dta-for-abstracts/): Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: [33722791](https://pubmed.ncbi.nlm.nih.gov/33722791/)\n\n \n\n[**PRISMA-CHM**](https://www.equator-network.org/reporting-guidelines/prisma-chinese-herbal-medicines-2020/): Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: [32907365](https://pubmed.ncbi.nlm.nih.gov/32907365/)\n\n \n\n[**PRISMA-M 2020**](https://www.equator-network.org/reporting-guidelines/prisma-extension-for-moxibustion-2020/): Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: [33100229](https://pubmed.ncbi.nlm.nih.gov/33100229/)\n\n \n\n[**PRISMA-S**](https://dev.equator-network.org/reporting-guidelines/prisma-s/): Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.\n\n Syst Rev. 2021;10(1):39. PMID: [33499930](https://pubmed.ncbi.nlm.nih.gov/33499930/)\n\n J Med Libr Assoc. 2021;109(2):174-200. PMID: [34285662](https://pubmed.ncbi.nlm.nih.gov/34285662/)\n\n \n\n[**PRISMA-COSMIN for OMIs**](https://www.equator-network.org/reporting-guidelines/guideline-for-reporting-systematic-reviews-of-outcome-measurement-instruments-omis-prisma-cosmin-for-omis-2024/): Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.\n\n J Clin Epidemiol. 2024:111422. PMID: [38849061](https://pubmed.ncbi.nlm.nih.gov/38849061/)\n\n Qual Life Res. 2024. PMID: [38980635](https://pubmed.ncbi.nlm.nih.gov/38980635/)\n\n Health Qual Life Outcomes. 2024;22(1):48. PMID: [38978063](https://pubmed.ncbi.nlm.nih.gov/38978063/)\n\n J Patient Rep Outcomes. 2024;8(1):64. PMID: [38977535](https://pubmed.ncbi.nlm.nih.gov/38977535/)\n\n \n\n[**PRISMA-LSR**](https://www.equator-network.org/reporting-guidelines/prisma-lsr/): Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: [39562017](https://pubmed.ncbi.nlm.nih.gov/39562017/)\n\n \n\n""), ('Reporting guideline website URL', '<http://www.prisma-statement.org/Extensions/DTA>'), ('Reporting guideline acronym', 'PRISMA-DTA'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Abstract, Whole report'), ('Additional information', 'Read the [guideline development executive summary (PDF)](/wp-content/uploads/2009/02/PRISMA-DTA-Executive-Summary.pdf) (November 2015)\n\n \n\n Read the [guideline development protocol (PDF)](/wp-content/uploads/2009/02/PRISMA-DTA-Protocol.pdf) (May 2017)\n\n \n\n'), ('Record last updated on', 'February 6, 2025')]"
15709,Structural brain development: A review of methodological approaches and best practices,Observational studies,"Neurology, Radiology","Intervention (exposure), Procedure/Method, Statistical methods and analyses, Study characteristics (participants etc.)", ,"adolescent, adolescents, brain, brain development, brain structure, child, children, longitudinal, longitudinal analyses, longitudinal analysis, longitudinal magnetic resonance imaging, magnetic resonance imaging, MRI, neuroimaging, neuroimaging technologies, neuroimaging technology, neurology, observational, observational method, observational research, radiology, structural brain development, structural MRI", ,"Vijayakumar N, Mills KL, Alexander-Bloch A, Tamnes CK, Whittle S. Structural brain development: A review of methodological approaches and best practices. Dev Cogn Neurosci. 2017.","Vijayakumar N, Mills KL, Alexander-Bloch A, Tamnes CK, Whittle S.",Developmental Cognitive Neuroscience [Dev Cogn Neurosci.],2017, , , , ,English, ,29221915,https://www.ncbi.nlm.nih.gov/pubmed/29221915, , , , , , ,Reporting methodological detail in longitudinal structural brain imaging studies., , , , , , , ,no,2018-01-11 14:56:19,2018-01-11 14:56:19,structural-brain-development-a-review-of-methodological-approaches-and-best-practices,"[('title', 'Structural brain development: A review of methodological approaches and best practices'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting methodological detail in longitudinal structural brain imaging studies.'), ('Full bibliographic reference', 'Vijayakumar N, Mills KL, Alexander-Bloch A, Tamnes CK, Whittle S. Structural brain development: A review of methodological approaches and best practices. Dev Cogn Neurosci. 2017.'), ('Language', 'English'), ('PubMed ID', '[29221915](https://www.ncbi.nlm.nih.gov/pubmed/29221915)'), ('Study design', 'Observational studies'), ('Clinical area', 'Neurology, Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Procedure/Method, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'January 11, 2018')]"
15707,"Improving the Development, Monitoring and Reporting of Stroke Rehabilitation Research: Consensus-Based Core Recommendations from the Stroke Recovery and Rehabilitation Roundtable","Clinical trials, Experimental studies","Neurology, Rehabilitation medicine",Intervention (exposure), ,"clinical trial, clinical trials, fidelity, intervention, intervention development, intervention fidelity, interventions, neurology, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, rehabilitation, stroke, stroke recovery, stroke rehabilitation, stroke rehabilitation intervention, stroke rehabilitation interventions, trial, trials", ,"Walker MF, Hoffmann TC, Brady MC, Dean CM, Eng JJ, Farrin AJ, Felix C, Forster A, Langhorne P, Lynch EA, Radford KA, Sunnerhagen KS, Watkins CL. Improving the Development, Monitoring and Reporting of Stroke Rehabilitation Research: Consensus-Based Core Recommendations from the Stroke Recovery and Rehabilitation Roundtable. Neurorehabil Neural Repair. 2017;31(10-11):877-884.","Walker MF, Hoffmann TC, Brady MC, Dean CM, Eng JJ, Farrin AJ, Felix C, Forster A, Langhorne P, Lynch EA, Radford KA, Sunnerhagen KS, Watkins CL.",Neurorehabilitation and Neural Repair [Neurorehabil Neural Repair.],2017,31,10-11,877-884, ,English, ,29233072,https://www.ncbi.nlm.nih.gov/pubmed/29233072, , , , , , ,Reporting of interventions in stroke rehabilitation research., , , , , , , ,no,2018-01-11 12:51:28,2022-04-26 17:21:33,improving-the-development-monitoring-and-reporting-of-stroke-rehabilitation-research-consensus-based-core-recommendations-from-the-stroke-recovery-and-rehabilitation-roundtable,"[('title', 'Improving the Development, Monitoring and Reporting of Stroke Rehabilitation Research: Consensus -Based Core Recommendations from the Stroke Recovery and Rehabilitation Roundtable'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of interventions in stroke rehabilitation research.'), ('Full bibliographic reference', 'Walker MF, Hoffmann TC, Brady MC, Dean CM, Eng JJ, Farrin AJ, Felix C, Forster A, Langhorne P, Lynch EA, Radford KA, Sunnerhagen KS, Watkins CL. Improving the Development, Monitoring and Reporting of Stroke Rehabilitation Research: Consensus-Based Core Recommendations from the Stroke Recovery and Rehabilitation Roundtable. Neurorehabil Neural Repair. 2017;31(10-11):877-884.'), ('Language', 'English'), ('PubMed ID', '[29233072](https://www.ncbi.nlm.nih.gov/pubmed/29233072)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Neurology, Rehabilitation medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'April 26, 2022')]"
15705,Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements,"Clinical trials, Experimental studies",Rheumatology,Outcomes (variables), ,"clinical trial, clinical trials, flare, flare rate, flares, gout, gout flare, gout flares, OMERACT, outcome, outcome measure, outcome measures, Outcome Measures in Rheumatology, outcomes, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, rheumatology, serum urate, SU, trial, trials, ULT, urate, urate lowering therapies, urate lowering therapy", ,"Stamp LK, Morillon MB, Taylor WJ, Dalbeth N, Singh JA, Lassere M, Christensen R. Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements. J Rheumatol. 2017.","Stamp LK, Morillon MB, Taylor WJ, Dalbeth N, Singh JA, Lassere M, Christensen R.",Journal of Rheumatology [ J Rheumatol.],2017, , , , ,English, ,29247147,https://www.ncbi.nlm.nih.gov/pubmed/29247147, , , , , , ,Reporting of serum urate and gout flares in gout clinical trials., , , , , , , ,no,2018-01-11 11:57:53,2018-01-11 11:57:53,variability-in-the-reporting-of-serum-urate-and-flares-in-gout-clinical-trials-need-for-minimum-reporting-requirements,"[('title', 'Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of serum urate and gout flares in gout clinical trials.'), ('Full bibliographic reference', 'Stamp LK, Morillon MB, Taylor WJ, Dalbeth N, Singh JA, Lassere M, Christensen R. Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements. J Rheumatol. 2017.'), ('Language', 'English'), ('PubMed ID', '[29247147](https://www.ncbi.nlm.nih.gov/pubmed/29247147)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Rheumatology'), ('Applies to the whole report or to individual sections of the report?', 'Outcomes (variables)'), ('Record last updated on', 'January 11, 2018')]"
15703,Methodology of assessment and reporting of safety in anti-malarial treatment efficacy studies of uncomplicated falciparum malaria in pregnancy: a systematic literature review,"Clinical trials, Experimental studies, Observational studies","Infectious diseases, Obstetrics and gynaecology","Harms/adverse effects/safety data, Study characteristics (participants etc.)", ,"adverse effect, adverse effects, adverse outcome, adverse outcomes, antenatal, anti-malarial, anti-malarial drug, anti-malarial drug efficacy, anti-malarial drugs, anti-malarials, birth, checklist for reporting pregnancy-related information in anti-malarial efficacy studies, drug efficacy, efficacy, gestational, harm, harms, malaria, maternal, maternal safety, obstetric, obstetrics, pregnancy, pregnancy outcome, safety, safety data, safety outcome, safety outcomes", ,"Saito M, Gilder ME, Nosten F, Gu\xe9rin PJ, McGready R. Methodology of assessment and reporting of safety in anti-malarial treatment efficacy studies of uncomplicated falciparum malaria in pregnancy: a systematic literature review. Malar J. 2017;16(1):491.","Saito M, Gilder ME, Nosten F, Gu\xe9rin PJ, McGready R.",Malaria Journal [Malar J.],2017,16,1,491, ,English, ,29254487,https://www.ncbi.nlm.nih.gov/pubmed/29254487, , , , , , ,Reporting of pregnancy-related information in anti-malarial efficacy studies., , , , , , , ,no,2018-01-11 10:36:03,2018-01-11 10:36:03,methodology-of-assessment-and-reporting-of-safety-in-anti-malarial-treatment-efficacy-studies-of-uncomplicated-falciparum-malaria-in-pregnancy-a-systematic-literature-review,"[('title', 'Methodology of assessment and reporting of safety in anti-malarial treatment efficacy studies of uncomplicated falciparum malaria in pregnancy: a systematic literature review'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of pregnancy-related information in anti-malarial efficacy studies.'), ('Full bibliographic reference', 'Saito M, Gilder ME, Nosten F, Guérin PJ, McGready R. Methodology of assessment and reporting of safety in anti-malarial treatment efficacy studies of uncomplicated falciparum malaria in pregnancy: a systematic literature review. Malar J. 2017;16(1):491.'), ('Language', 'English'), ('PubMed ID', '[29254487](https://www.ncbi.nlm.nih.gov/pubmed/29254487)'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Infectious diseases, Obstetrics and gynaecology'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Study characteristics (participants etc.)'), ('Record last updated on', 'January 11, 2018')]"
15701,Standards for UNiversal reporting of patient Decision Aid Evaluation studies: the development of SUNDAE Checklist,"Clinical trials, Experimental studies, Observational studies, Qualitative research", ,Whole report, ,"checklist, checklists, clinical trial, clinical trials, decision, decision aid, decision aids, decision making, decisions, observational, patient, patient decision aid, patient decision aid evaluation, patient decision aid evaluations, patient decision aids, patient education, patients, PDA, PDA evaluation, PDA evaluations, PDAs, qualitative, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, Standards for UNiversal reporting of patient Decision Aid Evaluations, SUNDAE, SUNDAE Checklist, trial, trials", ,"Sepucha KR, Abhyankar P, Hoffman AS, Bekker HL, LeBlanc A, Levin CA, Ropka M, Shaffer VA, Sheridan SL, Stacey D, Stalmeier P, Vo H, Wills CE, Thomson R. Standards for UNiversal reporting of patient Decision Aid Evaluation studies: the development of SUNDAE Checklist. BMJ Qual Saf. 2017.","Sepucha KR, Abhyankar P, Hoffman AS, Bekker HL, LeBlanc A, Levin CA, Ropka M, Shaffer VA, Sheridan SL, Stacey D, Stalmeier P, Vo H, Wills CE, Thomson R.",BMJ Quality and Safety [BMJ Qual Saf.],2017, , , , ,English, ,29269567,https://www.ncbi.nlm.nih.gov/pubmed/29269567,The full-text of this reporting guideline is freely available at: http://qualitysafety.bmj.com/content/early/2017/12/21/bmjqs-2017-006986.long,"Hoffman AS, Sepucha KR, Abhyankar P, Sheridan S, Bekker H, LeBlanc A, Levin C, Ropka M, Shaffer V, Stacey D, Stalmeier P, Vo H, Wills C, Thomson R. Explanation and elaboration of the Standards for UNiversal reporting of patient Decision Aid Evaluations (SUNDAE) guidelines: examples of reporting SUNDAE items from patient decision aid evaluation literature. BMJ Qual Saf. 2018. PMID: 29467235
Access the full-text at: http://qualitysafety.bmj.com/content/early/2018/02/21/bmjqs-2017-006985.long

", , , ,SUNDAE,Reporting of patient decision aid evaluation studies., , ,"Volk RJ, Coulter A. Advancing the science of patient decision aids through reporting guidelines. BMJ Qual Saf. 2017. Freely available at: http://qualitysafety.bmj.com/content/early/2018/01/25/bmjqs-2017-007657", , , , ,no,2018-01-11 10:00:24,2021-11-19 16:37:24,standards-for-universal-reporting-of-patient-decision-aid-evaluation-studies-the-development-of-sundae-checklist,"[('title', 'Standards for UNiversal reporting of patient Decision Aid Evaluation studies: the development of SUNDAE Checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of patient decision aid evaluation studies.'), ('Full bibliographic reference', 'Sepucha KR, Abhyankar P, Hoffman AS, Bekker HL, LeBlanc A, Levin CA, Ropka M, Shaffer VA, Sheridan SL, Stacey D, Stalmeier P, Vo H, Wills CE, Thomson R. Standards for UNiversal reporting of patient Decision Aid Evaluation studies: the development of SUNDAE Checklist. BMJ Qual Saf. 2017.'), ('Language', 'English'), ('PubMed ID', '[29269567](https://www.ncbi.nlm.nih.gov/pubmed/29269567)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available at: <http://qualitysafety.bmj.com/content/early/2017/12/21/bmjqs-2017-006986.long>'), ('Explanation and elaboration papers', 'Hoffman AS, Sepucha KR, Abhyankar P, Sheridan S, Bekker H, LeBlanc A, Levin C, Ropka M, Shaffer V, Stacey D, Stalmeier P, Vo H, Wills C, Thomson R. Explanation and elaboration of the Standards for UNiversal reporting of patient Decision Aid Evaluations (SUNDAE) guidelines: examples of reporting SUNDAE items from patient decision aid evaluation literature. BMJ Qual Saf. 2018. PMID: [29467235\n\n](https://www.ncbi.nlm.nih.gov/pubmed/29467235)Access the full-text at: <http://qualitysafety.bmj.com/content/early/2018/02/21/bmjqs-2017-006985.long>\n\n \n\n'), ('Reporting guideline acronym', 'SUNDAE'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Selected relevant editorials', 'Volk RJ, Coulter A. Advancing the science of patient decision aids through reporting guidelines. BMJ Qual Saf. 2017. Freely available at: <http://qualitysafety.bmj.com/content/early/2018/01/25/bmjqs-2017-007657>'), ('Record last updated on', 'November 19, 2021')]"
15699,Consideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studies-Statement From ATVB Council,Animal pre-clinical research,Cardiovascular medicine,Data, ,"AAA, abdominal aortic aneurysm, abdominal aortic aneurysms, acute aortic dissection, acute aortic dissections, animal model, animal models, animal research, animal studies, animal study, arterial disease, arterial diseases, atherosclerosis, atherosclerotic, biological variable, biological variables, cardiology, cardiovascular, CHD, coronary heart disease, myocardial infarction, PAD, peripheral arterial disease, pre clinical, preclinical, sex, sex difference, sex differences, thoracic aortic aneurysm, thoracic aortic aneurysms, vascular pathologies, vascular pathology", ,"Robinet P, Milewicz DM, Cassis LA, Leeper NJ, Lu HS, Smith JD. Consideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studies-Statement From ATVB Council. Arterioscler Thromb Vasc Biol. 2018.","Robinet P, Milewicz DM, Cassis LA, Leeper NJ, Lu HS, Smith JD.","Arteriosclerosis, Thrombosis and Vascular Biology [Arterioscler Thromb Vasc Biol.]",2018, , , , ,English, ,29301789,https://www.ncbi.nlm.nih.gov/pubmed/29301789, , , , , , ,"Reporting sex as a biological variable in animal models of atherosclerosis, thoracic and abdominal aortic aneurysms, and peripheral arterial disease.", , , , , , , ,no,2018-01-10 14:24:07,2018-01-10 14:24:07,consideration-of-sex-differences-in-design-and-reporting-of-experimental-arterial-pathology-studies-statement-from-atvb-council,"[('title', 'Consideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studies -Statement From ATVB Council'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting sex as a biological variable in animal models of atherosclerosis, thoracic and abdominal aortic aneurysms, and peripheral arterial disease.'), ('Full bibliographic reference', 'Robinet P, Milewicz DM, Cassis LA, Leeper NJ, Lu HS, Smith JD. Consideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studies-Statement From ATVB Council. Arterioscler Thromb Vasc Biol. 2018.'), ('Language', 'English'), ('PubMed ID', '[29301789](https://www.ncbi.nlm.nih.gov/pubmed/29301789)'), ('Study design', 'Animal pre-clinical research'), ('Clinical area', 'Cardiovascular medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'January 10, 2018')]"
15690,Guidelines for the Content of Statistical Analysis Plans in Clinical Trials,"Clinical trials, Experimental studies", ,Statistical analysis plan-whole report, ,"analysis plan, clinical trial, clinical trial SAP, clinical trial statistical analysis plan, clinical trials, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, SAP, SAP guidance, SAP guideline, SAPs, statistic, statistical, statistical analyses, statistical analysis, statistical analysis plan, trial, trials", ,"Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Dor\xe9 C, Williamson PR, Altman DG, Montgomery A, Lim P, Berlin J, Senn S, Day S, Barbachano Y, Loder E. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. JAMA. 2017;318(23):2337-2343.","Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E,
Dor\xe9 C, Williamson PR, Altman DG, Montgomery A, Lim P,
Berlin J, Senn S, Day S, Barbachano Y, Loder E.",Journal of the American Medical Association [JAMA],2017,318,23,2337-2343, ,English, ,29260229,https://pubmed.ncbi.nlm.nih.gov/29260229/,The full-text of this guideline is freely available at: https://jamanetwork.com/journals/jama/fullarticle/2666509,"The explanation and elaboration content for the SAP Statement (PDF) is freely available.

", ,"Specialised
Early phase clinical trial statistical analysis plans: Homer V, Yap C, Bond S, Holmes J, Stocken D, Walker K, Robinson EJ, Wheeler G, Brown S, Hinsley S, Schipper M, Weir CJ, Rantell K, Prior T, Yu LM, Kirkpatrick J, Bedding A, Gamble C, Gaunt P. Early phase clinical trials extension to guidelines for the content of statistical analysis plans. BMJ. 2022;376:e068177. PMID: 35131744

",http://lctc.org.uk/SAP-Statement, ,"Reporting of statistical analysis plans (SAPs) for clinical trials.



Statistical Analysis Plan (SAP) Checklist (Word)

", , , , , , , ,no,2018-01-10 09:32:16,2022-02-14 15:47:12,guidelines-for-the-content-of-statistical-analysis-plans-in-clinical-trials,"[('title', 'Guidelines for the Content of Statistical Analysis Plans in Clinical Trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of statistical analysis plans (SAPs) for clinical trials.\n\n \n\n \xa0\n\n \n\n[Statistical Analysis Plan (SAP) Checklist (Word)](http://lctc.org.uk/Content/SAP%202019%20Checklist.docx)\n\n \n\n'), ('Full bibliographic reference', 'Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Doré C, Williamson PR, Altman DG, Montgomery A, Lim P, Berlin J, Senn S, Day S, Barbachano Y, Loder E. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. JAMA. 2017;318(23):2337-2343.'), ('Language', 'English'), ('PubMed ID', '[29260229](https://pubmed.ncbi.nlm.nih.gov/29260229/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this guideline is freely available at: <https://jamanetwork.com/journals/jama/fullarticle/2666509>'), ('Explanation and elaboration papers', 'The [explanation and elaboration content for the SAP Statement (PDF)](http://lctc.org.uk/Content/SAP%20Statement_%20Elaboration%20Document%20v1.0.pdf) is freely available.\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Specialised**\n\n**[Early phase clinical trial statistical analysis plans](https://www.equator-network.org/reporting-guidelines/early-phase-clinical-trials-extension-to-guidelines-for-the-content-of-statistical-analysis-plans/)**: Homer V, Yap C, Bond S, Holmes J, Stocken D, Walker K, Robinson EJ, Wheeler G, Brown S, Hinsley S, Schipper M, Weir CJ, Rantell K, Prior T, Yu LM, Kirkpatrick J, Bedding A, Gamble C, Gaunt P. Early phase clinical trials extension to guidelines for the content of statistical analysis plans. BMJ. 2022;376:e068177. PMID: [35131744](https://pubmed.ncbi.nlm.nih.gov/35131744/)\n\n \n\n'), ('Reporting guideline website URL', '<http://lctc.org.uk/SAP-Statement>'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Statistical analysis plan-whole report'), ('Record last updated on', 'February 14, 2022')]"
15634,RECORDS: Improved reporting of Monte Carlo Radiation transport studies: Report of the AAPM Research Committee Task Group 268,"Clinical trials, Diagnostic and prognostic studies, Experimental studies",Radiology,"Narrative sections (discussion etc.), Procedure/Method, Results, Statistical methods and analyses, Title", ,"American Association of Physicists in Medicine, checklist, checklists, computer simulation, medical physics, Monte Carlo, Monte Carlo calculation, Monte Carlo calculations, Monte Carlo simulation, Monte Carlo studies, Monte Carlo study, Monte Carlo-based computer simulation, Monte Carlo-based computer simulations, Monte Carlo-based simulation studies, Monte Carlo-based simulation study, Monte Carlo-based studies, Monte Carlo-based study, particle, particles, physics, radiation, radiation transport, radiology, radiotherapy, simulation, simulations, x-ray", ,"Sechopoulos I, Rogers DWO, Bazalova-Carter M, Bolch WE, Heath EC, McNitt-Gray MF, Sempau J, Williamson JF. RECORDS: Improved reporting of Monte Carlo Radiation transport studies: Report of the AAPM Research Committee Task Group 268. Med Phys. 2017.","Sechopoulos I, Rogers DWO, Bazalova-Carter M, Bolch WE, Heath EC, McNitt-Gray MF, Sempau J, Williamson JF. RECORDS: Improved reporting of Monte Carlo Radiation transport studies: Report of the AAPM Research Committee Task Group 268.",Medical Physics [Med Phys.],2017, , , , ,English, ,29178605,https://www.ncbi.nlm.nih.gov/pubmed/29178605, , , , , ,RECORDS,Reporting of Monte Carlo studies in the medical physics literature., , , , , , , ,no,2017-12-11 14:07:36,2017-12-11 14:07:36,records-improved-reporting-of-monte-carlo-radiation-transport-studies-report-of-the-aapm-research-committee-task-group-268,"[('title', 'RECORDS : Improved reporting of Monte Carlo Radiation transport studies: Report of the AAPM Research Committee Task Group 268'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of Monte Carlo studies in the medical physics literature.'), ('Full bibliographic reference', 'Sechopoulos I, Rogers DWO, Bazalova-Carter M, Bolch WE, Heath EC, McNitt-Gray MF, Sempau J, Williamson JF. RECORDS: Improved reporting of Monte Carlo Radiation transport studies: Report of the AAPM Research Committee Task Group 268. Med Phys. 2017.'), ('Language', 'English'), ('PubMed ID', '[29178605](https://www.ncbi.nlm.nih.gov/pubmed/29178605)'), ('Reporting guideline acronym', 'RECORDS'), ('Study design', 'Clinical trials, Diagnostic and prognostic studies, Experimental studies'), ('Clinical area', 'Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Narrative sections (discussion etc.), Procedure/Method, Results, Statistical methods and analyses, Title'), ('Record last updated on', 'December 11, 2017')]"
15632,Ten simple rules for neuroimaging meta-analysis,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews,Neurology,"Data, Procedure/Method, Statistical methods and analyses", ,"brain, checklist, checklists, coordinate-based, coordinate-based meta-analysis, fMRI, functional neuroanatomy, image-based, image-based meta-analyses, meta analyses, meta analysis, meta-analytical, neuroanatomy, neuroimaging, neuroimaging data, neuroimaging studies, neuroimaging study, neurological, neurology, neuroscience, PET, review, reviews, systematic review, systematic reviews", ,"M\xfcller VI, Cieslik EC, Laird AR, Fox PT, Radua J, Mataix-Cols D, Tench CR, Yarkoni T, Nichols TE, Turkeltaub PE, Wager TD, Eickhoff SB. Ten simple rules for neuroimaging meta-analysis. Neurosci Biobehav Rev. 2017;84:151-161.","M\xfcller VI, Cieslik EC, Laird AR, Fox PT, Radua J, Mataix-Cols D, Tench CR, Yarkoni T, Nichols TE, Turkeltaub PE, Wager TD, Eickhoff SB.",Neuroscience and Biobehavioral Reviews [Neurosci Biobehav Rev.],2017,84, ,151-161, ,English, ,29180258,https://www.ncbi.nlm.nih.gov/pubmed/29180258, , , , , , ,Reporting of meta-analytical results of neuroimaging data., , , , , , , ,no,2017-12-11 13:38:36,2017-12-11 13:38:36,ten-simple-rules-for-neuroimaging-meta-analysis,"[('title', 'Ten simple rules for neuroimaging meta-analysis'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of meta-analytical results of neuroimaging data.'), ('Full bibliographic reference', 'Müller VI, Cieslik EC, Laird AR, Fox PT, Radua J, Mataix-Cols D, Tench CR, Yarkoni T, Nichols TE, Turkeltaub PE, Wager TD, Eickhoff SB. Ten simple rules for neuroimaging meta-analysis. Neurosci Biobehav Rev. 2017;84:151-161.'), ('Language', 'English'), ('PubMed ID', '[29180258](https://www.ncbi.nlm.nih.gov/pubmed/29180258)'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Clinical area', 'Neurology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method, Statistical methods and analyses'), ('Record last updated on', 'December 11, 2017')]"
15620,CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials,"Clinical trials, Experimental studies", ,Whole report, ,"checklist, checklists, clinical trial, clinical trials, CONSORT extension, CONSORT-Equity, CONSORT-Equity 2017, CONSORT-Equity extension, disadvantaged population, disadvantaged populations, disparities, disparity, equity, health disparities, health disparity, health equity, health inequalities, health inequality, health inequities, health inequity, inequalities, inequality, inequities, inequity, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, social disadvantage, trial, trials", ,"Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085.","Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium.",British Medical Journal [BMJ],2017,359, , , ,English, ,29170161,https://www.ncbi.nlm.nih.gov/pubmed/29170161,The reporting guideline abstract is available at: http://www.bmj.com/content/359/bmj.j5085, , ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.



BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,CONSORT-Equity,Reporting of intervention effects in randomised trials where health equity is relevant., ,"Read the CONSORT-Equity study protocol.

For a baseline assessment of quality of reporting before publication of the CONSORT-Equity extension please see:
Petkovic J, Jull J, Yoganathan M, Dewidar O, Baird S, Grimshaw JM, Johansson KA, Kristjansson E, McGowan J, Moher D, Petticrew M, Robberstad B, Shea B, Tugwell P, Volmink J, Wells GA, Whitehead M, Cuervo LG, White H, Taljaard M, Welch V. Reporting of health equity considerations in cluster and individually randomized trials. Trials. 2020 Apr 3;21(1):308. PMID: 32245522

", , , , , ,yes,2017-11-24 13:25:21,2025-05-30 09:21:56,consort-equity,"[('title', 'CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of intervention effects in randomised trials where health equity is relevant.'), ('Full bibliographic reference', 'Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085.'), ('Language', 'English'), ('PubMed ID', '[29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)'), ('Relevant URLs\n\n(full-text if available)', 'The reporting guideline abstract is available at: <http://www.bmj.com/content/359/bmj.j5085>'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n**[CONSORT 2025 Statement](https://dev.equator-network.org/reporting-guidelines/consort/)**:\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n \xa0\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](http://dev.equator-network.org/reporting-guidelines/consort-cluster/):\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](http://dev.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](http://dev.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](http://dev.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'CONSORT-Equity'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Read the [CONSORT-Equity study protocol](http://link.springer.com/article/10.1186/s13012-015-0332-z/fulltext.html).\n\n \n\n For a baseline assessment of quality of reporting before publication of the CONSORT-Equity extension please see:\n\n Petkovic J, Jull J, Yoganathan M, Dewidar O, Baird S, Grimshaw JM, Johansson KA, Kristjansson E, McGowan J, Moher D, Petticrew M, Robberstad B, Shea B, Tugwell P, Volmink J, Wells GA, Whitehead M, Cuervo LG, White H, Taljaard M, Welch V. Reporting of health equity considerations in cluster and individually randomized trials. Trials. 2020 Apr 3;21(1):308. PMID: [32245522](https://www.ncbi.nlm.nih.gov/pubmed/32245522)\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
15611,Preferred Reporting Items for Overviews of systematic reviews including harms checklist: A pilot tool to be used for balanced reporting of benefits and harms,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,"Harms/adverse effects/safety data, Whole report", ,"adverse event, adverse events, benefits, benefits and harms, checklist, checklists, harms, OoSRs, overview, overview of systematic reviews, overviews, Preferred Reporting Items for OoSRs, PRIO, PRIO-harms, PRIO-harms checklist, PRIO-harms tool, review, reviews, systematic review, systematic reviews, umbrella review, umbrella reviews", ,"Bougioukas KI, Liakos A, Tsapas A, Ntzani E, Haidich AB. Preferred Reporting Items for Overviews of systematic reviews including harms checklist: A pilot tool to be used for balanced reporting of benefits and harms. J Clin Epidemiol. 2017.","Bougioukas KI, Liakos A, Tsapas A, Ntzani E, Haidich AB.",Journal of Clinical Epidemiology [J Clin Epidemiol.],2017, , , , ,English, ,29037888,https://www.ncbi.nlm.nih.gov/pubmed/29037888, , , , , ,PRIO-harms,Reporting overviews of systematic reviews (OoSRs) to promote a more balanced reporting of benefits and harms., , , , , , , ,no,2017-11-20 16:25:28,2018-11-15 15:48:00,preferred-reporting-items-for-overviews-of-systematic-reviews-including-harms-checklist-a-pilot-tool-to-be-used-for-balanced-reporting-of-benefits-and-harms,"[('title', 'Preferred Reporting Items for Overviews of systematic reviews including harms checklist: A pilot tool to be used for balanced reporting of benefits and harms'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting overviews of systematic reviews (OoSRs) to promote a more balanced reporting of benefits and harms.'), ('Full bibliographic reference', 'Bougioukas KI, Liakos A, Tsapas A, Ntzani E, Haidich AB. Preferred Reporting Items for Overviews of systematic reviews including harms checklist: A pilot tool to be used for balanced reporting of benefits and harms. J Clin Epidemiol. 2017.'), ('Language', 'English'), ('PubMed ID', '[29037888](https://www.ncbi.nlm.nih.gov/pubmed/29037888)'), ('Reporting guideline acronym', 'PRIO-harms'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Whole report'), ('Record last updated on', 'November 15, 2018')]"
15573,Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations,Economic evaluations, ,"Ethical issues (consent etc.), Intervention (exposure), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.), Terminology/definitions", ,"Delphi, Delphi study, economic, economic evaluation, economic evaluations, economics, EE, expert, expert elicitation, expert elicitation studies, expert elicitation study, expert judgement, expert opinion, expert parameter value, expert parameter values, model-based economic evaluation, model-based economic evaluations, model-based EE", ,"Iglesias CP, Thompson A, Rogowski WH, Payne K. Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations. Pharmacoeconomics. 2016;34(11):1161-1172.","Iglesias CP, Thompson A, Rogowski WH, Payne K.",Pharmacoeconomics.,2016,34,11,1161-1172, ,English, ,27364887,https://www.ncbi.nlm.nih.gov/pubmed/27364887, , , , , , ,Reporting two types of study design to use expert judgement in model-based EE: (i) an expert elicitation study requiring 16 reporting criteria; and (ii) a Delphi study to collate expert opinion requiring 11 reporting criteria., , , , , , , ,no,2017-10-23 14:24:21,2017-10-23 14:25:53,reporting-guidelines-for-the-use-of-expert-judgement-in-model-based-economic-evaluations,"[('title', 'Reporting Guidelines for the Use of Expert Judgement in Model -Based Economic Evaluations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting two types of study design to use expert judgement in model-based EE: (i) an expert elicitation study requiring 16 reporting criteria; and (ii) a Delphi study to collate expert opinion requiring 11 reporting criteria.'), ('Full bibliographic reference', 'Iglesias CP, Thompson A, Rogowski WH, Payne K. Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations. Pharmacoeconomics. 2016;34(11):1161-1172.'), ('Language', 'English'), ('PubMed ID', '[27364887](https://www.ncbi.nlm.nih.gov/pubmed/27364887)'), ('Study design', 'Economic evaluations'), ('Applies to the whole report or to individual sections of the report?', 'Ethical issues (consent etc.), Intervention (exposure), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'October 23, 2017')]"
15571,Standards for reporting chronic periodontitis prevalence and severity in epidemiologic studies: Proposed standards from the Joint EU/USA Periodontal Epidemiology Working Group,Observational studies,Dentistry,"Procedure/Method, Statistical methods and analyses, Study characteristics (participants etc.), Terminology/definitions", ,"chronic periodontitis, dental, Dentist, Dentistry, epidemiologic, epidemiological, epidemiological studies, epidemiological study, epidemiological surveillance, epidemiology, Joint EU/USA Periodontal Epidemiology Working Group, observational, observational studies, observational study, oral, oral data, oral health, periodontal, periodontal data, periodontal disease, periodontal diseases, periodontitis, surveillance", ,"Holtfreter B, Albandar JM, Dietrich T, Dye BA, Eaton KA, Eke PI, Papapanou PN, Kocher T; Joint EU/USA Periodontal Epidemiology Working Group. Standards for reporting chronic periodontitis prevalence and severity in epidemiologic studies: Proposed standards from the Joint EU/USA Periodontal Epidemiology Working Group. J Clin Periodontol. 2015;42(5):407-412.","Holtfreter B, Albandar JM, Dietrich T, Dye BA, Eaton KA, Eke PI, Papapanou PN, Kocher T; Joint EU/USA Periodontal Epidemiology Working Group.",Journal of Clinical Periodontology [J Clin Periodontol.],2015,42,5,407-412, ,English, ,25808877, https://www.ncbi.nlm.nih.gov/pubmed/25808877, , , , , , ,Reporting of the prevalence and severity of periodontal diseases in epidemiological studies., , , , , , , ,no,2017-10-23 13:40:21,2017-10-23 13:43:31,standards-for-reporting-chronic-periodontitis-prevalence-and-severity-in-epidemiologic-studies-proposed-standards-from-the-joint-euusa-periodontal-epidemiology-working-group,"[('title', 'Standards for reporting chronic periodontitis prevalence and severity in epidemiologic studies: Proposed standards from the Joint EU / USA Periodontal Epidemiology Working Group'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of the prevalence and severity of periodontal diseases in epidemiological studies.'), ('Full bibliographic reference', 'Holtfreter B, Albandar JM, Dietrich T, Dye BA, Eaton KA, Eke PI, Papapanou PN, Kocher T; Joint EU/USA Periodontal Epidemiology Working Group. Standards for reporting chronic periodontitis prevalence and severity in epidemiologic studies: Proposed standards from the Joint EU/USA Periodontal Epidemiology Working Group. J Clin Periodontol. 2015;42(5):407-412.'), ('Language', 'English'), ('PubMed ID', '[25808877]( https://www.ncbi.nlm.nih.gov/pubmed/25808877)'), ('Study design', 'Observational studies'), ('Clinical area', 'Dentistry'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method, Statistical methods and analyses, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'October 23, 2017')]"
15569,Graphics and statistics for cardiology: designing effective tables for presentation and publication, ,Cardiovascular medicine,Figures/Graphs, ,"cardiology, cardiovascular, data, data visualisation, data visualization, figure, figures, flow diagram, flow diagrams, graph, graph design, graphics, graphs, statistics, table, table design, tables", ,Boers M. Graphics and statistics for cardiology: designing effective tables for presentation and publication. Heart. 2017.,Boers M.,Heart.,2017, , , , ,English, ,29030423,https://www.ncbi.nlm.nih.gov/pubmed/29030423, , , , , , ,Reporting data in tables and graphs., , , , , , , ,no,2017-10-23 10:10:24,2017-10-23 10:10:24,graphics-and-statistics-for-cardiology-designing-effective-tables-for-presentation-and-publication,"[('title', 'Graphics and statistics for cardiology: designing effective tables for presentation and publication'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting data in tables and graphs.'), ('Full bibliographic reference', 'Boers M. Graphics and statistics for cardiology: designing effective tables for presentation and publication. Heart. 2017.'), ('Language', 'English'), ('PubMed ID', '[29030423](https://www.ncbi.nlm.nih.gov/pubmed/29030423)'), ('Clinical area', 'Cardiovascular medicine'), ('Applies to the whole report or to individual sections of the report?', 'Figures/Graphs'), ('Record last updated on', 'October 23, 2017')]"
15550,Guidelines for reporting meta-epidemiological methodology research,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Whole report, ,"epidemiology, meta analyses, meta analysis, meta-epidemiological, meta-epidemiological methodology, meta-epidemiological methodology studies, meta-epidemiological methodology study, meta-epidemiological research, methodological analysis, methodology research, review, systematic review", ,"Murad MH, Wang Z. Guidelines for reporting meta-epidemiological methodology research. Evid Based Med. 2017 Aug;22(4):139-142.","Murad MH, Wang Z.",Evididence-Based Medicine [Evid Based Med.],2017,22,4,139-142, ,English, ,28701372,https://www.ncbi.nlm.nih.gov/pubmed/28701372, , , , , , ,Reporting meta-epidemiological methodology research studies., , , , , , , ,no,2017-10-13 15:06:46,2017-10-13 15:06:46,guidelines-for-reporting-meta-epidemiological-methodology-research,"[('title', 'Guidelines for reporting meta-epidemiological methodology research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting meta-epidemiological methodology research studies.'), ('Full bibliographic reference', 'Murad MH, Wang Z. Guidelines for reporting meta-epidemiological methodology research. Evid Based Med. 2017 Aug;22(4):139-142.'), ('Language', 'English'), ('PubMed ID', '[28701372](https://www.ncbi.nlm.nih.gov/pubmed/28701372)'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 13, 2017')]"
15548,Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0,Observational studies, ,"Data, Procedure/Method, Terminology/definitions", ,"data, database, databases, dataset, datasets, healthcare database, healthcare database research, healthcare database studies, healthcare database study, healthcare databases, ISPE, ISPOR, Joint ISPE?ISPOR Special Task Force on Real World Evidence in Health Care Decision Making, longitudinal data, longitudinal healthcare databases, observational, observational data, pharmacoepidemiology, replication, reproducibility", ,"Wang SV, Schneeweiss S, Berger ML, Brown J, de Vries F, Douglas I, Gagne JJ, Gini R, Klungel O, Mullins CD, Nguyen MD, Rassen JA, Smeeth L, Sturkenboom M; joint ISPE?ISPOR Special Task Force on Real World Evidence in Health Care Decision Making. Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0.

This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.

Value Health. 2017;20(8):1009-1022. PMID: 28964431
Pharmacoepidemiol Drug Saf. 2017;26(9):1018-1032. PMID: 28913963

","Wang SV, Schneeweiss S, Berger ML, Brown J, de Vries F, Douglas I, Gagne JJ, Gini R, Klungel O, Mullins CD, Nguyen MD, Rassen JA, Smeeth L, Sturkenboom M; joint ISPE?ISPOR Special Task Force on Real World Evidence in Health Care Decision Making.",Value in Health [Value Health.],2017,20,8,1009-1022, ,English, , , , , , , , , ,Reporting of design and implementation decisions in database studies., , , , , , , ,no,2017-10-13 14:08:38,2021-11-23 14:56:06,reporting-to-improve-reproducibility-and-facilitate-validity-assessment-for-healthcare-database-studies-v1-0,"[('title', 'Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of design and implementation decisions in database studies.'), ('Full bibliographic reference', 'Wang SV, Schneeweiss S, Berger ML, Brown J, de Vries F, Douglas I, Gagne JJ, Gini R, Klungel O, Mullins CD, Nguyen MD, Rassen JA, Smeeth L, Sturkenboom M; joint ISPE‐ISPOR Special Task Force on Real World Evidence in Health Care Decision Making. Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0.\n\n \n\n This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.\n\n \n\n Value Health. 2017;20(8):1009-1022. PMID: [28964431](https://www.ncbi.nlm.nih.gov/pubmed/28964431)\n\n Pharmacoepidemiol Drug Saf. 2017;26(9):1018-1032. PMID: [28913963](https://www.ncbi.nlm.nih.gov/pubmed/28913963)\n\n \n\n'), ('Language', 'English'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method, Terminology/definitions'), ('Record last updated on', 'November 23, 2021')]"
15546,Characteristics of funding of clinical trials: cross-sectional survey and proposed guidance,"Clinical trials, Experimental studies", ,Funding, ,"clinical trial, clinical trials, fund, funded, funder, funders, funding, funding contribution, funding contributions, funding information, funding role, funding source, funding sources, funding statement, funding type, grant, grant ID, grants, monetary support, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, support", ,"Hakoum MB, Jouni N, Abou-Jaoude EA, Hasbani DJ, Abou-Jaoude EA, Lopes LC, Khaldieh M, Hammoud MZ, Al-Gibbawi M, Anouti S, Guyatt G, Akl EA. Characteristics of funding of clinical trials: cross-sectional survey and proposed guidance. BMJ Open. 2017;7(10):e015997.","Hakoum MB, Jouni N, Abou-Jaoude EA, Hasbani DJ, Abou-Jaoude EA, Lopes LC, Khaldieh M, Hammoud MZ, Al-Gibbawi M, Anouti S, Guyatt G, Akl EA.",BMJ Open,2017,7,10,e015997, ,English, ,28982811,https://www.ncbi.nlm.nih.gov/pubmed/28982811, , , , , , ,Reporting of randomised controlled trial funding information., , , , , , , ,no,2017-10-13 13:03:38,2017-10-13 13:03:38,characteristics-of-funding-of-clinical-trials-cross-sectional-survey-and-proposed-guidance,"[('title', 'Characteristics of funding of clinical trials: cross-sectional survey and proposed guidance'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of randomised controlled trial funding information.'), ('Full bibliographic reference', 'Hakoum MB, Jouni N, Abou-Jaoude EA, Hasbani DJ, Abou-Jaoude EA, Lopes LC, Khaldieh M, Hammoud MZ, Al-Gibbawi M, Anouti S, Guyatt G, Akl EA. Characteristics of funding of clinical trials: cross-sectional survey and proposed guidance. BMJ Open. 2017;7(10):e015997.'), ('Language', 'English'), ('PubMed ID', '[28982811](https://www.ncbi.nlm.nih.gov/pubmed/28982811)'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Funding'), ('Record last updated on', 'October 13, 2017')]"
15497,Guidelines for Reporting on Latent Trajectory Studies (GRoLTS), , ,"Data, Results, Statistical methods and analyses", ,"checklist, checklists, data, GRoLTS, latent, latent class, latent class growth analysis, latent classes, latent growth mixture modeling, latent growth mixture modelling, latent trajectory analyses, latent trajectory analysis, latent trajectory model, latent trajectory models, latent trajectory studies, latent trajectory study, LCGA, LCGA studies, LCGA study, LGMM, LGMM studies, LGMM study, mixture model framework, mixture modeling, mixture modelling, SEM, statistic, statistical, statistical analyses, statistical analysis, statistical method, statistical methods, statistical model, statistical models, statistical technique, statistical techniques", ,"van de Schoot R, Sijbrandij M, Winter SD, Depaoli S, Vermunt JK. Guidelines for Reporting on Latent Trajectory Studies (GRoLTS). Structural Equation Modeling: A Multidisciplinary Journal. 2017;24(3):451-467.","van de Schoot R, Sijbrandij M, Winter SD, Depaoli S, Vermunt JK.",Structural Equation Modeling: A Multidisciplinary Journal,2017,24,3,451-467, ,English, , , ,The full-text of the this reporting guideline is available at: http://www.tandfonline.com/doi/full/10.1080/10705511.2016.1247646?scroll=top&amp;needAccess=true, , , , ,GRoLTS,Reporting the results of latent trajectory analysis across research fields., , , , , , , ,no,2017-10-09 11:57:01,2021-11-23 14:57:10,guidelines-for-reporting-on-latent-trajectory-studies-grolts,"[('title', 'Guidelines for Reporting on Latent Trajectory Studies (GRoLTS)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the results of latent trajectory analysis across research fields.'), ('Full bibliographic reference', 'van de Schoot R, Sijbrandij M, Winter SD, Depaoli S, Vermunt JK. Guidelines for Reporting on Latent Trajectory Studies (GRoLTS). Structural Equation Modeling: A Multidisciplinary Journal. 2017;24(3):451-467.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the this reporting guideline is available at: <http://www.tandfonline.com/doi/full/10.1080/10705511.2016.1247646?scroll=top&needAccess=true>'), ('Reporting guideline acronym', 'GRoLTS'), ('Applies to the whole report or to individual sections of the report?', 'Data, Results, Statistical methods and analyses'), ('Record last updated on', 'November 23, 2021')]"
15471,AMWA?EMWA?ISMPP Joint Position Statement on the Role of Professional Medical Writers, , ,"Acknowledgements, Conflict of interest, Ethical issues (consent etc.)", ,"American Medical Writers Association, AMWA, EMWA, European Medical Writers Association, International Society for Medical Publication Professionals, ISMPP, medical writer, medical writers, position statement, professional medical writer", ,Winchester C. AMWA?EMWA?ISMPP Joint Position Statement on the Role of Professional Medical Writers. Medical Writing. 2017;26(1).,Winchester c.,Medical Writing,2017,26,1, , ,English, , , ,The full-text of this statement is available at: AMWA?EMWA?ISMPP Joint Position Statement (PDF), , , , , ,Professional medical writers who develop medical and scientific publications., , , , , , , ,no,2017-10-02 11:32:00,2021-11-23 14:57:59,amwa%e2%80%92emwa%e2%80%92ismpp-joint-position-statement-on-the-role-of-professional-medical-writers,"[('title', 'AMWA ‒ EMWA ‒ ISMPP Joint Position Statement on the Role of Professional Medical Writers'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Professional medical writers who develop medical and scientific publications.'), ('Full bibliographic reference', 'Winchester C. AMWA‒EMWA‒ISMPP Joint Position Statement on the Role of Professional Medical Writers. Medical Writing. 2017;26(1).'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this statement is available at: [AMWA‒EMWA‒ISMPP Joint Position Statement (PDF)](http://www.ismpp.org/assets/docs/Inititives/amwa-emwa-ismpp%20joint%20position%20statement%20on%20the%20role%20of%20professional%20medical%20writers_january%202017.pdf)'), ('Applies to the whole report or to individual sections of the report?', 'Acknowledgements, Conflict of interest, Ethical issues (consent etc.)'), ('Record last updated on', 'November 23, 2021')]"
15418,"The STROCSS 2024 guideline: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery",Observational studies,Surgery,Whole report, ,"case control studies, case control study, checklist, checklists, cohort studies, cohort study, cross sectional studies, cross sectional study, observational, observational studies, observational study, Strengthening the Reporting of Cohort Studies in Surgery, STROCSS, STROCSS Checklist, STROCSS guideline, STROCSS statement, surgery, surgical", ,"Rashid R, Sohrabi C, Kerwan A, Franchi T, Mathew G, Nicola M, Agha RA. The STROCSS 2024 guideline: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. Int J Surg. 2024;110(6):3151?65.

","Rashid R, Sohrabi C, Kerwan A, Franchi T, Mathew G, Nicola M, Agha RA.",International Journal of Surgery [Int J Surg.],2024,110,6,3151?65, ,English, ,38445501,https://pubmed.ncbi.nlm.nih.gov/38445501/, , ,"STROCSS 2021
Agha R, Mathew G; STROCSS Group. STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery.
Int J Surg. 2021:106165. PMID: 34774726
Ann Med Surg (Lond). 2021;72:103026. PMID: 34820121

STROCSS 2019
Agha R, Abdall-Razak A, Crossley E, Dowlut N, Iosifidis C, Mathew G. STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery. Int J Surg. 2019;72:156-165. PMID: 31704426

STROCSS 2017
Agha RA, Borrelli MR, Vella-Baldacchino M, Thavayogan R, Orgill DP; STROCSS Group. The STROCSS statement: Strengthening the Reporting of Cohort Studies in Surgery. Int J Surg. 2017;46:198?202. PMID: 28890409

", ,http://www.strocssguideline.com/,STROCSS,"Reporting surgical cohort, cross-sectional and case-control studies.



","The STROCSS 2017 Checklist is available in Turkish (PDF).

",Read the protocol for the development of the STROCSS Statement., , , , , ,no,2017-09-20 09:54:20,2024-06-14 16:01:12,the-strocss-statement-strengthening-the-reporting-of-cohort-studies-in-surgery,"[('title', 'The STROCSS 2024 guideline: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting surgical cohort, cross-sectional and case-control studies.\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Rashid R, Sohrabi C, Kerwan A, Franchi T, Mathew G, Nicola M, Agha RA. The STROCSS 2024 guideline: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. Int J Surg. 2024;110(6):3151–65.\n\n \n\n'), ('Language', 'English'), ('PubMed ID', '[38445501](https://pubmed.ncbi.nlm.nih.gov/38445501/)'), ('Availability in additional languages', 'The STROCSS 2017 Checklist is available in [Turkish (PDF)](https://www.equator-network.org/wp-content/uploads/2020/11/STROCSS-Turkish-translation.pdf).\n\n \n\n'), ('Reporting guideline website URL', '<http://www.strocssguideline.com/>'), ('Reporting guideline acronym', 'STROCSS'), ('Study design', 'Observational studies'), ('Clinical area', 'Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Previous versions of this guideline / Guideline history', '**STROCSS 2021**\n\n Agha R, Mathew G; STROCSS Group. STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery.\n\n Int J Surg. 2021:106165. PMID: [34774726](https://pubmed.ncbi.nlm.nih.gov/34774726/)\n\n Ann Med Surg (Lond). 2021;72:103026. PMID: [34820121](https://pubmed.ncbi.nlm.nih.gov/34820121/)\n\n \n\n**STROCSS 2019**\n\n Agha R, Abdall-Razak A, Crossley E, Dowlut N, Iosifidis C, Mathew G. STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery. Int J Surg. 2019;72:156-165. PMID: [31704426](https://www.ncbi.nlm.nih.gov/pubmed/31704426)\n\n \n\n**STROCSS 2017**\n\n Agha RA, Borrelli MR, Vella-Baldacchino M, Thavayogan R, Orgill DP; STROCSS Group. The STROCSS statement: Strengthening the Reporting of Cohort Studies in Surgery. Int J Surg. 2017;46:198–202. PMID: [28890409](https://www.ncbi.nlm.nih.gov/pubmed/28890409)\n\n \n\n'), ('Additional information', '[Read the protocol](http://www.sciencedirect.com/science/article/pii/S2468357417300323?via%3Dihub) for the development of the STROCSS Statement.'), ('Record last updated on', 'June 14, 2024')]"
15410,Unique identification of research resources in the biomedical literature: the Resource Identification Initiative (RRID), , ,Biospecimen/bioresource information, ,"antibodies, antibody, biologic, biological resource, biological resources, biologics, bioresource, bioresources, cell line, cell lines, constructs, database, databases, knockdown reagent, knockdown reagents, model organisms, organism, organisms, research resource identifier, research resource identifiers, resource identification, resource identification initiative, RRID, RRIDs, sequence molecule, sequence molecules, software", ,"Vasilevsky NA, Brush MH, Paddock H, Ponting L, Tripathy SJ, LaRocca GM, Haendel MA. On the reproducibility of science: unique identification of research resources in the biomedical literature. PeerJ. 2013;1:e148.","Vasilevsky NA, Brush MH, Paddock H, Ponting L, Tripathy SJ, LaRocca GM, Haendel MA.",PeerJ,2013,1, ,148, ,English, ,24032093,https://www.ncbi.nlm.nih.gov/pubmed/24032093,"The full-text of this reporting guideline is freely available at: https://peerj.com/articles/148/

Access the summary reporting guideline checklist at: https://www.force11.org/group/resource-identification-initiative/recommended-reporting-guidelines-life-science-resources

", , , ,https://www.force11.org/group/resource-identification-initiative/, ,"Reporting the key resources used to produce the scientific findings reported in the biomedical literature such as antibodies, model organisms, and software projects.", ,"The Resource Identification Portal is available at: http://scicrunch.com/resources

","Bandrowski AE, Martone ME. RRIDs: A Simple Step toward Improving Reproducibility through Rigor and Transparency of Experimental Methods. Neuron. 2016;90(3):434-6. PMID: 27151636

", ,"Read about this initiative:
Bandrowski A, Brush M, Grethe JS et al. The Resource Identification Initiative: A cultural shift in publishing [version 2; referees: 2 approved]. F1000Research 2015, 4:134. PMID: 26594330

", , ,no,2017-09-18 14:21:46,2021-11-23 15:02:34,unique-identification-of-research-resources-in-the-biomedical-literature-the-resource-identification-initiative,"[('title', 'Unique identification of research resources in the biomedical literature: the Resource Identification Initiative (RRID)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the key resources used to produce the scientific findings reported in the biomedical literature such as antibodies, model organisms, and software projects.'), ('Full bibliographic reference', 'Vasilevsky NA, Brush MH, Paddock H, Ponting L, Tripathy SJ, LaRocca GM, Haendel MA. On the reproducibility of science: unique identification of research resources in the biomedical literature. PeerJ. 2013;1:e148.'), ('Language', 'English'), ('PubMed ID', '[24032093](https://www.ncbi.nlm.nih.gov/pubmed/24032093)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available at: <https://peerj.com/articles/148/>\n\n \n\n Access the summary reporting guideline checklist at: <https://www.force11.org/group/resource-identification-initiative/recommended-reporting-guidelines-life-science-resources>\n\n \n\n'), ('Reporting guideline website URL', '<https://www.force11.org/group/resource-identification-initiative/>'), ('Applies to the whole report or to individual sections of the report?', 'Biospecimen/bioresource information'), ('Other', 'Read about this initiative:\n\n Bandrowski A, Brush M, Grethe JS et al. The Resource Identification Initiative: A cultural shift in publishing [version 2; referees: 2 approved]. F1000Research 2015, 4:134. PMID: [26594330](https://www.ncbi.nlm.nih.gov/pubmed/26594330)\n\n \n\n'), ('Additional information', 'The Resource Identification Portal is available at: <http://scicrunch.com/resources>\n\n \n\n'), ('Selected relevant editorials', 'Bandrowski AE, Martone ME. RRIDs: A Simple Step toward Improving Reproducibility through Rigor and Transparency of Experimental Methods. Neuron. 2016;90(3):434-6. PMID: [27151636](https://www.ncbi.nlm.nih.gov/pubmed/27151636)\n\n \n\n'), ('Record last updated on', 'November 23, 2021')]"
15390,Checklist for One Health Epidemiological Reporting of Evidence (COHERE),Observational studies,Public health,"Acknowledgements, Ethical issues (consent etc.), Narrative sections (discussion etc.), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)", ,"animal, animal health, animal populations, checklist, checklists, COHERE, COHERE checklist, COHERE Standard, COHERE Standards, Ecohealth, environmental, environmental assessment, environmental health, epidemiological, epidemiological studies, epidemiological study, epidemiology, human health, human populations, interventional epidemiological studies, interventional epidemiological study, observational epidemiological studies, observational epidemiological study, observational studies, observational study, One Health, One Health Epidemiological, One Health studies, One Health study, veterinary", ,"Davis MF, Rankin SC, Schurer JM, Cole S, Conti L, Rabinowitz P; COHERE Expert Review Group. Checklist for One Health Epidemiological Reporting of Evidence (COHERE). One Health. 2017;4:14-21.","Davis MF, Rankin SC, Schurer JM, Cole S, Conti L, Rabinowitz P; COHERE Expert Review Group.",One Health.,2017,17,4,14-21, ,English, ,28825424,https://www.ncbi.nlm.nih.gov/pubmed/28825424, , , , , ,COHERE,Reporting of observational and interventional One Health studies that employ epidemiological methods., , , , , , , ,no,2017-08-25 14:09:44,2017-08-25 14:09:44,cohere,"[('title', 'Checklist for One Health Epidemiological Reporting of Evidence (COHERE)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of observational and interventional One Health studies that employ epidemiological methods.'), ('Full bibliographic reference', 'Davis MF, Rankin SC, Schurer JM, Cole S, Conti L, Rabinowitz P; COHERE Expert Review Group. Checklist for One Health Epidemiological Reporting of Evidence (COHERE). One Health. 2017;4:14-21.'), ('Language', 'English'), ('PubMed ID', '[28825424](https://www.ncbi.nlm.nih.gov/pubmed/28825424)'), ('Reporting guideline acronym', 'COHERE'), ('Study design', 'Observational studies'), ('Clinical area', 'Public health'), ('Applies to the whole report or to individual sections of the report?', 'Acknowledgements, Ethical issues (consent etc.), Narrative sections (discussion etc.), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'August 25, 2017')]"
15386,STARD for Abstracts: essential items for reporting diagnostic accuracy studies in journal or conference abstracts,Diagnostic and prognostic studies, ,"Abstract, Conference paper/abstract", ,"abstract, abstracts, checklist, checklists, conference abstract, conference abstracts, diagnosis, diagnostic, diagnostic accuracy, diagnostic accuracy research, diagnostic accuracy studies, diagnostic accuracy study, diagnostic accuracy test, diagnostic accuracy tests, diagnostic research, diagnostic studies, diagnostic study, journal abstract, journal abstracts, STARD extension, STARD for abstracts, STARD-abstracts", ,"Cohen JF, Korevaar DA, Gatsonis CA, Glasziou PP, Hooft L, Moher D, Reitsma JB, de Vet HC, Bossuyt PM; STARD Group. STARD for Abstracts: essential items for reporting diagnostic accuracy studies in journal or conference abstracts. BMJ. 2017;358:j3751.","Cohen JF, Korevaar DA, Gatsonis CA, Glasziou PP, Hooft L, Moher D, Reitsma JB, de Vet HC, Bossuyt PM; STARD Group.",BMJ.,2017,358, , , ,English, ,28819063, https://www.ncbi.nlm.nih.gov/pubmed/28819063,"The full-text of the STARD for Abstracts reporting guideline for diagnostic accuracy studies is available to download as a PDF file.

", , ,"Generic
STARD: Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, LijmerJG Moher D, Rennie D, de Vet HCW, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF, For the STARD Group. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies.

BMJ 2015;351:h5527. PMID: 26511519
Radiology. 2015:151516. PMID: 26509226
Clinical Chemistry 2015. pii: clinchem.2015.246280. PMID: 26510957

Specialised
STARDdem: Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, Davis D, Quinn TJ, Hyde C, Rutjes AW, Smailagic N, Marcus S, Black S, Blennow K, Brayne C, Fiorivanti M, Johnson JK, K\xf6pke S, Schneider LS, Simmons A, Mattsson N, Zetterberg H, Bossuyt PM, Wilcock G, McShane R. Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. Neurology. 2014;83(4):364-373. PMID: 24944261

STRADAS-paraTB: Gardner IA, Nielsen SS, Whittington RJ, Collins MT, Bakker D, Harris B, Sreevatsan S, Lombard JE, Sweeney R, Smith DR, Gavalchin J, Eda S. Consensus-based reporting standards for diagnostic test accuracy studies for paratuberculosis in ruminants. Prev Vet Med. 2011;101(1-2):18-34. PMID: 21601933

STARD-BLCM: Kostoulas P, Nielsen SS, Branscum AJ, Johnson WO, Dendukuri N, Dhand NK, Toft N, Gardner IA. STARD-BLCM: Standards for the Reporting of Diagnostic accuracy studies that use Bayesian Latent Class Models. Prev Vet Med. 2017; 138:37-47. PMID: 28237234

", , ,"Reporting diagnostic accuracy studies in journal or conference abstracts.



STARD for Abstracts checklist (Word)

", ,Read the protocol (PDF) for the development of STARD for Abstracts., , , , , ,yes,2017-08-22 12:53:01,2021-11-23 15:04:59,stard-abstracts,"[('title', 'STARD for Abstracts: essential items for reporting diagnostic accuracy studies in journal or conference abstracts'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting diagnostic accuracy studies in journal or conference abstracts.\n\n \n\n \xa0\n\n \n\n[STARD for Abstracts checklist (Word)](/wp-content/uploads/2017/08/STARD-for-Abstracts-checklist.docx)\n\n \n\n'), ('Full bibliographic reference', 'Cohen JF, Korevaar DA, Gatsonis CA, Glasziou PP, Hooft L, Moher D, Reitsma JB, de Vet HC, Bossuyt PM; STARD Group. STARD for Abstracts: essential items for reporting diagnostic accuracy studies in journal or conference abstracts. BMJ. 2017;358:j3751.'), ('Language', 'English'), ('PubMed ID', '[28819063]( https://www.ncbi.nlm.nih.gov/pubmed/28819063)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the STARD for Abstracts reporting guideline for diagnostic accuracy studies is available to download as a [PDF file](/wp-content/uploads/2017/08/STARD-for-Abstracts-online-manuscript.pdf).\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**STARD**](/reporting-guidelines/stard/): Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, LijmerJG Moher D, Rennie D, de Vet HCW, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF, For the STARD Group. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies.\n\n \n\n BMJ 2015;351:h5527. PMID: [26511519](http://www.ncbi.nlm.nih.gov/pubmed/26511519)\n\n Radiology. 2015:151516. PMID: [26509226](http://www.ncbi.nlm.nih.gov/pubmed/26509226)\n\n Clinical Chemistry 2015. pii: clinchem.2015.246280. PMID: [26510957](http://www.ncbi.nlm.nih.gov/pubmed/26510957)\n\n \n\n**Specialised**\n\n[**STARDdem**](/reporting-guidelines/starddem/): Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, Davis D, Quinn TJ, Hyde C, Rutjes AW, Smailagic N, Marcus S, Black S, Blennow K, Brayne C, Fiorivanti M, Johnson JK, Köpke S, Schneider LS, Simmons A, Mattsson N, Zetterberg H, Bossuyt PM, Wilcock G, McShane R. Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. Neurology. 2014;83(4):364-373. PMID: [24944261](http://www.ncbi.nlm.nih.gov/pubmed/24944261)\n\n \n\n[**STRADAS-paraTB**](/reporting-guidelines/consensus-based-reporting-standards-for-diagnostic-test-accuracy-studies-for-paratuberculosis-in-ruminants/): Gardner IA, Nielsen SS, Whittington RJ, Collins MT, Bakker D, Harris B, Sreevatsan S, Lombard JE, Sweeney R, Smith DR, Gavalchin J, Eda S. Consensus-based reporting standards for diagnostic test accuracy studies for paratuberculosis in ruminants. Prev Vet Med. 2011;101(1-2):18-34. PMID: [21601933](http://www.ncbi.nlm.nih.gov/pubmed/21601933)\n\n \n\n[**STARD-BLCM**](/reporting-guidelines/stard-blcm/): Kostoulas P, Nielsen SS, Branscum AJ, Johnson WO, Dendukuri N, Dhand NK, Toft N, Gardner IA. STARD-BLCM: Standards for the Reporting of Diagnostic accuracy studies that use Bayesian Latent Class Models. Prev Vet Med. 2017; 138:37-47. PMID: [28237234](https://www.ncbi.nlm.nih.gov/pubmed/28237234)\n\n \n\n'), ('Study design', 'Diagnostic and prognostic studies'), ('Applies to the whole report or to individual sections of the report?', 'Abstract, Conference paper/abstract'), ('Additional information', '[Read the protocol (PDF)](/wp-content/uploads/2009/02/STARD-for-Abstracts-protocol.pdf) for the development of STARD for Abstracts.'), ('Record last updated on', 'November 23, 2021')]"
15357,GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research,"Clinical practice guidelines, Clinical trials, Economic evaluations, Experimental studies, Observational studies, Qualitative research, Quality improvement studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,"Abstract, Narrative sections (discussion etc.), Procedure/Method, Results, Study characteristics (participants etc.)", ,"checklist, checklists, clinical guideline, clinical guidelines, clinical trial, clinical trials, community engagement, community-engaged research, engagement, GRIPP, GRIPP2, GRIPP2 checklist, GRIPP2 checklists, GRIPP2 long form, GRIPP2 short form, GRIPP2-LF, GRIPP2-SF, observational, observational studies, observational study, patient, patient and public involvement, patient charities, patient engagement, patient involvement, patient organisations, patient partners, patients, PPI, practice guideline, practice guidelines, public, public engagement, public involvement, qualitative, qualitative research, qualitative studies, qualitative study, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, review, systematic review, systematic reviews, trial, trials", ,"Staniszewska S, Simera I, Seers K, Mockford C, Goodlad S, Altman DG, Moher D, Barber R, Denegri S, Entwistle A, Littlejohns P, Morris C, Suleman R. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research.

This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.

BMJ. 2017;358:j3453. PMID: 28768629
Res Involv Engagem. 2017;3:13. PMID: 29062538

","Staniszewska S, Simera I, Seers K, Mockford C, Goodlad S, Altman DG, Moher D, Barber R, Denegri S, Entwistle A, Littlejohns P, MorrisC, Suleman R.", ,2017, , , , ,English, , , , , ,"Staniszewska S, Brett J, Mockford C, Barber R. The GRIPP checklist: strengthening the quality of patient and public involvement reporting in research. Int J Technol Assess Health Care. 2011 Oct;27(4):391-9. PMID: 22004782

", , ,GRIPP2,Reporting patient and public involvement in health and social care research., ,Read the project summary (PDF) (December 2010), , , , , ,no,2017-08-04 10:26:32,2025-07-08 22:28:59,gripp2-reporting-checklists-tools-to-improve-reporting-of-patient-and-public-involvement-in-research,"[('title', 'GRIPP 2 reporting checklists: tools to improve reporting of patient and public involvement in research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting patient and public involvement in health and social care research.'), ('Full bibliographic reference', 'Staniszewska S, Simera I, Seers K, Mockford C, Goodlad S, Altman DG, Moher D, Barber R, Denegri S, Entwistle A, Littlejohns P, Morris C, Suleman R. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research.\n\n \n\n This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.\n\n \n\n BMJ. 2017;358:j3453. PMID: [28768629](https://pubmed.ncbi.nlm.nih.gov/28768629/)\n\n Res Involv Engagem. 2017;3:13. PMID: [29062538](https://pubmed.ncbi.nlm.nih.gov/29062538/)\n\n \n\n'), ('Language', 'English'), ('Reporting guideline acronym', 'GRIPP2'), ('Study design', 'Clinical practice guidelines, Clinical trials, Economic evaluations, Experimental studies, Observational studies, Qualitative research, Quality improvement studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Abstract, Narrative sections (discussion etc.), Procedure/Method, Results, Study characteristics (participants etc.)'), ('Previous versions of this guideline / Guideline history', 'Staniszewska S, Brett J, Mockford C, Barber R. The GRIPP checklist: strengthening the quality of patient and public involvement reporting in research. Int J Technol Assess Health Care. 2011 Oct;27(4):391-9. PMID: [22004782](https://www.ncbi.nlm.nih.gov/pubmed/22004782)\n\n \n\n'), ('Additional information', 'Read the project [summary (PDF)](/wp-content/uploads/2013/09/3869_Guidelines-for-reporting-the-impact-of-patient-involvement.pdf) (December 2010)'), ('Record last updated on', 'July 8, 2025')]"
15353,"Single organ cutaneous vasculitis: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data",Observational studies,"Dermatology, Infectious diseases","Abstract, Data, Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Statistical methods and analyses, Terminology/definitions", ,"adverse, adverse event, Brighton Collaboration Single Organ Cutaneous Vasculitis Working Group, case, case definition, case report, case reports, case studies, case study, cutaneous, cutaneous vasculitis, CV, event, harm, harms, immunisation, immunization, leukocytoclastic vasculitis, lymphocytic vasculitis, observational, observational studies, observational study, single organ cutaneous vasculitis, skin, small vessel vasculitis of the skin, SOCV, vasculitides, vasculitis", ,"Zanoni G, Girolomoni G, Bonetto C, Trotta F, H\xe4usermann P, Opri R, Bonhoeffer J; Brighton Collaboration Single Organ Cutaneous Vasculitis Working Group. Single organ cutaneous vasculitis: Case definition &amp; guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2016;34(51):6561-6571.","Zanoni G, Girolomoni G, Bonetto C, Trotta F, H\xe4usermann P, Opri R, Bonhoeffer J; Brighton Collaboration Single Organ Cutaneous Vasculitis Working Group.",Vaccine,2016,34,51,6561-6571, ,English, ,28029543,https://www.ncbi.nlm.nih.gov/pubmed/28029543, , , , , , ,"Case definitions and guidelines for data collection, analysis, and presentation of single organ cutaneous vasculitis as an adverse event following immunisation.", , , , , , , ,no,2017-08-01 14:00:06,2017-08-01 14:05:04,single-organ-cutaneous-vasculitis-case-definition-guidelines-for-data-collection-analysis-and-presentation-of-immunization-safety-data,"[('title', 'Single organ cutaneous vasculitis: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Case definitions and guidelines for data collection, analysis, and presentation of single organ cutaneous vasculitis as an adverse event following immunisation.'), ('Full bibliographic reference', 'Zanoni G, Girolomoni G, Bonetto C, Trotta F, Häusermann P, Opri R, Bonhoeffer J; Brighton Collaboration Single Organ Cutaneous Vasculitis Working Group. Single organ cutaneous vasculitis: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2016;34(51):6561-6571.'), ('Language', 'English'), ('PubMed ID', '[28029543](https://www.ncbi.nlm.nih.gov/pubmed/28029543)'), ('Study design', 'Observational studies'), ('Clinical area', 'Dermatology, Infectious diseases'), ('Applies to the whole report or to individual sections of the report?', 'Abstract, Data, Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Statistical methods and analyses, Terminology/definitions'), ('Record last updated on', 'August 1, 2017')]"
15350,Improving the reporting of clinical trials of infertility treatments (IMPRINT): modifying the CONSORT statement,"Clinical trials, Experimental studies",Obstetrics and gynaecology,Whole report, ,"birth, clinical trial, clinical trials, CONSORT extension, fertility treatment, fertility treatments, gynaecological, gynaecology, gynecological, gynecology, IMPRINT, infertile, infertility, infertility treatment, infertility treatments, infertility trial, infertility trials, live birth, maternal-fetal medicine, obstetric, obstetrics, pregnancy, pregnant, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, reproductive, reproductive andrology, reproductive endocrinology, reproductive medicine, sterility, trial, trials", ,"Harbin Consensus Conference Workshop Group; Conference Chairs, Legro RS, Wu X; Scientific Committee, Barnhart KT, Farquhar C, Fauser BC, Mol B. Improving the reporting of clinical trials of infertility treatments (IMPRINT): modifying the CONSORT statement.

This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.

Hum Reprod. 2014;29(10):2075-2082. PMID: 25217611
Fertil Steril. 2014;102(4):952-959. PMID: 25225072

","Harbin Consensus Conference Workshop Group; Conference Chairs, Legro RS, Wu X; Scientific Committee, Barnhart KT, Farquhar C, Fauser BC, Mol B.", ,2014, , , , ,English, , , , ,"The 2014 Harbin Consensus Document with Explanation and Elaboration of the Modification of the CONSORT statement can be accessed at:
http://www.sciencedirect.com/science/article/pii/S0015028214020287?via%3Dihub#appsec1", , , ,IMPRINT,Reporting of clinical trials testing infertility treatment., , , , , , , ,no,2017-08-01 12:35:15,2021-11-23 15:07:48,improving-the-reporting-of-clinical-trials-of-infertility-treatments-imprint-modifying-the-consort-statement,"[('title', 'Improving the reporting of clinical trials of infertility treatments (IMPRINT) : modifying the CONSORT statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of clinical trials testing infertility treatment.'), ('Full bibliographic reference', 'Harbin Consensus Conference Workshop Group; Conference Chairs, Legro RS, Wu X; Scientific Committee, Barnhart KT, Farquhar C, Fauser BC, Mol B. Improving the reporting of clinical trials of infertility treatments (IMPRINT): modifying the CONSORT statement.\n\n \n\n This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.\n\n \n\n Hum Reprod. 2014;29(10):2075-2082. PMID: [25217611](https://www.ncbi.nlm.nih.gov/pubmed/25217611)\n\n Fertil Steril. 2014;102(4):952-959. PMID: [25225072](https://www.ncbi.nlm.nih.gov/pubmed/25225072)\n\n \n\n'), ('Language', 'English'), ('Explanation and elaboration papers', 'The 2014 Harbin Consensus Document with Explanation and Elaboration of the Modification of the CONSORT statement can be accessed at:\n\n<http://www.sciencedirect.com/science/article/pii/S0015028214020287?via%3Dihub#appsec1>'), ('Reporting guideline acronym', 'IMPRINT'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Obstetrics and gynaecology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 23, 2021')]"
15345,Improving the reporting of therapeutic exercise interventions in rehabilitation research,"Clinical trials, Experimental studies, Observational studies","Physiotherapy, Rehabilitation medicine, Sport and exercise medicine",Intervention (exposure), ,"case, case report, case reports, case studies, case study, CERT, CERT extension, checklist, checklists, clinical trial, clinical trials, exercise, exercise training, intervention, interventions, modified CERT, observational, observational studies, observational study, physical, physical therapies, physical therapy, physiotherapy, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, rehabilitation, therapeutic exercise, therapeutic exercise intervention, therapeutic exercise interventions, trial, trials", ,"Page P, Hoogenboom B, Voight M.Improving the reporting of therapeutic exercise interventions in rehabilitation research. Int J Sports Phys Ther. 2017;12(2):297-304.","Page P, Hoogenboom B, Voight M.",International Journal of Sports Physical Therapy [Int J Sports Phys Ther.],2017,12,2,297-304, ,English, ,28515984,https://www.ncbi.nlm.nih.gov/pubmed/28515984, , , ,"Generic
CERT: Slade SC, Dionne CE, Underwood M, Buchbinder R, Beck B, Bennell K, Brosseau L, Costa L, Cramp F, Cup E, Feehan L, Ferreira M, Forbes S, Glasziou P, Habets B, Harris S, Hay-Smith J, Hillier S, Hinman R, Holland A, Hondras M, Kelly G, Kent P, Lauret GJ, Long A, Maher C, Morso L, Osteras N, Peterson T, Quinlivan R, Rees K, Regnaux JP, Rietberg M, Saunders D, Skoetz N, Sogaard K, Takken T, van Tulder M, Voet N, Ward L, White C. Consensus on Exercise Reporting Template (CERT): Modified Delphi Study. Phys Ther. 2016;96(10):1514-1524. PMID: 27149962

", , ,Reporting therapeutic exercise interventions in rehabilitation research., , , , , , , ,no,2017-07-28 15:22:33,2022-04-26 17:22:28,improving-the-reporting-of-therapeutic-exercise-interventions-in-rehabilitation-research,"[('title', 'Improving the reporting of therapeutic exercise interventions in rehabilitation research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting therapeutic exercise interventions in rehabilitation research.'), ('Full bibliographic reference', 'Page P, Hoogenboom B, Voight M.Improving the reporting of therapeutic exercise interventions in rehabilitation research. Int J Sports Phys Ther. 2017;12(2):297-304.'), ('Language', 'English'), ('PubMed ID', '[28515984](https://www.ncbi.nlm.nih.gov/pubmed/28515984)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**[\n\n**CERT**](/reporting-guidelines/consensus-on-exercise-reporting-template-cert/): Slade SC, Dionne CE, Underwood M, Buchbinder R, Beck B, Bennell K, Brosseau L, Costa L, Cramp F, Cup E, Feehan L, Ferreira M, Forbes S, Glasziou P, Habets B, Harris S, Hay-Smith J, Hillier S, Hinman R, Holland A, Hondras M, Kelly G, Kent P, Lauret GJ, Long A, Maher C, Morso L, Osteras N, Peterson T, Quinlivan R, Rees K, Regnaux JP, Rietberg M, Saunders D, Skoetz N, Sogaard K, Takken T, van Tulder M, Voet N, Ward L, White C. Consensus on Exercise Reporting Template (CERT): Modified Delphi Study. Phys Ther. 2016;96(10):1514-1524. PMID: [27149962](https://www.ncbi.nlm.nih.gov/pubmed/27149962)\n\n \n\n'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Physiotherapy, Rehabilitation medicine, Sport and exercise medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'April 26, 2022')]"
15305,Guidance to develop individual dose recommendations for patients on chronic hemodialysis,Observational studies,"Haematology, Pharmaceutical medicine, Renal medicine","Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.)", ,"case, case report, case reports, case studies, case study, checklist, checklists, chronic haemodialysis, chronic hemodialysis, chronic kidney disease, clinical studies, clinical study, dialysis, dose, dose recommendation, dose recommendations, drug, drug dialysability, drugs, end-stage renal disease, haematology, haemodialysis, hematology, hemodialysis, impaired kidney function, individual dose, individualised dose, individualized dose, kidney, kidney function, pharmacokinetic, pharmacokinetic assessment, pharmacokinetic assessments, pharmacological, pharmacology, pharmacometric, pharmacometric modeling, pharmacometric modelling, renal, renal disease, renal impairment, renal replacement therapy", ,"Gotta V, Dao K, Rodieux F, Buclin T, Livio F, Pfister M. Guidance to develop individual dose recommendations for patients on chronic hemodialysis. Expert Rev Clin Pharmacol. 2017;10(7):737-752.","Gotta V, Dao K, Rodieux F, Buclin T, Livio F, Pfister M.",Expert Reviews in Clinical Pharmacology [Expert Rev Clin Pharmacol.],2017,10,10,737-752, ,English, ,28447486,https://www.ncbi.nlm.nih.gov/pubmed/28447486, , , , , , ,"Reporting of pharmacokinetics in case reports of haemodialysis patients.

", , , , , , , ,no,2017-07-26 09:59:47,2017-07-26 10:07:11,guidance-to-develop-individual-dose-recommendations-for-patients-on-chronic-hemodialysis,"[('title', 'Guidance to develop individual dose recommendations for patients on chronic hemodialysis'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of pharmacokinetics in case reports of haemodialysis patients.\n\n \n\n'), ('Full bibliographic reference', 'Gotta V, Dao K, Rodieux F, Buclin T, Livio F, Pfister M. Guidance to develop individual dose recommendations for patients on chronic hemodialysis. Expert Rev Clin Pharmacol. 2017;10(7):737-752.'), ('Language', 'English'), ('PubMed ID', '[28447486](https://www.ncbi.nlm.nih.gov/pubmed/28447486)'), ('Study design', 'Observational studies'), ('Clinical area', 'Haematology, Pharmaceutical medicine, Renal medicine'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'July 26, 2017')]"
15303,A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines,"Clinical trials, Experimental studies", ,Whole report, ,"adaptive, adaptive clinical trial, adaptive clinical trials, adaptive design, adaptive design method, adaptive design methodology, adaptive design methods, adaptive designs, adaptive enrichment, adaptive method, adaptive methods, adaptive randomisation, adaptive randomization, adaptive seamless, applied adaptive design method, applied adaptive design methodology, applied adaptive design methods, biomarker adaptive, cancer, checklist, checklists, clinical trial, clinical trials, flexible design, flexible designs, group sequential, interim analysis, multiple adaptive, oncology, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, sample size adjustment, sample size modification, sample size re-estimation, trial, trials, two-stage adaptive", ,"Mistry P, Dunn JA, Marshall A. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines. BMC Med Res Methodol. 2017;17(1):108.","Mistry P, Dunn JA, Marshall A.",BMC Medical Research Methodology [BMC Med Res Methodol.],2017,17, ,108, ,English, ,28720094,https://www.ncbi.nlm.nih.gov/pubmed/28720094, , , , , , ,Reporting applied adaptive design methodology in randomised controlled trials., , , , , , , ,no,2017-07-26 08:51:17,2017-10-24 13:14:23,a-literature-review-of-applied-adaptive-design-methodology-within-the-field-of-oncology-in-randomised-controlled-trials-and-a-proposed-extension-to-the-consort-guidelines,"[('title', 'A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting applied adaptive design methodology in randomised controlled trials.'), ('Full bibliographic reference', 'Mistry P, Dunn JA, Marshall A. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines. BMC Med Res Methodol. 2017;17(1):108.'), ('Language', 'English'), ('PubMed ID', '[28720094](https://www.ncbi.nlm.nih.gov/pubmed/28720094)'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 24, 2017')]"
15289,AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Whole report, ,"checklist, checklists, CI, complex intervention, complex interventions, health care intervention, health care interventions, intervention, interventions, meta analyses, meta analysis, Preferred Reporting Items for Systematic Reviews and Meta-analyses of Complex Interventions, PRISMA complex interventions, PRISMA extension, PRISMA-CI, review, reviews, systematic, systematic review, systematic reviews", ,"Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement &amp; Checklist. J Clin Epidemiol. 2017;90:43-50.","Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup.",Journal of Clinical Epidemiology [ J Clin Epidemiol.],2017,90, ,43-50, ,English, ,28720516,https://www.ncbi.nlm.nih.gov/pubmed/28720516, ,"Guise JM, Butler M, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 7: PRISMA-CI Elaboration &amp; Explanation. J Clin Epidemiol. 2017;90:51-58.\xa0 PMID: 28720513

", ,"Generic
PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

Specialised
PRISMA-Equity: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: 23222917

Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.
Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

PRISMA-Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.

PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246

PRISMA-IPD: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: 25919529

PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634

PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668

PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.\xa0PMID: 29362800

PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033

PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367

PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791

PRISMA-CHM: Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: 32907365

PRISMA-M 2020: Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: 33100229

PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.
Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535

PRISMA-LSR: Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: 39562017

", ,PRISMA-CI,Reporting of systematic reviews and meta-analyses of complex interventions., , , , , , , ,yes,2017-07-25 13:35:51,2025-02-06 12:02:43,prisma-ci-extension-statement-checklist,"[('title', 'AHRQ Series on Complex Intervention Systematic Reviews – Paper 6: PRISMA-CI Extension Statement & Checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of systematic reviews and meta-analyses of complex interventions.'), ('Full bibliographic reference', 'Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017;90:43-50.'), ('Language', 'English'), ('PubMed ID', '[28720516](https://www.ncbi.nlm.nih.gov/pubmed/28720516)'), ('Explanation and elaboration papers', 'Guise JM, Butler M, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 7: PRISMA-CI Elaboration & Explanation. J Clin Epidemiol. 2017;90:51-58.\xa0 PMID: [28720513](https://www.ncbi.nlm.nih.gov/pubmed/28720513)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic\n\n**[**PRISMA 2020 Statement**](http://dev.equator-network.org/reporting-guidelines/prisma/): Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.\n\n \n\n PLoS Med. 2021;18(3):e1003583. PMID: [33780438](https://pubmed.ncbi.nlm.nih.gov/33780438/)\n\n BMJ 2021;372:n71. PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)\n\n Int J Surg. 2021:105906. PMID: [33789826](https://pubmed.ncbi.nlm.nih.gov/33789826/)\n\n J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: [33789819](https://pubmed.ncbi.nlm.nih.gov/33789819/)\n\n Syst Rev. 2021;10(1):89. PMID: [33781348](https://pubmed.ncbi.nlm.nih.gov/33781348/)\n\n \n\n**Specialised**\n\n[**PRISMA-Equity**](http://dev.equator-network.org/reporting-guidelines/prisma-equity/): Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: [23222917](http://www.ncbi.nlm.nih.gov/pubmed/23222917)\n\n \n\n Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.\n\n Int J Equity Health. 2015;14(1):92. PMID: [26450828](http://www.ncbi.nlm.nih.gov/pubmed/26450828)\n\n J Clin Epidemiol. 2015. PMID: [26348799](http://www.ncbi.nlm.nih.gov/pubmed/26348799)\n\n \n\n[**PRISMA-Abstracts 2020:**](http://dev.equator-network.org/reporting-guidelines/prisma-abstracts/) The PRISMA 2020 for Abstracts reporting guideline is contained within the main [PRISMA 2020 Statement paper](https://www.equator-network.org/reporting-guidelines/prisma/).\n\n \n\n[**PRISMA-P**](http://dev.equator-network.org/reporting-guidelines/prisma-protocols/): Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: [25554246](http://www.ncbi.nlm.nih.gov/pubmed/25554246)\n\n \n\n[**PRISMA-IPD**](http://dev.equator-network.org/reporting-guidelines/prisma-ipd/): Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: [25919529](http://www.ncbi.nlm.nih.gov/pubmed/25919529)\n\n \n\n[**PRISMA extension for network meta-analyses**](http://dev.equator-network.org/reporting-guidelines/prisma-extension-network-meta-analyses/): Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: [26030634](http://www.ncbi.nlm.nih.gov/pubmed/26030634)\n\n \n\n[**PRISMA-harms**](http://dev.equator-network.org/reporting-guidelines/prisma-harms/): Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: [26830668](http://www.ncbi.nlm.nih.gov/pubmed/26830668)\n\n \n\n[**PRISMA-DTA**](http://dev.equator-network.org/reporting-guidelines/prisma-dta/): McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.\xa0PMID: [29362800](https://www.ncbi.nlm.nih.gov/pubmed/29362800)\n\n \n\n[**PRISMA-ScR**](http://dev.equator-network.org/reporting-guidelines/prisma-scr/): Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: [30178033](https://www.ncbi.nlm.nih.gov/pubmed/30178033)\n\n \n\n[**PRISMA-A**](https://dev.equator-network.org/reporting-guidelines/prisma-acupuncture/): Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: [31405367](https://www.ncbi.nlm.nih.gov/pubmed/31405367)\n\n \n\n[**PRISMA-DTA for Abstracts**](https://dev.equator-network.org/reporting-guidelines/prisma-dta-for-abstracts/): Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: [33722791](https://pubmed.ncbi.nlm.nih.gov/33722791/)\n\n \n\n[**PRISMA-CHM**](https://www.equator-network.org/reporting-guidelines/prisma-chinese-herbal-medicines-2020/): Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: [32907365](https://pubmed.ncbi.nlm.nih.gov/32907365/)\n\n \n\n[**PRISMA-M 2020**](https://www.equator-network.org/reporting-guidelines/prisma-extension-for-moxibustion-2020/): Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: [33100229](https://pubmed.ncbi.nlm.nih.gov/33100229/)\n\n \n\n[**PRISMA-S**](https://dev.equator-network.org/reporting-guidelines/prisma-s/): Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.\n\n Syst Rev. 2021;10(1):39. PMID: [33499930](https://pubmed.ncbi.nlm.nih.gov/33499930/)\n\n J Med Libr Assoc. 2021;109(2):174-200. PMID: [34285662](https://pubmed.ncbi.nlm.nih.gov/34285662/)\n\n \n\n[**PRISMA-COSMIN for OMIs**](https://www.equator-network.org/reporting-guidelines/guideline-for-reporting-systematic-reviews-of-outcome-measurement-instruments-omis-prisma-cosmin-for-omis-2024/): Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.\n\n J Clin Epidemiol. 2024:111422. PMID: [38849061](https://pubmed.ncbi.nlm.nih.gov/38849061/)\n\n Qual Life Res. 2024. PMID: [38980635](https://pubmed.ncbi.nlm.nih.gov/38980635/)\n\n Health Qual Life Outcomes. 2024;22(1):48. PMID: [38978063](https://pubmed.ncbi.nlm.nih.gov/38978063/)\n\n J Patient Rep Outcomes. 2024;8(1):64. PMID: [38977535](https://pubmed.ncbi.nlm.nih.gov/38977535/)\n\n \n\n[**PRISMA-LSR**](https://www.equator-network.org/reporting-guidelines/prisma-lsr/): Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: [39562017](https://pubmed.ncbi.nlm.nih.gov/39562017/)\n\n \n\n""), ('Reporting guideline acronym', 'PRISMA-CI'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'February 6, 2025')]"
15287,Adaptation of the CARE Guidelines for Therapeutic Massage and Bodywork Publications: Efforts To Improve the Impact of Case Reports,Observational studies,Complementary and alternative medicine,Whole report, ,"bodywork, CARE, CARE case extension, CARE extension, CARE guideline, case, case report, case reports, case studies, case study, checklist, checklists, manual therapy, massage, massage therapy, therapeutic massage, therapeutic massage and bodywork, TMB, TMB case report", ,"Munk N, Boulanger K. Adaptation of the CARE Guidelines for Therapeutic Massage and Bodywork Publications: Efforts To Improve the Impact of Case Reports. Int J Ther Massage Bodywork. 2014;7(3):32-40.","Munk N, Boulanger K.",International Journal of Therapeutic Massage and Bodywork. [Int J Ther Massage Bodywork.],2014,7,3,32-40, ,English, ,25184013,https://www.ncbi.nlm.nih.gov/pubmed/25184013, , , ,"Generic
CARE: Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; the CARE Group. The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development.

BMJ Case Rep. 2013; doi: 10.1136/bcr-2013-201554 PMID: 24155002
Global Adv Health Med. 2013;10.7453/gahmj.2013.008
Dtsch Arztebl Int. 2013;110(37):603-608. PMID: 24078847\xa0 Full-text in English / Full-text in German
J Clin Epidemiol. 2014;67(1):46-51. PMID: 24035173
J Med Case Rep. 2013;7(1):223. PMID: 24228906\xa0 Full-text.
J Diet Suppl. 2013;10(4):381-390. PMID: 24237192
Headache. 2013;53(10):1541-1547. PMID: 24266334

Specialised
CARE-radiology: Wang M, Luo X, Xiao X, Zhang L, Wang Q, Wang S, Wang X, Xue H, Zhang L, Chen Y, Lei J, ?tupnik T, Scarci M, Fiorelli A, Laisaar T, Fruscio R, Elkhayat H, Novoa NM, Davoli F, Waseda R, Estill J, Norris SL, Riley DS, Tian J. CARE-radiology statement explanation and elaboration: reporting guideline for radiological case reports. BMJ Evid Based Med. 2024:bmjebm-2023-112695. PMID: 38458654

", , ,Reporting therapeutic massage and bodywork case reports., , , , , , , ,no,2017-07-14 15:01:58,2024-04-02 15:29:02,adaptation-of-the-care-guidelines-for-therapeutic-massage-and-bodywork-publications-efforts-to-improve-the-impact-of-case-reports,"[('title', 'Adaptation of the CARE Guidelines for Therapeutic Massage and Bodywork Publications: Efforts To Improve the Impact of Case Reports'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting therapeutic massage and bodywork case reports.'), ('Full bibliographic reference', 'Munk N, Boulanger K. Adaptation of the CARE Guidelines for Therapeutic Massage and Bodywork Publications: Efforts To Improve the Impact of Case Reports. Int J Ther Massage Bodywork. 2014;7(3):32-40.'), ('Language', 'English'), ('PubMed ID', '[25184013](https://www.ncbi.nlm.nih.gov/pubmed/25184013)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CARE**](/reporting-guidelines/care/): Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; the CARE Group. The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development.\n\n \n\n BMJ Case Rep. 2013; doi: 10.1136/bcr-2013-201554 PMID: [24155002](http://www.ncbi.nlm.nih.gov/pubmed/24155002)\n\n Global Adv Health Med. 2013;[10.7453/gahmj.2013.008](http://www.gahmj.com/doi/abs/10.7453/gahmj.2013.008)\n\n Dtsch Arztebl Int. 2013;110(37):603-608. PMID: [24078847](http://www.ncbi.nlm.nih.gov/pubmed/24078847) [Full-text in English](http://www.aerzteblatt.de/int/archive/article/145667/The-CARE-Guidelines-Consensus-Based-Clinical-Case-Reporting-Guideline-Development) / [Full-text in German](http://www.aerzteblatt.de/archiv/145657/Die-Case-Reporting-%28CARE%29-Guideline-Entwicklung-einer-konsensbasierten-Leitlinie-fuer-die-Erstellung-klinischer-Fallberichte)\n\n J Clin Epidemiol. 2014;67(1):46-51. PMID: [24035173](http://www.ncbi.nlm.nih.gov/pubmed/24035173)\n\n J Med Case Rep. 2013;7(1):223. PMID: [24228906](http://www.ncbi.nlm.nih.gov/pubmed/24228906) [Full-text](http://www.jmedicalcasereports.com/content/7/1/223).\n\n J Diet Suppl. 2013;10(4):381-390. PMID: [24237192](http://www.ncbi.nlm.nih.gov/pubmed/24237192)\n\n Headache. 2013;53(10):1541-1547. PMID: [24266334](http://www.ncbi.nlm.nih.gov/pubmed/24266334)\n\n \n\n**Specialised**\n\n[**CARE-radiology**](https://www.equator-network.org/reporting-guidelines/care-radiology-statement-explanation-and-elaboration-reporting-guideline-for-radiological-case-reports/): Wang M, Luo X, Xiao X, Zhang L, Wang Q, Wang S, Wang X, Xue H, Zhang L, Chen Y, Lei J, Štupnik T, Scarci M, Fiorelli A, Laisaar T, Fruscio R, Elkhayat H, Novoa NM, Davoli F, Waseda R, Estill J, Norris SL, Riley DS, Tian J. CARE-radiology statement explanation and elaboration: reporting guideline for radiological case reports. BMJ Evid Based Med. 2024:bmjebm-2023-112695. PMID: [38458654](https://pubmed.ncbi.nlm.nih.gov/38458654/)\n\n \n\n'), ('Study design', 'Observational studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'April 2, 2024')]"
15285,A review of published analyses of case-cohort studies and recommendations for future reporting,Observational studies, ,"Statistical methods and analyses, Study characteristics (participants etc.)", ,"case, case-cohort, case-cohort studies, case-cohort study, checklist, checklists, cohort, nested case-control, observational, observational studies, observational study, statistic, statistical, statistical method, statistical methods, statistics, STROBE, STROBE extension, sub-cohort, subcohort", ,"Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176.","Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM.",PLoS One.,2014,9,6, , ,English, ,24972092,https://www.ncbi.nlm.nih.gov/pubmed/24972092, , , ,"Generic
STROBE: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Ann Intern Med. 2007;147(8):573-577. PMID: 17938396
PLoS Med. 2007;4(10):e296. PMID: 17941714
BMJ. 2007;335(7624):806-808. PMID: 17947786
Prev Med. 2007;45(4):247-251. PMID: 17950122
Epidemiology. 2007;18(6):800-804. PMID: 18049194
Lancet. 2007;370(9596):1453-1457. PMID: 18064739

Specialised
STREGA: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.

PLoS Med. 2009;6(2):e22. PMID: 19192942
Hum Genet. 2009;125(2):131-151. PMID: 19184668
Eur J Epidemiol. 2009;24(1):37-55. PMID: 19189221
Ann Intern Med. 2009;150(3):206-215. PMID: 19189911
J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: 19217256
Genet Epidemiol. 2009;33(7):581-598. PMID: 19278015
Eur J Clin Invest. 2009;39(4):247-266. PMID: 19297801

STROBE-ME: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: 22023344

STROBE checklist for conference abstracts
First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. Link to full text pdf

STROME-ID: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: 24631223

Longitudinal observational drug studies in rheumatology: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: 24058015

STROBE-RDS: White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: 26112433

RECORD: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: 26440803

STROBE-AMS: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schr\xf6der W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: 26895985

STROBE-nut: Lachat C, Hawwash D, Ock\xe9 MC, Berg C, Forsum E, H\xf6rnell A, Larsson C, Sonestedt E, Wirf\xe4lt E, \xc5kesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology?Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: 27270749

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

ROSES-I: Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: 27417916

STROBE-NI: Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: 27633910

Propensity score analysis: Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: 28376195

RECORD-PE: Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.

STROBE-SIIS: International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, H\xe4gglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).

Br J Sports Med. 2020;54(7):372-389. PMID: 32071062
Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: 32118084

STROBE-MR: Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: 34698778

", , ,Reporting of case-cohort studies., , , , , , , ,no,2017-07-14 13:36:58,2021-11-25 15:25:54,a-review-of-published-analyses-of-case-cohort-studies-and-recommendations-for-future-reporting,"[('title', 'A review of published analyses of case-cohort studies and recommendations for future reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of case-cohort studies.'), ('Full bibliographic reference', 'Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176.'), ('Language', 'English'), ('PubMed ID', '[24972092](https://www.ncbi.nlm.nih.gov/pubmed/24972092)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n**[STROBE](/reporting-guidelines/strobe/)**: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.\n\n \n\n Ann Intern Med. 2007;147(8):573-577. PMID: [17938396](http://www.ncbi.nlm.nih.gov/pubmed/17938396)\n\n PLoS Med. 2007;4(10):e296. PMID: [17941714](http://www.ncbi.nlm.nih.gov/pubmed/17941714)\n\n BMJ. 2007;335(7624):806-808. PMID: [17947786](http://www.ncbi.nlm.nih.gov/pubmed/17947786)\n\n Prev Med. 2007;45(4):247-251. PMID: [17950122](http://www.ncbi.nlm.nih.gov/pubmed/17950122)\n\n Epidemiology. 2007;18(6):800-804. PMID: [18049194](http://www.ncbi.nlm.nih.gov/pubmed/18049194)\n\n Lancet. 2007;370(9596):1453-1457. PMID: [18064739](http://www.ncbi.nlm.nih.gov/pubmed/18064739)\n\n \n\n**Specialised**\n\n[**STREGA**](/reporting-guidelines/strobe-strega/): Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.\n\n \n\n PLoS Med. 2009;6(2):e22. PMID: [19192942](http://www.ncbi.nlm.nih.gov/pubmed/19192942)\n\n Hum Genet. 2009;125(2):131-151. PMID: [19184668](http://www.ncbi.nlm.nih.gov/pubmed/19184668)\n\n Eur J Epidemiol. 2009;24(1):37-55. PMID: [19189221](http://www.ncbi.nlm.nih.gov/pubmed/19189221)\n\n Ann Intern Med. 2009;150(3):206-215. PMID: [19189911](http://www.ncbi.nlm.nih.gov/pubmed/19189911)\n\n J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: [19217256](http://www.ncbi.nlm.nih.gov/pubmed/19217256)\n\n Genet Epidemiol. 2009;33(7):581-598. PMID: [19278015](http://www.ncbi.nlm.nih.gov/pubmed/19278015)\n\n Eur J Clin Invest. 2009;39(4):247-266. PMID: [19297801](http://www.ncbi.nlm.nih.gov/pubmed/19297801)\n\n \n\n[**STROBE-ME**](/reporting-guidelines/strobe-me/): Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: [22023344](http://www.ncbi.nlm.nih.gov/pubmed/22023344)\n\n \n\n[**STROBE checklist for conference abstracts**](/reporting-guidelines/strobe-abstracts/)\n\n First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. [Link to full text pdf](https://www.strobe-statement.org/download/strobe-checklist-conference-abstracts)\n\n \n\n[**STROME-ID**](/reporting-guidelines/strome-id/): Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: [24631223](http://www.ncbi.nlm.nih.gov/pubmed/24631223)\n\n \n\n[**Longitudinal observational drug studies in rheumatology**](/reporting-guidelines/launch-of-a-checklist-for-reporting-longitudinal-observational-drug-studies-in-rheumatology-a-eular-extension-of-strobe-guidelines-based-on-experience-from-biologics-registries/): Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: [24058015](http://www.ncbi.nlm.nih.gov/pubmed/24058015)\n\n \n\n[**STROBE-RDS**](/reporting-guidelines/strobe-rds/): White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: [26112433](http://www.ncbi.nlm.nih.gov/pubmed/26112433)\n\n \n\n[**RECORD**](/reporting-guidelines/record/): Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: [26440803](http://www.ncbi.nlm.nih.gov/pubmed/26440803)\n\n \n\n[**STROBE-AMS**](/reporting-guidelines/strobe-ams/): Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schröder W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: [26895985](http://www.ncbi.nlm.nih.gov/pubmed/26895985)\n\n \n\n[**STROBE-nut**](/reporting-guidelines/strobe-nut/): Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology—Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: [27270749](https://www.ncbi.nlm.nih.gov/pubmed/27270749)\n\n \n\n[**Simulation Research**](/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**ROSES-I**](/reporting-guidelines/roses-i-statement/): Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: [27417916](https://www.ncbi.nlm.nih.gov/pubmed/27417916)\n\n \n\n[**STROBE-NI**](/reporting-guidelines/strobe-ni/): Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: [27633910](https://www.ncbi.nlm.nih.gov/pubmed/27633910)\n\n \n\n[**Propensity score analysis**](/reporting-guidelines/reporting-and-guidelines-in-propensity-score-analysis-a-systematic-review-of-cancer-and-cancer-surgical-studies/): Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: [28376195](https://www.ncbi.nlm.nih.gov/pubmed/28376195)\n\n \n\n[**RECORD-PE**](https://www.equator-network.org/reporting-guidelines/record-pe/): Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). [BMJ 2018;363:k3532](https://www.bmj.com/content/363/bmj.k3532.full).\n\n \n\n[**STROBE-SIIS**](https://www.equator-network.org/reporting-guidelines/strobe-extension-for-sports-injury-illness-surveillance/): International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, Hägglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).\n\n \n\n Br J Sports Med. 2020;54(7):372-389. PMID: [32071062](https://pubmed.ncbi.nlm.nih.gov/32071062/)\n\n Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: [32118084](https://pubmed.ncbi.nlm.nih.gov/32118084/)\n\n \n\n[**STROBE-MR**](https://www.equator-network.org/reporting-guidelines/strobe-mr-statement/): Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: [34698778](https://pubmed.ncbi.nlm.nih.gov/34698778/)\n\n \n\n'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'November 25, 2021')]"
15283,Guidelines for reporting evaluations based on observational methodology,Observational studies, ,"Intervention (exposure), Procedure/Method, Results", ,"checklist, checklists, evaluation, evaluation studies, evaluation study, evaluations, GREOM, Guidelines for Reporting Evaluations based on Observational Methodology, observational, observational method, observational methodology, observational methods, program evaluation, programme evaluation", ,"Portell M, Anguera MT, Chac\xf3n-Moscoso S, Sanduvete-Chaves S. Guidelines for reporting evaluations based on observational methodology. Psicothema. 2015;27(3): 283-289.","Portell M, Anguera MT, Chac\xf3n-Moscoso S, Sanduvete-Chaves S.",Psicothema.,2015,27,3,283-289, ,English, ,26260937,https://pubmed.ncbi.nlm.nih.gov/26260937/,The full-text of the GREOM reporting guideline (PDF) is freely available., , , , ,GREOM,Reporting observational studies in the field of program evaluation., , , , , , , ,no,2017-07-14 10:51:28,2021-09-09 11:58:52,guidelines-for-reporting-evaluations-based-on-observational-methodology,"[('title', 'Guidelines for reporting evaluations based on observational methodology'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting observational studies in the field of program evaluation.'), ('Full bibliographic reference', 'Portell M, Anguera MT, Chacón-Moscoso S, Sanduvete-Chaves S. Guidelines for reporting evaluations based on observational methodology. Psicothema. 2015;27(3): 283-289.'), ('Language', 'English'), ('PubMed ID', '[26260937](https://pubmed.ncbi.nlm.nih.gov/26260937/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the [GREOM reporting guideline (PDF)](http://www.psicothema.com/pdf/4265.pdf) is freely available.'), ('Reporting guideline acronym', 'GREOM'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Procedure/Method, Results'), ('Record last updated on', 'September 9, 2021')]"
15279,Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies,Observational studies,"Oncology, Surgery","Statistical methods and analyses, Whole report", ,"analyses, analysis, cancer, cancers, observational, observational data, observational studies, observational study, oncological, oncology, oncology studies, oncology study, propensity, propensity analyses, propensity analysis, propensity method, propensity methods, propensity score, propensity score analyses, propensity score analysis, propensity scores, PS, PS analysis, statistic, statistical, statistical test, statistical tests, statistics, STROBE, STROBE extension, surgery, surgical", ,"Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8).","Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH.",Journal of the National Cancer Institute [J Natl Cancer Inst.],2017,109,8, , ,English, ,28376195,https://www.ncbi.nlm.nih.gov/pubmed/28376195, , , ,"Generic
STROBE Statement: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Ann Intern Med. 2007;147(8):573-577. PMID: 17938396
PLoS Med. 2007;4(10):e296. PMID: 17941714
BMJ. 2007;335(7624):806-808. PMID: 17947786
Prev Med. 2007;45(4):247-251. PMID: 17950122
Epidemiology. 2007;18(6):800-804. PMID: 18049194
Lancet. 2007;370(9596):1453-1457. PMID: 18064739

Specialised
STREGA: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.

PLoS Med. 2009;6(2):e22. PMID: 19192942
Hum Genet. 2009;125(2):131-151. PMID: 19184668
Eur J Epidemiol. 2009;24(1):37-55. PMID: 19189221
Ann Intern Med. 2009;150(3):206-215. PMID: 19189911
J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: 19217256
Genet Epidemiol. 2009;33(7):581-598. PMID: 19278015
Eur J Clin Invest. 2009;39(4):247-266. PMID: 19297801

STROBE-ME: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: 22023344

STROBE checklist for conference abstracts
First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. Link to full text pdf

STROME-ID: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: 24631223

Longitudinal observational drug studies in rheumatology: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: 24058015

Case-cohort studies: Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: 24972092

STROBE-RDS: White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: 26112433

RECORD: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: 26440803

STROBE-AMS: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schr\xf6der W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: 26895985

STROBE-nut: Lachat C, Hawwash D, Ock\xe9 MC, Berg C, Forsum E, H\xf6rnell A, Larsson C, Sonestedt E, Wirf\xe4lt E, \xc5kesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology?Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: 27270749

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

ROSES-I: Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: 27417916

STROBE-NI: Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: 27633910

RECORD-PE: Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.

STROBE-SIIS: International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, H\xe4gglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).

Br J Sports Med. 2020;54(7):372-389. PMID: 32071062
Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: 32118084

STROBE-MR: Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: 34698778

", , ,Reporting of propensity score analyses., , , , , , , ,no,2017-07-14 09:56:27,2021-11-25 15:01:14,reporting-and-guidelines-in-propensity-score-analysis-a-systematic-review-of-cancer-and-cancer-surgical-studies,"[('title', 'Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of propensity score analyses.'), ('Full bibliographic reference', 'Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8).'), ('Language', 'English'), ('PubMed ID', '[28376195](https://www.ncbi.nlm.nih.gov/pubmed/28376195)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n STROBE Statement: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.\n\n \n\n Ann Intern Med. 2007;147(8):573-577. PMID: [17938396](http://www.ncbi.nlm.nih.gov/pubmed/17938396)\n\n PLoS Med. 2007;4(10):e296. PMID: [17941714](http://www.ncbi.nlm.nih.gov/pubmed/17941714)\n\n BMJ. 2007;335(7624):806-808. PMID: [17947786](http://www.ncbi.nlm.nih.gov/pubmed/17947786)\n\n Prev Med. 2007;45(4):247-251. PMID: [17950122](http://www.ncbi.nlm.nih.gov/pubmed/17950122)\n\n Epidemiology. 2007;18(6):800-804. PMID: [18049194](http://www.ncbi.nlm.nih.gov/pubmed/18049194)\n\n Lancet. 2007;370(9596):1453-1457. PMID: [18064739](http://www.ncbi.nlm.nih.gov/pubmed/18064739)\n\n \n\n**Specialised**\n\n[**STREGA**](/reporting-guidelines/strobe-strega/): Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.\n\n \n\n PLoS Med. 2009;6(2):e22. PMID: [19192942](http://www.ncbi.nlm.nih.gov/pubmed/19192942)\n\n Hum Genet. 2009;125(2):131-151. PMID: [19184668](http://www.ncbi.nlm.nih.gov/pubmed/19184668)\n\n Eur J Epidemiol. 2009;24(1):37-55. PMID: [19189221](http://www.ncbi.nlm.nih.gov/pubmed/19189221)\n\n Ann Intern Med. 2009;150(3):206-215. PMID: [19189911](http://www.ncbi.nlm.nih.gov/pubmed/19189911)\n\n J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: [19217256](http://www.ncbi.nlm.nih.gov/pubmed/19217256)\n\n Genet Epidemiol. 2009;33(7):581-598. PMID: [19278015](http://www.ncbi.nlm.nih.gov/pubmed/19278015)\n\n Eur J Clin Invest. 2009;39(4):247-266. PMID: [19297801](http://www.ncbi.nlm.nih.gov/pubmed/19297801)\n\n \n\n[**STROBE-ME**](/reporting-guidelines/strobe-me/): Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: [22023344](http://www.ncbi.nlm.nih.gov/pubmed/22023344)\n\n \n\n[**STROBE checklist for conference abstracts**](/reporting-guidelines/strobe-abstracts/)\n\n First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. [Link to full text pdf](https://www.strobe-statement.org/download/strobe-checklist-conference-abstracts)\n\n \n\n[**STROME-ID**](/reporting-guidelines/strome-id/): Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: [24631223](http://www.ncbi.nlm.nih.gov/pubmed/24631223)\n\n \n\n[**Longitudinal observational drug studies in rheumatology**](/reporting-guidelines/launch-of-a-checklist-for-reporting-longitudinal-observational-drug-studies-in-rheumatology-a-eular-extension-of-strobe-guidelines-based-on-experience-from-biologics-registries/): Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: [24058015](http://www.ncbi.nlm.nih.gov/pubmed/24058015)\n\n \n\n[**Case-cohort studies**](/reporting-guidelines/a-review-of-published-analyses-of-case-cohort-studies-and-recommendations-for-future-reporting/): Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: [24972092](https://www.ncbi.nlm.nih.gov/pubmed/24972092)\n\n \n\n[**STROBE-RDS**](/reporting-guidelines/strobe-rds/): White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: [26112433](http://www.ncbi.nlm.nih.gov/pubmed/26112433)\n\n \n\n[**RECORD**](/reporting-guidelines/record/): Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: [26440803](http://www.ncbi.nlm.nih.gov/pubmed/26440803)\n\n \n\n[**STROBE-AMS**](/reporting-guidelines/strobe-ams/): Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schröder W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: [26895985](http://www.ncbi.nlm.nih.gov/pubmed/26895985)\n\n \n\n[**STROBE-nut**](/reporting-guidelines/strobe-nut/): Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology—Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: [27270749](https://www.ncbi.nlm.nih.gov/pubmed/27270749)\n\n \n\n[**Simulation Research**](/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**ROSES-I**](/reporting-guidelines/roses-i-statement/): Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: [27417916](https://www.ncbi.nlm.nih.gov/pubmed/27417916)\n\n \n\n[**STROBE-NI**](/reporting-guidelines/strobe-ni/): Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: [27633910](https://www.ncbi.nlm.nih.gov/pubmed/27633910)\n\n \n\n[**RECORD-PE**](https://www.equator-network.org/reporting-guidelines/record-pe/): Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). [BMJ 2018;363:k3532](https://www.bmj.com/content/363/bmj.k3532.full).\n\n \n\n[**STROBE-SIIS**](https://www.equator-network.org/reporting-guidelines/strobe-extension-for-sports-injury-illness-surveillance/): International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, Hägglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).\n\n \n\n Br J Sports Med. 2020;54(7):372-389. PMID: [32071062](https://pubmed.ncbi.nlm.nih.gov/32071062/)\n\n Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: [32118084](https://pubmed.ncbi.nlm.nih.gov/32118084/)\n\n \n\n[**STROBE-MR**](https://www.equator-network.org/reporting-guidelines/strobe-mr-statement/): Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: [34698778](https://pubmed.ncbi.nlm.nih.gov/34698778/)\n\n \n\n'), ('Study design', 'Observational studies'), ('Clinical area', 'Oncology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses, Whole report'), ('Record last updated on', 'November 25, 2021')]"
15277,Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO): Platelet-Rich Plasma and Mesenchymal Stem Cells,"Clinical trials, Experimental studies, Observational studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews","Rheumatology, Sport and exercise medicine, Surgery","Ethical issues (consent etc.), Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)", ,"biologic, biologic strategies, biologic strategy, biologic therapies, biologic therapy, biologics, blood, cell, cell culture, cells, checklist, checklists, clinical orthopaedic studies, clinical orthopaedic study, clinical orthopedic studies, clinical orthopedic study, injuries, injury, mesenchymal, Mesenchymal Stem Cells, MIBO, Minimum Information for Studies Evaluating Biologics in Orthopaedics, MSCs, musculoskeletal, musculoskeletal injuries, musculoskeletal injury, orthopaedic, orthopaedic injuries, orthopaedic injury, orthopaedics, orthopedic, orthopedic injuries, orthopedic injury, orthopedics, plasma, platelet-rich plasma, post operative, PRP, sports injuries, sports injury, stem cell, stem cells, surgery, surgical, tissue", ,"Murray IR, Geeslin AG, Goudie EB, Petrigliano FA, LaPrade RF. Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO): Platelet-Rich Plasma and Mesenchymal Stem Cells. J Bone Joint Surg Am. 2017;99(10):809-819.","Murray IR, Geeslin AG, Goudie EB, Petrigliano FA, LaPrade RF.",Journal of Bone and Joint Surgery American Volume [J Bone Joint Surg Am.],2017,99,10,809-819, ,English, ,28509821,https://www.ncbi.nlm.nih.gov/pubmed/28509821, , , , ,https://www.mibo-statement.org/,MIBO,"Reporting of clinical studies evaluating platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs).



MIBO PRP checklist (PDF)

MIBO stem cells checklist (PDF)

", ,"Murray IR, Murray AD, Geeslin AG, Goudie EB, White TO, Petrigliano FA, LaPrade RF. Infographic: we need minimum reporting standards for biologics. Br J Sports Med. 2017. PMID: 28831016", , , , , ,no,2017-07-14 08:56:46,2021-11-25 17:13:44,minimum-information-for-studies-evaluating-biologics-in-orthopaedics-mibo-platelet-rich-plasma-and-mesenchymal-stem-cells,"[('title', 'Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO) : Platelet -Rich Plasma and Mesenchymal Stem Cells'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of clinical studies evaluating platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs).\n\n \n\n \xa0\n\n \n\n[MIBO PRP checklist (PDF)](https://docs.wixstatic.com/ugd/fab5aa_edd6afad280b46abb5d9df625eb8aaab.pdf)\n\n \n\n[MIBO stem cells checklist (PDF)](https://docs.wixstatic.com/ugd/fab5aa_5fa8e5e8f96a44f1ae8f3be50e00c316.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Murray IR, Geeslin AG, Goudie EB, Petrigliano FA, LaPrade RF. Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO): Platelet-Rich Plasma and Mesenchymal Stem Cells. J Bone Joint Surg Am. 2017;99(10):809-819.'), ('Language', 'English'), ('PubMed ID', '[28509821](https://www.ncbi.nlm.nih.gov/pubmed/28509821)'), ('Reporting guideline website URL', '<https://www.mibo-statement.org/>'), ('Reporting guideline acronym', 'MIBO'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Clinical area', 'Rheumatology, Sport and exercise medicine, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Ethical issues (consent etc.), Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)'), ('Additional information', 'Murray IR, Murray AD, Geeslin AG, Goudie EB, White TO, Petrigliano FA, LaPrade RF. Infographic: we need minimum reporting standards for biologics. Br J Sports Med. 2017. PMID: [28831016](https://www.ncbi.nlm.nih.gov/pubmed/28831016)'), ('Record last updated on', 'November 25, 2021')]"
15242,CONSORT 2010 statement: extension checklist for reporting within person randomised trials,"Clinical trials, Experimental studies", ,Whole report, ,"checklist, checklists, clinical trial, clinical trials, CONSORT extension, CONSORT split body, CONSORT within person, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, split body, within person, within person randomised trial, within person randomised trials, within person randomized trial, within person randomized trials, within person trial, within person trials", ,"Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials.

This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.

BMJ. 2017;357:j2835.\xa0PMID: 28667088
Br J Dermatol. 2019. PMID: 30609010

","Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG.", , , , , , ,English, , , , , , ,"Generic
CONSORT 2010 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", , ,"Reporting within person randomised trials.



", , , , , , , ,yes,2017-07-03 08:20:02,2025-05-30 09:21:07,consort-within-person-randomised-trials,"[('title', 'CONSORT 2010 statement: extension checklist for reporting within person randomised trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting within person randomised trials.\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials.\n\n \n\n This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.\n\n \n\n BMJ. 2017;357:j2835.\xa0PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n Br J Dermatol. 2019. PMID: [30609010](https://www.ncbi.nlm.nih.gov/pubmed/30609010)\n\n \n\n'), ('Language', 'English'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2010 Statement:**](https://www.equator-network.org/reporting-guidelines/consort/)Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](http://dev.equator-network.org/reporting-guidelines/consort-cluster/):\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](http://dev.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](http://dev.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](http://dev.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 30, 2025')]"
15238,"CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration","Clinical trials, Experimental studies",Complementary and alternative medicine,Whole report, ,"checklist, checklists, Chinese herbal, Chinese herbal medicine, Chinese herbal medicine formulas, Chinese herbal medicines, Chinese medicinal substances, Chinese medicine, Chinese medicines, CHM, clinical trial, clinical trials, CONSORT extension, CONSORT-CHM, CONSORT-CHM formula, CONSORT-CHM formulas, CONSORT-CHM Formulas 2017, herbal, herbal intervention, herbal interventions, herbal medicinal product, herbal medicinal products, herbal medicine, herbal medicine intervention, herbal medicine interventions, herbal medicines, herbal product, herbal products, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, TCM, traditional Chinese medicine, traditional Chinese medicines, trial, trials", ,"Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med.","Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group.",Annals of Internal Medicine [Ann Intern Med.],2017, , , , ,English, ,28654980,https://www.ncbi.nlm.nih.gov/pubmed/28654980,"Read the full-text of this reporting guideline.

", , ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.



BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", , CONSORT-CHM,"Reporting clinical trials of Chinese Herbal Medicine formulas.



","The CONSORT Extension for Chinese Herbal Medicine Formulas 2017 is also available in the following languages:

Traditional Chinese. PMID: 28654988
Simplified Chinese. PMID: 28654957

", , , , , , ,yes,2017-06-28 08:44:20,2025-05-30 09:20:52,consort-chinese-herbal-medicine-formulas,"[('title', 'CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting clinical trials of Chinese Herbal Medicine formulas.\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med.'), ('Language', 'English'), ('PubMed ID', '[28654980](https://www.ncbi.nlm.nih.gov/pubmed/28654980)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration) of this reporting guideline.\n\n \n\n'), ('Availability in additional languages', 'The CONSORT Extension for Chinese Herbal Medicine Formulas 2017 is also available in the following languages:\n\n \n\n Traditional Chinese. PMID: [28654988](https://www.ncbi.nlm.nih.gov/pubmed/28654988)\n\n Simplified Chinese. PMID: [28654957](https://www.ncbi.nlm.nih.gov/pubmed/28654957)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](https://www.equator-network.org/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n \xa0\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised\n\n**[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n**[CONSORT Non-inferiority](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/)**: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n**[CONSORT Cluster](http://dev.equator-network.org/reporting-guidelines/consort-cluster/)**:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](http://dev.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](http://dev.equator-network.org/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](http://dev.equator-network.org/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'CONSORT-CHM'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 30, 2025')]"
15144,Methods and processes of developing the strengthening the reporting of observational studies in epidemiology - veterinary (STROBE-Vet) statement,Observational studies, ,Whole report, ,"animal, animal health, animal populations, animal production, animal welfare, animals, food, food production, food safety, observational, observational research, observational studies, observational study, STROBE, STROBE veterinary, STROBE-Vet, STROBE-Vet checklist, STROBE-Vet Statement, vet, veterinary, veterinary medicine, veterinary practice, veterinary research", ,"Sargeant JM, O'Connor AM, Dohoo IR, Erb HN, Cevallos M, Egger M, Ersb\xf8ll AK, Martin SW, Nielsen LR, Pearl DL, Pfeiffer DU, Sanchez J, Torrence ME, Vigre H, Waldner C, Ward MP. Methods and processes of developing the strengthening the reporting of observational studies in epidemiology - veterinary (STROBE-Vet) statement.

This guideline was published simultaneously in 4 journals. You can read the guideline in any of these journals using the links below.

Prev Vet Med. 2016;134:188-196. PMID: 27836042
J Vet Intern Med. 2016 Nov;30(6):1887-1895. PMID: 27859753
Zoonoses Public Health. 2016 Dec;63(8):651-661. PMID: 27873478
J Food Prot. 2016 Dec;79(12):2211-2219. PMID: 28221964

", , ,2016, , , , ,English, , , ,"The STROBE-Vet Statement (PDF) is freely available.

","O'Connor AM, Sargeant JM, Dohoo IR, Erb HN, Cevallos M, Egger M, Ersb\xf8ll AK, Martin SW, Nielsen LR, Pearl DL, Pfeiffer DU, Sanchez J, Torrence ME, Vigre H, Waldner C, Ward MP. Explanation and Elaboration Document for the STROBE-Vet Statement: Strengthening the Reporting of Observational Studies in Epidemiology-Veterinary Extension.

The explanation and elaboration paper for this guideline was published simultaneously in 2 journals. You can read the explanation and elaboration paper in any of these journals using the links below.

J Vet Intern Med. 2016 Nov;30(6):1896-1928. PMID: 27859752
Zoonoses Public Health. 2016 Dec;63(8):662-698. PMID: 27873473

", , ,https://strobevet-statement.org/,STROBE-Vet,"Reporting of observational studies in veterinary research related to animal health, production, welfare, and food safety.



STROBE-Vet Checklist (PDF)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 STROBE-Vet Checklist (Word)



","The STROBE-Vet Statement is available in French and Spanish.

The STROBE-Vet Checklist is available in Turkish (PDF).

", , , , , , ,yes,2017-05-17 09:24:16,2021-11-25 17:31:30,strobe-vet-statement,"[('title', 'Methods and processes of developing the strengthening the reporting of observational studies in epidemiology – veterinary (STROBE-Vet) statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of observational studies in veterinary research related to animal health, production, welfare, and food safety.\n\n \n\n \xa0\n\n \n\n[STROBE-Vet Checklist (PDF)](https://strobevetstatement.files.wordpress.com/2016/09/strobe-vet-checklist.pdf) [STROBE-Vet Checklist (Word)](https://strobevetstatement.files.wordpress.com/2016/09/strobe-vet-checklist.docx)\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', ""Sargeant JM, O'Connor AM, Dohoo IR, Erb HN, Cevallos M, Egger M, Ersbøll AK, Martin SW, Nielsen LR, Pearl DL, Pfeiffer DU, Sanchez J, Torrence ME, Vigre H, Waldner C, Ward MP. Methods and processes of developing the strengthening the reporting of observational studies in epidemiology - veterinary (STROBE-Vet) statement.\n\n \n\n This guideline was published simultaneously in 4 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n Prev Vet Med. 2016;134:188-196. PMID: [27836042](https://www.ncbi.nlm.nih.gov/pubmed/27836042)\n\n J Vet Intern Med. 2016 Nov;30(6):1887-1895. PMID: [27859753](https://www.ncbi.nlm.nih.gov/pubmed/27859753)\n\n Zoonoses Public Health. 2016 Dec;63(8):651-661. PMID: [27873478](https://www.ncbi.nlm.nih.gov/pubmed/27873478)\n\n J Food Prot. 2016 Dec;79(12):2211-2219. PMID: [28221964](https://www.ncbi.nlm.nih.gov/pubmed/28221964)\n\n \n\n""), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The [STROBE-Vet Statement (PDF)](https://strobevetstatement.files.wordpress.com/2016/09/strobe-and-strobe-vet-statements.pdf) is freely available.\n\n \n\n'), ('Explanation and elaboration papers', ""O'Connor AM, Sargeant JM, Dohoo IR, Erb HN, Cevallos M, Egger M, Ersbøll AK, Martin SW, Nielsen LR, Pearl DL, Pfeiffer DU, Sanchez J, Torrence ME, Vigre H, Waldner C, Ward MP. Explanation and Elaboration Document for the STROBE-Vet Statement: Strengthening the Reporting of Observational Studies in Epidemiology-Veterinary Extension.\n\n \n\n The explanation and elaboration paper for this guideline was published simultaneously in 2 journals. You can read the explanation and elaboration paper in any of these journals using the links below.\n\n \n\n J Vet Intern Med. 2016 Nov;30(6):1896-1928. PMID: [27859752](https://www.ncbi.nlm.nih.gov/pubmed/27859752)\n\n Zoonoses Public Health. 2016 Dec;63(8):662-698. PMID: [27873473](https://www.ncbi.nlm.nih.gov/pubmed/27873473)\n\n \n\n""), ('Availability in additional languages', 'The STROBE-Vet Statement is available in [French](https://strobevet-statement.org/la-declaration-veterinaire-strobe/) and [Spanish](https://strobevet-statement.org/la-declaracion-de-strobe-vet/).\n\n \n\n The STROBE-Vet Checklist is available in [Turkish (PDF)](https://www.equator-network.org/wp-content/uploads/2020/11/STROBE-VET-Turkish-translation.pdf).\n\n \n\n'), ('Reporting guideline website URL', '<https://strobevet-statement.org/>'), ('Reporting guideline acronym', 'STROBE-Vet'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 25, 2021')]"
5515,CONSORT 2025 Statement: updated guideline for reporting randomised trials,"Clinical trials, Experimental studies", ,Whole report, ,"checklist, checklists, clinical trial, clinical trials, CONSORT, CONSORT 2010, CONSORT 2010 statement, CONSORT statement, experimental studies, experimental study, flow diagram, flow diagrams, parallel, parallel group randomised trial, parallel group randomised trials, parallel group randomized trial, parallel group randomized trials, parallel group trial, parallel group trials, randomised, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, trial, trials, two group", ,"Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials. 

This guideline was published simultaneously in 5 journals. You can read the guideline in any of these journals using the links below.

BMJ. 2025; 388:e081123. PMID: 40228833
JAMA. 2025. PMID: 40228499
Lancet. 2025. PMID: 40245901
Nat Med. 2025. PMID: 40229553
PLoS Med. 2025; 22(4): e1004587. PMID: 40228477


","Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, et al. ", ,2025, , , , ,English, , , ,https://www.consort-spirit.org/,"Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I.\xa0CONSORT 2025 explanation and elaboration: updated guideline for reporting randomised trials. BMJ. 2025; 388:e081124.PMID: 40228832
","CONSORT 2001

CONSORT 2010","Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

",https://www.consort-spirit.org/,CONSORT,"Reporting of randomised trials.



CONSORT 2025 Checklist (Download from CONSORT-SPIRIT website)

","CONSORT 2010 has been translated into the following languages: Chinese; French; German; Greek; Italian; Japanese; Persian; Polish; Portuguese; Russian; Spanish; Turkish.

Visit our translations page to find out what other reporting guidelines are available in languages other than English: reporting guideline translations

",Guidance for developing protocols for clinical trials is provided in the SPIRIT 2013 Statement. For further details please visit: SPIRIT Statement,Betz CL. Adoption of CONSORT statements for randomized control trials published in the Journal of Pediatric Nursing. J Pediatr Nurs. 2011;26(3):177-8. PMID: 21601140, ,"Contextualisation guidance for using the CONSORT guideline to report deprescribing trials has been developed:
Blom JW, Muth C, Glasziou P, McCormack JP, Perera R, Poortvliet RKE, Numans ME, Th\xfcrmann P, Thiem U, Thio SL, Van Driel M, Beyer M, Van den Akker M, Knottnerus JA. Describing deprescribing trials better: an elaboration of the CONSORT statement. J Clin Epidemiol. 2020;127:87-95.\xa0 PMID: 32707072

", , ,yes,2017-05-16 10:55:43,2025-04-18 15:18:36,consort,"[('title', 'CONSORT 2025 Statement: updated guideline for reporting randomised trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of randomised trials.\n\n \n\n \xa0\n\n \n\n[CONSORT 2025 Checklist (Download from CONSORT-SPIRIT website)](https://www.consort-spirit.org/)\n\n \n\n'), ('Full bibliographic reference', 'Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials. \n\n \n\n This guideline was published simultaneously in 5 journals. You can read the guideline in any of these journals using the links below.\n\n \n\nBMJ. 2025; 388:e081123. [PMID: 40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025. [PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025. [PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025. [PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587. [PMID: 40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n\n\n \n\n'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', '<https://www.consort-spirit.org/>'), ('Explanation and elaboration papers', 'Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I.CONSORT 2025 explanation and elaboration: updated guideline for reporting randomised trials. BMJ. 2025; 388:e081124.PMID: [40228832](https://pubmed.ncbi.nlm.nih.gov/40228832/)\n\n'), ('Availability in additional languages', 'CONSORT 2010 has been translated into the following languages: Chinese; French; German; Greek; Italian; Japanese; Persian; Polish; Portuguese; Russian; Spanish; Turkish.\n\n \n\n Visit our translations page to find out what other reporting guidelines are available in languages other than English: [reporting guideline translations](/library/translations-of-reporting-guidelines/)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Specialised\n\n[CONSORT Harms](https://www.equator-network.org/reporting-guidelines/consort-harms/)**: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](https://www.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](https://www.equator-network.org/reporting-guidelines/consort-cluster/):\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](https://www.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](https://www.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](https://www.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](https://www.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](https://www.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](https://www.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n**[CONSORT-CENT](https://www.equator-network.org/reporting-guidelines/consort-cent/)**: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](https://www.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n**[TIDieR](https://www.equator-network.org/reporting-guidelines/tidier/)**: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n**[Simulation Research](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/)**: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n**[CONSORT for pilot and feasibility trials](https://www.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/)**: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64.\xa0 PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](https://www.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](https://www.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://www.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](https://www.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](https://www.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](https://www.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](https://www.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](https://www.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://www.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://www.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n**[CONSORT-AI](https://www.equator-network.org/reporting-guidelines/consort-artificial-intelligence/)**: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://www.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline website URL', '<https://www.consort-spirit.org/>'), ('Reporting guideline acronym', 'CONSORT'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Previous versions of this guideline / Guideline history', 'CONSORT 2001\n\n \n\n CONSORT 2010'), ('Other', 'Contextualisation guidance for using the CONSORT guideline to report deprescribing trials has been developed:\n\n Blom JW, Muth C, Glasziou P, McCormack JP, Perera R, Poortvliet RKE, Numans ME, Thürmann P, Thiem U, Thio SL, Van Driel M, Beyer M, Van den Akker M, Knottnerus JA. Describing deprescribing trials better: an elaboration of the CONSORT statement. J Clin Epidemiol. 2020;127:87-95.\xa0 PMID: [32707072](https://pubmed.ncbi.nlm.nih.gov/32707072/)\n\n \n\n'), ('Additional information', 'Guidance for developing protocols for clinical trials is provided in the SPIRIT 2013 Statement. For further details please visit: [SPIRIT Statement](/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/)'), ('Selected relevant editorials', 'Betz CL. Adoption of CONSORT statements for randomized control trials published in the Journal of Pediatric Nursing. J Pediatr Nurs. 2011;26(3):177-8. PMID: [21601140](http://www.ncbi.nlm.nih.gov/pubmed/21601140)'), ('Record last updated on', 'April 18, 2025')]"
6122,STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies,"Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies", ,Whole report, ,"accuracy, checklist, diagnosis, diagnostic, diagnostic accuracy, diagnostic accuracy research, diagnostic accuracy studies, diagnostic accuracy study, diagnostic accuracy test, diagnostic accuracy testing, diagnostic accuracy tests, diagnostic test, diagnostic test accuracy, diagnostic testing, flow diagram, initiative, STARD, STARD 2015, STARD 2015 checklist, STARD 2015 statement, STARD checklist, STARD initiative, STARD statement, statement", ,"Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, LijmerJG Moher D, Rennie D, de Vet HCW, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF, For the STARD Group. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies.

This guideline was published simultaneously in 3 journals. You can read the guideline in any of these journals using the links below.

BMJ. 2015;351:h5527. PMID: 26511519
Radiology. 2015:151516. PMID: 26509226
Clinical Chemistry. 2015. pii: clinchem.2015.246280. PMID: 26510957

","Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, LijmerJG Moher D, Rennie D, de Vet HCW, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF, For the STARD Group.", ,2015, , , , ,English, , , ,"The full-text of the STARD 2015 reporting guideline for diagnostic accuracy studies is available to download as a\xa0PDF file.

","Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, Irwig L, Levine D, Reitsma JB, de Vet HCW, Bossuyt PMM. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open 2016;6:e012799
http://bmjopen.bmj.com/content/6/11/e012799.abstract

","The STARD reporting guideline was originally published in 2003.

Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy.

Clin Chem. 2003; 49(1):1-6. PMID: 12507953
BMJ. 2003; 326(7379):41-44. PMID: 12511463
Radiology. 2003; 226(1):24-28. PMID: 12511664
Ann Intern Med. 2003; 138(1):40-44. PMID: 12513043
Am J Clin Pathol. 2003; 119(1):18-22. PMID: 12520693
Clin Biochem. 2003; 36(1):2-7. PMID: 12554053
Clin Chem Lab Med. 2003; 41(1):68-73. PMID: 12636052

Explanation and elaboration
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.

Clin Chem. 2003; 49(1):7-18. PMID: 12507954
Ann Intern Med. 2003; 138(1):W1-12. PMID: 12513067

","Specialised
STARDdem: Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, Davis D, Quinn TJ, Hyde C, Rutjes AW, Smailagic N, Marcus S, Black S, Blennow K, Brayne C, Fiorivanti M, Johnson JK, K\xf6pke S, Schneider LS, Simmons A, Mattsson N, Zetterberg H, Bossuyt PM, Wilcock G, McShane R. Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. Neurology. 2014;83(4):364-373. PMID: 24944261

STRADAS-paraTB: Gardner IA, Nielsen SS, Whittington RJ, Collins MT, Bakker D, Harris B, Sreevatsan S, Lombard JE, Sweeney R, Smith DR, Gavalchin J, Eda S. Consensus-based reporting standards for diagnostic test accuracy studies for paratuberculosis in ruminants. Prev Vet Med. 2011;101(1-2):18-34. PMID: 21601933

STARD-BLCM: Kostoulas P, Nielsen SS, Branscum AJ, Johnson WO, Dendukuri N, Dhand NK, Toft N, Gardner IA. STARD-BLCM: Standards for the Reporting of Diagnostic accuracy studies that use Bayesian Latent Class Models. Prev Vet Med. 2017; 138:37-47. PMID: 28237234

STARD for Abstracts: Cohen JF, Korevaar DA, Gatsonis CA, Glasziou PP, Hooft L, Moher D, Reitsma JB, de Vet HC, Bossuyt PM; STARD Group. STARD for Abstracts: essential items for reporting diagnostic accuracy studies in journal or conference abstracts. BMJ. 2017;358:j3751. PMID: 28819063

", ,STARD 2015,"Studies of diagnostic accuracy.



STARD 2015 checklist (PDF)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 STARD 2015 flow diagram (PDF)

STARD 2015 checklist (Word)

","STARD 2015
The updated STARD 2015 reporting guideline for diagnostic accuracy studies is available in Italian.

The STARD 2015 Checklist is available in Turkish (PDF).

STARD 2003
The following translations of the original STARD guideline published in 2003 are available: Chinese; Dutch; French; Italian; German; Spanish.
The Japanese translation of the STARD Statement is published in the Official Journal of the Japanese Society of Laboratory Medicine. 2004. 52(5):465-471.

The STARD 2003 Checklist is available in\xa0Turkish (PDF).

","Objective of the STARD initiative
The objective of the STARD initiative is to improve the completeness and transparency of reporting of studies of diagnostic accuracy, to allow readers to assess the potential for bias in the study (internal validity) and to evaluate its generalisability (external validity).

Contact
To contact the STARD group please email\xa0J\xe9r\xe9mie Cohen,\xa0jeremie.cohen@inserm.fr

April 2014: The STARD Group and the EQUATOR Network are working together to enhance the information available on this website about the STARD guideline and initiative.

November 2014: The STARD Group is working to update the STARD guideline. A consensus meeting was held in Amsterdam, the Netherlands, in September 2014 and a first draft updated checklist was prepared. Those interested in the process can contact the STARD initiative for more details.

October 2015: The updated STARD 2015 guideline was published.

", , ,"An online fillable STARD checklist is also available via the GoodReports website at https://www.goodreports.org/reporting-checklists/stard/.



The STARD guideline developers have written a paper describing in detail the methods used in the updating process for this reporting guideline. The full-text of this paper is available at: Updating standards for reporting diagnostic accuracy: the development of STARD 2015

", , ,yes,2017-05-15 09:30:48,2023-03-06 11:38:54,stard,"[('title', 'STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Studies of diagnostic accuracy.\n\n \n\n \xa0\n\n \n\n[STARD 2015 checklist (PDF)](/wp-content/uploads/2015/03/STARD-2015-checklist.pdf) [STARD 2015 flow diagram (PDF)](/wp-content/uploads/2015/03/STARD-2015-flow-diagram.pdf)\n\n \n\n[STARD 2015 checklist (Word)](/wp-content/uploads/2015/10/STARD-2015-Checklist.docx)\n\n \n\n'), ('Full bibliographic reference', 'Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, LijmerJG Moher D, Rennie D, de Vet HCW, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF, For the STARD Group. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies.\n\n \n\n This guideline was published simultaneously in 3 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n BMJ. 2015;351:h5527. PMID: [26511519](http://www.ncbi.nlm.nih.gov/pubmed/26511519)\n\n Radiology. 2015:151516. PMID: [26509226](http://www.ncbi.nlm.nih.gov/pubmed/26509226)\n\n Clinical Chemistry. 2015. pii: clinchem.2015.246280. PMID: [26510957](http://www.ncbi.nlm.nih.gov/pubmed/26510957)\n\n \n\n'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the STARD 2015 reporting guideline for diagnostic accuracy studies is available to download as a[PDF](/wp-content/uploads/2015/03/STARD-2015-paper.pdf) file.\n\n \n\n'), ('Explanation and elaboration papers', 'Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, Irwig L, Levine D, Reitsma JB, de Vet HCW, Bossuyt PMM. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open 2016;6:e012799\n\n<http://bmjopen.bmj.com/content/6/11/e012799.abstract>\n\n \n\n'), ('Availability in additional languages', '**STARD 2015**\n\nThe updated STARD 2015 reporting guideline for diagnostic accuracy studies is available in [Italian](http://www.evidence.it/articolodettaglio/209/it/480/stard-2015-checklist-aggiornata-per-il-reporting-degli-studi-di/articolo).\n\n \n\n The STARD 2015 Checklist is available in [Turkish (PDF)](https://www.equator-network.org/wp-content/uploads/2020/11/STARD-2015-Turkish-translation.pdf).\n\n \n\n**STARD 2003**\n\nThe following translations of the original STARD guideline published in 2003 are available: [Chinese](http://caod.oriprobe.com/articles/11216244/Towards_Complete_and_Accurate_Reporting_of_Studies_of_Diagnostic_Accur.htm); [Dutch](http://www.ncbi.nlm.nih.gov/pubmed/12661118); [French](http://www.jle.com/fr/revues/medecine/med/e-docs/00/04/3A/30/resume.phtml); [Italian](http://www.sipmel.it/it/riviste/articolo.php/1057); [German](https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0031-1272979); [Spanish](http://www.sciencedirect.com/science/article/pii/S0025775305722107).\n\n The Japanese translation of the STARD Statement is published in the Official Journal of the Japanese Society of Laboratory Medicine. 2004. 52(5):465-471.\n\n \n\n The STARD 2003 Checklist is available in[Turkish (PDF)](https://www.equator-network.org/wp-content/uploads/2017/05/STARD-Turkish-translation.pdf).\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Specialised**\n\n[**STARDdem**](/reporting-guidelines/starddem/): Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, Davis D, Quinn TJ, Hyde C, Rutjes AW, Smailagic N, Marcus S, Black S, Blennow K, Brayne C, Fiorivanti M, Johnson JK, Köpke S, Schneider LS, Simmons A, Mattsson N, Zetterberg H, Bossuyt PM, Wilcock G, McShane R. Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. Neurology. 2014;83(4):364-373. PMID: [24944261](http://www.ncbi.nlm.nih.gov/pubmed/24944261)\n\n \n\n[**STRADAS-paraTB**](/reporting-guidelines/consensus-based-reporting-standards-for-diagnostic-test-accuracy-studies-for-paratuberculosis-in-ruminants/): Gardner IA, Nielsen SS, Whittington RJ, Collins MT, Bakker D, Harris B, Sreevatsan S, Lombard JE, Sweeney R, Smith DR, Gavalchin J, Eda S. Consensus-based reporting standards for diagnostic test accuracy studies for paratuberculosis in ruminants. Prev Vet Med. 2011;101(1-2):18-34. PMID: [21601933](http://www.ncbi.nlm.nih.gov/pubmed/21601933)\n\n \n\n**[STARD-BLCM](/reporting-guidelines/stard-blcm/)**: Kostoulas P, Nielsen SS, Branscum AJ, Johnson WO, Dendukuri N, Dhand NK, Toft N, Gardner IA. STARD-BLCM: Standards for the Reporting of Diagnostic accuracy studies that use Bayesian Latent Class Models. Prev Vet Med. 2017; 138:37-47. PMID: [28237234](https://www.ncbi.nlm.nih.gov/pubmed/28237234)\n\n \n\n[**STARD for Abstracts**](/reporting-guidelines/stard-abstracts/): Cohen JF, Korevaar DA, Gatsonis CA, Glasziou PP, Hooft L, Moher D, Reitsma JB, de Vet HC, Bossuyt PM; STARD Group. STARD for Abstracts: essential items for reporting diagnostic accuracy studies in journal or conference abstracts. BMJ. 2017;358:j3751. PMID: [28819063](https://www.ncbi.nlm.nih.gov/pubmed/28819063)\n\n \n\n'), ('Reporting guideline acronym', 'STARD 2015'), ('Study design', 'Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Previous versions of this guideline / Guideline history', 'The STARD reporting guideline was originally published in 2003.\n\n \n\n Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy.\n\n \n\n Clin Chem. 2003; 49(1):1-6. PMID: [12507953\n\n](http://www.ncbi.nlm.nih.gov/pubmed/12507953)BMJ. 2003; 326(7379):41-44. PMID: [12511463](http://www.ncbi.nlm.nih.gov/pubmed/12511463)\n\n Radiology. 2003; 226(1):24-28. PMID: [12511664](http://www.ncbi.nlm.nih.gov/pubmed/12511664)\n\n Ann Intern Med. 2003; 138(1):40-44. PMID: [12513043](http://www.ncbi.nlm.nih.gov/pubmed/12513043)\n\n Am J Clin Pathol. 2003; 119(1):18-22. PMID: [12520693](http://www.ncbi.nlm.nih.gov/pubmed/12520693)\n\n Clin Biochem. 2003; 36(1):2-7. PMID: [12554053](http://www.ncbi.nlm.nih.gov/pubmed/12554053)\n\n Clin Chem Lab Med. 2003; 41(1):68-73. PMID: [12636052](http://www.ncbi.nlm.nih.gov/pubmed/12636052)\n\n \n\n Explanation and elaboration\n\n Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.\n\n \n\n Clin Chem. 2003; 49(1):7-18. PMID: [12507954](http://www.ncbi.nlm.nih.gov/pubmed/12507954)\n\n Ann Intern Med. 2003; 138(1):W1-12. PMID: [12513067](http://www.ncbi.nlm.nih.gov/pubmed/12513067)\n\n \n\n'), ('Other', 'An online fillable STARD checklist is also available via the GoodReports website at <https://www.goodreports.org/reporting-checklists/stard/>.\n\n \n\n \xa0\n\n \n\n The STARD guideline developers have written a paper describing in detail the methods used in the updating process for this reporting guideline. The full-text of this paper is available at: [Updating standards for reporting diagnostic accuracy: the development of STARD 2015](http://researchintegrityjournal.biomedcentral.com/articles/10.1186/s41073-016-0014-7)\n\n \n\n'), ('Additional information', '**Objective of the STARD initiative**\n\n The objective of the STARD initiative is to improve the completeness and transparency of reporting of studies of diagnostic accuracy, to allow readers to assess the potential for bias in the study (internal validity) and to evaluate its generalisability (external validity).\n\n \n\n**Contact**\n\n To contact the STARD group please email\xa0Jérémie Cohen,[[email\xa0protected]](/cdn-cgi/l/email-protection#1f757a6d7a72767a317c70777a715f76716c7a6d7231796d)\n\n \n\n**April 2014**: The STARD Group and the EQUATOR Network are working together to enhance the information available on this website about the STARD guideline and initiative.\n\n \n\n**November 2014**: The STARD Group is working to update the STARD guideline. A consensus meeting was held in Amsterdam, the Netherlands, in September 2014 and a first draft updated checklist was prepared. Those interested in the process can contact the STARD initiative for more details.\n\n \n\n**October 2015**: The updated STARD 2015 guideline was published.\n\n \n\n'), ('Record last updated on', 'March 6, 2023')]"
5998,SPIRIT 2025 Statement: Defining standard protocol items for clinical trials,"Clinical trials, Experimental studies, Study protocols", ,Protocol-whole report, ,"checklist, clinical studies, clinical study, clinical trial, clinical trial protocol, clinical trial protocols, clinical trials, experimental studies, experimental study, intervention, interventional, interventional trial, interventional trials, interventions, protocol, protocols, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, SPIRIT, SPIRIT 2013, SPIRIT 2013 statement, SPIRIT statement, statement, trial, trial protocol, trial protocols, trials", ,"Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hr\xf3bjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.

This guideline was published simultaneously in 5 journals. You can read the guideline in any of these journals using the links below.

BMJ. 2025; 388:e081660. PMID:\xa040294956
JAMA. 2025.\xa0PMID: 40294593
Lancet 2025.
Nat Med. 2025.\xa0PMID: 40295741
PLoS Med. 2025; 22(4): e1004587.\xa0PMID: 40294521","Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hr\xf3bjartsson A",BMJ [BMJ],2025,389, ,e081660, ,English, , , ,https://www.consort-spirit.org/,"Hr\xf3bjartsson A, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Chan AW. SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials. BMJ. 2025;389:e081660. PMID: 40294956",SPIRIT 2013,"Specialised
SPIRIT-PRO: Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. Link to abstract

SPIRIT-TCM: Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: 30484022

SPENT 2019: Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. Link to full-text.

SPIRIT-AI: Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.
BMJ. 2020;370:m3210. PMID: 32907797
Nat Med. 2020;26(9):1351?1363. PMID: 32908284
Lancet Digital Health. 2020;2(10):e549-e560. PMID: 33328049

SPIRIT-Path: Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: 34592193

SPIRIT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: 36512367

SPIRIT-DEFINE: Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: 37863491

SPIRIT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: 38051535

SPIRIT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: 38981624

SPIRIT-iNeurostim: Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: 39610902

",http://www.spirit-statement.org/,SPIRIT 2013,"Defining standard protocol items for clinical trials



SPIRIT 2025 Checklist (Download from CONSORT-SPIRIT website)



", , , , ,"

", , ,yes,2017-05-14 13:23:02,2025-05-30 09:04:20,spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials,"[('title', 'SPIRIT 2025 Statement: Defining standard protocol items for clinical trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Defining standard protocol items for clinical trials\n\n \n\n \xa0\n\n \n\n[SPIRIT 2025 Checklist (Download from CONSORT-SPIRIT website)](https://www.consort-spirit.org/)\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hróbjartsson A.\xa0 SPIRIT 20205 statement: updated guideline for protocols of randomized trials.\n\n \n\n This guideline was published simultaneously in 5 journals. You can read the guideline in any of these journals using the links below.\n\n \n\nBMJ. 2025; 388:e081660. [PMID:40294956](https://pubmed.ncbi.nlm.nih.gov/40294956/)\n\n JAMA. 2025.[PMID:](https://pubmed.ncbi.nlm.nih.gov/40294593/) [40294593](https://pubmed.ncbi.nlm.nih.gov/40294593/)\n\n Lancet 2025.\n\n Nat Med. 2025.[PMID: 40295741](https://pubmed.ncbi.nlm.nih.gov/40295741)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID: 40294521](https://pubmed.ncbi.nlm.nih.gov/40294521/)'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', '<https://www.consort-spirit.org/>'), ('Explanation and elaboration papers', 'Hróbjartsson A, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Chan AW. SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials. BMJ. 2025;389:e081660. PMID: [40294956](https://pubmed.ncbi.nlm.nih.gov/40294956/)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Specialised**\n\n[**SPIRIT-PRO**](/reporting-guidelines/spirit-pro/): Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. [Link to abstract](https://jamanetwork.com/journals/jama/article-abstract/2671472)\n\n \n\n[**SPIRIT-TCM**](https://www.equator-network.org/reporting-guidelines/standard-protocol-items-for-clinical-trials-with-traditional-chinese-medicine-spirit-tcm-extension-2018/): Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: [30484022](https://www.ncbi.nlm.nih.gov/pubmed/30484022)\n\n \n\n[**SPENT 2019**](https://www.equator-network.org/reporting-guidelines/spirit-extension-n-of-1-trials-spent-2019/): Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. [Link to full-text](https://www.bmj.com/content/368/bmj.m122).\n\n \n\n[**SPIRIT-AI**](https://www.equator-network.org/reporting-guidelines/spirit-artificial-intelligence/): Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.\n\n BMJ. 2020;370:m3210. PMID: [32907797](https://pubmed.ncbi.nlm.nih.gov/32907797/)\n\n Nat Med. 2020;26(9):1351–1363. PMID: [32908284](https://pubmed.ncbi.nlm.nih.gov/32908284/)\n\n Lancet Digital Health. 2020;2(10):e549-e560. PMID: [33328049](https://pubmed.ncbi.nlm.nih.gov/33328049/)\n\n \n\n[**SPIRIT-Path**](https://www.equator-network.org/reporting-guidelines/spirit-path/): Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: [34592193](https://pubmed.ncbi.nlm.nih.gov/34592193/)\n\n \n\n[**SPIRIT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-protocols-the-spirit-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: [36512367](https://pubmed.ncbi.nlm.nih.gov/36512367/)\n\n \n\n[**SPIRIT-DEFINE**](https://www.equator-network.org/reporting-guidelines/spirit-define/): Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: [37863491](https://pubmed.ncbi.nlm.nih.gov/37863491/)\n\n \n\n[**SPIRIT Factorial**](https://www.equator-network.org/reporting-guidelines/consensus-statement-for-protocols-of-factorial-randomized-trials-extension-of-the-spirit-2013-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: [38051535](https://pubmed.ncbi.nlm.nih.gov/38051535/)\n\n \n\n[**SPIRIT-Surrogate**](https://www.equator-network.org/reporting-guidelines/spirit-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: [38981624](https://pubmed.ncbi.nlm.nih.gov/38981624/)\n\n \n\n[**SPIRIT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-protocols-of-randomised-controlled-trials-of-implantable-neurostimulation-devices-the-spirit-ineurostim-extension/): Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: [39610902](https://pubmed.ncbi.nlm.nih.gov/39610902/)\n\n \n\n""), ('Reporting guideline website URL', '<http://www.spirit-statement.org/>'), ('Reporting guideline acronym', 'SPIRIT 2013'), ('Study design', 'Clinical trials, Experimental studies, Study protocols'), ('Applies to the whole report or to individual sections of the report?', 'Protocol-whole report'), ('Previous versions of this guideline / Guideline history', 'SPIRIT 2013'), ('Other', '\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
15110,Best Practices in Data Analysis and Sharing in Neuroimaging using MRI,"Clinical trials, Experimental studies, Observational studies","Neurology, Radiology","Data, Images, Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.), Terminology/definitions", ,"brain, brain activity, brain imaging, COBIDAS, Committee on Best Practice in Data Analysis and Sharing, data, data analysis, fMRI, functional MRI, imaging, magnetic resonance, magnetic resonance imaging, MRI, neuroimaging, neurological, neurology, neuroscience, neuroscientific, Organization for Human Brain Mapping, radiologic, radiological, radiological image, radiological images, radiology", ,"Nichols TE, Das S, Eickhoff SB, Evans AC, Glatard T, Hanke M, Kriegeskorte N, Milham MP, Poldrack RA, Poline J-B, Proal E, Thirion B, Van Essen DC, White T, Yeo BTT. Best Practices in Data Analysis and Sharing in Neuroimaging using MRI. 2016;bioRxiv. doi: 10.1101/054262.","Nichols TE, Das S, Eickhoff SB, Evans AC, Glatard T, Hanke M, Kriegeskorte N, Milham MP, Poldrack RA, Poline J-B, Proal E, Thirion B, Van Essen DC, White T, Yeo BTT.", ,2016, , , , ,English, , , ,Full-text access to this reporting guideline and available checklists is available at: http://www.humanbrainmapping.org/COBIDASreport, , , ,http://www.humanbrainmapping.org/COBIDAS , ,Reporting in neuroimaging using magnetic resonance imaging (MRI)., ,"A commentary about this reporting guideline has been published in Nature Neuroscience:

Nichols TE, Das S, Eickhoff SB, Evans AC, Glatard T, Hanke M, Kriegeskorte N, Milham MP, Poldrack RA, Poline JB, Proal E, Thirion B, Van Essen DC, White T, Yeo BT. Best practices in data analysis and sharing in neuroimaging using MRI. Nat Neurosci. 2017;20(3):299-303. PMID: 28230846", , , , , ,no,2017-04-27 10:44:22,2021-11-25 18:04:17,best-practices-in-data-analysis-and-sharing-in-neuroimaging-using-mri,"[('title', 'Best Practices in Data Analysis and Sharing in Neuroimaging using MRI'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting in neuroimaging using magnetic resonance imaging (MRI).'), ('Full bibliographic reference', 'Nichols TE, Das S, Eickhoff SB, Evans AC, Glatard T, Hanke M, Kriegeskorte N, Milham MP, Poldrack RA, Poline J-B, Proal E, Thirion B, Van Essen DC, White T, Yeo BTT. Best Practices in Data Analysis and Sharing in Neuroimaging using MRI. 2016;bioRxiv. doi: [10.1101/054262](http://www.humanbrainmapping.org/cobidas).'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'Full-text access to this reporting guideline and available checklists is available at: <http://www.humanbrainmapping.org/COBIDASreport>'), ('Reporting guideline website URL', '[http://www.humanbrainmapping.org/COBIDAS](http://www.humanbrainmapping.org/COBIDAS )'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Neurology, Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Images, Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.), Terminology/definitions'), ('Additional information', 'A commentary about this reporting guideline has been published in Nature Neuroscience:\n\n \n\n Nichols TE, Das S, Eickhoff SB, Evans AC, Glatard T, Hanke M, Kriegeskorte N, Milham MP, Poldrack RA, Poline JB, Proal E, Thirion B, Van Essen DC, White T, Yeo BT. Best practices in data analysis and sharing in neuroimaging using MRI. Nat Neurosci. 2017;20(3):299-303. PMID: [28230846](https://www.ncbi.nlm.nih.gov/pubmed/28230846)'), ('Record last updated on', 'November 25, 2021')]"
15053,Latent Class Analysis: An example for reporting results,Observational studies,Pharmaceutical medicine,"Data, Statistical methods and analyses", ,"Bayesian Classification, cluster, latent class, latent class analysis, Latent Class Cluster Analysis, latent classes, Latent Structure Analysis, latent variable, LCA, Mixture Likelihood Clustering, Mixture-model Clustering, Model Based Clustering, observational, observational research, observational studies, observational study, statistical, statistical analyses, statistical analysis, statistical method, statistical methods, statistical model, statistical models, statistical technique, statistical techniques, statistics", ,Schreiber JB. Latent Class Analysis: An example for reporting results. Res Social Adm Pharm. 2016.,Schreiber JB.,Research in Social and Administrative Pharmacy [ Res Social Adm Pharm.],2016, , , , ,English, ,27955976,https://www.ncbi.nlm.nih.gov/pubmed/27955976, , , , , , , , , , , , , , ,no,2017-03-06 11:33:10,2017-03-06 11:33:10,latent-class-analysis-an-example-for-reporting-results,"[('title', 'Latent Class Analysis: An example for reporting results'), ('Full bibliographic reference', 'Schreiber JB. Latent Class Analysis: An example for reporting results. Res Social Adm Pharm. 2016.'), ('Language', 'English'), ('PubMed ID', '[27955976](https://www.ncbi.nlm.nih.gov/pubmed/27955976)'), ('Study design', 'Observational studies'), ('Clinical area', 'Pharmaceutical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data, Statistical methods and analyses'), ('Record last updated on', 'March 6, 2017')]"
15051,Guidelines for Developing and Reporting Machine Learning Predictive Models in Biomedical Research: A Multidisciplinary View,"Artificial intelligence/Machine learning studies, Diagnostic and prognostic studies", ,"Statistical methods and analyses, Whole report", ,"big data, clinical prediction rule, data, diagnosis, diagnostic, diagnostic research, diagnostic studies, diagnostic study, machine learning, machine learning model, machine learning models, machine learning predictive method, machine learning predictive methods, machine learning predictive model, machine learning predictive models, machine learning technique, machine learning techniques, prediction, prediction rule, predictive method, predictive methods, predictive model, predictive models, prognosis, prognostic, prognostic research, prognostic studies, prognostic study, statistical, statistical analyses, statistical analysis, statistical method, statistical methods, statistical model, statistical models, statistical technique, statistical techniques, statistics", ,"Luo W, Phung D, Tran T, Gupta S, Rana S, Karmakar C, Shilton A, Yearwood J, Dimitrova N, Ho TB, Venkatesh S, Berk M. Guidelines for Developing and Reporting Machine Learning Predictive Models in Biomedical Research: A Multidisciplinary View. J Med Internet Res. 2016;18(12):e323.","Luo W, Phung D, Tran T, Gupta S, Rana S, Karmakar C, Shilton A, Yearwood J, Dimitrova N, Ho TB, Venkatesh S, Berk M.",Jounal of Medical Internet Research [J Med Internet Res.],2016,18,12,e323, ,English, ,27986644,https://www.ncbi.nlm.nih.gov/pubmed/27986644, , , , , , ,Reporting of machine learning predictive model specifications and results in biomedical research., , , , , , , ,no,2017-03-06 11:08:10,2024-01-25 12:27:11,guidelines-for-developing-and-reporting-machine-learning-predictive-models-in-biomedical-research-a-multidisciplinary-view,"[('title', 'Guidelines for Developing and Reporting Machine Learning Predictive Models in Biomedical Research: A Multidisciplinary View'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of machine learning predictive model specifications and results in biomedical research.'), ('Full bibliographic reference', 'Luo W, Phung D, Tran T, Gupta S, Rana S, Karmakar C, Shilton A, Yearwood J, Dimitrova N, Ho TB, Venkatesh S, Berk M. Guidelines for Developing and Reporting Machine Learning Predictive Models in Biomedical Research: A Multidisciplinary View. J Med Internet Res. 2016;18(12):e323.'), ('Language', 'English'), ('PubMed ID', '[27986644](https://www.ncbi.nlm.nih.gov/pubmed/27986644)'), ('Study design', 'Artificial intelligence/Machine learning studies, Diagnostic and prognostic studies'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses, Whole report'), ('Record last updated on', 'January 25, 2024')]"
15049,Clarity in Reporting Terminology and Definitions of Set End Points in Resistance Training,"Clinical trials, Experimental studies, Observational studies, Other",Sport and exercise medicine,Terminology/definitions, ,"clinical trial, clinical trials, definition, definitions, end point, end points, energy, exercise, exercise physiology, exertion, fatigue, intensity of effort, MF, momentary failure, muscle, muscles, muscular, muscular failure, muscular fatigue, observational, observational research, observational studies, observational study, physical, physiology, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, repetition, repetition failure, resistance training, RT, set end point, set end points, terminology, trial, trials", ,"Steele J, Fisher J, Giessing J, Gentil P. Clarity in Reporting Terminology and Definitions of Set End Points in Resistance Training. Muscle Nerve. 2017.","Steele J, Fisher J, Giessing J, Gentil P.",Muscle &amp; Nerve [Muscle Nerve.],2017, , , , ,English, ,28044366,https://www.ncbi.nlm.nih.gov/pubmed/28044366, , , , , , ,"Reporting, interpretation, and application of resistance training interventions.", , , , , , , ,no,2017-03-06 10:33:46,2017-03-06 10:33:46,clarity-in-reporting-terminology-and-definitions-of-set-end-points-in-resistance-training,"[('title', 'Clarity in Reporting Terminology and Definitions of Set End Points in Resistance Training'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting, interpretation, and application of resistance training interventions.'), ('Full bibliographic reference', 'Steele J, Fisher J, Giessing J, Gentil P. Clarity in Reporting Terminology and Definitions of Set End Points in Resistance Training. Muscle Nerve. 2017.'), ('Language', 'English'), ('PubMed ID', '[28044366](https://www.ncbi.nlm.nih.gov/pubmed/28044366)'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Other'), ('Clinical area', 'Sport and exercise medicine'), ('Applies to the whole report or to individual sections of the report?', 'Terminology/definitions'), ('Record last updated on', 'March 6, 2017')]"
15047,An introduction to using Bayesian linear regression with clinical data,"Clinical trials, Experimental studies, Other",Psychology,Statistical methods and analyses, ,"Bayes theorem, Bayes's theorem, Bayesian, bayesian analyses, Bayesian analysis, Bayesian method, Bayesian methods, Bayesian model, Bayesian modeling, clinical research, clinical research study, clinical trial, clinical trials, EEG, electroencephalogram, ERN, error-related negativity, event-related potential, psychological, psychologist, psychology, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, regression model, regression models, statistical analyses, statistical analysis, statistical method, statistical methods, statistical model, statistical models, statistical technique, statistical techniques, statistics, trial, trials", ,"Baldwin SA, Larson MJ. An introduction to using Bayesian linear regression with clinical data. Behav Res Ther. 2016.","Baldwin SA, Larson MJ.",Behaviour Research and Therapy\xa0 [Behav Res Ther.],2016, , , , ,English, ,28081861,https://www.ncbi.nlm.nih.gov/pubmed/28081861, , , , , , ,Reporting Bayesian methods in psychology research studies., , , , , , , ,no,2017-03-06 09:29:42,2017-03-06 11:36:37,an-introduction-to-using-bayesian-linear-regression-with-clinical-data,"[('title', 'An introduction to using Bayesian linear regression with clinical data'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting Bayesian methods in psychology research studies.'), ('Full bibliographic reference', 'Baldwin SA, Larson MJ. An introduction to using Bayesian linear regression with clinical data. Behav Res Ther. 2016.'), ('Language', 'English'), ('PubMed ID', '[28081861](https://www.ncbi.nlm.nih.gov/pubmed/28081861)'), ('Study design', 'Clinical trials, Experimental studies, Other'), ('Clinical area', 'Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Record last updated on', 'March 6, 2017')]"
15045,Making economic evaluations more helpful for treatment choices in haemophilia,Economic evaluations,Haematology,"Procedure/Method, Results, Statistical methods and analyses", ,"checklist, checklists, CHEERS, CHEERS statement, economic, economic analyses, economic analysis, economic evaluation, economic evaluation studies, economic evaluation study, economic evaluations, economic studies, economic study, economics, haemophilia, haemophilia prophylaxis, health economic evaluation, health economic evaluations, health economics, hemophilia, hemophilia prophylaxis", ,"Drummond M, Houwing N, Slothuus U, Giangrande P. Making economic evaluations more helpful for treatment choices in haemophilia. Haemophilia. 2017.","Drummond M, Houwing N, Slothuus U, Giangrande P.",Haemophilia,2017, , , , ,English, ,28111847,https://www.ncbi.nlm.nih.gov/pubmed/28111847, , , , , , ,Reporting and conduct of economic evaluations within haemophilia., , , , , , , ,no,2017-03-06 08:58:11,2017-03-06 08:58:11,making-economic-evaluations-more-helpful-for-treatment-choices-in-haemophilia,"[('title', 'Making economic evaluations more helpful for treatment choices in haemophilia'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting and conduct of economic evaluations within haemophilia.'), ('Full bibliographic reference', 'Drummond M, Houwing N, Slothuus U, Giangrande P. Making economic evaluations more helpful for treatment choices in haemophilia. Haemophilia. 2017.'), ('Language', 'English'), ('PubMed ID', '[28111847](https://www.ncbi.nlm.nih.gov/pubmed/28111847)'), ('Study design', 'Economic evaluations'), ('Clinical area', 'Haematology'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method, Results, Statistical methods and analyses'), ('Record last updated on', 'March 6, 2017')]"
15042,Guideline for Reporting Interventions on Spinal Manipulative Therapy: Consensus on Interventions Reporting Criteria List for Spinal Manipulative Therapy (CIRCLe SMT),"Clinical trials, Experimental studies",Physiotherapy,Intervention (exposure), ,"checklist, checklists, CIRCLe SMT, CIRCLe SMT checklist, Consensus on Interventions Reporting Criteria List for Spinal Manipulative Therapy, intervention, interventions, manipulation, manipulation-based therapy, manipulative therapies, manipulative therapy, mobilisation, mobilisation technique, mobilisation techniques, mobilisation-based therapy, mobilization, mobilization technique, mobilization techniques, mobilization-based therapy, movement, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, SMT, SMT invention, SMT technique, SMT techniques, spinal, spinal manipulative therapy, spine, trial, trials", ,"Groeneweg R, Rubinstein SM, Oostendorp RA, Ostelo RW, van Tulder MW. Guideline for Reporting Interventions on Spinal Manipulative Therapy: Consensus on Interventions Reporting Criteria List for Spinal Manipulative Therapy (CIRCLe SMT). J Manipulative Physiol Ther. 2017;40(2):61-70.","Groeneweg R, Rubinstein SM, Oostendorp RA, Ostelo RW, van Tulder MW.",Journal of Manipulative and Physiological Therapeutics [J Manipulative Physiol Ther.],2017,40,2,61-70, ,English, ,28017603,https://www.ncbi.nlm.nih.gov/pubmed/28017603, , , , ,http://www.circle-smt.com/,CIRCLe SMT,Reporting spinal manipulative therapy (SMT)., , , , , , , ,no,2017-03-03 15:55:50,2017-03-03 16:02:24,guideline-for-reporting-interventions-on-spinal-manipulative-therapy-consensus-on-interventions-reporting-criteria-list-for-spinal-manipulative-therapy-circle-smt,"[('title', 'Guideline for Reporting Interventions on Spinal Manipulative Therapy: Consensus on Interventions Reporting Criteria List for Spinal Manipulative Therapy (CIRCLe  SMT)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting spinal manipulative therapy (SMT).'), ('Full bibliographic reference', 'Groeneweg R, Rubinstein SM, Oostendorp RA, Ostelo RW, van Tulder MW. Guideline for Reporting Interventions on Spinal Manipulative Therapy: Consensus on Interventions Reporting Criteria List for Spinal Manipulative Therapy (CIRCLe SMT). J Manipulative Physiol Ther. 2017;40(2):61-70.'), ('Language', 'English'), ('PubMed ID', '[28017603](https://www.ncbi.nlm.nih.gov/pubmed/28017603)'), ('Reporting guideline website URL', '<http://www.circle-smt.com/>'), ('Reporting guideline acronym', 'CIRCLe SMT'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Physiotherapy'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'March 3, 2017')]"
14998,Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: Recommendations based on a methodological systematic review,Clinical practice guidelines,Palliative care,Procedure/Method, ,"best practice guideline, best practice guidelines, clinical practice, clinical practice guideline, clinical practice guidelines, consensus, CREDES, Delphi, Delphi process, Delphi round, Delphi studies, Delphi studies in palliative care, Delphi study, Delphi survey, Delphi technique, Delphi techniques, end of life care, expert consensus, hospice and palliative care, modified Delphi, palliative, palliative care, palliative care research, palliative research, practice guideline, practice guidelines", ,"J\xfcnger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: Recommendations based on a methodological systematic review. Palliative Medicine. 2017;31(8):684-706.","J\xfcnger S, Payne SA, Brine J, Radbruch L, Brearley SG.",Palliative Medicine.,2017,31,8,684-706, ,English, ,28190381,https://www.ncbi.nlm.nih.gov/pubmed/28190381, , , , , ,CREDES,Reporting of Delphi studies in the context of studies using the Delphi technique for the development of best practice guidance in palliative care., ,A blog post about CREDES is available on the European Association of Palliative Care website., , , , , ,no,2017-02-14 15:25:24,2022-10-20 12:00:11,credes,"[('title', 'Guidance on Conducting and REporting  DElphi Studies (CREDES) in palliative care: Recommendations based on a methodological systematic review'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of Delphi studies in the context of studies using the Delphi technique for the development of best practice guidance in palliative care.'), ('Full bibliographic reference', 'Jünger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: Recommendations based on a methodological systematic review. Palliative Medicine. 2017;31(8):684-706.'), ('Language', 'English'), ('PubMed ID', '[28190381](https://www.ncbi.nlm.nih.gov/pubmed/28190381)'), ('Reporting guideline acronym', 'CREDES'), ('Study design', 'Clinical practice guidelines'), ('Clinical area', 'Palliative care'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method'), ('Additional information', 'A [blog post](https://eapcnet.wordpress.com/2018/08/13/the-taming-of-the-chameleon-guidance-on-conducting-and-reporting-delphi-studies-credes/) about CREDES is available on the European Association of Palliative Care website.'), ('Record last updated on', 'October 20, 2022')]"
14980,STARD-BLCM: Standards for the Reporting of Diagnostic accuracy studies that use Bayesian Latent Class Models,"Diagnostic and prognostic studies, Experimental studies, Observational studies", ,Whole report, ,"animal, animals, Bayesian, bayesian analyses, Bayesian analysis, Bayesian framework, Bayesian model, Bayesian modeling, Bayesian modelling, Bayesian models, BLCM, BLCMs, checklist, checklists, diagnosis, diagnostic, diagnostic accuracy, diagnostic accuracy studies, diagnostic accuracy study, disease status, latent class, latent class analyses, latent class analysis, latent class model, latent class models, LCMs, reference test, STARD, STARD 2015, STARD-BLCM, STARD-BLCM guidelines, STARD-BLCM standards, test accuracy, vet, veterinary, veterinary medicine, veterinary research", ,"Kostoulas P, Nielsen SS, Branscum AJ, Johnson WO, Dendukuri N, Dhand NK, Toft N, Gardner IA. STARD-BLCM: Standards for the Reporting of Diagnostic accuracy studies that use Bayesian Latent Class Models. Prev Vet Med. 2017; 138:37-47.

","Kostoulas P, Nielsen SS, Branscum AJ, Johnson WO, Dendukuri N, Dhand NK, Toft N, Gardner IA.",Preventive Veterinary Medicine [Prev Vet Med.],2017,138, ,37-47, ,English, ,28237234,https://www.ncbi.nlm.nih.gov/pubmed/28237234,Access the STARD-BLCM reporting guideline abstract at: http://www.sciencedirect.com/science/article/pii/S0167587717300284, , ,"Generic
STARD: Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, LijmerJG Moher D, Rennie D, de Vet HCW, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF, For the STARD Group. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies.

BMJ 2015;351:h5527. PMID: 26511519
Radiology. 2015:151516. PMID: 26509226
Clinical Chemistry 2015. pii: clinchem.2015.246280. PMID: 26510957

Specialised
STARDdem: Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, Davis D, Quinn TJ, Hyde C, Rutjes AW, Smailagic N, Marcus S, Black S, Blennow K, Brayne C, Fiorivanti M, Johnson JK, K\xf6pke S, Schneider LS, Simmons A, Mattsson N, Zetterberg H, Bossuyt PM, Wilcock G, McShane R. Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. Neurology. 2014;83(4):364-373. PMID: 24944261

STRADAS-paraTB: Gardner IA, Nielsen SS, Whittington RJ, Collins MT, Bakker D, Harris B, Sreevatsan S, Lombard JE, Sweeney R, Smith DR, Gavalchin J, Eda S. Consensus-based reporting standards for diagnostic test accuracy studies for paratuberculosis in ruminants. Prev Vet Med. 2011;101(1-2):18-34. PMID: 21601933

STARD for Abstracts: Cohen JF, Korevaar DA, Gatsonis CA, Glasziou PP, Hooft L, Moher D, Reitsma JB, de Vet HC, Bossuyt PM; STARD Group. STARD for Abstracts: essential items for reporting diagnostic accuracy studies in journal or conference abstracts. BMJ. 2017;358:j3751. PMID: 28819063

", ,STARD-BLCM,"Reporting on the design, conduct and results of diagnostic accuracy studies that use Bayesian latent class models.



STARD-BLCM Checklist (Word)

", , , , , , , ,yes,2017-02-03 14:33:07,2021-11-25 18:07:58,stard-blcm,"[('title', 'STARD-BLCM : Standards for the Reporting of Diagnostic accuracy studies that use Bayesian Latent Class Models'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting on the design, conduct and results of diagnostic accuracy studies that use Bayesian latent class models.\n\n \n\n \xa0\n\n \n\n[STARD-BLCM Checklist (Word)](/wp-content/uploads/2017/02/STARD-BLCM-Checklist.docx)\n\n \n\n'), ('Full bibliographic reference', 'Kostoulas P, Nielsen SS, Branscum AJ, Johnson WO, Dendukuri N, Dhand NK, Toft N, Gardner IA. STARD-BLCM: Standards for the Reporting of Diagnostic accuracy studies that use Bayesian Latent Class Models. Prev Vet Med. 2017; 138:37-47.\n\n \n\n'), ('Language', 'English'), ('PubMed ID', '[28237234](https://www.ncbi.nlm.nih.gov/pubmed/28237234)'), ('Relevant URLs\n\n(full-text if available)', 'Access the STARD-BLCM reporting guideline abstract at: <http://www.sciencedirect.com/science/article/pii/S0167587717300284>'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**STARD**](/reporting-guidelines/stard/): Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, LijmerJG Moher D, Rennie D, de Vet HCW, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF, For the STARD Group. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies.\n\n \n\n BMJ 2015;351:h5527. PMID: [26511519](http://www.ncbi.nlm.nih.gov/pubmed/26511519)\n\n Radiology. 2015:151516. PMID: [26509226](http://www.ncbi.nlm.nih.gov/pubmed/26509226)\n\n Clinical Chemistry 2015. pii: clinchem.2015.246280. PMID: [26510957](http://www.ncbi.nlm.nih.gov/pubmed/26510957)\n\n \n\n**Specialised**\n\n[**STARDdem**](/reporting-guidelines/starddem/): Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, Davis D, Quinn TJ, Hyde C, Rutjes AW, Smailagic N, Marcus S, Black S, Blennow K, Brayne C, Fiorivanti M, Johnson JK, Köpke S, Schneider LS, Simmons A, Mattsson N, Zetterberg H, Bossuyt PM, Wilcock G, McShane R. Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. Neurology. 2014;83(4):364-373. PMID: [24944261](http://www.ncbi.nlm.nih.gov/pubmed/24944261)\n\n \n\n[**STRADAS-paraTB**](/reporting-guidelines/consensus-based-reporting-standards-for-diagnostic-test-accuracy-studies-for-paratuberculosis-in-ruminants/): Gardner IA, Nielsen SS, Whittington RJ, Collins MT, Bakker D, Harris B, Sreevatsan S, Lombard JE, Sweeney R, Smith DR, Gavalchin J, Eda S. Consensus-based reporting standards for diagnostic test accuracy studies for paratuberculosis in ruminants. Prev Vet Med. 2011;101(1-2):18-34. PMID: [21601933](http://www.ncbi.nlm.nih.gov/pubmed/21601933)\n\n \n\n[**STARD for Abstracts**](/reporting-guidelines/stard-abstracts/): Cohen JF, Korevaar DA, Gatsonis CA, Glasziou PP, Hooft L, Moher D, Reitsma JB, de Vet HC, Bossuyt PM; STARD Group. STARD for Abstracts: essential items for reporting diagnostic accuracy studies in journal or conference abstracts. BMJ. 2017;358:j3751. PMID: [28819063](https://www.ncbi.nlm.nih.gov/pubmed/28819063)\n\n \n\n'), ('Reporting guideline acronym', 'STARD-BLCM'), ('Study design', 'Diagnostic and prognostic studies, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 25, 2021')]"
14706,A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement,Clinical practice guidelines, ,Whole report, ,"checklist, checklists, practice, practice guideline, practice guidelines, public health, Reporting Items for practice Guidelines in HealThcare, RIGHT, RIGHT Checklist, RIGHT Statement", ,"Chen Y, Yang K, Maru?i? A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Sch\xfcnemann HJ, Chan ESY, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; for the RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group.\xa0 A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166(2):128-132.","Chen Y, Yang K, Maru?i? A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Sch\xfcnemann HJ, Chan ESY, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; for the RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group.",Annals of Internal Medicine [Ann Intern Med.],2017,166,2,128-132, ,English, ,27893062,https://www.ncbi.nlm.nih.gov/pubmed/27893062,The abstract for the RIGHT Statement is available at: http://annals.org/aim/article/2587367/reporting-tool-practice-guidelines-health-care-right-statement,The authors have developed an explanation and elaboration document for RIGHT which is included as a supplement to the journal article., ,"Specialised
RIGHT-TCM: Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, Xia L, Guo Y. The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Pharmacol Res. 2020;160:105178. PMID: 32889127

RIGHT-PVG: Wang X, Chen Y, Akl EA, Tokali? R, Maru?i? A, Qaseem A, Falck-Ytter Y, Lee MS, Siedler M, Barber SL, Zhang M, Chan ESY, Estill J, Kwong JSW, Okumura A, Zhou Q, Yang K, Norris SL; RIGHT working group. The reporting checklist for public versions of guidelines: RIGHT-PVG. Implement Sci. 2021;16(1):10. PMID: 33430911

RIGHT for Acupuncture: Tang C, Duan Y, Zhang Y, Zhang Y, Chen Z, Tang X, Zeng J, Riley D, Lee MS, Kim YS, Zhao H, Marrone G, Zhu X, Ge S, Wen H, Zhao W, Zheng X, Solos I, Chen Y, Guyatt G, Lu L, Xu N; RIGHT (Reporting Items for Practice Guidelines in Healthcare) for Acupuncture Working Group. RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture. J Clin Epidemiol. 2021:S0895-4356(21)00173-6. PMID: 34091023

RIGHT for INT: Zhou Q, Xing D, Li Q, Zhang J, Luo X, Yang N, Wang X, Yang K, Tian J, Li H, Li B, Cai Y, Jin Y, Lv L, Sun F, Shang S, Yuan B, Li J, Ma B, Li X, Yuan Y, Wu L, Wang B, Jiang L, Wang Z, Chen Y, Liang D. An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT. J Evid Based Med. 2022;15(1):55-63. PMID: 35416438

RIGHT-Ad@pt: Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RWM, Arayssi T, Bhaumik S, Chen Y, Ghersi D, Langlois EV, Fuentes Padilla P, Sch\xfcnemann HJ, Akl EA, Mart\xednez Garc\xeda L; RIGHT-Ad@pt Working Group*, Amer Y, Arevalo-Rodriguez I, Barnes S, Barreto J, Collis D, Dyer S, Fahim C, Florez I, Gallegos-Rivero V, Klugar M, Kuijpers T, Mathew JL, Munn Z, Norris S, Pati\xf1o-Lugo DF, Pramesh CS, Rodriguez J, Roy S, Shin ES, Sosa O, Vandvik PO, Velez M, Woodcraft R; RIGHT-Ad@pt Working Group. A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Ann Intern Med. 2022;175(5):710-719. PMID: 35286143

RIGHT-COI&amp;F: Xun Y, Estill J, Khabsa J, Florez ID, Guyatt GH, Norris SL, Lee MS, Ozaki A, Qaseem A, Sch\xfcnemann HJ, Shao R, Chen Y, Akl EA; RIGHT-COI&amp;F Working Groups. Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI&amp;F Checklist. Ann Intern Med. 2024;177(6):782-790. PMID: 38739919

RIGHT for CPM: Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C. The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. Pharmacol Res. 2024;199:107015. PMID: 38036197

",http://www.right-statement.org/,RIGHT,"Reporting practice guidelines in health care.



","The RIGHT Statement is also available in Italian and in German.

The RIGHT checklist is also available in Chinese (simplified), Chinese (traditional), German, Italian, Japanese.

The RIGHT Explanation and Elaboration document is also available in Chinese (simplified).

Visit the RIGHT Statement website translations page to access these translations.

",Read the reporting guideline development project summary (PDF)., , , , , ,yes,2017-01-16 10:00:11,2024-07-26 15:17:28,right-statement,"[('title', 'A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting practice guidelines in health care.\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Chen Y, Yang K, Marušić A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Schünemann HJ, Chan ESY, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; for the RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group.\xa0 A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166(2):128-132.'), ('Language', 'English'), ('PubMed ID', '[27893062](https://www.ncbi.nlm.nih.gov/pubmed/27893062)'), ('Relevant URLs\n\n(full-text if available)', 'The abstract for the RIGHT Statement is available at: <http://annals.org/aim/article/2587367/reporting-tool-practice-guidelines-health-care-right-statement>'), ('Explanation and elaboration papers', 'The authors have developed an explanation and elaboration document for RIGHT which is included as a supplement to the journal article.'), ('Availability in additional languages', 'The RIGHT Statement is also available in [Italian](http://www.evidence.it/articolodettaglio/209/it/512/right-statement-strumento-per-il-reporting-delle-linee-guida-pe/articolo) and in [German](https://www.ncbi.nlm.nih.gov/pubmed/29128430).\n\n \n\n The RIGHT checklist is also available in Chinese (simplified), Chinese (traditional), German, Italian, Japanese.\n\n \n\n The RIGHT Explanation and Elaboration document is also available in Chinese (simplified).\n\n \n\n Visit the [RIGHT Statement website translations page](http://www.right-statement.org/translations) to access these translations.\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Specialised**\n\n[**RIGHT-TCM**](https://www.equator-network.org/reporting-guidelines/the-right-extension-statement-for-traditional-chinese-medicine-development-recommendations-and-explanation/): Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, Xia L, Guo Y. The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Pharmacol Res. 2020;160:105178. PMID: [32889127](https://pubmed.ncbi.nlm.nih.gov/32889127)\n\n \n\n[**RIGHT-PVG**](https://www.equator-network.org/reporting-guidelines/the-reporting-checklist-for-public-versions-of-guidelines-right-pvg/): Wang X, Chen Y, Akl EA, Tokalić R, Marušić A, Qaseem A, Falck-Ytter Y, Lee MS, Siedler M, Barber SL, Zhang M, Chan ESY, Estill J, Kwong JSW, Okumura A, Zhou Q, Yang K, Norris SL; RIGHT working group. The reporting checklist for public versions of guidelines: RIGHT-PVG. Implement Sci. 2021;16(1):10. PMID: [33430911](https://pubmed.ncbi.nlm.nih.gov/33430911/)\n\n \n\n[**RIGHT for Acupuncture**](https://www.equator-network.org/reporting-guidelines/right-for-acupuncture/): Tang C, Duan Y, Zhang Y, Zhang Y, Chen Z, Tang X, Zeng J, Riley D, Lee MS, Kim YS, Zhao H, Marrone G, Zhu X, Ge S, Wen H, Zhao W, Zheng X, Solos I, Chen Y, Guyatt G, Lu L, Xu N; RIGHT (Reporting Items for Practice Guidelines in Healthcare) for Acupuncture Working Group. RIGHT for Acupuncture: An Extension of the RIGHT Statement for Clinical Practice Guidelines on Acupuncture. J Clin Epidemiol. 2021:S0895-4356(21)00173-6. PMID: [34091023](https://pubmed.ncbi.nlm.nih.gov/34091023/)\n\n \n\n[**RIGHT for INT**](https://www.equator-network.org/reporting-guidelines/an-extension-of-the-right-statement-for-introductions-and-interpretations-of-clinical-practice-guidelines-right-for-int/): Zhou Q, Xing D, Li Q, Zhang J, Luo X, Yang N, Wang X, Yang K, Tian J, Li H, Li B, Cai Y, Jin Y, Lv L, Sun F, Shang S, Yuan B, Li J, Ma B, Li X, Yuan Y, Wu L, Wang B, Jiang L, Wang Z, Chen Y, Liang D. An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT. J Evid Based Med. 2022;15(1):55-63. PMID: [35416438](https://pubmed.ncbi.nlm.nih.gov/35416438/)\n\n \n\n[**RIGHT-Ad@pt**](https://www.equator-network.org/reporting-guidelines/a-reporting-tool-for-adapted-guidelines-in-health-care-the-right-adapt-checklist/): Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RWM, Arayssi T, Bhaumik S, Chen Y, Ghersi D, Langlois EV, Fuentes Padilla P, Schünemann HJ, Akl EA, Martínez García L; RIGHT-Ad@pt Working Group\\*, Amer Y, Arevalo-Rodriguez I, Barnes S, Barreto J, Collis D, Dyer S, Fahim C, Florez I, Gallegos-Rivero V, Klugar M, Kuijpers T, Mathew JL, Munn Z, Norris S, Patiño-Lugo DF, Pramesh CS, Rodriguez J, Roy S, Shin ES, Sosa O, Vandvik PO, Velez M, Woodcraft R; RIGHT-Ad@pt Working Group. A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Ann Intern Med. 2022;175(5):710-719. PMID: [35286143](https://pubmed.ncbi.nlm.nih.gov/35286143/)\n\n \n\n[**RIGHT-COI&F**](https://www.equator-network.org/reporting-guidelines/reporting-conflicts-of-interest-and-funding-in-health-care-guidelines-the-right-coif-checklist/): Xun Y, Estill J, Khabsa J, Florez ID, Guyatt GH, Norris SL, Lee MS, Ozaki A, Qaseem A, Schünemann HJ, Shao R, Chen Y, Akl EA; RIGHT-COI&F Working Groups. Reporting Conflicts of Interest and Funding in Health Care Guidelines: The RIGHT-COI&F Checklist. Ann Intern Med. 2024;177(6):782-790. PMID: [38739919](https://pubmed.ncbi.nlm.nih.gov/38739919/)\n\n \n\n[**RIGHT for CPM**](https://www.equator-network.org/reporting-guidelines/the-reporting-checklist-for-chinese-patent-medicine-guidelines-right-for-cpm/): Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C. The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. Pharmacol Res. 2024;199:107015. PMID: [38036197](https://pubmed.ncbi.nlm.nih.gov/38036197/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.right-statement.org/>'), ('Reporting guideline acronym', 'RIGHT'), ('Study design', 'Clinical practice guidelines'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Read the reporting guideline development [project summary (PDF)](/wp-content/uploads/2009/02/RIGHT-Guideline.pdf).'), ('Record last updated on', 'July 26, 2024')]"
13647,The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines,Clinical practice guidelines, ,Whole report, ,"AGREE, AGREE collaboration, AGREE II, AGREE reporting, AGREE reporting checklist, Appraisal of Guidelines Research and Evaluation, checklist, checklists, clinical practice, clinical practice guideline, clinical practice guidelines, practice guideline, practice guidelines", ,"Brouwers MC, Kerkvliet K, Spithoff K, AGREE Next Steps Consortium. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ. 2016;352:i1152.","Brouwers MC, Kerkvliet K, Spithoff K, AGREE Next Steps Consortium.",British Medical Journal [BMJ.],2016,352, , , ,English, ,26957104,https://www.ncbi.nlm.nih.gov/pubmed/26957104,The full-text of this reporting guideline is available from: http://www.bmj.com/content/352/bmj.i1152?etoc=, , , ,http://www.agreetrust.org/resource-centre/agree-reporting-checklist/,AGREE Reporting Guideline Checklist,"Reporting of clinical practice guidelines.



AGREE Reporting Checklist (PDF)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 AGREE Reporting Checklist (Word)

","The AGREE reporting checklist is also available in the following languages:

Italian (Word)

", , , , , , ,yes,2017-01-15 10:36:34,2021-11-25 18:11:19,the-agree-reporting-checklist-a-tool-to-improve-reporting-of-clinical-practice-guidelines,"[('title', 'The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of clinical practice guidelines.\n\n \n\n \xa0\n\n \n\n[AGREE Reporting Checklist (PDF)](/wp-content/uploads/2016/03/AGREE-Reporting-Checklist.pdf) [AGREE Reporting Checklist (Word)](/wp-content/uploads/2017/01/AGREE-Reporting-Guideline-Checklist.docx)\n\n \n\n'), ('Full bibliographic reference', 'Brouwers MC, Kerkvliet K, Spithoff K, AGREE Next Steps Consortium. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ. 2016;352:i1152.'), ('Language', 'English'), ('PubMed ID', '[26957104](https://www.ncbi.nlm.nih.gov/pubmed/26957104)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is available from: <http://www.bmj.com/content/352/bmj.i1152?etoc=>'), ('Availability in additional languages', 'The AGREE reporting checklist is also available in the following languages:\n\n \n\n[Italian (Word)](http://www.agreetrust.org/wp-content/uploads/2016/02/Italian-AGREE-Reporting-Checklist.doc)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.agreetrust.org/resource-centre/agree-reporting-checklist/>'), ('Reporting guideline acronym', 'AGREE Reporting Guideline Checklist'), ('Study design', 'Clinical practice guidelines'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 25, 2021')]"
7962,The REFLECT statement: methods and processes of creating reporting guidelines for randomized controlled trials for livestock and food safety by modifying the CONSORT statement, , ,Whole report, ,"animal, animal health, animals, checklist, food, food production, food safety, livestock, livestock population, livestock populations, pre harvest, randomised, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, REFLECT, REFLECT Statement, safety, vet, veterinary, whole report", ,"O'Connor AM, Sargeant JM, Gardner IA, Dickson JS, Torrence ME, Consensus Meeting Participants, Dewey CE, Dohoo IR, Evans RB, Gray JT, Greiner M, Keefe G, Lefebvre SL, Morley PS, Ramirez A, Sischo W, Smith DR, Snedeker K, Sofos J, Ward MP, Wills R. The REFLECT statement: methods and processes of creating reporting guidelines for randomized controlled trials for livestock and food safety by modifying the CONSORT statement.

This guideline was published simultaneously in 4 journals. You can read the guideline in any of these journals using the links below.

Zoonoses Public Health. 2010;57(2):95-104. PMID: 20070653
J Food Prot. 2010;73(1):132-139. PMID: 20051216
J Vet Intern Med. 2010;24(1):57-64. PMID: 20002546
Prev Vet Med. 2010;93(1):11-18. PMID: 19926151","O'Connor AM, Sargeant JM, Gardner IA, Dickson JS, Torrence ME, Consensus Meeting Participants, Dewey CE, Dohoo IR, Evans RB, Gray JT, Greiner M, Keefe G, Lefebvre SL, Morley PS, Ramirez A, Sischo W, Smith DR, Snedeker K, Sofos J, Ward MP, Wills R.", ,2010, , , , ,English, , , ,The REFLECT statement 22-item checklist is available to download from the Meridian Network website.,"Sargeant JM, O'Connor AM, Gardner IA, Dickson JS, Torrence ME; Consensus Meeting Participants. The REFLECT statement: reporting guidelines for randomized controlled trials in livestock and food safety: explanation and elaboration. Zoonoses Public Health. 2010;57(2):105-136. PMID: 20070652

Sargeant JM, O'Connor AM, Gardner IA, Dickson JS, Torrence ME, Dohoo IR, Lefebvre SL, Morley PS, Ramirez A, Snedeker K. The REFLECT statement: reporting guidelines for randomized controlled trials in livestock and food safety: explanation and elaboration. J Food Prot. 2010;73(3):579-603. PMID: 20202349

", , , ,REFLECT,Reporting randomised controlled trials for livestock and food safety,"The REFLECT statement checklist is available to download in Spanish and French from the Meridian Network website.

Visit our translations page to find out what other reporting guidelines are available in languages other than English: reporting guideline translations

", , , , , , ,yes,2017-01-15 09:57:19,2025-02-21 10:25:33,the-reflect-statement-methods-and-processes-of-creating-reporting-guidelines-for-randomized-controlled-trials-for-livestock-and-food-safety-by-modifying-the-consort-statement,"[('title', 'The REFLECT statement: methods and processes of creating reporting guidelines for randomized controlled trials for livestock and food safety by modifying the CONSORT statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting randomised controlled trials for livestock and food safety'), ('Full bibliographic reference', ""O'Connor AM, Sargeant JM, Gardner IA, Dickson JS, Torrence ME, Consensus Meeting Participants, Dewey CE, Dohoo IR, Evans RB, Gray JT, Greiner M, Keefe G, Lefebvre SL, Morley PS, Ramirez A, Sischo W, Smith DR, Snedeker K, Sofos J, Ward MP, Wills R. The REFLECT statement: methods and processes of creating reporting guidelines for randomized controlled trials for livestock and food safety by modifying the CONSORT statement.\n\n \n\n This guideline was published simultaneously in 4 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n Zoonoses Public Health. 2010;57(2):95-104. PMID: [20070653](http://www.ncbi.nlm.nih.gov/pubmed/20070653)\n\n J Food Prot. 2010;73(1):132-139. PMID: [20051216](http://www.ncbi.nlm.nih.gov/pubmed/20051216)\n\n J Vet Intern Med. 2010;24(1):57-64. PMID: [20002546](http://www.ncbi.nlm.nih.gov/pubmed/20002546)\n\n Prev Vet Med. 2010;93(1):11-18. PMID: [19926151](http://www.ncbi.nlm.nih.gov/pubmed/19926151)""), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The REFLECT statement 22-item checklist is available to download from the [Meridian Network website](https://meridian-network.org/reflect/).'), ('Explanation and elaboration papers', ""Sargeant JM, O'Connor AM, Gardner IA, Dickson JS, Torrence ME; Consensus Meeting Participants. The REFLECT statement: reporting guidelines for randomized controlled trials in livestock and food safety: explanation and elaboration. Zoonoses Public Health. 2010;57(2):105-136. PMID: [20070652\n\n](http://www.ncbi.nlm.nih.gov/pubmed/20070652)\n\n Sargeant JM, O'Connor AM, Gardner IA, Dickson JS, Torrence ME, Dohoo IR, Lefebvre SL, Morley PS, Ramirez A, Snedeker K. The REFLECT statement: reporting guidelines for randomized controlled trials in livestock and food safety: explanation and elaboration. J Food Prot. 2010;73(3):579-603. PMID: [20202349](http://www.ncbi.nlm.nih.gov/pubmed/20202349)\n\n \n\n""), ('Availability in additional languages', 'The REFLECT statement checklist is available to download in Spanish and French from the [Meridian Network website](https://meridian-network.org/reflect/).\n\n \n\n Visit our translations page to find out what other reporting guidelines are available in languages other than English: [reporting guideline translations](/library/translations-of-reporting-guidelines/)\n\n \n\n'), ('Reporting guideline acronym', 'REFLECT'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'February 21, 2025')]"
14923,Reporting Items for Updated Clinical Guidelines: Checklist for the Reporting of Updated Guidelines (CheckUp),Clinical practice guidelines, ,"Conflict of interest, Narrative sections (discussion etc.), Procedure/Method, Research recommendations", ,"checklist, checklists, CheckUp, clinical guideline, clinical guideline update, clinical guideline updates, clinical guidelines, guideline update, guideline updates, methodology, updated, updating, updating methodology, updating process, updating processes", ,"Vernooij RWM, Alonso-Coello P, Brouwers M, Mart\xednez Garc\xeda L, CheckUp Panel. Reporting Items for Updated Clinical Guidelines: Checklist for the Reporting of Updated Guidelines (CheckUp). PLOS Medicine. 2017;14(1): e1002207.","Vernooij RWM, Alonso-Coello P, Brouwers M, Mart\xednez Garc\xeda L, CheckUp Panel.",PLOS Medicine [PLOS Med.],2017,14,1, , ,English, , , ,"The CheckUp reporting guideline is available from: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002207?

",The explanation and elaboration document for CheckUp is available to download at: CheckUp E&amp;E (Word)., , , ,CheckUp,"Reporting of updated clinical guidelines.



CheckUp 2017 Checklist (PDF)

","The CheckUp reporting guideline checklist is also available in Spanish (PDF), Chinese (PDF) and Dutch (PDF).", , , , , , ,yes,2017-01-12 09:00:54,2021-11-25 18:14:59,reporting-items-for-updated-clinical-guidelines-checkup,"[('title', 'Reporting Items for Updated Clinical Guidelines: Checklist for the Reporting of Updated Guidelines (CheckUp)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of updated clinical guidelines.\n\n \n\n \xa0\n\n \n\n[CheckUp 2017 Checklist (PDF)](/wp-content/uploads/2017/01/CheckUp2017Checklist.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Vernooij RWM, Alonso-Coello P, Brouwers M, Martínez García L, CheckUp Panel. Reporting Items for Updated Clinical Guidelines: Checklist for the Reporting of Updated Guidelines (CheckUp). PLOS Medicine. 2017;14(1): e1002207.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The CheckUp reporting guideline is available from: <http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002207>\u200b\n\n \n\n'), ('Explanation and elaboration papers', 'The explanation and elaboration document for CheckUp is available to download at: [CheckUp E&E (Word)](https://doi.org/10.1371/journal.pmed.1002207.s001).'), ('Availability in additional languages', 'The CheckUp reporting guideline checklist is also available in [Spanish (PDF)](/wp-content/uploads/2017/01/CheckUp2017_Spanish.pdf), [Chinese (PDF)](/wp-content/uploads/2017/12/CheckUp_Chinese.pdf) and [Dutch (PDF)](/wp-content/uploads/2017/01/CheckUp2017_Dutch.pdf).'), ('Reporting guideline acronym', 'CheckUp'), ('Study design', 'Clinical practice guidelines'), ('Applies to the whole report or to individual sections of the report?', 'Conflict of interest, Narrative sections (discussion etc.), Procedure/Method, Research recommendations'), ('Record last updated on', 'November 25, 2021')]"
14888,Preferred Reporting Items for the Development of Evidence-based Clinical Practice Guidelines in Traditional Medicine (PRIDE-CPG-TM): Explanation and elaboration,Clinical practice guidelines,Complementary and alternative medicine,Whole report, ,"CAM, checklist, checklists, clinical practice guideline, clinical practice guidelines, complementary and alternative medicine, complementary medicine, CPG, CPGs, Preferred Reporting Items for Development of Evidence-based Clinical Practice Guideline in Traditional Medicine, PRIDE-CPG-TM, TCM, TM, traditional Chinese medicine, traditional Chinese medicines, traditional medicine", ,"Choia J, Choia T-Y, Juna JH, Leeb JA, Lee MS. Preferred Reporting Items for the Development of Evidence-based Clinical Practice Guidelines in Traditional Medicine (PRIDE-CPG-TM): Explanation and elaboration. Eur J Integr Med. 2016; 8(6):905-915.","Choia J, Choia T-Y, Juna JH, Leeb JA, Lee MS.",European Journal of Integrative Medicine [Eur J Integr Med.],2016,8,6,905-915, ,English, , , ,The PRIDE-CPG-TM guideline can be accessed at: http://dx.doi.org/10.1016/j.eujim.2016.07.027, , , , ,PRIDE-CPG-TM,Reporting of clinical practice guidelines in traditional medicine., , , , , , , ,no,2017-01-09 11:18:43,2021-11-25 18:15:51,preferred-reporting-items-for-the-development-of-evidence-based-clinical-practice-guidelines-in-traditional-medicine-pride-cpg-tm-explanation-and-elaboration,"[('title', 'Preferred Reporting Items for the Development of Evidence-based Clinical Practice Guidelines in Traditional Medicine (PRIDE-CPG-TM) : Explanation and elaboration'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of clinical practice guidelines in traditional medicine.'), ('Full bibliographic reference', 'Choia J, Choia T-Y, Juna JH, Leeb JA, Lee MS. Preferred Reporting Items for the Development of Evidence-based Clinical Practice Guidelines in Traditional Medicine (PRIDE-CPG-TM): Explanation and elaboration. Eur J Integr Med. 2016; 8(6):905-915.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The PRIDE-CPG-TM guideline can be accessed at: [http://dx.doi.org/10.1016/j.eujim.2016.07.027](https://dx.doi.org/10.1016/j.eujim.2016.07.027)'), ('Reporting guideline acronym', 'PRIDE-CPG-TM'), ('Study design', 'Clinical practice guidelines'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 25, 2021')]"
14817,Standards for Reporting Implementation Studies (StaRI) Statement,"Clinical trials, Economic evaluations, Experimental studies, Mixed methods studies, Observational studies, Qualitative research, Quality improvement studies", ,Whole report, ,"checklist, checklists, clinical trial, clinical trials, implementation, implementation research, implementation science, implementation strategies, implementation strategy, implementation studies, implementation study, observational, observational research, observational studies, observational study, phase 4, phase IV, phase IV implementation, phase IV implementation studies, phase IV implementation study, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, StaRi, StaRI checklist, StaRi Statement", ,"Pinnock H, Barwick M, Carpenter CR, Eldridge S, Grandes G, Griffiths CJ, Rycroft-Malone J, Meissner P, Murray E, Patel A, Sheikh A, Taylor SJC, for the StaRI group. Standards for Reporting Implementation Studies (StaRI) statement.\xa0 BMJ. 2017;356:i6795.","Pinnock H, Barwick M, Carpenter C, Eldridge S, Grandes G, Griffiths C, Rycroft-Malone J, Meissner P, Murray E, Patel A, Sheikh A, Taylor S, for the StaRI group.",British Medical Journal [BMJ.],2017,356, ,i6795, ,English, ,28264797,https://www.ncbi.nlm.nih.gov/pubmed/28264797,"The StaRI Statement is freely available to access at: http://www.bmj.com/content/356/bmj.i6795.full

","Pinnock H, Barwick M, Carpenter CR, Eldrige S, Grandes G, Griffiths CJ, Rycroft-Malone J, Meissner P, Murray E, Patel A, Sheikh A, Taylor S, for the StaRI group. Standards for Reporting Implementation Studies (StaRI): Explanation and Elaboration document. BMJ Open. 2017;7:e013318. PMID: 28373250

", ,"Specialised
RIMES-SE: Smith MY, Morrato EH, Mora N, Nguyen V, Pinnock H, Winterstein AG. The Reporting Recommendations Intended for Pharmaceutical Risk Minimization Evaluation Studies: Standards for Reporting of Implementation Studies Extension (RIMES-SE). Drug Saf. 2024. PMID: 38478350

", ,StaRI,"Reporting of implementation studies, employing a range of study designs to develop and evaluate implementation strategies with the aim of enhancing adoption and sustainability of effective interventions.



StaRI checklist (Word)

", ,Read the StaRI guideline development proposal document (PDF)., , ,Read a guide (PDF) to reporting guidelines relevant to implementation studies developed by researchers in the Centre for Implementation Science at King?s College London and King?s Improvement Science and led by the National Institute for Health Research Applied Research Collaboration South London (NIHR ARC South London) at King?s College Hospital NHS Foundation Trust and supported by King?s Improvement Science., , ,no,2017-01-05 09:35:37,2024-06-12 10:46:24,stari-statement,"[('title', 'Standards for Reporting Implementation Studies (StaRI) Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of implementation studies, employing a range of study designs to develop and evaluate implementation strategies with the aim of enhancing adoption and sustainability of effective interventions.\n\n \n\n \xa0\n\n \n\n[StaRI checklist (Word)](/wp-content/uploads/2017/01/StaRI-checklist-for-author-completion.docx)\n\n \n\n'), ('Full bibliographic reference', 'Pinnock H, Barwick M, Carpenter CR, Eldridge S, Grandes G, Griffiths CJ, Rycroft-Malone J, Meissner P, Murray E, Patel A, Sheikh A, Taylor SJC, for the StaRI group. Standards for Reporting Implementation Studies (StaRI) statement.\xa0 BMJ. 2017;356:i6795.'), ('Language', 'English'), ('PubMed ID', '[28264797](https://www.ncbi.nlm.nih.gov/pubmed/28264797)'), ('Relevant URLs\n\n(full-text if available)', 'The StaRI Statement is freely available to access at: <http://www.bmj.com/content/356/bmj.i6795.full>\n\n \n\n'), ('Explanation and elaboration papers', 'Pinnock H, Barwick M, Carpenter CR, Eldrige S, Grandes G, Griffiths CJ, Rycroft-Malone J, Meissner P, Murray E, Patel A, Sheikh A, Taylor S, for the StaRI group. Standards for Reporting Implementation Studies (StaRI): Explanation and Elaboration document. BMJ Open. 2017;7:e013318. PMID: [28373250](https://www.ncbi.nlm.nih.gov/pubmed/28373250)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Specialised**\n\n[**RIMES-SE**](https://www.equator-network.org/reporting-guidelines/the-reporting-recommendations-intended-for-pharmaceutical-risk-minimization-evaluation-studies-standards-for-reporting-of-implementation-studies-extension-rimes-se/): Smith MY, Morrato EH, Mora N, Nguyen V, Pinnock H, Winterstein AG. The Reporting Recommendations Intended for Pharmaceutical Risk Minimization Evaluation Studies: Standards for Reporting of Implementation Studies Extension (RIMES-SE). Drug Saf. 2024. PMID: [38478350](https://pubmed.ncbi.nlm.nih.gov/38478350/)\n\n \n\n'), ('Reporting guideline acronym', 'StaRI'), ('Study design', 'Clinical trials, Economic evaluations, Experimental studies, Mixed methods studies, Observational studies, Qualitative research, Quality improvement studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Other', '[Read a guide (PDF)](https://arc-sl.nihr.ac.uk/sites/default/files/uploads/files/Imp-Sci-reporting-guidelines-2023.pdf) to reporting guidelines relevant to implementation studies developed by researchers in the Centre for Implementation Science at King’s College London and King’s Improvement Science and led by the National Institute for Health Research Applied Research Collaboration South London (NIHR ARC South London) at King’s College Hospital NHS Foundation Trust and supported by King’s Improvement Science.'), ('Additional information', 'Read the StaRI [guideline development proposal document (PDF)](/wp-content/uploads/2013/09/Proposal-for-reporting-guidelines-of-Implementation-Research-StaRI.pdf).'), ('Record last updated on', 'June 12, 2024')]"
14795,Preferred Reporting Of Case Series in Surgery (PROCESS) 2023 guidelines,Observational studies,Surgery,Whole report, ,"case report, case series, checklist, checklists, PROCESS, PROCESS checklist, PROCESS guideline, PROCESS guidelines, surgery, surgery case series, surgical, surgical case series", ,"Mathew G, Sohrabi C, Franchi T, Nicola M, Kerwan A, Agha R; PROCESS Group. Preferred Reporting Of Case Series in Surgery (PROCESS) 2023 guidelines. Int J Surg. 2023;109(12):3760-3769.","Mathew G, Sohrabi C, Franchi T, Nicola M, Kerwan A, Agha R; PROCESS Group.",International Journal of Surgery [Int J Surg.],2023,109,12,3760-3769, ,English, ,37988417,https://pubmed.ncbi.nlm.nih.gov/37988417/, , ,"The PROCESS reporting guideline was originally published in 2016 and updated in 2018 and 2020.

2016
Agha RA, Fowler AJ, Rajmohan S, Barai I, Orgill DP; PROCESS Group. Preferred reporting of case series in surgery; the PROCESS guidelines. Int J Surg. 2016;36 (Pt A):319-323. PMID: 27770639

2018 update
Agha RA, Borrelli MR, Farwana R, Koshy K, Fowler A, Orgill DP; SCARE Group. The PROCESS 2018 Statement: Updating Consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) Guidelines. Int J Surg. 2018. PMID: 30359781

2020 update
Agha RA, Sohrabi C, Mathew G, Franchi T, Kerwan A, O'Neill N; PROCESS Group. The PROCESS 2020 Guideline: Updating Consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) Guidelines. Int J Surg. 2020:S1743-9191(20)30779-2. PMID: 33189880

", ,http://www.processguideline.com/,PROCESS,"Reporting surgical case series.



", , , , , , , ,no,2017-01-04 11:12:46,2024-02-02 15:12:06,preferred-reporting-of-case-series-in-surgery-the-process-guidelines,"[('title', 'Preferred Reporting Of Case Series in Surgery (PROCESS) 2023 guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting surgical case series.\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Mathew G, Sohrabi C, Franchi T, Nicola M, Kerwan A, Agha R; PROCESS Group. Preferred Reporting Of Case Series in Surgery (PROCESS) 2023 guidelines. Int J Surg. 2023;109(12):3760-3769.'), ('Language', 'English'), ('PubMed ID', '[37988417](https://pubmed.ncbi.nlm.nih.gov/37988417/)'), ('Reporting guideline website URL', '<http://www.processguideline.com/>'), ('Reporting guideline acronym', 'PROCESS'), ('Study design', 'Observational studies'), ('Clinical area', 'Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Previous versions of this guideline / Guideline history', ""The PROCESS reporting guideline was originally published in 2016 and updated in 2018 and 2020.\n\n \n\n 2016\n\n Agha RA, Fowler AJ, Rajmohan S, Barai I, Orgill DP; PROCESS Group. Preferred reporting of case series in surgery; the PROCESS guidelines. Int J Surg. 2016;36 (Pt A):319-323. PMID: [27770639](https://www.ncbi.nlm.nih.gov/pubmed/27770639)\n\n \n\n 2018 update\n\n Agha RA, Borrelli MR, Farwana R, Koshy K, Fowler A, Orgill DP; SCARE Group. The PROCESS 2018 Statement: Updating Consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) Guidelines. Int J Surg. 2018. PMID: [30359781](https://www.ncbi.nlm.nih.gov/pubmed/30359781)\n\n \n\n 2020 update\n\n Agha RA, Sohrabi C, Mathew G, Franchi T, Kerwan A, O'Neill N; PROCESS Group. The PROCESS 2020 Guideline: Updating Consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) Guidelines. Int J Surg. 2020:S1743-9191(20)30779-2. PMID: [33189880](https://pubmed.ncbi.nlm.nih.gov/33189880/)\n\n \n\n""), ('Record last updated on', 'February 2, 2024')]"
14630,Consensus on Exercise Reporting Template (CERT): Modified Delphi Study,"Clinical trials, Experimental studies",Sport and exercise medicine,Intervention (exposure), ,"aerobic, aerobic exercise, aerobics, balance training, CERT, clinical trial, clinical trials, complex intervention, complex interventions, Consensus on Exercise Reporting Template, CONSORT, exercise, exercise intervention, exercise interventions, exercise program, exercise programme, exercise programmes, exercise programs, flexibility training, movement training, Pilates, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, resistance training, SPIRIT, TIDieR, trial, trials, yoga", ,"Slade SC, Dionne CE, Underwood M, Buchbinder R, Beck B, Bennell K, Brosseau L, Costa L, Cramp F, Cup E, Feehan L, Ferreira M, Forbes S, Glasziou P, Habets B, Harris S, Hay-Smith J, Hillier S, Hinman R, Holland A, Hondras M, Kelly G, Kent P, Lauret GJ, Long A, Maher C, Morso L, Osteras N, Peterson T, Quinlivan R, Rees K, Regnaux JP, Rietberg M, Saunders D, Skoetz N, Sogaard K, Takken T, van Tulder M, Voet N, Ward L, White C. Consensus on Exercise Reporting Template (CERT): Modified Delphi Study. Phys Ther. 2016;96(10):1514-1524.","Slade SC, Dionne CE, Underwood M, Buchbinder R, Beck B, Bennell K, Brosseau L, Costa L, Cramp F, Cup E, Feehan L, Ferreira M, Forbes S, Glasziou P, Habets B, Harris S, Hay-Smith J, Hillier S, Hinman R, Holland A, Hondras M, Kelly G, Kent P, Lauret GJ, Long A, Maher C, Morso L, Osteras N, Peterson T, Quinlivan R, Rees K, Regnaux JP, Rietberg M, Saunders D, Skoetz N, Sogaard K, Takken T, van Tulder M, Voet N, Ward L, White C.",Physical Therapy [Phys Ther.],2016,96,10,1514-1524, ,English, ,27149962,https://www.ncbi.nlm.nih.gov/pubmed/27149962, ,"Slade SC, Dionne CE, Underwood M, Buchbinder R. Consensus on Exercise Reporting Template (CERT): Explanation and Elaboration Statement. Br J Sports Med. 2016. PMID: 27707738

", ,"Specialised
Therapeutic exercise interventions: Page P, Hoogenboom B, Voight M.Improving the reporting of therapeutic exercise interventions in rehabilitation research. Int J Sports Phys Ther. 2017;12(2):297-304. PMID: 28515984", ,CERT,Reporting exercise programs in clinical trials,The CERT Explanation and Elaboration Statement is also available in Italian (PDF)., , , ,"Contextualisation guidance for using the CERT guideline to report pelvic floor muscle training studies has been developed. Read about CERT-PFMT:
Slade SC, Morris ME, Frawley H, Hay-Smith J. Comprehensive reporting of pelvic floor muscle training for urinary incontinence: CERT-PFMT. Physiotherapy. 2021;112:103-112. PMID: 34062452

", , ,no,2016-11-07 14:55:36,2022-04-11 16:11:44,consensus-on-exercise-reporting-template-cert,"[('title', 'Consensus on Exercise Reporting Template (CERT) : Modified Delphi Study'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting exercise programs in clinical trials'), ('Full bibliographic reference', 'Slade SC, Dionne CE, Underwood M, Buchbinder R, Beck B, Bennell K, Brosseau L, Costa L, Cramp F, Cup E, Feehan L, Ferreira M, Forbes S, Glasziou P, Habets B, Harris S, Hay-Smith J, Hillier S, Hinman R, Holland A, Hondras M, Kelly G, Kent P, Lauret GJ, Long A, Maher C, Morso L, Osteras N, Peterson T, Quinlivan R, Rees K, Regnaux JP, Rietberg M, Saunders D, Skoetz N, Sogaard K, Takken T, van Tulder M, Voet N, Ward L, White C. Consensus on Exercise Reporting Template (CERT): Modified Delphi Study. Phys Ther. 2016;96(10):1514-1524.'), ('Language', 'English'), ('PubMed ID', '[27149962](https://www.ncbi.nlm.nih.gov/pubmed/27149962)'), ('Explanation and elaboration papers', 'Slade SC, Dionne CE, Underwood M, Buchbinder R. Consensus on Exercise Reporting Template (CERT): Explanation and Elaboration Statement. Br J Sports Med. 2016. PMID: [27707738](https://www.ncbi.nlm.nih.gov/pubmed/27707738)\n\n \n\n'), ('Availability in additional languages', 'The CERT Explanation and Elaboration Statement is also available in [Italian (PDF)](https://aifi.net/wp-content/uploads/2022/03/Articolo_CERT.pdf).'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Specialised**\n\n[**Therapeutic exercise interventions**](/reporting-guidelines/improving-the-reporting-of-therapeutic-exercise-interventions-in-rehabilitation-research/): Page P, Hoogenboom B, Voight M.Improving the reporting of therapeutic exercise interventions in rehabilitation research. Int J Sports Phys Ther. 2017;12(2):297-304. PMID: [28515984](https://www.ncbi.nlm.nih.gov/pubmed/28515984)'), ('Reporting guideline acronym', 'CERT'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Sport and exercise medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Other', 'Contextualisation guidance for using the CERT guideline to report pelvic floor muscle training studies has been developed. Read about CERT-PFMT:\n\n Slade SC, Morris ME, Frawley H, Hay-Smith J. Comprehensive reporting of pelvic floor muscle training for urinary incontinence: CERT-PFMT. Physiotherapy. 2021;112:103-112. PMID: [34062452](https://pubmed.ncbi.nlm.nih.gov/34062452/)\n\n \n\n'), ('Record last updated on', 'April 11, 2022')]"
14628,Development of the Anatomical Quality Assurance (AQUA) Checklist: guidelines for reporting original anatomical studies,Observational studies,"Pathology, Radiology, Surgery",Whole report, ,"anatomical, anatomical data, Anatomical Quality Assurance, Anatomical Quality Assurance Checklist, anatomical research, anatomical studies, anatomical study, anatomy, AQUA, AQUA Checklist, cadaveric, cadaveric studies, cadaveric study, checklist, checklists, clinical anatomy, developmental, dissection, dissection studies, dissection study, EBA, electrophysiological, electrophysiological studies, electrophysiological study, evidence-based anatomy, gross, imaging, imaging studies, imaging study, International Evidence-Based Anatomy Working Group, microscopic, observational, observational research, observational studies, observational study, pathology, radiological, radiology, surface, surgical, translational", ,"Tomaszewski KA, Henry BM, Ramakrishnan PK, Roy J, Vikse J, Loukas M, Tubbs RS, Walocha JA. Development of the Anatomical Quality Assurance (AQUA) Checklist: guidelines for reporting original anatomical studies. Clin Anat. 2016.","Tomaszewski KA, Henry BM, Ramakrishnan PK, Roy J, Vikse J, Loukas M, Tubbs RS, Walocha JA.",Clinical Anatomy [Clin Anat.],2016, , , , ,English, ,27801507,https://www.ncbi.nlm.nih.gov/pubmed/27801507,The AQUA checklist is freely available from: http://www.eba.cm.uj.edu.pl/about-aqua, , , ,http://www.eba.cm.uj.edu.pl/aqua,AQUA,"Reporting original anatomical studies



AQUA checklist\xa0 \xa0 \xa0PDF / Word

","The AQUA checklist is also available in French (PDF), Spanish (PDF) and Polish (PDF).","The AQUA reporting guideline development team have also produced consensus guidelines specifically for reporting study ethics in anatomical research within the framework of the AQUA checklist (relating to checklist items 6, 16 and 17):

Henry BM, Vikse J, Pekala P, Loukas M, Tubbs RS, Walocha JA, Jones DG, Tomaszewski KA. Consensus guidelines for the uniform reporting of study ethics in anatomical research within the framework of the anatomical quality assurance (AQUA) checklist. Clin Anat. 2018;31(4):521-524.\xa0PMID: 29532521

", , , , , ,no,2016-11-07 11:19:20,2021-11-26 10:51:46,development-of-the-anatomical-quality-assurance-aqua-checklist-guidelines-for-reporting-original-anatomical-studies,"[('title', 'Development of the Anatomical Quality Assurance (AQUA) Checklist: guidelines for reporting original anatomical studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting original anatomical studies\n\n \n\n \xa0\n\n \n\n AQUA checklist[PDF](https://drive.google.com/file/d/0B8aUZqV2goZkTFQwUXNnQW5CZjA/view?usp=sharing) / [Word](https://drive.google.com/file/d/0B8aUZqV2goZkRHFlQXJIMEROQjg/view?usp=sharing)\n\n \n\n'), ('Full bibliographic reference', 'Tomaszewski KA, Henry BM, Ramakrishnan PK, Roy J, Vikse J, Loukas M, Tubbs RS, Walocha JA. Development of the Anatomical Quality Assurance (AQUA) Checklist: guidelines for reporting original anatomical studies. Clin Anat. 2016.'), ('Language', 'English'), ('PubMed ID', '[27801507](https://www.ncbi.nlm.nih.gov/pubmed/27801507)'), ('Relevant URLs\n\n(full-text if available)', 'The AQUA checklist is freely available from: <http://www.eba.cm.uj.edu.pl/about-aqua>'), ('Availability in additional languages', 'The AQUA checklist is also available in [French (PDF)](https://drive.google.com/file/d/0B9oZi4t81NkcaUV1UWRRVFl6cnM/view?usp=sharing), [Spanish (PDF)](https://drive.google.com/file/d/0B_AZDPm1Mm0GQ2doTmdSTDlFRFE/view?usp=sharing) and [Polish (PDF)](https://drive.google.com/file/d/0B_AZDPm1Mm0GSmhqOXNtbFF0Z2c/view?usp=sharing).'), ('Reporting guideline website URL', '<http://www.eba.cm.uj.edu.pl/aqua>'), ('Reporting guideline acronym', 'AQUA'), ('Study design', 'Observational studies'), ('Clinical area', 'Pathology, Radiology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'The AQUA reporting guideline development team have also produced consensus guidelines specifically for reporting study ethics in anatomical research within the framework of the AQUA checklist (relating to checklist items 6, 16 and 17):\n\n \n\n Henry BM, Vikse J, Pekala P, Loukas M, Tubbs RS, Walocha JA, Jones DG, Tomaszewski KA. Consensus guidelines for the uniform reporting of study ethics in anatomical research within the framework of the anatomical quality assurance (AQUA) checklist. Clin Anat. 2018;31(4):521-524.\xa0PMID: [29532521](https://www.ncbi.nlm.nih.gov/pubmed/29532521)\n\n \n\n'), ('Record last updated on', 'November 26, 2021')]"
14419,CONSORT 2010 statement: extension to randomised pilot and feasibility trials,"Clinical trials, Experimental studies", ,Whole report, ,"checklist, checklists, CONSORT, CONSORT 2010, CONSORT 2010 statement, CONSORT abstract extension, CONSORT abstracts, CONSORT extension, CONSORT for abstracts extension, CONSORT Pilot and Feasibility Trials, CONSORT randomised pilot and feasibility trials, definitive RCT, definitive RCTs, extension to randomised pilot and feasibility trials, feasibility, feasibility RCT, feasibility studies, feasibility study, feasibility trial, feasibility trials, future RCT, future RCTs, pilot, pilot and feasibility randomised studies, pilot and feasibility randomised study, pilot and feasibility trial, pilot and feasibility trials, pilot RCT, pilot studies, pilot study, pilot trial, pilot trials, randomised controlled trial, randomised controlled trials, randomised feasibility, randomised feasibility study, randomised feasibility trial, randomised pilot, randomised pilot study, randomised pilot trial, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized feasibility, randomized pilot, randomized trial, randomized trials, RCT, RCTs", ,"Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials.

This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.

Pilot and Feasibility Studies. 2016;2:64. PMID: 27965879
BMJ. 2016;355:i5239. PMID: 27777223

","Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group.", ,2016, , , , ,English, , , , , , ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster: \xa0Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal: \xa0Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts: \xa0Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture: \xa0MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738. \xa0PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", , ,"Reporting randomised pilot and feasibility trials conducted in advance of a future definitive randomised controlled trial.

CONSORT extension Pilot and Feasibility Trials Checklist (Word)

", ,"Read the reporting guideline development summary (Word).

Read an article on the methods and processes for the development of this CONSORT extension for reporting pilot randomized controlled trials.

Read a related article in Nature Medicine.

", , ,"Additional recommendations for reporting progression criteria have been developed:

Mellor K, Albury C, Dutton SJ, Eldridge S, Hopewell S. Recommendations for progression criteria during external randomised pilot trial design, conduct, analysis and reporting. Pilot Feasibility Stud. 2023;9(1):59. PMID: 37061720

", , ,yes,2016-10-25 10:27:35,2025-05-30 09:20:23,consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials,"[('title', 'CONSORT 2010 statement: extension to randomised pilot and feasibility trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting randomised pilot and feasibility trials conducted in advance of a future definitive randomised controlled trial.\n\n \n\n[CONSORT extension Pilot and Feasibility Trials Checklist (Word)](https://www.equator-network.org/wp-content/uploads/2016/10/CONSORT-extension-Pilot-and-Feasibility-Trials-Checklist.doc)\n\n \n\n'), ('Full bibliographic reference', 'Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials.\n\n \n\n This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.\n\n \n\n Pilot and Feasibility Studies. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n BMJ. 2016;355:i5239. PMID: [27777223](https://www.ncbi.nlm.nih.gov/pubmed/27777223)\n\n \n\n'), ('Language', 'English'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n**[CONSORT 2025 Statement](/reporting-guidelines/consort/)**:\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n**[CONSORT Harms](https://www.equator-network.org/reporting-guidelines/consort-harms/)**: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](https://www.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](/reporting-guidelines/consort-cluster/): \xa0Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](/reporting-guidelines/consort-herbal/): \xa0Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](/reporting-guidelines/consort-abstracts/): \xa0Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](/reporting-guidelines/consort-stricta/): \xa0MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738. \xa0PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n[**CONSORT for orthodontic trials**](/reporting-guidelines/consort-cent/%20/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/): Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**TIDieR**](/reporting-guidelines/tidier/): Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT-CHM formulas**](/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://www.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://www.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://www.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://www.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://www.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Other', 'Additional recommendations for reporting progression criteria have been developed:\n\n \n\n Mellor K, Albury C, Dutton SJ, Eldridge S, Hopewell S. Recommendations for progression criteria during external randomised pilot trial design, conduct, analysis and reporting. Pilot Feasibility Stud. 2023;9(1):59. PMID: [37061720](https://pubmed.ncbi.nlm.nih.gov/37061720/)\n\n \n\n'), ('Additional information', 'Read the reporting guideline development [summary (Word)](/wp-content/uploads/2009/02/EQUATOR-website-summary-pilot-and-feasibility-studies.docx).\n\n \n\n Read an article on the [methods and processes for the development of this CONSORT extension for reporting pilot randomized controlled trials](https://www.ncbi.nlm.nih.gov/pubmed/27965844).\n\n \n\n Read a [related article](http://www.nature.com/nm/journal/v19/n7/full/nm0713-795.html) in Nature Medicine.\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
14416,Core Outcome Set-STAndards for Reporting: The COS-STAR Statement,"Clinical trials, Experimental studies", ,Whole report, ,"checklist, checklists, clinical trial, clinical trials, COMET, core outcome, core outcome development, core outcome set, core outcome set development studies, core outcome set development study, Core Outcome Set?STAndards for Reporting, core outcomes, COS, COS development, COS development studies, COS development study, COS studies, COS study, COS-STAR, COS-STAR checklist, COS-STAR Statement, outcome, outcomes, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trial outcome, trial outcomes, trials", ,"Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, Moher D, Schmitt J, Tugwell P, Tunis S, Williamson PR. Core Outcome Set-STAndards for Reporting: The COS-STAR Statement. PLoS Med. 2016;13(10):e1002148.","Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, Moher D, Schmitt J, Tugwell P, Tunis S, Williamson PR.",PLoS Medicine [PLoS Med.],2016,13,10,e1002148, ,English, ,27755541,https://www.ncbi.nlm.nih.gov/pubmed/27755541, ,The COS-STAR explanation and elaboration document is available at: http://journals.plos.org/plosmedicine/article/asset?unique&amp;id=info:doi/10.1371/journal.pmed.1002148.s005, , , ,COS-STAR,Reporting core outcome set studies, ,Read the protocol for the development of the COS-STAR reporting guideline., , , , , ,no,2016-10-25 09:24:20,2021-11-26 11:11:07,cos-star-statement,"[('title', 'Core Outcome Set -STAndards for Reporting: The COS-STAR Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting core outcome set studies'), ('Full bibliographic reference', 'Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, Moher D, Schmitt J, Tugwell P, Tunis S, Williamson PR. Core Outcome Set-STAndards for Reporting: The COS-STAR Statement. PLoS Med. 2016;13(10):e1002148.'), ('Language', 'English'), ('PubMed ID', '[27755541](https://www.ncbi.nlm.nih.gov/pubmed/27755541)'), ('Explanation and elaboration papers', 'The COS-STAR explanation and elaboration document is available at: <http://journals.plos.org/plosmedicine/article/asset?unique&id=info:doi/10.1371/journal.pmed.1002148.s005>'), ('Reporting guideline acronym', 'COS-STAR'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Read the [protocol](http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-015-0913-9) for the development of the COS-STAR reporting guideline.'), ('Record last updated on', 'November 26, 2021')]"
6647,Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement,"Clinical trials, Experimental studies, Other","Behavioural medicine, Public health",Whole report, ,"behavior, behavioral, behavioral intervention, behavioral medicine, behaviour, behavioural, behavioural intervention, behavioural medicine, checklist, evaluation, evaluations, experimental studies, experimental study, intervention, interventions, non-randomised, non-randomised evaluation, non-randomised evaluations, non-randomized, non-randomized evaluation, non-randomized evaluations, nonrandomised, nonrandomised evaluation, nonrandomised evaluations, nonrandomized, nonrandomized evaluation, nonrandomized evaluations, NRS, NRSs, public health, TREND, TREND statement", ,"Des Jarlais DC, Lyles C, Crepaz N, Trend Group. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health. 2004;94(3):361-366.","Des Jarlais DC, Lyles C, Crepaz N, Trend Group.",American Journal of Public Health [Am J Public Health.],2004,94,3,361-366, ,English, ,14998794,http://www.ncbi.nlm.nih.gov/pubmed/14998794,TREND website: https://www.cdc.gov/hivpartners/php/trend-statement/index.html, , , , ,TREND,"Reporting of intervention evaluation studies using nonrandomized designs

TREND Statement

TREND checklist", , , , , , , ,no,2016-10-23 13:37:44,2025-05-30 14:59:51,improving-the-reporting-quality-of-nonrandomized-evaluations-of-behavioral-and-public-health-interventions-the-trend-statement,"[('title', 'Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of intervention evaluation studies using nonrandomized designs\n\n \n\n[TREND Statement](https://stacks.cdc.gov/view/cdc/149676)\n\n \n\n[TREND checklist](https://stacks.cdc.gov/view/cdc/149677)'), ('Full bibliographic reference', 'Des Jarlais DC, Lyles C, Crepaz N, Trend Group. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health. 2004;94(3):361-366.'), ('Language', 'English'), ('PubMed ID', '[14998794](http://www.ncbi.nlm.nih.gov/pubmed/14998794)'), ('Relevant URLs\n\n(full-text if available)', 'TREND website: <https://www.cdc.gov/hivpartners/php/trend-statement/index.html>'), ('Reporting guideline acronym', 'TREND'), ('Study design', 'Clinical trials, Experimental studies, Other'), ('Clinical area', 'Behavioural medicine, Public health'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 30, 2025')]"
14408,Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic resonance imaging,"Clinical trials, Experimental studies","Oncology, Radiology",Images, ,"cancer, clinical trial, clinical trials, EORTC, EORTC?STBSG, European Organisation for Research and Treatment of Cancer, histopathological, histopathology, image, image guided radiotherapy, images, imaging, intensity modulated radiotherapy, magnetic resonance imaging, MRI, multiparametric magnetic resonance imaging, multiparametric MRI, neoadjuvant radiotherapy, neoadjuvant RT, neoadjuvant therapies, neoadjuvant therapy, oncology, pathological, pathology, radiological, radiology, radiotherapy, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, RT, sarcoma, sarcomas, soft tissue, Soft Tissue and Bone Sarcoma Group and Imaging Group, soft tissue sarcoma, soft tissue sarcomas, soft tissues, STS, trial, trials, tumor, tumor response, tumour, tumour response", ,"Messiou C, Bonvalot S, Gronchi A, Vanel D, Meyer M, Robinson P, Morosi C, Bloem JL, Terrier PH, Lazar A, Le P\xe9choux C, Wardelman E, Winfield JM, Boulet B, Bov\xe9e J, Haas RL; European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group; European Organization for Research and Treatment of Cancer - Imaging Group. Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic resonance imaging. Eur J Cancer. 2016;56:37-44.","Messiou C, Bonvalot S, Gronchi A, Vanel D, Meyer M, Robinson P, Morosi C, Bloem JL, Terrier PH, Lazar A, Le P\xe9choux C, Wardelman E, Winfield JM, Boulet B, Bov\xe9e J, Haas RL; European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group; European Organization for Research and Treatment of Cancer - Imaging Group.",European Journal of Cancer [Eur J Cancer.],2016,56, ,37-44, ,English, ,26802529,https://www.ncbi.nlm.nih.gov/pubmed/26802529, , , , , , ,Reporting MRI evaluation of response after neoadjuvant radiotherapy in soft tissue sarcoma, , , , , , , ,no,2016-10-21 08:49:12,2016-10-21 08:49:12,evaluation-of-response-after-pre-operative-radiotherapy-in-soft-tissue-sarcomas-the-european-organisation-for-research-and-treatment-of-cancer-soft-tissue-and-bone-sarcoma-group-eortc-stbsg-and-ima,"[('title', 'Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer -Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic resonance imaging'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting MRI evaluation of response after neoadjuvant radiotherapy in soft tissue sarcoma'), ('Full bibliographic reference', 'Messiou C, Bonvalot S, Gronchi A, Vanel D, Meyer M, Robinson P, Morosi C, Bloem JL, Terrier PH, Lazar A, Le Péchoux C, Wardelman E, Winfield JM, Boulet B, Bovée J, Haas RL; European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group; European Organization for Research and Treatment of Cancer - Imaging Group. Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic resonance imaging. Eur J Cancer. 2016;56:37-44.'), ('Language', 'English'), ('PubMed ID', '[26802529](https://www.ncbi.nlm.nih.gov/pubmed/26802529)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Oncology, Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Images'), ('Record last updated on', 'October 21, 2016')]"
14405,Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group,"Clinical trials, Experimental studies","Oncology, Pathology","Intervention (exposure), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions", ,"breast, breast cancer, breast carcinoma, cancer, clinical trial, clinical trials, histopathologic, histopathology, lumpectomy, mastectomy, microscopic, neoadjuvant specimen, neoadjuvant specimens, neoadjuvant systemic therapy, neoadjuvant systemic therapy specimen, neoadjuvant systemic therapy specimens, oncology, pathological, pathological complete response, pathology, postneoadjuvant, postneoadjuvant specimen, postneoadjuvant specimens, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, residual disease, Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration, specimen, specimens, surgical, trial, trials, tumor, tumour", ,"Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF; Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol. 2015;28(9):1185-1201.","Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF; Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration.",Modern Pathology [Mod Pathol.],2016,28,9,1185-1201, ,English, ,26205180,https://www.ncbi.nlm.nih.gov/pubmed/26205180, , , , , , ,Reporting of postneoadjuvant systemic therapy breast cancer specimens, , , , , , , ,no,2016-10-21 08:14:44,2016-10-21 08:14:44,standardization-of-pathologic-evaluation-and-reporting-of-postneoadjuvant-specimens-in-clinical-trials-of-breast-cancer-recommendations-from-an-international-working-group,"[('title', 'Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of postneoadjuvant systemic therapy breast cancer specimens'), ('Full bibliographic reference', 'Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF; Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol. 2015;28(9):1185-1201.'), ('Language', 'English'), ('PubMed ID', '[26205180](https://www.ncbi.nlm.nih.gov/pubmed/26205180)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Oncology, Pathology'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'October 21, 2016')]"
14386,Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria?A 10-Year Update, ,"Oncology, Radiology","Harms/adverse effects/safety data, Images, Intervention (exposure), Outcomes (variables), Results, Statistical methods and analyses, Study characteristics (participants etc.), Terminology/definitions", ,"ablation, cancer, Cardiovascular and Interventional Radiological Society of Europe, chemical ablation, CIRSE, cryoablation, focused ultrasound, image, image guided, image guided ablation, image-guided ablation therapies, image-guided ablation therapy, image-guided therapies, image-guided therapy, imaging, International Working Group on Image-guided Tumor Ablation, Interventional Oncology Sans Fronti\xe8res Expert Panel, IRE, IRE ablation, irreversible electroporation, laser ablation, microwave, microwave ablation, nonthermal ablation, oncology, radiology, RF ablation, Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe, Technology Assessment Committee of the Society of Interventional Radiology, terminology, thermal ablation, tumor, tumor ablation, tumour, tumour ablation, ultrasound ablation", ,"Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, Chen MH, Choi BI, de Ba\xe8re T, Dodd GD 3rd, Dupuy DE, Gervais DA, Gianfelice D, Gillams AR, Lee FT Jr, Leen E, Lencioni R, Littrup PJ, Livraghi T, Lu DS, McGahan JP, Meloni MF, Nikolic B, Pereira PL, Liang P, Rhim H, Rose SC, Salem R, Sofocleous CT, Solomon SB, Soulen MC, Tanaka M, Vogl TJ, Wood BJ, Goldberg SN; International Working Group on Image-guided Tumor Ablation; Interventional Oncology Sans Fronti\xe8res Expert Panel; Technology Assessment Committee of the Society of Interventional Radiology; Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe. Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria?A 10-Year Update.

Radiology. 2014; 273(1): 241?260. PMID: 24927329
J Vasc Interv Radiol. 2014;25(11):1691-705.e4. PMID: 25442132","Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, Chen MH, Choi BI, de Ba\xe8re T, Dodd GD 3rd, Dupuy DE, Gervais DA, Gianfelice D, Gillams AR, Lee FT Jr, Leen E, Lencioni R, Littrup PJ, Livraghi T, Lu DS, McGahan JP, Meloni MF, Nikolic B, Pereira PL, Liang P, Rhim H, Rose SC, Salem R, Sofocleous CT, Solomon SB, Soulen MC, Tanaka M, Vogl TJ, Wood BJ, Goldberg SN; International Working Group on Image-guided Tumor Ablation; Interventional Oncology Sans Fronti\xe8res Expert Panel; Technology Assessment Committee of the Society of Interventional Radiology; Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe.", ,2014, , , , ,English, , , , , , , , , ,Reporting the various aspects of image-guided ablation therapy, , , , , , , ,no,2016-10-19 14:34:37,2021-11-26 11:13:44,image-guided-tumor-ablation-standardization-of-terminology-and-reporting-criteria-a-10-year-update,"[('title', 'Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria—A 10 -Year Update'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the various aspects of image-guided ablation therapy'), ('Full bibliographic reference', 'Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, Chen MH, Choi BI, de Baère T, Dodd GD 3rd, Dupuy DE, Gervais DA, Gianfelice D, Gillams AR, Lee FT Jr, Leen E, Lencioni R, Littrup PJ, Livraghi T, Lu DS, McGahan JP, Meloni MF, Nikolic B, Pereira PL, Liang P, Rhim H, Rose SC, Salem R, Sofocleous CT, Solomon SB, Soulen MC, Tanaka M, Vogl TJ, Wood BJ, Goldberg SN; International Working Group on Image-guided Tumor Ablation; Interventional Oncology Sans Frontières Expert Panel; Technology Assessment Committee of the Society of Interventional Radiology; Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe. Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria—A 10-Year Update.\n\n \n\n Radiology. 2014; 273(1): 241–260. PMID: [24927329](https://www.ncbi.nlm.nih.gov/pubmed/24927329)\n\n J Vasc Interv Radiol. 2014;25(11):1691-705.e4. PMID: [25442132](https://www.ncbi.nlm.nih.gov/pubmed/25442132)'), ('Language', 'English'), ('Clinical area', 'Oncology, Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Images, Intervention (exposure), Outcomes (variables), Results, Statistical methods and analyses, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'November 26, 2021')]"
14384,Irreversible Electroporation (IRE): Standardization of Terminology and Reporting Criteria for Analysis and Comparison, ,"Oncology, Radiology","Data, Images, Terminology/definitions", ,"ablation, ablation techniques, ablation therapy, cancer, electroporation, image guided, images, IRE, IRE tumor ablation, irreversible electroporation, NanoKnife, NanoKnife System, oncology, terminology, tumor ablation, tumour ablation", ,"Wendler JJ, Fischbach K, Ricke J, J\xfcrgens J, Fischbach F, K\xf6llermann J, Porsch M, Baumunk D, Schostak M, Liehr UB, Pech M. Irreversible Electroporation (IRE): Standardization of Terminology and Reporting Criteria for Analysis and Comparison. Pol J Radiol. 2016;81:54-64.","Wendler JJ, Fischbach K, Ricke J, J\xfcrgens J, Fischbach F, K\xf6llermann J, Porsch M, Baumunk D, Schostak M, Liehr UB, Pech M.",Polish Journal of Radiology [Pol J Radiol.],2016,81, ,54-64, ,English, ,26966472,https://www.ncbi.nlm.nih.gov/pubmed/26966472, , , , , , ,Reporting image-guided irreversible electroporation ablation therapy, , , , , , , ,no,2016-10-19 10:03:05,2016-10-20 10:02:46,irreversible-electroporation-ire-standardization-of-terminology-and-reporting-criteria-for-analysis-and-comparison,"[('title', 'Irreversible Electroporation (IRE) : Standardization of Terminology and Reporting Criteria for Analysis and Comparison'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting image-guided irreversible electroporation ablation therapy'), ('Full bibliographic reference', 'Wendler JJ, Fischbach K, Ricke J, Jürgens J, Fischbach F, Köllermann J, Porsch M, Baumunk D, Schostak M, Liehr UB, Pech M. Irreversible Electroporation (IRE): Standardization of Terminology and Reporting Criteria for Analysis and Comparison. Pol J Radiol. 2016;81:54-64.'), ('Language', 'English'), ('PubMed ID', '[26966472](https://www.ncbi.nlm.nih.gov/pubmed/26966472)'), ('Clinical area', 'Oncology, Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Images, Terminology/definitions'), ('Record last updated on', 'October 20, 2016')]"
14382,Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review,"Clinical trials, Experimental studies",Oncology,"Data, Ethical issues (consent etc.), Intervention (exposure), Outcomes (variables), Procedure/Method, Research recommendations, Results, Study characteristics (participants etc.)", ,"cancer, chemotherapy, clinical electrochemotherapy, clinical electrochemotherapy studies, clinical electrochemotherapy study, clinical trial, clinical trials, cutaneous metastases, electro-chemotherapy, electrochemotherapy, electrochemotherapy studies, electrochemotherapy study, electrode, electroporation, malignant melanoma, melanoma, non-thermal ablative, oncology, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, skin, skin cancer, skin malignancy, skin metastases, skin tumor, skin tumors, skin tumour, skin tumours, trial, trials", ,"Campana LG, Clover AJ, Valpione S, Quaglino P, Gehl J, Kunte C, Snoj M, Cemazar M, Rossi CR, Miklavcic D, Sersa G. Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review. Radiol Oncol. 2016;50(1):1-13.","Campana LG, Clover AJ, Valpione S, Quaglino P, Gehl J, Kunte C, Snoj M, Cemazar M, Rossi CR, Miklavcic D, Sersa G.",Radiology and Oncology [Radiol Oncol.],2016,50,1,1-13, ,English, ,27069444,https://www.ncbi.nlm.nih.gov/pubmed/27069444, , , , , , ,Reporting clinical trial results on electrochemotherapy, , , , , , , ,no,2016-10-19 09:42:31,2016-10-19 10:07:01,recommendations-for-improving-the-quality-of-reporting-clinical-electrochemotherapy-studies-based-on-qualitative-systematic-review,"[('title', 'Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting clinical trial results on electrochemotherapy'), ('Full bibliographic reference', 'Campana LG, Clover AJ, Valpione S, Quaglino P, Gehl J, Kunte C, Snoj M, Cemazar M, Rossi CR, Miklavcic D, Sersa G. Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review. Radiol Oncol. 2016;50(1):1-13.'), ('Language', 'English'), ('PubMed ID', '[27069444](https://www.ncbi.nlm.nih.gov/pubmed/27069444)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Ethical issues (consent etc.), Intervention (exposure), Outcomes (variables), Procedure/Method, Research recommendations, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'October 19, 2016')]"
14362,"METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer","Clinical trials, Experimental studies","Nuclear medicine, Oncology, Radiology, Urology",Images, ,"advanced prostate cancer, APC, cancer, clinical trial, clinical trials, diffusion MRI, imaging, magnetic resonance, magnetic resonance imaging, MET-RADS-P, metastases, metastasis, METastasis Reporting and Data System for Prostate Cancer, metastatic, MRI, MRIs, multiorgan, oncology, prostate, prostate cancer, prostate magnetic resonance imaging, prostate MRI, radiological, radiological image, radiological images, radiology, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials, WB-MRI, whole-body, whole-body magnetic resonance imaging, whole-body MRI", ,"Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F, Collins DJ, Sala E, Schlemmer HP, Petralia G, Vargas HA, Fanti S, Tombal HB, de Bono J. METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. Eur Urol. 2017;71(1):81-92.","Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F, Collins DJ, Sala E, Schlemmer HP, Petralia G, Vargas HA, Fanti S, Tombal HB, de Bono J.",European Urology [Eur Urol.],2017,71,1,81-92, ,English, ,27317091,https://www.ncbi.nlm.nih.gov/pubmed/27317091, , , , , ,MET-RADS-P,"To promote standardisation and diminish variations in the acquisition, interpretation, and reporting of whole-body MRI scans for use in advanced prostate cancer", , , , , , , ,no,2016-10-18 15:12:06,2017-02-22 09:21:32,metastasis-reporting-and-data-system-for-prostate-cancer-practical-guidelines-for-acquisition-interpretation-and-reporting-of-whole-body-magnetic-resonance-imaging-based-evaluations-of-multiorgan-i,"[('title', 'METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'To promote standardisation and diminish variations in the acquisition, interpretation, and reporting of whole-body MRI scans for use in advanced prostate cancer'), ('Full bibliographic reference', 'Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F, Collins DJ, Sala E, Schlemmer HP, Petralia G, Vargas HA, Fanti S, Tombal HB, de Bono J. METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. Eur Urol. 2017;71(1):81-92.'), ('Language', 'English'), ('PubMed ID', '[27317091](https://www.ncbi.nlm.nih.gov/pubmed/27317091)'), ('Reporting guideline acronym', 'MET-RADS-P'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Nuclear medicine, Oncology, Radiology, Urology'), ('Applies to the whole report or to individual sections of the report?', 'Images'), ('Record last updated on', 'February 22, 2017')]"
14360,Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force,Observational studies,"Oncology, Radiology, Urology",Images, ,"active surveillance, cancer, case, case studies, case study, checklist, checklists, cohort, cohort studies, cohort study, cohorts, European School of Oncology, European School of Oncology Task Force, image, images, magnetic resonance, magnetic resonance imaging, male, man, men, MRI, observational, observational studies, observational study, oncology, PRECISE, PRECISE checklist, PRECISE recommendations, prostate, prostate cancer, Prostate Cancer Radiological Estimation of Change in Sequential Evaluation, prostate magnetic resonance imaging, prostate MRI, radiologic, radiological, radiological image, radiological images, radiology, surveillance", ,"Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, Carroll P, Haider M, Kasivisvanathan V, Kirkham A, Klotz L, Ouzzane A, Padhani AR, Panebianco V, Pinto P, Puech P, Rannikko A, Renard-Penna R, Touijera K, Turkbey B, van Poppel H, Valdagni R, Walz J, Schoots I. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations - A Report of a European School of Oncology Task Force. Eur Urol. 2017;71(4):648-655.","Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, Carroll P, Haider M, Kasivisvanathan V, Kirkham A, Klotz L, Ouzzane A, Padhani AR, Panebianco V, Pinto P, Puech P, Rannikko A, Renard-Penna R, Touijera K, Turkbey B, van Poppel H, Valdagni R, Walz J, Schoots I.",European Urology [Eur Urol.],2017,71,4,648-655, ,English, ,27349615,https://www.ncbi.nlm.nih.gov/pubmed/27349615, , , , , ,PRECISE,Reporting of individual MRI studies in men with prostate cancer on active surveillance and for reporting the outcomes of cohorts of men with prostate cancer having MRI on active surveillance, , , , , , , ,no,2016-10-18 14:45:33,2017-10-27 09:04:44,reporting-magnetic-resonance-imaging-in-men-on-active-surveillance-for-prostate-cancer-the-precise-recommendations-a-report-of-a-european-school-of-oncology-task-force,"[('title', 'Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations -A Report of a European School of Oncology Task Force'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of individual MRI studies in men with prostate cancer on active surveillance and for reporting the outcomes of cohorts of men with prostate cancer having MRI on active surveillance'), ('Full bibliographic reference', 'Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, Carroll P, Haider M, Kasivisvanathan V, Kirkham A, Klotz L, Ouzzane A, Padhani AR, Panebianco V, Pinto P, Puech P, Rannikko A, Renard-Penna R, Touijera K, Turkbey B, van Poppel H, Valdagni R, Walz J, Schoots I. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations - A Report of a European School of Oncology Task Force. Eur Urol. 2017;71(4):648-655.'), ('Language', 'English'), ('PubMed ID', '[27349615](https://www.ncbi.nlm.nih.gov/pubmed/27349615)'), ('Reporting guideline acronym', 'PRECISE'), ('Study design', 'Observational studies'), ('Clinical area', 'Oncology, Radiology, Urology'), ('Applies to the whole report or to individual sections of the report?', 'Images'), ('Record last updated on', 'October 27, 2017')]"
14357,"Transcription factor HIF1A: downstream targets, associated pathways, polymorphic hypoxia response element (HRE) sites, and initiative for standardization of reporting in scientific literature", ,"Genetics, Oncology",Data, ,"bioinformatics, cancer, checklist, checklists, gene expression, genomic, genomics, HIF, HIF-1?, HIF-1? target, HIF-1? target gene, HIF-1? target genes, HIF-1? targets, HIF-1?-TG, HIF-1?-TG interaction, HIF-1?-TG interactions, HIF-1?-TGs, HIF1A, HRE, HRE genomic, HRE genomic coordinates, HRE polymorphism, HRE polymorphisms, HRE site, HRE sites, hypoxia, hypoxia inducible factor, hypoxia response element, interactomic, interactomics, oncology, pathway, pathways, target gene, target genes, TF target gene, TF target genes, TF-target interaction, TF-target interactions, transcription factor, transcription factors, transcription regulation", ,"Slemc L, Kunej T. Transcription factor HIF1A: downstream targets, associated pathways, polymorphic hypoxia response element (HRE) sites, and initiative for standardization of reporting in scientific literature. Tumour Biol. 2016 Sep 19.","Slemc L, Kunej T.",Tumour Biology [Tumour Biol.],2016, , , , ,English, ,27644243,https://www.ncbi.nlm.nih.gov/pubmed/27644243, , , , , , ,Reporting\xa0HIF-1?-TG interactions, , , , , , , ,no,2016-10-18 11:00:15,2016-10-18 11:01:47,transcription-factor-hif1a-downstream-targets-associated-pathways-polymorphic-hypoxia-response-element-hre-sites-and-initiative-for-standardization-of-reporting-in-scientific-literature,"[('title', 'Transcription factor HIF 1A: downstream targets, associated pathways, polymorphic hypoxia response element (HRE) sites, and initiative for standardization of reporting in scientific literature'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting\xa0HIF-1α-TG interactions'), ('Full bibliographic reference', 'Slemc L, Kunej T. Transcription factor HIF1A: downstream targets, associated pathways, polymorphic hypoxia response element (HRE) sites, and initiative for standardization of reporting in scientific literature. Tumour Biol. 2016 Sep 19.'), ('Language', 'English'), ('PubMed ID', '[27644243](https://www.ncbi.nlm.nih.gov/pubmed/27644243)'), ('Clinical area', 'Genetics, Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'October 18, 2016')]"
14354,Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative,"Clinical trials, Experimental studies","Oncology, Paediatrics","Harms/adverse effects/safety data, Terminology/definitions", ,"adolescent, adolescents, adverse, adverse effect, adverse effects, adverse event, adverse event reporting, adverse event reports, adverse events, AE, AEs, cancer, child, children, clinical trial, clinical trials, common terminology, common terminology criteria for adverse events, oncology, oncology trial, oncology trials, paediatric, paediatric cancer, paediatric oncology, paediatrics, patient outcome, patient outcomes, patient-reported, patient-reported outcome, patient-reported outcomes, pediatric, pediatric cancer, pediatric oncology, pediatrics, PRO, PRO-CTCAE, PROs, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, terminology, trial, trials", ,"Reeve BB, McFatrich M, Pinheiro LC, Weaver MS, Sung L, Withycombe JS, Baker JN, Mack JW, Waldron MK, Gibson D, Tomlinson D, Freyer DR, Mowbray C, Jacobs S, Palma D, Martens CE, Gold SH, Jackson KD, Hinds PS. Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative. Pediatr Blood Cancer. 2017;64(3).","Reeve BB, McFatrich M, Pinheiro LC, Weaver MS, Sung L, Withycombe JS, Baker JN, Mack JW, Waldron MK, Gibson D, Tomlinson D, Freyer DR, Mowbray C, Jacobs S, Palma D, Martens CE, Gold SH, Jackson KD, Hinds PS.",Pediatric Blood and Cancer [Pediatr Blood Cancer.],2017,64,3, , ,English, ,27650708,https://www.ncbi.nlm.nih.gov/pubmed/27650708, , , , , , ,Common terminology criteria for paediatric reporting of adverse events in oncology trials, , , , , , , ,no,2016-10-18 10:23:48,2017-02-22 09:22:40,eliciting-the-childs-voice-in-adverse-event-reporting-in-oncology-trials-cognitive-interview-findings-from-the-pediatric-patient-reported-outcomes-version-of-the-common-terminology-criteria-for-adv,"[('title', 'Eliciting the child’s voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient -Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Common terminology criteria for paediatric reporting of adverse events in oncology trials'), ('Full bibliographic reference', ""Reeve BB, McFatrich M, Pinheiro LC, Weaver MS, Sung L, Withycombe JS, Baker JN, Mack JW, Waldron MK, Gibson D, Tomlinson D, Freyer DR, Mowbray C, Jacobs S, Palma D, Martens CE, Gold SH, Jackson KD, Hinds PS. Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative. Pediatr Blood Cancer. 2017;64(3).""), ('Language', 'English'), ('PubMed ID', '[27650708](https://www.ncbi.nlm.nih.gov/pubmed/27650708)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Oncology, Paediatrics'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Terminology/definitions'), ('Record last updated on', 'February 22, 2017')]"
14342,CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement,Observational studies,Infectious diseases,Whole report, ,"antibodies, antibody, CONCISE, Consortium for the Standardization of Influenza Seroepidemiology, epidemiologic, epidemiology, infection, infections, infectious, infectious disease, infectious diseases, influenza, influenza seroepidemiologic studies, influenza seroepidemiologic study, influenza virus, influenza viruses, respiratory, respiratory medicine, respiratory virus, ROSES, ROSES-I, ROSES-I Statement, seroepidemiologic, seroepidemiologic studies, seroepidemiologic study, seroepidemiology, seroincidence, serologic, serologic test, serologic testing, serologic tests, serological, serological test, serological testing, serological tests, serology, seroprevalence, STROBE extension, virus, viruses", ,"Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15.","Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee.",Influenza and Other Respiratory Viruses [Influenza Other Respir Viruses.],2016, , , , ,English, ,27417916,https://www.ncbi.nlm.nih.gov/pubmed/27417916, , , ,"Generic
STROBE: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Ann Intern Med. 2007;147(8):573-577. PMID: 17938396
PLoS Med. 2007;4(10):e296. PMID: 17941714
BMJ. 2007;335(7624):806-808. PMID: 17947786
Prev Med. 2007;45(4):247-251. PMID: 17950122
Epidemiology. 2007;18(6):800-804. PMID: 18049194
Lancet. 2007;370(9596):1453-1457. PMID: 18064739

Specialised
STREGA: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.

PLoS Med. 2009;6(2):e22. PMID: 19192942
Hum Genet. 2009;125(2):131-151. PMID: 19184668
Eur J Epidemiol. 2009;24(1):37-55. PMID: 19189221
Ann Intern Med. 2009;150(3):206-215. PMID: 19189911
J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: 19217256
Genet Epidemiol. 2009;33(7):581-598. PMID: 19278015
Eur J Clin Invest. 2009;39(4):247-266. PMID: 19297801

STROBE-ME: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: 22023344

STROBE checklist for conference abstracts
First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. Link to full text pdf

STROME-ID: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: 24631223

Longitudinal observational drug studies in rheumatology: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: 24058015

Case-cohort studies: Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: 24972092

STROBE-RDS: White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: 26112433

RECORD: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: 26440803

STROBE-AMS: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schr\xf6der W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: 26895985

STROBE-nut: Lachat C, Hawwash D, Ock\xe9 MC, Berg C, Forsum E, H\xf6rnell A, Larsson C, Sonestedt E, Wirf\xe4lt E, \xc5kesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology?Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: 27270749

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

STROBE-NI: Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: 27633910

Propensity score analysis: Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: 28376195

RECORD-PE: Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.

STROBE-SIIS: International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, H\xe4gglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).

Br J Sports Med. 2020;54(7):372-389. PMID: 32071062
Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: 32118084

STROBE-MR: Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: 34698778

", ,ROSES-I,Reporting influenza seroepidemiologic studies., , , , , , , ,yes,2016-10-13 07:55:50,2021-11-25 14:44:09,roses-i-statement,"[('title', 'CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting influenza seroepidemiologic studies.'), ('Full bibliographic reference', 'Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15.'), ('Language', 'English'), ('PubMed ID', '[27417916](https://www.ncbi.nlm.nih.gov/pubmed/27417916)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**STROBE**](/reporting-guidelines/strobe/): von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.\n\n \n\n Ann Intern Med. 2007;147(8):573-577. PMID: [17938396](http://www.ncbi.nlm.nih.gov/pubmed/17938396)\n\n PLoS Med. 2007;4(10):e296. PMID: [17941714](http://www.ncbi.nlm.nih.gov/pubmed/17941714)\n\n BMJ. 2007;335(7624):806-808. PMID: [17947786](http://www.ncbi.nlm.nih.gov/pubmed/17947786)\n\n Prev Med. 2007;45(4):247-251. PMID: [17950122](http://www.ncbi.nlm.nih.gov/pubmed/17950122)\n\n Epidemiology. 2007;18(6):800-804. PMID: [18049194](http://www.ncbi.nlm.nih.gov/pubmed/18049194)\n\n Lancet. 2007;370(9596):1453-1457. PMID: [18064739](http://www.ncbi.nlm.nih.gov/pubmed/18064739)\n\n \n\n**Specialised**\n\n[**STREGA**](/reporting-guidelines/strobe-strega/): Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.\n\n \n\n PLoS Med. 2009;6(2):e22. PMID: [19192942](http://www.ncbi.nlm.nih.gov/pubmed/19192942)\n\n Hum Genet. 2009;125(2):131-151. PMID: [19184668](http://www.ncbi.nlm.nih.gov/pubmed/19184668)\n\n Eur J Epidemiol. 2009;24(1):37-55. PMID: [19189221](http://www.ncbi.nlm.nih.gov/pubmed/19189221)\n\n Ann Intern Med. 2009;150(3):206-215. PMID: [19189911](http://www.ncbi.nlm.nih.gov/pubmed/19189911)\n\n J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: [19217256](http://www.ncbi.nlm.nih.gov/pubmed/19217256)\n\n Genet Epidemiol. 2009;33(7):581-598. PMID: [19278015](http://www.ncbi.nlm.nih.gov/pubmed/19278015)\n\n Eur J Clin Invest. 2009;39(4):247-266. PMID: [19297801](http://www.ncbi.nlm.nih.gov/pubmed/19297801)\n\n \n\n[**STROBE-ME**](/reporting-guidelines/strobe-me/): Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: [22023344](http://www.ncbi.nlm.nih.gov/pubmed/22023344)\n\n \n\n**[STROBE checklist for conference abstracts](/reporting-guidelines/strobe-abstracts/)**\n\n First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. [Link to full text pdf](https://www.strobe-statement.org/download/strobe-checklist-conference-abstracts)\n\n \n\n**[STROME-ID](/reporting-guidelines/strome-id/)**: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: [24631223](http://www.ncbi.nlm.nih.gov/pubmed/24631223)\n\n \n\n[**Longitudinal observational drug studies in rheumatology**](/reporting-guidelines/launch-of-a-checklist-for-reporting-longitudinal-observational-drug-studies-in-rheumatology-a-eular-extension-of-strobe-guidelines-based-on-experience-from-biologics-registries/): Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: [24058015](http://www.ncbi.nlm.nih.gov/pubmed/24058015)\n\n \n\n[**Case-cohort studies**](/reporting-guidelines/a-review-of-published-analyses-of-case-cohort-studies-and-recommendations-for-future-reporting/): Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: [24972092](https://www.ncbi.nlm.nih.gov/pubmed/24972092)\n\n \n\n[**STROBE-RDS**](/reporting-guidelines/strobe-rds/): White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: [26112433](http://www.ncbi.nlm.nih.gov/pubmed/26112433)\n\n \n\n[**RECORD**](/reporting-guidelines/record/): Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: [26440803](http://www.ncbi.nlm.nih.gov/pubmed/26440803)\n\n \n\n[**STROBE-AMS**](/reporting-guidelines/strobe-ams/): Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schröder W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: [26895985](http://www.ncbi.nlm.nih.gov/pubmed/26895985)\n\n \n\n[**STROBE-nut**](/reporting-guidelines/strobe-nut/): Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology—Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: [27270749](https://www.ncbi.nlm.nih.gov/pubmed/27270749)\n\n \n\n[**Simulation Research**](/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**STROBE-NI**](/reporting-guidelines/strobe-ni/): Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: [27633910](https://www.ncbi.nlm.nih.gov/pubmed/27633910)\n\n \n\n[**Propensity score analysis**](/reporting-guidelines/reporting-and-guidelines-in-propensity-score-analysis-a-systematic-review-of-cancer-and-cancer-surgical-studies/): Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: [28376195](https://www.ncbi.nlm.nih.gov/pubmed/28376195)\n\n \n\n[**RECORD-PE**](https://www.equator-network.org/reporting-guidelines/record-pe/): Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). [BMJ 2018;363:k3532](https://www.bmj.com/content/363/bmj.k3532.full).\n\n \n\n[**STROBE-SIIS**](https://www.equator-network.org/reporting-guidelines/strobe-extension-for-sports-injury-illness-surveillance/): International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, Hägglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).\n\n \n\n Br J Sports Med. 2020;54(7):372-389. PMID: [32071062](https://pubmed.ncbi.nlm.nih.gov/32071062/)\n\n Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: [32118084](https://pubmed.ncbi.nlm.nih.gov/32118084/)\n\n \n\n[**STROBE-MR**](https://www.equator-network.org/reporting-guidelines/strobe-mr-statement/): Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: [34698778](https://pubmed.ncbi.nlm.nih.gov/34698778/)\n\n \n\n'), ('Reporting guideline acronym', 'ROSES-I'), ('Study design', 'Observational studies'), ('Clinical area', 'Infectious diseases'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 25, 2021')]"
5551,REporting recommendations for tumour MARKer prognostic studies (REMARK),"Diagnostic and prognostic studies, Observational studies","Genetics, Oncology",Whole report, ,"assay, assays, biomarker, biomarkers, cancer, data presentation, European Organisation for Research and Treatment of Cancer, genetic, genetics, marker, markers, National Cancer Institute, observational, observational studies, observational study, oncology, prognosis, prognostic, prognostic marker, prognostic markers, prognostic studies, prognostic study, REMARK, specimen, statistical, tumor, tumor marker, tumor marker prognostic studies, tumor marker prognostic study, tumor markers, tumour, tumour marker, tumour marker prognostic studies, tumour marker prognostic study, tumour markers", ,"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387-391.","McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM.",British Journal of Cancer [Br J Cancer.],2005,93,4,387-391, ,English, ,16106245,http://www.ncbi.nlm.nih.gov/pubmed/16106245,Download the REMARK checklist (Word) for tumour marker prognostic studies.,"Abridged explanation and elaboration
Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration. J Natl Cancer Inst. 2018. PMID: 29873743

Detailed explanation and elaboration
Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

BMC Med. 2012;10:51. PMID: 22642691
PLoS Med. 9(5):e1001216. Link to full-text

", , , ,REMARK,Tumour marker prognostic studies, , , , , ,"REMARK profile to aid structured reporting
Sauerbrei W, Haeussler T, Balmford J, Huebner M. Structured reporting to improve transparency of analyses in prognostic marker studies. BMC Med. 2022;20(1):184. PMID: 35546237", ,no,2016-10-12 11:53:22,2022-05-16 12:44:23,reporting-recommendations-for-tumour-marker-prognostic-studies-remark,"[('title', 'REporting recommendations for tumour MARKer prognostic studies (REMARK)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Tumour marker prognostic studies'), ('Full bibliographic reference', 'McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387-391.'), ('Language', 'English'), ('PubMed ID', '[16106245](http://www.ncbi.nlm.nih.gov/pubmed/16106245)'), ('Relevant URLs\n\n(full-text if available)', 'Download the [REMARK checklist (Word)](https://www.equator-network.org/wp-content/uploads/2016/10/REMARK-checklist-for-EQUATOR-website-002.docx) for tumour marker prognostic studies.'), ('Explanation and elaboration papers', '**Abridged explanation and elaboration**\n\n Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration. J Natl Cancer Inst. 2018. PMID: [29873743](https://www.ncbi.nlm.nih.gov/pubmed/29873743)\n\n \n\n**Detailed explanation and elaboration**\n\n Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.\n\n \n\n BMC Med. 2012;10:51. PMID: [22642691](http://www.ncbi.nlm.nih.gov/pubmed/22642691)\n\n PLoS Med. 9(5):e1001216. [Link to full-text](http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001216)\n\n \n\n'), ('Reporting guideline acronym', 'REMARK'), ('Study design', 'Diagnostic and prognostic studies, Observational studies'), ('Clinical area', 'Genetics, Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), (""Other relevant research\n\n(i.e. research regarding the guideline's effectiveness usability, impact etc.)"", '**REMARK profile to aid structured reporting**\n\n Sauerbrei W, Haeussler T, Balmford J, Huebner M. Structured reporting to improve transparency of analyses in prognostic marker studies. BMC Med. 2022;20(1):184. PMID: [35546237](https://pubmed.ncbi.nlm.nih.gov/35546237/)'), ('Record last updated on', 'May 16, 2022')]"
14334,Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective,"Clinical trials, Experimental studies", ,Harms/adverse effects/safety data, ,"adverse, adverse drug interaction, adverse drug interactions, adverse drug reaction, adverse drug reactions, adverse effect, adverse effects, adverse event, adverse event data, adverse event reporting, adverse events, AE, AEs, clinical trial, clinical trials, clinically relevant, CONSORT Harms, drug, drug adverse event, drug adverse events, drug industry, editor, editors, harms, harms data, industry sponsored trial, industry sponsored trials, industry trial, industry trials, International Society for Medical Publication Professionals, journal, journal editor, journal editors, journals, Medical Publishing Insights and Practices, MPIP, pharmaceutical, pharmaceutical clinical trial, pharmaceutical clinical trials, pharmaceutical company, pharmaceutical industry, pharmaceutical trial, pharmaceutical trials, pharmacy, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Lineberry N, Berlin JA, Mansi B, Glasser S, Berkwits M, Klem C, Bhattacharya A, Citrome L, Enck R, Fletcher J, Haller D, Chen TT, Laine C. Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective.
BMJ. 2016;355:i5078.","Lineberry N, Berlin JA, Mansi B, Glasser S, Berkwits M, Klem C, Bhattacharya A, Citrome L, Enck R, Fletcher J, Haller D, Chen TT, Laine C.",British Medical Journal [BMJ],2016,355, ,i5078, ,English, ,27697753,https://www.ncbi.nlm.nih.gov/pubmed/27697753, , , , , , ,Reporting clinically relevant and more informative adverse event information in clinical trial publications., , , , , , , ,no,2016-10-11 10:08:12,2016-10-11 10:08:12,recommendations-to-improve-adverse-event-reporting-in-clinical-trial-publications-a-joint-pharmaceutical-industryjournal-editor-perspective,"[('title', 'Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting clinically relevant and more informative adverse event information in clinical trial publications.'), ('Full bibliographic reference', 'Lineberry N, Berlin JA, Mansi B, Glasser S, Berkwits M, Klem C, Bhattacharya A, Citrome L, Enck R, Fletcher J, Haller D, Chen TT, Laine C. Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective.\n\n BMJ. 2016;355:i5078.'), ('Language', 'English'), ('PubMed ID', '[27697753](https://www.ncbi.nlm.nih.gov/pubmed/27697753)'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data'), ('Record last updated on', 'October 11, 2016')]"
14306,Reporting studies on time to diagnosis: proposal of a guideline by an international panel (REST),Diagnostic and prognostic studies, ,Whole report, ,"checklist, checklists, diagnosis, diagnosis delay, diagnostic, diagnostic delay, diagnostic procedure, diagnostic procedures, diagnostic test, diagnostic testing, diagnostic tests, early diagnosis, REST, signs, signs and symptoms, symptoms, time to diagnosis, time to diagnosis studies, time to diagnosis study, TTD, TTD studies, TTD study", ,"Launay E, Cohen JF, Bossuyt PM, Buekens P, Deeks J, Dye T, Feltbower R, Ferrari A, Kramer M, Leeflang M, Moher D, Moons KG, von Elm E, Ravaud P, Chalumeau M. Reporting studies on time to diagnosis: proposal of a guideline by an international panel (REST). BMC Med. 2016;14(1):146.","Launay E, Cohen JF, Bossuyt PM, Buekens P, Deeks J, Dye T, Feltbower R, Ferrari A, Kramer M, Leeflang M, Moher D, Moons KG, von Elm E, Ravaud P, Chalumeau M.",BMC Medicine [BMC Med.],2016,14,1,146, ,English, ,27677259,https://www.ncbi.nlm.nih.gov/pubmed/27677259, , , , , ,REST,Reporting studies on time to diagnosis., ,"Read the guideline development summary (PDF).

Read a related paper on the quality of reporting of studies evaluating time to diagnosis in paediatrics.

", , , , , ,no,2016-09-30 13:22:11,2021-11-26 11:17:48,reporting-studies-on-time-to-diagnosis-proposal-of-a-guideline-by-an-international-panel-rest,"[('title', 'Reporting studies on time to diagnosis: proposal of a guideline by an international panel (REST)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting studies on time to diagnosis.'), ('Full bibliographic reference', 'Launay E, Cohen JF, Bossuyt PM, Buekens P, Deeks J, Dye T, Feltbower R, Ferrari A, Kramer M, Leeflang M, Moher D, Moons KG, von Elm E, Ravaud P, Chalumeau M. Reporting studies on time to diagnosis: proposal of a guideline by an international panel (REST). BMC Med. 2016;14(1):146.'), ('Language', 'English'), ('PubMed ID', '[27677259](https://www.ncbi.nlm.nih.gov/pubmed/27677259)'), ('Reporting guideline acronym', 'REST'), ('Study design', 'Diagnostic and prognostic studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Read the [guideline development summary (PDF)](/wp-content/uploads/2009/02/Reporting-studies-on-time-to-diagnosis-summary.pdf).\n\n \n\n Read a [related paper](http://adc.bmj.com/content/99/3/244.abstract?sid=404e9ae2-bcf9-4dc5-85f4-23f6251a8066) on the quality of reporting of studies evaluating time to diagnosis in paediatrics.\n\n \n\n'), ('Record last updated on', 'November 26, 2021')]"
14293,A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE),Economic evaluations, ,"Data, Intervention (exposure), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.), Terminology/definitions", ,"checklist, checklists, cost utility, CREATE, economic evaluation, economic evaluation studies, economic evaluation study, economic evaluations, health utility, instrument, instruments, MAUI, MAUIs, multi-attribute utility based instrument, QALY, QALYS, quality adjusted life years, reimbursement, reimbursement decisions, utility, valuation, valuation studies, valuation study, value set, value sets", ,"Xie F, Pickard AS, Krabbe PF, Revicki D, Viney R, Devlin N, Feeny D. A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE). Pharmacoeconomics. 2015;33(8):867-877.","Xie F, Pickard AS, Krabbe PF, Revicki D, Viney R, Devlin N, Feeny D.",Pharmacoeconomics.,2015,33,8,867-877, ,English, ,26026667,https://www.ncbi.nlm.nih.gov/pubmed/26026667, , , , , ,CREATE,Reporting valuation studies of multi-attribute utility instruments (MAUIs)., , , , , , , ,no,2016-09-28 09:34:28,2016-09-28 09:54:36,a-checklist-for-reporting-valuation-studies-of-multi-attribute-utility-based-instruments-create,"[('title', 'A Checklist for Reporting Valuation Studies of Multi -Attribute Utility -Based Instruments (CREATE)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting valuation studies of multi-attribute utility instruments (MAUIs).'), ('Full bibliographic reference', 'Xie F, Pickard AS, Krabbe PF, Revicki D, Viney R, Devlin N, Feeny D. A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE). Pharmacoeconomics. 2015;33(8):867-877.'), ('Language', 'English'), ('PubMed ID', '[26026667](https://www.ncbi.nlm.nih.gov/pubmed/26026667)'), ('Reporting guideline acronym', 'CREATE'), ('Study design', 'Economic evaluations'), ('Applies to the whole report or to individual sections of the report?', 'Data, Intervention (exposure), Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'September 28, 2016')]"
14225,Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research,Observational studies,"Infectious diseases, Obstetrics and gynaecology, Paediatrics","Ethical issues (consent etc.), Narrative sections (discussion etc.), Procedure/Method, Results", ,"aetiological, aetiological studies, aetiological study, aetiology, antimicrobial, babies, baby, bacterial data, checklist, epidemiological, epidemiological studies, epidemiological study, epidemiology, fungal data, infant, infants, infection, infections, infectious, infectious disease, infectious disease epidemiology, infectious diseases, meningitis, microbiological, molecular, neonatal, neonatal care, neonatal data, neonatal health, neonatal health research, neonatal infection, neonatal infection data, neonatal infection studies, neonatal infection study, neonatal infections, neonatal research, neonatal sepsis, neonate, neonatology, newborn, newborn infection, newborn infections, newborns, observational, observational data, observational studies, observational study, obstetrics, omphalitis, paediatrics, pathogen, pathogens, pediatrics, pneumonia, preterm, preterm birth, SPRING, SPRING group, Strengthening Publications Reporting Infection In Newborns Globally, Strengthening Publications Reporting Infection In Newborns Globally Group, STROBE, STROBE newborn infection, STROBE-NI, STROBE-NI checklist, tetanus, viral data", ,"Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13.","Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group.",Lancet Infectious Diseases.,2016,16,10,e202-13, ,English, ,27633910,https://www.ncbi.nlm.nih.gov/pubmed/27633910, , , ,"Generic
STROBE: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Ann Intern Med. 2007;147(8):573-577. PMID: 17938396
PLoS Med. 2007;4(10):e296. PMID: 17941714
BMJ. 2007;335(7624):806-808. PMID: 17947786
Prev Med. 2007;45(4):247-251. PMID: 17950122
Epidemiology. 2007;18(6):800-804. PMID: 18049194
Lancet. 2007;370(9596):1453-1457. PMID: 18064739

Specialised
STREGA: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.

PLoS Med. 2009;6(2):e22. PMID: 19192942
Hum Genet. 2009;125(2):131-151. PMID: 19184668
Eur J Epidemiol. 2009;24(1):37-55. PMID: 19189221
Ann Intern Med. 2009;150(3):206-215. PMID: 19189911
J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: 19217256
Genet Epidemiol. 2009;33(7):581-598. PMID: 19278015
Eur J Clin Invest. 2009;39(4):247-266. PMID: 19297801

STROBE-ME: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: 22023344

STROBE checklist for conference abstracts
First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. Link to full text pdf

STROME-ID: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: 24631223

Longitudinal observational drug studies in rheumatology: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: 24058015

Case-cohort studies: Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: 24972092

STROBE-RDS: White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: 26112433

RECORD: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: 26440803

STROBE-AMS: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schr\xf6der W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: 26895985

STROBE-nut: Lachat C, Hawwash D, Ock\xe9 MC, Berg C, Forsum E, H\xf6rnell A, Larsson C, Sonestedt E, Wirf\xe4lt E, \xc5kesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology?Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: 27270749

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

ROSES-I: Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: 27417916

Propensity score analysis: Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: 28376195

RECORD-PE: Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.

STROBE-SIIS: International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, H\xe4gglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).

Br J Sports Med. 2020;54(7):372-389. PMID: 32071062
Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: 32118084

STROBE-MR: Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: 34698778

", ,STROBE-NI,Reporting of neonatal infection studies., , , , , , , ,yes,2016-09-13 09:23:04,2021-11-25 14:50:30,strobe-ni,"[('title', 'Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI) : an extension of the STROBE statement for neonatal infection research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of neonatal infection studies.'), ('Full bibliographic reference', 'Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13.'), ('Language', 'English'), ('PubMed ID', '[27633910](https://www.ncbi.nlm.nih.gov/pubmed/27633910)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**STROBE**](/reporting-guidelines/strobe/): von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.\n\n \n\n Ann Intern Med. 2007;147(8):573-577. PMID: [17938396](http://www.ncbi.nlm.nih.gov/pubmed/17938396)\n\n PLoS Med. 2007;4(10):e296. PMID: [17941714](http://www.ncbi.nlm.nih.gov/pubmed/17941714)\n\n BMJ. 2007;335(7624):806-808. PMID: [17947786](http://www.ncbi.nlm.nih.gov/pubmed/17947786)\n\n Prev Med. 2007;45(4):247-251. PMID: [17950122](http://www.ncbi.nlm.nih.gov/pubmed/17950122)\n\n Epidemiology. 2007;18(6):800-804. PMID: [18049194](http://www.ncbi.nlm.nih.gov/pubmed/18049194)\n\n Lancet. 2007;370(9596):1453-1457. PMID: [18064739](http://www.ncbi.nlm.nih.gov/pubmed/18064739)\n\n \n\n**Specialised**\n\n[**STREGA**](/reporting-guidelines/strobe-strega/): Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.\n\n \n\n PLoS Med. 2009;6(2):e22. PMID: [19192942](http://www.ncbi.nlm.nih.gov/pubmed/19192942)\n\n Hum Genet. 2009;125(2):131-151. PMID: [19184668](http://www.ncbi.nlm.nih.gov/pubmed/19184668)\n\n Eur J Epidemiol. 2009;24(1):37-55. PMID: [19189221](http://www.ncbi.nlm.nih.gov/pubmed/19189221)\n\n Ann Intern Med. 2009;150(3):206-215. PMID: [19189911](http://www.ncbi.nlm.nih.gov/pubmed/19189911)\n\n J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: [19217256](http://www.ncbi.nlm.nih.gov/pubmed/19217256)\n\n Genet Epidemiol. 2009;33(7):581-598. PMID: [19278015](http://www.ncbi.nlm.nih.gov/pubmed/19278015)\n\n Eur J Clin Invest. 2009;39(4):247-266. PMID: [19297801](http://www.ncbi.nlm.nih.gov/pubmed/19297801)\n\n \n\n[**STROBE-ME**](/reporting-guidelines/strobe-me/): Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: [22023344](http://www.ncbi.nlm.nih.gov/pubmed/22023344)\n\n \n\n[**STROBE checklist for conference abstracts**](/reporting-guidelines/strobe-abstracts/)\n\n First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. [Link to full text pdf](https://www.strobe-statement.org/download/strobe-checklist-conference-abstracts)\n\n \n\n[**STROME-ID**](/reporting-guidelines/strome-id/): Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: [24631223](http://www.ncbi.nlm.nih.gov/pubmed/24631223)\n\n \n\n[**Longitudinal observational drug studies in rheumatology**](/reporting-guidelines/launch-of-a-checklist-for-reporting-longitudinal-observational-drug-studies-in-rheumatology-a-eular-extension-of-strobe-guidelines-based-on-experience-from-biologics-registries/): Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: [24058015](http://www.ncbi.nlm.nih.gov/pubmed/24058015)\n\n \n\n[**Case-cohort studies**](/reporting-guidelines/a-review-of-published-analyses-of-case-cohort-studies-and-recommendations-for-future-reporting/): Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: [24972092](https://www.ncbi.nlm.nih.gov/pubmed/24972092)\n\n \n\n[**STROBE-RDS**](/reporting-guidelines/strobe-rds/): White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: [26112433](http://www.ncbi.nlm.nih.gov/pubmed/26112433)\n\n \n\n[**RECORD**](/reporting-guidelines/record/): Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: [26440803](http://www.ncbi.nlm.nih.gov/pubmed/26440803)\n\n \n\n[**STROBE-AMS**](/reporting-guidelines/strobe-ams/): Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schröder W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: [26895985](http://www.ncbi.nlm.nih.gov/pubmed/26895985)\n\n \n\n[**STROBE-nut**](/reporting-guidelines/strobe-nut/): Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology—Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: [27270749](https://www.ncbi.nlm.nih.gov/pubmed/27270749)\n\n \n\n[**Simulation Research**](/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**ROSES-I**](/reporting-guidelines/roses-i-statement/): Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: [27417916](https://www.ncbi.nlm.nih.gov/pubmed/27417916)\n\n \n\n[**Propensity score analysis**](/reporting-guidelines/reporting-and-guidelines-in-propensity-score-analysis-a-systematic-review-of-cancer-and-cancer-surgical-studies/): Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: [28376195](https://www.ncbi.nlm.nih.gov/pubmed/28376195)\n\n \n\n[**RECORD-PE**](https://www.equator-network.org/reporting-guidelines/record-pe/): Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). [BMJ 2018;363:k3532](https://www.bmj.com/content/363/bmj.k3532.full).\n\n \n\n[**STROBE-SIIS**](https://www.equator-network.org/reporting-guidelines/strobe-extension-for-sports-injury-illness-surveillance/): International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, Hägglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).\n\n \n\n Br J Sports Med. 2020;54(7):372-389. PMID: [32071062](https://pubmed.ncbi.nlm.nih.gov/32071062/)\n\n Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: [32118084](https://pubmed.ncbi.nlm.nih.gov/32118084/)\n\n \n\n[**STROBE-MR**](https://www.equator-network.org/reporting-guidelines/strobe-mr-statement/): Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: [34698778](https://pubmed.ncbi.nlm.nih.gov/34698778/)\n\n \n\n'), ('Reporting guideline acronym', 'STROBE-NI'), ('Study design', 'Observational studies'), ('Clinical area', 'Infectious diseases, Obstetrics and gynaecology, Paediatrics'), ('Applies to the whole report or to individual sections of the report?', 'Ethical issues (consent etc.), Narrative sections (discussion etc.), Procedure/Method, Results'), ('Record last updated on', 'November 25, 2021')]"
14219,The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines,Observational studies,Surgery,Whole report, ,"CARE case extension, CARE extension, CARE guideline extension, case, case report, case reporting, case reports, case studies, case study, checklist, SCARE, SCARE checklist, SCARE guideline, SCARE Statement, surgery, surgical, surgical case report, surgical case reports, surgical case studies, surgical case study", ,"Agha RA, Franchi T, Sohrabi C, Mathew G, Kerwan A; SCARE Group. The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines. Int J Surg. 2020:S1743-9191(20)30771-8.","Agha RA, Franchi T, Sohrabi C, Mathew G, Kerwan A; SCARE Group.",International Journal of Surgery [Int J Surg.],2020, , , , ,English, ,33181358,https://pubmed.ncbi.nlm.nih.gov/33181358/, , ,"The SCARE Statement was originally published in 2016 and updated in 2018:

2016
Agha RA, Fowler AJ, Saeta A, Barai I, Rajmohan S, Orgill DP; SCARE Group. The SCARE Statement: Consensus-based surgical case report guidelines. Int J Surg. 2016;34:180-186. PMID: 27613565

2018 update
Agha RA, Borrelli MR, Farwana R, Koshy K, Fowler A, Orgill DP; SCARE Group. The SCARE 2018 Statement: Updating Consensus Surgical CAse REport (SCARE) Guidelines. Int J Surg. 2018;60:132-136. PMID: 30342279

", ,http://www.scareguideline.com/,SCARE,"Reporting of surgical case reports.



", ,"Read the protocol for the development of this reporting guideline:
http://www.sciencedirect.com/science/article/pii/S1743919116001047", , , , , ,no,2016-09-12 10:20:57,2021-11-26 11:19:59,the-scare-statement-consensus-based-surgical-case-report-guidelines,"[('title', 'The SCARE 2020 Guideline: Updating Consensus Surgical CAse  REport  (SCARE) Guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of surgical case reports.\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Agha RA, Franchi T, Sohrabi C, Mathew G, Kerwan A; SCARE Group. The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines. Int J Surg. 2020:S1743-9191(20)30771-8.'), ('Language', 'English'), ('PubMed ID', '[33181358](https://pubmed.ncbi.nlm.nih.gov/33181358/)'), ('Reporting guideline website URL', '<http://www.scareguideline.com/>'), ('Reporting guideline acronym', 'SCARE'), ('Study design', 'Observational studies'), ('Clinical area', 'Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Previous versions of this guideline / Guideline history', 'The SCARE Statement was originally published in 2016 and updated in 2018:\n\n \n\n 2016\n\n Agha RA, Fowler AJ, Saeta A, Barai I, Rajmohan S, Orgill DP; SCARE Group. The SCARE Statement: Consensus-based surgical case report guidelines. Int J Surg. 2016;34:180-186. PMID: [27613565](http://www.ncbi.nlm.nih.gov/pubmed/27613565)\n\n \n\n 2018 update\n\n Agha RA, Borrelli MR, Farwana R, Koshy K, Fowler A, Orgill DP; SCARE Group. The SCARE 2018 Statement: Updating Consensus Surgical CAse REport (SCARE) Guidelines. Int J Surg. 2018;60:132-136. PMID: [30342279](http://www.ncbi.nlm.nih.gov/pubmed/30342279)\n\n \n\n'), ('Additional information', 'Read the protocol for the development of this reporting guideline:\n\n<http://www.sciencedirect.com/science/article/pii/S1743919116001047>'), ('Record last updated on', 'November 26, 2021')]"
14215,Development and validation of the guideline for reporting evidence-based practice educational interventions and teaching (GREET),"Clinical trials, Experimental studies, Observational studies, Other, Quality improvement studies, Study protocols", ,Intervention (exposure), ,"checklist, EBP, EBP education, EBP educational intervention, EBP educational interventions, EBP educational research, EBP intervention, EBP interventions, EBP learning, education, educational, educational intervention, educational intervention studies, educational intervention study, educational intervention trial, educational intervention trials, educational interventions, educational research, educational research studies, educational research study, evidence based practice educational intervention, evidence based practice educational interventions, evidence based practice educational interventions and teaching, evidence based practice educational research, evidence based practice intervention, evidence based practice interventions, evidence based practice learning, evidence-based practice, GREET, GREET checklist, intervention, interventions", ,"Phillips AC, Lewis LK, McEvoy MP, Galipeau J, Glasziou P, Moher D, Tilson JK, Williams MT. Development and validation of the guideline for reporting evidence-based practice educational interventions and teaching (GREET). BMC Med Educ. 2016;16(1):237.","Phillips AC, Lewis LK, McEvoy MP, Galipeau J, Glasziou P, Moher D, Tilson JK, Williams MT.",BMC Medical Education [BMC Med Educ.],2016,16,1,237, ,English, ,27599967,http://www.ncbi.nlm.nih.gov/pubmed/27599967,The full-text of this guideline is freely available at: http://bmcmededuc.biomedcentral.com/articles/10.1186/s12909-016-0759-1,Access the GREET explanation and elaboration (E&amp;E) paper (Word)., , , ,GREET,Reporting of educational interventions for evidence-based practice (EBP).,"The GREET explanation and elaboration (E&amp;E) paper is freely available in Japanese at: https://webview.isho.jp/journal/detail/pdf/10.11477/mf.1681201769

","Read the protocol for the development of the guideline for reporting evidence-based practice educational interventions and teaching (GREET) statement.

Read a systematic review conducted to support the GREET guideline development on the topic of how studies describe educational interventions for evidence-based practice: stage 1 of the development of a reporting guideline.

Read a report of the Delphi survey conducted to help determine how educational interventions for evidence-based practice should be reported.

", , , , , ,no,2016-09-12 08:56:29,2024-11-25 10:02:09,greet,"[('title', 'Development and validation of the guideline for reporting evidence-based practice educational interventions and teaching (GREET)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of educational interventions for evidence-based practice (EBP).'), ('Full bibliographic reference', 'Phillips AC, Lewis LK, McEvoy MP, Galipeau J, Glasziou P, Moher D, Tilson JK, Williams MT. Development and validation of the guideline for reporting evidence-based practice educational interventions and teaching (GREET). BMC Med Educ. 2016;16(1):237.'), ('Language', 'English'), ('PubMed ID', '[27599967](http://www.ncbi.nlm.nih.gov/pubmed/27599967)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this guideline is freely available at: <http://bmcmededuc.biomedcentral.com/articles/10.1186/s12909-016-0759-1>'), ('Explanation and elaboration papers', 'Access the [GREET explanation and elaboration (E&E) paper (Word)](https://static-content.springer.com/esm/art%3A10.1186%2Fs12909-016-0759-1/MediaObjects/12909_2016_759_MOESM2_ESM.docx).'), ('Availability in additional languages', 'The GREET explanation and elaboration (E&E) paper is freely available in Japanese at: <https://webview.isho.jp/journal/detail/pdf/10.11477/mf.1681201769>\n\n \n\n'), ('Reporting guideline acronym', 'GREET'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Other, Quality improvement studies, Study protocols'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Additional information', '[Read the protocol](http://bmcmededuc.biomedcentral.com/articles/10.1186/1472-6920-13-9) for the development of the guideline for reporting evidence-based practice educational interventions and teaching (GREET) statement.\n\n \n\n[Read a systematic review](http://bmcmededuc.biomedcentral.com/articles/10.1186/1472-6920-14-152) conducted to support the GREET guideline development on the topic of how studies describe educational interventions for evidence-based practice: stage 1 of the development of a reporting guideline.\n\n \n\n[Read a report of the Delphi survey](http://bmcmededuc.biomedcentral.com/articles/10.1186/1472-6920-14-159) conducted to help determine how educational interventions for evidence-based practice should be reported.\n\n \n\n'), ('Record last updated on', 'November 25, 2024')]"
14209,Using theory of change to design and evaluate public health interventions: a systematic review,"Clinical trials, Experimental studies, Observational studies, Qualitative research",Public health,Procedure/Method, ,"change, checklist, checklists, clinical trial, clinicial trials, complex intervention, complex interventions, CONSORT, CReDECI2, evaluation, evaluations, intervention development, observational research, program theory, programme theory, public health, public health intervention, public health interventions, qualitative research, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, STROBE, theory driven, theory driven evaluation, theory of change, ToC, ToC approach, ToC approaches, ToC development, ToCs, trial, trials", ,"Breuer E, Lee L, De Silva M, Lund C. Using theory of change to design and evaluate public health interventions: a systematic review. Implement Sci. 2016;11:63.","Breuer E, Lee L, De Silva M, Lund C.",Implementation Science [Implement Sci.],2016,11, ,63, ,English, ,27153985,http://www.ncbi.nlm.nih.gov/pubmed/27153985,"The full-text of this reporting guideline is freely available at: http://implementationscience.biomedcentral.com/articles/10.1186/s13012-016-0422-6

", , , , , ,Reporting of theory of change (ToC) approaches in public health intervention studies., , , , , , , ,no,2016-08-24 14:55:33,2021-11-26 11:31:57,using-theory-of-change-to-design-and-evaluate-public-health-interventions-a-systematic-review,"[('title', 'Using theory of change to design and evaluate public health interventions: a systematic review'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of theory of change (ToC) approaches in public health intervention studies.'), ('Full bibliographic reference', 'Breuer E, Lee L, De Silva M, Lund C. Using theory of change to design and evaluate public health interventions: a systematic review. Implement Sci. 2016;11:63.'), ('Language', 'English'), ('PubMed ID', '[27153985](http://www.ncbi.nlm.nih.gov/pubmed/27153985)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available at: <http://implementationscience.biomedcentral.com/articles/10.1186/s13012-016-0422-6>\n\n \n\n'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Qualitative research'), ('Clinical area', 'Public health'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method'), ('Record last updated on', 'November 26, 2021')]"
14207,Homeopathic clinical case reports: Development of a supplement (HOM-CASE) to the CARE clinical case reporting guideline,Observational studies,Complementary and alternative medicine,Whole report,homeopath,"CAM, CARE, CARE case extension, CARE checklist, CARE extension, CARE guideline, CARE guideline extension, case, case report, case reporting, case reports, clinical case report, clinical case reporting, clinical case reports, complementary and alternative medicine, complementary medicine, HOM-CASE, homeopath, homeopathic, homeopathic clinical case report, homeopathic clinical case reports, homeopaths, homeopathy, homoeopath, homoeopathic, homoeopaths, homoeopathy", ,van Haselen RA. Homeopathic clinical case reports: Development of a supplement (HOM-CASE) to the CARE clinical case reporting guideline. Complement Ther Med. 2016;25:78-85.,van Haselen RA.,Complementary Therapies in Medicine [Complement Ther Med.],2016,25, ,78-85, ,English, ,27062953,http://www.ncbi.nlm.nih.gov/pubmed/27062953, , , , , ,HOM-CASE,Reporting clinical case reports in homeopathy., , , , , , , ,no,2016-08-24 13:54:01,2018-02-16 10:49:27,homeopathic-clinical-case-reports-development-of-a-supplement-hom-case-to-the-care-clinical-case-reporting-guideline,"[('title', 'Homeopathic clinical case reports: Development of a supplement (HOM-CASE) to the CARE clinical case reporting guideline'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting clinical case reports in homeopathy.'), ('Full bibliographic reference', 'van Haselen RA. Homeopathic clinical case reports: Development of a supplement (HOM-CASE) to the CARE clinical case reporting guideline. Complement Ther Med. 2016;25:78-85.'), ('Language', 'English'), ('PubMed ID', '[27062953](http://www.ncbi.nlm.nih.gov/pubmed/27062953)'), ('Reporting guideline acronym', 'HOM-CASE'), ('Study design', 'Observational studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Taxonomy terms', 'homeopath'), ('Record last updated on', 'February 16, 2018')]"
14205,Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements,"Clinical trials, Experimental studies, Observational studies", ,Whole report, ,"case control, case control studies, case control study, case-control, clinical trial, clinical trials, cohort, cohort studies, cohort study, CONSORT, CONSORT extension, cross sectional, cross sectional studies, cross sectional study, high fidelity mannequins, INSPIRE, INSPIRE Network, observational, observational studies, observational study, plastic models, randomised controlled trial, randomised controlled trials, randomized controlled trial, randomized controlled trials, RCT, RCTs, SBR, simulate, simulated, simulation, simulation based research, simulation education, simulation intervention, simulation research, simulation studies, simulation study, simulation-based, simulator, simulators, static mannequins, STROBE, STROBE extension, task trainers, virtual, virtual reality, virtual reality simulator, virtual reality simulators", ,"Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248.","Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators.",Simulation in Healthcare [Simul Healthc.],2016,11,4,238-248, ,English, ,27465839,http://www.ncbi.nlm.nih.gov/pubmed/27465839,The full-text of this reporting guideline is available at: http://advancesinsimulation.biomedcentral.com/articles/10.1186/s41077-016-0025-y,An explanation and elaboration of the simulation-specific extensions for the CONSORT and STROBE statements is available at: E&amp;E document (Word), , ,http://inspiresim.com/simreporting/, ,Reporting simulation-based research (SBR) studies., , , , , , , ,no,2016-08-23 13:47:28,2021-11-26 11:33:30,reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements,"[('title', 'Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting simulation-based research (SBR) studies.'), ('Full bibliographic reference', 'Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248.'), ('Language', 'English'), ('PubMed ID', '[27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is available at: <http://advancesinsimulation.biomedcentral.com/articles/10.1186/s41077-016-0025-y>'), ('Explanation and elaboration papers', 'An explanation and elaboration of the simulation-specific extensions for the CONSORT and STROBE statements is available at: [E&E document (Word)](https://static-content.springer.com/esm/art%3A10.1186%2Fs41077-016-0025-y/MediaObjects/41077_2016_25_MOESM2_ESM.docx)'), ('Reporting guideline website URL', '<http://inspiresim.com/simreporting/>'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 26, 2021')]"
14201,Guidelines for Reporting Articles on Psychiatry and Heart rate variability (GRAPH): recommendations to advance research communication,Observational studies,"Behavioural medicine, Cardiovascular medicine, Psychiatry","Data, Procedure/Method, Statistical methods and analyses, Study characteristics (participants etc.)", ,"behavior, behavioral, behaviour, behavioural, biobehavioral, biobehavioural, cardiovascular, cardiovascular disease, cardiovascular diseases, checklist, graph, GRAPH checklist, heart, heart rate, heart rate variability, HRV, IBI, interbeat, interbeat interval, psychiatric, psychiatrist, psychiatry", ,"Quintana DS, Alvares GA, Heathers JA. Guidelines for Reporting Articles on Psychiatry and Heart rate variability (GRAPH): recommendations to advance research communication. Transl Psychiatry. 2016;6:e803.","Quintana DS, Alvares GA, Heathers JA.",Translational Psychiatry [Transl Psychiatry],2016,6, ,e803, ,English, ,27163204,http://www.ncbi.nlm.nih.gov/pubmed/27163204,This guideline is freely available in full-text at: https://www.nature.com/articles/tp201673, , , , ,GRAPH,Reporting articles on psychiatry and heart rate variability., , , , , , , ,no,2016-08-19 14:38:21,2021-11-26 11:34:30,guidelines-for-reporting-articles-on-psychiatry-and-heart-rate-variability-graph-recommendations-to-advance-research-communication,"[('title', 'Guidelines for Reporting Articles on Psychiatry and Heart rate variability (GRAPH) : recommendations to advance research communication'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting articles on psychiatry and heart rate variability.'), ('Full bibliographic reference', 'Quintana DS, Alvares GA, Heathers JA. Guidelines for Reporting Articles on Psychiatry and Heart rate variability (GRAPH): recommendations to advance research communication. Transl Psychiatry. 2016;6:e803.'), ('Language', 'English'), ('PubMed ID', '[27163204](http://www.ncbi.nlm.nih.gov/pubmed/27163204)'), ('Relevant URLs\n\n(full-text if available)', 'This guideline is freely available in full-text at: <https://www.nature.com/articles/tp201673>'), ('Reporting guideline acronym', 'GRAPH'), ('Study design', 'Observational studies'), ('Clinical area', 'Behavioural medicine, Cardiovascular medicine, Psychiatry'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'November 26, 2021')]"
14199,RAMESES II reporting standards for realist evaluations,"Mixed methods studies, Qualitative research", ,Whole report, ,"evaluation, evaluations, initiative evaluation, initiatives evaluation, policy evaluation, policy evaluations, program evaluation, program evaluations, programme evaluation, programme evaluations, programme theories, programme theory, RAMESES, RAMESES 2, RAMESES II, RE, real world, real world experience, real world experiences, realist, realist approach, realist evaluation, realist evaluations, realist evaluator, realist evaluators, realist philosophy, realist programme, realist theories, realist theory, theory driven, theory driven evaluation", ,"Wong G, Westhorp G, Manzano A, Greenhalgh J, Jagosh J, Greenhalgh T. RAMESES II reporting standards for realist evaluations.\xa0 BMC Med. 2016;14(1):96.","Wong G, Westhorp G, Manzano A, Greenhalgh J, Jagosh J, Greenhalgh T.",BMC Medicine [BMC Med.],2016,14,1, , ,English, ,27342217,http://www.ncbi.nlm.nih.gov/pubmed/27342217,This reporting guideline is freely available in full-text at: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0643-1, , , ,http://www.ramesesproject.org/,RAMESES II,Reporting realist evaluations., , , , ,Read the protocol for development of this guideline: RAMESES II protocol, , ,no,2016-08-19 13:53:51,2021-11-26 11:35:48,rameses-ii-reporting-standards-for-realist-evaluations,"[('title', 'RAMESES  II reporting standards for realist evaluations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting realist evaluations.'), ('Full bibliographic reference', 'Wong G, Westhorp G, Manzano A, Greenhalgh J, Jagosh J, Greenhalgh T. RAMESES II reporting standards for realist evaluations.\xa0 BMC Med. 2016;14(1):96.'), ('Language', 'English'), ('PubMed ID', '[27342217](http://www.ncbi.nlm.nih.gov/pubmed/27342217)'), ('Relevant URLs\n\n(full-text if available)', 'This reporting guideline is freely available in full-text at: <https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0643-1>'), ('Reporting guideline website URL', '<http://www.ramesesproject.org/>'), ('Reporting guideline acronym', 'RAMESES II'), ('Study design', 'Mixed methods studies, Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Other', 'Read the protocol for development of this guideline: [RAMESES II protocol](http://www.ncbi.nlm.nih.gov/pubmed/26238395)'), ('Record last updated on', 'November 26, 2021')]"
14041,Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement,Observational studies, ,"Data, Narrative sections (discussion etc.), Results, Statistical methods and analyses, Study characteristics (participants etc.)", ,"checklist, checklists, data, data estimate, data estimates, estimate, estimates, GATHER, GATHER checklist, GATHER statement, global estimate, global estimates, global health, global health estimate, global health estimates, health estimate, health estimates, health indicator, health indicators, measurement, measurements, national estimate, national estimates, population estimate, population estimates, population health, regional estimate, regional estimates, statistic, statistical, statistical analyses, statistical analysis, statistical method, statistical methods, statistical methods and analyses, statistical model, statistical models, statistical result, statistical results, statistical synthesis, statistical technique, statistical techniques, statistics, subnational estimate, subnational estimates", ,"Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, Grove JT, Hogan DR, Hogan MC, Horton R, Lawn JE, Maru?i? A, Mathers CD, Murray CJ, Rudan I, Salomon JA, Simpson PJ, Vos T, Welch V; GATHER Working Group. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement.

Lancet. 2016. pii: S0140-6736(16)30388-9. PMID: 27371184
PLoS Med. 2016;13(6):e1002056. PMID: 27351744

","Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, Grove JT, Hogan DR, Hogan MC, Horton R, Lawn JE, Maru?i? A, Mathers CD, Murray CJ, Rudan I, Salomon JA, Simpson PJ, Vos T, Welch V; GATHER Working Group.", ,2016, , , , ,English, , , , , , , ,http://gather-statement.org/,GATHER,Reporting practices for studies that calculate health estimates for multiple populations (in time or space) using multiple information sources.,"The GATHER Statement has been translated into Portuguese (PDF), French (PDF), Spanish (PDF).

The GATHER checklist has been translated into the following languages:

Arabic\xa0 \xa0 \xa0PDF / Word

Chinese\xa0 \xa0 \xa0 PDF / Word

French\xa0 \xa0 \xa0PDF / Word

Portuguese\xa0 \xa0 \xa0PDF / Word

Russian\xa0 \xa0 \xa0PDF / Word

Spanish\xa0 \xa0 \xa0PDF / Word

",Read the report (PDF) from the guideline development working group meeting held in 2015., , , , , ,no,2016-08-03 14:27:54,2021-11-26 12:01:33,gather-statement,"[('title', 'Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting practices for studies that calculate health estimates for multiple populations (in time or space) using multiple information sources.'), ('Full bibliographic reference', 'Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, Grove JT, Hogan DR, Hogan MC, Horton R, Lawn JE, Marušić A, Mathers CD, Murray CJ, Rudan I, Salomon JA, Simpson PJ, Vos T, Welch V; GATHER Working Group. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement.\n\n \n\n Lancet. 2016. pii: S0140-6736(16)30388-9. PMID: [27371184](http://www.ncbi.nlm.nih.gov/pubmed/27371184)\n\n PLoS Med. 2016;13(6):e1002056. PMID: [27351744](http://www.ncbi.nlm.nih.gov/pubmed/27351744)\n\n \n\n'), ('Language', 'English'), ('Availability in additional languages', 'The GATHER Statement has been translated into [Portuguese (PDF)](http://scielo.iec.pa.gov.br/pdf/ess/v26n1/2237-9622-ess-26-01-00215.pdf), [French (PDF)](http://gather-statement.org/download/gather-statement-french-pdf/), [Spanish (PDF)](http://gather-statement.org/download/gather-statement-spanish-pdf/).\n\n \n\n The GATHER checklist has been translated into the following languages:\n\n \n\n Arabic[PDF](http://gather-statement.org/download/gather-checklist-arabic-pdf/) / [Word](http://gather-statement.org/download/gather-checklist-arabic-docx/)\n\n \n\n Chinese [PDF](http://gather-statement.org/download/gather-checklist-chinese-pdf/) / [Word](http://gather-statement.org/download/gather-checklist-chinese-docx/)\n\n \n\n French[PDF](http://gather-statement.org/download/gather-checklist-french-pdf/) / [Word](http://gather-statement.org/download/gather-checklist-french-docx/)\n\n \n\n Portuguese[PDF](http://gather-statement.org/download/gather-checklist-portuguese-pdf/) / [Word](http://gather-statement.org/download/gather-checklist-portuguese-docx/)\n\n \n\n Russian[PDF](http://gather-statement.org/download/gather-checklist-russian-pdf/) / [Word](http://gather-statement.org/download/gather-checklist-russian-docx/)\n\n \n\n Spanish[PDF](http://gather-statement.org/download/gather-checklist-spanish-pdf/) / [Word](http://gather-statement.org/download/gather-checklist-spanish-docx/)\n\n \n\n'), ('Reporting guideline website URL', '<http://gather-statement.org/>'), ('Reporting guideline acronym', 'GATHER'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Data, Narrative sections (discussion etc.), Results, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Additional information', 'Read the [report (PDF)](/wp-content/uploads/2009/02/GATHER-meeting-report.pdf) from the guideline development working group meeting held in 2015.'), ('Record last updated on', 'November 26, 2021')]"
14000,Medical abortion reporting of efficacy: the MARE guidelines.,"Clinical trials, Experimental studies, Observational studies",Obstetrics and gynaecology,Whole report, ,"abortion, abortion efficacy, abortion medication, checklist, checklists, CONSORT extension, early abortion, early medical abortion, early pregnancy termination, gynaecology, gynecology, labor induction abortion, labour induction abortion, MARE guideline, MARE guidelines, MARE Supplement, MARE Supplements, MARE-C, MARE-S, medical abortion, medical abortion efficacy, medication abortion, obstetric, obstetrics, outcome, outcomes, STROBE extension, termination, termination of pregnancy", ,"Creinin MD, Chen MJ. Medical abortion reporting of efficacy: the MARE guidelines. Contraception. 2016.","Creinin MD, Chen MJ.",Contraception.,2016, , , , ,English, ,27129936,http://www.ncbi.nlm.nih.gov/pubmed/27129936, , , , , ,MARE-C & MARE-S,Reporting early medical abortion efficacy studies., ,"The MARE guidelines are supplements to CONSORT and STROBE specific to medical abortion efficacy reporting; these checklists aim primarily to ensure appropriate reporting of the regimen used, number of women treated, number who had follow-up (outcome) data available, and outcomes by gestational age. Reporting outcomes in a standard manner will ensure that data is available for better synthesis into evidence-based guidelines.", , , , , ,no,2016-06-22 10:42:04,2016-06-22 10:58:19,medical-abortion-reporting-of-efficacy-the-mare-guidelines,"[('title', 'Medical abortion reporting of efficacy: the MARE guidelines.'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting early medical abortion efficacy studies.'), ('Full bibliographic reference', 'Creinin MD, Chen MJ. Medical abortion reporting of efficacy: the MARE guidelines. Contraception. 2016.'), ('Language', 'English'), ('PubMed ID', '[27129936](http://www.ncbi.nlm.nih.gov/pubmed/27129936)'), ('Reporting guideline acronym', 'MARE-C & MARE-S'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Obstetrics and gynaecology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'The MARE guidelines are supplements to CONSORT and STROBE specific to medical abortion efficacy reporting; these checklists aim primarily to ensure appropriate reporting of the regimen used, number of women treated, number who had follow-up (outcome) data available, and outcomes by gestational age. Reporting outcomes in a standard manner will ensure that data is available for better synthesis into evidence-based guidelines.'), ('Record last updated on', 'June 22, 2016')]"
13910,Strengthening the Reporting of Observational Studies in Epidemiology?Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement,Observational studies,Nutrition and dietetics,Whole report, ,"diet, diet and health, dietary, dietary assessment, dietary assessments, dietary intake, dietary supplement, dietary supplements, dietetics, epidemiology, food, nutrition, nutrition and dietetics, nutritional, nutritional assessment, nutritional epidemiology, observational, observational research, observational studies, observational study, STROBE extension, STROBE Extension for Nutritional Epidemiology, STROBE Extension for Nutritional Epidemiology (STROBE-nut), STROBE-nut, STROBE-nut checklist", ,"Lachat C, Hawwash D, Ock\xe9 MC, Berg C, Forsum E, H\xf6rnell A, Larsson C, Sonestedt E, Wirf\xe4lt E, \xc5kesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement.

This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.

PLoS Med. 2016;13(6):e1002036. PMID: 27270749
Nutr Bull. 2016;41(3):240-251. PMID: 27587981

","Lachat C, Hawwash D, Ock\xe9 MC, Berg C, Forsum E, H\xf6rnell A, Larsson C, Sonestedt E, Wirf\xe4lt E, \xc5kesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I.", ,2016, , , , ,English, , , , ,"H\xf6rnell A, Berg C, Forsum E, Larsson C, Sonestedt E, \xc5kesson A, Lachat C, Hawwash D, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Greenwood DC, Slimani N, Cevallos M, Egger M, Huybrechts I, Wirf\xe4lt E. Perspective: An Extension of the STROBE Statement for Observational Studies in Nutritional Epidemiology (STROBE-nut): Explanation and Elaboration. Adv Nutr. 2017;8(5):652-678. PMID: 28916567

", ,"Generic
STROBE: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Ann Intern Med. 2007;147(8):573-577. PMID: 17938396
PLoS Med. 2007;4(10):e296. PMID: 17941714
BMJ. 2007;335(7624):806-808. PMID: 17947786
Prev Med. 2007;45(4):247-251. PMID: 17950122
Epidemiology. 2007;18(6):800-804. PMID: 18049194
Lancet. 2007;370(9596):1453-1457. PMID: 18064739

Specialised
STREGA: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.

PLoS Med. 2009;6(2):e22. PMID: 19192942
Hum Genet. 2009;125(2):131-151. PMID: 19184668
Eur J Epidemiol. 2009;24(1):37-55. PMID: 19189221
Ann Intern Med. 2009;150(3):206-215. PMID: 19189911
J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: 19217256
Genet Epidemiol. 2009;33(7):581-598. PMID: 19278015
Eur J Clin Invest. 2009;39(4):247-266. PMID: 19297801

STROBE-ME: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: 22023344

STROBE checklist for conference abstracts
First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. Link to full text pdf

STROME-ID: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: 24631223

Longitudinal observational drug studies in rheumatology: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: 24058015

Case-cohort studies: Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: 24972092

STROBE-RDS: White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: 26112433

RECORD: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: 26440803

STROBE-AMS: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schr\xf6der W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: 26895985

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

ROSES-I: Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: 27417916

STROBE-NI: Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: 27633910

Propensity score analysis: Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: 28376195

RECORD-PE: Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.

STROBE-SIIS: International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, H\xe4gglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).

Br J Sports Med. 2020;54(7):372-389. PMID: 32071062
Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: 32118084

STROBE-MR: Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: 34698778

",http://www.strobe-nut.org/,STROBE-nut,Reporting nutritional epidemiology and dietary assessment research., ,"The protocol for the development of this guideline is available from: STROBE-nut protocol (PDF) (August 2014).

", , ,"An online fillable STROBE-Nut checklist is also available via the GoodReports website at https://www.goodreports.org/reporting-checklists/strobe-nut/.



Dietary assessment guidelines and interactive tools for the design and conduct of dietary assessment studies are available from: https://www.nutritools.org/

", , ,yes,2016-06-08 14:05:35,2023-03-06 11:48:08,strobe-nut,"[('title', 'Strengthening the Reporting of Observational Studies in Epidemiology—Nutritional Epidemiology (STROBE-nut) : An Extension of the STROBE Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting nutritional epidemiology and dietary assessment research.'), ('Full bibliographic reference', 'Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement.\n\n \n\n This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.\n\n \n\n PLoS Med. 2016;13(6):e1002036. PMID: [27270749](https://www.ncbi.nlm.nih.gov/pubmed/27270749)\n\n Nutr Bull. 2016;41(3):240-251. PMID: [27587981](https://www.ncbi.nlm.nih.gov/pubmed/27587981)\n\n \n\n'), ('Language', 'English'), ('Explanation and elaboration papers', 'Hörnell A, Berg C, Forsum E, Larsson C, Sonestedt E, Åkesson A, Lachat C, Hawwash D, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Greenwood DC, Slimani N, Cevallos M, Egger M, Huybrechts I, Wirfält E. Perspective: An Extension of the STROBE Statement for Observational Studies in Nutritional Epidemiology (STROBE-nut): Explanation and Elaboration. Adv Nutr. 2017;8(5):652-678. PMID: [28916567](https://www.ncbi.nlm.nih.gov/pubmed/28916567)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n**[STROBE](/reporting-guidelines/strobe/)**: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.\n\n \n\n Ann Intern Med. 2007;147(8):573-577. PMID: [17938396](http://www.ncbi.nlm.nih.gov/pubmed/17938396)\n\n PLoS Med. 2007;4(10):e296. PMID: [17941714](http://www.ncbi.nlm.nih.gov/pubmed/17941714)\n\n BMJ. 2007;335(7624):806-808. PMID: [17947786](http://www.ncbi.nlm.nih.gov/pubmed/17947786)\n\n Prev Med. 2007;45(4):247-251. PMID: [17950122](http://www.ncbi.nlm.nih.gov/pubmed/17950122)\n\n Epidemiology. 2007;18(6):800-804. PMID: [18049194](http://www.ncbi.nlm.nih.gov/pubmed/18049194)\n\n Lancet. 2007;370(9596):1453-1457. PMID: [18064739](http://www.ncbi.nlm.nih.gov/pubmed/18064739)\n\n \n\n**Specialised**\n\n[**STREGA**](/reporting-guidelines/strobe-strega/): Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.\n\n \n\n PLoS Med. 2009;6(2):e22. PMID: [19192942](http://www.ncbi.nlm.nih.gov/pubmed/19192942)\n\n Hum Genet. 2009;125(2):131-151. PMID: [19184668](http://www.ncbi.nlm.nih.gov/pubmed/19184668)\n\n Eur J Epidemiol. 2009;24(1):37-55. PMID: [19189221](http://www.ncbi.nlm.nih.gov/pubmed/19189221)\n\n Ann Intern Med. 2009;150(3):206-215. PMID: [19189911](http://www.ncbi.nlm.nih.gov/pubmed/19189911)\n\n J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: [19217256](http://www.ncbi.nlm.nih.gov/pubmed/19217256)\n\n Genet Epidemiol. 2009;33(7):581-598. PMID: [19278015](http://www.ncbi.nlm.nih.gov/pubmed/19278015)\n\n Eur J Clin Invest. 2009;39(4):247-266. PMID: [19297801](http://www.ncbi.nlm.nih.gov/pubmed/19297801)\n\n \n\n**[STROBE-ME](/reporting-guidelines/strobe-me/)**: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: [22023344](http://www.ncbi.nlm.nih.gov/pubmed/22023344)\n\n \n\n[**STROBE checklist for conference abstracts**](/reporting-guidelines/strobe-abstracts/)\n\n First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. [Link to full text pdf](https://www.strobe-statement.org/download/strobe-checklist-conference-abstracts)\n\n \n\n[**STROME-ID**](/reporting-guidelines/strome-id/): Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: [24631223](http://www.ncbi.nlm.nih.gov/pubmed/24631223)\n\n \n\n**[Longitudinal observational drug studies in rheumatology](/reporting-guidelines/launch-of-a-checklist-for-reporting-longitudinal-observational-drug-studies-in-rheumatology-a-eular-extension-of-strobe-guidelines-based-on-experience-from-biologics-registries/)**: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: [24058015](http://www.ncbi.nlm.nih.gov/pubmed/24058015)\n\n \n\n[**Case-cohort studies**](/reporting-guidelines/a-review-of-published-analyses-of-case-cohort-studies-and-recommendations-for-future-reporting/): Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: [24972092](https://www.ncbi.nlm.nih.gov/pubmed/24972092)\n\n \n\n[**STROBE-RDS**](/reporting-guidelines/strobe-rds/): White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: [26112433](http://www.ncbi.nlm.nih.gov/pubmed/26112433)\n\n \n\n[**RECORD**](/reporting-guidelines/record/): Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: [26440803](http://www.ncbi.nlm.nih.gov/pubmed/26440803)\n\n \n\n[**STROBE-AMS**](/reporting-guidelines/strobe-ams/): Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schröder W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: [26895985](http://www.ncbi.nlm.nih.gov/pubmed/26895985)\n\n \n\n[**Simulation Research**](/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**ROSES-I**](/reporting-guidelines/roses-i-statement/): Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: [27417916](https://www.ncbi.nlm.nih.gov/pubmed/27417916)\n\n \n\n[**STROBE-NI**](/reporting-guidelines/strobe-ni/): Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: [27633910](https://www.ncbi.nlm.nih.gov/pubmed/27633910)\n\n \n\n[**Propensity score analysis**](/reporting-guidelines/reporting-and-guidelines-in-propensity-score-analysis-a-systematic-review-of-cancer-and-cancer-surgical-studies/): Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: [28376195](https://www.ncbi.nlm.nih.gov/pubmed/28376195)\n\n \n\n[**RECORD-PE**](https://www.equator-network.org/reporting-guidelines/record-pe/): Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). [BMJ 2018;363:k3532](https://www.bmj.com/content/363/bmj.k3532.full).\n\n \n\n[**STROBE-SIIS**](https://www.equator-network.org/reporting-guidelines/strobe-extension-for-sports-injury-illness-surveillance/): International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, Hägglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).\n\n \n\n Br J Sports Med. 2020;54(7):372-389. PMID: [32071062](https://pubmed.ncbi.nlm.nih.gov/32071062/)\n\n Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: [32118084](https://pubmed.ncbi.nlm.nih.gov/32118084/)\n\n \n\n[**STROBE-MR**](https://www.equator-network.org/reporting-guidelines/strobe-mr-statement/): Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: [34698778](https://pubmed.ncbi.nlm.nih.gov/34698778/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.strobe-nut.org/>'), ('Reporting guideline acronym', 'STROBE-nut'), ('Study design', 'Observational studies'), ('Clinical area', 'Nutrition and dietetics'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Other', 'An online fillable STROBE-Nut checklist is also available via the GoodReports website at <https://www.goodreports.org/reporting-checklists/strobe-nut/>.\n\n \n\n \xa0\n\n \n\n Dietary assessment guidelines and interactive tools for the design and conduct of dietary assessment studies are available from: <https://www.nutritools.org/>\n\n \n\n'), ('Additional information', 'The protocol for the development of this guideline is available from: [STROBE-nut protocol (PDF)](/wp-content/uploads/2009/02/Protocol-food-intake-checklist-Modification.pdf) (August 2014).\n\n \n\n'), ('Record last updated on', 'March 6, 2023')]"
13873,Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use, , ,Whole report, ,"demographic, demographics, demography, equity, female, gender, gender bias, gender equity, gender identity, gender perspective, gender policies, gender policy, gender-based, gender-based analysis, gender-sensitive, gender-sensitive analysis, gender-specific, male, man, men, SAGER, SAGER guideline, SAGER guidelines, sex, Sex and Gender Equity in Research, Sex and Gender Equity in Research guidelines, sex policies, sex policy, sex- and gender-based analysis, sex- and gender-related policies, sex-disaggregated data, sex-specific, woman, women", ,"Heidari S, Babor T, De Castro P, Tort S, Curno M. Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use. Research Integrity and Peer Review. 2016;1:2.","Heidari S, Babor T, De Castro P, Tort S, Curno M.",Research Integrity and Peer Review.,2016,1,2, , ,English, , , ,"The full-text of this reporting guideline is freely available at: http://researchintegrityjournal.biomedcentral.com/articles/10.1186/s41073-016-0007-6

Checklists for studies including human participants and for studies that do not include human participants have been developed and can be accessed at:

Van Epps H, Astudillo O, Del Pozo Martin Y, Marsh J (2022) The Sex and Gender Equity in Research (SAGER) guidelines: Implementation and checklist development. European Science Editing 48: e86910.

", , , , ,SAGER,"Reporting of sex and gender information in study design, data analyses, results and interpretation of findings.","The SAGER reporting guidelines are available in the following languages:

Chinese\xa0 PDF
Korean\xa0 PDF
Portuguese\xa0 Full-text
Spanish\xa0 Full-text
Turkish\xa0 PDF
Vietnamese\xa0 PDF

",The Canadian Institute of Gender and Health has produced three online modules to improve the ability of health researchers and peer reviewers to account for sex and gender in the analysis of data from human participants., , , , , ,no,2016-05-26 14:28:08,2022-11-02 14:24:59,sager-guidelines,"[('title', 'Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of sex and gender information in study design, data analyses, results and interpretation of findings.'), ('Full bibliographic reference', 'Heidari S, Babor T, De Castro P, Tort S, Curno M. Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use. Research Integrity and Peer Review. 2016;1:2.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available at: <http://researchintegrityjournal.biomedcentral.com/articles/10.1186/s41073-016-0007-6>\n\n \n\n Checklists for studies including human participants and for studies that do not include human participants have been developed and can be accessed at:\n\n \n\n Van Epps H, Astudillo O, Del Pozo Martin Y, Marsh J (2022) The Sex and Gender Equity in Research (SAGER) guidelines: Implementation and checklist development. [European Science Editing 48: e86910](https://ese.arphahub.com/article/86910/list/9/).\n\n \n\n'), ('Availability in additional languages', 'The SAGER reporting guidelines are available in the following languages:\n\n \n\n Chinese [PDF](https://ease.org.uk/wp-content/uploads/2019/10/SAGER%E6%8C%87%E5%8D%97.pdf)\n\n Korean [PDF](https://www.ease.org.uk/wp-content/uploads/2019/05/Sex-and-gender-equity_in-Korean_FinalMay-23-2019.pdf)\n\n Portuguese [Full-text](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2237-96222017005001101&lng=en&nrm=iso&tlng=pt)\n\n Spanish [Full-text](https://doi.org/10.1016/j.gaceta.2018.04.003)\n\n Turkish [PDF](https://ease.org.uk/wp-content/uploads/2020/02/EASE-SAGER-guidelines-Turkish.pdf)\n\n Vietnamese [PDF](https://ease.org.uk/wp-content/uploads/2020/02/SAGER-VN-v1.pdf)\n\n \n\n'), ('Reporting guideline acronym', 'SAGER'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'The Canadian Institute of Gender and Health has produced [three online modules](http://www.cihr-irsc-igh-isfh.ca/) to improve the ability of health researchers and peer reviewers to account for sex and gender in the analysis of data from human participants.'), ('Record last updated on', 'November 2, 2022')]"
13787,The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement,"Experimental studies, Observational studies, Other",Behavioural medicine,Whole report, ,"behavior, behavioral intervention, behavioral interventions, behavioral medicine, behavioral science, behavioral sciences, behaviour, behavioural intervention, behavioural interventions, behavioural medicine, behavioural science, behavioural sciences, checklist, checklists, SCRIBE, SCRIBE 2016, SCRIBE checklist, SCRIBE Statement, single participant, single patient, single-case, single-case design, single-case experiment, single-case research", ,"Tate RL, Perdices M, Rosenkoetter U, Shadish W, Vohra S, Barlow DH, Horner R, Kazdin A, Kratochwill T, McDonald S, Sampson M, Shamseer L, Togher L, Albin R, Backman C, Douglas J, Evans JJ, Gast D, Manolov R, Mitchell G, Nickels L, Nikles J, Ownsworth T, Rose M, Schmid CH and Wilson B. The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement.

This guideline was published simultaneously in 9 journals. You can read the guideline in any of these journals using the links below.

J Clin Epidemiol. 2016;73:142-152. PMID: 27101888
Arch Sci Psychol. 2016;4(1):1-9. doi: 10.1037/arc0000026
Aphasiology. 2016;30(7):862-876. PMID: 27279674
Phys Ther. 2016;96(7):e1-e10. PMID: 27371692
Am J Occup Ther. 2016;70(4):7004320010p1-11. PMID: 27294998
J Sch Psychol. 2016;56:133-142. PMID: 27268573
Can J Occup Ther. 2016;83(3):184-195. PMID: 27231387
Evid Based Commun Assess Interv. 2016;10(1):44-58. PMID: 27499802
Neuropsychol Rehabil. 2016:1-15. PMID: 27499422

","Tate RL, Rosenkoetter U, Vohra S, Horner R, Kratochwill T, Sampson M, Togher L, Backman C, Evans JJ, Manolov R, Nickels L, Ownsworth T, Schmid CH, Perdices M, Shadish W, Barlow DH, Kazdin A, McDonald S, Shamseer L, Albin R, Douglas J, Gast D, Mitchell G, Nikles J, Rose M, Wilson B.", , , , , , ,English, , , , ,"Tate RL, Perdices M, Rosenkoetter U, McDonald S, Togher L, Shadish W, Horner R, Kratochwill T, Barlow DH, Kazdin A, Sampson M, Shamseer L and Vohra S, for the SCRIBE Group (2016). The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016: Explanation and elaboration. Arch Sci Psychol. 4(1): 10-31. doi:10.1037/arc0000027

", , , ,SCRIBE,Reporting single-case research., ,"Read the SCRIBE project abstract (PDF) which was prepared to outline development of this reporting guideline.

", , , , , ,no,2016-04-29 10:38:32,2025-02-18 10:45:07,scribe-statement,"[('title', 'The Single -Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting single-case research.'), ('Full bibliographic reference', 'Tate RL, Perdices M, Rosenkoetter U, Shadish W, Vohra S, Barlow DH, Horner R, Kazdin A, Kratochwill T, McDonald S, Sampson M, Shamseer L, Togher L, Albin R, Backman C, Douglas J, Evans JJ, Gast D, Manolov R, Mitchell G, Nickels L, Nikles J, Ownsworth T, Rose M, Schmid CH and Wilson B. The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement.\n\n \n\n This guideline was published simultaneously in 9 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n J Clin Epidemiol. 2016;73:142-152. PMID: [27101888](http://www.ncbi.nlm.nih.gov/pubmed/27101888)\n\n Arch Sci Psychol. 2016;4(1):1-9. doi: [10.1037/arc0000026](http://psycnet.apa.org/journals/arc/4/1/1.html)\n\n Aphasiology. 2016;30(7):862-876. PMID: [27279674](http://www.ncbi.nlm.nih.gov/pubmed/27279674)\n\n Phys Ther. 2016;96(7):e1-e10. PMID: [27371692](http://www.ncbi.nlm.nih.gov/pubmed/27371692)\n\n Am J Occup Ther. 2016;70(4):7004320010p1-11. PMID: [27294998\n\n](http://www.ncbi.nlm.nih.gov/pubmed/27294998)J Sch Psychol. 2016;56:133-142. PMID: [27268573](http://www.ncbi.nlm.nih.gov/pubmed/27268573)\n\n Can J Occup Ther. 2016;83(3):184-195. PMID: [27231387\n\n](http://www.ncbi.nlm.nih.gov/pubmed/27231387)Evid Based Commun Assess Interv. 2016;10(1):44-58. PMID: [27499802\n\n](http://www.ncbi.nlm.nih.gov/pubmed/27499802)Neuropsychol Rehabil. 2016:1-15. PMID: [27499422](http://www.ncbi.nlm.nih.gov/pubmed/27499422)\n\n \n\n'), ('Language', 'English'), ('Explanation and elaboration papers', 'Tate RL, Perdices M, Rosenkoetter U, McDonald S, Togher L, Shadish W, Horner R, Kratochwill T, Barlow DH, Kazdin A, Sampson M, Shamseer L and Vohra S, for the SCRIBE Group (2016). The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016: Explanation and elaboration. Arch Sci Psychol. 4(1): 10-31. [doi:10.1037/arc0000027](http://psycnet.apa.org/journals/arc/4/1/10.html)\n\n \n\n'), ('Reporting guideline acronym', 'SCRIBE'), ('Study design', 'Experimental studies, Observational studies, Other'), ('Clinical area', 'Behavioural medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Read the [SCRIBE project abstract (PDF)](/wp-content/uploads/2009/02/SCRIBE-development-abstract.pdf) which was prepared to outline development of this reporting guideline.\n\n \n\n'), ('Record last updated on', 'February 18, 2025')]"
13785,Consensus on Recording Deep Endometriosis Surgery: the CORDES statement,"Clinical trials, Experimental studies","Obstetrics and gynaecology, Surgery","Intervention (exposure), Procedure/Method, Results, Study characteristics (participants etc.), Terminology/definitions", ,"clinical trial, clinical trials, CORDES, CORDES statement, data, deep endometriosis, endometriosis, endometriosis surgery, gynaecological, gynaecology, gynecological, gynecology, intra-operative data, post-operative data, pre-operative data, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, surgery, surgical, surgical management, surgical outcome, surgical outcome trial, surgical outcome trials, surgical outcomes, surgical procedure, surgical procedures, surgical technique, surgical techniques, surgical treatment, surgical trial, surgical trials, trial, trials", ,"Vanhie A, Meuleman C, Tomassetti C, Timmerman D, D'Hoore A, Wolthuis A, Van Cleynenbreugel B, Dancet E, Van den Broeck U, Tsaltas J, Renner SP, Ebert AD, Carmona F, Abbott J, Stepniewska A, Taylor H, Saridogan E, Mueller M, Keckstein J, Pluchino N, Janik G, Zupi E, Minelli L, Cooper M, Dunselman G, Koh C, Abrao M, Chapron C, D'Hooghe T. Consensus on Recording Deep Endometriosis Surgery: the CORDES statement. Hum Reprod. 2016 Apr 19. pii: dew067.","Vanhie A, Meuleman C, Tomassetti C, Timmerman D, D'Hoore A, Wolthuis A, Van Cleynenbreugel B, Dancet E, Van den Broeck U, Tsaltas J, Renner SP, Ebert AD, Carmona F, Abbott J, Stepniewska A, Taylor H, Saridogan E, Mueller M, Keckstein J, Pluchino N, Janik G, Zupi E, Minelli L, Cooper M, Dunselman G, Koh C, Abrao M, Chapron C, D'Hooghe T.",Human Reproduction [Hum Reprod.],2016, , , , ,English, ,27094477,http://www.ncbi.nlm.nih.gov/pubmed/27094477, , , , , ,CORDES,Reporting surgical treatment in women with deep endometriosis., , , , , , , ,no,2016-04-27 10:07:27,2016-04-27 10:44:04,consensus-on-recording-deep-endometriosis-surgery-the-cordes-statement,"[('title', 'Consensus on Recording Deep Endometriosis Surgery: the CORDES statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting surgical treatment in women with deep endometriosis.'), ('Full bibliographic reference', ""Vanhie A, Meuleman C, Tomassetti C, Timmerman D, D'Hoore A, Wolthuis A, Van Cleynenbreugel B, Dancet E, Van den Broeck U, Tsaltas J, Renner SP, Ebert AD, Carmona F, Abbott J, Stepniewska A, Taylor H, Saridogan E, Mueller M, Keckstein J, Pluchino N, Janik G, Zupi E, Minelli L, Cooper M, Dunselman G, Koh C, Abrao M, Chapron C, D'Hooghe T. Consensus on Recording Deep Endometriosis Surgery: the CORDES statement. Hum Reprod. 2016 Apr 19. pii: dew067.""), ('Language', 'English'), ('PubMed ID', '[27094477](http://www.ncbi.nlm.nih.gov/pubmed/27094477)'), ('Reporting guideline acronym', 'CORDES'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Obstetrics and gynaecology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Procedure/Method, Results, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'April 27, 2016')]"
13774,Developing the Clarity and Openness in Reporting: E3-based (CORE) reference user manual for creation of clinical study reports in the era of clinical trial transparency,"Clinical trials, Experimental studies", ,Whole report, ,"Budapest Working Group, CCI, clarity and openness in reporting, clinical studies, clinical study, clinical study report, clinical study reports, clinical trial, clinical trials, commercially confidential information, CORE, CORE Reference, CORE Reference user manual, CSR, CSRs, disclosure, disclosure-ready, drug, E3, E3-based, E3-based reference, EMA Policy 0070, ICH E3, ICH guidelines, interventional, interventional clinical studies, interventional clinical study, medicinal, personal protected data, personal protected information, pharmaceutical, Policy 0070, PPD, PPI, proactive anonymisation, proactive anonymization, randomised clinical trial, randomised clinical trials, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized clinical trial, randomized clinical trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, regulatory, study report, study reports, therapeutic, transparency, trial, trials", ,"Hamilton S, Bernstein AB, Blakey G, Fagan V, Farrow T, Jordan D, Seiler W, Shannon A, Gertel A and for the Budapest Working Group. Developing the Clarity and Openness in Reporting: E3-based (CORE) reference user manual for creation of clinical study reports in the era of clinical trial transparency. Res Integr Peer Rev. 2016;1(4).","Hamilton S, Bernstein AB, Blakey G, Fagan V, Farrow T, Jordan D, Seiler W, Shannon A, Gertel A and for the Budapest Working Group.",Res Integr Peer Rev.,2016,1,4, , ,English, ,29451540,https://pubmed.ncbi.nlm.nih.gov/29451540/,"The full-text of this reporting guideline is freely available from: http://researchintegrityjournal.biomedcentral.com/articles/10.1186/s41073-016-0009-4

The CORE Reference Manual and Mapping Tool can be downloaded from:
http://www.core-reference.org/core-reference/

", , , ,http://?www.?core-reference.?org,CORE Reference,Reporting clinical study reports (CSRs)., ,"Additional documents prepared during the development of this guideline:

Hamilton, S, Seiler W, Gertel A. The EMWA Budapest Working Group: A 2-year collaboration to make recommendations for aligning the ICH E3 guidance with current practice and developing clinical study protocol guidance. Medical Writing 2014;23(4):281-288.\xa0 Link to paper

Press release (PDF) dated 28 January 2015

CORE Reference BWG team members list (PDF)

", , , , , ,no,2016-04-20 08:11:21,2021-11-26 12:11:26,core-reference,"[('title', 'Developing the Clarity and Openness in Reporting: E3-based (CORE) reference user manual for creation of clinical study reports in the era of clinical trial transparency'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting clinical study reports (CSRs).'), ('Full bibliographic reference', 'Hamilton S, Bernstein AB, Blakey G, Fagan V, Farrow T, Jordan D, Seiler W, Shannon A, Gertel A and for the Budapest Working Group. Developing the Clarity and Openness in Reporting: E3-based (CORE) reference user manual for creation of clinical study reports in the era of clinical trial transparency. Res Integr Peer Rev. 2016;1(4).'), ('Language', 'English'), ('PubMed ID', '[29451540](https://pubmed.ncbi.nlm.nih.gov/29451540/)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available from: <http://researchintegrityjournal.biomedcentral.com/articles/10.1186/s41073-016-0009-4>\n\n \n\n The CORE Reference Manual and Mapping Tool can be downloaded from:\n\n<http://www.core-reference.org/core-reference/>\n\n \n\n'), ('Reporting guideline website URL', '<http://\u200bwww.\u200bcore-reference.\u200borg>'), ('Reporting guideline acronym', 'CORE Reference'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Additional documents prepared during the development of this guideline:\n\n \n\n Hamilton, S, Seiler W, Gertel A. The EMWA Budapest Working Group: A 2-year collaboration to make recommendations for aligning the ICH E3 guidance with current practice and developing clinical study protocol guidance. Medical Writing 2014;23(4):281-288. [Link to paper](http://www.tandfonline.com/doi/full/10.1179/2047480614Z.000000000254)\n\n \n\n[Press release (PDF)](http://www.emwa.org/Documents/CORE%20Press%20Release-28jan15_final.pdf) dated 28 January 2015\n\n \n\n CORE Reference BWG [team members list (PDF)](http://www.emwa.org/Documents/CORE%20Team-02feb15.pdf)\n\n \n\n'), ('Record last updated on', 'November 26, 2021')]"
13696,SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee,Diagnostic and prognostic studies,"Cardiovascular medicine, Radiology","Images, Intervention (exposure), Procedure/Method, Results, Study characteristics (participants etc.)", ,"angiogram, angiograms, cardiac, cardiac CT, cardiology, cardiovascular, cardiovascular computed tomography, cardiovascular CT, computed tomography, coronary, coronary angiogram, coronary angiography, coronary arteries, coronary artery, coronary CT, coronary CT angiogram, coronary CT angiography, coronary CTA, CT, CT angiography, CT image, CT images, diagnosis, diagnostic, diagnostic studies, diagnostic study, prognosis, prognostic, SCCT, Society of Cardiovascular Computed Tomography", ,"Leipsic J, Abbara S, Achenbach S, Cury R, Earls JP, Mancini GJ, Nieman K, Pontone G, Raff GL. SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr. 2014;8(5):342-358.","Leipsic J, Abbara S, Achenbach S, Cury R, Earls JP, Mancini GJ, Nieman K, Pontone G, Raff GL.",Journal of Cardiovascular Computed Tomography [J Cardiovasc Comput Tomogr.],2014,8,5,342-358, ,English, ,25301040,http://www.ncbi.nlm.nih.gov/pubmed/25301040, , , , , , ,Reporting of cardiac CT angiography (CTA) studies., , , , , , , ,no,2016-03-22 16:07:46,2016-03-22 16:07:46,scct-guidelines-for-the-interpretation-and-reporting-of-coronary-ct-angiography-a-report-of-the-society-of-cardiovascular-computed-tomography-guidelines-committee,"[('title', 'SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of cardiac CT angiography (CTA) studies.'), ('Full bibliographic reference', 'Leipsic J, Abbara S, Achenbach S, Cury R, Earls JP, Mancini GJ, Nieman K, Pontone G, Raff GL. SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr. 2014;8(5):342-358.'), ('Language', 'English'), ('PubMed ID', '[25301040](http://www.ncbi.nlm.nih.gov/pubmed/25301040)'), ('Study design', 'Diagnostic and prognostic studies'), ('Clinical area', 'Cardiovascular medicine, Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Images, Intervention (exposure), Procedure/Method, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'March 22, 2016')]"
13694,Definition and classification of intraoperative complications (CLASSIC): Delphi study and pilot evaluation,"Clinical trials, Experimental studies, Observational studies",Surgery,"Harms/adverse effects/safety data, Terminology/definitions", ,"adverse effect, adverse effects, adverse event, adverse events, classification, classification of intraoperative complications, classifications, clinical trial, clinical trials, complication, complications, definition, definitions, harm, harms, intraoperative, intraoperative adverse event, intraoperative adverse events, intraoperative complications, intraoperative events, observational, observational research, observational studies, observational study, patient safety, randomised controlled trial, randomised controlled trials, randomized controlled trial, randomized controlled trials, RCT, RCTs, safety, skin closure, skin incision, surgery, surgical, trial, trials, unintended effect, unintended effects", ,"Rosenthal R, Hoffmann H, Clavien PA, Bucher HC, Dell-Kuster S. Definition and classification of intraoperative complications (CLASSIC): Delphi study and pilot evaluation. World J Surg. 2015;39(7):1663-1671.","Rosenthal R, Hoffmann H, Clavien PA, Bucher HC, Dell-Kuster S.",World Journal of Surgery [World J Surg.],2015,39,7,1663-1671, ,English, ,25665678,http://www.ncbi.nlm.nih.gov/pubmed/25665678, , , , , , ,Definition and classification of intraoperative complications., , , , , , , ,no,2016-03-22 14:45:32,2016-08-16 13:41:45,definition-and-classification-of-intraoperative-complications-classic-delphi-study-and-pilot-evaluation,"[('title', 'Definition and classification of intraoperative complications (CLASSIC) : Delphi study and pilot evaluation'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Definition and classification of intraoperative complications.'), ('Full bibliographic reference', 'Rosenthal R, Hoffmann H, Clavien PA, Bucher HC, Dell-Kuster S. Definition and classification of intraoperative complications (CLASSIC): Delphi study and pilot evaluation. World J Surg. 2015;39(7):1663-1671.'), ('Language', 'English'), ('PubMed ID', '[25665678](http://www.ncbi.nlm.nih.gov/pubmed/25665678)'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Terminology/definitions'), ('Record last updated on', 'August 16, 2016')]"
13692,"Improving research practice in rat orthotopic and partial orthotopic liver transplantation: a review, recommendation, and publication guide",Animal pre-clinical research,Hepatology,Whole report, ,"animal, animal experiment, animal experiments, animal model, animal models, animal pre clinical research, animal preclinical research, animal research, animal studies, animal study, ARRIVE, checklist, checklists, chronic liver disease, chronic liver diseases, donor liver, donor organ, experimental liver transplantation, in vivo, in vivo animal experiment, in vivo animal experiments, in vivo experiments, liver, liver disease, liver graft, liver transplant, liver transplantation, microsurgery, microsurgical, microsurgical model, microsurgical models, microsurgical training, OLT, orthotopic, orthotopic liver transplant, orthotopic liver transplantation, P-OLT, partial liver transplant, partial liver transplantation, partial orthotopic, partial orthotopic liver transplantation, pre clinical, pre clinical animal research, pre clinical experiment, pre clinical experiments, pre clinical model, pre clinical models, pre clinical research, pre clinical studies, pre clinical study, preclinical, preclinical animal research, preclinical studies, preclinical study, rat, rat liver, rat liver transplant, rat liver transplantation, rat model, rat models, rat OLT, rat orthotopic liver transplantation, rat P-OLT, small animal orthotopic liver transplantation, small for size syndrome, transplant, transplantation", ,"Czig\xe1ny Z, Iwasaki J, Yagi S, Nagai K, Szij\xe1rt\xf3 A, Uemoto S, Tolba RH. Improving Research Practice in Rat Orthotopic and Partial Orthotopic Liver Transplantation: A Review, Recommendation, and Publication Guide. Eur Surg Res. 2015;55(1-2):119-138.","Czig\xe1ny Z, Iwasaki J, Yagi S, Nagai K, Szij\xe1rt\xf3 A, Uemoto S, Tolba RH.",European Surgical Research [Eur Surg Res.],2015,55,1-2,119-138, ,English, ,26228574,http://www.ncbi.nlm.nih.gov/pubmed/26228574, , , , , , ,"Reporting in vivo experiments in the field of experimental transplantation research, with a special focus on rat OLT and P-OLT.", , , , , , , ,no,2016-03-22 11:44:34,2016-03-22 13:32:00,improving-research-practice-in-rat-orthotopic-and-partial-orthotopic-liver-transplantation-a-review-recommendation-and-publication-guide,"[('title', 'Improving research practice in rat orthotopic and partial orthotopic liver transplantation: a review, recommendation, and publication guide'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting in vivo experiments in the field of experimental transplantation research, with a special focus on rat OLT and P-OLT.'), ('Full bibliographic reference', 'Czigány Z, Iwasaki J, Yagi S, Nagai K, Szijártó A, Uemoto S, Tolba RH. Improving Research Practice in Rat Orthotopic and Partial Orthotopic Liver Transplantation: A Review, Recommendation, and Publication Guide. Eur Surg Res. 2015;55(1-2):119-138.'), ('Language', 'English'), ('PubMed ID', '[26228574](http://www.ncbi.nlm.nih.gov/pubmed/26228574)'), ('Study design', 'Animal pre-clinical research'), ('Clinical area', 'Hepatology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'March 22, 2016')]"
13690,Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review,Observational studies,Renal medicine,"Procedure/Method, Results, Study characteristics (participants etc.)", ,"biological sample, biological sample collection, biological samples, chronic kidney disease, chronic kidney disease prevalence, CKD, CKD prevalence, epidemiology, European CKD Burden Consortium, kidney, kidney disease, kidney disease prevalence, kidney function, kidneys, nephrology, observational, observational research, observational studies, observational study, population, renal, renal medicine, sample collection, sample selection, sampling, sampling frame, study population", ,"Br\xfcck K, Jager KJ, Dounousi E, Kainz A, Nitsch D, \xc4rnl\xf6v J, Rothenbacher D, Browne G, Capuano V, Ferraro PM, Ferrieres J, Gambaro G, Guessous I, Hallan S, Kastarinen M, Navis G, Gonzalez AO, Palmieri L, Romundstad S, Spoto B, Stengel B, Tomson C, Tripepi G, V\xf6lzke H, Wi?cek A, Gansevoort R, Sch\xf6ttker B, Wanner C, Vinhas J, Zoccali C, Van Biesen W, Stel VS; European CKD Burden Consortium. Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review. Nephrol Dial Transplant. 2015;30 Suppl 4:iv6-16.","Br\xfcck K, Jager KJ, Dounousi E, Kainz A, Nitsch D, \xc4rnl\xf6v J, Rothenbacher D, Browne G, Capuano V, Ferraro PM, Ferrieres J, Gambaro G, Guessous I, Hallan S, Kastarinen M, Navis G, Gonzalez AO, Palmieri L, Romundstad S, Spoto B, Stengel B, Tomson C, Tripepi G, V\xf6lzke H, Wi?cek A, Gansevoort R, Sch\xf6ttker B, Wanner C, Vinhas J, Zoccali C, Van Biesen W, Stel VS; European CKD Burden Consortium.",Nephrology Dialysis Transplantation [Nephrol Dial Transplant.],2015,30,4,6-16, ,English, ,26209739,http://www.ncbi.nlm.nih.gov/pubmed/26209739, , , , , , ,Reporting of chronic kidney disease prevalence studies., , , , , , , ,no,2016-03-22 10:50:14,2016-03-22 10:50:14,methodology-used-in-studies-reporting-chronic-kidney-disease-prevalence-a-systematic-literature-review,"[('title', 'Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of chronic kidney disease prevalence studies.'), ('Full bibliographic reference', 'Brück K, Jager KJ, Dounousi E, Kainz A, Nitsch D, Ärnlöv J, Rothenbacher D, Browne G, Capuano V, Ferraro PM, Ferrieres J, Gambaro G, Guessous I, Hallan S, Kastarinen M, Navis G, Gonzalez AO, Palmieri L, Romundstad S, Spoto B, Stengel B, Tomson C, Tripepi G, Völzke H, Wiȩcek A, Gansevoort R, Schöttker B, Wanner C, Vinhas J, Zoccali C, Van Biesen W, Stel VS; European CKD Burden Consortium. Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review. Nephrol Dial Transplant. 2015;30 Suppl 4:iv6-16.'), ('Language', 'English'), ('PubMed ID', '[26209739](http://www.ncbi.nlm.nih.gov/pubmed/26209739)'), ('Study design', 'Observational studies'), ('Clinical area', 'Renal medicine'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'March 22, 2016')]"
13681,Standardized outcomes reporting in metabolic and bariatric surgery,"Clinical trials, Experimental studies, Observational studies","Gastroenterology, Surgery",Outcomes (variables), ,"bariatric, bariatric surgery, BMI, body mass index, clinical research, clinical studies, clinical study, complication, complications, follow-up, gastrectomy, gastric bypass, gastric bypass surgery, metabolic, metabolic surgery, morbid obesity, obese, obesity, observational, observational research, observational studies, observational study, outcome, outcome measure, outcome measures, outcomes, quality of life, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, Roux-en-Y, surgery, trial, trials, weight loss, weight loss surgery", ,"Brethauer SA, Kim J, El Chaar M, Papasavas P, Eisenberg D, Rogers A, Ballem N, Kligman M, Kothari S; ASMBS Clinical Issues Committee. Standardized outcomes reporting in metabolic and bariatric surgery.

Surg Obes Relat Dis. 2015;11(3):489-506. PMID: 26093765
Obes Surg. 2015;25(4):587-606. PMID: 25802064

","Brethauer SA, Kim J, El Chaar M, Papasavas P, Eisenberg D, Rogers A, Ballem N, Kligman M, Kothari S; ASMBS Clinical Issues Committee.", ,2015, , , , ,English, , , , , , , , , ,Reporting standardised outcomes in metabolic and bariatric surgery research., , , , , , , ,no,2016-03-22 10:03:20,2021-11-26 16:51:34,standardized-outcomes-reporting-in-metabolic-and-bariatric-surgery,"[('title', 'Standardized outcomes reporting in metabolic and bariatric surgery'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting standardised outcomes in metabolic and bariatric surgery research.'), ('Full bibliographic reference', 'Brethauer SA, Kim J, El Chaar M, Papasavas P, Eisenberg D, Rogers A, Ballem N, Kligman M, Kothari S; ASMBS Clinical Issues Committee. Standardized outcomes reporting in metabolic and bariatric surgery.\n\n \n\n Surg Obes Relat Dis. 2015;11(3):489-506. PMID: [26093765](http://www.ncbi.nlm.nih.gov/pubmed/26093765)\n\n Obes Surg. 2015;25(4):587-606. PMID: [25802064](http://www.ncbi.nlm.nih.gov/pubmed/25802064)\n\n \n\n'), ('Language', 'English'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Gastroenterology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Outcomes (variables)'), ('Record last updated on', 'November 26, 2021')]"
13679,Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting,"Clinical trials, Diagnostic and prognostic studies, Experimental studies","Haematology, Oncology","Procedure/Method, Results", ,"antigen, antigens, bone marrow, bone marrow cells, bone marrow plasma cells, cancer, clinical trial, clinical trials, cytometry, flow cytometry, flow cytometry data sets, flow-MRD, gating parameters, minimal residual disease, minimal residual disease testing, MRD analyses, MRD analysis, multiple myeloma, myeloma, neoplasm, neoplasms, neoplastic, neoplastic plasma cells, oncology, phenotypic marker, phenotypic markers, plasma, plasma cell, plasma cell myeloma, prognosis, prognostic, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, residual disease analysis, trial, trials", ,"Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, Monreal M, de Tute R, Vergilio JA, Rawstron AC, Paiva B. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90(1):31-39.","Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, Monreal M, de Tute R, Vergilio JA, Rawstron AC, Paiva B.","Cytometry. Part B, Clinical Cytometry. [Cytometry B Clin Cytom.]",2016,19,1,31-39, ,English, ,25619868,http://www.ncbi.nlm.nih.gov/pubmed/25619868, , , , , , ,Flow cytometry minimal residual disease analysis and reporting in multiple myeloma., , , , , , , ,no,2016-03-18 15:58:34,2016-03-18 16:07:31,consensus-guidelines-on-plasma-cell-myeloma-minimal-residual-disease-analysis-and-reporting,"[('title', 'Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Flow cytometry minimal residual disease analysis and reporting in multiple myeloma.'), ('Full bibliographic reference', 'Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, Monreal M, de Tute R, Vergilio JA, Rawstron AC, Paiva B. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90(1):31-39.'), ('Language', 'English'), ('PubMed ID', '[25619868](http://www.ncbi.nlm.nih.gov/pubmed/25619868)'), ('Study design', 'Clinical trials, Diagnostic and prognostic studies, Experimental studies'), ('Clinical area', 'Haematology, Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method, Results'), ('Record last updated on', 'March 18, 2016')]"
13677,DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial,"Clinical trials, Experimental studies, Study protocols", ,Statistical methods and analyses, ,"clinical trial, clinical trials, clinically important difference, CONSORT, DELTA project, outcome, outcomes, primary outcome, protocol, protocols, randomised controlled trial, randomised controlled trials, randomized controlled trial, randomized controlled trials, RCT, RCTs, realistic difference, sample size, sample size calculation, sample size calculations, SPIRIT, statistic, statistical, statistical analyses, statistical analysis, statistical method, statistical methods, target difference, target difference specification, trial, trial protocol, trial protocols, trials", ,"Cook JA, Julious SA, Sones W, Hampson LV, Hewitt C, Berlin JA, Ashby D, Emsley R, Fergusson DA, Walters SJ, Wilson ECF, Maclennan G, Stallard N, Rothwell JC, Bland M, Brown L, Ramsay CR, Cook A, Armstrong D, Altman D, Vale LD. DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial.

This guideline was published simultaneously in 2 journals. You can read the guideline in either of the journals using the links below.

Trials. 2018;19(1):606. PMID: 30400926
BMJ. 2018;363:k3750. PMID: 30560792

","Cook JA, Julious SA, Sones W, Hampson LV, Hewitt C, Berlin JA, Ashby D, Emsley R, Fergusson DA, Walters SJ, Wilson ECF, Maclennan G, Stallard N, Rothwell JC, Bland M, Brown L, Ramsay CR, Cook A, Armstrong D, Altman D, Vale LD.", , , , , , ,English, , , , , ,"Cook JA, Hislop J, Altman DG, Fayers P, Briggs AH, Ramsay CR, Norrie JD, Harvey IM, Buckley B, Fergusson D, Ford I, Vale LD; DELTA group. Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers. Trials. 2015;16:12. PMID: 25928502", , ,DELTA2,Reporting the target difference (the effect size) in the sample size calculation of a randomised controlled trial., ,"Read the protocol for development of this guideline.

Read about the development of the DELTA2 guidance.", , , , , ,no,2016-03-18 14:51:56,2023-11-09 16:44:15,specifying-the-target-difference-in-the-primary-outcome-for-a-randomised-controlled-trial-guidance-for-researchers,"[('title', 'DELTA 2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the target difference (the effect size) in the sample size calculation of a randomised controlled trial.'), ('Full bibliographic reference', 'Cook JA, Julious SA, Sones W, Hampson LV, Hewitt C, Berlin JA, Ashby D, Emsley R, Fergusson DA, Walters SJ, Wilson ECF, Maclennan G, Stallard N, Rothwell JC, Bland M, Brown L, Ramsay CR, Cook A, Armstrong D, Altman D, Vale LD. DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial.\n\n \n\n This guideline was published simultaneously in 2 journals. You can read the guideline in either of the journals using the links below.\n\n \n\n Trials. 2018;19(1):606. PMID: [30400926](https://pubmed.ncbi.nlm.nih.gov/30400926/)\n\n BMJ. 2018;363:k3750. PMID: [30560792](https://pubmed.ncbi.nlm.nih.gov/30560792/)\n\n \n\n'), ('Language', 'English'), ('Reporting guideline acronym', 'DELTA2'), ('Study design', 'Clinical trials, Experimental studies, Study protocols'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Previous versions of this guideline / Guideline history', 'Cook JA, Hislop J, Altman DG, Fayers P, Briggs AH, Ramsay CR, Norrie JD, Harvey IM, Buckley B, Fergusson D, Ford I, Vale LD; DELTA group. Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers. Trials. 2015;16:12. PMID: [25928502](http://www.ncbi.nlm.nih.gov/pubmed/25928502)'), ('Additional information', '[Read the protocol](https://pubmed.ncbi.nlm.nih.gov/28606102/) for development of this guideline.\n\n \n\n[Read](https://pubmed.ncbi.nlm.nih.gov/30305155/) about the development of the DELTA2 guidance.'), ('Record last updated on', 'November 9, 2023')]"
13675,Transparent reporting of data quality in distributed data networks,Observational studies, ,Data, ,"administration, administrative, administrative data, administrative data research, checklist, checklists, clinical and administrative data, clinical data, data, data elements, data network, data processing, data quality, data quality assessment, data quality assessments, data quality transparency, data source, distributed data network, distributed network, distributed research network, distributed research networks, electronic data, observational, observational data, observational data quality, observational research, observational studies, observational study", ,"Kahn MG, Brown JS, Chun AT, Davidson BN, Meeker D, Ryan PB, Schilling LM, Weiskopf NG, Williams AE, Zozus MN. Transparent reporting of data quality in distributed data networks. EGEMS (Wash DC). 2015;3(1):1052.","Kahn MG, Brown JS, Chun AT, Davidson BN, Meeker D, Ryan PB, Schilling LM, Weiskopf NG, Williams AE, Zozus MN.",eGEMs (Generating Evidence &amp; Methods to improve patient outcomes). [EGEMS (Wash DC).],2015,3,1, , ,English, ,25992385,http://www.ncbi.nlm.nih.gov/pubmed/25992385, , , , , , ,Reporting of data quality measures for studies that use observational clinical and administrative data., , , , , , , ,no,2016-03-18 14:29:26,2016-03-18 14:29:26,transparent-reporting-of-data-quality-in-distributed-data-networks,"[('title', 'Transparent reporting of data quality in distributed data networks'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of data quality measures for studies that use observational clinical and administrative data.'), ('Full bibliographic reference', 'Kahn MG, Brown JS, Chun AT, Davidson BN, Meeker D, Ryan PB, Schilling LM, Weiskopf NG, Williams AE, Zozus MN. Transparent reporting of data quality in distributed data networks. EGEMS (Wash DC). 2015;3(1):1052.'), ('Language', 'English'), ('PubMed ID', '[25992385](http://www.ncbi.nlm.nih.gov/pubmed/25992385)'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'March 18, 2016')]"
13671,Quality of methods reporting in animal models of colitis,Animal pre-clinical research,Gastroenterology,Procedure/Method, ,"animal, animal experiment, animal experiments, animal model, animal models, animal pre clinical research, bowel disease, bowel diseases, checklist, checklists, chronic colitis, chronic inflammation, colitic, colitis, colitis experiment, colitis experiments, colitis model, colitis models, colitis research, colitis studies, colitis study, gastroenterology, gastrointestinal, IBD, inflammatory bowel disease, inflammatory bowel diseases, pre clinical, pre clinical animal research, pre clinical experiment, pre clinical experiments, pre clinical model, pre clinical models, pre clinical recommendations, pre clinical research, pre clinical studies, pre clinical study, pre clinical testing", ,"Bramhall M, Fl\xf3rez-Vargas O, Stevens R, Brass A, Cruickshank S. Quality of methods reporting in animal models of colitis. Inflamm Bowel Dis. 2015;21(6):1248-1259.","Bramhall M, Fl\xf3rez-Vargas O, Stevens R, Brass A, Cruickshank S.",Inflammatory Bowel Diseases [Inflamm Bowel Dis.],2015,21,6,1248-1259, ,English, ,25989337,http://www.ncbi.nlm.nih.gov/pubmed/25989337, , , , , , ,Reporting the results of animal models of colitis., , , , , , , ,no,2016-03-18 13:50:20,2016-03-18 13:51:32,quality-of-methods-reporting-in-animal-models-of-colitis,"[('title', 'Quality of methods reporting in animal models of colitis'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the results of animal models of colitis.'), ('Full bibliographic reference', 'Bramhall M, Flórez-Vargas O, Stevens R, Brass A, Cruickshank S. Quality of methods reporting in animal models of colitis. Inflamm Bowel Dis. 2015;21(6):1248-1259.'), ('Language', 'English'), ('PubMed ID', '[25989337](http://www.ncbi.nlm.nih.gov/pubmed/25989337)'), ('Study design', 'Animal pre-clinical research'), ('Clinical area', 'Gastroenterology'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method'), ('Record last updated on', 'March 18, 2016')]"
13673,Guidelines for reporting of health interventions using mobile phones: mobile health (mHealth) evidence reporting and assessment (mERA) checklist,"Clinical trials, Experimental studies, Observational studies", ,Intervention (exposure), ,"checklist, checklists, ICT, ICT intervention, ICT interventions, intervention, interventions, mERA, mERA checklist, mhealth, mHealth evidence reporting and assessment (mERA) checklist, mhealth intervention, mhealth interventions, mHealth research, mHealth studies, mHealth study, mobile, mobile health, mobile health intervention, mobile health interventions, mobile intervention, mobile interventions, mobile phone, mobile phones, mobiles, WHO, WHO mHealth Technical Evidence Review Group", ,"Agarwal S, LeFevre AE, Lee J, L'Engle K, Mehl G, Sinha C, Labrique A; for the WHO mHealth Technical Evidence Review Group. Guidelines for reporting of health interventions using mobile phones: mobile health (mHealth) evidence reporting and assessment (mERA) checklist. BMJ 2016;352:i1174.","Agarwal S, LeFevre AE, Lee J, L'Engle K, Mehl G, Sinha C, Labrique A; for the WHO mHealth Technical Evidence Review Group.",BMJ.,2016,352,i1174, , ,English, , , ,This reporting guideline can be accessed at: http://www.bmj.com/content/352/bmj.i1174?etoc=, , , , ,mERA,Reporting of mobile health (mHealth) interventions., ,"A viewpoint article about this reporting guideline is available at:

Agarwal S, Lefevre AE, Labrique AB. A Call to Digital Health Practitioners: New Guidelines Can Help Improve the Quality of Digital Health Evidence. JMIR Mhealth Uhealth. 2017;5(10):e136. PMID: 28986340

", , , , , ,no,2016-03-18 12:09:35,2021-11-26 16:54:41,guidelines-for-reporting-of-health-interventions-using-mobile-phones-mobile-health-mhealth-evidence-reporting-and-assessment-mera-checklist,"[('title', 'Guidelines for reporting of health interventions using mobile phones: mobile health (mHealth) evidence reporting and assessment (m ERA) checklist'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of mobile health (mHealth) interventions.'), ('Full bibliographic reference', ""Agarwal S, LeFevre AE, Lee J, L'Engle K, Mehl G, Sinha C, Labrique A; for the WHO mHealth Technical Evidence Review Group. Guidelines for reporting of health interventions using mobile phones: mobile health (mHealth) evidence reporting and assessment (mERA) checklist. BMJ 2016;352:i1174.""), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'This reporting guideline can be accessed at: <http://www.bmj.com/content/352/bmj.i1174?etoc=>'), ('Reporting guideline acronym', 'mERA'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Additional information', 'A viewpoint article about this reporting guideline is available at:\n\n \n\n Agarwal S, Lefevre AE, Labrique AB. A Call to Digital Health Practitioners: New Guidelines Can Help Improve the Quality of Digital Health Evidence. JMIR Mhealth Uhealth. 2017;5(10):e136. PMID: [28986340](https://www.ncbi.nlm.nih.gov/pubmed/28986340)\n\n \n\n'), ('Record last updated on', 'November 26, 2021')]"
13665,Quality of pain intensity assessment reporting: ACTTION systematic review and recommendations,"Clinical trials, Experimental studies, Observational studies","Anaesthesia, Neurology, Occupational therapy, Pharmaceutical medicine, Psychiatry, Psychology",Intervention (exposure), ,"ACTTION, NRS, numeric rating scale, pain, pain intensity, pain intensity assessment, pain intensity assessments, pain research, pain studies, pain study, VAS, VDS, verbal descriptor scale, verbal response scale, visual analog scale, VRS", ,"Smith SM, Hunsinger M, McKeown A, Parkhurst M, Allen R, Kopko S, Lu Y, Wilson HD, Burke LB, Desjardins P, McDermott MP, Rappaport BA, Turk DC, Dworkin RH. Quality of pain intensity assessment reporting: ACTTION systematic review and recommendations. J Pain. 2015;16(4):299-305.","Smith SM, Hunsinger M, McKeown A, Parkhurst M, Allen R, Kopko S, Lu Y, Wilson HD, Burke LB, Desjardins P, McDermott MP, Rappaport BA, Turk DC, Dworkin RH.",The Journal of Pain [J Pain.],2015,16,4,299-305, ,English, ,25637296,http://www.ncbi.nlm.nih.gov/pubmed/25637296, , , , , , ,Reporting pain intensity assessments in human adults., , , , , , , ,no,2016-03-17 16:07:18,2016-03-17 16:25:20,quality-of-pain-intensity-assessment-reporting-acttion-systematic-review-and-recommendations,"[('title', 'Quality of pain intensity assessment reporting: ACTTION systematic review and recommendations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting pain intensity assessments in human adults.'), ('Full bibliographic reference', 'Smith SM, Hunsinger M, McKeown A, Parkhurst M, Allen R, Kopko S, Lu Y, Wilson HD, Burke LB, Desjardins P, McDermott MP, Rappaport BA, Turk DC, Dworkin RH. Quality of pain intensity assessment reporting: ACTTION systematic review and recommendations. J Pain. 2015;16(4):299-305.'), ('Language', 'English'), ('PubMed ID', '[25637296](http://www.ncbi.nlm.nih.gov/pubmed/25637296)'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Anaesthesia, Neurology, Occupational therapy, Pharmaceutical medicine, Psychiatry, Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'March 17, 2016')]"
13663,An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards,"Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies",Hepatology,Whole report, ,"checklist, checklists, chronic liver disease, chronic liver diseases, cirrhosis, CLD, clinical trial, clinical trials, diagnostic, diagnostic accuracy, diagnostic accuracy research, diagnostic accuracy studies, diagnostic accuracy study, diagnostic accuracy testing, diagnostic accuracy tests, diagnostic studies, diagnostic study, diagnostic test accuracy, fibrosis, hepatology, liver, liver disease, liver fibrosis, liver fibrosis evaluation, liver fibrosis test, liver fibrosis tests, Liver-FibroSTARD, Liver-FibroSTARD checklist, Liver-FibroSTARD glossary, Liver-FibroSTARD standards, non-invasive liver fibrosis test, non-invasive liver fibrosis tests, observational, observational studies, observational study, STARD, STARD statement, trial, trials", ,"Boursier J, de Ledinghen V, Poynard T, Gu\xe9chot J, Carrat F, Leroy V, Wong GL, Friedrich-Rust M, Fraquelli M, Plebani M, Sebastiani G, Myers R, Angulo P, Bertrais S, Wendum D, Bricault I, Cal\xe8s P; ARDENT group; AFEF. An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. J Hepatol. 2015;62(4):807-815.","Boursier J, de Ledinghen V, Poynard T, Gu\xe9chot J, Carrat F, Leroy V, Wong GL, Friedrich-Rust M, Fraquelli M, Plebani M, Sebastiani G, Myers R, Angulo P, Bertrais S, Wendum D, Bricault I, Cal\xe8s P; ARDENT group; AFEF.",Journal of Hepatology [J Hepatol.],2015,62,4,807-815, ,English, ,25450206,http://www.ncbi.nlm.nih.gov/pubmed/25450206, , , , , ,Liver-FibroSTARD,"Reporting cross-sectional diagnostic accuracy studies of non-invasive liver fibrosis tests.



", , ,"Gu\xe9chot J, Boursier J, de Ledinghen V, Poynard T, Carrat F, Leroy V, Wong GL, Friedrich-Rust M, Fraquelli M, Plebani M, Sebastiani G, Myers R, Angulo P, Bertrais S, Wendum D, Bricault I, Cal\xe8s P; ARDENT group and/or AFEF. Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests. Clin Chem Lab Med. 2015;53(8):1135-1137. PMID: 25997161

", , , , ,no,2016-03-17 14:32:37,2023-05-16 11:05:59,an-extension-of-stard-statements-for-reporting-diagnostic-accuracy-studies-on-liver-fibrosis-tests-the-liver-fibrostard-standards,"[('title', 'An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver -FibroSTARD standards'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting cross-sectional diagnostic accuracy studies of non-invasive liver fibrosis tests.\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Boursier J, de Ledinghen V, Poynard T, Guéchot J, Carrat F, Leroy V, Wong GL, Friedrich-Rust M, Fraquelli M, Plebani M, Sebastiani G, Myers R, Angulo P, Bertrais S, Wendum D, Bricault I, Calès P; ARDENT group; AFEF. An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. J Hepatol. 2015;62(4):807-815.'), ('Language', 'English'), ('PubMed ID', '[25450206](http://www.ncbi.nlm.nih.gov/pubmed/25450206)'), ('Reporting guideline acronym', 'Liver-FibroSTARD'), ('Study design', 'Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies'), ('Clinical area', 'Hepatology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Selected relevant editorials', 'Guéchot J, Boursier J, de Ledinghen V, Poynard T, Carrat F, Leroy V, Wong GL, Friedrich-Rust M, Fraquelli M, Plebani M, Sebastiani G, Myers R, Angulo P, Bertrais S, Wendum D, Bricault I, Calès P; ARDENT group and/or AFEF. Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests. Clin Chem Lab Med. 2015;53(8):1135-1137. PMID: [25997161](http://www.ncbi.nlm.nih.gov/pubmed/25997161)\n\n \n\n'), ('Record last updated on', 'May 16, 2023')]"
13657,STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship,Observational studies,Infectious diseases,Whole report, ,"AMS, antibiotic, antibiotic resistance, antibiotic resistant, antibiotics, antimicrobial, antimicrobial exposure, antimicrobial resistance, antimicrobial stewardship, antimicrobial therapy, antimicrobial usage, antimicrobial use, antimicrobial-resistant infection, antimicrobial-resistant infections, checklist, checklists, epidemiologic, epidemiological, epidemiological studies, epidemiological study, epidemiology, infection, infections, infectious, infectious diseases, multidrug resistance, multidrug resistant, observational studies, observational study, STROBE, STROBE extension, STROBE-AMS", ,"Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schr\xf6der W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134.","Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schr\xf6der W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B.",BMJ Open.,2016,6,2, , ,English, ,26895985,http://www.ncbi.nlm.nih.gov/pubmed/26895985,The full-text of this reporting guideline is freely available from: http://bmjopen.bmj.com/content/6/2/e010134.long, , ,"Generic
STROBE: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Ann Intern Med. 2007;147(8):573-577. PMID: 17938396
PLoS Med. 2007;4(10):e296. PMID: 17941714
BMJ. 2007;335(7624):806-808. PMID: 17947786
Prev Med. 2007;45(4):247-251. PMID: 17950122
Epidemiology. 2007;18(6):800-804. PMID: 18049194
Lancet. 2007;370(9596):1453-1457. PMID: 18064739

Specialised
STREGA: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.

PLoS Med. 2009;6(2):e22. PMID: 19192942
Hum Genet. 2009;125(2):131-151. PMID: 19184668
Eur J Epidemiol. 2009;24(1):37-55. PMID: 19189221
Ann Intern Med. 2009;150(3):206-215. PMID: 19189911
J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: 19217256
Genet Epidemiol. 2009;33(7):581-598. PMID: 19278015
Eur J Clin Invest. 2009;39(4):247-266. PMID: 19297801

STROBE-ME: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: 22023344

STROBE checklist for conference abstracts
First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. Link to full text pdf

STROME-ID: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: 24631223

Longitudinal observational drug studies in rheumatology: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: 24058015

Case-cohort studies: Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: 24972092

STROBE-RDS: White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: 26112433

RECORD: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: 26440803

STROBE-nut: Lachat C, Hawwash D, Ock\xe9 MC, Berg C, Forsum E, H\xf6rnell A, Larsson C, Sonestedt E, Wirf\xe4lt E, \xc5kesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology?Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: 27270749

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

ROSES-I: Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: 27417916

STROBE-NI: Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: 27633910

Propensity score analysis: Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: 28376195

RECORD-PE: Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.

STROBE-SIIS: International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, H\xe4gglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).

Br J Sports Med. 2020;54(7):372-389. PMID: 32071062
Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: 32118084

STROBE-MR: Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: 34698778

", ,STROBE-AMS,Reporting epidemiologic studies focused on the link between antimicrobial-resistant bacteria and antibiotic usage., , , , , , , ,yes,2016-03-16 10:26:36,2021-11-25 14:27:39,strobe-ams,"[('title', 'STROBE-AMS : recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting epidemiologic studies focused on the link between antimicrobial-resistant bacteria and antibiotic usage.'), ('Full bibliographic reference', 'Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schröder W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134.'), ('Language', 'English'), ('PubMed ID', '[26895985](http://www.ncbi.nlm.nih.gov/pubmed/26895985)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available from: <http://bmjopen.bmj.com/content/6/2/e010134.long>'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**STROBE**](/reporting-guidelines/strobe/): von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.\n\n \n\n Ann Intern Med. 2007;147(8):573-577. PMID: [17938396](http://www.ncbi.nlm.nih.gov/pubmed/17938396)\n\n PLoS Med. 2007;4(10):e296. PMID: [17941714](http://www.ncbi.nlm.nih.gov/pubmed/17941714)\n\n BMJ. 2007;335(7624):806-808. PMID: [17947786](http://www.ncbi.nlm.nih.gov/pubmed/17947786)\n\n Prev Med. 2007;45(4):247-251. PMID: [17950122](http://www.ncbi.nlm.nih.gov/pubmed/17950122)\n\n Epidemiology. 2007;18(6):800-804. PMID: [18049194](http://www.ncbi.nlm.nih.gov/pubmed/18049194)\n\n Lancet. 2007;370(9596):1453-1457. PMID: [18064739](http://www.ncbi.nlm.nih.gov/pubmed/18064739)\n\n \n\n**Specialised**\n\n**[STREGA](/reporting-guidelines/strobe-strega/)**: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.\n\n \n\n PLoS Med. 2009;6(2):e22. PMID: [19192942](http://www.ncbi.nlm.nih.gov/pubmed/19192942)\n\n Hum Genet. 2009;125(2):131-151. PMID: [19184668](http://www.ncbi.nlm.nih.gov/pubmed/19184668)\n\n Eur J Epidemiol. 2009;24(1):37-55. PMID: [19189221](http://www.ncbi.nlm.nih.gov/pubmed/19189221)\n\n Ann Intern Med. 2009;150(3):206-215. PMID: [19189911](http://www.ncbi.nlm.nih.gov/pubmed/19189911)\n\n J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: [19217256](http://www.ncbi.nlm.nih.gov/pubmed/19217256)\n\n Genet Epidemiol. 2009;33(7):581-598. PMID: [19278015](http://www.ncbi.nlm.nih.gov/pubmed/19278015)\n\n Eur J Clin Invest. 2009;39(4):247-266. PMID: [19297801](http://www.ncbi.nlm.nih.gov/pubmed/19297801)\n\n \n\n**[STROBE-ME](/reporting-guidelines/strobe-me/)**: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: [22023344](http://www.ncbi.nlm.nih.gov/pubmed/22023344)\n\n \n\n**[STROBE checklist for conference abstracts](/reporting-guidelines/strobe-abstracts/)**\n\n First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. [Link to full text pdf](https://www.strobe-statement.org/download/strobe-checklist-conference-abstracts)\n\n \n\n**[STROME-ID](/reporting-guidelines/strome-id/)**: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: [24631223](http://www.ncbi.nlm.nih.gov/pubmed/24631223)\n\n \n\n**[Longitudinal observational drug studies in rheumatology](/reporting-guidelines/launch-of-a-checklist-for-reporting-longitudinal-observational-drug-studies-in-rheumatology-a-eular-extension-of-strobe-guidelines-based-on-experience-from-biologics-registries/)**: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: [24058015](http://www.ncbi.nlm.nih.gov/pubmed/24058015)\n\n \n\n[**Case-cohort studies**](/reporting-guidelines/a-review-of-published-analyses-of-case-cohort-studies-and-recommendations-for-future-reporting/): Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: [24972092](https://www.ncbi.nlm.nih.gov/pubmed/24972092)\n\n \n\n**[STROBE-RDS](/reporting-guidelines/strobe-rds/)**: White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: [26112433](http://www.ncbi.nlm.nih.gov/pubmed/26112433)\n\n \n\n**[RECORD](/reporting-guidelines/record/)**: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: [26440803](http://www.ncbi.nlm.nih.gov/pubmed/26440803)\n\n \n\n[**STROBE-nut**](/reporting-guidelines/strobe-nut/): Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology—Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: [27270749](https://www.ncbi.nlm.nih.gov/pubmed/27270749)\n\n \n\n[**Simulation Research**](/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**ROSES-I**](/reporting-guidelines/roses-i-statement/): Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: [27417916](https://www.ncbi.nlm.nih.gov/pubmed/27417916)\n\n \n\n[**STROBE-NI**](/reporting-guidelines/strobe-ni/): Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: [27633910](https://www.ncbi.nlm.nih.gov/pubmed/27633910)\n\n \n\n[**Propensity score analysis**](/reporting-guidelines/reporting-and-guidelines-in-propensity-score-analysis-a-systematic-review-of-cancer-and-cancer-surgical-studies/): Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: [28376195](https://www.ncbi.nlm.nih.gov/pubmed/28376195)\n\n \n\n[**RECORD-PE**](https://www.equator-network.org/reporting-guidelines/record-pe/): Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). [BMJ 2018;363:k3532](https://www.bmj.com/content/363/bmj.k3532.full).\n\n \n\n[**STROBE-SIIS**](https://www.equator-network.org/reporting-guidelines/strobe-extension-for-sports-injury-illness-surveillance/): International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, Hägglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).\n\n \n\n Br J Sports Med. 2020;54(7):372-389. PMID: [32071062](https://pubmed.ncbi.nlm.nih.gov/32071062/)\n\n Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: [32118084](https://pubmed.ncbi.nlm.nih.gov/32118084/)\n\n \n\n[**STROBE-MR**](https://www.equator-network.org/reporting-guidelines/strobe-mr-statement/): Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: [34698778](https://pubmed.ncbi.nlm.nih.gov/34698778/)\n\n \n\n'), ('Reporting guideline acronym', 'STROBE-AMS'), ('Study design', 'Observational studies'), ('Clinical area', 'Infectious diseases'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 25, 2021')]"
13651,Reporting guidelines for population pharmacokinetic analyses,"Clinical trials, Experimental studies",Pharmaceutical medicine,Whole report, ,"drug, drug development, drug exposure, Model-based Drug Development (MBDD) Consortium, pharmaceutical, pharmacokinetic, pharmacokinetic model, pharmacokinetic modelling, pharmacokinetic models, pharmacokinetic research, pharmacokinetics, pharmacokinetics studies, pharmacokinetics study, pharmacometric, pharmacometric analyses, pharmacometric analysis, pharmacometrics, pharmacy, PK, population, population covariate effect, population covariate effects, population pharmacokinetic, population pharmacokinetic analyses, population pharmacokinetic analysis, population pharmacokinetics, regulatory, regulatory submission", ,"Dykstra K, Mehrotra N, Torn\xf8e CW, Kastrissios H, Patel B, Al-Huniti N, Jadhav P, Wang Y, Byon W. Reporting guidelines for population pharmacokinetic analyses.

This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.

J Clin Pharmacol. 2015;55(8):875-887. PMID: 26148467
J Pharmacokinet Pharmacodyn. 2015;42(3):301-314. PMID: 25925797

","Dykstra K, Mehrotra N, Torn\xf8e CW, Kastrissios H, Patel B, Al-Huniti N, Jadhav P, Wang Y, Byon W.", ,2015, , , , ,English, , , , , , , , , ,Reporting population pharmacokinetic analyses., , , , , , , ,no,2016-03-11 16:22:10,2021-11-26 16:57:31,reporting-guidelines-for-population-pharmacokinetic-analyses,"[('title', 'Reporting guidelines for population pharmacokinetic analyses'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting population pharmacokinetic analyses.'), ('Full bibliographic reference', 'Dykstra K, Mehrotra N, Tornøe CW, Kastrissios H, Patel B, Al-Huniti N, Jadhav P, Wang Y, Byon W. Reporting guidelines for population pharmacokinetic analyses.\n\n \n\n This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.\n\n \n\n J Clin Pharmacol. 2015;55(8):875-887. PMID: [26148467](http://www.ncbi.nlm.nih.gov/pubmed/26148467)\n\n J Pharmacokinet Pharmacodyn. 2015;42(3):301-314. PMID: [25925797](http://www.ncbi.nlm.nih.gov/pubmed/25925797)\n\n \n\n'), ('Language', 'English'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Pharmaceutical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 26, 2021')]"
13638,Recommendations for the improved effectiveness and reporting of telemedicine programs in developing countries: results of a systematic literature review,"Experimental studies, Observational studies",Health informatics,"Intervention (exposure), Narrative sections (discussion etc.), Outcomes (variables), Procedure/Method", ,"asynchronous technology, developing countries, developing country, difficult to reach, health technologies, health technology, information technology, LMIC, LMICs, low income countries, low income country, low middle income countries, low middle income country, m-health, middle income countries, middle income country, mobile technology, mobile telemedicine, real-time teleconsultation, real-time teleconsultations, remote, remote diagnosis, remote treatment, synchronous technology, technologies, technology, telecommunication, telecommunications, teleconsultation, teleconsultations, telemedicine, telemedicine program, telemedicine programme, telemedicine programmes, telemedicine programs, telephone, telephones, videoconference, videoconferencing", ,"Khanal S, Burgon J, Leonard S, Griffiths M, Eddowes LA. Recommendations for the Improved Effectiveness and Reporting of Telemedicine Programs in Developing Countries: Results of a Systematic Literature Review. Telemed J E Health. 2015;21(11):903-915.","Khanal S, Burgon J, Leonard S, Griffiths M, Eddowes LA.",Telemedicine Journal and e-Health. [Telemed J E Health.],2015,21,11,903-915, ,English, ,26103465,http://www.ncbi.nlm.nih.gov/pubmed/26103465, , , , , , ,Reporting telemedicine programs in developing countries., , , , , , , ,no,2016-03-07 11:22:51,2016-03-07 11:22:51,recommendations-for-the-improved-effectiveness-and-reporting-of-telemedicine-programs-in-developing-countries-results-of-a-systematic-literature-review,"[('title', 'Recommendations for the improved effectiveness and reporting of telemedicine programs in developing countries: results of a systematic literature review'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting telemedicine programs in developing countries.'), ('Full bibliographic reference', 'Khanal S, Burgon J, Leonard S, Griffiths M, Eddowes LA. Recommendations for the Improved Effectiveness and Reporting of Telemedicine Programs in Developing Countries: Results of a Systematic Literature Review. Telemed J E Health. 2015;21(11):903-915.'), ('Language', 'English'), ('PubMed ID', '[26103465](http://www.ncbi.nlm.nih.gov/pubmed/26103465)'), ('Study design', 'Experimental studies, Observational studies'), ('Clinical area', 'Health informatics'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Narrative sections (discussion etc.), Outcomes (variables), Procedure/Method'), ('Record last updated on', 'March 7, 2016')]"
13636,Guidelines for the reporting of treatment trials for alcohol use disorders,"Clinical trials, Experimental studies","Behavioural medicine, Psychiatry, Psychology, Public health",Whole report, ,"alcohol, alcohol clinical trial, alcohol clinical trials, alcohol treatment, alcohol use, alcohol use disorder, alcohol use disorders, AUD, AUD treatment, AUD treatment trial, AUD treatment trials, AUDs, behavior, behavioral, behaviour, behavioural, checklist, checklists, clinical trial, clinical trials, psychiatric, psychiatry, psychological, psychology, public health, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Witkiewitz K, Finney JW, Harris AH, Kivlahan DR, Kranzler HR. Guidelines for the reporting of treatment trials for alcohol use disorders. Alcohol Clin Exp Res. 2015;39(9):1571-1581.","Witkiewitz K, Finney JW, Harris AH, Kivlahan DR, Kranzler HR.","Alcoholism, Clinical and Experimental Research [Alcohol Clin Exp Res.]",2015,39,9,1571-1581, ,English, ,26259958,http://www.ncbi.nlm.nih.gov/pubmed/26259958, , , , , , ,Reporting results of alcohol treatment trials., , , , , , , ,no,2016-03-07 10:26:48,2016-03-07 10:27:20,guidelines-for-the-reporting-of-treatment-trials-for-alcohol-use-disorders,"[('title', 'Guidelines for the reporting of treatment trials for alcohol use disorders'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting results of alcohol treatment trials.'), ('Full bibliographic reference', 'Witkiewitz K, Finney JW, Harris AH, Kivlahan DR, Kranzler HR. Guidelines for the reporting of treatment trials for alcohol use disorders. Alcohol Clin Exp Res. 2015;39(9):1571-1581.'), ('Language', 'English'), ('PubMed ID', '[26259958](http://www.ncbi.nlm.nih.gov/pubmed/26259958)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Behavioural medicine, Psychiatry, Psychology, Public health'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'March 7, 2016')]"
13631,Development of the Standards of Reporting of Neurological Disorders (STROND) checklist: A guideline for the reporting of incidence and prevalence studies in neuroepidemiology,Observational studies,Neurology,Whole report, ,"burden, checklist, checklists, description, descriptive, descriptive health policy research, descriptive health research, epidemiological, epidemiological studies, epidemiological study, epidemiology, global burden, incidence, incidence and prevalence studies, incidence and prevalence study, incidence studies, incidence study, neuroepidemiological, neuroepidemiology, neurologic condition, neurologic conditions, neurologic disease, neurologic diseases, neurologic disorder, neurologic disorders, neurological, neurological condition, neurological conditions, neurological disease, neurological diseases, neurological disorder, neurological disorders, neurology, prevalence, prevalence studies, prevalence study, STROND, STROND checklist", ,"Bennett DA, Brayne C, Feigin VL, Barker-Collo S, Brainin M, Davis D, Gallo V, Jett\xe9 N, Karch A, Kurtzke JF, Lavados PM, Logroscino G, Nagel G, Preux PM, Rothwell PM, Svenson LW. Development of the Standards of Reporting of Neurological Disorders (STROND) checklist: A guideline for the reporting of incidence and prevalence studies in neuroepidemiology.

This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.

Neurology. 2015;85(9):821-828. PMID: 26163431
Eur J Epidemiol. 2015 Jul;30(7):569-576. PMID: 26088602

", , ,2015, , , , ,English, , , , ,"Bennett DA, Brayne C, Feigin VL, Barker-Collo S, Brainin M, Davis D, Gallo V, Jett\xe9 N, Karch A, Kurtzke JF, Lavados PM, Logroscino G, Nagel G, Preux PM, Rothwell PM, Svenson LW. Explanation and Elaboration of the Standards of Reporting of Neurological Disorders Checklist: A Guideline for the Reporting of Incidence and Prevalence Studies in Neuroepidemiology. Neuroepidemiology. 2015;45(2):113-137. PMID: 26390430

", , , ,STROND,Reporting of incidence and prevalence studies in neuroepidemiology., ,"Resources produced during the development of this reporting guideline:

Project outline (PDF) (March 2013)
Conference presentation (PDF) outlining the project

", , , , , ,no,2016-03-04 15:23:58,2021-11-26 16:59:28,development-of-the-standards-of-reporting-of-neurological-disorders-strond-checklist-a-guideline-for-the-reporting-of-incidence-and-prevalence-studies-in-neuroepidemiology,"[('title', 'Development of the Standards of Reporting of Neurological Disorders (STROND) checklist: A guideline for the reporting of incidence and prevalence studies in neuroepidemiology'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of incidence and prevalence studies in neuroepidemiology.'), ('Full bibliographic reference', 'Bennett DA, Brayne C, Feigin VL, Barker-Collo S, Brainin M, Davis D, Gallo V, Jetté N, Karch A, Kurtzke JF, Lavados PM, Logroscino G, Nagel G, Preux PM, Rothwell PM, Svenson LW. Development of the Standards of Reporting of Neurological Disorders (STROND) checklist: A guideline for the reporting of incidence and prevalence studies in neuroepidemiology.\n\n \n\n This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.\n\n \n\n Neurology. 2015;85(9):821-828. PMID: [26163431](http://www.ncbi.nlm.nih.gov/pubmed/26163431)\n\n Eur J Epidemiol. 2015 Jul;30(7):569-576. PMID: [26088602](http://www.ncbi.nlm.nih.gov/pubmed/26088602)\n\n \n\n'), ('Language', 'English'), ('Explanation and elaboration papers', 'Bennett DA, Brayne C, Feigin VL, Barker-Collo S, Brainin M, Davis D, Gallo V, Jetté N, Karch A, Kurtzke JF, Lavados PM, Logroscino G, Nagel G, Preux PM, Rothwell PM, Svenson LW. Explanation and Elaboration of the Standards of Reporting of Neurological Disorders Checklist: A Guideline for the Reporting of Incidence and Prevalence Studies in Neuroepidemiology. Neuroepidemiology. 2015;45(2):113-137. PMID: [26390430](http://www.ncbi.nlm.nih.gov/pubmed/26390430)\n\n \n\n'), ('Reporting guideline acronym', 'STROND'), ('Study design', 'Observational studies'), ('Clinical area', 'Neurology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Resources produced during the development of this reporting guideline:\n\n \n\n[Project outline (PDF)](/wp-content/uploads/2009/02/6010_Guidelines+for+the+Reporting+of+Neuro-Epidemiological+Studies.pdf) (March 2013)\n\n[Conference presentation (PDF)](/wp-content/uploads/2009/02/6028_ICNE_Nice_talk_Nov_2012.pdf) outlining the project\n\n \n\n'), ('Record last updated on', 'November 26, 2021')]"
13629,A review of 40 years of enteric antimicrobial resistance research in Eastern Africa: what can be done better?,"Clinical trials, Experimental studies, Observational studies",Infectious diseases,"Procedure/Method, Results, Study characteristics (participants etc.)", ,"Africa, AMR, AMR prevalence, AMR research, antibiotic, antibiotic resistance, antibiotic resistant, antibiotics, antimicrobial, antimicrobial resistance, bacteria, checklist, checklists, East Africa, Eastern Africa, enteric, enteric bacteria, hospital-based, infection control, infectious, infectious diseases, laboratory, laboratory research, laboratory-based, microbial, pathogen, pathogens, sub-Saharan Africa", ,"Omulo S, Thumbi SM, Njenga MK, Call DR. A review of 40 years of enteric antimicrobial resistance research in Eastern Africa: what can be done better? Antimicrob Resist Infect Control. 2015;4:1.","Omulo S, Thumbi SM, Njenga MK, Call DR.",Antimicrobial Resistance and Infection Control. [Antimicrob Resist Infect Control.],2015,4,1, , ,English, ,25717374,http://www.ncbi.nlm.nih.gov/pubmed/25717374, , , , , , ,Reporting research on antimicrobial resistance., , , , , , , ,no,2016-03-04 15:04:41,2016-03-04 15:34:29,a-review-of-40-years-of-enteric-antimicrobial-resistance-research-in-eastern-africa-what-can-be-done-better,"[('title', 'A review of 40 years of enteric antimicrobial resistance research in Eastern Africa: what can be done better?'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting research on antimicrobial resistance.'), ('Full bibliographic reference', 'Omulo S, Thumbi SM, Njenga MK, Call DR. A review of 40 years of enteric antimicrobial resistance research in Eastern Africa: what can be done better? Antimicrob Resist Infect Control. 2015;4:1.'), ('Language', 'English'), ('PubMed ID', '[25717374](http://www.ncbi.nlm.nih.gov/pubmed/25717374)'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Infectious diseases'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'March 4, 2016')]"
13627,Ensuring consistent reporting of clinical pharmacy services to enhance reproducibility in practice: an improved version of DEPICT,"Clinical trials, Experimental studies",Pharmaceutical medicine,Intervention (exposure), ,"clinical pharmacy, clinical pharmacy service, clinical pharmacy services, component, components, DEPICT, DEPICT 1, DEPICT 2, intervention, intervention characteristic, intervention characteristics, intervention component, intervention components, intervention description, intervention descriptions, interventions, outcome, outcome and process assessment, outcome assessment, outcome evaluation, outcomes, patient health outcomes, pharmaceutical, pharmaceutical medicine, pharmaceutical service, pharmaceutical services, pharmacist, pharmacist intervention, pharmacist interventions, pharmacists, pharmacy, pharmacy service, pharmacy services, process assessment, process evaluation", ,"Rotta I, Salgado TM, Felix DC, Souza TT, Correr CJ, Fernandez-Llimos F. Ensuring consistent reporting of clinical pharmacy services to enhance reproducibility in practice: an improved version of DEPICT. J Eval Clin Pract. 2015;21(4):584-590.","Rotta I, Salgado TM, Felix DC, Souza TT, Correr CJ, Fernandez-Llimos F.",Journal of Evaluation in Clinical Practice [J Eval Clin Pract.],2015,21,4,584-590, ,English, ,25676042,http://www.ncbi.nlm.nih.gov/pubmed/25676042, , ,"An earlier version of this reporting guideline was published in 2013:

Correr CJ, Melchiors AC, de Souza TT, Rotta I, Salgado TM, Fernandez-Llimos F. A tool to characterize the components of pharmacist interventions in clinical pharmacy services: the DEPICT project. Ann Pharmacother. 2013;47(7-8):946-952. PMID: 23757389

", , ,DEPICT 2,Reporting intervention description across studies assessing the impact of clinical pharmacy activities., , , , , , , ,no,2016-03-04 13:44:41,2021-11-26 17:00:42,ensuring-consistent-reporting-of-clinical-pharmacy-services-to-enhance-reproducibility-in-practice-an-improved-version-of-depict,"[('title', 'Ensuring consistent reporting of clinical pharmacy services to enhance reproducibility in practice: an improved version of DEPICT'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting intervention description across studies assessing the impact of clinical pharmacy activities.'), ('Full bibliographic reference', 'Rotta I, Salgado TM, Felix DC, Souza TT, Correr CJ, Fernandez-Llimos F. Ensuring consistent reporting of clinical pharmacy services to enhance reproducibility in practice: an improved version of DEPICT. J Eval Clin Pract. 2015;21(4):584-590.'), ('Language', 'English'), ('PubMed ID', '[25676042](http://www.ncbi.nlm.nih.gov/pubmed/25676042)'), ('Reporting guideline acronym', 'DEPICT 2'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Pharmaceutical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Previous versions of this guideline / Guideline history', 'An earlier version of this reporting guideline was published in 2013:\n\n \n\n Correr CJ, Melchiors AC, de Souza TT, Rotta I, Salgado TM, Fernandez-Llimos F. A tool to characterize the components of pharmacist interventions in clinical pharmacy services: the DEPICT project. Ann Pharmacother. 2013;47(7-8):946-952. PMID: [23757389](http://www.ncbi.nlm.nih.gov/pubmed/23757389)\n\n \n\n'), ('Record last updated on', 'November 26, 2021')]"
13531,RiGoR: reporting guidelines to address common sources of bias in risk model development,"Diagnostic and prognostic studies, Observational studies", ,Whole report, ,"bias, biomarker, biomarkers, model-selection bias, optimistic bias, pedictive model, prediction, predictive models, resubstitution bias, RiGor, risk, risk factor, risk factors, risk model, risk model development, risk models, risk of bias, risk prediction, risk prediction model, risk prediction models, statistical bias", ,"Kerr KF, Meisner A, Thiessen-Philbrook H, Coca SG, Parikh CR. RiGoR: reporting guidelines to address common sources of bias in risk model development. Biomark Res. 2015;3(1):2.","Kerr KF, Meisner A, Thiessen-Philbrook H, Coca SG, Parikh CR.",Biomarker Research [Biomark Res.],2015,3,1,2, ,English, ,25642328,http://www.ncbi.nlm.nih.gov/pubmed/25642328,The full-text of this reporting guideline is freely available from: http://biomarkerres.biomedcentral.com/articles/10.1186/s40364-014-0027-7, , , , ,RiGoR,Reporting risk model development., , , , , , , ,no,2016-02-16 16:18:42,2021-11-26 17:01:42,rigor-reporting-guidelines-to-address-common-sources-of-bias-in-risk-model-development,"[('title', 'RiGoR: reporting guidelines to address common sources of bias in risk model development'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting risk model development.'), ('Full bibliographic reference', 'Kerr KF, Meisner A, Thiessen-Philbrook H, Coca SG, Parikh CR. RiGoR: reporting guidelines to address common sources of bias in risk model development. Biomark Res. 2015;3(1):2.'), ('Language', 'English'), ('PubMed ID', '[25642328](http://www.ncbi.nlm.nih.gov/pubmed/25642328)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available from: <http://biomarkerres.biomedcentral.com/articles/10.1186/s40364-014-0027-7>'), ('Reporting guideline acronym', 'RiGoR'), ('Study design', 'Diagnostic and prognostic studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 26, 2021')]"
13496,Reporting standards for guideline-based performance measures,Clinical practice guidelines, , , ,"clinical practice guideline, clinical practice guidelines, guideline, guideline-based performance measures, guidelines, implementation, performance indicator, performance indicators, performance measure, performance measure development, performance measure re-evaluation, performance measurement, performance measures, practice guideline, practice guidelines, process assessment, quality, quality assurance, quality improvement, quality indicator, quality indicators, quality measure, quality measures, re-evaluation", ,"Nothacker M, Stokes T, Shaw B, Lindsay P, Sipil\xe4 R, Follmann M, Kopp I; Guidelines International Network (G-I-N) Performance Measures Working Group. Reporting standards for guideline-based performance measures. Implement Sci. 2016;11(1):6.","Nothacker M, Stokes T, Shaw B, Lindsay P, Sipil\xe4 R, Follmann M, Kopp I; Guidelines International Network (G-I-N) Performance Measures Working Group.",Implementation Science [Implement Sci.],2016,11,1,6, ,English, ,26772173,http://www.ncbi.nlm.nih.gov/pubmed/26772173,The full-text of this reporting guideline is freely available from: http://implementationscience.biomedcentral.com/articles/10.1186/s13012-015-0369-z, , , , , ,Reporting standards for guideline-based performance measure development and re-evaluation., , , , , , , ,no,2016-02-16 14:13:02,2021-11-26 17:02:47,reporting-standards-for-guideline-based-performance-measures,"[('title', 'Reporting standards for guideline-based performance measures'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting standards for guideline-based performance measure development and re-evaluation.'), ('Full bibliographic reference', 'Nothacker M, Stokes T, Shaw B, Lindsay P, Sipilä R, Follmann M, Kopp I; Guidelines International Network (G-I-N) Performance Measures Working Group. Reporting standards for guideline-based performance measures. Implement Sci. 2016;11(1):6.'), ('Language', 'English'), ('PubMed ID', '[26772173](http://www.ncbi.nlm.nih.gov/pubmed/26772173)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available from: <http://implementationscience.biomedcentral.com/articles/10.1186/s13012-015-0369-z>'), ('Study design', 'Clinical practice guidelines'), ('Record last updated on', 'November 26, 2021')]"
13494,Utstein-style guidelines on uniform reporting of in-hospital cardiopulmonary resuscitation in dogs and cats,"Clinical trials, Experimental studies, Observational studies",Emergency medicine,"Data, Intervention (exposure), Outcomes (variables), Study characteristics (participants etc.), Terminology/definitions", ,"animal, animals, cardiac, cardiac arrest, cardiopulmonary, cardiopulmonary arrest, cardiopulmonary emergencies, cardiopulmonary emergency, cardiopulmonary resuscitation, cardiopulmonary resuscitation studies, cardiopulmonary resuscitation study, cat, cats, CPA, CPR, CPR studies, CPR study, CPR terminology, dog, dogs, in hospital 'Utstein style', in hospital resuscitation, small animal, small animal veterinary medicine, small animals, Utstein, Utstein style, vet, veterinary, veterinary CPR research, veterinary in hospital, veterinary in hospital CPR studies, veterinary in hospital CPR study, veterinary medicine, veterinary practice, veterinary research", ,"Boller M, Fletcher DJ, Brainard BM, Haskins S, Hopper K, Nadkarni VM, Morley PT, McMichael M, Nishimura R, Robben JH, Rozanski E, Rudloff E, Rush J, Shih A, Smarick S, Tello LH. Utstein-style guidelines on uniform reporting of in-hospital cardiopulmonary resuscitation in dogs and cats. A RECOVER statement. J Vet Emerg Crit Care (San Antonio). 2016;26(1): 11-34.","Boller M, Fletcher DJ, Brainard BM, Haskins S, Hopper K, Nadkarni VM, Morley PT, McMichael M, Nishimura R, Robben JH, Rozanski E, Rudloff E, Rush J, Shih A, Smarick S, Tello LH.",Journal of Vetinary Emergency Medicine and Critical Care [J Vet Emerg Crit Care (San Antonio).],2016,26,1,11-34, ,English, ,26744261,http://www.ncbi.nlm.nih.gov/pubmed/26744261, , , , , , ,Reporting clinical in-hospital cardiopulmonary resuscitation (CPR) events in dogs and cats., , , , , , , ,no,2016-02-12 10:38:43,2017-02-16 15:10:23,utstein-style-guidelines-on-uniform-reporting-of-in-hospital-cardiopulmonary-resuscitation-in-dogs-and-cats,"[('title', 'Utstein-style guidelines on uniform reporting of in-hospital cardiopulmonary resuscitation in dogs and cats'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting clinical in-hospital cardiopulmonary resuscitation (CPR) events in dogs and cats.'), ('Full bibliographic reference', 'Boller M, Fletcher DJ, Brainard BM, Haskins S, Hopper K, Nadkarni VM, Morley PT, McMichael M, Nishimura R, Robben JH, Rozanski E, Rudloff E, Rush J, Shih A, Smarick S, Tello LH. Utstein-style guidelines on uniform reporting of in-hospital cardiopulmonary resuscitation in dogs and cats. A RECOVER statement. J Vet Emerg Crit Care (San Antonio). 2016;26(1): 11-34.'), ('Language', 'English'), ('PubMed ID', '[26744261](http://www.ncbi.nlm.nih.gov/pubmed/26744261)'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Emergency medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data, Intervention (exposure), Outcomes (variables), Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'February 16, 2017')]"
13491,Guidelines for reporting embedded recruitment trials,"Clinical trials, Experimental studies", ,Whole report, ,"checklist, clinical trial, clinical trials, cluster randomised embedded trial, cluster randomised embedded trials, cluster randomized embedded trial, cluster randomized embedded trials, embedded methodology trial, embedded methodology trials, embedded randomised controlled trial, embedded randomised controlled trials, embedded recruitment, embedded recruitment trial, embedded recruitment trials, embedded trial, embedded trials, host trial, host trials, patient, patient recruitment, patients, randomised controlled trial, randomised controlled trials, randomised embedded trial, randomised embedded trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized embedded trial, randomized embedded trials, randomized trial, randomized trials, RCT, RCTs, recruit, recruiting, recruitment, recruitment outcome, recruitment outcomes, recruitment strategies, recruitment strategy, trial, trial recruitment, trials", ,Madurasinghe VW; Sandra Eldridge on behalf of MRC START Group and Gordon Forbes on behalf of the START Expert Consensus Group. Guidelines for reporting embedded recruitment trials. Trials. 2016;17(1):27.,Madurasinghe VW; Sandra Eldridge on behalf of MRC START Group and Gordon Forbes on behalf of the START Expert Consensus Group.,Trials,2016,17,1,27, ,English, ,26767365,http://www.ncbi.nlm.nih.gov/pubmed/26767365,The full-text of this reporting guideline is available from: http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-015-1126-y, , , , , ,Reporting embedded recruitment trials., , , , , , , ,no,2016-02-12 09:29:38,2021-11-26 17:03:53,guidelines-for-reporting-embedded-recruitment-trials,"[('title', 'Guidelines for reporting embedded recruitment trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting embedded recruitment trials.'), ('Full bibliographic reference', 'Madurasinghe VW; Sandra Eldridge on behalf of MRC START Group and Gordon Forbes on behalf of the START Expert Consensus Group. Guidelines for reporting embedded recruitment trials. Trials. 2016;17(1):27.'), ('Language', 'English'), ('PubMed ID', '[26767365](http://www.ncbi.nlm.nih.gov/pubmed/26767365)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is available from: <http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-015-1126-y>'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 26, 2021')]"
13485,PRISMA harms checklist: improving harms reporting in systematic reviews,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Harms/adverse effects/safety data, ,"adverse, adverse drug interaction, adverse drug interactions, adverse drug reaction, adverse drug reactions, adverse effect, adverse effects, adverse event, adverse events, checklist, harm, harms, harms checklist, meta analyses, meta analysis, PRISMA, PRISMA extension, PRISMA harms, PRISMA harms checklist, review, reviews, systematic, systematic review, systematic reviews, unintended effects, zero", ,"Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157.","Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group.",British Medical Journal [BMJ.],2016,352, , , ,English, ,26830668,http://www.ncbi.nlm.nih.gov/pubmed/26830668,"The full-text of this reporting guideline is freely available at: http://www.bmj.com/content/352/bmj.i157

Please note that a correction has been made to the text in table 1 of this reporting guideline. Further details can be found on the BMJ website at: http://www.bmj.com/content/353/bmj.i2229?etoc

", , ,"Generic
PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

Specialised
PRISMA-Equity: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: 23222917

Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.
Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

PRISMA-Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.

PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246

PRISMA-IPD: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: 25919529

PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634

PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement &amp; Checklist. J Clin Epidemiol. 2017. PMID: 28720516

PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.\xa0PMID: 29362800

PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033

PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367

PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791

PRISMA-CHM: Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: 32907365

PRISMA-M 2020: Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: 33100229

PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.
Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535

PRISMA-LSR: Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: 39562017

",http://www.prisma-statement.org/Extensions/Harms,PRISMA harms,"Reporting harms in systematic reviews, whether harms are a primary or secondary outcome.



PRISMA-Harms checklist Word / PDF

", , , , , , , ,yes,2016-02-10 14:58:30,2025-02-06 12:00:51,prisma-harms,"[('title', 'PRISMA harms checklist: improving harms reporting in systematic reviews'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting harms in systematic reviews, whether harms are a primary or secondary outcome.\n\n \n\n \xa0\n\n \n\n PRISMA-Harms checklist [Word](https://www.prisma-statement.org/s/PRISMA-Harms-checklist-items.docx) / [PDF](https://www.prisma-statement.org/s/PRISMA-Harms-checklist-items.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157.'), ('Language', 'English'), ('PubMed ID', '[26830668](http://www.ncbi.nlm.nih.gov/pubmed/26830668)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available at: <http://www.bmj.com/content/352/bmj.i157>\n\n \n\n Please note that a correction has been made to the text in table 1 of this reporting guideline. Further details can be found on the BMJ website at: <http://www.bmj.com/content/353/bmj.i2229?etoc>\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n**[PRISMA 2020 Statement](http://dev.equator-network.org/reporting-guidelines/prisma/)**: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.\n\n \n\n PLoS Med. 2021;18(3):e1003583. PMID: [33780438](https://pubmed.ncbi.nlm.nih.gov/33780438/)\n\n BMJ 2021;372:n71. PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)\n\n Int J Surg. 2021:105906. PMID: [33789826](https://pubmed.ncbi.nlm.nih.gov/33789826/)\n\n J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: [33789819](https://pubmed.ncbi.nlm.nih.gov/33789819/)\n\n Syst Rev. 2021;10(1):89. PMID: [33781348](https://pubmed.ncbi.nlm.nih.gov/33781348/)\n\n \n\n**Specialised**\n\n[**PRISMA-Equity**](http://dev.equator-network.org/reporting-guidelines/prisma-equity/): Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: [23222917](http://www.ncbi.nlm.nih.gov/pubmed/23222917)\n\n \n\n Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.\n\n Int J Equity Health. 2015;14(1):92. PMID: [26450828](http://www.ncbi.nlm.nih.gov/pubmed/26450828)\n\n J Clin Epidemiol. 2015. PMID: [26348799](http://www.ncbi.nlm.nih.gov/pubmed/26348799)\n\n \n\n**[PRISMA-Abstracts 2020:](http://dev.equator-network.org/reporting-guidelines/prisma-abstracts/)** The PRISMA 2020 for Abstracts reporting guideline is contained within the main [PRISMA 2020 Statement paper](https://www.equator-network.org/reporting-guidelines/prisma/).\n\n \n\n**[PRISMA-P](http://dev.equator-network.org/reporting-guidelines/prisma-protocols/)**: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: [25554246](http://www.ncbi.nlm.nih.gov/pubmed/25554246)\n\n \n\n**[PRISMA-IPD](http://dev.equator-network.org/reporting-guidelines/prisma-ipd/)**: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: [25919529](http://www.ncbi.nlm.nih.gov/pubmed/25919529)\n\n \n\n**[PRISMA extension for network meta-analyses](http://dev.equator-network.org/reporting-guidelines/prisma-extension-network-meta-analyses/)**: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: [26030634](http://www.ncbi.nlm.nih.gov/pubmed/26030634)\n\n \n\n[**PRISMA-CI**](http://dev.equator-network.org/reporting-guidelines/prisma-ci-extension-statement-checklist/): Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: [28720516](https://www.ncbi.nlm.nih.gov/pubmed/28720516)\n\n \n\n[**PRISMA-DTA**](http://dev.equator-network.org/reporting-guidelines/prisma-dta/): McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.\xa0PMID: [29362800](https://www.ncbi.nlm.nih.gov/pubmed/29362800)\n\n \n\n[**PRISMA-ScR**](http://dev.equator-network.org/reporting-guidelines/prisma-scr/): Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: [30178033](https://www.ncbi.nlm.nih.gov/pubmed/30178033)\n\n \n\n[**PRISMA-A**](https://dev.equator-network.org/reporting-guidelines/prisma-acupuncture/): Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: [31405367](https://www.ncbi.nlm.nih.gov/pubmed/31405367)\n\n \n\n[**PRISMA-DTA for Abstracts**](https://dev.equator-network.org/reporting-guidelines/prisma-dta-for-abstracts/): Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: [33722791](https://pubmed.ncbi.nlm.nih.gov/33722791/)\n\n \n\n[**PRISMA-CHM**](https://www.equator-network.org/reporting-guidelines/prisma-chinese-herbal-medicines-2020/): Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: [32907365](https://pubmed.ncbi.nlm.nih.gov/32907365/)\n\n \n\n[**PRISMA-M 2020**](https://www.equator-network.org/reporting-guidelines/prisma-extension-for-moxibustion-2020/): Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: [33100229](https://pubmed.ncbi.nlm.nih.gov/33100229/)\n\n \n\n[**PRISMA-S**](https://dev.equator-network.org/reporting-guidelines/prisma-s/): Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.\n\n Syst Rev. 2021;10(1):39. PMID: [33499930](https://pubmed.ncbi.nlm.nih.gov/33499930/)\n\n J Med Libr Assoc. 2021;109(2):174-200. PMID: [34285662](https://pubmed.ncbi.nlm.nih.gov/34285662/)\n\n \n\n[**PRISMA-COSMIN for OMIs**](https://www.equator-network.org/reporting-guidelines/guideline-for-reporting-systematic-reviews-of-outcome-measurement-instruments-omis-prisma-cosmin-for-omis-2024/): Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.\n\n J Clin Epidemiol. 2024:111422. PMID: [38849061](https://pubmed.ncbi.nlm.nih.gov/38849061/)\n\n Qual Life Res. 2024. PMID: [38980635](https://pubmed.ncbi.nlm.nih.gov/38980635/)\n\n Health Qual Life Outcomes. 2024;22(1):48. PMID: [38978063](https://pubmed.ncbi.nlm.nih.gov/38978063/)\n\n J Patient Rep Outcomes. 2024;8(1):64. PMID: [38977535](https://pubmed.ncbi.nlm.nih.gov/38977535/)\n\n \n\n[**PRISMA-LSR**](https://www.equator-network.org/reporting-guidelines/prisma-lsr/): Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: [39562017](https://pubmed.ncbi.nlm.nih.gov/39562017/)\n\n \n\n""), ('Reporting guideline website URL', '<http://www.prisma-statement.org/Extensions/Harms>'), ('Reporting guideline acronym', 'PRISMA harms'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data'), ('Record last updated on', 'February 6, 2025')]"
13043,Developing a methodological framework for organisational case studies: a rapid review and consensus development process,"Mixed methods studies, Observational studies, Qualitative research, Quality improvement studies", ,"Data, Procedure/Method, Results, Statistical methods and analyses", ,"activities, activity, behavior, behaviour, case studies, case study, case study research, context, organisation, organisational, organisational case studies, organisational case study, organisational case study research, organisational change, organisational changes, organization, organizational, organizational case studies, organizational case study, organizational case study research, organizational change, organizational changes, real life, real world, service delivery", ,"Rodgers M, Thomas S, Harden M, Parker G, Street A, Eastwood A. Developing a methodological framework for organisational case studies: a rapid review and consensus development process. Health Serv Deliv Res. 2016;4(1).","Rodgers M, Thomas S, Harden M, Parker G, Street A, Eastwood A.",Health Services and Delivery Research [Health Serv Deliv Res.],2016,4,1, , ,English, ,26740990,http://www.ncbi.nlm.nih.gov/pubmed/26740990,"The full-text of this guideline is available from: https://www.journalslibrary.nihr.ac.uk/hsdr/hsdr04010#/full-report

The reporting checklist is available from: https://www.journalslibrary.nihr.ac.uk/hsdr/hsdr04010#/table11

", , , , , ,"To improve the consistency, rigour and reporting of organisational case study research, without constraining methodological freedom, thereby making it more accessible and useful to different audiences.", ,"Read an evidence summary (PDF) about this reporting guideline for organisational case studies.

", , , , , ,no,2016-01-08 14:51:21,2021-12-17 14:40:52,developing-a-methodological-framework-for-organisational-case-studies-a-rapid-review-and-consensus-development-process,"[('title', 'Developing a methodological framework for organisational case studies: a rapid review and consensus development process'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'To improve the consistency, rigour and reporting of organisational case study research, without constraining methodological freedom, thereby making it more accessible and useful to different audiences.'), ('Full bibliographic reference', 'Rodgers M, Thomas S, Harden M, Parker G, Street A, Eastwood A. Developing a methodological framework for organisational case studies: a rapid review and consensus development process. Health Serv Deliv Res. 2016;4(1).'), ('Language', 'English'), ('PubMed ID', '[26740990](http://www.ncbi.nlm.nih.gov/pubmed/26740990)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this guideline is available from: <https://www.journalslibrary.nihr.ac.uk/hsdr/hsdr04010#/full-report>\n\n \n\n The reporting checklist is available from: <https://www.journalslibrary.nihr.ac.uk/hsdr/hsdr04010#/table11>\n\n \n\n'), ('Study design', 'Mixed methods studies, Observational studies, Qualitative research, Quality improvement studies'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method, Results, Statistical methods and analyses'), ('Additional information', '[Read an evidence summary (PDF)](https://www.york.ac.uk/media/crd/Evidence-summary-organisational-case-studies.pdf) about this reporting guideline for organisational case studies.\n\n \n\n'), ('Record last updated on', 'December 17, 2021')]"
5555,The PRISMA 2020 statement: An updated guideline for reporting systematic reviews,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Whole report, ,"checklist, checklists, flow diagram, flow diagrams, meta analyses, meta analysis, PRISMA, PRISMA 2009, PRISMA 2020, PRISMA Statement, QUOROM, QUORUM, review, reviews, systematic, systematic review, systematic reviews", ,"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

This guideline was published simultaneously in 5 journals. You can read the guideline in any of these journals using the links below.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

","Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D.",PLoS Medicine [PLoS Med.],2021,18,3, , ,English, , , ,"The PRISMA 2020 Statement and Explanation and Elaboration document are available at: https://www.prisma-statement.org/prisma-2020

All versions (including a Shiny App) of the PRISMA 2020 checklist are available at: https://www.prisma-statement.org/prisma-2020-checklist

All versions (including a Shiny App) of the PRISMA 2020 flow diagram are available (for both new and updated systematic reviews) at: https://www.prisma-statement.org/prisma-2020-flow-diagram

","Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, McKenzie JE. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021;372:n160.
https://www.bmj.com/content/372/bmj.n160

","PRISMA 2009

QUOROM guideline (PRISMA replaces QUOROM)

","Specialised
PRISMA-Equity: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: 23222917

Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.
Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

PRISMA-Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.

PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246

PRISMA-IPD: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: 25919529

PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634

PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668

PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement &amp; Checklist. J Clin Epidemiol. 2017. PMID: 28720516

PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.\xa0PMID: 29362800

PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033

PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367

PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791

PRISMA-CHM: Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: 32907365

PRISMA-M 2020: Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: 33100229

PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.
Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535

PRISMA-LSR: Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: 39562017

",http://www.prisma-statement.org/,PRISMA 2020,"Reporting systematic reviews and meta-analyses.



PRISMA 2020 checklist (Word) \xa0\xa0\xa0\xa0\xa0\xa0\xa0 PRISMA 2020 checklist (PDF)

PRISMA 2020 expanded checklist (PDF) \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 PRISMA 2020 checklist (Shiny App)

","PRISMA 2020 translations
The PRISMA 2020 Statement is available in Italian (PDF), Croation (PDF), Greek (PDF), Japanese (PDF), Brazilian Portuguese (PDF), and Spanish (PDF).

The PRISMA 2020 Checklist is available in Chinese Simplified (Word), Chinese Traditional (PDF), French (Word), Greek (PDF), Japanese (PDF), Korean (Word), European Portuguese (Word), and Turkish (PDF).

The PRISMA 2020 for Abstracts Checklist is available in Chinese Simplified (Word), Chinese Traditional (PDF), Japanese (PDF), Korean (Word), European Portuguese (Word) and Turkish (PDF).

Additional translations (including flow diagrams) are available at https://www.prisma-statement.org/translations

PRISMA 2009 translations
A full-text copy of the PRISMA 2009 Statement is available in German (PDF), Italian (PDF) and Portuguese (PDF).

The PRISMA 2009 checklist is available in Korean (PDF), Portuguese (PDF), Russian (PDF), German (PDF), Japanese (PDF), Turkish (PDF) and Italian (PDF).

The PRISMA 2009 flow diagram is available in French (PDF), German (PDF), Italian (PDF), Korean (PDF), Russian (PDF), Japanese (PDF), Turkish (PDF) and Portuguese (PDF).

The PRISMA 2009 Explanation and Elaboration document is available in Italian (PDF).

Visit our translations page to find out what other reporting guidelines are available in languages other than English: reporting guideline translations

","Read the protocol for the PRISMA Statement update.

Read about the the processes used to update the PRISMA 2009 statement:
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Moher D. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103-112. PMID: 33577987

Guidance for developing protocols for systematic reviews and meta-analyses is provided in the PRISMA-P Statement. For further details please visit: PRISMA-P Statement

", , ,"An online fillable PRISMA 2020 checklist is also available via the GoodReports website at https://www.goodreports.org/reporting-checklists/prisma/.

", , ,yes,2015-10-15 11:30:26,2025-02-06 11:49:20,prisma,"[('title', 'The PRISMA 2020 statement: An updated guideline for reporting systematic reviews'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting systematic reviews and meta-analyses.\n\n \n\n \xa0\n\n \n\n[PRISMA 2020 checklist (Word)](https://www.prisma-statement.org/s/PRISMA_2020_checklist-gely.docx)  [PRISMA 2020 checklist (PDF)](https://www.prisma-statement.org/s/PRISMA_2020_checklist-djgh.pdf)\n\n \n\n[PRISMA 2020 expanded checklist (PDF)](https://www.prisma-statement.org/s/PRISMA_2020_expanded_checklist-rp3l.pdf)  [PRISMA 2020 checklist (Shiny App)](https://prisma.shinyapps.io/checklist/)\n\n \n\n'), ('Full bibliographic reference', 'Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.\n\n \n\n This guideline was published simultaneously in 5 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n PLoS Med. 2021;18(3):e1003583. PMID: [33780438](https://pubmed.ncbi.nlm.nih.gov/33780438/)\n\n BMJ 2021;372:n71. PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)\n\n Int J Surg. 2021:105906. PMID: [33789826](https://pubmed.ncbi.nlm.nih.gov/33789826/)\n\n J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: [33789819](https://pubmed.ncbi.nlm.nih.gov/33789819/)\n\n Syst Rev. 2021;10(1):89. PMID: [33781348](https://pubmed.ncbi.nlm.nih.gov/33781348/)\n\n \n\n'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The PRISMA 2020 Statement and Explanation and Elaboration document are available at: <https://www.prisma-statement.org/prisma-2020>\n\n \n\n All versions (including a Shiny App) of the PRISMA 2020 checklist are available at: <https://www.prisma-statement.org/prisma-2020-checklist>\n\n \n\n All versions (including a Shiny App) of the PRISMA 2020 flow diagram are available (for both new and updated systematic reviews) at: <https://www.prisma-statement.org/prisma-2020-flow-diagram>\n\n \n\n'), ('Explanation and elaboration papers', 'Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, McKenzie JE. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021;372:n160.\n\n<https://www.bmj.com/content/372/bmj.n160>\n\n \n\n'), ('Availability in additional languages', '**PRISMA 2020 translations**\n\n The PRISMA 2020 Statement is available in [Italian (PDF)](https://www.prisma-statement.org/s/PRISMA-2020-Italian.pdf), [Croation (PDF)](https://www.prisma-statement.org/s/PRISMA_2020_statement_Croatian.pdf), [Greek (PDF)](https://www.prisma-statement.org/s/PRISMA_2020_Statement_Greek.pdf), [Japanese (PDF)](https://www.prisma-statement.org/s/PRISMA_2020_Japanese.pdf), [Brazilian Portuguese (PDF)](https://www.prisma-statement.org/s/PRISMA-2020-statement-BRAZILIAN-PORTUGUESE.pdf), and [Spanish (PDF)](https://www.prisma-statement.org/s/PRISMA-2020-Spanish.pdf).\n\n \n\n The PRISMA 2020 Checklist is available in [Chinese Simplified (Word)](https://www.prisma-statement.org/s/PRISMA_2020_checklist_Chinese.docx), [Chinese Traditional (PDF)](https://www.prisma-statement.org/s/PRISMA_2020-checklist_Traditional-Chinese_update.pdf), [French (Word)](https://www.prisma-statement.org/s/PRISMA_2020_checklist_fr-b26g.docx), [Greek (PDF)](https://www.prisma-statement.org/s/PRISMA_2020_checklist_Greek.pdf), [Japanese (PDF)](https://www.prisma-statement.org/s/PRISMA-Japanese-Table-1-PRISMA-2020-item-checklist.pdf), [Korean (Word)](https://www.prisma-statement.org/s/PRISMA_2020_Korean_Checklist-dyx5.docx), [European Portuguese (Word)](https://www.prisma-statement.org/s/PRISMA-2020-checklist-EUROPEAN-PORTUGUESE-8rrx.docx), and [Turkish (PDF)](https://www.prisma-statement.org/s/PRISMA-2020-checklist-Turkish-version.pdf).\n\n \n\n The PRISMA 2020 for Abstracts Checklist is available in [Chinese Simplified (Word)](https://www.prisma-statement.org/s/PRISMA_2020_abstract_checklist_Chinese.docx), [Chinese Traditional (PDF)](https://www.prisma-statement.org/s/PRISMA_2020_Abs-checklist_Traditional-Chinese_new.pdf), [Japanese (PDF)](https://www.prisma-statement.org/s/PRISMA-Japanese-Table-2-PRISMA-2020-for-Abstracts-checklist.pdf), [Korean (Word)](https://www.prisma-statement.org/s/PRISMA_2020_Korean_Abstract_Checklist-jna2.docx), [European Portuguese (Word)](https://www.prisma-statement.org/s/PRISMA-2020-abstract-checklist-EUROPEAN-PORTUGUESE-cytw.docx) and [Turkish (PDF)](https://www.prisma-statement.org/s/PRISMA-2020-for-Abstract-checklist-Turkish-version.pdf).\n\n \n\n Additional translations (including flow diagrams) are available at <https://www.prisma-statement.org/translations>\n\n \n\n**PRISMA 2009 translations**\n\n A full-text copy of the PRISMA 2009 Statement is available in [German (PDF)](http://www.prisma-statement.org/documents/PRISMA%20German%20Statement.pdf), [Italian (PDF)](http://www.prisma-statement.org/documents/PRISMA%20Italian%20Statement.pdf) and [Portuguese (PDF)](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2237-96222015000200335&lng=en&nrm=iso&tlng=pt).\n\n \n\n The PRISMA 2009 checklist is available in [Korean (PDF)](http://www.prisma-statement.org/documents/PRISMA%20Korean%20checklist.pdf), [Portuguese (PDF)](http://www.prisma-statement.org/documents/PRISMA%20Portugese%20checklist.pdf), [Russian (PDF)](http://www.prisma-statement.org/documents/PRISMA%20Russian%20checklist.pdf), [German (PDF)](http://www.prisma-statement.org/documents/PRISMA%20German%20checklist.pdf), [Japanese (PDF)](http://www.prisma-statement.org/documents/PRISMA%20Japanese%20checklist.pdf), [Turkish (PDF)](http://www.prisma-statement.org/documents/PRISMA%20Turkish%20checklist.pdf) and [Italian (PDF)](http://www.prisma-statement.org/documents/PRISMA%20Italian%20checklist.pdf).\n\n \n\n The PRISMA 2009 flow diagram is available in [French (PDF)](http://www.prisma-statement.org/documents/PRISMA%20French%20Flow%20Diagram.pdf), [German (PDF)](http://www.prisma-statement.org/documents/PRISMA%20German%20flow%20diagram.pdf), [Italian (PDF)](http://www.prisma-statement.org/documents/PRISMA%20Italian%20flow%20diagram.pdf), [Korean (PDF)](http://www.prisma-statement.org/documents/PRISMA%20Korean%20flow%20diagram.pdf), [Russian (PDF)](http://www.prisma-statement.org/documents/PRISMA%20Russian%20flow%20diagram.pdf), [Japanese (PDF)](http://www.prisma-statement.org/documents/PRISMA%20Japanese%20flow%20diagram.pdf), [Turkish (PDF)](http://www.prisma-statement.org/documents/PRISMA%20Turkish%20flow%20diagram.pdf) and [Portuguese (PDF)](http://www.prisma-statement.org/documents/PRISMA%20Portugese%20flow%20diagram.pdf).\n\n \n\n The PRISMA 2009 Explanation and Elaboration document is available in [Italian (PDF)](http://www.prisma-statement.org/documents/PRISMA%20Italian%20EandE.pdf).\n\n \n\n Visit our translations page to find out what other reporting guidelines are available in languages other than English: [reporting guideline translations](/library/translations-of-reporting-guidelines/)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Specialised**\n\n[**PRISMA-Equity**](https://www.equator-network.org/reporting-guidelines/prisma-equity/): Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: [23222917](http://www.ncbi.nlm.nih.gov/pubmed/23222917)\n\n \n\n Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.\n\n Int J Equity Health. 2015;14(1):92. PMID: [26450828](http://www.ncbi.nlm.nih.gov/pubmed/26450828)\n\n J Clin Epidemiol. 2015. PMID: [26348799](http://www.ncbi.nlm.nih.gov/pubmed/26348799)\n\n \n\n[**PRISMA-Abstracts 2020**](https://www.equator-network.org/reporting-guidelines/prisma-abstracts/): The PRISMA 2020 for Abstracts reporting guideline is contained within the main [PRISMA 2020 Statement paper](https://www.equator-network.org/reporting-guidelines/prisma/).\n\n \n\n[**PRISMA-P**](https://www.equator-network.org/reporting-guidelines/prisma-protocols/): Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: [25554246](http://www.ncbi.nlm.nih.gov/pubmed/25554246)\n\n \n\n**[PRISMA-IPD](https://www.equator-network.org/reporting-guidelines/prisma-ipd/)**: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: [25919529](http://www.ncbi.nlm.nih.gov/pubmed/25919529)\n\n \n\n**[PRISMA extension for network meta-analyses](https://www.equator-network.org/reporting-guidelines/prisma-extension-network-meta-analyses/)**: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: [26030634](http://www.ncbi.nlm.nih.gov/pubmed/26030634)\n\n \n\n**[PRISMA-harms](https://www.equator-network.org/reporting-guidelines/prisma-harms/)**: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: [26830668](http://www.ncbi.nlm.nih.gov/pubmed/26830668)\n\n \n\n[**PRISMA-CI**](https://www.equator-network.org/reporting-guidelines/prisma-ci-extension-statement-checklist/): Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: [28720516](https://www.ncbi.nlm.nih.gov/pubmed/28720516)\n\n \n\n[**PRISMA-DTA**](https://www.equator-network.org/reporting-guidelines/prisma-dta/): McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.\xa0PMID: [29362800](https://www.ncbi.nlm.nih.gov/pubmed/29362800)\n\n \n\n[**PRISMA-ScR**](https://www.equator-network.org/reporting-guidelines/prisma-scr/): Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: [30178033](https://www.ncbi.nlm.nih.gov/pubmed/30178033)\n\n \n\n[**PRISMA-A**](https://www.equator-network.org/reporting-guidelines/prisma-acupuncture/): Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: [31405367](https://www.ncbi.nlm.nih.gov/pubmed/31405367)\n\n \n\n[**PRISMA-DTA for Abstracts**](https://www.equator-network.org/reporting-guidelines/prisma-dta-for-abstracts/): Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: [33722791](https://pubmed.ncbi.nlm.nih.gov/33722791/)\n\n \n\n[**PRISMA-CHM**](https://www.equator-network.org/reporting-guidelines/prisma-chinese-herbal-medicines-2020/): Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: [32907365](https://pubmed.ncbi.nlm.nih.gov/32907365/)\n\n \n\n[**PRISMA-M 2020**](https://www.equator-network.org/reporting-guidelines/prisma-extension-for-moxibustion-2020/): Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: [33100229](https://pubmed.ncbi.nlm.nih.gov/33100229/)\n\n \n\n[**PRISMA-S**](https://www.equator-network.org/reporting-guidelines/prisma-s/): Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.\n\n Syst Rev. 2021;10(1):39. PMID: [33499930](https://pubmed.ncbi.nlm.nih.gov/33499930/)\n\n J Med Libr Assoc. 2021;109(2):174-200. PMID: [34285662](https://pubmed.ncbi.nlm.nih.gov/34285662/)\n\n \n\n[**PRISMA-COSMIN for OMIs**](https://www.equator-network.org/reporting-guidelines/guideline-for-reporting-systematic-reviews-of-outcome-measurement-instruments-omis-prisma-cosmin-for-omis-2024/): Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.\n\n J Clin Epidemiol. 2024:111422. PMID: [38849061](https://pubmed.ncbi.nlm.nih.gov/38849061/)\n\n Qual Life Res. 2024. PMID: [38980635](https://pubmed.ncbi.nlm.nih.gov/38980635/)\n\n Health Qual Life Outcomes. 2024;22(1):48. PMID: [38978063](https://pubmed.ncbi.nlm.nih.gov/38978063/)\n\n J Patient Rep Outcomes. 2024;8(1):64. PMID: [38977535](https://pubmed.ncbi.nlm.nih.gov/38977535/)\n\n \n\n[**PRISMA-LSR**](https://www.equator-network.org/reporting-guidelines/prisma-lsr/): Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: [39562017](https://pubmed.ncbi.nlm.nih.gov/39562017/)\n\n \n\n""), ('Reporting guideline website URL', '<http://www.prisma-statement.org/>'), ('Reporting guideline acronym', 'PRISMA 2020'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Previous versions of this guideline / Guideline history', 'PRISMA 2009\n\n \n\n QUOROM guideline (PRISMA replaces QUOROM)\n\n \n\n'), ('Other', 'An online fillable PRISMA 2020 checklist is also available via the GoodReports website at <https://www.goodreports.org/reporting-checklists/prisma/>.\n\n \n\n'), ('Additional information', '[Read the protocol](https://osf.io/xwcv5/) for the PRISMA Statement update.\n\n \n\n Read about the the processes used to update the PRISMA 2009 statement:\n\n Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Moher D. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103-112. PMID: [33577987](https://pubmed.ncbi.nlm.nih.gov/33577987/)\n\n \n\n Guidance for developing protocols for systematic reviews and meta-analyses is provided in the PRISMA-P Statement. For further details please visit: [PRISMA-P Statement](/reporting-guidelines/prisma-protocols/)\n\n \n\n'), ('Record last updated on', 'February 6, 2025')]"
5540,The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies,Observational studies, ,Whole report, ,"analytical epidemiology, case control, case-control, checklist, checklists, cohort, cross sectional, epidemiology, observational, observational studies, observational study, STROBE, STROBE statement", ,"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

This guideline was published simultaneously in 8 journals. You can read the guideline in any of these journals using the links below.

Ann Intern Med. 2007; 147(8):573-577. PMID: 17938396
PLoS Med. 2007;4(10):e296. PMID: 17941714
BMJ. 2007;335(7624):806-808. PMID: 17947786
Prev Med. 2007;45(4):247-251. PMID: 17950122
Epidemiology. 2007;18(6):800-804. PMID: 18049194
Lancet. 2007;370(9596):1453-1457. PMID: 18064739
J Clin Epidemiol. 2008;61(4):344-349. PMID: 18313558
Bull World Health Organ. 2007;85(11):867-872. PMID: 18038077

","von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP", ,2007, , , , ,English, , , , ,"Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration.

The explanation and elaboration paper for this guideline was published simultaneously in 3 journals. You can read the explanation and elaboration paper in any of these journals using the links below.

PLoS Med. 2007;4(10):e297. PMID: 17941715
Epidemiology. 2007;18(6):805-35. PMID: 18049195
Ann Intern Med. 2007;147(8):W163-94. PMID: 17938389

The EQUATOR team edited a textbook called Guidelines for Reporting Health Research: A User?s Manual. It includes chapters on the guidelines most commonly required by journals. Read Chapter 17, on STROBE (PDF).

",STROBE 2004/2005,"Specialised
STREGA: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.

PLoS Med. 2009;6(2):e22. PMID: 19192942
Hum Genet. 2009;125(2):131-151. PMID: 19184668
Eur J Epidemiol. 2009;24(1):37-55. PMID: 19189221
Ann Intern Med. 2009;150(3):206-215. PMID: 19189911
J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: 19217256
Genet Epidemiol. 2009;33(7):581-598. PMID: 19278015
Eur J Clin Invest. 2009;39(4):247-266. PMID: 19297801

STROBE-ME: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: 22023344

STROBE checklist for conference abstracts
First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. Link to full text pdf

STROME-ID: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: 24631223

Longitudinal observational drug studies in rheumatology: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: 24058015

Case-cohort studies: Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: 24972092

STROBE-RDS: White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: 26112433

RECORD: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: 26440803

STROBE-AMS: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schr\xf6der W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: 26895985

STROBE-nut: Lachat C, Hawwash D, Ock\xe9 MC, Berg C, Forsum E, H\xf6rnell A, Larsson C, Sonestedt E, Wirf\xe4lt E, \xc5kesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology?Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: 27270749

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

ROSES-I: Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: 27417916

STROBE-NI: Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: 27633910

Propensity score analysis: Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: 28376195

RECORD-PE: Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.

STROBE-SIIS: International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, H\xe4gglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).

Br J Sports Med. 2020;54(7):372-389. PMID: 32071062
Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: 32118084

STROBE-MR: Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: 34698778

",https://www.strobe-statement.org/,STROBE,"Observational studies in epidemiology (cohort, case-control studies, cross-sectional studies)



STROBE checklist: combined\xa0\xa0\xa0\xa0\xa0\xa0\xa0 Word / PDF

STROBE checklist: cohort studies\xa0\xa0\xa0\xa0\xa0\xa0 Word / PDF

STROBE checklist: case-control studies\xa0\xa0\xa0\xa0\xa0\xa0\xa0 Word / PDF

STROBE checklist: cross-sectional studies\xa0\xa0\xa0\xa0\xa0\xa0\xa0 Word / PDF

","The STROBE Statement has been translated into the following languages: Chinese (PDF); German (PDF); Greek (PDF); Japanese (PDF); Portuguese (PDF) (unofficial translation); Spanish (PDF); Italian (PDF).

The STROBE explanation and elaboration paper has been translated into the following languages: Japanese (PDF); Spanish (PDF).

The STROBE checklist has been translated into the following languages: Persian (PDF); Turkish (PDF).

Visit our translations page to find out what other reporting guidelines are available in languages other than English: reporting guideline translations

","What is STROBE?
STROBE stands for an international, collaborative initiative of epidemiologists, methodologists, statisticians, researchers and journal editors involved in the conduct and dissemination of observational studies, with the common aim of STrengthening the Reporting of OBservational studies in Epidemiology.
The STROBE Statement is being endorsed by a growing number of biomedical journals.

Aims and use of STROBE
Incomplete and inadequate reporting of research hampers the assessment of the strengths and weaknesses of the studies reported in the medical literature. Readers need to know what was planned (and what was not), what was done, what was found, and what the results mean. Recommendations on the reporting of studies that are endorsed by leading medical journals can improve the quality of reporting.
Observational research comprises several study designs and many topic areas. We aimed to establish a checklist of items that should be included in articles reporting such research - the STROBE Statement. We considered it reasonable to initially restrict the recommendations to the three main analytical designs that are used in observational research: cohort, case-control, and cross-sectional studies. We want to provide guidance on how to report observational research well. Our recommendations are not prescriptions for designing or conducting studies. Also, the checklist is not an instrument to evaluate the quality of observational research.

Further use:
The STROBE initiative should be seen as an ongoing process, with future revisions of the recommendations based on comments, critique and new evidence. We welcome translations into other languages and extensions to other observational study designs, for example nested case-control studies, and specific topic areas, for example, genetic and molecular epidemiology.
Note: We ask anyone intending to use the STROBE Statement for further extensions, translations or other STROBE-related work to contact the coordinating group through this website first. This will allow to coordinate efforts and to avoid duplication. The authors of the original STROBE articles hold the copyright. Please, contact us if you wish to re-publish STROBE material in additional journals, books or other media.

Contact the STROBE Initiative

","Uhlig K, Menon V, Schmid CH. Recommendations for Reporting of Clinical Research Studies. Am J Kidney Dis. 2007;49(1):3-7. PMID: 17185140", ,"Online fillable STROBE checklists are available via the GoodReports website for:

Case control studies
Cohort studies
Cross sectional studies

", , ,yes,2015-10-15 11:30:00,2023-03-06 11:34:10,strobe,"[('title', 'The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Observational studies in epidemiology (cohort, case-control studies, cross-sectional studies)\n\n \n\n \xa0\n\n \n\n STROBE checklist: combined [Word](/wp-content/uploads/2015/10/STROBE_checklist_v4_combined.docx) / [PDF](/wp-content/uploads/2015/10/STROBE_checklist_v4_combined.pdf)\n\n \n\n STROBE checklist: cohort studies [Word](/wp-content/uploads/2015/10/STROBE_checklist_cohort.docx) / [PDF](/wp-content/uploads/2015/10/STROBE_checklist_v4_cohort.pdf)\n\n \n\n STROBE checklist: case-control studies [Word](/wp-content/uploads/2015/10/STROBE_checklist_case-control.doc) / [PDF](/wp-content/uploads/2015/10/STROBE_checklist_v4_case-control.pdf)\n\n \n\n STROBE checklist: cross-sectional studies [Word](/wp-content/uploads/2015/10/STROBE_checklist_cross-sectional.docx) / [PDF](/wp-content/uploads/2015/10/STROBE_checklist_v4_cross-sectional.pdf)\n\n \n\n'), ('Full bibliographic reference', 'von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.\n\n \n\n This guideline was published simultaneously in 8 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n Ann Intern Med. 2007; 147(8):573-577. PMID: [17938396](http://www.ncbi.nlm.nih.gov/pubmed/17938396)\n\n PLoS Med. 2007;4(10):e296. PMID: [17941714](http://www.ncbi.nlm.nih.gov/pubmed/17941714)\n\n BMJ. 2007;335(7624):806-808. PMID: [17947786](http://www.ncbi.nlm.nih.gov/pubmed/17947786)\n\n Prev Med. 2007;45(4):247-251. PMID: [17950122](http://www.ncbi.nlm.nih.gov/pubmed/17950122)\n\n Epidemiology. 2007;18(6):800-804. PMID: [18049194](http://www.ncbi.nlm.nih.gov/pubmed/18049194)\n\n Lancet. 2007;370(9596):1453-1457. PMID: [18064739\n\n](http://www.ncbi.nlm.nih.gov/pubmed/18064739)J Clin Epidemiol. 2008;61(4):344-349. PMID: [18313558\n\n](http://www.ncbi.nlm.nih.gov/pubmed/18313558)Bull World Health Organ. 2007;85(11):867-872. PMID: [18038077](http://www.ncbi.nlm.nih.gov/pubmed/18038077)\n\n \n\n'), ('Language', 'English'), ('Explanation and elaboration papers', 'Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration.\n\n \n\n The explanation and elaboration paper for this guideline was published simultaneously in 3 journals. You can read the explanation and elaboration paper in any of these journals using the links below.\n\n \n\n PLoS Med. 2007;4(10):e297. PMID: [17941715](http://www.ncbi.nlm.nih.gov/pubmed/17941715)\n\n Epidemiology. 2007;18(6):805-35. PMID: [18049195](http://www.ncbi.nlm.nih.gov/pubmed/18049195)\n\n Ann Intern Med. 2007;147(8):W163-94. PMID: [17938389](http://www.ncbi.nlm.nih.gov/pubmed/17938389)\n\n \n\n The EQUATOR team edited a textbook called *Guidelines for Reporting Health Research: A User’s Manual*. It includes chapters on the guidelines most commonly required by journals. [Read Chapter 17, on STROBE (PDF)](https://www.equator-network.org/wp-content/uploads/2016/12/CevallosEgger-Chapter-17-Guidelines-for-Reporting-Health-Research-A-Users-Manual.pdf).\n\n \n\n'), ('Availability in additional languages', 'The STROBE Statement has been translated into the following languages: [Chinese (PDF)](/wp-content/uploads/2015/10/STROBE-Chinese.pdf); [German (PDF)](/wp-content/uploads/2015/10/STROBE_German.pdf); [Greek (PDF)](/wp-content/uploads/2015/10/STROBE_Greek.pdf); [Japanese (PDF)](/wp-content/uploads/2015/10/STROBE-Japanese.pdf); [Portuguese (PDF)](/wp-content/uploads/2015/10/STROBE_Portuguese.pdf) (unofficial translation); [Spanish (PDF)](/wp-content/uploads/2015/10/STROBE_Spanish.pdf); [Italian (PDF)](/wp-content/uploads/2015/10/STROBE_Italian.pdf).\n\n \n\n The STROBE explanation and elaboration paper has been translated into the following languages: [Japanese (PDF)](/wp-content/uploads/2015/10/STROBE-Exp-JAPANESE.pdf); [Spanish (PDF)](/wp-content/uploads/2015/10/STROBE-Exp-SPANISH.pdf).\n\n \n\n The STROBE checklist has been translated into the following languages: [Persian (PDF)](/wp-content/uploads/2015/10/STROBE_Persian_Combined.pdf); [Turkish (PDF)](https://www.equator-network.org/wp-content/uploads/2021/04/STROBE-Turkish-translation.pdf).\n\n \n\n Visit our translations page to find out what other reporting guidelines are available in languages other than English: [reporting guideline translations](/library/translations-of-reporting-guidelines/)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Specialised\n\n[STREGA](/reporting-guidelines/strobe-strega/)**: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.\n\n \n\n PLoS Med. 2009;6(2):e22. PMID: [19192942](http://www.ncbi.nlm.nih.gov/pubmed/19192942)\n\n Hum Genet. 2009;125(2):131-151. PMID: [19184668](http://www.ncbi.nlm.nih.gov/pubmed/19184668)\n\n Eur J Epidemiol. 2009;24(1):37-55. PMID: [19189221](http://www.ncbi.nlm.nih.gov/pubmed/19189221)\n\n Ann Intern Med. 2009;150(3):206-215. PMID: [19189911](http://www.ncbi.nlm.nih.gov/pubmed/19189911)\n\n J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: [19217256](http://www.ncbi.nlm.nih.gov/pubmed/19217256)\n\n Genet Epidemiol. 2009;33(7):581-598. PMID: [19278015](http://www.ncbi.nlm.nih.gov/pubmed/19278015)\n\n Eur J Clin Invest. 2009;39(4):247-266. PMID: [19297801](http://www.ncbi.nlm.nih.gov/pubmed/19297801)\n\n \n\n[**STROBE-ME**](/reporting-guidelines/strobe-me/): Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: [22023344](http://www.ncbi.nlm.nih.gov/pubmed/22023344)\n\n \n\n[**STROBE checklist for conference abstracts**](/reporting-guidelines/strobe-abstracts/)\n\n First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. Link to [full text pdf](https://www.strobe-statement.org/download/strobe-checklist-conference-abstracts)\n\n \n\n**[STROME-ID](/reporting-guidelines/strome-id/)**: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: [24631223](http://www.ncbi.nlm.nih.gov/pubmed/24631223)\n\n \n\n[**Longitudinal observational drug studies in rheumatology**](/reporting-guidelines/launch-of-a-checklist-for-reporting-longitudinal-observational-drug-studies-in-rheumatology-a-eular-extension-of-strobe-guidelines-based-on-experience-from-biologics-registries/): Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: [24058015](http://www.ncbi.nlm.nih.gov/pubmed/24058015)\n\n \n\n[**Case-cohort studies**](/reporting-guidelines/a-review-of-published-analyses-of-case-cohort-studies-and-recommendations-for-future-reporting/): Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: [24972092](https://www.ncbi.nlm.nih.gov/pubmed/24972092)\n\n \n\n**[STROBE-RDS:](/reporting-guidelines/strobe-rds/)** White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: [26112433](http://www.ncbi.nlm.nih.gov/pubmed/26112433)\n\n \n\n**[RECORD](/reporting-guidelines/record/)**: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: [26440803](http://www.ncbi.nlm.nih.gov/pubmed/26440803)\n\n \n\n**[STROBE-AMS](/reporting-guidelines/strobe-ams/)**: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schröder W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: [26895985](http://www.ncbi.nlm.nih.gov/pubmed/26895985)\n\n \n\n[**STROBE-nut**](/reporting-guidelines/strobe-nut/): Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology—Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: [27270749](https://www.ncbi.nlm.nih.gov/pubmed/27270749)\n\n \n\n[**Simulation Research**](/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**ROSES-I**](/reporting-guidelines/roses-i-statement/): Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: [27417916](https://www.ncbi.nlm.nih.gov/pubmed/27417916)\n\n \n\n[**STROBE-NI**](/reporting-guidelines/strobe-ni/): Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: [27633910](https://www.ncbi.nlm.nih.gov/pubmed/27633910)\n\n \n\n[**Propensity score analysis**](/reporting-guidelines/reporting-and-guidelines-in-propensity-score-analysis-a-systematic-review-of-cancer-and-cancer-surgical-studies/): Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: [28376195](https://www.ncbi.nlm.nih.gov/pubmed/28376195)\n\n \n\n[**RECORD-PE**](/reporting-guidelines/record-pe/): Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). [BMJ 2018;363:k3532](https://www.bmj.com/content/363/bmj.k3532.full).\n\n \n\n[**STROBE-SIIS**](https://www.equator-network.org/reporting-guidelines/strobe-extension-for-sports-injury-illness-surveillance/): International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, Hägglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).\n\n \n\n Br J Sports Med. 2020;54(7):372-389. PMID: [32071062](https://pubmed.ncbi.nlm.nih.gov/32071062/)\n\n Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: [32118084](https://pubmed.ncbi.nlm.nih.gov/32118084/)\n\n \n\n[**STROBE-MR**](https://www.equator-network.org/reporting-guidelines/strobe-mr-statement/): Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: [34698778](https://pubmed.ncbi.nlm.nih.gov/34698778/)\n\n \n\n'), ('Reporting guideline website URL', '<https://www.strobe-statement.org/>'), ('Reporting guideline acronym', 'STROBE'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Previous versions of this guideline / Guideline history', 'STROBE 2004/2005'), ('Other', 'Online fillable STROBE checklists are available via the GoodReports website for:\n\n \n\n[Case control studies](https://www.goodreports.org/reporting-checklists/strobe-case-control/)\n\n[Cohort studies](https://www.goodreports.org/reporting-checklists/strobe-cohort/)\n\n[Cross sectional studies](https://www.goodreports.org/reporting-checklists/strobe-cross-sectional/)\n\n \n\n'), ('Additional information', '**What is STROBE?**\n\n STROBE stands for an international, collaborative initiative of epidemiologists, methodologists, statisticians, researchers and journal editors involved in the conduct and dissemination of observational studies, with the common aim of STrengthening the Reporting of OBservational studies in Epidemiology.\n\n The STROBE Statement is being endorsed by a growing number of biomedical journals.\n\n \n\n**Aims and use of STROBE**\n\n Incomplete and inadequate reporting of research hampers the assessment of the strengths and weaknesses of the studies reported in the medical literature. Readers need to know what was planned (and what was not), what was done, what was found, and what the results mean. Recommendations on the reporting of studies that are endorsed by leading medical journals can improve the quality of reporting.\n\n Observational research comprises several study designs and many topic areas. We aimed to establish a checklist of items that should be included in articles reporting such research - the STROBE Statement. We considered it reasonable to initially restrict the recommendations to the three main analytical designs that are used in observational research: cohort, case-control, and cross-sectional studies. We want to provide guidance on how to report observational research well. Our recommendations are not prescriptions for designing or conducting studies. Also, the checklist is not an instrument to evaluate the quality of observational research.\n\n \n\n Further use:\n\n The STROBE initiative should be seen as an ongoing process, with future revisions of the recommendations based on comments, critique and new evidence. We welcome translations into other languages and extensions to other observational study designs, for example nested case-control studies, and specific topic areas, for example, genetic and molecular epidemiology.\n\n Note: We ask anyone intending to use the STROBE Statement for further extensions, translations or other STROBE-related work to contact the coordinating group through this website first. This will allow to coordinate efforts and to avoid duplication. The authors of the original STROBE articles hold the copyright. Please, contact us if you wish to re-publish STROBE material in additional journals, books or other media.\n\n \n\n[Contact](https://www.strobe-statement.org/contact) the STROBE Initiative\n\n \n\n'), ('Selected relevant editorials', 'Uhlig K, Menon V, Schmid CH. Recommendations for Reporting of Clinical Research Studies. Am J Kidney Dis. 2007;49(1):3-7. PMID: [17185140](http://www.ncbi.nlm.nih.gov/pubmed/17185140 ""View the PubMed abstract"")'), ('Record last updated on', 'March 6, 2023')]"
12706,A checklist to improve reporting of group-based behaviour-change interventions,"Experimental studies, Mixed methods studies, Observational studies, Qualitative research",Behavioural medicine,"Intervention (exposure), Study characteristics (participants etc.)", ,"behavior, behavior change, behavior change intervention, behavior change interventions, behavioral, behavioral medicine, behavioral science, behaviour, behaviour change, behaviour change intervention, behaviour change interventions, behavioural, behavioural intervention, behavioural interventions, behavioural medicine, behavioural science, characteristic, characteristics, checklist, checklists, educational change process, educational change processes, facilitation, facilitator, facilitators, GB-BCI, GB-BCIs, group based intervention, group based interventions, group characterisation, group characterization, group context, group dynamic, group dynamics, group facilitation, group intervention, group interventions, group participants, group participation, group session, group sessions, group-based, group-based behavior-change intervention, group-based behavior-change interventions, group-based behaviour-change intervention, group-based behaviour-change interventions, group-based health intervention, group-based health interventions, group-focused, individual behavior, individual behaviors, individual behaviour, individual behaviours, individual change, individual changes, intervention, intervention delivery, intervention description, intervention descriptions, interventions, mechanism of change, mechanisms of change, participant, participant characteristic, participant characteristics, participants, psychological change process, psychological change processes", ,"Borek AJ, Abraham C, Smith JR, Greaves CJ, Tarrant M. A checklist to improve reporting of group-based behaviour-change interventions. BMC Public Health. 2015;15(1):963.","Borek AJ, Abraham C, Smith JR, Greaves CJ, Tarrant M.",BMC Public Health,2015,1, ,963, ,English, ,26403082,http://www.ncbi.nlm.nih.gov/pubmed/26403082,Read the full-text of this reporting guideline (PDF)., , , , , ,Reporting of group-based behaviour-change interventions, , , , , , , ,no,2015-10-14 09:26:28,2021-09-09 16:20:37,a-checklist-to-improve-reporting-of-group-based-behaviour-change-interventions,"[('title', 'A checklist to improve reporting of group-based behaviour-change interventions'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of group-based behaviour-change interventions'), ('Full bibliographic reference', 'Borek AJ, Abraham C, Smith JR, Greaves CJ, Tarrant M. A checklist to improve reporting of group-based behaviour-change interventions. BMC Public Health. 2015;15(1):963.'), ('Language', 'English'), ('PubMed ID', '[26403082](http://www.ncbi.nlm.nih.gov/pubmed/26403082)'), ('Relevant URLs\n\n(full-text if available)', 'Read the [full-text of this reporting guideline (PDF)](http://www.biomedcentral.com/content/pdf/s12889-015-2300-6.pdf).'), ('Study design', 'Experimental studies, Mixed methods studies, Observational studies, Qualitative research'), ('Clinical area', 'Behavioural medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Study characteristics (participants etc.)'), ('Record last updated on', 'September 9, 2021')]"
12678,The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement,Observational studies, ,Whole report, ,"administration, administrative, administrative data, checklist, checklists, data, disease registries, disease registry, electronic health record data repositories, electronic health record data repository, epidemiological surveillance, extension, health administrative data, health data, health record data, observational routinely collected data, observational routinely collected health data, observational studies, observational study, primary care database, primary care databases, public health data, public health reporting data, RECORD, RECORD guidelines, RECORD Statement, routinely, routinely collected, routinely collected data, routinely collected health data, STROBE, STROBE extension", ,"Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885.","Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee.",PLoS Medicine [PLoS Med.],2015,10,5, , ,English, ,26440803,http://www.ncbi.nlm.nih.gov/pubmed/26440803,"The full-text of this reporting guideline can be accessed at: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001885

", , ,"Generic
STROBE Statement: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Ann Intern Med. 2007;147(8):573-577. PMID: 17938396
PLoS Med. 2007;4(10):e296. PMID: 17941714
BMJ. 2007;335(7624):806-808. PMID: 17947786
Prev Med. 2007;45(4):247-251. PMID: 17950122
Epidemiology. 2007;18(6):800-804. PMID: 18049194
Lancet. 2007;370(9596):1453-1457. PMID: 18064739

Specialised
STREGA: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.

PLoS Med. 2009;6(2):e22. PMID: 19192942
Hum Genet. 2009;125(2):131-151. PMID: 19184668
Eur J Epidemiol. 2009;24(1):37-55. PMID: 19189221
Ann Intern Med. 2009;150(3):206-215. PMID: 19189911
J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: 19217256
Genet Epidemiol. 2009;33(7):581-598. PMID: 19278015
Eur J Clin Invest. 2009;39(4):247-266. PMID: 19297801

STROBE-ME: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: 22023344

STROBE checklist for conference abstracts
First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. Link to full text pdf

STROME-ID: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: 24631223

Longitudinal observational drug studies in rheumatology: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: 24058015

Case-cohort studies: Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: 24972092

STROBE-RDS: White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: 26112433

STROBE-AMS: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schr\xf6der W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: 26895985

STROBE-nut: Lachat C, Hawwash D, Ock\xe9 MC, Berg C, Forsum E, H\xf6rnell A, Larsson C, Sonestedt E, Wirf\xe4lt E, \xc5kesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology?Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: 27270749

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

ROSES-I: Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: 27417916

STROBE-NI: Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: 27633910

Propensity score analysis: Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: 28376195

RECORD-PE: Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.

STROBE-SIIS: International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, H\xe4gglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).

Br J Sports Med. 2020;54(7):372-389. PMID: 32071062
Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: 32118084

STROBE-MR: Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: 34698778

",http://record-statement.org/,RECORD,"Reporting items specific to observational studies using routinely collected health data.



RECORD Checklist (PDF)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 RECORD Checklist (Word)

","The RECORD Statement is available in:

German: PMID: 27837958
French:\xa0http://www.cmaj.ca/content/191/8/E216
Simplified Chinese: PDF
Japanese: PDF

","Information about the development of the RECORD statement is published in PLoS One:

Nicholls SG, Quach P, von Elm E, Guttmann A, Moher D, Petersen I, S\xf8rensen HT, Smeeth L, Langan SM, Benchimol EI. The REporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) Statement: Methods for Arriving at Consensus and Developing Reporting Guidelines. PLoS One. 2015;10(5):e0125620. PMID: 25965407

", , , , , ,yes,2015-10-07 14:05:55,2022-11-04 10:08:12,record,"[('title', 'The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting items specific to observational studies using routinely collected health data.\n\n \n\n \xa0\n\n \n\n[RECORD Checklist (PDF)](http://www.record-statement.org/Files/checklist/RECORD%20Checklist.pdf) [RECORD Checklist (Word)](http://www.record-statement.org/Files/checklist/RECORD%20Checklist.docx)\n\n \n\n'), ('Full bibliographic reference', 'Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885.'), ('Language', 'English'), ('PubMed ID', '[26440803](http://www.ncbi.nlm.nih.gov/pubmed/26440803)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline can be accessed at: <http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001885>\n\n \n\n'), ('Availability in additional languages', 'The RECORD Statement is available in:\n\n \n\n German: PMID: [27837958](https://www.ncbi.nlm.nih.gov/pubmed/27837958)\n\n French:<http://www.cmaj.ca/content/191/8/E216>\n\n Simplified Chinese: [PDF](https://docs.google.com/viewer?url=http://www.record-statement.org/Files/pubs/2017%20-%20Chinese%20Journal%20of%20Evidence-Based%20Medicine%20-%20RECORD.pdf)\n\n Japanese: [PDF](https://docs.google.com/viewer?url=http://www.record-statement.org/Files/pubs/RECORD_check_list_Japanese.pdf)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n**[STROBE Statement](/reporting-guidelines/strobe/)**: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.\n\n \n\n Ann Intern Med. 2007;147(8):573-577. PMID: [17938396](http://www.ncbi.nlm.nih.gov/pubmed/17938396)\n\n PLoS Med. 2007;4(10):e296. PMID: [17941714](http://www.ncbi.nlm.nih.gov/pubmed/17941714)\n\n BMJ. 2007;335(7624):806-808. PMID: [17947786](http://www.ncbi.nlm.nih.gov/pubmed/17947786)\n\n Prev Med. 2007;45(4):247-251. PMID: [17950122](http://www.ncbi.nlm.nih.gov/pubmed/17950122)\n\n Epidemiology. 2007;18(6):800-804. PMID: [18049194](http://www.ncbi.nlm.nih.gov/pubmed/18049194)\n\n Lancet. 2007;370(9596):1453-1457. PMID: [18064739](http://www.ncbi.nlm.nih.gov/pubmed/18064739)\n\n \n\n**Specialised**\n\n**[STREGA](/reporting-guidelines/strobe-strega/)**: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.\n\n \n\n PLoS Med. 2009;6(2):e22. PMID: [19192942](http://www.ncbi.nlm.nih.gov/pubmed/19192942)\n\n Hum Genet. 2009;125(2):131-151. PMID: [19184668](http://www.ncbi.nlm.nih.gov/pubmed/19184668)\n\n Eur J Epidemiol. 2009;24(1):37-55. PMID: [19189221](http://www.ncbi.nlm.nih.gov/pubmed/19189221)\n\n Ann Intern Med. 2009;150(3):206-215. PMID: [19189911](http://www.ncbi.nlm.nih.gov/pubmed/19189911)\n\n J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: [19217256](http://www.ncbi.nlm.nih.gov/pubmed/19217256)\n\n Genet Epidemiol. 2009;33(7):581-598. PMID: [19278015](http://www.ncbi.nlm.nih.gov/pubmed/19278015)\n\n Eur J Clin Invest. 2009;39(4):247-266. PMID: [19297801](http://www.ncbi.nlm.nih.gov/pubmed/19297801)\n\n \n\n**[STROBE-ME](/reporting-guidelines/strobe-me/)**: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: [22023344](http://www.ncbi.nlm.nih.gov/pubmed/22023344)\n\n \n\n**[STROBE checklist for conference abstracts](/reporting-guidelines/strobe-abstracts/)**\n\n First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. [Link to full text pdf](https://www.strobe-statement.org/download/strobe-checklist-conference-abstracts)\n\n \n\n**[STROME-ID](/reporting-guidelines/strome-id/)**: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: [24631223](http://www.ncbi.nlm.nih.gov/pubmed/24631223)\n\n \n\n**[Longitudinal observational drug studies in rheumatology](/reporting-guidelines/launch-of-a-checklist-for-reporting-longitudinal-observational-drug-studies-in-rheumatology-a-eular-extension-of-strobe-guidelines-based-on-experience-from-biologics-registries/)**: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: [24058015](http://www.ncbi.nlm.nih.gov/pubmed/24058015)\n\n \n\n[**Case-cohort studies**](/reporting-guidelines/a-review-of-published-analyses-of-case-cohort-studies-and-recommendations-for-future-reporting/): Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: [24972092](https://www.ncbi.nlm.nih.gov/pubmed/24972092)\n\n \n\n**[STROBE-RDS](/reporting-guidelines/strobe-rds/)**: White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: [26112433](http://www.ncbi.nlm.nih.gov/pubmed/26112433)\n\n \n\n**[STROBE-AMS](/reporting-guidelines/strobe-ams/)**: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schröder W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: [26895985](http://www.ncbi.nlm.nih.gov/pubmed/26895985)\n\n \n\n[**STROBE-nut**](/reporting-guidelines/strobe-nut/): Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology—Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: [27270749](https://www.ncbi.nlm.nih.gov/pubmed/27270749)\n\n \n\n[**Simulation Research**](/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**ROSES-I**](/reporting-guidelines/roses-i-statement/): Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: [27417916](https://www.ncbi.nlm.nih.gov/pubmed/27417916)\n\n \n\n[**STROBE-NI**](/reporting-guidelines/strobe-ni/): Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: [27633910](https://www.ncbi.nlm.nih.gov/pubmed/27633910)\n\n \n\n[**Propensity score analysis**](/reporting-guidelines/reporting-and-guidelines-in-propensity-score-analysis-a-systematic-review-of-cancer-and-cancer-surgical-studies/): Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: [28376195](https://www.ncbi.nlm.nih.gov/pubmed/28376195)\n\n \n\n[**RECORD-PE**](/reporting-guidelines/record-pe/): Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). [BMJ 2018;363:k3532](https://www.bmj.com/content/363/bmj.k3532.full).\n\n \n\n[**STROBE-SIIS**](https://www.equator-network.org/reporting-guidelines/strobe-extension-for-sports-injury-illness-surveillance/): International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, Hägglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).\n\n \n\n Br J Sports Med. 2020;54(7):372-389. PMID: [32071062](https://pubmed.ncbi.nlm.nih.gov/32071062/)\n\n Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: [32118084](https://pubmed.ncbi.nlm.nih.gov/32118084/)\n\n \n\n[**STROBE-MR**](https://www.equator-network.org/reporting-guidelines/strobe-mr-statement/): Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: [34698778](https://pubmed.ncbi.nlm.nih.gov/34698778/)\n\n \n\n'), ('Reporting guideline website URL', '<http://record-statement.org/>'), ('Reporting guideline acronym', 'RECORD'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Information about the development of the RECORD statement is published in PLoS One:\n\n \n\n Nicholls SG, Quach P, von Elm E, Guttmann A, Moher D, Petersen I, Sørensen HT, Smeeth L, Langan SM, Benchimol EI. The REporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) Statement: Methods for Arriving at Consensus and Developing Reporting Guidelines. PLoS One. 2015;10(5):e0125620. PMID: [25965407](http://www.ncbi.nlm.nih.gov/pubmed/25965407)\n\n \n\n'), ('Record last updated on', 'November 4, 2022')]"
12540,Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement,Economic evaluations, ,Whole report, ,"algorithm, algorithms, checklist, cost, costs, economic, economic evaluation, economic evaluation studies, economic evaluation study, economic evaluations, economics, health economic evaluation, health economic evaluations, health economics, health utility, map, mapping, mapping onto preference based measures reporting standards, mapping research, mapping studies, mapping study, maps, MAPS statement, outcome, outcome measure, outcome measures, outcomes, preference based", ,"Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, Gray A. Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement.

J Med Econ. 2015;1-7. PMID: 26295698
Int J Technol Assess Health Care. 2015;31(4):1-6. PMID: 26235547
Health Qual Life Outcomes. 2015;13(1):106. PMID: 26232268
Pharmacoeconomics. 2015. PMID: 26232201
Appl Health Econ Health Policy. 2015. PMID: 26231987
Qual Life Res. 2015. PMID: 26231589
Medical Decision Making. 2015. Full-text article","Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, Gray A.", ,2015, , , , ,English, , , , ,"Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, Gray A. The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration. Pharmacoeconomics. 2015. PMID: 26232200", , , ,MAPS,Reporting of studies that map onto generic preference-based outcome measures., , , , , , , ,no,2015-09-08 13:26:51,2021-12-17 15:08:50,maps-statement,"[('title', 'Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of studies that map onto generic preference-based outcome measures.'), ('Full bibliographic reference', 'Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, Gray A. Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement.\n\n \n\n J Med Econ. 2015;1-7. PMID: [26295698](http://www.ncbi.nlm.nih.gov/pubmed/26295698)\n\n Int J Technol Assess Health Care. 2015;31(4):1-6. PMID: [26235547](http://www.ncbi.nlm.nih.gov/pubmed/26235547)\n\n Health Qual Life Outcomes. 2015;13(1):106. PMID: [26232268](http://www.ncbi.nlm.nih.gov/pubmed/26232268)\n\n Pharmacoeconomics. 2015. PMID: [26232201](http://www.ncbi.nlm.nih.gov/pubmed/26232201)\n\n Appl Health Econ Health Policy. 2015. PMID: [26231987](http://www.ncbi.nlm.nih.gov/pubmed/26231987)\n\n Qual Life Res. 2015. PMID: [26231589](http://www.ncbi.nlm.nih.gov/pubmed/26231589)\n\n Medical Decision Making. 2015. [Full-text article](http://mdm.sagepub.com/content/35/6/NP1.full)'), ('Language', 'English'), ('Explanation and elaboration papers', 'Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, Gray A. The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration. Pharmacoeconomics. 2015. PMID: [26232200](http://www.ncbi.nlm.nih.gov/pubmed/26232200)'), ('Reporting guideline acronym', 'MAPS'), ('Study design', 'Economic evaluations'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'December 17, 2021')]"
12441,A call for transparent reporting to optimize the predictive value of preclinical research,Animal pre-clinical research, ,"Data, Statistical methods and analyses", ,"Ad hoc, animal, animal experiment, animal experiments, animal preclinical research, animal research, animal studies, animal study, blinding, data, data analyses, data analysis, data handling, effect size, effect sizes, end point, end points, preclinical, preclinical animal research, preclinical research, preclinical studies, preclinical study, predictive, predictive value, randomisation, randomised, randomization, randomized, sample size, sample sizes, statistic, statistical, statistical analyses, statistical analysis, statistics, US National Institute of Neurological Disorders and Stroke, US National Institute of Neurological Disorders and Stroke (NINDS)", ,"Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490(7419): 187-191.","Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD.",Nature.,2012,490,7419,187-191, ,English, ,23060188,http://www.ncbi.nlm.nih.gov/pubmed/23060188, , , , , , ,For improving how the results of animal research are reported in manuscripts and grant applications., , , , , , , ,no,2015-08-10 14:08:30,2017-02-16 14:40:32,a-call-for-transparent-reporting-to-optimize-the-predictive-value-of-preclinical-research,"[('title', 'A call for transparent reporting to optimize the predictive value of preclinical research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'For improving how the results of animal research are reported in manuscripts and grant applications.'), ('Full bibliographic reference', 'Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490(7419): 187-191.'), ('Language', 'English'), ('PubMed ID', '[23060188](http://www.ncbi.nlm.nih.gov/pubmed/23060188)'), ('Study design', 'Animal pre-clinical research'), ('Applies to the whole report or to individual sections of the report?', 'Data, Statistical methods and analyses'), ('Record last updated on', 'February 16, 2017')]"
12390,Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders, ,Neurology,"Biospecimen/bioresource information, Whole report", ,"biomarker, biomarker studies, biomarker study, biomarkers, BioMS-eu, BioMS-eu consortium, body fluid, body fluid biomarker, body fluid biomarker research, body fluid biomarker studies, body fluid biomarker study, body fluid biomarkers, body fluids, checklist, checklists, fluid, fluids, MS, multiple sclerosis, neurologic, neurologic disorder, neurologic disorders, neurological, neurological disorder, neurological disorders, neurology, neuroscience, neuroscience biomarkers, neurosciences", ,"Gnanapavan S, Hegen H, Khalil M, Hemmer B, Franciotta D, Hughes S, Hintzen R, Jeromin A, Havrdova E, Tumani H, Bertolotto A, Comabella M, Frederiksen J, \xc1lvarez-Cerme\xf1o JC, Villar L, Galimberti D, Myhr KM, Dujmovic I, Fazekas F, Ionete C, Menge T, Kuhle J, Keir G, Deisenhammer F, Teunissen C, Giovannoni G. Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology. 2014;83(13):1210-1216.","Gnanapavan S, Hegen H, Khalil M, Hemmer B, Franciotta D, Hughes S, Hintzen R, Jeromin A, Havrdova E, Tumani H, Bertolotto A, Comabella M, Frederiksen J, \xc1lvarez-Cerme\xf1o JC, Villar L, Galimberti D, Myhr KM, Dujmovic I, Fazekas F, Ionete C, Menge T, Kuhle J, Keir G, Deisenhammer F, Teunissen C, Giovannoni G.",Neurology,2014,83,13,1210-1216, ,English, ,25150289,http://www.ncbi.nlm.nih.gov/pubmed/25150289, , , , , , ,Reporting body fluid biomarker research studies in neurologic disorders., , , , , , , ,no,2015-07-13 10:31:13,2015-07-13 10:31:13,guidelines-for-uniform-reporting-of-body-fluid-biomarker-studies-in-neurologic-disorders,"[('title', 'Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting body fluid biomarker research studies in neurologic disorders.'), ('Full bibliographic reference', 'Gnanapavan S, Hegen H, Khalil M, Hemmer B, Franciotta D, Hughes S, Hintzen R, Jeromin A, Havrdova E, Tumani H, Bertolotto A, Comabella M, Frederiksen J, Álvarez-Cermeño JC, Villar L, Galimberti D, Myhr KM, Dujmovic I, Fazekas F, Ionete C, Menge T, Kuhle J, Keir G, Deisenhammer F, Teunissen C, Giovannoni G. Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology. 2014;83(13):1210-1216.'), ('Language', 'English'), ('PubMed ID', '[25150289](http://www.ncbi.nlm.nih.gov/pubmed/25150289)'), ('Clinical area', 'Neurology'), ('Applies to the whole report or to individual sections of the report?', 'Biospecimen/bioresource information, Whole report'), ('Record last updated on', 'July 13, 2015')]"
12378,The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Whole report, ,"checklist, extension, meta analyses, meta analysis, mixed treatment, mixed treatment comparisons meta analyses, mixed treatment comparisons meta analysis, mixed treatments, multiple treatment, multiple treatment comparison, multiple treatment comparisons, multiple treatments meta analyses, multiple treatments meta analysis, network, network graph, network graphs, network meta analyses, network meta analysis, networks, PRISMA, PRISMA extension, PRISMA Statement, review, reviews, synthesis method, synthesis methods, systematic, systematic review, systematic reviews", ,"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784.","Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D.",Annals of Internal Medicine [Ann Intern Med.],2015,162,11,777-784, ,English, ,26030634,http://www.ncbi.nlm.nih.gov/pubmed/26030634, , , ,"Generic
PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

Specialised
PRISMA-Equity: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: 23222917

Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.
Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

PRISMA-Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.

PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246

PRISMA-IPD: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: 25919529

PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668

PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement &amp; Checklist. J Clin Epidemiol. 2017. PMID: 28720516

PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.\xa0PMID: 29362800

PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033

PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367

PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791

PRISMA-CHM: Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: 32907365

PRISMA-M 2020: Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: 33100229

PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.
Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535

PRISMA-LSR: Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: 39562017

",http://www.prisma-statement.org/Extensions/NetworkMetaAnalysis, ,"Reporting systematic reviews that incorporate network meta-analyses.



PRISMA-NMA checklist Word / PDF

", , , , , , , ,yes,2015-07-07 09:56:30,2025-02-06 11:59:07,prisma-extension-network-meta-analyses,"[('title', 'The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting systematic reviews that incorporate network meta-analyses.\n\n \n\n \xa0\n\n \n\n PRISMA-NMA checklist [Word](https://www.prisma-statement.org/s/PRISMA-NMA-checklist.docx) / [PDF](https://www.prisma-statement.org/s/PRISMA-NMA-checklist.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784.'), ('Language', 'English'), ('PubMed ID', '[26030634](http://www.ncbi.nlm.nih.gov/pubmed/26030634)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n[**PRISMA 2020 Statement**](http://dev.equator-network.org/reporting-guidelines/prisma/): Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.\n\n \n\n PLoS Med. 2021;18(3):e1003583. PMID: [33780438](https://pubmed.ncbi.nlm.nih.gov/33780438/)\n\n BMJ 2021;372:n71. PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)\n\n Int J Surg. 2021:105906. PMID: [33789826](https://pubmed.ncbi.nlm.nih.gov/33789826/)\n\n J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: [33789819](https://pubmed.ncbi.nlm.nih.gov/33789819/)\n\n Syst Rev. 2021;10(1):89. PMID: [33781348](https://pubmed.ncbi.nlm.nih.gov/33781348/)\n\n \n\n**Specialised**\n\n[**PRISMA-Equity**](http://dev.equator-network.org/reporting-guidelines/prisma-equity/): Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: [23222917](http://www.ncbi.nlm.nih.gov/pubmed/23222917)\n\n \n\n Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.\n\n Int J Equity Health. 2015;14(1):92. PMID: [26450828](http://www.ncbi.nlm.nih.gov/pubmed/26450828)\n\n J Clin Epidemiol. 2015. PMID: [26348799](http://www.ncbi.nlm.nih.gov/pubmed/26348799)\n\n \n\n**[PRISMA-Abstracts 2020:](http://dev.equator-network.org/reporting-guidelines/prisma-abstracts/)** The PRISMA 2020 for Abstracts reporting guideline is contained within the main [PRISMA 2020 Statement paper](https://www.equator-network.org/reporting-guidelines/prisma/).\n\n \n\n**[PRISMA-P](http://dev.equator-network.org/reporting-guidelines/prisma-protocols/)**: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: [25554246](http://www.ncbi.nlm.nih.gov/pubmed/25554246)\n\n \n\n**[PRISMA-IPD](http://dev.equator-network.org/reporting-guidelines/prisma-ipd/)**: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: [25919529](http://www.ncbi.nlm.nih.gov/pubmed/25919529)\n\n \n\n[**PRISMA-harms**](http://dev.equator-network.org/reporting-guidelines/prisma-harms/): Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: [26830668](http://www.ncbi.nlm.nih.gov/pubmed/26830668)\n\n \n\n[**PRISMA-CI**](http://dev.equator-network.org/reporting-guidelines/prisma-ci-extension-statement-checklist/): Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: [28720516](https://www.ncbi.nlm.nih.gov/pubmed/28720516)\n\n \n\n[**PRISMA-DTA**](http://dev.equator-network.org/reporting-guidelines/prisma-dta/): McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.\xa0PMID: [29362800](https://www.ncbi.nlm.nih.gov/pubmed/29362800)\n\n \n\n[**PRISMA-ScR**](http://dev.equator-network.org/reporting-guidelines/prisma-scr/): Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: [30178033](https://www.ncbi.nlm.nih.gov/pubmed/30178033)\n\n \n\n[**PRISMA-A**](https://dev.equator-network.org/reporting-guidelines/prisma-acupuncture/): Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: [31405367](https://www.ncbi.nlm.nih.gov/pubmed/31405367)\n\n \n\n[**PRISMA-DTA for Abstracts**](https://dev.equator-network.org/reporting-guidelines/prisma-dta-for-abstracts/): Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: [33722791](https://pubmed.ncbi.nlm.nih.gov/33722791/)\n\n \n\n[**PRISMA-CHM**](https://www.equator-network.org/reporting-guidelines/prisma-chinese-herbal-medicines-2020/): Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: [32907365](https://pubmed.ncbi.nlm.nih.gov/32907365/)\n\n \n\n[**PRISMA-M 2020**](https://www.equator-network.org/reporting-guidelines/prisma-extension-for-moxibustion-2020/): Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: [33100229](https://pubmed.ncbi.nlm.nih.gov/33100229/)\n\n \n\n[**PRISMA-S**](https://dev.equator-network.org/reporting-guidelines/prisma-s/): Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.\n\n Syst Rev. 2021;10(1):39. PMID: [33499930](https://pubmed.ncbi.nlm.nih.gov/33499930/)\n\n J Med Libr Assoc. 2021;109(2):174-200. PMID: [34285662](https://pubmed.ncbi.nlm.nih.gov/34285662/)\n\n \n\n[**PRISMA-COSMIN for OMIs**](https://www.equator-network.org/reporting-guidelines/guideline-for-reporting-systematic-reviews-of-outcome-measurement-instruments-omis-prisma-cosmin-for-omis-2024/): Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.\n\n J Clin Epidemiol. 2024:111422. PMID: [38849061](https://pubmed.ncbi.nlm.nih.gov/38849061/)\n\n Qual Life Res. 2024. PMID: [38980635](https://pubmed.ncbi.nlm.nih.gov/38980635/)\n\n Health Qual Life Outcomes. 2024;22(1):48. PMID: [38978063](https://pubmed.ncbi.nlm.nih.gov/38978063/)\n\n J Patient Rep Outcomes. 2024;8(1):64. PMID: [38977535](https://pubmed.ncbi.nlm.nih.gov/38977535/)\n\n \n\n[**PRISMA-LSR**](https://www.equator-network.org/reporting-guidelines/prisma-lsr/): Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: [39562017](https://pubmed.ncbi.nlm.nih.gov/39562017/)\n\n \n\n""), ('Reporting guideline website URL', '<http://www.prisma-statement.org/Extensions/NetworkMetaAnalysis>'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'February 6, 2025')]"
12375,Setting number of decimal places for reporting risk ratios: rule of four, , ,Statistical methods and analyses, ,"data, decimal, decimal place, decimal places, decimal point, fractional, fractional error, hazard ratio, hazard ratios, numerical, numerical data, odds ratio, odds ratios, precision, rate ratio, rate ratios, ratio, relative risk, relative risks, risk, risk ratio, risk ratios, rounding, rule of 4, rule of four, significant digit, significant digits, summary statistic, summary statistics", ,Cole TJ. Setting number of decimal places for reporting risk ratios: rule of four. BMJ. 2015;350:h1845.,Cole TJ.,British Medical Journal [BMJ.],2015, , , , ,English, ,25918351,http://www.ncbi.nlm.nih.gov/pubmed/25918351,The full-text of this reporting guideline is freely available from: http://www.bmj.com/content/350/bmj.h1845, , , , , ,A simple framework to guide authors in the appropriate number of decimal places to use when reporting risk ratios., , , , , , , ,no,2015-07-06 10:24:12,2021-12-17 15:15:23,setting-number-of-decimal-places-for-reporting-risk-ratios-rule-of-four,"[('title', 'Setting number of decimal places for reporting risk ratios: rule of four'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'A simple framework to guide authors in the appropriate number of decimal places to use when reporting risk ratios.'), ('Full bibliographic reference', 'Cole TJ. Setting number of decimal places for reporting risk ratios: rule of four. BMJ. 2015;350:h1845.'), ('Language', 'English'), ('PubMed ID', '[25918351](http://www.ncbi.nlm.nih.gov/pubmed/25918351)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available from: <http://www.bmj.com/content/350/bmj.h1845>'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Record last updated on', 'December 17, 2021')]"
12373,Too many digits: the presentation of numerical data, , ,Statistical methods and analyses, ,"data, decimal, decimal place, decimal places, decimal point, digit, digits, number, numbers, numerical data, precision, rounding, rule of 4, rule of four, significant digit, significant digits, statistic, statistical, statistical analyses, statistical analysis, statistical data, statistical method, statistical methods, statistical result, statistical results, statistics, summary statistic, summary statistics", ,Cole TJ. Too many digits: the presentation of numerical data. Arch Dis Child. 2015;100(7):608-609.,Cole TJ.,Archives of Disease in Childhood [Arch Dis Child.],2015,100,7,608-609, ,English, ,25877157,http://www.ncbi.nlm.nih.gov/pubmed/25877157,The full-text of this reporting guideline is freely available from: http://adc.bmj.com/content/100/7/608.long, , , , , ,Recommendations for rounding summary statistics., , , , , , , ,no,2015-07-06 09:43:30,2021-12-17 15:16:49,too-many-digits-the-presentation-of-numerical-data,"[('title', 'Too many digits: the presentation of numerical data'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Recommendations for rounding summary statistics.'), ('Full bibliographic reference', 'Cole TJ. Too many digits: the presentation of numerical data. Arch Dis Child. 2015;100(7):608-609.'), ('Language', 'English'), ('PubMed ID', '[25877157](http://www.ncbi.nlm.nih.gov/pubmed/25877157)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is freely available from: <http://adc.bmj.com/content/100/7/608.long>'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Record last updated on', 'December 17, 2021')]"
12038,The CONSORT Statement: Application within and adaptations for orthodontic trials,"Clinical trials, Experimental studies",Dentistry,Whole report, ,"checklist, clinical trial, clinical trials, CONSORT, CONSORT extension, Dentist, Dentistry, orthodontic, orthodontics, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679.","Pandis N, Fleming PS, Hopewell S, Altman DG.",American Journal of Orthodontics and Dentofacial Orthopedics [Am J Orthod Dentofacial Orthop],2015,147,6,663-679, ,English, ,26038070,http://www.ncbi.nlm.nih.gov/pubmed/26038070, , , ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", , ,Reporting randomised controlled trials in orthodontics, , , , , , , ,yes,2015-06-09 14:44:37,2025-05-30 09:19:12,the-consort-statement-application-within-and-adaptations-for-orthodontic-trials,"[('title', 'The CONSORT Statement: Application within and adaptations for orthodontic trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting randomised controlled trials in orthodontics'), ('Full bibliographic reference', 'Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679.'), ('Language', 'English'), ('PubMed ID', '[26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n**[CONSORT 2025 Statement](http://dev.equator-network.org/reporting-guidelines/consort/)**:\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n**[CONSORT Harms](http://dev.equator-network.org/reporting-guidelines/consort-harms/)**: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n**[CONSORT Non-inferiority](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/)**: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n**[CONSORT Cluster](http://dev.equator-network.org/reporting-guidelines/consort-cluster/)**:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n**[CONSORT Herbal](http://dev.equator-network.org/reporting-guidelines/consort-herbal/)**:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n**[CONSORT Non-pharmacological treatment interventions](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/)**: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n**[CONSORT Abstracts](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/)**:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n**[CONSORT Pragmatic Trials](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/)**: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n**[STRICTA Controlled trials of acupuncture](http://dev.equator-network.org/reporting-guidelines/consort-stricta/)**:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n**[CONSORT PRO](http://dev.equator-network.org/reporting-guidelines/consort-pro/)**: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n**[CONSORT-CENT](http://dev.equator-network.org/reporting-guidelines/consort-cent/)**: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n**[TIDieR](http://dev.equator-network.org/reporting-guidelines/tidier/)**: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Dentistry'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 30, 2025')]"
12026,A structured approach to documenting a search strategy for publication: a 12 step guideline for authors,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Procedure/Method, ,"bibliographic database, bibliographic databases, database search, database searches, literature review, literature reviews, literature search, literature search methods, literature searches, literature searching, literature searching methods, policy review, policy reviews, review, reviews, search, search strategies, search strategy, searching, systematic review, systematic reviews", ,"Kable AK, Pich J, Maslin-Prothero SE. A structured approach to documenting a search strategy for publication: a 12 step guideline for authors. Nurse Educ Today. 2012;32(8):878-886.","Kable AK, Pich J, Maslin-Prothero SE.",Nurse Education Today [Nurse Educ Today.],2012,32,8,878-886, ,English, ,22633885,http://www.ncbi.nlm.nih.gov/pubmed/22633885, , , , , , ,Reporting search strategies for literature reviews, ,"For terminology and reporting of citation searching use the TARCiS Checklist
Word | PDF | TARCiS website

", , , , , ,no,2015-05-29 10:18:02,2024-04-05 15:37:34,a-structured-approach-to-documenting-a-search-strategy-for-publication-a-12-step-guideline-for-authors,"[('title', 'A structured approach to documenting a search strategy for publication: a 12 step guideline for authors'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting search strategies for literature reviews'), ('Full bibliographic reference', 'Kable AK, Pich J, Maslin-Prothero SE. A structured approach to documenting a search strategy for publication: a 12 step guideline for authors. Nurse Educ Today. 2012;32(8):878-886.'), ('Language', 'English'), ('PubMed ID', '[22633885](http://www.ncbi.nlm.nih.gov/pubmed/22633885)'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method'), ('Additional information', 'For terminology and reporting of citation searching use the TARCiS Checklist\n\n[Word](https://ub.unibas.ch/fileadmin/user_upload/universitaetsbibliothek/Universitaetsbibliothek/5_Standorte/UB_Medizin/TARCiS/TARCiS_Checklist_for_Terminology_and_Reporting_of_Citation_Searching.docx) | [PDF](https://ub.unibas.ch/fileadmin/user_upload/universitaetsbibliothek/Universitaetsbibliothek/5_Standorte/UB_Medizin/TARCiS/TARCiS_Checklist_for_Terminology_and_Reporting_of_Citation_Searching.pdf) | [TARCiS website](https://ub.unibas.ch/de/ub-medizin/tarcis/)\n\n \n\n'), ('Record last updated on', 'April 5, 2024')]"
12024,Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group,"Experimental studies, Observational studies","Radiology, Urology",Whole report, ,"biopsies, biopsy, biopsy specimen, biopsy specimens, magnetic resonance, magnetic resonance imaging, MRI, MRI guided biopsy, MRI targeted biopsy, MRI targeted prostate biopsy, MRIs, prostate, prostate biopsy, prostate magnetic resonance imaging, prostate MRI, prostate specific antigen, PSA, START, START checklist, urology", ,"Moore CM, Kasivisvanathan V, Eggener S, Emberton M, F\xfctterer JJ, Gill IS, Grubb Iii RL, Hadaschik B, Klotz L, Margolis DJ, Marks LS, Melamed J, Oto A, Palmer SL, Pinto P, Puech P, Punwani S, Rosenkrantz AB, Schoots IG, Simon R, Taneja SS, Turkbey B, Ukimura O, van der Meulen J, Villers A, Watanabe Y; START Consortium. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol. 2013;64(4):544-552.","Moore CM, Kasivisvanathan V, Eggener S, Emberton M, F\xfctterer JJ, Gill IS, Grubb Iii RL, Hadaschik B, Klotz L, Margolis DJ, Marks LS, Melamed J, Oto A, Palmer SL, Pinto P, Puech P, Punwani S, Rosenkrantz AB, Schoots IG, Simon R, Taneja SS, Turkbey B, Ukimura O, van der Meulen J, Villers A, Watanabe Y; START Consortium.",European Urology [Eur Urol.],2013,64,4,544-552, ,English, ,23537686,http://www.ncbi.nlm.nih.gov/pubmed/23537686, , , , , ,START,Reporting MRI-targeted biopsy studies of the prostate, , , , , , , ,no,2015-05-29 09:59:42,2015-05-29 09:59:42,standards-of-reporting-for-mri-targeted-biopsy-studies-start-of-the-prostate-recommendations-from-an-international-working-group,"[('title', 'Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting MRI-targeted biopsy studies of the prostate'), ('Full bibliographic reference', 'Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Fütterer JJ, Gill IS, Grubb Iii RL, Hadaschik B, Klotz L, Margolis DJ, Marks LS, Melamed J, Oto A, Palmer SL, Pinto P, Puech P, Punwani S, Rosenkrantz AB, Schoots IG, Simon R, Taneja SS, Turkbey B, Ukimura O, van der Meulen J, Villers A, Watanabe Y; START Consortium. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol. 2013;64(4):544-552.'), ('Language', 'English'), ('PubMed ID', '[23537686](http://www.ncbi.nlm.nih.gov/pubmed/23537686)'), ('Reporting guideline acronym', 'START'), ('Study design', 'Experimental studies, Observational studies'), ('Clinical area', 'Radiology, Urology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 29, 2015')]"
12022,Standardized reporting guidelines for emergency department syncope risk-stratification research,Observational studies,Emergency medicine,"Data, Outcomes (variables), Study characteristics (participants etc.), Terminology/definitions", ,"checklist, emergency, emergency care, emergency department, emergency department syncope, emergency medicine, risk, risk evaluation, risk stratification, risk stratification research, risk stratification studies, risk stratification study, stratification, syncope, syncope risk stratification", ,"Sun BC, Thiruganasambandamoorthy V, Cruz JD; Consortium to Standardize ED Syncope Risk Stratification Reporting. Standardized reporting guidelines for emergency department syncope risk-stratification research. Acad Emerg Med. 2012;19(6):694-702.","Sun BC, Thiruganasambandamoorthy V, Cruz JD; Consortium to Standardize ED Syncope Risk Stratification Reporting.",Academic Emergency Medicine [Acad Emerg Med.],2012,19,6,694-702, ,English, ,22687184,http://www.ncbi.nlm.nih.gov/pubmed/22687184, , , , , , ,Reporting emergency department syncope risk-stratification research, , , , , , , ,no,2015-05-29 09:30:55,2015-05-29 09:30:55,standardized-reporting-guidelines-for-emergency-department-syncope-risk-stratification-research,"[('title', 'Standardized reporting guidelines for emergency department syncope risk-stratification research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting emergency department syncope risk-stratification research'), ('Full bibliographic reference', 'Sun BC, Thiruganasambandamoorthy V, Cruz JD; Consortium to Standardize ED Syncope Risk Stratification Reporting. Standardized reporting guidelines for emergency department syncope risk-stratification research. Acad Emerg Med. 2012;19(6):694-702.'), ('Language', 'English'), ('PubMed ID', '[22687184](http://www.ncbi.nlm.nih.gov/pubmed/22687184)'), ('Study design', 'Observational studies'), ('Clinical area', 'Emergency medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data, Outcomes (variables), Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'May 29, 2015')]"
12020,Designing and reporting case series in plastic surgery,Observational studies,Surgery,Whole report, ,"case, case series, cases, checklist, plastic, plastic surgery, plastics, surgery, surgical", ,"Coroneos CJ, Ignacy TA, Thoma A. Designing and reporting case series in plastic surgery. Plast Reconstr Surg. 2011;128(4):361e-368e.","Coroneos CJ, Ignacy TA, Thoma A.",Plastic and Reconstructive Surgery [Plast Reconstr Surg.],2011,128,4,361e-368e, ,English, ,21544010,http://www.ncbi.nlm.nih.gov/pubmed/21544010, , , , , , ,Reporting of case series in plastic surgery, , , , , , , ,no,2015-05-29 09:01:48,2015-05-29 09:01:48,designing-and-reporting-case-series-in-plastic-surgery,"[('title', 'Designing and reporting case series in plastic surgery'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of case series in plastic surgery'), ('Full bibliographic reference', 'Coroneos CJ, Ignacy TA, Thoma A. Designing and reporting case series in plastic surgery. Plast Reconstr Surg. 2011;128(4):361e-368e.'), ('Language', 'English'), ('PubMed ID', '[21544010](http://www.ncbi.nlm.nih.gov/pubmed/21544010)'), ('Study design', 'Observational studies'), ('Clinical area', 'Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 29, 2015')]"
12018,Disaster medicine reporting: the need for new guidelines and the CONFIDE statement,Observational studies,Emergency medicine,Whole report, ,"case report, case reporting, case reports, CONFIDE, CONFIDE Statement, disaster, disaster case report, disaster case reports, disaster management, disaster medicine, disaster relief, disasters, emergency, emergency care, emergency medicine, emergency response, field intervention, field interventions, intervention, interventions, national emergencies, national emergency", ,"Bradt DA, Aitken P. Disaster medicine reporting: the need for new guidelines and the CONFIDE statement. Emerg Med Australas. 2010;22(6):483-487.","Bradt DA, Aitken P.",Emergency Medicine Australasia [Emerg Med Australas.],2010,22,6,483-487, ,English, ,21143395,http://www.ncbi.nlm.nih.gov/pubmed/21143395, , , , , ,CONFIDE,Reporting field interventions in disasters and emergencies, , , , , , , ,no,2015-05-29 08:33:25,2015-05-29 08:33:25,disaster-medicine-reporting-the-need-for-new-guidelines-and-the-confide-statement,"[('title', 'Disaster medicine reporting: the need for new guidelines and the CONFIDE statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting field interventions in disasters and emergencies'), ('Full bibliographic reference', 'Bradt DA, Aitken P. Disaster medicine reporting: the need for new guidelines and the CONFIDE statement. Emerg Med Australas. 2010;22(6):483-487.'), ('Language', 'English'), ('PubMed ID', '[21143395](http://www.ncbi.nlm.nih.gov/pubmed/21143395)'), ('Reporting guideline acronym', 'CONFIDE'), ('Study design', 'Observational studies'), ('Clinical area', 'Emergency medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 29, 2015')]"
11944,Development and validation of reporting guidelines for studies involving data linkage, , ,Data, ,"checklist, data, data collection, data linkage, data linkage studies, data linkage study, data set, data sets, data source, data sources, linkage, linkages, linked data, linking data set, linking data sets, medical record linkage, record linkage", ,"Bohensky MA, Jolley D, Sundararajan V, Evans S, Ibrahim J, Brand C. Development and validation of reporting guidelines for studies involving data linkage. Aust N Z J Public Health. 2011;35(5):486-489.","Bohensky MA, Jolley D, Sundararajan V, Evans S, Ibrahim J, Brand C.",Australian and New Zealand Journal of Public Health [Aust N Z J Public Health.],2011,35,5,486-489, ,English, ,21973256,http://www.ncbi.nlm.nih.gov/pubmed/21973256, , , , , , ,Evaluating the methodological quality of studies using linked data., , , , , , , ,no,2015-05-22 14:35:01,2015-05-22 14:35:01,development-and-validation-of-reporting-guidelines-for-studies-involving-data-linkage,"[('title', 'Development and validation of reporting guidelines for studies involving data linkage'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Evaluating the methodological quality of studies using linked data.'), ('Full bibliographic reference', 'Bohensky MA, Jolley D, Sundararajan V, Evans S, Ibrahim J, Brand C. Development and validation of reporting guidelines for studies involving data linkage. Aust N Z J Public Health. 2011;35(5):486-489.'), ('Language', 'English'), ('PubMed ID', '[21973256](http://www.ncbi.nlm.nih.gov/pubmed/21973256)'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'May 22, 2015')]"
11939,A reporting guide for studies on individual differences in traffic safety,Qualitative research, ,Whole report, ,"accident, accident data, accident prediction, accident prediction studies, accident prediction study, accidents, data, driver, driving, individual difference, individual differences, prediction, risk, road, road user, road users, safety, safety research, traffic, traffic safety, traffic safety research", ,af W\xe5hlberg AE. A reporting guide for studies on individual differences in traffic safety. J Safety Res. 2010;41(4):381-383.,af W\xe5hlberg AE.,Journal of Safety Research [J Safety Res.],2010,41,4,381-383, ,English, ,20846555,http://www.ncbi.nlm.nih.gov/pubmed/20846555, , , , , , ,Reporting accident prediction studies., , , , , , , ,no,2015-05-22 11:17:15,2015-05-22 11:17:15,a-reporting-guide-for-studies-on-individual-differences-in-traffic-safety,"[('title', 'A reporting guide for studies on individual differences in traffic safety'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting accident prediction studies.'), ('Full bibliographic reference', 'af Wåhlberg AE. A reporting guide for studies on individual differences in traffic safety. J Safety Res. 2010;41(4):381-383.'), ('Language', 'English'), ('PubMed ID', '[20846555](http://www.ncbi.nlm.nih.gov/pubmed/20846555)'), ('Study design', 'Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 22, 2015')]"
11936,Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitioners,"Clinical trials, Experimental studies","Haematology, Oncology","Procedure/Method, Results", ,"BCR-ABL, chronic myelogenous leukaemia, chronic myelogenous leukemia, chronic myeloid leukaemia, chronic myeloid leukemia, clinical studies, clinical study, clinical trial, clinical trials, CML, CML molecular monitoring, leukaemia, leukemia, MMR, molecular, molecular detection, molecular monitoring, molecular testing, molecular therapy, myeloid leukaemia, myeloid leukemia, qRT-PCR, quantitative real-time transcriptase polymerase chain reaction, RCT, RCTs, results, TKI, trial, trials, tyrosine kinase, tyrosine kinase inhibition, tyrosine kinase inhibitor, tyrosine kinase inhibitors", ,"Akard LP, Wang YL. Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitioners. Clin Lymphoma Myeloma Leuk. 2011;11(5):385-395.","Akard LP, Wang YL.","Clinical Lymphoma, Myeloma and Leukemia. [Clin Lymphoma Myeloma Leuk.]",2011,11,5,385-395, ,English, ,21723805,http://www.ncbi.nlm.nih.gov/pubmed/21723805, , , , , , ,Reporting of BCR-ABL molecular testing., , , , , , , ,no,2015-05-22 10:32:48,2015-05-22 10:37:56,translating-trial-based-molecular-monitoring-into-clinical-practice-importance-of-international-standards-and-practical-considerations-for-community-practitioners,"[('title', 'Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitioners'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of BCR-ABL molecular testing.'), ('Full bibliographic reference', 'Akard LP, Wang YL. Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitioners. Clin Lymphoma Myeloma Leuk. 2011;11(5):385-395.'), ('Language', 'English'), ('PubMed ID', '[21723805](http://www.ncbi.nlm.nih.gov/pubmed/21723805)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Haematology, Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method, Results'), ('Record last updated on', 'May 22, 2015')]"
11899,Canadian Association of Gastroenterology consensus guidelines on safety and quality indicators in endoscopy, ,Gastroenterology,"Harms/adverse effects/safety data, Intervention (exposure), Procedure/Method, Results", ,"canada, canadian, Canadian Association of Gastroenterology, colonoscopy, digestion, digestive, digestive endoscopy, digestive system, endoscopic, endoscopy, endoscopy service, endoscopy services, esophagogastroduodenoscopy, gastroenterological, gastroenterology, gastrointestinal, gastrointestinal endoscopy, indicator, indicators, performance indicator, performance indicators, quality, quality assurance, quality data, quality improvement, safe, safety, safety data", ,"Armstrong D, Barkun A, Bridges R, Carter R, de Gara C, Dube C, Enns R, Hollingworth R, Macintosh D, Borgaonkar M, Forget S, Leontiadis G, Meddings J, Cotton P, Kuipers EJ; Canadian Association of Gastroenterology Safety and Quality Indicators in Endoscopy Consensus Group. Canadian Association of Gastroenterology consensus guidelines on safety and quality indicators in endoscopy. Can J Gastroenterol. 2012;26(1):17-31.","Armstrong D, Barkun A, Bridges R, Carter R, de Gara C, Dube C, Enns R, Hollingworth R, Macintosh D, Borgaonkar M, Forget S, Leontiadis G, Meddings J, Cotton P, Kuipers EJ; Canadian Association of Gastroenterology Safety and Quality Indicators in Endoscopy Consensus Group.",Canadian Journal of Gastroenterology [Can J Gastroenterol.],2012,26,1,17-31, ,English, ,22308578,http://www.ncbi.nlm.nih.gov/pubmed/22308578, , , , , , ,Safety and quality indicators in endoscopy., , , , , , , ,no,2015-05-20 15:19:32,2015-05-20 15:19:32,canadian-association-of-gastroenterology-consensus-guidelines-on-safety-and-quality-indicators-in-endoscopy,"[('title', 'Canadian Association of Gastroenterology consensus guidelines on safety and quality indicators in endoscopy'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Safety and quality indicators in endoscopy.'), ('Full bibliographic reference', 'Armstrong D, Barkun A, Bridges R, Carter R, de Gara C, Dube C, Enns R, Hollingworth R, Macintosh D, Borgaonkar M, Forget S, Leontiadis G, Meddings J, Cotton P, Kuipers EJ; Canadian Association of Gastroenterology Safety and Quality Indicators in Endoscopy Consensus Group. Canadian Association of Gastroenterology consensus guidelines on safety and quality indicators in endoscopy. Can J Gastroenterol. 2012;26(1):17-31.'), ('Language', 'English'), ('PubMed ID', '[22308578](http://www.ncbi.nlm.nih.gov/pubmed/22308578)'), ('Clinical area', 'Gastroenterology'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Procedure/Method, Results'), ('Record last updated on', 'May 20, 2015')]"
11897,A tool to analyze the transferability of health promotion interventions, , ,"Data, Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)", ,"adapt, adaptation, analysis tool, ASTAIRE, ASTAIRE tool, checklist, complex intervention, complex interventions, health promotion, health promotion intervention, health promotion interventions, implement, implementation, intervention transfer, intervention transferability, knowledge transfer, primary intervention, research transfer, tool, transfer, transferability", ,"Cambon L, Minary L, Ridde V, Alla F. A tool to analyze the transferability of health promotion interventions. BMC Public Health 2013, 13:1184. Access full-text","Cambon L, Minary L, Ridde V, Alla F.",BioMed Central Public Health [BMC Public Health],2013,13, ,1184, ,English, , , , , , , , ,ASTAIRE,Analysing transferability and to support the development and adaptation of health promotion interventions to new settings.,"This reporting guideline has also been published in French:

Cambon L, Minary L, Ridde V, Alla F. [ASTAIRE: Tool for the analysis of the transferability and facilitation of the adaptation of interventions in health promotion, V2-2014]. Sante Publique. 2014;26(6):787-794. PMID: 25629673

", , , , , , ,no,2015-05-20 13:19:03,2021-12-17 15:34:46,a-tool-to-analyze-the-transferability-of-health-promotion-interventions,"[('title', 'A tool to analyze the transferability of health promotion interventions'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Analysing transferability and to support the development and adaptation of health promotion interventions to new settings.'), ('Full bibliographic reference', 'Cambon L, Minary L, Ridde V, Alla F. A tool to analyze the transferability of health promotion interventions. BMC Public Health 2013, 13:1184. [Access full-text](http://www.biomedcentral.com/1471-2458/13/1184)'), ('Language', 'English'), ('Availability in additional languages', 'This reporting guideline has also been published in French:\n\n \n\n Cambon L, Minary L, Ridde V, Alla F. [ASTAIRE: Tool for the analysis of the transferability and facilitation of the adaptation of interventions in health promotion, V2-2014]. Sante Publique. 2014;26(6):787-794. PMID: [25629673](http://www.ncbi.nlm.nih.gov/pubmed/25629673)\n\n \n\n'), ('Reporting guideline acronym', 'ASTAIRE'), ('Applies to the whole report or to individual sections of the report?', 'Data, Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'December 17, 2021')]"
11893,A new manner of reporting pressure results after glaucoma surgery,Observational studies,Ophthalmology,Abstract, ,"abstract, abstracts, data, glaucoma, glaucoma surgery, intraocular, intraocular pressure, IOP, ophthalmic, ophthalmology, postoperative, postoperative intraocular, postoperative intraocular pressure, postoperative IOP, preoperative, preoperative intraocular, preoperative intraocular pressure, preoperative IOP, pressure, pressure results, results, statistic, statistical, statistics, surgery, surgical, surgical glaucoma", ,"Bordeianu CD, Ticu CE. A new manner of reporting pressure results after glaucoma surgery. Clin Ophthalmol. 2012;6:23-31.","Bordeianu CD, Ticu CE.",Clinical Ophthalmology [Clin Ophthalmol.],2012,6, ,23-31, ,English, ,22259232,http://www.ncbi.nlm.nih.gov/pubmed/22259232, , , , , , ,Reporting pressure results after glaucoma surgery., , , , , , , ,no,2015-05-19 15:04:29,2015-05-20 08:50:49,a-new-manner-of-reporting-pressure-results-after-glaucoma-surgery,"[('title', 'A new manner of reporting pressure results after glaucoma surgery'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting pressure results after glaucoma surgery.'), ('Full bibliographic reference', 'Bordeianu CD, Ticu CE. A new manner of reporting pressure results after glaucoma surgery. Clin Ophthalmol. 2012;6:23-31.'), ('Language', 'English'), ('PubMed ID', '[22259232](http://www.ncbi.nlm.nih.gov/pubmed/22259232)'), ('Study design', 'Observational studies'), ('Clinical area', 'Ophthalmology'), ('Applies to the whole report or to individual sections of the report?', 'Abstract'), ('Record last updated on', 'May 20, 2015')]"
11891,Do the media provide transparent health information? A cross-cultural comparison of public information about the HPV vaccine, ,"Obstetrics and gynaecology, Oncology", , ,"cancer of the cervix, cervical cancer, communication, communications, health communications, health information, HPV, HPV vaccination, HPV vaccine, human papillomavirus, human papillomavirus vaccine, internet, media, media analysis, media communication, media coverage, newspaper, newspapers, public information, vaccination, website, websites", ,"Bodemer N, M\xfcller SM, Okan Y, Garcia-Retamero R, Neumeyer-Gromen A. Do the media provide transparent health information? A cross-cultural comparison of public information about the HPV vaccine. Vaccine. 2012;30(25):3747-3756.","Bodemer N, M\xfcller SM, Okan Y, Garcia-Retamero R, Neumeyer-Gromen A.",Vaccine [Vaccine.],2012,30,25,3747-3756, ,English, ,22421558,http://www.ncbi.nlm.nih.gov/pubmed/22421558, , , , , , ,Standards for balanced reporting on websites and in newspapers., , , , , , , ,no,2015-05-19 14:11:07,2015-05-19 14:13:43,do-the-media-provide-transparent-health-information-a-cross-cultural-comparison-of-public-information-about-the-hpv-vaccine,"[('title', 'Do the media provide transparent health information? A cross-cultural comparison of public information about the HPV vaccine'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Standards for balanced reporting on websites and in newspapers.'), ('Full bibliographic reference', 'Bodemer N, Müller SM, Okan Y, Garcia-Retamero R, Neumeyer-Gromen A. Do the media provide transparent health information? A cross-cultural comparison of public information about the HPV vaccine. Vaccine. 2012;30(25):3747-3756.'), ('Language', 'English'), ('PubMed ID', '[22421558](http://www.ncbi.nlm.nih.gov/pubmed/22421558)'), ('Clinical area', 'Obstetrics and gynaecology, Oncology'), ('Record last updated on', 'May 19, 2015')]"
11889,Recommendations for the reporting of foot and ankle models, ,Rheumatology,Procedure/Method, ,"anatomical, anatomy, ankle, ankle biomechanics, ankle kinematics, ankle marker set, ankle marker sets, ankle model, ankle models, biomechanical, biomechanical model, biomechanical modelling, biomechanical models, biomechanical parameter, biomechanical parameters, biomechanics, foot, foot and ankle biomechanics, foot biomechanics, foot kinematics, foot marker set, foot marker sets, foot model, foot models, gait, joint, joint kinematics, kinematics, marker set, marker sets, model, modelling, models, motion", ,"Bishop C, Paul G, Thewlis D. Recommendations for the reporting of foot and ankle models. J Biomech. 2012;45(13):2185-2194.","Bishop C, Paul G, Thewlis D.",Journal of Biomechanics [J Biomech],2012,45, ,2185-2194, ,English, ,22832021,http://www.ncbi.nlm.nih.gov/pubmed/22832021, , , , , , ,Reporting standards to facilitate consistency and transparency when developing a new model of the foot and ankle., , , , , , , ,no,2015-05-19 13:29:48,2015-05-19 13:29:48,recommendations-for-the-reporting-of-foot-and-ankle-models,"[('title', 'Recommendations for the reporting of foot and ankle models'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting standards to facilitate consistency and transparency when developing a new model of the foot and ankle.'), ('Full bibliographic reference', 'Bishop C, Paul G, Thewlis D. Recommendations for the reporting of foot and ankle models. J Biomech. 2012;45(13):2185-2194.'), ('Language', 'English'), ('PubMed ID', '[22832021](http://www.ncbi.nlm.nih.gov/pubmed/22832021)'), ('Clinical area', 'Rheumatology'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method'), ('Record last updated on', 'May 19, 2015')]"
11887,An introduction to standardized clinical nomenclature for dysmorphic features: the Elements of Morphology project, ,"Genetics, Obstetrics and gynaecology, Paediatrics, Surgery",Terminology/definitions, ,"anomalies, anomaly, birth defects, clinical nomenclature, congenital anomalies, congenital anomaly, definition, definitions, dysmorphic, dysmorphic feature, dysmorphic features, Elements of Morphology, Elements of Morphology project, genotype, genotyping, human structural malformation, human structural malformations, malformation, malformation terminology, malformations, morphology, morphology project, nomenclature, phenotype, phenotyping, structural malformation, structural malformations, terminology", ,Biesecker LG. An introduction to standardized clinical nomenclature for dysmorphic features: the Elements of Morphology project. BMC Med. 2010;8:56.,Biesecker LG.,BMC Medicine [BMC Med.],2010,8, , , ,English, ,20920337,http://www.ncbi.nlm.nih.gov/pubmed/20920337, , , , ,http://elementsofmorphology.nih.gov/, ,Standardised terminology to describe human structural malformations., , , , , , , ,no,2015-05-19 12:42:19,2015-05-19 12:51:18,an-introduction-to-standardized-clinical-nomenclature-for-dysmorphic-features-the-elements-of-morphology-project,"[('title', 'An introduction to standardized clinical nomenclature for dysmorphic features: the Elements of Morphology project'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Standardised terminology to describe human structural malformations.'), ('Full bibliographic reference', 'Biesecker LG. An introduction to standardized clinical nomenclature for dysmorphic features: the Elements of Morphology project. BMC Med. 2010;8:56.'), ('Language', 'English'), ('PubMed ID', '[20920337](http://www.ncbi.nlm.nih.gov/pubmed/20920337)'), ('Reporting guideline website URL', '<http://elementsofmorphology.nih.gov/>'), ('Clinical area', 'Genetics, Obstetrics and gynaecology, Paediatrics, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Terminology/definitions'), ('Record last updated on', 'May 19, 2015')]"
11883,Strengthening the Reporting of Observational Studies in Epidemiology for Respondent-Driven Sampling Studies: ?STROBE-RDS? Statement.,Observational studies, ,Whole report, ,"checklist, checklists, data collection, epidemiological, epidemiology, hard-to-reach group, hard-to-reach groups, hard-to-reach population, hard-to-reach populations, observational, observational studies, observational study, RDS, RDS data, RDS studies, RDS study, respondent-driven, respondent-driven sampling, respondent-driven sampling studies, respondent-driven sampling study, sampling studies, sampling study, STROBE, STROBE extension, STROBE-RDS", ,"White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr, LR, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik WW. Strengthening the Reporting of Observational Studies in Epidemiology for Respondent-Driven Sampling Studies: ?STROBE-RDS? Statement. Journal of Clinical Epidemiology (2015).","White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr, LR, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik WW.",Journal of Clinical Epidemiology [J Clin Epidemiol.],2015, , , , ,English, ,26112433,http://www.ncbi.nlm.nih.gov/pubmed/26112433, , , ,"Generic
STROBE Statement: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Ann Intern Med. 2007;147(8):573-577. PMID: 17938396
PLoS Med. 2007;4(10):e296. PMID: 17941714
BMJ. 2007;335(7624):806-808. PMID: 17947786
Prev Med. 2007;45(4):247-251. PMID: 17950122
Epidemiology. 2007;18(6):800-804. PMID: 18049194
Lancet. 2007;370(9596):1453-1457. PMID: 18064739

Specialised
STREGA: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.

PLoS Med. 2009;6(2):e22. PMID: 19192942
Hum Genet. 2009;125(2):131-151. PMID: 19184668
Eur J Epidemiol. 2009;24(1):37-55. PMID: 19189221
Ann Intern Med. 2009;150(3):206-215. PMID: 19189911
J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: 19217256
Genet Epidemiol. 2009;33(7):581-598. PMID: 19278015
Eur J Clin Invest. 2009;39(4):247-266. PMID: 19297801

STROBE-ME: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: 22023344

STROBE checklist for conference abstracts
First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. Link to full text pdf

STROME-ID: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: 24631223

Longitudinal observational drug studies in rheumatology: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: 24058015

Case-cohort studies: Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: 24972092

RECORD: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: 26440803

STROBE-AMS: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schr\xf6der W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: 26895985

STROBE-nut: Lachat C, Hawwash D, Ock\xe9 MC, Berg C, Forsum E, H\xf6rnell A, Larsson C, Sonestedt E, Wirf\xe4lt E, \xc5kesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology?Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: 27270749

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

ROSES-I: Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: 27417916

STROBE-NI: Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: 27633910

Propensity score analysis: Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: 28376195

RECORD-PE: Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.

STROBE-SIIS: International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, H\xe4gglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).

Br J Sports Med. 2020;54(7):372-389. PMID: 32071062
Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: 32118084

STROBE-MR: Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: 34698778

", ,STROBE-RDS,Essential items to present in respondent-driven sampling studies, , , , , , , ,yes,2015-05-15 14:58:00,2021-11-25 15:24:02,strobe-rds,"[('title', 'Strengthening the Reporting of Observational Studies in Epidemiology for Respondent -Driven Sampling Studies: ‘ STROBE-RDS ’ Statement.'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Essential items to present in respondent-driven sampling studies'), ('Full bibliographic reference', 'White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr, LR, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik WW. Strengthening the Reporting of Observational Studies in Epidemiology for Respondent-Driven Sampling Studies: ‘STROBE-RDS’ Statement. Journal of Clinical Epidemiology (2015).'), ('Language', 'English'), ('PubMed ID', '[26112433](http://www.ncbi.nlm.nih.gov/pubmed/26112433)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n**[STROBE Statement](/reporting-guidelines/strobe/)**: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.\n\n \n\n Ann Intern Med. 2007;147(8):573-577. PMID: [17938396](http://www.ncbi.nlm.nih.gov/pubmed/17938396)\n\n PLoS Med. 2007;4(10):e296. PMID: [17941714](http://www.ncbi.nlm.nih.gov/pubmed/17941714)\n\n BMJ. 2007;335(7624):806-808. PMID: [17947786](http://www.ncbi.nlm.nih.gov/pubmed/17947786)\n\n Prev Med. 2007;45(4):247-251. PMID: [17950122](http://www.ncbi.nlm.nih.gov/pubmed/17950122)\n\n Epidemiology. 2007;18(6):800-804. PMID: [18049194](http://www.ncbi.nlm.nih.gov/pubmed/18049194)\n\n Lancet. 2007;370(9596):1453-1457. PMID: [18064739](http://www.ncbi.nlm.nih.gov/pubmed/18064739)\n\n \n\n**Specialised**\n\n**[STREGA](/reporting-guidelines/strobe-strega/)**: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.\n\n \n\n PLoS Med. 2009;6(2):e22. PMID: [19192942](http://www.ncbi.nlm.nih.gov/pubmed/19192942)\n\n Hum Genet. 2009;125(2):131-151. PMID: [19184668](http://www.ncbi.nlm.nih.gov/pubmed/19184668)\n\n Eur J Epidemiol. 2009;24(1):37-55. PMID: [19189221](http://www.ncbi.nlm.nih.gov/pubmed/19189221)\n\n Ann Intern Med. 2009;150(3):206-215. PMID: [19189911](http://www.ncbi.nlm.nih.gov/pubmed/19189911)\n\n J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: [19217256](http://www.ncbi.nlm.nih.gov/pubmed/19217256)\n\n Genet Epidemiol. 2009;33(7):581-598. PMID: [19278015](http://www.ncbi.nlm.nih.gov/pubmed/19278015)\n\n Eur J Clin Invest. 2009;39(4):247-266. PMID: [19297801](http://www.ncbi.nlm.nih.gov/pubmed/19297801)\n\n \n\n**[STROBE-ME](/reporting-guidelines/strobe-me/)**: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: [22023344](http://www.ncbi.nlm.nih.gov/pubmed/22023344)\n\n \n\n**[STROBE checklist for conference abstracts](/reporting-guidelines/strobe-abstracts/)**\n\n First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. [Link to full text pdf](https://www.strobe-statement.org/download/strobe-checklist-conference-abstracts)\n\n \n\n**[STROME-ID](/reporting-guidelines/strome-id/)**: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: [24631223](http://www.ncbi.nlm.nih.gov/pubmed/24631223)\n\n \n\n**[Longitudinal observational drug studies in rheumatology](/reporting-guidelines/launch-of-a-checklist-for-reporting-longitudinal-observational-drug-studies-in-rheumatology-a-eular-extension-of-strobe-guidelines-based-on-experience-from-biologics-registries/)**: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: [24058015](http://www.ncbi.nlm.nih.gov/pubmed/24058015)\n\n \n\n[**Case-cohort studies**](/reporting-guidelines/a-review-of-published-analyses-of-case-cohort-studies-and-recommendations-for-future-reporting/): Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: [24972092](https://www.ncbi.nlm.nih.gov/pubmed/24972092)\n\n \n\n**[RECORD](/reporting-guidelines/record/)**: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: [26440803](http://www.ncbi.nlm.nih.gov/pubmed/26440803)\n\n \n\n**[STROBE-AMS](/reporting-guidelines/strobe-ams/)**: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schröder W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: [26895985](http://www.ncbi.nlm.nih.gov/pubmed/26895985)\n\n \n\n[**STROBE-nut**](/reporting-guidelines/strobe-nut/): Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology—Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: [27270749](https://www.ncbi.nlm.nih.gov/pubmed/27270749)\n\n \n\n[**Simulation Research**](/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**ROSES-I**](/reporting-guidelines/roses-i-statement/): Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: [27417916](https://www.ncbi.nlm.nih.gov/pubmed/27417916)\n\n \n\n[**STROBE-NI**](/reporting-guidelines/strobe-ni/): Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: [27633910](https://www.ncbi.nlm.nih.gov/pubmed/27633910)\n\n \n\n[**Propensity score analysis**](/reporting-guidelines/reporting-and-guidelines-in-propensity-score-analysis-a-systematic-review-of-cancer-and-cancer-surgical-studies/): Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: [28376195](https://www.ncbi.nlm.nih.gov/pubmed/28376195)\n\n \n\n[**RECORD-PE**](https://www.equator-network.org/reporting-guidelines/record-pe/): Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). [BMJ 2018;363:k3532](https://www.bmj.com/content/363/bmj.k3532.full).\n\n \n\n[**STROBE-SIIS**](https://www.equator-network.org/reporting-guidelines/strobe-extension-for-sports-injury-illness-surveillance/): International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, Hägglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).\n\n \n\n Br J Sports Med. 2020;54(7):372-389. PMID: [32071062](https://pubmed.ncbi.nlm.nih.gov/32071062/)\n\n Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: [32118084](https://pubmed.ncbi.nlm.nih.gov/32118084/)\n\n \n\n[**STROBE-MR**](https://www.equator-network.org/reporting-guidelines/strobe-mr-statement/): Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: [34698778](https://pubmed.ncbi.nlm.nih.gov/34698778/)\n\n \n\n'), ('Reporting guideline acronym', 'STROBE-RDS'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 25, 2021')]"
11881,CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement,"Clinical trials, Experimental studies", ,Whole report, ,"CENT, CENT 2015, CENT checklist, CENT diagram, CENT diagrams, CENT guideline, CENT statement, CENT trial, CENT trials, checklist, checklists, clinical trial, clinical trials, CONSORT, CONSORT extension, CONSORT-CENT, extension, N-of-1, N-of-1 trial, N-of-1 trials, single, single patient, single study participant, single-case, single-case experiment, trial, trials", ,"Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. BMJ. 2015;350:h1738.","Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group.",British Medical Journal [BMJ],2015,350, , , ,English, ,25976398,http://www.ncbi.nlm.nih.gov/pubmed/25976398, ,"Shamseer L, Sampson M, Bukutu C, Schmid CH, Nikles J, Tate R, Johnston BC, Zucker D, Shadish WR, Kravitz R, Guyatt G, Altman DG, Moher D, Vohra S; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration. BMJ. 2015;350:h1793. PMID: 25976162

", ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477



Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,CONSORT-CENT,"Reporting of individual and series of N-of-1 trials.



", , , , , , , ,yes,2015-05-15 14:11:38,2025-05-30 09:18:50,consort-cent,"[('title', 'CONSORT extension for reporting N-of- 1 trials (CENT) 2015 Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of individual and series of N-of-1 trials.\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. BMJ. 2015;350:h1738.'), ('Language', 'English'), ('PubMed ID', '[25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)'), ('Explanation and elaboration papers', 'Shamseer L, Sampson M, Bukutu C, Schmid CH, Nikles J, Tate R, Johnston BC, Zucker D, Shadish WR, Kravitz R, Guyatt G, Altman DG, Moher D, Vohra S; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration. BMJ. 2015;350:h1793. PMID: [25976162](http://www.ncbi.nlm.nih.gov/pubmed/25976162)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n**[CONSORT 2025 Statement](/reporting-guidelines/consort/)**:\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n \xa0\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](https://www.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](https://www.equator-network.org/reporting-guidelines/consort-non-inferiority/): Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n**[CONSORT Cluster](/reporting-guidelines/consort-cluster/)**:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n**[CONSORT Herbal](/reporting-guidelines/consort-herbal/)**:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n**[CONSORT Non-pharmacological treatment interventions](/reporting-guidelines/consort-non-pharmacological/)**: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n**[CONSORT Abstracts](/reporting-guidelines/consort-abstracts/)**:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n**[CONSORT Pragmatic Trials](/reporting-guidelines/consort-pragmatic/)**: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n**[STRICTA Controlled trials of acupuncture](/reporting-guidelines/consort-stricta/)**:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n**[CONSORT PRO](/reporting-guidelines/consort-pro/)**: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n**[CONSORT for orthodontic trials](%20/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/)**: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n**[TIDieR](/reporting-guidelines/tidier/)**: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://www.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://www.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://www.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://www.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://www.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'CONSORT-CENT'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 30, 2025')]"
11869,"A protocol format for the preparation, registration and publication of systematic reviews of animal intervention studies","Animal pre-clinical research, Study protocols, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,Protocol-whole report, ,"animal, animal experiment, animal experiments, animal intervention studies, animal intervention study, animal pre clinical research, animal preclinical research, animal research, animal studies, animal study, animal systematic review, animal systematic reviews, CAMARADES, checklist, checklists, meta analyses, meta analyses protocol, meta analyses protocols, meta analysis, meta analysis protocol, meta analysis protocols, preclinical, preclinical animal research, preclinical research, preclinical studies, preclinical study, protocol, protocol format, protocols, review protocol, review protocols, SYRCLE, systematic review, systematic review protocol, systematic review protocols, systematic reviews", ,"de Vries RBM, Hooijmans CR, Langendam MW, van Luijk J, Leenaars M, Ritskes-Hoitinga M, Wever KE. A protocol format for the preparation, registration and publication of systematic reviews of animal intervention studies. Evidence-based Preclinical Medicine. 2015;2(1): 1?9.","de Vries RBM, Hooijmans CR, Langendam MW, van Luijk J, Leenaars M, Ritskes-Hoitinga M, Wever KE.",Evidence-based Preclinical Medicine,2015,2,1,1-9, ,English, , , ,The full-text of this reporting guideline is available at: http://onlinelibrary.wiley.com/doi/10.1002/ebm2.7/abstract, , , , , ,Protocols for systematic reviews of animal intervention studies., , , , , , , ,no,2015-05-12 14:30:49,2021-12-17 15:44:58,a-protocol-format-for-the-preparation-registration-and-publication-of-systematic-reviews-of-animal-intervention-studies,"[('title', 'A protocol format for the preparation, registration and publication of systematic reviews of animal intervention studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Protocols for systematic reviews of animal intervention studies.'), ('Full bibliographic reference', 'de Vries RBM, Hooijmans CR, Langendam MW, van Luijk J, Leenaars M, Ritskes-Hoitinga M, Wever KE. A protocol format for the preparation, registration and publication of systematic reviews of animal intervention studies. Evidence-based Preclinical Medicine. 2015;2(1): 1–9.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is available at: <http://onlinelibrary.wiley.com/doi/10.1002/ebm2.7/abstract>'), ('Study design', 'Animal pre-clinical research, Study protocols, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Protocol-whole report'), ('Record last updated on', 'December 17, 2021')]"
11867,Reporting standards for literature searches and report inclusion criteria: making research syntheses more transparent and easy to replicate, , ,Procedure/Method, ,"bibliographic database, bibliographic databases, citation search, citation searches, database search, database searches, inclusion, inclusion criteria, literature search, literature search methods, literature searches, literature searching, literature searching methods, reference database, reference databases, research syntheses, research synthesis, search, search methods, search strategies, search strategy, searching, searching methods, sifting, syntheses, synthesis", ,"Atkinson KM, Koenka AC, Sanchez CE, Moshontz H, Cooper H. Reporting standards for literature searches and report inclusion criteria: making research syntheses more transparent and easy to replicate. Research Synthesis Methods. 2015;6(1): 87?95.","Atkinson KM, Koenka AC, Sanchez CE, Moshontz H, Cooper H.",Research Synthesis Methods [Res Syn Meth],2015,6,1,87?95, ,English, , , ,The full-text of this reporting guideline is available at: http://onlinelibrary.wiley.com/doi/10.1002/jrsm.1127/abstract, , , , , ,Reporting the methods used in a literature search., ,"For terminology and reporting of citation searching use the TARCiS Checklist
Word | PDF | TARCiS website

", , , , , ,no,2015-05-12 13:16:55,2024-04-05 15:27:21,reporting-standards-for-literature-searches-and-report-inclusion-criteria-making-research-syntheses-more-transparent-and-easy-to-replicate,"[('title', 'Reporting standards for literature searches and report inclusion criteria: making research syntheses more transparent and easy to replicate'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the methods used in a literature search.'), ('Full bibliographic reference', 'Atkinson KM, Koenka AC, Sanchez CE, Moshontz H, Cooper H. Reporting standards for literature searches and report inclusion criteria: making research syntheses more transparent and easy to replicate. Research Synthesis Methods. 2015;6(1): 87–95.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is available at: <http://onlinelibrary.wiley.com/doi/10.1002/jrsm.1127/abstract>'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method'), ('Additional information', 'For terminology and reporting of citation searching use the TARCiS Checklist\n\n[Word](https://ub.unibas.ch/fileadmin/user_upload/universitaetsbibliothek/Universitaetsbibliothek/5_Standorte/UB_Medizin/TARCiS/TARCiS_Checklist_for_Terminology_and_Reporting_of_Citation_Searching.docx) | [PDF](https://ub.unibas.ch/fileadmin/user_upload/universitaetsbibliothek/Universitaetsbibliothek/5_Standorte/UB_Medizin/TARCiS/TARCiS_Checklist_for_Terminology_and_Reporting_of_Citation_Searching.pdf) | [TARCiS website](https://ub.unibas.ch/de/ub-medizin/tarcis/)\n\n \n\n'), ('Record last updated on', 'April 5, 2024')]"
11865,Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Whole report, ,"checklist, checklists, data, individual, individual data, individual level, individual participant, individual participant data, individual participant data meta analyses, individual participant data meta analysis, IPD, IPD checklist, IPD meta analyses, IPD meta analysis, IPD review, IPD synthesis, IPD systematic review, IPD systematic reviews, meta analyses, meta analysis, original data, participant, participant data, participants, PRISMA extension, PRISMA-IPD, PRISMA-IPD checklist, PRISMA-IPD extension, review, reviews, systematic, systematic review, systematic reviews", ,"Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665.","Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group.",Journal of the American Medical Association [JAMA],2015,313,16,1657-65, ,English, ,25919529,http://www.ncbi.nlm.nih.gov/pubmed/25919529, , , ,"Generic
PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

Specialised
PRISMA-Equity: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: 23222917

Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.
Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

PRISMA-Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.

PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246

PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634

PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668

PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement &amp; Checklist. J Clin Epidemiol. 2017. PMID: 28720516

PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.\xa0PMID: 29362800

PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033

PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367

PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791

PRISMA-CHM: Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: 32907365

PRISMA-M 2020: Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: 33100229

PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.
Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535

PRISMA-LSR: Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: 39562017

",http://www.prisma-statement.org/Extensions/IndividualPatientData,PRISMA-IPD,"Reporting systematic reviews and meta-analyses of individual participant data (IPD).



PRISMA-IPD checklist Word / PDF

PRISMA-IPD flow diagram Word / PDF

", , , , , , , ,yes,2015-05-12 10:16:15,2025-02-06 11:56:53,prisma-ipd,"[('title', 'Preferred Reporting Items for Systematic Review and Meta -Analyses of individual participant data: the PRISMA-IPD Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting systematic reviews and meta-analyses of individual participant data (IPD).\n\n \n\n \xa0\n\n \n\n PRISMA-IPD checklist [Word](https://www.prisma-statement.org/s/PRISMA-IPD-checklist.docx) / [PDF](https://www.prisma-statement.org/s/PRISMA-IPD-checklist.pdf)\n\n \n\n PRISMA-IPD flow diagram [Word](https://www.prisma-statement.org/s/PRISMA-IPD-Flow-Diagram.docx) / [PDF](https://www.prisma-statement.org/s/PRISMA-IPD-Flow-Diagram.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665.'), ('Language', 'English'), ('PubMed ID', '[25919529](http://www.ncbi.nlm.nih.gov/pubmed/25919529)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n**[PRISMA 2020 Statement](http://dev.equator-network.org/reporting-guidelines/prisma/)**: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.\n\n \n\n PLoS Med. 2021;18(3):e1003583. PMID: [33780438](https://pubmed.ncbi.nlm.nih.gov/33780438/)\n\n BMJ 2021;372:n71. PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)\n\n Int J Surg. 2021:105906. PMID: [33789826](https://pubmed.ncbi.nlm.nih.gov/33789826/)\n\n J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: [33789819](https://pubmed.ncbi.nlm.nih.gov/33789819/)\n\n Syst Rev. 2021;10(1):89. PMID: [33781348](https://pubmed.ncbi.nlm.nih.gov/33781348/)\n\n \n\n**Specialised**\n\n**[PRISMA-Equity](http://dev.equator-network.org/reporting-guidelines/prisma-equity/)**: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: [23222917](http://www.ncbi.nlm.nih.gov/pubmed/23222917)\n\n \n\n Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.\n\n Int J Equity Health. 2015;14(1):92. PMID: [26450828](http://www.ncbi.nlm.nih.gov/pubmed/26450828)\n\n J Clin Epidemiol. 2015. PMID: [26348799](http://www.ncbi.nlm.nih.gov/pubmed/26348799)\n\n \n\n**[PRISMA-Abstracts 2020:](http://dev.equator-network.org/reporting-guidelines/prisma-abstracts/)** The PRISMA 2020 for Abstracts reporting guideline is contained within the main [PRISMA 2020 Statement paper](https://www.equator-network.org/reporting-guidelines/prisma/).\n\n \n\n**[PRISMA-P](http://dev.equator-network.org/reporting-guidelines/prisma-protocols/)**: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: [25554246](http://www.ncbi.nlm.nih.gov/pubmed/25554246)\n\n \n\n**[PRISMA extension for network meta-analyses](http://dev.equator-network.org/reporting-guidelines/prisma-extension-network-meta-analyses/)**: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: [26030634](http://www.ncbi.nlm.nih.gov/pubmed/26030634)\n\n \n\n[**PRISMA-harms**](http://dev.equator-network.org/reporting-guidelines/prisma-harms/): Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: [26830668](http://www.ncbi.nlm.nih.gov/pubmed/26830668)\n\n \n\n[**PRISMA-CI**](http://dev.equator-network.org/reporting-guidelines/prisma-ci-extension-statement-checklist/): Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: [28720516](https://www.ncbi.nlm.nih.gov/pubmed/28720516)\n\n \n\n[**PRISMA-DTA**](http://dev.equator-network.org/reporting-guidelines/prisma-dta/): McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.\xa0PMID: [29362800](https://www.ncbi.nlm.nih.gov/pubmed/29362800)\n\n \n\n[**PRISMA-ScR**](http://dev.equator-network.org/reporting-guidelines/prisma-scr/): Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: [30178033](https://www.ncbi.nlm.nih.gov/pubmed/30178033)\n\n \n\n[**PRISMA-A**](https://dev.equator-network.org/reporting-guidelines/prisma-acupuncture/): Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: [31405367](https://www.ncbi.nlm.nih.gov/pubmed/31405367)\n\n \n\n[**PRISMA-DTA for Abstracts**](https://dev.equator-network.org/reporting-guidelines/prisma-dta-for-abstracts/): Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: [33722791](https://pubmed.ncbi.nlm.nih.gov/33722791/)\n\n \n\n[**PRISMA-CHM**](https://www.equator-network.org/reporting-guidelines/prisma-chinese-herbal-medicines-2020/): Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: [32907365](https://pubmed.ncbi.nlm.nih.gov/32907365/)\n\n \n\n[**PRISMA-M 2020**](https://www.equator-network.org/reporting-guidelines/prisma-extension-for-moxibustion-2020/): Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: [33100229](https://pubmed.ncbi.nlm.nih.gov/33100229/)\n\n \n\n[**PRISMA-S**](https://dev.equator-network.org/reporting-guidelines/prisma-s/): Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.\n\n Syst Rev. 2021;10(1):39. PMID: [33499930](https://pubmed.ncbi.nlm.nih.gov/33499930/)\n\n J Med Libr Assoc. 2021;109(2):174-200. PMID: [34285662](https://pubmed.ncbi.nlm.nih.gov/34285662/)\n\n \n\n[**PRISMA-COSMIN for OMIs**](https://www.equator-network.org/reporting-guidelines/guideline-for-reporting-systematic-reviews-of-outcome-measurement-instruments-omis-prisma-cosmin-for-omis-2024/): Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.\n\n J Clin Epidemiol. 2024:111422. PMID: [38849061](https://pubmed.ncbi.nlm.nih.gov/38849061/)\n\n Qual Life Res. 2024. PMID: [38980635](https://pubmed.ncbi.nlm.nih.gov/38980635/)\n\n Health Qual Life Outcomes. 2024;22(1):48. PMID: [38978063](https://pubmed.ncbi.nlm.nih.gov/38978063/)\n\n J Patient Rep Outcomes. 2024;8(1):64. PMID: [38977535](https://pubmed.ncbi.nlm.nih.gov/38977535/)\n\n \n\n[**PRISMA-LSR**](https://www.equator-network.org/reporting-guidelines/prisma-lsr/): Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: [39562017](https://pubmed.ncbi.nlm.nih.gov/39562017/)\n\n \n\n""), ('Reporting guideline website URL', '<http://www.prisma-statement.org/Extensions/IndividualPatientData>'), ('Reporting guideline acronym', 'PRISMA-IPD'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'February 6, 2025')]"
11808,Evaluating complex interventions in end of life care: the MORECare statement on good practice generated by a synthesis of transparent expert consultations and systematic reviews,"Experimental studies, Mixed methods studies, Observational studies",Palliative care,"Ethical issues (consent etc.), Outcomes (variables), Procedure/Method, Statistical methods and analyses, Study characteristics (participants etc.)", ,"checklist, checklists, complex intervention, complex interventions, end of life, end of life care, EoLC, hospice and palliative care, MORECare, MORECare statement, palliative, palliative care, palliative care patients, palliative care research, palliative research, service delivery, terminal care", ,"Higginson IJ, Evans CJ, Grande G, Preston N, Morgan M, McCrone P, Lewis P, Fayers P, Harding R, Hotopf M, Murray SA, Benalia H, Gysels M, Farquhar M, Todd C; MORECare. Evaluating complex interventions in end of life care: the MORECare statement on good practice generated by a synthesis of transparent expert consultations and systematic reviews. BMC Med. 2013;24;11:111.","Higginson IJ, Evans CJ, Grande G, Preston N, Morgan M, McCrone P, Lewis P, Fayers P, Harding R, Hotopf M, Murray SA, Benalia H, Gysels M, Farquhar M, Todd C; MORECare.",BMC Medicine [BMC Med.],2013,24,11, , ,English, ,23618406,http://www.ncbi.nlm.nih.gov/pubmed/23618406, , , , , ,MORECare,Research evaluating services and treatments in end of life care, ,"The following papers have also been published by the MORECare researchers:

Preston NJ, Fayers P, Walters SJ, Pilling M, Grande GE, Short V, Owen-Jones E, Evans CJ, Benalia H, Higginson IJ, Todd CJ; MORECare. Recommendations for managing missing data, attrition and response shift in palliative and end-of-life care research: part of the MORECare research method guidance on statistical issues. Palliat Med. 2013;27(10):899-907. PMID: 23652842

Evans CJ, Benalia H, Preston NJ, Grande G, Gysels M, Short V, Daveson BA, Bausewein C, Todd C, Higginson IJ; MORECare. The selection and use of outcome measures in palliative and end-of-life care research: the MORECare International Consensus Workshop. J Pain Symptom Manage. 2013;46(6):925-37. PMID: 23628515

Gysels M, Evans CJ, Lewis P, Speck P, Benalia H, Preston NJ, Grande GE, Short V, Owen-Jones E, Todd CJ, Higginson IJ. MORECare research methods guidance development: recommendations for ethical issues in palliative and end-of-life care research. Palliat Med. 2013;27(10):908-17. PMID: 23695828

Farquhar M, Preston N, Evans CJ, Grande G, Short V, Benalia H, Higginson IJ, Todd C; MOREcare. Mixed methods research in the development and evaluation of complex interventions in palliative and end-of-life care: report on the MORECare consensus exercise. J Palliat Med. 2013;16(12):1550-1560. PMID: 24195755

", , ,Further information is available from: MORECare Statement, , ,no,2015-03-25 16:07:09,2021-12-17 15:54:53,morecare-statement,"[('title', 'Evaluating complex interventions in end of life care: the MORECare statement on good practice generated by a synthesis of transparent expert consultations and systematic reviews'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Research evaluating services and treatments in end of life care'), ('Full bibliographic reference', 'Higginson IJ, Evans CJ, Grande G, Preston N, Morgan M, McCrone P, Lewis P, Fayers P, Harding R, Hotopf M, Murray SA, Benalia H, Gysels M, Farquhar M, Todd C; MORECare. Evaluating complex interventions in end of life care: the MORECare statement on good practice generated by a synthesis of transparent expert consultations and systematic reviews. BMC Med. 2013;24;11:111.'), ('Language', 'English'), ('PubMed ID', '[23618406](http://www.ncbi.nlm.nih.gov/pubmed/23618406)'), ('Reporting guideline acronym', 'MORECare'), ('Study design', 'Experimental studies, Mixed methods studies, Observational studies'), ('Clinical area', 'Palliative care'), ('Applies to the whole report or to individual sections of the report?', 'Ethical issues (consent etc.), Outcomes (variables), Procedure/Method, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Other', 'Further information is available from: [MORECare Statement](http://www.kcl.ac.uk/lsm/research/divisions/cicelysaunders/research/studies/morecare.aspx)'), ('Additional information', 'The following papers have also been published by the MORECare researchers:\n\n \n\n Preston NJ, Fayers P, Walters SJ, Pilling M, Grande GE, Short V, Owen-Jones E, Evans CJ, Benalia H, Higginson IJ, Todd CJ; MORECare. Recommendations for managing missing data, attrition and response shift in palliative and end-of-life care research: part of the MORECare research method guidance on statistical issues. Palliat Med. 2013;27(10):899-907. PMID: [23652842](http://www.ncbi.nlm.nih.gov/pubmed/23652842)\n\n \n\n Evans CJ, Benalia H, Preston NJ, Grande G, Gysels M, Short V, Daveson BA, Bausewein C, Todd C, Higginson IJ; MORECare. The selection and use of outcome measures in palliative and end-of-life care research: the MORECare International Consensus Workshop. J Pain Symptom Manage. 2013;46(6):925-37. PMID: [23628515](http://www.ncbi.nlm.nih.gov/pubmed/23628515)\n\n \n\n Gysels M, Evans CJ, Lewis P, Speck P, Benalia H, Preston NJ, Grande GE, Short V, Owen-Jones E, Todd CJ, Higginson IJ. MORECare research methods guidance development: recommendations for ethical issues in palliative and end-of-life care research. Palliat Med. 2013;27(10):908-17. PMID: [23695828](http://www.ncbi.nlm.nih.gov/pubmed/23695828)\n\n \n\n Farquhar M, Preston N, Evans CJ, Grande G, Short V, Benalia H, Higginson IJ, Todd C; MOREcare. Mixed methods research in the development and evaluation of complex interventions in palliative and end-of-life care: report on the MORECare consensus exercise. J Palliat Med. 2013;16(12):1550-1560. PMID: [24195755](http://www.ncbi.nlm.nih.gov/pubmed/24195755)\n\n \n\n'), ('Record last updated on', 'December 17, 2021')]"
5557,Biospecimen reporting for improved study quality (BRISQ), , ,Biospecimen/bioresource information, ,"biobank, biomedical research, biomedical studies, biomedical study, biospecimen, biospecimen information, biospecimen pre-analytical conditions, biospecimen preanalytical conditions, biospecimen research, biospecimen-related research, biospecimens, bodily fluids, BRISQ, BRISQ guidelines, BRISQ recommendations, data, data elements, experimental, human biospecimen, human biospecimens, human tissues, pre-analytical conditions, pre-analytical factors, preanalytical conditions, preanalytical factors, solid tissues", ,"Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, Hayes DF, Hainaut P, Kim P, Mansfield EA, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson P, Weier HU, Zhu C, Vaught J. Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol. 2011;119(2):92-101.","Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, Hayes DF, Hainaut P, Kim P, Mansfield EA, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson P, Weier HU, Zhu C, Vaught J.",Cancer Cytopathology [Cancer Cytopathol.],2011,119,2,92-101, ,English, ,21433001,http://www.ncbi.nlm.nih.gov/pubmed/21433001, , , , , ,BRISQ,Biospecimen reporting, , , , , , , ,yes,2015-03-25 14:46:12,2015-03-26 09:22:26,brisq,"[('title', 'Biospecimen reporting for improved study quality (BRISQ)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Biospecimen reporting'), ('Full bibliographic reference', 'Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, Hayes DF, Hainaut P, Kim P, Mansfield EA, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson P, Weier HU, Zhu C, Vaught J. Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol. 2011;119(2):92-101.'), ('Language', 'English'), ('PubMed ID', '[21433001](http://www.ncbi.nlm.nih.gov/pubmed/21433001)'), ('Reporting guideline acronym', 'BRISQ'), ('Applies to the whole report or to individual sections of the report?', 'Biospecimen/bioresource information'), ('Record last updated on', 'March 26, 2015')]"
11806,Developing a guideline to standardize the citation of bioresources in journal articles (CoBRA),"Experimental studies, Observational studies", ,Biospecimen/bioresource information, ,"biobank, biobanking, biobanks, bioinformatics, biological sample, biological samples, biomedical, biomedical research, biomedical studies, biomedical study, biomolecular, bioresource, bioresource citation, bioresource citations, Bioresource Research Impact Factor, bioresources, biosample, biospecimen, biospecimens, BRIF, checklist, checklists, citation, citations, cite, citing, CoBRA, data, data sharing, database, databases, registries, registry, repositories, repository, research data, translational", ,"Bravo E, Calzolari A, De Castro P, Mabile L, Napolitani F, Rossi AM, Cambon-Thomsen A. Developing a guideline to standardize the citation of bioresources in journal articles (CoBRA). BMC Med. 2015;13:33.","Bravo E, Calzolari A, De Castro P, Mabile L, Napolitani F, Rossi AM, Cambon-Thomsen A.",BMC Medicine [BMC Med.],2015,13, , , ,English, ,25855867,http://www.ncbi.nlm.nih.gov/pubmed/25855867, , , , , ,CoBRA,"Citation of bioresources in journal articles



CoBRA checklist (PDF)

", ,"Read the BRIF meeting report from a workshop with journal editors held in Rome in 2013: meeting report (PDF)

The following papers have also been published by the BRIF researchers:

The BRIF initiative: Laurence Mabile, Raymond Dalgleish, Gudmundur A Thorisson, Myl\xe8ne Desch\xeanes, Robert Hewitt, Jane Carpenter, Elena Bravo, Mirella Filocamo, Pierre Antoine Gourraud, Jennifer R Harris, Paul Hofman, Francine Kauffmann, Maria Angeles Mu\xf1oz-Fern\xe0ndez, Markus Pasterk, Anne Cambon-Thomsen and BRIF working group. Quantifying the use of bioresources for promoting their sharing in scientific research. GigaScience. 2013;2:7. Link to full-text

Elena Bravo, Anne Cambon-Thomsen, Paola De Castro, Laurence Mabile, Federica Napolitani, Mariarosaria Napolitano, Anna Maria Rossi. Citation of bioresources in journal articles: moving towards standards. European Science Editing. 2013;39(2):36-38. Link to full-text (PDF)

", , ,"A guideline for reporting biospecimen information more generally is available at: BRISQ guideline

", , ,yes,2015-03-25 14:44:21,2021-12-17 15:56:48,cobra,"[('title', 'Developing a guideline to standardize the citation of bioresources in journal articles (CoBRA)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Citation of bioresources in journal articles\n\n \n\n \xa0\n\n \n\n[CoBRA checklist (PDF)](/wp-content/uploads/2015/03/Cobra-check-list.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Bravo E, Calzolari A, De Castro P, Mabile L, Napolitani F, Rossi AM, Cambon-Thomsen A. Developing a guideline to standardize the citation of bioresources in journal articles (CoBRA). BMC Med. 2015;13:33.'), ('Language', 'English'), ('PubMed ID', '[25855867](http://www.ncbi.nlm.nih.gov/pubmed/25855867)'), ('Reporting guideline acronym', 'CoBRA'), ('Study design', 'Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Biospecimen/bioresource information'), ('Other', 'A guideline for reporting biospecimen information more generally is available at: [BRISQ guideline](https://www.equator-network.org/reporting-guidelines/brisq/)\n\n \n\n'), ('Additional information', 'Read the BRIF meeting report from a workshop with journal editors held in Rome in 2013: [meeting report (PDF)](/wp-content/uploads/2009/02/BRIF-guidelines-ROME-WORKSHOP-REPORT.pdf)\n\n \n\n The following papers have also been published by the BRIF researchers:\n\n \n\n The BRIF initiative: Laurence Mabile, Raymond Dalgleish, Gudmundur A Thorisson, Mylène Deschênes, Robert Hewitt, Jane Carpenter, Elena Bravo, Mirella Filocamo, Pierre Antoine Gourraud, Jennifer R Harris, Paul Hofman, Francine Kauffmann, Maria Angeles Muñoz-Fernàndez, Markus Pasterk, Anne Cambon-Thomsen and BRIF working group. Quantifying the use of bioresources for promoting their sharing in scientific research. GigaScience. 2013;2:7. [Link to full-text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655103/)\n\n \n\n Elena Bravo, Anne Cambon-Thomsen, Paola De Castro, Laurence Mabile, Federica Napolitani, Mariarosaria Napolitano, Anna Maria Rossi. Citation of bioresources in journal articles: moving towards standards. European Science Editing. 2013;39(2):36-38. [Link to full-text (PDF)](http://www.ease.org.uk/sites/default/files/essay_bioresources.pdf)\n\n \n\n'), ('Record last updated on', 'December 17, 2021')]"
11589,Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement,Experimental studies,Pharmaceutical medicine,Whole report, ,"bioavailability, checklist, clinical pharmacokinetics, clinical pharmacokinetics studies, clinical pharmacokinetics study, clinical trial, clinical trials, ClinPK, ClinPK statement, dose, dose calculation, dose specification, dosing, drug, drug bioavailability, drug delivery, drug dosing, drug studies, drug study, drug volume, drugs, extracorporeal, extracorporeal drug, non-compartmental analyses, non-compartmental analysis, pharmaceutical, pharmaceutical clinical trial, pharmaceutical clinical trials, pharmaceutical medicine, pharmacokinetic, pharmacokinetic parameter, pharmacokinetic parameters, pharmacokinetic research, pharmacokinetics, pharmacokinetics studies, pharmacokinetics study, pharmacological, pharmacology, pharmacotherapy, pharmacy, population pharmacokinetic, population pharmacokinetics, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, Edwards S, Ensom MH, Foster DR, Hardy B, Kiser TH, la Porte C, Roberts JA, Shulman R, Walker S, Zelenitsky S, Moher D. Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement. Clin Pharmacokinet. 2015. [Epub ahead of print]","Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, Edwards S, Ensom MH, Foster DR, Hardy B, Kiser TH, la Porte C, Roberts JA, Shulman R, Walker S, Zelenitsky S, Moher D.",Clinical Pharmacokinetics [Clin Pharmacokinet.],2015, , , , ,English, ,25637173,http://www.ncbi.nlm.nih.gov/pubmed/25637173, , , , , ,ClinPK,Reporting clinical pharmacokinetic studies, , , , , , , ,no,2015-03-17 11:12:23,2015-03-17 12:07:18,clinpk,"[('title', 'Reporting Guidelines for Clinical Pharmacokinetic Studies: The Clin PK Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting clinical pharmacokinetic studies'), ('Full bibliographic reference', 'Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, Edwards S, Ensom MH, Foster DR, Hardy B, Kiser TH, la Porte C, Roberts JA, Shulman R, Walker S, Zelenitsky S, Moher D. Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement. Clin Pharmacokinet. 2015. [Epub ahead of print]'), ('Language', 'English'), ('PubMed ID', '[25637173](http://www.ncbi.nlm.nih.gov/pubmed/25637173)'), ('Reporting guideline acronym', 'ClinPK'), ('Study design', 'Experimental studies'), ('Clinical area', 'Pharmaceutical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'March 17, 2015')]"
11644,Using the spinal cord injury common data elements,"Clinical trials, Experimental studies",Neurology,Data, ,"clinical studies, clinical study, clinical trial, clinical trials, common data, common data element, common data elements, core data, core data set, core data set variables, core data sets, data, data element, data elements, data set, International Spinal Cord Injury Core Data Set, International Spinal Cord Injury Data Sets, neurological, neurology, SCI core data set, SCI core data sets, SCI data set, SCI data sets, spinal, spinal cord injury, spinal injury, spine, trial, trials", ,"Biering-S\xf8rensen F, Charlifue S, Devivo MJ, Grinnon ST, Kleitman N, Lu Y, Odenkirchen J. Using the Spinal Cord Injury Common Data Elements. Top Spinal Cord Inj Rehabil. 2012;18(1):23-27.","Biering-S\xf8rensen F, Charlifue S, Devivo MJ, Grinnon ST, Kleitman N, Lu Y, Odenkirchen J.",Topics in Spinal Cord Injury Rehabilitation [Top Spinal Cord Inj Rehabil.],2012,18,1,23-27, ,English, ,22408366,http://www.ncbi.nlm.nih.gov/pubmed/22408366, , , , , , ,Reporting common data elements for spinal cord injury, , , , , , , ,no,2015-02-13 15:20:18,2015-02-13 15:20:18,using-the-spinal-cord-injury-common-data-elements,"[('title', 'Using the spinal cord injury common data elements'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting common data elements for spinal cord injury'), ('Full bibliographic reference', 'Biering-Sørensen F, Charlifue S, Devivo MJ, Grinnon ST, Kleitman N, Lu Y, Odenkirchen J. Using the Spinal Cord Injury Common Data Elements. Top Spinal Cord Inj Rehabil. 2012;18(1):23-27.'), ('Language', 'English'), ('PubMed ID', '[22408366](http://www.ncbi.nlm.nih.gov/pubmed/22408366)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Neurology'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'February 13, 2015')]"
11639,Guidelines for assessment of bone microstructure in rodents using micro-computed tomography,Animal pre-clinical research,Rheumatology,"Images, Procedure/Method, Results, Terminology/definitions", ,"animal, animals, bone, bone density, bone mass, bone microstructure, bone mineral density, bone morphology, bone morphometry, cortical, cortical bone, cortical bone morphometry, density, ex vivo, image, images, micro computed tomography, microcomputed tomography, microCT, microCT image, microCT images, microstructure, morphometry, nomenclature, rodent, rodents, scan, tissue, tissue density, tissue mineral density, trabecular, trabecular bone, trabecular bone morphometry", ,"Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, M\xfcller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010;25(7):1468-1486.","Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, M\xfcller R.",Journal of Bone and Mineral Research [J Bone Miner Res.],2010,25,7,1468-1486, ,English, ,20533309,http://www.ncbi.nlm.nih.gov/pubmed/20533309, , , , , , ,Reporting of microCT-derived bone morphometry and density measurements, , , , , , , ,no,2015-02-13 14:55:20,2015-02-13 14:55:20,guidelines-for-assessment-of-bone-microstructure-in-rodents-using-micro-computed-tomography,"[('title', 'Guidelines for assessment of bone microstructure in rodents using micro-computed tomography'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of microCT-derived bone morphometry and density measurements'), ('Full bibliographic reference', 'Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010;25(7):1468-1486.'), ('Language', 'English'), ('PubMed ID', '[20533309](http://www.ncbi.nlm.nih.gov/pubmed/20533309)'), ('Study design', 'Animal pre-clinical research'), ('Clinical area', 'Rheumatology'), ('Applies to the whole report or to individual sections of the report?', 'Images, Procedure/Method, Results, Terminology/definitions'), ('Record last updated on', 'February 13, 2015')]"
11634,Instrumental variable methods in comparative safety and effectiveness research,"Clinical trials, Experimental studies, Observational studies", ,Statistical methods and analyses, ,"bias, clinical trial, clinical trials, comparative effectiveness, comparative effectiveness research, comparative safety, comparative safety research, confounders, confounding, confounding bias, confounding factor, confounding factors, epidemiology, instrumental variable, instrumental variable analyses, instrumental variable analysis, instrumental variable methods, instrumental variable studies, instrumental variable study, instrumental variables, IV, IV analyses, IV analysis, IV methods, IV studies, IV study, randomised controlled trial, randomised controlled trials, randomized controlled trial, randomized controlled trials, RCT, RCTs, trial, trials, variable, variables", ,"Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf. 2010;19(6):537-554.","Brookhart MA, Rassen JA, Schneeweiss S.",Pharmacoepidemiology and Drug Safety [Pharmacoepidemiol Drug Saf.],2010,19,6,537-554, ,English, ,20354968,http://www.ncbi.nlm.nih.gov/pubmed/20354968, , , , , , ,Reporting of instrumental variable methods in comparative safety and effectiveness research, , , , , , , ,no,2015-02-13 14:18:26,2015-02-13 14:18:26,instrumental-variable-methods-in-comparative-safety-and-effectiveness-research,"[('title', 'Instrumental variable methods in comparative safety and effectiveness research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of instrumental variable methods in comparative safety and effectiveness research'), ('Full bibliographic reference', 'Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf. 2010;19(6):537-554.'), ('Language', 'English'), ('PubMed ID', '[20354968](http://www.ncbi.nlm.nih.gov/pubmed/20354968)'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Record last updated on', 'February 13, 2015')]"
11631,Protecting the power of interventions through proper reporting, , ,Intervention (exposure), ,"checklist, checklists, intervention, intervention research, intervention studies, intervention study, interventions, nursing, nursing intervention research, nursing research", ,"Conn VS, Groves PS. Protecting the power of interventions through proper reporting. Nurs Outlook. 2011;59(6):318-325.","Conn VS, Groves PS.",Nursing Outlook. [Nurs Outlook.],2011,59,6,318-325, ,English, ,21840555,http://www.ncbi.nlm.nih.gov/pubmed/21840555, , , , , , ,Reporting of interventions in research reports, , , , , , , ,no,2015-02-13 12:04:15,2015-02-13 12:04:15,protecting-the-power-of-interventions-through-proper-reporting,"[('title', 'Protecting the power of interventions through proper reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of interventions in research reports'), ('Full bibliographic reference', 'Conn VS, Groves PS. Protecting the power of interventions through proper reporting. Nurs Outlook. 2011;59(6):318-325.'), ('Language', 'English'), ('PubMed ID', '[21840555](http://www.ncbi.nlm.nih.gov/pubmed/21840555)'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'February 13, 2015')]"
11627,Reporting of data from out-of-hospital cardiac arrest has to involve emergency medical dispatching - taking the recommendations on reporting OHCA the Utstein style a step further, ,Emergency medicine,Data, ,"arrest, CA, cardiac, cardiac arrest, cardiopulmonary, cardiopulmonary resuscitation, CPR, dispatch, dispatch process, dispatching, dispatching process, EMCC, EMD, emergency, emergency call, emergency care, emergency medical communication centres, emergency medical dispatch, emergency medical dispatching, emergency medical response, emergency medicine, emergency response, emergency service, EMS, medical emergencies, medical emergency, OHCA, out of hospital cardiac arrest, prehospital, prehospital research, resuscitation, Utstein, Utstein style", ,"Castr\xe9n M, Bohm K, Kvam AM, Bovim E, Christensen EF, Steen-Hansen JE, Karlsten R. Reporting of data from out-of-hospital cardiac arrest has to involve emergency medical dispatching - taking the recommendations on reporting OHCA the Utstein style a step further. Resuscitation. 2011;82(12):1496-1500.","Castr\xe9n M, Bohm K, Kvam AM, Bovim E, Christensen EF, Steen-Hansen JE, Karlsten R.",Resuscitation,2011,82,12,1496-1500, ,English, ,21907688,http://www.ncbi.nlm.nih.gov/pubmed/21907688, , , , , , ,Reporting of the medical emergency dispatch process for out-of-hospital cardiac arrest,A Spanish translation (Word) of the summary of this article is available., , , , , , ,no,2015-02-13 11:43:30,2021-12-17 15:58:37,reporting-of-data-from-out-of-hospital-cardiac-arrest-has-to-involve-emergency-medical-dispatching-taking-the-recommendations-on-reporting-ohca-the-utstein-style-a-step-further,"[('title', 'Reporting of data from out-of-hospital cardiac arrest has to involve emergency medical dispatching – taking the recommendations on reporting OHCA the Utstein style a step further'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of the medical emergency dispatch process for out-of-hospital cardiac arrest'), ('Full bibliographic reference', 'Castrén M, Bohm K, Kvam AM, Bovim E, Christensen EF, Steen-Hansen JE, Karlsten R. Reporting of data from out-of-hospital cardiac arrest has to involve emergency medical dispatching - taking the recommendations on reporting OHCA the Utstein style a step further. Resuscitation. 2011;82(12):1496-1500.'), ('Language', 'English'), ('PubMed ID', '[21907688](http://www.ncbi.nlm.nih.gov/pubmed/21907688)'), ('Availability in additional languages', 'A [Spanish translation (Word)](http://www.sciencedirect.com/science/MiamiMultiMediaURL/1-s2.0-S0300957211005223/1-s2.0-S0300957211005223-mmc1.doc/271105/FULL/S0300957211005223/ad640d4e31e669c6f402a3699a5a06e5/mmc1.doc) of the summary of this article is available.'), ('Clinical area', 'Emergency medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'December 17, 2021')]"
11622,A position paper on standardizing the nonneoplastic kidney biopsy report, ,"Pathology, Renal medicine", , ,"biopsies, biopsy, biopsy specimen, biopsy specimens, immunofluorescence, kidney, kidney biopsies, kidney biopsy, kidney biopsy report, kidney biopsy reports, kidney transplant, microscopic, microscopy, nephrology, nephropathology, nonneoplastic, nonneoplastic kidney biopsies, nonneoplastic kidney biopsy, pathologic, pathologist, pathologists, pathology, pathology report, pathology reports, renal, renal biopsies, renal biopsy, Renal Pathology Society", ,"Chang A, Gibson IW, Cohen AH, Weening JJ, Jennette JC, Fogo AB; Renal Pathology Society. A position paper on standardizing the nonneoplastic kidney biopsy report. Clin J Am Soc Nephrol. 2012;7(8):1365-1368.","Chang A, Gibson IW, Cohen AH, Weening JJ, Jennette JC, Fogo AB; Renal Pathology Society.",Clinical Journal of the American Society of Nephrology CJASN [Clin J Am Soc Nephrol.],2012,7,8,1365-1368, ,English, ,22798541,http://www.ncbi.nlm.nih.gov/pubmed/22798541, , , , , , ,Reporting essential elements and pathologic parameters for nonneoplastic kidney biopsy reports, , , , , , , ,no,2015-02-13 10:50:48,2015-02-13 10:59:38,a-position-paper-on-standardizing-the-nonneoplastic-kidney-biopsy-report,"[('title', 'A position paper on standardizing the nonneoplastic kidney biopsy report'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting essential elements and pathologic parameters for nonneoplastic kidney biopsy reports'), ('Full bibliographic reference', 'Chang A, Gibson IW, Cohen AH, Weening JJ, Jennette JC, Fogo AB; Renal Pathology Society. A position paper on standardizing the nonneoplastic kidney biopsy report. Clin J Am Soc Nephrol. 2012;7(8):1365-1368.'), ('Language', 'English'), ('PubMed ID', '[22798541](http://www.ncbi.nlm.nih.gov/pubmed/22798541)'), ('Clinical area', 'Pathology, Renal medicine'), ('Record last updated on', 'February 13, 2015')]"
11617,Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations,Economic evaluations, ,"Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)", ,"attribute, attribute development, attribute generation, attributes, conjoint analysis, DCE, DCE studies, DCE study, DCEs, discrete choice experiment, discrete choice experiment studies, discrete choice experiment study, discrete choice experiments, economic, economic evaluation, economic evaluations, economic studies, economic study, health economics, qualitative, qualitative method, qualitative methods", ,"Coast J, Al-Janabi H, Sutton EJ, Horrocks SA, Vosper AJ, Swancutt DR, Flynn TN. Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations. Health Econ. 2012;21(6):730-741.","Coast J, Al-Janabi H, Sutton EJ, Horrocks SA, Vosper AJ, Swancutt DR, Flynn TN.",Health Economics [Health Econ.],2012,21,6,730-741, ,English, ,21557381,http://www.ncbi.nlm.nih.gov/pubmed/21557381, , , , , , ,Reporting of attribute development for discrete choice experiments, , , , , , , ,no,2015-02-13 09:48:06,2015-02-13 09:48:06,using-qualitative-methods-for-attribute-development-for-discrete-choice-experiments-issues-and-recommendations,"[('title', 'Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of attribute development for discrete choice experiments'), ('Full bibliographic reference', 'Coast J, Al-Janabi H, Sutton EJ, Horrocks SA, Vosper AJ, Swancutt DR, Flynn TN. Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations. Health Econ. 2012;21(6):730-741.'), ('Language', 'English'), ('PubMed ID', '[21557381](http://www.ncbi.nlm.nih.gov/pubmed/21557381)'), ('Study design', 'Economic evaluations'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method, Results, Statistical methods and analyses, Study characteristics (participants etc.)'), ('Record last updated on', 'February 13, 2015')]"
11613,Reporting of interaction, , ,Statistical methods and analyses, ,"additive interaction, additive scale, interaction, interaction effect, interaction effects, multiplicative model, multiplicative models, multiplicative scale, statistical model, statistical models, statistics", ,"de Jager DJ, de Mutsert R, Jager KJ, Zoccali C, Dekker FW. Reporting of interaction. Nephron Clin Pract. 2011;119(2):c158-161.","de Jager DJ, de Mutsert R, Jager KJ, Zoccali C, Dekker FW.",Nephron. Clinical Practice. [Nephron Clin Pract.],2011,119,2,c158-161, ,English, ,21757954,http://www.ncbi.nlm.nih.gov/pubmed/21757954, , , , , , ,Reporting of interaction effects, , , , , , , ,no,2015-02-12 15:58:31,2015-02-12 15:58:31,reporting-of-interaction,"[('title', 'Reporting of interaction'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of interaction effects'), ('Full bibliographic reference', 'de Jager DJ, de Mutsert R, Jager KJ, Zoccali C, Dekker FW. Reporting of interaction. Nephron Clin Pract. 2011;119(2):c158-161.'), ('Language', 'English'), ('PubMed ID', '[21757954](http://www.ncbi.nlm.nih.gov/pubmed/21757954)'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Record last updated on', 'February 12, 2015')]"
11606,"Head, neck, and brain tumor embolization guidelines","Clinical trials, Experimental studies","Neurology, Oncology, Radiology, Surgery",Terminology/definitions, ,"brain, brain tumor, brain tumour, cancer, embolisation, embolisation treatment, embolization, embolization treatment, endovascular embolisation, endovascular embolization, endovascular treatment, head, head and neck, head tumor, head tumour, interventional radiology, neck, neck tumor, neck tumour, neuroendovascular, neurointerventional, oncology, percutaneous, percutaneous embolisation, percutaneous embolization, perioperative, perioperative embolisation, perioperative embolization, perioperative vascular tumor embolisation, perioperative vascular tumor embolization, perioperative vascular tumour embolisation, perioperative vascular tumour embolization, radiology, Society of NeuroInterventional Surgery, surgery, surgical, tumor embolisation, tumor embolization, tumors, tumour embolisation, tumour embolization, tumours, vascular, vascular tumor, vascular tumors, vascular tumour, vascular tumours", ,"Duffis EJ, Gandhi CD, Prestigiacomo CJ, Abruzzo T, Albuquerque F, Bulsara KR, Derdeyn CP, Fraser JF, Hirsch JA, Hussain MS, Do HM, Jayaraman MV, Meyers PM, Narayanan S; Society for Neurointerventional Surgery. Head, neck, and brain tumor embolization guidelines. J Neurointerv Surg. 2012;4(4):251-255.","Duffis EJ, Gandhi CD, Prestigiacomo CJ, Abruzzo T, Albuquerque F, Bulsara KR, Derdeyn CP, Fraser JF, Hirsch JA, Hussain MS, Do HM, Jayaraman MV, Meyers PM, Narayanan S; Society for Neurointerventional Surgery.",Journal of Neurointerventional Surgery [Neurointerv Surg.],2012,4,4,251-255, ,English, ,22539531,http://www.ncbi.nlm.nih.gov/pubmed/22539531, , , , , , ,"Reporting embolisation treatment of vascular head, neck and brain tumours", , , , , , , ,no,2015-02-12 15:26:59,2015-06-24 13:21:18,head-neck-and-brain-tumor-embolization-guidelines,"[('title', 'Head, neck, and brain tumor embolization guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting embolisation treatment of vascular head, neck and brain tumours'), ('Full bibliographic reference', 'Duffis EJ, Gandhi CD, Prestigiacomo CJ, Abruzzo T, Albuquerque F, Bulsara KR, Derdeyn CP, Fraser JF, Hirsch JA, Hussain MS, Do HM, Jayaraman MV, Meyers PM, Narayanan S; Society for Neurointerventional Surgery. Head, neck, and brain tumor embolization guidelines. J Neurointerv Surg. 2012;4(4):251-255.'), ('Language', 'English'), ('PubMed ID', '[22539531](http://www.ncbi.nlm.nih.gov/pubmed/22539531)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Neurology, Oncology, Radiology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Terminology/definitions'), ('Record last updated on', 'June 24, 2015')]"
11602,Reporting outcomes of back pain trials: a modified Delphi study,"Clinical trials, Experimental studies",Rheumatology,Outcomes (variables), ,"back, back pain, clinical trial, clinical trials, continuous outcomes, continuous primary outcome, continuous primary outcome measure, continuous primary outcome measures, continuous primary outcomes, LBP, low back pain, outcome, outcomes, pain, patient outcome, patient outcomes, patient-reported outcome, patient-reported outcomes, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Froud R, Eldridge S, Kovacs F, Breen A, Bolton J, Dunn K, Fritz J, Keller A, Kent P, Lauridsen HH, Ostelo R, Pincus T, van Tulder M, Vogel S, Underwood M. Reporting outcomes of back pain trials: a modified Delphi study. Eur J Pain. 2011;15(10):1068-1074.","Froud R, Eldridge S, Kovacs F, Breen A, Bolton J, Dunn K, Fritz J, Keller A, Kent P, Lauridsen HH, Ostelo R, Pincus T, van Tulder M, Vogel S, Underwood M.",European Journal of Pain [Eur J Pain.],2011,15,10,1068-1074, ,English, ,21596600,http://www.ncbi.nlm.nih.gov/pubmed/21596600, , , , , , ,Reporting of patient-reported outcomes in low back pain trials, , , , , , , ,no,2015-02-11 16:13:38,2015-02-11 16:13:38,reporting-outcomes-of-back-pain-trials-a-modified-delphi-study,"[('title', 'Reporting outcomes of back pain trials: a modified Delphi study'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of patient-reported outcomes in low back pain trials'), ('Full bibliographic reference', 'Froud R, Eldridge S, Kovacs F, Breen A, Bolton J, Dunn K, Fritz J, Keller A, Kent P, Lauridsen HH, Ostelo R, Pincus T, van Tulder M, Vogel S, Underwood M. Reporting outcomes of back pain trials: a modified Delphi study. Eur J Pain. 2011;15(10):1068-1074.'), ('Language', 'English'), ('PubMed ID', '[21596600](http://www.ncbi.nlm.nih.gov/pubmed/21596600)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Rheumatology'), ('Applies to the whole report or to individual sections of the report?', 'Outcomes (variables)'), ('Record last updated on', 'February 11, 2015')]"
11597,A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints,"Clinical trials, Experimental studies",Oncology,Terminology/definitions, ,"breast, breast cancer, breast tumor, breast tumour, cancer, carcinoma, clinical trial, clinical trials, definition, definitions, endpoint, endpoint assessment, endpoint assessments, endpoints, imaging endpoint, imaging endpoints, neoadjuvant, neoadjuvant clinical trial, neoadjuvant clinical trials, neoadjuvant treatment, neoadjuvant trial, neoadjuvant trials, oncology, presurgical, survival endpoint, survival endpoints, trial, trials, tumor, tumour", ,"Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M; BIG-NABCG collaboration. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol. 2012;13(6):e240-248.","Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M; BIG-NABCG collaboration.",The Lancet. Oncology. [Lancet Oncol.],2012,13,6,e240-248, ,English, ,22652232,http://www.ncbi.nlm.nih.gov/pubmed/22652232, , , , , , ,Standard definitions and endpoints for neoadjuvant clinical trials in breast cancer, , , , , , , ,no,2015-02-11 15:31:07,2015-02-11 15:31:07,a-common-language-in-neoadjuvant-breast-cancer-clinical-trials-proposals-for-standard-definitions-and-endpoints,"[('title', 'A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Standard definitions and endpoints for neoadjuvant clinical trials in breast cancer'), ('Full bibliographic reference', 'Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M; BIG-NABCG collaboration. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol. 2012;13(6):e240-248.'), ('Language', 'English'), ('PubMed ID', '[22652232](http://www.ncbi.nlm.nih.gov/pubmed/22652232)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Terminology/definitions'), ('Record last updated on', 'February 11, 2015')]"
11579,"Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data","Clinical trials, Experimental studies, Observational studies",Infectious diseases,"Harms/adverse effects/safety data, Terminology/definitions", ,"adverse, adverse effect, adverse effects, adverse event, adverse events, adverse events following immunisation, adverse events following immunization, adverse reaction, adverse reactions, AEFI, Brighton Collaboration, case definition, case definitions, definition, definitions, harm, harms, immunisation, immunisation safety, immunisations, immunization, immunization safety, immunizations, multiple organ system failure, safety, safety data, unintended effect, unintended effects, vaccination, vaccinations, vaccine, vaccine safety, vaccine safety data, vaccines, viscerotropic, viscerotropic disease, VTD, YEL-AVD, yellow fever, yellow fever vaccine, yellow fever vaccine safety, YF vaccination, YF vaccine, YF vaccine associated viscerotropic disease", ,"Gershman MD, Staples JE, Bentsi-Enchill AD, Breugelmans JG, Brito GS, Camacho LA, Cottin P, Domingo C, Durbin A, Gascon J, Guenaneche F, Hayes EB, Jelenik Z, Khromava A, Martins Rde M, Wilson MM, Massy N, Nasidi A, Niedrig M, Sherwat A, Tsai T, Vilella A, Wilson ME, Kohl KS; Brighton Collaboration Viscerotropic Disease Working Group. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2012;30(33):5038-5058.","Gershman MD, Staples JE, Bentsi-Enchill AD, Breugelmans JG, Brito GS, Camacho LA, Cottin P, Domingo C, Durbin A, Gascon J, Guenaneche F, Hayes EB, Jelenik Z, Khromava A, Martins Rde M, Wilson MM, Massy N, Nasidi A, Niedrig M, Sherwat A, Tsai T, Vilella A, Wilson ME, Kohl KS; Brighton Collaboration Viscerotropic Disease Working Group.",Vaccine.,2012,30,33,5038-5058, ,English, ,22561144,http://www.ncbi.nlm.nih.gov/pubmed/22561144, , , , , , ,Definitions for viscerotropic disease as an adverse event following immunization, , , , , , , ,no,2015-02-11 11:55:03,2016-08-16 13:58:46,viscerotropic-disease-case-definition-and-guidelines-for-collection-analysis-and-presentation-of-immunization-safety-data,"[('title', 'Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Definitions for viscerotropic disease as an adverse event following immunization'), ('Full bibliographic reference', 'Gershman MD, Staples JE, Bentsi-Enchill AD, Breugelmans JG, Brito GS, Camacho LA, Cottin P, Domingo C, Durbin A, Gascon J, Guenaneche F, Hayes EB, Jelenik Z, Khromava A, Martins Rde M, Wilson MM, Massy N, Nasidi A, Niedrig M, Sherwat A, Tsai T, Vilella A, Wilson ME, Kohl KS; Brighton Collaboration Viscerotropic Disease Working Group. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2012;30(33):5038-5058.'), ('Language', 'English'), ('PubMed ID', '[22561144](http://www.ncbi.nlm.nih.gov/pubmed/22561144)'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Infectious diseases'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Terminology/definitions'), ('Record last updated on', 'August 16, 2016')]"
11576,"Diarrhea: case definition and guidelines for collection, analysis, and presentation of immunization safety data", ,Infectious diseases,"Harms/adverse effects/safety data, Terminology/definitions", ,"acute diarrhea, acute diarrhoea, adverse, adverse effect, adverse effects, adverse event, adverse events, adverse events following immunisation, adverse events following immunization, adverse reaction, adverse reactions, AEFI, bowel movement, bowel movements, case definition, case definitions, definition, definitions, diarrhea, diarrhoea, harm, harms, immunisation, immunisation safety, immunisation safety data, immunisations, immunization, immunization safety, immunization safety data, immunizations, safe, safety, safety data, surveillance, unintended effect, unintended effects, vaccination, vaccinations, vaccine, vaccine safety, vaccine safety data, vaccines", ,"Gidudu J, Sack DA, Pina M, Hudson MJ, Kohl KS, Bishop P, Chatterjee A, Chiappini E, Compingbutra A, da Costa C, Fernandopulle R, Fischer TK, Haber P, Masana W, de Menezes MR, Kang G, Khuri-Bulos N, Killion LA, Nair C, Poerschke G, Rath B, Salazar-Lindo E, Setse R, Wenger P, Wong VC, Zaman K; Brighton Collaboration Diarrhea Working Group. Diarrhea: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29(5):1053-1071.","Gidudu J, Sack DA, Pina M, Hudson MJ, Kohl KS, Bishop P, Chatterjee A, Chiappini E, Compingbutra A, da Costa C, Fernandopulle R, Fischer TK, Haber P, Masana W, de Menezes MR, Kang G, Khuri-Bulos N, Killion LA, Nair C, Poerschke G, Rath B, Salazar-Lindo E, Setse R, Wenger P, Wong VC, Zaman K; Brighton Collaboration Diarrhea Working Group.",Vaccine.,2011,29,5,1053-1071, ,English, ,21130754,http://www.ncbi.nlm.nih.gov/pubmed/21130754, , , , , , ,Definition of diarrhea as an adverse event following immunization, , , , , , , ,no,2015-02-04 15:13:58,2016-08-16 13:56:09,diarrhea-case-definition-and-guidelines-for-collection-analysis-and-presentation-of-immunization-safety-data,"[('title', 'Diarrhea: case definition and guidelines for collection, analysis, and presentation of immunization safety data'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Definition of diarrhea as an adverse event following immunization'), ('Full bibliographic reference', 'Gidudu J, Sack DA, Pina M, Hudson MJ, Kohl KS, Bishop P, Chatterjee A, Chiappini E, Compingbutra A, da Costa C, Fernandopulle R, Fischer TK, Haber P, Masana W, de Menezes MR, Kang G, Khuri-Bulos N, Killion LA, Nair C, Poerschke G, Rath B, Salazar-Lindo E, Setse R, Wenger P, Wong VC, Zaman K; Brighton Collaboration Diarrhea Working Group. Diarrhea: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29(5):1053-1071.'), ('Language', 'English'), ('PubMed ID', '[21130754](http://www.ncbi.nlm.nih.gov/pubmed/21130754)'), ('Clinical area', 'Infectious diseases'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Terminology/definitions'), ('Record last updated on', 'August 16, 2016')]"
11570,"Immunization site pain: case definition and guidelines for collection, analysis, and presentation of immunization safety data", ,Infectious diseases,"Harms/adverse effects/safety data, Terminology/definitions", ,"adverse, adverse effect, adverse effects, adverse event, adverse events, adverse events following immunisation, adverse events following immunization, adverse reaction, adverse reactions, AEFI, Brighton Collaboration, case definition, case definitions, definition, definitions, harm, harms, immunisation, immunisation pain, immunisation safety, immunisation safety data, immunisation site pain, immunisations, immunization, immunization pain, immunization safety, immunization safety data, immunization site pain, immunizations, injection pain, needle pain, pain, pain assessment, safety, safety data, site pain, surveillance, unintended effect, unintended effects, vaccination, vaccinations, vaccine, vaccine safety, vaccines", ,"Gidudu JF, Walco GA, Taddio A, Zempsky WT, Halperin SA, Calugar A, Gibbs NA, Hennig R, Jovancevic M, Netterlid E, O'Connor T, Oleske JM, Varricchio F, Tsai TF, Seifert H, Schuind AE; Brighton Immunization Site Pain Working Group. Immunization site pain: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2012;30(30):4558-4577.","Gidudu JF, Walco GA, Taddio A, Zempsky WT, Halperin SA, Calugar A, Gibbs NA, Hennig R, Jovancevic M, Netterlid E, O'Connor T, Oleske JM, Varricchio F, Tsai TF, Seifert H, Schuind AE; Brighton Immunization Site Pain Working Group.",Vaccine.,2012,30,30,4558-4577, ,English, ,22521267,http://www.ncbi.nlm.nih.gov/pubmed/22521267, , , , , , ,Definition of immunization site pain as an adverse event following immunization, , , , , , , ,no,2015-02-04 14:42:38,2016-08-16 13:53:51,immunization-site-pain-case-definition-and-guidelines-for-collection-analysis-and-presentation-of-immunization-safety-data,"[('title', 'Immunization site pain: case definition and guidelines for collection, analysis, and presentation of immunization safety data'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Definition of immunization site pain as an adverse event following immunization'), ('Full bibliographic reference', ""Gidudu JF, Walco GA, Taddio A, Zempsky WT, Halperin SA, Calugar A, Gibbs NA, Hennig R, Jovancevic M, Netterlid E, O'Connor T, Oleske JM, Varricchio F, Tsai TF, Seifert H, Schuind AE; Brighton Immunization Site Pain Working Group. Immunization site pain: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2012;30(30):4558-4577.""), ('Language', 'English'), ('PubMed ID', '[22521267](http://www.ncbi.nlm.nih.gov/pubmed/22521267)'), ('Clinical area', 'Infectious diseases'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Terminology/definitions'), ('Record last updated on', 'August 16, 2016')]"
11561,Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study, ,Infectious diseases,"Harms/adverse effects/safety data, Terminology/definitions", ,"adverse, adverse effect, adverse effects, adverse event, adverse events, adverse events following immunisation, adverse events following immunization, adverse reaction, adverse reactions, AEFI, AEFI reporting checklist, anaphylactic, anaphylaxis, Brighton Collaboration, case definition, case definitions, checklist, definition, definitions, harm, harms, immunisation, immunisation anaphylaxis, immunisation safety, immunisations, immunization, immunization anaphylaxis, immunization safety, immunizations, PMS, post marketing, post marketing surveillance, safety, safety data, surveillance, unintended effect, unintended effects, vaccination, vaccinations, vaccine, vaccine anaphylaxis, vaccine safety, vaccine safety data, vaccines", ,"Gold MS, Gidudu J, Erlewyn-Lajeunesse M, Law B; Brighton Collaboration Working Group on Anaphylaxis. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study. Vaccine. 2010;28(28):4487-4498.","Gold MS, Gidudu J, Erlewyn-Lajeunesse M, Law B; Brighton Collaboration Working Group on Anaphylaxis.",Vaccine.,2010,28,28,4487-4498, ,English, ,20434547,http://www.ncbi.nlm.nih.gov/pubmed/20434547, , , , , , ,Definitions for reporting adverse events following immunizations, , , , , , , ,no,2015-02-04 14:07:09,2016-08-16 13:51:48,can-the-brighton-collaboration-case-definitions-be-used-to-improve-the-quality-of-adverse-event-following-immunization-aefi-reporting-anaphylaxis-as-a-case-study,"[('title', 'Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Definitions for reporting adverse events following immunizations'), ('Full bibliographic reference', 'Gold MS, Gidudu J, Erlewyn-Lajeunesse M, Law B; Brighton Collaboration Working Group on Anaphylaxis. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study. Vaccine. 2010;28(28):4487-4498.'), ('Language', 'English'), ('PubMed ID', '[20434547](http://www.ncbi.nlm.nih.gov/pubmed/20434547)'), ('Clinical area', 'Infectious diseases'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Terminology/definitions'), ('Record last updated on', 'August 16, 2016')]"
11555,"Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet","Clinical trials, Experimental studies",Oncology,"Statistical methods and analyses, Terminology/definitions", ,"analyses, analysis, chronic myeloid leukaemia, chronic myeloid leukemia, clinical trial, clinical trials, CML, definition, definitions, end point, end points, endpoint, endpoints, European LeukemiaNet, events, leukaemia, leukemia, LeukemiaNet, methodology, myeloid leukaemia, myeloid leukemia, oncology, phase 3, phase 3 clinical trial, phase 3 clinical trials, phase 3 trial, phase 3 trials, phase III, phase III clinical trial, phase III clinical trials, phase III trial, phase III trials, statistics, trial, trials", ,"Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zaritskey A, Hehlmann R. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood. 2012;119(25):5963-5971.","Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zaritskey A, Hehlmann R.",Blood.,2012,119,25,5963-5971, ,English, ,22508936,http://www.ncbi.nlm.nih.gov/pubmed/22508936, , , , , , ,"Reporting definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia", , , , , , , ,no,2015-02-04 11:36:39,2015-02-04 11:38:49,definitions-methodological-and-statistical-issues-for-phase-3-clinical-trials-in-chronic-myeloid-leukemia-a-proposal-by-the-european-leukemianet,"[('title', 'Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia'), ('Full bibliographic reference', 'Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zaritskey A, Hehlmann R. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood. 2012;119(25):5963-5971.'), ('Language', 'English'), ('PubMed ID', '[22508936](http://www.ncbi.nlm.nih.gov/pubmed/22508936)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses, Terminology/definitions'), ('Record last updated on', 'February 4, 2015')]"
11542,A new standardized format for reporting hearing outcome in clinical trials,"Clinical trials, Experimental studies",Audiovestibular medicine,"Data, Outcomes (variables)", ,"acustic hearing, audiogram, audiological, audiology, audiometric, audiometrics, audiometry, audiovestibular, clinical studies, clinical study, clinical trial, clinical trials, conductive, conductive hearing loss, data, deaf, deafness, hear, hearing, hearing disability, hearing function, hearing loss, hearing outcome, hearing outcomes, hearing results, Meniere's disease, mixed, mixed hearing loss, neural, neural hearing loss, otolaryngology, otological, outcomes, profound deafness, profoundly deaf, pure tone, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, scattergram, sensory, sensory hearing loss, trial, trials, word recognition", ,"Gurgel RK, Jackler RK, Dobie RA, Popelka GR. A new standardized format for reporting hearing outcome in clinical trials. Otolaryngol Head Neck Surg. 2012;147(5):803-807.","Gurgel RK, Jackler RK, Dobie RA, Popelka GR.",Otolaryngology - head and neck surgery [Otolaryngol Head Neck Surg.],2012,147,5,803-807., ,English, ,22931898,http://www.ncbi.nlm.nih.gov/pubmed/22931898, , , , , , ,Reporting hearing outcomes in clinical trials, , , , , , , ,no,2015-02-04 10:56:29,2015-02-04 10:56:29,a-new-standardized-format-for-reporting-hearing-outcome-in-clinical-trials,"[('title', 'A new standardized format for reporting hearing outcome in clinical trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting hearing outcomes in clinical trials'), ('Full bibliographic reference', 'Gurgel RK, Jackler RK, Dobie RA, Popelka GR. A new standardized format for reporting hearing outcome in clinical trials. Otolaryngol Head Neck Surg. 2012;147(5):803-807.'), ('Language', 'English'), ('PubMed ID', '[22931898](http://www.ncbi.nlm.nih.gov/pubmed/22931898)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Audiovestibular medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data, Outcomes (variables)'), ('Record last updated on', 'February 4, 2015')]"
11545,A consensus approach toward the standardization of back pain definitions for use in prevalence studies,"Observational studies, Qualitative research",Rheumatology,Terminology/definitions, ,"back, back pain, back pain prevalence, definition, definitions, epidemiologic prevalence studies, epidemiological, epidemiology, long standing back pain, low back pain, pain, prevalence, prevalence studies, prevalence study, severe back pain, severe low back pain", ,"Dionne CE, Dunn KM, Croft PR, Nachemson AL, Buchbinder R, Walker BF, Wyatt M, Cassidy JD, Rossignol M, Leboeuf-Yde C, Hartvigsen J, Leino-Arjas P, Latza U, Reis S, Gil Del Real MT, Kovacs FM, Oberg B, Cedraschi C, Bouter LM, Koes BW, Picavet HS, van Tulder MW, Burton K, Foster NE, Macfarlane GJ, Thomas E, Underwood M, Waddell G, Shekelle P, Volinn E, Von Korff M. A consensus approach toward the standardization of back pain definitions for use in prevalence studies. Spine (Phila Pa 1976).2008;33(1):95-103.","Dionne CE, Dunn KM, Croft PR, Nachemson AL, Buchbinder R, Walker BF, Wyatt M, Cassidy JD, Rossignol M, Leboeuf-Yde C, Hartvigsen J, Leino-Arjas P, Latza U, Reis S, Gil Del Real MT, Kovacs FM, Oberg B, Cedraschi C, Bouter LM, Koes BW, Picavet HS, van Tulder MW, Burton K, Foster NE, Macfarlane GJ, Thomas E, Underwood M, Waddell G, Shekelle P, Volinn E, Von Korff M.",Spine (Phila Pa 1976),2008,33,1,95-103, ,English, ,18165754,http://www.ncbi.nlm.nih.gov/pubmed/18165754,The full-text of the definitions of low back pain prevalence is available from the DOLBaPP website., , , ,https://www.backpaindefs.org/index.html,DOLBaPP,Standardising definitions of low back pain for epidemiological prevalence studies,The Delphi Definitions of Low Back Pain Prevalence (DOLBaPP) standards are also available in other languages., , , , , , ,no,2015-02-04 09:02:01,2022-10-26 11:20:42,a-consensus-approach-toward-the-standardization-of-back-pain-definitions-for-use-in-prevalence-studies,"[('title', 'A consensus approach toward the standardization of back pain definitions for use in prevalence studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Standardising definitions of low back pain for epidemiological prevalence studies'), ('Full bibliographic reference', 'Dionne CE, Dunn KM, Croft PR, Nachemson AL, Buchbinder R, Walker BF, Wyatt M, Cassidy JD, Rossignol M, Leboeuf-Yde C, Hartvigsen J, Leino-Arjas P, Latza U, Reis S, Gil Del Real MT, Kovacs FM, Oberg B, Cedraschi C, Bouter LM, Koes BW, Picavet HS, van Tulder MW, Burton K, Foster NE, Macfarlane GJ, Thomas E, Underwood M, Waddell G, Shekelle P, Volinn E, Von Korff M. A consensus approach toward the standardization of back pain definitions for use in prevalence studies. Spine (Phila Pa 1976).2008;33(1):95-103.'), ('Language', 'English'), ('PubMed ID', '[18165754](http://www.ncbi.nlm.nih.gov/pubmed/18165754)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the definitions of low back pain prevalence is available from the [DOLBaPP website](https://www.backpaindefs.org/index.html).'), ('Availability in additional languages', 'The Delphi Definitions of Low Back Pain Prevalence (DOLBaPP) standards are also available in [other languages](https://www.backpaindefs.org/official_versions.html).'), ('Reporting guideline website URL', '<https://www.backpaindefs.org/index.html>'), ('Reporting guideline acronym', 'DOLBaPP'), ('Study design', 'Observational studies, Qualitative research'), ('Clinical area', 'Rheumatology'), ('Applies to the whole report or to individual sections of the report?', 'Terminology/definitions'), ('Record last updated on', 'October 26, 2022')]"
11540,A proposed taxonomy of terms to guide the clinical trial recruitment process,"Clinical trials, Experimental studies",Palliative care,Terminology/definitions, ,"accrual, accrual target, accrual targets, clinical trial, clinical trials, end of life, end of life care, hospice and palliative care, palliative, palliative care, palliative care patients, palliative care research, palliative research, patient, patient population, patient recruitment, patients, recruitment, taxonomy, terminology, trial, trial feasibility, trial recruitment, trials", ,"Hagen NA, Wu JS, Stiles CR. A proposed taxonomy of terms to guide the clinical trial recruitment process. J Pain Symptom Manage. 2010;40(1):102-110.","Hagen NA, Wu JS, Stiles CR.",Journal of Pain and Symptom Managemet [J Pain Symptom Manage.],2010,40,1,102-110, ,English, ,20488653,http://www.ncbi.nlm.nih.gov/pubmed/20488653, , , , , , ,Definitions of terms that can be used to inform clinical trial feasibility in palliative care, , , , , , , ,no,2015-01-29 15:03:14,2015-01-29 15:03:14,a-proposed-taxonomy-of-terms-to-guide-the-clinical-trial-recruitment-process,"[('title', 'A proposed taxonomy of terms to guide the clinical trial recruitment process'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Definitions of terms that can be used to inform clinical trial feasibility in palliative care'), ('Full bibliographic reference', 'Hagen NA, Wu JS, Stiles CR. A proposed taxonomy of terms to guide the clinical trial recruitment process. J Pain Symptom Manage. 2010;40(1):102-110.'), ('Language', 'English'), ('PubMed ID', '[20488653](http://www.ncbi.nlm.nih.gov/pubmed/20488653)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Palliative care'), ('Applies to the whole report or to individual sections of the report?', 'Terminology/definitions'), ('Record last updated on', 'January 29, 2015')]"
11534,Minimum data elements for research reports on CFS,"Observational studies, Qualitative research","Infectious diseases, Neurology",Data, ,"case control, case only, CFS, CFS research, chronic fatigue, chronic fatigue syndrome, cross sectional, cross sectional studies, cross sectional study, data, data element, data elements, fatigue, immune, immune system, longitudinal, longitudinal studies, longitudinal study, nervous sytem, neurological, neurology, neuromuscular, observational, observational studies, observational study, virus", ,"Jason LA, Unger ER, Dimitrakoff JD, Fagin AP, Houghton M, Cook DB, Marshall GD Jr, Klimas N, Snell C. Minimum data elements for research reports on CFS. Brain Behav Immun. 2012;26(3):401-406.","Jason LA, Unger ER, Dimitrakoff JD, Fagin AP, Houghton M, Cook DB, Marshall GD Jr, Klimas N, Snell C.","Brain, behavior and immunity. [Brain Behav Immun.]",2012,26,3,401-406, ,English, ,22306456,http://www.ncbi.nlm.nih.gov/pubmed/22306456, , , , , , ,Minimum data elements that should be reported in chronic fatigue syndrome (CFS) research reports, , , , , , , ,no,2015-01-29 12:02:12,2015-01-29 14:12:00,minimum-data-elements-for-research-reports-on-cfs,"[('title', 'Minimum data elements for research reports on CFS'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Minimum data elements that should be reported in chronic fatigue syndrome (CFS) research reports'), ('Full bibliographic reference', 'Jason LA, Unger ER, Dimitrakoff JD, Fagin AP, Houghton M, Cook DB, Marshall GD Jr, Klimas N, Snell C. Minimum data elements for research reports on CFS. Brain Behav Immun. 2012;26(3):401-406.'), ('Language', 'English'), ('PubMed ID', '[22306456](http://www.ncbi.nlm.nih.gov/pubmed/22306456)'), ('Study design', 'Observational studies, Qualitative research'), ('Clinical area', 'Infectious diseases, Neurology'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'January 29, 2015')]"
11527,Reporting standards for angiographic evaluation and endovascular treatment of cerebral arteriovenous malformations,"Clinical trials, Experimental studies, Study protocols",Neurology,"Harms/adverse effects/safety data, Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions", ,"angiographic, angiography, arteriovenous, arteriovenous malformation, arteriovenous malformations, AVM embolisation, AVM embolization, AVMs, central nervous system, cerebral, cerebral arteriovenous malformation, cerebral arteriovenous malformations, cerebral AVMs, clinical studies, clinical study, clinical trial, clinical trials, CNS, embolisation, embolization, endovascular, endovascular therapies, endovascular therapy, endovascular treatment, neurologic, neurology, neurosurgery, neurovascular, protocol, protocols, radiological, radiology, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, surgery, trial, trials", ,"Jayaraman MV, Meyers PM, Derdeyn CP, Fraser JF, Hirsch JA, Hussain MS, Blackham KA, Eskey CJ, Jensen ME, Moran CJ, Prestigiacomo CJ, Rasmussen PA, McDougall CG. Reporting standards for angiographic evaluation and endovascular treatment of cerebral arteriovenous malformations. J Neurointerv Surg. 2012;4(5):325-330.","Jayaraman MV, Meyers PM, Derdeyn CP, Fraser JF, Hirsch JA, Hussain MS, Blackham KA, Eskey CJ, Jensen ME, Moran CJ, Prestigiacomo CJ, Rasmussen PA, McDougall CG.",Journal of Neurointerventional Surgery [J Neurointerv Surg.],2012,4,5,325-330, ,English, ,22131440,http://www.ncbi.nlm.nih.gov/pubmed/22131440, , , , , , ,Reporting radiological evaluation and endovascular treatment of cerebral arteriovenous malformations, , , , , , , ,no,2015-01-29 11:14:39,2015-01-29 11:45:06,reporting-standards-for-angiographic-evaluation-and-endovascular-treatment-of-cerebral-arteriovenous-malformations,"[('title', 'Reporting standards for angiographic evaluation and endovascular treatment of cerebral arteriovenous malformations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting radiological evaluation and endovascular treatment of cerebral arteriovenous malformations'), ('Full bibliographic reference', 'Jayaraman MV, Meyers PM, Derdeyn CP, Fraser JF, Hirsch JA, Hussain MS, Blackham KA, Eskey CJ, Jensen ME, Moran CJ, Prestigiacomo CJ, Rasmussen PA, McDougall CG. Reporting standards for angiographic evaluation and endovascular treatment of cerebral arteriovenous malformations. J Neurointerv Surg. 2012;4(5):325-330.'), ('Language', 'English'), ('PubMed ID', '[22131440](http://www.ncbi.nlm.nih.gov/pubmed/22131440)'), ('Study design', 'Clinical trials, Experimental studies, Study protocols'), ('Clinical area', 'Neurology'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'January 29, 2015')]"
11522,How to report low-level laser therapy (LLLT)/photomedicine dose and beam parameters in clinical and laboratory studies,"Clinical trials, Experimental studies", ,Intervention (exposure), ,"beam, beam measurement, beam parameter, beam parameters, clinical studies, clinical study, dosage, dose, dose calculation, dose parameter, dose parameters, laboratory, laboratory research, laser, laser therapy, LED, LLLT, low level laser therapy, photomedicine, photomedicine dose, phototherapy", ,"Jenkins PA, Carroll JD. How to report low-level laser therapy (LLLT)/photomedicine dose and beam parameters in clinical and laboratory studies. Photomed Laser Surg. 2011;29(12):785-7.","Jenkins PA, Carroll JD.",Photomedicine and Laser Surgery [Photomed Laser Surg.],2011,29,12,785-787, ,English, ,22107486,http://www.ncbi.nlm.nih.gov/pubmed/22107486, , , , , , ,Reporting low-level laser therapy (LLLT)/photomedicine dose and beam parameters in clinical and laboratory studies, , , , , , , ,no,2015-01-28 15:47:41,2015-01-28 15:57:28,how-to-report-low-level-laser-therapy-llltphotomedicine-dose-and-beam-parameters-in-clinical-and-laboratory-studies,"[('title', 'How to report low-level laser therapy (LLLT) /photomedicine dose and beam parameters in clinical and laboratory studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting low-level laser therapy (LLLT)/photomedicine dose and beam parameters in clinical and laboratory studies'), ('Full bibliographic reference', 'Jenkins PA, Carroll JD. How to report low-level laser therapy (LLLT)/photomedicine dose and beam parameters in clinical and laboratory studies. Photomed Laser Surg. 2011;29(12):785-7.'), ('Language', 'English'), ('PubMed ID', '[22107486](http://www.ncbi.nlm.nih.gov/pubmed/22107486)'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'January 28, 2015')]"
11518,Common data elements for posttraumatic stress disorder research, ,Psychiatry,Data, ,"common data, common data element, common data elements, data, data element, data elements, demographics, measure, measures, outcome, outcome measure, outcome measures, outcomes, post traumatic, posttraumatic, posttraumatic distress, posttraumatic stress, posttraumatic stress disorder, posttraumatic stress disorder research, PTSD, PTSD research, rehabilitation, stress, stress disorder, stress disorders, trauma, variable, variables", ,"Kaloupek DG, Chard KM, Freed MC, Peterson AL, Riggs DS, Stein MB, Tuma F. Common data elements for posttraumatic stress disorder research. Arch Phys Med Rehabil. 2010;91(11):1684-91.","Kaloupek DG, Chard KM, Freed MC, Peterson AL, Riggs DS, Stein MB, Tuma F.",Archives of Physical Medicine and Rehabilitation [Arch Phys Med Rehabil.],2010,91,11,1684-1691, ,English, ,21044712,http://www.ncbi.nlm.nih.gov/pubmed/21044712, , , , , , ,Reporting data elements in posttraumatic stress disorder research, , , , , , , ,no,2015-01-28 14:47:15,2015-01-28 15:05:48,common-data-elements-for-posttraumatic-stress-disorder-research,"[('title', 'Common data elements for posttraumatic stress disorder research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting data elements in posttraumatic stress disorder research'), ('Full bibliographic reference', 'Kaloupek DG, Chard KM, Freed MC, Peterson AL, Riggs DS, Stein MB, Tuma F. Common data elements for posttraumatic stress disorder research. Arch Phys Med Rehabil. 2010;91(11):1684-91.'), ('Language', 'English'), ('PubMed ID', '[21044712](http://www.ncbi.nlm.nih.gov/pubmed/21044712)'), ('Clinical area', 'Psychiatry'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'January 28, 2015')]"
11513,American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants, ,"Genetics, Obstetrics and gynaecology",Biospecimen/bioresource information, ,"aCGH, autism, autism spectrum, chromosomal, chromosomal microarray, chromosomal microarrays, CMA, CNV, congenital, congenital anomalies, congenital anomaly, constitutional CNVs, constitutional copy number, constitutional copy number variants, copy number variant, copy number variants, copy number variation, cytogenetic, cytogenetic microarray, cytogenetic microarrays, cytogenomic, cytogenomic microarray, cytogenomic microarrays, DNA, DNA copy number, genetic, genetic testing, genetics, genome, genomic, genomic microarray, genomic microarray results, genomics, intellectual disability, laboratory, microarray, microarrays, mutation, mutations, pathogenic copy number, polymorphic variation, postnatal", ,"Kearney HM, Thorland EC, Brown KK, Quintero-Rivera F, South ST; Working Group of the American College of Medical Genetics Laboratory Quality Assurance Committee. American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. Genet Med. 2011;13(7):680-5.","Kearney HM, Thorland EC, Brown KK, Quintero-Rivera F, South ST; Working Group of the American College of Medical Genetics Laboratory Quality Assurance Committee.",Genetics in Medicine [Genet Med.],2011,13,7,680-685, ,English, ,21681106,http://www.ncbi.nlm.nih.gov/pubmed/21681106, , , , , , ,Reporting of genomic copy number microarrays used in the postnatal constitutional setting, , , , , , , ,no,2015-01-28 14:00:08,2015-01-29 10:59:40,american-college-of-medical-genetics-standards-and-guidelines-for-interpretation-and-reporting-of-postnatal-constitutional-copy-number-variants,"[('title', 'American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of genomic copy number microarrays used in the postnatal constitutional setting'), ('Full bibliographic reference', 'Kearney HM, Thorland EC, Brown KK, Quintero-Rivera F, South ST; Working Group of the American College of Medical Genetics Laboratory Quality Assurance Committee. American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. Genet Med. 2011;13(7):680-5.'), ('Language', 'English'), ('PubMed ID', '[21681106](http://www.ncbi.nlm.nih.gov/pubmed/21681106)'), ('Clinical area', 'Genetics, Obstetrics and gynaecology'), ('Applies to the whole report or to individual sections of the report?', 'Biospecimen/bioresource information'), ('Record last updated on', 'January 29, 2015')]"
11508,"Completeness of reporting of radiation therapy planning, dose, and delivery in veterinary radiation oncology manuscripts from 2005 to 2010","Clinical trials, Experimental studies", ,Intervention (exposure), ,"animal, animals, delivery, dose, dose specification, external beam, external beam radiation, external beam radiation therapy, ICRU, oncology, radiation, radiation dose, radiation oncology, radiation protocol, radiation therapies, radiation therapy, radiation therapy planning, radiation therapy protocol, radiation therapy protocols, radiotherapy, target dose, treatment, treatment delivery, treatment dose, treatment method, treatment planning, treatments, vet, veterinary, veterinary medicine, veterinary radiation, veterinary radiation oncology, veterinary research", ,"Keyerleber MA, McEntee MC, Farrelly J, Podgorsak M. Completeness of reporting of radiation therapy planning, dose, and delivery in veterinary radiation oncology manuscripts from 2005 to 2010. Vet Radiol Ultrasound. 2012;53(2):221-30.","Keyerleber MA, McEntee MC, Farrelly J, Podgorsak M.",Veterinary Radiology &amp; Ultrasound [Vet Radiol Ultrasound],2012,53,2,221-230, ,English, ,22092592,http://www.ncbi.nlm.nih.gov/pubmed/22092592, , , , , , ,Reporting of radiotherapy treatments in studies in clinical veterinary radiation oncology, , , , , , , ,no,2015-01-28 11:48:03,2017-02-16 15:02:47,completeness-of-reporting-of-radiation-therapy-planning-dose-and-delivery-in-veterinary-radiation-oncology-manuscripts-from-2005-to-2010,"[('title', 'Completeness of reporting of radiation therapy planning, dose, and delivery in veterinary radiation oncology manuscripts from 2005 to 2010'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of radiotherapy treatments in studies in clinical veterinary radiation oncology'), ('Full bibliographic reference', 'Keyerleber MA, McEntee MC, Farrelly J, Podgorsak M. Completeness of reporting of radiation therapy planning, dose, and delivery in veterinary radiation oncology manuscripts from 2005 to 2010. Vet Radiol Ultrasound. 2012;53(2):221-30.'), ('Language', 'English'), ('PubMed ID', '[22092592](http://www.ncbi.nlm.nih.gov/pubmed/22092592)'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'February 16, 2017')]"
11442,Criteria for Reporting the Development and Evaluation of Complex Interventions in healthcare: revised guideline (CReDECI 2),"Clinical trials, Experimental studies", ,Intervention (exposure), ,"checklist, checklists, complex, complex intervention, complex interventions, CReDECI, CReDECI 2, development, evaluation, intervention, intervention studies, intervention study, interventional, interventions, nursing", ,"M\xf6hler R, K\xf6pke S, Meyer G. Criteria for Reporting the Development and Evaluation of Complex Interventions in healthcare: revised guideline (CReDECI 2). Trials. 2015;16(1):204.","M\xf6hler R, K\xf6pke S, Meyer G.",Trials.,2015,16,1,'204.', ,English, ,25935741,http://www.ncbi.nlm.nih.gov/pubmed/25935741, , ,"M\xf6hler R, Bartoszek G, K\xf6pke S, Meyer G. Proposed criteria for reporting the development and evaluation of complex interventions in healthcare (CReDECI): guideline development. Int J Nurs Stud. 2012;49(1):40-46. PMID: 21924424", , ,CReDECI 2,Reporting the development and evaluation of complex interventions, , , , , , , ,no,2015-01-22 11:57:53,2021-12-17 16:04:40,credeci,"[('title', 'Criteria for Reporting the Development and Evaluation of Complex Interventions in healthcare: revised guideline (CReDECI 2)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the development and evaluation of complex interventions'), ('Full bibliographic reference', 'Möhler R, Köpke S, Meyer G. Criteria for Reporting the Development and Evaluation of Complex Interventions in healthcare: revised guideline (CReDECI 2). Trials. 2015;16(1):204.'), ('Language', 'English'), ('PubMed ID', '[25935741](http://www.ncbi.nlm.nih.gov/pubmed/25935741)'), ('Reporting guideline acronym', 'CReDECI 2'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Previous versions of this guideline / Guideline history', 'Möhler R, Bartoszek G, Köpke S, Meyer G. Proposed criteria for reporting the development and evaluation of complex interventions in healthcare (CReDECI): guideline development. Int J Nurs Stud. 2012;49(1):40-46. PMID: [21924424](http://www.ncbi.nlm.nih.gov/pubmed/21924424)'), ('Record last updated on', 'December 17, 2021')]"
11341,TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods,"Artificial intelligence/Machine learning studies, Diagnostic and prognostic studies, Observational studies", ,Whole report, ,"AI, artificial intelligence, bias, checklist, checklists, clinical decision making, clinical prediction, clinical prediction model, clinical prediction models, clinical predictions, decision making, diagnosis, diagnostic, diagnostic prediction, individual diagnosis, individual prognosis, machine learning, ML, multivariable, multivariable prediction model, multivariable prediction models, prediction, prediction model, prediction model studies, prediction model study, prediction modelling, prediction models, predictions, prognosis, prognostic, prognostic prediction, regression, risk of bias, TRIPOD, TRIPOD 2015, TRIPOD checklist, TRIPOD statement, TRIPOD+AI, TRIPOD+AI checklist, TRIPOD+AI checklists, TRIPOD+AI for Abstracts, TRIPOD+AI for Abstracts checklist", ,"Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, Ghassemi M, Liu X, Reitsma JB, van Smeden M, Boulesteix AL, Camaradou JC, Celi LA, Denaxas S, Denniston AK, Glocker B, Golub RM, Harvey H, Heinze G, Hoffman MM, Kengne AP, Lam E, Lee N, Loder EW, Maier-Hein L, Mateen BA, McCradden MD, Oakden-Rayner L, Ordish J, Parnell R, Rose S, Singh K, Wynants L, Logullo P. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378.","Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, Ghassemi M, Liu X, Reitsma JB, van Smeden M, Boulesteix AL, Camaradou JC, Celi LA, Denaxas S, Denniston AK, Glocker B, Golub RM, Harvey H, Heinze G, Hoffman MM, Kengne AP, Lam E, Lee N, Loder EW, Maier-Hein L, Mateen BA, McCradden MD, Oakden-Rayner L, Ordish J, Parnell R, Rose S, Singh K, Wynants L, Logullo P.",BMJ.,2024,385, ,e078378, ,English, ,38626948,https://pubmed.ncbi.nlm.nih.gov/38626948/,"Read the full-text of TRIPOD+AI.

The TRIPOD+AI checklist (PDF) is available in Supplementary Table 2.

The TRIPOD+AI Expanded Checklist (PDF) (Explanation &amp; Elaboration Light) is available in Supplementary Table 1.

The TRIPOD+AI for Abstracts checklist is available in Table 3 of the statement paper.

","Please continue to use the TRIPOD 2015 E&amp;E paper until the TRIPOD+AI E&amp;E paper is available:
Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, Vickers AJ, Ransohoff DF, Collins GS. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration. Ann Intern Med. 2015;162(1):W1-W73. PMID: 25560730

","TRIPOD 2015
Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement.

Ann Intern Med. 2015;162(1):55-63. PMID: 25560714
Br J Cancer. 2015 Jan 6. PMID: 25562432
Circulation. 2015 Jan 13;131(2):211-9. PMID: 25561516
BMJ 2015; 350:g7594. PMID: 25569120
J Clin Epidemiol. 2015 Feb;68(2):134-43. PMID: 25579640
Eur Urol. 2014 Dec 9. PMID: 25572824
BMC Med. 2015 Jan 6;13(1):1. PMID: 25563062
Eur J Clin Invest. 2015;45(2):204-214. PMID: 25623047
Br J Surg. 2015;102(3):148-158. PMID: 25627261
BJOG. 2015;122(3):434-443. PMID: 25623578
Diabet Med. 2015;32(2):146-154. PMID: 25600898

TRIPOD for Abstracts
Heus P, Reitsma JB, Collins GS, Damen JAAG, Scholten RJPM, Altman DG, Moons KGM, Hooft L. Transparent Reporting of Multivariable Prediction Models in Journal and Conference Abstracts: TRIPOD for Abstracts. Ann Intern Med. 2020. PMID: 32479165

","Specialised
TRIPOD-SRMA: Snell KIE, Levis B, Damen JAA, Dhiman P, Debray TPA, Hooft L, Reitsma JB, Moons KGM, Collins GS, Riley RD. Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA). BMJ. 2023;381:e073538. PMID: 37137496

TRIPOD-Cluster: Debray TPA, Collins GS, Riley RD, Snell KIE, Van Calster B, Reitsma JB, Moons KGM. Transparent reporting of multivariable prediction models developed or validated using clustered data: TRIPOD-Cluster checklist. BMJ. 2023;380:e071018. PMID: 36750242

TRIPOD-LLM: Gallifant J, Afshar M, Ameen S, Aphinyanaphongs Y, Chen S, Cacciamani G, Demner-Fushman D, Dligach D, Daneshjou R, Fernandes C, Hansen LH, Landman A, Lehmann L, McCoy LG, Miller T, Moreno A, Munch N, Restrepo D, Savova G, Umeton R, Gichoya JW, Collins GS, Moons KGM, Celi LA, Bitterman DS. The TRIPOD-LLM reporting guideline for studies using large language models. Nat Med. 2025. PMID: 39779929

",http://www.tripod-statement.org/,TRIPOD+AI,"Reporting of studies that develop a prediction model or evaluate its performance.

","TRIPOD 2015
The TRIPOD 2015 statement and reporting checklist are also available in the following languages:

TRIPOD 2015 Checklist (Chinese) Word
TRIPOD 2015 E&amp;E (Japanese) Word
TRIPOD 2015 Checklist (Japanese) Word\xa0 |\xa0 PDF
TRIPOD 2015 E&amp;E (Russian) PDF

","An adherence assessment form for measuring adherence to the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement has been developed.

Heus P, Damen JAAG, Pajouheshnia R, Scholten RJPM, Reitsma JB, Collins GS, Altman DG, Moons KGM, Hooft L.Uniformity in measuring adherence to reporting guidelines: the example of TRIPOD for assessing completeness of reporting of prediction model studies. BMJ Open. 2019;9(4):e025611. PMID: 31023756

The adherence assessment forms are available from: https://www.tripod-statement.org/adherence/

", , ,"Read the protocol for the development of TRIPOD+AI.

", , ,yes,2015-01-07 15:33:45,2025-01-10 15:43:09,tripod-statement,"[('title', 'TRIPOD + AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of studies that develop a prediction model or evaluate its performance.\n\n \n\n'), ('Full bibliographic reference', 'Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, Ghassemi M, Liu X, Reitsma JB, van Smeden M, Boulesteix AL, Camaradou JC, Celi LA, Denaxas S, Denniston AK, Glocker B, Golub RM, Harvey H, Heinze G, Hoffman MM, Kengne AP, Lam E, Lee N, Loder EW, Maier-Hein L, Mateen BA, McCradden MD, Oakden-Rayner L, Ordish J, Parnell R, Rose S, Singh K, Wynants L, Logullo P. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378.'), ('Language', 'English'), ('PubMed ID', '[38626948](https://pubmed.ncbi.nlm.nih.gov/38626948/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full-text](https://www.bmj.com/content/385/bmj-2023-078378) of TRIPOD+AI.\n\n \n\n The [TRIPOD+AI checklist (PDF)](https://www.bmj.com/content/bmj/suppl/2024/04/17/bmj-2023-078378.DC5/colg078378.wt2.pdf) is available in Supplementary Table 2.\n\n \n\n The [TRIPOD+AI Expanded Checklist (PDF)](https://www.bmj.com/content/bmj/suppl/2024/04/18/bmj-2023-078378.DC6/colg078378.wt1.pdf) (Explanation & Elaboration Light) is available in Supplementary Table 1.\n\n \n\n The [TRIPOD+AI for Abstracts checklist](https://www.bmj.com/content/385/bmj-2023-078378) is available in Table 3 of the statement paper.\n\n \n\n'), ('Explanation and elaboration papers', 'Please continue to use the TRIPOD 2015 E&E paper until the TRIPOD+AI E&E paper is available:\n\n Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, Vickers AJ, Ransohoff DF, Collins GS. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration. Ann Intern Med. 2015;162(1):W1-W73. PMID: [25560730](http://www.ncbi.nlm.nih.gov/pubmed/25560730)\n\n \n\n'), ('Availability in additional languages', '**TRIPOD 2015**\n\n The TRIPOD 2015 statement and reporting checklist are also available in the following languages:\n\n \n\n TRIPOD 2015 Checklist (Chinese) [Word](https://www.tripod-statement.org/wp-content/uploads/2020/01/Checklist-Chinese-1.docx)\n\n TRIPOD 2015 E&E (Japanese) [Word](https://www.tripod-statement.org/wp-content/uploads/2020/01/160404TRIPOD_EandE_Japanese.docx)\n\n TRIPOD 2015 Checklist (Japanese) [Word](https://www.tripod-statement.org/wp-content/uploads/2020/01/160404TRIPOD_Checklist_Japanese.docx)| [PDF](https://www.tripod-statement.org/wp-content/uploads/2020/01/primarycarevol2no4TRIPOD.pdf)\n\n TRIPOD 2015 E&E (Russian) [PDF](https://www.tripod-statement.org/wp-content/uploads/2023/01/Russian-TRIPOD-EE.pdf)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Specialised**\n\n[**TRIPOD-SRMA**](https://www.equator-network.org/reporting-guidelines/tripod-srma/): Snell KIE, Levis B, Damen JAA, Dhiman P, Debray TPA, Hooft L, Reitsma JB, Moons KGM, Collins GS, Riley RD. Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA). BMJ. 2023;381:e073538. PMID: [37137496](https://pubmed.ncbi.nlm.nih.gov/37137496/)\n\n \n\n[**TRIPOD-Cluster**](https://www.equator-network.org/reporting-guidelines/tripod-cluster/): Debray TPA, Collins GS, Riley RD, Snell KIE, Van Calster B, Reitsma JB, Moons KGM. Transparent reporting of multivariable prediction models developed or validated using clustered data: TRIPOD-Cluster checklist. BMJ. 2023;380:e071018. PMID: [36750242](https://pubmed.ncbi.nlm.nih.gov/36750242/)\n\n \n\n**[TRIPOD-LLM](https://www.equator-network.org/reporting-guidelines/the-tripod-llm-reporting-guideline-for-studies-using-large-language-models/)**: Gallifant J, Afshar M, Ameen S, Aphinyanaphongs Y, Chen S, Cacciamani G, Demner-Fushman D, Dligach D, Daneshjou R, Fernandes C, Hansen LH, Landman A, Lehmann L, McCoy LG, Miller T, Moreno A, Munch N, Restrepo D, Savova G, Umeton R, Gichoya JW, Collins GS, Moons KGM, Celi LA, Bitterman DS. The TRIPOD-LLM reporting guideline for studies using large language models. Nat Med. 2025. PMID: [39779929](https://pubmed.ncbi.nlm.nih.gov/39779929/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.tripod-statement.org/>'), ('Reporting guideline acronym', 'TRIPOD+AI'), ('Study design', 'Artificial intelligence/Machine learning studies, Diagnostic and prognostic studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Previous versions of this guideline / Guideline history', '**TRIPOD 2015**\n\n Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement.\n\n \n\n Ann Intern Med. 2015;162(1):55-63. PMID: [25560714](http://www.ncbi.nlm.nih.gov/pubmed/25560714)\n\n Br J Cancer. 2015 Jan 6. PMID: [25562432](http://www.ncbi.nlm.nih.gov/pubmed/25562432)\n\n Circulation. 2015 Jan 13;131(2):211-9. PMID: [25561516](http://www.ncbi.nlm.nih.gov/pubmed/25561516)\n\n BMJ 2015; 350:g7594. PMID: [25569120](http://www.ncbi.nlm.nih.gov/pubmed/25569120)\n\n J Clin Epidemiol. 2015 Feb;68(2):134-43. PMID: [25579640](http://www.ncbi.nlm.nih.gov/pubmed/25579640)\n\n Eur Urol. 2014 Dec 9. PMID: [25572824](http://www.ncbi.nlm.nih.gov/pubmed/25572824)\n\n BMC Med. 2015 Jan 6;13(1):1. PMID: [25563062](http://www.ncbi.nlm.nih.gov/pubmed/25563062)\n\n Eur J Clin Invest. 2015;45(2):204-214. PMID: [25623047](http://www.ncbi.nlm.nih.gov/pubmed/25623047)\n\n Br J Surg. 2015;102(3):148-158. PMID: [25627261](http://www.ncbi.nlm.nih.gov/pubmed/25627261)\n\n BJOG. 2015;122(3):434-443. PMID: [25623578](http://www.ncbi.nlm.nih.gov/pubmed/25623578)\n\n Diabet Med. 2015;32(2):146-154. PMID: [25600898](http://www.ncbi.nlm.nih.gov/pubmed/25600898)\n\n \n\n**TRIPOD for Abstracts**\n\n Heus P, Reitsma JB, Collins GS, Damen JAAG, Scholten RJPM, Altman DG, Moons KGM, Hooft L. Transparent Reporting of Multivariable Prediction Models in Journal and Conference Abstracts: TRIPOD for Abstracts. Ann Intern Med. 2020. PMID: [32479165](https://pubmed.ncbi.nlm.nih.gov/32479165/)\n\n \n\n'), ('Other', '[Read the protocol](https://pubmed.ncbi.nlm.nih.gov/34244270/) for the development of TRIPOD+AI.\n\n \n\n'), ('Additional information', 'An adherence assessment form for measuring adherence to the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement has been developed.\n\n \n\n Heus P, Damen JAAG, Pajouheshnia R, Scholten RJPM, Reitsma JB, Collins GS, Altman DG, Moons KGM, Hooft L.Uniformity in measuring adherence to reporting guidelines: the example of TRIPOD for assessing completeness of reporting of prediction model studies. BMJ Open. 2019;9(4):e025611. PMID: [31023756](https://www.ncbi.nlm.nih.gov/pubmed/31023756)\n\n \n\n The adherence assessment forms are available from: <https://www.tripod-statement.org/adherence/>\n\n \n\n'), ('Record last updated on', 'January 10, 2025')]"
11317,Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement,"Study protocols, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,Protocol-whole report, ,"checklist, meta analyses protocol, meta analyses protocols, meta analysis protocol, meta analysis protocols, PRISMA, PRISMA extension, PRISMA P statement, PRISMA Protocol, PRISMA Protocols, PRISMA-P, protocol, protocols, study protocol, systematic review protocol, systematic review protocols, systematic reviews protocol, systematic reviews protocols", ,"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.","Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA.",Systematic Reviews [Syst Rev],2015, , , , ,English, ,25554246,http://www.ncbi.nlm.nih.gov/pubmed/25554246, ,"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, the PRISMA-P Group. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015.349:g7647. PMID: 25555855

", ,"Generic
PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

Specialised
PRISMA-Equity: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: 23222917

Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.
Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

PRISMA-Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.

PRISMA-IPD: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: 25919529

PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634

PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668

PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement &amp; Checklist. J Clin Epidemiol. 2017. PMID: 28720516

PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.\xa0PMID: 29362800

PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033

PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367

PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791

PRISMA-CHM: Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: 32907365

PRISMA-M 2020: Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: 33100229

PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.
Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535

PRISMA-LSR: Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: 39562017

",http://www.prisma-statement.org/Extensions/Protocols,PRISMA-P,"Systematic review and meta-analysis protocols



PRISMA-P checklist\xa0 PDF | Word

", , , , ,An online fillable PRISMA-P checklist is also available via the GoodReports website at https://www.goodreports.org/reporting-checklists/prisma-p/., , ,yes,2015-01-07 10:29:01,2025-02-06 11:54:57,prisma-protocols,"[('title', 'Preferred Reporting Items for Systematic Review and Meta -Analysis Protocols (PRISMA-P) 2015 statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Systematic review and meta-analysis protocols\n\n \n\n \xa0\n\n \n\n PRISMA-P checklist [PDF](http://www.prisma-statement.org/documents/PRISMA-P-checklist.pdf) | [Word](http://www.prisma-statement.org/documents/PRISMA-P-checklist.doc)\n\n \n\n'), ('Full bibliographic reference', 'Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.'), ('Language', 'English'), ('PubMed ID', '[25554246](http://www.ncbi.nlm.nih.gov/pubmed/25554246)'), ('Explanation and elaboration papers', 'Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, the PRISMA-P Group. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015.349:g7647. PMID: [25555855](http://www.ncbi.nlm.nih.gov/pubmed/25555855)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic\n\n[PRISMA 2020 Statement](http://dev.equator-network.org/reporting-guidelines/prisma/)**: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.\n\n \n\n PLoS Med. 2021;18(3):e1003583. PMID: [33780438](https://pubmed.ncbi.nlm.nih.gov/33780438/)\n\n BMJ 2021;372:n71. PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)\n\n Int J Surg. 2021:105906. PMID: [33789826](https://pubmed.ncbi.nlm.nih.gov/33789826/)\n\n J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: [33789819](https://pubmed.ncbi.nlm.nih.gov/33789819/)\n\n Syst Rev. 2021;10(1):89. PMID: [33781348](https://pubmed.ncbi.nlm.nih.gov/33781348/)\n\n \n\n**Specialised**\n\n[**PRISMA-Equity**](http://dev.equator-network.org/reporting-guidelines/prisma-equity/): Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: [23222917](http://www.ncbi.nlm.nih.gov/pubmed/23222917)\n\n \n\n Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.\n\n Int J Equity Health. 2015;14(1):92. PMID: [26450828](http://www.ncbi.nlm.nih.gov/pubmed/26450828)\n\n J Clin Epidemiol. 2015. PMID: [26348799](http://www.ncbi.nlm.nih.gov/pubmed/26348799)\n\n \n\n[**PRISMA-Abstracts 2020:**](http://dev.equator-network.org/reporting-guidelines/prisma-abstracts/) The PRISMA 2020 for Abstracts reporting guideline is contained within the main [PRISMA 2020 Statement paper](https://www.equator-network.org/reporting-guidelines/prisma/).\n\n \n\n**[PRISMA-IPD](http://dev.equator-network.org/reporting-guidelines/prisma-ipd/)**: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: [25919529](http://www.ncbi.nlm.nih.gov/pubmed/25919529)\n\n \n\n**[PRISMA extension for network meta-analyses](http://dev.equator-network.org/reporting-guidelines/prisma-extension-network-meta-analyses/)**: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: [26030634](http://www.ncbi.nlm.nih.gov/pubmed/26030634)\n\n \n\n[**PRISMA-harms**](http://dev.equator-network.org/reporting-guidelines/prisma-harms/): Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: [26830668](http://www.ncbi.nlm.nih.gov/pubmed/26830668)\n\n \n\n[**PRISMA-CI**](http://dev.equator-network.org/reporting-guidelines/prisma-ci-extension-statement-checklist/): Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: [28720516](https://www.ncbi.nlm.nih.gov/pubmed/28720516)\n\n \n\n[**PRISMA-DTA**](http://dev.equator-network.org/reporting-guidelines/prisma-dta/): McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.\xa0PMID: [29362800](https://www.ncbi.nlm.nih.gov/pubmed/29362800)\n\n \n\n[**PRISMA-ScR**](http://dev.equator-network.org/reporting-guidelines/prisma-scr/): Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: [30178033](https://www.ncbi.nlm.nih.gov/pubmed/30178033)\n\n \n\n[**PRISMA-A**](https://dev.equator-network.org/reporting-guidelines/prisma-acupuncture/): Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: [31405367](https://www.ncbi.nlm.nih.gov/pubmed/31405367)\n\n \n\n[**PRISMA-DTA for Abstracts**](https://dev.equator-network.org/reporting-guidelines/prisma-dta-for-abstracts/): Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: [33722791](https://pubmed.ncbi.nlm.nih.gov/33722791/)\n\n \n\n[**PRISMA-CHM**](https://www.equator-network.org/reporting-guidelines/prisma-chinese-herbal-medicines-2020/): Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: [32907365](https://pubmed.ncbi.nlm.nih.gov/32907365/)\n\n \n\n[**PRISMA-M 2020**](https://www.equator-network.org/reporting-guidelines/prisma-extension-for-moxibustion-2020/): Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: [33100229](https://pubmed.ncbi.nlm.nih.gov/33100229/)\n\n \n\n[**PRISMA-S**](https://dev.equator-network.org/reporting-guidelines/prisma-s/): Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.\n\n Syst Rev. 2021;10(1):39. PMID: [33499930](https://pubmed.ncbi.nlm.nih.gov/33499930/)\n\n J Med Libr Assoc. 2021;109(2):174-200. PMID: [34285662](https://pubmed.ncbi.nlm.nih.gov/34285662/)\n\n \n\n[**PRISMA-COSMIN for OMIs**](https://www.equator-network.org/reporting-guidelines/guideline-for-reporting-systematic-reviews-of-outcome-measurement-instruments-omis-prisma-cosmin-for-omis-2024/): Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.\n\n J Clin Epidemiol. 2024:111422. PMID: [38849061](https://pubmed.ncbi.nlm.nih.gov/38849061/)\n\n Qual Life Res. 2024. PMID: [38980635](https://pubmed.ncbi.nlm.nih.gov/38980635/)\n\n Health Qual Life Outcomes. 2024;22(1):48. PMID: [38978063](https://pubmed.ncbi.nlm.nih.gov/38978063/)\n\n J Patient Rep Outcomes. 2024;8(1):64. PMID: [38977535](https://pubmed.ncbi.nlm.nih.gov/38977535/)\n\n \n\n[**PRISMA-LSR**](https://www.equator-network.org/reporting-guidelines/prisma-lsr/): Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: [39562017](https://pubmed.ncbi.nlm.nih.gov/39562017/)\n\n \n\n""), ('Reporting guideline website URL', '<http://www.prisma-statement.org/Extensions/Protocols>'), ('Reporting guideline acronym', 'PRISMA-P'), ('Study design', 'Study protocols, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Protocol-whole report'), ('Other', 'An online fillable PRISMA-P checklist is also available via the GoodReports website at <https://www.goodreports.org/reporting-checklists/prisma-p/>.'), ('Record last updated on', 'February 6, 2025')]"
11221,Reporting guidance for violence risk assessment predictive validity studies: the RAGEE Statement,"Diagnostic and prognostic studies, Observational studies, Reliability and agreement studies",Behavioural medicine,Whole report, ,"behavior, behavioral, behaviour, behavioural, checklist, criminal recidivism, efficacy, evaluation, evaluation of efficacy, prediction, predictive, predictive validity, predictive validity studies, predictive validity study, psychiatric, RAGEE, RAGEE Statement, RAGEE Statement checklist, reliability, risk assessment, risk assessment guidelines for the evaluation of efficacy, risk assessment predictive validity, risk prediction, validity, violence, violence prediction, violence risk, violence risk assessment", ,"Singh JP, Yang S, Mulvey EP; The RAGEE Group. Reporting Guidance for Violence Risk Assessment Predictive Validity Studies: The RAGEE Statement. Law Hum Behav. 2014 Aug 18.","Singh JP, Yang S, Mulvey EP; The RAGEE Group.",Law and Human Behavior [Law Hum Behav.],2014, , , , ,English, ,25133921,http://www.ncbi.nlm.nih.gov/pubmed/25133921, , , , , ,RAGEE,Predictive validity studies of violence risk assessments, , , , , , , ,no,2014-12-05 10:39:26,2014-12-08 08:50:39,reporting-guidance-for-violence-risk-assessment-predictive-validity-studies-the-ragee-statement,"[('title', 'Reporting guidance for violence risk assessment predictive validity studies: the RAGEE Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Predictive validity studies of violence risk assessments'), ('Full bibliographic reference', 'Singh JP, Yang S, Mulvey EP; The RAGEE Group. Reporting Guidance for Violence Risk Assessment Predictive Validity Studies: The RAGEE Statement. Law Hum Behav. 2014 Aug 18.'), ('Language', 'English'), ('PubMed ID', '[25133921](http://www.ncbi.nlm.nih.gov/pubmed/25133921)'), ('Reporting guideline acronym', 'RAGEE'), ('Study design', 'Diagnostic and prognostic studies, Observational studies, Reliability and agreement studies'), ('Clinical area', 'Behavioural medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'December 8, 2014')]"
11215,Standards for reporting qualitative research: a synthesis of recommendations,Qualitative research, ,Whole report, ,"checklist, checklists, experience, experiences, individual, perspective, perspectives, qualitative, qualitative approach, qualitative approaches, qualitative data, qualitative health research, qualitative method, qualitative methods, qualitative research, qualitative research methodologies, qualitative research methods, qualitative research review, qualitative research studies, qualitative research study, qualitative results, qualitative studies, qualitative study, social, SRQR, standards for reporting qualitative research", ,"O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245-1251.","O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA.",Academic Medicine: Journal of the Association of American Medical Colleges [Acad Med.],2014,89,9,1245-1251, ,English, ,24979285,http://www.ncbi.nlm.nih.gov/pubmed/24979285,"The full-text of this reporting guideline is available at: SRQR guideline

Detailed descriptions of each reporting item and examples are available in the supplementary material at:\xa0http://links.lww.com/ACADMED/A218

", , , , ,SRQR,Reporting of qualitative research studies.,The SRQR checklist is available in French., , , , , , ,yes,2014-12-03 15:16:32,2023-01-18 11:40:54,srqr,"[('title', 'Standards for reporting qualitative research: a synthesis of recommendations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of qualitative research studies.'), ('Full bibliographic reference', ""O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245-1251.""), ('Language', 'English'), ('PubMed ID', '[24979285](http://www.ncbi.nlm.nih.gov/pubmed/24979285)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this reporting guideline is available at: [SRQR guideline](https://journals.lww.com/academicmedicine/fulltext/2014/09000/Standards_for_Reporting_Qualitative_Research__A.21.aspx)\n\n \n\n Detailed descriptions of each reporting item and examples are available in the supplementary material at:<http://links.lww.com/ACADMED/A218>\n\n \n\n'), ('Availability in additional languages', 'The SRQR checklist is available in [French](https://www.sciencedirect.com/science/article/pii/S1779012322001504).'), ('Reporting guideline acronym', 'SRQR'), ('Study design', 'Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 18, 2023')]"
10953,A systematic review of systematic reviews and meta-analyses of animal experiments with guidelines for reporting,"Animal pre-clinical research, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,Whole report, ,"animal, animal experiment, animal experiments, animal model, animal models, animal pre clinical research, animal preclinical research, animal research, animal studies, animal study, animals, basic research, checklist, checklists, in vivo animal experiment, in vivo animal experiments, in vivo experiments, meta analyses, meta analysis, metaanalyses, metaanalysis, pre clinical, pre clinical animal research, pre clinical experiment, pre clinical experiments, pre clinical research, pre clinical studies, pre clinical study, preclinical, preclinical animal research, preclinical experiment, preclinical experiments, preclinical research, preclinical studies, preclinical study, review, reviews, systematic review, systematic reviews", ,"Peters JL, Sutton AJ, Jones DR, Rushton L, Abrams KR. A systematic review of systematic reviews and meta-analyses of animal experiments with guidelines for reporting. J Environ Sci Health B. 2006;41(7): 1245?1258.","Peters JL, Sutton AJ, Jones DR, Rushton L, Abrams KR.","Journal of Environmental Science and Health. Part B, Pesticides, food contaminants and agricultural wastes [J Environ Sci Health B.]",2006,41,7,1245?1258, ,English, ,16923604,http://www.ncbi.nlm.nih.gov/pubmed/16923604, , , , , , ,Reporting of systematic reviews and meta-analyses of animal experiments., , , , , , , ,no,2014-09-18 10:46:20,2014-09-18 10:59:08,a-systematic-review-of-systematic-reviews-and-meta-analyses-of-animal-experiments-with-guidelines-for-reporting,"[('title', 'A systematic review of systematic reviews and meta-analyses of animal experiments with guidelines for reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of systematic reviews and meta-analyses of animal experiments.'), ('Full bibliographic reference', 'Peters JL, Sutton AJ, Jones DR, Rushton L, Abrams KR. A systematic review of systematic reviews and meta-analyses of animal experiments with guidelines for reporting. J Environ Sci Health B. 2006;41(7): 1245–1258.'), ('Language', 'English'), ('PubMed ID', '[16923604](http://www.ncbi.nlm.nih.gov/pubmed/16923604)'), ('Study design', 'Animal pre-clinical research, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 18, 2014')]"
10923,Systematic reviews and meta-analysis of preclinical studies: why perform them and how to appraise them critically,"Animal pre-clinical research, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,Whole report, ,"animal, animal experiment, animal experiments, animal model, animal models, animal pre clinical research, animal preclinical research, animal research, animal studies, animal study, animals, basic research, checklist, checklists, laboratory animal, laboratory animals, laboratory research, meta analyses, meta analysis, metaanalyses, metaanalysis, pre clinical, pre clinical animal research, pre clinical experiment, pre clinical experiments, pre clinical research, pre clinical studies, pre clinical study, preclinical, preclinical animal research, preclinical experiments, preclinical research, preclinical studies, preclinical study, review, reviews, systematic review, systematic reviews", ,"Sena ES, Currie GL, McCann SK, Macleod MR, Howells DW. Systematic reviews and meta-analysis of preclinical studies: why perform them and how to appraise them critically. J Cereb Blood Flow Metab. 2014;34(5):737-742.","Sena ES, Currie GL, McCann SK, Macleod MR, Howells DW.",Journal of Cerebral Blood Flow and Metabolism [J Cereb Blood Flow Metab.],2014,34,5,737-742, ,English, ,24549183,http://www.ncbi.nlm.nih.gov/pubmed/24549183, , , , , , ,Reporting systematic reviews and meta-analyses of animal studies., , , , , , , ,no,2014-09-18 09:52:36,2014-09-18 10:27:05,systematic-reviews-and-meta-analysis-of-preclinical-studies-why-perform-them-and-how-to-appraise-them-critically,"[('title', 'Systematic reviews and meta-analysis of preclinical studies: why perform them and how to appraise them critically'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting systematic reviews and meta-analyses of animal studies.'), ('Full bibliographic reference', 'Sena ES, Currie GL, McCann SK, Macleod MR, Howells DW. Systematic reviews and meta-analysis of preclinical studies: why perform them and how to appraise them critically. J Cereb Blood Flow Metab. 2014;34(5):737-742.'), ('Language', 'English'), ('PubMed ID', '[24549183](http://www.ncbi.nlm.nih.gov/pubmed/24549183)'), ('Study design', 'Animal pre-clinical research, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 18, 2014')]"
10897,Guidelines for reporting case studies on extracorporeal treatments in poisonings: methodology,Observational studies,"Emergency medicine, Pharmaceutical medicine, Renal medicine, Toxicology",Whole report, ,"accident and emergency, case control studies, case control study, case report, case reporting, case reports, case studies, case study, checklist, checklists, clinical case report, clinical case reporting, clinical case reports, clinical toxicology, CRRT, dialysis, ECTR, ECTR TOX, ECTRs, ECTRTOX, ECTRTOX case report, ECTRTOX case reports, emergency department, emergency medicine, exchange transfusion, extracorporeal, extracorporeal therapies, extracorporeal therapy, extracorporeal treatment, extracorporeal treatments, extracorporeal treatments in poisoning, EXtracorporeal TReatments In Poisoning workgroup, EXTRIP, EXTRIP work group, EXTRIP workgroup, EXTRIP working group, haemodiafiltration, haemodialysis, haemofiltration, haemoperfusion, hemodiafiltration, hemodialysis, hemofiltration, hemoperfusion, ICU, intensive care unit, pharmaceutical, pharmaceutical medicine, pharmacological, pharmacology, plasma exchange, plasmaphaeresis, plasmapheresis, poison, poison removal, poisoned, poisoning, poisons, renal, renal dialysis, renal medicine, renal replacement therapy, toxicokinetic, toxicokinetic data, toxicology, toxicology case report, toxicology case reporting, toxicology case reports, toxin, toxins", ,"Lavergne V, Ouellet G, Bouchard J, Galvao T, Kielstein JT, Roberts DM, Kanji S, Mowry JB, Calello DP, Hoffman RS, Gosselin S, Nolin TD, Goldfarb DS, Burdmann EA, Dargan PI, Decker BS, Hoegberg LC, Maclaren R, Megarbane B, Sowinski KM, Yates C, Mactier R, Wiegand T, Ghannoum M. Guidelines for reporting case studies on extracorporeal treatments in poisonings: methodology. Semin Dial. 2014;27(4):407-14.","Lavergne V, Ouellet G, Bouchard J, Galvao T, Kielstein JT, Roberts DM, Kanji S, Mowry JB, Calello DP, Hoffman RS, Gosselin S, Nolin TD, Goldfarb DS, Burdmann EA, Dargan PI, Decker BS, Hoegberg LC, Maclaren R, Megarbane B, Sowinski KM, Yates C, Mactier R, Wiegand T, Ghannoum M.",Seminars in Dialysis [Semin Dial],2014,27,4,407-414, ,English, ,24890576,http://www.ncbi.nlm.nih.gov/pubmed/24890576, , , , , , ,Reporting case studies of poisoned patients undergoing extracorporeal treatments., , , , , , , ,no,2014-09-17 13:29:09,2019-11-28 14:44:32,guidelines-for-reporting-case-studies-on-extracorporeal-treatments-in-poisonings-methodology,"[('title', 'Guidelines for reporting case studies on extracorporeal treatments in poisonings: methodology'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting case studies of poisoned patients undergoing extracorporeal treatments.'), ('Full bibliographic reference', 'Lavergne V, Ouellet G, Bouchard J, Galvao T, Kielstein JT, Roberts DM, Kanji S, Mowry JB, Calello DP, Hoffman RS, Gosselin S, Nolin TD, Goldfarb DS, Burdmann EA, Dargan PI, Decker BS, Hoegberg LC, Maclaren R, Megarbane B, Sowinski KM, Yates C, Mactier R, Wiegand T, Ghannoum M. Guidelines for reporting case studies on extracorporeal treatments in poisonings: methodology. Semin Dial. 2014;27(4):407-14.'), ('Language', 'English'), ('PubMed ID', '[24890576](http://www.ncbi.nlm.nih.gov/pubmed/24890576)'), ('Study design', 'Observational studies'), ('Clinical area', 'Emergency medicine, Pharmaceutical medicine, Renal medicine, Toxicology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 28, 2019')]"
10534,Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative.,"Diagnostic and prognostic studies, Observational studies",Neurology,Whole report, ,"alzheimer, Alzheimer biomarkers, Alzheimer's, Alzheimer's disease, cognitive, cognitive disorders, cognitive impairment, dementia, dementia research, diagnosis, diagnostic accuracy, diagnostic accuracy research, diagnostic accuracy studies, diagnostic accuracy study, diagnostic accuracy test, diagnostic accuracy testing, diagnostic accuracy tests, diagnostic test, diagnostic test accuracy, diagnostic testing, STARD, STARD 2015, STARD 2015 checklist, STARD 2015 statement, STARD initiative, STARD statement, STARDdem, STARDdem Consensus Initiative, STARDdem Initiative, stardem, stardem initiative, stardem statement", ,"Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, Davis D, Quinn TJ, Hyde C, Rutjes AW, Smailagic N, Marcus S, Black S, Blennow K, Brayne C, Fiorivanti M, Johnson JK, K\xf6pke S, Schneider LS, Simmons A, Mattsson N, Zetterberg H, Bossuyt PM, Wilcock G, McShane R. Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. Neurology. 2014;83(4):364-373.","Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, Davis D, Quinn TJ, Hyde C, Rutjes AW, Smailagic N, Marcus S, Black S, Blennow K, Brayne C, Fiorivanti M, Johnson JK, K\xf6pke S, Schneider LS, Simmons A, Mattsson N, Zetterberg H, Bossuyt PM, Wilcock G, McShane R.",Neurology,2014, , , , ,English, ,24944261,http://www.ncbi.nlm.nih.gov/pubmed/24944261,The STARDdem guideline can also be accessed at: STARDdem, , ,"Generic
STARD: Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, LijmerJG Moher D, Rennie D, de Vet HCW, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF, For the STARD Group. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies.

BMJ 2015;351:h5527. PMID: 26511519
Radiology. 2015:151516. PMID: 26509226
Clinical Chemistry 2015. pii: clinchem.2015.246280. PMID: 26510957

Specialised
STRADAS-paraTB: Gardner IA, Nielsen SS, Whittington RJ, Collins MT, Bakker D, Harris B, Sreevatsan S, Lombard JE, Sweeney R, Smith DR, Gavalchin J, Eda S. Consensus-based reporting standards for diagnostic test accuracy studies for paratuberculosis in ruminants. Prev Vet Med. 2011;101(1-2):18-34. PMID: 21601933

STARD-BLCM: Kostoulas P, Nielsen SS, Branscum AJ, Johnson WO, Dendukuri N, Dhand NK, Toft N, Gardner IA. STARD-BLCM: Standards for the Reporting of Diagnostic accuracy studies that use Bayesian Latent Class Models. Prev Vet Med. 2017; 138:37-47. PMID: 28237234

STARD for Abstracts: Cohen JF, Korevaar DA, Gatsonis CA, Glasziou PP, Hooft L, Moher D, Reitsma JB, de Vet HC, Bossuyt PM; STARD Group. STARD for Abstracts: essential items for reporting diagnostic accuracy studies in journal or conference abstracts. BMJ. 2017;358:j3751. PMID: 28819063

",http://www.starddem.org/,STARDdem,Reporting studies of diagnostic test accuracy for dementia disorders., , , , , , , ,no,2014-06-24 11:37:42,2022-01-13 10:19:26,starddem,"[('title', 'Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative.'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting studies of diagnostic test accuracy for dementia disorders.'), ('Full bibliographic reference', 'Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, Davis D, Quinn TJ, Hyde C, Rutjes AW, Smailagic N, Marcus S, Black S, Blennow K, Brayne C, Fiorivanti M, Johnson JK, Köpke S, Schneider LS, Simmons A, Mattsson N, Zetterberg H, Bossuyt PM, Wilcock G, McShane R. Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. Neurology. 2014;83(4):364-373.'), ('Language', 'English'), ('PubMed ID', '[24944261](http://www.ncbi.nlm.nih.gov/pubmed/24944261)'), ('Relevant URLs\n\n(full-text if available)', 'The STARDdem guideline can also be accessed at: [STARDdem](http://www.neurology.org/content/early/2014/06/13/WNL.0000000000000621.short)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic\n\n[STARD](/reporting-guidelines/stard/):** Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, LijmerJG Moher D, Rennie D, de Vet HCW, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF, For the STARD Group. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies.\n\n \n\n BMJ 2015;351:h5527. PMID: [26511519](http://www.ncbi.nlm.nih.gov/pubmed/26511519)\n\n Radiology. 2015:151516. PMID: [26509226](http://www.ncbi.nlm.nih.gov/pubmed/26509226)\n\n Clinical Chemistry 2015. pii: clinchem.2015.246280. PMID: [26510957](http://www.ncbi.nlm.nih.gov/pubmed/26510957)\n\n \n\n**Specialised**\n\n[**STRADAS-paraTB**](/reporting-guidelines/consensus-based-reporting-standards-for-diagnostic-test-accuracy-studies-for-paratuberculosis-in-ruminants/): Gardner IA, Nielsen SS, Whittington RJ, Collins MT, Bakker D, Harris B, Sreevatsan S, Lombard JE, Sweeney R, Smith DR, Gavalchin J, Eda S. Consensus-based reporting standards for diagnostic test accuracy studies for paratuberculosis in ruminants. Prev Vet Med. 2011;101(1-2):18-34. PMID: [21601933](http://www.ncbi.nlm.nih.gov/pubmed/21601933)\n\n \n\n[**STARD-BLCM**](/reporting-guidelines/stard-blcm/): Kostoulas P, Nielsen SS, Branscum AJ, Johnson WO, Dendukuri N, Dhand NK, Toft N, Gardner IA. STARD-BLCM: Standards for the Reporting of Diagnostic accuracy studies that use Bayesian Latent Class Models. Prev Vet Med. 2017; 138:37-47. PMID: [28237234](https://www.ncbi.nlm.nih.gov/pubmed/28237234)\n\n \n\n[**STARD for Abstracts**](/reporting-guidelines/stard-abstracts/): Cohen JF, Korevaar DA, Gatsonis CA, Glasziou PP, Hooft L, Moher D, Reitsma JB, de Vet HC, Bossuyt PM; STARD Group. STARD for Abstracts: essential items for reporting diagnostic accuracy studies in journal or conference abstracts. BMJ. 2017;358:j3751. PMID: [28819063](https://www.ncbi.nlm.nih.gov/pubmed/28819063)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.starddem.org/>'), ('Reporting guideline acronym', 'STARDdem'), ('Study design', 'Diagnostic and prognostic studies, Observational studies'), ('Clinical area', 'Neurology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 13, 2022')]"
10272,Strengthening the reporting of molecular epidemiology for infectious diseases (STROME-ID): an extension of the STROBE statement,Observational studies,Infectious diseases,Whole report, ,"epidemiology, infectious, infectious disease epidemiology, infectious diseases, molecular, molecular epidemiology, STROBE, STROBE extension, STROBE statement, STROME, STROME-ID", ,"Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, MacCannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4.","Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, MacCannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I.",Lancet Infectious Diseases.,2014, , , , ,English, ,24631223,http://www.ncbi.nlm.nih.gov/pubmed/24631223,The full-text of this guideline can be freely accessed from the Lancet website: STROME-ID, , ,"Generic
STROBE Statement: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Ann Intern Med. 2007;147(8):573-577. PMID: 17938396
PLoS Med. 2007;4(10):e296. PMID: 17941714
BMJ. 2007;335(7624):806-808. PMID: 17947786
Prev Med. 2007;45(4):247-251. PMID: 17950122
Epidemiology. 2007;18(6):800-804. PMID: 18049194
Lancet. 2007;370(9596):1453-1457. PMID: 18064739

Specialised
STREGA: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.

PLoS Med. 2009;6(2):e22. PMID: 19192942
Hum Genet. 2009;125(2):131-151. PMID: 19184668
Eur J Epidemiol. 2009;24(1):37-55. PMID: 19189221
Ann Intern Med. 2009;150(3):206-215. PMID: 19189911
J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: 19217256
Genet Epidemiol. 2009;33(7):581-598. PMID: 19278015
Eur J Clin Invest. 2009;39(4):247-266. PMID: 19297801

STROBE-ME: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: 22023344

STROBE checklist for conference abstracts
First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. Link to full text pdf

Longitudinal observational drug studies in rheumatology: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: 24058015

Case-cohort studies: Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: 24972092

STROBE-RDS: White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: 26112433

RECORD: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: 26440803

STROBE-AMS: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schr\xf6der W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: 26895985

STROBE-nut: Lachat C, Hawwash D, Ock\xe9 MC, Berg C, Forsum E, H\xf6rnell A, Larsson C, Sonestedt E, Wirf\xe4lt E, \xc5kesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology?Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: 27270749

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

ROSES-I: Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: 27417916

STROBE-NI: Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: 27633910

Propensity score analysis: Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: 28376195

RECORD-PE: Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.

STROBE-SIIS: International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, H\xe4gglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).

Br J Sports Med. 2020;54(7):372-389. PMID: 32071062
Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: 32118084

STROBE-MR: Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: 34698778

", ,STROME-ID,Improving and standardising the reporting of infectious-disease molecular data in epidemiological research., , , , , , , ,yes,2014-03-18 14:58:56,2021-11-25 15:31:42,strome-id,"[('title', 'Strengthening the reporting of molecular epidemiology for infectious diseases (STROME-ID) : an extension of the STROBE statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Improving and standardising the reporting of infectious-disease molecular data in epidemiological research.'), ('Full bibliographic reference', 'Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, MacCannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4.'), ('Language', 'English'), ('PubMed ID', '[24631223](http://www.ncbi.nlm.nih.gov/pubmed/24631223)'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this guideline can be freely accessed from the Lancet website: [STROME-ID](http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(13)70324-4/abstract)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic\n\n[STROBE Statement](/reporting-guidelines/strobe/)**: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.\n\n \n\n Ann Intern Med. 2007;147(8):573-577. PMID: [17938396](http://www.ncbi.nlm.nih.gov/pubmed/17938396)\n\n PLoS Med. 2007;4(10):e296. PMID: [17941714](http://www.ncbi.nlm.nih.gov/pubmed/17941714)\n\n BMJ. 2007;335(7624):806-808. PMID: [17947786](http://www.ncbi.nlm.nih.gov/pubmed/17947786)\n\n Prev Med. 2007;45(4):247-251. PMID: [17950122](http://www.ncbi.nlm.nih.gov/pubmed/17950122)\n\n Epidemiology. 2007;18(6):800-804. PMID: [18049194](http://www.ncbi.nlm.nih.gov/pubmed/18049194)\n\n Lancet. 2007;370(9596):1453-1457. PMID: [18064739](http://www.ncbi.nlm.nih.gov/pubmed/18064739)\n\n \n\n**Specialised**\n\n[**STREGA**](/reporting-guidelines/strobe-strega/): Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.\n\n \n\n PLoS Med. 2009;6(2):e22. PMID: [19192942](http://www.ncbi.nlm.nih.gov/pubmed/19192942)\n\n Hum Genet. 2009;125(2):131-151. PMID: [19184668](http://www.ncbi.nlm.nih.gov/pubmed/19184668)\n\n Eur J Epidemiol. 2009;24(1):37-55. PMID: [19189221](http://www.ncbi.nlm.nih.gov/pubmed/19189221)\n\n Ann Intern Med. 2009;150(3):206-215. PMID: [19189911](http://www.ncbi.nlm.nih.gov/pubmed/19189911)\n\n J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: [19217256](http://www.ncbi.nlm.nih.gov/pubmed/19217256)\n\n Genet Epidemiol. 2009;33(7):581-598. PMID: [19278015](http://www.ncbi.nlm.nih.gov/pubmed/19278015)\n\n Eur J Clin Invest. 2009;39(4):247-266. PMID: [19297801](http://www.ncbi.nlm.nih.gov/pubmed/19297801)\n\n \n\n[**STROBE-ME**](/reporting-guidelines/strobe-me/): Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: [22023344](http://www.ncbi.nlm.nih.gov/pubmed/22023344)\n\n \n\n[**STROBE checklist for conference abstracts**](/reporting-guidelines/strobe-abstracts/)\n\n First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. [Link to full text pdf](https://www.strobe-statement.org/download/strobe-checklist-conference-abstracts)\n\n \n\n[**Longitudinal observational drug studies in rheumatology**](/reporting-guidelines/launch-of-a-checklist-for-reporting-longitudinal-observational-drug-studies-in-rheumatology-a-eular-extension-of-strobe-guidelines-based-on-experience-from-biologics-registries/): Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: [24058015](http://www.ncbi.nlm.nih.gov/pubmed/24058015)\n\n \n\n[**Case-cohort studies**](/reporting-guidelines/a-review-of-published-analyses-of-case-cohort-studies-and-recommendations-for-future-reporting/): Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: [24972092](https://www.ncbi.nlm.nih.gov/pubmed/24972092)\n\n \n\n**[STROBE-RDS:](/reporting-guidelines/strobe-rds/)** White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: [26112433](http://www.ncbi.nlm.nih.gov/pubmed/26112433)\n\n \n\n**[RECORD](/reporting-guidelines/record/)**: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: [26440803](http://www.ncbi.nlm.nih.gov/pubmed/26440803)\n\n \n\n**[STROBE-AMS](/reporting-guidelines/strobe-ams/)**: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schröder W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: [26895985](http://www.ncbi.nlm.nih.gov/pubmed/26895985)\n\n \n\n[**STROBE-nut**](/reporting-guidelines/strobe-nut/): Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology—Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: [27270749](https://www.ncbi.nlm.nih.gov/pubmed/27270749)\n\n \n\n[**Simulation Research**](/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**ROSES-I**](/reporting-guidelines/roses-i-statement/): Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: [27417916](https://www.ncbi.nlm.nih.gov/pubmed/27417916)\n\n \n\n[**STROBE-NI**](/reporting-guidelines/strobe-ni/): Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: [27633910](https://www.ncbi.nlm.nih.gov/pubmed/27633910)\n\n \n\n[**Propensity score analysis**](/reporting-guidelines/reporting-and-guidelines-in-propensity-score-analysis-a-systematic-review-of-cancer-and-cancer-surgical-studies/): Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: [28376195](https://www.ncbi.nlm.nih.gov/pubmed/28376195)\n\n \n\n[**RECORD-PE**](https://www.equator-network.org/reporting-guidelines/record-pe/): Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). [BMJ 2018;363:k3532](https://www.bmj.com/content/363/bmj.k3532.full).\n\n \n\n[**STROBE-SIIS**](https://www.equator-network.org/reporting-guidelines/strobe-extension-for-sports-injury-illness-surveillance/): International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, Hägglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).\n\n \n\n Br J Sports Med. 2020;54(7):372-389. PMID: [32071062](https://pubmed.ncbi.nlm.nih.gov/32071062/)\n\n Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: [32118084](https://pubmed.ncbi.nlm.nih.gov/32118084/)\n\n \n\n[**STROBE-MR**](https://www.equator-network.org/reporting-guidelines/strobe-mr-statement/): Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: [34698778](https://pubmed.ncbi.nlm.nih.gov/34698778/)\n\n \n\n'), ('Reporting guideline acronym', 'STROME-ID'), ('Study design', 'Observational studies'), ('Clinical area', 'Infectious diseases'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 25, 2021')]"
10181,Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide,"Clinical trials, Experimental studies, Observational studies, Study protocols, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,Intervention (exposure), ,"checklist, CONSORT extension, intervention, intervention description, intervention descriptions, intervention replication, intervention studies, intervention study, interventions, TIDieR, TIDieR checklist", ,"Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687.","Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S.",British Medical Journal [BMJ].,2014, , , , ,English, ,24609605,http://www.ncbi.nlm.nih.gov/pubmed/24609605,"The TIDieR Checklist is available to download as a\xa0PDF and a\xa0Word file.

Full text is available at http://www.bmj.com/content/348/bmj.g1687

", , ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477



Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

TIDieR-PHP: Campbell M, Katikireddi SV, Hoffmann T, Armstrong R, Waters E, Craig P. TIDieR-PHP: a reporting guideline for population health and policy interventions. BMJ. 2018;361:k1079. PMID:\xa029769210

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

",http://www.tidierguide.org/,TIDieR,Describing interventions in sufficient detail to allow their replication.,"The TIDieR guideline and reporting checklist are also available in the following languages:
TIDieR Checklist (French) PDF
TIDieR Guideline (French) PDF
TIDieR Guideline (German)
TIDieR Guideline (Italian)
TIDieR Checklist (Italian) MS Word
TIDieR Guideline (Spanish) PDF
TIDieR Checklist (Spanish) PDF
TIDieR Guideline (Turkish) PDF
TIDieR Guideline E&amp;E (Portuguese) PDF
TIDieR Checklist (Portuguese) MS Word
TIDieR Guideline (Chinese) PDF

", , , , , , ,yes,2014-03-07 16:04:24,2025-05-30 09:19:38,tidier,"[('title', 'Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Describing interventions in sufficient detail to allow their replication.'), ('Full bibliographic reference', 'Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687.'), ('Language', 'English'), ('PubMed ID', '[24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)'), ('Relevant URLs\n\n(full-text if available)', 'The TIDieR Checklist is available to download as a[PDF](/wp-content/uploads/2014/03/TIDieR-Checklist-PDF.pdf) and a[Word](/wp-content/uploads/2014/03/TIDieR-Checklist-Word.docx) file.\n\n \n\n Full text is available at <http://www.bmj.com/content/348/bmj.g1687>\n\n \n\n'), ('Availability in additional languages', 'The TIDieR guideline and reporting checklist are also available in the following languages:\n\n[TIDieR Checklist (French) PDF](/wp-content/uploads/2014/03/TIDieR-Checklist-Word_translation-FRENCH_Dec-2017.pdf)\n\n[TIDieR Guideline (French) PDF](/wp-content/uploads/2014/03/TIDIeR-Reporting-Guide_translation_French-Dec-2017-2.pdf)\n\n[TIDieR Guideline (German)](https://dx.doi.org/10.1055/s-0041-111066)\n\n[TIDieR Guideline (Italian)](https://www.evidence.it/articolodettaglio/209/it/540/migliorare-il-reporting-degli-interventi-sanitari-la-checklist-/articolo)\n\n[TIDieR Checklist (Italian) MS Word](https://www.evidence.it/articoli/pdf/e1000189_checklist.doc)\n\n[TIDieR Guideline (Spanish) PDF](https://www.equator-network.org/wp-content/uploads/2014/03/Guia-y-lista-de-verificacion-TiDier-Traduccion-espanol.pdf)\n\n[TIDieR Checklist (Spanish) PDF](https://www.equator-network.org/wp-content/uploads/2014/03/Apendice-3-Lista-de-verificacion-TiDier-Traduccion-espanol.pdf)\n\n[TIDieR Guideline (Turkish) PDF](https://www.equator-network.org/wp-content/uploads/2014/03/TIDieR-Turkish-translation.pdf)\n\n[TIDieR Guideline E&E (Portuguese) PDF](https://www.equator-network.org/wp-content/uploads/2022/09/TIDieR-EE-paper-Portuguese.pdf)\n\n[TIDieR Checklist (Portuguese) MS Word](https://www.equator-network.org/wp-content/uploads/2022/09/TIDieR-Checklist-fillable-Portuguese.docx)\n\n[TIDieR Guideline (Chinese) PDF](https://www.equator-network.org/wp-content/uploads/2022/09/TIDieR-Chinese-Translation.pdf)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n**[CONSORT 2025 Statement](http://dev.equator-network.org/reporting-guidelines/consort/)**:\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n \xa0\n\n \n\n**Specialised**\n\n**[CONSORT Harms](http://dev.equator-network.org/reporting-guidelines/consort-harms/)**: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n**[CONSORT Non-inferiority](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/)**: Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n**[CONSORT Cluster](http://dev.equator-network.org/reporting-guidelines/consort-cluster/)**:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n**[CONSORT Herbal](http://dev.equator-network.org/reporting-guidelines/consort-herbal/)**:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n**[CONSORT Non-pharmacological treatment interventions](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/)**: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n**[CONSORT Abstracts](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/)**:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n**[CONSORT Pragmatic Trials](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/)**: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n**[STRICTA Controlled trials of acupuncture](http://dev.equator-network.org/reporting-guidelines/consort-stricta/)**:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n**[CONSORT PRO](http://dev.equator-network.org/reporting-guidelines/consort-pro/)**: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n**[CONSORT-CENT](http://dev.equator-network.org/reporting-guidelines/consort-cent/)**: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n**[CONSORT for orthodontic trials](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/)**: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**TIDieR-PHP**](http://dev.equator-network.org/reporting-guidelines/tidier-php-a-reporting-guideline-for-population-health-and-policy-interventions/): Campbell M, Katikireddi SV, Hoffmann T, Armstrong R, Waters E, Craig P. TIDieR-PHP: a reporting guideline for population health and policy interventions. BMJ. 2018;361:k1079. PMID:[29769210](https://www.ncbi.nlm.nih.gov/pubmed/29769210)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n**[ACE Statement](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/)**: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.tidierguide.org/>'), ('Reporting guideline acronym', 'TIDieR'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Study protocols, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'May 30, 2025')]"
9084,Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries,Observational studies,Rheumatology,Whole report, ,"biologics, biologics register, biologics registers, biologics registries, biologics registry, checklist, drug studies, drug study, EULAR, European League against Rheumatism, longitudinal, longitudinal observational drug studies, longitudinal observational drug study, longitudinal observational studies, longitudinal observational study, observational, observational studies, observational study, rheumatology, safety data, safety data of biologics registers, STROBE, STROBE extension", ,"Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628.","Zavada J, Dixon WG, Askling J.",Annals of the Rheumatic Diseases [Ann Rheum Dis],2014,73,3,628, ,English, ,24058015,http://www.ncbi.nlm.nih.gov/pubmed/24058015,The checklist is freely available to download at: checklist for reporting longitudinal observational drug studies in rheumatology (Word), , ,"Generic
STROBE: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Ann Intern Med. 2007;147(8):573-577. PMID: 17938396
PLoS Med. 2007;4(10):e296. PMID: 17941714
BMJ. 2007;335(7624):806-808. PMID: 17947786
Prev Med. 2007;45(4):247-251. PMID: 17950122
Epidemiology. 2007;18(6):800-804. PMID: 18049194
Lancet. 2007;370(9596):1453-1457. PMID: 18064739

Specialised
STREGA: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.

PLoS Med. 2009;6(2):e22. PMID: 19192942
Hum Genet. 2009;125(2):131-151. PMID: 19184668
Eur J Epidemiol. 2009;24(1):37-55. PMID: 19189221
Ann Intern Med. 2009;150(3):206-215. PMID: 19189911
J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: 19217256
Genet Epidemiol. 2009;33(7):581-598. PMID: 19278015
Eur J Clin Invest. 2009;39(4):247-266. PMID: 19297801

STROBE-ME: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: 22023344

STROBE checklist for conference abstracts
First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. Link to full text pdf

STROME-ID: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: 24631223

Case-cohort studies: Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: 24972092

STROBE-RDS: White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: 26112433

RECORD: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: 26440803

STROBE-AMS: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schr\xf6der W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: 26895985

STROBE-nut: Lachat C, Hawwash D, Ock\xe9 MC, Berg C, Forsum E, H\xf6rnell A, Larsson C, Sonestedt E, Wirf\xe4lt E, \xc5kesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology?Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: 27270749

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

ROSES-I: Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: 27417916

STROBE-NI: Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: 27633910

Propensity score analysis: Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: 28376195

RECORD-PE: Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.

STROBE-SIIS: International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, H\xe4gglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).

Br J Sports Med. 2020;54(7):372-389. PMID: 32071062
Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: 32118084

STROBE-MR: Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: 34698778

",http://www.eular.org/index.cfm?framePage=/st_com_epidemiology_checklist_eralods.cfm, ,"Reporting longitudinal observational drug studies in rheumatology



Longitudinal observational drug studies in rheumatology checklist (Word)

", ,"Elucidation and context to the checklist items is provided in:

Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, Listing J, Nicola PJ, Tarp U, Zink A, Askling J. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis. 2010;69(9):1596-1602. PMID: 20525843

", , , , , ,no,2013-09-30 13:47:25,2021-11-25 15:27:51,launch-of-a-checklist-for-reporting-longitudinal-observational-drug-studies-in-rheumatology-a-eular-extension-of-strobe-guidelines-based-on-experience-from-biologics-registries,"[('title', 'Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting longitudinal observational drug studies in rheumatology\n\n \n\n \xa0\n\n \n\n[Longitudinal observational drug studies in rheumatology checklist (Word)](http://www.eular.org/myUploadData/files/EULAR_checklist_registries.doc)\n\n \n\n'), ('Full bibliographic reference', 'Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628.'), ('Language', 'English'), ('PubMed ID', '[24058015](http://www.ncbi.nlm.nih.gov/pubmed/24058015)'), ('Relevant URLs\n\n(full-text if available)', 'The checklist is freely available to download at: [checklist for reporting longitudinal observational drug studies in rheumatology (Word)](http://www.eular.org/myUploadData/files/EULAR_checklist_registries.doc)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**STROBE**](/reporting-guidelines/strobe/): von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.\n\n \n\n Ann Intern Med. 2007;147(8):573-577. PMID: [17938396](http://www.ncbi.nlm.nih.gov/pubmed/17938396)\n\n PLoS Med. 2007;4(10):e296. PMID: [17941714](http://www.ncbi.nlm.nih.gov/pubmed/17941714)\n\n BMJ. 2007;335(7624):806-808. PMID: [17947786](http://www.ncbi.nlm.nih.gov/pubmed/17947786)\n\n Prev Med. 2007;45(4):247-251. PMID: [17950122](http://www.ncbi.nlm.nih.gov/pubmed/17950122)\n\n Epidemiology. 2007;18(6):800-804. PMID: [18049194](http://www.ncbi.nlm.nih.gov/pubmed/18049194)\n\n Lancet. 2007;370(9596):1453-1457. PMID: [18064739](http://www.ncbi.nlm.nih.gov/pubmed/18064739)\n\n \n\n**Specialised**\n\n[**STREGA**](/reporting-guidelines/strobe-strega/): Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.\n\n \n\n PLoS Med. 2009;6(2):e22. PMID: [19192942](http://www.ncbi.nlm.nih.gov/pubmed/19192942)\n\n Hum Genet. 2009;125(2):131-151. PMID: [19184668](http://www.ncbi.nlm.nih.gov/pubmed/19184668)\n\n Eur J Epidemiol. 2009;24(1):37-55. PMID: [19189221](http://www.ncbi.nlm.nih.gov/pubmed/19189221)\n\n Ann Intern Med. 2009;150(3):206-215. PMID: [19189911](http://www.ncbi.nlm.nih.gov/pubmed/19189911)\n\n J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: [19217256](http://www.ncbi.nlm.nih.gov/pubmed/19217256)\n\n Genet Epidemiol. 2009;33(7):581-598. PMID: [19278015](http://www.ncbi.nlm.nih.gov/pubmed/19278015)\n\n Eur J Clin Invest. 2009;39(4):247-266. PMID: [19297801](http://www.ncbi.nlm.nih.gov/pubmed/19297801)\n\n \n\n[**STROBE-ME**](/reporting-guidelines/strobe-me/): Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: [22023344](http://www.ncbi.nlm.nih.gov/pubmed/22023344)\n\n \n\n[**STROBE checklist for conference abstracts**](/reporting-guidelines/strobe-abstracts/)\n\n First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. [Link to full text pdf](https://www.strobe-statement.org/download/strobe-checklist-conference-abstracts)\n\n \n\n[**STROME-ID**](/reporting-guidelines/strome-id/): Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: [24631223](http://www.ncbi.nlm.nih.gov/pubmed/24631223)\n\n \n\n[**Case-cohort studies**](/reporting-guidelines/a-review-of-published-analyses-of-case-cohort-studies-and-recommendations-for-future-reporting/): Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: [24972092](https://www.ncbi.nlm.nih.gov/pubmed/24972092)\n\n \n\n**[STROBE-RDS:](/reporting-guidelines/strobe-rds/)** White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: [26112433](http://www.ncbi.nlm.nih.gov/pubmed/26112433)\n\n \n\n**[RECORD](/reporting-guidelines/record/)**: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: [26440803](http://www.ncbi.nlm.nih.gov/pubmed/26440803)\n\n \n\n**[STROBE-AMS](/reporting-guidelines/strobe-ams/)**: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schröder W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: [26895985](http://www.ncbi.nlm.nih.gov/pubmed/26895985)\n\n \n\n[**STROBE-nut**](/reporting-guidelines/strobe-nut/): Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology—Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: [27270749](https://www.ncbi.nlm.nih.gov/pubmed/27270749)\n\n \n\n[**Simulation Research**](/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**ROSES-I**](/reporting-guidelines/roses-i-statement/): Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: [27417916](https://www.ncbi.nlm.nih.gov/pubmed/27417916)\n\n \n\n**[STROBE-NI](/reporting-guidelines/strobe-ni/)**: Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: [27633910](https://www.ncbi.nlm.nih.gov/pubmed/27633910)\n\n \n\n[**Propensity score analysis**](/reporting-guidelines/reporting-and-guidelines-in-propensity-score-analysis-a-systematic-review-of-cancer-and-cancer-surgical-studies/): Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: [28376195](https://www.ncbi.nlm.nih.gov/pubmed/28376195)\n\n \n\n[**RECORD-PE**](https://www.equator-network.org/reporting-guidelines/record-pe/): Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). [BMJ 2018;363:k3532](https://www.bmj.com/content/363/bmj.k3532.full).\n\n \n\n[**STROBE-SIIS**](https://www.equator-network.org/reporting-guidelines/strobe-extension-for-sports-injury-illness-surveillance/): International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, Hägglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).\n\n \n\n Br J Sports Med. 2020;54(7):372-389. PMID: [32071062](https://pubmed.ncbi.nlm.nih.gov/32071062/)\n\n Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: [32118084](https://pubmed.ncbi.nlm.nih.gov/32118084/)\n\n \n\n[**STROBE-MR**](https://www.equator-network.org/reporting-guidelines/strobe-mr-statement/): Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: [34698778](https://pubmed.ncbi.nlm.nih.gov/34698778/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.eular.org/index.cfm?framePage=/st_com_epidemiology_checklist_eralods.cfm>'), ('Study design', 'Observational studies'), ('Clinical area', 'Rheumatology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Elucidation and context to the checklist items is provided in:\n\n \n\n Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, Listing J, Nicola PJ, Tarp U, Zink A, Askling J. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis. 2010;69(9):1596-1602. PMID: [20525843](http://www.ncbi.nlm.nih.gov/pubmed/20525843)\n\n \n\n'), ('Record last updated on', 'November 25, 2021')]"
5787,"CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials","Clinical trials, Experimental studies", ,"Harms/adverse effects/safety data, Whole report", ,"adverse, adverse effect, adverse effects, adverse event, adverse events, adverse reaction, adverse reactions, checklist, clinical trial, clinical trials, CONSORT, CONSORT extension, data, extension, harm, harms, randomised, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, safety, trial, trials, unintended effect, unintended effects", ,"Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.

This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.

BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

", , , , , , , , , , , , , ,CONSORT Harms 2004.,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477



Specialised
CONSORT Non-inferiority:\xa0 Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,CONSORT Harms 2022,"Reporting of harms in randomized trials


CONSORT Harms 2022 Checklist (Word)


", , , , , , , ,yes,2013-09-30 10:45:26,2025-05-30 09:15:30,consort-harms,"[('title', 'CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of harms in randomized trials\n\n \n\n*\n\n[CONSORT Harms 2022 Checklist (Word)](https://www.equator-network.org/wp-content/uploads/2013/09/CONSORT-Harms-2022-checklist.docx)\n\n*\n\n \n\n'), ('Full bibliographic reference', 'Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n \n\n This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.\n\n \n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n \xa0\n\n \n\n**Specialised**\n\n[**CONSORT Non-inferiority**](/reporting-guidelines/consort-non-inferiority/):\xa0 Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](/reporting-guidelines/consort-cluster/):\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-3. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n**[CONSORT PRO](/reporting-guidelines/consort-pro/):** Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n[**CONSORT-CENT**](/reporting-guidelines/consort-cent/): Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n**[CONSORT for orthodontic trials](/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/)**: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n**[TIDieR](/reporting-guidelines/tidier/)**: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n**[Simulation Research](/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/)**: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n**[CONSORT for pilot and feasibility trials](/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/)**: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://www.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://www.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://www.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://www.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://www.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'CONSORT Harms 2022'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Whole report'), ('Previous versions of this guideline / Guideline history', 'CONSORT Harms 2004.'), ('Record last updated on', 'May 30, 2025')]"
8876,The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development,Observational studies, ,Whole report, ,"CARE, CARE checklist, CARE guideline, CARE guidelines, CARE writing template, case, case report, case reports, cases, checklist, clinical case report, clinical case reporting, clinical case reports, data analysis, medical narrative, medical narratives", ,"Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; the CARE Group. The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development.

This guideline was published simultaneously in 7 journals. You can read the guideline in any of these journals using the links below.

BMJ Case Rep. 2013; doi: 10.1136/bcr-2013-201554 PMID: 24155002
Global Adv Health Med. 2013;10.7453/gahmj.2013.008
Dtsch Arztebl Int. 2013;110(37):603-608. PMID: 24078847\xa0 Full-text in English / Full-text in German
J Clin Epidemiol. 2014;67(1):46-51. PMID: 24035173
J Med Case Rep. 2013;7(1):223. PMID: 24228906\xa0 Full-text.
J Diet Suppl. 2013;10(4):381-390. PMID: 24237192
Headache. 2013;53(10):1541-1547. PMID: 24266334

","Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; the CARE Group.", ,2013, , , , ,English, , , ,"The CARE Checklist is available to download in English as a PDF file.

","Riley DS, Barber MS, Kienle GS, Aronson JK, von Schoen-Angerer T, Tugwell P, Kiene H, Helfand M, Altman DG, Sox H, Werthmann PG, Moher D, Rison RA, Shamseer L, Koch CA, Sun GH, Hanaway P, Sudak NL, Kaszkin-Bettag M, Carpenter JE, Gagnier JJ. CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol. 2017. pii: S0895-4356(17)30037-9. PMID: 28529185", ,"Specialised
Therapeutic Massage and Bodywork: Munk N, Boulanger K. Adaptation of the CARE Guidelines for Therapeutic Massage and Bodywork Publications: Efforts To Improve the Impact of Case Reports. Int J Ther Massage Bodywork. 2014;7(3):32-40. PMID: 25184013

CARE-radiology: Wang M, Luo X, Xiao X, Zhang L, Wang Q, Wang S, Wang X, Xue H, Zhang L, Chen Y, Lei J, ?tupnik T, Scarci M, Fiorelli A, Laisaar T, Fruscio R, Elkhayat H, Novoa NM, Davoli F, Waseda R, Estill J, Norris SL, Riley DS, Tian J. CARE-radiology statement explanation and elaboration: reporting guideline for radiological case reports. BMJ Evid Based Med. 2024:bmjebm-2023-112695. PMID: 38458654

",http://www.care-statement.org/,CARE,"For completeness, transparency and data analysis in case reports and data from the point of care.



CARE checklist (PDF)

","The free-to-access CARE Checklist and Case Report Writing Outline for Authors have been translated into various languages and are available at: https://swihm.com/resources/

The CARE guideline paper has been translated into Italian: CARE Italian (PDF)

","The CARE steering group have developed a flow diagram for how a clinician should consider approaching collecting data when seeing a patient or doing a chart review so that it can be systematically collected and written with the CARE guidelines. The flow diagram is available to download: CARE Flow Diagram (PDF)

The CARE 2013 and 2017 articles as well as other free-to-access publications are available to download at https://www.care-statement.org/publications

Additional free-to-access online information including timeline examples and instructions for creating timelines are available at https://swihm.com/resources

", , ,"An online fillable CARE checklist is also available via the GoodReports website at https://www.goodreports.org/reporting-checklists/care/.

", , ,yes,2013-09-28 14:42:14,2024-04-02 15:27:04,care,"[('title', 'The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'For completeness, transparency and data analysis in case reports and data from the point of care.\n\n \n\n \xa0\n\n \n\n[CARE checklist (PDF)](https://static1.squarespace.com/static/5db7b349364ff063a6c58ab8/t/5db7bf175f869e5812fd4293/1572323098501/CARE-checklist-English-2013.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; the CARE Group. The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development.\n\n \n\n This guideline was published simultaneously in 7 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n BMJ Case Rep. 2013; doi: 10.1136/bcr-2013-201554 PMID: [24155002](http://www.ncbi.nlm.nih.gov/pubmed/24155002)\n\n Global Adv Health Med. 2013;[10.7453/gahmj.2013.008\n\n](http://www.gahmj.com/doi/abs/10.7453/gahmj.2013.008)Dtsch Arztebl Int. 2013;110(37):603-608. PMID: [24078847](http://www.ncbi.nlm.nih.gov/pubmed/24078847) [Full-text in English](http://www.aerzteblatt.de/int/archive/article/145667/The-CARE-Guidelines-Consensus-Based-Clinical-Case-Reporting-Guideline-Development) / [Full-text in German](http://www.aerzteblatt.de/archiv/145657/Die-Case-Reporting-%28CARE%29-Guideline-Entwicklung-einer-konsensbasierten-Leitlinie-fuer-die-Erstellung-klinischer-Fallberichte)\n\n J Clin Epidemiol. 2014;67(1):46-51. PMID: [24035173](http://www.ncbi.nlm.nih.gov/pubmed/24035173)\n\n J Med Case Rep. 2013;7(1):223. PMID: [24228906](http://www.ncbi.nlm.nih.gov/pubmed/24228906) [Full-text](http://www.jmedicalcasereports.com/content/7/1/223).\n\n J Diet Suppl. 2013;10(4):381-390. PMID: [24237192](http://www.ncbi.nlm.nih.gov/pubmed/24237192)\n\n Headache. 2013;53(10):1541-1547. PMID: [24266334](http://www.ncbi.nlm.nih.gov/pubmed/24266334)\n\n \n\n'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The CARE Checklist is available to download in English as a [PDF](https://static1.squarespace.com/static/5db7b349364ff063a6c58ab8/t/5db7bf175f869e5812fd4293/1572323098501/CARE-checklist-English-2013.pdf) file.\n\n \n\n'), ('Explanation and elaboration papers', 'Riley DS, Barber MS, Kienle GS, Aronson JK, von Schoen-Angerer T, Tugwell P, Kiene H, Helfand M, Altman DG, Sox H, Werthmann PG, Moher D, Rison RA, Shamseer L, Koch CA, Sun GH, Hanaway P, Sudak NL, Kaszkin-Bettag M, Carpenter JE, Gagnier JJ. CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol. 2017. pii: S0895-4356(17)30037-9. PMID: [28529185](https://www.ncbi.nlm.nih.gov/pubmed/28529185)'), ('Availability in additional languages', 'The free-to-access CARE Checklist and Case Report Writing Outline for Authors have been translated into various languages and are available at: <https://swihm.com/resources/>\n\n \n\n The CARE guideline paper has been translated into Italian: [CARE Italian (PDF)](http://www.evidence.it/articoli/pdf/e1000147.pdf)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Specialised**\n\n[**Therapeutic Massage and Bodywork**](/reporting-guidelines/adaptation-of-the-care-guidelines-for-therapeutic-massage-and-bodywork-publications-efforts-to-improve-the-impact-of-case-reports/): Munk N, Boulanger K. Adaptation of the CARE Guidelines for Therapeutic Massage and Bodywork Publications: Efforts To Improve the Impact of Case Reports. Int J Ther Massage Bodywork. 2014;7(3):32-40. PMID: [25184013](https://www.ncbi.nlm.nih.gov/pubmed/25184013)\n\n \n\n[**CARE-radiology**](https://www.equator-network.org/reporting-guidelines/care-radiology-statement-explanation-and-elaboration-reporting-guideline-for-radiological-case-reports/): Wang M, Luo X, Xiao X, Zhang L, Wang Q, Wang S, Wang X, Xue H, Zhang L, Chen Y, Lei J, Štupnik T, Scarci M, Fiorelli A, Laisaar T, Fruscio R, Elkhayat H, Novoa NM, Davoli F, Waseda R, Estill J, Norris SL, Riley DS, Tian J. CARE-radiology statement explanation and elaboration: reporting guideline for radiological case reports. BMJ Evid Based Med. 2024:bmjebm-2023-112695. PMID: [38458654](https://pubmed.ncbi.nlm.nih.gov/38458654/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.care-statement.org/>'), ('Reporting guideline acronym', 'CARE'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Other', 'An online fillable CARE checklist is also available via the GoodReports website at <https://www.goodreports.org/reporting-checklists/care/>.\n\n \n\n'), ('Additional information', 'The CARE steering group have developed a flow diagram for how a clinician should consider approaching collecting data when seeing a patient or doing a chart review so that it can be systematically collected and written with the CARE guidelines. The flow diagram is available to download: [CARE Flow Diagram (PDF)](/wp-content/uploads/2013/09/CAREFlowDiagram-updated-2019.pdf)\n\n \n\n The CARE 2013 and 2017 articles as well as other free-to-access publications are available to download at <https://www.care-statement.org/publications>\n\n \n\n Additional free-to-access online information including timeline examples and instructions for creating timelines are available at <https://swihm.com/resources>\n\n \n\n'), ('Record last updated on', 'April 2, 2024')]"
5549,Documenting Clinical and Laboratory Images in Publications: The CLIP Principles, , ,Images, ,"blots, cell imaging, clinical, CLIP, CLIP Principles, CT scan, CT scans, echocardiograph, echocardiographs, EEG, EEGs, flow cytometry, gels, image, images, imaging, infrared imaging, laboratory, light photography, micrographs, MRI, MRIs, plots, radiographs, scanning electron microscopy", ,"Lang TA, Talerico C, Siontis GCM. Documenting Clinical and Laboratory Images in Publications: The CLIP Principles. Chest. 2012;141(6):1626-1632.","Lang TA, Talerico C, Siontis GCM.",Chest.,2012,141,6,1626-1632, ,English, ,22670027,http://www.ncbi.nlm.nih.gov/pubmed/22670027, , , , , ,CLIP Principles,Clinical and laboratory images in publications, , , , , , , ,no,2013-08-22 11:52:56,2013-11-25 10:11:55,documenting-clinical-and-laboratory-images-in-publications-the-clip-principles,"[('title', 'Documenting Clinical and Laboratory Images in Publications: The CLIP Principles'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Clinical and laboratory images in publications'), ('Full bibliographic reference', 'Lang TA, Talerico C, Siontis GCM. Documenting Clinical and Laboratory Images in Publications: The CLIP Principles. Chest. 2012;141(6):1626-1632.'), ('Language', 'English'), ('PubMed ID', '[22670027](http://www.ncbi.nlm.nih.gov/pubmed/22670027)'), ('Reporting guideline acronym', 'CLIP Principles'), ('Applies to the whole report or to individual sections of the report?', 'Images'), ('Record last updated on', 'November 25, 2013')]"
7274,ICMJE: Uniform Format for Disclosure of Competing Interests in ICMJE Journals, , ,Conflict of interest, ,"COI, COI disclosure, COI policies, COI policy, COIs, competing interest, competing interests, conflict, conflict of interest, conflict of interest policies, conflict of interest policy, conflict of interests, conflicts of interest, declaration, declarations, disclosure, ICMJE, International Committee of Medical Journal Editors", ,ICMJE: Uniform Format for Disclosure of Competing Interests in ICMJE Journals. Updated February 2021.,International Committee of Medical Journal Editors (ICMJE), ,2010, , , , ,English, , , ,Download the disclosure form (Word)., , , , , ,Disclosure of competing interests in ICMJE Journals, , ,Read an ICMJE editorial (PDF) about competing interests disclosure., , , , ,no,2013-08-22 10:54:48,2022-01-13 12:00:43,icmje-uniform-format-for-disclosure-of-competing-interests-in-icmje-journals,"[('title', 'ICMJE : Uniform Format for Disclosure of Competing Interests in ICMJE Journals'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Disclosure of competing interests in ICMJE Journals'), ('Full bibliographic reference', 'ICMJE: Uniform Format for Disclosure of Competing Interests in ICMJE Journals. Updated February 2021.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'Download the [disclosure form (Word)](http://www.icmje.org/downloads/coi_disclosure.docx).'), ('Applies to the whole report or to individual sections of the report?', 'Conflict of interest'), ('Selected relevant editorials', 'Read an [ICMJE editorial (PDF)](http://www.icmje.org/news-and-editorials/proposed-disclosure-form-editorial.pdf) about competing interests disclosure.'), ('Record last updated on', 'January 13, 2022')]"
5642,Selection and presentation of imaging figures in the medical literature, , ,Images, ,"figure, figure presentation, figures, image, image presentation, images, imaging, imaging figures, presentation, presentation of images, quantitative, radiological, radiological image, radiological images, radiological imaging figures, radiology", ,"Siontis GC, Patsopoulos NA, Vlahos AP, Ioannidis JP. Selection and presentation of imaging figures in the medical literature. PLoS One. 2010;5(5):e10888.","Siontis GC, Patsopoulos NA, Vlahos AP, Ioannidis JP.",PLoS One.,2010,5,5, , ,English, ,20526360,http://www.ncbi.nlm.nih.gov/pubmed/20526360, , , , , , ,Selection and presentation of imaging figures, , , , , , , ,no,2013-08-21 15:03:26,2013-11-25 10:12:56,selection-and-presentation-of-imaging-figures-in-the-medical-literature,"[('title', 'Selection and presentation of imaging figures in the medical literature'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Selection and presentation of imaging figures'), ('Full bibliographic reference', 'Siontis GC, Patsopoulos NA, Vlahos AP, Ioannidis JP. Selection and presentation of imaging figures in the medical literature. PLoS One. 2010;5(5):e10888.'), ('Language', 'English'), ('PubMed ID', '[20526360](http://www.ncbi.nlm.nih.gov/pubmed/20526360)'), ('Applies to the whole report or to individual sections of the report?', 'Images'), ('Record last updated on', 'November 25, 2013')]"
8226,Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration,"Clinical trials, Experimental studies, Observational studies","Neurology, Radiology","Images, Terminology/definitions", ,"ageing, Alzheimer's, Alzheimer's disease, brain atrophy, cerebral, cerebral microbleed, cerebral microbleeds, cerebral small vessel disease, cerebrovascular, cerebrovascular disease, clinical trial, clinical trials, cognitive, cognitive decline, definition, dementia, experimental studies, experimental study, haemorrhagic lesion, haemorrhagic lesions, hemorrhagic lesion, hemorrhagic lesions, image, images, lacunar, lacunar infarctions, lacunar infarcts, lacunar strokes, lacune, magnetic resonance imaging, MRI, neurodegeneration, neurodegenerative, neurodegenerative disease, neurodegenerative diseases, neuroimaging, neurology, observational, observational studies, observational study, perivascular space, radiology, recent small subcortical infarct, small subcortical infarct, small vessel disease, STandards for ReportIng Vascular changes on nEuroimaging, STRIVE, stroke, SVD, terminology, trial, trials, vascular, vascular cognitive impairment, vascular dementia, vascular lesion, vascular lesions, white matter","Development: Consensus, Development: Evidence based, Focus: Clinical","Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge Rv, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-838.","Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge Rv, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1).",Lancet Neurology [Lancet Neurol.],2013,12,8,822-838, ,English, ,23867200,http://www.ncbi.nlm.nih.gov/pubmed/23867200, , , , , ,STRIVE,Reporting of changes related to small vessel disease (SVD) on neuroimaging, , , , , , , ,no,2013-08-20 10:51:50,2013-10-23 13:34:27,neuroimaging-standards-for-research-into-small-vessel-disease-and-its-contribution-to-ageing-and-neurodegeneration,"[('title', 'Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of changes related to small vessel disease (SVD) on neuroimaging'), ('Full bibliographic reference', ""Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge Rv, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-838.""), ('Language', 'English'), ('PubMed ID', '[23867200](http://www.ncbi.nlm.nih.gov/pubmed/23867200)'), ('Reporting guideline acronym', 'STRIVE'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Neurology, Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Images, Terminology/definitions'), ('Record last updated on', 'October 23, 2013')]"
8190,Finding What Works in Health Care: Standards for Systematic Reviews. Chapter 5 - Standards for Reporting Systematic Reviews,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Whole report, ,"Institute of Medicine, IOM, meta analyses, meta analysis, review, reviews, systematic, systematic review, systematic reviews, whole report", ,"Finding What Works in Health Care: Standards for Systematic Reviews. Chapter 5 - Standards for Reporting Systematic Reviews. Institute of Medicine (IOM) Consensus Report. 2011. Washington, DC: The National Academies Press.",Institute of Medicine (IOM)., ,2011, , , , ,English, , , ,The full-text of this consensus report is available at: Standards for Reporting Systematic Reviews, , , ,http://www.nationalacademies.org/hmd/Reports/2011/Finding-What-Works-in-Health-Care-Standards-for-Systematic-Reviews.aspx, ,Reporting the final report to the sponsor of a systematic review, , , , , , , ,no,2013-08-19 15:37:44,2022-01-13 12:03:34,finding-what-works-in-health-care-standards-for-systematic-reviews-chapter-5-standards-for-reporting-systematic-reviews,"[('title', 'Finding What Works in Health Care: Standards for Systematic Reviews. Chapter 5 – Standards for Reporting Systematic Reviews'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the final report to the sponsor of a systematic review'), ('Full bibliographic reference', 'Finding What Works in Health Care: Standards for Systematic Reviews. Chapter 5 - Standards for Reporting Systematic Reviews. Institute of Medicine (IOM) Consensus Report. 2011. Washington, DC: The National Academies Press.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this consensus report is available at: [Standards for Reporting Systematic Reviews](http://books.nap.edu/openbook.php?record_id=13059)'), ('Reporting guideline website URL', '<http://www.nationalacademies.org/hmd/Reports/2011/Finding-What-Works-in-Health-Care-Standards-for-Systematic-Reviews.aspx>'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 13, 2022')]"
8186,Systematic Reviews. CRD's guidance for undertaking reviews in health care,"Study protocols, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,Whole report, ,"Centre for Reviews and Dissemination, CRD, meta analyses, meta analysis, review, reviews, study protocol, systematic, systematic review, systematic reviews, whole report", ,"Systematic Reviews. CRD's guidance for undertaking reviews in health care. Centre for Reviews and Dissemination, University of York, 2009.","Centre for Reviews and Dissemination, University of York.", ,2009, , , , ,English, , ,http://www.york.ac.uk/inst/crd/index_guidance.htm,The full-text of this guidance is available from the CRD website at: CRD guidance for undertaking reviews in health care, , , ,http://www.york.ac.uk/inst/crd/index_guidance.htm, ,Systematic reviews in health care, , , , , , , ,no,2013-08-19 15:24:48,2022-01-13 12:05:17,systematic-reviews-crds-guidance-for-undertaking-reviews-in-health-care,"[('title', 'Systematic Reviews. CRD ’s guidance for undertaking reviews in health care'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Systematic reviews in health care'), ('Full bibliographic reference', ""Systematic Reviews. CRD's guidance for undertaking reviews in health care. Centre for Reviews and Dissemination, University of York, 2009.""), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this guidance is available from the CRD website at: [CRD guidance for undertaking reviews in health care](http://www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm)'), ('Reporting guideline website URL', '<http://www.york.ac.uk/inst/crd/index_guidance.htm>'), ('Study design', 'Study protocols, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 13, 2022')]"
8180,"The HuGENet? HuGE Review Handbook, version 1.0. Guidelines for systematic review and meta-analysis of gene disease association studies",Systematic reviews/Meta-analyses/Reviews/HTA/Overviews,Genetics,Whole report, ,"data, disease association, disease association studies, disease association study, gene, genes, genetic, genetic variant, genetic variants, genetics, handbook, HuGE review, HuGE Review Handbook, HuGE reviews, HuGENet, human genetic variant, human genetic variants, loci, meta analyses, meta analysis, population, population data, review, reviews, systematic, systematic review, systematic reviews, whole report", ,"Little J, Higgins JPT (editors). The HuGENet? HuGE Review Handbook, version 1.0. Centers for Disease Control and Prevention, 2006.","Little J, Higgins JPT (editors).", ,2006, , , , ,English, , , , , , , , , ,Reporting systematic review and meta-analysis of gene disease association studies, , , , , , , ,no,2013-08-19 15:09:40,2024-10-21 14:50:52,the-hugenet-huge-review-handbook-version-1-0-guidelines-for-systematic-review-and-meta-analysis-of-gene-disease-association-studies,"[('title', 'The Hu GENet ™ Hu GE Review Handbook, version 1.0. Guidelines for systematic review and meta-analysis of gene disease association studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting systematic review and meta-analysis of gene disease association studies'), ('Full bibliographic reference', 'Little J, Higgins JPT (editors). The HuGENet™ HuGE Review Handbook, version 1.0. Centers for Disease Control and Prevention, 2006.'), ('Language', 'English'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Clinical area', 'Genetics'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 21, 2024')]"
8169,Cochrane Handbook for Systematic Reviews of Interventions Version 6.1,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Whole report, ,"Cochrane, Cochrane Collaboration, Cochrane handbook, Cochrane intervention review, Cochrane intervention reviews, cochrane review, cochrane reviews, handbook, intervention review, intervention reviews, MECIR, meta analyses, meta analysis, plain language, plain language summaries, plain language summary, review, reviews, systematic, systematic review, systematic reviews, whole report", ,"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020.","Higgins JPT, Thomas J (Senior Editors).", ,2020, , , , ,English, , , ,The full-text of this handbook is freely available from: Cochrane Handbook, , , , , ,Systematic reviews of interventions., , , , ,"Other guidance available from the Cochrane Collaboration
Methodological expectations of Cochrane Intervention Reviews (MECIR): Standards for the conduct and reporting of new Cochrane Intervention Reviews, reporting of protocols and the planning, conduct and reporting of updates. Full-text available from: MECIR guidance

Methodological expectations of Cochrane Intervention Reviews (MECIR): Standards for the reporting of plain language summaries in new Cochrane Intervention Reviews 2013. Full-text available from: Plain language summaries (PDF)



The PRISMA flow diagram has been adapted for use in Cochrane systematic review updates. Further details are available in the article below:

Stovold E, Beecher D, Foxlee R, Noel-Storr A. Study flow diagrams in Cochrane systematic review updates: an adapted PRISMA flow diagram. Syst Rev. 2014 May 29;3:54. PMID: 24886533

", , ,no,2013-08-19 13:03:55,2022-01-13 12:09:04,cochrane-handbook-for-systematic-reviews-of-interventions,"[('title', 'Cochrane Handbook for Systematic Reviews of Interventions Version 6.1'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Systematic reviews of interventions.'), ('Full bibliographic reference', 'Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this handbook is freely available from: [Cochrane Handbook](https://training.cochrane.org/cochrane-handbook-systematic-reviews-interventions)'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Other', '**Other guidance available from the Cochrane Collaboration**\n\n Methodological expectations of Cochrane Intervention Reviews (MECIR): Standards for the conduct and reporting of new Cochrane Intervention Reviews, reporting of protocols and the planning, conduct and reporting of updates. Full-text available from: [MECIR guidance](https://community.cochrane.org/mecir-manual)\n\n \n\n Methodological expectations of Cochrane Intervention Reviews (MECIR): Standards for the reporting of plain language summaries in new Cochrane Intervention Reviews 2013. Full-text available from: [Plain language summaries (PDF)](https://methods.cochrane.org/sites/default/files/public/uploads/pleacs_2019.pdf)\n\n \n\n \xa0\n\n \n\n The PRISMA flow diagram has been adapted for use in Cochrane systematic review updates. Further details are available in the article below:\n\n \n\n Stovold E, Beecher D, Foxlee R, Noel-Storr A. Study flow diagrams in Cochrane systematic review updates: an adapted PRISMA flow diagram. Syst Rev. 2014 May 29;3:54. PMID: [24886533](http://www.ncbi.nlm.nih.gov/pubmed/24886533)\n\n \n\n'), ('Record last updated on', 'January 13, 2022')]"
8161,Writing for Publication in Veterinary Medicine. A Practical Guide for Researchers and Clinicians, , ,Whole report, ,"animal, animal health, animals, vet, veterinary, veterinary medicine, veterinary practice, veterinary research, veterinary studies, veterinary study, whole report", ,"Christopher MM, Young KM. Writing for Publication in Veterinary Medicine. A Practical Guide for Researchers and Clinicians. Wiley-Blackwell; 2011.","Christopher MM, Young KM.", ,2011, , , , ,English, , , ,The full-text of this guide is freely available from: Practical Guide, , , , , ,Writing for publication in veterinary medicine, , , , , , , ,no,2013-08-19 12:45:41,2022-01-13 12:10:49,writing-for-publication-in-veterinary-medicine-a-practical-guide-for-researchers-and-clinicians,"[('title', 'Writing for Publication in Veterinary Medicine. A Practical Guide for Researchers and Clinicians'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Writing for publication in veterinary medicine'), ('Full bibliographic reference', 'Christopher MM, Young KM. Writing for Publication in Veterinary Medicine. A Practical Guide for Researchers and Clinicians. Wiley-Blackwell; 2011.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of this guide is freely available from: [Practical Guide](http://eu.wiley.com/WileyCDA/Section/id-612222.html)'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 13, 2022')]"
8139,Publication of population data for forensic purposes, ,Genetics,Data, ,"allele, alleles, data, forensic, forensic population genetics, forensics, gene, genes, genetic, genetic data, genetics, haplotype, haplotypes, polymorphisms, population, population data, population genetic data, population genetics", ,"Carracedo A, Butler JM, Gusm\xe3o L, Parson W, Roewer L, Schneider PM. Publication of population data for forensic purposes. Forensic Sci Int Genet. 2010;4(3):145-147.","Carracedo A, Butler JM, Gusm\xe3o L, Parson W, Roewer L, Schneider PM.",Forensic Science International. Genetics. [Forensic Sci Int Genet.],2010,4,3,145-147, ,English, ,20215025,http://www.ncbi.nlm.nih.gov/pubmed/20215025, , , , , , ,Reporting of population genetic data for forensic purposes, , , , , , , ,no,2013-08-19 10:04:58,2013-08-19 10:37:17,publication-of-population-data-for-forensic-purposes,"[('title', 'Publication of population data for forensic purposes'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of population genetic data for forensic purposes'), ('Full bibliographic reference', 'Carracedo A, Butler JM, Gusmão L, Parson W, Roewer L, Schneider PM. Publication of population data for forensic purposes. Forensic Sci Int Genet. 2010;4(3):145-147.'), ('Language', 'English'), ('PubMed ID', '[20215025](http://www.ncbi.nlm.nih.gov/pubmed/20215025)'), ('Clinical area', 'Genetics'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'August 19, 2013')]"
8127,Publication of population data of linearly inherited DNA markers in the International Journal of Legal Medicine, ,Genetics,Data, ,"data, DNA marker, DNA markers, forensic genetics, gene, genes, genetic, genetics, haploid DNA marker, haploid DNA markers, haploid lineages, haploid marker, haploid markers, haplotype, haplotypes, mitochondrial DNA, mtDNA, mtDNA data, mtDNA population data, polymorphisms, population, population data, population studies, population study, short tandem repeat, short tandem repeat population data, SNP, STR, Y chromosomal, Y chromosomal polymorphisms, Y chromosome, Y STR marker, Y STR markers", ,"Parson W, Roewer L. Publication of population data of linearly inherited DNA markers in the International Journal of Legal Medicine. Int J Legal Med. 2010;124(5):505-509.","Parson W, Roewer L.",International Journal of Legal Medicine [Int J Legal Med.],2010,124,5,505-509, ,English, ,20652581, http://www.ncbi.nlm.nih.gov/pubmed/20652581, , , , , , ,Reporting of population studies on haploid DNA markers, , , , , , , ,no,2013-08-19 09:32:14,2013-08-19 10:00:05,publication-of-population-data-of-linearly-inherited-dna-markers-in-the-international-journal-of-legal-medicine,"[('title', 'Publication of population data of linearly inherited DNA markers in the International Journal of Legal Medicine'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of population studies on haploid DNA markers'), ('Full bibliographic reference', 'Parson W, Roewer L. Publication of population data of linearly inherited DNA markers in the International Journal of Legal Medicine. Int J Legal Med. 2010;124(5):505-509.'), ('Language', 'English'), ('PubMed ID', '[20652581]( http://www.ncbi.nlm.nih.gov/pubmed/20652581)'), ('Clinical area', 'Genetics'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'August 19, 2013')]"
8109,"Proposed definitions and criteria for reporting time frame, outcome, and complications for clinical orthopedic studies in veterinary medicine", ,Surgery,"Data, Harms/adverse effects/safety data, Outcomes (variables), Terminology/definitions", ,"animal, animal orthopaedics, animal orthopedics, animal research, animals, clinical orthopaedic studies, clinical orthopaedic study, clinical orthopedic studies, clinical orthopedic study, equine orthopaedics, equine orthopedics, orthopaedics, orthopedics, small animal orthopaedics, small animal orthopedics, surgery, vet, veterinary, veterinary orthopaedics, veterinary orthopedics", ,"Cook JL, Evans R, Conzemius MG, Lascelles BD, McIlwraith CW, Pozzi A, Clegg P, Innes J, Schulz K, Houlton J, Fortier L, Cross AR, Hayashi K, Kapatkin A, Brown DC, Stewart A. Proposed definitions and criteria for reporting time frame, outcome, and complications for clinical orthopedic studies in veterinary medicine. Vet Surg. 2010;39(8):905-908.","Cook JL, Evans R, Conzemius MG, Lascelles BD, McIlwraith CW, Pozzi A, Clegg P, Innes J, Schulz K, Houlton J, Fortier L, Cross AR, Hayashi K, Kapatkin A, Brown DC, Stewart A.",Veterinary Surgery [Vet Surg.],2010,39,8,905-908, ,English, ,21133952, http://www.ncbi.nlm.nih.gov/pubmed/21133952, , , , , , ,Documenting subjective results for clinical orthopedic studies in veterinary medicine, , , , , , , ,no,2013-08-16 14:05:55,2015-01-27 17:09:59,proposed-definitions-and-criteria-for-reporting-time-frame-outcome-and-complications-for-clinical-orthopedic-studies-in-veterinary-medicine,"[('title', 'Proposed definitions and criteria for reporting time frame, outcome, and complications for clinical orthopedic studies in veterinary medicine'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Documenting subjective results for clinical orthopedic studies in veterinary medicine'), ('Full bibliographic reference', 'Cook JL, Evans R, Conzemius MG, Lascelles BD, McIlwraith CW, Pozzi A, Clegg P, Innes J, Schulz K, Houlton J, Fortier L, Cross AR, Hayashi K, Kapatkin A, Brown DC, Stewart A. Proposed definitions and criteria for reporting time frame, outcome, and complications for clinical orthopedic studies in veterinary medicine. Vet Surg. 2010;39(8):905-908.'), ('Language', 'English'), ('PubMed ID', '[21133952]( http://www.ncbi.nlm.nih.gov/pubmed/21133952)'), ('Clinical area', 'Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Data, Harms/adverse effects/safety data, Outcomes (variables), Terminology/definitions'), ('Record last updated on', 'January 27, 2015')]"
8097,Recommended guidelines for the conduct and evaluation of prognostic studies in veterinary oncology, ,Oncology,"Narrative sections (discussion etc.), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.)", ,"animal, animal health, animal research, animals, cancer, neoplasms, neoplastic, oncology, predictive marker, predictive markers, prognosis, prognostic, prognostic marker, prognostic markers, prognostic studies, prognostic study, prognostication, tumor, tumors, tumour, tumours, verterinary oncology, vet, veterinary, veterinary neoplastic diseases, veterinary prognostic studies, veterinary prognostic study", ,"Webster JD, Dennis MM, Dervisis N, Heller J, Bacon NJ, Bergman PJ, Bienzle D, Cassali G, Castagnaro M, Cullen J, Esplin DG, Pe\xf1a L, Goldschmidt MH, Hahn KA, Henry CJ, Hellm\xe9n E, Kamstock D, Kirpensteijn J, Kitchell BE, Amorim RL, Lenz SD, Lipscomb TP, McEntee M, McGill LD, McKnight CA, McManus PM, Moore AS, Moore PF, Moroff SD, Nakayama H, Northrup NC, Sarli G, Scase T, Sorenmo K, Schulman FY, Shoieb AM, Smedley RC, Spangler WL, Teske E, Thamm DH, Valli VE, Vernau W, von Euler H, Withrow SJ, Weisbrode SE, Yager J, Kiupel M; American College of Veterinary Pathologists' Oncology Committee. Recommended guidelines for the conduct and evaluation of prognostic studies in veterinary oncology. Vet Pathol. 2011;48(1):7-18.","Webster JD, Dennis MM, Dervisis N, Heller J, Bacon NJ, Bergman PJ, Bienzle D, Cassali G, Castagnaro M, Cullen J, Esplin DG, Pe\xf1a L, Goldschmidt MH, Hahn KA, Henry CJ, Hellm\xe9n E, Kamstock D, Kirpensteijn J, Kitchell BE, Amorim RL, Lenz SD, Lipscomb TP, McEntee M, McGill LD, McKnight CA, McManus PM, Moore AS, Moore PF, Moroff SD, Nakayama H, Northrup NC, Sarli G, Scase T, Sorenmo K, Schulman FY, Shoieb AM, Smedley RC, Spangler WL, Teske E, Thamm DH, Valli VE, Vernau W, von Euler H, Withrow SJ, Weisbrode SE, Yager J, Kiupel M; American College of Veterinary Pathologists' Oncology Committee.",Veterinary Pathology [Vet Pathol.],2011,48,1,7-18, ,English, ,20664014,http://www.ncbi.nlm.nih.gov/pubmed/20664014, , , , , , ,Reporting of prognostic studies in veterinary oncology, , , , , , , ,no,2013-08-16 13:18:21,2013-08-21 13:24:54,recommended-guidelines-for-the-conduct-and-evaluation-of-prognostic-studies-in-veterinary-oncology,"[('title', 'Recommended guidelines for the conduct and evaluation of prognostic studies in veterinary oncology'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of prognostic studies in veterinary oncology'), ('Full bibliographic reference', ""Webster JD, Dennis MM, Dervisis N, Heller J, Bacon NJ, Bergman PJ, Bienzle D, Cassali G, Castagnaro M, Cullen J, Esplin DG, Peña L, Goldschmidt MH, Hahn KA, Henry CJ, Hellmén E, Kamstock D, Kirpensteijn J, Kitchell BE, Amorim RL, Lenz SD, Lipscomb TP, McEntee M, McGill LD, McKnight CA, McManus PM, Moore AS, Moore PF, Moroff SD, Nakayama H, Northrup NC, Sarli G, Scase T, Sorenmo K, Schulman FY, Shoieb AM, Smedley RC, Spangler WL, Teske E, Thamm DH, Valli VE, Vernau W, von Euler H, Withrow SJ, Weisbrode SE, Yager J, Kiupel M; American College of Veterinary Pathologists' Oncology Committee. Recommended guidelines for the conduct and evaluation of prognostic studies in veterinary oncology. Vet Pathol. 2011;48(1):7-18.""), ('Language', 'English'), ('PubMed ID', '[20664014](http://www.ncbi.nlm.nih.gov/pubmed/20664014)'), ('Clinical area', 'Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Narrative sections (discussion etc.), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'August 21, 2013')]"
7994,Update of the stroke therapy academic industry roundtable preclinical recommendations,Animal pre-clinical research,Neurology,"Conflict of interest, Outcomes (variables), Procedure/Method", ,"acute stroke, animal, animal experiment, animal experimentation, animal experiments, animal model, animal models, animal pre clinical research, animal preclinical research, animal research, animal studies, animal study, animals, basic research, clinical translation, ischaemic stroke models, ischemic stroke models, neurology, pre clinical, pre clinical experiment, pre clinical experiments, pre clinical recommendations, pre clinical research, pre clinical studies, pre clinical study, pre clinical testing, preclinical, preclinical experiment, preclinical experiments, preclinical recommendations, preclinical research, preclinical studies, preclinical study, preclinical testing, STAIR, STAIR pre clinical recommendations, STAIR preclinical recommendations, stroke, stroke model, stroke models, stroke therapies, stroke therapy, vet, veterinary", ,"Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH; STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40(6):2244-2250.","Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH; STAIR Group.",Stroke.,2009,40,6,2244-2250, ,English, ,19246690,http://www.ncbi.nlm.nih.gov/pubmed/19246690, , , , , , ,Preclinical testing of purported acute stroke therapies, , , , , , , ,no,2013-08-15 15:18:08,2014-09-18 10:17:06,update-of-the-stroke-therapy-academic-industry-roundtable-preclinical-recommendations,"[('title', 'Update of the stroke therapy academic industry roundtable preclinical recommendations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Preclinical testing of purported acute stroke therapies'), ('Full bibliographic reference', 'Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH; STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40(6):2244-2250.'), ('Language', 'English'), ('PubMed ID', '[19246690](http://www.ncbi.nlm.nih.gov/pubmed/19246690)'), ('Study design', 'Animal pre-clinical research'), ('Clinical area', 'Neurology'), ('Applies to the whole report or to individual sections of the report?', 'Conflict of interest, Outcomes (variables), Procedure/Method'), ('Record last updated on', 'September 18, 2014')]"
7989,Good laboratory practice: preventing introduction of bias at the bench,Animal pre-clinical research,Neurology,"Conflict of interest, Procedure/Method, Study characteristics (participants etc.)", ,"animal, animal experiment, animal experimentation, animal experiments, animal model, animal models, animal pre clinical research, animal preclinical research, animal research, animal studies, animal study, animals, basic research, cerebral ischaemia, cerebral ischemia, ischaemia, ischemia, laboratory, laboratory animal, laboratory animals, neurology, neuroprotective, neuroprotective efficacy, pre clinical, pre clinical animal research, pre clinical experiment, pre clinical experiments, pre clinical research, pre clinical studies, pre clinical study, preclinical, preclinical animal research, preclinical experiment, preclinical experiments, preclinical research, preclinical studies, preclinical study, stroke", ,"Macleod MR, Fisher M, O'Collins V, Sena ES, Dirnagl U, Bath PM, Buchan A, van der Worp HB, Traystman R, Minematsu K, Donnan GA, Howells DW. Good laboratory practice: preventing introduction of bias at the bench. Stroke. 2009;40(3):e50-e52.","Macleod MR, Fisher M, O'Collins V, Sena ES, Dirnagl U, Bath PM, Buchan A, van der Worp HB, Traystman R, Minematsu K, Donnan GA, Howells DW.",Stroke.,2009,40,3,e50-e52, ,English, ,18703798,http://www.ncbi.nlm.nih.gov/pubmed/18703798, , , , , , ,Reporting of animal experiments modeling human stroke, , , , , , , ,no,2013-08-15 14:54:51,2014-09-18 10:21:58,good-laboratory-practice-preventing-introduction-of-bias-at-the-bench,"[('title', 'Good laboratory practice: preventing introduction of bias at the bench'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of animal experiments modeling human stroke'), ('Full bibliographic reference', ""Macleod MR, Fisher M, O'Collins V, Sena ES, Dirnagl U, Bath PM, Buchan A, van der Worp HB, Traystman R, Minematsu K, Donnan GA, Howells DW. Good laboratory practice: preventing introduction of bias at the bench. Stroke. 2009;40(3):e50-e52.""), ('Language', 'English'), ('PubMed ID', '[18703798](http://www.ncbi.nlm.nih.gov/pubmed/18703798)'), ('Study design', 'Animal pre-clinical research'), ('Clinical area', 'Neurology'), ('Applies to the whole report or to individual sections of the report?', 'Conflict of interest, Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'September 18, 2014')]"
7986,Consensus-based reporting standards for diagnostic test accuracy studies for paratuberculosis in ruminants,Diagnostic and prognostic studies, ,Whole report, ,"animal, animal research, animals, cattle, checklist, diagnostic accuracy, diagnostic test accuracy, Johne's disease, livestock studies, livestock study, paratuberculosis, paratuberculosis test accuracy studies, ruminants, Standards for Reporting of Animal Diagnostic Accuracy Studies for paratuberculosis, STARD, STRADAS-paraTB, test accuracy, test accuracy studies, test accuracy study, vet, veterinary, veterinary microbiology, whole report", ,"Gardner IA, Nielsen SS, Whittington RJ, Collins MT, Bakker D, Harris B, Sreevatsan S, Lombard JE, Sweeney R, Smith DR, Gavalchin J, Eda S. Consensus-based reporting standards for diagnostic test accuracy studies for paratuberculosis in ruminants. Prev Vet Med. 2011;101(1-2):18-34.","Gardner IA, Nielsen SS, Whittington RJ, Collins MT, Bakker D, Harris B, Sreevatsan S, Lombard JE, Sweeney R, Smith DR, Gavalchin J, Eda S.",Preventive Veterinary Medicine [Prev Vet Med.],2011,101,1-2,18-34, ,English, ,21601933,http://www.ncbi.nlm.nih.gov/pubmed/21601933, , , ,"Generic
STARD: Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, LijmerJG Moher D, Rennie D, de Vet HCW, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF, For the STARD Group. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies.

BMJ 2015;351:h5527. PMID: 26511519
Radiology. 2015:151516. PMID: 26509226
Clinical Chemistry 2015. pii: clinchem.2015.246280. PMID: 26510957

Specialised
STARDdem: Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, Davis D, Quinn TJ, Hyde C, Rutjes AW, Smailagic N, Marcus S, Black S, Blennow K, Brayne C, Fiorivanti M, Johnson JK, K\xf6pke S, Schneider LS, Simmons A, Mattsson N, Zetterberg H, Bossuyt PM, Wilcock G, McShane R. Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. Neurology. 2014; 83(4):364-373. PMID: 24944261

STARD-BLCM: Kostoulas P, Nielsen SS, Branscum AJ, Johnson WO, Dendukuri N, Dhand NK, Toft N, Gardner IA. STARD-BLCM: Standards for the Reporting of Diagnostic accuracy studies that use Bayesian Latent Class Models. Prev Vet Med. 2017; 138:37-47. PMID: 28237234

STARD for Abstracts: Cohen JF, Korevaar DA, Gatsonis CA, Glasziou PP, Hooft L, Moher D, Reitsma JB, de Vet HC, Bossuyt PM; STARD Group. STARD for Abstracts: essential items for reporting diagnostic accuracy studies in journal or conference abstracts. BMJ. 2017;358:j3751. PMID: 28819063

", ,STRADAS-paraTB,Field-based test accuracy studies for individual and herd classification of MAP infection status, , , , , , , ,no,2013-08-15 14:14:27,2022-01-13 12:16:13,consensus-based-reporting-standards-for-diagnostic-test-accuracy-studies-for-paratuberculosis-in-ruminants,"[('title', 'Consensus-based reporting standards for diagnostic test accuracy studies for paratuberculosis in ruminants'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Field-based test accuracy studies for individual and herd classification of MAP infection status'), ('Full bibliographic reference', 'Gardner IA, Nielsen SS, Whittington RJ, Collins MT, Bakker D, Harris B, Sreevatsan S, Lombard JE, Sweeney R, Smith DR, Gavalchin J, Eda S. Consensus-based reporting standards for diagnostic test accuracy studies for paratuberculosis in ruminants. Prev Vet Med. 2011;101(1-2):18-34.'), ('Language', 'English'), ('PubMed ID', '[21601933](http://www.ncbi.nlm.nih.gov/pubmed/21601933)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n**[STARD](/reporting-guidelines/stard/)**: Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, LijmerJG Moher D, Rennie D, de Vet HCW, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF, For the STARD Group. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies.\n\n \n\n BMJ 2015;351:h5527. PMID: [26511519](http://www.ncbi.nlm.nih.gov/pubmed/26511519)\n\n Radiology. 2015:151516. PMID: [26509226](http://www.ncbi.nlm.nih.gov/pubmed/26509226)\n\n Clinical Chemistry 2015. pii: clinchem.2015.246280. PMID: [26510957](http://www.ncbi.nlm.nih.gov/pubmed/26510957)\n\n \n\n**Specialised**\n\n[**STARDdem**](/reporting-guidelines/starddem/): Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, Davis D, Quinn TJ, Hyde C, Rutjes AW, Smailagic N, Marcus S, Black S, Blennow K, Brayne C, Fiorivanti M, Johnson JK, Köpke S, Schneider LS, Simmons A, Mattsson N, Zetterberg H, Bossuyt PM, Wilcock G, McShane R. Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. Neurology. 2014; 83(4):364-373. PMID: [24944261](http://www.ncbi.nlm.nih.gov/pubmed/24944261)\n\n \n\n[**STARD-BLCM**](/reporting-guidelines/stard-blcm/): Kostoulas P, Nielsen SS, Branscum AJ, Johnson WO, Dendukuri N, Dhand NK, Toft N, Gardner IA. STARD-BLCM: Standards for the Reporting of Diagnostic accuracy studies that use Bayesian Latent Class Models. Prev Vet Med. 2017; 138:37-47. PMID: [28237234](https://www.ncbi.nlm.nih.gov/pubmed/28237234)\n\n \n\n[**STARD for Abstracts**](/reporting-guidelines/stard-abstracts/): Cohen JF, Korevaar DA, Gatsonis CA, Glasziou PP, Hooft L, Moher D, Reitsma JB, de Vet HC, Bossuyt PM; STARD Group. STARD for Abstracts: essential items for reporting diagnostic accuracy studies in journal or conference abstracts. BMJ. 2017;358:j3751. PMID: [28819063](https://www.ncbi.nlm.nih.gov/pubmed/28819063)\n\n \n\n'), ('Reporting guideline acronym', 'STRADAS-paraTB'), ('Study design', 'Diagnostic and prognostic studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 13, 2022')]"
7979,"A gold standard publication checklist to improve the quality of animal studies, to fully integrate the Three Rs, and to make systematic reviews more feasible",Animal pre-clinical research, ,Whole report, ,"animal, animal experimentation, animal pre clinical research, animal preclinical research, animal research, animal studies, animal study, animal welfare, animals, basic research, checklist, gold standard publication checklist, GSPC, laboratory animal, laboratory animals, laboratory research, pre clinical, pre clinical animal research, pre clinical experiment, pre clinical experiments, pre clinical research, pre clinical studies, pre clinical study, preclinical, preclinical animal research, preclinical experiment, preclinical experiments, preclinical research, publication checklist, whole report", ,"Hooijmans CR, Leenaars M, Ritskes-Hoitinga M. A gold standard publication checklist to improve the quality of animal studies, to fully integrate the Three Rs, and to make systematic reviews more feasible. Altern Lab Anim. 2010; 38(2):167-182.","Hooijmans CR, Leenaars M, Ritskes-Hoitinga M.",Alternatives to Laboratory Animals [Altern Lab Anim.],2010,38,2,167-182, ,English, ,20507187,http://www.ncbi.nlm.nih.gov/pubmed/20507187, , , , , ,GSPC,Reporting studies that have included animal experimentation, , , , , , , ,no,2013-08-15 13:37:29,2014-09-18 10:26:23,a-gold-standard-publication-checklist-to-improve-the-quality-of-animal-studies-to-fully-integrate-the-three-rs-and-to-make-systematic-reviews-more-feasible,"[('title', 'A gold standard publication checklist to improve the quality of animal studies, to fully integrate the Three Rs, and to make systematic reviews more feasible'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting studies that have included animal experimentation'), ('Full bibliographic reference', 'Hooijmans CR, Leenaars M, Ritskes-Hoitinga M. A gold standard publication checklist to improve the quality of animal studies, to fully integrate the Three Rs, and to make systematic reviews more feasible. Altern Lab Anim. 2010; 38(2):167-182.'), ('Language', 'English'), ('PubMed ID', '[20507187](http://www.ncbi.nlm.nih.gov/pubmed/20507187)'), ('Reporting guideline acronym', 'GSPC'), ('Study design', 'Animal pre-clinical research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 18, 2014')]"
7967,The ARRIVE Guidelines 2.0: updated guidelines for reporting animal research,Animal pre-clinical research, ,Whole report, ,"animal, animal experiment, animal experiments, animal pre clinical research, animal preclinical research, animal research, Animal Research Reporting of In Vivo Experiments, animal studies, animal study, animals, ARRIVE, ARRIVE 2.0, ARRIVE Guidelines 2.0, basic research, bioscience, checklist, in vivo, in vivo experiments, laboratory, laboratory animal, laboratory animals, pre clinical, pre clinical animal research, pre clinical experiment, pre clinical experiments, pre clinical research, pre clinical studies, pre clinical study, preclinical, preclinical animal research, preclinical experiment, preclinical experiments, preclinical research, preclinical studies, preclinical study, whole report", ,"Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen O, Rawle F, Peynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T and Wurbel H. The ARRIVE Guidelines 2.0: updated guidelines for reporting animal research.

This guideline was published simultaneously in 7 journals. You can read the guideline in any of these journals using the links below.

PLoS Biol. 2020;18(7):e3000411. PMID: 32663219
BMC Vet Res. 2020;16(1):242. PMID: 32660541
BMJ Open Science. 2020;4:e100115 (PDF).
Br J Pharmacol. 2020. PMID: 32662519
Exp Physiol. 2020. PMID: 32666546
J Cereb Blood Flow Metab. 2020. PMID: 32663096
J Physiol. 2020. PMID: 32666574

", , , , , , , ,English, , , ,"Full text PDF documents of the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines 2.0, ARRIVE 2.0 explanation and elaboration, and ARRIVE 2.0 checklists are available at https://www.arriveguidelines.org/resources

","Percie du Sert N, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Hurst V, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen O, Rawle F, Peynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T and Wurbel H. Reporting animal research: Explanation and Elaboration for the ARRIVE guidelines 2.0. PLoS Biol. 2020;18(7):e3000411. PMID: 32663221

","The ARRIVE reporting guideline was originally published in 2010.

The guideline was published simultaneously in 4 journals. You can read the 2010 guideline in any of these journals using the links below.

Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research.

PLoS Biol. 2010;8(6):e1000412. PMID: 20613859
Osteoarthritis Cartilage. 2012;20(4):256-260. PMID: 22424462
Vet Clin Pathol. 2012;41(1):27-31. PMID: 22390425
J Pharmacol Pharmacother. 2010;1(2):94-99. PMID: 21350617

", ,https://www.arriveguidelines.org,ARRIVE,Reporting any area of bioscience research using laboratory animals,"The ARRIVE guidelines 2.0 have been translated into the following languages: French; German; Chinese. These are available at https://www.arriveguidelines.org/resources

Translations of the original ARRIVE guidelines (published in 2010) are also available in: Italian; Japanese; Korean; Portuguese; Brazilian Portuguese; Spanish. These are also available at https://www.arriveguidelines.org/resources

", , , ,"An online fillable ARRIVE 2.0 checklist is also available via the GoodReports website at https://www.goodreports.org/reporting-checklists/arrive2/.

", , ,yes,2013-08-15 10:47:51,2023-03-06 11:59:01,improving-bioscience-research-reporting-the-arrive-guidelines-for-reporting-animal-research,"[('title', 'The ARRIVE Guidelines 2.0: updated guidelines for reporting animal research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting any area of bioscience research using laboratory animals'), ('Full bibliographic reference', 'Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen O, Rawle F, Peynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T and Wurbel H. The ARRIVE Guidelines 2.0: updated guidelines for reporting animal research.\n\n \n\n This guideline was published simultaneously in 7 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n PLoS Biol. 2020;18(7):e3000411. PMID: [32663219](https://pubmed.ncbi.nlm.nih.gov/32663219/)\n\n BMC Vet Res. 2020;16(1):242. PMID: [32660541](https://pubmed.ncbi.nlm.nih.gov/32660541/)\n\n BMJ Open Science. 2020;4:[e100115 (PDF)](https://openscience.bmj.com/content/bmjos/4/1/e100115.full.pdf).\n\n Br J Pharmacol. 2020. PMID: [32662519](https://pubmed.ncbi.nlm.nih.gov/32662519/)\n\n Exp Physiol. 2020. PMID: [32666546](https://pubmed.ncbi.nlm.nih.gov/32666546/)\n\n J Cereb Blood Flow Metab. 2020. PMID: [32663096](https://pubmed.ncbi.nlm.nih.gov/32663096/)\n\n J Physiol. 2020. PMID: [32666574](https://pubmed.ncbi.nlm.nih.gov/32666574/)\n\n \n\n'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'Full text PDF documents of the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines 2.0, ARRIVE 2.0 explanation and elaboration, and ARRIVE 2.0 checklists are available at <https://www.arriveguidelines.org/resources>\n\n \n\n'), ('Explanation and elaboration papers', 'Percie du Sert N, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Hurst V, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen O, Rawle F, Peynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T and Wurbel H. Reporting animal research: Explanation and Elaboration for the ARRIVE guidelines 2.0. PLoS Biol. 2020;18(7):e3000411. PMID: [32663221](http://www.ncbi.nlm.nih.gov/pubmed/32663221)\n\n \n\n'), ('Availability in additional languages', 'The ARRIVE guidelines 2.0 have been translated into the following languages: French; German; Chinese. These are available at <https://www.arriveguidelines.org/resources>\n\n \n\n Translations of the original ARRIVE guidelines (published in 2010) are also available in: Italian; Japanese; Korean; Portuguese; Brazilian Portuguese; Spanish. These are also available at <https://www.arriveguidelines.org/resources>\n\n \n\n'), ('Reporting guideline website URL', '<https://www.arriveguidelines.org>'), ('Reporting guideline acronym', 'ARRIVE'), ('Study design', 'Animal pre-clinical research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Previous versions of this guideline / Guideline history', 'The ARRIVE reporting guideline was originally published in 2010.\n\n \n\n The guideline was published simultaneously in 4 journals. You can read the 2010 guideline in any of these journals using the links below.\n\n \n\n Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research.\n\n \n\n PLoS Biol. 2010;8(6):e1000412. PMID: [20613859](http://www.ncbi.nlm.nih.gov/pubmed/20613859)\n\n Osteoarthritis Cartilage. 2012;20(4):256-260. PMID: [22424462](http://www.ncbi.nlm.nih.gov/pubmed/22424462)\n\n Vet Clin Pathol. 2012;41(1):27-31. PMID: [22390425](http://www.ncbi.nlm.nih.gov/pubmed/22390425)\n\n J Pharmacol Pharmacother. 2010;1(2):94-99. PMID: [21350617](http://www.ncbi.nlm.nih.gov/pubmed/21350617)\n\n \n\n'), ('Other', 'An online fillable ARRIVE 2.0 checklist is also available via the GoodReports website at <https://www.goodreports.org/reporting-checklists/arrive2/>.\n\n \n\n'), ('Record last updated on', 'March 6, 2023')]"
7954,International Society for Medical Publication Professionals Code of Ethics, , ,"Acknowledgements, Conflict of interest, Ethical issues (consent etc.)", ,"authorship, ghost author, ghost authors, ghost authorship, ghost writer, ghost writers, ghost writing, ghostwriter, ghostwriters, ghostwriting, industry, industry sponsored, industry sponsored research, International Society for Medical Publication Professionals, ISMPP, medical communication, medical ghostwriting, medical industry, pharmaceutical industry", ,International Society for Medical Publication Professionals Code of Ethics. The full-text is available from the ISMPP website: Code of Ethics,International Society for Medical Publication Professionals., , , , , , ,English, , , , , , , , , ,"Medical writers and communicators, publication planners, editors, publishers, and other professions", , , , , , , ,no,2013-08-14 14:35:58,2022-01-13 12:37:38,international-society-for-medical-publication-professionals-code-of-ethics,"[('title', 'International Society for Medical Publication Professionals Code of Ethics'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Medical writers and communicators, publication planners, editors, publishers, and other professions'), ('Full bibliographic reference', 'International Society for Medical Publication Professionals Code of Ethics. The full-text is available from the ISMPP website: [Code of Ethics](http://www.ismpp.org/ethics)'), ('Language', 'English'), ('Applies to the whole report or to individual sections of the report?', 'Acknowledgements, Conflict of interest, Ethical issues (consent etc.)'), ('Record last updated on', 'January 13, 2022')]"
7937,Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials,"Clinical trials, Experimental studies",Pharmaceutical medicine,"Conflict of interest, Ethical issues (consent etc.), Statistical methods and analyses", ,"clinical trial, clinical trials, company sponsored medical research, company sponsored research, conflict of interest, drug industry, experimental studies, experimental study, good practice, good publication practice, industry, industry sponsored, industry sponsored clinical trial, industry sponsored clinical trials, industry sponsored research, industry sponsored studies, industry sponsored study, industry sponsored trial, industry sponsored trials, pharmaceutical, pharmaceutical clinical trial, pharmaceutical clinical trials, pharmaceutical industry, pharmaceutical sponsored trial, pharmaceutical sponsored trials, pharmaceutical trial, pharmaceutical trials, pharmacology, statistician, statisticians, statistics, trial, trial statistician, trials", ,"Matcham J, Julious S, Pyke S, O'Kelly M, Todd S, Seldrup J, Day S. Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials. Pharm Stat. 2011;10(1):70-73.","Matcham J, Julious S, Pyke S, O'Kelly M, Todd S, Seldrup J, Day S.",Pharmaceutical Statistics [Pharm Stat.],2011,10,1,70-73, ,English, ,20187020,http://www.ncbi.nlm.nih.gov/pubmed/20187020, , , , , , ,Pharmaceutical industry-sponsored clinical trials, , , , , , , ,no,2013-08-14 09:30:33,2013-08-20 14:24:09,proposed-best-practice-for-statisticians-in-the-reporting-and-publication-of-pharmaceutical-industry-sponsored-clinical-trials,"[('title', 'Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Pharmaceutical industry-sponsored clinical trials'), ('Full bibliographic reference', ""Matcham J, Julious S, Pyke S, O'Kelly M, Todd S, Seldrup J, Day S. Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials. Pharm Stat. 2011;10(1):70-73.""), ('Language', 'English'), ('PubMed ID', '[20187020](http://www.ncbi.nlm.nih.gov/pubmed/20187020)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Pharmaceutical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Conflict of interest, Ethical issues (consent etc.), Statistical methods and analyses'), ('Record last updated on', 'August 20, 2013')]"
7926,What should be done to tackle ghostwriting in the medical literature?, , ,"Acknowledgements, Ethical issues (consent etc.)", ,"checklist, disclosure, ghost author, ghost authors, ghost authorship, ghost writer, ghost writers, ghost writing, ghostwriter, ghostwriters, ghostwriting, ICMJE, industry, industry sponsored, industry sponsored research, industry sponsored studies, industry sponsored study, International Committee of Medical Journal Editors, medical ghostwriting, medical writer, medical writers, pharmaceutical companies, pharmaceutical company, pharmaceutical industry, professional medical writer, professional medical writers, professional writer, professional writers, WAME, World Association of Medical Editors", ,"Gotzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, Hamilton C. What should be done to tackle ghostwriting in the medical literature? PLoS Med. 2009;6(2):e23.","Gotzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, Hamilton C.",PLoS Medicine [PLoS Med.],2009,6,2,e23, ,English, ,19192943,http://www.ncbi.nlm.nih.gov/pubmed/19192943, , , , , , ,Acknowledging professional medical writers and their funding source in the medical literature, , , , , , , ,no,2013-08-14 08:38:44,2013-08-14 09:09:15,what-should-be-done-to-tackle-ghostwriting-in-the-medical-literature,"[('title', 'What should be done to tackle ghostwriting in the medical literature?'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Acknowledging professional medical writers and their funding source in the medical literature'), ('Full bibliographic reference', 'Gotzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, Hamilton C. What should be done to tackle ghostwriting in the medical literature? PLoS Med. 2009;6(2):e23.'), ('Language', 'English'), ('PubMed ID', '[19192943](http://www.ncbi.nlm.nih.gov/pubmed/19192943)'), ('Applies to the whole report or to individual sections of the report?', 'Acknowledgements, Ethical issues (consent etc.)'), ('Record last updated on', 'August 14, 2013')]"
7918,Electrodermal activity at acupoints: literature review and recommendations for reporting clinical trials,"Clinical trials, Experimental studies",Complementary and alternative medicine,"Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.)", ,"acupoint, acupoints, acupoints research, acupuncture, acupuncture points, alternative medicine, CAM, capacitance, checklist, clinical trial, clinical trials, complementary and alternative medicine, complementary medicine, EDA, EDA measurement, EDA measurements, electric potentials, electroacupuncture, electrodermal, electrodermal activity, electrodermal measurement, electrodermal measurements, experimental studies, experimental study, psychophysiological, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, skin conduction, skin resistance, trial, trials", ,"Colbert AP, Spaulding K, Larsen A, Ahn AC, Cutro JA. Electrodermal activity at acupoints: literature review and recommendations for reporting clinical trials. J Acupunct Meridian Stud. 2011;4(1):5-13.","Colbert AP, Spaulding K, Larsen A, Ahn AC, Cutro JA.",Journal of Acupuncture and Meridian Studies [J Acupunct Meridian Stud.],2011,4,1,5-13, ,English, ,21440875,http://www.ncbi.nlm.nih.gov/pubmed/21440875, , , , , , ,Reporting of clinical trials that record electrodermal activity (EDA) at acupuncture points (acupoints), , , , , , , ,no,2013-08-14 07:02:35,2015-01-27 15:11:47,electrodermal-activity-at-acupoints-literature-review-and-recommendations-for-reporting-clinical-trials,"[('title', 'Electrodermal activity at acupoints: literature review and recommendations for reporting clinical trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of clinical trials that record electrodermal activity (EDA) at acupuncture points (acupoints)'), ('Full bibliographic reference', 'Colbert AP, Spaulding K, Larsen A, Ahn AC, Cutro JA. Electrodermal activity at acupoints: literature review and recommendations for reporting clinical trials. J Acupunct Meridian Stud. 2011;4(1):5-13.'), ('Language', 'English'), ('PubMed ID', '[21440875](http://www.ncbi.nlm.nih.gov/pubmed/21440875)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'January 27, 2015')]"
7914,Systematic review to determine best practice reporting guidelines for AFO interventions in studies involving children with cerebral palsy, ,"Neurology, Paediatrics","Intervention (exposure), Study characteristics (participants etc.)", ,"adolescent, adolescents, AFOs, ankle, ankle foot orthoses, ankle foot orthosis, cerebral palsy, children, CP, foot, gait, neurology, orthoses, orthosis, orthotic, orthotic device, orthotic devices, paediatric, paediatrics, palsy, pediatric, pediatrics", ,"Ridgewell E, Dobson F, Bach T, Baker R. A systematic review to determine best practice reporting guidelines for AFO interventions in studies involving children with cerebral palsy. Prosthet Orthot Int. 2010;34(2):129-145.","Ridgewell E, Dobson F, Bach T, Baker R.",Prosthetics and Orthotics International [Prosthet Orthot Int.],2010,34,2,129-145, ,English, ,20384548,http://www.ncbi.nlm.nih.gov/pubmed/20384548, , , , , , ,Reporting ankle-foot orthosis (AFO) intervention studies in children with cerebral palsy (CP), , , , , , , ,no,2013-08-13 15:04:35,2013-08-20 14:31:27,systematic-review-to-determine-best-practice-reporting-guidelines-for-afo-interventions-in-studies-involving-children-with-cerebral-palsy,"[('title', 'Systematic review to determine best practice reporting guidelines for AFO interventions in studies involving children with cerebral palsy'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting ankle-foot orthosis (AFO) intervention studies in children with cerebral palsy (CP)'), ('Full bibliographic reference', 'Ridgewell E, Dobson F, Bach T, Baker R. A systematic review to determine best practice reporting guidelines for AFO interventions in studies involving children with cerebral palsy. Prosthet Orthot Int. 2010;34(2):129-145.'), ('Language', 'English'), ('PubMed ID', '[20384548](http://www.ncbi.nlm.nih.gov/pubmed/20384548)'), ('Clinical area', 'Neurology, Paediatrics'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Study characteristics (participants etc.)'), ('Record last updated on', 'August 20, 2013')]"
7911,EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting, ,Nuclear medicine,"Images, Procedure/Method, Results", ,"checklist, clinical dosimetry, diagnostic agent, dosimetric, dosimetry, internal dosimetry, nuclear, nuclear medicine, radiation, radiometry, radiopharmaceutical, radiopharmaceuticals, radiotherapy, targeted radiotherapy, therapeutic agent", ,"Lassmann M, Chiesa C, Flux G, Bardi\xe8s M; EANM Dosimetry Committee. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging. 2011;38(1):192-200.","Lassmann M, Chiesa C, Flux G, Bardi\xe8s M; EANM Dosimetry Committee.",European Journal of Nuclear Medicine and Molecular Imaging [Eur J Nucl Med Mol Imaging.],2011,38,1,192-200, ,English, ,20799035, http://www.ncbi.nlm.nih.gov/pubmed/20799035, , , , , , ,"Reporting diagnostic, pretherapeutic and/or peritherapeutic clinical absorbed dose assessments", , , , , , , ,no,2013-08-13 14:43:09,2013-08-22 10:51:59,eanm-dosimetry-committee-guidance-document-good-practice-of-clinical-dosimetry-reporting,"[('title', 'EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting diagnostic, pretherapeutic and/or peritherapeutic clinical absorbed dose assessments'), ('Full bibliographic reference', 'Lassmann M, Chiesa C, Flux G, Bardiès M; EANM Dosimetry Committee. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging. 2011;38(1):192-200.'), ('Language', 'English'), ('PubMed ID', '[20799035]( http://www.ncbi.nlm.nih.gov/pubmed/20799035)'), ('Clinical area', 'Nuclear medicine'), ('Applies to the whole report or to individual sections of the report?', 'Images, Procedure/Method, Results'), ('Record last updated on', 'August 22, 2013')]"
7908,"ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis","Clinical trials, Experimental studies",Rheumatology,Data, ,"ankylosing, ankylosing spondylitis, anti inflammatory, axial, axial spondyloarthritis, clinical trial, clinical trials, data, experimental studies, experimental study, non steroidal anti inflammatory drugs, NSAID, NSAIDs, rheumatology, SpA, spondylitis, spondyloarthritis, trial, trials", ,"Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, van der Heijde D. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis. 2011;70(2):249-251.","Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, van der Heijde D.",Annals of the Rheumatic Diseases [Ann Rheum Dis.],2011,70,2,249-251, ,English, ,20829199,http://www.ncbi.nlm.nih.gov/pubmed/20829199, , , , , , ,Reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis, , , , , , , ,no,2013-08-13 14:19:11,2015-01-27 14:28:20,asas-recommendations-for-collecting-analysing-and-reporting-nsaid-intake-in-clinical-trialsepidemiological-studies-in-axial-spondyloarthritis,"[('title', 'ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis'), ('Full bibliographic reference', 'Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, van der Heijde D. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis. 2011;70(2):249-251.'), ('Language', 'English'), ('PubMed ID', '[20829199](http://www.ncbi.nlm.nih.gov/pubmed/20829199)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Rheumatology'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'January 27, 2015')]"
7904,International Spinal Cord Injury Core Data Set (version 3.0) - including standardization of reporting, ,Neurology,"Data, Results, Study characteristics (participants etc.)", ,"analysis, cord injury, core data set, data, data analysis, data set, International Spinal Cord Injury Core Data Set, neurological, neurology, SCI, SCI core data set, SCI core data sets, SCI data set, SCI data sets, spinal, spinal cord, spinal cord injury, spinal injury, spine, study participants", ,"Biering-S\xf8rensen F, Charlifue S, Chen Y, New PW, Noonan V, Post MWM, Rupp R, Vogel L. International Spinal Cord Injury Core Data Set (version 3.0) - including standardization of reporting. Spinal Cord. 2022.","Biering-S\xf8rensen F, Charlifue S, Chen Y, New PW, Noonan V, Post MWM, Rupp R, Vogel L.",Spinal Cord.,2022, , , , ,English, ,36307730,https://pubmed.ncbi.nlm.nih.gov/36307730/, , ,"2017
Biering-S\xf8rensen F, DeVivo MJ, Charlifue S, Chen Y, New PW, Noonan V, Post MWM, Vogel L. International Spinal Cord Injury Core Data Set (version 2.0) - including standardization of reporting. Spinal Cord. 2017;55(8):759-764. PMID: 28555665

2011
DeVivo MJ, Biering-S\xf8rensen F, New P, Chen Y; International Spinal Cord Injury Data Set. Standardization of data analysis and reporting of results from the International Spinal Cord Injury Core Data Set. Spinal Cord. 2011;49(5):596-599. PMID: 21135863

", , , ,Reporting of results using the International Spinal Cord Injury (SCI) Core Data Set, , , , , , , ,no,2013-08-13 13:43:54,2022-11-22 11:23:16,standardization-of-data-analysis-and-reporting-of-results-from-the-international-spinal-cord-injury-core-data-set,"[('title', 'International Spinal Cord Injury Core Data Set (version 3.0) – including standardization of reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of results using the International Spinal Cord Injury (SCI) Core Data Set'), ('Full bibliographic reference', 'Biering-Sørensen F, Charlifue S, Chen Y, New PW, Noonan V, Post MWM, Rupp R, Vogel L. International Spinal Cord Injury Core Data Set (version 3.0) - including standardization of reporting. Spinal Cord. 2022.'), ('Language', 'English'), ('PubMed ID', '[36307730](https://pubmed.ncbi.nlm.nih.gov/36307730/)'), ('Clinical area', 'Neurology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Results, Study characteristics (participants etc.)'), ('Previous versions of this guideline / Guideline history', '2017\n\n Biering-Sørensen F, DeVivo MJ, Charlifue S, Chen Y, New PW, Noonan V, Post MWM, Vogel L. International Spinal Cord Injury Core Data Set (version 2.0) - including standardization of reporting. Spinal Cord. 2017;55(8):759-764. PMID: [28555665](https://pubmed.ncbi.nlm.nih.gov/28555665/)\n\n \n\n 2011\n\n DeVivo MJ, Biering-Sørensen F, New P, Chen Y; International Spinal Cord Injury Data Set. Standardization of data analysis and reporting of results from the International Spinal Cord Injury Core Data Set. Spinal Cord. 2011;49(5):596-599. PMID: [21135863](http://www.ncbi.nlm.nih.gov/pubmed/21135863)\n\n \n\n'), ('Record last updated on', 'November 22, 2022')]"
7901,Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting,Observational studies,"Cardiovascular medicine, Respiratory medicine","Outcomes (variables), Study characteristics (participants etc.)", ,"anticoagulant, anticoagulant therapy, anticoagulants, anticoagulation, cardiovascular medicine, cohort studies, cohort study, deep vein thrombosis, DVT, observational, observational studies, observational study, PE, pulmonary embolism, recurrence rates, recurrent VTE, respiratory medicine, risk, risk factor, risk factors, stroke, thromboembolism, venous, venous thromboembolism, venous thrombosis, VTE", ,"Kearon C, Iorio A, Palareti G; Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. J Thromb Haemost. 2010; 8(10):2313-2315.","Kearon C, Iorio A, Palareti G; Subcommittee on Control of Anticoagulation of the SSC of the ISTH.",Journal of Thrombosis and Haemostasis [J Thromb Haemost.],2010,8,10,2313-2315, ,English, ,20738761,http://www.ncbi.nlm.nih.gov/pubmed/20738761, , , , , , ,Reporting risk of recurrent venous thromboembolism (VTE) after stopping anticoagulant therapy, , , , , , , ,no,2013-08-13 13:32:15,2015-01-27 12:14:03,risk-of-recurrent-venous-thromboembolism-after-stopping-treatment-in-cohort-studies-recommendation-for-acceptable-rates-and-standardized-reporting,"[('title', 'Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting risk of recurrent venous thromboembolism (VTE) after stopping anticoagulant therapy'), ('Full bibliographic reference', 'Kearon C, Iorio A, Palareti G; Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. J Thromb Haemost. 2010; 8(10):2313-2315.'), ('Language', 'English'), ('PubMed ID', '[20738761](http://www.ncbi.nlm.nih.gov/pubmed/20738761)'), ('Study design', 'Observational studies'), ('Clinical area', 'Cardiovascular medicine, Respiratory medicine'), ('Applies to the whole report or to individual sections of the report?', 'Outcomes (variables), Study characteristics (participants etc.)'), ('Record last updated on', 'January 27, 2015')]"
7899,The importance of uniform venous terminology in reports on varicose veins, ,"Cardiovascular medicine, Surgery",Terminology/definitions, ,"cardiovascular medicine, chronic venous disease, chronic venous disorder, chronic venous insufficiency, deep veins, definition, definitions, leg, leg veins, perforating veins, superficial veins, surgery, terminology, varicose vein, varicose veins, varicosities, vascular, vascular surgery, vein, venous, venous disease, venous insufficiency", ,"Vasquez MA, Munschauer CE. The importance of uniform venous terminology in reports on varicose veins. Semin Vasc Surg. 2010;23(2):70-77.","Vasquez MA, Munschauer CE.",Seminars in Vascular Surgery [Semin Vasc Surg.],2010,23,2,70-77, ,English, ,20685560,http://www.ncbi.nlm.nih.gov/pubmed/20685560, , , , , , ,Venous terminology in reports on varicose veins, , , , , , , ,no,2013-08-13 11:35:28,2013-08-20 14:41:19,the-importance-of-uniform-venous-terminology-in-reports-on-varicose-veins,"[('title', 'The importance of uniform venous terminology in reports on varicose veins'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Venous terminology in reports on varicose veins'), ('Full bibliographic reference', 'Vasquez MA, Munschauer CE. The importance of uniform venous terminology in reports on varicose veins. Semin Vasc Surg. 2010;23(2):70-77.'), ('Language', 'English'), ('PubMed ID', '[20685560](http://www.ncbi.nlm.nih.gov/pubmed/20685560)'), ('Clinical area', 'Cardiovascular medicine, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Terminology/definitions'), ('Record last updated on', 'August 20, 2013')]"
7894,Recommendations for reporting perioperative transoesophageal echo studies, ,"Anaesthesia, Cardiovascular medicine","Procedure/Method, Results, Study characteristics (participants etc.)", ,"anaesthesia, anaesthetic, anesthesia, anesthetic, cardiac, cardiology, cardiothoracic, cardiovascular medicine, echo, echo studies, echo study, echocardiography, heart, heart valve, heart valve disease, perioperative, perioperative TEE, perioperative transoesophageal echo studies, perioperative transoesophageal echo study, perioperative transoesophageal echocardiography, TEE, TEE report, transoesophageal, transoesophageal echo report, transoesophageal echo studies, transoesophageal echo study, transoesophageal echocardiography, transthoracic, ventricular", ,"Feneck R, Kneeshaw J, Fox K, Bettex D, Erb J, Flaschkampf F, Guarracino F, Ranucci M, Seeberger M, Sloth E, Tschernich H, Wouters P, Zamorano J; European Association of Cardiothoracic Anaesthesiologists (EACTA) and the European Association of Echocardiography (EAE). Recommendations for reporting perioperative transoesophageal echo studies. Eur J Echocardiogr. 2010;11(5):387-393.","Feneck R, Kneeshaw J, Fox K, Bettex D, Erb J, Flaschkampf F, Guarracino F, Ranucci M, Seeberger M, Sloth E, Tschernich H, Wouters P, Zamorano J; European Association of Cardiothoracic Anaesthesiologists (EACTA) and the European Association of Echocardiography (EAE).",European Journal of Echocardiography [Eur J Echocardiogr.],2010,11,5,387-393, ,English, ,20530602,http://www.ncbi.nlm.nih.gov/pubmed/20530602, , , , , , ,Reporting perioperative transoesophageal echo studies, , , , , , , ,no,2013-08-13 10:43:52,2015-01-27 14:22:36,recommendations-for-reporting-perioperative-transoesophageal-echo-studies,"[('title', 'Recommendations for reporting perioperative transoesophageal echo studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting perioperative transoesophageal echo studies'), ('Full bibliographic reference', 'Feneck R, Kneeshaw J, Fox K, Bettex D, Erb J, Flaschkampf F, Guarracino F, Ranucci M, Seeberger M, Sloth E, Tschernich H, Wouters P, Zamorano J; European Association of Cardiothoracic Anaesthesiologists (EACTA) and the European Association of Echocardiography (EAE). Recommendations for reporting perioperative transoesophageal echo studies. Eur J Echocardiogr. 2010;11(5):387-393.'), ('Language', 'English'), ('PubMed ID', '[20530602](http://www.ncbi.nlm.nih.gov/pubmed/20530602)'), ('Clinical area', 'Anaesthesia, Cardiovascular medicine'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'January 27, 2015')]"
7889,Guidelines for reporting an fMRI study, ,"Neurology, Psychiatry, Psychology, Radiology","Data, Ethical issues (consent etc.), Figures/Graphs, Images, Procedure/Method, Results, Study characteristics (participants etc.)", ,"checklist, data, fMRI, fMRI data, fMRI data acquisition, fMRI data analysis, fMRI methods, fMRI results, functional, functional magnetic resonance, functional magnetic resonance imaging, general linear model, image, imaging, magnetic resonance, magnetic resonance imaging, neuroimaging, neurological, neurology, psychiatric, psychiatrist, psychiatry, psychological, psychology, psychophysicist, radiological, radiology", ,"Poldrack RA, Fletcher PC, Henson RN, Worsley KJ, Brett M, Nichols TE. Guidelines for reporting an fMRI study. Neuroimage. 2008;40(2):409-414.","Poldrack RA, Fletcher PC, Henson RN, Worsley KJ, Brett M, Nichols TE.",NeuroImage.,2008,40,2,409-414, ,English, ,18191585,http://www.ncbi.nlm.nih.gov/pubmed/18191585, , , , , , ,Reporting of methods and results in functional magnetic resonance imaging studies, , , , , , , ,no,2013-08-13 10:11:08,2013-08-22 10:00:25,guidelines-for-reporting-an-fmri-study,"[('title', 'Guidelines for reporting an f MRI study'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of methods and results in functional magnetic resonance imaging studies'), ('Full bibliographic reference', 'Poldrack RA, Fletcher PC, Henson RN, Worsley KJ, Brett M, Nichols TE. Guidelines for reporting an fMRI study. Neuroimage. 2008;40(2):409-414.'), ('Language', 'English'), ('PubMed ID', '[18191585](http://www.ncbi.nlm.nih.gov/pubmed/18191585)'), ('Clinical area', 'Neurology, Psychiatry, Psychology, Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Ethical issues (consent etc.), Figures/Graphs, Images, Procedure/Method, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'August 22, 2013')]"
7886,Society for Cardiovascular Magnetic Resonance guidelines for reporting cardiovascular magnetic resonance examinations, ,"Cardiovascular medicine, Radiology","Images, Procedure/Method, Results, Study characteristics (participants etc.)", ,"cardiac, cardiac imaging, cardio, cardiovascular, cardiovascular disease, cardiovascular diseases, cardiovascular magnetic resonance, cardiovascular medicine, CMR, CMR examination, coronary, diagnostic imaging, examination, heart, image, imaging, magnetic resonance, radiology, vascular, vascular imaging", ,"Hundley WG, Bluemke D, Bogaert JG, Friedrich MG, Higgins CB, Lawson MA, McConnell MV, Raman SV, van Rossum AC, Flamm S, Kramer CM, Nagel E, Neubauer S. Society for Cardiovascular Magnetic Resonance guidelines for reporting cardiovascular magnetic resonance examinations. J Cardiovasc Magn Reson. 2009;11:5.","Hundley WG, Bluemke D, Bogaert JG, Friedrich MG, Higgins CB, Lawson MA, McConnell MV, Raman SV, van Rossum AC, Flamm S, Kramer CM, Nagel E, Neubauer S.",Journal of Cardiovascular Magnetic Resonance [J Cardiovasc Magn Reson.],2009,11,5, , ,English, ,19257889,http://www.ncbi.nlm.nih.gov/pubmed/19257889, , , , , , ,Cardiac and vascular imaging findings related to the performance of cardiovascular magnetic resonance (CMR) examinations, , , , , , , ,no,2013-08-13 09:41:15,2013-08-21 15:03:53,society-for-cardiovascular-magnetic-resonance-guidelines-for-reporting-cardiovascular-magnetic-resonance-examinations,"[('title', 'Society for Cardiovascular Magnetic Resonance guidelines for reporting cardiovascular magnetic resonance examinations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Cardiac and vascular imaging findings related to the performance of cardiovascular magnetic resonance (CMR) examinations'), ('Full bibliographic reference', 'Hundley WG, Bluemke D, Bogaert JG, Friedrich MG, Higgins CB, Lawson MA, McConnell MV, Raman SV, van Rossum AC, Flamm S, Kramer CM, Nagel E, Neubauer S. Society for Cardiovascular Magnetic Resonance guidelines for reporting cardiovascular magnetic resonance examinations. J Cardiovasc Magn Reson. 2009;11:5.'), ('Language', 'English'), ('PubMed ID', '[19257889](http://www.ncbi.nlm.nih.gov/pubmed/19257889)'), ('Clinical area', 'Cardiovascular medicine, Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Images, Procedure/Method, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'August 21, 2013')]"
7880,Criteria for evaluation of novel markers of cardiovascular risk,Observational studies,Cardiovascular medicine,"Outcomes (variables), Procedure/Method, Results", ,"assessment, cardiac, cardio, cardiology, cardiovascular, cardiovascular disease, cardiovascular medicine, cardiovascular risk, coronary, coronary disease, cost, cost effectiveness, costs, evaluation, genomic, heart, multimarker, multimarkers, novel, novel marker, novel markers, novel risk marker, observational, observational studies, observational study, prognosis, prognostic, proteomic, risk, risk assessment, risk assessment method, risk assessment methods, risk evaluation, risk marker, risk prediction, safety, validation", ,"Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O'Donnell CJ, Smith SC Jr, Wilson PW; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119(17):2408-2416.","Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O'Donnell CJ, Smith SC Jr, Wilson PW; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council.",Circulation.,2009,119,17,2408-2416, ,English, ,19364974,http://www.ncbi.nlm.nih.gov/pubmed/19364974, , , , , , ,Reporting the results of studies using novel markers in risk assessment, , , , , , , ,no,2013-08-12 15:40:07,2013-08-21 13:33:28,criteria-for-evaluation-of-novel-markers-of-cardiovascular-risk-a-scientific-statement-from-the-american-heart-association,"[('title', 'Criteria for evaluation of novel markers of cardiovascular risk'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the results of studies using novel markers in risk assessment'), ('Full bibliographic reference', ""Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O'Donnell CJ, Smith SC Jr, Wilson PW; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119(17):2408-2416.""), ('Language', 'English'), ('PubMed ID', '[19364974](http://www.ncbi.nlm.nih.gov/pubmed/19364974)'), ('Study design', 'Observational studies'), ('Clinical area', 'Cardiovascular medicine'), ('Applies to the whole report or to individual sections of the report?', 'Outcomes (variables), Procedure/Method, Results'), ('Record last updated on', 'August 21, 2013')]"
7877,"American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation","Clinical trials, Experimental studies","Infectious diseases, Surgery","Ethical issues (consent etc.), Harms/adverse effects/safety data, Outcomes (variables), Terminology/definitions", ,"bacterial, bacterial infection, bacterial infections, clinical trial, clinical trials, complications, experimental studies, experimental study, fungal, fungal infection, fungal infections, immunosuppression, immunosuppressive, immunosuppressive drug therapies, immunosuppressive drug therapy, infection, infectious complication, infectious complications, infectious diseases, infectious risks, laboratory, laboratory monitoring, organ transplant, organ transplantation, rejection, surgery, transplant, transplant associated infection, transplant associated infections, transplantation, trial, trials, viral, viral infection, viral infections, virus", ,"Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6(2):262-274.","Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring.",American Journal of Transplantation [Am J Transplant.],2006,6,2,262-274, ,English, ,16426310,http://www.ncbi.nlm.nih.gov/pubmed/16426310, , , , , , ,Reporting of infectious complications in immunosuppression trials in recipients of organ transplantation, , , , , , , ,no,2013-08-12 15:13:04,2013-08-20 14:48:43,american-society-of-transplantation-recommendations-for-screening-monitoring-and-reporting-of-infectious-complications-in-immunosuppression-trials-in-recipients-of-organ-transplantation,"[('title', 'American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of infectious complications in immunosuppression trials in recipients of organ transplantation'), ('Full bibliographic reference', 'Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6(2):262-274.'), ('Language', 'English'), ('PubMed ID', '[16426310](http://www.ncbi.nlm.nih.gov/pubmed/16426310)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Infectious diseases, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Ethical issues (consent etc.), Harms/adverse effects/safety data, Outcomes (variables), Terminology/definitions'), ('Record last updated on', 'August 20, 2013')]"
7872,Research reporting standards for radioembolization of hepatic malignancies, ,"Gastroenterology, Oncology, Radiology","Harms/adverse effects/safety data, Images, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions", ,"carcinoma, cost, cost effectiveness, costs, embolisation, embolization, gastroenterology, HCC, hepatic, hepatic malignancies, hepatic malignancy, hepatocellular, hepatocellular carcinoma, image guided, intrahepatic cholangiocarcinoma, liver, liver cancer, liver neoplasm, liver neoplasms, liver tumor, liver tumors, liver tumour, liver tumours, malignancies, malignancy, oncology, radioembolisation, radioembolization, radiology, transcatheter tumor therapy, transcatheter tumour therapy", ,"Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, Soulen MC, Geschwind JF, Kulik L, Kim YH, Spreafico C, Maccauro M, Bester L, Brown DB, Ryu RK, Sze DY, Rilling WS, Sato KT, Sangro B, Bilbao JI, Jakobs TF, Ezziddin S, Kulkarni S, Kulkarni A, Liu DM, Valenti D, Hilgard P, Antoch G, Muller SP, Alsuhaibani H, Mulcahy MF, Burrel M, Real MI, Spies S, Esmail AA, Raoul JL, Garin E, Johnson MS, Benson AB 3rd, Sharma RA, Wasan H, Lambert B, Memon K, Kennedy AS, Riaz A; Technology Assessment Committee; Interventional Oncology Task Force of the Society of Interventional Radiology. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011;22(3):265-278.","Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, Soulen MC, Geschwind JF, Kulik L, Kim YH, Spreafico C, Maccauro M, Bester L, Brown DB, Ryu RK, Sze DY, Rilling WS, Sato KT, Sangro B, Bilbao JI, Jakobs TF, Ezziddin S, Kulkarni S, Kulkarni A, Liu DM, Valenti D, Hilgard P, Antoch G, Muller SP, Alsuhaibani H, Mulcahy MF, Burrel M, Real MI, Spies S, Esmail AA, Raoul JL, Garin E, Johnson MS, Benson AB 3rd, Sharma RA, Wasan H, Lambert B, Memon K, Kennedy AS, Riaz A; Technology Assessment Committee; Interventional Oncology Task Force of the Society of Interventional Radiology.",Journal of Vascular and Interventional Radiology [J Vasc Interv Radiol.],2011,22,3,265-278, ,English, ,21353979,http://www.ncbi.nlm.nih.gov/pubmed/21353979, , , , , , ,Reporting clinical studies of radioembolization of hepatic malignancies, , , , , , , ,no,2013-08-12 14:03:30,2013-08-21 15:06:45,research-reporting-standards-for-radioembolization-of-hepatic-malignancies,"[('title', 'Research reporting standards for radioembolization of hepatic malignancies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting clinical studies of radioembolization of hepatic malignancies'), ('Full bibliographic reference', 'Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, Soulen MC, Geschwind JF, Kulik L, Kim YH, Spreafico C, Maccauro M, Bester L, Brown DB, Ryu RK, Sze DY, Rilling WS, Sato KT, Sangro B, Bilbao JI, Jakobs TF, Ezziddin S, Kulkarni S, Kulkarni A, Liu DM, Valenti D, Hilgard P, Antoch G, Muller SP, Alsuhaibani H, Mulcahy MF, Burrel M, Real MI, Spies S, Esmail AA, Raoul JL, Garin E, Johnson MS, Benson AB 3rd, Sharma RA, Wasan H, Lambert B, Memon K, Kennedy AS, Riaz A; Technology Assessment Committee; Interventional Oncology Task Force of the Society of Interventional Radiology. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011;22(3):265-278.'), ('Language', 'English'), ('PubMed ID', '[21353979](http://www.ncbi.nlm.nih.gov/pubmed/21353979)'), ('Clinical area', 'Gastroenterology, Oncology, Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Images, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'August 21, 2013')]"
7867,Research reporting standards for image-guided ablation of bone and soft tissue tumors, ,"Oncology, Radiology","Harms/adverse effects/safety data, Images, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.)", ,"ablation, ablative, benign, benign bone, benign bone tumor, benign bone tumors, benign bone tumour, benign bone tumours, bone, bone and soft tissue tumor, bone and soft tissue tumors, bone and soft tissue tumour, bone and soft tissue tumours, bone cancer, bone neoplasm, bone neoplasms, bone tumor, bone tumors, bone tumour, bone tumours, cancer, cost, cost effectiveness, costs, image, image guided, image guided ablation, image guided percutaneous ablation, image guided tumor ablation, image guided tumour ablation, metastases, metastatic, minimally invasive, neoplasm, neoplasms, oncology, osteoid osteoma, percutaneous, percutaneous ablation, quality, quality of life, radiology, soft tissue tumor, soft tissue tumors, soft tissue tumour, soft tissue tumours, tissue, tumor, tumors, tumour, tumours", ,"Callstrom MR, York JD, Gaba RC, Gemmete JJ, Gervais DA, Millward SF, Brown DB, Dupuy D, Goldberg SN, Kundu S, Rose SC, Thomas JJ, Cardella JF; Technology Assessment Committee of Society of Interventional Radiology. Research reporting standards for image-guided ablation of bone and soft tissue tumors. J Vasc Interv Radiol. 2009;20(12):1527-1540.","Callstrom MR, York JD, Gaba RC, Gemmete JJ, Gervais DA, Millward SF, Brown DB, Dupuy D, Goldberg SN, Kundu S, Rose SC, Thomas JJ, Cardella JF; Technology Assessment Committee of Society of Interventional Radiology.",Journal of Vascular and Interventional Radiology [J Vasc Interv Radiol.],2009,20,12,1527-1540, ,English, ,19864161,http://www.ncbi.nlm.nih.gov/pubmed/19864161, , , , , , ,Reporting clinical studies and research on the use of ablation methods for the treatment of benign bone tumors and metastases involving bone and soft tissues beyond the liver and lung, , , , , , , ,no,2013-08-12 10:06:15,2013-08-22 09:57:36,research-reporting-standards-for-image-guided-ablation-of-bone-and-soft-tissue-tumors,"[('title', 'Research reporting standards for image-guided ablation of bone and soft tissue tumors'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting clinical studies and research on the use of ablation methods for the treatment of benign bone tumors and metastases involving bone and soft tissues beyond the liver and lung'), ('Full bibliographic reference', 'Callstrom MR, York JD, Gaba RC, Gemmete JJ, Gervais DA, Millward SF, Brown DB, Dupuy D, Goldberg SN, Kundu S, Rose SC, Thomas JJ, Cardella JF; Technology Assessment Committee of Society of Interventional Radiology. Research reporting standards for image-guided ablation of bone and soft tissue tumors. J Vasc Interv Radiol. 2009;20(12):1527-1540.'), ('Language', 'English'), ('PubMed ID', '[19864161](http://www.ncbi.nlm.nih.gov/pubmed/19864161)'), ('Clinical area', 'Oncology, Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Images, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'August 22, 2013')]"
7863,"EANM procedure guidelines for brain neurotransmission SPECT using I-labelled dopamine transporter ligands, version 2", ,"Neurology, Nuclear medicine, Radiology","Images, Procedure/Method, Results, Study characteristics (participants etc.)", ,"brain, clinical dopamine transporter, computed tomography, DAT, DAT SPECT imaging, dopamine, dopamine transporter, European Association of Nuclear Medicine Neuroimaging Committee, ligands, movement disorders, neuroimaging, neurology, neurotransmission, nuclear medicine, parkinson, Parkinson?s, Parkinson?s disease, parkinsonian, parkinsonism, PD, PET, radiology, radiopharmaceuticals, single photon emission computed tomography, SPECT", ,"Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, N\xe5gren K, Nobili F, Walker Z, Van Laere K. EANM procedure guidelines for brain neurotransmission SPECT using I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37(2):443-450.","Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, N\xe5gren K, Nobili F, Walker Z, Van Laere K.",European Journal of Nuclear Medicine and Molecular Imaging [Eur J Nucl Med Mol Imaging.],2010,37,2,443-450, ,English, ,19838702, http://www.ncbi.nlm.nih.gov/pubmed/19838702, , , , , , ,Reporting the results of clinical dopamine transporter (DAT) single photon emission computed tomography (SPECT) studies using I-labelled radiopharmaceuticals, , , , , , , ,no,2013-08-12 08:36:42,2013-08-22 09:50:53,eanm-procedure-guidelines-for-brain-neurotransmission-spect-using-i-labelled-dopamine-transporter-ligands-version-2,"[('title', 'EANM procedure guidelines for brain neurotransmission SPECT using I-labelled dopamine transporter ligands, version 2'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the results of clinical dopamine transporter (DAT) single photon emission computed tomography (SPECT) studies using I-labelled radiopharmaceuticals'), ('Full bibliographic reference', 'Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, Någren K, Nobili F, Walker Z, Van Laere K. EANM procedure guidelines for brain neurotransmission SPECT using I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37(2):443-450.'), ('Language', 'English'), ('PubMed ID', '[19838702]( http://www.ncbi.nlm.nih.gov/pubmed/19838702)'), ('Clinical area', 'Neurology, Nuclear medicine, Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Images, Procedure/Method, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'August 22, 2013')]"
7840,Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria, ,"Gastroenterology, Oncology, Radiology, Surgery","Harms/adverse effects/safety data, Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions", ,"ablation, cancer, catheter, catheter directed therapy, chemoembolisation, chemoembolization, chemotherapeutic infusion, embolisation, embolization, gastroenterology, HCC, hepatic, hepatic malignancy, hepatic tumor, hepatic tumors, hepatic tumour, hepatic tumours, hepatocellular carcinoma, image guided transcatheter tumor therapy, image guided transcatheter tumour therapy, interventional oncology, intravascular, malignancy, oncology, radioembolization, radiology, surgery, transcatheter, transcatheter therapies, transcatheter therapy, transcatheter therapy for hepatic malignancy, tumor, tumors, tumour, tumours, unresectable hepatic tumor, unresectable hepatic tumors, unresectable hepatic tumour, unresectable hepatic tumours", ,"Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, Rilling WS, Geschwind JF, Salem R, Vedantham S, Cardella JF, Soulen MC; Society of Interventional Radiology Technology Assessment Committee and the International Working Group on Image-Guided Tumor Ablation. Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. J Vasc Interv Radiol. 2009;20(7 Suppl):S425-S434.","Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, Rilling WS, Geschwind JF, Salem R, Vedantham S, Cardella JF, Soulen MC; Society of Interventional Radiology Technology Assessment Committee and the International Working Group on Image-Guided Tumor Ablation.",Journal of Vascular and Interventional Radiology [J Vasc Interv Radiol.],2009,20,7 Suppl,S425-S434, ,English, ,19560030,http://www.ncbi.nlm.nih.gov/pubmed/19560030, , ,"Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, Rilling WS, Geschwind JF, Salem R, Vedantham S, Cardella JF, Soulen MC. Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. J Vasc Interv Radiol. 2007;18(12):1469-1478. PMID: 18057279", , , ,Transcatheter therapies for hepatic malignancy, , , , , , , ,no,2013-08-09 14:28:35,2022-01-13 12:44:42,transcatheter-therapy-for-hepatic-malignancy-standardization-of-terminology-and-reporting-criteria,"[('title', 'Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Transcatheter therapies for hepatic malignancy'), ('Full bibliographic reference', 'Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, Rilling WS, Geschwind JF, Salem R, Vedantham S, Cardella JF, Soulen MC; Society of Interventional Radiology Technology Assessment Committee and the International Working Group on Image-Guided Tumor Ablation. Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. J Vasc Interv Radiol. 2009;20(7 Suppl):S425-S434.'), ('Language', 'English'), ('PubMed ID', '[19560030](http://www.ncbi.nlm.nih.gov/pubmed/19560030)'), ('Clinical area', 'Gastroenterology, Oncology, Radiology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions'), ('Previous versions of this guideline / Guideline history', 'Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, Rilling WS, Geschwind JF, Salem R, Vedantham S, Cardella JF, Soulen MC. Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. J Vasc Interv Radiol. 2007;18(12):1469-1478. PMID: [18057279](http://www.ncbi.nlm.nih.gov/pubmed/18057279)'), ('Record last updated on', 'January 13, 2022')]"
7765,Reporting standards for percutaneous thermal ablation of renal cell carcinoma, ,"Oncology, Radiology, Renal medicine, Surgery","Harms/adverse effects/safety data, Images, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions", ,"ablation, cancer, carcinoma, cost, cost effectiveness, costs, kidney, neoplasm, neoplasms, nephrology, oncology, percutaneous, percutaneous thermal ablation of renal cell carcinoma, QALY, quality of life, radiology, RCC, renal, renal cell carcinoma, renal medicine, surgery, surgical, technology assessment, thermal ablation, tumor, tumors, tumour, tumours", ,"Clark TW, Millward SF, Gervais DA, Goldberg SN, Grassi CJ, Kinney TB, Phillips DA, Sacks D, Cardella JF; Technology Assessment Committee of the Society of Interventional Radiology. Reporting standards for percutaneous thermal ablation of renal cell carcinoma. J Vasc Interv Radiol. 2009; 20(7 Suppl):S409-S416.","Clark TW, Millward SF, Gervais DA, Goldberg SN, Grassi CJ, Kinney TB, Phillips DA, Sacks D, Cardella JF; Technology Assessment Committee of the Society of Interventional Radiology.",Journal of Vascular and Interventional Radiology [J Vasc Interv Radiol],2009,20,7 Suppl,S409-S416, ,English, ,19560028,http://www.ncbi.nlm.nih.gov/pubmed/19560028, , ,"Clark TW, Millward SF, Gervais DA, Goldberg SN, Grassi CJ, Kinney TB, Phillips DA, Sacks D, Cardella JF. Reporting standards for percutaneous thermal ablation of renal cell carcinoma. J Vasc Interv Radiol. 2006;17(10):1563-1570. PMID: 17056998", , , ,Percutaneous thermal ablation of primary renal cell carcinoma, , , , , , , ,no,2013-08-09 11:11:32,2022-01-13 12:50:35,reporting-standards-for-percutaneous-thermal-ablation-of-renal-cell-carcinoma,"[('title', 'Reporting standards for percutaneous thermal ablation of renal cell carcinoma'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Percutaneous thermal ablation of primary renal cell carcinoma'), ('Full bibliographic reference', 'Clark TW, Millward SF, Gervais DA, Goldberg SN, Grassi CJ, Kinney TB, Phillips DA, Sacks D, Cardella JF; Technology Assessment Committee of the Society of Interventional Radiology. Reporting standards for percutaneous thermal ablation of renal cell carcinoma. J Vasc Interv Radiol. 2009; 20(7 Suppl):S409-S416.'), ('Language', 'English'), ('PubMed ID', '[19560028](http://www.ncbi.nlm.nih.gov/pubmed/19560028)'), ('Clinical area', 'Oncology, Radiology, Renal medicine, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Images, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions'), ('Previous versions of this guideline / Guideline history', 'Clark TW, Millward SF, Gervais DA, Goldberg SN, Grassi CJ, Kinney TB, Phillips DA, Sacks D, Cardella JF. Reporting standards for percutaneous thermal ablation of renal cell carcinoma. J Vasc Interv Radiol. 2006;17(10):1563-1570. PMID: [17056998](http://www.ncbi.nlm.nih.gov/pubmed/17056998)'), ('Record last updated on', 'January 13, 2022')]"
7757,Research reporting standards for percutaneous vertebral augmentation, ,"Oncology, Radiology, Rheumatology, Surgery","Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)", ,"compression fracture, compression fractures, fracture, hemangioma, kyphoplasty, malignancy, neoplastic, neoplastic lesion, oncology, osteoporosis, osteoporotic, osteoporotic lesion, percutaneous, percutaneous cement injection, percutaneous vertebral augmentation, Polymethylmethacrylate, radiology, rheumatology, spinal, spine, surgery, vertebra, vertebral, vertebral augmentation, vertebroplasty", ,"Radvany MG, Murphy KJ, Millward SF, Barr JD, Clark TW, Halin NJ, Kinney TB, Kundu S, Sacks D, Wallace MJ, Cardella JF; Technology Assessment Committee of the Society of Interventional Radiology. Research reporting standards for percutaneous vertebral augmentation. J Vasc Interv Radiol. 2009;20(10):1279-1286.","Radvany MG, Murphy KJ, Millward SF, Barr JD, Clark TW, Halin NJ, Kinney TB, Kundu S, Sacks D, Wallace MJ, Cardella JF; Technology Assessment Committee of the Society of Interventional Radiology.",Journal of Vascular and Interventional Radiology [J Vasc Interv Radiol.],2009,20,10,1279-1286, ,English, ,19800540,http://www.ncbi.nlm.nih.gov/pubmed/19800540, , , , , , ,Percutaneous vertebral augmentation, , , , , , , ,no,2013-08-09 10:10:13,2013-08-21 13:41:37,research-reporting-standards-for-percutaneous-vertebral-augmentation,"[('title', 'Research reporting standards for percutaneous vertebral augmentation'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Percutaneous vertebral augmentation'), ('Full bibliographic reference', 'Radvany MG, Murphy KJ, Millward SF, Barr JD, Clark TW, Halin NJ, Kinney TB, Kundu S, Sacks D, Wallace MJ, Cardella JF; Technology Assessment Committee of the Society of Interventional Radiology. Research reporting standards for percutaneous vertebral augmentation. J Vasc Interv Radiol. 2009;20(10):1279-1286.'), ('Language', 'English'), ('PubMed ID', '[19800540](http://www.ncbi.nlm.nih.gov/pubmed/19800540)'), ('Clinical area', 'Oncology, Radiology, Rheumatology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'August 21, 2013')]"
7747,Reporting standards for percutaneous interventions in dialysis access, ,"Radiology, Renal medicine, Surgery","Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)", ,"angiography, cost, cost effectiveness, costs, dialysis, dialysis access, dialysis access revascularisation, dialysis access revascularization, haemodialysis, haemodialysis access, hemodialysis, hemodialysis access, kidney, nephrology, percutaneous, radiology, renal, renal dialysis, renal medicine, revascularisation, revascularization, surgery, surgical, technology assessment, thrombolysis, thrombosis", ,"Gray RJ, Sacks D, Martin LG, Trerotola SO; Society of Interventional Radiology Technology Assessment Committee. Reporting standards for percutaneous interventions in dialysis access. Technology Assessment Committee. J Vasc Interv Radiol. 2003;14(9 Pt2):S433-S442.","Gray RJ, Sacks D, Martin LG, Trerotola SO; Society of Interventional Radiology Technology Assessment Committee.",Journal of Vascular and Interventional Radiology [J Vasc Interv Radiol.],2003,14,9 Pt2,S433-S442, ,English, ,14514859,http://www.ncbi.nlm.nih.gov/pubmed/14514859, , ,"Gray RJ, Sacks D, Martin LG, Trerotola SO. Reporting standards for percutaneous interventions in dialysis access. Technology Assessment Committee. J Vasc Interv Radiol. 1999; 10(10):1405-1415. PMID: 10584659", , , ,Percutaneous interventions for permanent hemodialysis access, , , , , , , ,no,2013-08-08 15:32:42,2022-01-13 12:52:26,reporting-standards-for-percutaneous-interventions-in-dialysis-access-technology-assessment-committee,"[('title', 'Reporting standards for percutaneous interventions in dialysis access'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Percutaneous interventions for permanent hemodialysis access'), ('Full bibliographic reference', 'Gray RJ, Sacks D, Martin LG, Trerotola SO; Society of Interventional Radiology Technology Assessment Committee. Reporting standards for percutaneous interventions in dialysis access. Technology Assessment Committee. J Vasc Interv Radiol. 2003;14(9 Pt2):S433-S442.'), ('Language', 'English'), ('PubMed ID', '[14514859](http://www.ncbi.nlm.nih.gov/pubmed/14514859)'), ('Clinical area', 'Radiology, Renal medicine, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)'), ('Previous versions of this guideline / Guideline history', 'Gray RJ, Sacks D, Martin LG, Trerotola SO. Reporting standards for percutaneous interventions in dialysis access. Technology Assessment Committee. J Vasc Interv Radiol. 1999; 10(10):1405-1415. PMID: [10584659](http://www.ncbi.nlm.nih.gov/pubmed/10584659)'), ('Record last updated on', 'January 13, 2022')]"
7741,Reporting standards for clinical evaluation of new peripheral arterial revascularization devices, ,"Radiology, Surgery","Data, Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions", ,"angioplasty, balloon percutaneous transluminal angioplasty, cost, cost effectiveness, costs, device, devices, endoluminal, endoluminal revascularisation, endoluminal revascularization, peripheral arterial, peripheral arterial device, peripheral arterial devices, PTA, QALY, quality, quality of life, radiology, revascularisation, revascularisation device, revascularisation devices, revascularization, revascularization device, revascularization devices, surgery, surgical, technology assessment, transluminal", ,"Sacks D, Marinelli DL, Martin LG, Spies JB; Society of Interventional Radiology Technology Assessment Committee. Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. J Vasc Interv Radiol. 2003;14(9 Pt2):S395-S404.","Sacks D, Marinelli DL, Martin LG, Spies JB; Society of Interventional Radiology Technology Assessment Committee.",Journal of Vascular and Interventional Radiology [J Vasc Interv Radiol.],2003,14,9,S395-S404, ,English, ,14514855,http://www.ncbi.nlm.nih.gov/pubmed/14514855, , , , , , ,Clinical evaluation of new peripheral arterial revascularization devices, , , , , , , ,no,2013-08-08 15:04:37,2013-08-21 13:44:10,reporting-standards-for-clinical-evaluation-of-new-peripheral-arterial-revascularization-devices,"[('title', 'Reporting standards for clinical evaluation of new peripheral arterial revascularization devices'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Clinical evaluation of new peripheral arterial revascularization devices'), ('Full bibliographic reference', 'Sacks D, Marinelli DL, Martin LG, Spies JB; Society of Interventional Radiology Technology Assessment Committee. Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. J Vasc Interv Radiol. 2003;14(9 Pt2):S395-S404.'), ('Language', 'English'), ('PubMed ID', '[14514855](http://www.ncbi.nlm.nih.gov/pubmed/14514855)'), ('Clinical area', 'Radiology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Data, Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'August 21, 2013')]"
7727,Guidelines for the reporting of renal artery revascularization in clinical trials,"Clinical trials, Experimental studies","Radiology, Renal medicine, Surgery","Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions", ,"angioplasty, artery, atherosclerotic, atherosclerotic renal artery stenosis, clinical trial, clinical trials, experimental studies, experimental study, percutaneous angioplasty, radiology, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, renal, renal artery, renal artery revascularisation, renal artery revascularization, renal artery stenosis, renal medicine, renal revascularisation, renal revascularization, revascularisation, revascularization, stent, stent placement, stenting, stents, surgery, surgical, surgical revascularisation, surgical revascularization, trial, trials, vascular", ,"Rundback JH, Sacks D, Kent KC, Cooper C, Jones D, Murphy T, Rosenfield K, White C, Bettmann M, Cortell S, Puschett J, Clair DG, Cole P; Councils on Cardiovascular Radiology, High Blood Pressure Research, Kidney in Cardiovascular Disease, and Clinical Cardiology, American Heart Association; Society of Interventional Radiology FDA Device Forum Committee. Guidelines for the reporting of renal artery revascularization in clinical trials. J Vasc Interv Radiol. 2003;14(9 Pt2):S477-S492.","Rundback JH, Sacks D, Kent KC, Cooper C, Jones D, Murphy T, Rosenfield K, White C, Bettmann M, Cortell S, Puschett J, Clair DG, Cole P; Councils on Cardiovascular Radiology, High Blood Pressure Research, Kidney in Cardiovascular Disease, and Clinical Cardiology, American Heart Association; Society of Interventional Radiology FDA Device Forum Committee.",Journal of Vascular and Interventional Radiology [J Vasc Interv Radiol.],2003,14,9,S477-S492, ,English, ,14514863,http://www.ncbi.nlm.nih.gov/pubmed/14514863, , , , , , ,Reporting of renal artery revascularization RCTs, , , , , , , ,no,2013-08-08 13:57:22,2013-08-21 13:45:30,guidelines-for-the-reporting-of-renal-artery-revascularization-in-clinical-trials,"[('title', 'Guidelines for the reporting of renal artery revascularization in clinical trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of renal artery revascularization RCTs'), ('Full bibliographic reference', 'Rundback JH, Sacks D, Kent KC, Cooper C, Jones D, Murphy T, Rosenfield K, White C, Bettmann M, Cortell S, Puschett J, Clair DG, Cole P; Councils on Cardiovascular Radiology, High Blood Pressure Research, Kidney in Cardiovascular Disease, and Clinical Cardiology, American Heart Association; Society of Interventional Radiology FDA Device Forum Committee. Guidelines for the reporting of renal artery revascularization in clinical trials. J Vasc Interv Radiol. 2003;14(9 Pt2):S477-S492.'), ('Language', 'English'), ('PubMed ID', '[14514863](http://www.ncbi.nlm.nih.gov/pubmed/14514863)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Radiology, Renal medicine, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'August 21, 2013')]"
7724,Reporting standards for carotid interventions from the Society for Vascular Surgery, ,"Radiology, Surgery","Conflict of interest, Harms/adverse effects/safety data, Images, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions", ,"artery, carotid, carotid artery disease, carotid endarterectomy, carotid intervention, carotid interventions, carotid lesion, carotid lesions, carotid stenosis, carotid stenting, carotid stenting procedural data, cost, cost effectiveness, costs, endarterectomy, endovascular, open repair, procedural data, QALY, quality of life, radiology, revascularisation, revascularization, stent, stenting, stents, surgery, surgical, vascular", ,"Timaran CH, McKinsey JF, Schneider PA, Littooy F. Reporting standards for carotid interventions from the Society for Vascular Surgery. J Vasc Surg. 2011;53(6):1679-1695.","Timaran CH, McKinsey JF, Schneider PA, Littooy F.",Journal of Vascular Surgery [J Vasc Surg.],2011,53,6,1679-1695, ,English, ,21609800,http://www.ncbi.nlm.nih.gov/pubmed/21609800, , , , , , ,Data and outcomes related to the treatment of carotid artery disease, , , , , , , ,no,2013-08-08 13:11:22,2013-08-22 10:18:03,reporting-standards-for-carotid-interventions-from-the-society-for-vascular-surgery,"[('title', 'Reporting standards for carotid interventions from the Society for Vascular Surgery'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Data and outcomes related to the treatment of carotid artery disease'), ('Full bibliographic reference', 'Timaran CH, McKinsey JF, Schneider PA, Littooy F. Reporting standards for carotid interventions from the Society for Vascular Surgery. J Vasc Surg. 2011;53(6):1679-1695.'), ('Language', 'English'), ('PubMed ID', '[21609800](http://www.ncbi.nlm.nih.gov/pubmed/21609800)'), ('Clinical area', 'Radiology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Conflict of interest, Harms/adverse effects/safety data, Images, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'August 22, 2013')]"
7702,Reporting standards for carotid artery angioplasty and stent placement,"Clinical trials, Experimental studies","Radiology, Surgery","Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.), Terminology/definitions", ,"angioplasty, carotid, carotid artery, carotid artery angioplasty, carotid endarterectomy, carotid stenting, clinical trial, clinical trials, cost, cost effectiveness, costs, endarterectomy, endovascular, experimental studies, experimental study, radiology, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, revascularisation, revascularization, stent, stent placement, stroke, surgery, surgical, trial, trials, vascular", ,"Higashida RT, Meyers PM, Phatouros CC, Connors JJ, III, Barr JD, Sacks D; Technology Assessment Committees of the American Society of Interventional; Therapeutic Neuroradiology and the Society of Interventional Radiology. Reporting standards for carotid artery angioplasty and stent placement. Stroke. 2004;35(5):e112-e134.","Higashida RT, Meyers PM, Phatouros CC, Connors JJ, III, Barr JD, Sacks D; Technology Assessment Committees of the American Society of Interventional; Therapeutic Neuroradiology and the Society of Interventional Radiology.",Stroke.,2004,35,5,e112-e134, ,English, ,15105523,http://www.ncbi.nlm.nih.gov/pubmed/15105523, , , , , , ,Trials involving carotid artery angioplasty and stent placement, , , , , , , ,no,2013-08-07 10:10:59,2013-08-21 13:47:58,reporting-standards-for-carotid-artery-angioplasty-and-stent-placement,"[('title', 'Reporting standards for carotid artery angioplasty and stent placement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Trials involving carotid artery angioplasty and stent placement'), ('Full bibliographic reference', 'Higashida RT, Meyers PM, Phatouros CC, Connors JJ, III, Barr JD, Sacks D; Technology Assessment Committees of the American Society of Interventional; Therapeutic Neuroradiology and the Society of Interventional Radiology. Reporting standards for carotid artery angioplasty and stent placement. Stroke. 2004;35(5):e112-e134.'), ('Language', 'English'), ('PubMed ID', '[15105523](http://www.ncbi.nlm.nih.gov/pubmed/15105523)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Radiology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'August 21, 2013')]"
7699,Standardized definitions and clinical endpoints in carotid artery and supra-aortic trunk revascularization trials,"Clinical trials, Experimental studies",Surgery,"Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions", ,"aorta, aortic, carotid, carotid artery, clinical trial, clinical trials, DEFINE, DEFINE Group, endovascular, endovascular therapy, endovascular treatment, experimental studies, experimental study, open surgery, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, revascularisation, revascularization, stroke, supra aortic arteries, supra aortic artery, supra aortic trunk, supra aortic trunk revascularization, surgery, surgical, trial, trials, vascular", ,"Nedeltchev K, Pattynama PM, Biaminoo G, Diehm N, Jaff MR, Hopkins LN, Ramee S, van Sambeek M, Talen A, Vermassen F, Cremonesi A; DEFINE Group. Standardized definitions and clinical endpoints in carotid artery and supra-aortic trunk revascularization trials. Catheter Cardiovasc Interv. 2010;76(3):333-344.","Nedeltchev K, Pattynama PM, Biaminoo G, Diehm N, Jaff MR, Hopkins LN, Ramee S, van Sambeek M, Talen A, Vermassen F, Cremonesi A; DEFINE Group.",Catheterization and Cardiovascular Interventions [Catheter Cardiovasc Interv.],2010,76,3,333-344, ,English, ,20506555,http://www.ncbi.nlm.nih.gov/pubmed/20506555, , , , , , , , , , , , , , ,no,2013-08-07 10:02:12,2013-08-21 13:49:25,standardized-definitions-and-clinical-endpoints-in-carotid-artery-and-supra-aortic-trunk-revascularization-trials,"[('title', 'Standardized definitions and clinical endpoints in carotid artery and supra-aortic trunk revascularization trials'), ('Full bibliographic reference', 'Nedeltchev K, Pattynama PM, Biaminoo G, Diehm N, Jaff MR, Hopkins LN, Ramee S, van Sambeek M, Talen A, Vermassen F, Cremonesi A; DEFINE Group. Standardized definitions and clinical endpoints in carotid artery and supra-aortic trunk revascularization trials. Catheter Cardiovasc Interv. 2010;76(3):333-344.'), ('Language', 'English'), ('PubMed ID', '[20506555](http://www.ncbi.nlm.nih.gov/pubmed/20506555)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'August 21, 2013')]"
7688,Setting the standards for reporting ruptured abdominal aortic aneurysm, ,Surgery,"Study characteristics (participants etc.), Terminology/definitions", ,"abdominal, abdominal aortic aneurysm, abdominal aortic aneurysms, aneurysm, aneurysms, aortic, aortic aneurysm, aortic aneurysms, aortic rupture, definition, definitions, endovascular, endovascular repair, EVR, rAAA, rupture, ruptured abdominal aortic aneurysm, surgery, surgical, terminology, vascular", ,"Soong CV, Dasari BV, Loan W, Hannon R, Lee B, Lau L, Thompson M. Setting the standards for reporting ruptured abdominal aortic aneurysm. Vasc Endovascular Surg. 2010;44(6):449-453.","Soong CV, Dasari BV, Loan W, Hannon R, Lee B, Lau L, Thompson M.",Vascular and Endovascular Surgery [Vasc Endovascular Surg.],2010,44,6,449-453, ,English, ,20547575,http://www.ncbi.nlm.nih.gov/pubmed/20547575, , , , , , ,"Reporting the physiological state of patients at the induction for surgery, the CT scan findings and the severity of rupture at open surgery", , , , , , , ,no,2013-08-07 08:46:40,2013-08-20 15:08:35,setting-the-standards-for-reporting-ruptured-abdominal-aortic-aneurysm,"[('title', 'Setting the standards for reporting ruptured abdominal aortic aneurysm'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the physiological state of patients at the induction for surgery, the CT scan findings and the severity of rupture at open surgery'), ('Full bibliographic reference', 'Soong CV, Dasari BV, Loan W, Hannon R, Lee B, Lau L, Thompson M. Setting the standards for reporting ruptured abdominal aortic aneurysm. Vasc Endovascular Surg. 2010;44(6):449-453.'), ('Language', 'English'), ('PubMed ID', '[20547575](http://www.ncbi.nlm.nih.gov/pubmed/20547575)'), ('Clinical area', 'Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'August 20, 2013')]"
7676,Endovascular repair compared with operative repair of traumatic rupture of the thoracic aorta: a nonsystematic review and a plea for trauma-specific reporting guidelines, ,"Emergency medicine, Surgery","Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables)", ,"aorta, emergency, emergency medicine, endograft, endografts, endovascular repair, open repair, operative repair, rupture, surgery, surgical, TEVAR, thoracic, thoracic aorta, thoracic endovascular aortic repair, trauma, traumatic aortic injury, traumatic rupture of the thoracic aorta, vascular", ,"Karmy-Jones R, Ferrigno L, Teso D, Long WB 3rd, Shackford S. Endovascular repair compared with operative repair of traumatic rupture of the thoracic aorta: a nonsystematic review and a plea for trauma-specific reporting guidelines. J Trauma. 2011;71(4):1059-1072.","Karmy-Jones R, Ferrigno L, Teso D, Long WB 3rd, Shackford S.",Journal of Trauma [J Trauma.],2011,71,4,1059-1072, ,English, ,21986746,http://www.ncbi.nlm.nih.gov/pubmed/21986746, , , , , , ,Reporting the outcomes of treatment for blunt aortic repair, , , , , , , ,no,2013-08-06 14:21:02,2013-08-20 15:09:37,endovascular-repair-compared-with-operative-repair-of-traumatic-rupture-of-the-thoracic-aorta-a-nonsystematic-review-and-a-plea-for-trauma-specific-reporting-guidelines,"[('title', 'Endovascular repair compared with operative repair of traumatic rupture of the thoracic aorta: a nonsystematic review and a plea for trauma-specific reporting guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the outcomes of treatment for blunt aortic repair'), ('Full bibliographic reference', 'Karmy-Jones R, Ferrigno L, Teso D, Long WB 3rd, Shackford S. Endovascular repair compared with operative repair of traumatic rupture of the thoracic aorta: a nonsystematic review and a plea for trauma-specific reporting guidelines. J Trauma. 2011;71(4):1059-1072.'), ('Language', 'English'), ('PubMed ID', '[21986746](http://www.ncbi.nlm.nih.gov/pubmed/21986746)'), ('Clinical area', 'Emergency medicine, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables)'), ('Record last updated on', 'August 20, 2013')]"
7671,Reporting standards for thoracic endovascular aortic repair (TEVAR), ,Surgery,"Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Terminology/definitions", ,"aneurysm, aneurysm repair, aortic, aortic aneurysm, aortic aneurysms, aortic repair, aortic stent, definition, definitions, endograft, endografts, endovascular, endovascular graft, endovascular grafts, endovascular repair, graft, grafts, stent, stents, surgery, surgical, terminology, TEVAR, TEVAR reporting, thoracic, thoracic aorta, thoracic aortic, thoracic endograft, thoracic endografts, thoracic endovascular aneurysm repair, thoracic endovascular aortic repair, vascular", ,"Fillinger MF, Greenberg RK, McKinsey JF, Chaikof EL; Society for Vascular Surgery Ad Hoc Committee on TEVAR Reporting Standards. Reporting standards for thoracic endovascular aortic repair (TEVAR). J Vasc Surg. 2010;52(4):1022-1033, 1033.e15.","Fillinger MF, Greenberg RK, McKinsey JF, Chaikof EL; Society for Vascular Surgery Ad Hoc Committee on TEVAR Reporting Standards.",Journal of Vascular Surgery [J Vasc Surg.],2010,52,4,1022-1033, ,English, ,20888533,http://www.ncbi.nlm.nih.gov/pubmed/20888533, , , , , , ,Reporting thoracic endovascular aortic repair (TEVAR), , , , , , , ,no,2013-08-06 13:12:13,2015-01-27 14:14:15,reporting-standards-for-thoracic-endovascular-aortic-repair-tevar,"[('title', 'Reporting standards for thoracic endovascular aortic repair (TEVAR)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting thoracic endovascular aortic repair (TEVAR)'), ('Full bibliographic reference', 'Fillinger MF, Greenberg RK, McKinsey JF, Chaikof EL; Society for Vascular Surgery Ad Hoc Committee on TEVAR Reporting Standards. Reporting standards for thoracic endovascular aortic repair (TEVAR). J Vasc Surg. 2010;52(4):1022-1033, 1033.e15.'), ('Language', 'English'), ('PubMed ID', '[20888533](http://www.ncbi.nlm.nih.gov/pubmed/20888533)'), ('Clinical area', 'Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Terminology/definitions'), ('Record last updated on', 'January 27, 2015')]"
7666,Research reporting standards for endovascular treatment of pelvic venous insufficiency, ,"Obstetrics and gynaecology, Radiology, Surgery","Intervention (exposure), Outcomes (variables), Study characteristics (participants etc.), Terminology/definitions", ,"definition, definitions, embolisation, embolization, endovascular, endovascular treatment, gynaecology, gynecology, obstetric, obstetrics, PCS, pelvic, pelvic congestion, pelvic congestion syndrome, pelvic venous insufficiency, pelvis, PVI, radiology, surgery, surgical, terminology, vascular, venous insufficiency", ,"Black CM, Thorpe K, Venrbux A, Kim HS, Millward SF, Clark TW, Kundu S, Martin LG, Sacks D, York J, Cardella JF. Research reporting standards for endovascular treatment of pelvic venous insufficiency. J Vasc Interv Radiol. 2010;21(6):796-803.","Black CM, Thorpe K, Venrbux A, Kim HS, Millward SF, Clark TW, Kundu S, Martin LG, Sacks D, York J, Cardella JF.",Journal of Vascular and Interventional Radiology [J Vasc Interv Radiol.],2010,21,6,796-803, ,English, ,20494288,http://www.ncbi.nlm.nih.gov/pubmed/20494288, , , , , , ,Reporting endovascular treatment of pelvic venous insufficiency, , , , , , , ,no,2013-08-06 12:47:07,2013-08-20 15:12:25,research-reporting-standards-for-endovascular-treatment-of-pelvic-venous-insufficiency,"[('title', 'Research reporting standards for endovascular treatment of pelvic venous insufficiency'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting endovascular treatment of pelvic venous insufficiency'), ('Full bibliographic reference', 'Black CM, Thorpe K, Venrbux A, Kim HS, Millward SF, Clark TW, Kundu S, Martin LG, Sacks D, York J, Cardella JF. Research reporting standards for endovascular treatment of pelvic venous insufficiency. J Vasc Interv Radiol. 2010;21(6):796-803.'), ('Language', 'English'), ('PubMed ID', '[20494288](http://www.ncbi.nlm.nih.gov/pubmed/20494288)'), ('Clinical area', 'Obstetrics and gynaecology, Radiology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Outcomes (variables), Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'August 20, 2013')]"
7600,Reporting standards for endovascular treatment of pulmonary embolism,"Clinical trials, Experimental studies","Radiology, Respiratory medicine, Surgery","Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.), Terminology/definitions", ,"anticoagulation, catheter directed therapy, catheter directed thrombolysis, CDT, clinical trial, clinical trials, deep venous thrombosis, DVT, embolisation, embolism, embolization, endovascular, endovascular therapies, endovascular therapy, endovascular treatment, experimental studies, experimental study, inferior vena cava, IVC, IVC filter, IVC filters, mechanical thrombectomy, non-RCT, non-RCTs, nonrandomised trial, nonrandomized trial, PE, pulmonary embolism, radiological, radiology, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, respiratory, respiratory medicine, surgery, surgical, surgical embolectomy, systemic thrombolytic therapy, thrombectomy, thromboembolic, thrombolysis, thrombolytic, thrombolytic therapy, trial, trials, vascular", ,"Banovac F, Buckley DC, Kuo WT, Lough DM, Martin LG, Millward SF, Clark TW, Kundu S, Rajan DK, Sacks D, Cardella JF; Technology Assessment Committee of the Society of Interventional Radiology. Reporting standards for endovascular treatment of pulmonary embolism. J Vasc Interv Radiol. 2010;21(1):44-53.","Banovac F, Buckley DC, Kuo WT, Lough DM, Martin LG, Millward SF, Clark TW, Kundu S, Rajan DK, Sacks D, Cardella JF; Technology Assessment Committee of the Society of Interventional Radiology.",Journal of Vascular and Interventional Radiology [J Vasc Interv Radiol.],2010,21,1,44-53, ,English, ,20123190,http://www.ncbi.nlm.nih.gov/pubmed/20123190, , , , , , ,Endovascular treatment of pulmonary embolism, , , , , , , ,no,2013-08-06 10:42:28,2015-01-27 15:28:48,reporting-standards-for-endovascular-treatment-of-pulmonary-embolism,"[('title', 'Reporting standards for endovascular treatment of pulmonary embolism'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Endovascular treatment of pulmonary embolism'), ('Full bibliographic reference', 'Banovac F, Buckley DC, Kuo WT, Lough DM, Martin LG, Millward SF, Clark TW, Kundu S, Rajan DK, Sacks D, Cardella JF; Technology Assessment Committee of the Society of Interventional Radiology. Reporting standards for endovascular treatment of pulmonary embolism. J Vasc Interv Radiol. 2010;21(1):44-53.'), ('Language', 'English'), ('PubMed ID', '[20123190](http://www.ncbi.nlm.nih.gov/pubmed/20123190)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Radiology, Respiratory medicine, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'January 27, 2015')]"
7589,Reporting Standards for Endovascular Repair of Saccular Intracranial Cerebral Aneurysms,"Clinical trials, Experimental studies, Observational studies","Neurology, Radiology, Surgery","Harms/adverse effects/safety data, Images, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions", ,"aneurysm, aneurysms, brain aneurysm, brain aneurysms, cerebral, cerebral aneurysm, cerebral aneurysms, clinical trial, clinical trials, endovascular, endovascular treatment, experimental studies, experimental study, intracranial cerebral aneurysm, intracranial cerebral aneurysms, Joint Section on Cerebrovascular Neurosurgery of the American Association of Neurological Surgeons and Congress of Neurological Surgeons, neurological, neurology, neuroradiology, observational studies, observational study, radiological, radiology, saccular, saccular intracranial cerebral aneurysm, saccular intracranial cerebral aneurysms, Section of Stroke and Interventional Neurology of the American Academy of Neurology, Society of Interventional Radiology, Society of NeuroInterventional Surgery, surgery, surgical, Technology Assessment Committee, trial, trials, vascular", ,"Meyers PM, Schumacher HC, Higashida RT, Derdeyn CP, Nesbit GM, Sacks D, Wechsler LR, Bederson JB, Lavine SD, Rasmussen P. Reporting Standards for Endovascular Repair of Saccular Intracranial Cerebral Aneurysms. Stroke 2009;40(5):e366-e379.","Meyers PM, Schumacher HC, Higashida RT, Derdeyn CP, Nesbit GM, Sacks D, Wechsler LR, Bederson JB, Lavine SD, Rasmussen P.",Stroke.,2009,40,5,e366-e379, ,English, ,19246711,http://www.ncbi.nlm.nih.gov/pubmed/19246711, , , , , , ,"Reporting on the radiological evaluation and endovascular treatment of intracranial, cerebral aneurysms", , , , , , , ,no,2013-08-06 10:10:50,2013-08-22 11:16:16,reporting-standards-for-endovascular-repair-of-saccular-intracranial-cerebral-aneurysms,"[('title', 'Reporting Standards for Endovascular Repair of Saccular Intracranial Cerebral Aneurysms'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting on the radiological evaluation and endovascular treatment of intracranial, cerebral aneurysms'), ('Full bibliographic reference', 'Meyers PM, Schumacher HC, Higashida RT, Derdeyn CP, Nesbit GM, Sacks D, Wechsler LR, Bederson JB, Lavine SD, Rasmussen P. Reporting Standards for Endovascular Repair of Saccular Intracranial Cerebral Aneurysms. Stroke 2009;40(5):e366-e379.'), ('Language', 'English'), ('PubMed ID', '[19246711](http://www.ncbi.nlm.nih.gov/pubmed/19246711)'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Clinical area', 'Neurology, Radiology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Images, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'August 22, 2013')]"
7584,Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke,"Clinical trials, Experimental studies","Neurology, Radiology, Surgery","Harms/adverse effects/safety data, Images, Intervention (exposure), Outcomes (variables), Study characteristics (participants etc.), Terminology/definitions", ,"acute ischaemic stroke, acute ischemic stroke, case series, cerebral thrombolysis, clinical trial, clinical trials, experimental studies, experimental study, IA thrombolysis, intra arterial, ischaemic, ischaemic stroke, ischemic, ischemic stroke, neurological, neurology, radiological, radiology, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, stroke, surgery, surgical, thrombolysis, thrombolytic, trial, trials", ,"Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D. Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003;34(8):e109-e137.","Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D. Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology.",Stroke.,2003,34,8,e109-e137, ,English, ,12869717,http://www.ncbi.nlm.nih.gov/pubmed/12869717, , , , , , ,"Stroke trials involving intra-arterial thrombolytic agents, either alone or in combination with other therapies", , , , , , , ,no,2013-08-06 09:18:42,2013-08-22 11:18:36,trial-design-and-reporting-standards-for-intra-arterial-cerebral-thrombolysis-for-acute-ischemic-stroke,"[('title', 'Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Stroke trials involving intra-arterial thrombolytic agents, either alone or in combination with other therapies'), ('Full bibliographic reference', 'Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D. Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003;34(8):e109-e137.'), ('Language', 'English'), ('PubMed ID', '[12869717](http://www.ncbi.nlm.nih.gov/pubmed/12869717)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Neurology, Radiology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Images, Intervention (exposure), Outcomes (variables), Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'August 22, 2013')]"
7503,Target registration and target positioning errors in computer-assisted neurosurgery: proposal for a standardized reporting of error assessment, ,"Neurology, Surgery","Intervention (exposure), Procedure/Method, Terminology/definitions", ,"accuracy evaluation, anthropomorphic phantom, computed tomography, computer assisted, computer assisted neurosurgery, computer assisted surgery, CT, frameless stereotaxy, image, image guided, image guided surgery, imaging, navigation systems, navigation technology, neurological, neurology, neurosurgery, Non anthropomorphic phantom, Nonanthropomorphic phantom, phantom, skull phantom, surgery, surgical, target, target positioning error, target registration error, terminology, TPE, TRE", ,"Widmann G, Stoffner R, Sieb M, Bale R. Target registration and target positioning errors in computer-assisted neurosurgery: proposal for a standardized reporting of error assessment. Int J Med Robot. 2009;5(4):355-365.","Widmann G, Stoffner R, Sieb M, Bale R.",International Journal of Medical Robotics and Computer Assisted Surgery: MRCAS,2009,5,4,355-365, ,English, ,19565464,http://www.ncbi.nlm.nih.gov/pubmed/19565464, , , , , , ,Reporting criteria for error analysis/accuracy evaluation in computer-assisted neurosurgery, , , , , , , ,no,2013-07-19 13:54:33,2013-08-22 11:21:23,target-registration-and-target-positioning-errors-in-computer-assisted-neurosurgery-proposal-for-a-standardized-reporting-of-error-assessment,"[('title', 'Target registration and target positioning errors in computer-assisted neurosurgery: proposal for a standardized reporting of error assessment'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting criteria for error analysis/accuracy evaluation in computer-assisted neurosurgery'), ('Full bibliographic reference', 'Widmann G, Stoffner R, Sieb M, Bale R. Target registration and target positioning errors in computer-assisted neurosurgery: proposal for a standardized reporting of error assessment. Int J Med Robot. 2009;5(4):355-365.'), ('Language', 'English'), ('PubMed ID', '[19565464](http://www.ncbi.nlm.nih.gov/pubmed/19565464)'), ('Clinical area', 'Neurology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Procedure/Method, Terminology/definitions'), ('Record last updated on', 'August 22, 2013')]"
7499,Recommended guidelines for reporting on emergency medical dispatch when conducting research in emergency medicine: the Utstein style, ,Emergency medicine,"Data, Procedure/Method, Results, Terminology/definitions", ,"accident and emergency, AE, ambulance, dispatch, dispatching, emergency, emergency care, emergency medical communication centres, emergency medical dispatch, emergency medical dispatching, emergency medical response, emergency medicine, emergency response, emergency service, EMS, medical communication, medical emergencies, medical emergency, Utstein, Utstein style", ,"Castren M, Karlsten R, Lippert F, Christensen EF, Bovim E, Kvam AM, Robertson-Steel I, Overton J, Kraft T, Engerstrom L, Garcia-Castrill Riego L; Emergency Medical Dispatch expert group at the Utstein Consensus Symposium 2005. Recommended guidelines for reporting on emergency medical dispatch when conducting research in emergency medicine: the Utstein style. Resuscitation 2008;79(2):193-197.","Castren M, Karlsten R, Lippert F, Christensen EF, Bovim E, Kvam AM, Robertson-Steel I, Overton J, Kraft T, Engerstrom L, Garcia-Castrill Riego L; Emergency Medical Dispatch expert group at the Utstein Consensus Symposium 2005.",Resuscitation,2008,79,2,193-197, ,English, ,18805620,http://www.ncbi.nlm.nih.gov/pubmed/18805620, , , , , , ,Reporting results from studies in emergency medicine and prehospital care, , , , , , , ,no,2013-07-19 13:24:14,2013-08-22 11:32:40,recommended-guidelines-for-reporting-on-emergency-medical-dispatch-when-conducting-research-in-emergency-medicine-the-utstein-style,"[('title', 'Recommended guidelines for reporting on emergency medical dispatch when conducting research in emergency medicine: the Utstein style'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting results from studies in emergency medicine and prehospital care'), ('Full bibliographic reference', 'Castren M, Karlsten R, Lippert F, Christensen EF, Bovim E, Kvam AM, Robertson-Steel I, Overton J, Kraft T, Engerstrom L, Garcia-Castrill Riego L; Emergency Medical Dispatch expert group at the Utstein Consensus Symposium 2005. Recommended guidelines for reporting on emergency medical dispatch when conducting research in emergency medicine: the Utstein style. Resuscitation 2008;79(2):193-197.'), ('Language', 'English'), ('PubMed ID', '[18805620](http://www.ncbi.nlm.nih.gov/pubmed/18805620)'), ('Clinical area', 'Emergency medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method, Results, Terminology/definitions'), ('Record last updated on', 'August 22, 2013')]"
7496,"Recommended guidelines for reviewing, reporting, and conducting research on post-resuscitation care: the Utstein style", ,Emergency medicine,"Data, Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)", ,"accident and emergency, AE, ambulance, cardiac, cardiac arrest, cardiology, cardiopulmonary, cardiopulmonary resuscitation, cardiovascular, chain of survival, CPR, data, emergency, emergency care, emergency medicine, emergency service, in hospital post resuscitation, medical emergency, post resuscitation, post resuscitation period, quality of life, resuscitation, return of spontaneous circulation, spontaneous circulation, Utstein, Utstein style, Utstein template", ,"Langhelle A, Nolan J, Herlitz J, Castren M, Wenzel V, Soreide E, Engdahl J, Steen PA; 2003 Utstein Consensus Symposium. Recommended guidelines for reviewing, reporting, and conducting research on post-resuscitation care: the Utstein style. Resuscitation. 2005;66(3):271-283.","Langhelle A, Nolan J, Herlitz J, Castren M, Wenzel V, Soreide E, Engdahl J, Steen PA; 2003 Utstein Consensus Symposium.",Resuscitation,2005,66,3,271-283, ,English, ,16129543,http://www.ncbi.nlm.nih.gov/pubmed/16129543, , , , , , ,Reporting research during the post-resuscitation period in hospital, , , , , , , ,no,2013-07-19 13:02:41,2013-08-22 11:31:14,recommended-guidelines-for-reviewing-reporting-and-conducting-research-on-post-resuscitation-care-the-utstein-style,"[('title', 'Recommended guidelines for reviewing, reporting, and conducting research on post-resuscitation care: the Utstein style'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting research during the post-resuscitation period in hospital'), ('Full bibliographic reference', 'Langhelle A, Nolan J, Herlitz J, Castren M, Wenzel V, Soreide E, Engdahl J, Steen PA; 2003 Utstein Consensus Symposium. Recommended guidelines for reviewing, reporting, and conducting research on post-resuscitation care: the Utstein style. Resuscitation. 2005;66(3):271-283.'), ('Language', 'English'), ('PubMed ID', '[16129543](http://www.ncbi.nlm.nih.gov/pubmed/16129543)'), ('Clinical area', 'Emergency medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data, Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'August 22, 2013')]"
7491,Utstein-style guidelines for uniform reporting of laboratory CPR research,Animal pre-clinical research,Cardiovascular medicine,Whole report, ,"anaesthesia, anesthesia, animal, animal experiment, animal experimentation, animal experiments, animal model, animal models, animal studies, animal study, animals, blood flow, cardiac, cardiac arrest, cardiology, cardiopulmonary, cardiopulmonary resuscitation, CPR, defibrillation, laboratory, laboratory research, nomenclature, resuscitation, terminology, Utstein, Utstein style, ventilation", ,"Idris AH, Becker LB, Ornato JP, Hedges JR, Bircher NG, Chandra NC, Cummins RO, Dick W, Ebmeyer U, Halperin HR, Hazinski MF, Kerber RE, Kern KB, Safar P, Steen PA, Swindle MM, Tsitlik JE, von Planta I, von Planta M, Wears RL, Weil MH. Utstein-style guidelines for uniform reporting of laboratory CPR research. A statement for healthcare professionals from a task force of the American Heart Association, the American College of Emergency Physicians, the American College of Cardiology, the European Resuscitation Council, the Heart and Stroke Foundation of Canada, the Institute of Critical Care Medicine, the Safar Center for Resuscitation Research, and the Society for Academic Emergency Medicine. Writing Group. Circulation. 1996;94(9):2324-2336.","Idris AH, Becker LB, Ornato JP, Hedges JR, Bircher NG, Chandra NC, Cummins RO, Dick W, Ebmeyer U, Halperin HR, Hazinski MF, Kerber RE, Kern KB, Safar P, Steen PA, Swindle MM, Tsitlik JE, von Planta I, von Planta M, Wears RL, Weil MH.",Circulation,1996,94,9,2324-2336, ,English, ,8901707,http://www.ncbi.nlm.nih.gov/pubmed/8901707, , , , , , ,Reporting data from laboratory studies of CPR, , , , , , , ,no,2013-07-19 12:35:12,2017-02-16 14:47:21,utstein-style-guidelines-for-uniform-reporting-of-laboratory-cpr-research-a-statement-for-healthcare-professionals-from-a-task-force-of-the-american-heart-association-the-american-college-of-emergen,"[('title', 'Utstein-style guidelines for uniform reporting of laboratory CPR research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting data from laboratory studies of CPR'), ('Full bibliographic reference', 'Idris AH, Becker LB, Ornato JP, Hedges JR, Bircher NG, Chandra NC, Cummins RO, Dick W, Ebmeyer U, Halperin HR, Hazinski MF, Kerber RE, Kern KB, Safar P, Steen PA, Swindle MM, Tsitlik JE, von Planta I, von Planta M, Wears RL, Weil MH. Utstein-style guidelines for uniform reporting of laboratory CPR research. A statement for healthcare professionals from a task force of the American Heart Association, the American College of Emergency Physicians, the American College of Cardiology, the European Resuscitation Council, the Heart and Stroke Foundation of Canada, the Institute of Critical Care Medicine, the Safar Center for Resuscitation Research, and the Society for Academic Emergency Medicine. Writing Group. Circulation. 1996;94(9):2324-2336.'), ('Language', 'English'), ('PubMed ID', '[8901707](http://www.ncbi.nlm.nih.gov/pubmed/8901707)'), ('Study design', 'Animal pre-clinical research'), ('Clinical area', 'Cardiovascular medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'February 16, 2017')]"
7488,Recommendations for uniform reporting of data following major trauma--the Utstein style, ,Emergency medicine,"Data, Ethical issues (consent etc.), Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions", ,"advanced trauma, basic trauma, data, emergency, emergency care, emergency medicine, International Trauma Anaesthesia and Critical Care Society, ITACCS, life support, major trauma, medical emergencies, medical emergency, resuscitation, statistics, terminology, trauma, trauma care, trauma data, Utstein, Utstein style, utstein style template", ,"Dick WF, Baskett PJ. Recommendations for uniform reporting of data following major trauma--the Utstein style. A report of a working party of the International Trauma Anaesthesia and Critical Care Society (ITACCS). Resuscitation. 1999;42(2):81-100.","Dick WF, Baskett PJ.",Resuscitation,1999,42,2,81-100, ,English, ,10617327,http://www.ncbi.nlm.nih.gov/pubmed/10617327, , , , , , ,Reporting of data following trauma, , , , , , , ,no,2013-07-19 11:06:52,2013-08-22 11:38:08,recommendations-for-uniform-reporting-of-data-following-major-trauma-the-utstein-style-a-report-of-a-working-party-of-the-international-trauma-anaesthesia-and-critical-care-society-itaccs,"[('title', 'Recommendations for uniform reporting of data following major trauma–the Utstein style'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of data following trauma'), ('Full bibliographic reference', 'Dick WF, Baskett PJ. Recommendations for uniform reporting of data following major trauma--the Utstein style. A report of a working party of the International Trauma Anaesthesia and Critical Care Society (ITACCS). Resuscitation. 1999;42(2):81-100.'), ('Language', 'English'), ('PubMed ID', '[10617327](http://www.ncbi.nlm.nih.gov/pubmed/10617327)'), ('Clinical area', 'Emergency medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data, Ethical issues (consent etc.), Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'August 22, 2013')]"
7481,"Recommended guidelines for reviewing, reporting, and conducting research on in-hospital resuscitation: the in-hospital 'Utstein style'", ,"Cardiovascular medicine, Emergency medicine","Data, Ethical issues (consent etc.), Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)", ,"adult in hospital resuscitation, advanced cardiac life support, airway, cardiac arrest, cardiology, cardiopulmonary, cardiopulmonary emergencies, cardiopulmonary emergency, cardiopulmonary resuscitation, cardiovascular, CPR, defibrillation, emergency, emergency cardiac care, emergency care, emergency medicine, in hospital 'Utstein style', in hospital cardiac arrest, in hospital resuscitation, In Hospital Utstein Style Template, life support, resuscitation, Utstein, Utstein style", ,"Cummins RO, Chamberlain D, Hazinski MF, Nadkarni V, Kloeck W, Kramer E, Becker L, Robertson C, Koster R, Zaritsky A, Bossaert L, Ornato JP, Callanan V, Allen M, Steen P, Connolly B, Sanders A, Idris A, Cobbe S. Recommended guidelines for reviewing, reporting, and conducting research on in-hospital resuscitation: the in-hospital 'Utstein style'. A statement for healthcare professionals from the American Heart Association, the European Resuscitation Council, the Heart and Stroke Foundation of Canada, the Australian Resuscitation Council, and the Resuscitation Councils of Southern Africa. Resuscitation. 1997; 34(2):151-183.","Cummins RO, Chamberlain D, Hazinski MF, Nadkarni V, Kloeck W, Kramer E, Becker L, Robertson C, Koster R, Zaritsky A, Bossaert L, Ornato JP, Callanan V, Allen M, Steen P, Connolly B, Sanders A, Idris A, Cobbe S.",Resuscitation,1997,34,2,151-183, ,English, ,9141159,http://www.ncbi.nlm.nih.gov/pubmed/9141159, , , , , , ,Reporting research on in-hospital resuscitation, , , , , , , ,no,2013-07-18 15:04:39,2013-08-22 11:42:31,recommended-guidelines-for-reviewing-reporting-and-conducting-research-on-in-hospital-resuscitation-the-in-hospital-utstein-style-a-statement-for-healthcare-professionals-from-the-american-hea,"[('title', 'Recommended guidelines for reviewing, reporting, and conducting research on in-hospital resuscitation: the in-hospital ‘Utstein style’'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting research on in-hospital resuscitation'), ('Full bibliographic reference', ""Cummins RO, Chamberlain D, Hazinski MF, Nadkarni V, Kloeck W, Kramer E, Becker L, Robertson C, Koster R, Zaritsky A, Bossaert L, Ornato JP, Callanan V, Allen M, Steen P, Connolly B, Sanders A, Idris A, Cobbe S. Recommended guidelines for reviewing, reporting, and conducting research on in-hospital resuscitation: the in-hospital 'Utstein style'. A statement for healthcare professionals from the American Heart Association, the European Resuscitation Council, the Heart and Stroke Foundation of Canada, the Australian Resuscitation Council, and the Resuscitation Councils of Southern Africa. Resuscitation. 1997; 34(2):151-183.""), ('Language', 'English'), ('PubMed ID', '[9141159](http://www.ncbi.nlm.nih.gov/pubmed/9141159)'), ('Clinical area', 'Cardiovascular medicine, Emergency medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data, Ethical issues (consent etc.), Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'August 22, 2013')]"
7476,Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop, ,Ophthalmology,"Data, Outcomes (variables), Results, Terminology/definitions", ,"classification, clinical data, data, definitions, eye, inflammation, intraocular inflammation, IUSG, nomenclature, ophthalmic, ophthamology, outcomes, terminology, uveitic syndromes, uveitis, uveitis nomenclature, vision, visual, visual acuity, visual field", ,"Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509-516.","Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group.",American Journal of Ophthalmology [Am J Ophthalmol.],2005,140,3,509-516, ,English, ,16196117,http://www.ncbi.nlm.nih.gov/pubmed/16196117, , , , , , ,Standardization of uveitis nomenclature for reporting clinical data, , , , , , , ,no,2013-07-18 14:36:57,2013-08-22 13:11:33,standardization-of-uveitis-nomenclature-for-reporting-clinical-data-results-of-the-first-international-workshop,"[('title', 'Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Standardization of uveitis nomenclature for reporting clinical data'), ('Full bibliographic reference', 'Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509-516.'), ('Language', 'English'), ('PubMed ID', '[16196117](http://www.ncbi.nlm.nih.gov/pubmed/16196117)'), ('Clinical area', 'Ophthalmology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Outcomes (variables), Results, Terminology/definitions'), ('Record last updated on', 'August 22, 2013')]"
7473,EACTS/ESCVS best practice guidelines for reporting treatment results in the thoracic aorta, ,"Cardiovascular medicine, Surgery","Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions", ,"aneurysm, aorta, aortic, cardiothoracic, cardiovascular medicine, EACTS, endovascular, endovascular device, endovascular devices, endovascular mode, ESCVS, EVAR, OPEN, open surgical repair, surgery, surgical, TEVAR, thoracic, thoracic aorta, thoracic endovascular repair", ,"Turina MI, Shennib H, Dunning J, Cheng D, Martin J, Muneretto C, Schueler S, von Segesser L, Sergeant PT; EACTS/ESCVS committee. EACTS/ESCVS best practice guidelines for reporting treatment results in the thoracic aorta. Eur J Cardiothorac Surg. 2009;35(6):927-930.","Turina MI, Shennib H, Dunning J, Cheng D, Martin J, Muneretto C, Schueler S, von Segesser L, Sergeant PT; EACTS/ESCVS committee.",European Journal of Cardio-thoracic Surgery [Eur J Cardiothorac Surg.],2009,35,6,927-930, ,English, ,19339194,http://www.ncbi.nlm.nih.gov/pubmed/19339194, , , , , , ,Reporting results of treatment in the thoracic aorta, , , , , , , ,no,2013-07-18 13:51:12,2013-08-22 13:02:26,eactsescvs-best-practice-guidelines-for-reporting-treatment-results-in-the-thoracic-aorta,"[('title', 'EACTS / ESCVS best practice guidelines for reporting treatment results in the thoracic aorta'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting results of treatment in the thoracic aorta'), ('Full bibliographic reference', 'Turina MI, Shennib H, Dunning J, Cheng D, Martin J, Muneretto C, Schueler S, von Segesser L, Sergeant PT; EACTS/ESCVS committee. EACTS/ESCVS best practice guidelines for reporting treatment results in the thoracic aorta. Eur J Cardiothorac Surg. 2009;35(6):927-930.'), ('Language', 'English'), ('PubMed ID', '[19339194](http://www.ncbi.nlm.nih.gov/pubmed/19339194)'), ('Clinical area', 'Cardiovascular medicine, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'August 22, 2013')]"
7469,Consensus statement: Defining minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypass, ,"Cardiovascular medicine, Surgery","Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables)", ,"bypass, cardiac, cardiac surgery, cardiology, cardiopulmonary, cardiopulmonary bypass, cardiovascular, cardiovascular medicine, causal inflammatory markers, CPB, extracorporeal circulation, heart, heart lung bypass, inflammation, inflammatory, inflammatory response, organ injury, perfusion, surgery, surgical, systemic inflammatory response", ,"Landis RC, Arrowsmith JE, Baker RA, de Somer F, Dobkowski WB, Fisher G, Jonas RA, Likosky DS, Murkin JM, Poullis M, Stump DA, Verrier ED. Consensus statement: Defining minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypass. Heart Surg Forum. 2008;11(5):E316-E322.","Landis RC, Arrowsmith JE, Baker RA, de Somer F, Dobkowski WB, Fisher G, Jonas RA, Likosky DS, Murkin JM, Poullis M, Stump DA, Verrier ED.",Heart Surgery Forum [Heart Surg Forum.],2008,11,5,E316-E322, ,English, ,19131308,http://www.ncbi.nlm.nih.gov/pubmed/19131308, , , , , , ,Reporting the systemic inflammatory response to cardiopulmonary bypass, , , , , , , ,no,2013-07-18 13:13:06,2013-08-22 13:04:21,consensus-statement-defining-minimal-criteria-for-reporting-the-systemic-inflammatory-response-to-cardiopulmonary-bypass,"[('title', 'Consensus statement: Defining minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypass'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the systemic inflammatory response to cardiopulmonary bypass'), ('Full bibliographic reference', 'Landis RC, Arrowsmith JE, Baker RA, de Somer F, Dobkowski WB, Fisher G, Jonas RA, Likosky DS, Murkin JM, Poullis M, Stump DA, Verrier ED. Consensus statement: Defining minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypass. Heart Surg Forum. 2008;11(5):E316-E322.'), ('Language', 'English'), ('PubMed ID', '[19131308](http://www.ncbi.nlm.nih.gov/pubmed/19131308)'), ('Clinical area', 'Cardiovascular medicine, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables)'), ('Record last updated on', 'August 22, 2013')]"
7465,Guidelines for reporting data and outcomes for the surgical treatment of atrial fibrillation, ,"Cardiovascular medicine, Surgery","Data, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.)", ,"ablation, ablation technique, ablation techniques, arrhythmia, atrial, atrial fibrillation, cardiac rhythm, cardiac rhythm disturbance, cardiology, cardiovascular, cardiovascular medicine, catheter based treatment, catheter based treatment of atrial fibrillation, Cox-Maze procedure, fibrillation, heart, heart rhythm, surgery, surgical, thoracic", ,"Shemin RJ, Cox JL, Gillinov AM, Blackstone EH, Bridges CR; Workforce on Evidence-Based Surgery of the Society of Thoracic Surgeons. Guidelines for reporting data and outcomes for the surgical treatment of atrial fibrillation. Ann Thorac Surg. 2007;83(3):1225-1230.","Shemin RJ, Cox JL, Gillinov AM, Blackstone EH, Bridges CR; Workforce on Evidence-Based Surgery of the Society of Thoracic Surgeons.",Annals of Thoracic Surgery [Ann Thorac Surg.],2007,83,3,1225-1230, ,English, ,17307507,http://www.ncbi.nlm.nih.gov/pubmed/17307507, , , , , , ,Reporting clinical results derived from patients undergoing surgical procedures for atrial fibrillation, , , , , , , ,no,2013-07-18 10:46:01,2013-08-22 13:47:09,guidelines-for-reporting-data-and-outcomes-for-the-surgical-treatment-of-atrial-fibrillation,"[('title', 'Guidelines for reporting data and outcomes for the surgical treatment of atrial fibrillation'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting clinical results derived from patients undergoing surgical procedures for atrial fibrillation'), ('Full bibliographic reference', 'Shemin RJ, Cox JL, Gillinov AM, Blackstone EH, Bridges CR; Workforce on Evidence-Based Surgery of the Society of Thoracic Surgeons. Guidelines for reporting data and outcomes for the surgical treatment of atrial fibrillation. Ann Thorac Surg. 2007;83(3):1225-1230.'), ('Language', 'English'), ('PubMed ID', '[17307507](http://www.ncbi.nlm.nih.gov/pubmed/17307507)'), ('Clinical area', 'Cardiovascular medicine, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Data, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'August 22, 2013')]"
7463,Recommendations for reporting morbid events after heart valve surgery, ,"Cardiovascular medicine, Surgery","Data, Harms/adverse effects/safety data, Outcomes (variables)", ,"anticoagulant, anticoagulants, antithrombotic management, antithrombotic treatment, bleeding, cardiology, cardiovascular, cardiovascular medicine, embolic, embolism, embolisms, haemorrhage, haemorrhagic, heart, heart valve, heart valve surgery, hemorrhage, hemorrhagic, morbid, morbidity, surgery, surgical, thrombosis", ,"Horstkotte D, Lengyel M, Mistiaen WP, Piper C, Voller H; Working Group on Infection, Thrombosis, Embolism and Bleeding of the Society of; Heart Valve Disease. Recommendations for reporting morbid events after heart valve surgery. J Heart Valve Dis. 2005;14(1):1-7.","Horstkotte D, Lengyel M, Mistiaen WP, Piper C, Voller H; Working Group on Infection, Thrombosis, Embolism and Bleeding of the Society of; Heart Valve Disease.",Journal of Heart Valve Disease [J Heart Valve Dis.],2005,14,1,1-7, ,English, ,15700427,http://www.ncbi.nlm.nih.gov/pubmed/15700427, , , , , , ,Reporting morbid events after heart valve surgery, , , , , , , ,no,2013-07-18 10:39:43,2013-08-22 13:08:29,recommendations-for-reporting-morbid-events-after-heart-valve-surgery,"[('title', 'Recommendations for reporting morbid events after heart valve surgery'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting morbid events after heart valve surgery'), ('Full bibliographic reference', 'Horstkotte D, Lengyel M, Mistiaen WP, Piper C, Voller H; Working Group on Infection, Thrombosis, Embolism and Bleeding of the Society of; Heart Valve Disease. Recommendations for reporting morbid events after heart valve surgery. J Heart Valve Dis. 2005;14(1):1-7.'), ('Language', 'English'), ('PubMed ID', '[15700427](http://www.ncbi.nlm.nih.gov/pubmed/15700427)'), ('Clinical area', 'Cardiovascular medicine, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Data, Harms/adverse effects/safety data, Outcomes (variables)'), ('Record last updated on', 'August 22, 2013')]"
7461,Standards for reporting results of refractive surgery, ,"Ophthalmology, Surgery","Data, Outcomes (variables), Results", ,"data, eye, eye surgery, ophthalmic, ophthalmology, refractive, refractive surgery, surgery, surgical, vision, visual, visual acuity", ,Rosa N. Standards for reporting results of refractive surgery. J Refract Surg. 2001;17(4):473-474.,Rosa N.,Journal of Refractive Surgery [J Refract Surg.],2001,17,4,473-474, ,English, ,11472009,http://www.ncbi.nlm.nih.gov/pubmed/11472009, , , , , , ,Reporting results of refractive surgery, , , , , , , ,no,2013-07-18 10:09:03,2013-08-22 13:10:21,standards-for-reporting-results-of-refractive-surgery,"[('title', 'Standards for reporting results of refractive surgery'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting results of refractive surgery'), ('Full bibliographic reference', 'Rosa N. Standards for reporting results of refractive surgery. J Refract Surg. 2001;17(4):473-474.'), ('Language', 'English'), ('PubMed ID', '[11472009](http://www.ncbi.nlm.nih.gov/pubmed/11472009)'), ('Clinical area', 'Ophthalmology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Data, Outcomes (variables), Results'), ('Record last updated on', 'August 22, 2013')]"
7456,Quality of study methods in individual- and group-level HIV intervention research: critical reporting elements, ,Infectious diseases,"Data, Intervention (exposure), Outcomes (variables), Study characteristics (participants etc.)", ,"acquired immune deficiency syndrome, AIDS, group-level HIV, HIV, HIV infections, HIV intervention research, human immunodeficiency virus, individual-level HIV, infection, infectious, infectious diseases", ,"Flores SA, Crepaz N; HIV Prevention Research Synthesis Team. Quality of study methods in individual- and group-level HIV intervention research: critical reporting elements. AIDS Educ Prev. 2004;16(4):341-352.","Flores SA, Crepaz N; HIV Prevention Research Synthesis Team.",AIDS Education and Prevention [AIDS Educ Prev.],2004,16,4,341-352, ,English, ,15342336,http://www.ncbi.nlm.nih.gov/pubmed/15342336, , , , , , ,Quality of study methods (QSM) specifically for individual- and group-level HIV intervention research, , , , , , , ,no,2013-07-18 09:26:52,2013-08-22 13:17:28,quality-of-study-methods-in-individual-and-group-level-hiv-intervention-research-critical-reporting-elements,"[('title', 'Quality of study methods in individual- and group-level HIV intervention research: critical reporting elements'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Quality of study methods (QSM) specifically for individual- and group-level HIV intervention research'), ('Full bibliographic reference', 'Flores SA, Crepaz N; HIV Prevention Research Synthesis Team. Quality of study methods in individual- and group-level HIV intervention research: critical reporting elements. AIDS Educ Prev. 2004;16(4):341-352.'), ('Language', 'English'), ('PubMed ID', '[15342336](http://www.ncbi.nlm.nih.gov/pubmed/15342336)'), ('Clinical area', 'Infectious diseases'), ('Applies to the whole report or to individual sections of the report?', 'Data, Intervention (exposure), Outcomes (variables), Study characteristics (participants etc.)'), ('Record last updated on', 'August 22, 2013')]"
7447,Quality of reporting in evaluations of surgical treatment of trigeminal neuralgia: recommendations for future reports, ,"Neurology, Surgery","Abstract, Data, Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.), Terminology/definitions", ,"atypical trigeminal neuralgia, data, data collection, neuralgia, neurological, neurology, neurosurgery, pain, pain outcomes, quality of life, surgery, surgical, surgical treatment of trigeminal neuralgia, trigeminal, trigeminal neuralgia, typical trigeminal neuralgia", ,"Zakrzewska JM, Lopez BC. Quality of reporting in evaluations of surgical treatment of trigeminal neuralgia: recommendations for future reports. Neurosurgery. 2003;53(1):110-120.","Zakrzewska JM, Lopez BC.",Neurosurgery,2003,53,1,110-120, ,English, ,12823880,http://www.ncbi.nlm.nih.gov/pubmed/12823880, , , , , , ,Reporting outcomes of surgical treatment of trigeminal neuralgia, , , , , , , ,no,2013-07-17 14:33:33,2013-08-22 13:19:48,quality-of-reporting-in-evaluations-of-surgical-treatment-of-trigeminal-neuralgia-recommendations-for-future-reports,"[('title', 'Quality of reporting in evaluations of surgical treatment of trigeminal neuralgia: recommendations for future reports'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting outcomes of surgical treatment of trigeminal neuralgia'), ('Full bibliographic reference', 'Zakrzewska JM, Lopez BC. Quality of reporting in evaluations of surgical treatment of trigeminal neuralgia: recommendations for future reports. Neurosurgery. 2003;53(1):110-120.'), ('Language', 'English'), ('PubMed ID', '[12823880](http://www.ncbi.nlm.nih.gov/pubmed/12823880)'), ('Clinical area', 'Neurology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Abstract, Data, Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.), Terminology/definitions'), ('Record last updated on', 'August 22, 2013')]"
7442,Guidelines for reporting case series of tumours of the colon and rectum,Observational studies,"Gastroenterology, Oncology, Surgery","Data, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.)", ,"cancer, case series, colon, colorectal, colorectal cancer, colorectal tumor, colorectal tumors, colorectal tumour, colorectal tumours, gastroenterology, neoplasm, neoplasms, observational studies, observational study, oncology, rectum, surgery, surgical, tumor, tumors, tumour, tumours", ,"Rubino M, Pragnell MVC. Guidelines for reporting case series of tumours of the colon and rectum. Techniques in Coloproctology. 1999;3(2):93-97.","Rubino M, Pragnell MVC.",Techniques in Coloproctology,1999,3,2,93-97, ,English, , , , , , , , , , , , , , , , , ,no,2013-07-17 14:09:15,2013-08-22 13:24:09,guidelines-for-reporting-case-series-of-tumours-of-the-colon-and-rectum,"[('title', 'Guidelines for reporting case series of tumours of the colon and rectum'), ('Full bibliographic reference', 'Rubino M, Pragnell MVC. Guidelines for reporting case series of tumours of the colon and rectum. Techniques in Coloproctology. 1999;3(2):93-97.'), ('Language', 'English'), ('Study design', 'Observational studies'), ('Clinical area', 'Gastroenterology, Oncology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Data, Intervention (exposure), Outcomes (variables), Procedure/Method, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'August 22, 2013')]"
7433,Guidance on reporting ultrasound exposure conditions for bio-effects studies, ,Radiology,"Data, Harms/adverse effects/safety data, Intervention (exposure), Procedure/Method", ,"bio effect, bio effects, bio effects studies, bio effects study, biological effect, biological effects, calibration, diagnostic ultrasound, diagnostic ultrasound studies, diagnostic ultrasound study, exposure, exposure conditions, imaging, physiotherapy, physiotherapy ultrasound, therapeutic ultrasound, ultrasonography, ultrasound, ultrasound bio effect, ultrasound bio effects, ultrasound exposure conditions", ,"ter Haar G, Shaw A, Pye S, Ward B, Bottomley F, Nolan R, Coady AM. Guidance on reporting ultrasound exposure conditions for bio-effects studies. Ultrasound Med Biol. 2011;37(2):177-183.","ter Haar G, Shaw A, Pye S, Ward B, Bottomley F, Nolan R, Coady AM.",Ultrasound in Medicine and Biology [Ultrasound Med Biol.],2011,37,2,177-183, ,English, ,21257086,http://www.ncbi.nlm.nih.gov/pubmed/21257086, , , , , , ,Reporting ultrasound exposure conditions for bio-effects studies, , , , , , , ,no,2013-07-17 13:12:31,2013-08-22 13:31:08,reporting-ultrasound-exposure-conditions-for-bio-effects-studies,"[('title', 'Guidance on reporting ultrasound exposure conditions for bio-effects studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting ultrasound exposure conditions for bio-effects studies'), ('Full bibliographic reference', 'ter Haar G, Shaw A, Pye S, Ward B, Bottomley F, Nolan R, Coady AM. Guidance on reporting ultrasound exposure conditions for bio-effects studies. Ultrasound Med Biol. 2011;37(2):177-183.'), ('Language', 'English'), ('PubMed ID', '[21257086](http://www.ncbi.nlm.nih.gov/pubmed/21257086)'), ('Clinical area', 'Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Harms/adverse effects/safety data, Intervention (exposure), Procedure/Method'), ('Record last updated on', 'August 22, 2013')]"
7429,"American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS) ", ,"Cardiovascular medicine, Radiology","Images, Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)", ,"ACC, cardiac, cardiology, cardiovascular, cardiovascular medicine, coronary IVUS, coronary IVUS report, coronary IVUS reports, imaging, intravascular, intravascular ultrasound studies, intravascular ultrasound study, IVUS, IVUS analysis, IVUS examination, IVUS imaging, IVUS transducer, IVUS transducers, radiological, radiology, ultrasound, vascular", ,"Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM, Yock PG. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2001;37(5):1478-1492.","Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM, Yock PG.",Journal of the American College of Cardiology [J Am Coll Cardiol.],2001,37,5,1478-1492, ,English, ,11300468,http://www.ncbi.nlm.nih.gov/pubmed/11300468, , , , , , ,Intravascular ultrasound studies (IVUS), , , , , , , ,no,2013-07-17 10:35:34,2013-08-22 13:35:45,american-college-of-cardiology-clinical-expert-consensus-document-on-standards-for-acquisition-measurement-and-reporting-of-intravascular-ultrasound-studies-ivus-a-report-of-the-american-college-o,"[('title', 'American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Intravascular ultrasound studies (IVUS)'), ('Full bibliographic reference', 'Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM, Yock PG. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2001;37(5):1478-1492.'), ('Language', 'English'), ('PubMed ID', '[11300468](http://www.ncbi.nlm.nih.gov/pubmed/11300468)'), ('Clinical area', 'Cardiovascular medicine, Radiology'), ('Applies to the whole report or to individual sections of the report?', 'Images, Intervention (exposure), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'August 22, 2013')]"
7424,Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group,"Clinical trials, Experimental studies",Cardiovascular medicine,"Data, Harms/adverse effects/safety data, Outcomes (variables)", ,"ABC, academic bleeding consensus, ACs, acute coronary syndrome, acute coronary syndromes, antithrombotic agent, antithrombotic agents, antithrombotic regime, antithrombotic regimes, bleeding, bleeding complications, cardiovascular medicine, clinical trial, clinical trials, coronary, coronary syndrome, coronary syndromes, haemorrhage, haemorrhagic, haemorrhagic complications, heart, hemorrhage, hemorrhagic, hemorrhagic complications, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Rao SV, Eikelboom J, Steg PG, Lincoff AM, Weintraub WS, Bassand JP, Rao AK, Gibson CM, Petersen JL, Mehran R, Manoukian SV, Charnigo R, Lee KL, Moscucci M, Harrington RA; Academic Bleeding Consensus Multidisciplinary Working Group. Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. Am Heart J. 2009;158(6):881-886.","Rao SV, Eikelboom J, Steg PG, Lincoff AM, Weintraub WS, Bassand JP, Rao AK, Gibson CM, Petersen JL, Mehran R, Manoukian SV, Charnigo R, Lee KL, Moscucci M, Harrington RA; Academic Bleeding Consensus Multidisciplinary Working Group.",American Heart Journal [Am Heart J.],2009,158,6,881-886, ,English, ,19958852,http://www.ncbi.nlm.nih.gov/pubmed/19958852, , , , , , ,Reporting of bleeding complications for clinical investigations in acute coronary syndromes, , , , , , , ,no,2013-07-17 10:14:47,2013-08-22 13:49:06,standardized-reporting-of-bleeding-complications-for-clinical-investigations-in-acute-coronary-syndromes-a-proposal-from-the-academic-bleeding-consensus-abc-multidisciplinary-working-group,"[('title', 'Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of bleeding complications for clinical investigations in acute coronary syndromes'), ('Full bibliographic reference', 'Rao SV, Eikelboom J, Steg PG, Lincoff AM, Weintraub WS, Bassand JP, Rao AK, Gibson CM, Petersen JL, Mehran R, Manoukian SV, Charnigo R, Lee KL, Moscucci M, Harrington RA; Academic Bleeding Consensus Multidisciplinary Working Group. Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. Am Heart J. 2009;158(6):881-886.'), ('Language', 'English'), ('PubMed ID', '[19958852](http://www.ncbi.nlm.nih.gov/pubmed/19958852)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Cardiovascular medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data, Harms/adverse effects/safety data, Outcomes (variables)'), ('Record last updated on', 'August 22, 2013')]"
7420,Standardized reporting guidelines for studies evaluating risk stratification of ED patients with potential acute coronary syndromes, ,"Cardiovascular medicine, Emergency medicine","Intervention (exposure), Outcomes (variables), Study characteristics (participants etc.)", ,"A and E, A&amp;E patients, accident and emergency, ACs, acute coronary syndrome, acute coronary syndromes, AE, angina, cardiac, cardiology, cardiovascular medicine, chest pain, coronary, coronary arteries, coronary syndrome, coronary syndromes, ED, ED patients, EMCREG-I, emergency department, emergency department patients, emergency medicine, heart, MI, myocardial infarction, risk stratification, risk stratification studies, risk stratification study", ,"Hollander JE, Blomkalns AL, Brogan GX, Diercks DB, Field JM, Garvey JL, Gibler WB, Henry TD, Hoekstra JW, Holroyd BR, Hong Y, Kirk JD, O'Neil BJ, Jackson RE; Multidisciplinary Standardized Reporting Criteria Task Force. Standardized reporting guidelines for studies evaluating risk stratification of ED patients with potential acute coronary syndromes. Acad Emerg Med. 2004;11(12):1331-1340.","Hollander JE, Blomkalns AL, Brogan GX, Diercks DB, Field JM, Garvey JL, Gibler WB, Henry TD, Hoekstra JW, Holroyd BR, Hong Y, Kirk JD, O'Neil BJ, Jackson RE; Multidisciplinary Standardized Reporting Criteria Task Force.",Academic Emergency Medicine [Acad Emerg Med.],2004,11,12,1331-1340, ,English, ,15576525,http://www.ncbi.nlm.nih.gov/pubmed/15576525, , , , , , ,Studies involving emergency department (ED) patients with potential acute coronary syndromes (ACS), , , , , , , ,no,2013-07-17 09:23:00,2013-08-22 13:43:41,standardized-reporting-guidelines-for-studies-evaluating-risk-stratification-of-ed-patients-with-potential-acute-coronary-syndromes,"[('title', 'Standardized reporting guidelines for studies evaluating risk stratification of ED patients with potential acute coronary syndromes'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Studies involving emergency department (ED) patients with potential acute coronary syndromes (ACS)'), ('Full bibliographic reference', ""Hollander JE, Blomkalns AL, Brogan GX, Diercks DB, Field JM, Garvey JL, Gibler WB, Henry TD, Hoekstra JW, Holroyd BR, Hong Y, Kirk JD, O'Neil BJ, Jackson RE; Multidisciplinary Standardized Reporting Criteria Task Force. Standardized reporting guidelines for studies evaluating risk stratification of ED patients with potential acute coronary syndromes. Acad Emerg Med. 2004;11(12):1331-1340.""), ('Language', 'English'), ('PubMed ID', '[15576525](http://www.ncbi.nlm.nih.gov/pubmed/15576525)'), ('Clinical area', 'Cardiovascular medicine, Emergency medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Outcomes (variables), Study characteristics (participants etc.)'), ('Record last updated on', 'August 22, 2013')]"
7417,Calibration methods used in cancer simulation models and suggested reporting guidelines, ,Oncology,"Data, Procedure/Method", ,"calibration, calibration method, calibration methods, calibration procedure, calibration procedures, calibration protocol, calibration protocols, cancer, cancer prevention, cancer screening, cancer screening model, cancer screening models, cancer simulation model, cancer simulation modelling, cancer simulation models, checklist, computer simulation model, computer simulation models, model calibration, oncology, simulation, simulation model, simulation modelling, simulation models, unobservable parameter, unobservable parameters", ,"Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS. Calibration methods used in cancer simulation models and suggested reporting guidelines. PharmacoEconomics. 2009;27(7):533-545.","Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS.",PharmacoEconomics,2009,27,7,533-545, ,English, ,19663525,http://www.ncbi.nlm.nih.gov/pubmed/19663525, , , , , , ,Calibration methods used in cancer simulation models, , , , , , , ,no,2013-07-17 08:53:31,2013-08-22 13:51:38,calibration-methods-used-in-cancer-simulation-models-and-suggested-reporting-guidelines,"[('title', 'Calibration methods used in cancer simulation models and suggested reporting guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Calibration methods used in cancer simulation models'), ('Full bibliographic reference', 'Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS. Calibration methods used in cancer simulation models and suggested reporting guidelines. PharmacoEconomics. 2009;27(7):533-545.'), ('Language', 'English'), ('PubMed ID', '[19663525](http://www.ncbi.nlm.nih.gov/pubmed/19663525)'), ('Clinical area', 'Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method'), ('Record last updated on', 'August 22, 2013')]"
7411,Preschool vision screening: what should we be detecting and how should we report it? Uniform guidelines for reporting results of preschool vision screening studies, ,"Ophthalmology, Paediatrics","Data, Results, Study characteristics (participants etc.)", ,"amblyogenic factors, amblyopia, child, children, data, eye, ophthalmic, ophthalmology, paediatric, paediatrics, pediatric, pediatrics, preschool, preschool vision screening, risk factor, risk factors, screening, sensitivity and specificity data, sensitivity data, specificity data, vision, vision loss, vision screening, visual, young people", ,"Donahue SP, Arnold RW, Ruben JB; AAPOS Vision Screening Committee. Preschool vision screening: what should we be detecting and how should we report it? Uniform guidelines for reporting results of preschool vision screening studies. J AAPOS. 2003;7(5):314-316.","Donahue SP, Arnold RW, Ruben JB; AAPOS Vision Screening Committee.",Journal of AAPOS [J AAPOS.],2003,7,5,314-316, ,English, ,14566312,http://www.ncbi.nlm.nih.gov/pubmed/14566312, , , , , , ,Reporting results of preschool vision screening studies, , , , , , , ,no,2013-07-16 15:11:54,2013-08-22 13:53:27,preschool-vision-screening-what-should-we-be-detecting-and-how-should-we-report-it-uniform-guidelines-for-reporting-results-of-preschool-vision-screening-studies,"[('title', 'Preschool vision screening: what should we be detecting and how should we report it? Uniform guidelines for reporting results of preschool vision screening studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting results of preschool vision screening studies'), ('Full bibliographic reference', 'Donahue SP, Arnold RW, Ruben JB; AAPOS Vision Screening Committee. Preschool vision screening: what should we be detecting and how should we report it? Uniform guidelines for reporting results of preschool vision screening studies. J AAPOS. 2003;7(5):314-316.'), ('Language', 'English'), ('PubMed ID', '[14566312](http://www.ncbi.nlm.nih.gov/pubmed/14566312)'), ('Clinical area', 'Ophthalmology, Paediatrics'), ('Applies to the whole report or to individual sections of the report?', 'Data, Results, Study characteristics (participants etc.)'), ('Record last updated on', 'August 22, 2013')]"
7365,The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome, ,Oncology,Data, ,"cancer, data, data analyses, data analysis, data synthesis, dose volume, dose volume dependence, dose volume dependencies, dose volume toxicity studies, dose volume toxicity study, endpoint, endpoints, normal tissue, normal tissue injury, normal tissue toxicity, oncology, outcome, outcomes, QUANTEC, radiation, radiation therapies, radiation therapy, radiology, radiotherapy, statistical, statistical data, statistical synthesis, statistics, tissue toxicity, toxicities, toxicity, treatment outcome", ,"Jackson A, Marks LB, Bentzen SM, Eisbruch A, Yorke ED, Ten Haken RK, Constine LS, Deasy JO. The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S155-160.","Jackson A, Marks LB, Bentzen SM, Eisbruch A, Yorke ED, Ten Haken RK, Constine LS, Deasy JO.","International Journal of Radiation Oncology, Biology, Physics [Int J Radiat Oncol Biol Phys.]",2010,76,3 Suppl.,s155-s160, ,English, ,20171512,http://www.ncbi.nlm.nih.gov/pubmed/20171512, , , , , , ,Reporting and gathering data on dose-volume dependencies of treatment outcome, , , , , , , ,no,2013-07-15 15:27:54,2013-08-22 13:55:42,the-lessons-of-quantec-recommendations-for-reporting-and-gathering-data-on-dose-volume-dependencies-of-treatment-outcome,"[('title', 'The lessons of QUANTEC : recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting and gathering data on dose-volume dependencies of treatment outcome'), ('Full bibliographic reference', 'Jackson A, Marks LB, Bentzen SM, Eisbruch A, Yorke ED, Ten Haken RK, Constine LS, Deasy JO. The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S155-160.'), ('Language', 'English'), ('PubMed ID', '[20171512](http://www.ncbi.nlm.nih.gov/pubmed/20171512)'), ('Clinical area', 'Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'August 22, 2013')]"
7346,A reporting guideline for clinical platelet transfusion studies from the BEST Collaborative,"Clinical trials, Experimental studies","Haematology, Oncology","Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method", ,"BEST Collaborative, blood, checklist, clinical platelet transfusion studies, clinical platelet transfusion study, clinical research, clinical trial, clinical trials, experimental studies, experimental study, haematology, hematology, platelet transfusion, platelet transfusion therapy, plateletpheresis, PLT, PLT study checklist, PLT study reporting checklist, PLT transfusion, PLT transfusion studies, PLT transfusion study, PLT transfusion trial, PLT transfusion trials, PLT transfusions, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, transfusion, trial, trials", ,"Meyer E, Delaney M, Lin Y, Morris A, Pavenski K, Tinmouth A, Murphy M, Slichter SJ, Heddle N, Dumont LJ. A reporting guideline for clinical platelet transfusion studies from the BEST Collaborative. Transfusion. 2013;53(6):1328-1334.","Meyer E, Delaney M, Lin Y, Morris A, Pavenski K, Tinmouth A, Murphy M, Slichter SJ, Heddle N, Dumont LJ.",Transfusion.,2013,53,6,1328-1334, ,English, ,23003345,http://www.ncbi.nlm.nih.gov/pubmed/23003345, , , , , , ,Clinical platelet transfusion studies, , , , , , , ,no,2013-07-15 14:40:44,2013-08-22 13:59:52,a-reporting-guideline-for-clinical-platelet-transfusion-studies-from-the-best-collaborative,"[('title', 'A reporting guideline for clinical platelet transfusion studies from the BEST Collaborative'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Clinical platelet transfusion studies'), ('Full bibliographic reference', 'Meyer E, Delaney M, Lin Y, Morris A, Pavenski K, Tinmouth A, Murphy M, Slichter SJ, Heddle N, Dumont LJ. A reporting guideline for clinical platelet transfusion studies from the BEST Collaborative. Transfusion. 2013;53(6):1328-1334.'), ('Language', 'English'), ('PubMed ID', '[23003345](http://www.ncbi.nlm.nih.gov/pubmed/23003345)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Haematology, Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method'), ('Record last updated on', 'August 22, 2013')]"
7340,Clinical trials focusing on cancer pain educational interventions: core components to include during planning and reporting,"Clinical trials, Experimental studies",Oncology,Whole report, ,"cancer, cancer pain, cancer pain control, cancer pain education, clinical trial, clinical trials, education, educational, educational intervention, educational intervention studies, educational intervention study, educational intervention trial, educational intervention trials, educational interventions, experimental studies, experimental study, oncology, oncology pain management, pain, pain management, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Stiles CR, Biondo PD, Cummings G, Hagen NA. Clinical trials focusing on cancer pain educational interventions: core components to include during planning and reporting. J Pain Symptom Manage. 2010;40(2):301-308.","Stiles CR, Biondo PD, Cummings G, Hagen NA.",Journal of Pain and Symptom Management [J Pain Symptom Manage.],2010,40,2,301-308, ,English, ,20541899,http://www.ncbi.nlm.nih.gov/pubmed/20541899, , , , , , ,Clinical trials in cancer pain educational interventions, , , , , , , ,no,2013-07-15 14:01:12,2013-08-22 14:02:21,clinical-trials-focusing-on-cancer-pain-educational-interventions-core-components-to-include-during-planning-and-reporting,"[('title', 'Clinical trials focusing on cancer pain educational interventions: core components to include during planning and reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Clinical trials in cancer pain educational interventions'), ('Full bibliographic reference', 'Stiles CR, Biondo PD, Cummings G, Hagen NA. Clinical trials focusing on cancer pain educational interventions: core components to include during planning and reporting. J Pain Symptom Manage. 2010;40(2):301-308.'), ('Language', 'English'), ('PubMed ID', '[20541899](http://www.ncbi.nlm.nih.gov/pubmed/20541899)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'August 22, 2013')]"
7335,Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations,"Clinical trials, Experimental studies",Rheumatology,"Data, Outcomes (variables)", ,"ACR, American College of Rheumatology, arthritis, clinical trial, clinical trials, disease activity, disease activity state, disease activity states, EULAR, European League against Rheumatism, RA, RA trials, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, rheumatoid, rheumatoid arthritis, rheumatology, trial, trials", ,"Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Michaud K, O'Dell J, Paulus H, Pincus T, Richards P, Simon L, Siegel J, Smolen JS, Sokka T, Strand V, Tugwell P, van der Heijde D, van Riel P, Vlad S, van Vollenhoven R, Ward M, Weinblatt M, Wells G, White B, Wolfe F, Zhang B, Zink A, Felson D. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008;67(10):1360-1364.","Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Michaud K, O'Dell J, Paulus H, Pincus T, Richards P, Simon L, Siegel J, Smolen JS, Sokka T, Strand V, Tugwell P, van der Heijde D, van Riel P, Vlad S, van Vollenhoven R, Ward M, Weinblatt M, Wells G, White B, Wolfe F, Zhang B, Zink A, Felson D.",Annals of the Rheumatic Diseases [Ann Rheum Dis.],2008,67,10,1360-1364, ,English, ,18791055,http://www.ncbi.nlm.nih.gov/pubmed/18791055, , , , , , ,Reporting disease activity in clinical trials of rheumatoid arthritis, , , , , , , ,no,2013-07-15 13:26:49,2013-08-22 14:04:14,reporting-disease-activity-in-clinical-trials-of-patients-with-rheumatoid-arthritis-eularacr-collaborative-recommendations,"[('title', 'Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR / ACR collaborative recommendations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting disease activity in clinical trials of rheumatoid arthritis'), ('Full bibliographic reference', ""Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Michaud K, O'Dell J, Paulus H, Pincus T, Richards P, Simon L, Siegel J, Smolen JS, Sokka T, Strand V, Tugwell P, van der Heijde D, van Riel P, Vlad S, van Vollenhoven R, Ward M, Weinblatt M, Wells G, White B, Wolfe F, Zhang B, Zink A, Felson D. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008;67(10):1360-1364.""), ('Language', 'English'), ('PubMed ID', '[18791055](http://www.ncbi.nlm.nih.gov/pubmed/18791055)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Rheumatology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Outcomes (variables)'), ('Record last updated on', 'August 22, 2013')]"
7332,"Exercise therapy and low back pain: insights and proposals to improve the design, conduct, and reporting of clinical trials","Clinical trials, Experimental studies","Rheumatology, Sport and exercise medicine","Intervention (exposure), Outcomes (variables), Study characteristics (participants etc.)", ,"back, back pain, clinical trial, clinical trials, exercise, exercise protocol, exercise protocols, exercise therapies, exercise therapy, exercise trial, exercise trials, experimental studies, experimental study, LBP, low back pain, pain, randomised, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, rheumatology, subacute low back pain, trial, trial report, trials", ,"Helmhout PH, Staal JB, Maher CG, Petersen T, Rainville J, Shaw WS. Exercise therapy and low back pain: insights and proposals to improve the design, conduct, and reporting of clinical trials. Spine (Phila Pa 1976). 2008;33(16):1782-1788.","Helmhout PH, Staal JB, Maher CG, Petersen T, Rainville J, Shaw WS.",Spine (Phila Pa 1976).,2008,33,16,1782-1788, ,English, ,18628711,http://www.ncbi.nlm.nih.gov/pubmed/18628711, , , , , , ,Reporting of exercise therapies in clinical trials, , , , , , , ,no,2013-07-15 11:34:39,2017-03-06 10:39:01,exercise-therapy-and-low-back-pain-insights-and-proposals-to-improve-the-design-conduct-and-reporting-of-clinical-trials,"[('title', 'Exercise therapy and low back pain: insights and proposals to improve the design, conduct, and reporting of clinical trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of exercise therapies in clinical trials'), ('Full bibliographic reference', 'Helmhout PH, Staal JB, Maher CG, Petersen T, Rainville J, Shaw WS. Exercise therapy and low back pain: insights and proposals to improve the design, conduct, and reporting of clinical trials. Spine (Phila Pa 1976). 2008;33(16):1782-1788.'), ('Language', 'English'), ('PubMed ID', '[18628711](http://www.ncbi.nlm.nih.gov/pubmed/18628711)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Rheumatology, Sport and exercise medicine'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Outcomes (variables), Study characteristics (participants etc.)'), ('Record last updated on', 'March 6, 2017')]"
7325,Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group,"Clinical trials, Experimental studies","Oncology, Urology","Outcomes (variables), Study characteristics (participants etc.)", ,"clinical trial, clinical trials, experimental studies, experimental study, oncology, prostate, prostate cancer, prostate specific antigen, prostate specific antigen level, prostate specific antigen levels, prostate specific antigen measurement, prostate specific antigen monitoring, prostate specific antigen test, prostatectomy, PSA, PSA level, PSA levels, PSA measurement, PSA monitoring, PSA test, radical prostatectomy, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, rising prostate specific antigen, trial, trials, urological, urology", ,"Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004;22(3):537-556.","Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR.",Journal of Clinical Oncology [J Clin Oncol.],2004,22,3,537-556, ,English, ,14752077,http://www.ncbi.nlm.nih.gov/pubmed/14752077, , , , , , ,Clinical trials for patients in the state of a rising prostate-specific antigen, , , , , , , ,no,2013-07-15 10:29:11,2013-08-22 14:18:42,eligibility-and-outcomes-reporting-guidelines-for-clinical-trials-for-patients-in-the-state-of-a-rising-prostate-specific-antigen-recommendations-from-the-prostate-specific-antigen-working-group,"[('title', 'Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate -Specific Antigen Working Group'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Clinical trials for patients in the state of a rising prostate-specific antigen'), ('Full bibliographic reference', ""Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004;22(3):537-556.""), ('Language', 'English'), ('PubMed ID', '[14752077](http://www.ncbi.nlm.nih.gov/pubmed/14752077)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Oncology, Urology'), ('Applies to the whole report or to individual sections of the report?', 'Outcomes (variables), Study characteristics (participants etc.)'), ('Record last updated on', 'August 22, 2013')]"
7316,Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis,"Clinical trials, Experimental studies","Haematology, Oncology","Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)", ,"AL, amyloid, amyloidoses, amyloidosis, amyloids, blood, cancer, clinical research, clinical trial, clinical trials, experimental studies, experimental study, FLC, free light chain, haematology, hematology, immunoglobulin, immunoglobulin light chain amyloidosis, light chain amyloidosis, oncology, phase 1, phase 2, phase 3, phase I, phase II, phase III, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, systemic amyloidosis, systemic immunoglobulin light chain amyloidosis, trial, trials", ,"Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317-2325.","Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G.",Leukemia.,2012,26,11,2317-2325, ,English, ,22475872,http://www.ncbi.nlm.nih.gov/pubmed/22475872, , , , , , ,Clinical trials in systemic light-chain amyloidosis, , , , , , , ,no,2013-07-15 09:56:17,2015-06-24 13:36:26,consensus-guidelines-for-the-conduct-and-reporting-of-clinical-trials-in-systemic-light-chain-amyloidosis,"[('title', 'Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Clinical trials in systemic light-chain amyloidosis'), ('Full bibliographic reference', 'Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317-2325.'), ('Language', 'English'), ('PubMed ID', '[22475872](http://www.ncbi.nlm.nih.gov/pubmed/22475872)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Haematology, Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'June 24, 2015')]"
7313,"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","Clinical trials, Experimental studies","Haematology, Oncology","Intervention (exposure), Outcomes (variables), Procedure/Method", ,"acute leukaemia, acute leukemia, acute myelogenous leukaemia, acute myelogenous leukemia, acute myeloid leukaemia, acute myeloid leukemia, AML, cancer, clinical trial, clinical trials, European LeukemiaNet, experimental studies, experimental study, haematology, hematology, leukaemia, leukemia, myeloid leukaemia, myeloid leukemia, oncology, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"D\xf6hner H, Estey EH, Amadori S, Appelbaum FR, B\xfcchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, L\xf6wenberg B, Bloomfield CD; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.","D\xf6hner H, Estey EH, Amadori S, Appelbaum FR, B\xfcchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, L\xf6wenberg B, Bloomfield CD; European LeukemiaNet.",Blood.,2010,115,3,453-474, ,English, ,19880497,http://www.ncbi.nlm.nih.gov/pubmed/19880497, , , , , , ,Reporting system for correlation of cytogenetic and molecular genetic data with clinical data, , , , , , , ,no,2013-07-15 09:24:56,2013-08-22 14:26:03,diagnosis-and-management-of-acute-myeloid-leukemia-in-adults-recommendations-from-an-international-expert-panel-on-behalf-of-the-european-leukemianet,"[('title', 'Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting system for correlation of cytogenetic and molecular genetic data with clinical data'), ('Full bibliographic reference', 'Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Löwenberg B, Bloomfield CD; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.'), ('Language', 'English'), ('PubMed ID', '[19880497](http://www.ncbi.nlm.nih.gov/pubmed/19880497)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Haematology, Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure), Outcomes (variables), Procedure/Method'), ('Record last updated on', 'August 22, 2013')]"
7309,"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","Clinical trials, Experimental studies","Haematology, Oncology",Whole report, ,"acute leukaemia, acute leukemia, acute myelogenous leukaemia, acute myelogenous leukemia, acute myeloid leukaemia, acute myeloid leukemia, AML, blood, cancer, clinical trial, clinical trials, experimental studies, experimental study, haematology, hematology, leukaemia, leukemia, myelogenous leukaemia, myelogenous leukemia, myeloid leukaemia, myeloid leukemia, oncology, phase 1, phase 2, phase 3, phase I, phase II, phase III, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649.","Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.",Journal of Clinical Oncology [J Clin Oncol.],2003,21,24,4642-4649, ,English, ,14673054,http://www.ncbi.nlm.nih.gov/pubmed/14673054, , , , , , ,Therapeutic trials in acute myeloid leukaemia (AML), , , , , , , ,no,2013-07-12 15:27:23,2013-08-22 14:30:51,revised-recommendations-of-the-international-working-group-for-diagnosis-standardization-of-response-criteria-treatment-outcomes-and-reporting-standards-for-therapeutic-trials-in-acute-myeloid-leuk,"[('title', 'Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Therapeutic trials in acute myeloid leukaemia (AML)'), ('Full bibliographic reference', 'Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649.'), ('Language', 'English'), ('PubMed ID', '[14673054](http://www.ncbi.nlm.nih.gov/pubmed/14673054)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Haematology, Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'August 22, 2013')]"
7303,Methodological challenges when using actigraphy in research, ,"Behavioural medicine, Neurology, Psychiatry","Data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)", ,"actigraph, actigraphs, actigraphy, activity, behavior, behavioral, behavioral medicine, behaviour, behavioural, behavioural medicine, circadian, circadian rhythm, circadian rhythms, insomnia, neurological, neurology, psychiatry, sleep, wake", ,"Berger AM, Wielgus KK, Young-McCaughan S, Fischer P, Farr L, Lee KA. Methodological challenges when using actigraphy in research. J Pain Symptom Manage. 2008;36(2):191-199.","Berger AM, Wielgus KK, Young-McCaughan S, Fischer P, Farr L, Lee KA.",Journal of Pain and Symptom Management [J Pain Symptom Manage.],2008,36,2,191-199, ,English, ,18400460,http://www.ncbi.nlm.nih.gov/pubmed/18400460, , , , , , ,Actigraphy information to include in research reports, , , , , , , ,no,2013-07-12 14:58:39,2013-09-24 13:54:39,methodological-challenges-when-using-actigraphy-in-research,"[('title', 'Methodological challenges when using actigraphy in research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Actigraphy information to include in research reports'), ('Full bibliographic reference', 'Berger AM, Wielgus KK, Young-McCaughan S, Fischer P, Farr L, Lee KA. Methodological challenges when using actigraphy in research. J Pain Symptom Manage. 2008;36(2):191-199.'), ('Language', 'English'), ('PubMed ID', '[18400460](http://www.ncbi.nlm.nih.gov/pubmed/18400460)'), ('Clinical area', 'Behavioural medicine, Neurology, Psychiatry'), ('Applies to the whole report or to individual sections of the report?', 'Data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'September 24, 2013')]"
7298,Draft STROBE checklist for conference abstracts,Observational studies, ,Conference paper/abstract, ,"abstract, abstracts, checklist, conference, conference abstract, conference abstracts, observational, observational studies, observational study, STROBE, STROBE abstracts, STROBE conference, STROBE conference abstracts, STROBE extension", ,First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts., , ,2011, , , , ,English, , , ,"The draft STROBE checklist for conference abstracts is available from: full text PDF

", , ,"Generic
STROBE Statement: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Ann Intern Med. 2007;147(8):573-577. PMID: 17938396
PLoS Med. 2007;4(10):e296. PMID: 17941714
BMJ. 2007;335(7624):806-808. PMID: 17947786
Prev Med. 2007;45(4):247-251. PMID: 17950122
Epidemiology. 2007;18(6):800-804. PMID: 18049194
Lancet. 2007;370(9596):1453-1457. PMID: 18064739

Specialised
STREGA: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.

PLoS Med. 2009;6(2):e22. PMID: 19192942
Hum Genet. 2009;125(2):131-151. PMID: 19184668
Eur J Epidemiol. 2009;24(1):37-55. PMID: 19189221
Ann Intern Med. 2009;150(3):206-215. PMID: 19189911
J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: 19217256
Genet Epidemiol. 2009;33(7):581-598. PMID: 19278015
Eur J Clin Invest. 2009;39(4):247-266. PMID: 19297801

STROBE-ME: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: 22023344

STROME-ID: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: 24631223

Longitudinal observational drug studies in rheumatology: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: 24058015

Case-cohort studies: Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: 24972092

STROBE-RDS: White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: 26112433

RECORD: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: 26440803

STROBE-AMS: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schr\xf6der W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: 26895985

STROBE-nut: Lachat C, Hawwash D, Ock\xe9 MC, Berg C, Forsum E, H\xf6rnell A, Larsson C, Sonestedt E, Wirf\xe4lt E, \xc5kesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology?Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: 27270749

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

ROSES-I: Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: 27417916

STROBE-NI: Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: 27633910

Propensity score analysis: Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: 28376195

RECORD-PE: Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.

STROBE-SIIS: International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, H\xe4gglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).

Br J Sports Med. 2020;54(7):372-389. PMID: 32071062
Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: 32118084

STROBE-MR: Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: 34698778

",http://www.strobe-statement.org/,STROBE for conference abstracts,"Reporting observational studies in conference abstracts



STROBE conference abstracts checklist (PDF)

", , , , , , , ,yes,2013-07-12 14:23:44,2021-11-25 15:33:30,strobe-abstracts,"[('title', 'Draft STROBE checklist for conference abstracts'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting observational studies in conference abstracts\n\n \n\n \xa0\n\n \n\n[STROBE conference abstracts checklist (PDF)](https://www.strobe-statement.org/download/strobe-checklist-conference-abstracts)\n\n \n\n'), ('Full bibliographic reference', 'First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The draft STROBE checklist for conference abstracts is available from: [full text PDF](https://www.strobe-statement.org/download/strobe-checklist-conference-abstracts)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic\n\n[STROBE Statement](/reporting-guidelines/strobe/)**: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.\n\n \n\n Ann Intern Med. 2007;147(8):573-577. PMID: [17938396](http://www.ncbi.nlm.nih.gov/pubmed/17938396)\n\n PLoS Med. 2007;4(10):e296. PMID: [17941714](http://www.ncbi.nlm.nih.gov/pubmed/17941714)\n\n BMJ. 2007;335(7624):806-808. PMID: [17947786](http://www.ncbi.nlm.nih.gov/pubmed/17947786)\n\n Prev Med. 2007;45(4):247-251. PMID: [17950122](http://www.ncbi.nlm.nih.gov/pubmed/17950122)\n\n Epidemiology. 2007;18(6):800-804. PMID: [18049194](http://www.ncbi.nlm.nih.gov/pubmed/18049194)\n\n Lancet. 2007;370(9596):1453-1457. PMID: [18064739](http://www.ncbi.nlm.nih.gov/pubmed/18064739)\n\n \n\n**Specialised**\n\n[**STREGA**](/reporting-guidelines/strobe-strega/): Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.\n\n \n\n PLoS Med. 2009;6(2):e22. PMID: [19192942](http://www.ncbi.nlm.nih.gov/pubmed/19192942)\n\n Hum Genet. 2009;125(2):131-151. PMID: [19184668](http://www.ncbi.nlm.nih.gov/pubmed/19184668)\n\n Eur J Epidemiol. 2009;24(1):37-55. PMID: [19189221](http://www.ncbi.nlm.nih.gov/pubmed/19189221)\n\n Ann Intern Med. 2009;150(3):206-215. PMID: [19189911](http://www.ncbi.nlm.nih.gov/pubmed/19189911)\n\n J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: [19217256](http://www.ncbi.nlm.nih.gov/pubmed/19217256)\n\n Genet Epidemiol. 2009;33(7):581-598. PMID: [19278015](http://www.ncbi.nlm.nih.gov/pubmed/19278015)\n\n Eur J Clin Invest. 2009;39(4):247-266. PMID: [19297801](http://www.ncbi.nlm.nih.gov/pubmed/19297801)\n\n \n\n[**STROBE-ME**](/reporting-guidelines/strobe-me/): Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: [22023344](http://www.ncbi.nlm.nih.gov/pubmed/22023344)\n\n \n\n[**STROME-ID**](/reporting-guidelines/strome-id/): Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: [24631223](http://www.ncbi.nlm.nih.gov/pubmed/24631223)\n\n \n\n[**Longitudinal observational drug studies in rheumatology**](/reporting-guidelines/launch-of-a-checklist-for-reporting-longitudinal-observational-drug-studies-in-rheumatology-a-eular-extension-of-strobe-guidelines-based-on-experience-from-biologics-registries/): Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: [24058015](http://www.ncbi.nlm.nih.gov/pubmed/24058015)\n\n \n\n[**Case-cohort studies**](/reporting-guidelines/a-review-of-published-analyses-of-case-cohort-studies-and-recommendations-for-future-reporting/): Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: [24972092](https://www.ncbi.nlm.nih.gov/pubmed/24972092)\n\n \n\n**[STROBE-RDS:](/reporting-guidelines/strobe-rds/)** White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: [26112433](http://www.ncbi.nlm.nih.gov/pubmed/26112433)\n\n \n\n**[RECORD](/reporting-guidelines/record/)**: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: [26440803](http://www.ncbi.nlm.nih.gov/pubmed/26440803)\n\n \n\n**[STROBE-AMS](/reporting-guidelines/strobe-ams/)**: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schröder W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: [26895985](http://www.ncbi.nlm.nih.gov/pubmed/26895985)\n\n \n\n[**STROBE-nut**](/reporting-guidelines/strobe-nut/): Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology—Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: [27270749](https://www.ncbi.nlm.nih.gov/pubmed/27270749)\n\n \n\n[**Simulation Research**](/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**ROSES-I**](/reporting-guidelines/roses-i-statement/): Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: [27417916](https://www.ncbi.nlm.nih.gov/pubmed/27417916)\n\n \n\n[**STROBE-NI**](/reporting-guidelines/strobe-ni/): Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: [27633910](https://www.ncbi.nlm.nih.gov/pubmed/27633910)\n\n \n\n[**Propensity score analysis**](/reporting-guidelines/reporting-and-guidelines-in-propensity-score-analysis-a-systematic-review-of-cancer-and-cancer-surgical-studies/): Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: [28376195](https://www.ncbi.nlm.nih.gov/pubmed/28376195)\n\n \n\n[**RECORD-PE**](https://www.equator-network.org/reporting-guidelines/record-pe/): Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). [BMJ 2018;363:k3532](https://www.bmj.com/content/363/bmj.k3532.full).\n\n \n\n[**STROBE-SIIS**](https://www.equator-network.org/reporting-guidelines/strobe-extension-for-sports-injury-illness-surveillance/): International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, Hägglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).\n\n \n\n Br J Sports Med. 2020;54(7):372-389. PMID: [32071062](https://pubmed.ncbi.nlm.nih.gov/32071062/)\n\n Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: [32118084](https://pubmed.ncbi.nlm.nih.gov/32118084/)\n\n \n\n[**STROBE-MR**](https://www.equator-network.org/reporting-guidelines/strobe-mr-statement/): Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: [34698778](https://pubmed.ncbi.nlm.nih.gov/34698778/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.strobe-statement.org/>'), ('Reporting guideline acronym', 'STROBE for conference abstracts'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Conference paper/abstract'), ('Record last updated on', 'November 25, 2021')]"
7286,Conflict of Interest in Peer-Reviewed Medical Journals, , ,Conflict of interest, ,"COI, COI disclosure, COI policies, COI policy, COIs, competing interest, competing interests, conflict, conflict of interest, conflict of interest policies, conflict of interest policy, conflict of interests, conflicts of interest, declaration, declarations, disclosure", ,"Fletcher R, Ferris L, World Association of Medical Editors (WAME) Editorial Policy and Publication Ethics Committees. Conflict of Interest in Peer-Reviewed Medical Journals. WAME 2009.","Fletcher R, Ferris L,World Association of Medical Editors (WAME) Editorial Policy and Publication Ethics Committees.", ,2009, , , , ,English, , , ,The conflict of interest policy is available at: http://www.wame.org/conflict-of-interest-in-peer-reviewed-medical-journals, , , , , ,Conflict of interest in peer-reviewed medical journals, , , , , , , ,no,2013-07-12 13:53:07,2022-01-13 13:06:28,conflict-of-interest-in-peer-reviewed-medical-journals,"[('title', 'Conflict of Interest in Peer -Reviewed Medical Journals'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Conflict of interest in peer-reviewed medical journals'), ('Full bibliographic reference', 'Fletcher R, Ferris L, World Association of Medical Editors (WAME) Editorial Policy and Publication Ethics Committees. Conflict of Interest in Peer-Reviewed Medical Journals. WAME 2009.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The conflict of interest policy is available at: <http://www.wame.org/conflict-of-interest-in-peer-reviewed-medical-journals>'), ('Applies to the whole report or to individual sections of the report?', 'Conflict of interest'), ('Record last updated on', 'January 13, 2022')]"
7264,Financial Conflicts of Interest Checklist 2010 for clinical research studies,"Clinical trials, Experimental studies", ,Conflict of interest, ,"checklist, checklist 2010, clinical trial, clinical trials, COI, COIs, competing interest, competing interests, conflict, conflict of interest, conflict of interests, conflicts of interest, declaration, declarations, experimental studies, experimental study, fCOI, fCOI checklist 2010, fCOIs, finance, financial, financial conflict of interest, financial conflict of interests, financial conflicts of interest, Financial Conflicts of Interest Checklist 2010, financial declaration, funding, funding declaration, funding support, interest, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Paula A Rochon, John Hoey, An-Wen Chan, Lorraine E Ferris, Joel Lexchin, Sunila R Kalkar, Melanie Sekeres, Wei Wu, Marleen Van Laethem, Andrea Gruneir, M James Maskalyk, David L Streiner, Jennifer Gold, Nathan Taback, David Moher. Financial Conflicts of Interest Checklist 2010 for clinical research studies. Open Med. 2010;4(1):e69-91.","Paula A Rochon, John Hoey, An-Wen Chan, Lorraine E Ferris, Joel Lexchin, Sunila R Kalkar, Melanie Sekeres, Wei Wu, Marleen Van Laethem, Andrea Gruneir, M James Maskalyk, David L Streiner, Jennifer Gold, Nathan Taback, David Moher.",Open Medicine [Open Med.],2010,4,1,e69-91, ,English, ,21686297, http://www.ncbi.nlm.nih.gov/pubmed/21686297, , , , , , ,Detailed reporting of different aspects of financial conflicts of interest (fCOI), , , , , , , ,no,2013-07-12 09:35:28,2013-09-24 15:38:39,financial-conflicts-of-interest-checklist-2010-for-clinical-research-studies,"[('title', 'Financial Conflicts of Interest Checklist 2010 for clinical research studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Detailed reporting of different aspects of financial conflicts of interest (fCOI)'), ('Full bibliographic reference', 'Paula A Rochon, John Hoey, An-Wen Chan, Lorraine E Ferris, Joel Lexchin, Sunila R Kalkar, Melanie Sekeres, Wei Wu, Marleen Van Laethem, Andrea Gruneir, M James Maskalyk, David L Streiner, Jennifer Gold, Nathan Taback, David Moher. Financial Conflicts of Interest Checklist 2010 for clinical research studies. Open Med. 2010;4(1):e69-91.'), ('Language', 'English'), ('PubMed ID', '[21686297]( http://www.ncbi.nlm.nih.gov/pubmed/21686297)'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Conflict of interest'), ('Record last updated on', 'September 24, 2013')]"
7255,Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest, , ,Conflict of interest, ,"COI, COI disclosure, COI policies, COI policy, COIs, competing interest, competing interests, conflict, conflict of interest, conflict of interest policies, conflict of interest policy, conflict of interests, conflicts of interest, declaration, declarations, disclosure, industry, industry ties, interest, medical association, medical associations, medical device companies, medical device company, pharmaceutical companies, pharmaceutical company, pharmaceutical industry, pharmeceutical, professional, professional association, professional associations, professional medical association, professional medical associations", ,"Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH Jr, Thomson GE, Wofsy D. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009;301(13):1367-1372.","Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH Jr, Thomson GE, Wofsy D.",Journal of the American Medical Association [JAMA.],2009,301,13,1367-1372, ,English, ,19336712,http://www.ncbi.nlm.nih.gov/pubmed/19336712, , , , , , ,Reducing or eliminating conflicts of interest, , , , , , , ,no,2013-07-11 14:54:53,2013-09-24 15:43:02,professional-medical-associations-and-their-relationships-with-industry-a-proposal-for-controlling-conflict-of-interest,"[('title', 'Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reducing or eliminating conflicts of interest'), ('Full bibliographic reference', 'Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH Jr, Thomson GE, Wofsy D. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009;301(13):1367-1372.'), ('Language', 'English'), ('PubMed ID', '[19336712](http://www.ncbi.nlm.nih.gov/pubmed/19336712)'), ('Applies to the whole report or to individual sections of the report?', 'Conflict of interest'), ('Record last updated on', 'September 24, 2013')]"
7247,How to formulate research recommendations, , ,Research recommendations, ,"EPICOT, further research, recommendation, recommendations, recommendations for research, research recommendation, research recommendations", ,"Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, Forbes C, Glanville J, Hicks NJ, Moody J, Twaddle S, Timimi H, Young P. How to formulate research recommendations. BMJ. 2006;333(7572): 804-806.","Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, Forbes C, Glanville J, Hicks NJ, Moody J, Twaddle S, Timimi H, Young P.",British Medical Journal [BMJ.],2006,333,7572,804-806, ,English, ,17038740,http://www.ncbi.nlm.nih.gov/pubmed/17038740, , , , , , ,Formulating research recommendations, , , , , , , ,no,2013-07-11 14:31:36,2013-09-25 09:29:45,how-to-formulate-research-recommendations,"[('title', 'How to formulate research recommendations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Formulating research recommendations'), ('Full bibliographic reference', 'Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, Forbes C, Glanville J, Hicks NJ, Moody J, Twaddle S, Timimi H, Young P. How to formulate research recommendations. BMJ. 2006;333(7572): 804-806.'), ('Language', 'English'), ('PubMed ID', '[17038740](http://www.ncbi.nlm.nih.gov/pubmed/17038740)'), ('Applies to the whole report or to individual sections of the report?', 'Research recommendations'), ('Record last updated on', 'September 25, 2013')]"
7243,Suggestions for improving the reporting of clinical research: the role of narrative,"Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies", ,Narrative sections (discussion etc.), ,"clinical trial, clinical trials, diagnostic, diagnostic accuracy studies, diagnostic accuracy study, diagnostic test, experimental studies, experimental study, explanatory narrative, narrative, narrative description, narrative descriptions, narrative material, narrative section, observational, observational studies, observational study, online only appendices, online only appendix, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, supplementary material, supplementary narrative, trial, trials", ,Schriger DL. Suggestions for improving the reporting of clinical research: the role of narrative. Ann Emerg Med. 2005;45(4):437-443.,Schriger DL.,Annals of Emergency Medicine [Ann Emerg Med.],2005,45,4,437-443, ,English, ,15795727,http://www.ncbi.nlm.nih.gov/pubmed/15795727, , , , , , ,Narrative in reports of medical research, , , , , , , ,no,2013-07-11 13:51:51,2013-09-25 09:33:54,suggestions-for-improving-the-reporting-of-clinical-research-the-role-of-narrative,"[('title', 'Suggestions for improving the reporting of clinical research: the role of narrative'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Narrative in reports of medical research'), ('Full bibliographic reference', 'Schriger DL. Suggestions for improving the reporting of clinical research: the role of narrative. Ann Emerg Med. 2005;45(4):437-443.'), ('Language', 'English'), ('PubMed ID', '[15795727](http://www.ncbi.nlm.nih.gov/pubmed/15795727)'), ('Study design', 'Clinical trials, Diagnostic and prognostic studies, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Narrative sections (discussion etc.)'), ('Record last updated on', 'September 25, 2013')]"
7240,The case for structuring the discussion of scientific papers, , ,Narrative sections (discussion etc.), ,"discussion, discussion section, discussion structure, narrative section, structured discussion", ,"Docherty M, Smith R. The case for structuring the discussion of scientific papers. BMJ. 1999;318(7193):1224-1225.","Docherty M, Smith R.",British Medical Journal [BMJ.],1999,318,7193,1224-1225, ,English, ,10231230,http://www.ncbi.nlm.nih.gov/pubmed/10231230, , , , , , ,The discussion section of scientific papers, , , , , , , ,no,2013-07-11 13:09:02,2013-09-25 09:38:00,the-case-for-structuring-the-discussion-of-scientific-papers,"[('title', 'The case for structuring the discussion of scientific papers'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'The discussion section of scientific papers'), ('Full bibliographic reference', 'Docherty M, Smith R. The case for structuring the discussion of scientific papers. BMJ. 1999;318(7193):1224-1225.'), ('Language', 'English'), ('PubMed ID', '[10231230](http://www.ncbi.nlm.nih.gov/pubmed/10231230)'), ('Applies to the whole report or to individual sections of the report?', 'Narrative sections (discussion etc.)'), ('Record last updated on', 'September 25, 2013')]"
7237,More medical journals should inform their contributors about three key principles of graph construction, , ,Figures/Graphs, ,"data display, data elements, graph, graph construction, graph design, graph development, graphical, graphs, visual, visual detection", ,"Puhan MA, ter RG, Eichler K, Steurer J, Bachmann LM. More medical journals should inform their contributors about three key principles of graph construction. J Clin Epidemiol. 2006;59(10):1017-1022.","Puhan MA, ter RG, Eichler K, Steurer J, Bachmann LM.",Journal of Clinical Epidemiology [J Clin Epidemiol.],2006,59,10,1017-1022, ,English, ,16980140,http://www.ncbi.nlm.nih.gov/pubmed/16980140, , , , , , ,Graph construction, , , , , , , ,no,2013-07-11 11:33:49,2013-09-25 09:41:57,more-medical-journals-should-inform-their-contributors-about-three-key-principles-of-graph-construction,"[('title', 'More medical journals should inform their contributors about three key principles of graph construction'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Graph construction'), ('Full bibliographic reference', 'Puhan MA, ter RG, Eichler K, Steurer J, Bachmann LM. More medical journals should inform their contributors about three key principles of graph construction. J Clin Epidemiol. 2006;59(10):1017-1022.'), ('Language', 'English'), ('PubMed ID', '[16980140](http://www.ncbi.nlm.nih.gov/pubmed/16980140)'), ('Applies to the whole report or to individual sections of the report?', 'Figures/Graphs'), ('Record last updated on', 'September 25, 2013')]"
7232,Figures in clinical trial reports: current practice & scope for improvement,"Clinical trials, Experimental studies", ,Figures/Graphs, ,"bar chart, bar charts, box plot, box plots, clinical trial, clinical trials, cumulative distributions, data display, display, experimental studies, experimental study, figure, figures, flow diagram, flow diagrams, Forest plot, Forest plots, individual patient data display, Kaplan Meier Curve, Kaplan Meier Curves, Kaplan Meier plot, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, repeated measures over time, repeated measures plot, trial, trials, visual, visual display", ,"Pocock SJ, Travison TG, Wruck LM. Figures in clinical trial reports: current practice &amp; scope for improvement. Trials 2007;8:36.","Pocock SJ, Travison TG, Wruck LM.",Trials,2007,8,36, , ,English, ,18021449,http://www.ncbi.nlm.nih.gov/pubmed/18021449, , , , , , ,Use of figures in reports of randomised clinical trials, , , , , , , ,no,2013-07-11 10:50:00,2013-09-25 09:46:50,figures-in-clinical-trial-reports-current-practice-scope-for-improvement,"[('title', 'Figures in clinical trial reports: current practice & scope for improvement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Use of figures in reports of randomised clinical trials'), ('Full bibliographic reference', 'Pocock SJ, Travison TG, Wruck LM. Figures in clinical trial reports: current practice & scope for improvement. Trials 2007;8:36.'), ('Language', 'English'), ('PubMed ID', '[18021449](http://www.ncbi.nlm.nih.gov/pubmed/18021449)'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Figures/Graphs'), ('Record last updated on', 'September 25, 2013')]"
7224,Recommendations for the assessment and reporting of multivariable logistic regression in transplantation literature, ,"Cardiovascular medicine, Gastroenterology, Renal medicine, Respiratory medicine, Surgery",Statistical methods and analyses, ,"heart, heart transplant, kidney, kidney transplant, liver, liver transplant, logistic regression, logistic regression analyses, logistic regression analysis, logistic regression model, logistic regression models, lung, lung transplant, multivariable logistic regression, organ transplant, organ transplantation, organ transplants, renal transplant, solid organ transplant, statistic, statistical, statistical analyses, statistical analysis, statistical method, statistical methods, statistical methods and analyses, statistics, transplant, transplantation, transplants", ,"Kalil AC, Mattei J, Florescu DF, Sun J, Kalil RS. Recommendations for the assessment and reporting of multivariable logistic regression in transplantation literature. Am J Transplant. 2010;10(7):1686-1694.","Kalil AC, Mattei J, Florescu DF, Sun J, Kalil RS.",American Journal of Transplantation [Am J Transplant.],2010,10,7,1686-1694, ,English, ,20642690,http://www.ncbi.nlm.nih.gov/pubmed/20642690, , , , , , ,Multivariable logistic regression in organ transplantation, , , , , , , ,no,2013-07-10 15:34:06,2013-09-25 09:52:45,recommendations-for-the-assessment-and-reporting-of-multivariable-logistic-regression-in-transplantation-literature,"[('title', 'Recommendations for the assessment and reporting of multivariable logistic regression in transplantation literature'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Multivariable logistic regression in organ transplantation'), ('Full bibliographic reference', 'Kalil AC, Mattei J, Florescu DF, Sun J, Kalil RS. Recommendations for the assessment and reporting of multivariable logistic regression in transplantation literature. Am J Transplant. 2010;10(7):1686-1694.'), ('Language', 'English'), ('PubMed ID', '[20642690](http://www.ncbi.nlm.nih.gov/pubmed/20642690)'), ('Clinical area', 'Cardiovascular medicine, Gastroenterology, Renal medicine, Respiratory medicine, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Record last updated on', 'September 25, 2013')]"
7217,Reporting results of latent growth modeling and multilevel modeling analyses: some recommendations for rehabilitation psychology,Observational studies,"Psychology, Rehabilitation medicine","Data, Results, Statistical methods and analyses", ,"cohort, cohort studies, cohort study, data, data analysis, hierarchical linear modeling, hierarchical linear modelling, HLM, latent curve modeling, latent curve modelling, latent growth modeling, latent growth modelling, LGM, longitudinal, longitudinal analytic technique, longitudinal analytic techniques, longitudinal research, longitudinal studies, longitudinal study, MLM, modeling technique, modeling techniques, modelling technique, modelling techniques, multilevel modeling, multilevel modeling analyses, multilevel modeling analysis, multilevel modelling, multilevel modelling analyses, multilevel modelling analysis, nested data, observational, observational studies, observational study, psychology, rehabilitation, rehabilitation psychology, statistical methods and analyses", ,Jackson DL. Reporting results of latent growth modeling and multilevel modeling analyses: some recommendations for rehabilitation psychology. Rehabil Psychol. 2010;55(3):272-285.,Jackson DL.,Rehabilitation Psychology [Rehabil Psychol.],2010,55,3,272-285, ,English, ,20804271,http://www.ncbi.nlm.nih.gov/pubmed/20804271, , , , , , ,Reporting the findings from studies where multilevel modeling (MLM) and latent growth modeling (LGM) have been used to analyze the data, , , , , , , ,no,2013-07-10 14:50:58,2022-04-26 17:23:16,reporting-results-of-latent-growth-modeling-and-multilevel-modeling-analyses-some-recommendations-for-rehabilitation-psychology,"[('title', 'Reporting results of latent growth modeling and multilevel modeling analyses: some recommendations for rehabilitation psychology'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the findings from studies where multilevel modeling (MLM) and latent growth modeling (LGM) have been used to analyze the data'), ('Full bibliographic reference', 'Jackson DL. Reporting results of latent growth modeling and multilevel modeling analyses: some recommendations for rehabilitation psychology. Rehabil Psychol. 2010;55(3):272-285.'), ('Language', 'English'), ('PubMed ID', '[20804271](http://www.ncbi.nlm.nih.gov/pubmed/20804271)'), ('Study design', 'Observational studies'), ('Clinical area', 'Psychology, Rehabilitation medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data, Results, Statistical methods and analyses'), ('Record last updated on', 'April 26, 2022')]"
7212,Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls, ,Public health,"Data, Statistical methods and analyses", ,"clinical research, data, dataset, datasets, epidemiological, epidemiology, imputation model, imputation models, imputed dataset, imputed datasets, missing data, multiple imputation, multiple imputation analyses, multiple imputation analysis, statistic, statistical, statistical method, statistical methods, statistical methods and analyses, statistics", ,"Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393.","Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR.",British Medical Journal [BMJ.],2009,338,b2393, , ,English, ,19564179,http://www.ncbi.nlm.nih.gov/pubmed/19564179, , , , , , ,Analyses affected by missing data and analyses based on multiple imputation, , , , , , , ,no,2013-07-10 13:53:35,2013-09-25 09:56:49,multiple-imputation-for-missing-data-in-epidemiological-and-clinical-research-potential-and-pitfalls,"[('title', 'Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Analyses affected by missing data and analyses based on multiple imputation'), ('Full bibliographic reference', 'Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393.'), ('Language', 'English'), ('PubMed ID', '[19564179](http://www.ncbi.nlm.nih.gov/pubmed/19564179)'), ('Clinical area', 'Public health'), ('Applies to the whole report or to individual sections of the report?', 'Data, Statistical methods and analyses'), ('Record last updated on', 'September 25, 2013')]"
7207,Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal,"Clinical trials, Experimental studies", ,Statistical methods and analyses, ,"clinical trial, clinical trials, experimental studies, experimental study, heterogeneity, heterogeneity in treatment effects, HTE, multivariate analyses, multivariate analysis, multivariate risk based HTE, patient, patient population, patient populations, patients, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, statistical methods and analyses, subgroup, subgroup analyses, subgroup analysis, subgroups, treatment, treatment effect, treatments, treatments effects, trial, trial population, trial populations, trials", ,"Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85.","Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA.",Trials,2010,11,85, , ,English, ,20704705,http://www.ncbi.nlm.nih.gov/pubmed/20704705, , , , , , ,Multivariate risk-based heterogeneity in treatment effects (HTE) in clinical trials, , , , , , , ,no,2013-07-10 13:27:59,2013-09-25 10:08:09,assessing-and-reporting-heterogeneity-in-treatment-effects-in-clinical-trials-a-proposal,"[('title', 'Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Multivariate risk-based heterogeneity in treatment effects (HTE) in clinical trials'), ('Full bibliographic reference', 'Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85.'), ('Language', 'English'), ('PubMed ID', '[20704705](http://www.ncbi.nlm.nih.gov/pubmed/20704705)'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Record last updated on', 'September 25, 2013')]"
7203,Statistics in medicine--reporting of subgroup analyses in clinical trials,"Clinical trials, Experimental studies", ,Statistical methods and analyses, ,"clinical trial, clinical trials, experimental studies, experimental study, patient, patients, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, statistic, statistical, statistical method, statistical methods, statistical methods and analyses, statistics, subgroup, subgroup analyses, subgroup analysis, subgroups, trial, trials", ,"Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine--reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357(21):2189-2194.","Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM.",New England Journal of Medicine [N Engl J Med.],2007,357,21,2189-2194, ,English, ,18032770,http://www.ncbi.nlm.nih.gov/pubmed/18032770, , , , , , ,Subgroup analyses in clinical trials, , , , , , , ,no,2013-07-10 12:58:56,2013-09-25 10:21:13,statistics-in-medicine-reporting-of-subgroup-analyses-in-clinical-trials,"[('title', 'Statistics in medicine–reporting of subgroup analyses in clinical trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Subgroup analyses in clinical trials'), ('Full bibliographic reference', 'Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine--reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357(21):2189-2194.'), ('Language', 'English'), ('PubMed ID', '[18032770](http://www.ncbi.nlm.nih.gov/pubmed/18032770)'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Record last updated on', 'September 25, 2013')]"
7197,Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study, , ,Statistical methods and analyses, ,"Bayes, Bayes theorem, Bayes's theorem, Bayesian, bayesian analyses, Bayesian analysis, Bayesian method, Bayesian methods, checklist, clinical research, clinical studies, clinical study, Reporting Of Bayes Used in clinical STudies, ROBUST, ROBUST criteria, statistical methods and analyses", ,"Sung L, Hayden J, Greenberg ML, Koren G, Feldman BM, Tomlinson GA. Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. J Clin Epidemiol. 2005;58(3):261-268.","Sung L, Hayden J, Greenberg ML, Koren G, Feldman BM, Tomlinson GA.",Journal of Clinical Epidemiology [J Clin Epidemiol.],2005,58,3,261-268, ,English, ,15718115, http://www.ncbi.nlm.nih.gov/pubmed/15718115, , , , , ,ROBUST,Bayesian analysis of a clinical study, , , , , , , ,no,2013-07-10 11:05:27,2013-09-25 10:30:27,seven-items-were-identified-for-inclusion-when-reporting-a-bayesian-analysis-of-a-clinical-study,"[('title', 'Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Bayesian analysis of a clinical study'), ('Full bibliographic reference', 'Sung L, Hayden J, Greenberg ML, Koren G, Feldman BM, Tomlinson GA. Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. J Clin Epidemiol. 2005;58(3):261-268.'), ('Language', 'English'), ('PubMed ID', '[15718115]( http://www.ncbi.nlm.nih.gov/pubmed/15718115)'), ('Reporting guideline acronym', 'ROBUST'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Record last updated on', 'September 25, 2013')]"
7193,Bayesian methods in health technology assessment: a review,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Statistical methods and analyses, ,"Bayes, Bayes theorem, Bayes's theorem, Bayesian, Bayesian analysis, Bayesian checklist, Bayesian method, Bayesian methods, checklist, health technologies, health technology assessment, health technology assessments, HTA, statistical methods and analyses, technology assessment, technology assessments", ,"Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Bayesian methods in health technology assessment: a review. Health Technol Assess. 2000;4(38):1-130.","Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR.",Health Technology Assessment [Health Technol Assess.],2000,4,38,1-130, ,English, ,11134920,http://www.ncbi.nlm.nih.gov/pubmed/11134920, , , , , ,BayesWatch,Bayesian methods in health technology assessments, , , , , , , ,no,2013-07-10 10:35:12,2013-09-25 10:33:25,bayesian-methods-in-health-technology-assessment-a-review,"[('title', 'Bayesian methods in health technology assessment: a review'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Bayesian methods in health technology assessments'), ('Full bibliographic reference', 'Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Bayesian methods in health technology assessment: a review. Health Technol Assess. 2000;4(38):1-130.'), ('Language', 'English'), ('PubMed ID', '[11134920](http://www.ncbi.nlm.nih.gov/pubmed/11134920)'), ('Reporting guideline acronym', 'BayesWatch'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Record last updated on', 'September 25, 2013')]"
7187,Basic Statistical Reporting for Articles Published in Biomedical Journals: The ?Statistical Analyses and Methods in the Published Literature? or The SAMPL Guidelines, , ,Statistical methods and analyses, ,"analyses, analysis, SAMPL, SAMPL guideline, SAMPL guidelines, statistic, statistical, statistical analyses, statistical analysis, statistical method, statistical methods, statistical methods and analyses, statistical result, statistical results, statistics", ,"Lang TA, Altman DG. Basic statistical reporting for articles published in biomedical journals: the ""Statistical Analyses and Methods in the Published Literature"" or the SAMPL Guidelines. Int J Nurs Stud. 2015;52(1):5-9.

","Lang TA, Altman DG.","http://dev.equator-network.org/index.aspx?o=6190

Lang TA, Altman DG. Basic Statistical Reporting for Articles Published in Biomedical Journals: The ?Statistical Analyses and Methods in the Published Literature? or The SAMPL Guidelines in: Smart P, Maisonneuve H, Polderman A (eds). Science Editors' Handbook, European Association of Science Editors, 2013.",2013, , , , ,English, ,25441757,http://www.ncbi.nlm.nih.gov/pubmed/25441757,Download the SAMPL Guidelines (PDF), , , , ,SAMPL,Basic statistical reporting for articles published in biomedical journals, ,"These guidelines will also appear in ?Guidelines for reporting health research: A user?s manual,"" which will be released in early September 2013.", , ,"The SAMPL guidelines were also published in 2013 in: Smart P, Maisonneuve H, Polderman A (eds). Science Editors' Handbook, European Association of Science Editors, 2013.", , ,yes,2013-07-09 15:23:40,2022-01-13 14:01:33,sampl,"[('title', 'Basic Statistical Reporting for Articles Published in Biomedical Journals: The “Statistical Analyses and Methods in the Published Literature” or The SAMPL Guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Basic statistical reporting for articles published in biomedical journals'), ('Full bibliographic reference', 'Lang TA, Altman DG. Basic statistical reporting for articles published in biomedical journals: the ""Statistical Analyses and Methods in the Published Literature"" or the SAMPL Guidelines. Int J Nurs Stud. 2015;52(1):5-9.\n\n \n\n'), ('Language', 'English'), ('PubMed ID', '[25441757](http://www.ncbi.nlm.nih.gov/pubmed/25441757)'), ('Relevant URLs\n\n(full-text if available)', 'Download the [SAMPL Guidelines (PDF)](/wp-content/uploads/2013/07/SAMPL-Guidelines-6-27-13.pdf)'), ('Reporting guideline acronym', 'SAMPL'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Other', ""The SAMPL guidelines were also published in 2013 in: Smart P, Maisonneuve H, Polderman A (eds). Science Editors' Handbook, European Association of Science Editors, 2013.""), ('Additional information', 'These guidelines will also appear in “Guidelines for reporting health research: A user’s manual,"" which will be released in early September 2013.'), ('Record last updated on', 'January 13, 2022')]"
7179,Establishing a knowledge trail from molecular experiments to clinical trials,"Animal pre-clinical research, Clinical trials, Experimental studies, Other", ,Data, ,"animal, animal model, animal models, animals, antibody development, antibody therapies, antibody therapy, antibody therapy experiment data, antibody therapy experiments, biological model, biological models, cellular model, cellular models, checklist, clinical model, clinical models, clinical trial, clinical trials, data, data documentation, data recording, data sharing, dataset, datasets, early phase clinical trial, early phase clinical trials, experimental data, GIATE, Guidelines for information about therapy experiments, molecular model, molecular models, molecular target, molecular targets, therapeutic agent, therapeutic agents, therapy experiments", ,"Yong MY, Gonz\xe1lez-Beltr\xe1n A, Begent R. Establishing a knowledge trail from molecular experiments to clinical trials. N Biotechnol. 2011;28(5):464-480.","Yong MY, Gonz\xe1lez-Beltr\xe1n A, Begent R.",New Biotechnology [N Biotechnol.],2011,28,5,464-480, ,English, ,21473938,http://www.ncbi.nlm.nih.gov/pubmed/21473938,Further information about GIATE is available from: http://www.ucl.ac.uk/csm/projects/giate/resources, , , ,http://www.ucl.ac.uk/csm/projects/giate/resources,GIATE,Recording therapy experiment design and results (specifically addressing antibody therapies), , , , , , , ,no,2013-07-09 14:01:44,2022-01-13 14:03:00,establishing-a-knowledge-trail-from-molecular-experiments-to-clinical-trials,"[('title', 'Establishing a knowledge trail from molecular experiments to clinical trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Recording therapy experiment design and results (specifically addressing antibody therapies)'), ('Full bibliographic reference', 'Yong MY, González-Beltrán A, Begent R. Establishing a knowledge trail from molecular experiments to clinical trials. N Biotechnol. 2011;28(5):464-480.'), ('Language', 'English'), ('PubMed ID', '[21473938](http://www.ncbi.nlm.nih.gov/pubmed/21473938)'), ('Relevant URLs\n\n(full-text if available)', 'Further information about GIATE is available from: <http://www.ucl.ac.uk/csm/projects/giate/resources>'), ('Reporting guideline website URL', '<http://www.ucl.ac.uk/csm/projects/giate/resources>'), ('Reporting guideline acronym', 'GIATE'), ('Study design', 'Animal pre-clinical research, Clinical trials, Experimental studies, Other'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'January 13, 2022')]"
7172,"Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers","Clinical trials, Experimental studies, Observational studies", ,Data, ,"anonymisation, anonymised data, anonymised raw data, anonymity, anonymization, anonymized data, anonymized raw data, clinical data, clinical data sharing, clinical research data, clinical trial, clinical trials, data, data preparation, data publication, data sharing, dataset, datasets, de-identification, de-identifying dataset, de-identifying datasets, deidentification, deidentifying dataset, deidentifying datasets, experimental studies, experimental study, observational, observational studies, observational study, privacy, prospective data publication, publishing data, quantitative, quantitative research, randomised, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, raw clinical data, raw data, RCT, RCTs, retrospective data publication, sharing data, trial, trials, unprocessed data", ,"Hrynaszkiewicz I, Norton ML, Vickers AJ, Altman DG. Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers.

BMJ. 2010;340:c181. PMID: 20110312
Trials. 2010;11:9 PMID: 20113465","Hrynaszkiewicz I, Norton ML, Vickers AJ, Altman DG.", ,2010, , , , ,English, , , , , , , , , ,De-identifying datasets to ensure patient privacy when sharing clinical research data, , , , , , , ,no,2013-07-09 13:16:19,2022-01-13 14:04:34,preparing-raw-clinical-data-for-publication-guidance-for-journal-editors-authors-and-peer-reviewers,"[('title', 'Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'De-identifying datasets to ensure patient privacy when sharing clinical research data'), ('Full bibliographic reference', 'Hrynaszkiewicz I, Norton ML, Vickers AJ, Altman DG. Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers.\n\n \n\n BMJ. 2010;340:c181. PMID: [20110312](http://www.ncbi.nlm.nih.gov/pubmed/20110312)\n\n Trials. 2010;11:9 PMID: [20113465](http://www.ncbi.nlm.nih.gov/pubmed/20113465)'), ('Language', 'English'), ('Study design', 'Clinical trials, Experimental studies, Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'January 13, 2022')]"
7141,Best practices in the reporting of participatory action research: Embracing both the forest and the trees, ,Psychology,Whole report, ,"CBPR, community, community based participatory research, counseling, counseling psychologist, counseling psychologists, counseling psychology, counselling, counselling psychologist, counselling psychologists, counselling psychology, PAR, PAR project, PAR projects, PAR studies, PAR study, participatory action research, participatory action research project, participatory action research projects, participatory action research studies, participatory action research study, psychology", ,"Smith L, Rosenzweig L, Schmidt M. Best practices in the reporting of participatory action research: Embracing both the forest and the trees. The Counselling Psychologist. 2010;38(8):1115-1138.","Smith L, Rosenzweig L, Schmidt M.",The Counselling Psychologist.,2010,38,8,1115-1138, ,English, , , , , , , , , ,Participatory action research, , , , , , , ,no,2013-07-08 14:53:22,2013-09-25 10:50:07,best-practices-in-the-reporting-of-participatory-action-research-embracing-both-the-forest-and-the-trees,"[('title', 'Best practices in the reporting of participatory action research: Embracing both the forest and the trees'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Participatory action research'), ('Full bibliographic reference', 'Smith L, Rosenzweig L, Schmidt M. Best practices in the reporting of participatory action research: Embracing both the forest and the trees. The Counselling Psychologist. 2010;38(8):1115-1138.'), ('Language', 'English'), ('Clinical area', 'Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 25, 2013')]"
7134,A comprehensive checklist for reporting the use of OSCEs, ,Medical education,Whole report, ,"checklist, Dental Objective Structured Clinical Examination, DOSCE, education, educational, G-OSCE, GOSPE, Group Objective Structured Practical Examination, medical education, Objective Structured Clinical Assessment, Objective Structured Clinical Examination, Objective Structured Practical Examination, Objective Structured Video Exam, OSCA, OSCE, OSCE exam, OSCE exams, OSCE studies, OSCE study, OSCEs, OSPE, OSVE, Team Objective Structured Clinical Examination, TOSCE", ,"Patricio M, Juliao M, Fareleira F, Young M, Norman G, Vaz CA. A comprehensive checklist for reporting the use of OSCEs. Med Teach. 2009;31(2):112-124.","Patricio M, Juliao M, Fareleira F, Young M, Norman G, Vaz CA.",Medical Teacher [Med Teach.],2009,31,2,112-124, ,English, ,19330670,http://www.ncbi.nlm.nih.gov/pubmed/19330670, , , , , , ,Reporting of OSCE studies in medical education, , , , , , , ,no,2013-07-08 14:04:04,2013-09-25 10:52:49,a-comprehensive-checklist-for-reporting-the-use-of-osces,"[('title', 'A comprehensive checklist for reporting the use of OSCEs'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of OSCE studies in medical education'), ('Full bibliographic reference', 'Patricio M, Juliao M, Fareleira F, Young M, Norman G, Vaz CA. A comprehensive checklist for reporting the use of OSCEs. Med Teach. 2009;31(2):112-124.'), ('Language', 'English'), ('PubMed ID', '[19330670](http://www.ncbi.nlm.nih.gov/pubmed/19330670)'), ('Clinical area', 'Medical education'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 25, 2013')]"
7128,Quality of standardised patient research reports in the medical education literature: review and recommendations, ,Medical education,"Outcomes (variables), Procedure/Method", ,"education, educational, medical education, simulated patient, simulated patient encounter, simulated patient encounters, simulated patient method, simulated patient methods, simulated patient research, simulated patients, SP encounter, SP encounters, SP method, SP methodology, SP methods, SP research, SPs, standardised patient, standardised patient encounter, standardised patient encounters, standardised patient method, standardised patient methods, standardised patient research, standardised patients, standardized patient, standardized patient encounter, standardized patient encounters, standardized patient method, standardized patient methods, standardized patient research, standardized patients", ,"Howley L, Szauter K, Perkowski L, Clifton M, McNaughton N. Quality of standardised patient research reports in the medical education literature: review and recommendations. Med Educ. 2008;42(4):350-358.","Howley L, Szauter K, Perkowski L, Clifton M, McNaughton N.",Medical Education [Med Educ.],2008,42,4,350-358, ,English, ,18298448, http://www.ncbi.nlm.nih.gov/pubmed/18298448, , , , , , ,Reporting the use of standardised patients (SPs) in research, , , , , , , ,no,2013-07-08 13:14:22,2013-09-25 10:56:38,quality-of-standardised-patient-research-reports-in-the-medical-education-literature-review-and-recommendations,"[('title', 'Quality of standardised patient research reports in the medical education literature: review and recommendations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the use of standardised patients (SPs) in research'), ('Full bibliographic reference', 'Howley L, Szauter K, Perkowski L, Clifton M, McNaughton N. Quality of standardised patient research reports in the medical education literature: review and recommendations. Med Educ. 2008;42(4):350-358.'), ('Language', 'English'), ('PubMed ID', '[18298448]( http://www.ncbi.nlm.nih.gov/pubmed/18298448)'), ('Clinical area', 'Medical education'), ('Applies to the whole report or to individual sections of the report?', 'Outcomes (variables), Procedure/Method'), ('Record last updated on', 'September 25, 2013')]"
7121,Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data, , ,Whole report, ,"administration, administrative data, administrative data algorithms, administrative data research, checklist, data, health administration, health administrative data, health administrative database, health administrative databases, health service, health state, health states, identification accuracy studies, identification accuracy study, patient, validation, validation cohort, validation studies, validation study", ,"Benchimol EI, Manuel DG, To T, Griffiths AM, Rabeneck L, Guttmann A. Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data. J Clin Epidemiol. 2011;64(8):821-829.","Benchimol EI, Manuel DG, To T, Griffiths AM, Rabeneck L, Guttmann A.",Journal of Clinical Epidemiology [J Clin Epidemiol.],2011,64,8,821-829, ,English, ,21194889,http://www.ncbi.nlm.nih.gov/pubmed/21194889, , , , , , ,Studies validating administrative data identification algorithms, , , , , , , ,no,2013-07-05 14:44:42,2015-01-27 15:51:30,development-and-use-of-reporting-guidelines-for-assessing-the-quality-of-validation-studies-of-health-administrative-data,"[('title', 'Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Studies validating administrative data identification algorithms'), ('Full bibliographic reference', 'Benchimol EI, Manuel DG, To T, Griffiths AM, Rabeneck L, Guttmann A. Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data. J Clin Epidemiol. 2011;64(8):821-829.'), ('Language', 'English'), ('PubMed ID', '[21194889](http://www.ncbi.nlm.nih.gov/pubmed/21194889)'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 27, 2015')]"
7117,Perspective: Guidelines for reporting team-based learning activities in the medical and health sciences education literature, ,Medical education,Whole report, ,"curricula, curriculum, education, educational, learning, learning teams, medical education, medical school, small group, small groups, TBL, TBL curriculum, TBL element, TBL elements, TBL implementation, TBL implementations, TBL intervention, TBL interventions, TBL studies, TBL study, teaching, team based, team based learning, team learning", ,"Haidet P, Levine RE, Parmelee DX, Crow S, Kennedy F, Kelly PA, Perkowski L, Michaelsen L, Richards BF. Perspective: Guidelines for reporting team-based learning activities in the medical and health sciences education literature. Acad Med. 2012;87(3):292-299.","Haidet P, Levine RE, Parmelee DX, Crow S, Kennedy F, Kelly PA, Perkowski L, Michaelsen L, Richards BF.",Academic Medicine [Acad Med.],2012,87,3,292-299, ,English, ,22373620,http://www.ncbi.nlm.nih.gov/pubmed/22373620, , , , , , ,Team-based learning activities in the medical and health sciences education literature, , , , , , , ,no,2013-07-05 13:58:36,2015-01-27 16:02:35,perspective-guidelines-for-reporting-team-based-learning-activities-in-the-medical-and-health-sciences-education-literature,"[('title', 'Perspective: Guidelines for reporting team-based learning activities in the medical and health sciences education literature'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Team-based learning activities in the medical and health sciences education literature'), ('Full bibliographic reference', 'Haidet P, Levine RE, Parmelee DX, Crow S, Kennedy F, Kelly PA, Perkowski L, Michaelsen L, Richards BF. Perspective: Guidelines for reporting team-based learning activities in the medical and health sciences education literature. Acad Med. 2012;87(3):292-299.'), ('Language', 'English'), ('PubMed ID', '[22373620](http://www.ncbi.nlm.nih.gov/pubmed/22373620)'), ('Clinical area', 'Medical education'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 27, 2015')]"
7109,Authors' Submission Toolkit: a practical guide to getting your research published, ,Pharmaceutical medicine,Whole report, ,"author toolkit, authors? submission toolkit, checklist, drug industry, industry, industry sponsored, industry sponsored clinical trial, industry sponsored clinical trials, industry sponsored research, industry sponsored studies, industry sponsored study, International Society for Medical Publication Professionals, ISMPP, Medical Publishing Insights and Practices initiative, MPIP, pharmaceutical, pharmaceutical industry, pharmaceutical medicine, toolkit", ,"Chipperfield L, Citrome L, Clark J, David FS, Enck R, Evangelista M, Gonzalez J, Groves T, Magrann J, Mansi B, Miller C, Mooney LA, Murphy A, Shelton J, Walson PD, Weigel A. Authors' Submission Toolkit: a practical guide to getting your research published. Curr Med Res Opin. 2010;26(8):1967-1982.","Chipperfield L, Citrome L, Clark J, David FS, Enck R, Evangelista M, Gonzalez J, Groves T, Magrann J, Mansi B, Miller C, Mooney LA, Murphy A, Shelton J, Walson PD, Weigel A.",Current Medical Research and Opinion [Curr Med Res Opin.],2010,26,8,1967-1982, ,English, ,20569069,http://www.ncbi.nlm.nih.gov/pubmed/20569069, , , , , , ,Best practice in the preparation and submission of manuscripts describing sponsored research, , , , , , , ,no,2013-07-05 13:28:18,2013-09-26 09:12:27,authors-submission-toolkit-a-practical-guide-to-getting-your-research-published,"[('title', 'Authors’ Submission Toolkit: a practical guide to getting your research published'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Best practice in the preparation and submission of manuscripts describing sponsored research'), ('Full bibliographic reference', ""Chipperfield L, Citrome L, Clark J, David FS, Enck R, Evangelista M, Gonzalez J, Groves T, Magrann J, Mansi B, Miller C, Mooney LA, Murphy A, Shelton J, Walson PD, Weigel A. Authors' Submission Toolkit: a practical guide to getting your research published. Curr Med Res Opin. 2010;26(8):1967-1982.""), ('Language', 'English'), ('PubMed ID', '[20569069](http://www.ncbi.nlm.nih.gov/pubmed/20569069)'), ('Clinical area', 'Pharmaceutical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 26, 2013')]"
7100,Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update, , ,"Acknowledgements, Conflict of interest, Ethical issues (consent etc.)", ,"acknowledgement, acknowledgements, checklist, COI, COIs, companies, company, company sponsored, company sponsored medical research, company sponsored research, conflict of interest, conflict of interests, ethical, ethical issues, ethics, good publication practice, good publication practice guidelines, GPP, GPP1, GPP2, GPP2 checklist, GPP2 guidelines, industry, industry sponsored, industry sponsored research, industry sponsored studies, industry sponsored study, International Society for Medical Publication Professionals, ISMPP, medical company, medical industry, publication practice, publication practices, sponsor, sponsors", ,"DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, Baltzer L, Citrome L. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Ann Intern Med. 2022;175(9):1298-1304.","DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, Baltzer L, Citrome L.",Annals of Internal Medicine [Ann Intern Med.],2022, , , , ,English, ,36037471,https://pubmed.ncbi.nlm.nih.gov/36037471/, , ,"GPP 2022 replaces GPP3 [Battisti et al. 2015: PMID: 26259067], GPP2 [Graf et al. 2009; PMID: 19946142] and GPP [Wager et al. 2003; PMID: 12814125].", , , ,Communicating company sponsored medical research, , , , , , , ,no,2013-07-05 11:10:24,2024-09-27 15:33:12,good-publication-practice-for-communicating-company-sponsored-medical-research-gpp2022,"[('title', 'Good Publication Practice (GPP) Guidelines for Company -Sponsored Biomedical Research: 2022 Update'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Communicating company sponsored medical research'), ('Full bibliographic reference', 'DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, Baltzer L, Citrome L. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Ann Intern Med. 2022;175(9):1298-1304.'), ('Language', 'English'), ('PubMed ID', '[36037471](https://pubmed.ncbi.nlm.nih.gov/36037471/)'), ('Applies to the whole report or to individual sections of the report?', 'Acknowledgements, Conflict of interest, Ethical issues (consent etc.)'), ('Previous versions of this guideline / Guideline history', 'GPP 2022 replaces GPP3 [Battisti et al. 2015: PMID: [26259067](http://www.ncbi.nlm.nih.gov/pubmed/26259067)], GPP2 [Graf et al. 2009; PMID: [19946142](http://www.ncbi.nlm.nih.gov/pubmed/19946142)] and GPP [Wager et al. 2003; PMID: [12814125](http://www.ncbi.nlm.nih.gov/pubmed/12814125)].'), ('Record last updated on', 'September 27, 2024')]"
7094,Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization,Clinical practice guidelines, ,Whole report, ,"checklist, clinical guideline, clinical guidelines, clinical practice, clinical practice guideline, clinical practice guidelines, COGS, COGS checklist, COGS statement, Conference on Guideline Standardization, documentation, guideline, guideline documentation, guideline standardisation, guideline standardization, guidelines, implement, implementation, practice, practice guideline, practice guidelines, quality", ,"Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med. 2003;139(6):493-498.","Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM.",Annals of Internal Medicine [Ann Intern Med.],2003,139,6,493-498, ,English, ,13679327,http://www.ncbi.nlm.nih.gov/pubmed/13679327, , , ,Clinical practice guidelines, ,COGS,To support more comprehensive documentation of practice guidelines., , , , , , , ,no,2013-07-05 10:39:18,2016-02-16 15:17:39,standardized-reporting-of-clinical-practice-guidelines-a-proposal-from-the-conference-on-guideline-standardization,"[('title', 'Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'To support more comprehensive documentation of practice guidelines.'), ('Full bibliographic reference', 'Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med. 2003;139(6):493-498.'), ('Language', 'English'), ('PubMed ID', '[13679327](http://www.ncbi.nlm.nih.gov/pubmed/13679327)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', 'Clinical practice guidelines'), ('Reporting guideline acronym', 'COGS'), ('Study design', 'Clinical practice guidelines'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'February 16, 2016')]"
7086,A new structure for quality improvement reports,Quality improvement studies, ,Whole report, ,"quality, quality improvement, quality improvement report, quality improvement reporting, quality improvement reports, quality improvement studies, quality improvement study, quality improvements", ,"Moss F, Thompson R. A new structure for quality improvement reports. Qual Health Care. 1999;8(2):76.","Moss F, Thompson R.",Quality in Health Care [Qual Health Care.],1999,8,2,76, ,English, ,10557680,http://www.ncbi.nlm.nih.gov/pubmed/10557680, , , , , , ,Quality improvement reports, , , , , , , ,no,2013-07-05 10:13:16,2013-09-26 09:36:57,a-new-structure-for-quality-improvement-reports,"[('title', 'A new structure for quality improvement reports'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Quality improvement reports'), ('Full bibliographic reference', 'Moss F, Thompson R. A new structure for quality improvement reports. Qual Health Care. 1999;8(2):76.'), ('Language', 'English'), ('PubMed ID', '[10557680](http://www.ncbi.nlm.nih.gov/pubmed/10557680)'), ('Study design', 'Quality improvement studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 26, 2013')]"
7078,Guidelines for conducting and reporting economic evaluation of fall prevention strategies,Economic evaluations,Rheumatology, , ,"CBA, CEA, checklist, CMA, cost benefit analyses, Cost Benefit Analysis, cost effectiveness, cost effectiveness analyses, cost effectiveness analysis, cost minimisation, cost minimisation analyses, cost minimisation analysis, cost minimization, cost minimization analyses, cost minimization analysis, cost utility, cost utility analyses, Cost Utility Analysis, CUA, economic, economic evaluation, economic evaluations, elderly, fall, fall prevention, fall prevention intervention, fall prevention interventions, fall prevention strategies, fall prevention strategy, falls, older adult, older adults, QALY, QALYS, quality of life, rheumatology, senior, seniors", ,"Davis JC, Robertson MC, Comans T, Scuffham PA. Guidelines for conducting and reporting economic evaluation of fall prevention strategies. Osteoporos Int. 2011;22(9):2449-2459.","Davis JC, Robertson MC, Comans T, Scuffham PA.",Osteoporosis International [Osteoporos Int.],2011,22,9,2449-2459, ,English, ,21104231,http://www.ncbi.nlm.nih.gov/pubmed/21104231, , , , , , ,Economic evaluations of fall prevention interventions, , , , , , , ,no,2013-07-05 09:46:09,2015-01-27 14:52:26,guidelines-for-conducting-and-reporting-economic-evaluation-of-fall-prevention-strategies,"[('title', 'Guidelines for conducting and reporting economic evaluation of fall prevention strategies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Economic evaluations of fall prevention interventions'), ('Full bibliographic reference', 'Davis JC, Robertson MC, Comans T, Scuffham PA. Guidelines for conducting and reporting economic evaluation of fall prevention strategies. Osteoporos Int. 2011;22(9):2449-2459.'), ('Language', 'English'), ('PubMed ID', '[21104231](http://www.ncbi.nlm.nih.gov/pubmed/21104231)'), ('Study design', 'Economic evaluations'), ('Clinical area', 'Rheumatology'), ('Record last updated on', 'January 27, 2015')]"
7069,"Design, execution, interpretation, and reporting of economic evaluation studies in obstetrics",Economic evaluations,Obstetrics and gynaecology,Whole report, ,"CBA, CEA, checklist, CMA, cost analyses, cost analysis, cost benefit analyses, Cost Benefit Analysis, cost effectiveness, cost effectiveness analyses, cost effectiveness analysis, cost minimisation, cost minimisation analyses, cost minimisation analysis, cost minimization, cost minimization analyses, cost minimization analysis, cost utility, cost utility analyses, Cost Utility Analysis, CUA, economic, economic analyses, economic analysis, economic evaluation, economic evaluation studies, economic evaluation study, economic evaluations, obstetric, obstetrics", ,"Vintzileos AM, Beazoglou T. Design, execution, interpretation, and reporting of economic evaluation studies in obstetrics. Am J Obstet Gynecol. 2004;191(4):1070-1076.","Vintzileos AM, Beazoglou T.",American Journal of Obstetrics and Gynecology [Am J Obstet Gynecol.],2004,191,4,1070-1076, ,English, ,15507923,http://www.ncbi.nlm.nih.gov/pubmed/15507923, , , , , , ,Economic evaluation studies in obstetrics, , , , , , , ,no,2013-07-05 08:41:47,2013-09-26 09:39:59,design-execution-interpretation-and-reporting-of-economic-evaluation-studies-in-obstetrics,"[('title', 'Design, execution, interpretation, and reporting of economic evaluation studies in obstetrics'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Economic evaluation studies in obstetrics'), ('Full bibliographic reference', 'Vintzileos AM, Beazoglou T. Design, execution, interpretation, and reporting of economic evaluation studies in obstetrics. Am J Obstet Gynecol. 2004;191(4):1070-1076.'), ('Language', 'English'), ('PubMed ID', '[15507923](http://www.ncbi.nlm.nih.gov/pubmed/15507923)'), ('Study design', 'Economic evaluations'), ('Clinical area', 'Obstetrics and gynaecology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 26, 2013')]"
7064,"Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting",Economic evaluations, , , ,"CEA, cost effectiveness, cost effectiveness analyses, cost effectiveness analysis, decision analytic modeling, decision analytic modelling, decision analytical model, decision analytical modeling, decision analytical modelling, decision analytical models, economic, economic evaluation, economic evaluations, modeling based economic evaluation, modeling based economic evaluations, modelling based economic evaluation, modelling based economic evaluations", ,"Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ. 2011;342:d1766.","Petrou S, Gray A.",British Medical Journal [BMJ.],2011,342, ,d1766, ,English, ,21482590,http://www.ncbi.nlm.nih.gov/pubmed/21482590, , , , , , ,Economic evaluations using decision analytical modelling, , , , , , , ,no,2013-07-05 08:06:43,2013-09-26 09:48:53,economic-evaluation-using-decision-analytical-modelling-design-conduct-analysis-and-reporting,"[('title', 'Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Economic evaluations using decision analytical modelling'), ('Full bibliographic reference', 'Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ. 2011;342:d1766.'), ('Language', 'English'), ('PubMed ID', '[21482590](http://www.ncbi.nlm.nih.gov/pubmed/21482590)'), ('Study design', 'Economic evaluations'), ('Record last updated on', 'September 26, 2013')]"
7059,Reporting format for economic evaluation. Part II: Focus on modelling studies,Economic evaluations,Pharmaceutical medicine,Whole report, ,"decision analytic modeling, decision analytic modelling, decision analytical model, decision analytical modeling, decision analytical modelling, decision analytical models, economic evaluation, economic evaluations, modeling studies, modeling study, modelling studies, modelling study, pharmaceutical medicine, pharmacoeconomics", ,"Nuijten MJ, Pronk MH, Brorens MJ, Hekster YA, Lockefeer JH, de Smet PA, Bonsel G, van der Kuy A. Reporting format for economic evaluation. Part II: Focus on modelling studies. Pharmacoeconomics. 1998;14(3):259-268.","Nuijten MJ, Pronk MH, Brorens MJ, Hekster YA, Lockefeer JH, de Smet PA, Bonsel G, van der Kuy A.",PharmacoEconomics.,1998,14,3,259-268, ,English, ,10186465,http://www.ncbi.nlm.nih.gov/pubmed/10186465, , , , , , ,Economic evaluations based on modelling studies, , , , , , , ,no,2013-07-04 14:45:25,2013-09-26 09:41:32,reporting-format-for-economic-evaluation-part-ii-focus-on-modelling-studies,"[('title', 'Reporting format for economic evaluation. Part II : Focus on modelling studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Economic evaluations based on modelling studies'), ('Full bibliographic reference', 'Nuijten MJ, Pronk MH, Brorens MJ, Hekster YA, Lockefeer JH, de Smet PA, Bonsel G, van der Kuy A. Reporting format for economic evaluation. Part II: Focus on modelling studies. Pharmacoeconomics. 1998;14(3):259-268.'), ('Language', 'English'), ('PubMed ID', '[10186465](http://www.ncbi.nlm.nih.gov/pubmed/10186465)'), ('Study design', 'Economic evaluations'), ('Clinical area', 'Pharmaceutical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 26, 2013')]"
7046,"Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies",Economic evaluations, ,Whole report, ,"C/E, CEA, CEAs, checklist, cost effectiveness, cost effectiveness analyses, cost effectiveness analysis, decision analytic modeling, decision analytic modelling, economic, economic analyses, economic analysis, economic data, economic evaluation, economic evaluations, health technology assessment, HTA, modeling studies, modeling study, modelling studies, modelling study, patient level data, trial based studies, trial based study", ,"Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care. 2005;21(2):165-171.","Drummond M, Manca A, Sculpher M.",International Journal of Technology Assessment in Health Care [Int J Technol Assess Health Care.],2005,21,2,165-171, ,English, ,15921055,http://www.ncbi.nlm.nih.gov/pubmed/15921055, , , , , , ,Economic evaluations, , , , , , , ,no,2013-07-04 12:51:46,2013-09-26 09:51:09,increasing-the-generalizability-of-economic-evaluations-recommendations-for-the-design-analysis-and-reporting-of-studies,"[('title', 'Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Economic evaluations'), ('Full bibliographic reference', 'Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care. 2005;21(2):165-171.'), ('Language', 'English'), ('PubMed ID', '[15921055](http://www.ncbi.nlm.nih.gov/pubmed/15921055)'), ('Study design', 'Economic evaluations'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 26, 2013')]"
7037,Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report,Economic evaluations,Pharmaceutical medicine,Whole report, ,"C/E, CEA, CEAs, clinical trial, clinical trials, cost effectiveness, cost effectiveness analyses, cost effectiveness analysis, economic, economic analyses, economic analysis, economic data, economic evaluation, economic evaluations, International Society for Pharmacoeconomics and Outcomes Research, ISPOR, ISPOR RCT-CEA, pharmaceutical medicine, randomised, randomised clinical trial, randomised clinical trials, randomised clinical trials cost effectiveness analyses, randomised clinical trials cost effectiveness analysis, randomised trial, Randomised trials, randomized, randomized clinical trial, randomized clinical trials, randomized clinical trials cost effectiveness analyses, randomized clinical trials cost effectiveness analysis, randomized trial, randomized trials, RCT, RCTs", ,"Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H, Liljas B, Petitti D, Reed S. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005;8(5):521-533.","Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H, Liljas B, Petitti D, Reed S.",Value in Health [Value Health.],2005,8,5,521-533, ,English, ,16176491,http://www.ncbi.nlm.nih.gov/pubmed/16176491, , , , , , ,Cost-effectiveness analysis alongside clinical trials, , , , , , , ,no,2013-07-04 11:10:29,2013-09-26 09:58:36,good-research-practices-for-cost-effectiveness-analysis-alongside-clinical-trials-the-ispor-rct-cea-task-force-report,"[('title', 'Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR  RCT-CEA Task Force report'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Cost-effectiveness analysis alongside clinical trials'), ('Full bibliographic reference', 'Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H, Liljas B, Petitti D, Reed S. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005;8(5):521-533.'), ('Language', 'English'), ('PubMed ID', '[16176491](http://www.ncbi.nlm.nih.gov/pubmed/16176491)'), ('Study design', 'Economic evaluations'), ('Clinical area', 'Pharmaceutical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 26, 2013')]"
7032,"Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine",Economic evaluations, ,Whole report, ,"C/E, CEA, CEAs, checklist, cost benefit, cost benefit analyses, Cost Benefit Analysis, cost effectiveness, cost effectiveness analyses, cost effectiveness analysis, economic, economic analyses, economic analysis, economic evaluation, economic evaluations, EE, reference case, reference case analyses, reference case analysis, Second Panel on Cost-Effectiveness in Health and Medicine", ,"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316(10):1093-1103.","Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG.",Journal of the American Medical Association [JAMA.],2016,316,10,1093-1103, ,English, ,27623463,https://www.ncbi.nlm.nih.gov/pubmed/27623463, , ,"Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(16):1339-1341. PMID: 8861994", , , ,Reporting of cost-effectiveness analyses., , , , , , , ,yes,2013-07-04 10:41:28,2022-01-13 14:12:09,recommendations-for-reporting-cost-effectiveness-analyses,"[('title', 'Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost -Effectiveness in Health and Medicine'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of cost-effectiveness analyses.'), ('Full bibliographic reference', 'Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316(10):1093-1103.'), ('Language', 'English'), ('PubMed ID', '[27623463](https://www.ncbi.nlm.nih.gov/pubmed/27623463)'), ('Study design', 'Economic evaluations'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Previous versions of this guideline / Guideline history', 'Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(16):1339-1341. PMID: [8861994](http://www.ncbi.nlm.nih.gov/pubmed/8861994)'), ('Record last updated on', 'January 13, 2022')]"
7029,The quality of mixed methods studies in health services research,Mixed methods studies, ,"Data, Procedure/Method, Study characteristics (participants etc.)", ,"GRAMMS, health research, health service research, health services research, mixed method, mixed methods, mixed methods research, mixed methods studies, mixed methods study, mixed research, qualitative, qualitative method, qualitative methods, quantitative, quantitative method, quantitative methods", ,"O'Cathain A, Murphy E, Nicholl J. The quality of mixed methods studies in health services research. J Health Serv Res Policy. 2008;13(2):92-98.","O'Cathain A, Murphy E, Nicholl J.",Journal of Health Services Research and Policy. [J Health Serv Res Policy.],2008,13,2,92-98, ,English, ,18416914,http://www.ncbi.nlm.nih.gov/pubmed/18416914, , , , , ,GRAMMS,Mixed methods studies in health services research, , , , , , , ,no,2013-07-04 10:09:38,2013-09-26 10:03:20,the-quality-of-mixed-methods-studies-in-health-services-research,"[('title', 'The quality of mixed methods studies in health services research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Mixed methods studies in health services research'), ('Full bibliographic reference', ""O'Cathain A, Murphy E, Nicholl J. The quality of mixed methods studies in health services research. J Health Serv Res Policy. 2008;13(2):92-98.""), ('Language', 'English'), ('PubMed ID', '[18416914](http://www.ncbi.nlm.nih.gov/pubmed/18416914)'), ('Reporting guideline acronym', 'GRAMMS'), ('Study design', 'Mixed methods studies'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'September 26, 2013')]"
7025,Qualitative research review guidelines ? RATS,Qualitative research, ,Whole report, ,"qualitative, qualitative method, qualitative methodology, qualitative methods, qualitative research, qualitative research methods, qualitative research review, RATS", ,"Clark JP: How to peer review a qualitative manuscript. In Peer Review in Health Sciences. Second edition. Edited by Godlee F, Jefferson T. London: BMJ Books; 2003:219-235.",Clark JP., ,2003, , ,219-235, ,English, , , , , , , , ,RATS,Qualitative research reviews, , , , , , , ,no,2013-07-04 09:42:19,2021-09-10 15:48:38,qualitative-research-review-guidelines-rats,"[('title', 'Qualitative research review guidelines – RATS'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Qualitative research reviews'), ('Full bibliographic reference', 'Clark JP: *How to peer review a qualitative manuscript*. In *Peer Review in Health Sciences*. Second edition. Edited by Godlee F, Jefferson T. London: BMJ Books; 2003:219-235.'), ('Language', 'English'), ('Reporting guideline acronym', 'RATS'), ('Study design', 'Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 10, 2021')]"
7014,Evolving guidelines for publication of qualitative research studies in psychology and related fields,Qualitative research,Psychology,Whole report, ,"psychology, psychotherapy, qualitative, qualitative method, qualitative methods, qualitative research, qualitative research method, qualitative research methods, qualitative research studies, qualitative research study, qualitative studies, qualitative study", ,"Elliott R, Fischer CT, Rennie DL. Evolving guidelines for publication of qualitative research studies in psychology and related fields. Br J Clin. 1999;38(3):215-229.","Elliott R, Fischer CT, Rennie DL.",British Journal of Clinical Psychology [Br J Clin Psychol.],1999,38,3,215-229, ,English, ,10532145,http://www.ncbi.nlm.nih.gov/pubmed/10532145, , , , , , ,Qualitative research in psychology, , , , , , , ,no,2013-07-03 14:55:49,2013-10-23 14:25:50,evolving-guidelines-for-publication-of-qualitative-research-studies-in-psychology-and-related-fields,"[('title', 'Evolving guidelines for publication of qualitative research studies in psychology and related fields'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Qualitative research in psychology'), ('Full bibliographic reference', 'Elliott R, Fischer CT, Rennie DL. Evolving guidelines for publication of qualitative research studies in psychology and related fields. Br J Clin. 1999;38(3):215-229.'), ('Language', 'English'), ('PubMed ID', '[10532145](http://www.ncbi.nlm.nih.gov/pubmed/10532145)'), ('Study design', 'Qualitative research'), ('Clinical area', 'Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 23, 2013')]"
7011,Revealing the wood and the trees: reporting qualitative research,Qualitative research, ,Whole report, ,"qualitative, qualitative method, qualitative methods, qualitative research, qualitative research method, qualitative research methodologies, qualitative research methods, qualitative research studies, qualitative research study, qualitative studies, qualitative study", ,"Blignault I, Ritchie J. Revealing the wood and the trees: reporting qualitative research. Health Promot J Austr. 2009;20(2):140-145.","Blignault I, Ritchie J.",Health Promotion Journal of Australia [Health Promot J Austr.],2009,20,2,140-145, ,English, ,19642963,http://www.ncbi.nlm.nih.gov/pubmed/19642963, , , , , , ,Presenting qualitative research for publication, , , , , , , ,no,2013-07-03 14:18:38,2013-09-26 10:12:12,revealing-the-wood-and-the-trees-reporting-qualitative-research,"[('title', 'Revealing the wood and the trees: reporting qualitative research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Presenting qualitative research for publication'), ('Full bibliographic reference', 'Blignault I, Ritchie J. Revealing the wood and the trees: reporting qualitative research. Health Promot J Austr. 2009;20(2):140-145.'), ('Language', 'English'), ('PubMed ID', '[19642963](http://www.ncbi.nlm.nih.gov/pubmed/19642963)'), ('Study design', 'Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 26, 2013')]"
7004,"Qualitative research: standards, challenges, and guidelines",Qualitative research, ,Whole report, ,"qualitative, qualitative analyses, qualitative analysis, qualitative approach, qualitative data, qualitative inquiry, qualitative method, qualitative methods, qualitative research, qualitative research method, qualitative research methods, qualitative studies, qualitative study", ,"Malterud K. Qualitative research: standards, challenges, and guidelines. Lancet. 2001;358(9280):483-488.",Malterud K.,Lancet.,2001,358,9280,483-488, ,English, ,11513933,http://www.ncbi.nlm.nih.gov/pubmed/11513933, , , , , , ,Qualitative inquiry in medical research, , , , , , , ,no,2013-07-03 11:11:37,2013-09-26 10:13:24,qualitative-research-standards-challenges-and-guidelines,"[('title', 'Qualitative research: standards, challenges, and guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Qualitative inquiry in medical research'), ('Full bibliographic reference', 'Malterud K. Qualitative research: standards, challenges, and guidelines. Lancet. 2001;358(9280):483-488.'), ('Language', 'English'), ('PubMed ID', '[11513933](http://www.ncbi.nlm.nih.gov/pubmed/11513933)'), ('Study design', 'Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 26, 2013')]"
6982,RAMESES publication standards: meta-narrative reviews,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Whole report, ,"evidence syntheses, evidence synthesis, meta analysis, meta narrative, meta narrative evidence syntheses, meta narrative evidence synthesis, meta narrative review, meta narrative reviews, meta narrative syntheses, meta narrative synthesis, mixed method, mixed methods, narrative, qualitative, RAMESES, review, reviews, systematic, systematic review, systematic reviews", ,"Wong G, Greenhalgh T, Westhorp G, Buckingham J, Pawson R. RAMESES publication standards: meta-narrative reviews.

BMC Med. 2013;11:20. PMID: 23360661
J Adv Nurs. 2013;69(5):987?1004. PMID: 23356699","Wong G, Greenhalgh T, Westhorp G, Buckingham J, Pawson R.", ,2013, , , , ,English, , , ,"A full report of the RAMESES project is available at:

Wong G, Greenhalgh T, Westhorp G, Pawson R. Development of methodological guidance, publication standards and training materials for realist and meta-narrative reviews: the RAMESES (Realist And Meta-narrative Evidence Syntheses ? Evolving Standards) project. Southampton (UK): NIHR Journals Library; 2014 Sep. PMID: 25642521

", , , ,http://www.ramesesproject.org/,RAMESES: meta-narrative reviews,Reporting meta-narrative reviews, , , , , , , ,no,2013-07-01 15:16:31,2022-01-13 14:15:15,rameses-publication-standards-meta-narrative-reviews,"[('title', 'RAMESES publication standards: meta-narrative reviews'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting meta-narrative reviews'), ('Full bibliographic reference', 'Wong G, Greenhalgh T, Westhorp G, Buckingham J, Pawson R. RAMESES publication standards: meta-narrative reviews.\n\n \n\n BMC Med. 2013;11:20. PMID: [23360661](http://www.ncbi.nlm.nih.gov/pubmed/23360661)\n\n J Adv Nurs. 2013;69(5):987–1004. PMID: [23356699](http://www.ncbi.nlm.nih.gov/pubmed/23356699)'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'A full report of the RAMESES project is available at:\n\n \n\n Wong G, Greenhalgh T, Westhorp G, Pawson R. Development of methodological guidance, publication standards and training materials for realist and meta-narrative reviews: the RAMESES (Realist And Meta-narrative Evidence Syntheses – Evolving Standards) project. Southampton (UK): NIHR Journals Library; 2014 Sep. PMID: [25642521](http://www.ncbi.nlm.nih.gov/pubmed/25642521)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.ramesesproject.org/>'), ('Reporting guideline acronym', 'RAMESES: meta-narrative reviews'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 13, 2022')]"
6974,RAMESES publication standards: realist syntheses,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Whole report, ,"evidence syntheses, evidence synthesis, policy, RAMESES, realist, realist evidence syntheses, realist evidence synthesis, realist inquiry, realist philosophy, realist research, realist review, realist reviews, realist syntheses, realist synthesis, realist systematic reviews, review, reviews, systematic, systematic review, systematic reviews", ,"Wong G, Greenhalgh T, Westhorp G, Buckingham J, Pawson R. RAMESES publication standards: realist syntheses.

BMC Med. 2013;11:21. PMID: 23360677
J Adv Nurs. 2013;69(5),1005?1022. PMID: 23356726","Wong G, Greenhalgh T, Westhorp G, Buckingham J, Pawson R.", ,2013, , , , ,English, , , ,"A full report of the RAMESES project is available at:

Wong G, Greenhalgh T, Westhorp G, Pawson R. Development of methodological guidance, publication standards and training materials for realist and meta-narrative reviews: the RAMESES (Realist And Meta-narrative Evidence Syntheses ? Evolving Standards) project. Southampton (UK): NIHR Journals Library; 2014 Sep. PMID: 25642521

", , , ,http://www.ramesesproject.org/,RAMESES: realist syntheses,Reporting realist syntheses, , , , , , , ,no,2013-07-01 11:00:10,2022-01-13 14:17:45,rameses-publication-standards-realist-syntheses,"[('title', 'RAMESES publication standards: realist syntheses'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting realist syntheses'), ('Full bibliographic reference', 'Wong G, Greenhalgh T, Westhorp G, Buckingham J, Pawson R. RAMESES publication standards: realist syntheses.\n\n \n\n BMC Med. 2013;11:21. PMID: [23360677](http://www.ncbi.nlm.nih.gov/pubmed/23360677)\n\n J Adv Nurs. 2013;69(5),1005–1022. PMID: [23356726](http://www.ncbi.nlm.nih.gov/pubmed/23356726)'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'A full report of the RAMESES project is available at:\n\n \n\n Wong G, Greenhalgh T, Westhorp G, Pawson R. Development of methodological guidance, publication standards and training materials for realist and meta-narrative reviews: the RAMESES (Realist And Meta-narrative Evidence Syntheses – Evolving Standards) project. Southampton (UK): NIHR Journals Library; 2014 Sep. PMID: [25642521](http://www.ncbi.nlm.nih.gov/pubmed/25642521)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.ramesesproject.org/>'), ('Reporting guideline acronym', 'RAMESES: realist syntheses'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 13, 2022')]"
6971,Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews,Public health,Whole report, ,"case control, case series, checklist, cohort, cohort design, cross sectional, cross sectional studies, cross sectional study, effectiveness, epidemiology, etiologic, historical control, historical controls, meta analyses, meta analysis, MOOSE, observational, observational studies, observational study, systematic, systematic review, systematic reviews", ,"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-2012.","Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB.",Journal of the American Medical Association [JAMA.],2000,283,15,2008-2012, ,English, ,10789670,http://www.ncbi.nlm.nih.gov/pubmed/10789670, , , , , ,MOOSE,Meta-analysis of observational studies in epidemiology, , , , , , , ,no,2013-07-01 10:29:20,2013-09-26 10:21:30,meta-analysis-of-observational-studies-in-epidemiology-a-proposal-for-reporting-meta-analysis-of-observational-studies-in-epidemiology-moose-group,"[('title', 'Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Meta-analysis of observational studies in epidemiology'), ('Full bibliographic reference', 'Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-2012.'), ('Language', 'English'), ('PubMed ID', '[10789670](http://www.ncbi.nlm.nih.gov/pubmed/10789670)'), ('Reporting guideline acronym', 'MOOSE'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Clinical area', 'Public health'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 26, 2013')]"
6967,"Meta-analysis of individual participant data: rationale, conduct, and reporting",Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,"Data, Procedure/Method, Study characteristics (participants etc.)", ,"data, individual data, individual participant, individual participant data, individual participant data meta analyses, individual participant data meta analysis, meta analyses, meta analysis, participant, participant data, participants, review, reviews, statistical, statistical analysis, statistics, systematic, systematic review, systematic reviews", ,"Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221.","Riley RD, Lambert PC, Abo-Zaid G.",British Medical Journal [BMJ.],2010,340, ,c221, ,English, ,20139215,http://www.ncbi.nlm.nih.gov/pubmed/20139215, , , , , , ,Meta-analysis of individual participant data, , , , , , , ,no,2013-07-01 09:50:55,2013-09-26 10:23:26,meta-analysis-of-individual-participant-data-rationale-conduct-and-reporting,"[('title', 'Meta-analysis of individual participant data: rationale, conduct, and reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Meta-analysis of individual participant data'), ('Full bibliographic reference', 'Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221.'), ('Language', 'English'), ('PubMed ID', '[20139215](http://www.ncbi.nlm.nih.gov/pubmed/20139215)'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method, Study characteristics (participants etc.)'), ('Record last updated on', 'September 26, 2013')]"
6960,PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Whole report, ,"checklist, equities, equity, equity-focused, gender, health equity, health inequality, health inequities, health inequity, inequalities, inequality, inequities, inequity, meta analyses, meta analysis, PRISMA, PRISMA extension, PRISMA-E, PRISMA-E 2012, PRISMA-Equity, PRISMA-Equity 2012, review, reviews, social determinant, social determinants, socioeconomic, systematic, systematic review, systematic reviews", ,"Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10): e1001333.","Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group.",PLoS Medicine [PLoS Med.],2012,9,10,e1001333, ,English, ,23222917,http://www.ncbi.nlm.nih.gov/pubmed/23222917, ,"Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.

The explanation and elaboration paper for this guideline was published simultaneously in 2 journals. You can read the explanation and elaboration paper in either of these journals using the links below.

Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

", ,"Generic
PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

Specialised
PRISMA for Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.

PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246

PRISMA-IPD: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: 25919529

PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634

PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668

PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement &amp; Checklist. J Clin Epidemiol. 2017. PMID: 28720516

PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.\xa0PMID: 29362800

PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033

PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367

PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791

PRISMA-CHM: Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: 32907365

PRISMA-M 2020: Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: 33100229

PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.
Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535

PRISMA-LSR: Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: 39562017

",http://www.prisma-statement.org/Extensions/Equity,PRISMA-Equity 2012 or PRISMA-E 2012,"Systematic reviews with a focus on health equity.



PRISMA-Equity checklist Word / PDF

","The full-text of the PRISMA-Equity 2012 guideline is available in Spanish.

Visit our translations page to find out what other reporting guidelines are available in languages other than English: reporting guideline translations

",Guidance for developing protocols for systematic reviews and meta-analyses is provided in the PRISMA-P Statement. For further details please visit: PRISMA-P Statement, , , , , ,yes,2013-06-28 15:18:00,2025-02-06 11:50:50,prisma-equity,"[('title', 'PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Systematic reviews with a focus on health equity.\n\n \n\n \xa0\n\n \n\n PRISMA-Equity checklist [Word](https://www.prisma-statement.org/s/PRISMA-Equity-Checklist.docx) / [PDF](https://www.prisma-statement.org/s/PRISMA-Equity-Checklist.docx)\n\n \n\n'), ('Full bibliographic reference', ""Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10): e1001333.""), ('Language', 'English'), ('PubMed ID', '[23222917](http://www.ncbi.nlm.nih.gov/pubmed/23222917)'), ('Explanation and elaboration papers', 'Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.\n\n \n\n The explanation and elaboration paper for this guideline was published simultaneously in 2 journals. You can read the explanation and elaboration paper in either of these journals using the links below.\n\n \n\n Int J Equity Health. 2015;14(1):92. PMID: [26450828](http://www.ncbi.nlm.nih.gov/pubmed/26450828)\n\n J Clin Epidemiol. 2015. PMID: [26348799](http://www.ncbi.nlm.nih.gov/pubmed/26348799)\n\n \n\n'), ('Availability in additional languages', 'The full-text of the PRISMA-Equity 2012 guideline is available in [Spanish](http://iris.paho.org/xmlui/handle/123456789/9152).\n\n \n\n Visit our translations page to find out what other reporting guidelines are available in languages other than English: [reporting guideline translations](/library/translations-of-reporting-guidelines/)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n[**PRISMA 2020 Statement**](https://dev.equator-network.org/reporting-guidelines/prisma/): Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.\n\n \n\n PLoS Med. 2021;18(3):e1003583. PMID: [33780438](https://pubmed.ncbi.nlm.nih.gov/33780438/)\n\n BMJ 2021;372:n71. PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)\n\n Int J Surg. 2021:105906. PMID: [33789826](https://pubmed.ncbi.nlm.nih.gov/33789826/)\n\n J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: [33789819](https://pubmed.ncbi.nlm.nih.gov/33789819/)\n\n Syst Rev. 2021;10(1):89. PMID: [33781348](https://pubmed.ncbi.nlm.nih.gov/33781348/)\n\n \n\n**Specialised**\n\n**[PRISMA for Abstracts 2020:](http://dev.equator-network.org/reporting-guidelines/prisma-abstracts/)** The PRISMA 2020 for Abstracts reporting guideline is contained within the main [PRISMA 2020 Statement paper](https://www.equator-network.org/reporting-guidelines/prisma/).\n\n \n\n[**PRISMA-P**](http://dev.equator-network.org/reporting-guidelines/prisma-protocols/): Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: [25554246](http://www.ncbi.nlm.nih.gov/pubmed/25554246)\n\n \n\n**[PRISMA-IPD](http://dev.equator-network.org/reporting-guidelines/prisma-ipd/)**: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: [25919529](http://www.ncbi.nlm.nih.gov/pubmed/25919529)\n\n \n\n**[PRISMA extension for network meta-analyses](http://dev.equator-network.org/reporting-guidelines/prisma-extension-network-meta-analyses/)**: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: [26030634](http://www.ncbi.nlm.nih.gov/pubmed/26030634)\n\n \n\n**[PRISMA-harms](http://dev.equator-network.org/reporting-guidelines/prisma-harms/)**: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: [26830668](http://www.ncbi.nlm.nih.gov/pubmed/26830668)\n\n \n\n[**PRISMA-CI**](http://dev.equator-network.org/reporting-guidelines/prisma-ci-extension-statement-checklist/): Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: [28720516](https://www.ncbi.nlm.nih.gov/pubmed/28720516)\n\n \n\n[**PRISMA-DTA**](http://dev.equator-network.org/reporting-guidelines/prisma-dta/): McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.\xa0PMID: [29362800](https://www.ncbi.nlm.nih.gov/pubmed/29362800)\n\n \n\n[**PRISMA-ScR**](http://dev.equator-network.org/reporting-guidelines/prisma-scr/): Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: [30178033](https://www.ncbi.nlm.nih.gov/pubmed/30178033)\n\n \n\n[**PRISMA-A**](https://dev.equator-network.org/reporting-guidelines/prisma-acupuncture/): Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: [31405367](https://www.ncbi.nlm.nih.gov/pubmed/31405367)\n\n \n\n[**PRISMA-DTA for Abstracts**](https://dev.equator-network.org/reporting-guidelines/prisma-dta-for-abstracts/): Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: [33722791](https://pubmed.ncbi.nlm.nih.gov/33722791/)\n\n \n\n[**PRISMA-CHM**](https://www.equator-network.org/reporting-guidelines/prisma-chinese-herbal-medicines-2020/): Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: [32907365](https://pubmed.ncbi.nlm.nih.gov/32907365/)\n\n \n\n[**PRISMA-M 2020**](https://www.equator-network.org/reporting-guidelines/prisma-extension-for-moxibustion-2020/): Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: [33100229](https://pubmed.ncbi.nlm.nih.gov/33100229/)\n\n \n\n[**PRISMA-S**](https://dev.equator-network.org/reporting-guidelines/prisma-s/): Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.\n\n Syst Rev. 2021;10(1):39. PMID: [33499930](https://pubmed.ncbi.nlm.nih.gov/33499930/)\n\n J Med Libr Assoc. 2021;109(2):174-200. PMID: [34285662](https://pubmed.ncbi.nlm.nih.gov/34285662/)\n\n \n\n[**PRISMA-COSMIN for OMIs**](https://www.equator-network.org/reporting-guidelines/guideline-for-reporting-systematic-reviews-of-outcome-measurement-instruments-omis-prisma-cosmin-for-omis-2024/): Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.\n\n J Clin Epidemiol. 2024:111422. PMID: [38849061](https://pubmed.ncbi.nlm.nih.gov/38849061/)\n\n Qual Life Res. 2024. PMID: [38980635](https://pubmed.ncbi.nlm.nih.gov/38980635/)\n\n Health Qual Life Outcomes. 2024;22(1):48. PMID: [38978063](https://pubmed.ncbi.nlm.nih.gov/38978063/)\n\n J Patient Rep Outcomes. 2024;8(1):64. PMID: [38977535](https://pubmed.ncbi.nlm.nih.gov/38977535/)\n\n \n\n[**PRISMA-LSR**](https://www.equator-network.org/reporting-guidelines/prisma-lsr/): Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: [39562017](https://pubmed.ncbi.nlm.nih.gov/39562017/)\n\n \n\n""), ('Reporting guideline website URL', '<http://www.prisma-statement.org/Extensions/Equity>'), ('Reporting guideline acronym', 'PRISMA-Equity 2012 or PRISMA-E 2012'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Guidance for developing protocols for systematic reviews and meta-analyses is provided in the PRISMA-P Statement. For further details please visit: [PRISMA-P Statement](/reporting-guidelines/prisma-protocols/)'), ('Record last updated on', 'February 6, 2025')]"
6955,PRISMA 2020 for Abstracts: Reporting Systematic Reviews in Journal and Conference Abstracts,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,"Abstract, Conference paper/abstract", ,"abstract, abstracts, conference, conference abstract, conference abstracts, conferences, journal abstract, journal abstracts, meta analyses, meta analysis, PRISMA, PRISMA abstracts, PRISMA extension, PRISMA for abstracts, review, reviews, structured abstract, structured abstracts, structured summaries, structured summary, systematic, systematic review, systematic reviews", ,"The PRISMA 2020 for abstracts reporting guideline and checklist are contained within the main PRISMA 2020 Statement paper.

","Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H, Chalmers I, G\xf8tzsche PC, Lasserson T, Tovey D; PRISMA for Abstracts Group.",PLoS Medicine [PLoS Med.],2013,10,4,e1001419, ,English, , , , , ,"Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H, Chalmers I, G\xf8tzsche PC, Lasserson T, Tovey D; PRISMA for Abstracts Group. PRISMA for Abstracts: Reporting Systematic Reviews in Journal and Conference Abstracts. PLoS Med. 2013;10(4):e1001419. PMID: 23585737

","Generic
PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\xf3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

Specialised
PRISMA-Equity: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10): e1001333. PMID: 23222917

Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.
Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246

PRISMA-IPD: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: 25919529

PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\xe1-L\xf3pez F, G\xf8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634

PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668

PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement &amp; Checklist. J Clin Epidemiol. 2017. PMID: 28720516

PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.\xa0PMID: 29362800

PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\xe7alp \xd6, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033

PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367

PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791

PRISMA-CHM: Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: 32907365

PRISMA-M 2020: Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: 33100229

PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.
Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535

PRISMA-LSR: Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: 39562017

",https://www.prisma-statement.org/abstracts,PRISMA 2020 for Abstracts,"Reporting systematic reviews in journal and conference abstracts.



PRISMA 2020 for abstracts checklist\xa0 PDF/ Word

", ,Guidance for developing protocols for systematic reviews and meta-analyses is provided in the PRISMA-P Statement. For further details please visit: PRISMA-P Statement, , , , , ,yes,2013-06-28 14:15:26,2025-02-06 11:52:22,prisma-abstracts,"[('title', 'PRISMA 2020 for Abstracts: Reporting Systematic Reviews in Journal and Conference Abstracts'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting systematic reviews in journal and conference abstracts.\n\n \n\n \xa0\n\n \n\n PRISMA 2020 for abstracts checklist [PDF](https://www.prisma-statement.org/s/PRISMA_2020_abstract_checklist-tg6j.pdf)/ [Word](https://www.prisma-statement.org/s/PRISMA_2020_abstract_checklist-sac5.docx)\n\n \n\n'), ('Full bibliographic reference', 'The [PRISMA 2020 for abstracts](https://www.prisma-statement.org/abstracts) reporting guideline and checklist are contained within the main [PRISMA 2020 Statement](https://www.prisma-statement.org/prisma-2020) paper.\n\n \n\n'), ('Language', 'English'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', ""**Generic**\n\n**[PRISMA 2020 Statement](http://dev.equator-network.org/reporting-guidelines/prisma/):** Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.\n\n \n\n PLoS Med. 2021;18(3):e1003583. PMID: [33780438](https://pubmed.ncbi.nlm.nih.gov/33780438/)\n\n BMJ 2021;372:n71. PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)\n\n Int J Surg. 2021:105906. PMID: [33789826](https://pubmed.ncbi.nlm.nih.gov/33789826/)\n\n J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: [33789819](https://pubmed.ncbi.nlm.nih.gov/33789819/)\n\n Syst Rev. 2021;10(1):89. PMID: [33781348](https://pubmed.ncbi.nlm.nih.gov/33781348/)\n\n \n\n**Specialised**\n\n**[PRISMA-Equity](http://dev.equator-network.org/reporting-guidelines/prisma-equity/):** Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10): e1001333. PMID: [23222917](http://www.ncbi.nlm.nih.gov/pubmed/23222917)\n\n \n\n Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.\n\n Int J Equity Health. 2015;14(1):92. PMID: [26450828](http://www.ncbi.nlm.nih.gov/pubmed/26450828)\n\n J Clin Epidemiol. 2015. PMID: [26348799](http://www.ncbi.nlm.nih.gov/pubmed/26348799)\n\n \n\n[**PRISMA-P**](http://dev.equator-network.org/reporting-guidelines/prisma-protocols/): Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: [25554246](http://www.ncbi.nlm.nih.gov/pubmed/25554246)\n\n \n\n**[PRISMA-IPD](http://dev.equator-network.org/reporting-guidelines/prisma-ipd/)**: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: [25919529](http://www.ncbi.nlm.nih.gov/pubmed/25919529)\n\n \n\n**[PRISMA extension for network meta-analyses](http://dev.equator-network.org/reporting-guidelines/prisma-extension-network-meta-analyses/)**: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: [26030634](http://www.ncbi.nlm.nih.gov/pubmed/26030634)\n\n \n\n**[PRISMA-harms](http://dev.equator-network.org/reporting-guidelines/prisma-harms/)**: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: [26830668](http://www.ncbi.nlm.nih.gov/pubmed/26830668)\n\n \n\n[**PRISMA-CI**](http://dev.equator-network.org/reporting-guidelines/prisma-ci-extension-statement-checklist/): Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: [28720516](https://www.ncbi.nlm.nih.gov/pubmed/28720516)\n\n \n\n[**PRISMA-DTA**](http://dev.equator-network.org/reporting-guidelines/prisma-dta/): McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396.\xa0PMID: [29362800](https://www.ncbi.nlm.nih.gov/pubmed/29362800)\n\n \n\n[**PRISMA-ScR**](http://dev.equator-network.org/reporting-guidelines/prisma-scr/): Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: [30178033](https://www.ncbi.nlm.nih.gov/pubmed/30178033)\n\n \n\n[**PRISMA-A**](https://dev.equator-network.org/reporting-guidelines/prisma-acupuncture/): Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: [31405367](https://www.ncbi.nlm.nih.gov/pubmed/31405367)\n\n \n\n[**PRISMA-DTA for Abstracts**](https://dev.equator-network.org/reporting-guidelines/prisma-dta-for-abstracts/): Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: [33722791](https://pubmed.ncbi.nlm.nih.gov/33722791/)\n\n \n\n[**PRISMA-CHM**](https://www.equator-network.org/reporting-guidelines/prisma-chinese-herbal-medicines-2020/): Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: [32907365](https://pubmed.ncbi.nlm.nih.gov/32907365/)\n\n \n\n[**PRISMA-M 2020**](https://www.equator-network.org/reporting-guidelines/prisma-extension-for-moxibustion-2020/): Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: [33100229](https://pubmed.ncbi.nlm.nih.gov/33100229/)\n\n \n\n[**PRISMA-S**](https://dev.equator-network.org/reporting-guidelines/prisma-s/): Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.\n\n Syst Rev. 2021;10(1):39. PMID: [33499930](https://pubmed.ncbi.nlm.nih.gov/33499930/)\n\n J Med Libr Assoc. 2021;109(2):174-200. PMID: [34285662](https://pubmed.ncbi.nlm.nih.gov/34285662/)\n\n \n\n[**PRISMA-COSMIN for OMIs**](https://www.equator-network.org/reporting-guidelines/guideline-for-reporting-systematic-reviews-of-outcome-measurement-instruments-omis-prisma-cosmin-for-omis-2024/): Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.\n\n J Clin Epidemiol. 2024:111422. PMID: [38849061](https://pubmed.ncbi.nlm.nih.gov/38849061/)\n\n Qual Life Res. 2024. PMID: [38980635](https://pubmed.ncbi.nlm.nih.gov/38980635/)\n\n Health Qual Life Outcomes. 2024;22(1):48. PMID: [38978063](https://pubmed.ncbi.nlm.nih.gov/38978063/)\n\n J Patient Rep Outcomes. 2024;8(1):64. PMID: [38977535](https://pubmed.ncbi.nlm.nih.gov/38977535/)\n\n \n\n[**PRISMA-LSR**](https://www.equator-network.org/reporting-guidelines/prisma-lsr/): Akl EA, Khabsa J, Iannizzi C, Piechotta V, Kahale LA, Barker JM, McKenzie JE, Page MJ, Skoetz N; PRISMA-LSR Group. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183. PMID: [39562017](https://pubmed.ncbi.nlm.nih.gov/39562017/)\n\n \n\n""), ('Reporting guideline website URL', '<https://www.prisma-statement.org/abstracts>'), ('Reporting guideline acronym', 'PRISMA 2020 for Abstracts'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Abstract, Conference paper/abstract'), ('Previous versions of this guideline / Guideline history', 'Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H, Chalmers I, Gøtzsche PC, Lasserson T, Tovey D; PRISMA for Abstracts Group. PRISMA for Abstracts: Reporting Systematic Reviews in Journal and Conference Abstracts. PLoS Med. 2013;10(4):e1001419. PMID: [23585737](http://www.ncbi.nlm.nih.gov/pubmed/23585737)\n\n \n\n'), ('Additional information', 'Guidance for developing protocols for systematic reviews and meta-analyses is provided in the PRISMA-P Statement. For further details please visit: [PRISMA-P Statement](/reporting-guidelines/prisma-protocols/)'), ('Record last updated on', 'February 6, 2025')]"
6945,The STARD statement for reporting diagnostic accuracy studies: application to the history and physical examination,Diagnostic and prognostic studies, ,Whole report, ,"accuracy, clinical evaluation, clinical examination, diagnosis, diagnostic, diagnostic accuracy, diagnostic accuracy research, diagnostic accuracy studies, diagnostic accuracy study, diagnostic accuracy test, diagnostic accuracy testing, diagnostic test, diagnostic test accuracy, diagnostic testing, examination, examiner, history, patient, patient history, patients, physical examination, STARD, STARD initiative, STARD statement", ,"Simel DL, Rennie D, Bossuyt PM. The STARD statement for reporting diagnostic accuracy studies: application to the history and physical examination. J Gen Intern Med. 2008;23(6):768-74.","Simel DL, Rennie D, Bossuyt PM.",Journal of General Internal Medicine [J Gen Intern Med.],2008,23,6,768-774, ,English, ,18347878,http://www.ncbi.nlm.nih.gov/pubmed/18347878, , , , , , ,Diagnostic accuracy studies of the history and physical examination, , , , , , , ,no,2013-06-28 10:38:03,2022-01-13 14:26:56,the-stard-statement-for-reporting-diagnostic-accuracy-studies-application-to-the-history-and-physical-examination,"[('title', 'The STARD statement for reporting diagnostic accuracy studies: application to the history and physical examination'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Diagnostic accuracy studies of the history and physical examination'), ('Full bibliographic reference', 'Simel DL, Rennie D, Bossuyt PM. The STARD statement for reporting diagnostic accuracy studies: application to the history and physical examination. J Gen Intern Med. 2008;23(6):768-74.'), ('Language', 'English'), ('PubMed ID', '[18347878](http://www.ncbi.nlm.nih.gov/pubmed/18347878)'), ('Study design', 'Diagnostic and prognostic studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 13, 2022')]"
6939,"Capturing momentary, self-report data: a proposal for reporting guidelines","Observational studies, Qualitative research",Behavioural medicine,"Data, Intervention (exposure), Procedure/Method", ,"behavioral medicine, behavioural medicine, data, Ecological Momentary Assessment, EMA, momentary, momentary research, momentary research protocol, momentary research protocols, momentary research studies, momentary research study, observational studies, observational study, self-report, self-report data", ,"Stone AA, Shiffman S. Capturing momentary, self-report data: a proposal for reporting guidelines. Ann Behav Med. 2002; 24(3):236-243.","Stone AA, Shiffman S.",Annals of Behavioral Medicine [Ann Behav Med.],2002,24,3,236-243, ,English, ,12173681,http://www.ncbi.nlm.nih.gov/pubmed/12173681, , , , , , ,Reporting Ecological Momentary Assessment (EMA) studies., , , , , , , ,no,2013-06-27 15:28:04,2019-12-05 11:04:07,capturing-momentary-self-report-data-a-proposal-for-reporting-guidelines,"[('title', 'Capturing momentary, self-report data: a proposal for reporting guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting Ecological Momentary Assessment (EMA) studies.'), ('Full bibliographic reference', 'Stone AA, Shiffman S. Capturing momentary, self-report data: a proposal for reporting guidelines. Ann Behav Med. 2002; 24(3):236-243.'), ('Language', 'English'), ('PubMed ID', '[12173681](http://www.ncbi.nlm.nih.gov/pubmed/12173681)'), ('Study design', 'Observational studies, Qualitative research'), ('Clinical area', 'Behavioural medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data, Intervention (exposure), Procedure/Method'), ('Record last updated on', 'December 5, 2019')]"
6934,Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES),Observational studies, ,"Data, Intervention (exposure), Procedure/Method, Results, Study characteristics (participants etc.)", ,"checklist, CHERRIES, e-survey, e-surveys, internet e-survey, internet e-surveys, internet survey, observational studies, observational study, online survey, online surveys, questionnaire, questionnaires, survey, survey research, surveys, web survey, web surveys, web-based survey, web-based surveys", ,Eysenbach G. Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J Med Internet Res. 2004; 6(3):e34.,Eysenbach G.,Journal of Medical Internet Research [J Med Internet Res.],2004,6,3,e34, ,English, ,15471760,http://www.ncbi.nlm.nih.gov/pubmed/15471760, , , , , ,CHERRIES,Reporting Web-based surveys, ,A correction has been made to table 1 in this paper: link to correction, , , , , ,no,2013-06-27 15:06:56,2013-09-26 13:04:50,improving-the-quality-of-web-surveys-the-checklist-for-reporting-results-of-internet-e-surveys-cherries,"[('title', 'Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys  (CHERRIES)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting Web-based surveys'), ('Full bibliographic reference', 'Eysenbach G. Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J Med Internet Res. 2004; 6(3):e34.'), ('Language', 'English'), ('PubMed ID', '[15471760](http://www.ncbi.nlm.nih.gov/pubmed/15471760)'), ('Reporting guideline acronym', 'CHERRIES'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Data, Intervention (exposure), Procedure/Method, Results, Study characteristics (participants etc.)'), ('Additional information', 'A correction has been made to table 1 in this paper: [link to correction](http://www.jmir.org/2012/1/e8/)'), ('Record last updated on', 'September 26, 2013')]"
6930,Guidelines for field surveys of the quality of medicines: a proposal,Observational studies,Pharmaceutical medicine,Whole report, ,"checklist, counterfeit medicine, counterfeit medicines, degraded medicine, degraded medicines, drug, drug quality, drugs, field survey, field surveys, life-threatening disease, life-threatening diseases, medicine, medicine quality, Medicine Quality Assessment Reporting Guideline, Medicine Quality Assessment Reporting Guidelines, medicine quality survey, medicine quality surveys, medicines, MEDQUARG, observational studies, observational study, pharmaceutical medicine, poor quality medicine, poor quality medicines, substandard medicine, substandard medicines, survey, survey research, surveys", ,"Newton PN, Lee SJ, Goodman C, Fernandez FM, Yeung S, Phanouvong S, Kaur H, Amin AA, Whitty CJ, Kokwaro GO, Lindeg\xe5rdh N, Lukulay P, White LJ, Day NP, Green MD, White NJ. Guidelines for field surveys of the quality of medicines: a proposal. PLoS Med. 2009;6(3):e52.","Newton PN, Lee SJ, Goodman C, Fernandez FM, Yeung S, Phanouvong S, Kaur H, Amin AA, Whitty CJ, Kokwaro GO, Lindeg\xe5rdh N, Lukulay P, White LJ, Day NP, Green MD, White NJ.",PLoS Medicine [PLoS Med.],2009,6,3,e52, ,English, ,19320538, http://www.ncbi.nlm.nih.gov/pubmed/19320538, , , , , ,MEDQUARG,Field surveys of the quality of medicines, , , , , , , ,no,2013-06-27 14:36:33,2013-09-26 13:16:44,guidelines-for-field-surveys-of-the-quality-of-medicines-a-proposal,"[('title', 'Guidelines for field surveys of the quality of medicines: a proposal'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Field surveys of the quality of medicines'), ('Full bibliographic reference', 'Newton PN, Lee SJ, Goodman C, Fernandez FM, Yeung S, Phanouvong S, Kaur H, Amin AA, Whitty CJ, Kokwaro GO, Lindegårdh N, Lukulay P, White LJ, Day NP, Green MD, White NJ. Guidelines for field surveys of the quality of medicines: a proposal. PLoS Med. 2009;6(3):e52.'), ('Language', 'English'), ('PubMed ID', '[19320538]( http://www.ncbi.nlm.nih.gov/pubmed/19320538)'), ('Reporting guideline acronym', 'MEDQUARG'), ('Study design', 'Observational studies'), ('Clinical area', 'Pharmaceutical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 26, 2013')]"
6926,A guide for the design and conduct of self-administered surveys of clinicians,Observational studies, ,Whole report, ,"electronic survey, electronic surveys, observational studies, observational study, postal survey, postal surveys, questionnaire, questionnaires, self administered, survey, survey research, surveys", ,"Burns KE, Duffett M, Kho ME, Meade MO, Adhikari NK, Sinuff T, Cook DJ; ACCADEMY Group. A guide for the design and conduct of self-administered surveys of clinicians. CMAJ. 2008;179(3):245-252.","Burns KE, Duffett M, Kho ME, Meade MO, Adhikari NK, Sinuff T, Cook DJ; ACCADEMY Group.",Canadian Medical Association Journal [CMAJ.],2008,179,3,245-252, ,English, ,18663204,http://www.ncbi.nlm.nih.gov/pubmed/18663204, , , , , , ,The design and conduct of self-administered surveys of clinicians, , , , , , , ,no,2013-06-27 14:10:39,2013-09-26 13:19:04,a-guide-for-the-design-and-conduct-of-self-administered-surveys-of-clinicians,"[('title', 'A guide for the design and conduct of self-administered surveys of clinicians'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'The design and conduct of self-administered surveys of clinicians'), ('Full bibliographic reference', 'Burns KE, Duffett M, Kho ME, Meade MO, Adhikari NK, Sinuff T, Cook DJ; ACCADEMY Group. A guide for the design and conduct of self-administered surveys of clinicians. CMAJ. 2008;179(3):245-252.'), ('Language', 'English'), ('PubMed ID', '[18663204](http://www.ncbi.nlm.nih.gov/pubmed/18663204)'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'September 26, 2013')]"
6924,Good practice in the conduct and reporting of survey research,Observational studies, ,Whole report, ,"interview, interviews, observational studies, observational study, questionnaire, questionnaires, survey, survey research, surveys", ,"Kelley K, Clark B, Brown V, Sitzia J. Good practice in the conduct and reporting of survey research. Int J Qual Health Care. 2003;15(3):261-266.","Kelley K, Clark B, Brown V, Sitzia J.",International Journal for Quality in Health Care. [Int J Qual Health Care.],2003,15,3,261-266, ,English, ,12803354,http://www.ncbi.nlm.nih.gov/pubmed/12803354, , , , , , ,Conduct and reporting of survey research, , , , , , , ,no,2013-06-27 14:04:40,2013-10-23 14:34:24,good-practice-in-the-conduct-and-reporting-of-survey-research,"[('title', 'Good practice in the conduct and reporting of survey research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Conduct and reporting of survey research'), ('Full bibliographic reference', 'Kelley K, Clark B, Brown V, Sitzia J. Good practice in the conduct and reporting of survey research. Int J Qual Health Care. 2003;15(3):261-266.'), ('Language', 'English'), ('PubMed ID', '[12803354](http://www.ncbi.nlm.nih.gov/pubmed/12803354)'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 23, 2013')]"
6919,Reporting genetic results in research studies: summary and recommendations of an NHLBI working group,Observational studies,"Cardiovascular medicine, Genetics, Haematology, Respiratory medicine",Results, ,"blood, cardiology, cardiovascular, gene, genetic, genetic research, genetic results, genetic test, genetic testing, genetic tests, genetic variant, genetic variants, genetics, haematology, heart, hematology, lung, National Heart Lung and Blood Institute, NHLBI, observational, observational studies, observational study, respiratory, sleep", ,"Bookman E, Langehorne A, Eckfeldt J, Glass K, Jarvik G, Klag M, Koski G, Motulsky A, Wilfond B, Manolio T, Fabsitz R, Luepker R, V. Reporting genetic results in research studies: summary and recommendations of an NHLBI working group. Am J Med Genet A. 2006;140(10):1033-1040.","Bookman E, Langehorne A, Eckfeldt J, Glass K, Jarvik G, Klag M, Koski G, Motulsky A, Wilfond B, Manolio T, Fabsitz R, Luepker R, V.",American Journal of Medical Genetics Part A [Am J Med Genet A.],2006,140,10,1033-1040, ,English, ,16575896,http://www.ncbi.nlm.nih.gov/pubmed/16575896, , , , , , ,"Reporting individual results from genetic tests to participants of heart, lung, blood, and sleep research studies", , , , , , , ,no,2013-06-27 13:09:40,2013-10-23 14:35:07,reporting-genetic-results-in-research-studies-summary-and-recommendations-of-an-nhlbi-working-group,"[('title', 'Reporting genetic results in research studies: summary and recommendations of an NHLBI working group'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting individual results from genetic tests to participants of heart, lung, blood, and sleep research studies'), ('Full bibliographic reference', 'Bookman E, Langehorne A, Eckfeldt J, Glass K, Jarvik G, Klag M, Koski G, Motulsky A, Wilfond B, Manolio T, Fabsitz R, Luepker R, V. Reporting genetic results in research studies: summary and recommendations of an NHLBI working group. Am J Med Genet A. 2006;140(10):1033-1040.'), ('Language', 'English'), ('PubMed ID', '[16575896](http://www.ncbi.nlm.nih.gov/pubmed/16575896)'), ('Study design', 'Observational studies'), ('Clinical area', 'Cardiovascular medicine, Genetics, Haematology, Respiratory medicine'), ('Applies to the whole report or to individual sections of the report?', 'Results'), ('Record last updated on', 'October 23, 2013')]"
6915,Recommendations for biomarker identification and qualification in clinical proteomics,Observational studies, ,Biospecimen/bioresource information, ,"biological marker, biological markers, biomarker, biomarker identification, biomarkers, biospecimen, biospecimens, clinical proteomic studies, clinical proteomic study, clinical proteomics, observational studies, observational study, proteome, proteomic, proteomic biomarker, proteomic biomarker data, proteomic biomarker studies, proteomic biomarker study, proteomic biomarkers, proteomics", ,"Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, Bennett SE, Bischoff R, Bongcam-Rudloff E, Capasso G, Coon JJ, D'Haese P, Dominiczak AF, Dakna M, Dihazi H, Ehrich JH, Fernandez-Llama P, Fliser D, Frokiaer J, Garin J, Girolami M, Hancock WS, Haubitz M, Hochstrasser D, Holman RR, Ioannidis JP, Jankowski J, Julian BA, Klein JB, Kolch W, Luider T, Massy Z, Mattes WB, Molina F, Monsarrat B, Novak J, Peter K, Rossing P, S\xe1nchez-Carbayo M, Schanstra JP, Semmes OJ, Spasovski G, Theodorescu D, Thongboonkerd V, Vanholder R, Veenstra TD, Weissinger E, Yamamoto T, Vlahou A. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med. 2010;2(46):46ps42.","Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, Bennett SE, Bischoff R, Bongcam-Rudloff E, Capasso G, Coon JJ, D'Haese P, Dominiczak AF, Dakna M, Dihazi H, Ehrich JH, Fernandez-Llama P, Fliser D, Frokiaer J, Garin J, Girolami M, Hancock WS, Haubitz M, Hochstrasser D, Holman RR, Ioannidis JP, Jankowski J, Julian BA, Klein JB, Kolch W, Luider T, Massy Z, Mattes WB, Molina F, Monsarrat B, Novak J, Peter K, Rossing P, S\xe1nchez-Carbayo M, Schanstra JP, Semmes OJ, Spasovski G, Theodorescu D, Thongboonkerd V, Vanholder R, Veenstra TD, Weissinger E, Yamamoto T, Vlahou A.",Science Translational Medicine [Sci Transl Med.],2010,2,46,46ps42, ,English, ,20739680,http://www.ncbi.nlm.nih.gov/pubmed/20739680, , , , , , ,Scientific reporting of proteomic biomarker data, , , , , , , ,no,2013-06-27 10:04:28,2013-10-23 14:36:54,recommendations-for-biomarker-identification-and-qualification-in-clinical-proteomics,"[('title', 'Recommendations for biomarker identification and qualification in clinical proteomics'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Scientific reporting of proteomic biomarker data'), ('Full bibliographic reference', ""Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, Bennett SE, Bischoff R, Bongcam-Rudloff E, Capasso G, Coon JJ, D'Haese P, Dominiczak AF, Dakna M, Dihazi H, Ehrich JH, Fernandez-Llama P, Fliser D, Frokiaer J, Garin J, Girolami M, Hancock WS, Haubitz M, Hochstrasser D, Holman RR, Ioannidis JP, Jankowski J, Julian BA, Klein JB, Kolch W, Luider T, Massy Z, Mattes WB, Molina F, Monsarrat B, Novak J, Peter K, Rossing P, Sánchez-Carbayo M, Schanstra JP, Semmes OJ, Spasovski G, Theodorescu D, Thongboonkerd V, Vanholder R, Veenstra TD, Weissinger E, Yamamoto T, Vlahou A. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med. 2010;2(46):46ps42.""), ('Language', 'English'), ('PubMed ID', '[20739680](http://www.ncbi.nlm.nih.gov/pubmed/20739680)'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Biospecimen/bioresource information'), ('Record last updated on', 'October 23, 2013')]"
6910,Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines,Observational studies,Oncology,Data, ,"cancer, carcinoma, covariate, covariate data, covariates, data, missing data, neoplasm, neoplasms, observational studies, observational study, oncology, prognosis, prognostic, prognostic factor, prognostic factors, prognostic model, prognostic models, prognostic studies, prognostic study", ,"Burton A, Altman DG. Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer. 2004;91(1):4-8.","Burton A, Altman DG.",British Journal of Cancer [Br J Cancer.],2004,91,1,4-8, ,English, ,15188004,http://www.ncbi.nlm.nih.gov/pubmed/15188004, , , , , , ,Presenting prognostic studies with missing covariate data, , , , , , , ,no,2013-06-27 09:17:43,2013-10-23 14:37:37,missing-covariate-data-within-cancer-prognostic-studies-a-review-of-current-reporting-and-proposed-guidelines,"[('title', 'Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Presenting prognostic studies with missing covariate data'), ('Full bibliographic reference', 'Burton A, Altman DG. Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer. 2004;91(1):4-8.'), ('Language', 'English'), ('PubMed ID', '[15188004](http://www.ncbi.nlm.nih.gov/pubmed/15188004)'), ('Study design', 'Observational studies'), ('Clinical area', 'Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'October 23, 2013')]"
6835,Gene expression-based prognostic signatures in lung cancer: ready for clinical use?,Observational studies,"Genetics, Oncology, Respiratory medicine",Whole report, ,"cancer, carcinoma, expression-based, gene, gene expression, gene expression signature, gene expression signatures, genes, genetic, genetics, lung, lung cancer, lung neoplasm, lung neoplasms, neoplasm, neoplasms, non-small cell lung cancer, NSCLC, observational studies, observational study, oncology, prognosis, prognostic, prognostic factor, prognostic factor studies, prognostic factor study, prognostic factors, prognostic model, prognostic models, prognostic signature, prognostic signatures, respiratory medicine", ,"Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst. 2010;102(7):464-474.","Subramanian J, Simon R.",Journal of the National Cancer Institute [J Natl Cancer Inst.],2010,102,7,464-474, ,English, ,20233996,http://www.ncbi.nlm.nih.gov/pubmed/20233996, , , , , , ,The design and analysis of prognostic factor studies in non-small cell lung cancer (NSCLC), , , , , , , ,no,2013-06-26 13:56:02,2013-10-23 14:38:46,gene-expression-based-prognostic-signatures-in-lung-cancer-ready-for-clinical-use,"[('title', 'Gene expression-based prognostic signatures in lung cancer: ready for clinical use?'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'The design and analysis of prognostic factor studies in non-small cell lung cancer (NSCLC)'), ('Full bibliographic reference', 'Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst. 2010;102(7):464-474.'), ('Language', 'English'), ('PubMed ID', '[20233996](http://www.ncbi.nlm.nih.gov/pubmed/20233996)'), ('Study design', 'Observational studies'), ('Clinical area', 'Genetics, Oncology, Respiratory medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 23, 2013')]"
6816,Anecdotes as evidence,Observational studies,Pharmaceutical medicine,Harms/adverse effects/safety data, ,"ADR, ADRs, adverse, adverse drug interaction, adverse drug interactions, adverse drug reaction, adverse drug reactions, adverse effect, adverse effects, adverse event, adverse events, adverse interaction, adverse interactions, adverse reaction, adverse reactions, anecdotal, anecdotal report, anecdotal reports, anecdote, anecdotes, case report, case reports, drug interaction, drug interactions, drug reaction, drug reactions, harm, harms, observational studies, observational study, pharmaceutical medicine, safety, safety data, unintended effect, unintended effects", ,Aronson JK. Anecdotes as evidence. BMJ. 2003;326(7403):1346.,Aronson JK.,British Medical Journal [BMJ],2003,326,7403,1346, ,English, ,12816800,http://www.ncbi.nlm.nih.gov/pubmed/12816800, , , , , , , , , , , , , , ,no,2013-06-21 07:49:53,2016-08-16 13:49:49,anecdotes-as-evidence,"[('title', 'Anecdotes as evidence'), ('Full bibliographic reference', 'Aronson JK. Anecdotes as evidence. BMJ. 2003;326(7403):1346.'), ('Language', 'English'), ('PubMed ID', '[12816800](http://www.ncbi.nlm.nih.gov/pubmed/12816800)'), ('Study design', 'Observational studies'), ('Clinical area', 'Pharmaceutical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data'), ('Record last updated on', 'August 16, 2016')]"
6809,Recommendations for reporting adverse drug reactions and adverse events of traditional Chinese medicine,Observational studies,"Complementary and alternative medicine, Pharmaceutical medicine",Harms/adverse effects/safety data, ,"ADR, ADRs, adverse, adverse drug reaction, adverse drug reactions, adverse effect, adverse effects, adverse event, adverse event report, adverse event reports, adverse events, adverse reaction, adverse reactions, AE, AEs, alternative medicine, CAM, checklist, Chinese medicine, Chinese medicines, complimentary and alternative medicine, drug, drug safety, drugs, harm, harms, integrative medicine, observational studies, observational study, pharmaceutical medicine, pharmacovigilance, safety, safety data, TCM, traditional Chinese medicine, traditional Chinese medicines, unintended effect, unintended effects", ,"Wu T, Shang H, Bian Z, Zhang J, Li T, Li Y, Zhang B. Recommendations for reporting adverse drug reactions and adverse events of traditional Chinese medicine. J Evid Based Med. 2010;3(1):11-17.","Wu T, Shang H, Bian Z, Zhang J, Li T, Li Y, Zhang B.",Journal of Evidence-Based Medicine [J Evid Based Med.],2010,3,1,11-17, ,English, ,21349035,http://www.ncbi.nlm.nih.gov/pubmed/21349035, , , , , , ,Adverse drug reactions and adverse events from traditional Chinese medicine, , , , , , , ,no,2013-06-20 11:02:45,2016-08-16 13:47:12,recommendations-for-reporting-adverse-drug-reactions-and-adverse-events-of-traditional-chinese-medicine,"[('title', 'Recommendations for reporting adverse drug reactions and adverse events of traditional Chinese medicine'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Adverse drug reactions and adverse events from traditional Chinese medicine'), ('Full bibliographic reference', 'Wu T, Shang H, Bian Z, Zhang J, Li T, Li Y, Zhang B. Recommendations for reporting adverse drug reactions and adverse events of traditional Chinese medicine. J Evid Based Med. 2010;3(1):11-17.'), ('Language', 'English'), ('PubMed ID', '[21349035](http://www.ncbi.nlm.nih.gov/pubmed/21349035)'), ('Study design', 'Observational studies'), ('Clinical area', 'Complementary and alternative medicine, Pharmaceutical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data'), ('Record last updated on', 'August 16, 2016')]"
6799,Guidelines for submitting adverse event reports for publication,Observational studies,Pharmaceutical medicine,Harms/adverse effects/safety data, ,"ADR, adverse, adverse drug reaction, adverse drug reactions, adverse effect, adverse effects, adverse event, adverse event report, adverse event reports, adverse events, adverse reaction, adverse reactions, AE, biologicals, drug, drugs, harm, harms, International Society for Pharmacoepidemiology, International Society of Pharmacovigilance, ISoP, ISPE, medical product, medical products, medicine, medicines, observational studies, observational study, pharmaceutical, pharmaceutical medicine, pharmacoepidemiology, pharmacological, pharmacology, pharmacovigilance, pharmacy, safety, safety data, unintended effect, unintended effects, vaccine, vaccines", ,"Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards RI, Fernandez AM, Freedman SB, Goldsmith DI, Huang K, Jones JK, McLeay R, Moore N, Stather RH, Trenque T, Troutman WG, van Puijenbroek E, Williams F, Wise RP; International Society of Pharmacoepidemiology; International Society of Pharmacovigilance.\xa0Guidelines for submitting adverse event reports for publication.

Drug Saf. 2007;30(5):367-373. PMID: 17472416
Pharmacoepidemiol Drug Saf. 2007;16(5):581-587. PMID: 17471601","Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards RI, Fernandez AM, Freedman SB, Goldsmith DI, Huang K, Jones JK, McLeay R, Moore N, Stather RH, Trenque T, Troutman WG, van Puijenbroek E, Williams F, Wise RP; International Society of Pharmacoepidemiology; International Society of Pharmacovigilance.", ,2007, , , , ,English, , , , , , , , , ,Adverse event reports, , , , , , , ,no,2013-06-20 09:48:34,2016-08-16 13:44:28,guidelines-for-submitting-adverse-event-reports-for-publication,"[('title', 'Guidelines for submitting adverse event reports for publication'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Adverse event reports'), ('Full bibliographic reference', 'Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards RI, Fernandez AM, Freedman SB, Goldsmith DI, Huang K, Jones JK, McLeay R, Moore N, Stather RH, Trenque T, Troutman WG, van Puijenbroek E, Williams F, Wise RP; International Society of Pharmacoepidemiology; International Society of Pharmacovigilance.\xa0Guidelines for submitting adverse event reports for publication.\n\n \n\n Drug Saf. 2007;30(5):367-373. PMID: [17472416](http://www.ncbi.nlm.nih.gov/pubmed/17472416)\n\n Pharmacoepidemiol Drug Saf. 2007;16(5):581-587. PMID: [17471601](http://www.ncbi.nlm.nih.gov/pubmed/17471601)'), ('Language', 'English'), ('Study design', 'Observational studies'), ('Clinical area', 'Pharmaceutical medicine'), ('Applies to the whole report or to individual sections of the report?', 'Harms/adverse effects/safety data'), ('Record last updated on', 'August 16, 2016')]"
6793,Guidelines for clinical case reports in behavioral clinical psychology,Observational studies,"Behavioural medicine, Psychology",Whole report, ,"applied behavior analysis, applied behaviour analysis, behavior analyses, behavior analysis, behavior therapies, behavior therapy, behavioral medicine, behaviour analyses, behaviour analysis, behaviour therapies, behaviour therapy, behavioural medicine, case report, case reports, case studies, case study, CCR, CCRs, clinical case report, clinical case reporting, clinical case reports, cognitive-behavioral therapies, cognitive-behavioral therapy, cognitive-behavioural therapies, cognitive-behavioural therapy, observational studies, observational study, psychology, single-case experiment", ,Virues-Ortega J and Moreno-Rodriguez R. Guidelines for clinical case reports in behavioral clinical psychology. Int J Clin Health Psychology. 2008;8(3): 765-777.,Virues-Ortega J and Moreno-Rodriguez R.,International Journal of Clinical and Health Psychology [Int J Clin Health Psychology],2008,8,3,765-777, ,English, , , , , , , , , ,Clinical case reports in behavioural clinical psychology, , , , , , , ,no,2013-06-20 09:13:02,2013-10-23 14:42:13,guidelines-for-clinical-case-reports-in-behavioral-clinical-psychology,"[('title', 'Guidelines for clinical case reports in behavioral clinical psychology'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Clinical case reports in behavioural clinical psychology'), ('Full bibliographic reference', 'Virues-Ortega J and Moreno-Rodriguez R. Guidelines for clinical case reports in behavioral clinical psychology. Int J Clin Health Psychology. 2008;8(3): 765-777.'), ('Language', 'English'), ('Study design', 'Observational studies'), ('Clinical area', 'Behavioural medicine, Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 23, 2013')]"
6790,Instructions to authors for case reporting are limited: a review of a core journal list,Observational studies, ,Whole report, ,"case report, case reporting, case reports, checklist, observational studies, observational study", ,"Sorinola O, Olufowobi O, Coomarasamy A, Khan KS. Instructions to authors for case reporting are limited: a review of a core journal list. BMC Med Educ. 2004;4:4.","Sorinola O, Olufowobi O, Coomarasamy A, Khan KS.",BMC Medical Education [BMC Med Educ.],2004,4,4, , ,English, ,15043755,http://www.ncbi.nlm.nih.gov/pubmed/15043755, , , , , , , , , , , , , , ,no,2013-06-19 09:27:57,2013-10-23 14:42:49,instructions-to-authors-for-case-reporting-are-limited-a-review-of-a-core-journal-list,"[('title', 'Instructions to authors for case reporting are limited: a review of a core journal list'), ('Full bibliographic reference', 'Sorinola O, Olufowobi O, Coomarasamy A, Khan KS. Instructions to authors for case reporting are limited: a review of a core journal list. BMC Med Educ. 2004;4:4.'), ('Language', 'English'), ('PubMed ID', '[15043755](http://www.ncbi.nlm.nih.gov/pubmed/15043755)'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 23, 2013')]"
6786,Reporting participation in case-control studies,Observational studies, ,"Outcomes (variables), Study characteristics (participants etc.)", ,"case control, case control studies, case control study, case group, case groups, case-control, control group, control groups, enrollment, enrolment, observational studies, observational study, outcome, outcomes, participant, participants, participation, sampling, sampling frame", ,"Olson SH, Voigt LF, Begg CB, Weiss NS. Reporting participation in case-control studies. Epidemiology. 2002;13(2):123-126.","Olson SH, Voigt LF, Begg CB, Weiss NS.",Epidemiology.,2002,13,2,123-126, ,English, ,11880750, http://www.ncbi.nlm.nih.gov/pubmed/11880750, , , , , , ,Participation in case-control studies, , , , , , , ,no,2013-06-18 15:18:40,2013-10-23 14:43:44,reporting-participation-in-case-control-studies,"[('title', 'Reporting participation in case-control studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Participation in case-control studies'), ('Full bibliographic reference', 'Olson SH, Voigt LF, Begg CB, Weiss NS. Reporting participation in case-control studies. Epidemiology. 2002;13(2):123-126.'), ('Language', 'English'), ('PubMed ID', '[11880750]( http://www.ncbi.nlm.nih.gov/pubmed/11880750)'), ('Study design', 'Observational studies'), ('Applies to the whole report or to individual sections of the report?', 'Outcomes (variables), Study characteristics (participants etc.)'), ('Record last updated on', 'October 23, 2013')]"
6783,Conducting and reporting case series and audits--author guidelines for acupuncture in medicine,Observational studies,Complementary and alternative medicine,Whole report, ,"acupuncture, audit, audits, case series, complementary and alternative medicine, complementary medicine, observational, observational studies, observational study, pre- post-intervention, prospective, prospective case series, retrospective", ,White A. Conducting and reporting case series and audits--author guidelines for acupuncture in medicine. Acupunct Med. 2005;23(4):181-187.,White A.,Acupuncture in Medicine [Acupunct Med.],2005,23,4,181-187, ,English, ,16430126, http://www.ncbi.nlm.nih.gov/pubmed/16430126, , , , , , ,Case series and audits of acupuncture, , , , , , , ,no,2013-06-18 14:50:05,2013-10-23 14:44:23,conducting-and-reporting-case-series-and-audits-author-guidelines-for-acupuncture-in-medicine,"[('title', 'Conducting and reporting case series and audits–author guidelines for acupuncture in medicine'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Case series and audits of acupuncture'), ('Full bibliographic reference', 'White A. Conducting and reporting case series and audits--author guidelines for acupuncture in medicine. Acupunct Med. 2005;23(4):181-187.'), ('Language', 'English'), ('PubMed ID', '[16430126]( http://www.ncbi.nlm.nih.gov/pubmed/16430126)'), ('Study design', 'Observational studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 23, 2013')]"
6780,Appropriate use and reporting of uncontrolled case series in the medical literature,Observational studies,Ophthalmology,Whole report, ,"case series, observational, observational case series, observational studies, observational study, ophthalmic, ophthalmology, uncontrolled case series", ,Kempen JH. Appropriate use and reporting of uncontrolled case series in the medical literature. Am J Ophthalmol. 2011;151(1):7-10.e1.,Kempen JH.,American Journal of Ophthalmology [Am J Ophthalmol.],2011,151,1,7-10.e1., ,English, ,21163373,http://www.ncbi.nlm.nih.gov/pubmed/21163373, , , , , , ,Reporting of uncontrolled case series, , , , , , , ,no,2013-06-18 14:28:05,2013-10-01 09:30:37,appropriate-use-and-reporting-of-uncontrolled-case-series-in-the-medical-literature,"[('title', 'Appropriate use and reporting of uncontrolled case series in the medical literature'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of uncontrolled case series'), ('Full bibliographic reference', 'Kempen JH. Appropriate use and reporting of uncontrolled case series in the medical literature. Am J Ophthalmol. 2011;151(1):7-10.e1.'), ('Language', 'English'), ('PubMed ID', '[21163373](http://www.ncbi.nlm.nih.gov/pubmed/21163373)'), ('Study design', 'Observational studies'), ('Clinical area', 'Ophthalmology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 1, 2013')]"
6710,Improving the reporting of clinical case series,Observational studies,Ophthalmology,Data, ,"case series, clinical case series, data, data analyses, data analysis, data presentation, observational, observational studies, observational study, ophthalmic, ophthalmology, statistical analyses, statistical analysis, statistics", ,Jabs DA. Improving the Reporting of Clinical Case Series. Am J Ophthalmol. 2005;139(5):900-905.,Jabs DA.,American Journal of Ophthalmology [Am J Ophthalmol.],2005,139,5,900-905, ,English, ,15860297,http://www.ncbi.nlm.nih.gov/pubmed/15860297, , , , , , ,Reporting case series data, , , , , , , ,no,2013-06-18 11:05:44,2013-10-23 14:45:57,improving-the-reporting-of-clinical-case-series,"[('title', 'Improving the reporting of clinical case series'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting case series data'), ('Full bibliographic reference', 'Jabs DA. Improving the Reporting of Clinical Case Series. Am J Ophthalmol. 2005;139(5):900-905.'), ('Language', 'English'), ('PubMed ID', '[15860297](http://www.ncbi.nlm.nih.gov/pubmed/15860297)'), ('Study design', 'Observational studies'), ('Clinical area', 'Ophthalmology'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'October 23, 2013')]"
6708,"EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology",Observational studies,Rheumatology,Whole report, ,"biological therapies, biological therapy, biologics, biologics register, biologics registers, biologics registries, biologics registry, drug register, drug registers, drug safety, EULAR, European League against Rheumatism, observational, observational studies, observational study, register, registers, registries, registry, rheumatic, rheumatic dieseases, rheumatic disease, rheumatology, rheumatology biologics register, rheumatology biologics registers, safety data, safety data of biologics registers", ,"Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, Listing J, Nicola PJ, Tarp U, Zink A, Askling J. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis. 2010;69(9):1596-1602.","Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, Listing J, Nicola PJ, Tarp U, Zink A, Askling J.",Annals of the Rheumatic Diseases [Ann Rheum Dis.],2010,69,9,1596-1602, ,English, ,20525843, http://www.ncbi.nlm.nih.gov/pubmed/20525843, , , , , , ,"The establishment, analysis and presentation of data from biologics registers in rheumatology", , , , , , , ,no,2013-06-18 10:32:39,2015-01-27 14:36:25,eular-points-to-consider-when-establishing-analysing-and-reporting-safety-data-of-biologics-registers-in-rheumatology,"[('title', 'EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'The establishment, analysis and presentation of data from biologics registers in rheumatology'), ('Full bibliographic reference', 'Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, Listing J, Nicola PJ, Tarp U, Zink A, Askling J. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis. 2010;69(9):1596-1602.'), ('Language', 'English'), ('PubMed ID', '[20525843]( http://www.ncbi.nlm.nih.gov/pubmed/20525843)'), ('Study design', 'Observational studies'), ('Clinical area', 'Rheumatology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 27, 2015')]"
6706,Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology,Observational studies,Rheumatology,Whole report, ,"longitudinal, longitudinal observational studies, longitudinal observational study, LOS, observational, observational studies, observational study, rheumatic, rheumatology", ,"Wolfe F, Lassere M, van der HD, Stucki G, Suarez-Almazor M, Pincus T, Eberhardt K, Kvien TK, Symmons D, Silman A, van Riel P, Tugwell P, Boers M. Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. J Rheumatol. 1999;26(2):484-489.","Wolfe F, Lassere M, van der HD, Stucki G, Suarez-Almazor M, Pincus T, Eberhardt K, Kvien TK, Symmons D, Silman A, van Riel P, Tugwell P, Boers M.",Journal of Rheumatology [J Rheumatol.],1999,26,2,484-489, ,English, ,9972992,http://www.ncbi.nlm.nih.gov/pubmed/9972992, , , , , , ,Longitudinal observational studies in rheumatology, , , , , , , ,no,2013-06-18 10:01:12,2013-10-23 14:47:39,preliminary-core-set-of-domains-and-reporting-requirements-for-longitudinal-observational-studies-in-rheumatology,"[('title', 'Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Longitudinal observational studies in rheumatology'), ('Full bibliographic reference', 'Wolfe F, Lassere M, van der HD, Stucki G, Suarez-Almazor M, Pincus T, Eberhardt K, Kvien TK, Symmons D, Silman A, van Riel P, Tugwell P, Boers M. Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. J Rheumatol. 1999;26(2):484-489.'), ('Language', 'English'), ('PubMed ID', '[9972992](http://www.ncbi.nlm.nih.gov/pubmed/9972992)'), ('Study design', 'Observational studies'), ('Clinical area', 'Rheumatology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 23, 2013')]"
6702,A community standard for immunogenomic data reporting and analysis: proposal for a STrengthening the REporting of Immunogenomic Studies statement,Observational studies,Genetics,"Data, Narrative sections (discussion etc.), Procedure/Method", ,"community data, disease association, genetic, genetics, genome-wide, genomic, genomics, GWAS, histocompatibility, immunogenetic, immunogenetics, immunogenomic, immunogenomic data, immunogenomic studies, immunogenomic study, immunogenomics, immunogenomics data, immunogenomics studies, immunogenomics study, observational, observational studies, observational study", ,"Hollenbach JA, Mack SJ, Gourraud PA, Single RM, Maiers M, Middleton D, Thomson G, Marsh SG, Varney MD; for the Immunogenomics Data Analysis Working Group. A community standard for immunogenomic data reporting and analysis: proposal for a STrengthening the REporting of Immunogenomic Studies statement. Tissue Antigens. 2011;78(5):333-344.","Hollenbach JA, Mack SJ, Gourraud PA, Single RM, Maiers M, Middleton D, Thomson G, Marsh SG, Varney MD; for the Immunogenomics Data Analysis Working Group.",Tissue Antigens.,2011,78,5,333-344, ,English, ,21988720,http://www.ncbi.nlm.nih.gov/pubmed/21988720, , , , , ,STREIS,Immunogenomic data reporting and analysis, , , , , , , ,no,2013-06-18 08:57:18,2013-10-23 14:48:31,a-community-standard-for-immunogenomic-data-reporting-and-analysis-proposal-for-a-strengthening-the-reporting-of-immunogenomic-studies-statement,"[('title', 'A community standard for immunogenomic data reporting and analysis: proposal for a STrengthening the REporting of Immunogenomic Studies statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Immunogenomic data reporting and analysis'), ('Full bibliographic reference', 'Hollenbach JA, Mack SJ, Gourraud PA, Single RM, Maiers M, Middleton D, Thomson G, Marsh SG, Varney MD; for the Immunogenomics Data Analysis Working Group. A community standard for immunogenomic data reporting and analysis: proposal for a STrengthening the REporting of Immunogenomic Studies statement. Tissue Antigens. 2011;78(5):333-344.'), ('Language', 'English'), ('PubMed ID', '[21988720](http://www.ncbi.nlm.nih.gov/pubmed/21988720)'), ('Reporting guideline acronym', 'STREIS'), ('Study design', 'Observational studies'), ('Clinical area', 'Genetics'), ('Applies to the whole report or to individual sections of the report?', 'Data, Narrative sections (discussion etc.), Procedure/Method'), ('Record last updated on', 'October 23, 2013')]"
6696,STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement,Observational studies,Public health,Whole report, ,"biological marker, biological markers, biomarker, biomarkers, checklist, epidemiologic, epidemiological, epidemiology, molecular, molecular epidemiology, observational, observational studies, observational study, public health, STROBE, STROBE extension, STROBE-ME", ,"Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement.

This guideline was published simultaneously in 7 journals. You can read the guideline in any of these journals using the links below.

Eur J Clin Invest. 2012;42(1):1-16. PMID: 22023344
PLoS Med. 2011 Oct;8(10):e1001117. PMID: 22039356
Eur J Epidemiol. 2011;26(10):797-810. PMID: 22037796
J Clin Epidemiol. 2011;64(12):1350-63. PMID: 22030070
Prev Med. 2011;53(6):377-87. PMID: 22029945
Mutagenesis. 2012;27(1):17-29. PMID: 22027842
J Epidemiol Community Health. 2012;66(9):844-54. PMID: 22025194

","Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P.",European Journal of clinical Investigation [Eur J Clin Invest.],2012,42,1,1-16, ,English, ,22023344,http://www.ncbi.nlm.nih.gov/pubmed/22023344, , , ,"Generic
STROBE Statement: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Ann Intern Med. 2007;147(8):573-577. PMID: 17938396
PLoS Med. 2007;4(10):e296. PMID: 17941714
BMJ. 2007;335(7624):806-808. PMID: 17947786
Prev Med. 2007;45(4):247-251. PMID: 17950122
Epidemiology. 2007;18(6):800-804. PMID: 18049194
Lancet. 2007;370(9596):1453-1457. PMID: 18064739

Specialised
STREGA: Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.

PLoS Med. 2009;6(2):e22. PMID: 19192942
Hum Genet. 2009; 125(2):131-151. PMID: 19184668
Eur J Epidemiol. 2009;24(1):37-55. PMID: 19189221
Ann Intern Med. 2009;150(3):206-215. PMID: 19189911
J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: 19217256
Genet Epidemiol. 2009;33(7):581-598. PMID: 19278015
Eur J Clin Invest. 2009;39(4):247-266. PMID: 19297801

STROBE checklist for conference abstracts: First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. Link to full text pdf

STROME-ID: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: 24631223

Longitudinal observational drug studies in rheumatology: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: 24058015

Case-cohort studies: Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: 24972092

STROBE-RDS: White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: 26112433

RECORD: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: 26440803

STROBE-AMS: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schr\xf6der W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: 26895985

STROBE-nut: Lachat C, Hawwash D, Ock\xe9 MC, Berg C, Forsum E, H\xf6rnell A, Larsson C, Sonestedt E, Wirf\xe4lt E, \xc5kesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology?Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: 27270749

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

ROSES-I: Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: 27417916

STROBE-NI: Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: 27633910

Propensity score analysis: Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: 28376195

RECORD-PE: Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.

STROBE-SIIS: International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, H\xe4gglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).

Br J Sports Med. 2020;54(7):372-389. PMID: 32071062
Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: 32118084

STROBE-MR: Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: 34698778

", ,STROBE-ME,Reporting of observational studies in molecular epidemiology, , , , , , , ,yes,2013-06-17 14:45:52,2021-11-25 15:35:15,strobe-me,"[('title', 'STrengthening the Reporting of OBservational studies in Epidemiology – Molecular Epidemiology (STROBE-ME) : An extension of the STROBE statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of observational studies in molecular epidemiology'), ('Full bibliographic reference', 'Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement.\n\n \n\n This guideline was published simultaneously in 7 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n Eur J Clin Invest. 2012;42(1):1-16. PMID: [22023344](https://pubmed.ncbi.nlm.nih.gov/22023344/)\n\n PLoS Med. 2011 Oct;8(10):e1001117. PMID: [22039356](https://pubmed.ncbi.nlm.nih.gov/22039356/)\n\n Eur J Epidemiol. 2011;26(10):797-810. PMID: [22037796](https://pubmed.ncbi.nlm.nih.gov/22037796/)\n\n J Clin Epidemiol. 2011;64(12):1350-63. PMID: [22030070](https://pubmed.ncbi.nlm.nih.gov/22030070/)\n\n Prev Med. 2011;53(6):377-87. PMID: [22029945](https://pubmed.ncbi.nlm.nih.gov/22029945/)\n\n Mutagenesis. 2012;27(1):17-29. PMID: [22027842](https://pubmed.ncbi.nlm.nih.gov/22027842/)\n\n J Epidemiol Community Health. 2012;66(9):844-54. PMID: [22025194](https://pubmed.ncbi.nlm.nih.gov/22025194/)\n\n \n\n'), ('Language', 'English'), ('PubMed ID', '[22023344](http://www.ncbi.nlm.nih.gov/pubmed/22023344)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n**[STROBE Statement](/reporting-guidelines/strobe/):** von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.\n\n \n\n Ann Intern Med. 2007;147(8):573-577. PMID: [17938396](http://www.ncbi.nlm.nih.gov/pubmed/17938396)\n\n PLoS Med. 2007;4(10):e296. PMID: [17941714](http://www.ncbi.nlm.nih.gov/pubmed/17941714)\n\n BMJ. 2007;335(7624):806-808. PMID: [17947786](http://www.ncbi.nlm.nih.gov/pubmed/17947786)\n\n Prev Med. 2007;45(4):247-251. PMID: [17950122](http://www.ncbi.nlm.nih.gov/pubmed/17950122)\n\n Epidemiology. 2007;18(6):800-804. PMID: [18049194](http://www.ncbi.nlm.nih.gov/pubmed/18049194)\n\n Lancet. 2007;370(9596):1453-1457. PMID: [18064739](http://www.ncbi.nlm.nih.gov/pubmed/18064739)\n\n \n\n**Specialised**\n\n**[STREGA](/reporting-guidelines/strobe-strega/):** Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.\n\n \n\n PLoS Med. 2009;6(2):e22. PMID: [19192942](http://www.ncbi.nlm.nih.gov/pubmed/19192942)\n\n Hum Genet. 2009; 125(2):131-151. PMID: [19184668](http://www.ncbi.nlm.nih.gov/pubmed/19184668)\n\n Eur J Epidemiol. 2009;24(1):37-55. PMID: [19189221](http://www.ncbi.nlm.nih.gov/pubmed/19189221)\n\n Ann Intern Med. 2009;150(3):206-215. PMID: [19189911](http://www.ncbi.nlm.nih.gov/pubmed/19189911)\n\n J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: [19217256](http://www.ncbi.nlm.nih.gov/pubmed/19217256)\n\n Genet Epidemiol. 2009;33(7):581-598. PMID: [19278015](http://www.ncbi.nlm.nih.gov/pubmed/19278015)\n\n Eur J Clin Invest. 2009;39(4):247-266. PMID: [19297801](http://www.ncbi.nlm.nih.gov/pubmed/19297801)\n\n \n\n**[STROBE checklist for conference abstracts](/reporting-guidelines/strobe-abstracts/):** First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. [Link to full text pdf](https://www.strobe-statement.org/download/strobe-checklist-conference-abstracts)\n\n \n\n[**STROME-ID**](/reporting-guidelines/strome-id/): Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: [24631223](http://www.ncbi.nlm.nih.gov/pubmed/24631223)\n\n \n\n[**Longitudinal observational drug studies in rheumatology**](/reporting-guidelines/launch-of-a-checklist-for-reporting-longitudinal-observational-drug-studies-in-rheumatology-a-eular-extension-of-strobe-guidelines-based-on-experience-from-biologics-registries/): Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: [24058015](http://www.ncbi.nlm.nih.gov/pubmed/24058015)\n\n \n\n[**Case-cohort studies**](/reporting-guidelines/a-review-of-published-analyses-of-case-cohort-studies-and-recommendations-for-future-reporting/): Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: [24972092](https://www.ncbi.nlm.nih.gov/pubmed/24972092)\n\n \n\n**[STROBE-RDS:](/reporting-guidelines/strobe-rds/)** White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: [26112433](http://www.ncbi.nlm.nih.gov/pubmed/26112433)\n\n \n\n**[RECORD](/reporting-guidelines/record/)**: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: [26440803](http://www.ncbi.nlm.nih.gov/pubmed/26440803)\n\n \n\n**[STROBE-AMS](/reporting-guidelines/strobe-ams/)**: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schröder W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: [26895985](http://www.ncbi.nlm.nih.gov/pubmed/26895985)\n\n \n\n[**STROBE-nut**](/reporting-guidelines/strobe-nut/): Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology—Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: [27270749](https://www.ncbi.nlm.nih.gov/pubmed/27270749)\n\n \n\n[**Simulation Research**](/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**ROSES-I**](/reporting-guidelines/roses-i-statement/): Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: [27417916](https://www.ncbi.nlm.nih.gov/pubmed/27417916)\n\n \n\n[**STROBE-NI**](/reporting-guidelines/strobe-ni/): Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: [27633910](https://www.ncbi.nlm.nih.gov/pubmed/27633910)\n\n \n\n[**Propensity score analysis**](/reporting-guidelines/reporting-and-guidelines-in-propensity-score-analysis-a-systematic-review-of-cancer-and-cancer-surgical-studies/): Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: [28376195](https://www.ncbi.nlm.nih.gov/pubmed/28376195)\n\n \n\n[**RECORD-PE**](https://www.equator-network.org/reporting-guidelines/record-pe/): Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). [BMJ 2018;363:k3532](https://www.bmj.com/content/363/bmj.k3532.full).\n\n \n\n[**STROBE-SIIS**](https://www.equator-network.org/reporting-guidelines/strobe-extension-for-sports-injury-illness-surveillance/): International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, Hägglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).\n\n \n\n Br J Sports Med. 2020;54(7):372-389. PMID: [32071062](https://pubmed.ncbi.nlm.nih.gov/32071062/)\n\n Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: [32118084](https://pubmed.ncbi.nlm.nih.gov/32118084/)\n\n \n\n[**STROBE-MR**](https://www.equator-network.org/reporting-guidelines/strobe-mr-statement/): Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: [34698778](https://pubmed.ncbi.nlm.nih.gov/34698778/)\n\n \n\n'), ('Reporting guideline acronym', 'STROBE-ME'), ('Study design', 'Observational studies'), ('Clinical area', 'Public health'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'November 25, 2021')]"
6689,STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.,Observational studies,Genetics,"Narrative sections (discussion etc.), Procedure/Method", ,"checklist, gene, genes, genetic, genetic association, genetic association studies, genetic association study, genetic associations, genetics, genome-wide, human genomics, observational, observational studies, observational study, STREGA, STROBE, STROBE extension", ,"Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.

This guideline was published simultaneously in 7 journals. You can read the guideline in any of these journals using the links below.

PLoS Med. 2009;6(2):e22. PMID: 19192942
Hum Genet. 2009;125(2):131-151. PMID: 19184668
Eur J Epidemiol. 2009;24(1):37-55. PMID: 19189221
Ann Intern Med. 2009;150(3):206-215. PMID: 19189911
J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: 19217256
Genet Epidemiol. 2009;33(7):581-598. PMID: 19278015
Eur J Clin Invest. 2009;39(4):247-266. PMID: 19297801","Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies.", ,2009, , , , ,English, , , , , , ,"Generic
STROBE: von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Ann Intern Med. 2007;147(8):573-577. PMID: 17938396
PLoS Med. 2007;4(10):e296. PMID: 17941714
BMJ. 2007;335(7624):806-808. PMID: 17947786
Prev Med. 2007;45(4):247-251. PMID: 17950122
Epidemiology. 2007;18(6):800-804. PMID: 18049194
Lancet. 2007;370(9596):1453-1457. PMID: 18064739

Specialised
STROBE-ME: Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: 22023344

STROBE checklist for conference abstracts: First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. Link to full text pdf

STROME-ID: Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: 24631223

Longitudinal observational drug studies in rheumatology: Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: 24058015

Case-cohort studies: Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: 24972092

STROBE-RDS: White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: 26112433

RECORD: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\xf8rensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: 26440803

STROBE-AMS: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schr\xf6der W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: 26895985

STROBE-nut: Lachat C, Hawwash D, Ock\xe9 MC, Berg C, Forsum E, H\xf6rnell A, Larsson C, Sonestedt E, Wirf\xe4lt E, \xc5kesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology?Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: 27270749

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

ROSES-I: Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: 27417916

STROBE-NI: Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: 27633910

Propensity score analysis: Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: 28376195

RECORD-PE: Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3532.

STROBE-SIIS: International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, H\xe4gglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).

Br J Sports Med. 2020;54(7):372-389. PMID: 32071062
Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: 32118084

STROBE-MR: Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: 34698778

", ,STREGA,Reporting the results of genetic association studies, , , , ,An online fillable STREGA checklist is also available via the GoodReports website at https://www.goodreports.org/reporting-checklists/strega/., , ,yes,2013-06-17 13:26:16,2023-03-06 11:45:36,strobe-strega,"[('title', 'STrengthening the REporting of Genetic Association Studies (STREGA) : An Extension of the STROBE Statement.'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting the results of genetic association studies'), ('Full bibliographic reference', 'Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement.\n\n \n\n This guideline was published simultaneously in 7 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n PLoS Med. 2009;6(2):e22. PMID: [19192942](http://www.ncbi.nlm.nih.gov/pubmed/19192942)\n\n Hum Genet. 2009;125(2):131-151. PMID: [19184668](http://www.ncbi.nlm.nih.gov/pubmed/19184668)\n\n Eur J Epidemiol. 2009;24(1):37-55. PMID: [19189221](http://www.ncbi.nlm.nih.gov/pubmed/19189221)\n\n Ann Intern Med. 2009;150(3):206-215. PMID: [19189911](http://www.ncbi.nlm.nih.gov/pubmed/19189911)\n\n J Clin Epidemiol. 2009;62(6):597-608.e4. PMID: [19217256](http://www.ncbi.nlm.nih.gov/pubmed/19217256)\n\n Genet Epidemiol. 2009;33(7):581-598. PMID: [19278015](http://www.ncbi.nlm.nih.gov/pubmed/19278015)\n\n Eur J Clin Invest. 2009;39(4):247-266. PMID: [19297801](http://www.ncbi.nlm.nih.gov/pubmed/19297801)'), ('Language', 'English'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n**[STROBE](/reporting-guidelines/strobe/):** von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.\n\n \n\n Ann Intern Med. 2007;147(8):573-577. PMID: [17938396](http://www.ncbi.nlm.nih.gov/pubmed/17938396)\n\n PLoS Med. 2007;4(10):e296. PMID: [17941714](http://www.ncbi.nlm.nih.gov/pubmed/17941714)\n\n BMJ. 2007;335(7624):806-808. PMID: [17947786](http://www.ncbi.nlm.nih.gov/pubmed/17947786)\n\n Prev Med. 2007;45(4):247-251. PMID: [17950122](http://www.ncbi.nlm.nih.gov/pubmed/17950122)\n\n Epidemiology. 2007;18(6):800-804. PMID: [18049194](http://www.ncbi.nlm.nih.gov/pubmed/18049194)\n\n Lancet. 2007;370(9596):1453-1457. PMID: [18064739](http://www.ncbi.nlm.nih.gov/pubmed/18064739)\n\n \n\n**Specialised**\n\n**[STROBE-ME](/reporting-guidelines/strobe-me/):** Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1-16. PMID: [22023344](http://www.ncbi.nlm.nih.gov/pubmed/22023344)\n\n \n\n**[STROBE checklist for conference abstracts](/reporting-guidelines/strobe-abstracts/):** First draft of the STROBE checklist of items to be included when reporting observational studies in conference abstracts. [Link to full text pdf](https://www.strobe-statement.org/download/strobe-checklist-conference-abstracts)\n\n \n\n[**STROME-ID**](/reporting-guidelines/strome-id/): Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, Vineis P, Abubakar I. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis. 2014. pii: S1473-3099(13)70324-4. doi: 10.1016/S1473-3099(13)70324-4. PMID: [24631223](http://www.ncbi.nlm.nih.gov/pubmed/24631223)\n\n \n\n[**Longitudinal observational drug studies in rheumatology**](/reporting-guidelines/launch-of-a-checklist-for-reporting-longitudinal-observational-drug-studies-in-rheumatology-a-eular-extension-of-strobe-guidelines-based-on-experience-from-biologics-registries/): Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014;73(3):628. PMID: [24058015](http://www.ncbi.nlm.nih.gov/pubmed/24058015)\n\n \n\n[**Case-cohort studies**](/reporting-guidelines/a-review-of-published-analyses-of-case-cohort-studies-and-recommendations-for-future-reporting/): Sharp SJ, Poulaliou M, Thompson SG, White IR, Wood AM. A review of published analyses of case-cohort studies and recommendations for future reporting. PLoS One. 2014;9(6):e101176. PMID: [24972092](https://www.ncbi.nlm.nih.gov/pubmed/24972092)\n\n \n\n**[STROBE-RDS:](/reporting-guidelines/strobe-rds/)** White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, Drake A, Wilson D, Orroth K, Egger M, Hladik W. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: ""STROBE-RDS"" statement. J Clin Epidemiol. 2015 May 1. PMID: [26112433](http://www.ncbi.nlm.nih.gov/pubmed/26112433)\n\n \n\n**[RECORD](/reporting-guidelines/record/)**: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. PMID: [26440803](http://www.ncbi.nlm.nih.gov/pubmed/26440803)\n\n \n\n**[STROBE-AMS](/reporting-guidelines/strobe-ams/)**: Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schröder W, Foschi F, De Angelis G, De Waure C, Cadeddu C, Mutters NT, Gastmeier P, Cookson B. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6(2):e010134. PMID: [26895985](http://www.ncbi.nlm.nih.gov/pubmed/26895985)\n\n \n\n[**STROBE-nut**](/reporting-guidelines/strobe-nut/): Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology—Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med; 2016:13(6):e1002036. PMID: [27270749](https://www.ncbi.nlm.nih.gov/pubmed/27270749)\n\n \n\n[**Simulation Research**](/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**ROSES-I**](/reporting-guidelines/roses-i-statement/): Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. Influenza Other Respir Viruses. 2016 Jul 15. PMID: [27417916](https://www.ncbi.nlm.nih.gov/pubmed/27417916)\n\n \n\n[**STROBE-NI**](/reporting-guidelines/strobe-ni/): Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, Bojang K, Campbell H, Cousens S, Darmstadt GL, Madhi SA, Meulen AS, Modi N, Patterson J, Qazi S, Schrag SJ, Stoll BJ, Wall SN, Wammanda RD, Lawn JE, on behalf of the SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16(10):e202-13. PMID: [27633910](https://www.ncbi.nlm.nih.gov/pubmed/27633910)\n\n \n\n[**Propensity score analysis**](/reporting-guidelines/reporting-and-guidelines-in-propensity-score-analysis-a-systematic-review-of-cancer-and-cancer-surgical-studies/): Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017;109(8). PMID: [28376195](https://www.ncbi.nlm.nih.gov/pubmed/28376195)\n\n \n\n[**RECORD-PE**](https://www.equator-network.org/reporting-guidelines/record-pe/): Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). [BMJ 2018;363:k3532](https://www.bmj.com/content/363/bmj.k3532.full).\n\n \n\n[**STROBE-SIIS**](https://www.equator-network.org/reporting-guidelines/strobe-extension-for-sports-injury-illness-surveillance/): International Olympic Committee Injury and Illness Epidemiology Consensus Group, Bahr R, Clarsen B, Derman W, Dvorak J, Emery CA, Finch CF, Hägglund M, Junge A, Kemp S, Khan KM, Marshall SW, Meeuwisse W, Mountjoy M, Orchard JW, Pluim B, Quarrie KL, Reider B, Schwellnus M, Soligard T, Stokes KA, Timpka T, Verhagen E, Bindra A, Budgett R, Engebretsen L, Erdener U, Chamari K. International Olympic Committee Consensus Statement: Methods for Recording and Reporting of Epidemiological Data on Injury and Illness in Sports 2020 (Including the STROBE Extension for Sports Injury and Illness Surveillance (STROBE-SIIS)).\n\n \n\n Br J Sports Med. 2020;54(7):372-389. PMID: [32071062](https://pubmed.ncbi.nlm.nih.gov/32071062/)\n\n Orthop J Sports Med. 2020;8(2):2325967120902908. PMID: [32118084](https://pubmed.ncbi.nlm.nih.gov/32118084/)\n\n \n\n[**STROBE-MR**](https://www.equator-network.org/reporting-guidelines/strobe-mr-statement/): Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. PMID: [34698778](https://pubmed.ncbi.nlm.nih.gov/34698778/)\n\n \n\n'), ('Reporting guideline acronym', 'STREGA'), ('Study design', 'Observational studies'), ('Clinical area', 'Genetics'), ('Applies to the whole report or to individual sections of the report?', 'Narrative sections (discussion etc.), Procedure/Method'), ('Other', 'An online fillable STREGA checklist is also available via the GoodReports website at <https://www.goodreports.org/reporting-checklists/strega/>.'), ('Record last updated on', 'March 6, 2023')]"
6679,Guidelines for conducting and reporting mixed research in the field of counseling and beyond,"Experimental studies, Mixed methods studies, Observational studies, Other, Qualitative research",Psychology,Whole report, ,"checklist, counseling, counselling, experimental studies, experimental study, mixed methods, mixed methods research, mixed methods studies, mixed methods study, mixed research, observational, observational studies, observational study, qualitative, qualitative research, quantitative", ,"Leech NL, Onwuegbuzie AJ. Guidelines for conducting and reporting mixed research in the field of counseling and beyond. Journal of Counseling and Development. 2010;88(1):61-69.","Leech NL, Onwuegbuzie AJ.",Journal of Counseling and Development [J Couns Dev.],2010,88,1,61-69, ,English, , , ,Access this reporting guideline., , , , , ,Reporting mixed research in the field of counseling, , , , , , , ,no,2013-06-17 11:05:28,2023-07-11 14:34:11,guidelines-for-conducting-and-reporting-mixed-research-in-the-field-of-counseling-and-beyond,"[('title', 'Guidelines for conducting and reporting mixed research in the field of counseling and beyond'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting mixed research in the field of counseling'), ('Full bibliographic reference', 'Leech NL, Onwuegbuzie AJ. Guidelines for conducting and reporting mixed research in the field of counseling and beyond. Journal of Counseling and Development. 2010;88(1):61-69.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', '[Access](https://onlinelibrary.wiley.com/doi/10.1002/j.1556-6678.2010.tb00151.x) this reporting guideline.'), ('Study design', 'Experimental studies, Mixed methods studies, Observational studies, Other, Qualitative research'), ('Clinical area', 'Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'July 11, 2023')]"
6675,Reporting experiments in homeopathic basic research (REHBaR) - a detailed guideline for authors,"Clinical trials, Experimental studies, Other",Complementary and alternative medicine,Whole report, ,"basic research, checklist, complementary and alternative medicine, complementary medicine, experiment, experimental studies, experimental study, experiments, homeopath, homeopathic, homeopathy, homoeopath, homoeopathic, homoeopaths, homoeopathy, REHBaR", ,"Stock-Schroer B, Albrecht H, Betti L, Endler PC, Linde K, Ludtke R, Musial F, van Wijk R, Witt C, Baumgartner S. Reporting experiments in homeopathic basic research (REHBaR) - a detailed guideline for authors. Homeopathy. 2009;98(4):287-298.","Stock-Schroer B, Albrecht H, Betti L, Endler PC, Linde K, Ludtke R, Musial F, van Wijk R, Witt C, Baumgartner S.",Homeopathy.,2009,98,4,287-298, ,English, ,19945681,http://www.ncbi.nlm.nih.gov/pubmed/19945681, , , , , ,REHBaR,Reporting experiments in homeopathic basic research, , , , , , , ,no,2013-06-17 10:47:30,2018-02-16 10:50:51,reporting-experiments-in-homeopathic-basic-research-rehbar-a-detailed-guideline-for-authors,"[('title', 'Reporting experiments in homeopathic basic research (REHBaR) – a detailed guideline for authors'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting experiments in homeopathic basic research'), ('Full bibliographic reference', 'Stock-Schroer B, Albrecht H, Betti L, Endler PC, Linde K, Ludtke R, Musial F, van Wijk R, Witt C, Baumgartner S. Reporting experiments in homeopathic basic research (REHBaR) - a detailed guideline for authors. Homeopathy. 2009;98(4):287-298.'), ('Language', 'English'), ('PubMed ID', '[19945681](http://www.ncbi.nlm.nih.gov/pubmed/19945681)'), ('Reporting guideline acronym', 'REHBaR'), ('Study design', 'Clinical trials, Experimental studies, Other'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'February 16, 2018')]"
6668,"Guidelines for the design, conduct and reporting of human intervention studies to evaluate the health benefits of foods","Clinical trials, Experimental studies, Other",Nutrition and dietetics,Whole report, ,"checklist, diet, dietary, dietary supplement, dietary supplements, dietetics, experimental studies, experimental study, food, foods, health benefit, health benefits, human intervention studies, human intervention study, nutrition, nutrition and dietetics, nutritional", ,"Welch RW, Antoine JM, Berta JL, Bub A, de Vries J, Guarner F, Hasselwander O, Hendriks H, J\xe4kel M, Koletzko BV, Patterson CC, Richelle M, Skarp M, Theis S, Vidry S, Woodside JV; International Life Sciences Institute Europe Functional Foods Task Force. Guidelines for the design, conduct and reporting of human intervention studies to evaluate the health benefits of foods. Br J Nutr. 2011;106 Suppl 2:S3-15","Welch RW, Antoine JM, Berta JL, Bub A, de Vries J, Guarner F, Hasselwander O, Hendriks H, J\xe4kel M, Koletzko BV, Patterson CC, Richelle M, Skarp M, Theis S, Vidry S, Woodside JV; International Life Sciences Institute Europe Functional Foods Task Force.",British Journal of Nutrition [Br J Nutr.],2011,106,Suppl 2.,s3-15, ,English, ,22129662,http://www.ncbi.nlm.nih.gov/pubmed/22129662, , , , , , ,Human intervention studies to evaluate the health benefits of foods, , , , , , , ,no,2013-06-17 09:44:28,2013-10-01 13:54:02,guidelines-for-the-design-conduct-and-reporting-of-human-intervention-studies-to-evaluate-the-health-benefits-of-foods,"[('title', 'Guidelines for the design, conduct and reporting of human intervention studies to evaluate the health benefits of foods'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Human intervention studies to evaluate the health benefits of foods'), ('Full bibliographic reference', 'Welch RW, Antoine JM, Berta JL, Bub A, de Vries J, Guarner F, Hasselwander O, Hendriks H, Jäkel M, Koletzko BV, Patterson CC, Richelle M, Skarp M, Theis S, Vidry S, Woodside JV; International Life Sciences Institute Europe Functional Foods Task Force. Guidelines for the design, conduct and reporting of human intervention studies to evaluate the health benefits of foods. Br J Nutr. 2011;106 Suppl 2:S3-15'), ('Language', 'English'), ('PubMed ID', '[22129662](http://www.ncbi.nlm.nih.gov/pubmed/22129662)'), ('Study design', 'Clinical trials, Experimental studies, Other'), ('Clinical area', 'Nutrition and dietetics'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 1, 2013')]"
6663,"Good research practices for comparative effectiveness research: Defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources ","Clinical trials, Experimental studies, Observational studies, Other", ,Whole report, ,"comparative effectiveness, comparative effectiveness research, data, data source, data sources, database, database analysis, experimental studies, experimental study, ISPOR, non-randomised, non-randomized, non-RCT, non-RCTs, nonrandomised, nonrandomised studies, nonrandomised study, nonrandomized, nonrandomized studies, nonrandomized study, NRS, NRSs, retrospective, retrospective database analysis, secondary data, secondary data source, secondary data sources, secondary databases, treatment, treatments", ,"Berger ML, Mamdani M, Atkins D, Johnson ML. Good research practices for comparative effectiveness research: Defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: The ISPOR good research practices for retrospective database analysis task force report - Part i. Value Health. 2009;12(8):1044-1052.","Berger ML, Mamdani M, Atkins D, Johnson ML.",Value in Health [Value Health.],2009,12,8,1044-1052, ,English, ,19793072,http://www.ncbi.nlm.nih.gov/pubmed/19793072, , , , , , ,"Defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources", , , , , , , ,no,2013-06-17 09:03:55,2013-10-23 14:54:58,good-research-practices-for-comparative-effectiveness-research-defining-reporting-and-interpreting-nonrandomized-studies-of-treatment-effects-using-secondary-data-sources-the-ispor-good-research-pr,"[('title', 'Good research practices for comparative effectiveness research: Defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources'), ('Full bibliographic reference', 'Berger ML, Mamdani M, Atkins D, Johnson ML. Good research practices for comparative effectiveness research: Defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: The ISPOR good research practices for retrospective database analysis task force report - Part i. Value Health. 2009;12(8):1044-1052.'), ('Language', 'English'), ('PubMed ID', '[19793072](http://www.ncbi.nlm.nih.gov/pubmed/19793072)'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Other'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 23, 2013')]"
6651,Guidelines for reporting non-randomised studies,"Clinical trials, Experimental studies, Other", ,Whole report, ,"cohort studies, cohort study, experimental studies, experimental study, non-randomised, non-randomised studies, non-randomised study, non-randomized, non-randomized studies, non-randomized study, non-RCT, non-RCTs, nonrandomised, nonrandomized, NRS, NRSs", ,"Reeves BC, Gaus W. Guidelines for reporting non-randomised studies. Forsch Komplementarmed Klass Naturheilkd. 2004;11 Suppl 1:46-52.","Reeves BC, Gaus W.",Forsch Komplementarmed Klass Naturheilkd.,2004,11,Suppl 1.,46-52, ,English, ,15353903, http://www.ncbi.nlm.nih.gov/pubmed/15353903, , , , , , ,Non-randomised studies, , , , , , , ,no,2013-06-14 14:16:02,2013-10-23 14:55:37,guidelines-for-reporting-non-randomised-studies,"[('title', 'Guidelines for reporting non-randomised studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Non-randomised studies'), ('Full bibliographic reference', 'Reeves BC, Gaus W. Guidelines for reporting non-randomised studies. Forsch Komplementarmed Klass Naturheilkd. 2004;11 Suppl 1:46-52.'), ('Language', 'English'), ('PubMed ID', '[15353903]( http://www.ncbi.nlm.nih.gov/pubmed/15353903)'), ('Study design', 'Clinical trials, Experimental studies, Other'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 23, 2013')]"
6627,Setting the bar in phase II trials: the use of historical data for determining ?go/no go? decision for definitive phase III testing,"Clinical trials, Experimental studies",Oncology,"Data, Procedure/Method", ,"cancer, data, experimental studies, experimental study, historical data, null, oncology, phase 2, phase 2 trial, phase 2 trials, phase 3, phase 3 testing, phase II, phase II trial, phase II trials, phase III, phase III testing, trial, trials", ,"Vickers AJ, Ballen V, Scher HI. Setting the bar in phase II trials: the use of historical data for determining ?go/no go? decision for definitive phase III testing. Clin Cancer Res. 2007;13(3):972-976.","Vickers AJ, Ballen V, Scher HI.",Clinical Cancer Research [Clin Cancer Res.],2007,13,3,972-976., ,English, ,17277252,http://www.ncbi.nlm.nih.gov/pubmed/17277252, , , , , , ,"Use of historical data for determining ""go/no go"" decision for definitive phase III testing", , , , , , , ,no,2013-06-13 15:08:38,2013-10-23 14:56:56,setting-the-bar-in-phase-ii-trials-the-use-of-historical-data-for-determining-gono-go-decision-for-definitive-phase-iii-testing,"[('title', 'Setting the bar in phase II trials: the use of historical data for determining “go/no go” decision for definitive phase III testing'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Use of historical data for determining ""go/no go"" decision for definitive phase III testing'), ('Full bibliographic reference', 'Vickers AJ, Ballen V, Scher HI. Setting the bar in phase II trials: the use of historical data for determining “go/no go” decision for definitive phase III testing. Clin Cancer Res. 2007;13(3):972-976.'), ('Language', 'English'), ('PubMed ID', '[17277252](http://www.ncbi.nlm.nih.gov/pubmed/17277252)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Data, Procedure/Method'), ('Record last updated on', 'October 23, 2013')]"
6623,GNOSIS: Guidelines for Neuro-Oncology: Standards for Investigational Studies - reporting of surgically based therapeutic clinical trials,"Clinical trials, Experimental studies","Neurology, Oncology, Surgery",Whole report, ,"checklist, clinical trial, clinical trials, experimental studies, experimental study, GNOSIS, investigational studies, investigational study, neuro-oncology, neurology, oncology, surgery, surgical, surgically, therapeutic, therapy, trial, trials", ,"Chang S, Vogelbaum M, Lang FF, Haines S, Kunwar S, Chiocca EA, Olivi A, Quinones-Hinojosa A, Parsa A, Warnick R; American Association of Neurological Surgeons and Congress of Neurological Surgeons (AANS/CNS). GNOSIS: Guidelines for Neuro-Oncology: Standards for Investigational Studies - reporting of surgically based therapeutic clinical trials. J Neurooncol. 2007;82(2):211-220.","Chang S, Vogelbaum M, Lang FF, Haines S, Kunwar S, Chiocca EA, Olivi A, Quinones-Hinojosa A, Parsa A, Warnick R; American Association of Neurological Surgeons and Congress of Neurological Surgeons (AANS/CNS).",Journal of Neuro-Oncology [J Neurooncol.],2007,82,2,211-220, ,English, ,17146595,http://www.ncbi.nlm.nih.gov/pubmed/17146595, , , , , ,GNOSIS,Surgically-based therapeutic clinical trials, , , , , , , ,no,2013-06-13 14:20:25,2013-10-23 14:57:28,gnosis-guidelines-for-neuro-oncology-standards-for-investigational-studies-reporting-of-surgically-based-therapeutic-clinical-trials,"[('title', 'GNOSIS : Guidelines for Neuro -Oncology : Standards for Investigational Studies – reporting of surgically based therapeutic clinical trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Surgically-based therapeutic clinical trials'), ('Full bibliographic reference', 'Chang S, Vogelbaum M, Lang FF, Haines S, Kunwar S, Chiocca EA, Olivi A, Quinones-Hinojosa A, Parsa A, Warnick R; American Association of Neurological Surgeons and Congress of Neurological Surgeons (AANS/CNS). GNOSIS: Guidelines for Neuro-Oncology: Standards for Investigational Studies - reporting of surgically based therapeutic clinical trials. J Neurooncol. 2007;82(2):211-220.'), ('Language', 'English'), ('PubMed ID', '[17146595](http://www.ncbi.nlm.nih.gov/pubmed/17146595)'), ('Reporting guideline acronym', 'GNOSIS'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Neurology, Oncology, Surgery'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 23, 2013')]"
6620,The standard of reporting of health-related quality of life in clinical cancer trials,"Clinical trials, Experimental studies",Oncology,Outcomes (variables), ,"cancer, clinical trial, clinical trials, experimental studies, experimental study, health-related, health-related quality of life, HRQL, oncology, quality, quality of life, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Lee CW, Chi KN. The standard of reporting of health-related quality of life in clinical cancer trials. J Clin Epidemiol. 2000;53(5):451-458.","Lee CW, Chi KN.",Journal of Clinical Epidemiology [J Clin Epidemiol.],2000,53,5,451-458, ,English, ,10812316,http://www.ncbi.nlm.nih.gov/pubmed/10812316, , , , , , ,Reporting of health-related quality of life in clinical cancer trials, , , , , , , ,no,2013-06-13 14:10:15,2013-10-23 14:58:09,the-standard-of-reporting-of-health-related-quality-of-life-in-clinical-cancer-trials,"[('title', 'The standard of reporting of health-related quality of life in clinical cancer trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of health-related quality of life in clinical cancer trials'), ('Full bibliographic reference', 'Lee CW, Chi KN. The standard of reporting of health-related quality of life in clinical cancer trials. J Clin Epidemiol. 2000;53(5):451-458.'), ('Language', 'English'), ('PubMed ID', '[10812316](http://www.ncbi.nlm.nih.gov/pubmed/10812316)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Outcomes (variables)'), ('Record last updated on', 'October 23, 2013')]"
6618,"A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials","Clinical trials, Experimental studies",Paediatrics,Data, ,"adolescent, adolescents, child, children, clinical trial, clinical trials, data, data monitoring, Data Monitoring Committee, Data Monitoring Committees, DMC, DMCs, experimental studies, experimental study, interim analyses, interim analysis, paediatric, paediatrics, pediatric, pediatrics, randomised, randomised controlled trial, randomised controlled trials, randomized, randomized controlled trial, randomized controlled trials, RCT, RCTs, terminated, termination, trial, trials", ,"Fernandes RM, van der Lee JH, Offringa M. A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials. BMC Pediatr. 2009;9:77.","Fernandes RM, van der Lee JH, Offringa M.",BMC Pediatrics [BMC Pediatr.],2009,9,77, , ,English, ,20003383,http://www.ncbi.nlm.nih.gov/pubmed/20003383, , , , , , ,"Reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials", , , , , , , ,no,2013-06-13 13:44:11,2013-10-01 14:29:00,a-systematic-review-of-the-reporting-of-data-monitoring-committees-roles-interim-analysis-and-early-termination-in-pediatric-clinical-trials,"[('title', 'A systematic review of the reporting of Data Monitoring Committees’ roles, interim analysis and early termination in pediatric clinical trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', ""Reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials""), ('Full bibliographic reference', ""Fernandes RM, van der Lee JH, Offringa M. A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials. BMC Pediatr. 2009;9:77.""), ('Language', 'English'), ('PubMed ID', '[20003383](http://www.ncbi.nlm.nih.gov/pubmed/20003383)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Paediatrics'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'October 1, 2013')]"
6570,"""Brimful of STARLITE"": toward standards for reporting literature searches", , ,Procedure/Method, ,"information retrieval, IR, literature search, literature searches, literature searching, search, search method, search methods, STARLITE", ,"Booth A. ""Brimful of STARLITE"": toward standards for reporting literature searches. J Med Libr Assoc. 2006;94(4):421-429, e205.",Booth A.,Journal of the Medical Library Association [J Med Libr Assoc.],2006,94,4,421-429, ,English, ,17082834,http://www.ncbi.nlm.nih.gov/pubmed/17082834, , , , , ,STARLITE,Reporting literature searches., ,"For terminology and reporting of citation searching use the TARCiS Checklist
Word | PDF | TARCiS website

", , , , , ,no,2013-06-11 12:39:14,2024-04-05 15:34:54,brimful-of-starlite-toward-standards-for-reporting-literature-searches,"[('title', '“Brimful of STARLITE ”: toward standards for reporting literature searches'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting literature searches.'), ('Full bibliographic reference', 'Booth A. ""Brimful of STARLITE"": toward standards for reporting literature searches. J Med Libr Assoc. 2006;94(4):421-429, e205.'), ('Language', 'English'), ('PubMed ID', '[17082834](http://www.ncbi.nlm.nih.gov/pubmed/17082834)'), ('Reporting guideline acronym', 'STARLITE'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method'), ('Additional information', 'For terminology and reporting of citation searching use the TARCiS Checklist\n\n[Word](https://ub.unibas.ch/fileadmin/user_upload/universitaetsbibliothek/Universitaetsbibliothek/5_Standorte/UB_Medizin/TARCiS/TARCiS_Checklist_for_Terminology_and_Reporting_of_Citation_Searching.docx) | [PDF](https://ub.unibas.ch/fileadmin/user_upload/universitaetsbibliothek/Universitaetsbibliothek/5_Standorte/UB_Medizin/TARCiS/TARCiS_Checklist_for_Terminology_and_Reporting_of_Citation_Searching.pdf) | [TARCiS website](https://ub.unibas.ch/de/ub-medizin/tarcis/)\n\n \n\n'), ('Record last updated on', 'April 5, 2024')]"
6539,Systematic prioritization of the STARE-HI reporting items. An application to short conference papers on health informatics evaluation, ,Health informatics,Conference paper/abstract, ,"conference, conference paper, conference papers, conferences, evaluation, evaluation studies, evaluation study, evaluations, health informatics, health informatics evaluation, informatics, STARE, STARE-HI, STARE-HI Conference papers", ,"de Keizer NF, Talmon J, Ammenwerth E, Brender J, Rigby M, Nykanen P. Systematic prioritization of the STARE-HI reporting items. An application to short conference papers on health informatics evaluation. Methods Inf Med. 2012;51(2):104-111.","de Keizer NF, Talmon J, Ammenwerth E, Brender J, Rigby M, Nykanen P.",Methods of Information in Medicine [Methods Inf Med.],2012,51,2,104-111, ,English, ,21373719,http://www.ncbi.nlm.nih.gov/pubmed/21373719, , , ,"Talmon J, Ammenwerth E, Brender J, de Keizer N, Nykanen P, Rigby M. STARE-HI - Statement on reporting of evaluation studies in Health Informatics. Int J Med Inform 2009;78(1):1-9. PMID: 18930696", ,STARE-HI Conference papers,Short conference papers on health informatics evaluation, , , , , , , ,no,2013-06-10 13:40:50,2013-10-23 15:00:01,systematic-prioritization-of-the-stare-hi-reporting-items-an-application-to-short-conference-papers-on-health-informatics-evaluation,"[('title', 'Systematic prioritization of the STARE-HI reporting items. An application to short conference papers on health informatics evaluation'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Short conference papers on health informatics evaluation'), ('Full bibliographic reference', 'de Keizer NF, Talmon J, Ammenwerth E, Brender J, Rigby M, Nykanen P. Systematic prioritization of the STARE-HI reporting items. An application to short conference papers on health informatics evaluation. Methods Inf Med. 2012;51(2):104-111.'), ('Language', 'English'), ('PubMed ID', '[21373719](http://www.ncbi.nlm.nih.gov/pubmed/21373719)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', 'Talmon J, Ammenwerth E, Brender J, de Keizer N, Nykanen P, Rigby M. STARE-HI - Statement on reporting of evaluation studies in Health Informatics. Int J Med Inform 2009;78(1):1-9. PMID: [18930696](http://www.ncbi.nlm.nih.gov/pubmed/18930696)'), ('Reporting guideline acronym', 'STARE-HI Conference papers'), ('Clinical area', 'Health informatics'), ('Applies to the whole report or to individual sections of the report?', 'Conference paper/abstract'), ('Record last updated on', 'October 23, 2013')]"
6461,CONSORT-EHEALTH: improving and standardizing evaluation reports of Web-based and mobile health interventions,"Clinical trials, Experimental studies", ,Intervention (exposure), ,"clinical studies, clinical study, clinical trial, clinical trials, CONSORT, CONSORT E-Health, CONSORT EHealth, CONSORT extension, e-health, eHealth, electronic tools, evaluation report, evaluation reports, experimental studies, experimental study, internet intervention, internet interventions, internet-based, intervention, interventions, m-health, mhealth, mhealth intervention, mhealth interventions, mobile, mobile intervention, mobile interventions, mobile platform, mobile platforms, non-RCT, randomised, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials, web intervention, web interventions, web-based", ,Eysenbach G; CONSORT-EHEALTH Group. CONSORT-EHEALTH: improving and standardizing evaluation reports of Web-based and mobile health interventions. J Med Internet Res. 2011;13(4):e126.,Eysenbach G; CONSORT-EHEALTH Group.,Journal of Medical Internet Research [J Med Internet Res.],2011,13,4,e126, ,English, ,22209829,http://www.ncbi.nlm.nih.gov/pubmed/22209829, , , , , ,CONSORT-EHEALTH,Evaluation reports of Web-based and mobile health interventions, , , , , , , ,yes,2013-06-05 15:27:36,2022-01-13 14:50:31,consort-ehealth-improving-and-standardizing-evaluation-reports-of-web-based-and-mobile-health-interventions,"[('title', 'CONSORT-EHEALTH : improving and standardizing evaluation reports of Web-based and mobile health interventions'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Evaluation reports of Web-based and mobile health interventions'), ('Full bibliographic reference', 'Eysenbach G; CONSORT-EHEALTH Group. CONSORT-EHEALTH: improving and standardizing evaluation reports of Web-based and mobile health interventions. J Med Internet Res. 2011;13(4):e126.'), ('Language', 'English'), ('PubMed ID', '[22209829](http://www.ncbi.nlm.nih.gov/pubmed/22209829)'), ('Reporting guideline acronym', 'CONSORT-EHEALTH'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'January 13, 2022')]"
6444,Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension,"Clinical trials, Experimental studies", ,Outcomes (variables), ,"checklist, clinical studies, clinical study, clinical trial, clinical trials, CONSORT, CONSORT extension, CONSORT-PRO, experimental studies, experimental study, extension, outcome, outcomes, patient, patient outcome, patient outcomes, patient-reported, patient-reported outcome, patient-reported outcomes, PRO, PROs, randomised, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822.","Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group.",Journal of the American Medical Association [JAMA],2013,309,8,814-822, ,English, ,23443445,http://www.ncbi.nlm.nih.gov/pubmed/23443445, , , ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialist
CONSORT Harms:\xa0Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority:\xa0 Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-283. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,CONSORT-PRO,"Patient-reported outcomes in randomized trials



",The CONSORT-PRO Extension is available in Japanese (PDF)., , , , , , ,yes,2013-06-05 14:11:32,2025-05-30 09:18:25,consort-pro,"[('title', 'Reporting of patient-reported outcomes in randomized trials: the CONSORT  PRO extension'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Patient-reported outcomes in randomized trials\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822.'), ('Language', 'English'), ('PubMed ID', '[23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)'), ('Availability in additional languages', 'The CONSORT-PRO Extension is available in [Japanese (PDF)](https://www.lifescience.co.jp/pro/pro_pdf/PDF8.pdf).'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n**[CONSORT 2025 Statement](http://dev.equator-network.org/reporting-guidelines/consort/):**Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialist**\n\n**[CONSORT Harms](http://dev.equator-network.org/reporting-guidelines/consort-harms/):**Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n**[CONSORT Non-inferiority](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/):**Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n**[CONSORT Cluster](http://dev.equator-network.org/reporting-guidelines/consort-cluster/):**Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n**[CONSORT Herbal](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):**Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n**[CONSORT Non-pharmacological treatment interventions](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/):** Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n**[CONSORT Abstracts](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):**Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-283. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n**[CONSORT Pragmatic Trials](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/):** Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n**[STRICTA Controlled trials of acupuncture](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):**MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n**[CONSORT-CENT](http://dev.equator-network.org/reporting-guidelines/consort-cent/)**: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n**[CONSORT for orthodontic trials](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/)**: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n**[TIDieR](http://dev.equator-network.org/reporting-guidelines/tidier/)**: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'CONSORT-PRO'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Outcomes (variables)'), ('Record last updated on', 'May 30, 2025')]"
6127,Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations,Economic evaluations, ,Whole report, ,"checklist, CHEERS, CHEERS 2022, CHEERS statement, economic, economic evaluation, economic evaluations, economics, evaluation, evaluations, health economic evaluation, health economic evaluations, health economics, intervention, interventions, ISPOR, pharmacoeconomics", ,"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S; CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.

This guideline was published simultaneously in the following journals. You can read the guideline in any of these journals using the links below.

Value Health. 2022;25(1):3-9. PMID: 35031096
BMC Med. 2022;20(1):23. PMID: 35022047
J Manag Care Spec Pharm. 2022:1-10. PMID: 35016547
BMJ. 2022;376:e067975. PMID: 35017145
Pharmacoeconomics. 2022. PMID: 35015272
Appl Health Econ Health Policy. 2022. PMID: 35015207
Int J Technol Assess Health Care. 2022;38(1):e13. PMID: 35007499
J Med Econ. 2022;25(sup1):1-7. PMID: 35012427
BJOG. 2022;129(3):336-344. PMID: 35014160
Eur J Health Econ. 2022. PMID: 35084632
BMC Health Serv Res. 2022;22(1):114. PMID: 35081957
BMC Public Health. 2022;22(1):179. PMID: 35081920
Health Policy OPEN. Volume 3, December 2022.
MDM Policy Pract. 2022;7(1):23814683211061097. PMID: 35036563
Clin Ther. 2022;S0149-2918(22)00016-9. PMID: 35168801

","Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S; CHEERS 2022 ISPOR Good Research Practices Task Force.", ,2022, , , , ,English, , , ,"Further information about the CHEERS Statement is available from: the International Society for Pharmacoeconomics and Outcomes (ISPOR) website

","Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25(1):10-31.\xa0 PMID: 35031088

","CHEERS 2013

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

This guideline was published simultaneously in 10 journals.

Eur J Health Econ. 2013;14(3):367-372. PMID: 23526140
Value Health. 2013;16(2):e1-e5. PMID: 23538200
Clin Ther. 2013;35(4):356-363. PMID: 23537754
Cost Eff Resour Alloc. 2013;11(1):6. PMID: 23531194
BMC Med. 2013;11:80. PMID: 23531108
BMJ. 2013;346:f1049. PMID: 23529982
Pharmacoeconomics. 2013;31(5):361-367. PMID: 23529207
J Med Econ. 2013;16(6):713-719. PMID: 23521434
Int J Technol Assess Health Care. 2013;29(2):117-122. PMID: 23587340
BJOG. 2013;120(6):765-770. PMID: 23565948

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E; on behalf of the ISPOR Health Economic Evaluation Publication Guidelines - CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)- Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231-250. PMID: 23538175

","Specialised
CHEERS-VOI: Kunst N, Siu A, Drummond M, Grimm S, Grutters J, Husereau D, Koffijberg H, Rothery C, Wilson EC, Heath A. CHEERS Value of Information (CHEERS-VOI) Reporting Standards - Explanation and Elaboration. Value Health. 2023. PMID: 37414276

CHEERS-AI: Elvidge J, Hawksworth C, Av?ar TS, Zemplenyi A, Chalkidou A, Petrou S, Petyk\xf3 Z, Srivastava D, Chandra G, Delaye J, Denniston A, Gomes M, Knies S, Nousios P, Siirtola P, Wang J, Dawoud D. Consolidated Health Economic Evaluation Reporting Standards for Interventions that use Artificial Intelligence (CHEERS-AI). Value Health. 2024:S1098-3015(24)02366-0. PMID: 38795956

", ,CHEERS 2022,"Economic evaluations of health interventions



CHEERS 2022 checklist (PDF)

Interactive CHEERS 2022 checklist to generate a completed Word or PDF checklist

","CHEERS 2022

Augustovski F, Garc\xeda Mart\xed S, Espinoza MA, Palacios A, Husereau D, Pichon-Riviere A. Est\xe1ndares Consolidados de Reporte de Evaluaciones Econ\xf3micas Sanitarias: adaptaci\xf3n al espa\xf1ol de la lista de comprobaci\xf3n CHEERS 2022. Value Health Reg Issues. 2022;27:110-114. Spanish translation

Saygin Av?ar T, Yi?it V, Yi?it A, O?uz Ar? H, Tecirli G, Dilma\xe7 E, Husereau D. Konsolide Sa?l?k Ekonomisi De?erlendirme Raporlama Standartlar? T\xfcrk\xe7e: Sa?l?k Hizmetlerinin Ekonomik De?erlendirmesinde Raporlama Standartlar?n?n T\xfcrkiye Uyarlamas?. Turkiye Klinikleri J Health Sci. 2023. Turkish translation

Guertin JR, B\xe9nard E, Aubin M-C, Diaby V, Dragomir A, Latimer E, Tarride J-E, Husereau D. French Translation of the 2022 Version of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Canadian Journal of Health Technologies. 2023;3(10). French translation

Don Husereau, Michael Drummond, Federico Augustovski, Esther de Bekker-Grob, Andrew H Briggs, Chris Carswell, Lisa Caulley, Nathorn Chaiyakunapruk, Dan Greenberg, Elizabeth Loder, Josephine Mauskopf, C Daniel Mullins, Stavros Petrou, Raoh-Fang Pwu, Sophie Staniszewska, ??(??), ???(??), ???(??), ???(??), ??(??), ???(??), ???(??) on behalf of CHEERS 2022 ISPOR Good Research Practices Task Force. ?????????????2022?CHEERS 2022)?????????????????. ?????????. 2022:25(8):460-465. Chinese translation

Shiroiwa T, Noto S, Kobayashi M, Fukuda T. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration. Journal of the National Institute of Public Health. 2023;72(4):344-369. Japanese translation

Werbrouck A, de Bekker-Grob E, Al M, Putman K, Willems R. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS II) statement: a validated Dutch translation. Expert Rev Pharmacoecon Outcomes Res. 2024;24(4):551-557. Dutch translation

CHEERS 2013

The CHEERS Statement (2013) has been translated into Spanish, Chinese,
Japanese (PDF) and Portuguese.

","Read a commentary advocating for greater public involvement in health economic evaluation, including a guide for patient representatives and organisations (available in additional file 1 of the supplementary information) following suggestions made by the CHEERS 2022 Public Reference Group.", , , , , ,yes,2013-04-03 14:12:15,2024-06-18 09:30:07,cheers,"[('title', 'Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Economic evaluations of health interventions\n\n \n\n \xa0\n\n \n\n[CHEERS 2022 checklist (PDF)](https://www.equator-network.org/wp-content/uploads/2013/04/CHEERS-2022-checklist-1.pdf)\n\n \n\n[Interactive CHEERS 2022 checklist to generate a completed Word or PDF checklist](https://don-husereau.shinyapps.io/CHEERS/)\n\n \n\n'), ('Full bibliographic reference', 'Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S; CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.\n\n \n\n This guideline was published simultaneously in the following journals. You can read the guideline in any of these journals using the links below.\n\n \n\n Value Health. 2022;25(1):3-9. PMID: [35031096](https://pubmed.ncbi.nlm.nih.gov/35031096/)\n\n BMC Med. 2022;20(1):23. PMID: [35022047](https://pubmed.ncbi.nlm.nih.gov/35022047/)\n\n J Manag Care Spec Pharm. 2022:1-10. PMID: [35016547](https://pubmed.ncbi.nlm.nih.gov/35016547/)\n\n BMJ. 2022;376:e067975. PMID: [35017145](https://pubmed.ncbi.nlm.nih.gov/35017145/)\n\n Pharmacoeconomics. 2022. PMID: [35015272](https://pubmed.ncbi.nlm.nih.gov/35015272/)\n\n Appl Health Econ Health Policy. 2022. PMID: [35015207](https://pubmed.ncbi.nlm.nih.gov/35015207/)\n\n Int J Technol Assess Health Care. 2022;38(1):e13. PMID: [35007499](https://pubmed.ncbi.nlm.nih.gov/35007499/)\n\n J Med Econ. 2022;25(sup1):1-7. PMID: [35012427](https://pubmed.ncbi.nlm.nih.gov/35012427/)\n\n BJOG. 2022;129(3):336-344. PMID: [35014160](https://pubmed.ncbi.nlm.nih.gov/35014160/)\n\n Eur J Health Econ. 2022. PMID: [35084632](https://pubmed.ncbi.nlm.nih.gov/35084632/)\n\n BMC Health Serv Res. 2022;22(1):114. PMID: [35081957](https://pubmed.ncbi.nlm.nih.gov/35081957/)\n\n BMC Public Health. 2022;22(1):179. PMID: [35081920](https://pubmed.ncbi.nlm.nih.gov/35081920/)\n\n Health Policy OPEN. [Volume 3, December 2022](https://doi.org/10.1016/j.hpopen.2021.100063).\n\n MDM Policy Pract. 2022;7(1):23814683211061097. PMID: [35036563](https://pubmed.ncbi.nlm.nih.gov/35036563/)\n\n Clin Ther. 2022;S0149-2918(22)00016-9. PMID: [35168801](https://pubmed.ncbi.nlm.nih.gov/35168801/)\n\n \n\n'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'Further information about the CHEERS Statement is available from: [the International Society for Pharmacoeconomics and Outcomes (ISPOR) website](https://www.ispor.org/heor-resources/good-practices/article/consolidated-health-economic-evaluation-reporting-standards-2022-(cheers-2022)-statement-updated-reporting-guidance-for-health-economic-evaluations)\n\n \n\n'), ('Explanation and elaboration papers', 'Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25(1):10-31.\xa0 PMID: [35031088](https://pubmed.ncbi.nlm.nih.gov/35031088)\n\n \n\n'), ('Availability in additional languages', 'CHEERS 2022\n\n \n\n Augustovski F, García Martí S, Espinoza MA, Palacios A, Husereau D, Pichon-Riviere A. Estándares Consolidados de Reporte de Evaluaciones Económicas Sanitarias: adaptación al español de la lista de comprobación CHEERS 2022. Value Health Reg Issues. 2022;27:110-114. [Spanish translation](https://pubmed.ncbi.nlm.nih.gov/35031081)\n\n \n\n Saygin Avşar T, Yiğit V, Yiğit A, Oğuz Arı H, Tecirli G, Dilmaç E, Husereau D. Konsolide Sağlık Ekonomisi Değerlendirme Raporlama Standartları Türkçe: Sağlık Hizmetlerinin Ekonomik Değerlendirmesinde Raporlama Standartlarının Türkiye Uyarlaması. Turkiye Klinikleri J Health Sci. 2023. [Turkish translation](https://www.turkiyeklinikleri.com/inpress_article/tr-konsolide-saglik-ekonomisi-degerlendirme-raporlama-standartlari-turkce-saglik-hizmetlerinin-ekonomikdegerlendirmesinde-raporlama-standartlarinin-turkiye-uyarlamasi-104015.html)\n\n \n\n Guertin JR, Bénard E, Aubin M-C, Diaby V, Dragomir A, Latimer E, Tarride J-E, Husereau D. French Translation of the 2022 Version of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Canadian Journal of Health Technologies. 2023;3(10). [French translation](https://canjhealthtechnol.ca/index.php/cjht/article/view/754)\n\n \n\n Don Husereau, Michael Drummond, Federico Augustovski, Esther de Bekker-Grob, Andrew H Briggs, Chris Carswell, Lisa Caulley, Nathorn Chaiyakunapruk, Dan Greenberg, Elizabeth Loder, Josephine Mauskopf, C Daniel Mullins, Stavros Petrou, Raoh-Fang Pwu, Sophie Staniszewska, 肖月(译者), 邱英鹏(译者), 史黎炜(译者), 张治国(译者), 张歆(译者), 王海银(译者), 翟铁民(译者) on behalf of CHEERS 2022 ISPOR Good Research Practices Task Force. 卫生经济学评价报告标准共识2022（CHEERS 2022)：卫生经济学评价报告指导意见更新版. 英国医学杂志中文版. 2022:25(8):460-465. [Chinese translation](https://rs.yiigle.com/CN113904202208/1414478.htm)\n\n \n\n Shiroiwa T, Noto S, Kobayashi M, Fukuda T. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration. Journal of the National Institute of Public Health. 2023;72(4):344-369. [Japanese translation](https://www.jstage.jst.go.jp/article/jniph/72/4/72_344/_article/-char/en)\n\n \n\n Werbrouck A, de Bekker-Grob E, Al M, Putman K, Willems R. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS II) statement: a validated Dutch translation. Expert Rev Pharmacoecon Outcomes Res. 2024;24(4):551-557. [Dutch translation](https://pubmed.ncbi.nlm.nih.gov/38400836/)\n\n \n\n CHEERS 2013\n\n \n\n The CHEERS Statement (2013) has been translated into [Spanish,](https://www.ncbi.nlm.nih.gov/pubmed/29702767)  [Chinese](http://rs.yiigle.com/resource_static.jspx?contentId=657115),\n\n[Japanese (PDF)](https://www.niph.go.jp/journal/data/62-6/201362060009.pdf) and [Portuguese](https://pubmed.ncbi.nlm.nih.gov/29211152/).\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Specialised**\n\n[**CHEERS-VOI**](https://www.equator-network.org/reporting-guidelines/cheers-voi/): Kunst N, Siu A, Drummond M, Grimm S, Grutters J, Husereau D, Koffijberg H, Rothery C, Wilson EC, Heath A. CHEERS Value of Information (CHEERS-VOI) Reporting Standards - Explanation and Elaboration. Value Health. 2023. PMID: [37414276](https://pubmed.ncbi.nlm.nih.gov/37414276/)\n\n \n\n[**CHEERS-AI**](https://www.equator-network.org/reporting-guidelines/consolidated-health-economic-evaluation-reporting-standards-for-interventions-that-use-artificial-intelligence-cheers-ai/): Elvidge J, Hawksworth C, Avşar TS, Zemplenyi A, Chalkidou A, Petrou S, Petykó Z, Srivastava D, Chandra G, Delaye J, Denniston A, Gomes M, Knies S, Nousios P, Siirtola P, Wang J, Dawoud D. Consolidated Health Economic Evaluation Reporting Standards for Interventions that use Artificial Intelligence (CHEERS-AI). Value Health. 2024:S1098-3015(24)02366-0. PMID: [38795956](https://pubmed.ncbi.nlm.nih.gov/38795956/)\n\n \n\n'), ('Reporting guideline acronym', 'CHEERS 2022'), ('Study design', 'Economic evaluations'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Previous versions of this guideline / Guideline history', 'CHEERS 2013\n\n \n\n Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.\n\n \n\n This guideline was published simultaneously in 10 journals.\n\n \n\n Eur J Health Econ. 2013;14(3):367-372. PMID: [23526140](http://www.ncbi.nlm.nih.gov/pubmed/23526140)\n\n Value Health. 2013;16(2):e1-e5. PMID: [23538200](http://www.ncbi.nlm.nih.gov/pubmed/23538200)\n\n Clin Ther. 2013;35(4):356-363. PMID: [23537754](http://www.ncbi.nlm.nih.gov/pubmed/23537754)\n\n Cost Eff Resour Alloc. 2013;11(1):6. PMID: [23531194](http://www.ncbi.nlm.nih.gov/pubmed/23531194)\n\n BMC Med. 2013;11:80. PMID: [23531108](http://www.ncbi.nlm.nih.gov/pubmed/23531108)\n\n BMJ. 2013;346:f1049. PMID: [23529982](http://www.ncbi.nlm.nih.gov/pubmed/23529982)\n\n Pharmacoeconomics. 2013;31(5):361-367. PMID: [23529207](http://www.ncbi.nlm.nih.gov/pubmed/23529207)\n\n J Med Econ. 2013;16(6):713-719. PMID: [23521434](http://www.ncbi.nlm.nih.gov/pubmed/23521434)\n\n Int J Technol Assess Health Care. 2013;29(2):117-122. PMID: [23587340](http://www.ncbi.nlm.nih.gov/pubmed/23587340)\n\n BJOG. 2013;120(6):765-770. PMID: [23565948](http://www.ncbi.nlm.nih.gov/pubmed/23565948)\n\n \n\n Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E; on behalf of the ISPOR Health Economic Evaluation Publication Guidelines - CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)- Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231-250. PMID: [23538175](http://www.ncbi.nlm.nih.gov/pubmed/23538175)\n\n \n\n'), ('Additional information', '[Read a commentary](https://researchinvolvement.biomedcentral.com/articles/10.1186/s40900-023-00444-3) advocating for greater public involvement in health economic evaluation, including a guide for patient representatives and organisations (available in additional file 1 of the supplementary information) following suggestions made by the CHEERS 2022 Public Reference Group.'), ('Record last updated on', 'June 18, 2024')]"
6125,Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ,"Qualitative research, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews", ,"Narrative sections (discussion etc.), Procedure/Method", ,"checklist, ENTREQ, ENTREQ Statement, qualitative, qualitative health research, qualitative method, qualitative methods, qualitative research, qualitative research methods, research, research synthesis, review, reviews, syntheses, synthesis, systematic review, systematic reviews", ,"Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ. BMC Med Res Methodol. 2012;12(1):181.","Tong A, Flemming K, McInnes E, Oliver S, Craig J.",BMC Medical Research Methodology [BMC Med Res Methodol.],2012,12,1,181, ,English, ,23185978,http://www.ncbi.nlm.nih.gov/pubmed/23185978, , , , , ,ENTREQ,Synthesis of qualitative research, , , , , , , ,yes,2013-04-03 13:46:06,2014-01-24 10:27:16,entreq,"[('title', 'Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Synthesis of qualitative research'), ('Full bibliographic reference', 'Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ. BMC Med Res Methodol. 2012;12(1):181.'), ('Language', 'English'), ('PubMed ID', '[23185978](http://www.ncbi.nlm.nih.gov/pubmed/23185978)'), ('Reporting guideline acronym', 'ENTREQ'), ('Study design', 'Qualitative research, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Narrative sections (discussion etc.), Procedure/Method'), ('Record last updated on', 'January 24, 2014')]"
5947,Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal,"Clinical trials, Experimental studies", ,"Appendix, Procedure/Method", ,"ACs, adjudication, adjudication committee, adjudication committees, clinical endpoint committee, clinical endpoint committees, clinical event committee, clinical event committees, clinical trial, clinical trials, committee, committees, endpoint, endpoint assessment, endpoints, event, events, experimental studies, experimental study, panel review committee, panel review committees, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Dechartres A, Boutron I, Roy C, Ravaud P. Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal. J Clin Epidemiol. 2009;62(7):695-702.","Dechartres A, Boutron I, Roy C, Ravaud P.",Journal of Clinical Epidemiology [J Clin Epidemiol.],2009,62,7,695-702, ,English, ,19135860,http://www.ncbi.nlm.nih.gov/pubmed/19135860, , , , , , ,Reporting of adjudication committees in clinical trials, , , , , , , ,no,2013-03-04 16:47:25,2013-10-01 15:19:50,inadequate-planning-and-reporting-of-adjudication-committees-in-clinical-trials-recommendation-proposal,"[('title', 'Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of adjudication committees in clinical trials'), ('Full bibliographic reference', 'Dechartres A, Boutron I, Roy C, Ravaud P. Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal. J Clin Epidemiol. 2009;62(7):695-702.'), ('Language', 'English'), ('PubMed ID', '[19135860](http://www.ncbi.nlm.nih.gov/pubmed/19135860)'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Appendix, Procedure/Method'), ('Record last updated on', 'October 1, 2013')]"
5945,Relevance of CONSORT reporting criteria for research on eHealth interventions,"Clinical trials, Experimental studies",Health informatics,Intervention (exposure), ,"clinical trial, clinical trials, CONSORT, e-health, e-health intervention, e-health interventions, eHealth, eHealth intervention, eHealth interventions, electronic media, health promotion, intervention, interventions, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Baker TB, Gustafson DH, Shaw B, Hawkins R, Pingree S, Roberts L, Strecher V. Relevance of CONSORT reporting criteria for research on eHealth interventions. Patient Educ Couns. 2010;81 Suppl:S77-86.","Baker TB, Gustafson DH, Shaw B, Hawkins R, Pingree S, Roberts L, Strecher V.",Patient Education and Counseling [Patient Educ Couns.],2010,81,Supplement 1,S77-S86, ,English, ,20843621,http://www.ncbi.nlm.nih.gov/pubmed/20843621, , , , , , ,Research on eHealth interventions, , , , , , , ,no,2013-03-04 16:18:05,2013-10-01 15:22:54,relevance-of-consort-reporting-criteria-for-research-on-ehealth-interventions,"[('title', 'Relevance of CONSORT reporting criteria for research on eHealth interventions'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Research on eHealth interventions'), ('Full bibliographic reference', 'Baker TB, Gustafson DH, Shaw B, Hawkins R, Pingree S, Roberts L, Strecher V. Relevance of CONSORT reporting criteria for research on eHealth interventions. Patient Educ Couns. 2010;81 Suppl:S77-86.'), ('Language', 'English'), ('PubMed ID', '[20843621](http://www.ncbi.nlm.nih.gov/pubmed/20843621)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Health informatics'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'October 1, 2013')]"
5864,Reporting guidelines for music-based interventions,"Experimental studies, Other", ,Intervention (exposure), ,"checklist, experimental studies, experimental study, intervention, interventions, music, music intervention, music interventions, music therapies, music therapy, music-based, music-based intervention, music-based interventions", ,"Robb SL, Springs S, Edwards E, Golden TL, Johnson JK, Burns DS, Belgrave M, Bradt J, Gold C, Habibi A, Iversen JR, Lense M, MacLean JA, Perkins SM. Reporting Guidelines for Music-based Intervention: an update and validation study. Front Psychol. 2025:16:1551920.","Robb SL, Springs S, Edwards E, Golden TL, Johnson JK, Burns DS, Belgrave M, Bradt J, Gold C, Habibi A, Iversen JR, Lense M, MacLean JA, Perkins SM.",Front Psychol,2025,16, ,1551920,2025,English,10.3389/fpsyg.2025.1551920,40528854,https://pubmed.ncbi.nlm.nih.gov/40528854/,"Read the full text of the guideline.

Read the full text of the Explanation and Elaboration.","Robb SL,Maya Story K. Maya Story, Harman E, Burns DS, Bradt J, Edwards E, Golden TL, GOld C, Iverson JR, Habibi A, Johnson JK, Lense M, Perkins SM, Springs S. Reporting Guidelines for Music-based Interventions checklist: explanation and elaboration guide. Front Psychol. 2025. 16.","Robb SL, Carpenter JS, Burns DS. Reporting guidelines for music-based interventions.

J Health Psychol. 2011;16(2):342-352. PMID: 20709884
Music Med. 2011;3(4):271-279. PMID: 23646227", , , ,Reporting music-based interventions, , , , , , , ,no,2013-01-28 13:54:28,2025-06-19 08:33:30,reporting-guidelines-for-music-based-interventions,"[('title', 'Reporting guidelines for music-based interventions'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting music-based interventions'), ('Full bibliographic reference', 'Robb SL, Springs S, Edwards E, Golden TL, Johnson JK, Burns DS, Belgrave M, Bradt J, Gold C, Habibi A, Iversen JR, Lense M, MacLean JA, Perkins SM. Reporting Guidelines for Music-based Intervention: an update and validation study. Front Psychol. 2025:16:1551920.'), ('Date of publication / Ahead of print date', '2025'), ('Language', 'English'), ('DOI', '10.3389/fpsyg.2025.1551920'), ('PubMed ID', '[40528854](https://pubmed.ncbi.nlm.nih.gov/40528854/)'), ('Relevant URLs\n\n(full-text if available)', '[Read the full text](https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2025.1551920/full) of the guideline.\n\n \n\n[Read the full text](https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2025.1552659/full) of the Explanation and Elaboration.'), ('Explanation and elaboration papers', 'Robb SL,Maya Story K. Maya Story, Harman E, Burns DS, Bradt J, Edwards E, Golden TL, GOld C, Iverson JR, Habibi A, Johnson JK, Lense M, Perkins SM, Springs S. Reporting Guidelines for Music-based Interventions checklist: explanation and elaboration guide. Front Psychol. 2025. 16.'), ('Study design', 'Experimental studies, Other'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Previous versions of this guideline / Guideline history', 'Robb SL, Carpenter JS, Burns DS. Reporting guidelines for music-based interventions.\n\n \n\n J Health Psychol. 2011;16(2):342-352. PMID: [20709884](http://www.ncbi.nlm.nih.gov/pubmed/20709884)\n\n Music Med. 2011;3(4):271-279. PMID: [23646227](http://www.ncbi.nlm.nih.gov/pubmed/23646227)'), ('Record last updated on', 'June 19, 2025')]"
5861,Reporting whole-body vibration intervention studies: recommendations of the International Society of Musculoskeletal and Neuronal Interactions,"Experimental studies, Other",Rheumatology,Intervention (exposure), ,"bone density, bone mass, checklist, experimental studies, experimental study, intervention, intervention studies, intervention study, interventions, musculoskeletal, neuromuscular, rheumatology, treatment, vibration, WBV, whole body vibration, whole-body", ,"Rauch F, Sievanen H, Boonen S, Cardinale M, Degens H, Felsenberg D, Roth J, Schoenau E, Verschueren S, Rittweger J. Reporting whole-body vibration intervention studies: recommendations of the International Society of Musculoskeletal and Neuronal Interactions. J Musculoskelet Neuronal Interact. 2010;10(3):193-198.","Rauch F, Sievanen H, Boonen S, Cardinale M, Degens H, Felsenberg D, Roth J, Schoenau E, Verschueren S, Rittweger J.",Journal of Musculoskeletal and Neuronal Interactions [J Musculoskelet Neuronal Interact.],2010,10,3,193-198, ,English, ,20811143,http://www.ncbi.nlm.nih.gov/pubmed/20811143, , , , , , ,Whole-body vibration intervention studies, , , , , , , ,no,2013-01-28 11:58:50,2013-10-24 10:31:29,reporting-whole-body-vibration-intervention-studies-recommendations-of-the-international-society-of-musculoskeletal-and-neuronal-interactions,"[('title', 'Reporting whole-body vibration intervention studies: recommendations of the International Society of Musculoskeletal and Neuronal Interactions'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Whole-body vibration intervention studies'), ('Full bibliographic reference', 'Rauch F, Sievanen H, Boonen S, Cardinale M, Degens H, Felsenberg D, Roth J, Schoenau E, Verschueren S, Rittweger J. Reporting whole-body vibration intervention studies: recommendations of the International Society of Musculoskeletal and Neuronal Interactions. J Musculoskelet Neuronal Interact. 2010;10(3):193-198.'), ('Language', 'English'), ('PubMed ID', '[20811143](http://www.ncbi.nlm.nih.gov/pubmed/20811143)'), ('Study design', 'Experimental studies, Other'), ('Clinical area', 'Rheumatology'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'October 24, 2013')]"
5858,Reporting standards for studies of tailored interventions,"Experimental studies, Other", ,Intervention (exposure), ,"checklist, communication, experimental studies, experimental study, intervention, interventions, JARS, message, tailor, tailored, tailored intervention, tailored intervention research, tailored interventions, tailored message, tailored messages, tailoring, tailoring literature", ,"Harrington NG, Noar SM. Reporting standards for studies of tailored interventions. Health Educ Res. 2012;27(2):331-342.","Harrington NG, Noar SM.",Health Education Research [Health Educ Res.],2012,27,2,331-342, ,English, ,22156230,http://www.ncbi.nlm.nih.gov/pubmed/22156230, , , , , , ,Studies of tailored interventions, , , , , , , ,no,2013-01-28 11:36:05,2015-01-27 13:58:14,reporting-standards-for-studies-of-tailored-interventions,"[('title', 'Reporting standards for studies of tailored interventions'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Studies of tailored interventions'), ('Full bibliographic reference', 'Harrington NG, Noar SM. Reporting standards for studies of tailored interventions. Health Educ Res. 2012;27(2):331-342.'), ('Language', 'English'), ('PubMed ID', '[22156230](http://www.ncbi.nlm.nih.gov/pubmed/22156230)'), ('Study design', 'Experimental studies, Other'), ('Applies to the whole report or to individual sections of the report?', 'Intervention (exposure)'), ('Record last updated on', 'January 27, 2015')]"
5855,Reporting data on homeopathic treatments (RedHot): A supplement to CONSORT,"Clinical trials, Experimental studies",Complementary and alternative medicine,Data, ,"checklist, clinical trial, clinical trials, complementary and alternative medicine, complementary medicine, CONSORT, data, experimental studies, experimental study, homeopath, homeopathic, homeopathic treatment, homeopathic treatments, homeopaths, homeopathy, homoeopath, homoeopathic, homoeopaths, homoeopathy, prescribe, prescribing, randomised, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, RedHot, treatment, treatments, trial, trials", ,"Dean ME, Coulter MK, Fisher P, Jobst K, Walach H. Reporting data on homeopathic treatments (RedHot): A supplement to CONSORT. Forsch Komplementmed. 2006;13(6):368-371.","Dean ME, Coulter MK, Fisher P, Jobst K, Walach H.",Forschende Komplementarmedizin und Klassische Naturheilkunde [Forsch Komplementmed.],2006,13,6,368-371, ,English, ,17200612,http://www.ncbi.nlm.nih.gov/pubmed/17200612, , , , , ,RedHot,Homeopathic methods and treatments, , , , , , , ,no,2013-01-28 11:10:09,2018-02-16 10:52:20,reporting-data-on-homeopathic-treatments-redhot-a-supplement-to-consort,"[('title', 'Reporting data on homeopathic treatments (RedHot) : A supplement to CONSORT'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Homeopathic methods and treatments'), ('Full bibliographic reference', 'Dean ME, Coulter MK, Fisher P, Jobst K, Walach H. Reporting data on homeopathic treatments (RedHot): A supplement to CONSORT. Forsch Komplementmed. 2006;13(6):368-371.'), ('Language', 'English'), ('PubMed ID', '[17200612](http://www.ncbi.nlm.nih.gov/pubmed/17200612)'), ('Reporting guideline acronym', 'RedHot'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Data'), ('Record last updated on', 'February 16, 2018')]"
5853,Evaluating the quality of reporting occupational therapy randomized controlled trials by expanding the CONSORT criteria,"Clinical trials, Experimental studies",Occupational therapy,Whole report, ,"checklist, CONSORT, experimental studies, experimental study, Nelson-Moberg Expanded CONSORT Instrument, NMECI, occupational therapies, occupational therapy, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Moberg-Mogren E, Nelson D. Evaluating the quality of reporting occupational therapy randomized controlled trials by expanding the CONSORT criteria. Am J Occup Ther. 2006;60(2):226-235.","Moberg-Mogren E, Nelson D.",American Journal of Occupational Therapy [Am J Occup Ther.],2006,60,2,226-235, ,English, ,16596926,http://www.ncbi.nlm.nih.gov/pubmed/16596926, , , , , , ,Occupational therapy randomised controlled trials, , , , , , , ,no,2013-01-28 10:58:37,2013-10-24 10:33:04,evaluating-the-quality-of-reporting-occupational-therapy-randomized-controlled-trials-by-expanding-the-consort-criteria,"[('title', 'Evaluating the quality of reporting occupational therapy randomized controlled trials by expanding the CONSORT criteria'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Occupational therapy randomised controlled trials'), ('Full bibliographic reference', 'Moberg-Mogren E, Nelson D. Evaluating the quality of reporting occupational therapy randomized controlled trials by expanding the CONSORT criteria. Am J Occup Ther. 2006;60(2):226-235.'), ('Language', 'English'), ('PubMed ID', '[16596926](http://www.ncbi.nlm.nih.gov/pubmed/16596926)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Occupational therapy'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 24, 2013')]"
5851,WIDER recommendations for reporting of behaviour change interventions,"Clinical trials, Experimental studies",Behavioural medicine,Whole report, ,"BCI, BCI evaluation, BCI evaluations, BCIs, behavior, behavior change, behavior change evaluation, behavior change evaluations, behavior change intervention, behavior change interventions, behavioral medicine, behaviour, behaviour change, behaviour change evaluation, behaviour change evaluations, behaviour change intervention, behaviour change interventions, behavioural medicine, CONSORT, experimental studies, experimental study, psychological intervention, psychological interventions, psychology, randomised, randomised trial, randomised trials, randomized, randomized trial, randomized trials, trial, trials, WIDER, WIDER recommendations", ,WIDER recommendations for reporting of behaviour change interventions. On behalf of the Workgroup for Intervention Development and Evaluation Research.,On behalf of the Workgroup for Intervention Development and Evaluation Research., ,2009, , , , ,English, , , ,Download the WIDER recommendations (PDF), , , , ,WIDER,Scientific reporting of behavior change interventions (BCIs) and evaluations of BCIs, ,"Albrecht L, Archibald M, Arseneau D, Scott SD. Development of a checklist to assess the quality of reporting of knowledge translation interventions using the Workgroup for Intervention Development and Evaluation Research (WIDER) recommendations. Implement Sci. 2013;8:52. PMID: 23680355", , , , , ,no,2013-01-28 10:50:26,2022-01-13 16:19:18,wider-recommendations-for-reporting-of-behaviour-change-interventions,"[('title', 'WIDER recommendations for reporting of behaviour change interventions'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Scientific reporting of behavior change interventions (BCIs) and evaluations of BCIs'), ('Full bibliographic reference', 'WIDER recommendations for reporting of behaviour change interventions. On behalf of the Workgroup for Intervention Development and Evaluation Research.'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'Download the [WIDER recommendations (PDF)](http://www.implementationscience.com/content/supplementary/1748-5908-7-70-s4.pdf)'), ('Reporting guideline acronym', 'WIDER'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Behavioural medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'Albrecht L, Archibald M, Arseneau D, Scott SD. Development of a checklist to assess the quality of reporting of knowledge translation interventions using the Workgroup for Intervention Development and Evaluation Research (WIDER) recommendations. Implement Sci. 2013;8:52. PMID: [23680355](http://www.ncbi.nlm.nih.gov/pubmed/23680355)'), ('Record last updated on', 'January 13, 2022')]"
5849,Evidence-based behavioral medicine: what is it and how do we achieve it?,"Clinical trials, Experimental studies",Behavioural medicine,Whole report, ,"adherence, behavior, behavioral, behavioral medicine, behaviour, behavioural, behavioural medicine, checklist, experimental studies, experimental study, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, treatment, trial, trials", ,"Davidson KW, Goldstein M, Kaplan RM, Kaufmann PG, Knatterud GL, Orleans CT, Spring B, Trudeau KJ, Whitlock EP. Evidence-based behavioral medicine: what is it and how do we achieve it? Ann Behav Med. 2003;26(3):161-171.","Davidson KW, Goldstein M, Kaplan RM, Kaufmann PG, Knatterud GL, Orleans CT, Spring B, Trudeau KJ, Whitlock EP.",Annals of Behavioral Medicine [Ann Behav Med.],2003,26,3,161-171, ,English, ,14644692,http://www.ncbi.nlm.nih.gov/pubmed/14644692, , , , , , ,Behavioural medicine research, , , , , , , ,no,2013-01-28 10:38:58,2013-10-24 10:34:42,evidence-based-behavioral-medicine-what-is-it-and-how-do-we-achieve-it,"[('title', 'Evidence-based behavioral medicine: what is it and how do we achieve it?'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Behavioural medicine research'), ('Full bibliographic reference', 'Davidson KW, Goldstein M, Kaplan RM, Kaufmann PG, Knatterud GL, Orleans CT, Spring B, Trudeau KJ, Whitlock EP. Evidence-based behavioral medicine: what is it and how do we achieve it? Ann Behav Med. 2003;26(3):161-171.'), ('Language', 'English'), ('PubMed ID', '[14644692](http://www.ncbi.nlm.nih.gov/pubmed/14644692)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Behavioural medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 24, 2013')]"
5847,CONSORT 2010: CONSORT-C (children),"Clinical trials, Experimental studies",Paediatrics,Whole report, ,"adolescent, adolescents, checklist, child, children, CONSORT, CONSORT 2010, CONSORT-C(hildren), experimental studies, experimental study, newborn, newborns, paediatrics, pediatrics, randomised, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Saint-Raymond A, Hill S, Martines J, Bahl R, Fontaine O, Bero L. CONSORT 2010. Lancet. 2010;376(9737):229-230.","Saint-Raymond A, Hill S, Martines J, Bahl R, Fontaine O, Bero L.",Lancet.,2010,376,9737,229-230, ,English, ,20656114,http://www.ncbi.nlm.nih.gov/pubmed/20656114, , , , , ,CONSORT -C(hildren),Paediatric trials, , , , , , , ,no,2013-01-28 10:25:12,2022-06-14 17:11:23,consort-children,"[('title', 'CONSORT 2010: CONSORT-C (children)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Paediatric trials'), ('Full bibliographic reference', 'Saint-Raymond A, Hill S, Martines J, Bahl R, Fontaine O, Bero L. CONSORT 2010. Lancet. 2010;376(9737):229-230.'), ('Language', 'English'), ('PubMed ID', '[20656114](http://www.ncbi.nlm.nih.gov/pubmed/20656114)'), ('Reporting guideline acronym', 'CONSORT -C(hildren)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Paediatrics'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'June 14, 2022')]"
5844,The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper,"Clinical trials, Experimental studies",Allergy,Whole report, ,"allergen, allergen-specific, allergen-specific immunotherapy, allergens, allergic disease, allergic diseases, allergy, checklist, clinical research, CONSORT, CONSORT statement checklist for immunotherapy trials, experimental studies, experimental study, GA2LEN, immunotherapy, phase 3, phase III, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, SIT, trial, trials", ,"Bousquet PJ, Brozek J, Bachert C, Bieber T, Bonini S, Burney P, et al. The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. Allergy. 2009;64(12):1737-1745.","Bousquet PJ, Brozek J, Bachert C, Bieber T, Bonini S, Burney P, Calderon M, Canonica GW, Compalati E, Daures JP, Delgado L, Demoly P, Dahl R, Durham SR, Kowalski ML, Malling HJ, Merk H, Papadopoulos N, Passalacqua G, Simon HU, Worms M, Wahn U, Zuberbier T, Sch\xfcnemann HJ, Bousquet J.",Allergy.,2009,64,12,1737-1745, ,English, ,19860788,http://www.ncbi.nlm.nih.gov/pubmed/19860788, , , , , , ,Trials in allergen-specific immunotherapy, , , , , , , ,no,2013-01-28 10:16:11,2013-10-24 10:36:15,the-consort-statement-checklist-in-allergen-specific-immunotherapy-a-ga2len-paper,"[('title', 'The CONSORT statement checklist in allergen-specific immunotherapy: a GA 2 LEN paper'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Trials in allergen-specific immunotherapy'), ('Full bibliographic reference', 'Bousquet PJ, Brozek J, Bachert C, Bieber T, Bonini S, Burney P, et al. The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. Allergy. 2009;64(12):1737-1745.'), ('Language', 'English'), ('PubMed ID', '[19860788](http://www.ncbi.nlm.nih.gov/pubmed/19860788)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Allergy'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 24, 2013')]"
5833,Improving the reporting of pragmatic trials: an extension of the CONSORT statement,"Clinical trials, Experimental studies", ,Whole report, ,"applicability, checklist, CONSORT, CONSORT extension, decision making, decisions, experimental studies, experimental study, extension, external validity, generalisability, practice, Practihc, pragmatic, pragmatic trial, pragmatic trials, randomised, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390.","Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group.",British Medical journal [BMJ.],2008,337, , , ,English, ,19001484,http://www.ncbi.nlm.nih.gov/pubmed/19001484, , , ,"Generic
CONSORT 2025 Statement: Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority:\xa0 Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008;5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-283. PMID: 18221781

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,CONSORT Pragmatic trials,"Reporting of pragmatic trials in healthcare.



", , , , , , , ,yes,2013-01-25 16:24:34,2025-05-30 09:17:52,consort-pragmatic,"[('title', 'Improving the reporting of pragmatic trials: an extension of the CONSORT statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of pragmatic trials in healthcare.\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390.'), ('Language', 'English'), ('PubMed ID', '[19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](http://dev.equator-network.org/reporting-guidelines/consort/): Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/):\xa0 Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](http://dev.equator-network.org/reporting-guidelines/consort-cluster/):\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008;5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-283. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n**[CONSORT PRO](http://dev.equator-network.org/reporting-guidelines/consort-pro/):** Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n**[CONSORT-CENT](http://dev.equator-network.org/reporting-guidelines/consort-cent/)**: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n**[CONSORT for orthodontic trials](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/)**: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n**[TIDieR](http://dev.equator-network.org/reporting-guidelines/tidier/)**: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'CONSORT Pragmatic trials'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 30, 2025')]"
5814,CONSORT for reporting randomised trials in journal and conference abstracts,"Clinical trials, Experimental studies", ,"Abstract, Conference paper/abstract", ,"abstract, abstracts, checklist, conference, conference abstract, conference abstracts, conference proceedings, conferences, CONSORT, CONSORT extension, experimental studies, experimental study, extension, journal abstract, journal abstracts, journal article, journal articles, randomised, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-283.","Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group.",Lancet.,2008,371,9609,281-283, ,English, ,18221781,http://www.ncbi.nlm.nih.gov/pubmed/18221781, ,"Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008;5(1):e20. PMID: 18215107

", ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority:\xa0 Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,CONSORT for abstracts,"Reporting randomised trials in journal and conference abstracts



", , , , , , , ,yes,2013-01-25 15:12:48,2025-05-30 09:17:35,consort-abstracts,"[('title', 'CONSORT for reporting randomised trials in journal and conference abstracts'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting randomised trials in journal and conference abstracts\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-283.'), ('Language', 'English'), ('PubMed ID', '[18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)'), ('Explanation and elaboration papers', 'Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008;5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](http://dev.equator-network.org/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/):\xa0 Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](http://dev.equator-network.org/reporting-guidelines/consort-cluster/):\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n**[CONSORT PRO](http://dev.equator-network.org/reporting-guidelines/consort-pro/):** Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n**[CONSORT-CENT](http://dev.equator-network.org/reporting-guidelines/consort-cent/)**: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n**[CONSORT for orthodontic trials](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/)**: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n**[TIDieR](http://dev.equator-network.org/reporting-guidelines/tidier/)**: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'CONSORT for abstracts'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Abstract, Conference paper/abstract'), ('Record last updated on', 'May 30, 2025')]"
5811,CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts,"Clinical trials, Experimental studies", ,"Abstract, Whole report", ,"checklist, CONSORT, CONSORT extension, experimental studies, experimental study, extension, intervention, interventions, non-pharmacologic, non-pharmacologic treatment, non-pharmacologic treatments, non-pharmacological, nonpharmacologic, nonpharmacologic treatment, nonpharmacologic treatments, nonpharmacological, randomised, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, treatment, treatments, trial, trials", ,"Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47.","Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group.",Annals of Internal Medicine [Ann Intern Med.],2017,167,1,40-47, ,English, ,28630973,https://www.ncbi.nlm.nih.gov/pubmed/28630973, , ,"Boutron I, Moher D, Altman DG, Schulz K, Ravaud P, for the CONSORT group. Methods and Processes of the CONSORT Group: Example of an Extension for Trials Assessing Nonpharmacologic Treatments. Ann Intern Med. 2008:W60-W67. PMID: 18283201

Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. 2008;148(4):295-309. PMID: 18283207

","Generic
CONSORT 2025 Statement: Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477



Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority:\xa0 Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-283. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,CONSORT Non-pharmacologic treatment interventions,"Trials assessing nonpharmacologic treatments



", , , , , , , ,yes,2013-01-25 14:19:21,2025-05-30 09:17:18,consort-non-pharmacological,"[('title', 'CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Trials assessing nonpharmacologic treatments\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47.'), ('Language', 'English'), ('PubMed ID', '[28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](http://dev.equator-network.org/reporting-guidelines/consort/): Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n \xa0\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/):\xa0 Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](http://dev.equator-network.org/reporting-guidelines/consort-cluster/):\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-283. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n[**CONSORT PRO**](http://dev.equator-network.org/reporting-guidelines/consort-pro/): Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n**[CONSORT-CENT](http://dev.equator-network.org/reporting-guidelines/consort-cent/)**: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n**[CONSORT for orthodontic trials](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/)**: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n**[TIDieR](http://dev.equator-network.org/reporting-guidelines/tidier/)**: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n**[Simulation Research](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/)**: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'CONSORT Non-pharmacologic treatment interventions'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Abstract, Whole report'), ('Previous versions of this guideline / Guideline history', 'Boutron I, Moher D, Altman DG, Schulz K, Ravaud P, for the CONSORT group. Methods and Processes of the CONSORT Group: Example of an Extension for Trials Assessing Nonpharmacologic Treatments. Ann Intern Med. 2008:W60-W67. PMID: [18283201](http://www.ncbi.nlm.nih.gov/pubmed/18283201)\n\n \n\n Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. 2008;148(4):295-309. PMID: [18283207](http://www.ncbi.nlm.nih.gov/pubmed/18283207)\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
5807,"Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement","Clinical trials, Experimental studies",Complementary and alternative medicine,Whole report, ,"checklist, complementary and alternative medicine, complementary medicine, CONSORT, CONSORT extension, experimental studies, experimental study, extension, herbal, herbal intervention, herbal interventions, herbal medicinal product, herbal medicinal products, herbal medicine, herbal medicine intervention, herbal medicine interventions, herbal medicines, herbal product, herbal products, medicinal, medicinal product, medicinal products, randomised, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting Randomized, Controlled Trials of Herbal Interventions: An Elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367.","Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group.",Annals of Internal Medicine [Ann Intern Med.],2006,144,5,364-367, ,English, ,16520478,http://www.ncbi.nlm.nih.gov/pubmed/16520478, ,"Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol. 2006;59(11):1134-1149. PMID: 17027423

", ,"Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477



Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority:\xa0 Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-283. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,CONSORT Herbal,"Controlled trials of herbal interventions



", , , , , , , ,yes,2013-01-25 12:39:32,2025-05-30 09:16:58,consort-herbal,"[('title', 'Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Controlled trials of herbal interventions\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting Randomized, Controlled Trials of Herbal Interventions: An Elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367.'), ('Language', 'English'), ('PubMed ID', '[16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)'), ('Explanation and elaboration papers', 'Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol. 2006;59(11):1134-1149. PMID: [17027423](http://www.ncbi.nlm.nih.gov/pubmed/17027423)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](http://dev.equator-network.org/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n \xa0\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/):\xa0 Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](http://dev.equator-network.org/reporting-guidelines/consort-cluster/):\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-283. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n**[STRICTA Controlled trials of acupuncture](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):**MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n**[CONSORT PRO](http://dev.equator-network.org/reporting-guidelines/consort-pro/):** Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n**[CONSORT-CENT](http://dev.equator-network.org/reporting-guidelines/consort-cent/)**: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n**[CONSORT for orthodontic trials](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/)**: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n**[TIDieR](http://dev.equator-network.org/reporting-guidelines/tidier/)**: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'CONSORT Herbal'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'May 30, 2025')]"
5799,Consort 2010 statement: extension to cluster randomised trials,"Clinical trials, Experimental studies", ,Whole report, ,"checklist, cluster, cluster randomisation, cluster randomised trial, cluster randomised trials, cluster randomization, cluster randomized trial, cluster randomized trials, cluster trial, cluster trials, community, community based trial, community based trials, community trial, community trials, CONSORT, CONSORT 2010, CONSORT extension, experimental studies, experimental study, extension, field, field trial, field trials, group, group randomised trial, group randomised trials, group randomized trial, group randomized trials, group trial, group trials, place, place based trial, place based trials, randomised, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Campbell MK, Piaggio G, Elbourne DR, Altman DG; for the CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661.","Campbell MK, Piaggio G, Elbourne DR, Altman DG; for the CONSORT Group.",British Medical Journal [BMJ.],2012,345, , , ,English, ,22951546,http://www.ncbi.nlm.nih.gov/pubmed/22951546, , ,"The CONSORT 2010 statement: extension to cluster trials replaces the CONSORT statement: extension to cluster randomised trials published in 2004 (PMID: 15031246).

","Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477



Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority:\xa0 Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-283. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,CONSORT Cluster,"Cluster randomised trials



", , , , , , , ,yes,2013-01-25 11:44:48,2025-05-30 09:16:36,consort-cluster,"[('title', 'Consort 2010 statement: extension to cluster randomised trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Cluster randomised trials\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Campbell MK, Piaggio G, Elbourne DR, Altman DG; for the CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661.'), ('Language', 'English'), ('PubMed ID', '[22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](http://dev.equator-network.org/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n \xa0\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/):\xa0 Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-283. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n**[CONSORT PRO](http://dev.equator-network.org/reporting-guidelines/consort-pro/):** Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n**[CONSORT-CENT](http://dev.equator-network.org/reporting-guidelines/consort-cent/)**: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n**[CONSORT for orthodontic trials](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/)**: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n**[TIDieR](http://dev.equator-network.org/reporting-guidelines/tidier/)**: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'CONSORT Cluster'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Previous versions of this guideline / Guideline history', 'The CONSORT 2010 statement: extension to cluster trials replaces the CONSORT statement: extension to cluster randomised trials published in 2004 (PMID: [15031246](http://www.ncbi.nlm.nih.gov/pubmed/15031246)).\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
5791,Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement,"Clinical trials, Experimental studies", ,Whole report, ,"checklist, CONSORT, CONSORT 2010, CONSORT extension, equivalence, equivalence trial, equivalence trials, experimental studies, experimental study, extension, non-inferiority, noninferiority, noninferiority and equivalence trial, noninferiority and equivalence trials, noninferiority trial, noninferiority trials, randomised, randomised controlled trial, randomised controlled trials, randomised trial, randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308(24):2594-2604.","Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG; CONSORT Group.",Journal of the American Medical Association [JAMA.],2012,308,24,2594-2604, ,English, ,23268518,http://www.ncbi.nlm.nih.gov/pubmed/23268518, , ,"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement replaces reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement published in 2006 (PMID: 16522836).

","Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477



Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-283. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

STRICTA Controlled trials of acupuncture:\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: 20543992

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

", ,CONSORT Non-inferiority,"Reporting of noninferiority and equivalence randomized trials



", , , , , , , ,yes,2013-01-25 11:16:12,2025-05-30 09:16:14,consort-non-inferiority,"[('title', 'Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reporting of noninferiority and equivalence randomized trials\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308(24):2594-2604.'), ('Language', 'English'), ('PubMed ID', '[23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic**\n\n[**CONSORT 2025 Statement**](http://dev.equator-network.org/reporting-guidelines/consort/):\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n \xa0\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Cluster**](http://dev.equator-network.org/reporting-guidelines/consort-cluster/):\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-283. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n[**STRICTA Controlled trials of acupuncture**](http://dev.equator-network.org/reporting-guidelines/consort-stricta/):\xa0 MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261. PMID: [20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)\n\n \n\n**[CONSORT PRO](http://dev.equator-network.org/reporting-guidelines/consort-pro/):** Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n**[CONSORT-CENT](http://dev.equator-network.org/reporting-guidelines/consort-cent/)**: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n**[CONSORT for orthodontic trials](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/)**: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n**[TIDieR](http://dev.equator-network.org/reporting-guidelines/tidier/)**: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline acronym', 'CONSORT Non-inferiority'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Previous versions of this guideline / Guideline history', 'Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement replaces reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement published in 2006 (PMID: [16522836](http://www.ncbi.nlm.nih.gov/pubmed/16522836)).\n\n \n\n'), ('Record last updated on', 'May 30, 2025')]"
5780,Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement,"Clinical trials, Experimental studies",Complementary and alternative medicine,Whole report, ,"acupuncture, acupuncture controlled trial, acupuncture controlled trials, acupuncture trial, acupuncture trials, checklist, clinical, clinical trial, clinical trials, complementary and alternative medicine, complementary medicine, CONSORT, CONSORT extension, experimental studies, experimental study, extension, intervention, interventions, practitioner, regimen, STRICTA, trial, trials", ,"MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261.","MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group.",PLoS Medicine [PLoS Med.],2010,7,6, , ,English, ,20543992,http://www.ncbi.nlm.nih.gov/pubmed/20543992,The STRICTA checklist is available from the STRICTA website., ,"This revised guidance replaces STRICTA 2001 (PMID: 12184354 , PMID: 11926601, PMID: 11890439)","Generic
CONSORT 2025 Statement:\xa0Hopewell S, Chan AW, Collins GS, Hr\xf3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025; 388:e081123.\xa0PMID:\xa040228833
JAMA. 2025.\xa0PMID: 40228499
Lancet. 2025.\xa0PMID: 40245901
Nat Med. 2025.\xa0PMID: 40229553
PLoS Med. 2025; 22(4): e1004587.\xa0PMID:\xa040228477

Specialised
CONSORT Harms: Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, G\xf8tzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
BMJ. 2023;381:e073725. PMID: 37094878
J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: 37100738

CONSORT Non-inferiority:\xa0 Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: 23268518

CONSORT Cluster:\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: 22951546

CONSORT Herbal:\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: 16520478

CONSORT Non-pharmacological treatment interventions: Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: 28630973

CONSORT Abstracts:\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: 18215107

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-283. PMID: 18221781

CONSORT Pragmatic Trials: Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: 19001484

CONSORT PRO: Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822. PMID: 23443445

CONSORT-CENT: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: 25976398

CONSORT for orthodontic trials: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: 26038070

TIDieR: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: 24609605

Simulation Research: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: 27465839

CONSORT for pilot and feasibility trials: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: 27965879

CONSORT-CHM formulas: Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. Link to full-text.

CONSORT for within person randomised trials: Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: 28667088

CONSORT Equity: Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: 29170161

CONSORT-SPI: Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: 30060754

Stepped wedge cluster randomised trials: Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: 30413417

CONSORT for multi-arm parallel-group randomised trials: Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: 31012939

CONSORT 2010 extension to randomised crossover trials: Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: 31366597

CENT for TCM: Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: 31519276

STRICTOC: Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: 32021646

ACE Statement: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
BMJ. 2020;369:m115. PMID: 32554564
Trials. 2020;21(1):528. PMID: 32546273

CONSORT-AI: Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.
BMJ 2020;370:m3164. PMID: 32909959
Nat Med. 2020:26(9):1364?1374. PMID: 32908283
Lancet Digital Health. 2020;2(10):e537-e548. PMID: 33328048

CONSORT-ROUTINE: Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fr\xf6bert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauv\xe9 M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: 33926904

CONSORT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: 36511921

CONSORT-DEFINE: Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: 37863501

CONSORT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: 38051324

CONSORT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hr\xf3bjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: 38981645

CONSORT-iNeurostim: Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: 39606687

CONSORT CRXO: McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: 39761979

",http://www.stricta.info/,STRICTA,"Interventions in clinical trials of acupuncture



","The STRICTA statement has been translated into the following languages: Chinese; Japanese; Korean; Russian. ?Please visit the following URL for more information and full-text downloads: http://www.stricta.info/translations.htm

Visit our translations page to find out what other reporting guidelines are available in languages other than English: reporting guideline translations

", , , , , , ,yes,2013-01-24 16:08:43,2025-05-30 09:18:05,consort-stricta,"[('title', 'Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) : extending the CONSORT statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Interventions in clinical trials of acupuncture\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D; STRICTA Revision Group. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7(6):e1000261.'), ('Language', 'English'), ('PubMed ID', '[20543992](http://www.ncbi.nlm.nih.gov/pubmed/20543992)'), ('Relevant URLs\n\n(full-text if available)', 'The [STRICTA checklist](https://stricta.info/checklist/) is available from the STRICTA website.'), ('Availability in additional languages', 'The STRICTA statement has been translated into the following languages: Chinese; Japanese; Korean; Russian. \u2028Please visit the following URL for more information and full-text downloads: <http://www.stricta.info/translations.htm>\n\n \n\n Visit our translations page to find out what other reporting guidelines are available in languages other than English: [reporting guideline translations](/library/translations-of-reporting-guidelines/)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Generic\n\n[CONSORT 2025 Statement](http://dev.equator-network.org/reporting-guidelines/consort/)**:\xa0Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials.\n\n \n\n BMJ. 2025; 388:e081123.[PMID:40228833](https://pubmed.ncbi.nlm.nih.gov/40228833/)\n\n JAMA. 2025.[PMID: 40228499](https://pubmed.ncbi.nlm.nih.gov/40228499/)\n\n Lancet. 2025.[PMID: 40245901](https://pubmed.ncbi.nlm.nih.gov/40245901/)\n\n Nat Med. 2025.[PMID: 40229553](https://pubmed.ncbi.nlm.nih.gov/40229553/)\n\n PLoS Med. 2025; 22(4): e1004587.[PMID:40228477](https://pubmed.ncbi.nlm.nih.gov/40228477/)\n\n \n\n**Specialised**\n\n[**CONSORT Harms**](http://dev.equator-network.org/reporting-guidelines/consort-harms/): Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche PC, Moher D, Ioannidis JPA, Vohra S; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.\n\n BMJ. 2023;381:e073725. PMID: [37094878](https://pubmed.ncbi.nlm.nih.gov/37094878/)\n\n J Clin Epidemiol. 2023:S0895-4356(23)00090-2. PMID: [37100738](https://pubmed.ncbi.nlm.nih.gov/37100738/)\n\n \n\n[**CONSORT Non-inferiority**](http://dev.equator-network.org/reporting-guidelines/consort-non-inferiority/):\xa0 Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-2604. PMID: [23268518](http://www.ncbi.nlm.nih.gov/pubmed/23268518)\n\n \n\n[**CONSORT Cluster**](http://dev.equator-network.org/reporting-guidelines/consort-cluster/):\xa0 Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. PMID: [22951546](http://www.ncbi.nlm.nih.gov/pubmed/22951546)\n\n \n\n[**CONSORT Herbal**](http://dev.equator-network.org/reporting-guidelines/consort-herbal/):\xa0 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement. Ann Intern Med. 2006;144(5):364-367. PMID: [16520478](http://www.ncbi.nlm.nih.gov/pubmed/16520478)\n\n \n\n[**CONSORT Non-pharmacological treatment interventions**](http://dev.equator-network.org/reporting-guidelines/consort-non-pharmacological/): Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. PMID: [28630973](https://www.ncbi.nlm.nih.gov/pubmed/28630973)\n\n \n\n[**CONSORT Abstracts**](http://dev.equator-network.org/reporting-guidelines/consort-abstracts/):\xa0 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1):e20. PMID: [18215107](http://www.ncbi.nlm.nih.gov/pubmed/18215107)\n\n \n\n Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, the CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-283. PMID: [18221781](http://www.ncbi.nlm.nih.gov/pubmed/18221781)\n\n \n\n[**CONSORT Pragmatic Trials**](http://dev.equator-network.org/reporting-guidelines/consort-pragmatic/): Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. PMID: [19001484](http://www.ncbi.nlm.nih.gov/pubmed/19001484)\n\n \n\n**[CONSORT PRO](http://dev.equator-network.org/reporting-guidelines/consort-pro/):** Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822. PMID: [23443445](http://www.ncbi.nlm.nih.gov/pubmed/23443445)\n\n \n\n**[CONSORT-CENT](http://dev.equator-network.org/reporting-guidelines/consort-cent/)**: Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.BMJ. 2015;350:h1738.\xa0 PMID: [25976398](http://www.ncbi.nlm.nih.gov/pubmed/25976398)\n\n \n\n**[CONSORT for orthodontic trials](http://dev.equator-network.org/reporting-guidelines/the-consort-statement-application-within-and-adaptations-for-orthodontic-trials/)**: Pandis N, Fleming PS, Hopewell S, Altman DG. The CONSORT Statement: Application within and adaptations for orthodontic trials. Am J Orthod Dentofacial Orthop. 2015;147(6):663-679. PMID: [26038070](http://www.ncbi.nlm.nih.gov/pubmed/26038070)\n\n \n\n**[TIDieR](http://dev.equator-network.org/reporting-guidelines/tidier/)**: Hoffmann T, Glasziou P, Boutron I, Milne R, Perera R, Moher D, Altman D, Barbour V, Macdonald H, Johnston M, Lamb S, Dixon-Woods M, McCulloch P, Wyatt J, Chan A, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. PMID: [24609605](http://www.ncbi.nlm.nih.gov/pubmed/24609605)\n\n \n\n[**Simulation Research**](http://dev.equator-network.org/reporting-guidelines/reporting-guidelines-for-health-care-simulation-research-extensions-to-the-consort-and-strobe-statements/): Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. Simul Healthc. 2016;11(4):238-248. PMID: [27465839](http://www.ncbi.nlm.nih.gov/pubmed/27465839)\n\n \n\n[**CONSORT for pilot and feasibility trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-pilot-and-feasibility-trials/): Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Stud. 2016;2:64. PMID: [27965879](https://www.ncbi.nlm.nih.gov/pubmed/27965879)\n\n \n\n[**CONSORT-CHM formulas**](http://dev.equator-network.org/reporting-guidelines/consort-chinese-herbal-medicine-formulas/): Cheng C-W, Wu T-X, Shang H-C, Li Y-P, Altman DG, Moher D, Bian Z-X; for the CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. 2017. Ann Intern Med. [Link to full-text](http://annals.org/aim/article/2633843/consort-extension-chinese-herbal-medicine-formulas-2017-recommendations-explanation-elaboration).\n\n \n\n[**CONSORT for within person randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-within-person-randomised-trials/): Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ. 2017;357:j2835. PMID: [28667088](https://www.ncbi.nlm.nih.gov/pubmed/28667088)\n\n \n\n[**CONSORT Equity**](https://dev.equator-network.org/reporting-guidelines/consort-equity/): Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. BMJ. 2017;359:j5085. PMID: [29170161](https://www.ncbi.nlm.nih.gov/pubmed/29170161)\n\n \n\n[**CONSORT-SPI**](http://dev.equator-network.org/reporting-guidelines/consort-spi/): Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; on behalf of the CONSORT-SPI Group. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407. PMID: [30060754](https://www.ncbi.nlm.nih.gov/pubmed/30060754)\n\n \n\n[**Stepped wedge cluster randomised trials**](http://dev.equator-network.org/reporting-guidelines/reporting-of-stepped-wedge-cluster-randomised-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, Dixon-Woods M, Aldcroft A, Doussau A, Grayling M, Kristunas C, Goldstein CE, Campbell MK, Girling A, Eldridge S, Campbell MJ, Lilford RJ, Weijer C, Forbes AB, Grimshaw JM. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. PMID: [30413417](https://www.ncbi.nlm.nih.gov/pubmed/30413417)\n\n \n\n[**CONSORT for multi-arm parallel-group randomised trials**](http://dev.equator-network.org/reporting-guidelines/consort-multi-arm-parallel-group-randomized-trials/): Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019;321(16):1610-1620. PMID: [31012939](https://www.ncbi.nlm.nih.gov/pubmed/31012939)\n\n \n\n[**CONSORT 2010 extension to randomised crossover trials**](http://dev.equator-network.org/reporting-guidelines/consort-2010-statement-extension-to-randomised-crossover-trials/): Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378. PMID: [31366597](https://www.ncbi.nlm.nih.gov/pubmed/31366597)\n\n \n\n[**CENT for TCM**](http://dev.equator-network.org/reporting-guidelines/consort-extension-for-reporting-n-of-1-trials-for-traditional-chinese-medicine/): Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, Tian JH, Ma B, Yang KH, Dai M, Tian GH, Shang HC; CENT for TCM Working Group. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180-188. PMID: [31519276](https://www.ncbi.nlm.nih.gov/pubmed/31519276)\n\n \n\n[**STRICTOC**](https://dev.equator-network.org/reporting-guidelines/standards-for-reporting-interventions-in-clinical-trials-of-cupping-strictoc-extending-the-consort-statement/): Zhang X, Tian R, Lam WC, Duan Y, Liu F, Zhao C, Wu T, Shang H, Tang X, Lyu A, Bian Z. Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. Chin Med. 2020;15:10. PMID: [32021646](https://www.ncbi.nlm.nih.gov/pubmed/32021646)\n\n \n\n[**ACE Statement**](https://dev.equator-network.org/reporting-guidelines/the-adaptive-designs-consort-extension-ace-statement/): Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.\n\n BMJ. 2020;369:m115. PMID: [32554564](https://pubmed.ncbi.nlm.nih.gov/32554564/)\n\n Trials. 2020;21(1):528. PMID: [32546273](https://pubmed.ncbi.nlm.nih.gov/32546273/)\n\n \n\n[**CONSORT-AI**](https://dev.equator-network.org/reporting-guidelines/consort-artificial-intelligence/): Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension.\n\n BMJ 2020;370:m3164. PMID: [32909959](https://pubmed.ncbi.nlm.nih.gov/32909959/)\n\n Nat Med. 2020:26(9):1364–1374. PMID: [32908283](https://pubmed.ncbi.nlm.nih.gov/32908283/)\n\n Lancet Digital Health. 2020;2(10):e537-e548. PMID: [33328048](https://pubmed.ncbi.nlm.nih.gov/33328048/)\n\n \n\n[**CONSORT-ROUTINE**](https://dev.equator-network.org/reporting-guidelines/consort-routine/): Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thombs BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ. 2021;373:n857. PMID: [33926904](https://pubmed.ncbi.nlm.nih.gov/33926904/)\n\n \n\n[**CONSORT-Outcomes**](https://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-outcomes-in-trial-reports-the-consort-outcomes-2022-extension/): Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252-2264. PMID: [36511921](https://pubmed.ncbi.nlm.nih.gov/36511921/)\n\n \n\n[**CONSORT-DEFINE**](https://www.equator-network.org/reporting-guidelines/consort-define/): Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. 2023;383:e076387. PMID: [37863501](https://pubmed.ncbi.nlm.nih.gov/37863501/)\n\n \n\n[**CONSORT Factorial**](https://www.equator-network.org/reporting-guidelines/reporting-of-factorial-randomized-trials-extension-of-the-consort-2010-statement/): Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-2114. PMID: [38051324](https://pubmed.ncbi.nlm.nih.gov/38051324/)\n\n \n\n[**CONSORT-Surrogate**](https://www.equator-network.org/reporting-guidelines/consort-surrogate/): Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078524. PMID: [38981645](https://pubmed.ncbi.nlm.nih.gov/38981645/)\n\n \n\n[**CONSORT-iNeurostim**](https://www.equator-network.org/reporting-guidelines/reporting-guidelines-for-randomised-controlled-trial-reports-of-implantable-neurostimulation-devices-the-consort-ineurostim-extension/): Duarte RV, Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS. Reporting guidelines for randomised controlled trial reports of implantable neurostimulation devices: the CONSORT-iNeurostim extension. EClinicalMedicine. 2024;78:102932. PMID: [39606687](https://pubmed.ncbi.nlm.nih.gov/39606687/)\n\n \n\n[**CONSORT CRXO**](https://www.equator-network.org/reporting-guidelines/reporting-of-cluster-randomised-crossover-trials-extension-of-the-consort-2010-statement-with-explanation-and-elaboration/): McKenzie JE, Taljaard M, Hemming K, Arnup SJ, Giraudeau B, Eldridge S, Hooper R, Kahan BC, Li T, Moher D, Turner EL, Grimshaw JM, Forbes AB. Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2025;388:e080472. PMID: [39761979](https://pubmed.ncbi.nlm.nih.gov/39761979/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.stricta.info/>'), ('Reporting guideline acronym', 'STRICTA'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Complementary and alternative medicine'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Previous versions of this guideline / Guideline history', 'This revised guidance replaces STRICTA 2001 (PMID: [12184354](http://www.ncbi.nlm.nih.gov/pubmed/12184354) , PMID: [11926601](http://www.ncbi.nlm.nih.gov/pubmed/11926601), PMID: [11890439](http://www.ncbi.nlm.nih.gov/pubmed/11890439))'), ('Record last updated on', 'May 30, 2025')]"
5647,STARE-HI - Statement on reporting of evaluation studies in Health Informatics, ,Health informatics,Whole report, ,"evaluation, evaluation studies, evaluation study, evaluations, evidence based health informatics, health informatics, health informatics application, health informatics applications, health informatics evaluation, health informatics evaluations, health informatics intervention, health informatics interventions, health informatics studies, health informatics study, informatics, information technology, IT, STARE-HI", ,"Talmon J, Ammenwerth E, Brender J, de Keizer N, Nykanen P, Rigby M. STARE-HI - Statement on reporting of evaluation studies in Health Informatics. Int J Med Inform. 2009;78(1):1-9.","Talmon J, Ammenwerth E, Brender J, de Keizer N, Nykanen P, Rigby M.",International Journal of Medical Informatics [Int J Med Inform.],2009,78,1,1-9, ,English, ,18930696,http://www.ncbi.nlm.nih.gov/pubmed/18930696, ,"Brender J, Talmon J, de Keizer N, Nykanen P, Rigby M, Ammenwerth E.\xa0 STARE-HI - Statement on Reporting of Evaluation Studies in Health Informatics: Explanation and Elaboration. Appl Clin Inform. 2013;4(3):331-358. PMID: 24155788

", ,"Specialised
STARE-HI Conference papers: de Keizer NF, Talmon J, Ammenwerth E, Brender J, Rigby M, Nykanen P. Systematic prioritization of the STARE-HI reporting items. An application to short conference papers on health informatics evaluation. Methods Inf Med. 2012;51(2):104-111. PMID: 21373719", ,STARE-HI,Evaluation studies in health informatics, , , , , , , ,no,2012-12-05 15:51:00,2022-01-14 16:17:58,stare-hi-statement-on-reporting-of-evaluation-studies-in-health-informatics,"[('title', 'STARE-HI – Statement on reporting of evaluation studies in Health Informatics'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Evaluation studies in health informatics'), ('Full bibliographic reference', 'Talmon J, Ammenwerth E, Brender J, de Keizer N, Nykanen P, Rigby M. STARE-HI - Statement on reporting of evaluation studies in Health Informatics. Int J Med Inform. 2009;78(1):1-9.'), ('Language', 'English'), ('PubMed ID', '[18930696](http://www.ncbi.nlm.nih.gov/pubmed/18930696)'), ('Explanation and elaboration papers', 'Brender J, Talmon J, de Keizer N, Nykanen P, Rigby M, Ammenwerth E.\xa0 STARE-HI - Statement on Reporting of Evaluation Studies in Health Informatics: Explanation and Elaboration. Appl Clin Inform. 2013;4(3):331-358. PMID: [24155788](https://www.ncbi.nlm.nih.gov/pubmed/24155788)\n\n \n\n'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Specialised**\n\n**STARE-HI Conference papers**: de Keizer NF, Talmon J, Ammenwerth E, Brender J, Rigby M, Nykanen P. Systematic prioritization of the STARE-HI reporting items. An application to short conference papers on health informatics evaluation. Methods Inf Med. 2012;51(2):104-111. PMID: [21373719](http://www.ncbi.nlm.nih.gov/pubmed/21373719)'), ('Reporting guideline acronym', 'STARE-HI'), ('Clinical area', 'Health informatics'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 14, 2022')]"
5644,The ORION statement: guidelines for transparent reporting of Outbreak Reports and Intervention studies Of Nosocomial infection,"Clinical trials, Experimental studies, Observational studies, Other",Infectious diseases,Whole report, ,"antimicrobial resistance, checklist, clinical studies, clinical study, experimental studies, experimental study, HCAI, health-care associated infection, health-care associated infections, hospital, hospital epidemiology, infection, infection control, infectious disease epidemiology, infectious diseases, interrupted time series, intervention studies, intervention study, non-randomised, non-randomized, nonrandomised, nonrandomized, nosocomial, nosocomial infection, observational studies, observational study, ORION, ORION statement, outbreak report, outbreak reports, quasi experimental, quasi-experimental studies, quasi-experimental study, statistical technique, statistical techniques", ,"Stone SP, Cooper BS, Kibbler CC, Cookson BD, Roberts JA, Medley GF, Duckworth G, Lai R, Ebrahim S, Brown EM, Wiffen PJ, Davey PG. The ORION statement: guidelines for transparent reporting of Outbreak Reports and Intervention studies Of Nosocomial infection.

This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.

J Antimicrob Chemother. 2007;59(5):833-840. PMID: 17387116
Lancet Infect Dis. 2007;7(4):282?288. PMID: 17376385","Stone SP, Cooper BS, Kibbler CC, Cookson BD, Roberts JA, Medley GF, Duckworth G, Lai R, Ebrahim S, Brown EM, Wiffen PJ, Davey PG.", ,2007, , , , ,English, , , ,The full-text of the ORION Statement and checklist is available from: https://www.ucl.ac.uk/amr/Reporting_Guidelines/ORION, , , ,https://www.ucl.ac.uk/amr/Reporting_Guidelines/ORION,ORION,"Outbreak reports and intervention studies of nosocomial infection.



ORION Checklist (PDF)

", ,"A version of the ORION checklist has also been developed for conference submissions: ORION for abstracts (PDF)

A version of the ORION checklist has also been developed for peer reviewers: ORION peer review checklist (PDF)

", , , , , ,no,2012-12-05 15:26:11,2022-01-14 16:20:15,the-orion-statement-guidelines-for-transparent-reporting-of-outbreak-reports-and-intervention-studies-of-nosocomial-infection,"[('title', 'The ORION statement: guidelines for transparent reporting of Outbreak Reports and Intervention studies Of Nosocomial infection'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Outbreak reports and intervention studies of nosocomial infection.\n\n \n\n \xa0\n\n \n\n[ORION Checklist (PDF)](https://www.ucl.ac.uk/drupal/site_antimicrobial-resistance/sites/antimicrobial-resistance/files/checklist_authors.pdf)\n\n \n\n'), ('Full bibliographic reference', 'Stone SP, Cooper BS, Kibbler CC, Cookson BD, Roberts JA, Medley GF, Duckworth G, Lai R, Ebrahim S, Brown EM, Wiffen PJ, Davey PG. The ORION statement: guidelines for transparent reporting of Outbreak Reports and Intervention studies Of Nosocomial infection.\n\n \n\n This guideline was published simultaneously in 2 journals. You can read the guideline in either of these journals using the links below.\n\n \n\n J Antimicrob Chemother. 2007;59(5):833-840. PMID: [17387116](http://www.ncbi.nlm.nih.gov/pubmed/17387116)\n\n Lancet Infect Dis. 2007;7(4):282–288. PMID: [17376385](http://www.ncbi.nlm.nih.gov/pubmed/17376385)'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the ORION Statement and checklist is available from: <https://www.ucl.ac.uk/amr/Reporting_Guidelines/ORION>'), ('Reporting guideline website URL', '<https://www.ucl.ac.uk/amr/Reporting_Guidelines/ORION>'), ('Reporting guideline acronym', 'ORION'), ('Study design', 'Clinical trials, Experimental studies, Observational studies, Other'), ('Clinical area', 'Infectious diseases'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Additional information', 'A version of the ORION checklist has also been developed for conference submissions: [ORION for abstracts (PDF)](https://www.ucl.ac.uk/drupal/site_antimicrobial-resistance/sites/antimicrobial-resistance/files/checklist_abstracts.pdf)\n\n \n\n A version of the ORION checklist has also been developed for peer reviewers: [ORION peer review checklist (PDF)](https://www.ucl.ac.uk/drupal/site_antimicrobial-resistance/sites/antimicrobial-resistance/files/checklist_reviewers.pdf)\n\n \n\n'), ('Record last updated on', 'January 14, 2022')]"
5640,Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1,"Clinical trials, Experimental studies","Haematology, Oncology",Whole report, ,"cancer, clinical trial, clinical trials, experimental studies, experimental study, haematology, hematology, International Myeloma Workshop Consensus Panel, multiple myeloma, myeloma, oncology, plasma cell myeloma, response criteria, trial, trials", ,"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-4695.","Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J; International Myeloma Workshop Consensus Panel 1.",Blood.,2011,117,18,4691-4695, , , ,21292775,http://www.ncbi.nlm.nih.gov/pubmed/21292775, , , , , , ,Myeloma clinical trials, , , , , , , ,no,2012-12-05 14:34:35,2013-10-24 11:10:33,consensus-recommendations-for-the-uniform-reporting-of-clinical-trials-report-of-the-international-myeloma-workshop-consensus-panel-1,"[('title', 'Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Myeloma clinical trials'), ('Full bibliographic reference', 'Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-4695.'), ('PubMed ID', '[21292775](http://www.ncbi.nlm.nih.gov/pubmed/21292775)'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Haematology, Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 24, 2013')]"
5637,"Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting","Clinical trials, Economic evaluations, Experimental studies", ,Whole report, ,"cost effectiveness, costs, decision analytical model, decision analytical models, economic evaluation, economic evaluations, experimental studies, experimental study, health benefit, health benefits, individual patient data, patient data, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Petrou S, Gray A. Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. BMJ. 2011;342:d1548.","Petrou S, Gray A.",British Medical Journal [BMJ.],2011, ,342, , ,English, ,21474510,http://www.ncbi.nlm.nih.gov/pubmed/21474510, , , , , , ,Economic evaluation alongside randomised controlled trials, , , , , , , ,no,2012-12-05 14:26:19,2013-10-02 15:30:51,economic-evaluation-alongside-randomised-controlled-trials-design-conduct-analysis-and-reporting,"[('title', 'Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Economic evaluation alongside randomised controlled trials'), ('Full bibliographic reference', 'Petrou S, Gray A. Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. BMJ. 2011;342:d1548.'), ('Language', 'English'), ('PubMed ID', '[21474510](http://www.ncbi.nlm.nih.gov/pubmed/21474510)'), ('Study design', 'Clinical trials, Economic evaluations, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 2, 2013')]"
5634,Reporting and presenting information retrieval processes: the need for optimizing common practice in health technology assessment,Systematic reviews/Meta-analyses/Reviews/HTA/Overviews, ,Procedure/Method, ,"bibliographic database, bibliographic databases, database, databases, hand search, hand searches, hand searching, health technology assessment, HTA, information retrieval, IR, literature search, literature searches, literature searching, quality control, retrieval, search, search histories, search history, search strategies, search strategy, searching, technology assessment, templates", ,"Niederstadt C, Droste S. Reporting and presenting information retrieval processes: the need for optimizing common practice in health technology assessment. Int J Technol Assess Health Care. 2010;26(4):450-457.","Niederstadt C, Droste S.",International Journal of Technology Assessment in Health Care [Int J Technol Assess Health Care.],2010,26,4,450-457, ,English, ,20942989,http://www.ncbi.nlm.nih.gov/pubmed/20942989, , , , , , ,Information retrieval processes in health technology assessment, ,"For terminology and reporting of citation searching use the TARCiS Checklist
Word | PDF | TARCiS website

", , , , , ,no,2012-12-05 14:10:43,2024-04-05 15:30:54,reporting-and-presenting-information-retrieval-processes-the-need-for-optimizing-common-practice-in-health-technology-assessment,"[('title', 'Reporting and presenting information retrieval processes: the need for optimizing common practice in health technology assessment'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Information retrieval processes in health technology assessment'), ('Full bibliographic reference', 'Niederstadt C, Droste S. Reporting and presenting information retrieval processes: the need for optimizing common practice in health technology assessment. Int J Technol Assess Health Care. 2010;26(4):450-457.'), ('Language', 'English'), ('PubMed ID', '[20942989](http://www.ncbi.nlm.nih.gov/pubmed/20942989)'), ('Study design', 'Systematic reviews/Meta-analyses/Reviews/HTA/Overviews'), ('Applies to the whole report or to individual sections of the report?', 'Procedure/Method'), ('Additional information', 'For terminology and reporting of citation searching use the TARCiS Checklist\n\n[Word](https://ub.unibas.ch/fileadmin/user_upload/universitaetsbibliothek/Universitaetsbibliothek/5_Standorte/UB_Medizin/TARCiS/TARCiS_Checklist_for_Terminology_and_Reporting_of_Citation_Searching.docx) | [PDF](https://ub.unibas.ch/fileadmin/user_upload/universitaetsbibliothek/Universitaetsbibliothek/5_Standorte/UB_Medizin/TARCiS/TARCiS_Checklist_for_Terminology_and_Reporting_of_Citation_Searching.pdf) | [TARCiS website](https://ub.unibas.ch/de/ub-medizin/tarcis/)\n\n \n\n'), ('Record last updated on', 'April 5, 2024')]"
5632,Guidelines for reporting reliability and agreement studies (GRRAS) were proposed,Reliability and agreement studies, ,Whole report, ,"agreement, classification, classifications, GRRAS, instrument, instruments, interrater, interrater agreement, interrater reliability, interrater reliability and agreement studies, interrater reliability and agreement study, intrarater, intrarater agreement, intrarater reliability, intrarater reliability and agreement studies, intrarater reliability and agreement study, reliability, reliability and agreement, reliability and agreement studies, reliability and agreement study, scale, scales", ,"Kottner J, Audig\xe9 L, Brorson S, Donner A, Gajeweski BJ, Hr\xf3bjartsson A, Robersts C, Shoukri M, Streiner DL. Guidelines for reporting reliability and agreement studies (GRRAS) were proposed.

J Clin Epidemiol.\xa0 2011;64(1):96-106 PMID: 21130355
Int J Nurs Stud. 2011;48(6):661-671. PMID: 21514934","Kottner J, Audig\xe9 L, Brorson S, Donner A, Gajeweski BJ, Hr\xf3bjartsson A, Robersts C, Shoukri M, Streiner DL.", ,2011, , , , ,English, , , , , , , , ,GRRAS,"Reliability and agreement studies.



", , , , , , , ,no,2012-12-05 11:56:46,2022-01-14 16:21:56,guidelines-for-reporting-reliability-and-agreement-studies-grras-were-proposed,"[('title', 'Guidelines for reporting reliability and agreement studies (GRRAS) were proposed'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Reliability and agreement studies.\n\n \n\n \xa0\n\n \n\n'), ('Full bibliographic reference', 'Kottner J, Audigé L, Brorson S, Donner A, Gajeweski BJ, Hróbjartsson A, Robersts C, Shoukri M, Streiner DL. Guidelines for reporting reliability and agreement studies (GRRAS) were proposed.\n\n \n\n J Clin Epidemiol.\xa0 2011;64(1):96-106 PMID: [21130355](http://www.ncbi.nlm.nih.gov/pubmed/21130355)\n\n Int J Nurs Stud. 2011;48(6):661-671. PMID: [21514934](http://www.ncbi.nlm.nih.gov/pubmed?term=21514934)'), ('Language', 'English'), ('Reporting guideline acronym', 'GRRAS'), ('Study design', 'Reliability and agreement studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 14, 2022')]"
5630,SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process,Quality improvement studies, ,Whole report, ,"healthcare improvement, improvement, improvement program, improvement programme, improvement programmes, improvement programs, improvement studies, improvement study, improvement work, improvements, quality, quality improvement, quality improvement intervention, quality improvement interventions, quality improvement studies, quality improvement study, quality improvement work, quality improvements, safety, SQUIRE, SQUIRE 1.0, SQUIRE 2.0, SQUIRE 2.0 guidelines, SQUIRE 2.0 statement, SQUIRE statement, value", ,"Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.

This guideline was published simultaneously in 7 journals. You can read the guideline in any of these journals using the links below.

BMJ Qual Saf. 2015. PMID: 26369893
J Nurs Care Qual. 2015. PMID: 26429125
Am J Crit Care. 2015. PMID: 26523003
Perm J. 2015. PMID: 26517437
J Surg Res. 2015. PMID: 26515734
J Contin Educ Nurs. 2015. PMID: 26509402
J Am Coll Surg. 2016;222(3):317-323. PMID: 26385723

","Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D.", ,2015, , , , ,English, , , ,"The full-text of the SQUIRE 2.0 update, published in 2015, is available from: SQUIRE 2.0","Goodman D, Ogrinc G, Davies L, Baker GR, Barnsteiner J, Foster TC, Gali K, Hilden J, Horwitz L, Kaplan HC, Leis J, Matulis JC, Michie S, Miltner R, Neily J, Nelson WA, Niedner M, Oliver B, Rutman L, Thomson R, Thor J. Explanation and elaboration of the SQUIRE (Standards for Quality Improvement Reporting Excellence) Guidelines, V.2.0: examples of SQUIRE elements in the healthcare improvement literature. BMJ Qual Saf. 2016;25(12):e7. PMID: 27076505

","SQUIRE 1.0
The SQUIRE reporting guideline was originally published in 2008.

Davidoff F, Batalden P, Stevens D, Ogrinc G, Mooney S. Publication guidelines for quality improvement in health care: evolution of the SQUIRE project.

Qual Saf Health Care. 2008;17 Suppl 1:i3-i9. PMID: 18836063
BMJ. 2009; 338:a3152. PMID: 19153129
Jt Comm J Qual Patient Saf. 2008;34(11):681-687. PMID: 19025090
Ann Intern Med. 2008;149(9):670-676. PMID: 18981488
J Gen Intern Med. 2008;23(12):2125-2130. PMID: 18830766

Ogrinc G, Mooney SE, Estrada C, Foster T, Goldmann D, Hall LW, Huizinga MM, Liu SK, Mills P, Neily J, Nelson W, Pronovost PJ, Provost L, Rubenstein LV, Speroff T, Splaine M, Thomson R, Tomolo AM, Watts B. The SQUIRE (Standards for QUality Improvement Reporting Excellence) guidelines for quality improvement reporting: explanation and elaboration. Qual Saf Health Care. 2008;17 Suppl 1:i13-32. PMID: 18836062

","Specialised
SQUIRE-EDU: Ogrinc G, Armstrong GE, Dolansky MA, Singh MK, Davies L. SQUIRE-EDU (Standards for QUality Improvement Reporting Excellence in Education): Publication Guidelines for Educational Improvement. Acad Med. 2019 Oct;94(10):1461-1470. PMID: 30998575

SQUIRE-SIM: Stone KP, Rutman L, Calhoun AW, Reid J, Maa T, Bajaj K, Auerbach MA, Cheng A, Davies L, Deutsch E, Harwayne-Gidansky I, Kessler DO, Ogrinc G, Patterson M, Thomas A, Doughty C; And for the International Network in Simulation-Based Innovation, Research and Education (INSPIRE) SQUIRE-SIM Reporting Guidelines Investigators. SQUIRE-SIM (Standards for Quality Improvement Reporting Excellence for SIMulation): Publication Guidelines for Simulation-Based Quality Improvement Projects. Simul Healthc. 2024. PMID: 39162794

",http://www.squire-statement.org/,SQUIRE 2.0,"Quality improvement in health care



SQUIRE 2.0 checklist (PDF) - 2015 update

",The SQUIRE 2.0 guideline is available in Italian., , , ,"An online fillable SQUIRE checklist is also available via the GoodReports website at https://www.goodreports.org/reporting-checklists/squire/.

", , ,yes,2012-12-05 11:44:23,2025-03-26 14:48:45,squire,"[('title', 'SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Quality improvement in health care\n\n \n\n \xa0\n\n \n\n[SQUIRE 2.0 checklist (PDF)](/wp-content/uploads/2012/12/SQUIRE-2.0-checklist.pdf) - 2015 update\n\n \n\n'), ('Full bibliographic reference', 'Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.\n\n \n\n This guideline was published simultaneously in 7 journals. You can read the guideline in any of these journals using the links below.\n\n \n\n BMJ Qual Saf. 2015. PMID: [26369893](http://www.ncbi.nlm.nih.gov/pubmed/26369893)\n\n J Nurs Care Qual. 2015. PMID: [26429125](http://www.ncbi.nlm.nih.gov/pubmed/26429125)\n\n Am J Crit Care. 2015. PMID: [26523003](http://www.ncbi.nlm.nih.gov/pubmed/26523003)\n\n Perm J. 2015. PMID: [26517437](http://www.ncbi.nlm.nih.gov/pubmed/26517437)\n\n J Surg Res. 2015. PMID: [26515734](http://www.ncbi.nlm.nih.gov/pubmed/26515734)\n\n J Contin Educ Nurs. 2015. PMID: [26509402](http://www.ncbi.nlm.nih.gov/pubmed/26509402)\n\n J Am Coll Surg. 2016;222(3):317-323. PMID: [26385723](http://www.ncbi.nlm.nih.gov/pubmed/26385723)\n\n \n\n'), ('Language', 'English'), ('Relevant URLs\n\n(full-text if available)', 'The full-text of the SQUIRE 2.0 update, published in 2015, is available from: [SQUIRE 2.0](http://www.squire-statement.org/index.cfm?fuseaction=page.viewPage&pageID=471)'), ('Explanation and elaboration papers', 'Goodman D, Ogrinc G, Davies L, Baker GR, Barnsteiner J, Foster TC, Gali K, Hilden J, Horwitz L, Kaplan HC, Leis J, Matulis JC, Michie S, Miltner R, Neily J, Nelson WA, Niedner M, Oliver B, Rutman L, Thomson R, Thor J. Explanation and elaboration of the SQUIRE (Standards for Quality Improvement Reporting Excellence) Guidelines, V.2.0: examples of SQUIRE elements in the healthcare improvement literature. BMJ Qual Saf. 2016;25(12):e7. PMID: [27076505](https://pubmed.ncbi.nlm.nih.gov/27076505/)\n\n \n\n'), ('Availability in additional languages', 'The SQUIRE 2.0 guideline is available in [Italian](http://www.evidence.it/articolodettaglio/209/it/470/squire-20-standard-per-leccellenza-nel-reporting-degli-stud/articolo).'), ('Relevant more generic / specialised reporting guidelines\n\n(i.e. main generic guideline or extension to a generic guideline)', '**Specialised**\n\n[**SQUIRE-EDU**](https://www.equator-network.org/reporting-guidelines/squire-edu-standards-for-quality-improvement-reporting-excellence-in-education-publication-guidelines-for-educational-improvement/): Ogrinc G, Armstrong GE, Dolansky MA, Singh MK, Davies L. SQUIRE-EDU (Standards for QUality Improvement Reporting Excellence in Education): Publication Guidelines for Educational Improvement. Acad Med. 2019 Oct;94(10):1461-1470. PMID: [30998575](https://pubmed.ncbi.nlm.nih.gov/30998575/)\n\n \n\n[**SQUIRE-SIM**](https://www.equator-network.org/reporting-guidelines/squire-sim-standards-for-quality-improvement-reporting-excellence-for-simulation-publication-guidelines-for-simulation-based-quality-improvement-projects/): Stone KP, Rutman L, Calhoun AW, Reid J, Maa T, Bajaj K, Auerbach MA, Cheng A, Davies L, Deutsch E, Harwayne-Gidansky I, Kessler DO, Ogrinc G, Patterson M, Thomas A, Doughty C; And for the International Network in Simulation-Based Innovation, Research and Education (INSPIRE) SQUIRE-SIM Reporting Guidelines Investigators. SQUIRE-SIM (Standards for Quality Improvement Reporting Excellence for SIMulation): Publication Guidelines for Simulation-Based Quality Improvement Projects. Simul Healthc. 2024. PMID: [39162794](https://pubmed.ncbi.nlm.nih.gov/39162794/)\n\n \n\n'), ('Reporting guideline website URL', '<http://www.squire-statement.org/>'), ('Reporting guideline acronym', 'SQUIRE 2.0'), ('Study design', 'Quality improvement studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Previous versions of this guideline / Guideline history', '**SQUIRE 1.0\n\n**The SQUIRE reporting guideline was originally published in 2008.\n\n \n\n Davidoff F, Batalden P, Stevens D, Ogrinc G, Mooney S. Publication guidelines for quality improvement in health care: evolution of the SQUIRE project.\n\n \n\n Qual Saf Health Care. 2008;17 Suppl 1:i3-i9. PMID: [18836063\n\n](http://www.ncbi.nlm.nih.gov/pubmed/18836063)BMJ. 2009; 338:a3152. PMID: [19153129](http://www.ncbi.nlm.nih.gov/pubmed/19153129)\n\n Jt Comm J Qual Patient Saf. 2008;34(11):681-687. PMID: [19025090](http://www.ncbi.nlm.nih.gov/pubmed/19025090)\n\n Ann Intern Med. 2008;149(9):670-676. PMID: [18981488](http://www.ncbi.nlm.nih.gov/pubmed/18981488)\n\n J Gen Intern Med. 2008;23(12):2125-2130. PMID: [18830766](http://www.ncbi.nlm.nih.gov/pubmed/18830766)\n\n \n\n Ogrinc G, Mooney SE, Estrada C, Foster T, Goldmann D, Hall LW, Huizinga MM, Liu SK, Mills P, Neily J, Nelson W, Pronovost PJ, Provost L, Rubenstein LV, Speroff T, Splaine M, Thomson R, Tomolo AM, Watts B. The SQUIRE (Standards for QUality Improvement Reporting Excellence) guidelines for quality improvement reporting: explanation and elaboration. Qual Saf Health Care. 2008;17 Suppl 1:i13-32. PMID: [18836062](http://www.ncbi.nlm.nih.gov/pubmed/18836062)\n\n \n\n'), ('Other', 'An online fillable SQUIRE checklist is also available via the GoodReports website at <https://www.goodreports.org/reporting-checklists/squire/>.\n\n \n\n'), ('Record last updated on', 'March 26, 2025')]"
5627,Refining a checklist for reporting patient populations and service characteristics in hospice and palliative care research, ,Palliative care,Study characteristics (participants etc.), ,"applicability, checklist, external validity, generalisability, generalizability, health systems, hospice, hospice and palliative care, hospice care, hospice care research, hospice research, hospices, palliative, palliative care, palliative care research, palliative research, patient, patient population, patient populations, patients, population, populations, service characteristics, service configuration, service delivery, study characteristics, supportive care", ,"Currow DC, Tieman JJ, Greene A, Zafar SY, Wheeler JL, Abernethy AP. Refining a checklist for reporting patient populations and service characteristics in hospice and palliative care research. J Pain Symptom Manage. 2012;43(5):902-910.","Currow DC, Tieman JJ, Greene A, Zafar SY, Wheeler JL, Abernethy AP.",Journal of Pain and Symptom Management [J Pain Symptom Manage.],2012,43,5,902-910, ,English, ,22445274,http://www.ncbi.nlm.nih.gov/pubmed/22445274, , , , , , ,Patient populations and service characteristics in hospice and palliative care research, , , , , , , ,no,2012-12-05 11:27:01,2015-01-27 15:01:46,refining-a-checklist-for-reporting-patient-populations-and-service-characteristics-in-hospice-and-palliative-care-research,"[('title', 'Refining a checklist for reporting patient populations and service characteristics in hospice and palliative care research'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Patient populations and service characteristics in hospice and palliative care research'), ('Full bibliographic reference', 'Currow DC, Tieman JJ, Greene A, Zafar SY, Wheeler JL, Abernethy AP. Refining a checklist for reporting patient populations and service characteristics in hospice and palliative care research. J Pain Symptom Manage. 2012;43(5):902-910.'), ('Language', 'English'), ('PubMed ID', '[22445274](http://www.ncbi.nlm.nih.gov/pubmed/22445274)'), ('Clinical area', 'Palliative care'), ('Applies to the whole report or to individual sections of the report?', 'Study characteristics (participants etc.)'), ('Record last updated on', 'January 27, 2015')]"
5625,"Point and interval estimates of effect sizes for the case-controls design in neuropsychology: rationale, methods, implementations, and proposed reporting standards",Observational studies,"Neurology, Psychology",Statistical methods and analyses, ,"Bayesian, Bayesian inferential method, Bayesian inferential methods, case control, case-control, classical inferential method, classical inferential methods, computer program, computer programme, computer programmes, computer programs, effect size, effect sizes, estimations, inferential, interval estimate, interval estimates, neurology, neuropsychology, observational studies, observational study, point and interval estimates, point estimate, point estimates, psychology, single-case", ,"Crawford JR, Garthwaite PH, Porter S. Point and interval estimates of effect sizes for the case-controls design in neuropsychology: rationale, methods, implementations, and proposed reporting standards. Cogn Neuropsychol. 2010;27(3):245-260.","Crawford JR, Garthwaite PH, Porter S.",Cognitive Neuropsychology [Cogn Neuropsychol.],2010,27,3,245-260, ,English, ,20936548,http://www.ncbi.nlm.nih.gov/pubmed/20936548, , , , , , ,Point and interval estimates of effect sizes for case-controls design in neuropsychology, , , , , , , ,no,2012-12-05 11:15:22,2013-10-24 11:18:27,point-and-interval-estimates-of-effect-sizes-for-the-case-controls-design-in-neuropsychology-rationale-methods-implementations-and-proposed-reporting-standards,"[('title', 'Point and interval estimates of effect sizes for the case-controls design in neuropsychology: rationale, methods, implementations, and proposed reporting standards'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Point and interval estimates of effect sizes for case-controls design in neuropsychology'), ('Full bibliographic reference', 'Crawford JR, Garthwaite PH, Porter S. Point and interval estimates of effect sizes for the case-controls design in neuropsychology: rationale, methods, implementations, and proposed reporting standards. Cogn Neuropsychol. 2010;27(3):245-260.'), ('Language', 'English'), ('PubMed ID', '[20936548](http://www.ncbi.nlm.nih.gov/pubmed/20936548)'), ('Study design', 'Observational studies'), ('Clinical area', 'Neurology, Psychology'), ('Applies to the whole report or to individual sections of the report?', 'Statistical methods and analyses'), ('Record last updated on', 'October 24, 2013')]"
5565,Recommended guidelines for uniform reporting of pediatric advanced life support: the pediatric Utstein style, ,Paediatrics,Whole report, ,"advanced life support, ALS, American Academy of Pediatrics, American Heart Association, child, children, data, life support, paediatric, paediatric advanced life support, paediatric ALS, paediatric resuscitation, paediatric Utstein, paediatrics, pediatric, pediatric advanced life support, pediatric ALS, pediatric resuscitation, pediatric Utstein, pediatrics, resuscitation, task force, Utstein", ,"Zaritsky A, Nadkarni V, Hazinski MF, Foltin G, Quan L, Wright J, Fiser D, Zideman D, O'Malley P, Chameides L. Recommended guidelines for uniform reporting of pediatric advanced life support: the pediatric Utstein style. Ann Emerg Med. 1995;26(4):487-503.","Zaritsky A, Nadkarni V, Hazinski MF, Foltin G, Quan L, Wright J, Fiser D, Zideman D, O'Malley P, Chameides L.","Annals of Emergency Medicine [Ann Emerg Med.]

",1995,26,4,487-503, ,English, ,7574133,http://www.ncbi.nlm.nih.gov/pubmed/7574133, , , , , , ,Paediatric advanced life support, , , , , , , ,no,2012-11-29 11:57:48,2013-10-24 11:19:06,recommended-guidelines-for-uniform-reporting-of-pediatric-advanced-life-support-the-pediatric-utstein-style,"[('title', 'Recommended guidelines for uniform reporting of pediatric advanced life support: the pediatric Utstein style'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Paediatric advanced life support'), ('Full bibliographic reference', ""Zaritsky A, Nadkarni V, Hazinski MF, Foltin G, Quan L, Wright J, Fiser D, Zideman D, O'Malley P, Chameides L. Recommended guidelines for uniform reporting of pediatric advanced life support: the pediatric Utstein style. Ann Emerg Med. 1995;26(4):487-503.""), ('Language', 'English'), ('PubMed ID', '[7574133](http://www.ncbi.nlm.nih.gov/pubmed/7574133)'), ('Clinical area', 'Paediatrics'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 24, 2013')]"
5563,Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups,Qualitative research, ,Whole report, ,"checklist, checklists, COREQ, data collection, discussion, discussions, focus group, focus groups, in-depth interviews, interview, interviews, qualitative, qualitative health research, qualitative method, qualitative methods, qualitative research, qualitative studies, qualitative study, sampling, semi-structured interviews, validation", ,"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349-357.","Tong A, Sainsbury P, Craig J.",International Journal of Quality in Health Care [Int J Qual Health Care.],2007,19,6,349-357, ,English, ,17872937,http://www.ncbi.nlm.nih.gov/Pubmed/17872937,Full-text available from: http://intqhc.oxfordjournals.org/content/19/6/349.long, , , , ,COREQ,Qualitative research interviews and focus groups,The COREQ checklist is available in Portuguese (Brazil) (PDF) and Spanish., , , , , , ,yes,2012-11-29 11:57:24,2023-12-06 17:25:15,coreq,"[('title', 'Consolidated criteria for reporting qualitative research (COREQ) : a 32-item checklist for interviews and focus groups'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Qualitative research interviews and focus groups'), ('Full bibliographic reference', 'Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349-357.'), ('Language', 'English'), ('PubMed ID', '[17872937](http://www.ncbi.nlm.nih.gov/Pubmed/17872937)'), ('Relevant URLs\n\n(full-text if available)', 'Full-text available from: <http://intqhc.oxfordjournals.org/content/19/6/349.long>'), ('Availability in additional languages', 'The COREQ checklist is available in [Portuguese (Brazil) (PDF)](https://www.equator-network.org/wp-content/uploads/2021/03/VERSA%CC%83O-FINAL-COREQ.pdf) and [Spanish](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-03192023000100046&lng=es&nrm=iso).'), ('Reporting guideline acronym', 'COREQ'), ('Study design', 'Qualitative research'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'December 6, 2023')]"
5561,Guidelines for reporting results of quality of life assessments in clinical trials,"Clinical trials, Experimental studies", ,Whole report, ,"assessment, checklist, clinical trial, clinical trials, data, experimental studies, experimental study, health-related quality of life, instrument, psychometric, QoL, QoL assessment, QoL assessments, QoL data, quality, quality of life, quality of life assessment, quality of life assessments, quality of life measurement, quality of life measurements, randomised, randomised controlled trial, randomised controlled trials, randomised trial, Randomised trials, randomized, randomized controlled trial, randomized controlled trials, randomized trial, randomized trials, RCT, RCTs, trial, trials", ,"Staquet M, Berzon R, Osoba D, Machin D. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res. 1996;5(5):496-502.","Staquet M, Berzon R, Osoba D, Machin D.",Quality of Life Research [Qual Life Res.],1996,5,5,496-502, ,English, ,8973129,http://www.ncbi.nlm.nih.gov/pubmed/8973129, , , , , , ,Quality of life assessments in clinical trials, , , , , , , ,no,2012-11-29 11:56:56,2013-10-24 11:20:21,guidelines-for-reporting-results-of-quality-of-life-assessments-in-clinical-trials,"[('title', 'Guidelines for reporting results of quality of life assessments in clinical trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Quality of life assessments in clinical trials'), ('Full bibliographic reference', 'Staquet M, Berzon R, Osoba D, Machin D. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res. 1996;5(5):496-502.'), ('Language', 'English'), ('PubMed ID', '[8973129](http://www.ncbi.nlm.nih.gov/pubmed/8973129)'), ('Study design', 'Clinical trials, Experimental studies'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 24, 2013')]"
5559,Recommendations for reporting economic evaluations of haemophilia prophylaxis,Economic evaluations,Haematology,Whole report, ,"CBA, core standards, cost, Cost Benefit Analysis, Cost Utility Analysis, costs, CUA, economic analysis, economic evaluation, economic evaluations, economic impact, haematology, haemophilia, haemophilia prophylaxis, hematology, hemophilia, hemophilia prophylaxis, International Prophylaxis Study Group, IPSG, NGT, Nominal Groups Technique, prophylaxis", ,"Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A,\xa0 Hoots K, Mantovani L, Schramm W, van Hout BA, Willan AR, Feldman BM. Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group. Haemophilia. 2008;14(1):127-132.","Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Schramm W, van Hout BA, Willan AR, Feldman BM.",Haemophilia.,2008,14,1,127-132, ,English, ,18005148,http://www.ncbi.nlm.nih.gov/pubmed/18005148, , , , , , ,Economic evaluations of haemophilia prophylaxis, , , , , , , ,no,2012-11-29 11:56:24,2013-10-24 11:20:58,recommendations-for-reporting-economic-evaluations-of-haemophilia-prophylaxis-a-nominal-groups-consensus-statement-on-behalf-of-the-economics-expert-working-group-of-the-international-prophylaxis-stu,"[('title', 'Recommendations for reporting economic evaluations of haemophilia prophylaxis'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Economic evaluations of haemophilia prophylaxis'), ('Full bibliographic reference', 'Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A,\xa0 Hoots K, Mantovani L, Schramm W, van Hout BA, Willan AR, Feldman BM. Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group. Haemophilia. 2008;14(1):127-132.'), ('Language', 'English'), ('PubMed ID', '[18005148](http://www.ncbi.nlm.nih.gov/pubmed/18005148)'), ('Study design', 'Economic evaluations'), ('Clinical area', 'Haematology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 24, 2013')]"
5553,Overview of methods used in cross-cultural comparisons of menopausal symptoms and their determinants: Guidelines for Strengthening the Reporting of Menopause and Aging (STROMA) studies,Observational studies,Obstetrics and gynaecology,Whole report, ,"age, aging, cross-cultural, gynaecological, gynaecology, gynecological, gynecology, menopausal, menopausal symptoms, menopause, menopause symptoms, observational, observational studies, observational study, psychological, psychology, recall, sexual, somatic, STROMA, symptom, symptoms, vasomotor", ,"Melby MK, Sievert LL, Anderson D, Obermeyer CM. Overview of methods used in cross-cultural comparisons of menopausal symptoms and their determinants: Guidelines for Strengthening the Reporting of Menopause and Aging (STROMA) studies. Maturitas. 2011;70(2):99-109.","Melby MK, Sievert LL, Anderson D, Obermeyer CM.",Maturitas.,2011,70,2,99-109, ,English, ,21840143,http://www.ncbi.nlm.nih.gov/pubmed/21840143, , , , , ,STROMA,Menopause and aging studies, , , , , , , ,no,2012-11-29 11:53:56,2013-10-04 12:32:48,overview-of-methods-used-in-cross-cultural-comparisons-of-menopausal-symptoms-and-their-determinants-guidelines-for-strengthening-the-reporting-of-menopause-and-aging-stroma-studies,"[('title', 'Overview of methods used in cross-cultural comparisons of menopausal symptoms and their determinants: Guidelines for Strengthening the Reporting of Menopause and Aging (STROMA) studies'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Menopause and aging studies'), ('Full bibliographic reference', 'Melby MK, Sievert LL, Anderson D, Obermeyer CM. Overview of methods used in cross-cultural comparisons of menopausal symptoms and their determinants: Guidelines for Strengthening the Reporting of Menopause and Aging (STROMA) studies. Maturitas. 2011;70(2):99-109.'), ('Language', 'English'), ('PubMed ID', '[21840143](http://www.ncbi.nlm.nih.gov/pubmed/21840143)'), ('Reporting guideline acronym', 'STROMA'), ('Study design', 'Observational studies'), ('Clinical area', 'Obstetrics and gynaecology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 4, 2013')]"
5547,Strengthening the reporting of Genetic RIsk Prediction Studies: the GRIPS Statement,"Diagnostic and prognostic studies, Observational studies",Genetics,Whole report, ,"algorithms, gene, genetic, genetic risk, genetic risk prediction, genetic risk prediction studies, genetic risk prediction study, genetic risks, genetics, GRIPS, GRIPS statement, Human Genome Epidemiology Network, model, models, observational, observational studies, observational study, prediction, predictive, risk factor, risk factors, risk prediction", ,"Janssens AC, Ioannidis JP, van Duijn CM, Little J, Khoury MJ; GRIPS Group. Strengthening the reporting of Genetic RIsk Prediction Studies: the GRIPS Statement.

PLoS Med. 2011 8(3):e1000420. PMID: 21423587
Genet Med. 2011;13(5):453-456. PMID: 21502867
Eur J Clin Inves. 2011;41(9):1004-1009. PMID: 21434891
Eur J Epidemiol. 2011;26(4):255-259. PMID: 21431409
J Clin Epidemiol. 2011;64(8):843-847. PMID: 21414754
BMJ. 2011;16:342:d631. PMID: 21411493
Genome Med. 2011;3(3):16. PMID: 21410995
Eur J Hum Genet. 2011;19(8):833-836. PMID: 21407265
Circ Cardiovasc Genet. 2011;4(2):206-209. PMID: 21406688
Ann Intern Med. 2011;154(6):421-425. PMID: 21403077","Janssens AC, Ioannidis JP, van Duijn CM, Little J, Khoury MJ; GRIPS Group", ,2011, , , , ,English, , , , ,"ACJW Janssens, JPA Ioannidis, S Bedrosian, P Boffetta, SM Dolan, N Dowling, I Fortier, AN Freedman, JM Grimshaw, J Gulcher, M Gwinn, MA Hlatky, H Janes, P Kraft, S Melillo, CJ O?Donnell, MJ Pencina, D Ransohoff, SD Schully, D Seminara, DM Winn, CF Wright, CM van Duijn, J Little, MJ Khoury. Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.

Eur J Clin Invest. 2011;41(9):1010-1035. PMID: 21434890
Eur J Epidemiol. 2011;26(4):313-337. PMID: 21424820
J Clin Epidemiol. 2011;64(8):e1-22. PMID: 21414753
Eur J Hum Genet. 2011;19(5):18. PMID: 21407270", , , ,GRIPS,Genetic risk prediction studies, , , , , , , ,no,2012-11-29 11:52:37,2022-01-14 16:31:44,strengthening-the-reporting-of-genetic-risk-prediction-studies-the-grips-statement,"[('title', 'Strengthening the reporting of Genetic RIsk Prediction Studies: the GRIPS Statement'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Genetic risk prediction studies'), ('Full bibliographic reference', 'Janssens AC, Ioannidis JP, van Duijn CM, Little J, Khoury MJ; GRIPS Group. Strengthening the reporting of Genetic RIsk Prediction Studies: the GRIPS Statement.\n\n \n\n PLoS Med. 2011 8(3):e1000420. PMID: [21423587](http://www.ncbi.nlm.nih.gov/pubmed/21423587)\n\n Genet Med. 2011;13(5):453-456. PMID: [21502867](http://www.ncbi.nlm.nih.gov/pubmed/21502867)\n\n Eur J Clin Inves. 2011;41(9):1004-1009. PMID: [21434891](http://www.ncbi.nlm.nih.gov/pubmed/21434891)\n\n Eur J Epidemiol. 2011;26(4):255-259. PMID: [21431409](http://www.ncbi.nlm.nih.gov/pubmed/21431409)\n\n J Clin Epidemiol. 2011;64(8):843-847. PMID: [21414754](http://www.ncbi.nlm.nih.gov/pubmed/21414754)\n\n BMJ. 2011;16:342:d631. PMID: [21411493](http://www.ncbi.nlm.nih.gov/pubmed/21411493)\n\n Genome Med. 2011;3(3):16. PMID: [21410995](http://www.ncbi.nlm.nih.gov/pubmed/21410995)\n\n Eur J Hum Genet. 2011;19(8):833-836. PMID: [21407265](http://www.ncbi.nlm.nih.gov/pubmed/21407265)\n\n Circ Cardiovasc Genet. 2011;4(2):206-209. PMID: [21406688](http://www.ncbi.nlm.nih.gov/pubmed/21406688)\n\n Ann Intern Med. 2011;154(6):421-425. PMID: [21403077](http://www.ncbi.nlm.nih.gov/pubmed/21403077)'), ('Language', 'English'), ('Explanation and elaboration papers', 'ACJW Janssens, JPA Ioannidis, S Bedrosian, P Boffetta, SM Dolan, N Dowling, I Fortier, AN Freedman, JM Grimshaw, J Gulcher, M Gwinn, MA Hlatky, H Janes, P Kraft, S Melillo, CJ O’Donnell, MJ Pencina, D Ransohoff, SD Schully, D Seminara, DM Winn, CF Wright, CM van Duijn, J Little, MJ Khoury. Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.\n\n \n\n Eur J Clin Invest. 2011;41(9):1010-1035. PMID: [21434890](http://www.ncbi.nlm.nih.gov/pubmed/21434890)\n\n Eur J Epidemiol. 2011;26(4):313-337. PMID: [21424820](http://www.ncbi.nlm.nih.gov/pubmed/21424820)\n\n J Clin Epidemiol. 2011;64(8):e1-22. PMID: [21414753](http://www.ncbi.nlm.nih.gov/pubmed/21414753)\n\n Eur J Hum Genet. 2011;19(5):18. PMID: [21407270](http://www.ncbi.nlm.nih.gov/pubmed/21407270)'), ('Reporting guideline acronym', 'GRIPS'), ('Study design', 'Diagnostic and prognostic studies, Observational studies'), ('Clinical area', 'Genetics'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'January 14, 2022')]"
5545,GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials,"Clinical trials, Experimental studies","Neurology, Oncology",Whole report, ,"brain tumor, brain tumour, checklist, checklists, clinical trial, clinical trials, early phase, efficacy, experimental studies, experimental study, GNOSIS, neuro-oncology, neurology, oncology, phase 1, phase 2, phase I, phase II, safety, trial, trials", ,"Chang SM, Reynolds SL, Butowski N, Lamborn KR, Buckner JC, Kaplan RS, Bigner DD. GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. Neuro Oncol. 2005;7(4):425-434.","Chang SM, Reynolds SL, Butowski N, Lamborn KR, Buckner JC, Kaplan RS, Bigner DD.","


Neuro-Oncology [Neuro Oncol.]",2005,7,4,425-434, ,English, ,16212807,http://www.ncbi.nlm.nih.gov/pubmed/16212807, , , , , ,GNOSIS,Phase 1 and phase 2 clinical trials in neuro-oncology, , , , , , , ,no,2012-11-29 11:52:11,2013-10-24 11:27:53,gnosis-guidelines-for-neuro-oncology-standards-for-investigational-studies-reporting-of-phase-1-and-phase-2-clinical-trials,"[('title', 'GNOSIS : guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', 'Phase 1 and phase 2 clinical trials in neuro-oncology'), ('Full bibliographic reference', 'Chang SM, Reynolds SL, Butowski N, Lamborn KR, Buckner JC, Kaplan RS, Bigner DD. GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. Neuro Oncol. 2005;7(4):425-434.'), ('Language', 'English'), ('PubMed ID', '[16212807](http://www.ncbi.nlm.nih.gov/pubmed/16212807)'), ('Reporting guideline acronym', 'GNOSIS'), ('Study design', 'Clinical trials, Experimental studies'), ('Clinical area', 'Neurology, Oncology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 24, 2013')]"
5517,Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS-PD), ,Neurology,Whole report, ,"checklist, checklists, clinical studies, clinical study, data element, data elements, DBS, deep brain stimulation, deep brain stimulation studies, deep brain stimulation study, Guide4DBS-PD, minimal set, movement disorder, movement disorders, neurological, neurological disorder, neurological disorders, neurology, Parkinson?s, Parkinson?s disease, PD, psychiatric, standardise, standardize, study parameters", ,"Vitek JL, Lyons KE, Bakay R, Benabid AL, Deuschl G, Hallett M, et al. Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS-PD). Mov Disord. 2010;25(11):1530-1537.","Vitek JL, Lyons KE, Bakay R, Benabid AL, Deuschl G, Hallett M, et al.",Movement Disorders [Mov Disord.],2010,25,11,1530-1537, ,English, ,20544809,http://www.ncbi.nlm.nih.gov/pubmed/20544809, , , , , ,Guide4DBS-PD,Deep brain stimulation studies in Parkinson's disease, , , , , , , ,no,2012-11-28 11:01:17,2013-10-24 11:30:23,standard-guidelines-for-publication-of-deep-brain-stimulation-studies-in-parkinsons-disease-guide4dbs-pd,"[('title', 'Standard guidelines for publication of deep brain stimulation studies in Parkinson’s disease (Guide 4 DBS-PD)'), ('Reporting guideline provided for?\n\n(i.e. exactly what the authors state in the paper)', ""Deep brain stimulation studies in Parkinson's disease""), ('Full bibliographic reference', ""Vitek JL, Lyons KE, Bakay R, Benabid AL, Deuschl G, Hallett M, et al. Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS-PD). Mov Disord. 2010;25(11):1530-1537.""), ('Language', 'English'), ('PubMed ID', '[20544809](http://www.ncbi.nlm.nih.gov/pubmed/20544809)'), ('Reporting guideline acronym', 'Guide4DBS-PD'), ('Clinical area', 'Neurology'), ('Applies to the whole report or to individual sections of the report?', 'Whole report'), ('Record last updated on', 'October 24, 2013')]"
